<SEC-DOCUMENT>0001746473-22-000010.txt : 20220301
<SEC-HEADER>0001746473-22-000010.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220228182903
ACCESSION NUMBER:		0001746473-22-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLIANT THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001746473
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474272481
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39303
		FILM NUMBER:		22692510

	BUSINESS ADDRESS:	
		STREET 1:		260 LITTLEFIELD AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-481-6770

	MAIL ADDRESS:	
		STREET 1:		260 LITTLEFIELD AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>plrx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d1d6b725-1763-4d57-8800-c62b80275ac0,g:d0b89192-8a0d-4134-a7bf-5cb6b0f5f7ce,d:988625df783e4cc0a27bd76df388da57--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:plrx="http://www.pliantrx.com/20211231" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>plrx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N180L2ZyYWc6NjEwMmUwMzA3NmI1NGIwZWFjMDU5MDE1MjgxZmU3MWEvdGFibGU6ZTA2OTNmZWQwNmU4NDQ2OWEyNjlmNjAzY2FlNmU2YzMvdGFibGVyYW5nZTplMDY5M2ZlZDA2ZTg0NDY5YTI2OWY2MDNjYWU2ZTZjM18yLTEtMS0xLTEyNjU5_68444f7e-0299-4858-8e98-1dccdf47a348">false</ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N180L2ZyYWc6NjEwMmUwMzA3NmI1NGIwZWFjMDU5MDE1MjgxZmU3MWEvdGFibGU6ZTA2OTNmZWQwNmU4NDQ2OWEyNjlmNjAzY2FlNmU2YzMvdGFibGVyYW5nZTplMDY5M2ZlZDA2ZTg0NDY5YTI2OWY2MDNjYWU2ZTZjM18zLTEtMS0xLTEyNjU5_d111b5ce-f34d-4dcf-82d4-dc41082bc4f9">2021</ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N180L2ZyYWc6NjEwMmUwMzA3NmI1NGIwZWFjMDU5MDE1MjgxZmU3MWEvdGFibGU6ZTA2OTNmZWQwNmU4NDQ2OWEyNjlmNjAzY2FlNmU2YzMvdGFibGVyYW5nZTplMDY5M2ZlZDA2ZTg0NDY5YTI2OWY2MDNjYWU2ZTZjM180LTEtMS0xLTEyNjU5_8cfe8b82-e290-4657-ad24-0b1379efa38f">FY</ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N180L2ZyYWc6NjEwMmUwMzA3NmI1NGIwZWFjMDU5MDE1MjgxZmU3MWEvdGFibGU6ZTA2OTNmZWQwNmU4NDQ2OWEyNjlmNjAzY2FlNmU2YzMvdGFibGVyYW5nZTplMDY5M2ZlZDA2ZTg0NDY5YTI2OWY2MDNjYWU2ZTZjM181LTEtMS0xLTEyNjU5_4c370458-89c0-4204-8403-67dad86dcbb8">0001746473</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ia6f0aba9c8a241cea27a247b44371de6_D20200522-20200522" decimals="8" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzgxL2ZyYWc6MzkwZTg4OGVlOGE4NGRhZjk1MmFhYTk4MDI5MjA4N2UvdGFibGU6NmQ4ZjM4MTI2ZmZkNDk1NjhhM2FjZTg5ODMwYWM1YTYvdGFibGVyYW5nZTo2ZDhmMzgxMjZmZmQ0OTU2OGEzYWNlODk4MzBhYzVhNl8xLTEtMS0xLTI4ODcy_539f4045-4aa4-4e80-98c6-79465e1d5439">0.13986014</ix:nonFraction><ix:nonNumeric contextRef="i290aba2015df4504b16ad472119c117d_D20200501-20200531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzM1NTY_17d5b407-5e02-4666-bc12-447640c0a66b">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i962e48e9796f47aeb0fff9145b63f53a_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzU0NDE_e2781c43-be0a-4144-b7b0-5f65f0005fa6">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzg4L2ZyYWc6ZTZlNzBiN2FiNDAzNDQ5NDg3MTUzOGNiNzRmNjcwNGQvdGFibGU6MTgwOGVlM2FiMmFjNGI2ZGJlNWU0NjFjNTQ4MWJjYzUvdGFibGVyYW5nZToxODA4ZWUzYWIyYWM0YjZkYmU1ZTQ2MWM1NDgxYmNjNV8wLTEtMS0xLTI5MTE4_19bb4197-5d4e-4e30-8e1d-1f07af176d27">0</ix:nonNumeric><ix:nonNumeric contextRef="i342e8370c50840b5ab283afd24abbf11_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTQvZnJhZzpjMWJjY2ViYWVhZmI0ZjE1OGMwYzJjYThiMTBlNjIxYy90YWJsZTowNGI3YjBlMzNmMjE0YmJkODA1ZDE4MzQ1ZDcwNjIyNS90YWJsZXJhbmdlOjA0YjdiMGUzM2YyMTRiYmQ4MDVkMTgzNDVkNzA2MjI1XzEtMS0xLTEtMTI2NTk_9cae239d-06d8-4567-bd46-100e22c9650b">3</ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:DefinedContributionPlanPlanNameExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjAvZnJhZzo3ODE2YmQ0ODM3ZWE0MWY0YmJmMzgxNjMxMGMwMGFjNS90YWJsZTpiNjJjMDJiNTlkOTk0ODcyOGIzZGJhOGFmZDIwNTY2Ny90YWJsZXJhbmdlOmI2MmMwMmI1OWQ5OTQ4NzI4YjNkYmE4YWZkMjA1NjY3XzEtMS0xLTEtMTI2NTk_8bef088e-aadc-4f23-8e2d-0ef293c964d4">http://fasb.org/us-gaap/2021-01-31#RetirementPlanNameOtherMember</ix:nonNumeric><ix:nonNumeric contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" name="us-gaap:DefinedContributionPlanPlanNameExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjAvZnJhZzo3ODE2YmQ0ODM3ZWE0MWY0YmJmMzgxNjMxMGMwMGFjNS90YWJsZTpiNjJjMDJiNTlkOTk0ODcyOGIzZGJhOGFmZDIwNTY2Ny90YWJsZXJhbmdlOmI2MmMwMmI1OWQ5OTQ4NzI4YjNkYmE4YWZkMjA1NjY3XzEtMi0xLTEtMTI2NTk_a460edb0-8c21-4471-a022-a409c9f0d680">http://fasb.org/us-gaap/2021-01-31#RetirementPlanNameOtherMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="plrx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0452ce794f54f2bb9a119d0f2ddb847_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8320fd52a1ae40e18b77aefd41de8571_I20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4c2aeb24bd264584a324aec3746051a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19974a4386bd4627a7211a58dab7ab17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id682893acc45496a970c56af4620e9fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fad418d5e0c4442b3c947090aa4197d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1140261f7add41b5b728c3a650671ec6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e75b3a2844245b397c0918c42b28f6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id19e6266bc8b4ecca92ba96df80eff19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c3089f6aa24936b58640c2e6b7da25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105a9ac3dc914251920a2e0a79bd4eef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a323ae54ce842b387531c5805e9f231_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i352bc25f1a8b4f56a69867979fce6c4b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95bbcd616eec42679d3f2ba166e8427e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5f0f71b08940e796377b4b0153bd67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaef884d5c4ad4ddc992fd9dc8a744804_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0ee10d79d854a2aa094cc081ddee51d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8427be0929874da48269b8a87d7e8ba7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd41145a7974d92a2226a3fc35633a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25794e7f363a4bf1abd2e657b1000f09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5a281e3e5b42d79b8b4f9a04af5d63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ad7fa9b65442f2ba3cba3af87805a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb689d41a0fc49d096930b208671ff5a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc82fb340f724ed2902d29a505bc74c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i826b025c166f473987892842e39f1549_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6bbff1d55944244a3110049517d61da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe3207e1e714584bed5756b07541340_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c41e7454f6a4547977cbf6b6a2349d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if537cc7d047f4502af240fda53df5d71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7fb96ee1b444920b7e071c2562a2d93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac12187e1ff4ab9bc07add5cf0d39c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4029b81cb5354eb6ae5e85b44506260f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763102559694449eb64cf66afe0a616f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6338bf9158f4706b6ad1a45102335fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f8cb5576bbf476b8d7705a54bb4ff2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c7626359c74441b6a578b9d935f19c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8589e12213434e09abcb711b749141bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52ffdf994934ba09ae03636d3857089_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8f4455a8e244490bb265a1a4f8a8cb0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ce83dd4cd2843efa13d02a41dcfe432_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5401e3f0f3d449e8847afa47baa6f9a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc20870287540578a9e62621b62c833_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62be0d4030cf4d84a89b73f59b635fc1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecc4ce257ab041eab3f3f31f4101a94f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e1e2bb434c4f519e0a4c7d227fc9d1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic95cde64854f441a96044b55c63e47c5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3740b71577f46c7aa6db36ccc8e9008_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb6e46e8589417fbb6dce85ec4707e9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e2e2d92973409c98c50757da18b62d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic527f172d0e443c493b5b9528858fff0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i062d513c3af24fb8a871914681ad6ed0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4f89da1832e4c048b3bf07808761b7c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4ededd465745ac8a09d27d629bf294_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61761cf5edab4bc4a348e46cd23dc2f4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3902b908614fb1b9c4a93bf96af64c_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae29663b5db54f749ffcf7b5c72df914_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plrx:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a558379cd44a9ab226783aa88f48a7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ibc3d94b8d41948578ccb00771371441d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9550253bdd3e4a6da0f6c0d34c9b9d1a_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib16143c3aac54e6ca3119c33948ae5eb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">plrx:PliantTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f0aba9c8a241cea27a247b44371de6_D20200522-20200522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-22</xbrli:startDate><xbrli:endDate>2020-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ff395e311847909da6a655116394ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>plrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i97ba5b3806e14f8cb378e134282cefff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72575f12fa974fe28bf756200624bdba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6401410f7ef49438a2f863fbc13df66_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a0d9e0cac2348ca84c706c8288bceb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79933d3e8de4b1dbcd02a40640ad95c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i502608fba6ca409d9d1c9db643401ed1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ccce3ad26234845a35af7149a3ec646_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc5aed3e7a8426487bf4c221631f7c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i771d84b1911848a9bbe7a4b3d4704f30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad109a114dc8411c89edb8c84d2b1e18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ada465fe97416585c2b4b0679231ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ed66f76be545c297192eb65c6e90ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i741c7a0fae7340c89c0beeec92183dff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c3fbf9468164232b5a4585f59962a25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fedf72de50140c3b7b150892abda892_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7be8fb727d34fd78dee97819061e39f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88eb8ff0e0954c70883407fca7e46607_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbd310f10677481088f4abcc6a267dac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">plrx:MatureInOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762f167b21754e29a50cab9db8dacfac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">plrx:MatureInOneToTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i788f10f5c97047c98f3a91d33d462adc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb9d77c8aeb443b8744a5d136c48c67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0147962f3a43ae98dc9257ca855342_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f177c3974b433093600a48912c81ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb37502688b5432890a52460645ba22c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id16f08eb632f4af58a00d176e37ebf70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i604392abc5a0452d940c039026024807_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e78efdd427f4cb090c0239dd860231c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ceadd77d9b4e6091731d2900ea887e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8691f274c844ea689788aa8180fc7ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaafcff2da3c4e68a71fc38bc8eaeeef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8516b91fd4c4e219c9d323eabb5f186_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc186515959f44048d743426dc3fdbb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac21b42661c400488b1fa60189baec8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="research"><xbrli:measure>plrx:research</xbrli:measure></xbrli:unit><xbrli:context id="i4a11a4aeb6da425289c1166b59fd1bef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4063173b5147aaa5ea48ffb9a0b41a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementRDForPLN1474Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20b043448f24ec285209cd2157d817f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementRDForIntegrinResearchTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65678d1f069d4f07b494357695afab1c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementRDForPLN1474Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3487dc6202fc4061837be6f1764523cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementRDForIntegrinResearchTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f8872e361484321beb5a17ef1f8345f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d55eaa32322449995997cb4bfd779d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plrx:AchievementOfFirstPatientDosingMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aab796f0bd54438a683ab44e486ff52_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8fe1712787414792033f6f6a6693aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1401fc63110c46cca48abbee90d24210_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plrx:AchievementOfFirstPatientDosingMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fd2e317fcf496da3fadf37239b10a7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia854acc757a14f42801309f5de85921c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">plrx:LicenseFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i935a529a108b4fe0854d7b486b19bf50_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief48b07f768842d19a26be0c2fdd1f5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1584a412397045a9b86f15e94c5effa9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia97bea2e62e046a3b667360c66ca83de_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plrx:UCRegentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325f7f2d873247748a03caa8aa5d4255_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">plrx:AdimabAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis">plrx:FullTimeEmployeeCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d58d249d30a4738b31d13b2325bbf0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">plrx:AdimabAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis">plrx:FullTimeEmployeeCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b24333fd1f4bc6a82043ff6caa6b4b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">plrx:AdimabAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis">plrx:FullTimeEmployeeCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i854a3335aa6a4adc9776beabc85e03a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>plrx:vote</xbrli:measure></xbrli:unit><xbrli:context id="i39ce7df93a7d4382a3b7d79316b6d848_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8e01ec8dfa4b258bddae261451f4ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08bb42e6ee74106be86d58f7fcbc58f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d9b60a984584a44a4ee09a45e5275aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ff87434abfc452d80645776f0f00c77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cf105f8083b45429f14ea888203d42a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f33d4df0354eefb5a56946ce9457da_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978188554a324ce7b6a888947d74558d_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290aba2015df4504b16ad472119c117d_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc83290d82c40ddb10360a0b1a2183c_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f0177dc3e04d418b662056854c1e4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">plrx:AccruedExpensesAndOtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica5a99276a1147c19fe6753da55b633a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">plrx:AccruedExpensesAndOtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ea8b06f17a484f9edfb9c294799d18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia016e7bdf0174df7a7fba019617bf8ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0866a31e05374ddab8c0a62345cc2249_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i962e48e9796f47aeb0fff9145b63f53a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0db696ccde415882e24106f2b32245_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d838bfb91454b308b74f37279c3dce3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f90bc5eed144f31928518fb768afba8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4dac08fa4ec49c8b7257c8ac25cdc21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda313aa08fc4436871f7a8d1f6538ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b95e5be86744cfb426abbbd9280039_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93980ffa2b4c48c69c6aeaa148e56ca5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee36529cae34a1880d776adf134e69e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib513e9b41ca0401988a6ebdb0da1f635_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36ef4c5abf7430991b10fecc4a30686_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08b0d8bbc764ddfa7bbdedd05be39a6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff90f11d0095440091e5fe52c4904b74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63754797203a4fa396889e7f6f569993_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c2c45617c474b8d8d2f5c5ec54bc1cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a1619e7cc641e895b0a776ffb7951c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dcffcd3361d45578bb203270ca62583_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d49e2ef8b934a9ca9872c2da4874dc1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc85e58f5bc489fbe3f59c43aa576af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8619df5f4bbc4c15a77403491fcf90bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9b2f94dc394411bb306ac98316895ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90cfc2ccdd64c42ad8668e78941f9b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e35f96e1d3a4ff1b9a03fab757d000c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb5094414c244a28314369adcc54cc5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31bce1e599344a70a32426478b95d1df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">plrx:StartingFromJanuary12018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73826d9211d549b896476358b41d3bde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">plrx:BeforeJanuary12018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7f1036aa4b454fb82af94ab3f2ce41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3ebd1303b143afb79b5a5535c7e658_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f33c2bafe3843d8bf470ed2c96ee5fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia814f0994a1449ce83dd2ebd288a95a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29fe77ab043541358883b2c7d9041522_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddb8c639eb9a45ed83884b3db05c0ffd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="taxexamination"><xbrli:measure>plrx:taxExamination</xbrli:measure></xbrli:unit><xbrli:context id="ia6b323227a6846f1b65d034e58f88164_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i598f80db39ac4c599c0538ab9aae3c30_I20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib125d2281fd7483b97614c1e8f176399_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic31ace94ac1847898d10e8026fbd8b04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c910fd3e4444dd2b8564e3ace9a8326_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54765707cbc04888952c42feb9bd45de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i429668ed867b4b9eb0766f77046f00f3_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339a84165f6b4c48adba2aba4271bc4a_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7166be69743e4e60a692a5adc04dcd3f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">plrx:ThirdRockVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48fa76d3d2dd4c4c86df500aed228234_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">plrx:ThirdRockVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f553a0f5fd4433b0cc4baba93fea24_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plrx:NonemployeeDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">plrx:ThirdRockVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342e8370c50840b5ab283afd24abbf11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plrx:NonemployeeDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">plrx:ThirdRockVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47e995f177284199bb8b0695a7c9725d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0035b443cb469b9de089f502f3e9c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18bd16bfffe94894922846cadcd48ed0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24ad985733c48bfb53bfbd864d91f27_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68e2483823f6420cb6185c251c58ac55_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib34337582e984ae1ba7584d1346e1780_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4eb9436dd324df99ee7f4d8e63df7e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plrx:RestrictedStockAwardsGrantedAndNotPurchasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf1265c8744c461286d3671e01ec1cc8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plrx:RestrictedStockAwardsGrantedAndNotPurchasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9964d5d87c0b4f47a4e7b2802949d585_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plrx:RestrictedStockAwardsGrantedAndNotPurchasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i123f913abe274f3b80052d070e8729c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31f0ac37c034f85b050eb91b4830b28_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a427494f6ff428e8b8a4b08835c85f7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001746473</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i988625df783e4cc0a27bd76df388da57_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDAx_d4800754-f591-45a9-9e00-8346608d0fc5">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark&#160;One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6YWUzYTQ5NTY0ZjBhNDkwMDg1Y2VkZjdhOWIwZDM1NzcvdGFibGVyYW5nZTphZTNhNDk1NjRmMGE0OTAwODVjZWRmN2E5YjBkMzU3N18wLTAtMS0xLTEyNjU5_a158dc0e-9f77-433f-b9dd-cc19cc5efcb6">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8yMjA_6b4fe0e2-5568-4981-81fd-6a93521569c8"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8yMjA_56bd5d2d-47aa-4916-a0fc-daf8dda8e2cd">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6YTQ4YzM0NWE3N2M2NGQ4ODk3ZjNiNTUwOGE4MGMzNDkvdGFibGVyYW5nZTphNDhjMzQ1YTc3YzY0ZDg4OTdmM2I1NTA4YTgwYzM0OV8wLTAtMS0xLTEyNjU5_d282ec58-c0ad-4622-b713-34f63d8c256c">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDAy_b23d0afa-adab-4b32-b2a2-0d4a3db0f063">001-39303</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDAz_abc6c56c-758a-4d1d-a42c-be56aa162cc8">PLIANT THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:5pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.000%"><tr><td style="width:1.0%"></td><td style="width:28.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8wLTAtMS0xLTE5NDYy_cbe1feac-af77-47df-a603-4f0e09156c7e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8wLTMtMS0xLTEyNjU5_222e7dc2-ba43-4268-9538-a072a0972730">47-4272481</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8yLTAtMS0xLTEyNjU5_7ce98c30-4e3e-47ca-bcb1-c4bce9bb7cc3">260 Littlefield Avenue</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8zLTAtMS0xLTEyNjU5_59f3bd92-449a-493f-a4be-1e398b48a5d9">South San Francisco</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8zLTItMS0xLTEyNjU5_0fbc302f-9ed8-429a-bb26-9457709be03b">CA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8zLTMtMS0xLTEyNjU5_3a72fa63-5eb5-434d-ad85-0031d0336c77">94080</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDA0_eab2688a-532d-486e-9124-6e91130a8108">650</ix:nonNumeric>) <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zMzk3_239abe10-2342-40a6-99a3-67f7794a34a3">481-6770</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on which Securities are</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class of Securities Registered</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6ZDI1ZGZkOTVjNTMzNDc2N2IxNmU1MzdkZGRhODA3NjQvdGFibGVyYW5nZTpkMjVkZmQ5NWM1MzM0NzY3YjE2ZTUzN2RkZGE4MDc2NF8yLTAtMS0xLTEyNjU5_162eff64-018d-4109-9434-9e18c0dcaa14">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6ZDI1ZGZkOTVjNTMzNDc2N2IxNmU1MzdkZGRhODA3NjQvdGFibGVyYW5nZTpkMjVkZmQ5NWM1MzM0NzY3YjE2ZTUzN2RkZGE4MDc2NF8yLTEtMS0xLTEyNjU5_04fd1c7e-dd84-4019-aae9-9306dfa59078">PLRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6ZDI1ZGZkOTVjNTMzNDc2N2IxNmU1MzdkZGRhODA3NjQvdGFibGVyYW5nZTpkMjVkZmQ5NWM1MzM0NzY3YjE2ZTUzN2RkZGE4MDc2NF8yLTItMS0xLTE5NDY0_b916fde9-322e-4253-9a12-0d27c375f498">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xNDI5MzY1MTE2NDU3NQ_17bca756-fd1b-4fc6-831e-5f7194993a24">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xNDI5MzY1MTE2NDU3OQ_4bc90d9b-e8ed-44ab-953d-baf04a653e99">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xNDI5MzY1MTE2NDU4NQ_66bf38bf-98b8-4cdd-87f0-ed38995b39e1">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xNDI5MzY1MTE2NDU5MQ_67ec24ea-b891-46fc-94ed-570d63e13ada">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6MDJjMDc4ZmE5MWI1NDU1OTlhMmFkYTkyMGQ5MmVhZWQvdGFibGVyYW5nZTowMmMwNzhmYTkxYjU0NTU5OWEyYWRhOTIwZDkyZWFlZF8wLTAtMS0xLTI4NDQ0_199342c4-b432-40d6-8c15-13881a699077">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6MDJjMDc4ZmE5MWI1NDU1OTlhMmFkYTkyMGQ5MmVhZWQvdGFibGVyYW5nZTowMmMwNzhmYTkxYjU0NTU5OWEyYWRhOTIwZDkyZWFlZF8yLTQtMS0xLTEyNjU5_e912b925-9a74-4bbf-b6de-f2945eb10e76">&#168;</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6MDJjMDc4ZmE5MWI1NDU1OTlhMmFkYTkyMGQ5MmVhZWQvdGFibGVyYW5nZTowMmMwNzhmYTkxYjU0NTU5OWEyYWRhOTIwZDkyZWFlZF80LTEtMS0xLTEyNjU5_727256ef-aa4b-4705-95e0-63d31c76d238">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV80Mzk4MDQ2NTE0NTEz_2a751655-6c9c-42ce-875e-0e9f17069a8c">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zMjk4NTM0ODg2NzYy_e22f25ee-f369-4132-b917-8f1a84b0c962">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Stock Market on June 30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="ia0452ce794f54f2bb9a119d0f2ddb847_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8yODk5_eea67725-3c9c-4f5a-ab74-37613baf925c">751,814,002</ix:nonFraction>.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of Registrant&#8217;s Common Stock outstanding as of February&#160;25, 2022 was <ix:nonFraction unitRef="shares" contextRef="i8320fd52a1ae40e18b77aefd41de8571_I20220225" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xMjY0NDM4MzcyMjk1NA_a96803c6-5764-4e70-981f-c8f929ad1514">36,113,521</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDAw_ada5e995-3971-40b2-9bfa-29f394833761" escape="true"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K</span></div></ix:nonNumeric><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_10">Special Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_13">Summary of Risks Associated With Our Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_13">2</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_19">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Risk Factors</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_25">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_25">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_28">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_28">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_31">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_31">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_34">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_34">93</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_37">PART&#160;II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_40">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_40">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_43">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_43">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_43">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_46">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_46">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_76">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_76">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_79">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_79">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_79">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_166">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_166">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_166">135</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_169">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_169">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_169">135</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_172">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_172">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_172">136</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_175">PART&#160;III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_178">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_178">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_178">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_181">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_181">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_181">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_184">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_184">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_184">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_187">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_187">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_187">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_190">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_190">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_190">137</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_193">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_196">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_196">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_196">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_199">Item&#160;16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_199">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_199">140</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K, or this Report, contains forward-looking statements that involve risks, uncertainties, and assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Report include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">The success, cost and timing of our product development activities and clinical trials of our lead product candidate, PLN-74809, as well as PLN-1474 and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our estimates regarding the impact of the COVID-19 pandemic on our business and operations, and our ability to manage such impacts;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our or our current or future collaborators plans to initiate, recruit and enroll patients in, and conduct our clinical trials at the pace that we project;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our plans and strategy to obtain and maintain regulatory approvals of our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our plans and strategy to obtain funding for our operations, including funding necessary to complete further development and, upon successful development, if approved, commercialize any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">The potential benefit of orphan drug designations for PLN-74809;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our ability to compete with companies currently marketing or engaged in the development of treatments for fibrosis;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our plans and strategy regarding obtaining and maintaining intellectual property protection for our product candidates and the duration of such protection;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our plans and strategy regarding the manufacture of our product candidates for clinical trials and for commercial use, if approved;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our dependence on current and future collaborators for developing, obtaining regulatory approval for and commercializing product candidates in the collaboration;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our receipt and timing of any milestone payments or royalties under any current or future research collaboration or license agreements or arrangements;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our plans and strategy regarding the commercialization of any products that are approved for marketing and our ability to establish adequate pricing in the U.S. and international markets;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">The size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in combination with others;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our ability to attract and retain qualified employees and key personnel; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our expectations regarding government and third-party payor coverage and reimbursement.</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are based on the beliefs and assumptions of our management, which are in turn based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results and timing expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled &#8220;Risk Factors&#8221; included under Part I, Item 1A in this Report. Furthermore, such forward-looking statements speak only as of the date of this Report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business involves significant risks, some of which are summarized below. The summary risk factors listed below should be read together with the text of the full risk factors discussed in "Part I, Item 1A. Risk Factors" in this Report. You should carefully consider the risks described below, as well as the other information in this Report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as in other documents that we file with the Securities and Exchange Commission, or the SEC. The occurrence of any of the events or developments described in this Report could have a material adverse effect on our business, financial condition, results of operations, growth prospects and stock price. In such an event, the market price of our common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and the market price of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">We have incurred significant net losses since inception, and we expect to continue to incur significant net losses for the foreseeable future.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Research and Development and the Biopharmaceutical Industry</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our business is highly dependent on the success of our lead product candidate, PLN-74809, as well as PLN-1474 and any other product candidates that we advance into the clinic. All of our product candidates will require significant additional preclinical and clinical development before we may be able to seek regulatory approval for and launch a product commercially.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our approach to drug discovery and development in the area of fibrotic diseases is unproven and may not result in marketable products.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Clinical development involves a lengthy, complex, and expensive process, with an uncertain outcome.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of PLN-74809 or any other product candidates.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">We may fail to obtain and maintain orphan designations in some jurisdictions and therefore fail to secure orphan exclusivity in those jurisdictions.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our success depends in part on our ability to obtain patent term extensions and to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our collaborators may assert ownership or commercial rights to inventions they develop from research we support, or that we develop from our use of the tissue samples or other biological materials which they provide to us, or otherwise arising from the collaboration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">We have entered into a collaboration agreement with Novartis Institutes for Biomedical Research, Inc., or Novartis, for the development of PLN-1474 and may in the future seek to enter into collaborations with third parties for the development and commercialization of other product candidates. If we fail to enter into such collaborations, or if our collaborations are not successful, we may be unable to continue development of such product candidates, we would not receive any contemplated milestone payments or royalties, and we could fail to capitalize on the market potential of such product candidates.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials and for tissue samples and other materials required for our research and development activities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Managing Our Business and Operations</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">The ongoing COVID-19 pandemic could adversely impact our business, including our preclinical studies and clinical trials.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Our loss of key management personnel, or our failure to recruit additional highly skilled personnel, will impair our ability to develop current product candidates or identify and develop new product candidates, could result in loss of markets or market share and could make us less competitive.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i988625df783e4cc0a27bd76df388da57_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Our initial focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-&#946;. We have applied our deep understanding of fibrosis biology, along with our medicinal chemistry and translational medicine expertise to develop a set of proprietary tools designed to discover and de-risk product candidates quickly and efficiently. Our wholly-owned lead product candidate, PLN-74809, is an oral small molecule, dual selective inhibitor of &#945;v&#223;6 and &#945;v&#223;1 integrins that we are developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. We have completed a Phase 1a SAD/MAD trial and a Phase 1b proof-of-mechanism trial of PLN-74809 in IPF and are currently conducting three Phase 2a trials in our lead indications: two in IPF and one in PSC. We announced interim data from our first Phase 2a IPF trial in September 2021. Our Phase 2a INTEGRIS-IPF trial has completed enrollment and we expect to release data mid-2022. Our Phase 2a INTEGRIS-PSC trial is currently enrolling with full enrollment expected in mid-2022, with data readout expected by late 2022 or early 2023. We have also developed a second product candidate, PLN-1474, a Phase 2-ready small molecule selective inhibitor of &#945;v&#223;1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, for which we have partnered with Novartis. In addition to our clinical programs, we currently have preclinical integrin-based programs targeting oncology and muscular dystrophies.</span></div><div style="margin-top:6pt;text-indent:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we announced positive interim results from a Phase 2a positron emission tomography, or PET, imaging trial evaluating target engagement of PLN-74809 in the lungs of IPF patients. Each patient across the four dose cohorts tested achieved target engagement levels greater than 50% in the most fibrotic portions of their lungs after only one dose of PLN-74809.  Target engagement of 50% was previously established in a Phase 1b trial as the threshold for predicted clinical anti-fibrotic effect. In addition, there was a dose- and plasma concentration-dependent response with the two highest doses approaching target saturation.  PLN-74809 was well tolerated in the trial with no serious adverse events, or SAEs, reported.  The interim data confirm that PLN-74809 penetrates the highly fibrotic lung tissue of IPF patients, and potently binds to its target.  These interim data allow us to construct a full exposure-target engagement curve model, decoding our ongoing Phase 2a trials and guiding future clinical development of PLN-74809.</span></div><div style="margin-top:6pt;text-indent:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced positive results from an expanded PLN-74809 Phase 1b proof-of-mechanism trial.  This study evaluated PLN-74809's ability to suppress TGF-&#946; activation in the lungs of healthy volunteers as measured through relative pSmad2 levels in alveolar macrophages collected through bronchioalveolar lavage (BAL) at 6 hours and 24 hours after the last dose. The trial was conducted in two parts. Part 1 evaluated PLN-74809 at doses of 80 mg and 160 mg versus placebo and Part 2 evaluated PLN-74809 at 320 mg versus placebo. PLN-74809 demonstrated clear evidence of on-target biological activity in the lungs of healthy participants. Results showed that PLN-74809 inhibited TGF-&#946; activation by up to 92% and 76% at 6- and 24-hours, respectively, following dosing. PLN-74809 was well tolerated with mostly mild adverse events, and no severe adverse events. There was no dose relationship associated with adverse events, no serious adverse events (SAEs) and no treatment discontinuations due to adverse events. This trial further defines the relationship between plasma exposure of PLN-74809 and TGF-&#946; inhibition in the lung and will guide dose selection in future trials.</span></div><div style="margin-top:6pt;text-indent:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fibrosis refers to the abnormal thickening and scarring of connective tissue due to the production and deposition of excess collagen in the extra-cellular matrix. Fibrosis can occur in many different tissues including lung, liver, kidney, muscle, skin and the gastrointestinal tract, and often causes severe and debilitating disease potentially leading to organ failure and death. Fibrosis has historically proven difficult to treat, which we believe is due to the complexity of the disease biology and the challenge of targeting fibrotic tissues selectively without affecting healthy tissues.</span></div><div style="margin-top:6pt;text-indent:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that tissue-specific inhibition of TGF-&#946; may hold the key to successfully treating fibrosis. In normal tissues, TGF-&#946; is activated in response to tissue injury which initiates a cascade that results in collagen production and, ultimately, scar formation to heal the tissue. In fibrosis, however, TGF-&#946; signaling becomes dysregulated, with TGF-&#946; being continuously activated, leading to excess collagen deposition, even in the absence of acute tissue injury. TGF-&#946;, while implicated in fibrosis pathophysiology, is expressed, and intermittently activated across all tissue types and plays important, context-specific roles in tissue homeostasis. Therefore, TGF-&#946; cannot be blocked systemically without disrupting these homeostatic functions and causing significant toxicities. To treat fibrosis more precisely in specific tissues, we believe it is crucial to discover and treat the underlying mechanism causing excess TGF-&#946; activation.</span></div><div style="margin-top:6pt;text-indent:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientific founders are pioneers in elucidating the role of specific extracellular receptors known as integrins as a key element in the activation of TGF-&#946;. While the role of integrins in TGF-&#946; activation has been well-characterized over the past 10 years, integrins have historically been difficult to target therapeutically using small </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">molecules due to the difficulty of engineering molecules with high receptor selectivity and bioavailability. We believe that we have addressed these challenges with our platform. We have built a library of compounds that includes bioavailable, selective and potent inhibitors of multiple integrins that may be used to target a range of fibrotic diseases across different tissues.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="margin-top:10pt"><img src="plrx-20211231_g1.jpg" alt="plrx-20211231_g1.jpg" style="height:261px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead wholly-owned product candidate, PLN-74809, is an oral small molecule, dual-selective inhibitor of &#945;v&#223;6 and &#945;v&#223;1 that we are advancing in IPF and PSC. While expressed at very low levels in normal tissues, &#945;v&#223;6 and &#945;v&#223;1 are upregulated in the pulmonary tissues of IPF patients, and in the liver tissues of PSC patients. They both serve as activators of TGF-&#946;, leading to increased collagen production and fibrosis in these tissues. By blocking TGF-&#946; activation by both &#945;v&#223;6 and &#945;v&#223;1, we believe PLN-74809 may slow and potentially halt the progression of fibrosis in these patient populations. PLN-74809 has been granted orphan drug designation by the FDA for both IPF and PSC.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPF is the most common and severe form of progressive pulmonary fibrosis, affecting approximately 140,000 patients in the United States. While the underlying cause of IPF is unknown, the course of the disease is well documented, with progressive scarring that destroys the structure and function of the lungs over time. The average life expectancy for patients with confirmed IPF is between three and five years. There are currently two FDA-approved therapies for IPF. Both have shown modest slowing of disease progression. However, both therapies have raised significant safety and tolerability concerns.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSC is a progressive liver disorder affecting approximately 30,000 to 45,000 patients in the United States. The disease is characterized by fibrosis originating in the bile ducts that ultimately results in bile flow obstruction or cholestasis, causing liver damage and progressive fibrosis of the liver. Patients have a median survival of 10 to 12 years without intervention and carry high lifetime risk of developing gastrointestinal malignancies. There are currently no FDA-approved therapies for PSC.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our live human tissue assay, PLN-74809 showed a greater than 50 percent decrease in the expression of pro-fibrotic genes, such as collagen type I alpha1 chain, or </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL1A1, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and collagen type 3 alpha1 chain, or </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL3A1, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that are responsible for collagen production in human IPF and PSC tissues. Additionally, we have completed a study in non-human primates in which we showed that inhibition of &#945;v&#223;6 and &#945;v&#223;1 reduced TGF-&#946; activation by greater than 75% in cells isolated from the lungs after seven days of treatment.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed Phase 1a single ascending dose, or SAD, multiple ascending dose, or MAD, and food effect clinical trials in which PLN-74809 was shown to be orally bioavailable and generally well tolerated with a half-life that may support once-daily dosing.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also completed a Phase 1b proof-of-mechanism trial in healthy volunteers evaluating PLN-74809&#8217;s ability to inhibit TGF-&#946; activation as measured through pSMAD2/3 levels. pSMADs act as signaling molecules directly downstream from the TGF-&#946; receptor, and therefore pSMAD2/3 levels can be used as a reliable biomarker for TGF-&#946; activation. In the Phase 1b trial, and subsequent Phase 1b extension trial, PLN-74809 was shown to inhibit TGF-&#946; activation in alveolar macrophages collected from healthy volunteers, by up to 92% and 76% at 6- and 24-hours, respectively. Additionally, PLN-74809 was well tolerated with only mild adverse events and no drug-related adverse events.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting two Phase 2a trials of PLN-74809 in IPF. In the first of these trials, we are enrolling up to 12 IPF patients and utilizing a positron emission tomography, or PET, ligand to measure &#945;v&#223;6 target engagement by PLN-74809 in the lungs post-treatment with ascending single doses of PLN-74809. We announced positive interim data from this trial in September of 2021. Enrollment of this trial continues. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second trial is a 12-week randomized, double-blind, placebo-controlled trial enrolling approximately 84 IPF patients across four cohorts consisting of three dose cohorts of PLN-74809 and one placebo cohort that will evaluate safety, tolerability and pharmacokinetics, or PK. We also plan to employ exploratory efficacy endpoints including Quantitative Lung Fibrosis, or QLF, imaging analysis, biomarkers and pulmonary function tests including Forced Vital Capacity, or FVC. This trial completed enrollment in December 2021, and we expect to release data mid-2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also recruiting a Phase 2a trial of PLN-74809 in PSC. The trial is a 12-week randomized, double-blind, placebo-controlled trial enrolling approximately 84 PSC patients across four cohorts consisting of three dose cohorts of PLN-74809 and one placebo cohort that will evaluate safety, tolerability and PK. We also plan to employ exploratory efficacy endpoints including fibrosis biomarkers such as Pro-C3 and ELF, as well as ALP and liver imaging. This trial is currently on track to complete enrollment by mid-2022, with data readout expected by late 2022 or early 2023.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also developed a second clinical stage product candidate, PLN-1474, which is a small molecule, selective inhibitor of TGF-&#946; activation by the integrin &#945;v&#223;1 in development for treatment of liver fibrosis associated with NASH. &#945;v&#223;1 serves as an activator of TGF-&#946; and its expression has been shown to be upregulated in hepatic stellate cells in late-stage NASH-associated liver fibrosis. In October 2019, we entered into a collaboration and license agreement with Novartis in which Novartis licensed global rights to PLN-1474. Under the terms of the agreement, we received a $50.0 million license fee, as well as $30.0 million of equity investment. Additionally, we are eligible to receive up to $416.0 million in total milestone payments, as well as tiered royalties on products commercialized from the collaboration. To date, we have received $25.0 million in contingent payments and $391.0 million remain eligible for achievement.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a first-in-human, randomized, double-blind, placebo-controlled Phase 1 dose escalation trial that enrolled 84 healthy volunteers across single ascending dose and multiple ascending dose cohorts. Results showed that PLN-1474 was rapidly absorbed and well tolerated with no dose- or treatment-limiting toxicities observed with adverse events that were mostly mild with no severe or serious adverse events observed. The PLN-1474 Investigational New Drug, or IND, application was transferred to Novartis in the first quarter of 2021. Novartis is responsible for all future development, manufacturing and commercialization activities for PLN-1474.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical programs, we are developing two additional preclinical integrin-based programs. The first of these is our oncology program. As TGF-&#946; biology has been elucidated, it has become increasingly understood in the scientific literature that TGF-&#946; plays an important anti-inflammatory role in the tumor micro-environment, preventing T-cell infiltration and inhibiting release of various cytokines. This mechanism is becoming increasingly recognized as a potential cause of the resistance to checkpoint inhibitors such as anti-PD-1 therapies seen in many tumors. We are targeting the TGF-&#946; activating integrin &#945;v&#946;8, which is upregulated in certain tumors with the goal of sensitizing tumors to checkpoint inhibitors. This program has generated positive data in preclinical tumor models and our candidate is currently undergoing IND-enabling studies. We expect to submit an IND application for our oncology program by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including Duchenne Muscular Dystrophy, or DMD. The target integrin is upregulated on muscle cells across multiple muscular dystrophy indications, acting as a substitute for dystrophin and helping to anchor muscle cells to the extracellular matrix. The program utilizes an allosteric agonistic antibody to activate the target in order to augment the naturally occurring compensatory mechanism. Because the antibody is not mutation specific, it could potentially be effective as a single therapy or in combination with other treatment modalities across multiple muscular dystrophy indications. Our muscular dystrophy candidate is currently undergoing IND enabling studies with submission of an IND application by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled an executive team with highly relevant experience in fibrosis, small molecule drug discovery and clinical development. Bernard Coulie, M.D., Ph.D., our President and Chief Executive Officer, has over 20 years of experience in drug development, previously serving as Chief Executive Officer and Chief Medical Officer of ActoGeniX, as well as holding senior roles at Johnson &amp; Johnson. &#201;ric Lefebvre, M.D., our Chief Medical Officer, brings deep experience in clinical development in liver disease. He previously served as head of clinical research and development for the NASH program at Allergan. Prior to Allergan, Dr. Lefebvre led HIV and HCV development at Janssen and later served as Chief Medical Officer at Tobira. Our science builds on the research of world-renowned researchers Dean Sheppard, M.D., Rik Derynck, Ph.D., Bill DeGrado, Ph.D. and Hal Chapman, M.D., all from the University of California, San Francisco, who bring broad experience in fibrosis biology and small molecule chemistry among other related disciplines.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Strategy</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">Our goal is to become a world-leading fibrosis company, developing and commercializing disease- modifying therapies across a spectrum of fibrotic diseases. To achieve this, we are focused on the following key strategies:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Rapidly advance PLN-74809 through clinical development and commercialization in IPF and PSC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing our lead oral small molecule inhibitor of &#945;v&#223;6 and &#945;v&#223;1 as a novel therapy for IPF and PSC, each an area of high unmet medical need. Both IPF and PSC are orphan indications that we believe we can commercialize on our own in key geographies using targeted sales forces.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Selectively evaluate additional partnerships in indications and geographies where we believe partners can add significant commercial and/or development capabilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fibrotic diseases represent a broad set of disease indications to pursue. Our focus is to commercialize our assets in orphan fibrosis indications and to selectively work with partners in larger indications and in geographies outside of North America. Given the size and competitive dynamics of the NASH indication, we believe that our collaboration with Novartis provides PLN-1474 a strong platform for advancement. Furthermore, we will evaluate and potentially choose to partner our unpartnered product candidates in indications outside of fibrosis.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Explore opportunities for our pipeline assets in additional fibrotic indications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating the potential benefit of our product candidates outside of their lead indications. Our product candidates have shown anti-fibrotic activity in multiple animal models as well as human tissue in indications outside of IPF, PSC and NASH. We will continue to evaluate additional indications to maximize the potential of our pipeline.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Leverage our industry leading tools and capabilities to advance our mission of becoming a leading fibrosis company. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding, we have endeavored to advance the understanding of fibrosis biology, uncover new targets and advance novel product candidates. Currently, our proprietary capabilities include a target expression atlas, an expansive library of over 10,000 integrin binding molecules, an integrin screening assay platform, a live fibrotic human tissue program, a PET-ligand imaging program and biomarker assays. We continue to expand our integrin inhibitor library and develop tools such as additional PET-ligands as well as novel disease biomarkers. In addition, we have a library of over 70,000 compounds for non-integrin targets. We intend to leverage these tools and capabilities in a target- and modality-agnostic manner to expand our pipeline with a mission to become a world-leading fibrosis company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fibrosis: A Condition of Uncontrolled Scarring</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fibrosis refers to excessive scarring often resulting from aberrant tissue repair processes. In normal tissues, fibrotic pathways represent a repair mechanism by which the tissues heal themselves in response to injury or disease. These pathways are normally deactivated upon completion of tissue repair. However, when they become dysregulated and remain activated, excess collagen deposition can cause tissues to thicken and become stiff, ultimately impairing their physiological function.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fibrosis is a disease of connective tissue. Normal connective tissue forms a supportive network between cells, lending structure and integrity to tissues built up of many cell types. Connective tissue is composed of collagenous and elastic fibers, as well as a number of supporting cells such as fibroblasts and white blood cells. These supporting cells are embedded in a gel-like matrix made up of proteins known as the extra-cellular matrix. The most important protein in this matrix is collagen, which takes the form of elongated, fine fibers, providing flexible support to the surrounding cells. In fibrotic tissues, initial insults such as tissue damage or inflammation spur the deposition of excess collagen. Normally such responses are balanced in finely controlled feedback loops, but in fibrotic disease these feedback loops are dysregulated, resulting in progressive scarring, thickening, and loss of function.</span></div><div style="margin-top:6pt;text-indent:54pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="plrx-20211231_g2.jpg" alt="plrx-20211231_g2.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:417px"/></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fibrosis occurs in many organ systems throughout the body including the lungs, liver, kidneys, gastrointestinal tract, skin, and muscles. While the exact pathologies of diseases in these organs vary, the development of fibrosis involves many common cell types and biochemical pathways, including the TGF-&#946; signaling pathway. The ultimate result is similar across many tissues: secretion and extracellular activation of growth factors that stimulate fibroblasts to secrete excess collagen, leading to runaway growth of scar tissue.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that selectively inhibiting TGF-&#946; activation holds the key to successfully treating fibrosis across multiple tissues and organs. TGF-&#946; is secreted by nearly all cells and organs in mammals and stored in large amounts outside of cells, in the extra-cellular matrix, as part of an inactive complex. In healthy tissues, TGF-&#946; is transiently activated in response to tissue injury which initiates a cascade that results in collagen production and, ultimately, healing of the tissue. In fibrosis, however TGF-&#946; signaling becomes dysregulated and perpetuated, with TGF-&#946; being continuously activated, leading to excess collagen deposition in the absence of acute tissue injury. Moreover, induced activation of TGF-&#946; alone in animal models has been shown to be sufficient to induce fibrosis, and inhibition of TGF-&#946; activation has been shown to prevent or reduce fibrosis.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TGF-&#946; can be activated in multiple ways in response to specific tissue injury. One important class of cell-surface proteins that activate TGF-&#946; in fibrosis are integrins. Integrins have a variety of functions, including signaling inside the cells, providing tissue structure and stability through adhesion between cells. Integrins are heterodimeric proteins, meaning they are composed of two different protein subunits paired together. These are known as &#945; and &#946; subunits. In humans, there are eighteen distinct &#945; subunits and eight distinct &#946; subunits, which combine to form 24 known and functional integrin pairs.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain integrins bind the inactive TGF-&#946; complex. In response to tissue injury, the cells expressing these integrins are induced to contract, exerting physical force on the bound TGF-&#946; complex. This mechanical force changes the shape of the complex, releasing active TGF-&#946;. This activation triggers a biological cascade which results in collagen production, and when dysregulated leads to fibrosis. As depicted in the figure below, this cascade involves (i) binding of active TGF-&#946; to its receptor, the TGF-&#946; type I receptor kinase also known as ALK5; (ii) phosphorylation of immediate downstream signaling proteins known as SMAD2 and SMAD3; (iii) formation of a transcription initiation complex by pSMAD2, pSMAD3 and SMAD4; and (iv) subsequent transcription of target genes that encode fibrotic proteins such as collagen. Importantly, whereas certain TGF-&#946;-activating integrins are expressed at very low levels in healthy tissues, the TGF-&#946; cascade can lead to the upregulation of these integrins resulting in a TGF-&#946;-driven positive feed-forward loop which further increases TGF-&#946; activation. Furthermore, as fibrosis progresses and the fibrotic organ gets stiffer, it becomes progressively easier for contracting cells to activate integrin-bound TGF-&#946;. It is because of this continued, tissue-specific upregulation of integrins and their key roles in continued TGF-&#946;-activation that we believe that integrins provide an avenue to selectively inhibit TGF-&#946; activation in fibrotic tissue without affecting TGF-&#946;&#8217;s important physiological roles in healthy tissues.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#945;v</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Integrins promote fibrosis through activation of TGF-&#946;</span></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g3.jpg" alt="plrx-20211231_g3.jpg" style="height:288px;margin-bottom:5pt;vertical-align:text-bottom;width:659px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Model of integrin regulation of TGF-</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> signaling</span></div><div style="margin-top:10pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Historical Challenges to Drug Development in Fibrosis</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fibrosis has historically been a difficult therapeutic area to target pharmaceutically. The biology and underlying causes of fibrosis are complex and, in many diseases, poorly understood. In the past, many patients with fibrotic disease were treated with anti-inflammatory agents such as steroids. While steroids may have a mild anti-fibrotic effect in some forms of fibrosis, they can exacerbate others, such as IPF. Additionally, the negative effects of chronic steroid exposure make it difficult to treat patients with these agents for long-term periods.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, it has become well understood that regardless of the underlying cause, TGF-&#946; activation is at the heart of several key processes that drive fibrosis, including collagen formation, deposition of extracellular matrix proteins and activation and proliferation of fibroblast cells. As such, much of the historic drug development efforts to treat fibrosis have been aimed at systemically inhibiting or disrupting the TGF-&#946; signaling pathway by either (i) blocking TGF-&#946; binding to the TGF-&#946; receptors with an antibody or (ii) preventing the type I TGF-&#946; receptor, also known as ALK5, from activating the SMADs using a small molecule kinase inhibitor. However, because of TGF-&#946;&#8217;s role in normal physiology, these approaches cause substantial toxicity and dysregulation of normal functions. For example, documented toxicities that arise from systemic inhibition of TGF-&#946; signaling include cardiac toxicity, inflammation and focal epithelial hyperplasia.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A potentially safer approach to fibrosis therapy is to inhibit specific pro-fibrotic signaling molecules, such as connective tissue growth factor and autotaxin, which operate downstream of TGF-&#946; activation, thereby mitigating the tolerability issues associated with systemic TGF-&#946; inhibition. While tolerability has been shown to improve with this approach, the efficacy shown to date has been modest, likely because TGF-&#946; activates multiple pro-fibrotic signaling pathways in addition to those targeted by these approaches.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another recent approach is to prevent TGF-&#946; activation by stabilizing TGF-&#946; in its inactive form. However, it is not known whethe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r latent TGF-&#946; stabilization can be accomplished in a tissue specific manner.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the historical difficulty in targeting TGF-&#946;, clinical development for the treatment of fibrosis has also been limited by the lack of tools to understand this complex multicellular process. Only certain parts of this process can be modeled using cellular assays. More complete representations of fibrosis can be generated in animal models, but these models tend to be acute in nature and do not accurately represent disease pathology in humans which, in most cases, develops over decades. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Integrin Inhibitors as a Potential Treatment for Fibrosis</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A targeted approach to fibrosis treatment would be one that inhibits TGF-&#946; activation in only those tissues where fibrosis is occurring. One potential way to accomplish this is to inhibit the integrin proteins that are known to be overexpressed in specific fibrotic tissue and cause the abnormal activation of TGF-&#946;. In several forms of fibrosis, namely IPF and PSC, TGF-&#946; activating integrins such as &#945;v&#223;6 and &#945;v&#223;1 are over-expressed. These integrins are normally </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expressed at low levels in healthy tissue. Therefore, it may be possible to avoid off-target toxicity effects by selectively inhibiting &#945;v&#223;6 and &#945;v&#223;1. By inhibiting fibrosis-specific TGF-&#946; activators such as these specific integrins, it is possible to block abnormal TGF-&#946; activation in the specific tissues where fibrosis occurs, without affecting TGF-&#946; signaling in healthy tissues. However, integrin drug development has historically been challenging due to the difficulty of developing small molecule integrin inhibitors that are both selective for specific integrins and bioavailable. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilizing our proprietary discovery and development capabilities, we believe that we have overcome key historical challenges to the development of integrin inhibitors, including potency, selectivity and bioavailability. We have identified two bioavailable and highly potent and selective integrin inhibitors. Our lead product candidate, PLN-74809, has demonstrated good oral bioavailability with a once daily oral dosing profile in Phase 1a trials, and demonstrated target engagement in an interim analysis from our Phase 2a PET ligand trial. We also believe our integrin library, integrin screening assay platform, live fibrotic human tissue program, PET-ligand imaging program and use of novel disease biomarkers provide a robust platform to drive future drug discovery and development.</span></div><div style="margin-top:6pt;text-indent:56pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Our Capability and Approach to Fibrosis Drug Discovery and Development</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to drug development in fibrosis combines our deep knowledge of the biology of fibrosis with various cellular, tissue, and </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assays developed in house to interrogate the biology of fibrosis and uncover pathways and potential targets. We developed an extensive panel of cell assays, precision cut tissue assays and animal models covering various types of fibrotic diseases. These assays allow us to evaluate target expression in fibrotic tissues as well as the anti-fibrotic activity of our candidates after treatment and begin to establish proof-of-biological-mechanism in both animal models and human tissue prior to initiating clinical trials. We believe these collective capabilities uniquely allow us to (i) efficiently identify targets, (ii) optimize the potency and selectivity of candidates and (iii) de-risk product candidates in advance of human proof-of-concept.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first tool we use in our discovery process is our target expression atlas. Utilizing samples from normal and fibrotic human tissue, we developed a quantitative atlas of gene and protein expression across multiple fibrotic diseases. This database represents a wealth of data that we use to quantify expression of tissue specific targets for potential therapeutics. The atlas is continuously expanding through acquisition of additional samples as well as additional analyses. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second important tool in our discovery process is our compound library that we screen for activity against targets identified through our target atlas. While we are agnostic to treatment modality, our initial targeted chemistry effort has been focused on integrin inhibitors, and our medicinal chemistry team has developed a proprietary library of over 10,000 integrin binding molecules. The goal of the library is to maximize structural diversity while targeting optimal absorption, distribution, metabolism and excretion, or ADME, properties. We expect that the library will continue to grow as we investigate new structures. We have designed the library based on in silico known X-ray structures/homology models, structure-activity relationships of structural motifs of known integrin inhibitors, and de novo molecular design. In addition to our proprietary integrin inhibitor library, we have a non-integrin compound library of over 70,000 compounds that we screen against non-integrin targets.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once we have identified a potential target through our target expression atlas, we screen our library of compounds against the target. We have developed screening assays for all 24 known integrins and use these assays to evaluate the potency and selectivity of binding for our potential drug candidates prior to preclinical studies. Given the selectivity and potency challenges that have hampered integrin drug development, we believe our integrin assay panel represents a major step forward in integrin-based drug development.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe a key advantage of our development strategy is our ability to test our product candidates in live human fibrotic tissue, which helps us to bridge the gap between animal models and clinical proof-of-concept. We have developed proprietary protocols that extend the viability of live human explant tissue samples which allow us to reproducibly perform multiday experiments. Our access to these live tissue samples allows us to evaluate the effects of our product candidates on multiple markers of anti-fibrotic activity. The data from these experiments increase our confidence that the tested product candidates will show anti-fibrotic effects in patients. In this way, our human tissue program serves to further de-risk product candidates and increase their likelihood of success in the clinic.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once in clinical development, we seek to further de-risk our programs by designing clinical trials that allow us to show proof-of-mechanism in advance of clinical efficacy data. Because fibrosis is a chronic disease, proof-of-efficacy in human trials is expensive and takes relatively large patient numbers and years to demonstrate statistically relevant safety and efficacy data. We utilize pharmacodynamic biomarkers and advanced imaging techniques, including PET, to evaluate target engagement by our product candidates over relatively short time periods and observe whether the product candidate is having the anticipated effect. We believe obtaining these clinical data points in an efficient manner allows us to optimize our clinical development strategy and resource allocation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners also proactively conduct observational, natural history trials in target diseases to better understand disease pathophysiology and progression and develop new molecular biomarkers. Through these trials, we have gone on to develop patient registries and establish relationships with clinicians at leading medical research institutions dedicated to bringing novel fibrosis therapies to their patients.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing an extensive biomarker discovery and validation program. We are seeking to develop biomarkers to (i) identify patients at high risk of rapid disease progression, (ii) identify patients more likely to respond to treatment and (iii) monitor early treatment responses. We are conducting clinical studies and other research with leading academic centers to track disease progression and collect biological samples such as blood, urine, and tissue biopsies which we can use to discover and validate novel biomarkers.</span></div><div style="margin-top:6pt"><img src="plrx-20211231_g4.jpg" alt="plrx-20211231_g4.jpg" style="height:248px;margin-bottom:5pt;vertical-align:text-bottom;width:652px"/></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Systematic Approach to Identifying and Targeting Integrins in Fibrosis</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selective inhibition of TGF-&#946; activation in fibrotic tissues could potentially be the safest and most effective approach to treating fibrosis. One way to accomplish this is to inhibit the integrin receptors that drive excessive activation of TGF-&#946;. Given the importance of integrins in regulating the initial steps in fibrosis, we have focused our initial drug discovery efforts on a dual approach. This approach includes both biological profiling to identify which integrins are important in various diseased tissues and chemical profiling of libraries containing proprietary integrin inhibitors to help determine their selectivity and potency for individual integrins.  </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilizing our extensive in-house medicinal chemistry expertise, we have created a library of over 10,000 integrin binding molecules. We screen this library against the integrin targets that we identify through our expression atlas and or biological profiling process. To our knowledge, this type of industrial-scale, systematic biological and chemical profiling, seeking selective inhibitors of one or more integrins, has not previously been carried out. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Central to our integrin inhibitor discovery process are our integrin assay panels. A key challenge in integrin inhibition, historically, has been selectivity for specific integrins. To address this challenge, we have developed assays against all known integrins. We use these screening assays to measure potency and selectivity of potential candidates against these integrins. This allows us to quickly optimize the integrin binding profiles of potential development candidates in an iterative process.  </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our deep understanding of integrin biology, we have gained significant insight in structure-activity relationships that determine integrin selectivity and optimal pharmacokinetic, or PK, profiles. Utilizing this knowledge, we are now able to precisely engineer bioavailable integrin inhibitors with high potency and desired selectivity.  </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our integrin inhibitor profiling capability has enabled us to quickly identify inhibitors that target individual integrins such as PLN-1474, which selectively inhibits &#945;v&#223;1, as well as dual inhibitors such PLN-74809 which selectively targets both &#945;v&#223;6 and &#945;v&#223;1. Combining the data from our biological profiling and chemical profiling sets has enabled us to identify compounds that we believe have the highest potential for therapeutic activity in specific fibrotic diseases. Our iterative drug discovery effort focuses on drug-like properties of compounds early in the testing process. Compounds are screened for </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potency/selectivity and ADME/PK properties. This enables us to move from compound optimization to </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing in a matter of months.  </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our broad proprietary library of integrin binding compounds to identify additional product candidates to treat fibrotic diseases. Furthermore, our approach allows us to use our discovery and development capabilities to develop non-integrin therapeutic modalities to treat fibrotic diseases. Our rich library also provides a deep </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">series of potential backup molecules with structurally unique chemotypes that we believe can enhance the probability of clinical success.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with all development efforts, a key approach to preclinically de-risking our integrin inhibitor candidates is evaluation of candidates in live human fibrotic tissue obtained following transplant procedures. The ability to observe effects of our product candidates on gene expression in human tissues prior to entering the clinic provides a bridge from animal models to clinical proof-of-concept and helps give us additional confidence as we move toward human trials. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As fibrosis is a chronic disease, proof-of-efficacy in human trials is expensive and takes years to complete. We utilize pharmacodynamic biomarkers and advanced imaging techniques, including PET, to evaluate target engagement by our product candidates over relatively short time periods and de-risk our programs by designing clinical trials that allow us to show proof-of-mechanism in advance of clinical efficacy data. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using &#945;v&#223;6 PET ligand imaging technology in our ongoing Phase 2a PLN-74809 trial to evaluate the level of &#945;v&#223;6 expression in the lungs of IPF patients, as well as to measure our product candidate&#8217;s ability to bind &#945;v&#223;6. In September 2021, we released positive interim data from this ongoing trial demonstrating PLN-74809&#8217;s ability to penetrate highly fibrotic lung tissue and bind to &#945;v&#223;6. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the &#945;v&#223;6 PET ligand, we have developed an &#945;v&#223;1PET tracer to evaluate the level of &#945;v&#223;1 expression in fibrotic tissues, as well as to measure the ability of our product candidates to penetrate fibrotic tissues and bind to &#945;v&#223;1. We filed an IND for this program in December 2020 and the U.S. Food and Drug Administration, or FDA, has since issued a &#8220;safe to proceed&#8221; letter. We have initiated a Phase 1 clinical trial of our &#945;v&#223;1 PET ligand.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idiopathic Pulmonary Fibrosis Background</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPF is a debilitating, age-related lung disease of unknown causes that has few treatment options. It is a form of progressive pulmonary fibrosis that leads to thickening and stiffening of the lung tissue resulting in the loss of lung function. As tissue scarring progresses, the lungs&#8217; ability to transfer oxygen into the bloodstream becomes increasingly impaired. Average life expectancy at the time of confirmatory diagnosis of IPF is estimated to be between three and four years. Approximately 60 to 80 percent of patients die within five years of diagnosis. These survival rates are worse than those of many late-stage cancers, such as stage 3 breast cancer.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with IPF experience debilitating symptoms, including shortness of breath and difficulty performing routine functions, such as walking and talking. Other symptoms include a chronic, dry, hacking cough; fatigue; weakness; discomfort in the chest; loss of appetite; and weight loss. IPF is a rare disease that affects approximately 140,000 people in the United States. There are an estimated 30,000 to 40,000 new cases diagnosed each year.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there is no pharmacological cure for IPF and only a small proportion of late-stage IPF patients may be eligible for a lung transplant. The current non-transplant standard of care aims to slow the disease progression and improve the quality of life. Two therapies to treat IPF have recently been approved by the FDA: Esbriet&#174; (pirfenidone), marketed by Roche Holding AG, and OFEV&#174; (nintedanib), marketed by Boehringer Ingelheim. After decades during which the FDA approved no new treatments for IPF, the approvals of pirfenidone and nintedanib represented a major breakthrough for IPF patients. However, while these therapies may help slow the decline of lung function, neither drug has been shown to stop the progression of IPF. We believe that, despite the approval of pirfenidone and nintedanib by FDA, there remains an unmet need for IPF patients that we plan to address through our product candidate.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite its mechanism of action being unknown, pirfenidone has been shown in registrational trials to have a modest effect on slowing the progression of IPF as measured by FVC, in approximately fifteen percent of patients. Recent studies suggest that pirfenidone may have an impact on survival compared to placebo, but these results have not been confirmed. In March 2020, the FDA granted breakthrough therapy designation for pirfenidone for treatment of unclassifiable lung fibrosis. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nintedanib is an inhibitor of multiple tyrosine kinases that are receptors for growth factors such as platelet- derived growth factor, or PDGF, fibroblast growth factor, or FGF, and vascular endothelial growth factor, or VEGF. Nintedanib reduced the rate of decline of pulmonary function in multiple trials by approximately half and led to significant delays in the time to acute disease exacerbation. While treatment was associated with a trend towards increased survival in registration trials, it has not been shown conclusively to have a survival benefit. Recent exploratory analyses from pooled data from six clinical trials of nintedanib suggest that nintedanib may extend life expectancy in patients with IPF. The FDA approved nintedanib for the treatment of lung fibrosis associated with systemic sclerosis in September 2019, and for the treatment of chronic fibrosing interstitial lung disease, or ILD with a progressive phenotype in March 2020.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevated liver enzymes have been observed with both of these drugs, requiring monitoring of liver tests and potentially temporary dose reduction and discontinuation. Cases of drug-induced liver injury, including one fatal outcome, have been reported in patients treated with nintedanib. Pirfenidone&#8217;s prescribing information also carries a similar warning about elevated liver enzymes. Despite the remaining unmet need, combined sales of pirfenidone and nintedanib in 2020 were over $3.6 billion. IPF remains a major cause of morbidity and mortality and an area of high unmet medical need for which a commercial opportunity remains.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Primary Sclerosing Cholangitis Background</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSC is a progressive liver disorder characterized by inflammation and fibrosis of the bile ducts which transport bile from the liver to the intestines. This type of fibrosis often results in obstruction or interruption of bile flow from the liver, a condition known as cholestasis, leading to liver fibrosis. Cirrhosis eventually develops and many individuals ultimately require a liver transplant. PSC patients are also at a higher risk of developing hepatobiliary cancers, including a 5 to 20 percent lifetime chance of developing cholangiocarcinoma, a typically rare form of cancer with an especially poor prognosis. The exact cause of PSC is unknown. PSC is normally diagnosed at middle age, with a median age at diagnosis of approximately 40 years old. The prevalence of PSC in the United States is estimated to be between 30,000 and 45,000 patients.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of liver transplant, median survival of PSC patients is 10 to 12 years following diagnosis without intervention. There are currently no approved pharmacological treatments for PSC. A number of immunosuppressive and anti-inflammatory agents have been studied in patients with PSC, but none has been conclusively proven to slow progression. Liver transplantation is the only available treatment for PSC patients; however, disease has been shown to recur in up to 20 percent of patients following transplantation.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution, PLN-74809</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLN-74809 is an oral small-molecule that selectively inhibits both &#945;v&#223;6&#160;and &#945;v&#223;1&#160;integrins that we are developing as a potential therapy for IPF and PSC. We have determined that TGF-&#946; activation in fibrosis associated with IPF and PSC involves both &#945;v&#223;6&#160;and &#945;v&#223;1&#160;integrins. It has been shown that expression of both &#945;v&#223;6&#160;on epithelial cells and &#945;v&#223;1&#160;on fibroblasts can lead to excessive activation of TGF-&#946; in fibrosis. Epithelial tissue includes any tissue that lines the surfaces of the body such as alveoli, bile ducts, urinary tract, skin, and gastrointestinal tract. Each of these tissues contains multiple cell types including epithelial cells and fibroblasts. An important secondary effect of the TGF-&#946; cascade is that it promotes upregulation of&#160;&#945;v&#223;1&#160;on epithelial cells. The increased expression of these integrins on the cell surface contributes in turn to further TGF-&#946; activation in a TGF-&#946;-driven positive feed-forward loop.</span></div><div style="margin-top:6pt"><img src="plrx-20211231_g5.jpg" alt="plrx-20211231_g5.jpg" style="height:271px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Epithelial tissue fibrosis is driven by two types of integrins</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from our lab, as well as scientific literature, have shown that &#945;v&#223;6&#160;and &#945;v&#223;1&#160;proteins are overexpressed in at least two different fibrosis indications: IPF and PSC. In lung tissue from IPF patients we and others have shown that alveolar epithelial cells have elevated &#945;v&#223;6&#160;expression, and that the level of over-expression correlates with disease severity. We have also shown that in these patients, &#945;v&#223;1&#160;expression is upregulated. In liver tissue from PSC patients, we have shown that &#945;v&#223;6&#160;is upregulated in cholangiocytes, the epithelial cells that line the bile ducts, and that &#945;v&#223;1&#160;is upregulated in whole fibrotic liver tissue. &#945;v&#223;6&#160;and &#945;v&#223;1&#160;are normally expressed at very low levels in healthy tissue making them ideal targets for selectively inhibiting TGF-&#946; activation in IPF and PSC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g6.jpg" alt="plrx-20211231_g6.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#945;v&#223;6&#160;is upregulated in the lung tissue of IPF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">patients and the liver tissue of PSC patients</span></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g7.jpg" alt="plrx-20211231_g7.jpg" style="height:237px;margin-bottom:5pt;vertical-align:text-bottom;width:477px"/></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">= p &lt; 0.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="padding-left:67.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) A p-value is the probability that the reported result was achieved purely by chance, such that a p-value of less than or equal to 0.05 or 0.01 means that there is a 5.0% or 1.0% or less probability, respectively, that the difference between the control group and the treatment group is purely due to chance. A p-value of 0.05 or less typically represents a statistically significant result.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#945;v&#223;1&#160;expression is upregulated in lung and liver fibrosis</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted a non-interventional clinical trial in IPF patients to assess the expression of integrin &#945;v&#223;6&#160;using a PET ligand. This trial confirmed that patients with IPF have high levels of integrin &#945;v&#223;6&#160;expression, which tend to be co-localized with fibrotic regions of the lungs. This trial was published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Communications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2019. The specificity of this PET ligand can be seen in images from an IPF patient who received a unilateral lung transplant. The PET ligand is only taken up in the diseased lung but not in the transplanted healthy lung.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g8.jpg" alt="plrx-20211231_g8.jpg" style="height:222px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonary &#945;v&#223;6&#160;PET ligand uptake in an IPF patient with a unilateral lung transplantation is confined to the IPF lung</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have shown that inhibition of both &#945;v&#223;6&#160;and &#945;v&#223;1&#160;integrins is required to maximally inhibit the expression of&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL1A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a key gene that encodes type I collagen, in models of lung and biliary fibrosis as well as in human IPF tissue.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL1A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is a TGF-&#946; regulated gene that is expressed in fibrotic tissue. The expression level of&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL1A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;correlates with the amount of collagen deposited as measured by the standard biochemical method of quantification of hydroxyproline, an amino acid that is a major component of collagen.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development of PLN-74809</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current and Planned Clinical Trials for IPF and PSC</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting three Phase 2a trials of PLN-74809, two in patients with IPF and one in patients with PSC, subject to the impact of the COVID-19 pandemic. The first of these is an ongoing Phase 2a randomized, double-blind, placebo-controlled IPF trial evaluating up to three doses of PLN-74809 in IPF patients. We are exploring doses up to 160 mg per day at the highest dose. This is a 12-week trial evaluating safety and tolerability, as well as PK in IPF patients. We plan to evaluate exploratory endpoints including pulmonary function tests, biomarkers and imaging, including Quantitative Lung Fibrosis HRCT imaging, or QLF. This is a multinational trial with approximately 60 sites in the United States, Canada, Australia, New Zealand and multiple countries in Europe. This trial has completed enrollment and data release is expected in mid-2022.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the FDA authorized evaluation of long-term dosing of PLN-74809 up to 320 mg in patients with IPF. This appr</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oval enables the evaluation of PLN-74809 in larger, long-term pivotal trials in IPF. We initiated a 6-month Phase 2a trial of PLN-74809 at 320 mg in IPF patients in the first quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12-Week Safety, PK, Biomarker Trial in IPF Patients</span></div><div><span><br/></span></div><div><img src="plrx-20211231_g9.jpg" alt="plrx-20211231_g9.jpg" style="height:219px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Design of 12-week Phase 2a IPF Trial</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our 12-week Phase 2a IPF trial, we will utilize QLF as a biomarker for early detection of changes in lung fibrosis. QLF is a fibrosis biomarker assessed using high resolution computerized tomography, or CT, imaging and utilizes quantitative image analysis to measure the density of lung tissue and quantify the volume of fibrosis present in the lung. QLF technology was developed by MedQIA, and has been evaluated in over 5,000 ILD patients, showing an ability to predict FVC decline in patients with IPF. While we will measure both endpoints, we believe QLF may allow us to detect changes in lung fibrosis in a more specific way than FVC.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QLF has been utilized in recent clinical trials to evaluate early treatment effects in the amount of lung fibrosis present. In Biogen&#8217;s Phase 2a trial of BG00011, a mAb targeting &#945;v&#223;6, dose-dependent trends in QLF were seen at 8 weeks, with the 1 mg/kg cohort showing a decrease in the amount of fibrosis present with a r=-0.49 correlation to FVC.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, FibroGen utilized QLF in their Phase 2 trial of pamrevlumab, their anti-CTGF mAb, in IPF. FibroGen showed 71% and 50% reductions in progression of fibrosis versus placebo at 24 and 48 weeks, respectively, as measured by QLF. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a 12-week Phase 2a randomized, double-blind, placebo-controlled trial of PLN-74809 in PSC patients. We are evaluating up to three cohort doses of PLN-74809 (40 mg, 80 mg or 160 mg) or placebo. This is a multinational trial with approximately 60 sites in the United States, Canada, Australia, New Zealand and multiple countries in Europe. This trial is currently on track to complete enrollment by mid-2022, with data readout expected by late 2022 or early 2023.</span></div><div style="margin-top:6pt;text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12-Week Safety, PK, Biomarker Trial in PSC Patients</span></div><div style="margin-top:6pt;text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Design of 12-week Phase 2a PSC trial</span></div><div style="margin-top:6pt;text-align:center"><img src="plrx-20211231_g10.jpg" alt="plrx-20211231_g10.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints for our Phase 2a PSC trial will be safety and tolerability, as well as PK. We will also employ exploratory endpoints including fibrosis biomarkers including PRO-C3 and ELF, which are predictive of transplant-free survival in PSC patients, change in alkaline phosphatase and liver imaging. Regulators have suggested that composite endpoints including biomarkers such as alkaline phosphatase, PRO-C3 and ELF coupled with liver histology may support approval in PSC. Both Gilead and Dr. Falk Pharma are including liver histology as a primary endpoint in their respective Phase 3 PSC trials. NGM Biopharmaceuticals, Inc., or NGM, showed dose-dependent changes in PRO-C3 and ELF at 12 weeks in its Phase 2a PSC trial, with levels returning to baseline after the removal of treatment.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also conducting an open-label trial utilizing a PET ligand to &#945;v&#223;6 that allows imaging of target engagement by PLN-74809 in the lungs of IPF patients during treatment. Patients will receive a single dose of PLN-74809 across a dose range starting at 60 mg. We will obtain a PET scan at baseline to evaluate &#945;v&#223;6 expression levels in the patients&#8217; lungs and then initiate treatment with PLN-74809. A post-treatment PET scan will be performed at approximately three hours after administration of the dose, which will enable us to evaluate PLN-74809&#8217;s target engagement in patients&#8217; lungs at maximum drug concentration. Images are analyzed for regions of high fibrotic activity, which are then evaluated for target engagement. Following completion of a standard washout period, patients may consent to receive a second dose of PLN-74809 at a different dose level followed by a second post-dose PET scan.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When PLN-74809 binds to the &#945;v&#223;6 receptor, we would expect to see decreased PET ligand uptake in the lungs post-treatment when compared to pre-treatment levels. The relationship between dose and target engagement is important to confirm penetration of PLN-74809 into fibrotic tissue, establish a PK/pharmacodynamic, or PD, relationship between PLN-74809 plasma exposure and &#945;v&#223;6 target engagement, link biological activity shown in Phase 1b healthy volunteer BAL study to &#945;v&#223;6 target engagement in IPF lungs and guide dose selection in future studies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced positive interim results from the Phase 2a PET imaging trial of PLN-74809 in September 2021. Each patient across the four dose cohorts tested achieved target engagement levels of greater than 50% in the most fibrotic portions of their lungs after only one dose of PLN-74809. Target engagement of 50% was previously established in a Phase 1b trial as the threshold for predicted clinical anti-fibrotic effect. In addition, there was a dose- and plasma concentration-dependent response with the two highest doses approaching target saturation. PLN-74809 was well tolerated in the trial with no serious adverse events reported. The interim data confirm that PLN-74809 penetrates the highly fibrotic lung tissue of IPF patients, and potently binds to its target. The data allow us to construct a full exposure curve model, decoding our ongoing Phase 2a trials and guiding future clinical development of PLN-74809.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four IPF patients were administered six single doses of PLN-74809 across cohorts of 60 mg, 120 mg, 240 mg and 320 mg, generating a total of six patient scans. Single doses of 60 mg, 120 mg and 240 mg were predicted to achieve serum concentrations similar to those seen at Cmax at steady state for doses of 40 mg, 80 mg and 160 mg, respectively, which the Company is studying as part of its ongoing Phase 2a INTEGRIS-IPF trial in IPF patients. Preliminary results are as follows: </span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLN-74809 Demonstrated Lung Penetration, with Greater than 50% Target Engagement Achieved in the Lungs of All IPF Patients Across All Dose Cohorts</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Up to 98% target engagement of PLN-74809 achieved</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Greater than 50% target engagement of PLN-74809 achieved across all doses</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Dose and Plasma Concentration Response Established</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">PLN-74809 achieved a dose response across all single-doses from 60 mg to 320 mg</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Suggests target engagement levels along the entire exposure curve of PLN-74809</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">Supports potential anti-fibrotic activity of PLN-74809 at the doses being evaluated in the ongoing Phase 2a INTEGRIS-IPF trial</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLN-74809 Well-Tolerated Across All Doses</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">No serious adverse events reported</span></div><div style="margin-top:6pt;padding-left:90.36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><img src="plrx-20211231_g11.jpg" alt="plrx-20211231_g11.jpg" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:373px"/></div><div style="margin-top:6pt;text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLN-74809 Percent Target Engagement Across Multiple Single-Dose Cohorts</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Potential Development Plans for PLN-74809 in Pulmonary and Hepatic Indications</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently exploring the potential effects of PLN-74809 in fibrotic diseases outside of IPF and PSC and may choose to explore the development of PLN-74809 in additional indications in the future. For example, we believe PLN-74809 could provide anti-fibrotic benefits in several pulmonary and hepatic fibrosis diseases where there is over-expression of &#945;v&#223;6, including pulmonary fibrosis associated with systemic sclerosis, pulmonary fibrosis associated with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rheumatoid arthritis, pulmonary fibrosis associated with other forms of interstitial lung disease, primary biliary cholangitis, or PBC, biliary atresia and progressive familial intrahepatic cholestasis, or PFIC. Additionally, we believe that PLN-74809 could provide anti-fibrotic benefits in the setting of end-stage renal disease.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 Trials</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed an extended Phase 1a first-in-human, or FIH, SAD/MAD and food effect clinical trial of PLN-74809 in healthy volunteers. In the SAD portion of the trial, single doses of PLN-74809 were administered to 32 volunteers across four cohorts at doses of 15 mg, 30 mg, 50 mg and 75 mg. Eight additional volunteers in the SAD portion of the trial received placebo. In the MAD portion of the trial, PLN-74809 was administered orally to 27 volunteers, once-daily over 14 days at 10 mg, 20 mg, 40 mg. Six additional volunteers in the MAD portion of the trial received placebo. In the food effect part of the trial, PLN-74809 was administered to 12 volunteers, administered as a single dose with and without food. PLN-74809 was shown to be well tolerated with no dose-related adverse events. All but two adverse events reported in the entire trial were mild except for a moderate adverse event of dental abscess (SAD, 30 mg dose cohort) and a moderate adverse event of viral syndrome (MAD, 40 mg dose cohort). All adverse events resolved or recovered and no dose relationship for adverse events was observed. No notable findings were observed for laboratory abnormalities, vital signs, or ECG/telemetry.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since completing the Phase 1 FIH trial, we have conducted a Phase 1 extended dose escalation trial evaluating PLN-74809 at higher doses.&#160;This was a randomized, double-blind, placebo-controlled trial evaluating safety and tolerability as well as PK in 96 healthy volunteers at single doses up to 640 mg and multiple doses up to 320 mg. The PK profile of the higher dose cohorts remained in line with previous cohorts, and PLN-74809 remained well tolerated with no serious adverse events or severe adverse events reported in either cohort.</span></div><div style="text-align:center"><img src="plrx-20211231_g12.jpg" alt="plrx-20211231_g12.jpg" style="height:225px;margin-bottom:5pt;vertical-align:text-bottom;width:418px"/></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Participants</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">with Drug Related</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverse Events in PLN-74809</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">in Phase 1a Trials</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><img src="plrx-20211231_g13.jpg" alt="plrx-20211231_g13.jpg" style="height:237px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">PLN-74809 MAD Steady-State C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">max </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">and AUC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">0-24</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, PLN-74809 was well absorbed, and displayed a half-life of approximately 50 hours. PLN-74809 reached steady state plasma concentrations after seven days of dosing. Co-administration of PLN-74809 with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">food decreased drug concentrations relative to the fasted state, with AUC decreasing by approximately 40 percent and Cmax by approximately 50 percent.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also completed a Phase 1b proof-of-mechanism trial in healthy volunteers. The purpose of this randomized, double-blind, ascending-dose, placebo-controlled trial was to evaluate PLN-74809&#8217;s ability to inhibit TGF-&#946; activation in the lung as measured by pSMAD2 levels in pulmonary alveolar macrophages collected from bronchoalveolar lavage, or BAL, fluid and to further characterize the PK/PD relationship in humans. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enrolled 18 volunteers across four dose cohorts (each cohort randomized 3:1 active to placebo). Two cohorts were dosed at 20 mg once daily and two cohorts were dosed at 40 mg once daily. Volunteers underwent an initial BAL procedure prior to treatment to measure baseline pSMAD levels. They were then treated with PLN-74809 or placebo for seven days, after which they underwent two additional BAL procedures to measure the amount of pSMAD reduction post-treatment at multiple time points. By utilizing two cohorts each for the 20 mg and 40 mg doses, we were able to measure pSMAD and drug levels at 4 different time points post treatment for each dose (3-, 6-, 12- and 24-hours post-dose on day 7), allowing assessment of PK/PD relationship over a 24-hour period.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Phase 1b trial, 16 participants completed pre- and post-treatment BAL procedures. Four out of six participants (66%) receiving the high dose of PLN-74809 experienced mean reductions of 58.6% (6.9%) in pSMAD2 levels at six hours post-dose relative to baseline levels. Notably, all four of the volunteers in the high dose cohort with reductions in pSMAD2 levels also achieved plasma concentrations of PLN-74809 corresponding to the predicted plasma protein adjusted IC50 of 700 ng/ml. The two volunteers in the high dose cohort who did not achieve these concentrations did not experience reductions in pSMAD2 levels. In the low dose cohort, no volunteers achieved plasma protein adjusted IC50, and only one volunteer experienced significant reduction in pSMAD2 levels post treatment, relative to baseline levels. These results demonstrate PLN-74809&#8217;s effect on reducing TGF-&#946; activation in the lungs in a dose- and exposure-dependent manner, supporting a PK/PD relationship in humans. These data support the biological activity of PLN-74809 and guided dose selection and trial design of our ongoing Phase 2a trials.</span></div><div style="margin-top:6pt;text-align:center"><img src="plrx-20211231_g14.jpg" alt="plrx-20211231_g14.jpg" style="height:276px;margin-bottom:5pt;vertical-align:text-bottom;width:520px"/></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment with PLN-74809 was well tolerated with no drug-related adverse events. None of the adverse events reported were observed in more than one participant. In the 40 mg dose cohort, two trial participants discontinued treatment prematurely (one participant receiving PLN-74809 and one receiving placebo) and did not undergo post-treatment BAL procedures; these participants were subsequently replaced.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adverse Events Reported by Participants Receiving PLN-74809 in Phase 1b Trial</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:13.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#303b8d;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Groups</span></td><td colspan="3" style="background-color:#303b8d;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adverse Event</span></td><td colspan="3" style="background-color:#303b8d;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severity</span></td><td colspan="3" style="background-color:#303b8d;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Drug Related?</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="background-color:#d2cee4;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n = 6)</span></td><td colspan="3" style="background-color:#d2cee4;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deafness </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</span></div></td><td colspan="3" style="background-color:#d2cee4;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mild</span></td><td colspan="3" style="background-color:#d2cee4;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#e9e8ed;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frequent Bowel Movements</span></td><td colspan="3" style="background-color:#e9e8ed;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mild</span></td><td colspan="3" style="background-color:#e9e8ed;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#d2cee4;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Middle Ear Infusion</span></td><td colspan="3" style="background-color:#d2cee4;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mild</span></td><td colspan="3" style="background-color:#d2cee4;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="3" style="background-color:#e9e8ed;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n = 7) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">b</span></div></td><td colspan="3" style="background-color:#e9e8ed;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ECG QT Interval Elongated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">c</span></div></td><td colspan="3" style="background-color:#e9e8ed;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mild</span></td><td colspan="3" style="background-color:#e9e8ed;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">a- Unilateral earwax for 6 hr on day 1; subject completed 7 days dosing without recurrence or additional adverse events.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">b- One subject was replaced due to prolonged QT interval.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">c- ECG finding after first dose; baseline ECG abnormalities were already present.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="text-indent:54pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted an expanded Phase 1b proof-of-mechanism trial evaluating the inhibition of TGF-&#946; signaling as measured through relative pSmad2 levels in alveolar macrophages collected through bronchioalveolar lavage (BAL) at 6 hours and 24 hours after the last dose in the lungs of healthy volunteers. The trial was conducted in two parts. Part 1 evaluated PLN-74809 at doses of 80 mg and 160 mg once-daily versus placebo and Part 2 evaluated PLN-74809 at 320 mg once-daily versus placebo. In addition to safety and pharmacokinetics, the trial evaluated PLN-74809's ability to suppress TGF-&#946; activation in the lungs of healthy volunteers as measured through relative pSmad2 levels in alveolar macrophages collected through bronchioalveolar lavage (BAL) at 6 hours and 24 hours after the last dose. pSmad2 is a marker of TGF-&#946; activation. This trial further defines the relationship between plasma exposure of PLN-74809 and TGF-&#946; inhibition in the lung and will guide dose selection in future trials. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All PLN-74809 treatment groups across Part 1 and Part 2 showed pSmad2 suppression relative to placebo at 6 hours and 24 hours.</span></div><div style="text-align:center;text-indent:54pt"><img src="plrx-20211231_g15.jpg" alt="plrx-20211231_g15.jpg" style="height:255px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">pSmad2/Smad2 percentage change from baseline, delta versus placebo in Part 1 and Part 2</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part 1</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLN-74809 dosed at 80 mg once-daily demonstrated mean pSmad2 reductions of 41% and 37% from baseline at 6 and 24 hours, respectively, with up to 76% reduction seen at 24 hours. PLN-74809 dosed at 160 mg once-daily demonstrated pSmad2 reductions of 58% and 53% from baseline at 6 and 24 hours, respectively, with up to 92% reduction seen at 6 hours. Statistical significance (p &lt; 0.0001) was achieved at 24 hours for both the 80 mg and 160 mg doses when compared to placebo. Both the 80 mg and the 160 mg dose cohorts demonstrated exposures above the 50% target inhibitory concentration (IC50) of &#945;v&#946;6 for 24 hours after dosing.</span></div><div><img src="plrx-20211231_g16.jpg" alt="plrx-20211231_g16.jpg" style="height:222px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"></td><td style="width:2.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Alveolar pSmad2/Smad2 Percentage </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Change from Baseline at 24 hours </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:107%">(Part 1: 80 mg and 160 mg)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Mean PK/PD response </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:107%">(Part 1: 80 mg and 160 mg)</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part 2</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLN-74809 dosed at 320 mg once-daily demonstrated a mean pSmad2 reduction of 46% from baseline at 6 hours and a mean increase of 16% from baseline at 24 hours. The placebo group experienced a mean pSmad2 reduction of 8% from baseline at 6 hours and a mean increase of 151% from baseline at 24 hours. At both timepoints in the PLN-74809 arm, pSmad2 levels decreased relative to placebo. The Part 2 treated group showed exposures above IC50 of &#945;v&#946;6 for 24 hours after dosing.</span></div><div style="text-align:center"><img src="plrx-20211231_g17.jpg" alt="plrx-20211231_g17.jpg" style="height:280px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/></div><div style="text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alveolar pSmad2/Smad2 percentage change from baseline at 24 hours (Part 2: 320 mg)</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On Day 7 at 24 hours post dose, the placebo groups in both Part 1 and Part 2 showed mean pSmad2 increases of 74% and 151%, respectively. These increases in pSmad2 may have been associated with the 6 hour BAL procedure. All PLN-74809 treatment groups showed pSmad2 suppression relative to placebo at 24 hours, suggesting that PLN-74809 treatment was able to inhibit TGF-&#946; activation triggered by BAL procedures. Acute phase response following BAL procedures has been previously described in healthy volunteers and patients.</span></div><div><img src="plrx-20211231_g18.jpg" alt="plrx-20211231_g18.jpg" style="height:283px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of placebo and trial drug response in Part 1 and Part 2</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PLN-74809 was well-tolerated with mostly mild adverse events, and no severe adverse events. There was no dose relationship associated with adverse events, no serious adverse events (SAEs) and no treatment discontinuations due to adverse events. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 2022, more than 450 study participants, including healthy volunteers and patients, with no drug-related serious adverse events or severe adverse advents reported to date. The most common treatment emergent adverse events, or TEAEs, in PLN-74809-treated volunteers were mild headache (12/184 [6.5%] participants) and mild constipation (6/184 [3.3%] participants).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a wholly-owned PET tracer of the protein integrin of &#945;v&#223;1. We filed an IND in December 2020, and the FDA has since issued a &#8220;safe to proceed&#8221; letter. We plan to use this PET tracer to evaluate expression levels of &#945;v&#223;1 in various fibrotic tissues. Additionally, this tracer may allow us to evaluate tissue penetration and target engagement of developmental candidates that bind &#945;v&#223;1, similar to the current Phase 2a PET trial we are running in IPF.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLN-1474 and NASH</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLN-1474 is a selective inhibitor of &#945;v&#223;1 integrin that is in development for the treatment of liver fibrosis in patients with NASH. PLN-1474 is an orally bioavailable inhibitor that has shown anti-fibrotic activity in multiple animal models of liver fibrosis as well as in live human NASH fibrotic liver tissue. In October 2019, we entered into a license and collaboration agreement with Novartis under which Novartis received global rights to develop and commercialize PLN-1474 the treatment of NASH associated liver fibrosis. We have completed a first-in-human, randomized, double-blind, placebo-controlled Phase 1 dose escalation trial of PLN-1474 that enrolled 84 healthy volunteers across single ascending dose and multiple ascending dose cohorts. Results showed that PLN-1474 was well tolerated with no dose- or treatment-limiting toxicities with adverse events that were mostly mild with no severe or serious adverse events observed. The IND application for PLN-1474 was transferred to Novartis in the first quarter of 2021, and Novartis is responsible for all development, manufacturing and commercialization activities.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background on Liver Fibrosis and NASH</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NASH is a severe form of non-alcoholic fatty liver disease, or NAFLD, that is associated with the development of liver fibrosis and potentially life-threatening liver dysfunction. NAFLD is characterized by increased fat in the liver, or steatosis, and is believed to occur due to a combination of factors including high caloric diet, obesity and metabolic syndrome, type 2 diabetes mellitus and genetics. Early stages of the disease often have no symptoms other than slightly elevated or fluctuating levels of liver enzymes in some patients.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As excess fat builds up in the liver, it can cause inflammation and injury to the liver tissues. Over time, NASH can lead to fibrosis of the liver. Fibrosis can progress to cirrhosis, resulting in impaired liver function and increased risk of liver-related complications and mortality. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is estimated that 30 to 40 percent of adults in the United States have NAFLD and approximately 30 percent of these patients, or up to 12 percent of adults, will develop NASH. NASH is already highly prevalent, affecting approximately 16.5 million adults in the United States with approximately 3.3 million at stage F3/F4 liver fibrosis. NASH is a growing problem with U.S. cases expected to top 27 million by 2030, with approximately eight million at stage F3/F4 liver fibrosis.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Solution, PLN-1474</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLN-1474 is a bioavailable, small molecule, selective inhibitor of &#945;v&#223;1 mediated TGF-&#946; activation. PLN-1474 is an anti-fibrotic therapy for patients with liver fibrosis associated with NASH. We have shown that in human fibrotic liver tissue from patients with NASH that the levels of &#945;v&#223;1 are significantly elevated in tissue from patients with late-stage fibrotic disease. Overexpression of &#945;v&#223;1 is correlated with TGF-&#946; activation as measured by pSMAD3 levels. Therefore, we believe a single-selective inhibitor of &#945;v&#223;1 is a promising and differentiated approach to treating NASH associated liver fibrosis. In October 2019, we entered into a license and collaboration agreement with Novartis through which Novartis obtained a global license to PLN-1474. We have completed a Phase 1 trial of PLN-1474 in healthy volunteers with Novartis reimbursing us for all associated development activities. The IND application for PLN-1474 was transferred to Novartis in the first quarter of 2021, and Novartis is responsible for all development, manufacturing and commercialization activities.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Applying our Fibrosis Expertise in Developing Additional Products</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing potential uses of PLN-74809 in additional fibrotic indications. We use our precision cut human fibrotic tissue assays in addition to our animal model data to inform our clinical development programs and potentially select additional indications where we think our pipeline candidates could have an effect.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to advance the understanding of fibrosis by building a biology-, chemistry- and screening- based engine to drive drug development across the spectrum of fibrotic diseases. While our initial focus is on small molecule integrin inhibitors in lung and liver fibrosis, we are actively pursuing additional treatment modalities across fibrosis indications in multiple different organs. We have identified other potential non-integrin targets related to TGF-&#946; signaling as well as other pathways across multiple fibrosis indications, such as regulators of epithelial-to-mesenchymal transition, a critical process in fibrosis. In addition, while our initial focus is on small molecule drug candidates, we are agnostic to treatment modalities in the development of our pipeline.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Oncology Program-TGF-&#946; Signaling in the Tumor Microenvironment</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, the checkpoint inhibitor class of immuno-oncology drugs has changed the way many cancers are treated. Checkpoint inhibitors work to block signals that prevent the body&#8217;s immune system from recognizing tumor cells. By blocking checkpoint signals such as PD-1, these drugs have the ability to sensitize T-cells, allowing them to recognize and kill tumor cells. While checkpoint inhibitors have led to dramatic improvements in survival rates for certain cancer indications, there are still a significant proportion of patients who do not respond to the drugs. Much effort is being devoted to understanding the root causes of checkpoint inhibitor resistance.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As TGF-&#946; biology has been elucidated, it has become increasingly understood in the scientific literature that TGF-&#946; plays an important anti-inflammatory role in the tumor microenvironment. One of TGF-&#946;&#8217;s core physiologic roles is an anti-inflammatory effect that it provides in the wound healing process. In the tumor microenvironment, however, certain integrins, such as &#945;v&#946;8, can be overexpressed on multiple different cell types, resulting in increased activation and signaling of TGF-&#946;. This over activation of TGF-&#946; can lead to a strong anti-inflammatory effect in the tumor microenvironment, resulting in decreased T-cell infiltration and decreased release of pro-inflammatory cytokines such as granzyme B and interferon g. This mechanism is becoming increasingly recognized as a potential cause of the resistance to checkpoint inhibitors such as anti-PD-1 therapies seen in many tumors. We are targeting TGF-&#946; activating integrins such as &#945;v&#946;8 that are upregulated in certain tumors with the goal of removing the anti-inflammatory effect and, ultimately, sensitizing tumors to checkpoint inhibitors. This program has generated positive data in preclinical tumor models and our candidate is currently undergoing IND-enabling studies with IND submission expected by the end of 2022.</span></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g19.jpg" alt="plrx-20211231_g19.jpg" style="height:290px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:6pt;text-align:center;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Integrin Upregulation in the Tumor Microenvironment</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing small molecule inhibitors against &#945;v&#946;8 as well as other TGF-&#946;-activating integrins that have been shown to be upregulated in the tumor microenvironment. We have shown in an EMT6 anti-PD-1 resistant tumor mouse model that our small molecule inhibitors of &#945;v&#946;8-mediated TGF-&#946; activation are able to sensitize tumors to anti-PD-1 therapy and extend survival. We have shown in an EMT6 pancreatic cancer model that tumor growth inhibition by our lead &#945;v&#946;8 and &#945;v&#946;1 is significantly greater than what can be seen with an anti- &#945;v&#946;8 antibody. Additionally, our molecules perform similarly to monoclonal antibodies against the &#945;v&#223;8 integrin receptor. We are currently in preclinical stage of our oncology program.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="text-align:center"><img src="plrx-20211231_g20.gif" alt="plrx-20211231_g20.gif" style="height:234px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Small</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Molecule</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#945;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">v&#946;8</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inhibitors</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Enhanced</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PD-1 Activity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in an EMT6</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-PD-1 Resistant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Mouse Tumor Model</span></div><div style="text-align:center"><img src="plrx-20211231_g21.jpg" alt="plrx-20211231_g21.jpg" style="height:248px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lead &#945;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">V</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#946;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">8/1</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> Inhibitor Superior to Clinical Stage &#945;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">V</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#946;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">8</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> Antibody in Pan02 Pancreatic Mouse Syngeneic </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Model</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Muscular Dystrophy Program</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Muscular Dystrophy comprises a group of inherited diseases, all characterized by inborn errors in dystrophin, a protein that anchors muscle cells to the extracellular matrix, or ECM, and facilitates contraction of skeletal muscles. Mutations in the gene that codes for dystrophin can cause the dystrophin protein to be misshapen and ineffective in anchoring the muscle cell to the extracellular matrix. The lack of dystrophin anchoring results in damage to skeletal muscle cells upon contraction. Over time, muscle cells are unable to regenerate, and are eventually replaced by fat and fibrosis, resulting in loss of muscle function. Severe forms of muscular dystrophy cause progressive weakening of the heart and diaphragm, leading to death.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common form of muscular dystrophy is Duchenne muscular dystrophy, or DMD, which affects 1 in 3,500 boys worldwide. Disease progression varies, usually presenting with muscle weakness around age four. Most DMD patients need a wheelchair by age 12, with most dying in their 20&#8217;s. DMD is caused by mutations to the DMD gene, which codes for dystrophin.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment for DMD is mostly focused on mitigating the symptoms. Aggressive management of dilated cardiomyopathy with anti-congestive medications is used, including cardiac transplantation in severe cases. Assistive devices for respiratory complications may be needed, especially at night. The steroid prednisone is given to improve the strength and function of individuals with DMD. Prednisone has been shown to prolong the ability to walk by 2 to 5 years. While a new treatment, eteplirsen, was recently approved in a subset of patients, this remains an area of tremendous unmet medical need. There are a number of novel modalities such as gene therapy and CRISPR being explored as potential treatments for DMD, but they remain years from approval.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified a target integrin receptor that acts as a natural compensatory mechanism that anchors the muscle cell to the ECM in DMD, as well as other types of muscular dystrophy. It is expressed on the surface of skeletal muscle cells and has been shown to be upregulated in patients with muscular dystrophy. The target integrin is able to bind to laminin in the ECM and serve as a substitute for the dystrophin complex that normally holds muscle cells to the ECM. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This compensatory mechanism serves to stabilize the muscle cell membrane, which decreases muscle damage upon contraction. Moreover, mutations in this integrin, or in the laminin protein that it binds to, have been reported, and result in congenital myopathies with phenotypes similar to those of muscular dystrophy. Like other integrins, our integrin target can exist in various conformations, some of which are active, and others that are not. The natural compensatory ability of the target is limited by the number of integrin receptors in the active conformation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any given</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time.</span></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g22.jpg" alt="plrx-20211231_g22.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"/></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our muscular dystrophy program utilizes an allosteric, agonistic, monoclonal antibody which binds to the alpha subunit of the target integrin and stabilizes it in its active conformation. By maximizing the number of target integrins that are active, the mAb is designed to increase the overall binding of the muscle cell membrane to the ECM and to stabilize the membrane.</span></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g23.jpg" alt="plrx-20211231_g23.jpg" style="height:285px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allosteric agonistic monoclonal antibody binds to the inactive integrin inducing conformational change increasing laminin binding</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a humanized antibody that is highly potent and selective for the alpha subunit of the target integrin. Our mAb candidate has been tested in an mdx /DBA2 DMD mouse model where it showed significantly decreased muscle damage as measured through clinical biomarkers including serum creatinine kinase and troponin.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g24.gif" alt="plrx-20211231_g24.gif" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treatment with mAb resulted in decreased muscle damage in a mdx/DBA2 mouse model</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to protecting against muscle damage, the antibody showed an increase in diaphragm contractility in the mice tested. The antibody was able to return diaphragm contractility to near the same level as the wild type controls. This is crucial, given that the primary cause of death in patients with muscular dystrophy is cardiopulmonary failure resulting from progressive wasting of cardiac and respiratory muscles.</span></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g25.gif" alt="plrx-20211231_g25.gif" style="height:329px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agonistic mAb restored diaphragm force back to the same level </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> wild type control</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The antibody protected the gastrocnemius muscle from eccentric injury in which the muscle loses contractile force over a series of contractions. Interestingly, mice treated with an antibody that blocks the integrin receptor showed an increase in eccentric injury.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g26.jpg" alt="plrx-20211231_g26.jpg" style="height:168px;margin-bottom:5pt;vertical-align:text-bottom;width:603px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Integrin Agonistic Antibody Protected Gastrocnemius Muscle from Eccentric Injury While Antagonistic Antibody Increased Injury</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, our mAb showed a reduction in hydroxyproline levels in the gastrocnemius muscles of the test mice, suggesting less fibrosis in the muscles, possibly as a result of decreased muscle damage.</span></div><div style="margin-top:10pt;text-align:center"><img src="plrx-20211231_g27.jpg" alt="plrx-20211231_g27.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="margin-top:10pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agonistic mAb significantly reduced collagen content in gastrocnemius muscles of treated mice</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have nominated a development candidate and are currently conducting chemistry, manufacturing and controls, or CMC, scale-up activities. This program is currently undergoing IND enabling studies with IND submission expected by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused and continues to cause significant industry-wide delays in clinical trials. There are multiple causes of these delays, including reluctance of patients to enroll or continue in trials for fear of exposure to coronavirus, local and regional shelter-in-place orders and regulations that discourage, hamper, or prohibit patient visits, healthcare providers and health systems shifting away from clinical trials toward the acute care of COVID-19 patients and the FDA and other regulators making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to the pandemic.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">People living with IPF are considered at higher risk for developing serious illness if they become infected by the coronavirus. These patients may be instructed to avoid non-essential visits to medical centers, and to instead self-isolate at home. We have successfully implemented a hybrid approach to clinical trial participation with home-health solutions for both our IPF and PSC clinical trials designed to minimize the requirements for visits to healthcare facilities in order to mitigate COVID-19 infection risk in these vulnerable populations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We note the high level of difficulty in projecting the effects of the COVID-19 pandemic on our programs and our company, given the rapid and dramatic evolution in the course and impact of the pandemic and the societal and governmental response to it.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, strong competition and an emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific personnel provide us with competitive advantages, we face substantial competition from many different sources, including larger pharmaceutical companies with greater resources. Smaller specialty biotechnology and biopharmaceutical companies, academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies, including through collaborative arrangements with large and established biopharmaceutical companies. We also face competition in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and enrolling patients for clinical trials, and acquiring technologies complementary to, or necessary for, our programs. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, convenience, method of administration, cost, level of promotional activity and intellectual property protection.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of biopharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of fibrosis. Companies that we are aware of that are targeting the treatment of various fibrosis indications through inhibiting various parts of the TGF-&#946; pathway include large companies with significant financial resources such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie Inc., AstraZeneca plc, Bristol Myers Squibb Co., Corbus Pharmaceutical, DiCE Therapeutics, Inc., FibroGen, Inc., Gilead Sciences, Inc., Galapagos NV, Morphic Therapeutics, Inc., Novartis AG, and Takeda Pharmaceutical Company</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, we know of no other companies currently in clinical development with an orally bioavailable small molecule, selective integrin inhibitor.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to February 2021, Galapagos&#8217; Phase 3 autotaxin inhibitor GLPG-1690 and FibroGen&#8217;s Phase 3 monoclonal antibody against connective tissue growth factor, or CTGF, were the two most advanced development candidates for treatment of IPF. Galapagos announced that it terminated both of its Phase 3 trials of GLPG-1690 in IPF in February 2021 due to an unfavorable benefit-risk profile.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our novel approach is unique from most other existing or investigational therapies across the disease areas where we are focusing our development, we will need to compete with currently approved therapies, and potentially those in currently in development if they are approved. We are aware of several marketed and investigational products in our leading disease areas, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:59.5pt">IPF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: There are currently two approved products for the treatment of IPF; Esbriet, marketed by Roche Holding AG, and Ofev, marketed by Boehringer Ingelheim GmbH. Companies currently developing product candidates in IPF include AbbVie, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Endeavor Biomedicines,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FibroGen, Galapagos, Kadmon Holdings, Inc., Galecto Biotech, Inc., Roche Holding AG and Liminal BioSciences, Inc.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:59.5pt">PSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: There are currently no approved therapies for the treatment of PSC. Companies currently developing product candidates in PSC include Gilead Sciences, Inc., AbbVie Inc., Dr. Falk Pharma and Intercept Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:59.5pt">NASH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: There are currently no FDA-approved therapies for the treatment of NASH. There are a number of companies developing product candidates for the treatment of NASH including Intercept, Pfizer Inc., Gilead, AbbVie, Novartis, AstraZeneca plc, Eli Lilly &amp; Company, GlaxoSmithKline plc, Amgen, Inc., BMS, Johnson &amp; Johnson, Merck &amp; Co., Inc., Roche, Sanofi S.A., Takeda Pharmace</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uticals, Novo Nordisk, Genfit SA, Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Cirius Therapeutics, Inc., NGM Biopharmaceuticals, Akero Therapeutics, Inc. and Metacrine, Inc. Most of the drugs currently in development for NASH are focused on decreasing liver fat or improving liver inflammation as opposed to direct liver anti-fibrotic approaches.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our product candidates, if approved for marketing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we do, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of fibrosis that may be important for the development of our business. We additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity, and patent term extensions, where available.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, enforcement of these rights may depend on third party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 25, 2022, we own, co-own or license over 170 pending patent applications worldwide in over 20 patent families, including United States and corresponding foreign patent applications. As of February 25, 2022, four U.S. patents and one Japanese patent have issued to us that are generally expected to expire between the years 2037 to 2039, subject to possible patent term adjustment and/or extension. Our policy is to file patent applications to protect technology, inventions and improvements to inventions that are commercially important to the development of our business. We seek United States and foreign patent protection for a variety of technologies, including, research compounds and methods, candidate compounds and antibodies for modulating the activity of integrins, methods for treating diseases of interest, and methods for manufacturing our products. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel products. We seek protection, in part, through confidentiality and proprietary information agreements. We are a party to various other license agreements that give us rights to use specific technologies in our research and development.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company Owned IP</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own multiple families of patent applications that are directed to small-molecule compositions capable of modulating integrins and methods for treating or preventing diseases associated with integrins. Certain applications in these families relate to our PLN-74809 and PLN-1474 small-molecule product candidates, backup compounds and structural analogs, various unit dosages, dosing regimens, and routes of administration. We are also pursuing innovative ways to modulate integrin function using antibodies and have six pending patent application to that technology in the United States. Patents that may issue from these company owned applications are generally expected to expire between the years 2037 to 2042, subject to possible patent term adjustment and/or extension.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademark Protection</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two registered U.S. trademarks for use in connection with our products. We may pursue additional registrations for future products in markets of interest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secret Protection</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely, in some circumstances, on trade secrets to protect our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, we have established expertise and development capabilities focused in the areas of preclinical research and development, manufacturing and manufacturing process development, quality control, quality </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance, regulatory affairs, and clinical trial design and implementation. We believe that our focus and expertise will help us develop products based on our proprietary intellectual property.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Collaboration and License Agreement</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we entered into a collaboration and license agreement, or the Novartis Agreement, with Novartis Institutes for Biomedical Research, Inc., or Novartis, for the research, development, and commercialization of PLN-1474, and up to three additional integrin targets, or the Research Targets. Under the terms of the Novartis Agreement, we will be responsible for the clinical development and manufacture of PLN-1474 through the first-in-human study and Novartis will then be responsible for all future development, manufacturing, and commercialization. Following the completion of our Phase 1 clinical trial for PLN-1474, the PLN-1474 IND was transferred to Novartis in the first quarter of 2021.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research term, which shall initially be three years and extendable, we will collaborate, through a joint steering committee, with Novartis on up to three separate research programs, to biologically validate certain potential Research Targets and identify and synthesize potential research compounds for each Research Target in accordance with the applicable research plan. We will be responsible for advancing product candidates targeting selected Research Targets to development candidate stage and Novartis will then be responsible for all future development, manufacturing, and commercialization.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also granted to Novartis an (i) exclusive (even as to us), transferable, sublicensable license to certain of our technology to commercialize licensed products in the field and (ii) co-exclusive (with us), transferable, sublicensable license to research, develop and manufacture certain licensed compounds and licensed products for disease treatment worldwide. Upon the completion of the first Phase 1 study, such co-exclusive license shall become exclusive for Novartis.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Novartis Agreement, we have granted to Novartis and its affiliates an (i) exclusive (even as to us), transferable, sublicensable license to certain of our technology to commercialize certain research products in the field and (ii) a coexclusive (with us), transferable, sublicensable license to develop, manufacture, and commercialize certain selected research compounds and research products for disease treatment worldwide. Upon the selection of relevant candidate small molecule compound selective modulator, such co-exclusive license shall become exclusive for Novartis.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, we received an upfront, non-refundable license fee of $50.0 million and $25.0 million upon first patient dosed in our Phase 1 trial of PLN-1474. Additional contingent payments totaling $391.0 million are due to us upon achievement of specified research, development, regulatory and commercial events and Novartis shall pay us tiered royalties, on a product-by-product basis based on annual nets sales of products at percentages ranging from high-single digits to low teens of the applicable licensed products and mid-single digits to high-single digits for any products resulting from the research programs. Also, Novartis agreed to provide up to $19.6 million and up to $13.4 million in funding for the research and development activities associated with PLN-1474 and integrin research targets, respectively. As of December 31, 2021 approximately $2.0 million of aggregate research and development funding remains available for use under the arrangement. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Novartis Agreement will expire upon the expiration of all royalty obligations. The royalty period will expire on a product-by-product and country-by-country basis upon the later of (i) ten years from the first commercial sale, (ii) the expiration of all regulatory or data exclusivity and (iii) the expiration of the last-to-expire valid patent claim. Novartis has the right to terminate the Novartis Agreement for convenience on a target-by-target basis upon sixty (60) days&#8217; prior written notice, so long as such right is exercised prior to the first commercial sale of any licensed product or research product with respect to the applicable target. After the first commercial sale, Novartis has the right to terminate the Novartis Agreement for convenience on a target-by-target basis upon six (6) months&#8217; prior written notice. We may not terminate the agreement for convenience. Either we or Novartis may terminate the Novartis Agreement if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Novartis may terminate the Novartis Agreement in the event of specified insolvency events involving the other party. If we terminate the agreement as a result of Novartis&#8217; uncured material breach or Novartis terminates at will, we retain a royalty-bearing, non-exclusive license to certain Novartis technology in order to develop, manufacture and commercialize certain compounds and products as set forth in the Novartis Agreement, subject to certain conditions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adimab Collaboration Agreement</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a collaboration agreement, or the Adimab Agreement, with Adimab, LLC, or Adimab, for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Adimab </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has granted to us an exclusive option to acquire the rights to a number of discovered antibodies for development and commercialization as biopharmaceutical products. We have granted Adimab a non-exclusive, non-sublicensable license under our technology during each research program to perform Adimab&#8217;s responsibilities under such research plan.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we choose to exercise our option with respect to a specific research program, we are required to pay Adimab a non-creditable, non-refundable high six-figure option exercise fee, and milestone payments upon the achievement of certain clinical and regulatory milestone events in the development of therapeutic products and diagnostic products which use the antibodies we have obtained pursuant to our exclusive option of approximately $12 million for each therapeutic product. For any product that is commercialized pursuant to the Adimab Agreement, we are required to pay Adimab low single digit percentage tiered royalty payments based on annual aggregate worldwide net sales thresholds for such products, subject to reduction as specified in the Adimab Agreement. Royalty terms with respect to each product will expire on a country-by-country basis upon the later of (a) ten years after the first commercial sale of such product in such country and (b) the expiration of the last patent related to any antibody acquired by us pursuant to our option from a specified research program.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates, PLN-74809 and PLN-1474, are small molecule inhibitors amenable to standard formulation technologies. We have confirmed the utility of the synthetic process and manufactured multi-kilogram quantities sufficient to provide drug product for our clinical trials. The manufacturing process of the drug substance for such product candidates is robust and accessed from readily available starting materials. The synthetic route is amenable to large-scale production and does not require unusual equipment or handling during the manufacturing process. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate facilities for clinical drug manufacturing, storage, distribution, or quality testing. All of our clinical manufacturing is outsourced to third-party manufacturers. Our agreements with third-party manufacturers include confidentiality and intellectual property provisions as well as routine quality audits. We also rely on internal personnel with extensive cGMP manufacturing experience in order to ensure effective technology transfer and to manage the manufacturing and development processes conducted by third-party manufacturers. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established an adequate supply of the drug substance for PLN-74809 from our North American, European and Asian contract manufacturing organizations, or CMOs, to satisfy both our clinical and preclinical requirements. To mitigate supply chain risk and maximize flexibility, we have qualified two, geographically disparate CMOs for the manufacture of PLN-74809 active pharmaceutical ingredient and are currently engaging secondary raw material suppliers and drug product manufacturers to further mitigate global supply chain risk. The responsibility for manufacture and supply of drug substance for PLN-1474 has been transferred to Novartis pursuant to our collaboration and license agreement.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our development programs expand and we build new process efficiencies, we expect to continually evaluate this strategy with the objective of satisfying demand for our clinical trials and, if approved, the manufacture, sale, and distribution of commercial products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing. These agencies and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. government regulation of drug products</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The FDA also regulates biological products under the FDCA and the Public Health Service Act, or PHSA. If we advance clinical development of a biological product candidate in the future, these development activities will be subject to additional regulatory requirements specific to biological products. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending New Drug Applications, or NDAs, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Submission to the FDA of an NDA;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Payment of user fees and securing FDA approval of the NDA; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical studies</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing approval</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. An Agreed Initial Pediatric Study Plan requesting a waiver from the requirement to conduct clinical studies has been submitted to the FDA.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation and exclusivity</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. marketing exclusivity</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for the original non-modified version of the drug. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-approval requirements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products and the establishments where such products are manufactured, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted by a manufacturer and any third parties acting on behalf of a manufacturer only for the approved indications and in a manner consistent with the approved label for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other healthcare laws</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians, and third party payors play a primary role in the recommendation and prescription of drug products for which we obtain marketing approval. Arrangements with third party payors, healthcare providers and physicians, in connection with the clinical research, sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud and abuse and other healthcare laws and regulations. In the United States, these laws include, without limitation, state and federal anti- kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.85pt">the federal Anti-Kickback Statute, or AKS, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA. A conviction for violation of the federal Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal health care programs. Exclusion from the federal healthcare programs may also be imposed if the government determines that an entity has committed acts that are prohibited by the federal Anti-Kickback Statute. Although there are a number of statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.03pt">the federal civil and criminal false claims laws, including the FCA, which can be enforced through &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or statement for violations;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the creation, use, receipt, maintenance or disclosure of individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Physician Payments Sunshine Act, created under Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its implementing regulations, which require manufacturers of drugs, devices, biological products and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services, or CMS, under the Open Payments Program, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made during the previous year to certain non-physician providers such as physician assistants and nurse practitioners; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection, transparency and disclosure laws, and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws, it is possible that some of a pharmaceutical manufacturer&#8217;s business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that a pharmaceutical manufacturer&#8217;s business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, imprisonment, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations and oversight if a pharmaceutical manufacturer becomes subject to integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations, any of which could adversely affect a pharmaceutical manufacturer&#8217;s ability to operate its business and the results of operations. In addition, commercialization of any drug product outside the United States will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., numerous federal and state laws, and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For example, in June 2018, the State of California enacted the California Consumer Privacy Act of 2018, or the CCPA, which came into effect on January 1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA impacts certain of our business activities. The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic Area, or EEA, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, further to the UK&#8217;s exit from the EU on January 31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law (referred to as the 'UK GDPR'). The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. The UK, however, is now regarded as a third country under the EU&#8217;s GDPR which means that transfers of personal data from the EEA to the UK will be restricted unless an appropriate safeguard, as recognized by the EU&#8217;s GDPR, has been put in place. Although, under the EU-UK Trade Cooperation Agreement it is lawful to transfer personal data between the UK and the EEA for a 6-month period following the end of the transition period, with a view to achieving an adequacy decision from the European Commission during that period. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection (this means that personal data transfers from the UK to the EEA remain free flowing).</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, our operations may also be subject to increased scrutiny or attention from foreign data protection authorities. For example, our clinical trial programs and research collaborations in the EU may implicate the EU General Data Protection Regulation (EU) 2016/679 (EU GDPR) and certain national EU Member State laws amending the same. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU GDPR governs the processing of personal data (i.e., data which identifies an individual or from which an individual is identifiable), including clinical trial data (even in a key-coded form), and grants individuals various data protection rights (e.g., the right to erasure of personal data). The EU GDPR imposes a number of obligations on companies, including inter alia: (i) accountability and transparency requirements, and enhanced requirements for obtaining valid consent; (ii) obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; and (iii) obligations to implement appropriate technical and organizational measures to safeguard personal data and to report certain personal data breaches to the supervisory authority without undue delay (and no later than 72 hours where feasible). The EU GDPR also provides that EU Member States may introduce further restrictions at a national level, restricting the processing of genetic and/or health data, which could result in increased compliance costs / efforts. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the EU GDPR prohibits the transfer of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws unless a data transfer mechanism has been put in place. In July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield for purposes of international transfers and imposed further restrictions on use of standard contractual clauses (SCCs) (i.e., an EU-style data transfer agreement) including, a requirement for companies to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. Moreover, new versions of the SCCs (new EU SCCs) have recently been published requiring additional compliance and implementation efforts.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative fines for non-compliance with the EU GDPR can be significant and can amount to up to the greater of &#8364;20 million or 4% of annual worldwide turnover. The EU GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the EU GDPR. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relatedly, following the United Kingdom&#8217;s withdrawal from the EU (i.e., Brexit), the EU GDPR has been implemented in the United Kingdom (as the UK GDPR). The UK GDPR site alongside the UK Data Protection Act 2018 which implements certain derogations in the EU GDPR into UK law. The requirements of the UK GDPR are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines for non-compliance of up to &#163;17.5 million or 4% of annual worldwide turnover. As a result, we are potentially exposed to two parallel data protection regimes, each of which authorizes fines and the potential for divergent enforcement actions. It should also be noted that the new EU SCCs do not automatically apply in the UK since Brexit, and the UK Government has not yet formally acknowledged the new EU SCCs, i.e., as a valid data transfer mechanism under the UK GDPR. Indeed, on 11 August 2021, the UK Information Commissioner&#8217;s Office (ICO) launched a public consultation on its draft international data transfer agreement and guidance. This included the publication of a draft UK addendum that can be used with the new EU SCCs &#8211; however, this is not (at this time) finalized and as such, for the time being transfers from the UK to a third country should continue to be made in reliance on the &#8216;old&#8217; SCCs.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future healthcare reform legislation</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system. In the United States, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private payors, and significantly affected the pharmaceutical industry. The ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. There have been numerous historic judicial, administrative, executive, and legislative challenges and amendments (including recent amendments that expand access to care) to certain aspects of the ACA.  In June 2021, the Supreme Court dismissed a lawsuit challenging the constitutionality of certain aspects of the AC, without ruling on the meris of the constitutionality arguments.  In the future, there may be additional legislative, regulatory, executive, or judicial actions that result in healthcare reform. It remains to be seen precisely what any new reforms will provide, when or if they will be enacted, and what impact they will have on the availability and cost of healthcare items and services, including drug products. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative and regulatory changes have been proposed or adopted in the United States since the ACA was enacted, including several legislative and regulatory changes that are focused on capping or reducing healthcare costs, as well as measures that would address healthcare fraud and abuse, value-based care, drug pricing and other reforms. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative, regulatory and enforcement interest in the United States with respect to specialty drug pricing practices. For example, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control biopharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws, regulations, and actions, and any state or federal healthcare reform measures that may be adopted in the future, could reduce coverage or reimbursement Medicare and other government programs, may result in a similar reduction in coverage or payment from private payers, and may otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Additionally, we expect to experience pricing pressures in connection with the sale of any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals, and enactment of laws, at the foreign, federal, and state levels, directed at containing or lowering the cost of healthcare, will likely continue into the future.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rest of World Regulation</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product development, the conduct of clinical trials, manufacturing, distribution, marketing approval, product licensing, pricing and reimbursement vary from country to country. Additionally, clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, to the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Union clinical trials regulation</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, a Clinical Trial Application, or CTA, must be submitted for each clinical trial to each country&#8217;s national competent authority, or NCA, and at least one independent Ethics Committee, or EC, much like the FDA and an IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, the corresponding clinical trial may proceed. Under the current regime (the EU Clinical Trials Directive 2001/20/EC and corresponding national laws) all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, or Regulation, which entered into effect on January 31, 2022. The Regulation replaces the Clinical Trials Directive 2001/20/EC and overhauls the current system of approvals for clinical trials in the EU. Specifically, the Regulation is directly applicable in all Member States (meaning that no national implementing legislation in each EU Member State is required) and aims at simplifying and streamlining the approval of clinical trials in the EU. For instance, the new Regulation provides for a streamlined application procedure via a single-entry point and strictly defined deadlines for the assessment of CTAs. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to data privacy requirements, many jurisdictions have mandatory clinical trial information obligations on sponsors. In the EU this is under the Transparency Regulation No 1049/ 2001, EMA Policy 0043, EMA Policy 0070, as well as the Clinical Trials Regulation No 536/2014, all of which impose on sponsors the obligation to make publicly available certain information stemming from clinical studies. In the EU, the transparency framework provides for a wide right for (EU-based at the moment) interested parties to submit an access to documents request to the EMA for information included in the marketing authorization application dossier for approved medicinal products. Only very limited information is exempted from disclosure, i.e. commercially confidential information (which is construed increasingly narrowly) and protected personal data. It is possible for competitors to access and use this data in their own research and development programs anywhere in the world, once this data is in the public domain.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European drug review and approval</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain a marketing authorization in the European Economic Area, or EEA (comprising the EU Member States, plus Norway, Iceland, and Liechtenstein), a company may submit marketing authorization applications either under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by competent authorities in the EEA Member States (decentralized procedure, national procedure, or mutual recognition procedure). The centralized procedure is compulsory for certain medicines, including those produced by biotechnology, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue-engineered products) and those with a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, autoimmune and other immune dysfunctions, viral diseases, or diabetes. The centralized procedure is optional for those medicines which contain a new active substance, or which are a significant therapeutic, scientific, or technical innovation or whose authorization would be in the interest of public health. The centralized procedure provides for the grant of a single marketing authorization that is&#160;valid throughout the EEA. Under the centralized procedure, the maximum timeframe for the evaluation of a marketing&#160;authorization application, or MAA, by the EMA is 210 days, excluding clock stops, when additional written or oral&#160;information is to be provided by the applicant in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">response to questions asked by the Committee for Medicinal Products for&#160;Human Use, or CHMP. Clock stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days. Where&#160;the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European&#160;Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment. As far as pediatric marketing authorization applications are concerned, all applications for marketing authorization for new medicines have to include the results of studies as described in an agreed Pediatric Investigation Plan (PIP), unless the medicine is exempt because of a deferral or waiver.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the decentralized procedure, a medicinal product that has not yet been authorized in the EEA can be simultaneously authorized in several EEA Member States. The mutual recognition procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to other EEA Member States. Within 90 days of receiving the applications and assessment reports, each Member State involved must decide whether to recognize the approval. If a Member State does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain a marketing authorization in Switzerland, a company must submit a marketing authorization application to Swissmedic, Switzerland&#8217;s national authorization and supervisory authority for medicinal products and medical devices. There are no international agreements on mutual recognition of authorizations in relation to medicinal products. However, marketing authorization dossiers can be submitted to Swissmedic with clinical data, irrespective of the location where a clinical trial was conducted, that were collected in accordance with globally applicable international standards such as the Good clinical Practice (GCP) of the International Conference on Harmonization (ICH), which are based on the Declaration of Helsinki. Furthermore, if a medicinal product or procedure is already authorized in a country having equivalent medicinal product control, the results of tests carried out for this purpose shall be taken into account. According to Swissmedic's practice, this includes the authorization procedures of the following countries: Australia, the member states of the EU, the EFTA states in the EEA (Liechtenstein, Norway and Iceland), Japan, Canada, New Zealand, Singapore and the United States.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Now that the UK (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January 1, 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure. A separate application will, however, still be required.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MHRA has launched the Innovative Licensing and Access Pathway (ILAP), a new accelerated assessment procedure for marketing authorization applications that enables companies to enter the UK market faster.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European orphan drug designation and exclusivity</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the U.S., we may apply for designation of a product candidate as an orphan drug for the treatment of a specific indication in the EEA before the application for marketing authorization is made. The criteria for designating an &#8220;orphan medicinal product&#8221; in the EEA are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (1) is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; and (2) either the prevalence of such condition must not be more than five in 10,000 persons in the EU when the application is made, or without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the EU to justify the investment needed for its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Sponsors of orphan drugs can enjoy economic and marketing benefits, including a reduction of fees or fee waivers and up to ten years of market exclusivity for the approved indication which can be further extended by two years under certain circumstances; namely when the pediatric studies have been conducted in accordance with an agreed PIP and other requirements are satisfied. During such period of market exclusivity, marketing authorization applications for &#8220;similar medicinal products&#8221; will not be accepted, unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product, the marketing authorization holder consents to the second </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orphan medicinal product application, or where the marketing authorization holder cannot supply enough orphan medicinal product. In the EEA, a &#8220;similar medicinal product&#8221; is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify the maintenance of market exclusivity.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brexit and the Regulatory Framework in the United Kingdom</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020. A transition period began on February 1, 2020, during which EU pharmaceutical law remained applicable to the UK. This transition period ended on December 31, 2020. Since the regulatory framework in the UK covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the UK, as UK legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the UK in the long-term. The MHRA published detailed guidance for industry and organizations to follow which will&#160;be updated as the UK&#8217;s regulatory position on medicinal products evolves over time.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for medicines that existed before the end of the transition period following Brexit has been preserved in UK domestic legislation as &#8216;retained EU law,&#8217; which has prevented substantial divergence to the regulation of medicines. However, some changes to the UK legislation have been necessary, including the implementation of the Northern Ireland Protocol (NIP), pursuant to which the EU pharmaceutical legal framework continues to apply in Northern Ireland (subject to periodic consent of the Northern Ireland Legislative Assembly), and only products compliant with EU law can be placed in the Northern Ireland market. This dynamic adds an extra layer of regulatory complexity for companies withing to commercialize medicinal products in Great Britain (namely, England, Wales and Scotland, as EU law continues to apply in Northern Ireland), as such companies now need to comply with separate UK regulatory legal framework. The UK government is currently trying to renegotiate certain aspects of the Northern Ireland Protocol so this is an unpredictable area for companies in the near future. The Trade and Cooperation Agreement signed between the UK and the EU allows for future deviation from the current regulatory framework and it is not known if and/or when any deviations may occur, which may have an impact on development, manufacture, marketing authorization, commercial sales and distribution of pharmaceutical products.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of new drug products depends in part on the extent to which coverage and reimbursement, as applicable, for those drug products will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will cover and pay for and establish reimbursement levels. The availability and extent of coverage and reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which drugs are covered and the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or covered and reimbursed by government health administration authorities, private health coverage insurers and other third-party payors.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular drug products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the decisions about Medicare reimbursement for new drug products are typically made by CMS, an agency within the HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS coverage guidelines. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescription drugs. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each Part D prescription drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class and with some exceptions for certain classes of drugs. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs for which we obtain marketing approval. Any negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA Part D plan policies applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policies and payment limitations in setting their own payment rates coverage guidelines. Any reduction in payment restrictions in Part D coverage that results from the MMA may result in a similar reduction in payment restrictions from non-governmental payors.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the average manufacturer price, or AMP, and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the law these newly eligible entities (with the exception of children&#8217;s hospitals) will not be eligible to receive discounted 340B pricing on orphan drugs. As 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase. The 340B drug pricing program may be subject to future changes in light of ongoing litigation and attempts to reform the program. It is unclear how any such changes could affect our obligation to offer 340B pricing to certain entities.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. The outcome of HTA assessments is decided on a national basis and some payors may not reimburse the use of assessed products or may reduce the rate of reimbursement for such products. In December 2021, the EU adopted a new Regulation on Health Technology Assessment. The Regulation creates collaborative structures and procedures that allow Member States to carry out joint clinical assessments, effect joint clinical consultations and identify jointly emerging health technologies and will come into effect in 2025.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other countries may allow companies to fix their own prices for products but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had 91 full-time employees, including 37 with Ph.D. or M.D. degrees and 64 who are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements, and we have experienced no work stoppages. We consider our relationship with our employees to be good.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on skilled, experienced, and innovative employees to conduct the operations of our company and we continue to face intense competition for our personnel from our competitors and other companies throughout our industry. The biotechnology industry is very competitive and recruiting and retaining such employees is important to the continued success of our business. We are committed to building an outstanding, committed team and we focus on a culture that values a focus on scientific innovation, inclusion, collaboration, and equity. We believe that each employee brings unique perspectives and strengths, and by embracing these strengths, we can do our best work for patients. We focus on recruiting, retaining, and developing employees from a diverse range of backgrounds to conduct our research, development, and clinical activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our measures to attract and retain a highly skilled workforce, we provide a number of benefits to our full-time employees, including medical, dental and vision insurance, life insurance, 401k retirement program with a company match, flexible spending accounts, and paid holiday and vacation time. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development opportunities that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives. In addition, we regularly conduct an employee survey to gauge employee engagement and identify areas of focus.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we maintained the employee benefits enhancements that were implemented in response to the COVID-19 pandemic. For example, we increased company-wide flexible work arrangements, provided resources to enable employees to work from home, and introduced weekly onsite COVID-19 testing for all employees routinely working onsite. Our management has continued to assess and respond to the evolving needs of our workforce throughout the pandemic.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Available Information</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in June 2015. Our principal executive office is located at 260 Littlefield Avenue, South San Francisco, California 94080, and our telephone number is (650) 481-6770. Our website address is https://pliantrx.com.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file or furnish electronically with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make copies of these reports available free of charge through our investor relations website as soon as reasonably practicable after we file or furnish them with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information contained on or accessible through our websites is not incorporated into, and does not form a part of, this Annual Report or any other report or document we file with the SEC, and any references to our websites are intended to be inactive textual references only.</span></div><div id="i988625df783e4cc0a27bd76df388da57_1760"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses since our inception and have financed our operations principally through equity financing and our collaboration with Novartis. We continue to incur significant research and development and other expenses related to our ongoing operations. Our net loss was $97.3 million $41.5 million and $631,000 for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $215.1 million. We have devoted substantially all of our resources and efforts to research and development, and we expect that it will be at least several years, if ever, before we generate revenue from product sales. Even if we receive marketing approval for and commercialize one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses in order to further develop and, if approved, market additional potential product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant losses for the foreseeable future, and we anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">advance our lead product candidate, PLN-74809, and our other product candidates through clinical development, and, if successful, later-stage clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">discover and develop new product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">advance our preclinical development programs into clinical development;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">further develop manufacturing processes and manufacture our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">experience delays or interruptions to preclinical studies, clinical trials, our receipt of services from our third-party service providers on whom we rely, or our supply chain due to the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">commercialize PLN-74809, our other product candidates and any future product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">increase the amount of research and development activities to identify and develop product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">hire additional clinical development, quality control, scientific and management personnel;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development and manufacturing efforts and our operations as a public company;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">invest in or in-license other technologies or product candidates; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">continue to build out our organization to engage in such activities.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing, and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive, and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our planned clinical trials of PLN-74809 and any future product candidates that we may develop, seek regulatory approvals for our product candidates and to launch and commercialize any products for which we receive regulatory approval. We also expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce, or eliminate one or more of our research and drug development programs or future commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had approximately $200.6 million in cash, cash equivalents and short-term investments. Based on our current operating plan, we believe that our existing cash, cash equivalents and short-term investments, will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2023. However, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital in order to complete clinical development of any of our current programs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development, marketing, and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the clinical development plans we establish for these product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the timelines of our clinical trials and the overall costs to conduct and complete the clinical trials due to the COVID-19 pandemic;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost and capital commitments required for developing manufacturing processes for our product candidates and manufacturing our product candidates at clinical and commercial scales;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the number and characteristics of product candidates that we develop;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">whether we are able to maintain our existing collaboration with Novartis and enter into additional collaboration agreements and the terms of any such agreements;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also may be required to seek collaborators for any of our product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Market volatility resulting from the COVID-19 pandemic or other financial markets factors could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our ability to successfully recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may receive;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost of manufacturing our product candidates, which may vary depending on the difficulty of manufacture, quantity of production and the terms of our agreements with manufacturers;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our ability to attract, hire and retain qualified personnel;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">expenditures that we will or may incur to develop additional product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the level of demand for our product candidates should they receive approval, which may vary significantly;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future therapeutics that compete with our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">general market conditions or extraordinary external events, such as recessions or the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the changing and volatile U.S. and global economic environments; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">future accounting pronouncements or changes in our accounting policies.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Research and Development and the Biopharmaceutical Industry</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history. We were incorporated in 2015, have no products approved for commercial sale and have not generated any revenue from product sales to date. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product candidates and our technology related to transforming growth factor beta, or TGF-&#946;, signaling and integrin biology, medicinal chemistry, translational screening technologies, and clinical insights to discover and develop novel therapies for the treatment of fibrosis. Our approach to the discovery and development of product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value. In addition, our lead product candidate, PLN-74809, is in early clinical development for the treatment of IPF and PSC, and a second product candidate, PLN-1474, is in early clinical development. Both programs will require substantial additional development and clinical research time and resources, either from us or our collaborators, before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We have not yet demonstrated the ability to progress any product candidate through clinical trials. We are still in preclinical and early clinical development and may be unable to obtain regulatory approval, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields. Consequently, we have no meaningful history of operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing drug products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is highly dependent on the success of our lead product candidate, PLN-74809, as well as PLN-1474 and any other product candidates that we advance into the clinic. All of our product candidates will require significant additional preclinical and clinical development before we may be able to seek regulatory approval for and launch a product commercially.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We are very early in our clinical development for both PLN-74809 and PLN-1474. Because PLN-74809 is our lead product candidate, if PLN-74809 encounters safety or efficacy problems, development delays, regulatory issues or other problems, our development plans and business would be significantly harmed. We have completed various Phase 1 trials of PLN-74809. We are enrolling two Phase 2a trials in IPF, including a PET imaging trial. We are also conducting a Phase 2a PSC trial which is currently enrolling patients. We are also collaborating with Novartis to develop PLN-1474 for liver fibrosis associated with NASH and have completed a Phase 1a SAD/MAD study evaluating PLN-1474 in healthy volunteers. The IND for this candidate was transferred to Novartis in the first quarter of 2021, and Novartis is responsible for all PLN-1474 development, manufacturing, and commercialization activities after the initial development period. All of the risks and uncertainties that apply to PLN-74809 or any candidates that we develop independently apply equally to our collaborator with respect to advancement of PLN-1474. In addition, we also face risks resulting from our reliance on Novartis for development of this candidate. See &#8220;&#8212;Risks Related to Our Reliance on Third Parties.&#8221;</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can generate any revenue from sales of our lead product candidate, PLN-74809, or any of our other product candidates, we must undergo additional preclinical and clinical development, regulatory review, and approval in one or more jurisdictions. In addition, if one or more of our product candidates are approved, we must ensure access to sufficient commercial manufacturing capacity and conduct significant marketing efforts in connection with any commercial launch. These efforts will require substantial investment, and we may not have the financial resources to continue development of our product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience setbacks that could delay or prevent regulatory approval of, or the extent of regulatory protection or our ability to commercialize, our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">product-related side effects experienced by subjects in our clinical trials or by individuals using drugs or therapeutics similar to our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">delays in enrolling subjects in clinical trials, including due to the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">high drop-out rates of subjects from clinical trials; </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">challenges manufacturing our product candidates to regulatory requirements in a cost effective manner;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">greater than anticipated clinical trial costs;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">inability to compete with other therapies;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">failure to secure or maintain orphan designation in some jurisdictions;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">poor efficacy of our product candidates during clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">varying interpretations of data by the FDA and similar foreign regulatory agencies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to drug discovery and development in the area of fibrotic diseases, with an initial focus on tissue-specific integrin modulation and TGF-&#946; signaling inhibition, is unproven and may not result in marketable products.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach is designed to discover and develop targeted treatments for fibrosis with an initial focus on the antagonism of tissue-specific TGF-&#946; signaling through the inhibition of integrins known to mediate the release of activated TGF-&#946; in fibrotic tissue. However, although multiple studies are currently underway, to date, this mechanism has not been definitively proven to successfully treat fibrosis. Targeting integrins to treat fibrosis is a novel approach in a rapidly developing field, and there can be no assurance that we will not experience currently unknown problems or delays in developing our product candidates, that such problems or delays will not result in unanticipated costs, or that any such development problems can be solved. We have primarily tested our lead product candidate, PLN-74809, in healthy volunteers. Therefore, we may ultimately discover that our approach and any product candidates resulting therefrom do not possess properties required for therapeutic effectiveness. As a result, we may never succeed in developing a marketable product.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we have developed an extensive panel of cell assays and precision cut tissue assays and have utilized animal models to uncover biological pathways, understood gene expression changes and optimized the potency and selectivity of our potential product candidates, there can be no assurance that our technology will yield their intended benefits. While we believe our assays represent a differentiator in our approach to drug development, our approach has not yet been clinically proven to yield results. Our practice of evaluating our product candidates in live human fibrotic tissue samples before advancing them into the clinic is intended to serve as a bridge between animal models and clinical proof-of-concept. However, there can be no assurance that positive results observed from preclinical animal testing and human fibrotic tissue models will be replicated when a program is advanced into clinical development. In addition, our practice of utilizing live human fibrotic tissue as part of our development efforts may become more widespread in the future, and this approach may be adopted and replicated by others, including our competitors.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Studies involving human tissue samples may also be subject to institutional and government human subject privacy policies that may vary by territory. We or our partners who provide us with human tissue samples or conduct tissue and/or animal studies on our behalf, may be found to be in violation of one or more of these regulations or policies and may be subject to closure, censure or other penalties. In some cases, these penalties could materially impact the performance, availability, or validity of studies conducted by us or on our behalf. Even in the absence of violations resulting in penalties, regulatory and other authorities may refuse to authorize the conduct or to accept the results of studies for regulatory or ethical reasons.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy, complex, and expensive process, with an uncertain outcome.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, the general approach for FDA approval of a new drug is dispositive data from two well-controlled, Phase 3 clinical trials of the relevant drug in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. A product candidate can fail at any stage of testing, even after observing promising signals of activity in earlier preclinical studies or clinical trials. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our future clinical trials will ultimately be successful or support further clinical development of PLN-74809 or any of our other product candidates. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">preclinical studies or clinical trials may show the product candidates to be less effective than expected (e.g., a clinical trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">failure to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">failure to receive the necessary regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">development of competing products in the same disease state;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that make a product candidate uneconomical; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the proprietary rights of others and their competing products and technologies that may prevent one of our product candidates from being commercialized.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Further, as we rely on novel technologies including sophisticated imaging technologies to generate data relating to our clinical endpoints, there is an increased risk that we may not properly measure, analyze or interpret this data. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. Additionally, some of our trials are open-label studies, where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Therefore, it is possible that positive results observed in open-label trials will not be replicated in later placebo-controlled trials.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the standards that the FDA and comparable foreign regulatory authorities use when regulating us require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Although we are initially focusing our efforts on development of small molecule drug products, we are also considering the development of biological products, including a potential candidate for muscular dystrophies, which could make us subject to additional regulatory requirements. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations. Examples of such regulations include future legislation or administrative action, or changes in FDA policy during the period of product development and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain approval of any product candidates that we develop.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we seek to conduct clinical trials in foreign countries or pursue marketing approvals in foreign jurisdictions, we must comply with numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful completion of clinical trials is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable foreign regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We may experience negative or inconclusive results, which may result in our deciding, or our being required by regulators, to conduct additional clinical studies or trials or abandon some or all of our product development programs, which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of PLN-74809 or any other product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in initiating or completing clinical trials. We also may experience numerous unforeseen events during, or as a result of, any future clinical trials that could delay or prevent our ability to receive marketing approval or commercialize PLN-74809 or any other product candidates, including: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the FDA or other comparable regulatory authorities may disagree with our clinical trial design, including with respect to dosing levels administered in our planned clinical trials, which may delay or prevent us from initiating our clinical trials with our originally intended trial design;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">due to the impact of the COVID-19 pandemic, we have experienced, and may continue to experience, delays and interruptions to our preclinical studies and clinical trials, we may experience delays or interruptions to our manufacturing supply chain, or we could suffer delays in reaching, or we may fail to reach, agreement on acceptable terms with third-party service providers on whom we rely;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">additional delays and interruptions to our clinical trials could extend the duration of the trials and increase the overall costs to finish the trials as our fixed costs are not substantially reduced during delays;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may elect to, or regulators, IRBs, Data Safety Monitoring Boards, or DSMBs, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may not have the financial resources available to begin and complete the planned trials, or the cost of clinical trials of any product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the FDA or other comparable foreign regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience additional delays in clinical testing or in obtaining marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. If we do not achieve our product development goals in the timeframes we announce and expect, the approval and commercialization of our product candidates may be delayed or prevented entirely. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition, and results of operations significantly.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed our Phase 1a clinical trial of our lead product candidate PLN-74809 in healthy volunteers, and, with the exception of a number of reported minor adverse events, the product candidate was observed to be generally well-tolerated across all doses in 71 trial participants. However, if significant adverse events or other side effects are observed in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of our ongoing or future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts altogether. In addition, in our ongoing Phase 2a clinical trials, we are evaluating PLN-74809 administered with approved IPF agents. As a result, we may encounter unexpected drug-drug interactions in our planned trials, and may be required to further test these candidates, including in drug-drug interaction studies, which may be expensive, time-consuming and result in delays to our programs. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some potential therapeutics developed in the biopharmaceutical industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the patient eligibility and exclusion criteria defined in the protocol;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the willingness or availability (including legality under any future or reinstated COVID-19 shelter-in-place regulations) of patients to participate in our trials (including due to fears of contracting COVID-19);</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the proximity of patients to trial sites;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the design of the trial;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the availability of competing commercially available therapies and other competing product candidates&#8217; clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our ability to obtain and maintain patient informed consents; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we are initially developing PLN-74809 for the treatment of IPF and PSC, each of which is an orphan indication. In the United States, IPF is estimated to affect approximately 140,000 patients, while PSC is estimated to affect approximately 30,000 to 45,000 patients. As a result, we may encounter difficulties enrolling subjects in our clinical trials of PLN-74809 due, in part, to the small size of these patient populations. Moreover, our Phase 2a PET imaging IPF trial is being conducted at a single site, which could limit the availability of IPF patients at the site and may slow enrollment in that specific trial. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters, including, among other things, pandemics. For example, our clinical trial sites have been affected by the COVID-19 pandemic. Commencement of enrollment of our clinical trials of PLN-74809 in IPF and PSC was delayed. While these trials have resumed patient enrollment, we believe we are experiencing slower than expected enrollment due to the pandemic. Also, while the Phase 1 trial of PLN-1474 has completed, this trial experienced delays due to COVID-19. In addition, after enrollment in these trials, if patients contract COVID-19 during participation in our trials or are subject to isolation or shelter-in-place restrictions, this may cause them to drop out of our trials, miss scheduled doses or follow-up visits or otherwise fail to follow trial protocols. If patients are unable to follow the trial protocols or if our trial results are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise disputed due to the effects of the COVID-19 pandemic or actions taken to mitigate its spread, the integrity of data from our trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some factors from the COVID-19 pandemic that we believe may adversely affect enrollment in our trials include:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the diversion of healthcare resources away from the conduct of clinical trial matters to focus on pandemic concerns, including the attention of infectious disease physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">given that our clinical trials target respiratory indications, patients who would otherwise be candidates for enrollment in our clinical trials, may become infected with coronavirus, which may kill some patients and render others too ill to participate, limiting the available pool of participants for our trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the inability of patients to come to hospitals and universities to participate in our trial, which may force us to conduct our trials in patients&#8217; homes, rendering the trials more difficult and costly to conduct;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">limitations on travel that interrupt key trial activities, such as clinical trial site initiations and monitoring;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">interruption in global shipping affecting the transport of clinical trial materials, such as investigational drug product and comparator drugs used in our trials; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">employee furlough days that delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of the COVID-19 pandemic continues to evolve and the conduct of our trials may continue to be adversely affected, despite efforts to mitigate this impact.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The design or execution of our ongoing and future clinical trials may not support marketing approval.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design or execution of a clinical trial can determine whether its results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced. We are currently recruiting two Phase 2a trials of PLN-74809 in IPF. In the first of these trials, the study is designed to enroll IPF patients and utilize a positron emission tomography, or PET, ligand to measure &#945;v&#223;6 target engagement by PLN-74809 in the lungs post-treatment. The second trial is a 12-week double-blind placebo-controlled trial to evaluate safety, tolerability and PK of up three doses of PLN-74809. It is possible that we may need to amend our clinical trial, which would require us to resubmit our clinical trial protocols to competent authorities and ethics committees for reexamination, and may impact the costs, timing, or successful completion of such clinical trial. In addition, we may desire to test PLN-74809 at doses exceeding those evaluated in an ongoing Phase 1a trial and may not be able to do so.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in some instances, there can be significant variability in safety or efficacy results between different trials with the same product candidate due to numerous factors, including differences in trial protocols, size and type of the patient populations, variable adherence to the dosing regimen or other protocol requirements and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we conduct will demonstrate consistent or adequate efficacy and safety to obtain marketing approval to market our product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether marketing approval will be obtained for any of our product candidates. Our product candidates may not be approved even if they achieve their primary endpoints in future Phase 3 clinical trials or registrational trials. The FDA or comparable foreign regulatory authorities may disagree with our trial designs and our interpretation of data from preclinical studies or clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 or registrational clinical trial. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or comparable foreign regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates, if approved.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we have received U.S. orphan drug designation for PLN-74809 for IPF and PSC indications, we may be unable to obtain and maintain orphan drug designation for our other product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and other major markets, may designate drugs intended to treat conditions or diseases affecting relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have received U.S. orphan drug designation for PLN-74809 for IPF and PSC indications, the designation of any of our product candidates as an orphan drug does not mean that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates of other companies that treat the same indications as our product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or foreign regulatory authorities from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. The applicable period is seven years in the United States. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition in the United States. Even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain orphan designation in the EEA, the product must fulfill certain challenging criteria. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (1) such product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either the prevalence of such condition must not be more than five in 10,000 persons in the EU when the application is made, or without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the EU to justify the investment needed for its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. Additionally, if we advance a biological candidate into IND-enabling studies, the manufacturing processes for biological products is more complex and expensive than with small molecule products and additional manufacturing suppliers may be needed to manufacture clinical supplies for these programs. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates in the future.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our inability to design such product candidates with the pharmacological properties that we desire or attractive pharmacokinetics; or</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial, and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited financial and human resources and intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. In addition, we seek to accelerate our development timelines, including by initiating certain clinical trials of our product candidates before earlier-stage studies have been completed. This approach may cause us to commit significant resources to prepare for and conduct later-stage trials for one or more product candidates that subsequently fail earlier-stage clinical testing. Therefore, our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities or expend resources on product candidates that are not viable.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of testing PLN-74809 and any of our other product candidates in clinical trials and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">inability to bring a product candidate to the market;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">decreased demand for our products;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">injury to our reputation;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">withdrawal of clinical trial participants and inability to continue clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">initiation of investigations by regulators;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">fines, injunctions or criminal penalties;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">substantial monetary awards to trial participants;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">exhaustion of any available insurance and our capital resources;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the inability to commercialize any product candidate, if approved; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">decline in our share price.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We will need to obtain additional insurance for clinical trials as PLN-74809 continues clinical development and as additional product candidates enter the clinic. However, we may be unable to obtain, or may obtain on unfavorable terms, clinical trial insurance in amounts adequate to cover any liabilities from any of our clinical trials. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than us.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of biopharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of fibrosis. Companies that we are aware of that are targeting the treatment of various fibrosis indications through inhibiting various parts of the TGF-&#946; pathway include companies with significant financial resources such as AbbVie Inc., AstraZeneca plc,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bristol Myers Squibb Co., Corbus Pharmaceutical, DiCE Therapeutics, Inc., FibroGen, Inc., Gilead Sciences, Inc., Galapagos NV, Morphic Therapeutics, Inc., Novartis AG, and Takeda Pharmaceutical Company.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, more convenient or less expensive than any products that we may develop. Furthermore, products currently approved for other indications could be discovered to be effective treatments of fibrosis as well, which could give such products significant regulatory and market timing advantages over PLN-74809 or other product candidates that we may identify. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete and we may not be successful in marketing any product candidates we may develop against competitors. The availability of competitive products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if PLN-74809 or any other product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients and third-party payors. In addition, the availability of coverage by third-party payors may be affected by existing and future health care reform measures designed to reduce the cost of health care. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">efficacy and potential advantages compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the ability to offer our products, if approved, for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the recommendations with respect to our product candidates in guidelines published by various scientific organizations applicable to us and our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the ability to obtain sufficient third-party coverage and adequate reimbursement; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the prevalence and severity of any side effects.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If government and other third-party payors do not provide coverage and adequate reimbursement levels for any products we commercialize, market acceptance and commercial success would be reduced.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory marketing approval will depend, in part, on the availability of coverage and adequacy of reimbursement from third-party payors. Third-party payors include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost. We cannot be sure that coverage and adequate reimbursement will be available for any product that we may develop and, if reimbursement is available, what the level of reimbursement will be.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">a covered benefit under its health plan;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">appropriate for the specific patient;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">cost-effective; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">neither experimental nor investigational.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement for products may vary depending on the payor, the insurance plan, and other factors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. A primary trend in the healthcare industry is cost containment as government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement available for certain medications. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates, once approved. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates, if approved.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the United States health care industry is toward cost containment, as government authorities, third-party payors, and others have attempted to control costs by limiting coverage and the amount of reimbursement available for certain treatments. Such third-party payers, including Medicare, may question the coverage of, and challenge the prices charged for medical products, and many third-party payers limit coverage and reimbursement for newly approved health care products. Moreover, reimbursement, if available, may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers, by any future laws limiting drug prices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payers for any approved products that we develop there could be a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to these current laws and state and federal healthcare reform measures that may be adopted in the future that impact coverage and reimbursement for drug or biologic products may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties, and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing, or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we expect to establish a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of biopharmaceutical products. Arrangements with third-party payors and customers can expose biopharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, as detailed in Part I, Item 1 - Business - Government Regulation - Other Healthcare Laws. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, and certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs, remuneration provided to health care professionals and their affiliates, charitable donations and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of biopharmaceutical products.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Any action for violation of these laws, even if successfully defended, could cause a biopharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continued compliance with current Good Manufacturing Practice, or cGMP, and Good Clinical Practice, or GCP, requirements for any clinical trials that we conduct post-approval.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and their facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategies, or REMS, program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">fines, warning letters or holds on clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">voluntary or mandatory product recalls and related publicity requirements;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">total or partial suspension of production;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">product seizure or detention or refusal to permit the import or export of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is not inconsistent with the labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulations, statutes or the interpretation of existing regulations governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the pricing, coverage and reimbursement thereof could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs, as detailed in Part I, Item 1 &#8211; Business &#8211; Government Regulation &#8211; Current and Future Healthcare Reform Legislation. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature, or extent of health reform initiatives that may arise from future legislation or administrative action. However, we expect these initiatives to increase pressure on drug pricing. Further, certain broader legislation that is not targeted to the health care industry may nonetheless adversely affect our profitability.  If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Separately, since March 2020 when foreign and domestic inspections were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections and resumed inspections in China and India in early 2021. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be appropriate, the agency has stated that it generally intends to issue a complete response letter.  Further, if there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an inspection can be completed. Additionally, as of March 18, 2021, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with the FDA quality standards. Acknowledging the need for transparency an planning for the resumption of inspection activities, FDA released a roadmap plan in May 2021, and an update in November 2021, to address FDA&#8217;s risk-based approach to addressing postponed inspection work and its goal of transitioning back to conducting domestic surveillance inspections as quickly as possible. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. Ongoing surges in COVID-19 case numbers with the emergence of new variants (e.g., the Omicron variant in late 2021) have contributed to interruptions in FDA&#8217;s surveillance capabilities. In light of high positivity rates and hospitalizations, FDA made temporary changes in late 2021, including temporarily postponing certain inspection activities from December 29, 2021 to January 19, 2022. Accordingly, during the COVID-19 pandemic, several companies have announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European Union member states.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to induce or reward improper performance generally to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to induce or reward improper performance generally is governed by the national anti-bribery laws of EU Member States, and in respect of the U.K. (which is no longer a member of the EU), the Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the U.K. despite its departure from the EU.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in most foreign countries, including the European Economic Area, or EEA, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional laws and regulations governing international operations could negatively impact or restrict our operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S. individual or business entity from paying, offering, authorizing payment, or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biopharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals and healthcare providers in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information products classified for national security purposes, as well as certain products, technology and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, synthetic intermediates, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities and whether a court would issue an injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue, obtain, or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and biopharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our technology, including our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications, we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we were the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the United States Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. Similarly, for United States applications in which at least one claim is not entitled to a priority date before March 16, 2013, derivation proceedings can be instituted to determine whether the subject matter of a patent claim was derived from a prior inventor&#8217;s disclosure.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent or patent application claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, would adequately protect our product candidates, or would be found by a court to be infringed by a competitor&#8217;s technology or product. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities and consider that we are free to operate in relation to our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights or will design around the claims of patents that may issue that cover our products.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the United States moved from a &#8220;first to invent&#8221; to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#8220;first-to-file&#8221; provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the Act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">others may be able to make or use compounds that are similar to the compositions of our product candidates but that are not covered by the claims of our patents or those of our licensors;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">it is possible that our pending patent applications will not result in issued patents;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may not be able to extend the patent term in some jurisdictions;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents, as the case may be, or parts of our or their patents;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">it is possible that others may circumvent our owned or in-licensed patents;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we have engaged in scientific collaborations in the past and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights; or</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply with our obligations under such future agreements with third parties, we could lose license rights that may be important to our future business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our efforts to expand our pipeline of product candidates, we may enter into certain licenses or other collaboration agreements in the future pertaining to the in-license of rights to additional candidates. Such agreements may impose various diligence, milestone payment, royalty, insurance, or other obligations on us. If we fail to comply with these obligations, our licensor or collaboration partners may have the right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licensed intellectual property.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding, or defense activities may be less vigorous than had we conducted them ourselves.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. For example, our clinical development strategy includes the testing of live tissue samples, and our techniques for preserving and testing these samples are proprietary and confidential. If one or more third parties obtain or are otherwise able to replicate these techniques, an important feature and differentiator of our clinical development strategy will become available to potential competitors. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information concerning our business or financial affairs developed by or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies, or methods.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third-party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">if a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products and any license that is available may be non-exclusive, which could result in our competitors gaining access to the same intellectual property; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition, and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop from our use of the tissue samples or other biological materials, which they provide to us, or otherwise arising from the collaboration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collaborate with several institutions, universities, medical centers, physicians, and researchers in scientific matters and expect to continue to enter into additional collaboration agreements. In certain cases, we do not have written agreements with these collaborators, or the written agreements we have do not cover intellectual property rights. Also, we rely on numerous third parties to provide us with tissue samples and biological materials that we use to conduct our research activities and develop our product candidates. If we cannot successfully negotiate sufficient ownership and commercial rights to any inventions that result from our use of a third-party collaborator&#8217;s materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator&#8217;s samples, or data developed in a collaborator&#8217;s study, we may be limited in our ability to capitalize on the market potential of these inventions or developments.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be third-party patents of which we are currently unaware with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment that encompass the composition, use or manufacture of our product candidates. There may be currently pending patent applications of which we are currently unaware which may later result in issued patents that our product candidates or their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patent were held by a court of competent jurisdiction to cover our product candidates, intermediates used in the manufacture of our product candidates or our materials generally, aspects of our formulations or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and biopharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations to work effectively and efficiently, and these rights may be held by others. We may develop products containing our compounds and pre-existing biopharmaceutical compounds. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our current or future licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to challenge the patentability of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-examination, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#8217;s patent in patent opposition proceedings in the European Patent Office, or EPO, or other foreign patent office.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of these opposition proceedings could be substantial and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent application may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference or derivation proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In certain circumstances, even inadvertent noncompliance events may permanently and irrevocably jeopardize patent rights. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO (or foreign patent offices).</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensors initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, results of operations, financial condition and prospects. We own pending patent applications covering our proprietary technologies or our product candidates that if issued as patents are expected to expire from 2037 through 2042, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO, EPO or other relevant foreign patent offices will grant any of these patent applications.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On March 16, 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter-partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of biopharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the United States. Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the enforcement of, and may require a compulsory license to, patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the EU level, the Court of Justice of the European Union (CJEU) has recently narrowed the availability of patent term extension for second medical use therefore affecting the scope of patent protection available. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, within the EU, regulatory protections afforded to medicinal products such as data exclusivity, marketing protection, market exclusivity for orphan indications and pediatric extensions are currently under review and could be curtailed in future years. If we are unable to obtain patent term extension or the term of any such extension is less than we request, or if data exclusivity or other regulatory protections are reduced, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:24.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="text-indent:24.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">others may be able to make drug candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that cover our drug candidates, drug products or uses thereof in the United States or in other foreign countries;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">if enforced, a court may not hold that our patents are valid, enforceable and/or infringed;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">we may fail to adequately protect and police our trademarks and trade secrets; </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">other parties may independently develop the technology covered by our trade secrets; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-indent:54pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into a collaboration agreement with Novartis for the development of PLN-1474, and may in the future seek to enter into collaborations with third parties for the development and commercialization of other product candidates. If we fail to enter into such collaborations, or if our collaborations are not successful, we may be unable to continue development of such product candidates, we would not receive any contemplated milestone payments or royalties, and we could fail to capitalize on the market potential of such product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we entered into a license and collaboration agreement with Novartis for the development and commercialization of our then preclinical product candidate, PLN-1474, and up to three integrin research targets. In December 2019, we received an upfront license payment of $50.0 million for the worldwide exclusive license to PLN-1474 and, upon achievement of the first patient dosing milestone, received a payment of $25.0 million in the second quarter of 2020. Pursuant to the Novartis Agreement, we expect to receive research and development funding totaling up to $19.6 million for PLN-1474 development services and funding of up to $13.4 million for optional research and development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services on the integrin research targets. Additionally, we are eligible to receive additional developmental, regulatory and commercial milestone payments of up to $391.0 million if defined development, regulatory and commercialization milestones are achieved and tiered royalties, on a product-by-product basis based on annual net sales of products, at percentages ranging from high-single digits to low teens of the applicable licensed products and mid-single digits to high-single digits for any products resulting from the research programs. The IND application candidate was transferred to Novartis in the first quarter of 2021, and Novartis is responsible for all PLN-1474 development, manufacturing, and commercialization activities after the initial development period. As a result, we are reliant on Novartis and its efforts and capabilities with respect to the advancement of this candidate. If we or our collaborators are unable to successfully advance the development of our product candidates, including PLN-1474, or achieve milestones, revenue and cash resources from milestone payments under our collaboration agreements will be substantially less than expected.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent that any of our existing or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product candidates, including funding preclinical or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend upon third parties to conduct certain aspects of our preclinical studies and clinical trials, under agreements with universities, medical institutions, CROs, strategic collaborators and others. We expect to have to negotiate budgets and contracts with such third parties, which may result in delays to our development timelines and increased costs.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will rely especially heavily on third parties over the course of our clinical trials, and, as a result, will have limited control over the clinical investigators and limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical protocol. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP requirements.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third parties conducting aspects of our preclinical studies or clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons or if due to federal or state orders or absenteeism due to the COVID-19 pandemic they are unable to meet their contractual and regulatory obligations, our development timelines, including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties for tissue samples and other materials required for our research and development activities, and if we are unable to reach agreements with these third parties our research and development activities would be delayed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties, primarily hospitals, health clinics and academic institutions, for the provision of tissue samples and other materials required in our research and development activities. Obtaining these materials requires various approvals as well as reaching a commercial agreement on acceptable terms with the hospital or other provider of the materials. While we currently have agreements in place with the institutions from which we receive our tissue samples, we do not have any exclusive arrangements with such sources and there is no guarantee that we will be able to maintain or renew such agreements on commercially reasonable terms, if at all. If we were unable to maintain or renew such agreements, we would be forced to seek new arrangements with new hospitals, clinics or health institutions. If so, we may not be able to reach agreements with alternative partners or do so on terms acceptable to us. If we are unable to enter into such agreements, our research and development activities will be delayed and our ability to implement a key part of our development strategy will be compromised.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we rely on third-party manufacturing and supply vendors, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party contract manufacturers to manufacture our product candidates for preclinical studies and clinical trials. We do not own manufacturing facilities for producing any clinical trial product supplies. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. For example, the extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In addition, three vaccines for COVID-19 were granted Emergency Use Authorization by the FDA in late 2020 and early 2021, and more are likely to be authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, equivalent foreign legislation or heightened demand on manufacturers may make it more difficult to obtain materials or manufacturing slots for the products needed for our development efforts, which could lead to delays in our clinical trials and scientific development efforts.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for PLN-74809 or any other product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">able to develop and commercialize our product candidates successfully. Our or a third-party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">an inability to initiate or continue clinical trials of product candidates under development;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">loss of the cooperation of an existing or future collaborator;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">requirements to cease distribution or to recall batches of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a sole supplier for the manufacture of PLN-74809. If this sole supplier is unable to supply to us in the quantities we require, or at all, or otherwise defaults on its supply obligations to us, we may not be able to obtain alternative supplies from other suppliers on acceptable terms, in a timely manner, or at all. We also do not have long-term supply agreements with any of our suppliers. Our current contracts with certain suppliers may be canceled or not extended by such suppliers and, therefore, do not afford us with protection against a reduction or interruption in supplies. Moreover, in the event any of these suppliers breach their contracts with us, our legal remedies associated with such a breach may be insufficient to compensate us for any damages we may suffer.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we contract with fill and finishing providers with the appropriate expertise, facilities and scale to meet our needs. Failure to maintain cGMP can result in a contractor receiving FDA sanctions, which can impact our ability to operate or lead to delays in any clinical development programs. We believe that our current fill and finish contractor is operating in accordance with cGMP, but we can give no assurance that FDA or other regulatory agencies will not conclude that a lack of compliance exists. In addition, any delay in contracting for fill and finish services, or failure of the contract manufacturer to perform the services as needed, may delay any clinical trials, registration and launches, which could negatively affect our business. In the future, if we advance a biological product candidate into IND-enabling studies, we will need to identify and contract with suppliers who are able to produce biological product candidates and adhere to additional cGMP compliance obligations required for biologicals.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing collaborations and future collaborations are and will be important to our business. If we are unable to enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A part of our strategy is to selectively evaluate partnerships in indications and geographies where we believe partners can add significant commercial and/or development capabilities. Further, we have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we have and may in the future enter into collaborations with other companies to provide us with important technologies and funding for our programs and technology.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing collaborations and any future collaborations we enter into may pose a number of risks, including the following:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators have significant discretion in determining the efforts and resources that they will apply;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators may not perform their obligations as expected;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators may not provide us with timely and accurate information regarding development progress and activity under any future license agreement, which could adversely impact our ability to report progress to our investors and otherwise plan development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing collaborations and any future collaborations we enter into do not result in the successful discovery, development and commercialization of product candidates or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Report also apply to the activities of our therapeutic collaborators.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one of our existing or future collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators for our product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully establish a collaboration for one or more of our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into future collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts to establish new strategic collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any delay in entering into new strategic collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators, prospective collaborators, and suppliers may need assurances that our financial resources and stability on a stand-alone basis are sufficient to satisfy their requirements for doing or continuing to do business with us. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaborators, prospective collaborators, and suppliers may need assurances that our financial resources and stability on a stand-alone basis are sufficient to satisfy their requirements for doing or continuing to do business with us. If our collaborators, prospective collaborators or suppliers are not satisfied with our financial resources and stability, it could have a material adverse effect on our ability to develop our drug candidates, enter into licenses or other agreements and on our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Our Business and Operations</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of the coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of the coronavirus disease, COVID-19, was identified in Wuhan, China. This virus has spread to a number of countries globally, including the United States. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we significantly limited access to our executive offices with the majority of our administrative employees continuing their work outside of our offices and limited the presence of our staff in the laboratory and in the administrative spaces to levels that adhere to social distancing protocols. As a result of the COVID-19 pandemic, we have experienced disruptions and may continue to experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">delays or difficulties in commencing enrollment of patients in our clinical trials, including our Phase 2a clinical trials of PLN-74809 in IPF and PSC and our Phase 1 clinical trial of PLN-1474. With respect to the Phase 2a trials of PLN-74809 in IPF and PSC, following delays in site initiation due to the impacts of COVID-19, both trials have resumed active enrollment of patients. With respect to the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 trial of PLN-1474, the Phase 1 trial site experienced delays due to its location in an area heavily impacted by COVID-19; however, the trial site reopened and completed dosing the remaining cohorts, and the trial was subsequently completed;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">the impact from potential delays, including potential difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures that are deemed non-essential, which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">interruptions in preclinical studies due to restricted or limited operations at our laboratory facility;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">interruption or delays to our sourced discovery and clinical activities.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve and new variants of the virus continue to emerge. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.The foregoing disruptions, and other continued disruptions to our business in connection with the COVID-19 pandemic, could have a material adverse impact on our business, financial condition or results of operations. In addition, the COVID-19 pandemic heightens many of the other risks and uncertainties discussed herein.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth, which could adversely affect our operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 91 full-time employees. As our clinical development and commercialization plans and strategies develop, and as we transition into operating as a public company, we will need to expand our managerial, clinical, regulatory, sales, marketing, financial, development, manufacturing and legal capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future growth would impose significant added responsibilities on members of management, including:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">managing our development and commercialization efforts effectively, including the clinical and FDA review process for PLN-74809 and any other product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including contract manufacturers and companies focused on research and development and discovery activities. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize PLN-74809 or any other product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially harm our business, including the diversion of management&#8217;s attention from core business concerns, failure to effectively exploit acquired technologies, failure to successfully integrate the acquired business or realize expected synergies or the loss of key employees from either our business or the acquired businesses.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, scientific and medical personnel, including Bernard Coulie, M.D., Ph.D., our President and Chief Executive Officer, Keith Cummings, M.D., our Chief Financial Officer, Johannes (Hans) Hull, J.D., our Chief Business Officer and &#201;ric Lefebvre, M.D., our Chief Medical Officer. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our operations at our facility in South San Francisco, California. This region is headquarters to many other biopharmaceutical companies, biotechnology companies and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our key employees are at-will employees, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior scientific and medical personnel.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes, outbreak of disease or other natural disasters.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are located in our facilities in South San Francisco, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes or other natural disasters </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. In addition, global climate change could result in certain types of natural disasters occurring more frequently or with more intense effects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners, collaborators, and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws will also increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing, and education programs. We adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use and generate materials that may expose us to material liability.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research programs involve the use of hazardous materials and chemicals, which are currently only handled by third parties. We are subject to foreign, federal, state, and local environmental and health and safety laws and regulations governing, among other matters, the use, manufacture, handling, storage and disposal of hazardous materials and waste products such as human tissue samples that may have the potential to transmit diseases. We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. In addition, we cannot completely eliminate the risk of contamination or injury from hazardous materials and may incur material liability as a result of such contamination or injury. In the event of an accident, an injured party may seek to hold us liable for any damages that result. Any liability could exceed the limits or fall outside the coverage of our workers&#8217; compensation, property and business interruption insurance and we may not be able to maintain insurance on acceptable terms, if at all. We currently carry no insurance specifically covering environmental claims.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers&#8217; compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Welfare Act, or AWA, is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment, and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering, and shipping conditions. Third parties with whom we contract are subject to registration, inspections, and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had net operating loss carryforwards for U.S. federal and state income tax purposes of $184.7 million and $183.0 million, respectively, some of which will begin to expire in 2035. As of December&#160;31, 2021, we also had available tax credit carryforwards for U.S. federal income tax purposes of $14.1 million, which begin to expire in 2036, and state income tax purposes of $4.1 million, which can be carried forward indefinitely. Under Section 382 of the Internal Revenue Code, as amended, or the Code, changes in our ownership may limit the amount of our net operating loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50 percentage points within a three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards before they expire. We completed a Section 382 study of transactions in our stock ownership through December 31, 2021 and concluded that we have experienced ownership changes since inception and our utilization of pre-change net operating loss and credit carryforwards will be subject to the limitation. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in our stock ownership. Any such limitation could have a material adverse effect on our results of operations in future years. Our ability to utilize those net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased tax liability to us. Net operating losses generated after December 31, 2017 are not subject to expiration, but may not be carried back to prior taxable years, except that net operating losses generated in 2018, 2019 and 2020 may be carried back five taxable years. Additionally, the deductibility of such U.S. federal net operating losses is limited to 80% of our taxable income in any taxable year beginning after December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active or liquid market for our common stock may not be sustained.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our initial public offering in June 2020, there was no public market for shares of our common stock. In connection with our initial public offering, our common stock was listed for trading on the Nasdaq Global Select Market. However, an active or liquid market in our common stock may not be sustained.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Report, these factors include:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">the commencement, enrollment or results of our current Phase 2a clinical trials of PLN-74809 and any other clinical trials for our product candidates conducted by us or our collaborators;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">any delay in identifying and advancing a clinical candidate for our other development programs;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">any delay in our regulatory filings for PLN-74809 or our other product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">adverse results or delays in future clinical trials;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">adverse regulatory decisions, including failure to receive regulatory approval of PLN-74809 or any other product candidate;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">changes in laws or regulations applicable to PLN-74809 or any other product candidate, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">adverse developments concerning our manufacturers;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">our inability to establish collaborations, if needed;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">our failure to commercialize our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">unanticipated serious safety concerns related to the use of PLN-74809 or any other product candidate;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">introduction of new products or services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">our cash position;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">publication of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">changes in the structure of the healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">ineffectiveness of our internal controls;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">general political and economic conditions; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including as a result of the COVID-19 pandemic. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the development, operation and growth of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and their affiliates and our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on shares outstanding as of December&#160;31, 2021, our executive officers, directors and their affiliates and our principal stockholders beneficially held, in the aggregate, approximately a quarter of our outstanding voting stock. These stockholders, acting together, would be able to significantly influence all matters requiring stockholder approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If there are substantial sales of shares of our common stock, the price of our common stock could decline.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity compensation plans will become eligible for sale in the public market as they become vested. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. Additionally, the number of shares of our common stock reserved for issuance under our 2020 Stock Option and Incentive Plan will automatically increase on January 1 of each year by 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors or compensation committee. Moreover, the number of shares of our common </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock reserved for issuance under our 2020 Employee Stock Purchase Plan, or ESPP, will automatically increase on January 1 of each year by the lesser of 700,000 shares of common stock, 1% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors or compensation committee. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of over 20 million shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act of 1933, as amended, or the Securities Act, as provided under the terms of an investors&#8217; rights agreement between us and certain of our stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders, or the perception that such sales could occur, could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation and bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:58.8pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our certificate of incorporation and bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our bylaws designate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">certain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">courts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">as the exclusive</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">forum</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">for</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">certain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">litigation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">that</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">be initiated</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">by our stockholders,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">which could limit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our stockholders&#8217;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to litigate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">disputes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">with us in a different</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">judicial forum.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ursuant to our bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (iii) any action asserting a claim against us arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws; (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (v) any action asserting a claim governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or the Delaware forum provision. This exclusive forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Unless we consent in writing to the selection of an alternate forum, the federal district courts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the federal forum provision. In addition, our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the Delaware forum provision and the federal forum provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware forum provision and the federal forum provision may impose additional litigation costs on stockholders who assert the provision is not enforceable and may impose more general additional litigation costs in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the State of California. In addition, these forum selection clauses in our bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum provision. If the federal forum provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The federal forum provision may also impose additional litigation costs on stockholders who assert the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></div><div style="margin-top:6pt;text-indent:54pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">we fail</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to maintain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">an effective</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">system</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of internal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">control</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">over</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">reporting,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">we may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">not be able</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to accurately</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">report</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or prevent</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">fraud. As a result,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">stockholders</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">could lose</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">confidence</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in our financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">reporting,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">which would harm our business</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and the trading</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">price</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of our common</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">stock.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">controls</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and procedures</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">not prevent</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or detect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">all</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">errors</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or acts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of fraud.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public reporting company, we are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our issuance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">capital</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in connection</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">with financings,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">acquisitions,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">investments,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our stock incentive</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">plans or otherwise</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">will</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">dilute</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">all</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">stockholders.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to continue to grant equity awards to employees, directors, and consultants under our stock incentive plans. We may also raise capital through equity financings in the future, including an "at-the-market" offering pursuant to our Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Agreement with Cantor Fitzgerald &amp; Co. As part of our business strategy, we may acquire or make investments in complementary companies, products or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">securities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or industry</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">analysts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">do not publish</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or publish</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">inaccurate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or unfavorable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">research about our business,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our stock</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">price</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and trading</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">volume</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">could decline.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">increased</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">as a result</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of operating</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">as a public</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">company,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and our management</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">is required</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to devote</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">substantial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">time</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to new compliance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">initiatives.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the Nasdaq Stock Market, or Nasdaq, to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, there are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, particularly as we ceased to be an emerging growth company on December 31, 2021. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">incur substantial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">costs</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in our efforts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to comply</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">with evolving</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">global</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">data protection</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">laws and regulations,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and any failure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or perceived</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">failure</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">by us to comply</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">with such laws and regulations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">harm our business</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal data, such as information that we collect about participants and healthcare providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business, affect our or our service providers&#8217; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws and regulations, including HIPAA and HITECH, govern the collection, dissemination, security, use and confidentiality of patient-identifiable health information or personal information. In the course of performing our business we obtain personally identifiable information (PII), including health-related information. Such laws and regulations relating to privacy, data protection, and consumer protection are evolving and subject to potentially differing interpretations. These requirements may be interpreted and applied in a manner that varies from one jurisdiction to another and/or may conflict with other laws or regulations. HIPAA establishes national privacy and security standards for the protection of individually identifiable health information, including protected health information (PHI) for certain covered entities, including healthcare providers that submit certain covered transactions electronically, as well as their &#8216;&#8216;business associates.&#8221; Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly depending on the failure and could include civil monetary or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. The Department of Health and Human Services Office for Civil Rights (OCR) has recently increased its enforcement efforts on compliance with HIPAA, including the security regulations (Security Rule), bringing actions against entities which have failed to implement security measures sufficient to reduce risks to electronic protected health information or to conduct an accurate and thorough risk analysis, among other violations. HIPAA enforcement actions may lead to monetary penalties and costly and burdensome corrective action plans. Additionally, on December 10, 2020, OCR issued a proposed rule aimed at strengthening individuals&#8217; rights to access their own health information, as well as reducing administrative burdens on HIPAA covered health care providers and health plans, among other changes. While a final rule has not yet been issued, if adopted, these proposed changes may require us to update our HIPAA policies and procedures to comply with the new requirements.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California passed the California Consumer Protection Act of 2018, or the CCPA, which went into effect in January 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. Failure to comply with the CCPA risks regulatory fines, and the CCPA grants a private right of action and statutory damages for an unauthorized access and exfiltration, theft, or disclosure of certain types of personal information resulting from the company&#8217;s violation of a duty to maintain reasonable security procedures and practices. The CCPA also provides authority to the California Attorney General to seek civil penalties for intentional violations of the CCPA. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. How this HIPAA exception is enforced and interpreted may also impact our business activities. Additionally, this exception does not apply to the private cause of action afforded to individuals for information security incidents.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the CCPA will be expanded on January 1, 2023, when the California Privacy Rights Act of 2020, or the CPRA, becomes operative. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, further restrict the use of cross-contextual advertising, establish restrictions on the retention of personal information, expand the types of data breaches subject to the CCPA&#8217;s private right of action, provide for increased penalties for CPRA violations concerning California residents under the age of 16, and establish a new California Privacy Protection Agency to implement and enforce the new law. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how it is interpreted. In the interim, the CPRA will require additional investment in compliance programs and potential modifications to business processes</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the United States, as other states or the federal government may follow California&#8217;s lead and increase protections for U.S. residents. For example, on March 2, 2021, the Virginia Consumer Data Protection Act, which will take effect on January 1, 2023, was signed into law and on July 8, 2021, the Colorado Privacy Act, which will take effect on July 1, 2023, was signed into law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2021, the Uniform Law Commission published the Uniform Personal Data Protection Act, which states may begin to adopt. The CCPA has already prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, add layers of complexity to compliance in the U.S. market, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Federal Trade Commission (FTC) and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the collection, use, dissemination and security of health-related and other personal information. Courts may also adopt the standards for fair information practices </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promulgated by the FTC, which concern consumer notice, choice, security and access. Consumer protection laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. If such information that we publish is considered untrue, we may be subject to government claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences. Furthermore, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5 of the FTC Act. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business relies on secure and continuous processing of information and the availability of our Information Technology (IT) networks and IT resources, as well as critical IT vendors that support our technology and data processing operations. Security breaches, computer malware and computer hacking attacks have become more prevalent across industries and may occur on our systems or those of our third-party service providers. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. OCR, in partnership with the Healthcare and Public Health Sector Coordinating Council, recently issued cybersecurity guidelines for healthcare organizations that reflect consensus-based, voluntary practices to cost-effectively reduce cybersecurity risks for organizations of varying sizes. Although these HHS-backed guidelines, entitled &#8220;Health Industry Cybersecurity Practices: Managing Threats and Protecting Patients,&#8221; are voluntary, they are likely to serve as an important reference point for the healthcare industry, and may cause us to invest additional resources in technology, personnel and programmatic cybersecurity controls as the cybersecurity risks we face continue to evolve. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly monitor, defend against and respond to attacks to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third party service providers, may be vulnerable to privacy and information security incidents such as data breaches, viruses or other malicious code, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological vulnerabilities or human error. If we, or any of our IT support vendors, fail to comply with laws requiring the protection of sensitive personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, we may be subject to regulatory enforcement and fines as well as private civil actions. We may be required to expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our operations in the United States, which may be subject to healthcare and other laws relating to the privacy and security of health information and other personal data, we may seek to conduct clinical trials in the EEA and may become subject to additional EEA data privacy laws, regulations and guidelines. The General Data Protection Regulation, (EU) 2016/679, or EU GDPR, became effective on May 25, 2018, and deals with the collection, use, storage, disclosure, transfer or other processing of personal data, including personal health data, regarding individuals in the EEA. The EU GDPR imposes a broad range of strict requirements on companies subject to the EU GDPR, including requirements relating to having legal bases for processing personal data (i.e., data relating to identifiable individuals) and transferring such personal data outside the EEA, including to the United States, and providing details to those individuals regarding the processing of their personal data, keeping personal data secure, having data processing agreements with third parties who process personal data on our behalf, responding to individuals&#8217; requests to exercise their rights in respect of their personal data, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments and record-keeping. Further, national laws of member states of the EU may partially deviate from the EU GDPR and impose different obligations from country to country, so that we do not expect to operate in a uniform legal landscape in the EEA. In particular, as it relates to processing and transfer of genetic data and health data, the EU GDPR specifically allows national laws to impose additional and more specific requirements or restrictions, and European laws have historically differed quite substantially in this field, leading to additional uncertainty. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU GDPR increases substantially the penalties to which we could be subject in the event of any non-compliance, including fines of up to &#8364;10,000,000 or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to &#8364;20,000,000 or up to 4% of our total worldwide annual turnover, whichever is greater, for more serious offenses. The EU GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the EU GDPR. If our efforts to comply with EU GDPR or other applicable EU laws and regulations are not successful, or are perceived to be unsuccessful, it could adversely affect our business in the EU. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU GDPR also prohibits the transfer of personal data from the EEA to the United States and most other countries that are not recognized as having &#8220;adequate&#8221; data protection laws by the European Commission unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowing U.S. companies to import personal data from the EEA has been certification to the EU-U.S. Privacy Shield framework administered by the U.S. Department of Commerce. However,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the European Court of Justice, or the ECJ, issued a decision in July 2020 which invalidated the EU-U.S. Privacy Shield framework for international transfers (Schrems II) and imposed further restrictions on the use of standard contractual clauses (SCCs) including, a requirement for companies to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under the SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EU. Following that decision, the Swiss Federal Data Protection and Information Commissioner (FDPIC) took a similar view and considered that data transfers based on the Swiss-U.S. Privacy Shield framework are no longer lawful (despite the fact that Schrems II is not directly applicable in Switzerland (unless the Swiss based company is subject to the EU GDPR) and the Swiss-U.S. Privacy Shield has not been officially invalidated).</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the European Commission recently published new EU SCCs, which place onerous obligations on the contracting parties. At present, there are few, if any, viable alternatives to the SCCs. These developments could restrict our activities in the EEA/Switzerland, limit our ability to provide our products and services in the EEA/Switzerland, and/or increase our costs and obligations and impose limitations upon our ability to efficiently transfer personal data from the EEA/Switzerland to the United States.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the U.K.&#8217;s departure from the EU (Brexit), the EU GDPR&#8217;s data protection obligations continue to apply to the UK in substantially unvaried form under the so-called &#8220;UK GDPR&#8221;. The UK GDPR exists alongside the UK Data Protection Act 2018 which implements certain derogations in the UK GDPR into UK law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the UK GDPR, companies not established in the UK but who process personal data in relation to the offering of goods or services to individuals in the UK, or to monitor their behavior will be subject to the UK GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover. As a result, we are potentially exposed to two parallel data protection regimes, each of which authorizes fines and the potential for divergent enforcement actions. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we commence clinical trials in the EEA, the UK or Switzerland, applicable data protection laws may increase our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms and safeguards to ensure compliance, including as implemented by individual countries. Compliance with data protection laws in the EEA, the UK and Switzerland will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. We expect that we will continue to face uncertainty as to whether our efforts to comply with any obligations under European privacy laws will be sufficient. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or biopharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national clients or biopharmaceutical partners to continue to use our products and solutions due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law. Such clients or biopharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the forgoing could materially harm our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Following Brexit, legal, political</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and economic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">uncertainty</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">surrounding the exit</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of the U.K.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">from</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">the EU</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">be a source</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of instability</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in international</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">markets,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">create</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">significant</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">currency</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">fluctuations,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">adversely</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">affect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our operations in the U.K.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and pose additional</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">risks</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to our business,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">revenue,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">condition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020, the U.K. ceased being a Member State of the EU. The U.K. and the EU signed a EU-UK Trade and Cooperation Agreement, or TCA, which became effective on May 1, 2021. Such a withdrawal from the EU is unprecedented, and it is unclear how the restrictions on the U.K.&#8217;s access to the European single market for goods, capital, services and labor within the EU, or single market, and the wider commercial, legal and regulatory environment, will impact our current and future operations (including business activities conducted by third parties and contract manufacturers on our behalf) and clinical activities in the U.K.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also face new regulatory costs and challenges that could have an adverse effect on our operations. Since the regulatory framework in the U.K. covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime with respect to the approval of our product candidates in the U.K., now that U.K. legislation may depart from EU legislation. For instance, now the transition period </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has expired, Great Britain will no longer be covered by the centralized procedure for obtaining an EEA-wide marketing authorization from the European Medicines Agency, or EMA, and a separate process for authorization of drug products, including our product candidates and products in the U.K., will be required in Great Britain resulting in an authorization covering the UK or Great Britain only. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the U.K. and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. and/or EU for our product candidates, which could significantly and materially harm our business. </span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK government is currently trying to renegotiate fundamental aspects of the Northern Ireland Protocol so this is an unpredictable area for companies in the near future. The TCA allows for future deviation from the current regulatory framework and it is not known if and/or when any deviations may occur, which may have an impact on development, manufacture, marketing authorization, commercial sales and distribution of pharmaceutical products.</span></div><div style="margin-top:6pt;text-indent:66pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">tax law could adversely</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">affect</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our financial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">condition</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and results</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the U.S. Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. tax laws on an investment in our common stock.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">computer</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">systems,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or those</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of our collaborators</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">contractors</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or consultants,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">fail or suffer</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">security</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">breaches,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">which could result</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in a material</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">disruption</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">of our product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">development programs.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our current and any future collaborators, other contractors or consultants, and third-party suppliers (i.e. our supply chain) are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We exercise little or no direct control over how these third parties operate their networks, which increases our vulnerability to problems with their systems. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release, exposure or loss of information maintained in the information systems and networks of our company and our vendors, including personal information of our employees and study subjects, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information in order to gain access to our data and/or systems. We may experience threats to our data and systems, including malicious code and viruses, supply chain attacks, phishing and other cyberattacks. The number and complexity of these threats continue to increase over time. If a material breach of, or accidental or intentional loss of data from, our information technology systems or those of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to vendors, engage in more electronic transactions with payors </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patients, and rely more on cloud- based information systems, the related security risks will increase and we will need to expend additional resources to protect our technology and information systems.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there can be no assurance that our internal information technology systems or those of our third- party contractors, or our consultants&#8217; efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks which could result in financial, legal, business or reputational harm.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we maintain, insurance policies that may cover certain liabilities in connection with a cybersecurity incident, we cannot be certain that the insurance coverage will be adequate for liabilities actually incurred, that insurance will continue to be available to us on commercially reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. The successful assertion of one or more large claims that exceed available insurance coverage, or the occurrence of changes in insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, including its financial condition, results of operations and reputation.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials costlier to operate. Furthermore, the most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, including due to the impact of the COVID-19 pandemic, and rising interest rates could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or international trade disputes could also strain our suppliers, some of which are located outside of the United States, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts following approval of our product candidates, if any. Social media practices in the biopharmaceutical industry continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to off-label marketing or other prohibited activities. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></div><div style="text-align:justify;text-indent:64pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">Our estimates</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">of market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">opportunity</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">and forecasts</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">of market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">growth may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">prove</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">to be inaccurate,</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">and even if the markets</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">in which we compete</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">achieve</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">the forecasted</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">growth, our business</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">may</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">not grow at similar</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:104%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:104%">rates, or at all.</span></div><div style="text-indent:24.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_25"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a facility containing 32,974 square feet of laboratory and office space, which is located at 260 Littlefield Avenue, South San Francisco, California 94080. The lease expires on February 28, 2025. We believe that our current facilities are sufficient to meet our current and near-term needs and that, should it be needed, suitable additional space will be available.</span></div><div id="i988625df783e4cc0a27bd76df388da57_31"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, we are not party to any material legal matters or claims. We may become party to legal matters and claims arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="i988625df783e4cc0a27bd76df388da57_34"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i988625df783e4cc0a27bd76df388da57_40"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#8220;PLRX&#8221; since June 3, 2020. Prior to that date, there was no public trading market for our common stock.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the close of business on February 25, 2022, there were 55 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and future earnings, if any, for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Registered Securities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial public offering of common stock was effected under a Registration Statement on Form S-1 (File No. 333-238146), which was declared effective by the SEC on May 11, 2020. There has been no material change in the use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b) and other periodic reports previously filed with the SEC</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2020, we consummated a concurrent private placement for shares of our common stock in connection with the consummation of our initial public offering. Novartis Institutes for Biomedical Research, Inc., our strategic partner and one of our existing stockholders has purchased $10.0 million in shares of our common stock at $16.00 per share.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from our Public Offering of Common Stock</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, our Registration Statement on Form S-1 (No. 333-2381146) was declared effective by the SEC pursuant to which we issued and sold an aggregate of 10,350,000 shares of common stock (inclusive of 9,000,000 shares of common stock and 1,350,000 shares of common stock pursuant to the underwriters&#8217; exercise of their over-allotment option) at a public offering price of $16.00 per share for aggregate net cash proceeds of $148.3 million, after deducting underwriting discounts, commissions and offering costs. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale and issuance of 10,350,000 shares closed on June 5, 2020. Citigroup Global Markets Inc., Cowen and Company, LLC and Piper Sandler &amp; Co. acted as joint book-running managers for the offering.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the planned use of proceeds from our initial public offering from that described in the Prospectus.</span></div><div id="i988625df783e4cc0a27bd76df388da57_43"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_46"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of&#160;Financial Condition and Results of Operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report. This discussion and analysis contains forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intention, beliefs and projections. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part I, Item 1A and elsewhere in this Annual Report. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this Annual Report. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate we have conducted exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div id="i988625df783e4cc0a27bd76df388da57_49"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Our initial focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-&#946;. We have applied our deep understanding of fibrosis biology, along with our medicinal chemistry and translational medicine expertise to develop a set of proprietary tools designed to discover and de-risk product candidates quickly and efficiently. Our wholly owned lead product candidate, PLN-74809, is an oral, small-molecule, dual selective inhibitor of &#945;v&#223;6 and &#945;v&#223;1 integrins that we are developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. We have completed a Phase 1a SAD/MAD trial and a Phase 1b proof-of-mechanism trial of PLN-74809 in IPF and are currently recruiting three Phase 2a trials in our lead indications: two in IPF and one in PSC. </span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, PLN-1474, is a small-molecule selective inhibitor of &#945;v&#223;1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which we have partnered with Novartis. PLN-1474 successfully completed a Phase 1 SAD/MAD trial in March 2021, and the Investigational New Drug, or IND, application was transferred to Novartis in the first quarter of 2021. Novartis is responsible for all PLN-1474 development, manufacturing and commercialization activities and we earn research and development services revenue in supporting certain aspects of the development plan. </span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical programs, we currently have preclinical integrin-based programs targeting oncology and muscular dystrophies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Highlights</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Results from expanded PLN-74809 Phase 1b proof-of-mechanism trial demonstrated clear evidence of on-target biological activity in the lungs of healthy participants. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earlier today, the Company announced that positive data from an expanded PLN-74809 Phase 1b proof-of-mechanism trial demonstrated clear evidence of on-target biological activity in the lungs of 36 healthy participants. Results demonstrated that PLN-74809 inhibited TGF-&#946; activation by up to 92% and 76% at 6- and 24-hours, respectively, following seven days of once-daily dosing. At all dose levels, PLN-74809 demonstrated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:126.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">durable pSmad suppression relative to placebo at 6 hours and 24 hours. PLN-74809 was well tolerated with mostly mild adverse events, and no severe adverse events. </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Enrollment was completed in the PLN-74809 Phase 2a INTEGRIS-IPF trial in idiopathic pulmonary fibrosis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INTEGRIS-IPF is a 12-week randomized, dose-ranging, double-blind, placebo-controlled trial evaluating the safety, tolerability and pharmacokinetics of PLN-74809 at doses of 40, 80 or 160 mg in approximately 84 IPF patients. Exploratory endpoints include quantitative lung fibrosis (QLF) imaging, pulmonary function tests as well as select biomarkers. Topline data is anticipated mid-2022.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">The U.S. Food and Drug Administration (FDA) authorized the evaluation of long-term treatment with PLN-74809 in patients with IPF.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The FDA has authorized evaluation of long-term dosing of PLN-74809 up to 320 mg daily in patients with IPF.  This authorization will facilitate longer-term pivotal trials in IPF. PLN-74809 has been administered to over 450 study participants, including healthy volunteers and patients, with no drug-related serious adverse events or severe adverse advents reported to date. </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Independent Data Safety Monitoring Board (DSMB) recommended INTEGRIS-IPF Phase 2a Trial continue without modifications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the full enrollment of the INTEGRIS-IPF Phase 2a trial, on February 17, 2022, the DSMB recommended the INTEGRIS-IPF trial continue without modification. This review included all patients enrolled in all dose cohorts of the trial. To date, no safety concerns have been identified by the DSMB.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Commenced enrollment of a Phase 2a trial of PLN-74809 at a dose of 320 mg in patients with IPF. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began enrollment in a randomized, double-blind, placebo-controlled trial evaluating PLN-74809 at doses of 320 mg administered daily over at least six months, and up to 48 weeks, in approximately 28 patients with IPF. The primary endpoint is the evaluation of PLN-74809 safety and tolerability and the secondary endpoint is the assessment of  pharmacokinetics. Exploratory endpoints will measure QLF imaging and pulmonary function tests as well as select biomarkers over 6 months of treatment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">PLN-74809 Phase 2a trial in primary sclerosing cholangitis (PSC) enrollment on track to be completed mid-2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INTEGRIS-PSC is a 12-week randomized, dose-ranging, double-blind, placebo-controlled trial evaluating the safety, tolerability, and pharmacokinetics of PLN-74809 at doses of 40, 80 or 160 mg in approximately 84 PSC patients. Exploratory endpoints include fibrosis biomarkers such as Pro-C3 and ELF, changes in ALP and liver imaging.  Topline data is expected in late 2022 or early 2023.</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:59.5pt">Oncology and muscular dystrophy programs progressing through Investigational New Drug (IND) enabling studies.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both programs on track with IND application submissions planned by the end of 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the outbreak of a coronavirus, or COVID-19, as a pandemic, which, to date, continues to spread throughout the United States and worldwide. We have been, and in the future could be, materially and adversely affected by the risks, or the public perception of the risks, related to an epidemic, pandemic, outbreak, or other public health crisis, such as the outbreak of COVID-19. While difficult to predict or quantify the overall impact to our operations, among other things, our clinical trials have experienced delays, and may experience additional delays in the future, extending the timelines and increasing the overall costs to finish the clinical trials, as our fixed costs are not substantially reduced while the clinical trials are delayed. For example, the clinical site conducting our Phase 2a PET trial of PLN-74809 in IPF was closed to clinical research in March 2020, but resumed enrollment and trial activities in the third quarter of 2020. The ultimate extent of the impact of any epidemic, pandemic, outbreak, or other public health crisis on our business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic, pandemic, outbreak, or other public health crisis and actions taken to contain or prevent the further spread, among others. Accordingly, we cannot predict the extent to which our business, financial condition and results of operations have been and will be affected. We remain focused on maintaining a strong balance sheet, liquidity and financial flexibility and continue to monitor developments as we deal with the disruptions and uncertainties from a business and financial perspective relating to COVID-19.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue from product sales and do not expect to do so in the near future. Our revenue to date is derived from a Collaboration and License Agreement with Novartis, or the "Novartis Agreement," that was executed in 2019. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novartis Agreement is for the development and commercialization of PLN-1474 and up to three additional integrin research targets. Under the terms of the Novartis Agreement, we received an upfront license fee payment of $50.0 million for the worldwide, exclusive license to PLN-1474 and an additional $25.0 million upon first patient dosed in our Phase 1 trial of PLN-1474 in the first quarter of 2020. We are eligible to receive additional milestone payments of up to $391.0 million in total, if defined developmental, regulatory and commercialization milestones are achieved, and tiered royalties on a product-by-product basis based on annual nets sales of products. Additionally, Novartis agreed to provide up to $19.6 million and up to $13.4 million in funding for the research and development activities associated with PLN-1474 and integrin research targets, respectively. As of December 31, 2021 approximately $2.0 million of aggregate research and development funding remains available for use under the arrangement.   </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the years ended December 31, 2021, 2020 and 2019 were $7.6 million, $41.8 million and $57.1 million, respectively.  </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist of expenses incurred in connection with the development of our product candidates. Research and development expenses include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">employee-related expenses, which include salaries, benefits and stock-based compensation for our research and development personnel;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">expenses incurred under agreements with third-party contract organizations for pre-clinical studies, clinical trials and consultants that conduct research and development activities on our behalf;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">costs associated with the manufacture of supplies to support research and development, preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">depreciation of laboratory equipment and costs of equipment and supplies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">costs associated with technology and intellectual property licenses; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">facilities and other allocated expenses, which include expenses for rent and other facility related costs and other supplies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,730&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,301&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,385&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside and consulting services for preclinical studies and research and development activities by third party contract organizations</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,043&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,263&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,907&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of lab equipment and costs of equipment and supplies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,968&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology and intellectual property licenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other allocated expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,065&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,548&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,193&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,353&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense all research and development costs in the periods in which they are incurred. We do not allocate our internal costs by product candidates or by preclinical programs as these are in early stages of development. Additionally, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">although external third-party costs are allocable between product candidates and programs, we do not perform this allocation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates and our preclinical programs and as they advance into later stages of development. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses consist primarily of salaries, benefits and stock-based compensation for our general and administrative personnel, allocated facilities costs, insurance and other expenses for outside professional services, including legal, marketing, investor relations, human resource and accounting services. We expect general and administrative expenses to increase for the foreseeable future as does the size of our administrative function to support the growth of our business. In addition, if we obtain regulatory approval for any of our product candidates and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing and distribution activities.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income (Expense), net</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest and other income (expense), net consists of interest income earned on cash and cash equivalents, money market funds and short-term investments, realized gains and losses on investments.</span></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_52"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2021 and 2020</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,572&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,245)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.9&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,549)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,193)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,558)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,289)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,107)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,462)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,645)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,535)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,645)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,890)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income (expense), net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,263)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,533)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM:&#160;&#160;Results not meaningful</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue was $7.6 million and $41.8 million for the years ended December 31, 2021 and 2020, respectively. The decrease of $34.2&#160;million was primarily due to the&#160;recognition of a $25.0 million milestone payment in the first quarter of 2020 due to the achievement of first patient dosing in the Phase 1 trial of PLN-1474 as well as decreased research and development services revenues associated with PLN-1474, which were substantially complete in the first quarter of 2021. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our revenue to be derived from the Novartis Agreement for the foreseeable future and may fluctuate significantly based on the amount of research and development services required to further the development of PLN-1474 and integrin research targets as well as the potential achievement of developmental, regulatory and commercial milestones identified in the Novartis Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses was $77.5&#160;million and $66.2&#160;million for the years ended December 31, 2021 and 2020, respectively. The increase of $11.4&#160;million was primarily due to:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$5.4&#160;million increase in employee-related costs owing to the increase in our research and development workforce and stock-based compensation; </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$1.0&#160;million increase in outside and consulting services for preclinical studies and research and development activities by third party contract organizations; </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$5.4&#160;million increase in clinical trial expenses largely due to ramping costs in our Phase 2 trials of PLN-74809 and the commencement of several Phase 1 trials, which was partially offset by a decrease in the Phase 1 clinical trial costs for PLN-1474 which was substantially completed in the first quarter of 2021;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$1.2&#160;million increase in depreciation of lab equipment and costs of equipment and supplies; </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$2.4&#160;million decrease in technology and intellectual property licenses resulting from the payment to the Regents of the University of California in connection with our IPO in the second quarter of 2020; and </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$0.8&#160;million increase in facilities and other allocated expenses </span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses was $27.6&#160;million and $17.3&#160;million for the years ended December 31, 2021 and 2020, respectively. The increase of $10.3&#160;million was primarily due to a $7.3 million increase in employee-related costs, including stock-based compensation, and a $1.1 million increase in legal, accounting and other professional services largely due to operating as a public company. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income (expense), net</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income (expense), net was $272,000 and $112,000 for the years ended December 31, 2021 and 2020, respectively. The increase of $160,000 was due to higher average investment balances in 2021 compared to 2020 resulting from significant financing activities occurring mid-year 2020.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2020 and 2019</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.242%"><tr><td style="width:1.0%"></td><td style="width:40.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,052&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,235)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,193)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,353)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,840)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,930)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,339)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,462)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,283)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,179)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,645)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,231)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,414)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income (expense), net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,533)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(631)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40,902)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,482.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM:&#160;&#160;Results not meaningful</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of 15.2 million, or 26.7%, in revenue-related party for the year ended December 31, 2020 compared to the year ended December 31, 2019 was primarily due to the&#160;recognition of $50.0 million in upfront license fee revenue in 2019, offset by the&#160;recognition of $25.0&#160;million milestone payment from the achievement with the first patient dosing under the Novartis agreement in the first quarter of 2020 and the&#160;$9.8 million&#160;increase&#160;in research and development services revenue in 2020.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses was $66.2&#160;million and $47.4&#160;million for the years ended December 31, 2020 and 2019, respectively. The increase of $18.8&#160;million was primarily due to:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$4.9&#160;million increase in employee related costs owing to the increase in our research and development workforce and stock based compensation, including the introduction of our employee stock purchase plan in the third quarter of 2020; </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">7 million decrease in outside and consulting services for preclinical studies and research and development activities by third party contract organizations as our lead programs moved into clinical development stage in 2020;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$17.2&#160;million increase in clinical trial expenses primarily attributable to our Phase 1 and Phase 2 trials of PLN-74809 and the Phase 1 clinical trial for PLN-1474; </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$2.2&#160;million increase in technology and intellectual property licenses resulting from the payment to the Regents of the University of California in connection with our IPO in the second quarter of 2020; and </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">$1.9&#160;million increase in facilities and other allocated expenses </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses was $17.3&#160;million and $10.9&#160;million for the years ended December 31, 2020 and 2019, respectively. The increase of $6.3&#160;million was primarily due to $2.8 million of increased professional and consulting services costs, $1.6 million of increased compensation costs, $0.9 million of increased stock-based compensation expense, $0.5 million of increased charitable contributions and $0.5 million of increased insurance expenses, partially offset by $0.5 million decrease in travel expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional and consulting costs increased primarily as a result of increased legal, marketing, investor relations and accounting fees. Compensation costs and stock-based compensation costs increased as a result of increased headcount and the implementation of the employee stock purchase plan in the third quarter of 2020. Insurance expenses increased due to additional cost for insurance as a public company. Travel expenses decreased primarily due to decreased executive travel as a result of the COVID-19 pandemic.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income (expense), net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income (expense), net was $112,000 and $600,000 for the years ended December 31, 2020 and 2019, respectively. The decrease of $488,000 was primarily due to lower interest rates in 2020 when compared to 2019.</span></div><div id="i988625df783e4cc0a27bd76df388da57_55"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had cash, cash equivalents and short-term investments of $200.6&#160;million. Our cash, cash equivalents and short-term investments consist of U.S. Treasury securities, U.S. Government agency securities and highly rated, investment-grade corporate debt securities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have been financed primarily through the issuance and sale of convertible preferred stock, our collaboration with Novartis and issuance of common stock via our IPO. We completed our IPO in June 2020 and received $148.3 million, net of underwriting discounts, commissions and offering expenses. Concurrent with the completion of the IPO, we also issued 625,000 shares of our common stock to Novartis for proceeds of $10.0 million. During the third quarter of 2021, we entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co., as sales agent, pursuant to which we may issue and sell up to $150.0 million of shares of common stock from time to time. The issuance and sale of these shares pursuant to the Sales Agreement are deemed an &#8220;at-the-market&#8221; offering and are registered under the Securities Act of 1933, as amended. We have not issued any shares pursuant to any at-the-market offerings but may do so at a future date. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources, together with interest thereon, will be sufficient to meet our projected operating requirements for at least the next 12 months from the date of this filing and into the second half of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. We currently have no credit facility or committed sources of capital other than potential milestones receivable under our current collaboration and license agreements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the clinical development plans we establish for these product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the timelines of our clinical trials and the overall costs to conduct and complete the clinical trials, which may be impacted by the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the number and characteristics of product candidates that we develop;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, and other comparable foreign regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">whether we enter into any collaboration agreements and the terms of any such agreements;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities;  </span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and</span></div><div style="margin-top:6pt;padding-left:126.36pt;text-indent:-63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:59.5pt">the cost of operating as a public company.</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development expenditures. If we need to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our preclinical studies, clinical trials, research and development programs or commercialization efforts. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations and other licensing arrangements. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us.</span></div><div id="i988625df783e4cc0a27bd76df388da57_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(75,443)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37,271)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,750)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,699&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(210,866)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,931)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,527&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213,212&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,539&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34,925)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,858&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $75.4 million for the year ended December 31, 2021 compared to $37.3 million for the year ended December 31, 2020. The increase in cash used in operating activities of $38.2&#160;million between the year ended December 31, 2021 and 2020 was primarily due to decreased revenues and related receipts from our collaboration partner, Novartis, during 2021 coupled with an increase in operating expenses of $21.6&#160;million.     </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $37.3 million for the year ended December 31, 2020 compared to $2.8 million for the year ended December 31, 2019. The increase in cash used in operating activities of $34.5&#160;million between the year ended December 31, 2020 and 2019 was primarily due to an overall increase in operating expenses of $25.2&#160;million plus decreased revenues from Novartis of $15.2&#160;million as the $25.0 million milestone earned in the first quarter of 2020 was more than offset by the $50.0 million upfront license fee earned in 2019 plus. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by (Used in) Investing Activities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the year ended December 31, 2021 was $73.7&#160;million compared to net cash used in investing activities of $210.9&#160;million during the year ended December 31, 2020. The increase in cash provided by investing activities of $284.6&#160;million between the year ended December 31, 2021 and 2020 is a function of the timing of investment purchases versus maturities between the years. The significant shift from 2020 to 2021 is a result of significant financing inflows in 2020 compared to 2021 resulting in increased purchases of short-term investments in 2020. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities during the year ended December 31, 2020 was $210.9&#160;million compared to net cash used in investing activities of $17.9&#160;million during the year ended December 31, 2019. The increase in cash used in investing activities of $192.9&#160;million between the year ended December 31, 2020 and 2019 is a function of the timing of investment purchases versus maturities between the years. The significant shift from 2019 to 2020 resulted from increased financing activities in 2020 compared to 2019 resulting in increased purchases of short-term investments in 2020.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $2.5 million during the year ended December 31, 2021 as compared to $213.2 million during the year ended December 31, 2020. The decrease in cash provided by financing activities of $210.7 million between the year ended December 31, 2021 and 2020 was primarily due to 2020 financing activities including the issuance of common stock upon completion of our IPO of $150.8 million, issuance of common stock upon completion of the private placement with Novartis of $10.0 million and the issuance of our Series C convertible preferred stock of $52.0 million. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $213.2 million during the year ended December 31, 2020 as compared to $45.5 million during the year ended December 31, 2019. The increase in cash provided by financing activities of $167.7 million between the year ended December 31, 2020 and 2019 was primarily due to the above mentioned 2020 financing events, partially offset by net proceeds from the 2019 issuance of our Series C redeemable convertible preferred stock of $47.9 million. </span></div><div id="i988625df783e4cc0a27bd76df388da57_61"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements or holdings in any variable interest entities.</span></div><div id="i988625df783e4cc0a27bd76df388da57_64"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our material cash requirements as of December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1 to 3<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3 to 5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">More Than<br/>5 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,098&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,418&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,144&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,660&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total obligations</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,098&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,418&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,144&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,660&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, non-clinical studies and testing, manufacturing and other services and products. These contracts generally provide for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">termination following a certain period after notice and therefore we believe that our cancelable obligations under these agreements are not material and they are not included in the table above.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not included milestone or royalty payments or other contractual payment obligations in the table above if the timing and amount of such obligations are unknown or uncertain.</span></div><div id="i988625df783e4cc0a27bd76df388da57_67"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Polices and Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail&#160;in Note 2&#160;to our financial statements appearing elsewhere in this&#160;Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, all of our revenue to date has been generated from the Novartis Agreement. We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("Topic 606") we perform the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to our customer.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identification of the Contracts with the Customers</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate every contract to determine whether it in its entirety or in part represent a contract with a customer, or a collaboration agreement and, based on this determination, apply appropriate accounting guidance.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for a contract with a customer that is within the scope of Topic 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations, (ii) each party&#8217;s rights regarding the goods or services to be transferred can be identified, (iii) the payment terms for the goods or services to be transferred can be identified, (iv) the arrangement has commercial substance and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods or services that will be transferred to the customer is probable.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identification of the Performance Obligations</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised goods or services in our collaboration and option arrangements consist of license and research and development services. The arrangements also have options for additional items (i.e., license rights). Options are considered to be marketing offers and are to be accounted for as separate contracts when the customer elects such options, unless we determine the option provides a material right which would not be provided without entering into the contract. The determination as to whether such options are material rights requires significant management judgment, and management considers factors such as other similar arrangements, market data and the terms of the contractual arrangement to make such conclusion. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when: (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of our customer to develop the intellectual property on their own and whether the required expertise is readily available.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Determination of the Transaction Price</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, we evaluate the amount of the potential payments and the likelihood that the payments will be received. We utilize either the most likely amount method or expected value method to estimate the transaction price based on which method better predicts the amount of consideration expected to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent future payments, which include research, development, regulatory, and sales-based royalty payments, have not been considered in the initial analysis, as they are contingent upon option(s) being exercised or are subject to significant risk of achievement.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allocation of Transaction Price</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the transaction price based on the estimated standalone selling price. We must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. We utilize key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts we would expect to receive for satisfying each performance obligation.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recognition of Revenue</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue at the point in time when distinct, functional licenses are transferred to the licensee and/or over the period of time which we perform research and development services. We utilize a cost-based input method to measure proportional performance, as such costs have direct relationship between our effort and the progress made towards satisfying its performance obligations to Novartis.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Prepaid Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accrued expenses for estimated costs of our research and development activities activities which include the conduct of clinical studies and preclinical studies by third-party service providers. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and include these costs in accrued liabilities in the balance sheets and within research and development expenses in the statements of operations and comprehensive loss. These costs are a significant component of our research and development expenses. We record accrued expenses for these costs based on factors such as estimates of the work completed and in accordance with agreements established with these third-party service providers. Any payments made in advance of services provided are recorded as prepaid assets, which are expensed as the contracted services are performed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the amount of work completed through review of detailed budgets and timelines included in our contracts and agreements, and update these estimates with information obtained from third-party service providers and internal personnel on a quarterly basis. We make significant judgments and estimates in determining the accrued and/or prepaid balance in each reporting period. As actual costs become known, we adjust our estimates. Our accrued expenses and prepaid research and development expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations, other third-party service providers and internal research and development personnel. If we under estimate or over-estimate the level of services performed or the costs of these services, our accrued expenses could differ from our estimates. For the periods presented, we have experienced no material differences between our accrued expenses and actual expenses.</span></div><div id="i988625df783e4cc0a27bd76df388da57_70"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status and JOBS Act Accounting Election</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the market value of our common stock held by our non-affiliates as of June 30, 2021, we are considered a &#8220;large accelerated filer&#8221; on December 31, 2021 and thus lost our status as an emerging growth company as of such date. Accordingly, we can no longer rely upon exemptions and reduced reporting requirements provided by the JOBS Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under Note 2 to the financial statements under the caption &#8220;Recently Issued Accounting Pronouncements&#8221; is incorporated herein by reference.</span></div><div id="i988625df783e4cc0a27bd76df388da57_76"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:10pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_82">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_82">107</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_85">Balance Sheets as of December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_85">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_85"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_85">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_85">109</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_91">Statements of Operations and Comprehensive Loss for the Years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_91">21</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_91">, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_91"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_91">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_91">110</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_94">Statements of Stockholders&#8217; Equity (Deficit) for the Years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_94">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_94">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_94">20 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_94">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_94">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_94">111</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_97">Statements of Cash Flows for the Years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_97">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_97">, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_97"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_97">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_97">114</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_100">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i988625df783e4cc0a27bd76df388da57_100">116</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the stockholders and the Board of Directors of Pliant Therapeutics, Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Pliant Therapeutics, Inc. (the "Company") as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows, for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2022, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Accounting Principle </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2 to the financial statements, the Company has changed its method of accounting for leases effective January 1, 2021 due to the adoption of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Update (&#8220;ASU&#8221;) Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), using the modified retrospective approach.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities and Prepaid Expenses and Other Current Assets &#8211; Accrued and Prepaid Research and Development Expenses &#8212; Refer to Notes 2, 5 and 6 to the financial statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accrued expenses for costs of research and development activities which include the conduct of clinical studies and preclinical studies by third-party service providers, based upon the estimated amount of services provided but not yet invoiced. Any payments made in advance of services provided are recorded as prepaid assets, which are expensed as the contracted services are performed. The Company estimates the amount of work completed through review of detailed budgets and timelines included in its contracts and agreements, and updates these estimates with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information obtained from third-party service providers and internal personnel on a quarterly basis. As of December 31, 2021, accrued research and development expenses were $5.9 million and prepaid research and development expenses were $2.8 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant judgments made by management in estimating the progress or stage of completion of the services, auditing the Company&#8217;s accrued and prepaid research and development expenses was especially challenging. Specifically, because the amount of accrued and prepaid research and development expenses is dependent on management&#8217;s receipt of timely and accurate reporting from third-party service providers, management&#8217;s estimates of work completed as of the balance sheet date, and management&#8217;s estimates of the period over which this work will be performed, auditing accrued and prepaid research and development expenses required a high degree of auditor judgment and an increased extent of effort. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the Company&#8217;s accrued and prepaid research and development expenses included the following, among others: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We tested the design and operating effectiveness of internal controls related to the estimation of accrued and prepaid research and development expenses.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">For a sample of agreements and contracts, we read the related statement of work, purchase order, and inspected information the Company received from its third-party service providers. We tested the accuracy and completeness of the underlying information used in the estimates and evaluated the significant assumptions that are used by management to estimate the recorded amounts by performing the following procedures:</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Performed corroborating inquiries with the Company&#8217;s research and development personnel that oversee the preclinical and clinical studies to obtain information regarding the nature and extent of progress of preclinical and clinical studies. </span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Obtained external written confirmations from the Company&#8217;s third-party service providers regarding the accuracy and completeness of contracted amounts and percentage of completion. </span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Evaluated management&#8217;s judgments using the evidence obtained.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">For a sample of agreements and contracts, we obtained the corresponding invoices and evidence of payment to test the Company&#8217;s disbursements made to third-party service providers as of December 31, 2021.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We compared invoices received by the Company subsequent to December 31, 2021 to the accrued research and development expenses recognized by the Company as of that date. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184Mi9mcmFnOjNkOWJkOTBhZWZkNDRmZGI5YmU4MGUzMWNiY2E5NDYxL3RleHRyZWdpb246M2Q5YmQ5MGFlZmQ0NGZkYjliZTgwZTMxY2JjYTk0NjFfMzI5ODUzNDkwNDAwMg_1a523547-3eef-4038-9a7c-dd3ca5025ea3">Deloitte &amp; Touche LLP</ix:nonNumeric> (PCAOB ID No. <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184Mi9mcmFnOjNkOWJkOTBhZWZkNDRmZGI5YmU4MGUzMWNiY2E5NDYxL3RleHRyZWdpb246M2Q5YmQ5MGFlZmQ0NGZkYjliZTgwZTMxY2JjYTk0NjFfMTM3NDM4OTUzNjc4OTY_14b98500-dfe4-4a11-9cc3-f0c1f501bddb">34</ix:nonNumeric>) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184Mi9mcmFnOjNkOWJkOTBhZWZkNDRmZGI5YmU4MGUzMWNiY2E5NDYxL3RleHRyZWdpb246M2Q5YmQ5MGFlZmQ0NGZkYjliZTgwZTMxY2JjYTk0NjFfMzI5ODUzNDkwNDAwNA_810cbe85-25af-466c-81da-54208d911ca7">San Francisco, California</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2018.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except number of shares and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMy0xLTEtMS0xMjY1OQ_e7deb152-abee-44b4-b7fc-0b5cf7ab3641">51,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMy0zLTEtMS0xMjY1OQ_08053b56-0e73-4cd3-a0af-8600aad70499">50,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNC0xLTEtMS0xMjY1OQ_fa470899-ca96-48e2-8901-31cd19b125b6">148,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNC0zLTEtMS0xMjY1OQ_6cfeac8b-dd56-429f-938c-98ba514a1587">226,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNS0xLTEtMS0xMjY1OQ_76b2cd9e-a749-4ef6-831b-b7b290859374">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNS0zLTEtMS0xMjY1OQ_e6b3b567-4360-40a6-a0ca-b7b997abffad">9,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credit receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNi0xLTEtMS0xMjY1OQ_02dc2f80-9a18-4431-91ee-a03986e19ea3">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNi0zLTEtMS0xMjY1OQ_ff13470d-1483-4c8d-8240-bbd1f425635b">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNy0xLTEtMS0xMjY1OQ_ff8117c2-a332-4289-a672-6e6cc97fcb89">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNy0zLTEtMS0xMjY1OQ_16a5b38c-6395-43cc-8d8b-c2fc994b90b8">4,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfOC0xLTEtMS0xMjY1OQ_935f263a-4714-41cc-aedb-f0eff95b7721">209,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfOC0zLTEtMS0xMjY1OQ_cd851040-5e0c-486b-a09d-1dd58c57ef45">290,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfOS0xLTEtMS0xMjY1OQ_33aa4132-e982-4e41-b4bd-7d200e0bdc5f">4,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfOS0zLTEtMS0xMjY1OQ_028dfb27-8a7d-4703-b6ab-6e9baf5e53d4">4,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTAtMS0xLTEtMTk3Mjc_5db5fdd6-5502-4b31-b6f2-bcae4d21edb7">6,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTAtMy0xLTEtMTk3MzM_41064ec3-0ba6-461d-a784-d42e89ff9081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTAtMS0xLTEtMTI2NTk_76df5775-505d-4c69-9fb3-ce272d606613">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTAtMy0xLTEtMTI2NTk_91c7252b-afd6-4111-aa13-30f196450721">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTEtMS0xLTEtMTI2NTk_1709e975-3a4c-4258-b6c8-6137edfdd191">221,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTEtMy0xLTEtMTI2NTk_a8fe6f21-3607-45c5-9ff4-ca746f49c8bf">295,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and stockholders&#8217; equity </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTQtMS0xLTEtMTI2NTk_76b4999b-5505-4a76-867a-33cc7c3a148d">2,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTQtMy0xLTEtMTI2NTk_141a695e-b848-4034-b61f-6b0c3432ed7a">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTUtMS0xLTEtMTI2NTk_1fe250eb-80db-4f89-a9f9-8a394dedb483">11,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTUtMy0xLTEtMTI2NTk_655ba4c0-86cb-4ae2-b1d7-33f013aaaf9e">9,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTctMS0xLTEtMTk3Mzk_c882a4bd-6a81-4d1b-9917-ac86358bcd14">1,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTctMy0xLTEtMTk3NDU_dbcaa39b-48a6-4ae6-a6b5-d10bccfccd17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTYtMS0xLTEtMTI2NTk_911cffa7-1c77-4f87-b956-4208c7379d8c">16,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTYtMy0xLTEtMTI2NTk_333e9b42-8ed5-442b-9c6e-fcc19e180c1e">11,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTktMS0xLTEtMTk3NjA_dbc176cd-221b-4eb9-9e22-2af9c04c0a95">5,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTktMy0xLTEtMTk3NjY_7f1bd2a7-6f9a-4208-bf94-cb33b6ce2f2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTctMS0xLTEtMTI2NTk_731c7101-e59d-4f5e-a46c-f702b03b59de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTctMy0xLTEtMTI2NTk_852e86e1-05f8-476b-ae87-dff66f024158">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTgtMS0xLTEtMTI2NTk_dd9fb72f-9640-400c-88fb-174669e245c9">22,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTgtMy0xLTEtMTI2NTk_def455d4-65c8-4b82-9a9b-9fefc0e05e8e">12,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTktMS0xLTEtMTI2NTk_617d5230-c2b7-4f07-98cc-2b1f14036d15"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTktMy0xLTEtMTI2NTk_32bf95a7-ef6f-468d-bdb8-23a81d5d7880"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDU3_06ec65b1-4e0e-4136-8ed4-4d266d613446"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDU3_a5dbced0-200d-4a5e-a7ca-dd841d2da932">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDQ3_039875d4-ad47-4614-8498-5e9f29f96071"><ix:nonFraction unitRef="shares" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDQ3_74e28157-f445-4817-9ba0-e4359ea0bd44">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2021 and 2020; and <ix:nonFraction unitRef="shares" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDIw_3b36e164-3130-4847-8679-38aa64344bf5"><ix:nonFraction unitRef="shares" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDIw_c1cff679-d571-4b1d-bd95-e030bff1ae70">36,083,301</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDMz_4a2060e6-c652-4a58-b8d8-cdb57393dd96"><ix:nonFraction unitRef="shares" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDMz_9a7a5254-5c80-4f72-9194-a65aaea50f4e">35,552,795</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and 2020, respectively;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjUtMS0xLTEtMTI2NTk_6d8aa990-5683-4a4a-b158-8ab3d8a4eb5d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjUtMy0xLTEtMTI2NTk_8eaee3ad-dcdf-4a75-93e8-bab6daf2cf4f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjYtMS0xLTEtMTI2NTk_cdec4b03-2266-4c18-840e-e53b1bf9ffbe">414,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjYtMy0xLTEtMTI2NTk_78838422-686f-4f58-85c9-ae91a10cd6b4">400,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjctMS0xLTEtMTI2NTk_c418c687-7ef8-4be5-9418-2c65d57864c4">215,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjctMy0xLTEtMTI2NTk_3f2d4caf-9b69-4f0e-a4f5-1fd5dba00c55">117,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjgtMS0xLTEtMTI2NTk_d48f1ddf-02e8-44cd-af7d-d0c77bf2c1d1">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjgtMy0xLTEtMTI2NTk_1627e30b-c6fa-4e6d-9f00-80559956f1b5">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjktMS0xLTEtMTI2NTk_7796c29a-ff8b-4250-84c5-0fa7a95d3eb6">199,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjktMy0xLTEtMTI2NTk_ac681f87-168d-455a-8b97-bce75cf816ac">283,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMzAtMS0xLTEtMTI2NTk_fe35aa22-96d6-4f44-9ad9-329e36839765">221,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMzAtMy0xLTEtMTI2NTk_5c5196f5-92a6-4f27-a31d-86850ecce292">295,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except number of shares and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMi0xLTEtMS0xMjY1OQ_43709db1-a733-4215-a87e-85a4db810e25">7,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMi0zLTEtMS0xMjY1OQ_8d8e731f-4216-4563-a8f3-e3c49dde5e10">41,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMi01LTEtMS0xNjQ5Mw_6509f84c-2b42-4ac9-9c2d-6850edc346e0">57,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNC0xLTEtMS0xMjY1OQ_a7f0b0e3-67de-4f89-aff2-1156b2e35afa">77,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNC0zLTEtMS0xMjY1OQ_1cd8467b-858c-44d4-bc8b-36420d40970c">66,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNC01LTEtMS0xNjQ5Mw_1fcc95b9-cf53-4654-8ee6-bba2e1130991">47,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNS0xLTEtMS0xMjY1OQ_d5ef6fc7-1f7c-485b-bd50-c81193310b32">27,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNS0zLTEtMS0xMjY1OQ_ac750d54-36e0-45ab-9611-23d8c6778658">17,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNS01LTEtMS0xNjQ5Mw_549b3457-0671-480e-9075-cea7f5ce27d6">10,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNi0xLTEtMS0xMjY1OQ_49166be8-5122-4dfe-b569-be637636cf37">105,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNi0zLTEtMS0xMjY1OQ_3785fa9b-75c2-4a86-a3fb-a92ddec845e7">83,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNi01LTEtMS0xNjQ5Mw_38e176b9-22c6-4e57-a116-1c81a4ad969f">58,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNy0xLTEtMS0xMjY1OQ_f38d5948-f6d8-4f75-9ccd-2084737e0b4d">97,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNy0zLTEtMS0xMjY1OQ_e65e6b0f-422a-4d44-8eba-041cb1f70d09">41,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNy01LTEtMS0xNjQ5Mw_795840a3-09e9-43da-8b31-99edf154eb06">1,231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="plrx:InterestAndOtherIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfOC0xLTEtMS0xMjY1OQ_a6f12709-8801-4cab-8788-ff82e9f3c51f">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="plrx:InterestAndOtherIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfOC0zLTEtMS0xMjY1OQ_43ccc982-5fdb-4a14-b22d-15b106bb8597">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="plrx:InterestAndOtherIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfOC01LTEtMS0xNjQ5Mw_20834711-4f53-41f4-a166-1423acdcfe7c">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTAtMS0xLTEtMTI2NTk_df162a57-2d70-4034-ac6f-f61210a5fc59">97,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTAtMy0xLTEtMTI2NTk_9caeafb3-9d8b-4a56-afd8-c3891c82bf7f">41,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTAtNS0xLTEtMTY0OTM_e4ceb873-d4b9-4da2-b031-38e70d4e919a">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accretion to redemption value and dividends on redeemable convertible </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;preferred stock</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTEtMS0xLTEtMTI2NTk_fdd4dab4-dcdc-4c35-91ae-42357c2793d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTEtMy0xLTEtMTI2NTk_de64c902-fc2f-402e-a7ec-0fe07f75f99e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTEtNS0xLTEtMTY0OTM_231dfe55-2309-48dd-aba6-e5ef6789c01d">6,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTItMS0xLTEtMTI2NTk_c3f4e9ce-1e94-40b0-b9c4-97df27bca875">97,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTItMy0xLTEtMTI2NTk_487f266b-e7cb-484b-8451-47a031c90e5d">41,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTItNS0xLTEtMTY0OTM_26d10232-c1b4-4e4f-8c92-a4c2b1b02923">6,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, attributable to common stockholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTQtMS0xLTEtMTI2NTk_fba350fc-bb6b-460e-b303-15c4ff3ade47">2.71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTQtMy0xLTEtMTI2NTk_fd5318b9-6efa-4991-bb83-170bf81e125f">1.95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTQtNS0xLTEtMTY0OTM_1ec160aa-b579-48af-80c8-5394055bcb5d">4.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTUtMS0xLTEtMTI2NTk_d2e8ab20-b744-4b26-a366-cba978c03cbf">2.71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTUtMy0xLTEtMTI2NTk_fc5b2c57-57b6-4861-90af-87407c3df2ff">1.95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTUtNS0xLTEtMTY0OTM_d79744b6-848d-480c-b98a-8db51a281440">4.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share attributable to common <br/>&#160;stockholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTctMS0xLTEtMTI2NTk_9d10dc74-8372-4936-b4a3-aa35bdabd89b">35,846,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTctMy0xLTEtMTI2NTk_ac593688-8c97-4073-8ffb-c290805c8c8e">21,344,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTctNS0xLTEtMTY0OTM_39295e0c-e1b9-43b7-bd52-3ce77bae651e">1,623,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTgtMS0xLTEtMTI2NTk_3301c863-8364-448b-bd79-cd06b80e275b">35,846,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTgtMy0xLTEtMTI2NTk_b87ea826-6c35-46b7-a500-147ffe3b4a01">21,344,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTgtNS0xLTEtMTY0OTM_023c991c-ef55-417f-9385-d917a6131409">1,623,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjAtMS0xLTEtMTI2NTk_033a4c42-6fd8-46f7-adb2-c72eafaa02f1">97,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjAtMy0xLTEtMTI2NTk_1eb81e1a-8855-487f-b5ea-ef583f3f7286">41,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjAtNS0xLTEtMTY0OTM_a841dcda-ee17-4ef9-9f33-4dda3a656166">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized loss on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjItMS0xLTEtMTI2NTk_a3ee09c6-2038-4e4d-ba1b-dde2fdf2f7d3">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjItMy0xLTEtMTI2NTk_a7a77d9f-b29d-4538-89ec-050c4e9d1b09">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjItNS0xLTEtMTY0OTM_f18f50d2-1535-4d16-a530-897b5b257f07">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjMtMS0xLTEtMTI2NTk_b02b73c7-7846-49b8-a10a-2442a41065bb">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjMtMy0xLTEtMTI2NTk_983ce3c0-fb00-4c6b-bbb7-99bcbb60db30">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjMtNS0xLTEtMTY0OTM_522dd3fd-746e-4f73-9c94-8d152397f28d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjQtMS0xLTEtMTI2NTk_ba94f668-be85-4fa3-8e11-e05214b1a8a1">97,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjQtMy0xLTEtMTI2NTk_f742d346-b000-468f-9395-54e5de67ecf1">41,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjQtNS0xLTEtMTY0OTM_6a7cc289-99ca-4a09-a7c0-cc9278fc5414">632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except number of shares and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.469%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series A</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series B</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8fad418d5e0c4442b3c947090aa4197d_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xLTEtMS0xMjY1OQ_74c1220b-1fee-4538-b57a-2c6cb09755af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8fad418d5e0c4442b3c947090aa4197d_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0zLTEtMS0xMjY1OQ_8609d43c-20fe-4e36-842d-dc2ecba8e3a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1140261f7add41b5b728c3a650671ec6_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy01LTEtMS0xMjY1OQ_472db416-346a-447a-8c61-170b85405fe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1140261f7add41b5b728c3a650671ec6_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy03LTEtMS0xMjY1OQ_86979281-e67f-4edb-8dfa-f06489cbbbb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7e75b3a2844245b397c0918c42b28f6d_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy05LTEtMS0xMjY1OQ_946c1a04-d94b-4e94-8056-46fe0f572192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e75b3a2844245b397c0918c42b28f6d_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xMS0xLTEtMTI2NTk_384bd584-67be-4e11-804e-3f835e4aed1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xMy0xLTEtMTI2NTk_389baf30-53f9-4814-a0b5-73fcb75b5109">35,552,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xNS0xLTEtMTI2NTk_40f67bd8-387c-4b6f-bc5f-e38d94dcfd65">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id19e6266bc8b4ecca92ba96df80eff19_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xNy0xLTEtMTI2NTk_a515ee42-0802-454a-bd20-84d117679a7d">400,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i76c3089f6aa24936b58640c2e6b7da25_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xOS0xLTEtMTI2NTk_fd3052f1-0a05-42d1-833c-b639cffa39f8">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i105a9ac3dc914251920a2e0a79bd4eef_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0yMS0xLTEtMTI2NTk_00e394e6-c743-420a-8830-bc455a6c2ad6">117,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0yMy0xLTEtMTI2NTk_8ca3c0a6-6839-41ad-a0b0-2e39ff3defc5">283,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Vesting of restricted stock awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7a323ae54ce842b387531c5805e9f231_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOC0xMy0xLTEtMTI2NTk_1b5634c7-232f-4079-ad0a-cee5534b152d">103,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i352bc25f1a8b4f56a69867979fce6c4b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOC0xNy0xLTEtMTI2NTk_7481d474-7c65-48c6-9405-4b742c74633e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOC0yMy0xLTEtMTI2NTk_18764d74-654a-4649-befb-775a910b3003">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Option exercises</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7a323ae54ce842b387531c5805e9f231_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOS0xMy0xLTEtMTI2NTk_15b0831d-edbc-4bee-85a6-e3fa1a977d6e">427,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i352bc25f1a8b4f56a69867979fce6c4b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOS0xNy0xLTEtMTI2NTk_ea7bd513-ab60-4d8c-9e1d-54f189882897">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOS0yMy0xLTEtMTI2NTk_933c0f82-a254-46d6-882f-d016b0cb5530">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i352bc25f1a8b4f56a69867979fce6c4b_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTAtMTctMS0xLTEyNjU5_4e4d1c89-c4f5-42b7-8540-d693ee0b74ad">10,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTAtMjMtMS0xLTEyNjU5_7a50b888-b5d3-46fc-ae2e-67b06ca85153">10,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net unrealized loss on short-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i95bbcd616eec42679d3f2ba166e8427e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTEtMTktMS0xLTEyNjU5_0840dac0-7141-4cb9-942b-adc5c16f767a">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTEtMjMtMS0xLTEyNjU5_c11d7b31-5672-4ef2-b4da-e80867a87960">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d5f0f71b08940e796377b4b0153bd67_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTItMjEtMS0xLTEyNjU5_221cea42-96f9-4931-926c-06466d0973a6">97,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTItMjMtMS0xLTEyNjU5_2f9a88bf-ebfb-4b8d-9f7c-4ad7fd7fe150">97,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaef884d5c4ad4ddc992fd9dc8a744804_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMS0xLTEtMTI2NTk_4041d095-be3e-456c-9109-82e628d6a831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaef884d5c4ad4ddc992fd9dc8a744804_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMy0xLTEtMTI2NTk_c2618104-ea96-410b-86bd-ce21b00ccb5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if0ee10d79d854a2aa094cc081ddee51d_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtNS0xLTEtMTI2NTk_edbacc9d-cc43-4058-a9db-2952f4a0e714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0ee10d79d854a2aa094cc081ddee51d_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtNy0xLTEtMTI2NTk_3f45c628-be76-46d7-8b83-39b83610ace0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8427be0929874da48269b8a87d7e8ba7_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtOS0xLTEtMTI2NTk_beee8b4f-9d1f-42a8-b88d-f1b1c26a70ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8427be0929874da48269b8a87d7e8ba7_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTEtMS0xLTEyNjU5_6b11e280-b467-4f0b-a701-9577a1f33eb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9dd41145a7974d92a2226a3fc35633a9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTMtMS0xLTEyNjU5_6fc568f7-2924-4e84-b4df-abfe5a9542a7">36,083,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9dd41145a7974d92a2226a3fc35633a9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTUtMS0xLTEyNjU5_d4fc6217-2bf3-4f9b-8ffd-96902c2180a4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25794e7f363a4bf1abd2e657b1000f09_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTctMS0xLTEyNjU5_2f65ae20-5a5c-4026-9e97-af9c4f202f36">414,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ife5a281e3e5b42d79b8b4f9a04af5d63_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTktMS0xLTEyNjU5_48525e99-5b56-4d3d-824a-2092b7b20ed5">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i77ad7fa9b65442f2ba3cba3af87805a0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMjEtMS0xLTEyNjU5_678b5500-9897-4e07-a514-8e2a95b7841d">215,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMjMtMS0xLTEyNjU5_df23b086-1bbe-45f7-becc-ed210c7a8042">199,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except number of shares and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.136%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total <br/>Stockholders'<br/>Equity<br/>(Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series A</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series B</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idb689d41a0fc49d096930b208671ff5a_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xLTEtMS0xMjY1OQ_62ed75ca-0e62-4a67-8a80-50dd53ca8a23">56,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb689d41a0fc49d096930b208671ff5a_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0zLTEtMS0xMjY1OQ_a16f9b3b-6bf1-4929-850e-0479bbd44405">62,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibc82fb340f724ed2902d29a505bc74c7_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy01LTEtMS0xMjY1OQ_c665fb37-0bde-4b21-850f-e2b5136a7859">49,501,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc82fb340f724ed2902d29a505bc74c7_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy03LTEtMS0xMjY1OQ_50da6a55-20c3-4614-86c7-a3e239f96350">75,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy05LTEtMS0xMjY1OQ_3c52a9f8-31f9-4ab1-9ee3-b01b7ec58a78">26,360,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xMS0xLTEtMTI2NTk_4d29f2f5-6010-4656-8984-66a432f80313">47,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i826b025c166f473987892842e39f1549_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xMy0xLTEtMTI2NTk_a09d8106-5510-47da-bbf5-d045731a6502">1,846,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i826b025c166f473987892842e39f1549_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xNS0xLTEtMTI2NTk_3b1b74b2-7b92-426c-9fd4-cee538093df1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6bbff1d55944244a3110049517d61da_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xNy0xLTEtMTI2NTk_e589c622-a4a9-4f54-b553-c766c1f4e1c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iffe3207e1e714584bed5756b07541340_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xOS0xLTEtMTI2NTk_6ef51cd1-5d5b-445e-b90b-542fb2d349cf">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3c41e7454f6a4547977cbf6b6a2349d3_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0yMS0xLTEtMTI2NTk_a76a6963-c5a4-4d04-a5bd-c90485475c9d">76,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0yMy0xLTEtMTI2NTk_1df113a7-cc9a-471a-bbb3-14d08b910149">76,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Series C redeemable preferred stock, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if537cc7d047f4502af240fda53df5d71_D20200101-20201231" decimals="INF" name="plrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNC05LTEtMS0xMjY1OQ_f947ddaa-33fe-4a28-97e6-1a0f24a14901">28,527,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if537cc7d047f4502af240fda53df5d71_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNC0xMS0xLTEtMTI2NTk_9b80572e-7ddd-4a13-a79b-88d4ab1ef8d1">52,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock <br/>&#160;&#160;&#160;&#160;upon initial public offering,<br/>&#160;&#160;&#160;&#160;net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if7fb96ee1b444920b7e071c2562a2d93_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xMy0xLTEtMTY1OTI_eb09a541-aea8-4c7c-9d38-5eac2e586d9c">10,350,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7fb96ee1b444920b7e071c2562a2d93_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xNS0xLTEtMTY1OTg_c0f4018b-10f5-4e20-bee0-410f6b93aa79">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ac12187e1ff4ab9bc07add5cf0d39c5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xNy0xLTEtMTY2MDQ_61df1731-0ba3-4978-a99b-b87340bc15ac">148,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4029b81cb5354eb6ae5e85b44506260f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0yMy0xLTEtMTY2MjI_1186da5c-be5f-46be-b2d6-7d71c89339f0">148,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock <br/>&#160;&#160;&#160;upon private placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i763102559694449eb64cf66afe0a616f_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0xMy0xLTEtMTY1OTI_473735dd-c5bc-4e74-8f17-375b676b3cde">625,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6338bf9158f4706b6ad1a45102335fb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0xNy0xLTEtMTY2MDQ_e13732db-3a7a-4fae-8d38-831ac0f7380a">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2f8cb5576bbf476b8d7705a54bb4ff2a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0yMy0xLTEtMTY2MjI_d0ae5cc2-bc76-4498-bff9-3ac6e409d047">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of Series A, B, C <br/>&#160;&#160;&#160;convertible preferred stock<br/>&#160;&#160;&#160;to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i53c7626359c74441b6a578b9d935f19c_D20200101-20201231" decimals="INF" sign="-" name="plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xLTEtMS0xNjU1Ng_5ab8ba6c-17a1-41f5-9726-1021497a437b">56,000,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i53c7626359c74441b6a578b9d935f19c_D20200101-20201231" decimals="-3" sign="-" name="plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0zLTEtMS0xNjU2Mg_60d0f6b6-96e8-4705-8d00-8aeda409866b">62,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8589e12213434e09abcb711b749141bd_D20200101-20201231" decimals="INF" sign="-" name="plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy01LTEtMS0xNjU2OA_6c547d5f-2d6e-4e8a-9bce-906916e22bc4">49,501,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8589e12213434e09abcb711b749141bd_D20200101-20201231" decimals="-3" sign="-" name="plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy03LTEtMS0xNjU3NA_e5ba5567-6631-4283-a30d-eee8beca6cf4">75,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="if537cc7d047f4502af240fda53df5d71_D20200101-20201231" decimals="INF" sign="-" name="plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy05LTEtMS0xNjU4MA_3b109066-396c-48f7-a4de-966f42823c6f">54,888,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if537cc7d047f4502af240fda53df5d71_D20200101-20201231" decimals="-3" sign="-" name="plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xMS0xLTEtMTY1ODY_0fd3c0a9-288a-4cca-bf8a-729091a2f261">99,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xMy0xLTEtMTY1OTI_6a6ebde5-0308-4ca6-9963-be267b5b0afa">22,432,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xNS0xLTEtMTY1OTg_d3be7632-6c2a-4110-abbf-bc972d1b6b7a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id52ffdf994934ba09ae03636d3857089_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xNy0xLTEtMTY2MDQ_a6e1b966-0263-4da3-a145-4b6e46dde1e9">238,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id8f4455a8e244490bb265a1a4f8a8cb0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0yMS0xLTEtMTY2MTY_6877a44d-9bbc-4364-9155-8d48ab49bd59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0yMy0xLTEtMTY2MjI_72522c3e-5f77-437e-b12a-014a8deb27a2">238,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Vesting of founders&#8217; common stock and restricted stock awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xMy0xLTEtMTI2NTk_df9a66e9-7d46-482a-ab9b-f2cabbfa6542">163,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id52ffdf994934ba09ae03636d3857089_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xNy0xLTEtMTI2NTk_2cfdab7a-0d24-4fe9-8789-e3fadc4c12e2">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0yMy0xLTEtMTI2NTk_a61bceab-2393-4db4-92b4-89fcca731419">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Option exercises</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0xMy0xLTEtMTI2NTk_62a61122-288c-4de7-9a68-e4abb2429cf7">136,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id52ffdf994934ba09ae03636d3857089_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0xNy0xLTEtMTI2NTk_3e82af2e-cc14-4a5f-907c-b4ff9edefd47">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0yMy0xLTEtMTI2NTk_36bc4153-3bb6-4aa1-bb5e-8f20681ecbb4">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id52ffdf994934ba09ae03636d3857089_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfOC0xNy0xLTEtMTI2NTk_ced8ae3a-be59-4b11-a663-563b15669c6d">3,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfOC0yMy0xLTEtMTI2NTk_0469fa6a-7fdd-4853-8b58-49ccc70aa5ed">3,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net unrealized loss on short- term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4ce83dd4cd2843efa13d02a41dcfe432_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfOS0xOS0xLTEtMTI2NTk_6e40e117-77a2-4632-92a2-9fda757b3bc9">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfOS0yMy0xLTEtMTI2NTk_dac6e76b-d106-47eb-9b45-c25d0b6dd1ac">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id8f4455a8e244490bb265a1a4f8a8cb0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTAtMjEtMS0xLTEyNjU5_83153806-b257-4a01-a6d7-9ed50965aabc">41,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTAtMjMtMS0xLTEyNjU5_d317b939-0c7d-4f20-91d8-9ad7c28b4d4f">41,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8fad418d5e0c4442b3c947090aa4197d_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMS0xLTEtMTI2NTk_e5fd3b49-910d-4908-b92d-622bd89bcebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8fad418d5e0c4442b3c947090aa4197d_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMy0xLTEtMTI2NTk_f6b4138e-a03c-4605-a1d4-54f5bd2fd0c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1140261f7add41b5b728c3a650671ec6_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtNS0xLTEtMTI2NTk_11645f96-4f75-4147-9a27-0ff8f953c794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1140261f7add41b5b728c3a650671ec6_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtNy0xLTEtMTI2NTk_23cedd57-ea26-4d4e-9d53-559c9bb970bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7e75b3a2844245b397c0918c42b28f6d_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtOS0xLTEtMTI2NTk_e16d3827-78f5-4126-894f-52980be36b52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e75b3a2844245b397c0918c42b28f6d_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTEtMS0xLTEyNjU5_4c279138-02d7-4e90-a89c-b6e2462da702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTMtMS0xLTEyNjU5_1dab5505-3964-485b-96e7-be46efc5ab31">35,552,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTUtMS0xLTEyNjU5_3ea090eb-bcdc-4c0d-91e2-bbc827b2d285">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id19e6266bc8b4ecca92ba96df80eff19_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTctMS0xLTEyNjU5_d5404b6e-2a87-4e7b-bcab-0d388eeb1e43">400,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i76c3089f6aa24936b58640c2e6b7da25_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTktMS0xLTEyNjU5_d4336ba7-e697-498c-9656-50c4f3757fa2">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i105a9ac3dc914251920a2e0a79bd4eef_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMjEtMS0xLTEyNjU5_63fb4249-a867-4076-b0a2-593bf245b7bc">117,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMjMtMS0xLTEyNjU5_f91f2096-79cb-4cae-8f87-cd34f541b2b2">283,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except number of shares and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.136%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total <br/>Stockholders'<br/>Equity<br/>(Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series A</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series B</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie5401e3f0f3d449e8847afa47baa6f9a_I20181231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xLTEtMS0xODQ5MQ_fec2b7f6-a157-423a-bf6a-ae16b48d829c">56,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie5401e3f0f3d449e8847afa47baa6f9a_I20181231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0zLTEtMS0xODQ5MQ_867083d0-c600-4b45-ad5b-f545ca107ffe">61,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icbc20870287540578a9e62621b62c833_I20181231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy01LTEtMS0xODQ5MQ_3ec1b6da-6d54-4eea-ac34-5bc7d68f9d87">49,501,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icbc20870287540578a9e62621b62c833_I20181231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy03LTEtMS0xODQ5MQ_b054b994-2e7f-46bf-b307-29af2838e1f1">70,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i62be0d4030cf4d84a89b73f59b635fc1_I20181231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy05LTEtMS0xODQ5MQ_5e5c741b-72c3-45a5-b981-16c57e944a2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i62be0d4030cf4d84a89b73f59b635fc1_I20181231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xMS0xLTEtMTg0OTE_241aed9a-1350-426a-a4ad-3301fb8b98c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iecc4ce257ab041eab3f3f31f4101a94f_I20181231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xMy0xLTEtMTg0OTE_5547312d-239a-4107-afb8-d49351a7a120">1,363,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iecc4ce257ab041eab3f3f31f4101a94f_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xNS0xLTEtMTg0OTE_df729cad-ea7d-4aae-b564-738d9ae30b8d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0e1e2bb434c4f519e0a4c7d227fc9d1_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xNy0xLTEtMTg0OTE_85be2b46-5552-4a97-b669-e0a8583db3ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic95cde64854f441a96044b55c63e47c5_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xOS0xLTEtMTg0OTE_04d2db2c-806f-4d98-adc8-d5aeb4f7aefc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib3740b71577f46c7aa6db36ccc8e9008_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0yMS0xLTEtMTg0OTE_c9a87193-3593-44b5-a249-a1df593aff56">71,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="idcb6e46e8589417fbb6dce85ec4707e9_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0yMy0xLTEtMTg0OTE_c55655bf-5a7a-4dad-8a09-6c496adbf848">71,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Series C redeemable preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7e2e2d92973409c98c50757da18b62d_D20190101-20191231" decimals="INF" name="plrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNC05LTEtMS0xODQ5MQ_199a9ef7-2748-47f5-a055-047ce3fde498">26,360,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic7e2e2d92973409c98c50757da18b62d_D20190101-20191231" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNC0xMS0xLTEtMTg0OTE_5e9d0ae3-399e-4583-913f-18c2a53dc2c4">47,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vesting of founders&#8217; common stock and restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic527f172d0e443c493b5b9528858fff0_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNy0xMy0xLTEtMTg0OTE_12e14df0-f4b5-40df-b309-59ebdd3b9316">440,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNy0xNy0xLTEtMTg0OTE_7bfd44b6-cf61-482a-8e50-644b90fa919d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNy0yMy0xLTEtMTg0OTE_e7728967-86be-4c3f-96d6-dd486e377cbc">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic527f172d0e443c493b5b9528858fff0_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOC0xMy0xLTEtMTg0OTE_353a3e7b-f3d3-4687-9721-e0549d14a931">42,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOC0xNy0xLTEtMTg0OTE_d4aeec7b-d771-41f0-8bc0-6a52abd2fa2d">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOC0yMy0xLTEtMTg0OTE_9f9fa9cc-227e-4d82-b3ea-f0f8569371b0">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accretion to redemption value and cumulative dividends on redeemable convertible stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i062d513c3af24fb8a871914681ad6ed0_D20190101-20191231" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS0zLTEtMS0xODQ5MQ_dc17cd0b-8a41-4460-a865-b7fd498f7f3d">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic4f89da1832e4c048b3bf07808761b7c_D20190101-20191231" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS03LTEtMS0xODQ5MQ_602235ab-9d23-4d67-bf2d-bc3d7785cb1c">5,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231" decimals="-3" name="plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS0xNy0xLTEtMTg0OTE_8067d1de-a480-4696-a70b-7231cffb454b">2,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5f4ededd465745ac8a09d27d629bf294_D20190101-20191231" decimals="-3" name="plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS0yMS0xLTEtMTg0OTE_3cc2eb2a-e3a4-48ac-9b7d-c200f4368008">4,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS0yMy0xLTEtMTg0OTE_cecff902-187d-493b-a66b-956fc456d87f">6,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTAtMTctMS0xLTE4NDkx_ab3129f1-17ef-4954-9fb3-43c81e4923d8">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTAtMjMtMS0xLTE4NDkx_897c3d30-acf5-4489-b3f0-665f5a3d1064">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net unrealized loss on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i61761cf5edab4bc4a348e46cd23dc2f4_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTEtMTktMS0xLTE4NDkx_350e4c4f-c022-4724-91e4-fcd529e87530">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTEtMjMtMS0xLTE4NDkx_10ea5fbe-33c8-491a-b901-cf35386329fa">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5f4ededd465745ac8a09d27d629bf294_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTItMjEtMS0xLTE4NDkx_b11c6cc5-bb25-40e5-bb75-08ed4a4b4819">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTItMjMtMS0xLTE4NDkx_7b06d43e-6b30-4d7b-ab66-6edbd9c72f98">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idb689d41a0fc49d096930b208671ff5a_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMS0xLTEtMTg0OTE_f07faa90-955c-46b5-b6ef-28578f1b8608">56,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb689d41a0fc49d096930b208671ff5a_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMy0xLTEtMTg0OTE_48b3d804-f3cc-4679-b588-ef02b138747d">62,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibc82fb340f724ed2902d29a505bc74c7_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtNS0xLTEtMTg0OTE_22049891-36f0-4d9e-ad85-b259449d95a0">49,501,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc82fb340f724ed2902d29a505bc74c7_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtNy0xLTEtMTg0OTE_d43a9e61-88fd-4098-b6da-bacbf6a8cf8e">75,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtOS0xLTEtMTg0OTE_881a1ad2-d676-4ecf-8cf2-dfbd354d4c2a">26,360,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTEtMS0xLTE4NDkx_365b6d5b-daee-4dbb-ad5a-ae6f732a6e44">47,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i826b025c166f473987892842e39f1549_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTMtMS0xLTE4NDkx_91a4ac62-1fac-47f2-a09a-66a400e06e14">1,846,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i826b025c166f473987892842e39f1549_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTUtMS0xLTE4NDkx_b26042cf-2214-4f5c-b3c5-16a7222f5c85">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6bbff1d55944244a3110049517d61da_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTctMS0xLTE4NDkx_23217169-7d9b-4ff8-b90b-bf02f2586806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iffe3207e1e714584bed5756b07541340_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTktMS0xLTE4NDkx_2265fde7-ebd4-41b8-8a3d-16d0511bb071">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3c41e7454f6a4547977cbf6b6a2349d3_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMjEtMS0xLTE4NDkx_0fc2f349-49ac-4132-be27-47e8b57d2c39">76,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMjMtMS0xLTE4NDkx_130dbf0d-6e65-4f12-a081-02d01232e853">76,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMy0xLTEtMS0xMjY1OQ_42d35e4e-f495-469e-b784-4cb9a40821af">97,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMy0zLTEtMS0xMjY1OQ_cb412252-6f9b-49b8-8581-6f256540decc">41,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMy01LTEtMS0xODQ0Nw_8061be47-ba31-4d74-9c42-db8bd2dabc10">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNS0xLTEtMS0xMjY1OQ_75cbc93d-df99-4871-9cd8-08614ca9dbbb">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNS0zLTEtMS0xMjY1OQ_9a56ea03-d4d6-41e2-8fcf-069ca6b007c5">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNS01LTEtMS0xODQ0Nw_b2d99ae6-55b2-4169-9416-fc2f42e2ed55">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNi0xLTEtMS0xMjY1OQ_678d51f7-1b8b-4274-bf90-42fb8793b411">10,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNi0zLTEtMS0xMjY1OQ_a223ff3e-f2b0-4ad4-8d6e-d42cd1947fa9">3,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNi01LTEtMS0xODQ0Nw_ba6908c2-a4a5-4237-bb6f-8c381767cc5f">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy0xLTEtMS0xNTk2NA_70158265-33e0-459f-8012-4450451fec28">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy0zLTEtMS0xNTk3MQ_3e9e4fb0-be83-448f-9cdb-c3b8533336a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy01LTEtMS0xODQ0Nw_1a11da20-773c-4be5-be27-1435a9743e80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="plrx:OtherLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy0xLTEtMS0xMjY1OQ_7b35be12-8be9-4c82-9cfa-0a9becca9c50">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="plrx:OtherLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy0zLTEtMS0xMjY1OQ_7fc43161-33a1-4235-80d0-9e46a337812c">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="plrx:OtherLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfOC01LTEtMS0xODQ0Nw_371e7a09-4667-430d-9f26-7496d7b9669f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credit receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfOS0xLTEtMS0xMjY1OQ_a3fa2b42-df1c-47f5-82c6-c89a3d3676e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfOS0zLTEtMS0xMjY1OQ_ba17bcda-75ab-4517-8c01-198cf25db4ac">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTAtNS0xLTEtMTg0NDc_b0da2207-d07a-4d3c-b1eb-243dfb254ff6">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTAtMS0xLTEtMTI2NTk_0d603106-91f8-4670-8fe4-407fd854c2be">7,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTAtMy0xLTEtMTI2NTk_a1e67a64-9f16-4be0-909b-5a2ef367b4e5">2,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTEtNS0xLTEtMTg0NDc_c18ce9d0-a85a-41c9-ad81-77403baad318">7,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTEtMS0xLTEtMTI2NTk_7bec9951-44c8-4ab5-b52d-17c3d6069208">2,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTEtMy0xLTEtMTI2NTk_557d94a7-cb69-4fc2-9672-4bf02b1c005a">2,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTItNS0xLTEtMTg0NDc_26645dff-1679-4a55-b349-16c798782139">1,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTItMS0xLTEtMTI2NTk_51388638-43c2-4716-b3c1-0598816d0028">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTItMy0xLTEtMTI2NTk_348da33c-8df6-4a02-9fce-a77963182633">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTMtNS0xLTEtMTg0NDc_f6cc81ff-9458-482a-bd73-bed8e0dd75a0">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTMtMS0xLTEtMTI2NTk_9644e992-2c54-4288-9398-9a48ae2158a3">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTMtMy0xLTEtMTI2NTk_67efcc68-c679-4708-8f3a-fdfd0bf20d7f">922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTQtNS0xLTEtMTg0NDc_6a78e463-32de-4d5d-9a86-ff0849a111ef">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTQtMS0xLTEtMTI2NTk_4e4ab3e0-edc5-4644-9e62-c5629a566a08">2,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTQtMy0xLTEtMTI2NTk_e692ad84-1f9b-4fc3-956c-1b6e9b2ef79d">2,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTUtNS0xLTEtMTg0NDc_c81045f2-c856-4ffa-b8b7-6d5a79f2022f">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtMS0xLTEtMjA2NzQ_929e7683-8c10-469d-9976-0f70c203287c">1,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtMy0xLTEtMjA2NzQ_1ce30f18-0afc-4585-a6d8-e4010f0f2a6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtNS0xLTEtMjA2NzQ_75aafa8b-f3a3-409e-972e-e52663dc4b65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent and other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTUtMS0xLTEtMTI2NTk_1bf17e4b-40da-4287-a8fa-0dd73ca0d419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTUtMy0xLTEtMTI2NTk_9f7fdc87-93fe-468d-9ccf-4db5181cb27a">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtNS0xLTEtMTg0NDc_617a1b73-a51e-4bf2-a1cb-35aebfc0572c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtMS0xLTEtMTI2NTk_e558cd47-cdd0-4a34-ba26-95f7323ef66d">75,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtMy0xLTEtMTI2NTk_539612c0-87e2-486c-b5d1-e12061045b76">37,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTctNS0xLTEtMTg0NDc_f06b7fdc-905c-4fd3-8247-c52aa9915aaf">2,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTgtMS0xLTEtMTI2NTk_057f1727-7dcb-494d-a5b5-90c338e26499">219,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTgtMy0xLTEtMTI2NTk_a5a3f421-9c76-46f7-94fe-2afe56930268">322,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTktNS0xLTEtMTg0NDc_9766f0d6-678c-4962-b2b2-d137ddb38dcb">51,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accretion on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="plrx:AccretionOfShortTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTktMS0xLTEtMTI2NTk_7dd9e1f5-12c6-4883-b79b-d008df2d0a44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="plrx:AccretionOfShortTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTktMy0xLTEtMTI2NTk_ebefce8e-36ba-4a75-a0cd-f14d5c80f850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="plrx:AccretionOfShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjAtNS0xLTEtMTg0NDc_17416340-7ac0-44a1-93bc-85b48f1e437a">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjAtMS0xLTEtMTI2NTk_40516cde-72ae-4190-9dec-7cacf9e72100">295,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjAtMy0xLTEtMTI2NTk_eb734cc4-ea66-48af-8488-d81594d0fa85">113,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjEtNS0xLTEtMTg0NDc_f0d9cae7-cf60-4de0-97e8-95273fd01256">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjEtMS0xLTEtMTI2NTk_99b11d9a-238d-43c5-998b-60d1b3d9bac6">1,953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjEtMy0xLTEtMTI2NTk_fcdb7ef9-8837-4831-ba00-b16f1dfe7c27">1,532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjItNS0xLTEtMTg0NDc_954bfc7a-fa85-448b-a001-721452d73f20">964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjItMS0xLTEtMTI2NTk_2b0a1130-5930-46b9-b9dc-aaed913a644b">73,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjItMy0xLTEtMTI2NTk_f99ecb31-67ee-4dfc-8061-c5b7590434cb">210,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjMtNS0xLTEtMTg0NDc_06170ad1-fcdd-4d38-97ca-517b94ffcfbc">17,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjQtMS0xLTEtMTI2NTk_b25a4afb-59cb-4761-a53b-fd6828c1282e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjQtMy0xLTEtMTI2NTk_145f39ba-0049-4af3-9bcc-462611fc0b21">150,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjUtNS0xLTEtMTg0NDc_edfa8836-f802-423e-abdc-aacd6e417639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock upon completion of private placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjUtMS0xLTEtMTI2NTk_049d1749-3212-4d4a-b94a-e7629b7a5836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjUtMy0xLTEtMTI2NTk_21f24b04-b8d6-4221-8442-1253dbe546b9">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjYtNS0xLTEtMTg0NDc_0793c9cc-aaa3-4646-8d39-c91737ae637d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of Series C preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjYtMS0xLTEtMTI2NTk_16dfc32d-9d05-45e9-913e-6d6236bc0257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjYtMy0xLTEtMTI2NTk_df7cbdd3-b780-4107-8f64-5c2e289ef239">52,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjctNS0xLTEtMTg0NDc_2fde7406-2394-4b88-bdd2-d5a3818b3967">47,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuances of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjctMS0xLTEtMTI2NTk_7dd735d9-c77d-47cc-abcf-164c105cc022">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjctMy0xLTEtMTI2NTk_dfcb656b-7e17-4547-ba47-c384bbd290e4">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjgtNS0xLTEtMTg0NDc_4b07be56-68fe-44c5-9b35-719691a8791b">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjgtMS0xLTEtMTI2NTk_a93f7f9b-38c0-4fb4-8522-c501ab6760fc">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjgtMy0xLTEtMTI2NTk_efc8f5a4-bb66-4b7a-977a-a8a657a91f83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjktNS0xLTEtMTg0NDc_ec0c7736-e53f-43e3-b552-ce257a6eb6cf">2,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjktMS0xLTEtMTI2NTk_889ab773-9dcd-415a-ba13-b00a117e1e70">2,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjktMy0xLTEtMTI2NTk_ed43c3ac-c8f4-4e1c-a749-754f168c5d91">213,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzAtNS0xLTEtMTg0NDc_478c14bd-7d55-456a-9200-d098659183ab">45,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzAtMS0xLTEtMTI2NTk_80fa12e2-58ab-4ae5-b2d6-db7c49ef43c9">783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzAtMy0xLTEtMTI2NTk_eb27bfc7-5af5-4f39-94a0-89ca979eae12">34,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzEtNS0xLTEtMTg0NDc_203f8b33-3a38-476b-aa7e-5e13e1413d2e">24,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzEtMS0xLTEtMTI2NTk_9c957a4b-00fb-41cb-8a6f-1a3d57c5144b">50,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzEtMy0xLTEtMTI2NTk_47670a3f-39a3-47af-aebe-ba34a61be78c">85,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idcb6e46e8589417fbb6dce85ec4707e9_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzItNS0xLTEtMTg0NDc_a30460a7-d121-4959-bc7c-703756f37bfe">60,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzItMS0xLTEtMTI2NTk_fb107b96-d32e-46e8-8610-ab779271592b">51,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzItMy0xLTEtMTI2NTk_bd208a45-337f-457c-82f2-eb86c9ce1783">50,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzMtNS0xLTEtMTg0NDc_6e2af041-6e4a-4de1-8181-c94079347e2a">85,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental disclosures of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of property and equipment in accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzQtMS0xLTEtMTI2NTk_e5845180-47ce-4105-b191-34712b41e3ae">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzQtMy0xLTEtMTI2NTk_4bbf00e5-9f58-4e3b-bbb9-de1ed2b6bcaf">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzktNS0xLTEtMTg0NDc_699c4051-2fc7-4fe0-8e68-808f8cb8c0f0">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification of restricted stock awards from liabilities to common stock upon vesting</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzUtMS0xLTEtMTI2NTk_f3618ef8-d7a3-4fe4-abd0-3680784b98f3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzUtMy0xLTEtMTI2NTk_1403d89d-a05f-43df-ba1e-372d427af70d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNDAtNS0xLTEtMTg0NDc_b7fba357-f4f8-441f-8eee-3fe70a07ee41">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accretion to redemption value and dividends on redeemable convertible preferred stock</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzYtMS0xLTEtMTI2NTk_4fdc42b6-29cf-441c-9f18-2046d28d4675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzYtMy0xLTEtMTI2NTk_401d97f4-4e0e-4a84-95ca-dae4d07161b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNDEtNS0xLTEtMTg0NDc_bf17a2c3-d8ee-42f4-a70f-4ff83b5d4713">6,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred offering costs in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzctMS0xLTEtMTI2NTk_8e1150dc-6253-463e-ad24-5b10a5d5e150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzctMy0xLTEtMTI2NTk_5b0ac021-8408-4b5b-8101-3b51e9c25c50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNDItNS0xLTEtMTg0NDc_1366bcb2-0264-48bd-b04c-ff01462fb836">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized loss on short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzgtMS0xLTEtMTI2NTk_88dfb8db-8669-4369-9e64-680d36186363">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzgtMy0xLTEtMTI2NTk_a5362efa-0869-425d-8c52-b2614b2eecd1">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNDMtNS0xLTEtMTg0NDc_141359e7-0a40-4439-b498-f200157a0016">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pliant Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div id="i988625df783e4cc0a27bd76df388da57_103"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI5OTk_9b6aeebc-b13c-407e-aa24-dc98f10312de" continuedAt="ib38b290635d242ee8b3fd942bbb0d700" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="ib38b290635d242ee8b3fd942bbb0d700"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pliant Therapeutics, Inc. (the &#8220;Company&#8221; or "Pliant" or &#8220;we&#8221; or &#8220;our&#8221; or &#8220;us&#8221;) is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis with an initial focus on treating fibrosis by inhibiting integrin-mediated activation of TGF-&#946;. Fibrosis refers to the abnormal thickening and scarring of connective tissue due to the production and deposition of excess collagen in the extra-cellular matrix. Fibrosis can occur in many different tissues including lung, liver, kidney, muscle, skin and the GI tract, and often causes severe and debilitating disease leading to organ failure. The Company is located in South San Francisco, California, and was incorporated in the state of Delaware in June 2015.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;22, 2020, the Company implemented a 1-for-7.15 reverse stock split of the Company&#8217;s common stock. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&#8217;s convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. As of June 3, 2020, all outstanding preferred stock had been converted into common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company completed its initial public offering (the &#8220;IPO&#8221;), in which the Company issued and sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzE4OTM_2d106352-e177-4f0e-8568-a1635c919c4f">10,350,000</ix:nonFraction> shares of common stock, which consisted of <ix:nonFraction unitRef="shares" contextRef="i1b3902b908614fb1b9c4a93bf96af64c_D20200601-20200630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzE5MzU_346b83fa-a7f2-4cc8-8161-b5bf648d8c5d">9,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="iae29663b5db54f749ffcf7b5c72df914_D20200601-20200630" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzE5NjU_aef584ec-5a42-4c93-abf4-84694eb87458">1,350,000</ix:nonFraction> shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i81a558379cd44a9ab226783aa88f48a7_I20200630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzIxMTI_33049bdc-27ba-44f3-9d6d-80d45a5eebf9">16.00</ix:nonFraction> per share. The aggregate net proceeds received by the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzIyMDA_9f22773c-8390-4f1d-934e-b2c0ab660e10">148.3</ix:nonFraction> million, net of underwriting discounts, commissions and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzIyNzI_e146f029-4a6a-408b-822f-f78e7ad6e973">5.7</ix:nonFraction> million. Upon the closing of the IPO, <ix:nonFraction unitRef="shares" contextRef="i81a558379cd44a9ab226783aa88f48a7_I20200630" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzIzNjY_3b874795-5e94-4627-b5a2-770db7f8ce01">160,389,279</ix:nonFraction> shares of the Company&#8217;s outstanding convertible preferred stock were automatically converted to common stock on a <ix:nonFraction unitRef="number" contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI0ODM_4cfcfa27-fe81-4d9d-be34-5fd68201d08f">7.15</ix:nonFraction>:1 basis and the related carrying amount of $<ix:nonFraction unitRef="usd" contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI1Mjg_c8ff0c7b-6a25-46d8-9750-ce20718d4c1a">238.3</ix:nonFraction> million was reclassified to common stock and additional paid-in capital within stockholders&#8217; equity (deficit). </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the completion of the IPO, the Company also issued <ix:nonFraction unitRef="shares" contextRef="ibc3d94b8d41948578ccb00771371441d_I20200630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI3MDE_3d492d95-e7cb-4da4-898a-299a49328acc">625,000</ix:nonFraction> shares of its common stock to Novartis Institutes for Biomedical Research, Inc. (&#8220;Novartis&#8221;), a strategic partner and existing stockholder of the Company, in a private placement at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc3d94b8d41948578ccb00771371441d_I20200630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI4NTU_705204b5-08c7-461f-b3ea-d4ec7549721b">16.00</ix:nonFraction> per share for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9550253bdd3e4a6da0f6c0d34c9b9d1a_D20200601-20200630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI4ODQ_1bee15ad-7b39-431b-b7af-a7764d810be8">10.0</ix:nonFraction> million, which resulted in Novartis owning approximately <ix:nonFraction unitRef="number" contextRef="ib16143c3aac54e6ca3119c33948ae5eb_I20200630" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI5MzY_e4e65ad7-9194-4385-b84c-3acb6b11864f">6.1</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock immediately after the IPO.</span></div></ix:continuation><div id="i988625df783e4cc0a27bd76df388da57_106"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTA5_afdd737a-7695-4e50-8b46-28789ee935e8" continuedAt="ibd2a94022e714b22a5c9a0bbc42b6583" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ibd2a94022e714b22a5c9a0bbc42b6583" continuedAt="i889bf80f3d7a45e6ba0490ceffc468de"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE1_5d33cfd3-19f1-4410-ac91-69470d749bab" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Certain prior year reported amounts have been reclassified to conform with the current period presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE2_836d4661-c21e-4386-83fd-a6ec6eefb6a3" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development costs, fair value of assets and liabilities, stock-based compensation, income taxes and uncertain tax positions. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, however, actual results may differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i889bf80f3d7a45e6ba0490ceffc468de" continuedAt="ibb42fb5fe29b4487b3f98a6cd713df9e"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE3_edbabebf-8431-4c20-95fe-96c809c049a8" continuedAt="i62a3870aa0ef45ec83ed1c0e2cc58139" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topic 606). To determine revenue recognition for arrangements that fall within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, our revenues have been generated solely from the Collaboration and License Agreement with Novartis (the &#8220;Novartis Agreement&#8221;). The Novartis Agreement includes licenses of intellectual property, cost reimbursements, research and development services, upfront signing fees, milestone payments and royalties on future licensee&#8217;s product sales.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of accounting for this arrangement, we must apply judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the contract. To determine the stand-alone selling price, we rely on assumptions which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and license revenue in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development services </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to research and development services are recognized as the related services or activities are performed, in accordance with the contract terms. The cost associated with full-time equivalent researchers is estimated each period and billable to Novartis based at specified full-time equivalent rates.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales-based royalties, including milestone payments based on the level of sales, are considered to be predominately related to the license included in the arrangement, and we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue from the Novartis Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize contract assets when we have a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditional on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration (i.e., only the passage of time is required before payment becomes due). A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="ibb42fb5fe29b4487b3f98a6cd713df9e" continuedAt="i5369c70374e248b6b5e5ca5ced9a52f0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i62a3870aa0ef45ec83ed1c0e2cc58139">Receivables cannot be netted against contract liabilities and would be presented separately from contract assets. Contract assets and contract liabilities are netted at the contract level.</ix:continuation> </span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE4_b479e59d-62ea-45b4-b5c2-6122a436ff7d" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The carrying amount of the Company&#8217;s financial instruments, including cash and cash equivalents, short-term investments, tax credit receivable, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short-term maturities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE5_3cf70967-62ad-4cb9-b6ba-6933136205de" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. The Company invests in money market funds, treasury bill and notes, government notes and corporate debt securities. The Company limits its credit risk associated with its cash and cash equivalents by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. However, the Company had deposits in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limit of $250,000. <ix:nonNumeric contextRef="if4ff395e311847909da6a655116394ff_D20210101-20211231" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTI2_f0273549-dbe8-437b-85c3-25eecc37af46">The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base.</ix:nonNumeric> During the years ended December&#160;31, 2021,  2020 and 2019, Novartis accounted for <ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="INF" name="plrx:PercentageOfRevenueContributedByRelatedParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2NDkyNjc0ODU0MjM_27ac5b90-af2a-4016-97ec-0df02ab96410"><ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="INF" name="plrx:PercentageOfRevenueContributedByRelatedParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2NDkyNjc0ODU0MjM_8be87384-311d-40e6-9f22-a1d0b343c2ce"><ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="INF" name="plrx:PercentageOfRevenueContributedByRelatedParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2NDkyNjc0ODU0MjM_9de788e7-ed1e-4f03-9c05-d35624466f36">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s revenue and accounts receivable.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future results of operations involve several other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products, including those that may be developed or marketed by larger companies, securing and protecting intellectual property, strategic relationships and dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTEw_cbe5bc8a-560e-4e00-bfb1-b8922474c009" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as <ix:nonFraction unitRef="segment" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEyMTU5_26761c0b-f1e3-4916-a4cd-71ecec68b0b2"><ix:nonFraction unitRef="segment" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEyMTU5_b5fad364-028c-4011-9dfb-6f2ce5e43d8c">one</ix:nonFraction></ix:nonFraction> reportable and operating segment, which is the business of developing and commercializing novel therapies for fibrotic diseases. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. All long-lived assets are maintained in the United States of America.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTI3_d5dd6f67-5c35-4eb4-a9d0-26a7163d308e" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEyNjY0_32b62ec9-ffc5-4101-a2f6-089db3dbc78a">three months</ix:nonNumeric> or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in Money Market Funds, United States (&#8220;U.S.&#8221;) treasury securities, U.S. government agency securities and corporate debt securities and are stated at fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTI4_566e4b31-5ace-4dac-ad27-ede84e50941e" continuedAt="i1f3e409a146244e6a8b934abd653ed94" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investments consist of U.S. Treasury securities, U.S. government agency securities and corporate debt securities with remaining maturities beyond three months at the date of purchase. The Company has classified and accounted for its short-term investments as available-for-sale securities as the Company may sell these securities at any time even prior to maturity and such investments represent cash available for current operations. As a result, short-term investments may include securities with maturities beyond twelve months that are classified within </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i5369c70374e248b6b5e5ca5ced9a52f0" continuedAt="iba8b645d68c94dc4a19421b3c6fc764e"><ix:continuation id="i1f3e409a146244e6a8b934abd653ed94"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current assets in the Balance Sheets. As of December&#160;31, 2021 and 2020, all of the Company&#8217;s short-term investments were classified as available-for-sale and were carried at fair market value with unrealized losses recorded in other comprehensive loss in the statements of operations and comprehensive loss. See Note 3 for further details.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are considered impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its short-term investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, the duration and extent to which the fair value is less than cost and its intent and ability to hold the investment. Once a decline in fair value is determined to be other-than-temporary, an impairment charge will be recorded to other expense, net, in the statements of operations and comprehensive loss and a new cost basis in the short-term investment will be established. As of&#160;December&#160;31, 2021, the Company had not recorded any impairment related to other-than-temporary declines in the fair value of short-term investments.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;) as of January&#160;1, 2021, which did not have a significant impact on its financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires the Company to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if the Company&#8217;s estimate of fair value for the investment increases. To determine whether to record a credit loss, the Company considers issuer specific credit ratings and historical losses as well as current economic conditions and its expectations for future economic conditions.</span></div></ix:continuation><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTIw_de9e16df-6c86-42e9-8fae-c5404d508e7a" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost net of accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTEx_32996c9e-6690-4266-896a-0cda93e730b3" continuedAt="ie8bdbaf7ff38431b894e4c6ba5f8f4cd" escape="true">The useful lives of property and equipment are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ie8bdbaf7ff38431b894e4c6ba5f8f4cd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97ba5b3806e14f8cb378e134282cefff_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90YWJsZTo1MWM0MjgyMWExY2M0MDZjYTQxNTBlNzdhOWVjNGQ2Yi90YWJsZXJhbmdlOjUxYzQyODIxYTFjYzQwNmNhNDE1MGU3N2E5ZWM0ZDZiXzAtMS0xLTEtMTI2NTk_722a3183-375e-41e6-a3f4-e0c4c1525872">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i72575f12fa974fe28bf756200624bdba_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90YWJsZTo1MWM0MjgyMWExY2M0MDZjYTQxNTBlNzdhOWVjNGQ2Yi90YWJsZXJhbmdlOjUxYzQyODIxYTFjYzQwNmNhNDE1MGU3N2E5ZWM0ZDZiXzEtMS0xLTEtMTI2NTk_8f363407-eedd-465c-8214-5dada8bb9293">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of remaining lease term or estimated useful life</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the balance sheets and the resulting gain or loss is recorded to the statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzQzOTgwNDY1ODczNDE_f89dcb4a-567d-4dc2-8105-907b22cced83" continuedAt="ib572902b224644d1aa229e9cddf870aa" escape="true"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzQzOTgwNDY1ODczNDI_b84dcd14-a71e-4796-a9c5-b54fe79ea50e" continuedAt="i555b623116ef4bffa7d0d423eb68bdb2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, Leases (&#8220;ASC 842&#8221;), the Company determines if an arrangement contains a lease at the inception of the contract and a records right-of-use (&#8220;ROU&#8221;) asset and lease liability on the balance sheet at lease commencement based on the present value of remaining lease payments over the lease term. The Company only considers payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases with an initial term greater than 12 months, lease liabilities are recognized based on the present value of the future minimum lease payments discounted by the Company&#8217;s estimated incremental borrowing rate. The Company measures ROU assets based on the corresponding lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred and (iii) tenant incentives under the lease. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the present value of future minimum lease payments using its estimated incremental borrowing rate when the discount rate implicit in the lease is not known. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. In determining its incremental borrowing rate, the Company gives consideration to its credit risk, term of the lease, total lease payments and an analysis of peer companies with profiles similar to its own.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the short-term lease practical expedient to exclude leases with a term less than 12 months from its ROU assets and lease liabilities. The Company records rent expense for short-term leases in its statements </span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="iba8b645d68c94dc4a19421b3c6fc764e" continuedAt="i0eef491a92344a29bbe90e3debd52691"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib572902b224644d1aa229e9cddf870aa"><ix:continuation id="i555b623116ef4bffa7d0d423eb68bdb2">of operations on a straight-line basis over the lease term and records variable lease payments as incurred. The Company has also elected to not separate lease and non-lease components and, as a result, accounts for any lease and non-lease components as a single lease component.</ix:continuation></ix:continuation></span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTIz_67f84f9d-dcfe-4160-aa5b-bc580b060a70" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There was <ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2MDA1_06119dd3-5df9-4c2a-87ed-f6ee23750962"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2MDA1_29adf15c-e3b2-4362-9ad4-18486440e01d"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2MDA1_86d3ef9f-a48b-4fd9-9b20-0ba284961118">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of long-lived assets during the years ended December&#160;31, 2021, 2020 and 2019.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTI0_7539af19-2a6e-41f9-9ffd-4ff49d24edfa" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All preferred stock was automatically converted into common stock upon the Company&#8217;s IPO in June 2020. Prior to this conversion, the Company classified redeemable convertible preferred stock outside of stockholders&#8217; equity (deficit) because, upon the occurrence of certain change in control events that were outside the Company&#8217;s control, including liquidation, sale or transfer of the Company&#8217;s assets, holders of the redeemable convertible preferred stock could have caused redemption for cash. At any time on or after December 19, 2024, the holders of a majority of the outstanding redeemable convertible preferred stock could also have required the Company to redeem the redeemable convertible preferred stock by providing the Company a written notice requesting such redemption. The Company recognized changes in the redemption value immediately as they occurred, for example changes in fair value of preferred stock, and adjustments in the carrying amount of the redeemable convertible preferred stock to equal the redemption value at the end of each reporting period up through December 19, 2019, when the Company entered into the Series C Preferred Stock Purchase Agreement. See Note 9 for further details. In the absence of retained earnings these accretion charges were recorded against additional paid in capital, if any, and then to accumulated deficit. The Company analyzed all embedded derivatives and beneficial conversion features for its redeemable convertible preferred stock and concluded that none required bifurcation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE0_8f563438-efe3-4c23-9d97-1aedd0c088fc" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist primarily of personnel costs for the Company&#8217;s research and development employees. Also included are non-personnel costs such as fees paid to consultants and third parties for preclinical and clinical studies, research and development services, laboratory supplies and equipment maintenance costs, license costs, contract manufacturing costs and allocations of facility related costs. The Company estimates preclinical and clinical studies and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. We estimate the amount of work completed through review of detailed budgets and timelines included in our contracts and agreements, and update these estimates with information obtained from third-party service providers and internal personnel on a quarterly basis. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and are expensed as services are rendered.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTIx_7e9297db-bf39-4a54-86ea-254591c35349" continuedAt="i693069a99948433bb1930918018c48d0" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based equity awards include restricted stock awards, stock options and shares that will be issued under the Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). Stock-based compensation for awards that are granted to employees is accounted at fair value on the award grant date and the expense is recognized over the period the employee is required to provide service in exchange for the award, which is generally on a straight-line basis over the vesting period of the award. The expense is recorded in either research and development or general and administrative expenses in the statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i0eef491a92344a29bbe90e3debd52691" continuedAt="i605f1d99ec354d698f63dd5315e79c3e"><ix:continuation id="i693069a99948433bb1930918018c48d0"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model, used to estimate fair value of stock-based awards, requires the use of the following assumptions:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term for the Company&#8217;s stock options was calculated utilizing the simplified method, which represents the average of the weighted-average vesting term and the contract period of the awards. The expected term for the ESPP is the offering period.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Prior to the Company being public, the Company did not have any trading history for its common stock, the expected&#160;volatility was estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their size, stage in the life cycle or area of specialty. As the Company went public in June 2020, the Company will continue to apply this process for stock options and ESPP awards until enough historical information regarding the volatility of its stock price becomes available.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S.&#160;Treasury notes with maturities approximately equal to the expected term of the awards.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on the common stock and has no plans to pay dividends on the common stock.&#160;Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzIyMzkz_91b6a1db-9038-40ea-852e-4682baa56d3c">zero</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our IPO, the fair value of our common stock has been determined using independent third-party valuations based on relevant valuation methodologies as outlined in the American Institute of Certified Public Accountants (AICPA) Practice Aid,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Valuation of Privately-Held-Company Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Issued as Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. The Company also considered the amount of time between the independent third-party valuation dates and the grant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dates and used interpolation of the fair value between the two valuation dates to estimate common stock fair value at each grant date. This determination included an evaluation of whether the subsequent valuation indicated that any significant change in valuation had occurred between the previous valuation and the grant date. Following our IPO, the Company uses our stock price traded on NASDAQ to determine its fair value.</span></div></ix:continuation><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTMw_e7e04ef7-edef-4f66-b26c-6b11aea3a2df" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax basis of assets and liabilities and net operating loss and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all the tax benefits will not be realized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with ASC No. 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes any penalties and interest expense related to income taxes as a component of income tax expense, as necessary.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTIy_63c57716-96cb-408c-89db-9a088ae17838" continuedAt="if56485b9b3d3437aa6a47840c699c9fe" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if56485b9b3d3437aa6a47840c699c9fe">Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's comprehensive loss represents unrealized losses on short-term investments.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i605f1d99ec354d698f63dd5315e79c3e" continuedAt="iff35d3f0df184a58abdfefd2758f5f1b"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTMx_87cb7b60-2c40-4407-80b3-e3df71a2f22c" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss attributed to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the conversion of our preferred stock in our IPO, net loss or income per share attributable to common stockholders was calculated using the two-class method, which is based on an earnings allocation formula that determines net loss or income per share for the Company&#8217;s common stockholders and holders of participating securities. The holders of preferred stock were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on the common stock. Under this method, net loss or income is increased or reduced by the amount of any dividends earned and accretion of redeemable convertible preferred stock to its redemption value, if any, during the period. The undistributed earnings are allocated to common stock and each series of redeemable convertible preferred stock to the extent that each preferred security may share in the earnings as if all of the earnings for the period had been distributed. Net loss or income attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Diluted net loss or income per share is computed using the more dilutive of (a) the two-class method or (b) the as-converted method. The Company allocated earnings first to redeemable convertible preferred shares stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss or income gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalent shares are excluded from the computation of diluted net loss or income per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders during the years ended December&#160;31, 2021, 2020 and 2019.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzQzOTgwNDY1ODczMzg_54a365ea-dbc5-4718-a1ab-8f0b3dc5e946" continuedAt="ieb459b90e1df4b9ba342f3f67eee0d9a" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 842&#8221;), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. Subsequent to this, the FASB issued various amendments to ASC 842, which affected certain aspects of the previously issued guidance. One of the amendments included an additional transition option that allowed entities to apply the new standard on the adoption date and recognize a cumulative effect adjustment to the opening balance of retained earnings. These updates were effective for public companies for annual periods beginning after December 15, 2018, including interim periods therein. Because the Company lost its EGC status on December 31, 2021, the standard became effective for the Company for its annual period beginning January 1, 2021. Amounts prior to January 1, 2021 were not adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASC 842 and all related amendments effective January 1, 2021 using the modified retrospective transition approach. The Company elected the package of practical expedients upon adoption, which permitted the Company to not reassess under the new standard the Company's prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease exception policy, permitting it to exclude the recognition requirements of this standard from leases with initial terms of 12 months or less.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASC 842 effective January 1, 2021 resulted in the recognition of operating lease ROU assets of $<ix:nonFraction unitRef="usd" contextRef="ib6401410f7ef49438a2f863fbc13df66_I20210101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEwOTk1MTE3MDM5NjA_0fe736a7-1f30-4cd5-8670-9c64050dcb8e">8.0</ix:nonFraction>&#160;million and operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="ib6401410f7ef49438a2f863fbc13df66_I20210101" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEwOTk1MTE3MDM5Nzc_bdfe679f-442e-42ff-9d49-16742c4a60b6">8.9</ix:nonFraction>&#160;million in the Company&#8217;s balance sheet. In connection with the adoption, pre-existing liabilities for deferred rent and lease incentives totaling $<ix:nonFraction unitRef="usd" contextRef="ib6401410f7ef49438a2f863fbc13df66_I20210101" decimals="-5" name="us-gaap:DeferredRentCreditCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEwOTk1MTE3MDM5OTM_ef0e985e-dd84-4b6f-837f-5f59c84f7c40">0.9</ix:nonFraction>&#160;million were reclassified as an offset to the operating lease ROU assets. The Company&#8217;s financial position and operating results for reporting periods prior to January 1, 2021 have not been adjusted and continue to be presented in accordance with the accounting standard in effect at that time. The adoption of ASC 842 did not have a material impact on the 2021 quarterly or annual results of operations or cash flows and had no impact on retained earnings. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff35d3f0df184a58abdfefd2758f5f1b"><ix:continuation id="ieb459b90e1df4b9ba342f3f67eee0d9a">allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2021. The adoption of ASU 2016-13 did not have an impact on the Company&#8217;s financial statements.</ix:continuation></ix:continuation></span></div><div id="i988625df783e4cc0a27bd76df388da57_109"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzUzMzQ_002e3832-a7c9-49ac-a7b5-8e6979b38b18" continuedAt="i8a43ab311ccf494cb3a18a98030cb954" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i8a43ab311ccf494cb3a18a98030cb954" continuedAt="i7a2b82dc18944525b3482f8a3a3fd6c4"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investments consist of U.S. Treasury securities, U.S. Government agency securities and highly rated, investment-grade corporate debt securities with original maturities beyond three months at the date of purchase. The Company has classified and accounted for its short-term investments as available-for-sale securities as the Company may sell these securities at any time even prior to maturity and such investments represent cash available for current operations. As a result, short-term investments may include securities with maturities beyond twelve months that are classified within current assets in the Balance Sheets. The Company&#8217;s short-term investments classified as available-for-sale are carried at fair market value with unrealized losses or income recognized in other comprehensive loss.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the Balance Sheets and assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for&#160;identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or&#160;no market data.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalent Money Market Funds are classified as Level 1 because they are valued using quoted market prices. The fair value of the Company&#8217;s U.S. Treasury securities, U.S. government agency securities and corporate debt securities are classified as Level 2 because they are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency and include U.S. government agency securities, U.S. Treasury securities and corporate debt securities. These Level 2 instruments require more management judgment and subjectivity compared to Level 1 instruments which include determining which instruments are most similar to the instrument being priced, determining whether the market is active and determining which model-derived valuations are to be used when calculating fair value. The Company performs its analysis with the assistance of investment advisors.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets or liabilities as of December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i7a2b82dc18944525b3482f8a3a3fd6c4"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzUzMzU_193e1500-8ba5-4131-8782-f84266b5b13e" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash and cash equivalents, Money Market Funds and short-term investments by significant investment category as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a0d9e0cac2348ca84c706c8288bceb7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzMtMS0xLTEtMTI2NTk_2f13d16a-f78d-41a1-9ca6-3ac9e129624d">15,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie79933d3e8de4b1dbcd02a40640ad95c_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzMtMy0xLTEtMTI2NTk_bbaa59b1-0c16-415c-98c2-b11fa95df5d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie79933d3e8de4b1dbcd02a40640ad95c_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzMtNS0xLTEtMTI2NTk_66d7c58e-7a9f-468c-8298-4ae562590a64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a0d9e0cac2348ca84c706c8288bceb7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzMtNy0xLTEtMTI2NTk_2d859941-12be-4863-9543-d7882f592ac7">15,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i502608fba6ca409d9d1c9db643401ed1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzYtMS0xLTEtMTI2NTk_2a76feb9-ac35-41b5-81bf-5fc5a2a47ae7">5,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ccce3ad26234845a35af7149a3ec646_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzYtMy0xLTEtMTI2NTk_7eea580f-0c65-4374-ae9c-a35fe145929f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ccce3ad26234845a35af7149a3ec646_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzYtNS0xLTEtMTI2NTk_dd2b3f59-92d5-49e2-a9f6-b8c40f21aa5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i502608fba6ca409d9d1c9db643401ed1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzYtNy0xLTEtMTI2NTk_481456de-d1c9-41eb-8720-392a661277c1">5,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities included in cash and cash equivalents and short-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iddc5aed3e7a8426487bf4c221631f7c7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzctMS0xLTEtMTI2NTk_4f0ce7f4-b71c-4be9-a329-eb90b97d09a8">163,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i771d84b1911848a9bbe7a4b3d4704f30_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzctMy0xLTEtMTI2NTk_6c024407-9381-4dd5-a00d-453bdfd6aef9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i771d84b1911848a9bbe7a4b3d4704f30_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzctNS0xLTEtMTI2NTk_76da95ce-2584-4f21-93df-e6e568081e36">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iddc5aed3e7a8426487bf4c221631f7c7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzctNy0xLTEtMTI2NTk_4cde4d71-e9be-48b6-89e6-d94a952b3117">163,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzgtMS0xLTEtMTI2NTk_819f4dfc-4b04-41cb-9200-17a45156bb5b">183,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzgtMy0xLTEtMTI2NTk_949b8c2b-8bde-45a2-a70f-58584b3c7bd9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzgtNS0xLTEtMTI2NTk_ea55d99b-3d5d-40b8-a753-55ced7f8e56e">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzgtNy0xLTEtMTI2NTk_2f7299e2-8a09-4ac7-946b-99639e564831">183,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad109a114dc8411c89edb8c84d2b1e18_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzMtMS0xLTEtMTI2NTk_9566f6ff-a00f-49df-8a6d-ac54ef52a354">27,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29ada465fe97416585c2b4b0679231ca_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzMtMy0xLTEtMTI2NTk_6db50b19-ae16-4caa-b413-17e8bd313fe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29ada465fe97416585c2b4b0679231ca_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzMtNS0xLTEtMTI2NTk_2d04174f-6241-413c-9e07-a31e92ec46af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad109a114dc8411c89edb8c84d2b1e18_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzMtNy0xLTEtMTI2NTk_f1c7fd51-4756-404c-97c0-fcdbd13e9d8c">27,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95ed66f76be545c297192eb65c6e90ef_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzUtMS0xLTEtMTI2NTk_cd1e8a76-42f6-4ecb-a6e2-d9d5b40a14a1">63,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i741c7a0fae7340c89c0beeec92183dff_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzUtMy0xLTEtMTI2NTk_0dabb25c-00f5-4944-80d7-34aac3fb7c3e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i741c7a0fae7340c89c0beeec92183dff_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzUtNS0xLTEtMTI2NTk_755743d6-3c99-4657-b884-e8da387b6952">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95ed66f76be545c297192eb65c6e90ef_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzUtNy0xLTEtMTI2NTk_9ba146ac-e885-44f6-8f71-d50c376a6efe">63,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c3fbf9468164232b5a4585f59962a25_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzYtMS0xLTEtMTI2NTk_c2dd4305-1a25-4654-9b9c-856810bcba4c">54,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0fedf72de50140c3b7b150892abda892_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzYtMy0xLTEtMTI2NTk_7d33b7bb-117b-4f09-bcc7-47da0ce1b10a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0fedf72de50140c3b7b150892abda892_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzYtNS0xLTEtMTI2NTk_ae007553-da3c-492d-91e8-2a9741e1e175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c3fbf9468164232b5a4585f59962a25_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzYtNy0xLTEtMTI2NTk_486dc19e-3bcc-4809-ab49-dee5b47a3c8b">54,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities included in cash and cash<br/>&#160;&#160;&#160;equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7be8fb727d34fd78dee97819061e39f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctMS0xLTEtMTgyMzQ_82d99c83-84c5-4d93-b76b-021443c36d2e">118,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eb8ff0e0954c70883407fca7e46607_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctMy0xLTEtMTgyNDA_1426d3af-26a0-4226-8fe5-c75ffab7e5a6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i88eb8ff0e0954c70883407fca7e46607_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctNS0xLTEtMTgyNDY_49c5d9dc-8918-46d8-a718-ad527f12421b">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7be8fb727d34fd78dee97819061e39f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctNy0xLTEtMTgyNTI_157e8055-ab77-4ef2-8f17-df7ab8e5f9ea">118,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctMS0xLTEtMTI2NTk_2ac248ab-f61e-4d67-9370-7f79fd2eb19d">263,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctMy0xLTEtMTI2NTk_c688968e-f062-48e9-8d71-02d23075df5b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctNS0xLTEtMTI2NTk_945b262b-fa00-4a63-9144-e68f22f7388d">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctNy0xLTEtMTI2NTk_974772e1-a219-4472-89d3-47b8d317df7f">263,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may sell certain of its short-term securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.</span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzUzMzY_03ed00ed-b8a2-4dcc-8af8-290f7846d046" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the remaining contractual maturities of the Company&#8217;s short-term investments as of December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mature in 1 year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbd310f10677481088f4abcc6a267dac_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzEtMS0xLTEtMTI2NTk_9097fc82-d230-4dc0-b870-fe064e4b2c6c">114,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbd310f10677481088f4abcc6a267dac_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzEtMy0xLTEtMTI2NTk_7907be7e-6dca-411d-aaed-efd5310d3e2e">113,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mature in 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i762f167b21754e29a50cab9db8dacfac_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzItMS0xLTEtMTI2NTk_9ec246d9-d5dd-4e5c-87ad-0f5dcb47eadd">35,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i762f167b21754e29a50cab9db8dacfac_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzItMy0xLTEtMTI2NTk_b3ce58e0-d72d-45b9-95f3-91d8111c744b">34,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i788f10f5c97047c98f3a91d33d462adc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzMtMS0xLTEtMTI2NTk_4421ddc4-918d-44f1-af80-eb5d107fea31">149,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i788f10f5c97047c98f3a91d33d462adc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzMtMy0xLTEtMTI2NTk_8b93712d-3b62-473a-ab54-5ccfb9df1f29">148,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ibfb9d77c8aeb443b8744a5d136c48c67_I20201231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQxMDg_22e1b2c9-84a2-43f7-8da6-aed4b2b0ba27"><ix:nonFraction unitRef="usd" contextRef="iad0147962f3a43ae98dc9257ca855342_I20211231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQxMDg_6c427bb8-bad9-4a31-8514-08999a79cc98">no</ix:nonFraction></ix:nonFraction> liabilities measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020. There have been <ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQyMDA_7965b4ed-8d30-4358-8d83-626b2f6ac564"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="INF" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQyMDA_ccd56b9b-3310-4749-a72f-f59d8c45167b">no</ix:nonFraction></ix:nonFraction> transfers between fair value measurement levels during the years ended December&#160;31, 2021 and 2020. In addition, there were <ix:nonFraction unitRef="usd" contextRef="i48f177c3974b433093600a48912c81ba_I20201231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQzMDk_87392369-a321-4a1d-b67a-9aa2c25ef43b"><ix:nonFraction unitRef="usd" contextRef="idb37502688b5432890a52460645ba22c_I20211231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQzMDk_a23ceb6d-eaf8-4c30-824e-b8bb2aa2753b">no</ix:nonFraction></ix:nonFraction> assets or liabilities measured at fair value on a non-recurring basis as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had not recorded any impairment related to other-than-temporary declines in the fair value of short-term investments.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records interest income and accretion income earned on Money Market Funds and U.S. Treasury, U.S. government agency and corporate debt securities to interest and other income (expense), net in its statement of operations and comprehensive loss.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE4OA_1b07e4c4-dbce-4185-8dfd-e165fae909aa" continuedAt="i9985b420974d499ea1f0c3acaee76bf8" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="i9985b420974d499ea1f0c3acaee76bf8"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE4OQ_b8a2f950-a77e-40d0-9bcc-0c8dcb3c12de" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id16f08eb632f4af58a00d176e37ebf70_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzItMS0xLTEtMTI2NTk_11db932d-a9b0-4500-8be4-110c3fcc6cc1">7,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i604392abc5a0452d940c039026024807_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzItMy0xLTEtMTI2NTk_1f9362b6-d113-4c5d-94c7-2155864a2667">6,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e78efdd427f4cb090c0239dd860231c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzMtMS0xLTEtMTI2NTk_97aa3802-e663-425d-8777-e2242b4acdf0">1,618</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib3ceadd77d9b4e6091731d2900ea887e_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzMtMy0xLTEtMTI2NTk_09bfe3a3-6a07-4560-a226-2b1d632297be">947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id8691f274c844ea689788aa8180fc7ea_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzQtMS0xLTEtMTI2NTk_edf4f3a1-7495-4f7d-8b2c-55385ac5c8dc">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icaafcff2da3c4e68a71fc38bc8eaeeef_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzQtMy0xLTEtMTI2NTk_7b2549a7-34f4-4eec-98df-638a5e1e26b7">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic8516b91fd4c4e219c9d323eabb5f186_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzUtMS0xLTEtMTI2NTk_40ba1f0d-69ac-4497-ae60-891311775739">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc186515959f44048d743426dc3fdbb4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzUtMy0xLTEtMTI2NTk_d547d435-a97b-416e-bfda-59fd519a6424">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzYtMS0xLTEtMTI2NTk_0c8dc86f-a6dd-4f23-a252-ba15b8395bb8">9,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzYtMy0xLTEtMTI2NTk_c610d476-57fb-49f7-a1ed-287e689def57">7,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzctMS0xLTEtMTI2NTk_aff8c90f-2de9-42d0-8495-08d991e664d1">5,019</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzctMy0xLTEtMTI2NTk_a3007d69-a29e-4a7b-8c66-d6a52fe46674">3,488</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzgtMS0xLTEtMTI2NTk_ec5ed227-e365-4a40-88c7-e0af78c9aa85">4,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzgtMy0xLTEtMTI2NTk_977b3b88-0e72-455f-af13-b74ef895ea3b">4,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE2NDkyNjc0NDE4OTg_0b62bd7a-de7e-4452-9e11-7cab089483e0">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE2NDkyNjc0NDE5MDI_877b2e45-add4-479f-ae13-5a1d3c05f593">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE2NDkyNjc0NDE5MDY_1db2a9e0-61e1-4812-9d0c-ab29e936af01">1.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i988625df783e4cc0a27bd76df388da57_1736"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGV4dHJlZ2lvbjplMDg4MjIxYTA0N2U0NzI1YmY2NTU3NzQxYTM2ZTJkYl80Mzk4MDQ2NTExMjQw_d381c70a-de29-4a1c-b49d-0b90c00cad2c" continuedAt="idff595e6000b4b0ebb4f50aebfe60a57" escape="true">Prepaid expenses and other current assets</ix:nonNumeric></span></div><ix:continuation id="idff595e6000b4b0ebb4f50aebfe60a57"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGV4dHJlZ2lvbjplMDg4MjIxYTA0N2U0NzI1YmY2NTU3NzQxYTM2ZTJkYl80Mzk4MDQ2NTExMjQx_b8b69808-9aca-4814-9dc1-624318d70225" escape="true"><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="plrx:PrepaidResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV8yLTEtMS0xLTI2ODk1_e3741363-6a0d-428d-b4c7-16d6e125c46d">2,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="plrx:PrepaidResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV8yLTMtMS0xLTI2ODk1_bc4fa9dd-139b-43ac-b304-00a128cffcbd">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV8zLTEtMS0xLTI2ODk1_2c5c688c-4c12-4650-aeb5-52ae223d2eaf">2,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV8zLTMtMS0xLTI2ODk1_0ff0bd8c-e978-4da3-926a-e179b999fe07">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="plrx:PrepaidLicensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV80LTEtMS0xLTI2ODk1_d2c4ad64-8318-4f5e-bfa5-abd2c41c1c60">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="plrx:PrepaidLicensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV80LTMtMS0xLTI2ODk1_16ba04f2-2d13-4b8d-8a9d-95a367f30acb">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:PrepaidInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV81LTEtMS0xLTI2ODk1_1f428aaf-4333-4d44-9c3f-0727f4075007">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:PrepaidInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV81LTMtMS0xLTI2ODk1_079d66f4-0b4c-4cbb-b421-1dcd160ac32f">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV82LTEtMS0xLTI2ODk1_89ea7b5a-89fa-48c0-9b72-6aeea275a83b">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV82LTMtMS0xLTI2ODk1_6b2da7c6-f5d1-4a2e-93a9-b393458b2e04">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV83LTEtMS0xLTI2ODk1_227469e5-abb4-4078-a299-fa614690662c">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV83LTMtMS0xLTI2ODk1_47f87fa7-5280-4fe8-8e61-ddc539fdd4d3">4,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i988625df783e4cc0a27bd76df388da57_118"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90ZXh0cmVnaW9uOjc4YzQ1YzE1YTZmMTQ1YmFhYjJlODU1ZTMwYzBmYmUyXzMzOA_7e05c977-94c4-4fd2-b55e-e92ce29e3d17" continuedAt="i15a7f60594c94d95b4139c2f3e3d2718" escape="true">Accrued Liabilities and Other Long-Term Liabilities</ix:nonNumeric></span></div><ix:continuation id="i15a7f60594c94d95b4139c2f3e3d2718" continuedAt="i7b2496ace5ea4659b32e7cce6a63e04c"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90ZXh0cmVnaW9uOjc4YzQ1YzE1YTZmMTQ1YmFhYjJlODU1ZTMwYzBmYmUyXzMzOQ_90180e94-e627-4321-b862-9659483f7f1f" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="plrx:AccruedResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzItMS0xLTEtMTI2NTk_1286deb8-5178-4ae4-969f-e67213ac9eaf">5,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="plrx:AccruedResearchAndDevelopmentExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzItMy0xLTEtMTI2NTk_c21c03f3-0a12-4656-851f-7057de4761f4">3,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzMtMS0xLTEtMTI2NTk_4a34c87b-5231-43c7-96dd-b60a8954e05e">5,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzMtMy0xLTEtMTI2NTk_8f18fef6-58e6-4745-8611-4c9a5396fb0d">4,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzQtMS0xLTEtMTI2NTk_cb41c97f-62a5-4bce-a9b2-c967f14ab218">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzQtMy0xLTEtMTI2NTk_d9e21c55-b064-4883-b472-b6863e34601d">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="plrx:DeferredRentAndLeaseholdIncentiveObligationCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzUtMS0xLTEtMTI2NTk_3de26c56-3e23-4562-b4ab-2ceb8c8c0174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="plrx:DeferredRentAndLeaseholdIncentiveObligationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzUtMy0xLTEtMTI2NTk_96e73467-4b88-48ef-ab9b-cfa7bd741b78">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzYtMS0xLTEtMTI2NTk_607173a7-2fab-40bf-8110-19e2d9b89a79">11,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzYtMy0xLTEtMTI2NTk_da82de78-8484-4771-8b1e-1c63d41db821">9,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits consist primarily of accrued bonuses and accrued vacation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i7b2496ace5ea4659b32e7cce6a63e04c"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-Term Liabilities</span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90ZXh0cmVnaW9uOjc4YzQ1YzE1YTZmMTQ1YmFhYjJlODU1ZTMwYzBmYmUyXzM0MA_515ef14b-b16f-46cf-8ad3-0f7f712a0ac9" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredRentCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzItMS0xLTEtMTI2NTk_3902768a-d128-4cea-846c-1f7b5436631d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredRentCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzItMy0xLTEtMTI2NTk_1d414265-e808-4357-9866-d93d442aa555">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold incentive obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:IncentiveFromLessor" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzMtMS0xLTEtMTI2NTk_65413f9e-9dfb-4276-a2c1-549c3690cc92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:IncentiveFromLessor" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzMtMy0xLTEtMTI2NTk_c51e90e1-9f57-489e-a895-d0562f781478">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities &#8212; deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzQtMS0xLTEtMTI2NTk_e2a0d485-e72b-4659-b73a-79ae8c0e3349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzQtMy0xLTEtMTI2NTk_7f23e8f0-ffc0-41df-bf0f-2251dada51e4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzUtMS0xLTEtMTI2NTk_4b09dbca-0e0f-4ab4-84d9-c9b2d3a559e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzUtMy0xLTEtMTI2NTk_c055235b-a323-4c5f-bc8d-8169c6616100">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_121"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzcxODU_98916e3c-a44b-4836-aab2-1bddbe6dadd3" continuedAt="i1ccc663ab4fe427b8bc1ca4d2ddf95f3" escape="true">Novartis Collaboration and License Agreement (the "Novartis Agreement")</ix:nonNumeric></span></div><ix:continuation id="i1ccc663ab4fe427b8bc1ca4d2ddf95f3"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into the Novartis Agreement, for the development and commercialization of our preclinical product candidate, PLN-1474 and up to <ix:nonFraction unitRef="research" contextRef="iaac21b42661c400488b1fa60189baec8_D20190101-20191231" decimals="INF" name="plrx:NumberOfIntegrinResearchTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NDk0NTk_158c1bda-6d68-4ba8-896f-635e7b6d2f4e">three</ix:nonFraction> additional integrin research targets. PLN-1474 is an internally discovered small molecule selective inhibitor of integrin &#945;v&#946;1, currently being developed for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (&#8220;NASH&#8221;). Pursuant to the agreement, we received an upfront, non-refundable license fee of $<ix:nonFraction unitRef="usd" contextRef="i4a11a4aeb6da425289c1166b59fd1bef_D20190101-20191231" decimals="-5" name="plrx:ProceedsFromUpfrontNonRefundableLicenseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5MTc_9a3ee829-9792-4e3a-987a-5b3b7cd9cb85">50.0</ix:nonFraction> million and were eligible to receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="iaac21b42661c400488b1fa60189baec8_D20190101-20191231" decimals="-5" name="plrx:CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5MjM_0c85a3da-2929-4be1-b921-c42666bdb25a">416.0</ix:nonFraction> million contingent upon achievement of specified research, development, regulatory and commercial events and royalties on world-wide net sales thereafter. Additionally, Novartis agreed to fund up to $<ix:nonFraction unitRef="usd" contextRef="icf4063173b5147aaa5ea48ffb9a0b41a_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5MzE_18ac8592-9cd5-4c4f-aae3-a1157ae665c0">19.6</ix:nonFraction> million associated with research and development services for PLN-1474 and up to $<ix:nonFraction unitRef="usd" contextRef="id20b043448f24ec285209cd2157d817f_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5Mzg_b0652a8a-cfb6-42d5-bd97-fbd5ba6e4ff8">13.4</ix:nonFraction> million for research and development services on the integrin research targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the Novartis Agreement in accordance with ASC 606 and determined that Novartis is a customer and identified the following performance obligations: (1) to provide worldwide license rights to PLN-1474, (2) to provide research and development services for PLN-1474, (3) to provide non-exclusive license rights to integrin research targets, and (4) to provide research and development services on integrin research targets.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the license to PLN-1474 was functional intellectual property and distinct as Novartis is capable to benefit from the license on its own or together with other resources that are readily available, and the research and development services we promise to deliver are not transformative in nature. Additionally, we concluded that the non-exclusive license rights to integrin research targets were not distinct in the context of the arrangement as the promised research and development services on integrin research targets were expected to significantly modify the license and Novartis could not benefit from the non-exclusive license without such services. Therefore, the non-exclusive license rights and research and development services on integrin research targets were considered a single performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the transaction price of the PLN-1474 research and development services and integrin target research and development services was $<ix:nonFraction unitRef="usd" contextRef="i65678d1f069d4f07b494357695afab1c_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NzQ4MzA_b730288d-84be-45bd-a8b7-d89e8b6e0257">20.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3487dc6202fc4061837be6f1764523cd_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NzQ4NDU_583084f4-369a-43cc-b04d-467e767f9b6a">13.4</ix:nonFraction>&#160;million, respectively, as of December 31, 2021, and the performance obligations associated with the aggregate unrecognized transaction price of $<ix:nonFraction unitRef="usd" contextRef="i7f8872e361484321beb5a17ef1f8345f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NzQ4NjA_41d45a1e-acb3-4382-98f2-2c935dd66d3a">2.0</ix:nonFraction>&#160;million would be satisfied in 2022. As of December 31, 2021, variable consideration associated with specified research and development milestones totaling $<ix:nonFraction unitRef="usd" contextRef="i8d55eaa32322449995997cb4bfd779d4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NzQ4NzQ_33c80521-30e5-4266-b082-2036afccd3a7">391</ix:nonFraction>&#160;million have been constrained from the transaction prices but remain eligible for achievement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are utilizing a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. We believe this is the best measure of progress because other measures do not reflect how we transfer the performance obligation to our counterparty. In applying the cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of third-party contract costs and internal full-time equivalent effort. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the performance obligations. The cumulative effect of revisions to estimated costs to complete the performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i7aab796f0bd54438a683ab44e486ff52_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5NjM_0988e298-8dae-4129-a57f-816e8eea7666">7.6</ix:nonFraction>&#160;million which consisted of revenue generated from research and development services. During the year ended December&#160;31, 2020, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="iac8fe1712787414792033f6f6a6693aa_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwMDM_52c4020a-e6d2-4966-ad77-11c6db876e9e">41.8</ix:nonFraction> million, which consisted of $<ix:nonFraction unitRef="usd" contextRef="i1401fc63110c46cca48abbee90d24210_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwMTA_f38e5a33-1ce9-4566-840c-3e38ddb25d97">25.0</ix:nonFraction>&#160;million from the achievement of the first patient dosing milestone of the Novartis agreement in the first quarter of 2020 and $<ix:nonFraction unitRef="usd" contextRef="ic8fd2e317fcf496da3fadf37239b10a7_D20200101-20200331" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwMTc_d18b527c-6f58-40e3-a671-1f56f4460ef2">16.8</ix:nonFraction> million of revenue generated from research and development services performed during the year.&#160;During the year ended December&#160;31, 2019, Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ia854acc757a14f42801309f5de85921c_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwMzk_9157af09-c664-4b2d-9ee6-7f392c03ee42">50.0</ix:nonFraction> million related to the license fee and $<ix:nonFraction unitRef="usd" contextRef="i935a529a108b4fe0854d7b486b19bf50_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwNDY_9ab9b920-b47b-4f93-99ee-c46bfabf3cc7">7.1</ix:nonFraction> million from research and development services.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, there was a receivable of $<ix:nonFraction unitRef="usd" contextRef="ief48b07f768842d19a26be0c2fdd1f5b_I20211231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwNjU_56909548-b80f-4e8d-9e8e-0329e77c986d">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1584a412397045a9b86f15e94c5effa9_I20201231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwNTg_25826552-5914-4e78-8d6f-c9def415bfb4">9.3</ix:nonFraction> million, respectively, related to the Novartis Agreement. There were <ix:nonFraction unitRef="usd" contextRef="i1584a412397045a9b86f15e94c5effa9_I20201231" decimals="INF" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwODU_05d70b5a-500e-4ab5-896b-5a03c852966f"><ix:nonFraction unitRef="usd" contextRef="i1584a412397045a9b86f15e94c5effa9_I20201231" decimals="INF" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwODU_643c1056-4044-43ad-a6f8-7b4dc5f22435"><ix:nonFraction unitRef="usd" contextRef="ief48b07f768842d19a26be0c2fdd1f5b_I20211231" decimals="INF" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwODU_765f44ac-87c3-4692-a5cd-67356eea5e4d"><ix:nonFraction unitRef="usd" contextRef="ief48b07f768842d19a26be0c2fdd1f5b_I20211231" decimals="INF" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwODU_c906da23-1c0d-464e-b86c-77f4e6c3579c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities as of December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_124"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:LicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjQvZnJhZzoyYTE1ZmM5ZDZkNTE0YmIxYWRlMDgwZDgwNjFmMTQwYi90ZXh0cmVnaW9uOjJhMTVmYzlkNmQ1MTRiYjFhZGUwODBkODA2MWYxNDBiXzIzMjM_d2527c20-d05f-422b-bd66-a6cf3dd849c7" continuedAt="ica965d1b6bdd41ca94b4d9afad508a91" escape="true">Regents of the University of California License Agreement (the &#8220;UC Agreement&#8221;) </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ica965d1b6bdd41ca94b4d9afad508a91">In 2015, we entered into the UC Agreement to obtain an exclusive, worldwide license relating to the use of certain patents and technology relating to &#945;v&#223;1 compound in fibrosis indications. Pursuant to the UC Agreement, we made a $<ix:nonFraction unitRef="usd" contextRef="ia97bea2e62e046a3b667360c66ca83de_D20200601-20200630" decimals="-5" name="plrx:MilestoneAndAnnualRoyaltyPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjQvZnJhZzoyYTE1ZmM5ZDZkNTE0YmIxYWRlMDgwZDgwNjFmMTQwYi90ZXh0cmVnaW9uOjJhMTVmYzlkNmQ1MTRiYjFhZGUwODBkODA2MWYxNDBiXzk4OTU2MDQ2NjA4ODU_fcad15b3-979a-4d10-b62e-36d5e20d7c09">2.4</ix:nonFraction> million milestone payment upon the close of our IPO in June 2020. Subsequently, we determined the licensed technology was no longer relevant to the development of our product candidates and, therefore, we exercised our right to terminate the UC Agreement which became effective in the first quarter of 2021. No further obligations or financial commitments survive the termination.</ix:continuation></span></div><div id="i988625df783e4cc0a27bd76df388da57_127"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjcvZnJhZzphNGVjZmYxM2QwYzM0MTQ3OWY5YjBiZjcxODk1NTg4NC90ZXh0cmVnaW9uOmE0ZWNmZjEzZDBjMzQxNDc5ZjliMGJmNzE4OTU1ODg0XzM0NjY_9568ccd3-0d45-4956-b576-d8053b8ff0ba" continuedAt="i4cf9c5dfd41b458dbb7e3bc14dc5a735" escape="true">Adimab Development and Option Agreement (the "Adimab Agreement")</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4cf9c5dfd41b458dbb7e3bc14dc5a735" continuedAt="id4dd083a07224b0eafe0dc55eb7406e7">In 2018, we entered into a development and option agreement with Adimab, LLC (&#8220;Adimab&#8221;) for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the Adimab Agreement, we will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. We are required to pay Adimab an agreed upon rate for its full-time employees during the discovery period while Adimab performs research on each target under the applicable research plan. We have an exclusive option to obtain a worldwide, royalty-bearing, sublicensable license under Adimab platform patents and other Adimab technology to research, develop and commercialize up to 24 antibodies of our selection.</ix:continuation></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id4dd083a07224b0eafe0dc55eb7406e7">During the years ended December&#160;31, 2021, 2020 and 2019, we recognized research and development expenses associated with full-time employee costs of $<ix:nonFraction unitRef="usd" contextRef="i325f7f2d873247748a03caa8aa5d4255_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjcvZnJhZzphNGVjZmYxM2QwYzM0MTQ3OWY5YjBiZjcxODk1NTg4NC90ZXh0cmVnaW9uOmE0ZWNmZjEzZDBjMzQxNDc5ZjliMGJmNzE4OTU1ODg0XzE2NDkyNjc0NDYxMDQ_daff8b00-848e-4332-82b9-6f9356b56e18">28,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i5d58d249d30a4738b31d13b2325bbf0f_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjcvZnJhZzphNGVjZmYxM2QwYzM0MTQ3OWY5YjBiZjcxODk1NTg4NC90ZXh0cmVnaW9uOmE0ZWNmZjEzZDBjMzQxNDc5ZjliMGJmNzE4OTU1ODg0XzE2NDkyNjc0NDU4Mzc_b779cf02-24c2-4ae4-ab2a-c6202fc57b48">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i92b24333fd1f4bc6a82043ff6caa6b4b_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjcvZnJhZzphNGVjZmYxM2QwYzM0MTQ3OWY5YjBiZjcxODk1NTg4NC90ZXh0cmVnaW9uOmE0ZWNmZjEzZDBjMzQxNDc5ZjliMGJmNzE4OTU1ODg0XzE2NDkyNjc0NDU5MTk_b2ed0ad4-5844-494f-8270-08a698ee115d">0.2</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div id="i988625df783e4cc0a27bd76df388da57_133"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:RedeemableConvertiblePreferredStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzMvZnJhZzozNmMzNGZhZmMwNjM0OGQ4OTA2OTc2NTUzNGQ1NTk1My90ZXh0cmVnaW9uOjM2YzM0ZmFmYzA2MzQ4ZDg5MDY5NzY1NTM0ZDU1OTUzXzc2MDI_10d2c34c-e3f4-4932-8dff-90168451928b" continuedAt="i2d4cd60137d148708c17a24bae3a02a2" escape="true">Redeemable Convertible Preferred Stock</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2d4cd60137d148708c17a24bae3a02a2">Under the Company&#8217;s Amended and Restated Certificate of Incorporation (&#8220;Certificate of Incorporation&#8221;), the Company is authorized to issue two classes of shares: preferred and common stock. The preferred stock may be issued in series, and the Company&#8217;s Board of Directors is authorized to determine the rights, preferences, and terms of each series. These rights preferences and terms could include dividend rights, conversion rights, voting rights, terms of redemptions, liquidation preferences and sinking fund terms. As a result of the IPO in June 2020, all then outstanding convertible preferred stock was converted into shares of common stock. There are <ix:nonFraction unitRef="shares" contextRef="i854a3335aa6a4adc9776beabc85e03a9_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzMvZnJhZzozNmMzNGZhZmMwNjM0OGQ4OTA2OTc2NTUzNGQ1NTk1My90ZXh0cmVnaW9uOjM2YzM0ZmFmYzA2MzQ4ZDg5MDY5NzY1NTM0ZDU1OTUzXzEwOTk1MTE2MzU4MDU_8b4e83c4-94bf-4b96-8390-c56c5386af1f">no</ix:nonFraction> outstanding shares of preferred stock as of December&#160;31, 2021.</ix:continuation></span></div><div id="i988625df783e4cc0a27bd76df388da57_139"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzI1NTQ_21dd2b76-9d17-4f0a-b083-4fa0a060f11f" continuedAt="i59dd08a6731f44568eb5fac33ce939ed" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="i59dd08a6731f44568eb5fac33ce939ed" continuedAt="i5d0a5e1da99742a9b7090b9f4d20df55"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MDQ_2ccffb89-c00d-4b90-8a9d-9ab6243ccdb0"><ix:nonFraction unitRef="shares" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MDQ_93313fe3-9f67-4f3f-9e2a-f0a486e31ddf">300,000,000</ix:nonFraction></ix:nonFraction> authorized shares of common stock, at a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MTI_ad34b9f4-fc04-4fa4-a594-e429436ed6e1"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MTI_e42bb063-e0b4-4dfd-9585-934eb0d6b3f1">0.0001</ix:nonFraction></ix:nonFraction> per share. The common stock has the following rights and privileges:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="plrx:NumberOfVotesPerShareOfCommonStock" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzQzOTgwNDY1MTU4MzE_96e3709b-4b50-4dd7-81ad-5bc5b8435fb3">one</ix:nonFraction> vote for each share of common stock held at any meeting of stockholders and at the time of any written action in lieu of a meeting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of common stock are entitled to receive dividends, when declared by the Company&#8217;s Board of Directors. Cash dividends may not be declared or paid to holders of shares of common stock until all unpaid dividends on the Preferred Stock have been paid in accordance with their terms. <ix:nonFraction unitRef="usdPerShare" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MTY_20aea35e-ac10-4274-81f2-2e76cf4b2f0c">No</ix:nonFraction> dividends have been declared or paid by the Company since its inception.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After payment of the respective liquidation preferences to the holders of shares of Preferred Stock, the holders of shares of common stock are entitled to share ratably in the Company&#8217;s remaining assets available for distribution to its stockholders in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or upon occurrence of a deemed liquidation event.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><ix:continuation id="i5d0a5e1da99742a9b7090b9f4d20df55"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzI1NTU_e26cd78c-f22f-4e6a-805f-23950ee55210" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares reserved for future issuance</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i39ce7df93a7d4382a3b7d79316b6d848_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzMtMS0xLTEtMTI2NTk_618f22d9-5504-4e1a-9986-5cbcf42c2eeb">3,620,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d8e01ec8dfa4b258bddae261451f4ff_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzMtMy0xLTEtMTI2NTk_de66bb72-2854-4487-b8a3-ec9b7b233775">2,993,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock available for future grants under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id08bb42e6ee74106be86d58f7fcbc58f_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzUtMS0xLTEtMTI2NTk_53c9f35f-758d-4f0b-ac61-dda4149dada4">4,234,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d9b60a984584a44a4ee09a45e5275aa_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzUtMy0xLTEtMTI2NTk_19dd7b0f-d932-463d-bb31-322af7a293a3">3,644,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3ff87434abfc452d80645776f0f00c77_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzYtMS0xLTEtMTI2NTk_6b6d1c99-4b15-46d4-bad6-3371be4258b1">613,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cf105f8083b45429f14ea888203d42a_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzYtMy0xLTEtMTI2NTk_daadcb29-5b3b-4df0-a412-e4f6f9dee9e5">700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzctMS0xLTEtMTI2NTk_53b90144-a8d9-4273-bb4f-dee678d68d99">8,467,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzctMy0xLTEtMTI2NTk_120425e4-fda7-4b36-b08f-b3c3d5b88ded">7,338,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i988625df783e4cc0a27bd76df388da57_142"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjI_7dfefe51-639e-496e-bb2e-b2b9e9a7004d" continuedAt="i6bb04abf2f6a4ec58f5c3e370fbb897e" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i6bb04abf2f6a4ec58f5c3e370fbb897e" continuedAt="i30e304c3a18d4bdc9b9324a34852831d"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Company's Board of Directors adopted the 2015 Equity Incentive Plan, as amended in 2018, 2019 and 2020 (the &#8220;2015 Plan&#8221;), which provided for the grant of incentive stock options, nonqualified stock options or other awards including stock appreciation rights and restricted stock awards to the Company&#8217;s employees, officers, directors, advisors, and consultants.  In May 2020, the Board of Directors adopted the 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;) and suspended the 2015 Plan. Awards outstanding under either the 2015 Plan or 2020 Plan that are cancelled, expire or otherwise terminated subsequent to May 2020 will become available for issuance as common stock under the 2020 Plan. Additionally, the 2020 Plan is subject to automatic increases on January 1 of each year beginning January 1, 2021. The number of shares added each January 1 will be equal to the lesser of: (i) <ix:nonFraction unitRef="number" contextRef="if6f33d4df0354eefb5a56946ce9457da_D20200501-20200531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzk4OTU2MDQ2NjQ3NjU_a417b0c9-08b4-465e-80fd-b976e2f0bbdd">5</ix:nonFraction>% of the outstanding shares on the immediately preceding December&#160;31 or (ii) such amount as determined by the administrator of the 2020 Plan, which is the compensation committee of the Board of Directors of the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan provides for the grant of incentive stock options, nonqualified stock options or other awards including stock appreciation rights, restricted stock awards and restricted stock units to the Company&#8217;s employees, officers, directors, advisors, and consultants. As of December 31, 2021, the 2020 Plan had <ix:nonFraction unitRef="shares" contextRef="id08bb42e6ee74106be86d58f7fcbc58f_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzk4OTU2MDQ2NjU4NjE_53c9f35f-758d-4f0b-ac61-dda4149dada4">4,234,213</ix:nonFraction> shares of common stock available for future issuance.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Options under the 2020 Plan may be granted for periods of up to <ix:nonNumeric contextRef="i978188554a324ce7b6a888947d74558d_D20200501-20200531" name="plrx:ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzI5MTg_79c7ab2b-51a1-4a34-ac3e-e8f96d03b2c9">10</ix:nonNumeric> years and at prices no less than the market price of the Company&#8217;s common stock on the date of grant, provided, however, that the exercise price of an incentive stock option granted to a <ix:nonFraction unitRef="number" contextRef="if6f33d4df0354eefb5a56946ce9457da_D20200501-20200531" decimals="INF" name="plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzMxMDI_49d1f026-1d7a-442b-ac63-db1b4973b1eb">10</ix:nonFraction>% shareholder shall not be less than <ix:nonFraction unitRef="number" contextRef="i978188554a324ce7b6a888947d74558d_D20200501-20200531" decimals="INF" name="plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzMxNDA_df8d02cd-5414-4e32-9a45-f70d0e95b194">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant and the option is not exercisable after the expiration of <ix:nonNumeric contextRef="if6f33d4df0354eefb5a56946ce9457da_D20200501-20200531" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzMyNjQ_45618d20-1462-46d5-bc2d-a6cfa49851ac">five years</ix:nonNumeric> from the date of grant.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Restricted Common Stock Awards</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted restricted stock awards under the 2015 Plan. The purchase price of the restricted common stock awards was the estimated fair value as determined by the Company's Board of Directors at the issuance date. The shares vest from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzM1NTY_17d5b407-5e02-4666-bc12-447640c0a66b">one</span> to <ix:nonNumeric contextRef="i2fc83290d82c40ddb10360a0b1a2183c_D20200501-20200531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzM1NjI_02891c67-866b-41dd-9c27-96021fd20ea9">four years</ix:nonNumeric> and vesting could be accelerated upon a change in control. A holder of an award may pay a total purchase price or a part of the purchase price for granted shares at any time during the vesting periods. Upon termination of employment, the Company has the right to repurchase any unvested restricted shares. The repurchase price for unvested shares of common stock will be the lower of (i) the fair market value on the date of repurchase or (ii) their original purchase price. During the vesting term, holders of restricted stock awards are deemed to be common stock shareholders and have dividends and voting rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for restricted stock awards as early exercised options and recognized a liability in other liabilities when cash was received for the purchase of shares of restricted stock. As shares of restricted stock vested, the Company reclassified the liability to common stock and additional paid in capital. As of December&#160;31, 2021 and&#160;2020, the Company recorded a liability included in accrued expenses and other liabilities of $<ix:nonFraction unitRef="usd" contextRef="i82f0177dc3e04d418b662056854c1e4f_I20211231" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NzI_6b91a4cd-6c91-421a-ace5-b4eca0e09c75">2,000</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="usd" contextRef="ica5a99276a1147c19fe6753da55b633a_I20201231" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5Njg_7e69ba1f-fc40-41ff-8178-3766e85ba34a">10,000</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzQ2NDg_5b94a3b1-514d-4dbd-bea1-4b30059c88c3">no</ix:nonFraction> grants of restricted stock awards during the years ended December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i30e304c3a18d4bdc9b9324a34852831d" continuedAt="i8ad502ef560842f18032e92930df133d"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjU_d4edb2b5-f7c6-4eec-8af5-c3c72c898eb8" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during the year ended December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested, as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i58ea8b06f17a484f9edfb9c294799d18_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzEtMS0xLTEtMTI2NTk_0d42410d-2b35-48fa-a711-4731755bbbec">126,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58ea8b06f17a484f9edfb9c294799d18_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzEtMy0xLTEtMTI2NTk_3b46ad5f-8a10-4ce6-91db-56d872f78cfa">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzItMS0xLTEtMTI2NTk_9901b1ae-3389-492d-9c83-c138ca6ec841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzItMy0xLTEtMTI2NTk_dd488920-f3c1-40bd-a9e9-79825d8e1717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzMtMS0xLTEtMTI2NTk_eefd8a81-9edf-4c19-a58f-b37675bacb85">103,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzMtMy0xLTEtMTI2NTk_7bde19db-84ca-42cc-988f-4b2619fa61d0">1.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231" decimals="INF" name="plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzQtMS0xLTEtMTI2NTk_fe0057f3-9b48-4270-876b-1ea2775da479">1,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231" decimals="2" name="plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzQtMy0xLTEtMTI2NTk_824a9964-5236-4ee8-964e-a241ee81321d">2.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested, as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia016e7bdf0174df7a7fba019617bf8ba_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzUtMS0xLTEtMTI2NTk_c5e9ed11-6cb3-485a-8d5b-c8e934d5ed45">21,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia016e7bdf0174df7a7fba019617bf8ba_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzUtMy0xLTEtMTI2NTk_8512e126-471c-4c71-9427-64103bb2d6aa">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate fair value of restricted stock awards vested during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i0866a31e05374ddab8c0a62345cc2249_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NzY_c82d7df2-d143-422b-bd66-45de3a6c87de"><ix:nonFraction unitRef="usd" contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NzY_ed485ec2-9deb-465a-bdb3-b19d4b090c10">0.2</ix:nonFraction></ix:nonFraction>&#160;million each year. Total intrinsic value of outstanding unvested restricted stock awards as of December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ia016e7bdf0174df7a7fba019617bf8ba_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2MzkwMjI_26817646-a094-4e16-8743-d712ad321c56">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i58ea8b06f17a484f9edfb9c294799d18_I20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2MzkwMTQ_fd860020-8c42-4714-87f1-11922647ad07">2.9</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Options and Nonqualified Stock Options</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued under either the 2015 Plan or the 2020 Plan generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzU0NDE_e2781c43-be0a-4144-b7b0-5f65f0005fa6">four</span> years and expire <ix:nonNumeric contextRef="i962e48e9796f47aeb0fff9145b63f53a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzU0Njc_15c3c7e8-ea76-4b87-9d9e-6c4e1e24381e">ten years</ix:nonNumeric> from the date of grant. Certain options provide for accelerated vesting if there is a change in control, as defined in the respective plans.</span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNTk_52617833-febd-4e10-b007-4db0408365e3" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for stock option awards with the following assumptions:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"></td><td style="width:37.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.807%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItMS0xLTEtMTI2NTk_60ae17c9-043e-4272-9515-171b37350371">74.83</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItMy0xLTEtMTI2NTk_642b533f-32ba-422b-bead-269a22ba54c9">76.31</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItNS0xLTEtMTI2NTk_823b962d-e410-41fc-9484-810e89444d93">72.10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItNy0xLTEtMTI2NTk_d48d3c1a-23e3-41f5-bb70-9fe163e09b80">77.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc0db696ccde415882e24106f2b32245_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItOS0xLTEtMjE2MjE_189f9e81-41e1-4f8c-8e40-80f2b75271af">74.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc0db696ccde415882e24106f2b32245_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItMTEtMS0xLTIxNjIx_8b7109c8-142b-4b7e-b4e8-a3ee57bdf74b">82.53</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtMS0xLTEtMTI2NTk_19c571d7-a44f-4118-bda4-59158aab7ed6">0.61</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtMy0xLTEtMTI2NTk_5bc775bd-17c9-46a6-8cbb-7a7eb44b68d9">1.39</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtNS0xLTEtMTI2NTk_e8d84e45-b51d-4ccc-83f2-27a687dd6aa6">0.27</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtNy0xLTEtMTI2NTk_b9c7ec18-49fe-4e6e-bb15-340b216a4d3a">0.82</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc0db696ccde415882e24106f2b32245_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtOS0xLTEtMjE2MjE_6bac2fe1-47a6-48e6-b9b1-4505edc74004">1.43</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc0db696ccde415882e24106f2b32245_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtMTEtMS0xLTIxNjIx_017e90a9-836f-4fd2-a44e-7406a42cadde">2.59</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzQtMS0xLTEtMTI2NTk_fc750bfc-56dc-47bf-b607-573c5083b5ea">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzQtNS0xLTEtMTI2NTk_5514d5fd-503e-4483-a717-d4c213288296">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzQtOS0xLTEtMjE2MjE_47751ba2-553e-41f8-a7c3-e3de1b685405">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d838bfb91454b308b74f37279c3dce3_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtMS0xLTEtMTI2NTk_e862fb8d-b22e-45ec-98a0-937f4c4f218f">5.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4f90bc5eed144f31928518fb768afba8_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtMy0xLTEtMTI2NTk_013ecd9d-ee15-4301-a89e-db1f5da5b293">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4dac08fa4ec49c8b7257c8ac25cdc21_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtNS0xLTEtMTI2NTk_68baf194-8f23-4564-adbb-3cfa1e534492">5.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idda313aa08fc4436871f7a8d1f6538ec_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtNy0xLTEtMTI2NTk_326abb99-8381-46a9-8e51-96998484c716">6.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96b95e5be86744cfb426abbbd9280039_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtOS0xLTEtMjE2MjE_e709e27a-b273-464e-b92c-48b0927ab085">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93980ffa2b4c48c69c6aeaa148e56ca5_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtMTEtMS0xLTIxNjIx_5273b47f-3899-4742-af08-58615593703a">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underlying common stock fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d838bfb91454b308b74f37279c3dce3_D20210101-20211231" decimals="2" name="plrx:UnderlyingCommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtMS0xLTEtMTI2NTk_17b72188-7856-4cf9-8cbd-fb070399570b">15.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f90bc5eed144f31928518fb768afba8_D20210101-20211231" decimals="2" name="plrx:UnderlyingCommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtMy0xLTEtMTI2NTk_2e96038b-f105-41a1-bfd9-af9871e912cb">38.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4dac08fa4ec49c8b7257c8ac25cdc21_D20200101-20201231" decimals="2" name="plrx:UnderlyingCommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtNS0xLTEtMTI2NTk_c98d9be2-1cb8-483a-9ca2-ed4d4ce74286">6.22</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="idda313aa08fc4436871f7a8d1f6538ec_D20200101-20201231" decimals="2" name="plrx:UnderlyingCommonStockFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtNy0xLTEtMTI2NTk_f6556017-7301-4ce2-82e9-f39cd9708689">28.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96b95e5be86744cfb426abbbd9280039_D20190101-20191231" decimals="2" name="plrx:UnderlyingCommonStockFairValue" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtOS0xLTEtMjE2MjE_bfcac742-7cfc-4fbf-9e83-7cc43b625f92">5.15</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93980ffa2b4c48c69c6aeaa148e56ca5_D20190101-20191231" decimals="2" name="plrx:UnderlyingCommonStockFairValue" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtMTEtMS0xLTIxNjIx_b0e61c87-1e55-42ab-86a4-ac7f2a79cf6c">7.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjA_61dd4013-81d3-4920-a642-4f4022aa7b25" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the 2015 Plan and the 2020 Plan is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average&#160;Exercise<br/>Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(in&#160;Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaee36529cae34a1880d776adf134e69e_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzEtMS0xLTEtMTI2NTk_ae169bdb-a8ef-45c1-ba74-7e8cd4ce69e2">2,993,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaee36529cae34a1880d776adf134e69e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzEtMy0xLTEtMTI2NTk_3091000c-cc60-46ae-a3c2-dcb98013d510">8.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib513e9b41ca0401988a6ebdb0da1f635_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzEtNS0xLTEtMTI2NTk_28a5dbdc-5c5e-4f51-93f2-6478aeb9c6b5">8.84</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaee36529cae34a1880d776adf134e69e_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzEtNy0xLTEtMTI2NTk_5e091356-8516-475c-b2a9-bc5da81a97a7">43,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzItMS0xLTEtMTI2NTk_aa4ae01b-2f7f-45bf-800b-e5d7dd0a5f9d">1,520,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzItMy0xLTEtMTI2NTk_e3094504-410e-4032-87f2-fd4f83393730">26.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzMtMS0xLTEtMTI2NTk_700a30aa-3690-4d7a-8981-3d50a1c313f5">336,340</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzMtMy0xLTEtMTI2NTk_2b716fed-65b3-4a89-9b0d-d72e00cdd58f">5.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzQtMS0xLTEtMTI2NTk_8bd27a0d-7fb2-4642-a044-d8e8bb5d49ca">557,726</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzQtMy0xLTEtMTI2NTk_0a1083e6-522a-42ce-b061-b1001729f641">16.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzUtMS0xLTEtMTI2NTk_98e6b1a9-1ef9-44ea-8de1-ca485a105231">3,620,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzUtMy0xLTEtMTI2NTk_b8d6ee86-6e80-4f9f-a4fb-f7efa24221c3">14.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzUtNS0xLTEtMTI2NTk_d69d1baf-d660-4ddc-940a-eff50f2fabd6">8.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzUtNy0xLTEtMTI2NTk_f4293830-83d7-4b30-85f2-26c77fcba276">16,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzYtMS0xLTEtMTI2NTk_7646a557-401e-4c46-8125-f07c9ffbb281">1,368,543</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzYtMy0xLTEtMTI2NTk_2c9d4cbe-0625-47b6-aad4-997b0787cae9">9.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzYtNS0xLTEtMTI2NTk_305ea2aa-dcb3-4fb2-ab10-5e8cc85d7cab">7.66</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzYtNy0xLTEtMTI2NTk_65770196-e25d-4c3f-99e6-2bceed8a6e46">9,426</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzctMS0xLTEtMTI2NTk_b6def006-ef64-46b0-8c3a-9cc81846602b">3,620,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzctMy0xLTEtMTI2NTk_b9e32694-c56f-4623-a84d-432e455fc88c">14.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzctNS0xLTEtMTI2NTk_1a1255f5-06c2-4261-a067-4c6d5601e193">7.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzctNy0xLTEtMTI2NTk_56d585fa-5961-4c43-88d9-aa0c60de0f43">16,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the difference between the fair value of the underlying common stock and the exercise price as of December&#160;31, 2021 and 2020. The weighted-average grant date fair value of options granted during years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5MjM_70ef29d0-b0c6-4794-ae4b-60d26858b9f3">16.94</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5MTg_0bd68be1-e933-48b5-aae3-41d228f217dc">7.27</ix:nonFraction> per share, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, the Company adopted the Company's 2020 Employee Stock Purchase Plan (the "2020 ESPP"). The Company reserved <ix:nonFraction unitRef="shares" contextRef="ie08b0d8bbc764ddfa7bbdedd05be39a6_I20200630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5Mjc_9e41f2fe-a83e-4329-862b-4db2dd699eeb">700,000</ix:nonFraction> shares of common stock for future issuance under the plan. <ix:nonNumeric contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjY_0f2c7ffa-6c3f-43c1-884f-bd55d5878975" continuedAt="i1b16f0bae9544fa097b395a3b2d95608">The 2020 ESPP provides that the </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i8ad502ef560842f18032e92930df133d"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i1b16f0bae9544fa097b395a3b2d95608">number of shares reserved and available for issuance will automatically increase on January 1 of each calendar year, beginning January 1, 2021, by the least of (i) <ix:nonFraction unitRef="number" contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzY4MTc_6373db44-1fa7-49dc-accb-1867264fb054">1.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) <ix:nonFraction unitRef="shares" contextRef="ie08b0d8bbc764ddfa7bbdedd05be39a6_I20200630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzY5MzA_ae9bd7f7-a54b-411f-8c5c-01ca977203cc">700,000</ix:nonFraction> shares or (iii) such lesser amount as determined by the administrator of the 2020 ESPP, which is the compensation committee of the Board of Directors of the Company.</ix:continuation></span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 ESPP, eligible employees may purchase shares of our common stock through payroll deductions that cannot exceed <ix:nonFraction unitRef="number" contextRef="iff90f11d0095440091e5fe52c4904b74_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzcyMTA_b2426f0b-61ba-4a32-9719-f8865eee7a2d">15</ix:nonFraction>% of each employee&#8217;s salary. The 2020 ESPP provides for a <ix:nonNumeric contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630" name="plrx:EmployeeStockPurchasePlanOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzQzOTgwNDY1MjcyMjc_5131feda-1488-4dfc-8e8f-4e82be8cb4fb">six-month</ix:nonNumeric> offering period. At the end of the purchase period, eligible employees are permitted to purchase shares of common stock at the lower of <ix:nonFraction unitRef="number" contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630" decimals="2" name="plrx:CommonStockFairMarketValuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzc0MTQ_0927e627-3301-4eaa-960c-02cc0aadbf45">85</ix:nonFraction>% of the fair market value at the beginning of the offering period or <ix:nonFraction unitRef="number" contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630" decimals="2" name="plrx:CommonStockFairMarketValuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzc0ODU_cd49915a-0871-4c98-919c-2c3677b18c2b">85</ix:nonFraction>% of the fair market value at the end of the purchase period, subject to tax limitations on the total value of the purchase. The 2020 ESPP is considered a compensatory plan, and the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzc2ODU_d5d7c2e5-1ae2-4b9f-97b4-61e40d464145">0.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzk4Nzc_b83af22d-1e76-45ce-b146-a62e63be23d1">0.5</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzk4NTM_b91b488e-224d-4422-8bca-fdce62135b4d">nil</ix:nonFraction> in stock-based compensation expense for year ended December&#160;31, 2021, 2020 and 2019. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzc4ODc_ee002bbf-d5f7-41ba-a636-d64c918f71d3">86,902</ix:nonFraction> shares of common stock were issued under the 2020 ESPP. <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjc_1527d02e-d867-4f08-a353-1d24366d38e6" continuedAt="i308b5108d9804a97932158a2c63d0c94" escape="true">The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for the 2020 ESPP with the following assumptions:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i308b5108d9804a97932158a2c63d0c94"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.575%"><tr><td style="width:1.0%"></td><td style="width:52.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i63754797203a4fa396889e7f6f569993_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzItMS0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpkNzVjMTViYzZjYzI0MDRiYTQ5NGY2MzA1ZmE0YmRiY184Nzk2MDkzMDIyMjIy_6a1f048a-0059-4ba8-89b5-5a49bd79c1c9">0.06</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6c2c45617c474b8d8d2f5c5ec54bc1cb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzItMS0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpkNzVjMTViYzZjYzI0MDRiYTQ5NGY2MzA1ZmE0YmRiY184Nzk2MDkzMDIyMjI4_73aa175f-f8da-451c-adc5-6137458b3448">0.07</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzItMy0xLTEtMTI2NTk_2e5bccff-4311-47f6-91cd-3e625b42d29a">0.11</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzItNS0xLTEtMjE2OTU_b684448d-2451-4cac-b726-b3827b3d65d2">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term of options (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzMtMS0xLTEtMTI2NTk_1836f0df-2532-4466-9a3b-683001dcc372">0.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzMtMy0xLTEtMTI2NTk_0ca1aefc-8136-459b-8279-1d7d30f75bec">0.58</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i63754797203a4fa396889e7f6f569993_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzQtMS0xLTEtMTI2NTkvdGV4dHJlZ2lvbjoxZDE0Yzk1Y2UwZWU0YjNmOGNkYWI5ZTk2MDM4MjM1NV84Nzk2MDkzMDIyMjEy_ff6f8fa0-1f8d-44f7-bdfa-8995050cca4b">67.16</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6c2c45617c474b8d8d2f5c5ec54bc1cb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzQtMS0xLTEtMTI2NTkvdGV4dHJlZ2lvbjoxZDE0Yzk1Y2UwZWU0YjNmOGNkYWI5ZTk2MDM4MjM1NV84Nzk2MDkzMDIyMjE4_37803f02-9359-4920-b9a6-217f1ed73d00">89.51</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzQtMy0xLTEtMTI2NTk_8686c4d9-5efa-4769-928e-defe20584ff3">83.72</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzQtNS0xLTEtMjE2OTU_ae8582fd-c230-4002-b263-d61185ea1599">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzUtMS0xLTEtMTI2NTk_7a0584f6-9751-4b8a-8d52-3c64c15f1cb1">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzUtMy0xLTEtMTI2NTk_eca17cb5-1bad-4495-adee-0d394d46ea8d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzUtNS0xLTEtMjE2OTU_100431f8-1f87-4d32-bc18-477934fd4bed">&#8212;</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjE_805c50cc-8d79-4e15-b775-77fb4f7f0e14" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense during the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:57.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28a1619e7cc641e895b0a776ffb7951c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzItMS0xLTEtMTI2NTk_f634b582-9ecc-4572-adb0-b01ca0e8ce13">3,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4dcffcd3361d45578bb203270ca62583_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzItMy0xLTEtMTI2NTk_47ee72b7-7d01-4a79-94cc-cc9971be2a3a">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d49e2ef8b934a9ca9872c2da4874dc1_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzItNS0xLTEtMjE3MjU_dfbd0d61-2cd6-40b2-9c0f-d1f872a13b67">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0bc85e58f5bc489fbe3f59c43aa576af_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzMtMS0xLTEtMTI2NTk_9ce20751-a5fa-43be-b62b-dcfcf98f07a6">6,509</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8619df5f4bbc4c15a77403491fcf90bb_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzMtMy0xLTEtMTI2NTk_1dee61d3-c893-4c7e-9540-07ac3f904cd0">2,176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9b2f94dc394411bb306ac98316895ab_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzMtNS0xLTEtMjE3MjU_d8a61ca2-a3b7-41ff-bbf7-11dd43e83616">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzQtMS0xLTEtMTI2NTk_9b4ab56d-1ed3-4c67-907e-902c5237fba9">10,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzQtMy0xLTEtMTI2NTk_2f146879-b2db-47d4-b402-7e31becf249b">3,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzQtNS0xLTEtMjE3MjU_b6878444-3b77-4f37-8db5-ece34b7b6848">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ib90cfc2ccdd64c42ad8668e78941f9b4_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NTE_99afcaa3-7c6b-44dd-90bf-03e2ef2eff5c">37,000</ix:nonFraction> of unrecognized compensation costs that is expected to be recognized over the weighted-average periods of <ix:nonNumeric contextRef="i6e35f96e1d3a4ff1b9a03fab757d000c_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NTU_5363b5ca-944a-4176-802a-c792d6304596">0.38</ix:nonNumeric> years related to restricted stock awards. As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i39ce7df93a7d4382a3b7d79316b6d848_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NDA_f61a8914-cb27-487d-a269-2eb7c63c660c">24.2</ix:nonFraction> million of unrecognized compensation costs that is expected to be recognized over the weighted-average periods of <ix:nonNumeric contextRef="i8eb5094414c244a28314369adcc54cc5_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NDU_c673a3e0-b92b-42b1-aa56-8982e1790ac2">2.5</ix:nonNumeric> years related to stock options.</span></div></ix:continuation><div><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_145"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTU_ee917d2b-fbc7-4113-80c2-a444b1d93074" continuedAt="iffeb78ebb64640e9a3fefba68e52d050" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iffeb78ebb64640e9a3fefba68e52d050" continuedAt="i37690a0ba7e54bbba72c37e4df2ea17f">The Company had a pre-tax U.S. book loss of $<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzY2_aa18a6e7-971b-44bd-8689-5f50d72ac983">97.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzEwOTk1MTE2MzA5Mzk_0565c01a-11a9-4b68-991d-d543ac114eb0">41.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzE2NDkyNjc0NDUwNzA_ec922d02-c6bd-48c3-890c-e96800f84859">0.6</ix:nonFraction> million for the years ended December&#160;31, 2021,  2020 and 2019 respectively. During the years ended December&#160;31, 2021, 2020 and 2019, the Company did not record an income tax provision. The Company will continue to maintain a <ix:nonFraction unitRef="number" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="INF" name="plrx:ValuationAllowanceAsPercentageOnDeferredTaxAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzI0NA_67512e77-0044-400a-921b-6c38d2306683">100</ix:nonFraction>% valuation allowance on total deferred tax assets. The Company believes it is more likely than not that the related deferred tax assets will not be realized.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i37690a0ba7e54bbba72c37e4df2ea17f" continuedAt="i0fb92867c8704ce887957cc8a597fe6c"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTY_0008fb0a-584f-4a75-b079-2194d4c18f5b" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax computed at federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzItMS0xLTEtMTI2NTk_d5490ed9-b331-4ddd-9a3e-f67e502012ed">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzItMy0xLTEtMTI2NTk_c060bdec-8238-489d-b5c9-e954adf45d05">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzItNS0xLTEtMTc2MTM_f1b0b244-a128-4416-828f-c47f6cafa90d">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzMtMS0xLTEtMTI2NTk_d97994b2-ab95-4d58-8e67-421a2e02c001">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzMtMy0xLTEtMTI2NTk_90375e82-4fcd-4574-8b76-49f55133d4d5">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzMtNS0xLTEtMTc2MTM_adefea75-485c-483c-9919-2a01563b65a9">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General business credit&#8212;federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="3" name="plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzQtMS0xLTEtMTI2NTk_6e9e468f-33e9-4c58-ab59-0638d46bc401">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="3" name="plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzQtMy0xLTEtMTI2NTk_0c60dc6f-ae84-4c05-a6bc-479f7a319701">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="3" name="plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzQtNS0xLTEtMTc2MTM_ba005a10-d0c3-4f8d-a491-ed7aa5d2e0b8">295.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzUtMS0xLTEtMTI2NTk_1dcf2d00-8e94-44db-9188-0b1fefed48f4">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzUtMy0xLTEtMTI2NTk_6cb61e9a-ed94-4909-af9b-bc93a6a8a78a">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzUtNS0xLTEtMTc2MTM_6e99008d-e684-4002-8cb7-d494d72d40d7">50.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzYtMS0xLTEtMTI2NTk_0c83fe91-cdba-44da-8493-58c326c6a2d3">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzYtMy0xLTEtMTI2NTk_4791bc44-1df1-4b67-847b-14505889b3c0">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzYtNS0xLTEtMTc2MTM_e3ef0a6b-2a2f-49ef-a43c-ad5a7e2342b6">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzctMS0xLTEtMTI2NTk_58b1b2a9-be85-4c7b-af3d-d06656e114b7">33.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzctMy0xLTEtMTI2NTk_5ce8d979-9456-4f76-8b91-44c62c238213">32.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzctNS0xLTEtMTc2MTM_951c7646-f2d0-450f-a203-d92ad4d159c0">267.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzgtMS0xLTEtMTI2NTk_4c2b2782-6743-44df-8f1a-149f50fdf224">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzgtMy0xLTEtMTI2NTk_3e55a4d9-00c0-4721-8106-f378e9248894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzgtNS0xLTEtMTc2MTM_77be8c65-ea56-4773-ae37-cab10d5f2569">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTc_363a1479-3ee9-43fc-ab22-c986f383d4fa" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzMtMS0xLTEtMTI2NTk_844ad894-c6ff-409a-9441-48ab7d053ced">51,554</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzMtMy0xLTEtMTI2NTk_4189a5a6-55e1-4125-bb14-92376fe15391">27,047</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzQtMS0xLTEtMTI2NTk_9735d55b-e0be-44c5-b9ab-e55a3c137cda">13,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzQtMy0xLTEtMTI2NTk_22d24856-fb47-4fc0-8a63-9a03cef8a5b3">7,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzUtMS0xLTEtMTI2NTk_a8f09584-f538-4af2-949c-2d8354dd5329">292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzUtMy0xLTEtMTI2NTk_247c78d7-ceb0-4d0e-bae6-5da2e8c3f54d">291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzYtMS0xLTEtMTI2NTk_ffc8d088-64c3-494e-84e9-60c053fd7e00">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzYtMy0xLTEtMTI2NTk_54a65d8e-1f50-4699-a406-d8b6810320b2">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzctMS0xLTEtMTI2NTk_2e956673-f040-4b9c-a408-662804da6242">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzctMy0xLTEtMTI2NTk_61a82152-8a54-4acb-a856-63a0b8ef23f5">266</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="plrx:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzgtMS0xLTEtMjgzMTk_76af69ba-aa83-4435-a87d-4b57259fcf5c">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="plrx:DeferredTaxAssetsLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzgtMy0xLTEtMjgzMjY_07d520c4-cb50-449e-a46b-05aba13a6f0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzgtMS0xLTEtMTI2NTk_f42b0e15-543f-4544-860d-8188f4c9ffc7">1,816</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzgtMy0xLTEtMTI2NTk_d3639ee9-57fb-4150-8b3f-7e375fe77f87">428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzktMS0xLTEtMTI2NTk_144a1131-c89a-4d96-a95f-e8577eff24f9">70,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzktMy0xLTEtMTI2NTk_e86c860d-f67d-469b-a678-bbefaccc6c8c">36,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="plrx:DeferredTaxLiabilitiesFixedAssetBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzExLTEtMS0xLTEyNjU5_0f50fa2e-24bd-4750-8e76-dc9ecca2eb0e">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="plrx:DeferredTaxLiabilitiesFixedAssetBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzExLTMtMS0xLTEyNjU5_73d54795-6a96-49d4-8274-c0e86df0f29d">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzEyLTEtMS0xLTEyNjU5_916250b5-d282-4265-9d86-620fd72574a1">921</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzEyLTMtMS0xLTEyNjU5_765d5401-8fe1-430f-8092-7d04fa4d2700">558</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="plrx:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE0LTEtMS0xLTI4MzM3_0f6faefb-5c57-4f51-ad89-8aaa2e82f7f6">1,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="plrx:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE0LTMtMS0xLTI4MzQ1_c1ef713d-177c-41b7-b07d-ca9aaae37972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzEzLTEtMS0xLTEyNjU5_a2c2230b-e210-4131-8bbe-f597b5347956">2,742</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzEzLTMtMS0xLTEyNjU5_326fcd22-20b9-4328-8f5f-b99301728f15">682</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE0LTEtMS0xLTEyNjU5_375484d2-1ce6-4254-95f6-1d5fa4e4c84c">67,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE0LTMtMS0xLTEyNjU5_b3e06d91-0b6d-4dd4-8401-09042c110a11">35,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred taxes</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE1LTEtMS0xLTEyNjU5_82fde880-6214-4528-9acd-a00695de2239">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE1LTMtMS0xLTEyNjU5_9d7cc8e9-e79f-44fe-be5f-bf28372df7c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTg_46066fd6-6407-4117-8678-5f892b8ae833" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Year</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal (starting from January 1, 2018)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i31bce1e599344a70a32426478b95d1df_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzEtMS0xLTEtMTI2NTk_6c04f3cf-be48-4f5e-95ac-ce40a4ad655b">155,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Does not expire</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal (before January 1, 2018)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i73826d9211d549b896476358b41d3bde_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzItMS0xLTEtMTI2NTk_dd07a38b-f008-4a44-8ca6-ca149e6fd53b">29,486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iff7f1036aa4b454fb82af94ab3f2ce41_D20210101-20211231" name="plrx:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzItMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpiM2IyZWVjMmY1ZDA0M2E4YmJkZWQ3NDlkZGQxMTZiZl80_f708323f-026f-485f-beeb-31380d5b32fe">2035</ix:nonNumeric>-<ix:nonNumeric contextRef="i6a3ebd1303b143afb79b5a5535c7e658_D20210101-20211231" name="plrx:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzItMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpiM2IyZWVjMmY1ZDA0M2E4YmJkZWQ3NDlkZGQxMTZiZl83_273d84bd-9377-47d1-b3b9-d17f35a8a9f4">2037</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f33c2bafe3843d8bf470ed2c96ee5fc_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzMtMS0xLTEtMTI2NTk_be59b562-7c97-484c-8844-c66433785127">182,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia814f0994a1449ce83dd2ebd288a95a6_D20210101-20211231" name="plrx:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzMtMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjo5YWJlNWM4OTU3YmE0Mjk1OGJhNDAwMTAwMzY0ZWNlNV80_9b595ce0-4d86-4996-91b8-6e7d006c0900">2035</ix:nonNumeric>-<ix:nonNumeric contextRef="i29fe77ab043541358883b2c7d9041522_D20210101-20211231" name="plrx:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzMtMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjo5YWJlNWM4OTU3YmE0Mjk1OGJhNDAwMTAwMzY0ZWNlNV83_75156977-bc36-479b-9b69-9d08caf9e5b8">2041</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits, federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iddb8c639eb9a45ed83884b3db05c0ffd_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzQtMS0xLTEtMTI2NTk_5fc118d9-af95-46a3-b32c-d0fe3a2f454b">14,094</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia814f0994a1449ce83dd2ebd288a95a6_D20210101-20211231" name="plrx:TaxCreditCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzQtMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpjMzlmYTllYmM2MjU0ZTVjYmM4MDkyZTlhNzNlMWE4NV80_c8fd520c-5a17-4785-89ec-5d47e2de163c">2036</ix:nonNumeric>-<ix:nonNumeric contextRef="i29fe77ab043541358883b2c7d9041522_D20210101-20211231" name="plrx:TaxCreditCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzQtMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpjMzlmYTllYmM2MjU0ZTVjYmM4MDkyZTlhNzNlMWE4NV83_039b76e0-22ad-4cf8-baf2-ab1eead71735">2041</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits, state</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f33c2bafe3843d8bf470ed2c96ee5fc_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzUtMS0xLTEtMTI2NTk_002116e7-67a3-42d8-b32e-fbd0d3f3a57f">4,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Does not expire</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating loss carryforwards and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code (&#8220;IRC&#8221;) and similar state provisions. Annual limitations may result in the expiration of the net operating losses and tax credit carryforwards before they are utilized. The Company performed a IRC Section 382 analysis through December&#160;31, 2021 and does not expect any previous ownership changes to result in a limitation that will reduce the total amount of net operating loss and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i0fb92867c8704ce887957cc8a597fe6c"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax credit carryforwards disclosed that can be utilized. Subsequent ownership changes may affect the limitation in future years.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021&#160;and 2020, the Company recorded a full valuation allowance on federal and state deferred balances since management does not forecast the Company to be in a profitable position in the near future.&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTk_54f30032-0c5b-4d2e-9a0e-cc215ea0662f" continuedAt="i25ba9f316a4a4d99b56beb1148eadc97" escape="true">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2021&#160;and 2020 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i25ba9f316a4a4d99b56beb1148eadc97"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzItMS0xLTEtMTI2NTk_71fb7452-3c1c-4e34-a45e-00938f5fb8d6">35,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzItMy0xLTEtMTI2NTk_46c461ab-4560-4602-8f8f-abf847abb194">21,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzMtMS0xLTEtMTI2NTk_900caed5-5fa0-4229-86c7-f8205b895b41">32,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzMtMy0xLTEtMTI2NTk_5d03f6bb-83a5-4e21-9c58-17c1bbe45693">13,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzQtMS0xLTEtMTI2NTk_990ae354-b127-4a0e-9b2b-54276a387121">67,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzQtMy0xLTEtMTI2NTk_d9d39e63-4ce3-41a5-8cd5-2e4a949b6084">35,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2017 through December 31, 2021. There are currently <ix:nonFraction unitRef="taxexamination" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="INF" name="plrx:IncomeTaxExaminationNumberOfExaminationsPending" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzE5MDE_605f9340-8b55-443c-9c36-a24ef4899b08">no</ix:nonFraction> pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entire amount of the unrecognized tax benefits would not impact the Company&#8217;s effective tax rate if recognized. The Company's accounting policy is to include interest and penalties as a component of tax expense. During the years ended December&#160;31, 2021,  2020 and 2019, the Company did <ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzI0NDI_80dad6bb-bdfa-49c0-9888-0b9654d52996"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzI0NDI_caf8652a-c45e-47b5-bc0b-83ff4cc487dc"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzI0NDI_fcfc041c-1aa8-471f-874e-55bb61d4d6e1">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months.</span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTQ_6f4dc6f5-f8fe-4e0e-b303-d575a11d88e7" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzItMS0xLTEtMTI2NTk_bc78e259-d283-4bac-b41b-552f1fa3b1d7">2,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzItMy0xLTEtMTI2NTk_6071c3a8-9928-4642-9ed2-0a0a5685eba0">1,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idcb6e46e8589417fbb6dce85ec4707e9_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzItNS0xLTEtMjg5MDY_80e891e7-58a6-4c22-a47d-4d4a1c821334">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzMtMS0xLTEtMTI2NTk_2634d419-bcbb-40b3-8190-1aa3bdd24332">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzMtMy0xLTEtMTI2NTk_4a0a4e0c-a2cd-4b33-9207-9201c7dc0a7e">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzMtNS0xLTEtMjg5MDY_04ec61d1-e127-4a02-98d1-20f694c8cf0e">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions (reductions) for tax positions of prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzQtMS0xLTEtMTI2NTk_aa18ab38-c8e5-4d07-9526-6b1fbce35ea7">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzQtMy0xLTEtMTI2NTk_040966c5-9e2f-4eca-a46e-1f2b370da277">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzQtNS0xLTEtMjg5MDY_21cb9691-ed71-4dc0-8a47-3268e7ae68c0">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzUtMS0xLTEtMTI2NTk_531d1441-6e7d-4c86-85de-0e3058830b6f">3,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzUtMy0xLTEtMTI2NTk_7f0651ef-16b6-4e22-b2c5-1f1f18ef4d42">2,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzUtNS0xLTEtMjg5MDY_679e5cf6-eb94-4722-9351-eb1f8778712e">1,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the "Cares Act") was enacted. The CARES Act changed net loss carryforward and back provisions and the business interest expenses limitation. The Company has evaluated the impact of the CARES Act and determined that none of the changes would result in a material cash benefit to the Company.</span></div></ix:continuation><div id="i988625df783e4cc0a27bd76df388da57_148"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDgvZnJhZzpmNWI1ZmY0OTViODg0YzIyYjc1ZDZkMjdmN2U3NmQyYS90ZXh0cmVnaW9uOmY1YjVmZjQ5NWI4ODRjMjJiNzVkNmQyN2Y3ZTc2ZDJhXzMzMDc_23c97baf-f0e3-4310-8652-740bd41ab961" continuedAt="i11cf81dae6744467bae46bd3910992ce" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i11cf81dae6744467bae46bd3910992ce" continuedAt="i1874871706cb4f0db9001a4708fb45f0"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contractual arrangements with research and development organizations and suppliers; however, these contracts are generally cancellable on <ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:ContractualArrangementsCancellationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDgvZnJhZzpmNWI1ZmY0OTViODg0YzIyYjc1ZDZkMjdmN2U3NmQyYS90ZXh0cmVnaW9uOmY1YjVmZjQ5NWI4ODRjMjJiNzVkNmQyN2Y3ZTc2ZDJhXzIxMw_33d3be2a-bf0e-429b-933b-820a39731d22">30</ix:nonNumeric> days&#8217; notice and the obligations under these contracts are largely based on services performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential payments related to the Company&#8217;s license and research agreements, including milestone and royalty payments, are detailed in Notes 6 and 7.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of business. The Company record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. Management is currently not aware of any legal matters that could have a material adverse effect on our financial position, results of operations or cash flows.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i1874871706cb4f0db9001a4708fb45f0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance.</span></div></ix:continuation><div style="margin-top:10pt"><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_1698"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF80Mzk4MDQ2NTE1MjEz_edfcee80-5089-424f-b959-de97aa2325b0" continuedAt="i4a9352c10b024a8e9a131768094fd486" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i4a9352c10b024a8e9a131768094fd486" continuedAt="i62fa79c2c0164457b238d8bf19ef2814"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 1, 2021, the Company adopted ASC 842 and the following disclosures as of and for the year ended December 31, 2021 are presented under ASC 842.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a non-cancelable lease agreement (the &#8220;Lease&#8221;) for premises consisting of approximately <ix:nonFraction unitRef="sqft" contextRef="ia6b323227a6846f1b65d034e58f88164_D20180201-20180228" decimals="INF" name="plrx:LeasedSpaceUnderNonCancellableOperatingLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI3OTA5_4144565f-e7ea-4392-8f43-f6a361c4ace9">32,974</ix:nonFraction> square feet located in South San Francisco, California (the &#8220;Premises&#8221;). The Company moved into the Premises in July 2018. The Premises is being used for the Company&#8217;s corporate headquarters and principal operating facility. The term of the Lease is <ix:nonNumeric contextRef="i598f80db39ac4c599c0538ab9aae3c30_I20180228" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4MTYz_b456def0-51eb-4221-b957-ac65657c359d">eighty-four months</ix:nonNumeric>, which commenced on July 1, 2018. Base rent was abated for the first <ix:nonNumeric contextRef="ib125d2281fd7483b97614c1e8f176399_D20180201-20180228" name="plrx:PeriodOfBaseRentAbatement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMjY0NDM4MzcyNjY0NA_b36e1998-fb31-4016-a152-33355da9c0c9">two months</ix:nonNumeric> of the lease term and thereafter is $<ix:nonFraction unitRef="usd" contextRef="ib125d2281fd7483b97614c1e8f176399_D20180201-20180228" decimals="-3" name="plrx:BaseRentAbatedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4Mjgz_f841c18a-46bc-49a9-a3d1-4113466228d1">0.2</ix:nonFraction> million per month during the first year of the lease term, with specified annual increases thereafter. The Company paid a refundable security deposit of approximately $<ix:nonFraction unitRef="usd" contextRef="ic31ace94ac1847898d10e8026fbd8b04_I20211231" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NDQ2_6702c845-49c1-4c3d-b9c3-034f9ce64fe7"><ix:nonFraction unitRef="usd" contextRef="i4c910fd3e4444dd2b8564e3ace9a8326_I20201231" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NDQ2_ba739d4b-46c7-4e59-972d-2ddd65d78b82">0.4</ix:nonFraction></ix:nonFraction> million, which is included in other non-current assets in the Balance Sheets at December&#160;31, 2021 and 2020. The Company has the right to extend the lease term by <ix:nonNumeric contextRef="i54765707cbc04888952c42feb9bd45de_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NTg5_77b953c4-7730-427a-beca-25bfbaff6010">seven years</ix:nonNumeric> upon written notice not more than <ix:nonNumeric contextRef="i429668ed867b4b9eb0766f77046f00f3_D20180201-20180228" name="plrx:LeaseTermExtensionNoticePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NjI3_f0260496-9972-45b7-ade9-395d24839586">twelve months</ix:nonNumeric> nor less than <ix:nonNumeric contextRef="i339a84165f6b4c48adba2aba4271bc4a_D20180201-20180228" name="plrx:LeaseTermExtensionNoticePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NjQ1_51b48131-3091-430e-9ba2-d325b36bb1ae">nine months</ix:nonNumeric> prior to the expiration of the original lease term, with monthly payments equal to the &#8220;fair rental value&#8221; as defined in the Lease. The exercise of lease renewal options is at the sole discretion of the Company and is not included in the ROU asset and lease liability as it is not reasonably certain of exercise. This lease does not contain material variable rent payments, residual value guarantees, covenants, or other restrictions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, the Company recognized expenses associated with the operating leases of  $<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjMxODYy_38dd1cad-7b77-421b-9974-4be0f5d402ad">2.3</ix:nonFraction>&#160;million. Additionally, the Company incurred variable lease costs of $<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjMxODUz_9b084ffc-431d-4d76-8952-6a9918c8231d">0.9</ix:nonFraction> million which is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance. Short-term lease expense and variable lease payments recorded in operating expenses were immaterial for the year ended December 31, 2021. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjM0MzE1_53499496-d3a0-4361-b943-a5423778f37b">2.4</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF80Mzk4MDQ2NTE1MjEy_d9d60c37-8808-4f36-9e8c-20caea75b8fe" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maturities of the Company's operating lease liability as of December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV8xLTItMS0xLTE1NDEy_650c06bc-55b5-4304-9e9b-e8b061881f4b">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV8yLTItMS0xLTE1NDEy_c3e2096c-f2d5-41f0-8435-16c5f577c527">2,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV8zLTItMS0xLTE1NDEy_0d19d880-5e57-476a-863d-91c69b8a4b92">2,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV80LTItMS0xLTE1NDEy_fd6f9450-6658-4cc2-891c-91e56ba0bca9">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV81LTItMS0xLTE1NDEy_b1b2cbc1-1143-4e7c-9094-3f52eafff848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV82LTItMS0xLTE1NDEy_6bb96d65-4140-472f-a0f6-3b1defc5f3e7">8,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV83LTItMS0xLTE5OTYx_1b89fa83-0647-4b6d-923d-11bf48af7f09">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV84LTItMS0xLTE5OTYx_180fd4b5-2a6a-45b6-9b88-c6d419dfb412">7,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="plrx:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMjY0NDM4MzcyNjY0Mw_8f59776d-e636-4d98-8022-993d1306e966" escape="true"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The weighted-average remaining lease terms and discount rates related to the Company's operating leases were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6NjIyNTk3ODEyNTliNDFiNmJiZjdmZDZlZTA2MjEzYmEvdGFibGVyYW5nZTo2MjI1OTc4MTI1OWI0MWI2YmJmN2ZkNmVlMDYyMTNiYV8xLTItMS0xLTE1NTk1_19485ac6-3bc2-44c8-b043-61bcdc81dd31">3.40</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6NjIyNTk3ODEyNTliNDFiNmJiZjdmZDZlZTA2MjEzYmEvdGFibGVyYW5nZTo2MjI1OTc4MTI1OWI0MWI2YmJmN2ZkNmVlMDYyMTNiYV8yLTItMS0xLTE1NTk1_8bc952b4-e81d-485d-aafd-176bd69b4a8c">7.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total rent expense under ASC 840 was $<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-5" name="us-gaap:LeaseAndRentalExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8yMTk5MDIzMjU5NTE3_0f741759-6c34-4610-9fc9-b55bf2613a7d"><ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-5" name="us-gaap:LeaseAndRentalExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8yMTk5MDIzMjU5NTE3_b6f738f8-edef-4843-bac2-30a74527908d">2.5</ix:nonFraction></ix:nonFraction> million during each of the years ending December&#160;31, 2020 and 2019. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="i62fa79c2c0164457b238d8bf19ef2814"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF80Mzk4MDQ2NTE4MTc3_f7abaaa6-ecb3-4fa5-a17c-b30708785739" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Future minimum lease payments under the Lease as of December 31, 2021 were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54765707cbc04888952c42feb9bd45de_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl8xLTItMS0xLTI3Mzc0_2148b6b0-208a-4573-b486-5a3970925a27">2,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54765707cbc04888952c42feb9bd45de_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl8yLTItMS0xLTI3Mzc0_c45ed3c1-e014-41a4-9ab9-8005fb1b4d35">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54765707cbc04888952c42feb9bd45de_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl8zLTItMS0xLTI3Mzc0_d43c46ca-2990-4efb-af42-7a0ac743c0ac">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54765707cbc04888952c42feb9bd45de_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl80LTItMS0xLTI3Mzc0_c3aa6ca7-4569-4e6a-99e5-06fa8856bb00">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54765707cbc04888952c42feb9bd45de_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl81LTItMS0xLTI3Mzc0_89735b13-1d1b-420e-a2bc-f53ba848fc52">7,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_151"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzIyNTY_dba0097d-ae0c-4d58-9ccb-8949d64b64f1" continuedAt="i2b0ef113f26a456782709b1b50973710" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2b0ef113f26a456782709b1b50973710" continuedAt="i87d6214bf6c5427eb1e9d63213d3e056">In 2019, certain employees of Third Rock Ventures, a stockholder of the Company, provided consulting services to the Company. Commencing January 2020, Third Rock Ventures ceased providing management consulting services to the Company.&#160;The Company recorded <ix:nonFraction unitRef="usd" contextRef="i7166be69743e4e60a692a5adc04dcd3f_D20210101-20211231" decimals="INF" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzI5Mg_0b873e56-4b32-41f8-a675-d81da435c1fa">no</ix:nonFraction> consulting expenses for consulting services provided by Third Rock Ventures during&#160;the years ended December&#160;31, 2021 and 2020.&#160;The Company recorded Third Rock Ventures consulting expenses to general and administrative expense of $<ix:nonFraction unitRef="usd" contextRef="i48fa76d3d2dd4c4c86df500aed228234_D20200101-20201231" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzQ5OQ_11ce0a5a-a991-48f6-92a4-efc3f9b2678e">36,000</ix:nonFraction> during the year ended December&#160;31, 2019.</ix:continuation></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i87d6214bf6c5427eb1e9d63213d3e056" continuedAt="i9e6258fb1973405a8670d402f7206718"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzEwOTk1MTE2MzIxNjQ_0c1d1ada-220a-4872-b7e3-f8904ca712ca">26,572</ix:nonFraction> stock options with a grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630" decimals="-5" name="plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzEwOTk1MTE2MzIxODQ_a9f9c0e8-a355-4064-aa05-6ab36892b969">0.5</ix:nonFraction> million to partners of Third Rock Ventures who are also serving as non-employee directors on the Company's Board of Directors. The shares of common stock subject to these options ve</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">st <ix:nonFraction unitRef="number" contextRef="i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzQzOTgwNDY1MTU1NDA_05d672c0-4643-47c3-a701-cb12fabcd7c1">25</ix:nonFraction>% on</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i9e6258fb1973405a8670d402f7206718"> the first day of each calendar quarter for three quarters with the final vest date being the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting of Stockholders. In March 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="ic1f553a0f5fd4433b0cc4baba93fea24_D20200301-20200331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzU1Mg_9f8588db-c8ec-4983-880b-b1dbedfade56">26,573</ix:nonFraction> stock options with a grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="ic1f553a0f5fd4433b0cc4baba93fea24_D20200301-20200331" decimals="-5" name="plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzYwMQ_a3452e37-09b9-4ab3-aa98-69991f64a8c0">0.1</ix:nonFraction> million to a partner at Third Rock Ventures, who is also serving as a non-employee director on the Company&#8217;s Board of Directors. <ix:nonNumeric contextRef="i342e8370c50840b5ab283afd24abbf11_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzcyNQ_39ff8f93-346c-4334-a6f1-0929b53bf82c">The common shares subject to these options vest 1/12th on the last day of each calendar quarter over a three-year period and commenced vesting upon our IPO.</ix:nonNumeric> In order to vest at each calendar quarter end date, the shareholder must be providing continuous service to the Company through such vesting date. The stock-based compensation expense related to these options was immaterial during the years ended December&#160;31, 2021.</ix:continuation> </span></div><div id="i988625df783e4cc0a27bd76df388da57_157"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:DefinedContributionPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTcvZnJhZzpjYWM2YjMzZmE4NDY0NzJiODFiYWU2Yzc3ZmQzMTYzOS90ZXh0cmVnaW9uOmNhYzZiMzNmYTg0NjQ3MmI4MWJhZTZjNzdmZDMxNjM5XzQyOQ_26e190ba-be27-4d52-8ff6-8671ebeadead" continuedAt="i452d59e2c0434ac7a6ba84157aff8c2e" escape="true">Defined Contribution Plan</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i452d59e2c0434ac7a6ba84157aff8c2e">The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. The Company made contributions to the plan of $<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTcvZnJhZzpjYWM2YjMzZmE4NDY0NzJiODFiYWU2Yzc3ZmQzMTYzOS90ZXh0cmVnaW9uOmNhYzZiMzNmYTg0NjQ3MmI4MWJhZTZjNzdmZDMxNjM5XzM3Ng_aac38d2d-b4d2-4097-9091-208e1eeaa394">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTcvZnJhZzpjYWM2YjMzZmE4NDY0NzJiODFiYWU2Yzc3ZmQzMTYzOS90ZXh0cmVnaW9uOmNhYzZiMzNmYTg0NjQ3MmI4MWJhZTZjNzdmZDMxNjM5XzM4Mw_d5de81cf-f944-453b-86f0-98ad23890831">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTcvZnJhZzpjYWM2YjMzZmE4NDY0NzJiODFiYWU2Yzc3ZmQzMTYzOS90ZXh0cmVnaW9uOmNhYzZiMzNmYTg0NjQ3MmI4MWJhZTZjNzdmZDMxNjM5XzEwOTk1MTE2MjgyOTI_73db2d88-e211-482d-b461-a967f5e04cd4">0.2</ix:nonFraction> million during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</ix:continuation></span></div><div id="i988625df783e4cc0a27bd76df388da57_163"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90ZXh0cmVnaW9uOjdjZDM1MjZkMmQ3MzQ0ZGU4ODU5ZDE0NTk1NWRiZjQ0XzUzNg_c8d6c426-24fa-4103-8b7f-1c0da7748d45" continuedAt="ifcfb789efa334d7e8173c1ecfa2f82c6" escape="true">Net Loss Per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="ifcfb789efa334d7e8173c1ecfa2f82c6" continuedAt="if594b3b0609940a59045b562d4317e0a"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90ZXh0cmVnaW9uOjdjZDM1MjZkMmQ3MzQ0ZGU4ODU5ZDE0NTk1NWRiZjQ0XzUzNw_1496fab3-c44e-4a79-aca8-7348483e537b" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been antidilutive:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:57.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redeemable convertible preferred stock (on an as-converted basis)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i47e995f177284199bb8b0695a7c9725d_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzItMS0xLTEtMTc4OTc_d3433095-447e-4fd7-b3c7-4e594d216968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2c0035b443cb469b9de089f502f3e9c5_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzItMy0xLTEtMTc5MDM_41ce48e3-120d-4c37-9034-4fe668ed48eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i18bd16bfffe94894922846cadcd48ed0_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzItNS0xLTEtMTc4NjA_58a30fc1-cd87-49e1-a9d0-6642a25c5a48">18,442,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie24ad985733c48bfb53bfbd864d91f27_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzMtMS0xLTEtMTI2NTk_06e861d1-4bd8-470e-9a01-4c031bfe76f9">3,620,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i68e2483823f6420cb6185c251c58ac55_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzMtMy0xLTEtMTI2NTk_68a83a9b-d9b2-4633-b7b3-4e3071dae3cf">2,993,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib34337582e984ae1ba7584d1346e1780_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzMtNS0xLTEtMTc4NjA_ed60ec29-7e8e-48c4-8d34-7c21b56baa1f">1,337,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards granted and not purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id4eb9436dd324df99ee7f4d8e63df7e7_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzQtMS0xLTEtMTI2NTk_3b0ab701-85a8-45d9-ae87-92d8773003f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icf1265c8744c461286d3671e01ec1cc8_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzQtMy0xLTEtMTI2NTk_e806190b-b992-4a79-8fa7-de5c0895e121">4,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9964d5d87c0b4f47a4e7b2802949d585_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzQtNS0xLTEtMTc4NjA_99292222-927b-4e32-acdc-5f03790fbbe6">4,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i123f913abe274f3b80052d070e8729c7_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzUtMS0xLTEtMTI2NTk_9cf40cb1-2f77-4e71-8402-7ece916e7920">21,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib31f0ac37c034f85b050eb91b4830b28_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzUtMy0xLTEtMTI2NTk_bfe11d34-f009-47c4-99b7-ca46893e24e5">126,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4a427494f6ff428e8b8a4b08835c85f7_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzUtNS0xLTEtMTc4NjA_df7ce5da-2598-42fb-8412-af179c99d40d">302,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzYtMS0xLTEtMTI2NTk_f46da389-0387-4866-91b2-5173e06c7d61">3,642,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzYtMy0xLTEtMTI2NTk_068d1579-e96e-4f80-b72d-0b6443f9948e">3,124,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzYtNS0xLTEtMTc4NjA_68045170-beac-43bf-b95e-b81d715f6756">20,086,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><ix:continuation id="if594b3b0609940a59045b562d4317e0a"><ix:nonNumeric contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90ZXh0cmVnaW9uOjdjZDM1MjZkMmQ3MzQ0ZGU4ODU5ZDE0NTk1NWRiZjQ0XzUzOA_9d5955af-cd6a-450e-ba05-34a8545875fe" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net loss per share attributable to common stockholders is as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"></td><td style="width:57.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzQtMS0xLTEtMTI2NTk_46aea6f7-f9c3-4758-a294-b83aa50f17eb">97,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzQtMy0xLTEtMTI2NTk_e43ecd6b-3927-4e65-a4a6-ca010a97a99b">41,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzQtNS0xLTEtMTc5NDE_3f954780-2b62-4556-b0f9-b98f7367df67">631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accretion to redemption value and dividends on redeemable convertible preferred shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzUtMS0xLTEtMTI2NTk_6d7b0a31-cf49-4ce2-86a2-8658aaef8a97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzUtMy0xLTEtMTI2NTk_9f7d239b-63fc-487b-b634-73221647485e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzUtNS0xLTEtMTc5NDE_f2382147-8ecd-4bd3-a67f-0d93e5ddb556">6,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzYtMS0xLTEtMTI2NTk_9f9aac8a-3182-476a-a3b0-10c6db234e02">97,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzYtMy0xLTEtMTI2NTk_d90e0f17-daaa-406f-b5e8-8511e6c3919f">41,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzYtNS0xLTEtMTc5NDE_c32cd8e8-bf76-4f39-a4c3-f08547448baa">6,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzktMS0xLTEtMTI2NTk_fd59c366-8bd0-4b1b-9ccf-b6d48acb9a80">35,846,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzktMy0xLTEtMTI2NTk_e01452c5-e6b0-409d-8671-358b208db464">21,344,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzktNS0xLTEtMTc5NDE_cd5b159a-6922-4c1c-98cf-359f7f58cbce">1,623,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEwLTEtMS0xLTEyNjU5_bae34ac6-9520-42ee-bd94-f82de65a6736">35,846,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEwLTMtMS0xLTEyNjU5_b9ecfa96-8b1c-4a7e-b382-9ba880846a38">21,344,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEwLTUtMS0xLTE3OTQx_9a17d35c-a486-46b1-9c54-e83d27f1cdf9">1,623,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to common stockholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEyLTEtMS0xLTEyNjU5_53973df0-8426-4e70-8b7b-42a88899f0d1">2.71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEyLTMtMS0xLTEyNjU5_07cc6539-0413-446b-97f5-a09e492d3e1c">1.95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEyLTUtMS0xLTE3OTQx_fd8b0e2e-fe60-4848-94cd-fe34ea19aa21">4.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEzLTEtMS0xLTEyNjU5_9fd87362-12b2-40c2-bcdc-f549a6f8d890">2.71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEzLTMtMS0xLTEyNjU5_db21e319-bff6-49cd-a786-a1a84f24b40f">1.95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEzLTUtMS0xLTE3OTQx_ec25fe1f-b923-46f6-9f24-5b2822e649aa">4.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i988625df783e4cc0a27bd76df388da57_166"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i988625df783e4cc0a27bd76df388da57_169"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2021. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established in &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Our management concluded that our internal control over financial reporting was effective as of December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, Deloitte and Touche LLP, has audited the effectiveness of our internal control over financial reporting as of December 31, 2021 as stated in their report which is included herein.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We considered our internal controls over financial reporting in regards to the impact of COVID-19 and concluded that our controls continue to operate in a remote environment without material effect on our internal controls over financial reporting.</span></div><div id="i988625df783e4cc0a27bd76df388da57_172"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_175"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i988625df783e4cc0a27bd76df388da57_178"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item regarding directors and director nominees, executive officers, the board of directors and its committees, and certain corporate governance matters is incorporated by reference to the information set forth under the captions &#8220;Proposal No. 1&#8212;Election of Directors,&#8221; &#8220;Corporate Governance and Board Matters&#8221; and &#8220;Executive Officers&#8221; in our Proxy Statement for our 2021 Annual Meeting of Stockholders. Information required by this item regarding compliance with Section 16(a) of the Exchange Act is incorporated by reference to the information set forth under the caption &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Proxy Statement.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our written code of business conduct and ethics (the &#8220;Code of Conduct&#8221;) applies to all of our employees, officers and directors, including our principal executive officer, principal financial officer and principal accounting officer or controller. The Code of Conduct is available on our corporate website at https://pliantrx.com. If we make any substantive amendments to our Code of Conduct or grant any of our directors or executive officers any waiver, including any implicit waiver, from a provision of our Code of Conduct, we will disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8-K.</span></div><div id="i988625df783e4cc0a27bd76df388da57_181"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item regarding executive compensation is incorporated by reference to the information set forth under the captions &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; in our Proxy Statement.</span></div><div id="i988625df783e4cc0a27bd76df388da57_184"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item regarding security ownership of certain beneficial owners and management is incorporated by reference to the information set forth under the caption &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation&#8221; in our Proxy Statement.</span></div><div id="i988625df783e4cc0a27bd76df388da57_187"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item regarding certain relationships, related transactions and director independence is incorporated by reference to the information set forth under the caption &#8220;Transactions with Related Persons and Indemnification&#8221; and &#8220;Corporate Governance and Board Matters&#8221; in our Proxy Statement.</span></div><div id="i988625df783e4cc0a27bd76df388da57_190"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item regarding principal accounting fees and services is incorporated by reference to the information set forth under the caption &#8220;Proposal No. 2&#8212;Ratification of Selection of Independent Registered Public Accounting Firm&#8221; in our Proxy Statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_193"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i988625df783e4cc0a27bd76df388da57_196"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The following documents are filed as part of this Annual Report:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statements.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. None. All financial statement schedules are omitted because they are not applicable, not</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required under the instructions, or the requested information is included in the financial statements or notes thereto.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following is a list of exhibits filed with this Annual Report or incorporated herein by reference:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:8.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Filing<br/>Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File<br/>Herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-39303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated Bylaws of the Registrant, as currently in effect.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-39303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 15, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specimen Common Stock Certificate of the Registrant.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 26, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated Investors&#8217; Right Agreement by and among the Registrant and certain of its stockholders, dated December 19, 2010.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 26, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description of the Registrant&#8217;s Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 Stock Option and Incentive Plan and forms of award agreement.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 26, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2015 Equity Incentive Plan and forms of award agreements thereunder.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 Employee Stock Purchase Plan.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 26, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Executive Cash Incentive Bonus Plan.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-Employee Director Compensation Policy.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 26, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Severance Plan.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offer Letter, by and between the Registrant and Mike Ouimette, dated August 17, 2020.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-39303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 10. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offer Letter, by and between the Registrant and Barbara Howes, dated May&#160;1, 2019.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offer Letter, by and between the Registrant and &#201;ric Lefebvre, M.D., dated February&#160;28, 2018.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offer Letter, by and between the Registrant and Keith Cummings, M.D., MBA, dated November 29, 2018.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:8.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Filing<br/>Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File<br/>Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offer Letter, by and between the Registrant and Hans Hull, J.D., dated February&#160;10, 2016.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offer Letter, by and between the Registrant and Bernard Coulie, M.D., Ph.D., dated October 12, 2015.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Indemnification Agreement, by and between the Registrant and each of its directors and certain officers.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office Lease, by and between the Registrant and 260 Littlefield Avenue South San Francisco, California 94080, dated February 6, 2018.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and License Agreement, by and between the Registrant and Novartis Institutes For Biomedical Research, Inc., dated October 17, 2019.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-238146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="non-employeedirectorcompen.htm">Amended and Restated Non-Employee Director Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ye2021ex311.htm">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ye2021-ex312.htm">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ye2021-ex321.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Annual Report on Form 10-K and will not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Represents management compensation plan, contract or arrangement.</span></div><div id="i988625df783e4cc0a27bd76df388da57_199"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="i988625df783e4cc0a27bd76df388da57_202"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;28, 2022</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PLIANT THERAPEUTICS, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bernard Coulie</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernard Coulie, M.D., Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Keith Cummings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keith Cummings, M.D., M.B.A.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, Bernard Coulie and Keith Cummings and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i988625df783e4cc0a27bd76df388da57_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:28.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Bernard Coulie</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bernard Coulie, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Keith Cummings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Keith Cummings, M.D., M.B.A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Hoyoung Huh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board, Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hoyoung Huh, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Suzanne Bruhn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suzanne Bruhn, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Gayle Crowell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gayle Crowell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;John Curnutte</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Curnutte, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Neil Exter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neil Exter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Charles Homcy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charles Homcy, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Smital Shah</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smital Shah</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;David Pyott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Pyott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16#
<SEQUENCE>2
<FILENAME>non-employeedirectorcompen.htm
<DESCRIPTION>EX-10.16#
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iab61d926f24c4255b46be4dcfb5a97ef_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PLIANT THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The purpose of this Non-Employee Director Compensation Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) of Pliant Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Outside Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:115%">This Policy was reviewed and updated by the Compensation Committee of the Board of Directors of the Company on December 15, 2022 and shall be effective for all Outside Director compensation after that date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.34pt;text-decoration:underline">Cash Retainers</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Retainer for Board Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; $35,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter.  No additional compensation for attending individual Board meetings.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Annual Retainers for Committee Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          Audit Committee Chairperson&#58;                                                                      $15,000</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          Audit Committee member&#58;                                                                              $7,500</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          Compensation Committee Chairperson&#58;                                                        $10,000</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          Compensation Committee member&#58;                                                                $5,000</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          Nominating and Corporate Governance Committee Chairperson&#58;                  $8,000</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          Nominating and Corporate Governance Committee member&#58;                        $4,000</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          Research and Development Committee Chairperson&#58;                                     $8,000</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          Research and Development Committee member&#58;                                           $4,000</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Retainer for Non-Executive Chairperson or Lead Director of the Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; $30,000 to acknowledge the additional responsibilities and time commitment of the Chairperson role, or in the absence of a Chairperson, of the Outside Director designated Lead Director.  </font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Equity Retainers</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with the following provisions&#58;</font></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to (i) any award of stock options the grant date fair value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under ASC 718&#59; and (ii) any award of restricted stock and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">restricted stock units the product of (A) the closing market price on The Nasdaq Global Market (or such other market on which the Company&#8217;s Common Stock is then principally listed) of one share of the Company&#8217;s Common Stock on the effective date of grant, or if no closing price is reported for such date, the closing price on the last date preceding such date for which a closing price is reported and (B) the aggregate number of shares pursuant to such award.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sale Event Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of a Sale Event (as defined in the Company&#8217;s 2020 Stock Option and Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)), the equity retainer awards granted to Outside Directors pursuant to this Policy shall become 100% vested and exercisable.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon initial election or appointment to the Board of Directors, each new Outside Director will receive an initial, one-time grant of a non-statutory stock option to purchase 30,000 shares of the Company&#8217;s Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with an exercise price per share equal to the closing price of a share of the Company&#8217;s Common Stock on the date of grant and a term of ten years, that vests substantially equal monthly installments over three years beginning on the grant date&#59; provided, however, that all vesting ceases if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.  If any Initial Grant to an Outside Director is to become effective as of the date of the Company&#8217;s initial public offering, it shall have an exercise price per share equal to the per share &#8220;price to the public&#8221; (or equivalent) set forth on the cover page for the final prospectus relating to the Company&#8217;s initial public offering.  This Initial Grant applies to Outside Directors who are first elected or appointed to, and who were not previously serving on, the Board of Directors effective as of or subsequent to the Company&#8217;s initial public offering.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On the date of the Company&#8217;s Annual Meeting of Stockholders, each Outside Director who will continue as a member of the Board of Directors following such Annual Meeting of Stockholders will receive a grant of a non-statutory stock option to purchase 15,000 shares of the Company&#8217;s Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on the date of such Annual Meeting with an exercise price per share equal to the closing price of a share of the Company&#8217;s Common Stock on the date of grant and a term of ten years, with 25% of the Annual Grant vesting on the first day of each calendar quarter following the grant date for three calendar quarters and the remaining 25% of the Annual Grant vesting on the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting of Stockholders&#59; provided, however, that all vesting ceases if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.  </font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Expenses</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any Committee thereof.</font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Maximum Annual Compensation</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any Outside Director in a calendar year period shall not exceed (i) $1,000,000 in the first calendar year an individual becomes an Outside Director and (ii) $750,000 in any other year (or in each case, such other limits as may be set forth in Section 3(b) of the 2020 Plan or any similar provision of a successor plan).  For this purpose, the &#8220;amount&#8221; of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with ASC 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting conditions.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date Policy Approved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; December 15, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ye2021ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib5cd61bfb9af4938ae551685470b51e3_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Bernard Coulie, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Pliant Therapeutics, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13A-15(F) and 15D-15(F)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:81pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;  Bernard Coulie</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bernard Coulie, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ye2021-ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idfe605c834534a78b05cc71c8189d09b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Keith Cummings, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Pliant Therapeutics, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13A-15(F) and 15D-15(F)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant is made known to us during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Keith Cummings</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Keith Cummings, M.D., MBA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ye2021-ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2570343d7c854483b9cac656ce66b3ac_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Pliant Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;  Bernard Coulie</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bernard Coulie, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;  Keith Cummings</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Keith Cummings, M.D., MBA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>plrx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d1d6b725-1763-4d57-8800-c62b80275ac0,g:d0b89192-8a0d-4134-a7bf-5cb6b0f5f7ce-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plrx="http://www.pliantrx.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pliantrx.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="plrx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pliantrx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.pliantrx.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.pliantrx.com/role/BalanceSheets">
        <link:definition>1001003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.pliantrx.com/role/BalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperationsandComprehensiveLoss" roleURI="http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss">
        <link:definition>1003005 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>1004006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.pliantrx.com/role/StatementsofCashFlows">
        <link:definition>1005007 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.pliantrx.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessAdditionalInformationDetail" roleURI="http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Organization and Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails" roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.pliantrx.com/role/FinancialInstruments">
        <link:definition>2108103 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.pliantrx.com/role/FinancialInstrumentsTables">
        <link:definition>2309302 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails" roleURI="http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails">
        <link:definition>2410404 - Disclosure - Financial Instruments - Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails" roleURI="http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails">
        <link:definition>2411405 - Disclosure - Financial Instruments - Summery of Remaining Contractual Maturities of Company's Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails">
        <link:definition>2412406 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnet">
        <link:definition>2113104 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnetTables">
        <link:definition>2314303 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails">
        <link:definition>2415407 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnetAdditionalInformationDetails">
        <link:definition>2416408 - Disclosure - Property and Equipment, net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Prepaidexpensesandothercurrentassets" roleURI="http://www.pliantrx.com/role/Prepaidexpensesandothercurrentassets">
        <link:definition>2117105 - Disclosure - Prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesandothercurrentassetsTables" roleURI="http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsTables">
        <link:definition>2318304 - Disclosure - Prepaid expenses and other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesandothercurrentassetsDetails" roleURI="http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails">
        <link:definition>2419409 - Disclosure - Prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesandOtherLongTermLiabilities" roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilities">
        <link:definition>2120106 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesandOtherLongTermLiabilitiesTables" roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesTables">
        <link:definition>2321305 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails" roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails">
        <link:definition>2422410 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails" roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails">
        <link:definition>2423411 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NovartisCollaborationandLicenseAgreementtheNovartisAgreement" roleURI="http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreement">
        <link:definition>2124107 - Disclosure - Novartis Collaboration and License Agreement (the "Novartis Agreement")</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails">
        <link:definition>2425412 - Disclosure - Novartis Collaboration and License Agreement (the "Novartis Agreement") - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement" roleURI="http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement">
        <link:definition>2126108 - Disclosure - Regents of the University of California License Agreement (the &#8220;UC Agreement&#8221;)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails">
        <link:definition>2427413 - Disclosure - Regents of the University of California License Agreement (the &#8220;UC Agreement&#8221;) - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdimabDevelopmentandOptionAgreementtheAdimabAgreement" roleURI="http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreement">
        <link:definition>2128109 - Disclosure - Adimab Development and Option Agreement (the "Adimab Agreement")</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails">
        <link:definition>2429414 - Disclosure - Adimab Development and Option Agreement (the "Adimab Agreement") - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStock" roleURI="http://www.pliantrx.com/role/RedeemableConvertiblePreferredStock">
        <link:definition>2130110 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>2431415 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.pliantrx.com/role/CommonStock">
        <link:definition>2132111 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://www.pliantrx.com/role/CommonStockTables">
        <link:definition>2333306 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails">
        <link:definition>2434416 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockScheduleofSharesReservedforFutureIssuanceDetails" roleURI="http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails">
        <link:definition>2435417 - Disclosure - Common Stock - Schedule of Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.pliantrx.com/role/StockBasedCompensation">
        <link:definition>2136112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.pliantrx.com/role/StockBasedCompensationTables">
        <link:definition>2337307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2438418 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedStockActivityDetails" roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails">
        <link:definition>2439419 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails" roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails">
        <link:definition>2440420 - Disclosure - Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails" roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails">
        <link:definition>2441421 - Disclosure - Stock-Based Compensation - Summary of Option Activity Under the 2015 Plan and 2020 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails">
        <link:definition>2442422 - Disclosure - Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails" roleURI="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails">
        <link:definition>2443423 - Disclosure - Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails" roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails">
        <link:definition>2444424 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.pliantrx.com/role/IncomeTaxes">
        <link:definition>2145113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.pliantrx.com/role/IncomeTaxesTables">
        <link:definition>2346308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2447425 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails" roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails">
        <link:definition>2448426 - Disclosure - Income Taxes - Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company&#8217;s Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2449427 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails" roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails">
        <link:definition>2450428 - Disclosure - Income Taxes - Summary of Net Operating Losses and Tax Credit Carry Forwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails" roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails">
        <link:definition>2451429 - Disclosure - Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>2452430 - Disclosure - Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.pliantrx.com/role/CommitmentsandContingencies">
        <link:definition>2153114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2454431 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.pliantrx.com/role/Leases">
        <link:definition>2155115 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.pliantrx.com/role/LeasesTables">
        <link:definition>2356309 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.pliantrx.com/role/LeasesAdditionalinformationDetails">
        <link:definition>2457432 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseLiabilityDetails" roleURI="http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails">
        <link:definition>2458433 - Disclosure - Leases - Schedule of Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails" roleURI="http://www.pliantrx.com/role/LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails">
        <link:definition>2459434 - Disclosure - Leases - Weighted-average Remaining Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2460435 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.pliantrx.com/role/RelatedPartyTransactions">
        <link:definition>2161116 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2462436 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlan" roleURI="http://www.pliantrx.com/role/DefinedContributionPlan">
        <link:definition>2163117 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlanAdditionalInformationDetails" roleURI="http://www.pliantrx.com/role/DefinedContributionPlanAdditionalInformationDetails">
        <link:definition>2464437 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholders" roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholders">
        <link:definition>2165118 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersTables" roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables">
        <link:definition>2366310 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails">
        <link:definition>2467438 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>2468439 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="plrx_TaxCreditCarryforwardsExpirationYear" abstract="false" name="TaxCreditCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="plrx_LicenseAgreementsAbstract" abstract="true" name="LicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="plrx_NumberOfVotesPerShareOfCommonStock" abstract="false" name="NumberOfVotesPerShareOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="plrx_IncomeTaxExaminationNumberOfExaminationsPending" abstract="false" name="IncomeTaxExaminationNumberOfExaminationsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" abstract="true" name="IncentiveStockOptionsAndNonqualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_MatureInOneToTwoYearsMember" abstract="true" name="MatureInOneToTwoYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_NovartisAgreementMember" abstract="true" name="NovartisAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_PrepaidLicensesCurrent" abstract="false" name="PrepaidLicensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" abstract="false" name="ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="plrx_LeasedSpaceUnderNonCancellableOperatingLease" abstract="false" name="LeasedSpaceUnderNonCancellableOperatingLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="plrx_NumberOfIntegrinResearchTargets" abstract="false" name="NumberOfIntegrinResearchTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_AchievementOfFirstPatientDosingMilestoneMember" abstract="true" name="AchievementOfFirstPatientDosingMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_StartingFromJanuary12018Member" abstract="true" name="StartingFromJanuary12018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_PliantTherapeuticsIncMember" abstract="true" name="PliantTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_EmployeeStockPurchasePlanOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="plrx_UCRegentsMember" abstract="true" name="UCRegentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_RedeemableConvertiblePreferredStockTextBlock" abstract="false" name="RedeemableConvertiblePreferredStockTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember" abstract="true" name="TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_LicenseAgreementsTextBlock" abstract="false" name="LicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_NovartisAgreementRDForIntegrinResearchTargetsMember" abstract="true" name="NovartisAgreementRDForIntegrinResearchTargetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="plrx_AccountingPoliciesTable" abstract="true" name="AccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="plrx_MilestoneAndAnnualRoyaltyPaid" abstract="false" name="MilestoneAndAnnualRoyaltyPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_OperatingLossCarryforwardsExpirationYear" abstract="false" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_InterestAndOtherIncomeNet" abstract="false" name="InterestAndOtherIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" abstract="false" name="AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_PeriodOfBaseRentAbatement" abstract="false" name="PeriodOfBaseRentAbatement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" abstract="false" name="AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_LicenseAgreementsLineItems" abstract="true" name="LicenseAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="plrx_AdimabAgreementMember" abstract="true" name="AdimabAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_AccountingPoliciesLineItems" abstract="true" name="AccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" abstract="false" name="CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" abstract="false" name="ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="plrx_RestrictedCommonStockAwardsMember" abstract="true" name="RestrictedCommonStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember" abstract="true" name="RestrictedStockAwardsGrantedAndNotPurchasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_ProceedsFromUpfrontNonRefundableLicenseFee" abstract="false" name="ProceedsFromUpfrontNonRefundableLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_MatureInOneYearOrLessMember" abstract="true" name="MatureInOneYearOrLessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_AccruedExpensesAndOtherLiabilitiesMember" abstract="true" name="AccruedExpensesAndOtherLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_ContractualArrangementsCancellationPeriod" abstract="false" name="ContractualArrangementsCancellationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="plrx_DeferredTaxLiabilitiesFixedAssetBasis" abstract="false" name="DeferredTaxLiabilitiesFixedAssetBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_SeriesCRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesCRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_BeforeJanuary12018Member" abstract="true" name="BeforeJanuary12018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_RestrictedStockAwardsMember" abstract="true" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent" abstract="false" name="DeferredRentAndLeaseholdIncentiveObligationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_PercentageOfRevenueContributedByRelatedParty" abstract="false" name="PercentageOfRevenueContributedByRelatedParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="plrx_PrepaidResearchAndDevelopmentCurrent" abstract="false" name="PrepaidResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_CommonStockFairMarketValuePercentage" abstract="false" name="CommonStockFairMarketValuePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="plrx_UnderwritersMember" abstract="true" name="UnderwritersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" abstract="false" name="DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_UnderlyingCommonStockFairValue" abstract="false" name="UnderlyingCommonStockFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="plrx_LeaseTermExtensionNoticePeriod" abstract="false" name="LeaseTermExtensionNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" abstract="false" name="ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="plrx_AccruedResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_LicenseAgreementsTable" abstract="true" name="LicenseAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" abstract="false" name="EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="plrx_NonemployeeDirectorMember" abstract="true" name="NonemployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_ThirdRockVenturesMember" abstract="true" name="ThirdRockVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_TwoThousandTwentyEquityIncentivePlanMember" abstract="true" name="TwoThousandTwentyEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" abstract="false" name="RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="plrx_AccretionOfShortTermInvestments" abstract="false" name="AccretionOfShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="plrx_NovartisAgreementRDForPLN1474Member" abstract="true" name="NovartisAgreementRDForPLN1474Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets" abstract="false" name="ValuationAllowanceAsPercentageOnDeferredTaxAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="plrx_OtherLosses" abstract="false" name="OtherLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" abstract="false" name="DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="plrx_SeriesBRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesBRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_FullTimeEmployeeCostMember" abstract="true" name="FullTimeEmployeeCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_BaseRentAbatedAmount" abstract="false" name="BaseRentAbatedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndTwentyEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_SeriesARedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesARedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="plrx_LicenseFeeMember" abstract="true" name="LicenseFeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>plrx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d1d6b725-1763-4d57-8800-c62b80275ac0,g:d0b89192-8a0d-4134-a7bf-5cb6b0f5f7ce-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pliantrx.com/role/BalanceSheets" xlink:type="simple" xlink:href="plrx-20211231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0c4ce03e-5dba-4c98-8c4e-b2b0ff332e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_017c2fb6-9808-4872-a347-be1c69cae143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0c4ce03e-5dba-4c98-8c4e-b2b0ff332e4a" xlink:to="loc_us-gaap_AccountsPayableCurrent_017c2fb6-9808-4872-a347-be1c69cae143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e6c63ecd-a89c-42bd-86be-15a2b62dd5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0c4ce03e-5dba-4c98-8c4e-b2b0ff332e4a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e6c63ecd-a89c-42bd-86be-15a2b62dd5f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4fc25a90-ad81-46dd-b06d-0b135aed4ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0c4ce03e-5dba-4c98-8c4e-b2b0ff332e4a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4fc25a90-ad81-46dd-b06d-0b135aed4ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7cd82f36-5d91-4cd7-943f-4df0724dafd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bad7e3d1-3faf-48b4-9975-9e2924989282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cd82f36-5d91-4cd7-943f-4df0724dafd0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bad7e3d1-3faf-48b4-9975-9e2924989282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_8e9923ef-bf5f-4145-baa8-c5f79acf1b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cd82f36-5d91-4cd7-943f-4df0724dafd0" xlink:to="loc_us-gaap_ShortTermInvestments_8e9923ef-bf5f-4145-baa8-c5f79acf1b61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9d97d735-aa97-48c8-94e2-28cd0232c500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cd82f36-5d91-4cd7-943f-4df0724dafd0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9d97d735-aa97-48c8-94e2-28cd0232c500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_941321c4-84ae-4a18-906c-eb4cfd5281ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cd82f36-5d91-4cd7-943f-4df0724dafd0" xlink:to="loc_us-gaap_IncomeTaxesReceivable_941321c4-84ae-4a18-906c-eb4cfd5281ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6bad52f2-dab9-44ec-b423-2f758147330d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7cd82f36-5d91-4cd7-943f-4df0724dafd0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6bad52f2-dab9-44ec-b423-2f758147330d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_118f400b-fbc2-4993-be32-aedec44bed60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5a14a185-7039-4c7e-ab76-4c69b750363c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_118f400b-fbc2-4993-be32-aedec44bed60" xlink:to="loc_us-gaap_Liabilities_5a14a185-7039-4c7e-ab76-4c69b750363c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9b702f2b-8900-44ce-bc72-dbce90de8d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_118f400b-fbc2-4993-be32-aedec44bed60" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9b702f2b-8900-44ce-bc72-dbce90de8d63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61c6eef6-8e4e-4d17-a6ff-f6e642533164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_118f400b-fbc2-4993-be32-aedec44bed60" xlink:to="loc_us-gaap_StockholdersEquity_61c6eef6-8e4e-4d17-a6ff-f6e642533164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b36b4467-2c1b-4c83-9f50-a3660fc876e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_a507fd48-2be2-4701-848d-35ed57e33017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b36b4467-2c1b-4c83-9f50-a3660fc876e1" xlink:to="loc_us-gaap_CommonStockValueOutstanding_a507fd48-2be2-4701-848d-35ed57e33017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_64536da7-c360-4190-9fc1-5b318e29a361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b36b4467-2c1b-4c83-9f50-a3660fc876e1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_64536da7-c360-4190-9fc1-5b318e29a361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5c6a39ef-7037-4362-829a-760057d94952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b36b4467-2c1b-4c83-9f50-a3660fc876e1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5c6a39ef-7037-4362-829a-760057d94952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4aa8c94d-8d0c-4165-9075-117c46362cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b36b4467-2c1b-4c83-9f50-a3660fc876e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4aa8c94d-8d0c-4165-9075-117c46362cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_298d4ac6-d7ef-4ae8-b111-cac004872b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f8741074-2693-4767-87d4-c814e15844d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_298d4ac6-d7ef-4ae8-b111-cac004872b8a" xlink:to="loc_us-gaap_AssetsCurrent_f8741074-2693-4767-87d4-c814e15844d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6e0f96f7-dfaa-4311-9aa8-07fb0ac2ae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_298d4ac6-d7ef-4ae8-b111-cac004872b8a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6e0f96f7-dfaa-4311-9aa8-07fb0ac2ae8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5e98b250-5c64-4da2-a154-67a1726ea154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_298d4ac6-d7ef-4ae8-b111-cac004872b8a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5e98b250-5c64-4da2-a154-67a1726ea154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_268d840f-ed68-43d7-b550-07074a154d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_298d4ac6-d7ef-4ae8-b111-cac004872b8a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_268d840f-ed68-43d7-b550-07074a154d54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_81ff62ee-d5ca-47b6-9951-6ea27ffed43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_168f1fdd-5a3d-4275-9062-53d3ee2476df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_81ff62ee-d5ca-47b6-9951-6ea27ffed43b" xlink:to="loc_us-gaap_LiabilitiesCurrent_168f1fdd-5a3d-4275-9062-53d3ee2476df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8878c4e5-ba67-439d-9977-69db5d7fed74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_81ff62ee-d5ca-47b6-9951-6ea27ffed43b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8878c4e5-ba67-439d-9977-69db5d7fed74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3da5d6ca-3791-4dcf-a840-82e5dd69e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_81ff62ee-d5ca-47b6-9951-6ea27ffed43b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3da5d6ca-3791-4dcf-a840-82e5dd69e39b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="plrx-20211231.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bfff54cb-5cf0-46e8-b4b5-f61d85f5c489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3205a107-8761-4f23-a51b-23fa6d1331ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bfff54cb-5cf0-46e8-b4b5-f61d85f5c489" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3205a107-8761-4f23-a51b-23fa6d1331ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9504db9e-66b1-47fd-8302-a786481672b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bfff54cb-5cf0-46e8-b4b5-f61d85f5c489" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9504db9e-66b1-47fd-8302-a786481672b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7573ee50-12cb-46cd-9db5-5a442534deee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_076e5624-6693-48b9-9fe3-ffb018474054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7573ee50-12cb-46cd-9db5-5a442534deee" xlink:to="loc_us-gaap_OperatingIncomeLoss_076e5624-6693-48b9-9fe3-ffb018474054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_InterestAndOtherIncomeNet_0d9fcedc-fa4c-4c58-8443-4fe5630df249" xlink:href="plrx-20211231.xsd#plrx_InterestAndOtherIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7573ee50-12cb-46cd-9db5-5a442534deee" xlink:to="loc_plrx_InterestAndOtherIncomeNet_0d9fcedc-fa4c-4c58-8443-4fe5630df249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c56d85e3-289a-45f7-a101-13dc4f7190bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c0b1ff9f-0532-4398-bbbd-51eb4930e105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c56d85e3-289a-45f7-a101-13dc4f7190bb" xlink:to="loc_us-gaap_NetIncomeLoss_c0b1ff9f-0532-4398-bbbd-51eb4930e105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_56d81fc5-68a2-4efd-916d-fd986bcc3fec" xlink:href="plrx-20211231.xsd#plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c56d85e3-289a-45f7-a101-13dc4f7190bb" xlink:to="loc_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_56d81fc5-68a2-4efd-916d-fd986bcc3fec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a13d40a-af48-407b-9291-33eddc4119d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fb91e30f-ab74-4561-8de9-38602f0eed9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a13d40a-af48-407b-9291-33eddc4119d5" xlink:to="loc_us-gaap_NetIncomeLoss_fb91e30f-ab74-4561-8de9-38602f0eed9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_305a8cb3-8e6b-4660-b337-ae293ca30c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2a13d40a-af48-407b-9291-33eddc4119d5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_305a8cb3-8e6b-4660-b337-ae293ca30c45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_19eec30c-19f8-4568-a0df-faf40c41b5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_13b2327b-302a-4016-af78-8245209c4e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_19eec30c-19f8-4568-a0df-faf40c41b5c0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_13b2327b-302a-4016-af78-8245209c4e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fefc3802-6d79-4dab-9fc9-195bba426636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_19eec30c-19f8-4568-a0df-faf40c41b5c0" xlink:to="loc_us-gaap_OperatingExpenses_fefc3802-6d79-4dab-9fc9-195bba426636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_154dca6c-0728-43aa-92f8-c72b22aed8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_47390c74-7b7c-4fc5-b943-51628b156e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_154dca6c-0728-43aa-92f8-c72b22aed8dc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_47390c74-7b7c-4fc5-b943-51628b156e36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="plrx-20211231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6b74fb7e-1df1-4486-b023-b7f67cbbcff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_ProfitLoss_6b74fb7e-1df1-4486-b023-b7f67cbbcff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_dcb355ec-516c-4cb8-b7d5-a624c6d7e4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_Depreciation_dcb355ec-516c-4cb8-b7d5-a624c6d7e4e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fa315454-a96d-4cf6-b6db-8676dc106a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_ShareBasedCompensation_fa315454-a96d-4cf6-b6db-8676dc106a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0c5d2a81-abe7-423c-a4e1-f9d3d76e95e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0c5d2a81-abe7-423c-a4e1-f9d3d76e95e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_OtherLosses_26f51f5e-5ba2-4073-9658-1abd4315d32e" xlink:href="plrx-20211231.xsd#plrx_OtherLosses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_plrx_OtherLosses_26f51f5e-5ba2-4073-9658-1abd4315d32e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_a10c59c1-c073-4a78-8a26-5ae3e217066c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_a10c59c1-c073-4a78-8a26-5ae3e217066c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_aed845e1-618f-4993-b6d0-26488d5073a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_aed845e1-618f-4993-b6d0-26488d5073a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c02e622c-4c9d-400f-9870-515c8fa6930e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c02e622c-4c9d-400f-9870-515c8fa6930e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e4b64ad0-8241-43d7-bd59-792e79342926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e4b64ad0-8241-43d7-bd59-792e79342926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9abbbb71-21e3-4505-8bb5-a4a5d1c30982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9abbbb71-21e3-4505-8bb5-a4a5d1c30982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c428404-23de-4478-8dc9-8c2b29c7b9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c428404-23de-4478-8dc9-8c2b29c7b9f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4d30e612-bf66-4a6b-8a4a-696623ee46be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4d30e612-bf66-4a6b-8a4a-696623ee46be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_129d19b1-d0a6-4cbd-893a-311ce5f23ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e512f06-e7fb-46ac-b2c0-154f307106d5" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_129d19b1-d0a6-4cbd-893a-311ce5f23ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_83c0088b-45e2-4e5f-849b-2db3176a8148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_404fe5df-07af-4daf-a3ef-ae6517c15520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_83c0088b-45e2-4e5f-849b-2db3176a8148" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_404fe5df-07af-4daf-a3ef-ae6517c15520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionOfShortTermInvestments_82825152-3831-45d2-8c3b-ebac71f13067" xlink:href="plrx-20211231.xsd#plrx_AccretionOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_83c0088b-45e2-4e5f-849b-2db3176a8148" xlink:to="loc_plrx_AccretionOfShortTermInvestments_82825152-3831-45d2-8c3b-ebac71f13067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_bf6f5db0-34ea-466e-ac9a-91c501066c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_83c0088b-45e2-4e5f-849b-2db3176a8148" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_bf6f5db0-34ea-466e-ac9a-91c501066c21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_be781e0b-eab1-46ca-a2af-a7d9dd93675f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_83c0088b-45e2-4e5f-849b-2db3176a8148" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_be781e0b-eab1-46ca-a2af-a7d9dd93675f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44a1a231-3924-4278-9f35-2c2b5749cba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_58f08f0b-5fb1-4854-8ea8-40e21b06650a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44a1a231-3924-4278-9f35-2c2b5749cba1" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_58f08f0b-5fb1-4854-8ea8-40e21b06650a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fe59142f-10fe-4b22-87c1-93fb9cd7a240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44a1a231-3924-4278-9f35-2c2b5749cba1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fe59142f-10fe-4b22-87c1-93fb9cd7a240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_13d8ad5a-a76b-4a84-ac97-bb5fc5a72f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44a1a231-3924-4278-9f35-2c2b5749cba1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_13d8ad5a-a76b-4a84-ac97-bb5fc5a72f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0233209f-994f-4565-a32e-d320dfe20fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44a1a231-3924-4278-9f35-2c2b5749cba1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0233209f-994f-4565-a32e-d320dfe20fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_65e2636c-845b-42ac-951a-49492cbbc8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44a1a231-3924-4278-9f35-2c2b5749cba1" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_65e2636c-845b-42ac-951a-49492cbbc8cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a977036e-fcfb-4ebb-a844-9e089a790ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2c83b5f-5e10-42fd-b2c0-19a3504f6797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a977036e-fcfb-4ebb-a844-9e089a790ccb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2c83b5f-5e10-42fd-b2c0-19a3504f6797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7464b3a9-a9bc-44f7-9f18-ff239429f66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a977036e-fcfb-4ebb-a844-9e089a790ccb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7464b3a9-a9bc-44f7-9f18-ff239429f66f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a8407d-7bac-4372-b1a4-b13085f41b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a977036e-fcfb-4ebb-a844-9e089a790ccb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41a8407d-7bac-4372-b1a4-b13085f41b27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_98afbe7c-ebbb-4c0e-aa4d-ac92d6773486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_dcf7f010-f316-4eb8-bdc6-974fa7f8fc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_98afbe7c-ebbb-4c0e-aa4d-ac92d6773486" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_dcf7f010-f316-4eb8-bdc6-974fa7f8fc3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6339cc38-713e-41b0-8401-127b98346fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_98afbe7c-ebbb-4c0e-aa4d-ac92d6773486" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6339cc38-713e-41b0-8401-127b98346fab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#PrepaidexpensesandothercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_863920b9-4fbc-4626-adc8-43c8189dd917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PrepaidResearchAndDevelopmentCurrent_b16f5b5d-9b20-4f2f-afab-bd3eb23b8ddb" xlink:href="plrx-20211231.xsd#plrx_PrepaidResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_863920b9-4fbc-4626-adc8-43c8189dd917" xlink:to="loc_plrx_PrepaidResearchAndDevelopmentCurrent_b16f5b5d-9b20-4f2f-afab-bd3eb23b8ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_21807ae3-4ff6-444a-955f-c17539ff637a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_863920b9-4fbc-4626-adc8-43c8189dd917" xlink:to="loc_us-gaap_PrepaidInsurance_21807ae3-4ff6-444a-955f-c17539ff637a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PrepaidLicensesCurrent_0cf5730b-f840-4c93-96a6-0f57c9f3a37b" xlink:href="plrx-20211231.xsd#plrx_PrepaidLicensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_863920b9-4fbc-4626-adc8-43c8189dd917" xlink:to="loc_plrx_PrepaidLicensesCurrent_0cf5730b-f840-4c93-96a6-0f57c9f3a37b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInterest_d5c9c252-fd8f-4de2-8c49-1dbf147423ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_863920b9-4fbc-4626-adc8-43c8189dd917" xlink:to="loc_us-gaap_PrepaidInterest_d5c9c252-fd8f-4de2-8c49-1dbf147423ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_a802b890-de93-4370-93e8-82a7c1fc1f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_863920b9-4fbc-4626-adc8-43c8189dd917" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_a802b890-de93-4370-93e8-82a7c1fc1f28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2fb41518-6e9e-4b3c-8f2a-5f48914a7328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b84fd09c-8f4f-4a37-a51e-d78632f4d54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fb41518-6e9e-4b3c-8f2a-5f48914a7328" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b84fd09c-8f4f-4a37-a51e-d78632f4d54c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccruedResearchAndDevelopmentExpensesCurrent_0f7bbdb9-bb59-4ec5-9880-875e31036605" xlink:href="plrx-20211231.xsd#plrx_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fb41518-6e9e-4b3c-8f2a-5f48914a7328" xlink:to="loc_plrx_AccruedResearchAndDevelopmentExpensesCurrent_0f7bbdb9-bb59-4ec5-9880-875e31036605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_eaee0048-6300-4b54-9264-1323e509b3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fb41518-6e9e-4b3c-8f2a-5f48914a7328" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_eaee0048-6300-4b54-9264-1323e509b3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent_dabe258b-9fd8-4195-831a-7c9197c25e91" xlink:href="plrx-20211231.xsd#plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fb41518-6e9e-4b3c-8f2a-5f48914a7328" xlink:to="loc_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent_dabe258b-9fd8-4195-831a-7c9197c25e91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8286a3b4-8643-440c-a0c1-6c16e7c0dc83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCredit_b93ae176-231e-4f1c-ad05-38174108a308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8286a3b4-8643-440c-a0c1-6c16e7c0dc83" xlink:to="loc_us-gaap_DeferredRentCredit_b93ae176-231e-4f1c-ad05-38174108a308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor_40c596f1-8260-4b56-be88-b300bb38fd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveFromLessor"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8286a3b4-8643-440c-a0c1-6c16e7c0dc83" xlink:to="loc_us-gaap_IncentiveFromLessor_40c596f1-8260-4b56-be88-b300bb38fd59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_66a064c9-8c7b-44ac-8cbe-fd192e4c09e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8286a3b4-8643-440c-a0c1-6c16e7c0dc83" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_66a064c9-8c7b-44ac-8cbe-fd192e4c09e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_492253a3-854f-4f13-8d81-f2fe3755a0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c07f776b-5e85-4683-92d4-be867062b4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_492253a3-854f-4f13-8d81-f2fe3755a0b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c07f776b-5e85-4683-92d4-be867062b4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_12db905a-343c-413c-9340-46bdb8faaf53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_492253a3-854f-4f13-8d81-f2fe3755a0b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_12db905a-343c-413c-9340-46bdb8faaf53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal_81c54ad3-c003-4382-bf8d-db07654a1c2d" xlink:href="plrx-20211231.xsd#plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_492253a3-854f-4f13-8d81-f2fe3755a0b1" xlink:to="loc_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal_81c54ad3-c003-4382-bf8d-db07654a1c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_de0663af-e303-4257-8634-ea1f6a167278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_492253a3-854f-4f13-8d81-f2fe3755a0b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_de0663af-e303-4257-8634-ea1f6a167278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_2b8f6dc4-6fdf-435c-96e0-4b972a4aa0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_492253a3-854f-4f13-8d81-f2fe3755a0b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_2b8f6dc4-6fdf-435c-96e0-4b972a4aa0a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_10d1ca18-80e0-4de5-ae42-b7921cd31c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_492253a3-854f-4f13-8d81-f2fe3755a0b1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_10d1ca18-80e0-4de5-ae42-b7921cd31c4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_48337619-5ef1-4bc8-ad0b-d45a84195dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxLiabilitiesRightOfUseAsset_83fe6840-9586-4272-8a4e-187cb063212a" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_48337619-5ef1-4bc8-ad0b-d45a84195dfb" xlink:to="loc_plrx_DeferredTaxLiabilitiesRightOfUseAsset_83fe6840-9586-4272-8a4e-187cb063212a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxLiabilitiesFixedAssetBasis_c93d8313-99d2-4990-95b8-5b3d4f806357" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxLiabilitiesFixedAssetBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_48337619-5ef1-4bc8-ad0b-d45a84195dfb" xlink:to="loc_plrx_DeferredTaxLiabilitiesFixedAssetBasis_c93d8313-99d2-4990-95b8-5b3d4f806357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d596b522-d42e-4cd4-a2f5-fbdfcb2fc34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_48337619-5ef1-4bc8-ad0b-d45a84195dfb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d596b522-d42e-4cd4-a2f5-fbdfcb2fc34e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7e09c834-53de-4ae1-885e-8c41f2cc7af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1d7a2f92-eb2d-485a-bfae-ec9fb92a02bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7e09c834-53de-4ae1-885e-8c41f2cc7af3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1d7a2f92-eb2d-485a-bfae-ec9fb92a02bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_73d3182f-18b8-43f9-a3fe-d46461db1654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7e09c834-53de-4ae1-885e-8c41f2cc7af3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_73d3182f-18b8-43f9-a3fe-d46461db1654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0725e18e-b8c7-4914-89cc-245fe2f76deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_7e09c834-53de-4ae1-885e-8c41f2cc7af3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0725e18e-b8c7-4914-89cc-245fe2f76deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6f57bead-33d4-4e2c-b5fd-c816074b0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f06b4fff-ed33-4c1c-bb20-02e598eb2529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f57bead-33d4-4e2c-b5fd-c816074b0d3f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f06b4fff-ed33-4c1c-bb20-02e598eb2529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4f67b3d0-fdde-49ec-a60d-fab73752dba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f57bead-33d4-4e2c-b5fd-c816074b0d3f" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4f67b3d0-fdde-49ec-a60d-fab73752dba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_678f6f0a-8aac-43f1-8503-08fcd7af652d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f57bead-33d4-4e2c-b5fd-c816074b0d3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_678f6f0a-8aac-43f1-8503-08fcd7af652d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_253ffb67-7bc3-4a80-a184-fa490cb55a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f57bead-33d4-4e2c-b5fd-c816074b0d3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_253ffb67-7bc3-4a80-a184-fa490cb55a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_4b35092f-390c-47b8-a217-8e24713c81d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f57bead-33d4-4e2c-b5fd-c816074b0d3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_4b35092f-390c-47b8-a217-8e24713c81d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxAssetsLeaseLiability_68a400c6-81d4-4cd4-acee-7957ace1c413" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f57bead-33d4-4e2c-b5fd-c816074b0d3f" xlink:to="loc_plrx_DeferredTaxAssetsLeaseLiability_68a400c6-81d4-4cd4-acee-7957ace1c413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f5bcabb4-4612-4317-8960-0bd04d222d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f57bead-33d4-4e2c-b5fd-c816074b0d3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f5bcabb4-4612-4317-8960-0bd04d222d37" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesScheduleofOperatingLeaseLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2329386-bbff-4f1b-9637-4ff62b4332a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fc33c4d4-91d0-4ad5-85aa-b3aa27c1580d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2329386-bbff-4f1b-9637-4ff62b4332a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fc33c4d4-91d0-4ad5-85aa-b3aa27c1580d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_016becdf-ba37-436e-836c-f6ea4ea8c6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2329386-bbff-4f1b-9637-4ff62b4332a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_016becdf-ba37-436e-836c-f6ea4ea8c6c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5086d02f-c4c0-425a-a86d-aca22644ea2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2329386-bbff-4f1b-9637-4ff62b4332a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5086d02f-c4c0-425a-a86d-aca22644ea2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be4c2137-6e7d-4e65-bc34-b6a405e48c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2329386-bbff-4f1b-9637-4ff62b4332a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be4c2137-6e7d-4e65-bc34-b6a405e48c37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cd6244d4-926b-4d96-823c-00d19919699f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2329386-bbff-4f1b-9637-4ff62b4332a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cd6244d4-926b-4d96-823c-00d19919699f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_038c2842-db4a-47b1-83b3-49357ca10d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e3749af4-aee1-49bc-aad6-97a5b909067b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_038c2842-db4a-47b1-83b3-49357ca10d49" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e3749af4-aee1-49bc-aad6-97a5b909067b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_0b3394a5-3a8e-4f1d-821d-1a69868773ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_038c2842-db4a-47b1-83b3-49357ca10d49" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_0b3394a5-3a8e-4f1d-821d-1a69868773ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_a8f1a6c7-294b-45c2-91a4-1812adab97c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_038c2842-db4a-47b1-83b3-49357ca10d49" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_a8f1a6c7-294b-45c2-91a4-1812adab97c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_aa681abf-ee69-4a80-8b13-884a5c06dfac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_038c2842-db4a-47b1-83b3-49357ca10d49" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_aa681abf-ee69-4a80-8b13-884a5c06dfac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7c4a92a7-46a6-4c63-a8a7-28ce6fa39b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4dc60809-1e24-479a-8ed3-856a7042ec6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7c4a92a7-46a6-4c63-a8a7-28ce6fa39b11" xlink:to="loc_us-gaap_NetIncomeLoss_4dc60809-1e24-479a-8ed3-856a7042ec6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_12a909dc-5c7c-425c-94b3-bc0884c7dac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7c4a92a7-46a6-4c63-a8a7-28ce6fa39b11" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_12a909dc-5c7c-425c-94b3-bc0884c7dac9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>plrx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d1d6b725-1763-4d57-8800-c62b80275ac0,g:d0b89192-8a0d-4134-a7bf-5cb6b0f5f7ce-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="plrx-20211231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="i004b0e347d514cb78db863356755fa44_StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8042b61c-686a-47a0-9a16-11abcf27aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8042b61c-686a-47a0-9a16-11abcf27aa1f" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_75a5d04b-4a75-4d62-b381-6d27489dda04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_75a5d04b-4a75-4d62-b381-6d27489dda04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f8d18651-3f0f-451e-acab-a45d39100e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f8d18651-3f0f-451e-acab-a45d39100e94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c119d7af-7e0c-463a-9245-d1325d1e72b6" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c119d7af-7e0c-463a-9245-d1325d1e72b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_aeb4cd91-5afb-441f-b4af-7429feb1412f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_aeb4cd91-5afb-441f-b4af-7429feb1412f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fd645ed7-ae11-4ba1-98f6-fbde792aba51" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fd645ed7-ae11-4ba1-98f6-fbde792aba51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_569c185f-3958-4361-9d8a-960259c98a4a" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_569c185f-3958-4361-9d8a-960259c98a4a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_5e7f60e0-0541-4ee9-a896-518ad1951403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b918d44f-8b3a-4207-b4ba-cc7d06b30d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8042b61c-686a-47a0-9a16-11abcf27aa1f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_776e9ad3-ebc9-4e7d-ac51-74f2eaf0b7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_776e9ad3-ebc9-4e7d-ac51-74f2eaf0b7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_08776307-831c-4280-86a4-388115b0dd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockholdersEquity_08776307-831c-4280-86a4-388115b0dd46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88dc3ab6-46b2-4335-9b1b-c2e7379b84dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88dc3ab6-46b2-4335-9b1b-c2e7379b84dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_04f9ab5b-ae08-4e0f-a45c-398493697629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_04f9ab5b-ae08-4e0f-a45c-398493697629" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28765ab5-05d3-467b-9c54-5e596bf593ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28765ab5-05d3-467b-9c54-5e596bf593ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_24dfd55d-971b-4ccd-b3b2-80ceb948d9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_24dfd55d-971b-4ccd-b3b2-80ceb948d9cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_42501b71-4445-4b11-8f1c-0dd68696c2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_42501b71-4445-4b11-8f1c-0dd68696c2c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c93f7e45-56ac-4357-9844-6d4d839aac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c93f7e45-56ac-4357-9844-6d4d839aac8a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b8ac214f-b2a4-4d97-b2b4-e6e29e9f0a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b8ac214f-b2a4-4d97-b2b4-e6e29e9f0a98" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_13c0228c-4ca7-4671-b34d-1b33aa464150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_13c0228c-4ca7-4671-b34d-1b33aa464150" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_576f6b2f-d2cd-4d9e-bf02-b240d8c302bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_576f6b2f-d2cd-4d9e-bf02-b240d8c302bf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c5e48325-e0e0-432f-a73d-0b29bbce0320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c5e48325-e0e0-432f-a73d-0b29bbce0320" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_49176d17-9094-46a4-8d98-6a445cb24269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_49176d17-9094-46a4-8d98-6a445cb24269" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock_27c4f896-2c49-4a57-992f-396905f189ae" xlink:href="plrx-20211231.xsd#plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock_27c4f896-2c49-4a57-992f-396905f189ae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_860edc62-4f8c-4f17-aab8-fbed495e5dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_860edc62-4f8c-4f17-aab8-fbed495e5dba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ddffe590-341b-4f4a-854a-a47a57d7769d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ddffe590-341b-4f4a-854a-a47a57d7769d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15243171-5d1d-4f61-b860-31a9a05d9b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_NetIncomeLoss_15243171-5d1d-4f61-b860-31a9a05d9b5a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a1e50c0d-be05-4121-adc6-e76d9ddefc58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ae533004-2093-4c1f-ad65-cb299b57171b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8042b61c-686a-47a0-9a16-11abcf27aa1f" xlink:to="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d9072601-215c-4338-adae-e8c1e600c19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d9072601-215c-4338-adae-e8c1e600c19b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d9072601-215c-4338-adae-e8c1e600c19b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9072601-215c-4338-adae-e8c1e600c19b" xlink:to="loc_us-gaap_ClassOfStockDomain_d9072601-215c-4338-adae-e8c1e600c19b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9072601-215c-4338-adae-e8c1e600c19b" xlink:to="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesARedeemableConvertiblePreferredStockMember_feb46cf0-d296-4396-a484-dd7487a3ee70" xlink:href="plrx-20211231.xsd#plrx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:to="loc_plrx_SeriesARedeemableConvertiblePreferredStockMember_feb46cf0-d296-4396-a484-dd7487a3ee70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesBRedeemableConvertiblePreferredStockMember_fb1ac43d-0498-40f7-a422-6d58a26b4250" xlink:href="plrx-20211231.xsd#plrx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:to="loc_plrx_SeriesBRedeemableConvertiblePreferredStockMember_fb1ac43d-0498-40f7-a422-6d58a26b4250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesCRedeemableConvertiblePreferredStockMember_18a59419-7925-4896-aa98-7fbe433dc52c" xlink:href="plrx-20211231.xsd#plrx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:to="loc_plrx_SeriesCRedeemableConvertiblePreferredStockMember_18a59419-7925-4896-aa98-7fbe433dc52c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_484ad698-da0c-42da-b215-1547df9d2fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_484ad698-da0c-42da-b215-1547df9d2fea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_484ad698-da0c-42da-b215-1547df9d2fea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_484ad698-da0c-42da-b215-1547df9d2fea" xlink:to="loc_us-gaap_EquityComponentDomain_484ad698-da0c-42da-b215-1547df9d2fea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_484ad698-da0c-42da-b215-1547df9d2fea" xlink:to="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0423a75-f90c-416b-ae06-c526c4d26d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:to="loc_us-gaap_CommonStockMember_c0423a75-f90c-416b-ae06-c526c4d26d2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5bf7020f-1745-4825-bc24-3baf9ac6a11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5bf7020f-1745-4825-bc24-3baf9ac6a11b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8c9feb1-2261-46f5-98b0-1202205fadb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8c9feb1-2261-46f5-98b0-1202205fadb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a34cb84a-a68b-463e-b1f2-b9faf7abeec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:to="loc_us-gaap_RetainedEarningsMember_a34cb84a-a68b-463e-b1f2-b9faf7abeec3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_383cb10d-4912-4805-8203-67fe5859c1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_383cb10d-4912-4805-8203-67fe5859c1d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_383cb10d-4912-4805-8203-67fe5859c1d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_383cb10d-4912-4805-8203-67fe5859c1d4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_383cb10d-4912-4805-8203-67fe5859c1d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4e0806-167b-41d6-8d1d-50b40fdad91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_383cb10d-4912-4805-8203-67fe5859c1d4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4e0806-167b-41d6-8d1d-50b40fdad91c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_218bedd5-454a-4bb7-a86d-129553f853a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4e0806-167b-41d6-8d1d-50b40fdad91c" xlink:to="loc_us-gaap_IPOMember_218bedd5-454a-4bb7-a86d-129553f853a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_12c255ea-b0b7-4a03-bfed-bea49ae461d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4e0806-167b-41d6-8d1d-50b40fdad91c" xlink:to="loc_us-gaap_PrivatePlacementMember_12c255ea-b0b7-4a03-bfed-bea49ae461d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail" xlink:type="simple" xlink:href="plrx-20211231.xsd#OrganizationandDescriptionofBusinessAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail" xlink:type="extended" id="i2de8840ced1e409a93940dbc57d6ce52_OrganizationandDescriptionofBusinessAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_274dee9e-7848-43cb-93a7-2c9913aa2ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_274dee9e-7848-43cb-93a7-2c9913aa2ac2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_89f35451-6112-4ab0-81a9-2895b838a664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_89f35451-6112-4ab0-81a9-2895b838a664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0e7daa16-e04e-4ab0-81a6-2b990035a956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0e7daa16-e04e-4ab0-81a6-2b990035a956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8678c4b5-039e-48e7-a54e-e74e0df650f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8678c4b5-039e-48e7-a54e-e74e0df650f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_debd16d3-be78-47f5-a440-baa9f4dc542c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_debd16d3-be78-47f5-a440-baa9f4dc542c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b53226e0-dc63-41fd-81be-554ded333eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b53226e0-dc63-41fd-81be-554ded333eff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_ef139771-8e76-4be5-8176-b865da466ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_ef139771-8e76-4be5-8176-b865da466ce3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_953be374-b268-435a-900e-587754ddac2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_CommonStockSharesIssued_953be374-b268-435a-900e-587754ddac2e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0ed75829-257d-4a04-bfbe-b53c7e44e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_SharePrice_0ed75829-257d-4a04-bfbe-b53c7e44e0b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_794cd013-567e-4099-a59c-09783beef554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_794cd013-567e-4099-a59c-09783beef554" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3df96a2a-8bf7-4655-a072-017080d2b398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3df96a2a-8bf7-4655-a072-017080d2b398" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f583307b-7626-437f-8e0d-77545e310370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f583307b-7626-437f-8e0d-77545e310370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f583307b-7626-437f-8e0d-77545e310370_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f583307b-7626-437f-8e0d-77545e310370" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f583307b-7626-437f-8e0d-77545e310370_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_189d08c8-eaef-48f1-b833-d26dc8ae329e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f583307b-7626-437f-8e0d-77545e310370" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_189d08c8-eaef-48f1-b833-d26dc8ae329e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_12ccf3fe-11a9-4768-9bfa-bbe8922a4ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_189d08c8-eaef-48f1-b833-d26dc8ae329e" xlink:to="loc_us-gaap_IPOMember_12ccf3fe-11a9-4768-9bfa-bbe8922a4ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_18eddc1e-9249-4c2b-b0bb-ecfd76651547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_189d08c8-eaef-48f1-b833-d26dc8ae329e" xlink:to="loc_us-gaap_PrivatePlacementMember_18eddc1e-9249-4c2b-b0bb-ecfd76651547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56e66939-dc94-4300-b04d-10e290b5f675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_56e66939-dc94-4300-b04d-10e290b5f675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56e66939-dc94-4300-b04d-10e290b5f675_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56e66939-dc94-4300-b04d-10e290b5f675" xlink:to="loc_us-gaap_EquityComponentDomain_56e66939-dc94-4300-b04d-10e290b5f675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_94d75752-7f10-4fe4-93c9-5663839c4062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56e66939-dc94-4300-b04d-10e290b5f675" xlink:to="loc_us-gaap_EquityComponentDomain_94d75752-7f10-4fe4-93c9-5663839c4062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bd377b4d-a2b5-4555-aee5-356d0efeec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94d75752-7f10-4fe4-93c9-5663839c4062" xlink:to="loc_us-gaap_CommonStockMember_bd377b4d-a2b5-4555-aee5-356d0efeec1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2ab8c093-0924-4f10-abf8-4add2d4acb4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_srt_CounterpartyNameAxis_2ab8c093-0924-4f10-abf8-4add2d4acb4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ab8c093-0924-4f10-abf8-4add2d4acb4a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2ab8c093-0924-4f10-abf8-4add2d4acb4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ab8c093-0924-4f10-abf8-4add2d4acb4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6db6baa-6b9c-4176-b2c8-eb3aa2fd599e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2ab8c093-0924-4f10-abf8-4add2d4acb4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6db6baa-6b9c-4176-b2c8-eb3aa2fd599e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UnderwritersMember_41aaee7f-c867-4015-9915-c151d539bdbf" xlink:href="plrx-20211231.xsd#plrx_UnderwritersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6db6baa-6b9c-4176-b2c8-eb3aa2fd599e" xlink:to="loc_plrx_UnderwritersMember_41aaee7f-c867-4015-9915-c151d539bdbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_13d29649-3b53-4852-91d3-ca65dbb1923f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_srt_OwnershipAxis_13d29649-3b53-4852-91d3-ca65dbb1923f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_13d29649-3b53-4852-91d3-ca65dbb1923f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_13d29649-3b53-4852-91d3-ca65dbb1923f" xlink:to="loc_srt_OwnershipDomain_13d29649-3b53-4852-91d3-ca65dbb1923f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2efa8450-dc3c-4b21-b389-26e6735e8417" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_13d29649-3b53-4852-91d3-ca65dbb1923f" xlink:to="loc_srt_OwnershipDomain_2efa8450-dc3c-4b21-b389-26e6735e8417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PliantTherapeuticsIncMember_36e7c4fc-a3dd-41c1-83ed-26b702ed9d31" xlink:href="plrx-20211231.xsd#plrx_PliantTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2efa8450-dc3c-4b21-b389-26e6735e8417" xlink:to="loc_plrx_PliantTherapeuticsIncMember_36e7c4fc-a3dd-41c1-83ed-26b702ed9d31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1254e746-1290-462a-9fff-d11972e4bdc2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_dei_LegalEntityAxis_1254e746-1290-462a-9fff-d11972e4bdc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1254e746-1290-462a-9fff-d11972e4bdc2_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1254e746-1290-462a-9fff-d11972e4bdc2" xlink:to="loc_dei_EntityDomain_1254e746-1290-462a-9fff-d11972e4bdc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8a62be9-4ab1-44a2-8b16-82a83bb68293" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1254e746-1290-462a-9fff-d11972e4bdc2" xlink:to="loc_dei_EntityDomain_e8a62be9-4ab1-44a2-8b16-82a83bb68293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisMember_49d79acd-5407-48bd-b673-483201b08d57" xlink:href="plrx-20211231.xsd#plrx_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e8a62be9-4ab1-44a2-8b16-82a83bb68293" xlink:to="loc_plrx_NovartisMember_49d79acd-5407-48bd-b673-483201b08d57" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i8789e328a3ab47ffb7d78a88eee47a6f_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:href="plrx-20211231.xsd#plrx_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_5da56f52-994a-45d4-a87b-42b2c4321309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_5da56f52-994a-45d4-a87b-42b2c4321309" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PercentageOfRevenueContributedByRelatedParty_7825fd2e-c333-4e0f-b8c1-3b0d46b7ae45" xlink:href="plrx-20211231.xsd#plrx_PercentageOfRevenueContributedByRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_plrx_PercentageOfRevenueContributedByRelatedParty_7825fd2e-c333-4e0f-b8c1-3b0d46b7ae45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_917c3f9f-54f5-4369-b3cf-202f30bd2e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_NumberOfOperatingSegments_917c3f9f-54f5-4369-b3cf-202f30bd2e21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_27a6160b-51d5-4935-bd4a-0f26f39bb453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_NumberOfReportableSegments_27a6160b-51d5-4935-bd4a-0f26f39bb453" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase_44f45264-a671-425f-a659-14bfc66f7b9f" xlink:href="plrx-20211231.xsd#plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase_44f45264-a671-425f-a659-14bfc66f7b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_42bba2b6-5f08-4a47-a59c-3c7d50559cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_42bba2b6-5f08-4a47-a59c-3c7d50559cdd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9b93bcb2-48ae-4c72-afee-b6ebd4851cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9b93bcb2-48ae-4c72-afee-b6ebd4851cdd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_82241340-d7cd-460c-9d28-4e4e527b5980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_82241340-d7cd-460c-9d28-4e4e527b5980" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_748b77a6-a0c3-480b-a0e2-baad363036cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_OperatingLeaseLiability_748b77a6-a0c3-480b-a0e2-baad363036cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_d631d415-497f-403a-b208-4f3645f451ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_d631d415-497f-403a-b208-4f3645f451ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:href="plrx-20211231.xsd#plrx_AccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_bed2d048-13de-4efa-88cf-d675a134d610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_bed2d048-13de-4efa-88cf-d675a134d610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_bed2d048-13de-4efa-88cf-d675a134d610_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_bed2d048-13de-4efa-88cf-d675a134d610" xlink:to="loc_us-gaap_TypeOfAdoptionMember_bed2d048-13de-4efa-88cf-d675a134d610_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_24991256-8d18-43ec-a23e-d13c26005efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_bed2d048-13de-4efa-88cf-d675a134d610" xlink:to="loc_us-gaap_TypeOfAdoptionMember_24991256-8d18-43ec-a23e-d13c26005efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_e049289a-d69d-4e2a-b7f0-e5794345a6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_24991256-8d18-43ec-a23e-d13c26005efc" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_e049289a-d69d-4e2a-b7f0-e5794345a6f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ab6e54fc-db23-402a-9518-68eb897d52cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ab6e54fc-db23-402a-9518-68eb897d52cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab6e54fc-db23-402a-9518-68eb897d52cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ab6e54fc-db23-402a-9518-68eb897d52cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ab6e54fc-db23-402a-9518-68eb897d52cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e9fa71e-8855-4313-b555-63a26d3fc144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ab6e54fc-db23-402a-9518-68eb897d52cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e9fa71e-8855-4313-b555-63a26d3fc144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementMember_6a8b86ea-51b6-4a48-ac7b-498731ce9102" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e9fa71e-8855-4313-b555-63a26d3fc144" xlink:to="loc_plrx_NovartisAgreementMember_6a8b86ea-51b6-4a48-ac7b-498731ce9102" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended" id="if35fd93cb2004999acee44c3437ed2f8_SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6446ff12-c8a3-45fb-a9e2-a1d69363a5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_56447ec1-851c-43d4-9619-5359b4290088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6446ff12-c8a3-45fb-a9e2-a1d69363a5de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_56447ec1-851c-43d4-9619-5359b4290088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb2be8fc-4dbc-4684-8e15-f9e9c01fa047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6446ff12-c8a3-45fb-a9e2-a1d69363a5de" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb2be8fc-4dbc-4684-8e15-f9e9c01fa047" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb2be8fc-4dbc-4684-8e15-f9e9c01fa047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ddf8970-73ad-47ff-89f7-09645cc60b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ddf8970-73ad-47ff-89f7-09645cc60b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f02ac652-a1da-4bcd-af5f-900bfa5faf72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ddf8970-73ad-47ff-89f7-09645cc60b17" xlink:to="loc_us-gaap_EquipmentMember_f02ac652-a1da-4bcd-af5f-900bfa5faf72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ComputerEquipmentAndSoftwareMember_2bdaa9c2-eec7-4320-9f5f-0f8e7dfc64c5" xlink:href="plrx-20211231.xsd#plrx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ddf8970-73ad-47ff-89f7-09645cc60b17" xlink:to="loc_plrx_ComputerEquipmentAndSoftwareMember_2bdaa9c2-eec7-4320-9f5f-0f8e7dfc64c5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails" xlink:type="extended" id="i79c5910746cd470ea837e5d1c1607d4a_FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3eafd2f4-7584-428a-9d46-d04388ca4a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3eafd2f4-7584-428a-9d46-d04388ca4a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_c50f77d4-bf2d-45cb-ae62-9d8114403127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_c50f77d4-bf2d-45cb-ae62-9d8114403127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_12c89797-e9c1-4e04-a732-911f83329fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_12c89797-e9c1-4e04-a732-911f83329fe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_75d4b10d-d75f-4e11-a738-7c21ee631fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_75d4b10d-d75f-4e11-a738-7c21ee631fd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e549c7af-88da-49d9-af24-4bd76e87bcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e549c7af-88da-49d9-af24-4bd76e87bcd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e549c7af-88da-49d9-af24-4bd76e87bcd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e549c7af-88da-49d9-af24-4bd76e87bcd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e549c7af-88da-49d9-af24-4bd76e87bcd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f8469a2-b658-44c4-9d00-b9917010187f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e549c7af-88da-49d9-af24-4bd76e87bcd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f8469a2-b658-44c4-9d00-b9917010187f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_34ae936a-1be8-41a4-b1dd-391f21f18814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f8469a2-b658-44c4-9d00-b9917010187f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_34ae936a-1be8-41a4-b1dd-391f21f18814" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e68bdba2-b57a-4886-8ceb-09abbedb290b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f8469a2-b658-44c4-9d00-b9917010187f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e68bdba2-b57a-4886-8ceb-09abbedb290b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3efcab56-8111-4903-be8b-2e022f997242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3efcab56-8111-4903-be8b-2e022f997242" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3efcab56-8111-4903-be8b-2e022f997242_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3efcab56-8111-4903-be8b-2e022f997242" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3efcab56-8111-4903-be8b-2e022f997242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3efcab56-8111-4903-be8b-2e022f997242" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5305a226-a434-4c36-b29a-c7d54c2e3512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5305a226-a434-4c36-b29a-c7d54c2e3512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7da54301-13ff-4cd0-8efe-ad0814c45458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7da54301-13ff-4cd0-8efe-ad0814c45458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9229cf88-b682-45cd-b8f3-b4e434ea55c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9229cf88-b682-45cd-b8f3-b4e434ea55c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6766ebb7-990e-4594-b333-ecf9666622a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:to="loc_us-gaap_InvestmentTypeAxis_6766ebb7-990e-4594-b333-ecf9666622a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6766ebb7-990e-4594-b333-ecf9666622a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_6766ebb7-990e-4594-b333-ecf9666622a9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6766ebb7-990e-4594-b333-ecf9666622a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e041ca76-4742-45f8-9c4a-306e26c42b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_6766ebb7-990e-4594-b333-ecf9666622a9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e041ca76-4742-45f8-9c4a-306e26c42b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_82a10e0c-1959-4bb9-982e-03334d21aa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e041ca76-4742-45f8-9c4a-306e26c42b81" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_82a10e0c-1959-4bb9-982e-03334d21aa1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails" xlink:type="extended" id="if097075e452b4a0e8feb63ef27803ddc_FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d3c6100d-7339-4637-84b5-532d69cb25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_36dd176d-f9c5-4996-8012-03954981f4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d3c6100d-7339-4637-84b5-532d69cb25bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_36dd176d-f9c5-4996-8012-03954981f4e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2de7b15-4f41-487c-a65b-8f9af58760ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d3c6100d-7339-4637-84b5-532d69cb25bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2de7b15-4f41-487c-a65b-8f9af58760ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d3c6100d-7339-4637-84b5-532d69cb25bc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:to="loc_us-gaap_InvestmentTypeAxis_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3f8938bb-6ee3-4af7-8c3a-126454370d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3f8938bb-6ee3-4af7-8c3a-126454370d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_d56a21b9-7d1a-47b8-bbdb-ce54d312503b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3f8938bb-6ee3-4af7-8c3a-126454370d89" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_d56a21b9-7d1a-47b8-bbdb-ce54d312503b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_5d43777c-b05e-4fe3-ab36-a96e395faef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_5d43777c-b05e-4fe3-ab36-a96e395faef0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_5d43777c-b05e-4fe3-ab36-a96e395faef0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_5d43777c-b05e-4fe3-ab36-a96e395faef0" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_5d43777c-b05e-4fe3-ab36-a96e395faef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_31130fa2-c203-4706-b099-c2f65580becc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_5d43777c-b05e-4fe3-ab36-a96e395faef0" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_31130fa2-c203-4706-b099-c2f65580becc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MatureInOneYearOrLessMember_178202bd-beff-4dbb-87fd-861d769fe5d5" xlink:href="plrx-20211231.xsd#plrx_MatureInOneYearOrLessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_31130fa2-c203-4706-b099-c2f65580becc" xlink:to="loc_plrx_MatureInOneYearOrLessMember_178202bd-beff-4dbb-87fd-861d769fe5d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MatureInOneToTwoYearsMember_535d868d-9a1a-4b1d-bd37-138853e62e6b" xlink:href="plrx-20211231.xsd#plrx_MatureInOneToTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_31130fa2-c203-4706-b099-c2f65580becc" xlink:to="loc_plrx_MatureInOneToTwoYearsMember_535d868d-9a1a-4b1d-bd37-138853e62e6b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i9ff41a80b1c145c783ea88e7e132628b_FinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0175b69-4ecd-4b66-83f5-d894f1ab1e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_012aa7e7-2d46-4137-a105-416bc1b0c7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0175b69-4ecd-4b66-83f5-d894f1ab1e98" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_012aa7e7-2d46-4137-a105-416bc1b0c7e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_bb54a168-264a-41c9-9db7-3c0f350e89c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0175b69-4ecd-4b66-83f5-d894f1ab1e98" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_bb54a168-264a-41c9-9db7-3c0f350e89c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2e473d9e-bebf-423d-a55a-10b1fcda7bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0175b69-4ecd-4b66-83f5-d894f1ab1e98" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2e473d9e-bebf-423d-a55a-10b1fcda7bd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2e473d9e-bebf-423d-a55a-10b1fcda7bd3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_98ba8f07-6901-447f-9d60-a23eb9d64e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_98ba8f07-6901-447f-9d60-a23eb9d64e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a6a45c93-51b1-4a32-b5e5-957cdad25a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_98ba8f07-6901-447f-9d60-a23eb9d64e13" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a6a45c93-51b1-4a32-b5e5-957cdad25a63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_f3a1a02f-1c2a-47e4-a47b-31f5073808a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_98ba8f07-6901-447f-9d60-a23eb9d64e13" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_f3a1a02f-1c2a-47e4-a47b-31f5073808a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="i559ce38d3e48466e92346b27d667275d_PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2283667d-5c6c-46d8-9ca0-0f2321903e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2283667d-5c6c-46d8-9ca0-0f2321903e89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7596c86d-ee79-47ac-a4d0-371e08770a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7596c86d-ee79-47ac-a4d0-371e08770a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1b9510f9-dd90-4ea3-bd8e-efda9f337b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1b9510f9-dd90-4ea3-bd8e-efda9f337b3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ed8e4128-6a48-4add-9450-c1b69eaba0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ed8e4128-6a48-4add-9450-c1b69eaba0be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f76e90-51a3-4424-91bb-878d8f5c9509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ed8e4128-6a48-4add-9450-c1b69eaba0be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f76e90-51a3-4424-91bb-878d8f5c9509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_25f76e90-51a3-4424-91bb-878d8f5c9509_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f76e90-51a3-4424-91bb-878d8f5c9509" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_25f76e90-51a3-4424-91bb-878d8f5c9509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f76e90-51a3-4424-91bb-878d8f5c9509" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_0d6372f1-cd0a-4d04-8c19-f98de0ae7422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:to="loc_us-gaap_EquipmentMember_0d6372f1-cd0a-4d04-8c19-f98de0ae7422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_67c54a41-9219-4788-8a12-e56dc92463a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_67c54a41-9219-4788-8a12-e56dc92463a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a41d8528-9777-4608-939e-df794ff18e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:to="loc_us-gaap_ConstructionInProgressMember_a41d8528-9777-4608-939e-df794ff18e77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ComputerEquipmentAndSoftwareMember_18fbe9cb-047e-430f-8670-9e32ae38abd2" xlink:href="plrx-20211231.xsd#plrx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:to="loc_plrx_ComputerEquipmentAndSoftwareMember_18fbe9cb-047e-430f-8670-9e32ae38abd2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails" xlink:type="extended" id="i002f2df528344be1b9fc43213d39972b_NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NumberOfIntegrinResearchTargets_1e276c49-d2d7-4a0d-89dc-0f94c06f1080" xlink:href="plrx-20211231.xsd#plrx_NumberOfIntegrinResearchTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_plrx_NumberOfIntegrinResearchTargets_1e276c49-d2d7-4a0d-89dc-0f94c06f1080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ProceedsFromUpfrontNonRefundableLicenseFee_98b0fb4b-716e-40cb-b53d-2eefc41ae66d" xlink:href="plrx-20211231.xsd#plrx_ProceedsFromUpfrontNonRefundableLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_plrx_ProceedsFromUpfrontNonRefundableLicenseFee_98b0fb4b-716e-40cb-b53d-2eefc41ae66d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount_f2168ef8-69a3-44bd-8366-183df605be6a" xlink:href="plrx-20211231.xsd#plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount_f2168ef8-69a3-44bd-8366-183df605be6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1277df23-03d6-49be-bf72-f2274a6b987d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1277df23-03d6-49be-bf72-f2274a6b987d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_4912d975-ccd5-4c5f-a062-455761eddcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_RevenueFromRelatedParties_4912d975-ccd5-4c5f-a062-455761eddcf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_51e4e40f-1f73-4c90-82b9-6140e828f187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_51e4e40f-1f73-4c90-82b9-6140e828f187" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_983956d3-e7e7-4544-8712-bde7a736bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_983956d3-e7e7-4544-8712-bde7a736bd7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_307e31a2-6bad-486d-bc30-77c829745352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_307e31a2-6bad-486d-bc30-77c829745352" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ce48235c-6de7-4156-b7ef-f128d6ee0503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ce48235c-6de7-4156-b7ef-f128d6ee0503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce48235c-6de7-4156-b7ef-f128d6ee0503_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce48235c-6de7-4156-b7ef-f128d6ee0503" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce48235c-6de7-4156-b7ef-f128d6ee0503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce48235c-6de7-4156-b7ef-f128d6ee0503" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementMember_c96051ad-0779-415b-9e6d-721edf48a31d" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:to="loc_plrx_NovartisAgreementMember_c96051ad-0779-415b-9e6d-721edf48a31d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementRDForPLN1474Member_a58d20b2-d315-4bfe-a34f-8aad5044383f" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementRDForPLN1474Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:to="loc_plrx_NovartisAgreementRDForPLN1474Member_a58d20b2-d315-4bfe-a34f-8aad5044383f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember_82b9b5bb-087d-4052-bbb9-60be72fa18aa" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementRDForIntegrinResearchTargetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:to="loc_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember_82b9b5bb-087d-4052-bbb9-60be72fa18aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_785aa916-88e4-44b9-b591-5ec296cc3bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_785aa916-88e4-44b9-b591-5ec296cc3bba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_785aa916-88e4-44b9-b591-5ec296cc3bba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_785aa916-88e4-44b9-b591-5ec296cc3bba" xlink:to="loc_us-gaap_RelatedPartyDomain_785aa916-88e4-44b9-b591-5ec296cc3bba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a9db8a5a-6961-448b-90ab-133fd5ed1464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_785aa916-88e4-44b9-b591-5ec296cc3bba" xlink:to="loc_us-gaap_RelatedPartyDomain_a9db8a5a-6961-448b-90ab-133fd5ed1464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisMember_faa39aac-e892-4d06-8244-985420ba8317" xlink:href="plrx-20211231.xsd#plrx_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a9db8a5a-6961-448b-90ab-133fd5ed1464" xlink:to="loc_plrx_NovartisMember_faa39aac-e892-4d06-8244-985420ba8317" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_srt_RangeAxis_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc" xlink:to="loc_srt_RangeMember_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2591859a-5bd3-4fb9-b2bf-392565505b66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc" xlink:to="loc_srt_RangeMember_2591859a-5bd3-4fb9-b2bf-392565505b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6d9d61f1-8604-46c9-977e-f3d6cab0b682" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2591859a-5bd3-4fb9-b2bf-392565505b66" xlink:to="loc_srt_MaximumMember_6d9d61f1-8604-46c9-977e-f3d6cab0b682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0a82b2a3-c96e-43e6-8a5e-9f1fb5e5f905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0a82b2a3-c96e-43e6-8a5e-9f1fb5e5f905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e6b7973-4896-454c-8e44-46c512cc87a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a82b2a3-c96e-43e6-8a5e-9f1fb5e5f905" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e6b7973-4896-454c-8e44-46c512cc87a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseFeeMember_f455e8fd-6801-4bfd-a4ca-683a136d0022" xlink:href="plrx-20211231.xsd#plrx_LicenseFeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a82b2a3-c96e-43e6-8a5e-9f1fb5e5f905" xlink:to="loc_plrx_LicenseFeeMember_f455e8fd-6801-4bfd-a4ca-683a136d0022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_39e26c01-309d-4e0e-b01f-af2e5edb1c02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_srt_ProductOrServiceAxis_39e26c01-309d-4e0e-b01f-af2e5edb1c02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_39e26c01-309d-4e0e-b01f-af2e5edb1c02_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_39e26c01-309d-4e0e-b01f-af2e5edb1c02" xlink:to="loc_srt_ProductsAndServicesDomain_39e26c01-309d-4e0e-b01f-af2e5edb1c02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b6ff19fe-d564-44b8-922c-e817534761cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_39e26c01-309d-4e0e-b01f-af2e5edb1c02" xlink:to="loc_srt_ProductsAndServicesDomain_b6ff19fe-d564-44b8-922c-e817534761cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AchievementOfFirstPatientDosingMilestoneMember_e4fe580e-4d28-466b-9ddd-664921b00cc8" xlink:href="plrx-20211231.xsd#plrx_AchievementOfFirstPatientDosingMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b6ff19fe-d564-44b8-922c-e817534761cd" xlink:to="loc_plrx_AchievementOfFirstPatientDosingMilestoneMember_e4fe580e-4d28-466b-9ddd-664921b00cc8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails" xlink:type="extended" id="ifb4b5d5d615f4947878631f736371a02_RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsLineItems_d58b336c-2355-4380-9673-66a5f08e7936" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MilestoneAndAnnualRoyaltyPaid_af36a3e3-4653-4bf5-8df5-5962a0a54793" xlink:href="plrx-20211231.xsd#plrx_MilestoneAndAnnualRoyaltyPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plrx_LicenseAgreementsLineItems_d58b336c-2355-4380-9673-66a5f08e7936" xlink:to="loc_plrx_MilestoneAndAnnualRoyaltyPaid_af36a3e3-4653-4bf5-8df5-5962a0a54793" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plrx_LicenseAgreementsLineItems_d58b336c-2355-4380-9673-66a5f08e7936" xlink:to="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_01d2686f-ab06-4966-90ce-6787a5908742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_01d2686f-ab06-4966-90ce-6787a5908742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01d2686f-ab06-4966-90ce-6787a5908742_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_01d2686f-ab06-4966-90ce-6787a5908742" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_01d2686f-ab06-4966-90ce-6787a5908742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6cf7d2db-c4ca-4917-aba5-950ac3d613c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_01d2686f-ab06-4966-90ce-6787a5908742" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6cf7d2db-c4ca-4917-aba5-950ac3d613c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_7cce4e22-548f-4fdf-9275-167d20043aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6cf7d2db-c4ca-4917-aba5-950ac3d613c9" xlink:to="loc_us-gaap_LicensingAgreementsMember_7cce4e22-548f-4fdf-9275-167d20043aca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd0f2138-eecc-4f8a-bb15-c1ec66734285" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:to="loc_srt_ProductOrServiceAxis_bd0f2138-eecc-4f8a-bb15-c1ec66734285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bd0f2138-eecc-4f8a-bb15-c1ec66734285_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bd0f2138-eecc-4f8a-bb15-c1ec66734285" xlink:to="loc_srt_ProductsAndServicesDomain_bd0f2138-eecc-4f8a-bb15-c1ec66734285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88f742b1-8d2e-4b47-9d1a-f1a930725862" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bd0f2138-eecc-4f8a-bb15-c1ec66734285" xlink:to="loc_srt_ProductsAndServicesDomain_88f742b1-8d2e-4b47-9d1a-f1a930725862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UCRegentsMember_a080de4c-61b3-4e08-94a7-8406a4598049" xlink:href="plrx-20211231.xsd#plrx_UCRegentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_88f742b1-8d2e-4b47-9d1a-f1a930725862" xlink:to="loc_plrx_UCRegentsMember_a080de4c-61b3-4e08-94a7-8406a4598049" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails" xlink:type="extended" id="i81c60a7fc32a46bf813640ff541cbbea_AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ffb4f1a-9c99-4909-8d66-a6db8596524a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7fb48263-21d3-4246-ac6f-e39b0c126921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ffb4f1a-9c99-4909-8d66-a6db8596524a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7fb48263-21d3-4246-ac6f-e39b0c126921" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ffb4f1a-9c99-4909-8d66-a6db8596524a" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_719269f5-3c29-4f33-9f6a-f88479ea7f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_719269f5-3c29-4f33-9f6a-f88479ea7f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_719269f5-3c29-4f33-9f6a-f88479ea7f75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_719269f5-3c29-4f33-9f6a-f88479ea7f75" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_719269f5-3c29-4f33-9f6a-f88479ea7f75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_c459bac3-e97e-443b-bca6-f8fd37a059a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_719269f5-3c29-4f33-9f6a-f88479ea7f75" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_c459bac3-e97e-443b-bca6-f8fd37a059a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_FullTimeEmployeeCostMember_9eb73d65-c8fa-438e-8c06-6f6493205862" xlink:href="plrx-20211231.xsd#plrx_FullTimeEmployeeCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_c459bac3-e97e-443b-bca6-f8fd37a059a5" xlink:to="loc_plrx_FullTimeEmployeeCostMember_9eb73d65-c8fa-438e-8c06-6f6493205862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_40b6b6b1-123d-40d6-af72-ea548d8d0a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_40b6b6b1-123d-40d6-af72-ea548d8d0a67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40b6b6b1-123d-40d6-af72-ea548d8d0a67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_40b6b6b1-123d-40d6-af72-ea548d8d0a67" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40b6b6b1-123d-40d6-af72-ea548d8d0a67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f38b826d-b429-4fd2-9bce-36e5c5487beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_40b6b6b1-123d-40d6-af72-ea548d8d0a67" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f38b826d-b429-4fd2-9bce-36e5c5487beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AdimabAgreementMember_016e26a0-dfd2-449f-993d-e665d36e9b98" xlink:href="plrx-20211231.xsd#plrx_AdimabAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f38b826d-b429-4fd2-9bce-36e5c5487beb" xlink:to="loc_plrx_AdimabAgreementMember_016e26a0-dfd2-449f-993d-e665d36e9b98" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#RedeemableConvertiblePreferredStockAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="extended" id="ib1eeded92ed94a329799bee8a4b2d3f7_RedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_5ec7fec3-defc-4821-a7e5-4877b2374a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7573d7cf-7cf1-49df-8881-f2c0cad4441e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_5ec7fec3-defc-4821-a7e5-4877b2374a8f" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7573d7cf-7cf1-49df-8881-f2c0cad4441e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_7d7aa398-1093-4ed8-a8cc-87c62b177610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_5ec7fec3-defc-4821-a7e5-4877b2374a8f" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_7d7aa398-1093-4ed8-a8cc-87c62b177610" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b266464f-8171-4687-a24c-8640683f9cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_7d7aa398-1093-4ed8-a8cc-87c62b177610" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b266464f-8171-4687-a24c-8640683f9cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b266464f-8171-4687-a24c-8640683f9cb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b266464f-8171-4687-a24c-8640683f9cb8" xlink:to="loc_us-gaap_ClassOfStockDomain_b266464f-8171-4687-a24c-8640683f9cb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6433a8a3-d98f-496f-9c07-f32666a0582c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b266464f-8171-4687-a24c-8640683f9cb8" xlink:to="loc_us-gaap_ClassOfStockDomain_6433a8a3-d98f-496f-9c07-f32666a0582c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_4f89f244-b015-4119-aa49-ee7483cd6db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6433a8a3-d98f-496f-9c07-f32666a0582c" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_4f89f244-b015-4119-aa49-ee7483cd6db0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#CommonStockScheduleofSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails" xlink:type="extended" id="ic7b8aaeacf1542c8b6b0c3847b83c023_CommonStockScheduleofSharesReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_32bd6c49-e181-43c7-a897-d433beec6dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60381ac4-b8cd-4ecf-abf9-0034d2fcb0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_32bd6c49-e181-43c7-a897-d433beec6dcc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60381ac4-b8cd-4ecf-abf9-0034d2fcb0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_32bd6c49-e181-43c7-a897-d433beec6dcc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c5126dd9-0782-4330-84f0-3bdab7a89f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:to="loc_us-gaap_AwardTypeAxis_c5126dd9-0782-4330-84f0-3bdab7a89f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5126dd9-0782-4330-84f0-3bdab7a89f83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c5126dd9-0782-4330-84f0-3bdab7a89f83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5126dd9-0782-4330-84f0-3bdab7a89f83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f217149-885a-4cfb-b210-ce2759af8836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c5126dd9-0782-4330-84f0-3bdab7a89f83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f217149-885a-4cfb-b210-ce2759af8836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_45faba43-b36c-4151-a3cd-dddf983d990d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f217149-885a-4cfb-b210-ce2759af8836" xlink:to="loc_us-gaap_EmployeeStockOptionMember_45faba43-b36c-4151-a3cd-dddf983d990d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7380bd69-7599-4520-81b6-763cd1de3338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:to="loc_us-gaap_PlanNameAxis_7380bd69-7599-4520-81b6-763cd1de3338" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7380bd69-7599-4520-81b6-763cd1de3338_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7380bd69-7599-4520-81b6-763cd1de3338" xlink:to="loc_us-gaap_PlanNameDomain_7380bd69-7599-4520-81b6-763cd1de3338_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c58d61ef-08d4-4cb4-b801-ea788d92fc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7380bd69-7599-4520-81b6-763cd1de3338" xlink:to="loc_us-gaap_PlanNameDomain_c58d61ef-08d4-4cb4-b801-ea788d92fc5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember_ffe8a30f-2507-4c1d-9750-23fbdfecbf2c" xlink:href="plrx-20211231.xsd#plrx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c58d61ef-08d4-4cb4-b801-ea788d92fc5e" xlink:to="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember_ffe8a30f-2507-4c1d-9750-23fbdfecbf2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_cb4f9f6d-367a-4fef-98a7-70fbd1f34ac5" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c58d61ef-08d4-4cb4-b801-ea788d92fc5e" xlink:to="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_cb4f9f6d-367a-4fef-98a7-70fbd1f34ac5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i3572aaf805684b399ba55197c5e6f3b1_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a2a305a2-f2b3-4bac-8dbb-dd3f75fa01ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a2a305a2-f2b3-4bac-8dbb-dd3f75fa01ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63ae3e14-2bc5-462f-aec2-6f044590e2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63ae3e14-2bc5-462f-aec2-6f044590e2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods_964f3ffb-fad0-4fc4-8a63-355d0bcfc629" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods_964f3ffb-fad0-4fc4-8a63-355d0bcfc629" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders_f06758d4-d261-48f5-a940-6855fa45be14" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders_f06758d4-d261-48f5-a940-6855fa45be14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bad2d9d7-c9b3-4c63-804b-67e088f4b322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bad2d9d7-c9b3-4c63-804b-67e088f4b322" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9221158f-b3aa-4d3b-aa18-dc3e1a411bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9221158f-b3aa-4d3b-aa18-dc3e1a411bbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_3713764e-d979-4863-8a39-e96b3d642330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_3713764e-d979-4863-8a39-e96b3d642330" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_147b3dea-9b6b-4dd1-9d62-91d327ebc7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_147b3dea-9b6b-4dd1-9d62-91d327ebc7c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_f0638c6c-3dec-4fb6-91db-d8d390f84e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_f0638c6c-3dec-4fb6-91db-d8d390f84e73" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d0f1fed5-cfa6-42d8-9034-dafdd1c7af53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d0f1fed5-cfa6-42d8-9034-dafdd1c7af53" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8feb47d0-f2dd-4382-95a6-e2671178eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8feb47d0-f2dd-4382-95a6-e2671178eae6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5afaba1d-060c-4e27-9226-33f6f1bc994f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5afaba1d-060c-4e27-9226-33f6f1bc994f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_49881ecf-b50a-45d2-bbd1-cf29fd441a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_49881ecf-b50a-45d2-bbd1-cf29fd441a9f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eb674acb-5fe2-4781-a323-2315f6a84be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eb674acb-5fe2-4781-a323-2315f6a84be9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b2d917a1-7056-4712-93e0-c085ee93a356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_us-gaap_PlanNameAxis_b2d917a1-7056-4712-93e0-c085ee93a356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b2d917a1-7056-4712-93e0-c085ee93a356_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b2d917a1-7056-4712-93e0-c085ee93a356" xlink:to="loc_us-gaap_PlanNameDomain_b2d917a1-7056-4712-93e0-c085ee93a356_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b2d917a1-7056-4712-93e0-c085ee93a356" xlink:to="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember_e04fd3b2-09a0-4c54-8c03-5817c0a66c19" xlink:href="plrx-20211231.xsd#plrx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:to="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember_e04fd3b2-09a0-4c54-8c03-5817c0a66c19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedCommonStockAwardsMember_73e8a30b-9de3-4065-ab31-e595abbb8b2a" xlink:href="plrx-20211231.xsd#plrx_RestrictedCommonStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:to="loc_plrx_RestrictedCommonStockAwardsMember_73e8a30b-9de3-4065-ab31-e595abbb8b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_2b07c4f2-6df0-4995-9c78-cf20ce4edd98" xlink:href="plrx-20211231.xsd#plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:to="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_2b07c4f2-6df0-4995-9c78-cf20ce4edd98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_srt_RangeAxis_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e" xlink:to="loc_srt_RangeMember_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6015452d-53f6-4677-bd4a-2d7f3c4e0f76" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e" xlink:to="loc_srt_RangeMember_6015452d-53f6-4677-bd4a-2d7f3c4e0f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1df1d71e-6364-4b5b-96c6-69c2b6612cff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6015452d-53f6-4677-bd4a-2d7f3c4e0f76" xlink:to="loc_srt_MaximumMember_1df1d71e-6364-4b5b-96c6-69c2b6612cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_306ce66a-656b-4299-9f46-6911eac93a14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6015452d-53f6-4677-bd4a-2d7f3c4e0f76" xlink:to="loc_srt_MinimumMember_306ce66a-656b-4299-9f46-6911eac93a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c57f326-cb73-40fb-807d-b5e4d3aee722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c57f326-cb73-40fb-807d-b5e4d3aee722" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6c57f326-cb73-40fb-807d-b5e4d3aee722_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c57f326-cb73-40fb-807d-b5e4d3aee722" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6c57f326-cb73-40fb-807d-b5e4d3aee722_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cc4b0abc-b759-4ccf-9ada-a5825944a0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c57f326-cb73-40fb-807d-b5e4d3aee722" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cc4b0abc-b759-4ccf-9ada-a5825944a0f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccruedExpensesAndOtherLiabilitiesMember_ae274914-1357-49b3-834d-a8c34631da12" xlink:href="plrx-20211231.xsd#plrx_AccruedExpensesAndOtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cc4b0abc-b759-4ccf-9ada-a5825944a0f0" xlink:to="loc_plrx_AccruedExpensesAndOtherLiabilitiesMember_ae274914-1357-49b3-834d-a8c34631da12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_52ef8111-b8b5-4cf1-85c7-25f143712442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_us-gaap_AwardTypeAxis_52ef8111-b8b5-4cf1-85c7-25f143712442" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52ef8111-b8b5-4cf1-85c7-25f143712442_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_52ef8111-b8b5-4cf1-85c7-25f143712442" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52ef8111-b8b5-4cf1-85c7-25f143712442_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_52ef8111-b8b5-4cf1-85c7-25f143712442" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_36a6c34a-a2aa-4562-a0ae-622fc0daeae0" xlink:href="plrx-20211231.xsd#plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:to="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_36a6c34a-a2aa-4562-a0ae-622fc0daeae0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedStockAwardsMember_8088fb6a-1aac-40e4-a522-b9966aa9c0e8" xlink:href="plrx-20211231.xsd#plrx_RestrictedStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:to="loc_plrx_RestrictedStockAwardsMember_8088fb6a-1aac-40e4-a522-b9966aa9c0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a2f90cd7-da18-4c82-bd0d-25fed200ccd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a2f90cd7-da18-4c82-bd0d-25fed200ccd8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="idaa806e6de994a8aa81289a6dfd72c3b_StockBasedCompensationSummaryofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39f573c9-afb3-459c-a946-debb16650bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39f573c9-afb3-459c-a946-debb16650bfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31d652b4-dcb1-4471-8398-7aab3a498aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31d652b4-dcb1-4471-8398-7aab3a498aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_04e4d234-84ed-4bee-acc9-f565aa405237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_04e4d234-84ed-4bee-acc9-f565aa405237" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod_a5c00f37-1187-4a19-a341-eee974f6f11d" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod_a5c00f37-1187-4a19-a341-eee974f6f11d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cd1702c0-ffdd-4fe0-ba7d-1fdf2fdb6b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f166f3f-ba33-493c-92c3-add2a70e8a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f166f3f-ba33-493c-92c3-add2a70e8a7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_faf5d4dd-aacc-4ac9-b99e-20aecbf2457b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_faf5d4dd-aacc-4ac9-b99e-20aecbf2457b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_36c0f19b-e1e1-4815-925a-900ebca124b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_36c0f19b-e1e1-4815-925a-900ebca124b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue_80151e5c-c565-489a-aefb-5ec85596d052" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue_80151e5c-c565-489a-aefb-5ec85596d052" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6cfbdc37-fdf3-499e-9ef7-849bc1510235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f1bab86-c3fe-4a36-8ed7-f2e3912d4da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f1bab86-c3fe-4a36-8ed7-f2e3912d4da4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2f32049c-92d4-482f-b423-d9b497f6ce48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f1bab86-c3fe-4a36-8ed7-f2e3912d4da4" xlink:to="loc_us-gaap_PlanNameAxis_2f32049c-92d4-482f-b423-d9b497f6ce48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2f32049c-92d4-482f-b423-d9b497f6ce48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2f32049c-92d4-482f-b423-d9b497f6ce48" xlink:to="loc_us-gaap_PlanNameDomain_2f32049c-92d4-482f-b423-d9b497f6ce48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3a629f38-a06f-4240-b7d6-8ac602ac5c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2f32049c-92d4-482f-b423-d9b497f6ce48" xlink:to="loc_us-gaap_PlanNameDomain_3a629f38-a06f-4240-b7d6-8ac602ac5c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedCommonStockAwardsMember_1ab87a5e-ce65-4205-a292-f0a17926c44f" xlink:href="plrx-20211231.xsd#plrx_RestrictedCommonStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3a629f38-a06f-4240-b7d6-8ac602ac5c1c" xlink:to="loc_plrx_RestrictedCommonStockAwardsMember_1ab87a5e-ce65-4205-a292-f0a17926c44f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails" xlink:type="extended" id="if90fb3d7c0cd4c6bb9edb0d6ddd99eb7_StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9c609348-90c0-4c06-846c-493eb9dc12e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9c609348-90c0-4c06-846c-493eb9dc12e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0d4202f7-9e34-4911-adca-fe722cab9bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0d4202f7-9e34-4911-adca-fe722cab9bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e9bbb331-2130-4abd-a44d-dea7e2e7abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e9bbb331-2130-4abd-a44d-dea7e2e7abd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d9ddac86-cf5c-43f5-b6cf-8b8972a5046b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d9ddac86-cf5c-43f5-b6cf-8b8972a5046b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_82514061-6093-4849-8d21-67a090666dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_82514061-6093-4849-8d21-67a090666dcb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1e37824-b85b-4bff-a34b-0cdcb5eefcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1e37824-b85b-4bff-a34b-0cdcb5eefcb7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UnderlyingCommonStockFairValue_aefb884c-b31b-4510-b31d-9ff78363c02c" xlink:href="plrx-20211231.xsd#plrx_UnderlyingCommonStockFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_plrx_UnderlyingCommonStockFairValue_aefb884c-b31b-4510-b31d-9ff78363c02c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:to="loc_us-gaap_AwardTypeAxis_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce5c9a50-5e13-4c75-9135-e112fefba982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce5c9a50-5e13-4c75-9135-e112fefba982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_ee11ef15-c39d-4fa4-a3b3-6dd3197b9944" xlink:href="plrx-20211231.xsd#plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce5c9a50-5e13-4c75-9135-e112fefba982" xlink:to="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_ee11ef15-c39d-4fa4-a3b3-6dd3197b9944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_9e00cb26-71b3-40e1-8830-aef460f8ea86" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce5c9a50-5e13-4c75-9135-e112fefba982" xlink:to="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_9e00cb26-71b3-40e1-8830-aef460f8ea86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:to="loc_srt_RangeAxis_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8" xlink:to="loc_srt_RangeMember_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c846fdb9-73c5-4ca7-88e1-b1db9451c34e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8" xlink:to="loc_srt_RangeMember_c846fdb9-73c5-4ca7-88e1-b1db9451c34e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff120b46-b9d2-4a74-977d-1450f475e79f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c846fdb9-73c5-4ca7-88e1-b1db9451c34e" xlink:to="loc_srt_MinimumMember_ff120b46-b9d2-4a74-977d-1450f475e79f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce483d4a-9eef-48e8-afbf-5f4697ca5aca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c846fdb9-73c5-4ca7-88e1-b1db9451c34e" xlink:to="loc_srt_MaximumMember_ce483d4a-9eef-48e8-afbf-5f4697ca5aca" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails" xlink:type="extended" id="id040d7a13bb2403f80770ad4b4037eb1_StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d472d2e-afb1-4c75-866d-09e35bc66877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d472d2e-afb1-4c75-866d-09e35bc66877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96e7eaed-80a2-48f9-a358-389c64b9ac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96e7eaed-80a2-48f9-a358-389c64b9ac3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d8b8b55-b863-429c-99a4-f4b731c87052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d8b8b55-b863-429c-99a4-f4b731c87052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_426f459b-2a98-4e86-b2ab-cbeebbf543dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_426f459b-2a98-4e86-b2ab-cbeebbf543dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc6b7d23-cae4-4d8e-9650-098679ba8637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_be3f086e-c5d7-46c0-b58f-50cfe721ce4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_be3f086e-c5d7-46c0-b58f-50cfe721ce4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e139db35-f7b7-4502-a66e-734d1553f5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e139db35-f7b7-4502-a66e-734d1553f5e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_07827de6-2944-4f2f-94aa-671976635e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_07827de6-2944-4f2f-94aa-671976635e3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8adf0c65-3c73-4d5d-a46e-5d881d10158c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8adf0c65-3c73-4d5d-a46e-5d881d10158c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4b6e0f71-29d3-441c-8269-8ee8b896af66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4b6e0f71-29d3-441c-8269-8ee8b896af66" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f44d9caf-544c-4fca-87d4-011d3a2cdda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f44d9caf-544c-4fca-87d4-011d3a2cdda8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2fd87be0-31fe-44bf-9592-1132df25d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17e8615d-705c-4282-9282-e5fbbeddc2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17e8615d-705c-4282-9282-e5fbbeddc2cb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9e387ce7-a4d1-4ec6-94e0-356eb22d79c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9e387ce7-a4d1-4ec6-94e0-356eb22d79c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d24dc97e-0ee3-4c60-88f5-b85e983458d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d24dc97e-0ee3-4c60-88f5-b85e983458d8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9c9251e6-4c21-4f42-af97-a0db9a2c4d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9c9251e6-4c21-4f42-af97-a0db9a2c4d4f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8252dcc8-c543-4eec-a32a-d34f287dec96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8252dcc8-c543-4eec-a32a-d34f287dec96" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_566a3821-9fc7-4b77-a376-00e51b4d4ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_566a3821-9fc7-4b77-a376-00e51b4d4ed8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f0071503-2d7d-4aca-8b83-849ab9ca547a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f0071503-2d7d-4aca-8b83-849ab9ca547a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_449b0df2-8c2a-4c12-9f13-3eb8d360953e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_449b0df2-8c2a-4c12-9f13-3eb8d360953e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7a8694b8-8b61-4884-9f2d-72ee1361dfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:to="loc_us-gaap_PlanNameAxis_7a8694b8-8b61-4884-9f2d-72ee1361dfa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7a8694b8-8b61-4884-9f2d-72ee1361dfa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7a8694b8-8b61-4884-9f2d-72ee1361dfa5" xlink:to="loc_us-gaap_PlanNameDomain_7a8694b8-8b61-4884-9f2d-72ee1361dfa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d116b46b-597e-4cb0-b2d4-8f01c6b7d1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7a8694b8-8b61-4884-9f2d-72ee1361dfa5" xlink:to="loc_us-gaap_PlanNameDomain_d116b46b-597e-4cb0-b2d4-8f01c6b7d1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_a23b9b59-fcf1-4219-bd1d-13fde3807a38" xlink:href="plrx-20211231.xsd#plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d116b46b-597e-4cb0-b2d4-8f01c6b7d1f8" xlink:to="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_a23b9b59-fcf1-4219-bd1d-13fde3807a38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:to="loc_us-gaap_AwardTypeAxis_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a23aaf17-e519-4280-bbef-f5cddd7257cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a23aaf17-e519-4280-bbef-f5cddd7257cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_4c3a57e9-a249-4f10-9c19-f15c0f1a1625" xlink:href="plrx-20211231.xsd#plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a23aaf17-e519-4280-bbef-f5cddd7257cf" xlink:to="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_4c3a57e9-a249-4f10-9c19-f15c0f1a1625" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails" xlink:type="extended" id="ia77fd56ba02644c68a3cf0b6ef771628_StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6810eb7d-5489-4f4d-a609-4d386dab3398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6810eb7d-5489-4f4d-a609-4d386dab3398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_84ba75e7-08a4-46d3-a636-e8808d861844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_84ba75e7-08a4-46d3-a636-e8808d861844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_ce5d510e-d17c-4e38-8918-ac4ee3bae87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_ce5d510e-d17c-4e38-8918-ac4ee3bae87b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8910fb81-185f-4407-8a73-9fb86bf20308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8910fb81-185f-4407-8a73-9fb86bf20308" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_EmployeeStockPurchasePlanOfferingPeriod_6ae39765-ae48-457e-b18a-b95866647e38" xlink:href="plrx-20211231.xsd#plrx_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_plrx_EmployeeStockPurchasePlanOfferingPeriod_6ae39765-ae48-457e-b18a-b95866647e38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_CommonStockFairMarketValuePercentage_58b63aac-297d-46d4-b7b6-8465cca7b69e" xlink:href="plrx-20211231.xsd#plrx_CommonStockFairMarketValuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_plrx_CommonStockFairMarketValuePercentage_58b63aac-297d-46d4-b7b6-8465cca7b69e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_34cf7edd-5116-4f50-8637-1aa8e3c0800c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_34cf7edd-5116-4f50-8637-1aa8e3c0800c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f971be40-081f-4058-b9b7-3a544307c748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f971be40-081f-4058-b9b7-3a544307c748" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d65d3692-ec40-4f6a-bd7d-979bb0a41806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d65d3692-ec40-4f6a-bd7d-979bb0a41806" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_656891af-7972-4cc6-a348-65a6cca528e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d65d3692-ec40-4f6a-bd7d-979bb0a41806" xlink:to="loc_us-gaap_AwardTypeAxis_656891af-7972-4cc6-a348-65a6cca528e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_656891af-7972-4cc6-a348-65a6cca528e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_656891af-7972-4cc6-a348-65a6cca528e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_656891af-7972-4cc6-a348-65a6cca528e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e57eb61-3b64-4f1a-bdd3-d72af88225c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_656891af-7972-4cc6-a348-65a6cca528e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e57eb61-3b64-4f1a-bdd3-d72af88225c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_3550f19a-5ba1-494a-ae6e-aaf5d58ba721" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e57eb61-3b64-4f1a-bdd3-d72af88225c1" xlink:to="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_3550f19a-5ba1-494a-ae6e-aaf5d58ba721" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails" xlink:type="extended" id="i96c350d13cb54c40bc75e21b37db9ee2_StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb3ebcda-ca68-4dee-abcd-a16cb0bb36a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb3ebcda-ca68-4dee-abcd-a16cb0bb36a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ad6e3b1f-8795-49c9-8870-10863d88f43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ad6e3b1f-8795-49c9-8870-10863d88f43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35906f0e-6c0d-4ad3-8fe1-15a111966ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35906f0e-6c0d-4ad3-8fe1-15a111966ea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1da5a2f5-5abe-429a-abab-573c1bf8de7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1da5a2f5-5abe-429a-abab-573c1bf8de7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:to="loc_us-gaap_AwardTypeAxis_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cfd8ef-7700-4b84-b278-bd62749e0478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cfd8ef-7700-4b84-b278-bd62749e0478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_ab2c58f3-9157-4601-af1e-142c6665e26d" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cfd8ef-7700-4b84-b278-bd62749e0478" xlink:to="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_ab2c58f3-9157-4601-af1e-142c6665e26d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_380db0e2-9a0f-4857-9ff5-f34a8e290ac1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:to="loc_srt_RangeAxis_380db0e2-9a0f-4857-9ff5-f34a8e290ac1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_380db0e2-9a0f-4857-9ff5-f34a8e290ac1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_380db0e2-9a0f-4857-9ff5-f34a8e290ac1" xlink:to="loc_srt_RangeMember_380db0e2-9a0f-4857-9ff5-f34a8e290ac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e95f0906-d9f5-49c2-a542-31f898d9cfd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_380db0e2-9a0f-4857-9ff5-f34a8e290ac1" xlink:to="loc_srt_RangeMember_e95f0906-d9f5-49c2-a542-31f898d9cfd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_218515a4-01b6-435b-8f20-8ae8372c5ecb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e95f0906-d9f5-49c2-a542-31f898d9cfd2" xlink:to="loc_srt_MinimumMember_218515a4-01b6-435b-8f20-8ae8372c5ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a3fcc40b-3e82-4145-ac19-89631ed573ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e95f0906-d9f5-49c2-a542-31f898d9cfd2" xlink:to="loc_srt_MaximumMember_a3fcc40b-3e82-4145-ac19-89631ed573ff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i2a5a3985115f408b84849c5479b7e1a6_StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fb19074-2b22-4c87-8fe5-06650fa58278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18de7fcb-10f6-4cf8-a78c-95b996c26401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fb19074-2b22-4c87-8fe5-06650fa58278" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18de7fcb-10f6-4cf8-a78c-95b996c26401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81d5a4fd-2bdf-4725-aa15-eb7f280fa18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fb19074-2b22-4c87-8fe5-06650fa58278" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81d5a4fd-2bdf-4725-aa15-eb7f280fa18a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_452418a3-519a-4af3-9c07-4ea4fb9b99e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81d5a4fd-2bdf-4725-aa15-eb7f280fa18a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_452418a3-519a-4af3-9c07-4ea4fb9b99e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_452418a3-519a-4af3-9c07-4ea4fb9b99e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_452418a3-519a-4af3-9c07-4ea4fb9b99e1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_452418a3-519a-4af3-9c07-4ea4fb9b99e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fc432aa9-c028-44c4-b789-da9cee25e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_452418a3-519a-4af3-9c07-4ea4fb9b99e1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fc432aa9-c028-44c4-b789-da9cee25e36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fae1a122-9022-442d-8d3a-0d6d5bf7a382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fc432aa9-c028-44c4-b789-da9cee25e36c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fae1a122-9022-442d-8d3a-0d6d5bf7a382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4eb28dbd-5622-40db-9783-3d3483888c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fc432aa9-c028-44c4-b789-da9cee25e36c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4eb28dbd-5622-40db-9783-3d3483888c3d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails" xlink:type="extended" id="ibe3ea8b4b1c14df18a71100f25f65829_IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ff9763ac-0cbe-40bf-91bd-cd04c17dd727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ff9763ac-0cbe-40bf-91bd-cd04c17dd727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7e681765-58e9-4447-93d4-f825dcfbc9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7e681765-58e9-4447-93d4-f825dcfbc9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_OperatingLossCarryforwardsExpirationYear_da0e6008-c10f-4f5a-9226-2d950323f5b2" xlink:href="plrx-20211231.xsd#plrx_OperatingLossCarryforwardsExpirationYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_plrx_OperatingLossCarryforwardsExpirationYear_da0e6008-c10f-4f5a-9226-2d950323f5b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TaxCreditCarryforwardsExpirationYear_ba0402b5-d449-4517-b2b9-f47c6ecc980b" xlink:href="plrx-20211231.xsd#plrx_TaxCreditCarryforwardsExpirationYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_plrx_TaxCreditCarryforwardsExpirationYear_ba0402b5-d449-4517-b2b9-f47c6ecc980b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5b0269c8-4547-40c8-8c47-5c3d5c720179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5b0269c8-4547-40c8-8c47-5c3d5c720179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bb0a78f0-f8bb-42e5-9cfb-64e787274067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5b0269c8-4547-40c8-8c47-5c3d5c720179" xlink:to="loc_us-gaap_DomesticCountryMember_bb0a78f0-f8bb-42e5-9cfb-64e787274067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9f8b967e-3ee5-4db5-aa83-13c337612185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5b0269c8-4547-40c8-8c47-5c3d5c720179" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9f8b967e-3ee5-4db5-aa83-13c337612185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_aab1c74c-1280-48b4-b89b-abc553c51476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:to="loc_us-gaap_TaxPeriodAxis_aab1c74c-1280-48b4-b89b-abc553c51476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_aab1c74c-1280-48b4-b89b-abc553c51476_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_aab1c74c-1280-48b4-b89b-abc553c51476" xlink:to="loc_us-gaap_TaxPeriodDomain_aab1c74c-1280-48b4-b89b-abc553c51476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_aab1c74c-1280-48b4-b89b-abc553c51476" xlink:to="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_StartingFromJanuary12018Member_a8e1c9f8-7452-49ed-b6a6-ca5569775456" xlink:href="plrx-20211231.xsd#plrx_StartingFromJanuary12018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:to="loc_plrx_StartingFromJanuary12018Member_a8e1c9f8-7452-49ed-b6a6-ca5569775456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_BeforeJanuary12018Member_5cedaf78-7e5a-4ee0-8918-6b77ce7d8b23" xlink:href="plrx-20211231.xsd#plrx_BeforeJanuary12018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:to="loc_plrx_BeforeJanuary12018Member_5cedaf78-7e5a-4ee0-8918-6b77ce7d8b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_d2aa3ceb-f415-45fc-9b9c-b1878f184b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:to="loc_us-gaap_EarliestTaxYearMember_d2aa3ceb-f415-45fc-9b9c-b1878f184b33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_10ee1b11-7b69-43e2-8f6f-e3f1b347c99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:to="loc_us-gaap_LatestTaxYearMember_10ee1b11-7b69-43e2-8f6f-e3f1b347c99b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="i89924ceaf2cb438eb51c5a9871ad7f11_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LeasedSpaceUnderNonCancellableOperatingLease_cac58fa0-724a-4d52-b0cb-3a94733c2628" xlink:href="plrx-20211231.xsd#plrx_LeasedSpaceUnderNonCancellableOperatingLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_plrx_LeasedSpaceUnderNonCancellableOperatingLease_cac58fa0-724a-4d52-b0cb-3a94733c2628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3972be56-43ef-4af0-8654-a9ca651c82bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3972be56-43ef-4af0-8654-a9ca651c82bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PeriodOfBaseRentAbatement_0a4a8cf3-3f7a-4045-b5b5-4d4ccfd82813" xlink:href="plrx-20211231.xsd#plrx_PeriodOfBaseRentAbatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_plrx_PeriodOfBaseRentAbatement_0a4a8cf3-3f7a-4045-b5b5-4d4ccfd82813" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_BaseRentAbatedAmount_1fb827ef-ec14-4a53-a211-12cc30dcb30d" xlink:href="plrx-20211231.xsd#plrx_BaseRentAbatedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_plrx_BaseRentAbatedAmount_1fb827ef-ec14-4a53-a211-12cc30dcb30d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_2eb2e69d-1db5-4ef2-921a-8099405011ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_SecurityDeposit_2eb2e69d-1db5-4ef2-921a-8099405011ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_de61a875-2ad4-43d2-a6cf-993c5fc9b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_de61a875-2ad4-43d2-a6cf-993c5fc9b8bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LeaseTermExtensionNoticePeriod_40780eaf-dc9c-4367-97aa-edc102bd942c" xlink:href="plrx-20211231.xsd#plrx_LeaseTermExtensionNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_plrx_LeaseTermExtensionNoticePeriod_40780eaf-dc9c-4367-97aa-edc102bd942c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_50cf32f8-9726-4d9c-b6e8-d0f4d193772b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_OperatingLeaseCost_50cf32f8-9726-4d9c-b6e8-d0f4d193772b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_13f41126-c9c6-4048-99ec-d33368b85f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_VariableLeaseCost_13f41126-c9c6-4048-99ec-d33368b85f9e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_66b09e0f-c56b-4630-a8f8-2600682e4fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_LeaseAndRentalExpense_66b09e0f-c56b-4630-a8f8-2600682e4fa1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a390012b-3d03-40a0-af14-32909c6a134e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_OperatingLeasePayments_a390012b-3d03-40a0-af14-32909c6a134e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd893cf2-eb38-43b1-8fe1-e003f5ede3da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:to="loc_srt_StatementGeographicalAxis_cd893cf2-eb38-43b1-8fe1-e003f5ede3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd893cf2-eb38-43b1-8fe1-e003f5ede3da_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cd893cf2-eb38-43b1-8fe1-e003f5ede3da" xlink:to="loc_srt_SegmentGeographicalDomain_cd893cf2-eb38-43b1-8fe1-e003f5ede3da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ac5c3c8f-9096-48cc-9758-2bff9b83ab16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cd893cf2-eb38-43b1-8fe1-e003f5ede3da" xlink:to="loc_srt_SegmentGeographicalDomain_ac5c3c8f-9096-48cc-9758-2bff9b83ab16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_ce720db3-15c4-4947-9426-34f5156cdcc3" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ac5c3c8f-9096-48cc-9758-2bff9b83ab16" xlink:to="loc_stpr_CA_ce720db3-15c4-4947-9426-34f5156cdcc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4aac1fae-303b-4e5e-897c-fdc27f319fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4aac1fae-303b-4e5e-897c-fdc27f319fbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4aac1fae-303b-4e5e-897c-fdc27f319fbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4aac1fae-303b-4e5e-897c-fdc27f319fbd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4aac1fae-303b-4e5e-897c-fdc27f319fbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_36c655c0-d204-4387-97fb-d35f91b3abe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4aac1fae-303b-4e5e-897c-fdc27f319fbd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_36c655c0-d204-4387-97fb-d35f91b3abe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_4d475f99-6799-4cee-9355-e4c5a8401711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_36c655c0-d204-4387-97fb-d35f91b3abe0" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_4d475f99-6799-4cee-9355-e4c5a8401711" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c74250e-58b5-44ec-a373-fe5175e06188" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:to="loc_srt_RangeAxis_3c74250e-58b5-44ec-a373-fe5175e06188" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c74250e-58b5-44ec-a373-fe5175e06188_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3c74250e-58b5-44ec-a373-fe5175e06188" xlink:to="loc_srt_RangeMember_3c74250e-58b5-44ec-a373-fe5175e06188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85257a69-857a-4f1a-981f-863304043169" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3c74250e-58b5-44ec-a373-fe5175e06188" xlink:to="loc_srt_RangeMember_85257a69-857a-4f1a-981f-863304043169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_54de6567-753d-4e47-857d-4a1c715dc15b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85257a69-857a-4f1a-981f-863304043169" xlink:to="loc_srt_MinimumMember_54de6567-753d-4e47-857d-4a1c715dc15b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e7ed3c8-3bd3-42ac-af1d-4f76136ea062" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85257a69-857a-4f1a-981f-863304043169" xlink:to="loc_srt_MaximumMember_1e7ed3c8-3bd3-42ac-af1d-4f76136ea062" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="if198e97ffbae414391b43703da53ea16_LeasesFutureMinimumLeasePaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_812823ad-e1d6-4030-bea1-0ace9c7d0a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_812823ad-e1d6-4030-bea1-0ace9c7d0a19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_525bc8e0-0434-4957-bd4c-8925010e07ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_525bc8e0-0434-4957-bd4c-8925010e07ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_890b1ec2-8c92-4d3b-9939-1c1cda78e1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_890b1ec2-8c92-4d3b-9939-1c1cda78e1fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4a1d185c-649b-431d-8933-e32730676054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4a1d185c-649b-431d-8933-e32730676054" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e1cef70e-e010-437e-93d6-0809fd9ff8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e1cef70e-e010-437e-93d6-0809fd9ff8b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_78d48a04-07ba-4438-86b1-2256208dc1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_78d48a04-07ba-4438-86b1-2256208dc1d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_78d48a04-07ba-4438-86b1-2256208dc1d1" xlink:to="loc_srt_StatementGeographicalAxis_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193" xlink:to="loc_srt_SegmentGeographicalDomain_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cdc9dbd6-af9f-44ce-9809-c5cd105b0a73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193" xlink:to="loc_srt_SegmentGeographicalDomain_cdc9dbd6-af9f-44ce-9809-c5cd105b0a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_41270be1-0516-499b-9c6d-a613760ee91f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cdc9dbd6-af9f-44ce-9809-c5cd105b0a73" xlink:to="loc_stpr_CA_41270be1-0516-499b-9c6d-a613760ee91f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="ia5ed097e7f2f4071b3b6a731fb0154ea_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f3bdeb70-4c56-4744-9a3c-9aafb7510a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f3bdeb70-4c56-4744-9a3c-9aafb7510a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b370498d-0021-4087-a226-82712cfab7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b370498d-0021-4087-a226-82712cfab7f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_ca2cf4e7-16b2-4433-803e-3e13c89c8168" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_ca2cf4e7-16b2-4433-803e-3e13c89c8168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e8ae3505-44d3-48ce-897c-95ca110e036d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e8ae3505-44d3-48ce-897c-95ca110e036d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_32904dae-9b20-4287-8ca7-35eaae2a105d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_32904dae-9b20-4287-8ca7-35eaae2a105d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_167b6a33-4fb5-47b9-a32d-b4d37e738091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_167b6a33-4fb5-47b9-a32d-b4d37e738091" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e9eded6c-3a90-4bde-b478-73034df03632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e9eded6c-3a90-4bde-b478-73034df03632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e9eded6c-3a90-4bde-b478-73034df03632_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9eded6c-3a90-4bde-b478-73034df03632" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e9eded6c-3a90-4bde-b478-73034df03632_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5eefda44-8115-4b7d-a048-0303d40a33f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9eded6c-3a90-4bde-b478-73034df03632" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5eefda44-8115-4b7d-a048-0303d40a33f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d9fe87b6-6e47-4db3-83b3-3dee0b974494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5eefda44-8115-4b7d-a048-0303d40a33f0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d9fe87b6-6e47-4db3-83b3-3dee0b974494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c45c4a07-a7ef-4b46-99c6-49ab8f34d456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c45c4a07-a7ef-4b46-99c6-49ab8f34d456" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c45c4a07-a7ef-4b46-99c6-49ab8f34d456_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c45c4a07-a7ef-4b46-99c6-49ab8f34d456" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c45c4a07-a7ef-4b46-99c6-49ab8f34d456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_916820b5-fe54-4bcb-9b14-9e1cb048a8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c45c4a07-a7ef-4b46-99c6-49ab8f34d456" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_916820b5-fe54-4bcb-9b14-9e1cb048a8f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ThirdRockVenturesMember_45405ac3-3a27-4c44-b695-e24001b80f49" xlink:href="plrx-20211231.xsd#plrx_ThirdRockVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_916820b5-fe54-4bcb-9b14-9e1cb048a8f0" xlink:to="loc_plrx_ThirdRockVenturesMember_45405ac3-3a27-4c44-b695-e24001b80f49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5fa4f65a-6988-4ba6-b098-c18e4315324a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_srt_TitleOfIndividualAxis_5fa4f65a-6988-4ba6-b098-c18e4315324a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5fa4f65a-6988-4ba6-b098-c18e4315324a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5fa4f65a-6988-4ba6-b098-c18e4315324a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5fa4f65a-6988-4ba6-b098-c18e4315324a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1dcc73bd-9190-4afe-b014-bdec15d2274b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5fa4f65a-6988-4ba6-b098-c18e4315324a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1dcc73bd-9190-4afe-b014-bdec15d2274b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NonemployeeDirectorMember_b1008310-26fe-4ba8-bb4f-7e37de233ca2" xlink:href="plrx-20211231.xsd#plrx_NonemployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1dcc73bd-9190-4afe-b014-bdec15d2274b" xlink:to="loc_plrx_NonemployeeDirectorMember_b1008310-26fe-4ba8-bb4f-7e37de233ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f69d8ef5-036d-471a-b277-9480ec24cf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_us-gaap_AwardTypeAxis_f69d8ef5-036d-471a-b277-9480ec24cf6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f69d8ef5-036d-471a-b277-9480ec24cf6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f69d8ef5-036d-471a-b277-9480ec24cf6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f69d8ef5-036d-471a-b277-9480ec24cf6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2734e6-d733-4780-a0a0-530a190c3b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f69d8ef5-036d-471a-b277-9480ec24cf6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2734e6-d733-4780-a0a0-530a190c3b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_374c38b1-169c-4ec7-aa48-58d5e3e8c885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2734e6-d733-4780-a0a0-530a190c3b54" xlink:to="loc_us-gaap_EmployeeStockOptionMember_374c38b1-169c-4ec7-aa48-58d5e3e8c885" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="extended" id="i659f7bddecf24b759c327398e5e210f9_NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cef095e6-70bc-49ec-b834-1ba9be8182f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_790e10cf-7626-4a74-a171-0f9e5ef676f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cef095e6-70bc-49ec-b834-1ba9be8182f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_790e10cf-7626-4a74-a171-0f9e5ef676f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cef095e6-70bc-49ec-b834-1ba9be8182f8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_48673178-1af7-4783-ada5-8c16dac407ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_48673178-1af7-4783-ada5-8c16dac407ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_48673178-1af7-4783-ada5-8c16dac407ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_48673178-1af7-4783-ada5-8c16dac407ab" xlink:to="loc_us-gaap_ClassOfStockDomain_48673178-1af7-4783-ada5-8c16dac407ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a5d782cc-7cca-4d36-b981-1cf8c37dda4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_48673178-1af7-4783-ada5-8c16dac407ab" xlink:to="loc_us-gaap_ClassOfStockDomain_a5d782cc-7cca-4d36-b981-1cf8c37dda4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7ae3fcb7-7745-41ff-934d-c335dd7fce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a5d782cc-7cca-4d36-b981-1cf8c37dda4b" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7ae3fcb7-7745-41ff-934d-c335dd7fce4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbadd256-1938-4ef2-a359-c4e71d0313e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbadd256-1938-4ef2-a359-c4e71d0313e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fbadd256-1938-4ef2-a359-c4e71d0313e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbadd256-1938-4ef2-a359-c4e71d0313e8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fbadd256-1938-4ef2-a359-c4e71d0313e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbadd256-1938-4ef2-a359-c4e71d0313e8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40f31879-518a-4093-a0cf-b5a3cd6b19ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40f31879-518a-4093-a0cf-b5a3cd6b19ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember_639f9121-def3-42b4-b2e3-9abb59774ac3" xlink:href="plrx-20211231.xsd#plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:to="loc_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember_639f9121-def3-42b4-b2e3-9abb59774ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1d93158f-2892-4667-a084-d576e9031a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:to="loc_us-gaap_RestrictedStockMember_1d93158f-2892-4667-a084-d576e9031a5a" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>plrx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d1d6b725-1763-4d57-8800-c62b80275ac0,g:d0b89192-8a0d-4134-a7bf-5cb6b0f5f7ce-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1280822e-eb53-4c86-96d1-7a78fdff87d9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax computed at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_59cf31e6-2d91-45af-afd6-48460fc378d6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1dc32fb9-ce91-4f7a-9234-24f632b23e20_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_669309f6-02de-4e97-8b0a-994ba7d9df3c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d14b5fbf-ca00-4711-84d4-664b02a3987a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e10942b4-668d-43ef-87d4-e0c62b9f7599_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_dd9f7989-62f0-4ed7-94d8-73b6684a3e3c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount_d712c57a-346d-468c-a7f4-c03bf7eb9cf8_terseLabel_en-US" xlink:label="lab_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement, integrin research targets amount</link:label>
    <link:label id="lab_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount_label_en-US" xlink:label="lab_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement Integrin Research Targets Amount</link:label>
    <link:label id="lab_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount_documentation_en-US" xlink:label="lab_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement integrin research targets amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" xlink:href="plrx-20211231.xsd#plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" xlink:to="lab_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5c7f2b46-0197-4079-8364-254f9762599c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d1ea0698-ba5d-448d-94b8-fdb841e96014_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ff789a9e-4941-4c2e-ae1b-0cf177b9a656_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7aef12c6-5f24-4627-a8e7-4c4ece805853_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f39bb29d-62bd-42fd-980e-b12553cfa531_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f8d64fcf-f8cf-4727-a0ef-92d6bdc8bb23_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_54f30ad4-0beb-4f1d-99ec-bb9465ab9fe8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_12ba4b51-37dc-44ef-a191-f71bc88f5daf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_5c32791a-467c-4308-9108-6f807b1e9ca7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_be90db62-da0a-4c64-82ab-790c96d5e28f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e0dfda83-b68f-45af-b619-a0f3711c1cf7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_55a24f52-596c-4114-a6da-aca2fda6106d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting_1ea82d43-4b35-42d5-a1d1-595b2fabe87f_terseLabel_en-US" xlink:label="lab_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of restricted stock awards from liabilities to common stock upon vesting</link:label>
    <link:label id="lab_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting_label_en-US" xlink:label="lab_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting</link:label>
    <link:label id="lab_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting_documentation_en-US" xlink:label="lab_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of restricted stock awards from liabilities to common stock upon vesting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" xlink:href="plrx-20211231.xsd#plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" xlink:to="lab_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_8491e065-9471-4c83-8653-41b602d10922_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_bd30d58e-1e78-42ed-ab7e-b6bfa52ded6c_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_302027e2-429c-45c5-8eb4-187f76495d00_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4f277092-24ac-4d40-be0c-3dea25adc3c9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cacd174b-f61a-4664-b780-f54d0e7647de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_PliantTherapeuticsIncMember_d38d37a4-2a3f-4dcb-94fe-0f4242338c05_terseLabel_en-US" xlink:label="lab_plrx_PliantTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pliant Therapeutics, Inc.</link:label>
    <link:label id="lab_plrx_PliantTherapeuticsIncMember_label_en-US" xlink:label="lab_plrx_PliantTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pliant Therapeutics Inc [Member]</link:label>
    <link:label id="lab_plrx_PliantTherapeuticsIncMember_documentation_en-US" xlink:label="lab_plrx_PliantTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pliant Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PliantTherapeuticsIncMember" xlink:href="plrx-20211231.xsd#plrx_PliantTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_PliantTherapeuticsIncMember" xlink:to="lab_plrx_PliantTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCredit_969ba203-6816-418c-87d2-87f87e3ac35b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCredit_label_en-US" xlink:label="lab_us-gaap_DeferredRentCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCredit" xlink:to="lab_us-gaap_DeferredRentCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_79af5e90-8725-4a5d-9750-bfb36ef990ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_de2b7ec0-6dd2-4dfb-8c6e-53232b52e234_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a67cea4e-d75f-4ac4-bb1c-b32e7b4c1b03_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_017d5970-f64f-43fd-9b9b-a85838b6ab5f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bd95147-637e-4118-a91f-2bb446bb2b04_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b277f533-c2e9-45b9-8507-fb5b2bb7db8a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_fac38e89-d754-46f5-84de-eaa5dcba42aa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting service expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_PrepaidLicensesCurrent_b15b559f-2fe7-42b4-8f12-f7f7b3356a0a_terseLabel_en-US" xlink:label="lab_plrx_PrepaidLicensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid licenses</link:label>
    <link:label id="lab_plrx_PrepaidLicensesCurrent_label_en-US" xlink:label="lab_plrx_PrepaidLicensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Licenses, Current</link:label>
    <link:label id="lab_plrx_PrepaidLicensesCurrent_documentation_en-US" xlink:label="lab_plrx_PrepaidLicensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Licenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PrepaidLicensesCurrent" xlink:href="plrx-20211231.xsd#plrx_PrepaidLicensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_PrepaidLicensesCurrent" xlink:to="lab_plrx_PrepaidLicensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_UnderlyingCommonStockFairValue_a24e19f2-c3db-46b4-9583-cfc27752bc05_terseLabel_en-US" xlink:label="lab_plrx_UnderlyingCommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying common stock fair value</link:label>
    <link:label id="lab_plrx_UnderlyingCommonStockFairValue_label_en-US" xlink:label="lab_plrx_UnderlyingCommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Common Stock Fair Value</link:label>
    <link:label id="lab_plrx_UnderlyingCommonStockFairValue_documentation_en-US" xlink:label="lab_plrx_UnderlyingCommonStockFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying common stock fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UnderlyingCommonStockFairValue" xlink:href="plrx-20211231.xsd#plrx_UnderlyingCommonStockFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_UnderlyingCommonStockFairValue" xlink:to="lab_plrx_UnderlyingCommonStockFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_7acf90d6-1795-4083-bc2e-ea107266ec69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d10b461a-2dea-403c-bced-f13aac7e86b5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_2d6130e6-2b69-4442-b24b-f1311d81df71_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AccountingPoliciesLineItems_dab0a76a-5fb0-4917-ae4a-6128cc31ed22_terseLabel_en-US" xlink:label="lab_plrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_plrx_AccountingPoliciesLineItems_label_en-US" xlink:label="lab_plrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_plrx_AccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_plrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccountingPoliciesLineItems" xlink:href="plrx-20211231.xsd#plrx_AccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AccountingPoliciesLineItems" xlink:to="lab_plrx_AccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_20a7908f-e4db-4c2a-81cc-016f43ce7e46_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease payments</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03aa22e8-9c1b-468d-87bc-263ffed53a77_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2280e352-f2ae-496b-be10-3b9316df5762_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceAbstract_f9273c6f-0311-4daf-970d-e1caca694cb2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Abstract]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceAbstract" xlink:to="lab_us-gaap_ValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a9237fb9-132e-48ac-af64-12a0a6e50b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_86957c7a-a4fc-44fd-973e-9f311d9c7f2e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_994a7530-a1b4-42dc-984c-228b71dcc35f_terseLabel_en-US" xlink:label="lab_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options and Nonqualified Stock Options</link:label>
    <link:label id="lab_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_label_en-US" xlink:label="lab_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options And Nonqualified Stock Options [Member]</link:label>
    <link:label id="lab_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options and nonqualified stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:href="plrx-20211231.xsd#plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:to="lab_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_02fa4a0c-2e03-4686-aca3-48ad2cfe122a_terseLabel_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts, commissions and offering expenses</link:label>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_label_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_f7c5e44e-9177-44aa-82ee-e756b4676dc9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_SeriesCRedeemableConvertiblePreferredStockMember_9563fe65-74c4-48bf-827a-fa9bc10ed872_terseLabel_en-US" xlink:label="lab_plrx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C</link:label>
    <link:label id="lab_plrx_SeriesCRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_plrx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_plrx_SeriesCRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_plrx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C redeemable convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:href="plrx-20211231.xsd#plrx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="lab_plrx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_a9a7e9ed-fcb1-4c2b-8626-14fa2f79f26b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_fd16ff74-244b-4ddd-a00f-d3ff25927749_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_e737f0aa-54d2-44d8-8ea6-7949423623cb_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e7d2354-9e43-41bc-9d96-3fd214c0207a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date fair value, Issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_9aa368c3-84c7-4131-8af6-c52c9a4a70f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from related party transactions</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_8fcb869a-b5e8-43f4-b49a-cf5f8f7b14e2_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09981d82-46b9-47e4-af7b-ac5bff1b6ac0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_112711f4-0b3e-4b12-9d38-46af0adc5628_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_dd0301d4-16cc-4f30-b484-82087ba66fc6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of outstanding unvested restricted stock awards</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_879d3670-1d1d-4dc7-8e8f-0c21657b6e05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_be31f9f8-37ed-4d64-b3f1-d129c6e6fa0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting rights</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7e9c1a34-241d-4097-8329-846c06ec732e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d8ecafff-1c44-4dfd-a2a3-cd1b264bf6a6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_ba6b9d1f-4cf5-4a76-a634-a5e72a85be8b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_17ae3319-915e-4a16-a3a4-36c810c3be13_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Non-recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_36c1d45f-1c43-495b-9958-0dab130e4766_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4e049bdb-d6b8-4eca-b2a5-1be63ba7be1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_65dfb01f-89df-4d66-a010-7bb9a9e7ff49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_073d8a18-23a9-48b6-833c-c67044dd7b64_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summery of Remaining Contractual Maturities of Company&#8217;s Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e9f961a9-f5a1-4145-b68c-525bb5681006_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c7cce47e-b78b-49ae-8f2f-29e4ec1f9eb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_NovartisAgreementMember_5a973bc0-41c0-4c55-ad04-be3e422ffd23_terseLabel_en-US" xlink:label="lab_plrx_NovartisAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Agreement</link:label>
    <link:label id="lab_plrx_NovartisAgreementMember_label_en-US" xlink:label="lab_plrx_NovartisAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Agreement [Member]</link:label>
    <link:label id="lab_plrx_NovartisAgreementMember_documentation_en-US" xlink:label="lab_plrx_NovartisAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementMember" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_NovartisAgreementMember" xlink:to="lab_plrx_NovartisAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d536c1d4-f4a7-4c8f-8449-13aac2ef542d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f04813e6-6bc9-4178-afe5-395194ca5cd6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae7db83f-cef3-46ee-ac1e-1c397de5d08f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_01cc7894-16d5-42b3-a483-71bdedbcdf10_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d8f6da42-c84e-447e-af00-259367c10f4c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_005267b4-1a8a-47b8-83d5-bc7e82f76ba6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_6949e5cd-5cda-4de7-82fc-5e379b85d8e7_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dc17918c-accc-4d47-933a-c6d258c9320f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AssetsAndLiabilitiesLesseeTableTextBlock_2707ef4b-1107-4854-8196-fc3766570a80_terseLabel_en-US" xlink:label="lab_plrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-average Remaining Lease Terms and Discount Rates</link:label>
    <link:label id="lab_plrx_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_plrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_plrx_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_plrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="plrx-20211231.xsd#plrx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_plrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5d3c9281-8974-4c19-b0b2-f9182091c37e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f6a1d34e-2a45-447d-a116-1df67f93126c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A, B, C convertible preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a9b67083-8a1d-42ff-a785-e90a569c78f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ThirdRockVenturesMember_fbb2bb68-949f-424c-8978-237cf21c6069_terseLabel_en-US" xlink:label="lab_plrx_ThirdRockVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Rock Ventures</link:label>
    <link:label id="lab_plrx_ThirdRockVenturesMember_label_en-US" xlink:label="lab_plrx_ThirdRockVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Rock Ventures [Member]</link:label>
    <link:label id="lab_plrx_ThirdRockVenturesMember_documentation_en-US" xlink:label="lab_plrx_ThirdRockVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Rock Ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ThirdRockVenturesMember" xlink:href="plrx-20211231.xsd#plrx_ThirdRockVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ThirdRockVenturesMember" xlink:to="lab_plrx_ThirdRockVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b3c6e5a0-b389-45f0-a237-37cb106464ef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_55530f79-dda3-4691-960b-b4bc902f4a39_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e5e255ff-ee2c-4cc4-aab6-a4ead61c90fd_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInterest_432ce34c-ac9b-4454-bb72-eaa785e2f521_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_PrepaidInterest_label_en-US" xlink:label="lab_us-gaap_PrepaidInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInterest" xlink:to="lab_us-gaap_PrepaidInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bb7843ad-d364-4498-af98-6f7668639d9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_64303914-ee7c-4606-b4f3-bfdf30a13c2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of payroll deductions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3899b05e-2ac6-4e48-8941-70012b163123_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_310e7314-7bda-4c15-9c32-6a7261f8ee17_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_18ff9f8b-0986-4c57-a9ec-a313f0dadbd4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting rights, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_428bb962-94bc-4836-a18a-6fcfe1ba9669_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_LicenseAgreementsLineItems_b23d0139-0ed9-425d-8e2b-9b320f2403c4_terseLabel_en-US" xlink:label="lab_plrx_LicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Line Items]</link:label>
    <link:label id="lab_plrx_LicenseAgreementsLineItems_label_en-US" xlink:label="lab_plrx_LicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Line Items]</link:label>
    <link:label id="lab_plrx_LicenseAgreementsLineItems_documentation_en-US" xlink:label="lab_plrx_LicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsLineItems" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_LicenseAgreementsLineItems" xlink:to="lab_plrx_LicenseAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_c1f93d1f-e7cb-40ee-adaf-e1a074edfbd5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adimab Development and Option Agreement (the "Adimab Agreement")</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_5737632d-15ca-4dd1-a3f5-a0c158cf73d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_a785d0dd-2e17-4311-9639-dac218ddf041_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncentiveFromLessor_b602adfc-80b5-40b8-a518-990aedbc5de1_terseLabel_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold incentive obligation</link:label>
    <link:label id="lab_us-gaap_IncentiveFromLessor_label_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive from Lessor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveFromLessor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveFromLessor" xlink:to="lab_us-gaap_IncentiveFromLessor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c0dd9ddc-58cc-473f-a8a6-4cbfb436e50b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember_02817ff4-a86d-41cf-bbc4-57fe5ea5bd8f_terseLabel_en-US" xlink:label="lab_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Agreement RD For Integrin Research Targets</link:label>
    <link:label id="lab_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember_label_en-US" xlink:label="lab_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Agreement RD For Integrin Research Targets [Member]</link:label>
    <link:label id="lab_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember_documentation_en-US" xlink:label="lab_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Agreement RD For Integrin Research Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementRDForIntegrinResearchTargetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember" xlink:to="lab_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7fc1f0f1-0236-40c9-b278-99812958dd38_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1c0846e8-5d28-4eb4-8ab5-7f1a51a8dfd1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0b394145-06d7-47ea-955b-7a3c7ad926f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LatestTaxYearMember_852e9172-d53d-478a-8d4f-b9d1ec98f296_terseLabel_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year</link:label>
    <link:label id="lab_us-gaap_LatestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_LatestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LatestTaxYearMember" xlink:to="lab_us-gaap_LatestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71e3f7a4-dfbf-44de-9b28-0e01a208132d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Outstanding and unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04add005-e2c2-4edc-a612-60a409e00c74_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Outstanding and unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_c87b8fc1-2262-4b43-87cd-2fe536c8059b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made under defined contribution plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d84d276e-a8a3-4a25-abe2-6c6c85d9ee46_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanPlanNameExtensibleList_7cbcc303-7dc8-4470-82e8-9ac2bcc3b1d9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Plan Name [Extensible List]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanPlanNameExtensibleList_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Plan Name [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanPlanNameExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:to="lab_us-gaap_DefinedContributionPlanPlanNameExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_98b7bfa4-b637-4db1-a5c2-848b4bd0934a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_3b7709dd-ca52-4479-b19f-6c8cbbe3b4b3_terseLabel_en-US" xlink:label="lab_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Equity and 2020 Incentive Plan</link:label>
    <link:label id="lab_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_label_en-US" xlink:label="lab_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen And Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand fifteen and two thousand twenty equity incentive plan .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember" xlink:href="plrx-20211231.xsd#plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember" xlink:to="lab_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_94e0cae7-88cc-45de-be9c-ab38c0b87abb_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bf2c987d-be4d-41d1-b630-c200bb5ec470_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_e50337dc-a2ba-485b-8ceb-40f1b068dcca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_fcfd90a0-8a7b-4a70-84e7-d623ce647498_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_23e2ff94-605a-4c72-a04f-93926855a02f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f3ecd26a-ccd9-418f-b331-5d0546d70cfa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_14e7eca7-d6aa-433e-9d76-ba30d1d6a389_terseLabel_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of stock option</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_label_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_documentation_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options grants in period fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_4d48d57a-b59d-4b96-b75e-2a931f3006b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent and other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_820e575f-83e1-457f-aba1-af6890fadcca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_af96f2dd-74a0-4c04-9136-52dd5c1bc7eb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e32c4006-e3a8-4d82-ba67-8e4f95afadab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, After Adoption of 842:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_19846343-90f2-4b53-825f-950d73b8395a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2ccf0017-4ab1-4f98-b9aa-79d895671af5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_RedeemableConvertiblePreferredStockTextBlock_6d63f139-5abd-4080-905a-653f6d300873_terseLabel_en-US" xlink:label="lab_plrx_RedeemableConvertiblePreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_plrx_RedeemableConvertiblePreferredStockTextBlock_label_en-US" xlink:label="lab_plrx_RedeemableConvertiblePreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Text Block]</link:label>
    <link:label id="lab_plrx_RedeemableConvertiblePreferredStockTextBlock_documentation_en-US" xlink:label="lab_plrx_RedeemableConvertiblePreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RedeemableConvertiblePreferredStockTextBlock" xlink:href="plrx-20211231.xsd#plrx_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_RedeemableConvertiblePreferredStockTextBlock" xlink:to="lab_plrx_RedeemableConvertiblePreferredStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_8fb0a652-63bc-46d4-8241-8e8e332db469_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b9fc5be1-f28c-487d-bd18-6337e24d3de4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0e43274f-17bd-46cf-934b-985bbe60d760_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_07bdd3dd-1b72-4e98-a426-ff4ff8f89549_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_94cbea27-db13-434c-b7c3-420edb11fc83_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_90ddc551-7574-44cd-8061-a8fe0f9ba83f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers of assets between Level 1 and Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_e43d9a9c-ce83-45d2-bef0-6ed89d718883_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AccretionOfShortTermInvestments_0fb98780-4082-4793-886d-57a82bf0223a_negatedLabel_en-US" xlink:label="lab_plrx_AccretionOfShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion on short-term investments</link:label>
    <link:label id="lab_plrx_AccretionOfShortTermInvestments_label_en-US" xlink:label="lab_plrx_AccretionOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion Of Short Term Investments</link:label>
    <link:label id="lab_plrx_AccretionOfShortTermInvestments_documentation_en-US" xlink:label="lab_plrx_AccretionOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of short-term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionOfShortTermInvestments" xlink:href="plrx-20211231.xsd#plrx_AccretionOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AccretionOfShortTermInvestments" xlink:to="lab_plrx_AccretionOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_dd1f5434-e33e-494c-8dee-e24855771bd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b7b59c8c-54c8-42a9-967c-86ff7c17060a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_15c6511d-5dd7-4a95-8733-5a58fb0ea451_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_LicenseAgreementsTextBlock_ddb4715b-b065-4117-8925-f3b13d18f049_terseLabel_en-US" xlink:label="lab_plrx_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regents of the University of California License Agreement (the &#8220;UC Agreement&#8221;)</link:label>
    <link:label id="lab_plrx_LicenseAgreementsTextBlock_label_en-US" xlink:label="lab_plrx_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:label id="lab_plrx_LicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_plrx_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsTextBlock" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_LicenseAgreementsTextBlock" xlink:to="lab_plrx_LicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4af1df10-2777-45ed-9b8f-598b98691e46_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b6c7857b-a9b0-48c3-8e75-3813ad7852a6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_BaseRentAbatedAmount_78e96029-a69c-4cdc-95b4-7f2b2c2cbb14_terseLabel_en-US" xlink:label="lab_plrx_BaseRentAbatedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent abated amount</link:label>
    <link:label id="lab_plrx_BaseRentAbatedAmount_label_en-US" xlink:label="lab_plrx_BaseRentAbatedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rent Abated Amount</link:label>
    <link:label id="lab_plrx_BaseRentAbatedAmount_documentation_en-US" xlink:label="lab_plrx_BaseRentAbatedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent abated amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_BaseRentAbatedAmount" xlink:href="plrx-20211231.xsd#plrx_BaseRentAbatedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_BaseRentAbatedAmount" xlink:to="lab_plrx_BaseRentAbatedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_MatureInOneToTwoYearsMember_2a0a1b61-dd49-4555-86c7-f2fed9498553_terseLabel_en-US" xlink:label="lab_plrx_MatureInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature in 1 to 2 years</link:label>
    <link:label id="lab_plrx_MatureInOneToTwoYearsMember_label_en-US" xlink:label="lab_plrx_MatureInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature In One To Two Years [Member]</link:label>
    <link:label id="lab_plrx_MatureInOneToTwoYearsMember_documentation_en-US" xlink:label="lab_plrx_MatureInOneToTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature in one to two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MatureInOneToTwoYearsMember" xlink:href="plrx-20211231.xsd#plrx_MatureInOneToTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_MatureInOneToTwoYearsMember" xlink:to="lab_plrx_MatureInOneToTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_aad2095c-374d-4e69-a0a1-0fa0ee3106e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_aad41f91-0d6a-4e90-835b-8d3595ce9820_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e5503233-50a5-4d99-823e-7d3480bd568e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_ea6627e2-63ce-4742-944e-2749ed284890_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9bfbfbac-a0fc-4817-ad61-d1771e5ec3c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_38d20b9f-37c3-46d3-8138-36098e1e9996_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_895340bd-04ce-4465-a6db-2f14e63de0a3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_5edc0a07-8261-4c38-8b61-830f32dfd717_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_4fa1d2b8-6df5-451a-a032-1d041d7cc453_terseLabel_en-US" xlink:label="lab_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs In Accounts Payable And Accrued Liabilities</link:label>
    <link:label id="lab_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_documentation_en-US" xlink:label="lab_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs in accounts payable and accrued liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:href="plrx-20211231.xsd#plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:to="lab_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3a5c4e4-7718-4139-97e0-0122bc90172b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_11173cd9-c045-42b6-a452-41a85f820d83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_085e7c01-fbad-4723-bc88-d47508f469b9_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_60e346d7-429e-4c3c-aa23-5d26ed981b55_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_ff1500cc-c27f-42d3-9e57-2259691e56c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_e2d4ed99-6f18-488b-a4cd-ae78e849c1c5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_148db131-bfaa-4a82-96bc-627e58c51e77_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5399128e-63a2-46c0-a002-1fa35a3945f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_c1002b26-7258-4fce-8dc4-aacd8fb321a1_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ae3e2e08-44c2-4d77-a50a-eade7365be58_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_590111c9-e059-4108-9285-f8b5a6c45f8f_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities included in short-term investments</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c81d9d6b-739a-480a-81a3-7ea12945aefd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon initial public offering/private placement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_UnderwritersMember_62627a2c-0ced-4d23-9da0-b3dba3bec8cd_terseLabel_en-US" xlink:label="lab_plrx_UnderwritersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters</link:label>
    <link:label id="lab_plrx_UnderwritersMember_label_en-US" xlink:label="lab_plrx_UnderwritersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters [Member]</link:label>
    <link:label id="lab_plrx_UnderwritersMember_documentation_en-US" xlink:label="lab_plrx_UnderwritersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UnderwritersMember" xlink:href="plrx-20211231.xsd#plrx_UnderwritersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_UnderwritersMember" xlink:to="lab_plrx_UnderwritersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f29ca66a-0e5c-428a-85ac-b862367fac7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e06716ff-36b4-4859-94d2-424fcc20f065_negatedLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cba7454e-a31d-4cfa-a0b6-941a8670fcf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_959dd4e7-a90d-46d5-b0a6-62e47e478511_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_4d0a9b3b-a350-4605-9e67-ef7608fc6cad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases and Rent Expense</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7b5edb98-b61e-4db0-93dd-d08872dc62a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5c39202a-3424-4239-9472-142f7d77903a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in Years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_b9a70e05-ef4e-4a75-b614-94a222bd9341_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b2db22bd-e6c1-4239-80a7-376c000169b3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon initial public offering/private placement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_386bea5e-ffac-4a71-93db-5af495913481_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_dd449db5-f6c6-447b-b670-df4a11c0d704_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_PercentageOfRevenueContributedByRelatedParty_8bda78ee-44ff-4e2f-b5d3-d29520b57144_terseLabel_en-US" xlink:label="lab_plrx_PercentageOfRevenueContributedByRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue contributed by related party</link:label>
    <link:label id="lab_plrx_PercentageOfRevenueContributedByRelatedParty_label_en-US" xlink:label="lab_plrx_PercentageOfRevenueContributedByRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Contributed By Related Party</link:label>
    <link:label id="lab_plrx_PercentageOfRevenueContributedByRelatedParty_documentation_en-US" xlink:label="lab_plrx_PercentageOfRevenueContributedByRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue contributed by related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PercentageOfRevenueContributedByRelatedParty" xlink:href="plrx-20211231.xsd#plrx_PercentageOfRevenueContributedByRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_PercentageOfRevenueContributedByRelatedParty" xlink:to="lab_plrx_PercentageOfRevenueContributedByRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_d00549d3-0af1-4ece-86c0-b06b50f15a2a_terseLabel_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A, B, C convertible preferred stock to common stock</link:label>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity stock issued during period value conversion of convertible securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_72285b33-bc0d-4b09-9c46-2b556c59b7d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b0457dce-a6d4-4f62-8c68-fdab317c9f5f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_607a999c-45cf-4c0b-87c7-1c216358213e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accretion to redemption value and dividends on redeemable convertible preferred shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88dae1a9-1845-4bf4-8087-26dfbcd1f51f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense, weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_b674e036-cad2-4b79-a6a0-43925d9bf70d_terseLabel_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series C redeemable preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity stock issued during period shares new issues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1435f93f-8a50-42f8-90f2-aa9d3f40e31d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date fair value, Outstanding and unvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55573041-27fa-4f19-b62c-2b6fc3d975b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date fair value, Outstanding and unvested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AchievementOfFirstPatientDosingMilestoneMember_c70aba86-0076-4733-8d07-89c5924a52fc_terseLabel_en-US" xlink:label="lab_plrx_AchievementOfFirstPatientDosingMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of First Patient Dosing Milestone</link:label>
    <link:label id="lab_plrx_AchievementOfFirstPatientDosingMilestoneMember_label_en-US" xlink:label="lab_plrx_AchievementOfFirstPatientDosingMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of First Patient Dosing Milestone [Member]</link:label>
    <link:label id="lab_plrx_AchievementOfFirstPatientDosingMilestoneMember_documentation_en-US" xlink:label="lab_plrx_AchievementOfFirstPatientDosingMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first patient dosing milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AchievementOfFirstPatientDosingMilestoneMember" xlink:href="plrx-20211231.xsd#plrx_AchievementOfFirstPatientDosingMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AchievementOfFirstPatientDosingMilestoneMember" xlink:to="lab_plrx_AchievementOfFirstPatientDosingMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AccruedResearchAndDevelopmentExpensesCurrent_757107cd-e2f6-4ba2-bb0a-459f6fb8a126_terseLabel_en-US" xlink:label="lab_plrx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_plrx_AccruedResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_plrx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses, Current</link:label>
    <link:label id="lab_plrx_AccruedResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_plrx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:href="plrx-20211231.xsd#plrx_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="lab_plrx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4f0ec639-a140-43f1-a3b0-ba83288db56c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_386ad819-7258-4ac5-a209-492363a68801_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_5343c3a9-ba2f-4848-bf10-f1111ba18a59_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f3b20ac6-fac9-44b1-a2d1-45c53bd3e2d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7bbcdb34-f331-45fa-946b-c9f70d0920fc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_76c6476f-5475-4393-ac79-79cec5b142e9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods</link:label>
    <link:label id="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_label_en-US" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AccruedExpensesAndOtherLiabilitiesMember_2fcb1f03-b19a-472f-992a-45827c3036ce_terseLabel_en-US" xlink:label="lab_plrx_AccruedExpensesAndOtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_plrx_AccruedExpensesAndOtherLiabilitiesMember_label_en-US" xlink:label="lab_plrx_AccruedExpensesAndOtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Liabilities [Member]</link:label>
    <link:label id="lab_plrx_AccruedExpensesAndOtherLiabilitiesMember_documentation_en-US" xlink:label="lab_plrx_AccruedExpensesAndOtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccruedExpensesAndOtherLiabilitiesMember" xlink:href="plrx-20211231.xsd#plrx_AccruedExpensesAndOtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AccruedExpensesAndOtherLiabilitiesMember" xlink:to="lab_plrx_AccruedExpensesAndOtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_a0095b29-6fb1-4258-bffb-5c938c19f157_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_87d3fa9b-1d42-4939-9044-5b3216dbdead_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_BeforeJanuary12018Member_ebd6b2f4-ecef-4a88-a052-29dca9a89f33_terseLabel_en-US" xlink:label="lab_plrx_BeforeJanuary12018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Before January 1, 2018</link:label>
    <link:label id="lab_plrx_BeforeJanuary12018Member_label_en-US" xlink:label="lab_plrx_BeforeJanuary12018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Before January12018 [Member]</link:label>
    <link:label id="lab_plrx_BeforeJanuary12018Member_documentation_en-US" xlink:label="lab_plrx_BeforeJanuary12018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Before January 1,2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_BeforeJanuary12018Member" xlink:href="plrx-20211231.xsd#plrx_BeforeJanuary12018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_BeforeJanuary12018Member" xlink:to="lab_plrx_BeforeJanuary12018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_48cc1521-712b-4e06-a49a-7b49207b0b50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5535f430-0645-4203-9d5b-506c8f17b941_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_58a3c5bd-8ff4-49c9-9084-55c364cfb57b_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4b034e3a-3371-432f-a577-9dced3eed302_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_08b29c38-9f14-4e20-b14e-fcf49251a7c5_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_27fed13d-c5b2-4143-86ee-5fd14463a3b7_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_LicenseAgreementsTable_89d55438-f544-4084-aacb-5ff1646c55d9_terseLabel_en-US" xlink:label="lab_plrx_LicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Table]</link:label>
    <link:label id="lab_plrx_LicenseAgreementsTable_label_en-US" xlink:label="lab_plrx_LicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Table]</link:label>
    <link:label id="lab_plrx_LicenseAgreementsTable_documentation_en-US" xlink:label="lab_plrx_LicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsTable" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_LicenseAgreementsTable" xlink:to="lab_plrx_LicenseAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_cb7cbafd-db2d-4a9c-a6bb-2ee34ca6d59b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_10617821-c759-45b1-8e13-ddddd44090c1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_459c1449-8f2d-4b4a-8204-b0a3d903a9a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_2bf41dd5-9d47-4a9f-9bdc-0f6c6bb91868_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_66535eed-ff05-4741-94ab-c248ac634db2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_39e9f5a9-e4bc-494b-9404-04179282d624_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value discount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_2db4174e-d62e-4d44-875e-56eb98df8614_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_UCRegentsMember_522478d7-eb08-4bf9-8ace-3d9add531f88_terseLabel_en-US" xlink:label="lab_plrx_UCRegentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UC Regents</link:label>
    <link:label id="lab_plrx_UCRegentsMember_label_en-US" xlink:label="lab_plrx_UCRegentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U C Regents [Member]</link:label>
    <link:label id="lab_plrx_UCRegentsMember_documentation_en-US" xlink:label="lab_plrx_UCRegentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UC Regents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UCRegentsMember" xlink:href="plrx-20211231.xsd#plrx_UCRegentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_UCRegentsMember" xlink:to="lab_plrx_UCRegentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_DeferredTaxLiabilitiesRightOfUseAsset_71620b56-11aa-43c7-a27b-3787cf8e6f3c_negatedTerseLabel_en-US" xlink:label="lab_plrx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_plrx_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_plrx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:label id="lab_plrx_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_plrx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_plrx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_9babee7d-4fd7-4d21-9fae-c86d6af8d1e4_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_7a98cb3a-6c2b-49c1-b1bf-22be74513dc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8d71379b-25c6-4528-8740-5fe3479658ed_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the initial public offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_NovartisMember_8a34d7c6-fd84-4712-a255-d696b126bc9f_terseLabel_en-US" xlink:label="lab_plrx_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_plrx_NovartisMember_label_en-US" xlink:label="lab_plrx_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_plrx_NovartisMember_documentation_en-US" xlink:label="lab_plrx_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisMember" xlink:href="plrx-20211231.xsd#plrx_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_NovartisMember" xlink:to="lab_plrx_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_b15812f1-7e2e-4d07-8365-e069306272c5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of convertible preferred stock into additional paid in capital upon initial public offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_77a88b8a-6fc8-4388-9b74-bbdfed099dbd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6d625997-a484-4cb3-adcf-b9c45f576e26_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_3b23843d-0e4d-4d59-921b-82786d1075a3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_efbb7ad4-8857-42cb-bb0f-c7011136927c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b8ef4702-b726-454d-96e8-8e11fe795687_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d60efba3-db54-47bc-9aa6-399b94ffa138_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_93a81746-6b2e-4001-8b39-d115477a925e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9a4fa918-fa3b-45a2-a4e1-ca7b636bfec7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_11af1d19-b8fe-42c2-8592-a5d437fe7821_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_478c27b3-e825-4b03-9110-5dd0deeec189_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0f211c3d-be9e-44a9-ae72-f36354ab029e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1b714178-abd2-4eb0-9cca-1c4628207449_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon completion of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1e75d0d1-9d68-4069-a094-f9767cf9bba8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_db08ed59-73a3-4bd7-8726-8e3cf5b66eaa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock option awards</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bfad7d7a-2273-41e9-a4fd-804ca1d0538f_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_099e526d-ca55-432a-8f9f-39f396919573_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_20dee24e-48ae-4b79-ad01-b9101192c4e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8324aa99-ef53-4113-993c-d09226051f41_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_443b3ac3-5d95-4a8e-a5c9-1ba8e11aaeaf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_be23d50f-53ed-45d5-b2bd-cd0c429e4a29_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_eb70a7ae-fc2d-4e16-abdb-6222c7db1234_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_19610b8d-d4c2-4a82-b447-bbda446c84a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_MatureInOneYearOrLessMember_70a909fd-47a0-431a-8d8f-1b213a500ec1_terseLabel_en-US" xlink:label="lab_plrx_MatureInOneYearOrLessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature in 1 year or less</link:label>
    <link:label id="lab_plrx_MatureInOneYearOrLessMember_label_en-US" xlink:label="lab_plrx_MatureInOneYearOrLessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature In One Year Or Less [Member]</link:label>
    <link:label id="lab_plrx_MatureInOneYearOrLessMember_documentation_en-US" xlink:label="lab_plrx_MatureInOneYearOrLessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mature in one year or less.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MatureInOneYearOrLessMember" xlink:href="plrx-20211231.xsd#plrx_MatureInOneYearOrLessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_MatureInOneYearOrLessMember" xlink:to="lab_plrx_MatureInOneYearOrLessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_78e6fade-4da3-426c-bae3-974d2130b570_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e14a162c-07c8-4722-ac3b-4c595702fb4c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_041d66c0-df26-4cec-b7f8-301fddfd0813_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Collaboration and License Agreement (the "Novartis Agreement")</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_0ace4823-8917-4939-ae33-15d4c58625cc_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series C redeemable preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2974fb77-73a4-488b-bd86-22b65c7bc483_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_dc4dd73a-ff2c-43ba-b181-67e4ed4a5eca_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_0e2fbacd-7fbf-4035-ba89-bdeac4d96e4d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Assets Acquired Other than Through Business Combination by Transaction</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Assets Acquired Other than Through Business Combination by Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_aa945208-43a8-4a87-a9d6-18f0c4c131bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7a23c5c8-197e-4036-a0e5-7c53bcf8c908_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1041f849-a850-488e-a7d1-e6badda08240_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_cf145da3-e07d-4192-8fa7-6bffc81e01c4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e45ea04c-d090-4245-a48b-96a3199b0580_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_5ae9ff95-8b67-4166-bfa9-88333d761b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_148912ab-a714-41bd-886e-fd686c2ca4c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c2ce1db1-b4e8-44ce-8676-175603e12bb5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price of Novartis agreement</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent_2261ee86-b337-4260-8400-be2739988ede_terseLabel_en-US" xlink:label="lab_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent_label_en-US" xlink:label="lab_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent And Leasehold Incentive Obligation Current</link:label>
    <link:label id="lab_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent_documentation_en-US" xlink:label="lab_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent and leasehold incentive obligation-current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent" xlink:href="plrx-20211231.xsd#plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent" xlink:to="lab_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_67316815-4771-4d38-bde7-b8a01bb9b84b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_388c97ec-a814-4530-aaa0-759bb8cdb263_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1a1385b8-23e9-4038-bf21-8c61a03c0eef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_32a1e7ef-0ab3-495a-b237-587f559f38ec_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_093db565-cc73-4e5f-94c2-cfb3a0cde6d8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_9eb38d76-c9cf-4255-9520-869392d87f26_terseLabel_en-US" xlink:label="lab_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions (reductions) for tax positions of prior year</link:label>
    <link:label id="lab_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="plrx-20211231.xsd#plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a91f3c5f-48f4-444f-87b3-bc3321374121_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6dd7951e-ccef-4f2b-b540-985a0088653d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_a6c5942f-c712-4dfd-a1d7-db6f8e01d4b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan, description</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d6a14c80-26be-4eec-a490-ae761bd3cca9_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_e28dd7d5-a97a-4f78-9296-090aae298c2f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2baef04b-f564-4362-95fe-1cd6b5d33d29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_52356c38-4893-4a09-baf6-e82791a7661a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26c3e01e-fa17-44c5-bee4-8cfa7fd1bc89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ead4f058-918b-43b0-826c-b77866cdc574_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d266fb86-fbd1-4300-baae-ad618b82d77a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1b36a4d8-892b-4a67-878a-1b4b341590d5_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bec11e7e-d1c7-47e4-9cb7-258ed3848e3b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_419bbf4a-7ed3-4559-b9f1-20a5d61da5a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_dc166737-1cf1-47a7-b7db-9addd374017e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_05cc6877-20ab-40db-abec-460fcd3e0297_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3a624bef-c7a6-4348-b41e-00fd23d7dbee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c042f51b-d07f-40c8-b895-86d107e9605f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_cae9c1c0-9afd-462d-8e7d-09e065521024_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of customer payment terms</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_030e7bb6-00a6-4f12-abab-832eb1b63d9b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7ec477d8-dc61-4397-988f-44a5163fed8e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e1f5ea2c-b318-4d64-9369-8f37a7ec9713_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_RestrictedStockAwardsMember_f5abd7f0-8cd5-472a-acb6-a302bef43b0a_terseLabel_en-US" xlink:label="lab_plrx_RestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards</link:label>
    <link:label id="lab_plrx_RestrictedStockAwardsMember_label_en-US" xlink:label="lab_plrx_RestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
    <link:label id="lab_plrx_RestrictedStockAwardsMember_documentation_en-US" xlink:label="lab_plrx_RestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedStockAwardsMember" xlink:href="plrx-20211231.xsd#plrx_RestrictedStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_RestrictedStockAwardsMember" xlink:to="lab_plrx_RestrictedStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_f41665ad-aa58-4e3f-9b7b-87c91ef79d4e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ebdd52fc-2915-48cc-9cb8-6c2f29120ef4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_fb24afcb-6d6e-4862-ba3b-91e73b316a49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2e509ea6-2de8-4f56-a983-2ea76f6477b0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties Policy</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_13812be4-e761-49e0-8b64-b5247990cb42_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_489be6fb-6010-409b-a505-04b4b3970a3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5c4fcb3a-3fdc-4f35-9c42-d43b20f61b47_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f0b3c911-299e-474b-bdaa-a14957560fa2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_IncomeTaxExaminationNumberOfExaminationsPending_46170dde-1505-42a0-a14a-59bb5cb6f539_terseLabel_en-US" xlink:label="lab_plrx_IncomeTaxExaminationNumberOfExaminationsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of income tax examinations pending</link:label>
    <link:label id="lab_plrx_IncomeTaxExaminationNumberOfExaminationsPending_label_en-US" xlink:label="lab_plrx_IncomeTaxExaminationNumberOfExaminationsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination Number Of Examinations Pending</link:label>
    <link:label id="lab_plrx_IncomeTaxExaminationNumberOfExaminationsPending_documentation_en-US" xlink:label="lab_plrx_IncomeTaxExaminationNumberOfExaminationsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax examination, number pending.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncomeTaxExaminationNumberOfExaminationsPending" xlink:href="plrx-20211231.xsd#plrx_IncomeTaxExaminationNumberOfExaminationsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_IncomeTaxExaminationNumberOfExaminationsPending" xlink:to="lab_plrx_IncomeTaxExaminationNumberOfExaminationsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5164df1e-4815-4271-9807-00b3f611d322_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_e234a690-a525-47ae-aaa7-ddf0b6f0f551_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_522146ea-d4d8-4bb2-8a25-03d0839a693a_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1e610bac-5790-403f-af04-d842918f89e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_e4f729fa-1122-4ad9-88d8-fd4b38a5db39_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_fa51b419-ebb9-449a-878a-4663e436d3d2_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e3547f19-0876-4ca9-8540-940352bcfc6d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_PeriodOfBaseRentAbatement_890e770b-2f31-494c-a297-7633c3ee56af_terseLabel_en-US" xlink:label="lab_plrx_PeriodOfBaseRentAbatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of base rent abatement</link:label>
    <link:label id="lab_plrx_PeriodOfBaseRentAbatement_label_en-US" xlink:label="lab_plrx_PeriodOfBaseRentAbatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Base Rent Abatement</link:label>
    <link:label id="lab_plrx_PeriodOfBaseRentAbatement_documentation_en-US" xlink:label="lab_plrx_PeriodOfBaseRentAbatement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Base Rent Abatement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PeriodOfBaseRentAbatement" xlink:href="plrx-20211231.xsd#plrx_PeriodOfBaseRentAbatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_PeriodOfBaseRentAbatement" xlink:to="lab_plrx_PeriodOfBaseRentAbatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_73c4cf71-8a30-476f-bd21-0cd2f874d287_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e6962870-ae6c-497d-a112-4c3892eabab3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period from date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2df95c6f-d5bf-4087-8ea3-9a11b888701b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_42b9ab24-5c33-4f0a-b9ee-b623599f4b56_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_35431fcc-4ea2-4703-946a-0a3124a97d70_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset, Transaction</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset, Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_9c71a3f6-d262-48e6-a8ce-36b3d71c2134_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_FullTimeEmployeeCostMember_164943e4-1775-4e18-8cad-087adc4d3402_terseLabel_en-US" xlink:label="lab_plrx_FullTimeEmployeeCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FTE costs</link:label>
    <link:label id="lab_plrx_FullTimeEmployeeCostMember_label_en-US" xlink:label="lab_plrx_FullTimeEmployeeCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Full Time Employee Cost [Member]</link:label>
    <link:label id="lab_plrx_FullTimeEmployeeCostMember_documentation_en-US" xlink:label="lab_plrx_FullTimeEmployeeCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Full-time employee cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_FullTimeEmployeeCostMember" xlink:href="plrx-20211231.xsd#plrx_FullTimeEmployeeCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_FullTimeEmployeeCostMember" xlink:to="lab_plrx_FullTimeEmployeeCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e3cfc2d4-235a-4ec0-b634-cbd9e547f8ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_20842067-a518-4963-bec8-5aac13baa512_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities included in short-term investments</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6ec6319c-1372-4f2e-bba3-9a62f4b59650_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a83a941b-deeb-4e43-a853-fdbe207baefa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_NumberOfIntegrinResearchTargets_6dda47eb-d4f2-43a0-ac1d-de489ff8c109_terseLabel_en-US" xlink:label="lab_plrx_NumberOfIntegrinResearchTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Integrin research targets</link:label>
    <link:label id="lab_plrx_NumberOfIntegrinResearchTargets_label_en-US" xlink:label="lab_plrx_NumberOfIntegrinResearchTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Integrin Research Targets</link:label>
    <link:label id="lab_plrx_NumberOfIntegrinResearchTargets_documentation_en-US" xlink:label="lab_plrx_NumberOfIntegrinResearchTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Integrin research targets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NumberOfIntegrinResearchTargets" xlink:href="plrx-20211231.xsd#plrx_NumberOfIntegrinResearchTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_NumberOfIntegrinResearchTargets" xlink:to="lab_plrx_NumberOfIntegrinResearchTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_209cfa5f-6288-40e9-9da8-f0896ede4377_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-current Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_TwoThousandTwentyEquityIncentivePlanMember_19683c32-76ee-410d-acb4-fa41e027dbc5_terseLabel_en-US" xlink:label="lab_plrx_TwoThousandTwentyEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:label id="lab_plrx_TwoThousandTwentyEquityIncentivePlanMember_label_en-US" xlink:label="lab_plrx_TwoThousandTwentyEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_plrx_TwoThousandTwentyEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_plrx_TwoThousandTwentyEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember" xlink:href="plrx-20211231.xsd#plrx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="lab_plrx_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_35cee383-c383-4924-9d4e-b4ad0b9899e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_b0749f4b-fc69-4e70-bfba-d24330f95726_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_186657e2-2e07-4216-b9d5-b5b4a0e6c01e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7a3d24e5-1aba-43bf-9d88-6d4462c7c1d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4e2b6793-4bdc-48ad-8cec-23fe90fbabd3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4066eb35-0da5-416b-9b20-0d6693220f9e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AccountingPoliciesTable_4d4a9dc7-a6f1-4d93-88f5-ad4b1292c774_terseLabel_en-US" xlink:label="lab_plrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_plrx_AccountingPoliciesTable_label_en-US" xlink:label="lab_plrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_plrx_AccountingPoliciesTable_documentation_en-US" xlink:label="lab_plrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccountingPoliciesTable" xlink:href="plrx-20211231.xsd#plrx_AccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AccountingPoliciesTable" xlink:to="lab_plrx_AccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_94185015-5769-41ba-993d-ba46349455d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_15132374-e211-4a9f-968b-1f203849ced7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a42b90a5-b9a3-401f-9436-014023b038fd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f0b4254d-c367-44e4-81c4-0d1ecb0f9c60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_990a9201-c85e-474f-bbba-f64e4a9e5585_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_3f1da95e-4c44-4199-968d-93f217f8b2a6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_bce75c23-d961-4aaa-b155-8d25696c5af5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_fc18ebd8-98ab-4b7c-ab8e-842a18035460_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d1866155-e9e2-4d13-8383-9187fb0a4257_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_74123d86-9847-47df-b441-41df66bb3820_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_22cdbc11-de49-4452-8106-305447efbe52_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c5c3d7b0-08ea-455c-88b9-010e3d51c17f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_LicenseFeeMember_42ca8f48-7788-4bad-98a0-03982f303133_terseLabel_en-US" xlink:label="lab_plrx_LicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_plrx_LicenseFeeMember_label_en-US" xlink:label="lab_plrx_LicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee [Member]</link:label>
    <link:label id="lab_plrx_LicenseFeeMember_documentation_en-US" xlink:label="lab_plrx_LicenseFeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseFeeMember" xlink:href="plrx-20211231.xsd#plrx_LicenseFeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_LicenseFeeMember" xlink:to="lab_plrx_LicenseFeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0b7a3609-f222-44dc-bb93-ac5bdd841014_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_538b55ab-7810-4257-b51c-442eebe9388e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_a72687b8-66af-44a7-bef3-815bfb859586_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refundable security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cd4d6e89-15cb-4b31-96cc-e4bc7fc2c8d1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases recorded to income tax provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_32fec34e-48da-4250-acdc-70bed165e549_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4849ba27-0a6c-4396-b44c-109839b55974_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_74312fd3-fbc7-40c6-8c67-d2f29e48b08b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_LeasedSpaceUnderNonCancellableOperatingLease_4a1bf077-a837-4e18-ab78-b57a375ab020_terseLabel_en-US" xlink:label="lab_plrx_LeasedSpaceUnderNonCancellableOperatingLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased premises under non cancelable operating lease</link:label>
    <link:label id="lab_plrx_LeasedSpaceUnderNonCancellableOperatingLease_label_en-US" xlink:label="lab_plrx_LeasedSpaceUnderNonCancellableOperatingLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased Space Under Non Cancellable Operating Lease</link:label>
    <link:label id="lab_plrx_LeasedSpaceUnderNonCancellableOperatingLease_documentation_en-US" xlink:label="lab_plrx_LeasedSpaceUnderNonCancellableOperatingLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased space under non cancellable operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LeasedSpaceUnderNonCancellableOperatingLease" xlink:href="plrx-20211231.xsd#plrx_LeasedSpaceUnderNonCancellableOperatingLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_LeasedSpaceUnderNonCancellableOperatingLease" xlink:to="lab_plrx_LeasedSpaceUnderNonCancellableOperatingLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_25cfcd33-40c1-4c27-91c2-29402e0b1934_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_98773acc-d3aa-45e9-a3eb-4a8bd03cc185_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_80429a46-44ea-407f-9655-737f28e77f4e_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_cca69b41-31db-4635-a572-3f9198930d34_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_39eaaf55-c182-4c82-99d2-23b219adbea9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ac802acf-fd66-426e-983c-061e0657c2ea_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_208a80d1-b119-4a74-8972-ab34041dd5ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of stock option (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_70818df5-641a-4142-b946-b4c28bf2d997_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_23032720-5877-4f17-9f17-74b60beadb45_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_d676f1ed-7731-462f-8652-a504f810537c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7544002c-e293-40ef-8e17-8389fe748ced_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of founders&#8217; common stock and restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2209f347-381c-4038-b1eb-af18773de01e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d993bfe3-0f81-400b-ae98-7d1d1df500e0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember_caeab780-22df-49dc-830c-f5e5cbbe2fc9_terseLabel_en-US" xlink:label="lab_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted and not purchased</link:label>
    <link:label id="lab_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember_label_en-US" xlink:label="lab_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards Granted And Not Purchased [Member]</link:label>
    <link:label id="lab_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember_documentation_en-US" xlink:label="lab_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted and not purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember" xlink:href="plrx-20211231.xsd#plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember" xlink:to="lab_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c4c36ce3-0b90-4270-8621-d92a86fc51fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b1bc68f5-343e-48e3-96be-aa132de92261_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock_712251cd-b8dd-4c86-a129-6ca553e28912_terseLabel_en-US" xlink:label="lab_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Operating Losses and Tax Credit Carryforwards</link:label>
    <link:label id="lab_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock_label_en-US" xlink:label="lab_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Net Operating Losses And Tax Credit Carryforwards Table [Table Text Block]</link:label>
    <link:label id="lab_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock_documentation_en-US" xlink:label="lab_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of net operating losses and tax credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" xlink:href="plrx-20211231.xsd#plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" xlink:to="lab_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_953ccafc-dd08-45bc-88f8-56831bbdb69a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_07f870d5-75dc-4540-8348-7db132697d9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AdimabAgreementMember_840d1917-ef04-4962-ad8d-3d11047672cf_terseLabel_en-US" xlink:label="lab_plrx_AdimabAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adimab Agreement</link:label>
    <link:label id="lab_plrx_AdimabAgreementMember_label_en-US" xlink:label="lab_plrx_AdimabAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adimab Agreement [Member]</link:label>
    <link:label id="lab_plrx_AdimabAgreementMember_documentation_en-US" xlink:label="lab_plrx_AdimabAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adimab agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AdimabAgreementMember" xlink:href="plrx-20211231.xsd#plrx_AdimabAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AdimabAgreementMember" xlink:to="lab_plrx_AdimabAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_76634a75-f40f-47b9-973f-dd219cc5b12a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of founders&#8217; common stock and restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_f4ac96bd-7749-432d-a07a-da5681fbb1d3_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e7979b5c-2761-438b-ab9c-43248c68600c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_69be07cf-199a-4d75-920f-fc87072040c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8dedc2c1-b9c1-4677-a242-4555f6869d12_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1d792931-9a09-450c-b820-76e8161aac22_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_5f26436c-a1e4-4ee1-ab79-4ce4b34eb3f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_525bc7a6-ac31-4347-b559-2936577eeaa9_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_56cf0fcd-ee3e-4381-a6b1-17c4d004c63c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_c9b5a125-19ef-43a0-af88-4b3d52d8f0d8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_PrepaidResearchAndDevelopmentCurrent_1d9300da-7815-4cc6-9561-47afa6a23172_terseLabel_en-US" xlink:label="lab_plrx_PrepaidResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_plrx_PrepaidResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_plrx_PrepaidResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development, Current</link:label>
    <link:label id="lab_plrx_PrepaidResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_plrx_PrepaidResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PrepaidResearchAndDevelopmentCurrent" xlink:href="plrx-20211231.xsd#plrx_PrepaidResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_PrepaidResearchAndDevelopmentCurrent" xlink:to="lab_plrx_PrepaidResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_882b3242-7509-4d69-823f-d769b267b244_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_1f5df341-ca86-40df-9862-1f61dc1841eb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7ee4e91c-9754-4c95-a013-0fa6a09f341b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6523cd03-02b8-45fe-84b6-145a2475ddd9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_19d100cb-1602-4501-b504-4d79d9475751_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_92970288-21c1-442e-884c-d7844b54645c_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at the end of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_e2011ed6-3ece-44e5-bf12-b78f8e479fdf_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_e0cfb2dc-e7eb-44f7-bd7e-dff9467fc5d3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2673c088-376d-427e-a693-cf566eada5b0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_00d4ab72-a635-4ca8-8b55-ea04f6b76127_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c094423d-cbd5-46bf-b08b-26bb98a24765_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_973501a1-31c3-4489-b993-9c731c9ccae8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_390eb856-a75e-4875-bd1e-f620b75e3bf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8f5ac47e-5148-430d-b0ef-72bbbb2fe2af_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_259a279e-d98a-419f-ab34-66cf461924b7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_5aaca5ef-295f-4083-87d9-d46226dadcda_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent and lease incentives</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3a5f6db8-594b-429a-ba25-f50b8e1d70aa_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_a99ccf8f-7102-40a9-b699-c708bfd03da2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_e2e5c5d6-813a-496d-bd13-b1700a6d9129_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_73ed1023-1558-480f-9e8f-385dd189e5ee_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_582337a2-56c8-45c2-ae77-441f79c54c22_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4b7bf996-fa13-4cda-92ad-113e05e54190_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue_ccfa76d7-d468-455a-91c7-6b613e9ead16_terseLabel_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date fair value, Repurchases (in dollars per share)</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchases Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options repurchases weighted average grant date fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" xlink:to="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ae402a6a-b230-4dc0-ae27-0d4e8dd37bdd_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_StartingFromJanuary12018Member_88db4ac4-e009-419c-a575-f71f88c6d8e9_terseLabel_en-US" xlink:label="lab_plrx_StartingFromJanuary12018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Starting from January 1, 2018</link:label>
    <link:label id="lab_plrx_StartingFromJanuary12018Member_label_en-US" xlink:label="lab_plrx_StartingFromJanuary12018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Starting From January12018 [Member]</link:label>
    <link:label id="lab_plrx_StartingFromJanuary12018Member_documentation_en-US" xlink:label="lab_plrx_StartingFromJanuary12018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Starting from January 1, 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_StartingFromJanuary12018Member" xlink:href="plrx-20211231.xsd#plrx_StartingFromJanuary12018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_StartingFromJanuary12018Member" xlink:to="lab_plrx_StartingFromJanuary12018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_79f02662-422b-47e1-8625-b0dc80a8232c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_65a9f306-739a-4dff-8e40-9bcbc107924b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3163bc4a-33f4-475b-a492-cb98800e5e9d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c55febf2-6857-4ae1-947b-eb4236b47202_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_36994ebc-5478-4c27-bbab-414a1f5dc124_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_428c044f-4b21-4f90-8797-d0da4e1385aa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_NumberOfVotesPerShareOfCommonStock_9c52c6f8-81b8-4782-a30c-e7bc1b12b763_terseLabel_en-US" xlink:label="lab_plrx_NumberOfVotesPerShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, voting rights</link:label>
    <link:label id="lab_plrx_NumberOfVotesPerShareOfCommonStock_label_en-US" xlink:label="lab_plrx_NumberOfVotesPerShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Share Of Common Stock</link:label>
    <link:label id="lab_plrx_NumberOfVotesPerShareOfCommonStock_documentation_en-US" xlink:label="lab_plrx_NumberOfVotesPerShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Share Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NumberOfVotesPerShareOfCommonStock" xlink:href="plrx-20211231.xsd#plrx_NumberOfVotesPerShareOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_NumberOfVotesPerShareOfCommonStock" xlink:to="lab_plrx_NumberOfVotesPerShareOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_2825484d-1d0f-4040-9ca7-1dbc8f8baba7_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_NovartisAgreementRDForPLN1474Member_d5f44232-3de5-4f93-b6c5-46c6ff3448a0_terseLabel_en-US" xlink:label="lab_plrx_NovartisAgreementRDForPLN1474Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Agreement RD For PLN-1474</link:label>
    <link:label id="lab_plrx_NovartisAgreementRDForPLN1474Member_label_en-US" xlink:label="lab_plrx_NovartisAgreementRDForPLN1474Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Agreement RD For PLN-1474 [Member]</link:label>
    <link:label id="lab_plrx_NovartisAgreementRDForPLN1474Member_documentation_en-US" xlink:label="lab_plrx_NovartisAgreementRDForPLN1474Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Agreement RD For PLN-1474</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementRDForPLN1474Member" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementRDForPLN1474Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_NovartisAgreementRDForPLN1474Member" xlink:to="lab_plrx_NovartisAgreementRDForPLN1474Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0f5cbead-0e90-4e10-af27-b4a19cf25db1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term extension period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_083d4f18-09c1-48f8-a468-127ade362f5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal_beade065-8074-4492-adde-d0ccacd2b40a_terseLabel_en-US" xlink:label="lab_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credit&#8212;federal</link:label>
    <link:label id="lab_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal_label_en-US" xlink:label="lab_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation General Business Tax Credits Federal</link:label>
    <link:label id="lab_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal_documentation_en-US" xlink:label="lab_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation general business tax credits federal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" xlink:href="plrx-20211231.xsd#plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" xlink:to="lab_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8484ab99-7ff7-4d31-9e97-259c9e446731_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b557da27-2def-4c0d-bf10-201f435b9710_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_df223dc3-132f-4489-be79-e23c31dc6704_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_d5ace2fd-e03b-4300-99d4-d0aafef151e6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_09638667-ff82-4539-b2d8-49e0bec1efb8_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_e87eafea-f332-42b2-a18a-9b109a67b73c_verboseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock (on an as-converted basis)</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_16169fc9-52dc-4e2b-a29e-ff52eea58d8f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee9b8d44-0fd0-4b63-b1bd-8461ec680f33_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1296d1f3-889a-4c06-974d-00744d6c3571_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_8837d03b-ed61-4e40-a4db-f21397e2a263_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8d98241a-c29d-4188-9e4a-797a44e53184_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price of shares issued in initial public offering (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_61563a00-f5c8-448c-9433-9ea30227ec40_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock_e081bfa6-616f-4c79-af81-397c9b4fbe1b_negatedLabel_en-US" xlink:label="lab_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion to redemption value and cumulative dividends on redeemable convertible stock</link:label>
    <link:label id="lab_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion To Redemption Value And Cumulative Dividend On Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock_documentation_en-US" xlink:label="lab_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion to redemption value and cumulative dividend on redeemable convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" xlink:href="plrx-20211231.xsd#plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" xlink:to="lab_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_0d4386b3-9b9f-4847-b471-8bc4431845b8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9947a851-2264-435c-aadb-5a77de97f99c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5408cd56-d4e9-480e-a0b5-40e3df87bd96_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_c16d204c-7a2b-47b6-848e-ea39428f90b1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_7d8ccf54-3251-410c-ae30-e08e26e0b3d5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_NonemployeeDirectorMember_1b52cd5b-ae66-4a96-b666-6e665f191091_terseLabel_en-US" xlink:label="lab_plrx_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Director</link:label>
    <link:label id="lab_plrx_NonemployeeDirectorMember_label_en-US" xlink:label="lab_plrx_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:label id="lab_plrx_NonemployeeDirectorMember_documentation_en-US" xlink:label="lab_plrx_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NonemployeeDirectorMember" xlink:href="plrx-20211231.xsd#plrx_NonemployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_NonemployeeDirectorMember" xlink:to="lab_plrx_NonemployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_29b5de58-a02b-4538-b075-fc2e0d7126b2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_298a24c5-87c7-4e4d-9104-c8b155df6efc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share attributable to common stockholders:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_81393950-92b7-4b61-bcb8-9a829da64dc0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_f9605816-d40a-45a3-9510-e32184042894_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e1b89208-3bc0-49eb-9d14-994381a2e6c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_bd7ef482-d71d-470c-9f2e-461d9b4427e5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2850da60-f44a-4214-b2f6-1e7aac52f4b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A, B, C convertible preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_4a10ad23-12d6-4a38-bbff-1f73da30ca44_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities included in cash and cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a226c903-993e-489a-898e-509ea579ef26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company&#8217;s Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_46290f74-7b9c-4ce8-9dc5-9b2395fd89d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ee4b432c-e63d-4a11-8e91-6b58920437c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_30d2da81-e4b8-427e-bcf6-e92977c878f2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ae902fd0-e077-408c-b46c-71497cac0544_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_b059974d-b5f3-425d-a22d-6b429f740cdd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_39af6100-b2cc-42b9-baac-096acfc77cb4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8c4e13c9-bd8d-45d5-9620-699e8a79ba70_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bb12dd3b-c56f-4ad9-a535-d947e777e9dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_2eff5b0a-6051-4109-9639-15a15583b6d8_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_30d9329b-f6fd-4541-91e9-3d6635de7b70_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_ec541150-70f5-486a-bfb8-0918a97351c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities &#8212; deposits</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6ccc0a95-85d2-459a-b58d-ee3a68348742_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a7e9c813-362b-44a8-b987-e7938594b0fe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_MilestoneAndAnnualRoyaltyPaid_0e7c357f-243c-4f55-ad03-125532a32443_terseLabel_en-US" xlink:label="lab_plrx_MilestoneAndAnnualRoyaltyPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone and annual royalty paid</link:label>
    <link:label id="lab_plrx_MilestoneAndAnnualRoyaltyPaid_label_en-US" xlink:label="lab_plrx_MilestoneAndAnnualRoyaltyPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone And Annual Royalty Paid</link:label>
    <link:label id="lab_plrx_MilestoneAndAnnualRoyaltyPaid_documentation_en-US" xlink:label="lab_plrx_MilestoneAndAnnualRoyaltyPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone and annual royalty paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MilestoneAndAnnualRoyaltyPaid" xlink:href="plrx-20211231.xsd#plrx_MilestoneAndAnnualRoyaltyPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_MilestoneAndAnnualRoyaltyPaid" xlink:to="lab_plrx_MilestoneAndAnnualRoyaltyPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e525f3a0-3186-4949-a393-ef08678712e2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d121ad53-ee0d-489b-a7e5-49462b6018d9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_8aa9c522-086e-427e-941e-423dd65f9652_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock_f8bce2e6-74af-440a-87be-19106eee9e21_terseLabel_en-US" xlink:label="lab_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock_label_en-US" xlink:label="lab_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Policy Policy [Policy Text Block]</link:label>
    <link:label id="lab_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" xlink:href="plrx-20211231.xsd#plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" xlink:to="lab_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_DeferredTaxAssetsLeaseLiability_b400e97d-2160-4e97-bda2-5f7a71d0afb1_terseLabel_en-US" xlink:label="lab_plrx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_plrx_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_plrx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_plrx_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_plrx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxAssetsLeaseLiability" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_DeferredTaxAssetsLeaseLiability" xlink:to="lab_plrx_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_6dcd6e28-ee36-4276-8de2-9ec8cabf9dac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_79393f1e-4fb0-439a-8a62-a4eaa7d412da_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_336b5b22-3079-4944-9057-052eced6d257_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_dda91032-7a7c-4ce0-b5c4-67fbddcb90ee_terseLabel_en-US" xlink:label="lab_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_label_en-US" xlink:label="lab_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Table [Table Text Block]</link:label>
    <link:label id="lab_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_documentation_en-US" xlink:label="lab_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of common stock reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:href="plrx-20211231.xsd#plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:to="lab_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_be7c2714-6b88-45b1-81ab-5a5c18690a8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_295d67e9-0226-4129-bd92-4a56a01e69af_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_69f30fb3-ba19-495e-a385-f2c15e8e40d5_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_EmployeeStockPurchasePlanOfferingPeriod_71cea6ca-fcaf-46d8-b688-27c606a4a61a_terseLabel_en-US" xlink:label="lab_plrx_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan offering period</link:label>
    <link:label id="lab_plrx_EmployeeStockPurchasePlanOfferingPeriod_label_en-US" xlink:label="lab_plrx_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Offering Period</link:label>
    <link:label id="lab_plrx_EmployeeStockPurchasePlanOfferingPeriod_documentation_en-US" xlink:label="lab_plrx_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_EmployeeStockPurchasePlanOfferingPeriod" xlink:href="plrx-20211231.xsd#plrx_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_EmployeeStockPurchasePlanOfferingPeriod" xlink:to="lab_plrx_EmployeeStockPurchasePlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_5ea0abf3-a3f2-4a64-85f3-8aac1a91a18a_terseLabel_en-US" xlink:label="lab_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and twenty employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:to="lab_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f5b62437-292b-40a0-8763-b3fcc238722d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b421fc59-a9c6-4108-9c1d-369882ecb5f8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods_6377137d-2f53-4619-af53-1134d5517280_terseLabel_en-US" xlink:label="lab_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options under plan may be granted for periods</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods_label_en-US" xlink:label="lab_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Options Under Plan May Be Granted For Periods</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods_documentation_en-US" xlink:label="lab_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation options under plan may be granted for periods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" xlink:to="lab_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_6db6ad4f-8424-46e6-b204-970387670234_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b6d0b5f8-7553-4e45-b7eb-c7d4bf3d3eb2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_65f49feb-48dc-4ded-95d6-63cf74dbf1a9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2cd99135-388d-4f89-bafb-c6b83fcbe60a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6a7d6926-0a64-4eda-b5bb-fc88a1d41d58_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ComputerEquipmentAndSoftwareMember_907fe7ba-075f-447e-890e-316491e034a0_terseLabel_en-US" xlink:label="lab_plrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_plrx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_plrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_plrx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_plrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ComputerEquipmentAndSoftwareMember" xlink:href="plrx-20211231.xsd#plrx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_plrx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_LeaseTermExtensionNoticePeriod_71590b14-b213-4ff0-a50c-74f9ea8d9356_terseLabel_en-US" xlink:label="lab_plrx_LeaseTermExtensionNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term extension notice period</link:label>
    <link:label id="lab_plrx_LeaseTermExtensionNoticePeriod_label_en-US" xlink:label="lab_plrx_LeaseTermExtensionNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Term Extension Notice Period</link:label>
    <link:label id="lab_plrx_LeaseTermExtensionNoticePeriod_documentation_en-US" xlink:label="lab_plrx_LeaseTermExtensionNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term extension notice period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LeaseTermExtensionNoticePeriod" xlink:href="plrx-20211231.xsd#plrx_LeaseTermExtensionNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_LeaseTermExtensionNoticePeriod" xlink:to="lab_plrx_LeaseTermExtensionNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e5acb05a-dfbe-43e5-b9f4-977ebac57fa1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b661f31b-70b5-40a1-baec-4d4762beb5b0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, attributable to common stockholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_90526ad7-e105-46c9-b254-c890b9a8ead9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods</link:label>
    <link:label id="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_label_en-US" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_71177aa0-3563-4402-9ef7-f705c29354bd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5a2ff3a3-c414-4ab9-b7dd-bdb6cf127a7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_e6a67b3d-3e82-4443-8e9f-ada1b182c8cc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_SeriesARedeemableConvertiblePreferredStockMember_cf779163-78e8-40d8-b1c7-8be0b10f26e6_terseLabel_en-US" xlink:label="lab_plrx_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_plrx_SeriesARedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_plrx_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_plrx_SeriesARedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_plrx_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A redeemable convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesARedeemableConvertiblePreferredStockMember" xlink:href="plrx-20211231.xsd#plrx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="lab_plrx_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0096fe90-057f-45ff-89b2-5d61129fdb2d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Series C preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_623a962e-c43b-4b09-8c04-c4ea0b1de3e4_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock_465a73b7-e3be-42fc-9dc0-91837848f467_terseLabel_en-US" xlink:label="lab_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock_label_en-US" xlink:label="lab_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Useful Lives Table [Table Text Block]</link:label>
    <link:label id="lab_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock_documentation_en-US" xlink:label="lab_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of property plant and equipment useful lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" xlink:href="plrx-20211231.xsd#plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" xlink:to="lab_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AuditorInformationAbstract_label_en-US" xlink:label="lab_plrx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_plrx_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_plrx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AuditorInformationAbstract" xlink:href="plrx-20211231.xsd#plrx_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AuditorInformationAbstract" xlink:to="lab_plrx_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9aa4b5a5-18e4-4717-a84e-46e00216f93c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20d39e6d-d6b0-4d46-93db-a58f2efbf9b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Outstanding, Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cdf25d90-7479-4d7c-ad32-1d8506d6d9b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share, Outstanding, Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_RestrictedCommonStockAwardsMember_f4ca5ab9-0d9b-405f-b386-cb7775f68491_terseLabel_en-US" xlink:label="lab_plrx_RestrictedCommonStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock Awards</link:label>
    <link:label id="lab_plrx_RestrictedCommonStockAwardsMember_label_en-US" xlink:label="lab_plrx_RestrictedCommonStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock Awards [Member]</link:label>
    <link:label id="lab_plrx_RestrictedCommonStockAwardsMember_documentation_en-US" xlink:label="lab_plrx_RestrictedCommonStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted common stock awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedCommonStockAwardsMember" xlink:href="plrx-20211231.xsd#plrx_RestrictedCommonStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_RestrictedCommonStockAwardsMember" xlink:to="lab_plrx_RestrictedCommonStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47372863-a165-4b8b-a576-bd56910b3e88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_00ae441e-fbe6-43d5-863b-086cda44909e_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_26bdcff0-ecde-430f-946c-db7ce3f085ff_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_TaxCreditCarryforwardsExpirationYear_e218f130-62a2-41f7-b5d9-830a880af34c_terseLabel_en-US" xlink:label="lab_plrx_TaxCreditCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits Expiration year</link:label>
    <link:label id="lab_plrx_TaxCreditCarryforwardsExpirationYear_label_en-US" xlink:label="lab_plrx_TaxCreditCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforwards Expiration Year</link:label>
    <link:label id="lab_plrx_TaxCreditCarryforwardsExpirationYear_documentation_en-US" xlink:label="lab_plrx_TaxCreditCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward expiration year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TaxCreditCarryforwardsExpirationYear" xlink:href="plrx-20211231.xsd#plrx_TaxCreditCarryforwardsExpirationYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_TaxCreditCarryforwardsExpirationYear" xlink:to="lab_plrx_TaxCreditCarryforwardsExpirationYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c15c193c-2659-48b6-8d2d-22b925603163_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in Years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_aac326b4-e9b2-4de0-a048-a1bc422411a1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_07320ffa-45d9-494c-b56b-1625d13a424c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3d0914a0-bd1a-4add-860e-d7fb143067ac_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of noncontrolling ownership</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f1d3c2e-f603-48f0-b66c-220009cf6f27_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets_4bb09f9f-62c1-43cd-b182-04c0e26e5929_terseLabel_en-US" xlink:label="lab_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance as a percentage on total deferred tax assets</link:label>
    <link:label id="lab_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets_label_en-US" xlink:label="lab_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance As Percentage On Deferred Tax Assets</link:label>
    <link:label id="lab_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets_documentation_en-US" xlink:label="lab_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance as percentage on deferred tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets" xlink:href="plrx-20211231.xsd#plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets" xlink:to="lab_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_a795a15d-277e-497d-b1f5-a4c66a37ac5f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock converted into common shares</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_35ea6db6-2fb2-4e83-b4b8-ca3e488b214f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_b5230d9b-2edb-4c99-b2e4-b7e74d548846_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ProceedsFromUpfrontNonRefundableLicenseFee_249df862-81d9-4878-b834-b01654c512e6_terseLabel_en-US" xlink:label="lab_plrx_ProceedsFromUpfrontNonRefundableLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from upfront non-refundable license fee</link:label>
    <link:label id="lab_plrx_ProceedsFromUpfrontNonRefundableLicenseFee_label_en-US" xlink:label="lab_plrx_ProceedsFromUpfrontNonRefundableLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Upfront Non Refundable License Fee</link:label>
    <link:label id="lab_plrx_ProceedsFromUpfrontNonRefundableLicenseFee_documentation_en-US" xlink:label="lab_plrx_ProceedsFromUpfrontNonRefundableLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from upfront non-refundable license fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ProceedsFromUpfrontNonRefundableLicenseFee" xlink:href="plrx-20211231.xsd#plrx_ProceedsFromUpfrontNonRefundableLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ProceedsFromUpfrontNonRefundableLicenseFee" xlink:to="lab_plrx_ProceedsFromUpfrontNonRefundableLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_aa941cdc-10cd-4763-b386-46234cdead1d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_86be1f77-ee9d-4991-9c52-f44308568d86_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eac796ae-9d6b-4fd2-a99a-db485b192958_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4fea2f64-4177-486f-9dc1-09ce01d5bcf5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cd44639a-32e7-4af9-9c0f-e11a2f095831_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_79fc062d-56eb-4cdb-bd5c-3a1ae4669d62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5e0e0925-dce3-4b39-8be2-4b601a81a1ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_75693401-bf92-4c09-afd1-3ba6d93b2979_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1b96fe5b-a798-4aa5-8b13-da86c73f0cb3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_70941d24-a005-4914-aaf5-d97564c62942_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e6b46991-29f4-4a4b-afa1-1f4b23731741_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod_c3f0e690-c180-4c5c-9d59-295f289b240e_negatedLabel_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Repurchases (in shares)</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod_label_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchases In Period</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod_documentation_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that were repurchased during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" xlink:to="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_CommonStockFairMarketValuePercentage_ae17305a-a7fb-4282-b3e3-c637aa213827_terseLabel_en-US" xlink:label="lab_plrx_CommonStockFairMarketValuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock fair market value percentage</link:label>
    <link:label id="lab_plrx_CommonStockFairMarketValuePercentage_label_en-US" xlink:label="lab_plrx_CommonStockFairMarketValuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Fair Market Value Percentage</link:label>
    <link:label id="lab_plrx_CommonStockFairMarketValuePercentage_documentation_en-US" xlink:label="lab_plrx_CommonStockFairMarketValuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock fair market value percentage .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_CommonStockFairMarketValuePercentage" xlink:href="plrx-20211231.xsd#plrx_CommonStockFairMarketValuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_CommonStockFairMarketValuePercentage" xlink:to="lab_plrx_CommonStockFairMarketValuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_8552d247-dccc-4556-9446-6fbf47511301_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7bda2114-7efd-4c5f-a30b-856fe202f132_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_cf6b98a2-dba3-4992-a464-068fb56788e9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_DeferredTaxLiabilitiesFixedAssetBasis_34f70594-9971-45fe-8ab7-93d5435437bf_negatedLabel_en-US" xlink:label="lab_plrx_DeferredTaxLiabilitiesFixedAssetBasis" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed asset basis</link:label>
    <link:label id="lab_plrx_DeferredTaxLiabilitiesFixedAssetBasis_label_en-US" xlink:label="lab_plrx_DeferredTaxLiabilitiesFixedAssetBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fixed Asset Basis</link:label>
    <link:label id="lab_plrx_DeferredTaxLiabilitiesFixedAssetBasis_documentation_en-US" xlink:label="lab_plrx_DeferredTaxLiabilitiesFixedAssetBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fixed Asset Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxLiabilitiesFixedAssetBasis" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxLiabilitiesFixedAssetBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_DeferredTaxLiabilitiesFixedAssetBasis" xlink:to="lab_plrx_DeferredTaxLiabilitiesFixedAssetBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6399b79a-9ac2-4335-84eb-acaa9ad81ecb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_842edd15-167e-4942-9eda-7095e4153c5b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_OtherLosses_d8b64567-ef92-4571-9d28-071bc10a069f_terseLabel_en-US" xlink:label="lab_plrx_OtherLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_plrx_OtherLosses_label_en-US" xlink:label="lab_plrx_OtherLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Losses</link:label>
    <link:label id="lab_plrx_OtherLosses_documentation_en-US" xlink:label="lab_plrx_OtherLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_OtherLosses" xlink:href="plrx-20211231.xsd#plrx_OtherLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_OtherLosses" xlink:to="lab_plrx_OtherLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ad218ae3-1286-4a92-baf1-4749ca3b6ad7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e92ad1f4-f271-43fc-befc-e21744afc112_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_3a38ff04-4fd2-4d51-b8fb-58b941845686_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of restricted stock awards vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a915ec05-2718-4c59-8b81-cf4f2ef06c5f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_83c23864-86da-47f1-a29a-16aafa36ec49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax U.S. book loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders_1f119a79-eed1-4800-943b-7ec77b9ed144_terseLabel_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price as a percentage of estimated grant date fair value of shares</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders_label_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Exercise Price With Purchase Price Of Common Stock Percentage Of Estimated Grant Date Fair Value For Shareholders</link:label>
    <link:label id="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders_documentation_en-US" xlink:label="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award exercise price with purchase price of common stock percentage of estimated grant date fair value for shareholders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" xlink:to="lab_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e29481b2-e182-4d1b-9256-0d7cb9e63272_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_b9acd32e-6455-4fb5-9222-15f2b413dd7f_terseLabel_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest Tax Year</link:label>
    <link:label id="lab_us-gaap_EarliestTaxYearMember_label_en-US" xlink:label="lab_us-gaap_EarliestTaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarliestTaxYearMember" xlink:to="lab_us-gaap_EarliestTaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0d36bd7c-b82f-415c-b6e9-d38bb3259271_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0645bf1b-eca0-4795-946f-2923a847a91a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00f73188-145b-4c38-954e-9108ac53261c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Option Activity Under the 2015 Plan and 2020 Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3477a33a-6dac-462e-be24-ad8ebac4387b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_SeriesBRedeemableConvertiblePreferredStockMember_446d0032-52ee-44eb-bc3c-e2bbec8799f1_terseLabel_en-US" xlink:label="lab_plrx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B</link:label>
    <link:label id="lab_plrx_SeriesBRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_plrx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_plrx_SeriesBRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_plrx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B redeemable convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:href="plrx-20211231.xsd#plrx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="lab_plrx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c33c3e99-6740-4ba7-aa1a-26918c132a99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_244e9d4a-df80-4bbf-9f5b-fd3a0b3f1d52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_61b51a98-666a-4022-b752-dd347fe77077_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5a153279-eb5b-40fa-ad6b-56dc3a5e178e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fde99cb8-69d4-48f6-b4a9-49a30e34d3fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_17d0afa4-d5c5-4dae-8044-0d448b86ac9d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e28a7ef-29d3-44fb-981d-0f5661ea58b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_09bc074f-2a0b-4476-9535-cdc60f27d609_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_aaa5054a-6951-4992-bfb9-e78f5c729f6b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6ad28f4b-2720-4914-a0e3-b03f67826a72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0e62e9e6-bb00-482a-9378-9558fa07cede_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date fair value, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a2a7e578-63b7-4067-b9bb-6e3665e39307_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a98a4a3e-88c9-4b3b-b3d8-2405536d8115_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_48c77803-dc04-4879-afe5-0cf3bf63d16f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cbe97e00-2159-4d22-8738-b71731b4db67_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_48732bb0-c00b-4a02-adbe-22964f8af2d6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_46e2158f-b3e2-40be-8d55-ec915fe31b30_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_bc5b4fee-5619-430a-a6c8-3ce23b2f67a7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_41223754-8016-40e2-9562-714428929a1c_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_499f848d-ca21-48bd-8058-88b8915e6c52_terseLabel_en-US" xlink:label="lab_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:label id="lab_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_documentation_en-US" xlink:label="lab_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="plrx-20211231.xsd#plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="lab_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_c5cf0e06-839f-4bcd-95e6-f97557685db7_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Valuation Allowance for Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d7466900-c5b0-4ecc-8a1f-e0f67cd7f6e6_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_16f1f532-dd4b-4c6b-9f22-802220162ea4_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion to redemption value and cumulative dividends on redeemable convertible stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a2be5c22-0cd2-49ce-83e8-f686738f7607_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_93c22bc2-f467-44f6-851a-5b383d806574_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_e02b0355-d3bb-4a0e-b74f-f5220e49fd68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares outstanding percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_94516b84-f9b6-431b-baa5-025c4ed680ae_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_306d6ccc-f5b2-48e3-a2a7-6f692237f8bf_negatedLabel_en-US" xlink:label="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion to redemption value and dividends on redeemable convertible preferred stock</link:label>
    <link:label id="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_2a06cc5b-2999-4da4-9f3c-6140233f39c8_terseLabel_en-US" xlink:label="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion to redemption value and dividends on redeemable convertible preferred stock</link:label>
    <link:label id="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_documentation_en-US" xlink:label="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion to redemption value and dividends on redeemable convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" xlink:href="plrx-20211231.xsd#plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" xlink:to="lab_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_502c2a0d-c5cb-4520-b5c3-9af0b3789dd2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e06a4d7f-06a6-4335-b0e3-eae048b2f843_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1e5ac43b-84ac-4c3e-a150-c2bdd0b18c88_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_305c8483-0711-46ea-b0dd-2bd11fbf0336_terseLabel_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A, B, C convertible preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label id="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity stock issued during period shares conversion of convertible securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_53be8157-07f9-4bf3-a9b9-3bd43bb02844_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_02e9aee6-0968-437a-bcbc-7678bf73e00f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_047b61ba-fc37-4ea8-a956-c35777810b82_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ContractualArrangementsCancellationPeriod_63ef5067-93be-4b5b-8167-7d43d8eeb835_terseLabel_en-US" xlink:label="lab_plrx_ContractualArrangementsCancellationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual arrangements cancellation period</link:label>
    <link:label id="lab_plrx_ContractualArrangementsCancellationPeriod_label_en-US" xlink:label="lab_plrx_ContractualArrangementsCancellationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangements Cancellation Period</link:label>
    <link:label id="lab_plrx_ContractualArrangementsCancellationPeriod_documentation_en-US" xlink:label="lab_plrx_ContractualArrangementsCancellationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual arrangements cancellation period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ContractualArrangementsCancellationPeriod" xlink:href="plrx-20211231.xsd#plrx_ContractualArrangementsCancellationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ContractualArrangementsCancellationPeriod" xlink:to="lab_plrx_ContractualArrangementsCancellationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_f4c37cb1-dad8-457b-b599-82ed2c093f57_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14e67a98-031f-4e1e-acab-7600c0c8d773_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_0f66e9f5-1a6d-4021-bfb2-0ef2b911744a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2021 and 2020; and 36,083,301 and 35,552,795 shares issued and outstanding at December 31, 2021 and 2020, respectively;</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f9eb01aa-fd2b-4390-84f3-af76020f3a4d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase_06e3040c-a84f-497f-a12e-53ee87cba655_terseLabel_en-US" xlink:label="lab_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument remaining maturity period at date of purchase</link:label>
    <link:label id="lab_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase_label_en-US" xlink:label="lab_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Remaining Maturity Period At Date Of Purchase</link:label>
    <link:label id="lab_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase_documentation_en-US" xlink:label="lab_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument remaining maturity period at date of purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" xlink:href="plrx-20211231.xsd#plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" xlink:to="lab_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_06255b5d-e56e-4842-b18b-31f992d03937_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_92633bb6-114f-41d5-84b3-fb7d2999607a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_700ee7e1-2cd4-4996-8076-8ec4048aa71f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_InterestAndOtherIncomeNet_01ad3f13-7422-49f4-8a24-575f8b1f32e1_terseLabel_en-US" xlink:label="lab_plrx_InterestAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income (expense), net</link:label>
    <link:label id="lab_plrx_InterestAndOtherIncomeNet_label_en-US" xlink:label="lab_plrx_InterestAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Income, Net</link:label>
    <link:label id="lab_plrx_InterestAndOtherIncomeNet_documentation_en-US" xlink:label="lab_plrx_InterestAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_InterestAndOtherIncomeNet" xlink:href="plrx-20211231.xsd#plrx_InterestAndOtherIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_InterestAndOtherIncomeNet" xlink:to="lab_plrx_InterestAndOtherIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_OperatingLossCarryforwardsExpirationYear_1c2fb5e9-043b-4301-b256-09b27cdd56d9_terseLabel_en-US" xlink:label="lab_plrx_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses, Expiration year</link:label>
    <link:label id="lab_plrx_OperatingLossCarryforwardsExpirationYear_label_en-US" xlink:label="lab_plrx_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label id="lab_plrx_OperatingLossCarryforwardsExpirationYear_documentation_en-US" xlink:label="lab_plrx_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year that operating loss carryforwards expire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_OperatingLossCarryforwardsExpirationYear" xlink:href="plrx-20211231.xsd#plrx_OperatingLossCarryforwardsExpirationYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_plrx_OperatingLossCarryforwardsExpirationYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_650936d3-f548-40ba-88aa-856f3737ba67_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_LicenseAgreementsAbstract_ebf1f3fa-fb4b-472f-a263-2d7100fe3140_terseLabel_en-US" xlink:label="lab_plrx_LicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:label id="lab_plrx_LicenseAgreementsAbstract_label_en-US" xlink:label="lab_plrx_LicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:label id="lab_plrx_LicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_plrx_LicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsAbstract" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_LicenseAgreementsAbstract" xlink:to="lab_plrx_LicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_a48fec42-2852-4573-9526-9c5473a8ac69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0673a6bb-a960-407b-a76f-54280a5a5476_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_03ee9a1e-3b40-47d2-ac23-6e61f846d30b_terseLabel_en-US" xlink:label="lab_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="plrx-20211231.xsd#plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f468b36c-08c3-4f2f-a3fc-62e62b8d03d3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in Years), Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameOtherMember_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameOtherMember" xlink:to="lab_us-gaap_RetirementPlanNameOtherMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>plrx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d1d6b725-1763-4d57-8800-c62b80275ac0,g:d0b89192-8a0d-4134-a7bf-5cb6b0f5f7ce-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pliantrx.com/role/Cover" xlink:type="simple" xlink:href="plrx-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a64b266b-1e19-4f2b-b7d1-1b3ed7012df2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_DocumentType_a64b266b-1e19-4f2b-b7d1-1b3ed7012df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_d7c4b8fb-c8b9-46e1-97a7-9e63e9a13582" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_DocumentAnnualReport_d7c4b8fb-c8b9-46e1-97a7-9e63e9a13582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ddd90226-9a80-4366-b564-1f43f8b48ada" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_DocumentPeriodEndDate_ddd90226-9a80-4366-b564-1f43f8b48ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1de3f828-3de3-4056-ac27-1f63c8011899" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_CurrentFiscalYearEndDate_1de3f828-3de3-4056-ac27-1f63c8011899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6620670b-4fce-44bb-8d5b-c6b3ac978cb4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_DocumentTransitionReport_6620670b-4fce-44bb-8d5b-c6b3ac978cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_921ae8bf-f56a-4734-afd9-6b6a02eab04b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityFileNumber_921ae8bf-f56a-4734-afd9-6b6a02eab04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5731fd43-70f0-4209-bee3-b76f027e3037" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityRegistrantName_5731fd43-70f0-4209-bee3-b76f027e3037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bb47d553-333d-445b-84c3-8bb307e11607" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bb47d553-333d-445b-84c3-8bb307e11607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e70c2d66-e910-4735-8d87-bea5994a7f9f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityTaxIdentificationNumber_e70c2d66-e910-4735-8d87-bea5994a7f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a8a31dfb-e133-41f5-bc42-818085f4d26f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityAddressAddressLine1_a8a31dfb-e133-41f5-bc42-818085f4d26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_061ad4bc-6af2-4da6-ac2f-58acba9ab071" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityAddressCityOrTown_061ad4bc-6af2-4da6-ac2f-58acba9ab071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a7148885-f0a3-470e-8051-a0da8367cc50" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityAddressStateOrProvince_a7148885-f0a3-470e-8051-a0da8367cc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_060d325f-3f1f-40df-a5ea-975b64413784" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityAddressPostalZipCode_060d325f-3f1f-40df-a5ea-975b64413784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b78a1f1a-b4e1-41b0-ba99-6442e5c48f2a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_CityAreaCode_b78a1f1a-b4e1-41b0-ba99-6442e5c48f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d89eddb7-eb70-4da0-9c9a-d7a0df36d66b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_LocalPhoneNumber_d89eddb7-eb70-4da0-9c9a-d7a0df36d66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_adac8ea4-b1ba-4901-9883-7ee16f8226b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_Security12bTitle_adac8ea4-b1ba-4901-9883-7ee16f8226b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9991c728-22ac-4548-97c8-f72196d62e34" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_TradingSymbol_9991c728-22ac-4548-97c8-f72196d62e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ea7ed714-7a28-4293-b3b1-b96396f10e3f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_SecurityExchangeName_ea7ed714-7a28-4293-b3b1-b96396f10e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_eccf7a5f-2a06-41d6-9e25-39a4efac6129" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_eccf7a5f-2a06-41d6-9e25-39a4efac6129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_725d6bea-87b5-4cea-8b01-d8c32abb4fff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityVoluntaryFilers_725d6bea-87b5-4cea-8b01-d8c32abb4fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c337bc93-37c4-4001-92fe-5942dacb0b8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityCurrentReportingStatus_c337bc93-37c4-4001-92fe-5942dacb0b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e2512004-931e-4d3d-8962-7f460b931a69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityInteractiveDataCurrent_e2512004-931e-4d3d-8962-7f460b931a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bafc8820-6aaf-42ad-85e7-d64854ef7a48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityFilerCategory_bafc8820-6aaf-42ad-85e7-d64854ef7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2487d2a3-c2c1-469b-af3b-168f6090a751" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntitySmallBusiness_2487d2a3-c2c1-469b-af3b-168f6090a751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_71c6aeb4-e0bb-47dd-85d7-7bd24367adf6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityEmergingGrowthCompany_71c6aeb4-e0bb-47dd-85d7-7bd24367adf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_e4f64d07-12b7-4d8a-acce-8bbc6170dc3b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_IcfrAuditorAttestationFlag_e4f64d07-12b7-4d8a-acce-8bbc6170dc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f3bd333a-5624-47ad-a6b9-d026eebaa369" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityShellCompany_f3bd333a-5624-47ad-a6b9-d026eebaa369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4d72827f-7b05-458f-abb8-70cfb3ada15f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityPublicFloat_4d72827f-7b05-458f-abb8-70cfb3ada15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9b740692-f1fe-455c-b257-1f27acb4d157" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9b740692-f1fe-455c-b257-1f27acb4d157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1a363ccf-6997-49c3-a5b6-411e492aaa0e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1a363ccf-6997-49c3-a5b6-411e492aaa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3ba74678-e241-49cf-b952-1a3a420b9e5c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_AmendmentFlag_3ba74678-e241-49cf-b952-1a3a420b9e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5925337b-4222-47a6-9408-79533e8bf63e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_DocumentFiscalYearFocus_5925337b-4222-47a6-9408-79533e8bf63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b13644dd-db81-497b-b84b-0bebbdc346dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b13644dd-db81-497b-b84b-0bebbdc346dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_152bb238-f096-492b-8029-4126bff3936b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_41d53361-6154-461b-a083-0ee50907e72f" xlink:to="loc_dei_EntityCentralIndexKey_152bb238-f096-492b-8029-4126bff3936b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AuditInformation" xlink:type="simple" xlink:href="plrx-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AuditorInformationAbstract_0cba3084-10d7-45ef-bbbe-cd255c5639e7" xlink:href="plrx-20211231.xsd#plrx_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_10ae10e7-d664-482c-bde1-6262b6165d3b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AuditorInformationAbstract_0cba3084-10d7-45ef-bbbe-cd255c5639e7" xlink:to="loc_dei_AuditorName_10ae10e7-d664-482c-bde1-6262b6165d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_36c745be-c5af-4dc6-9c59-5898a908dce0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AuditorInformationAbstract_0cba3084-10d7-45ef-bbbe-cd255c5639e7" xlink:to="loc_dei_AuditorFirmId_36c745be-c5af-4dc6-9c59-5898a908dce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_f0944da2-e455-49dc-9ddd-8ce8696853c8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AuditorInformationAbstract_0cba3084-10d7-45ef-bbbe-cd255c5639e7" xlink:to="loc_dei_AuditorLocation_f0944da2-e455-49dc-9ddd-8ce8696853c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/BalanceSheets" xlink:type="simple" xlink:href="plrx-20211231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1cb8222d-2d0e-4f28-96d5-a9612edd9b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_928be568-3974-496d-ab0d-d4db329c2dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1cb8222d-2d0e-4f28-96d5-a9612edd9b45" xlink:to="loc_us-gaap_AssetsAbstract_928be568-3974-496d-ab0d-d4db329c2dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_18b1c426-0d63-424f-84ba-b32d06b4c527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_928be568-3974-496d-ab0d-d4db329c2dfd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_18b1c426-0d63-424f-84ba-b32d06b4c527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a286a5c-45fc-43a8-b75d-43772ea38afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_18b1c426-0d63-424f-84ba-b32d06b4c527" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a286a5c-45fc-43a8-b75d-43772ea38afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_57be89f7-ecc0-401c-9b57-aaab74a775d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_18b1c426-0d63-424f-84ba-b32d06b4c527" xlink:to="loc_us-gaap_ShortTermInvestments_57be89f7-ecc0-401c-9b57-aaab74a775d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_58d05a0c-3325-4295-86de-5ca17d62d3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_18b1c426-0d63-424f-84ba-b32d06b4c527" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_58d05a0c-3325-4295-86de-5ca17d62d3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_875c6600-d402-4ce6-9b98-2a2cffa234fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_18b1c426-0d63-424f-84ba-b32d06b4c527" xlink:to="loc_us-gaap_IncomeTaxesReceivable_875c6600-d402-4ce6-9b98-2a2cffa234fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07ee66f1-83a8-40e8-bc91-fdbc9cdffb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_18b1c426-0d63-424f-84ba-b32d06b4c527" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07ee66f1-83a8-40e8-bc91-fdbc9cdffb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9ff6d9c7-058e-4954-b89c-aa1da0895032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_18b1c426-0d63-424f-84ba-b32d06b4c527" xlink:to="loc_us-gaap_AssetsCurrent_9ff6d9c7-058e-4954-b89c-aa1da0895032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b69bcef0-c953-4a99-b77c-059ef74f03f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_928be568-3974-496d-ab0d-d4db329c2dfd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b69bcef0-c953-4a99-b77c-059ef74f03f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0bcfeb6d-3787-4a7e-86c8-a7244c1f7d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_928be568-3974-496d-ab0d-d4db329c2dfd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0bcfeb6d-3787-4a7e-86c8-a7244c1f7d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bee1cc53-8d97-49a8-8acf-bb213d00a153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_928be568-3974-496d-ab0d-d4db329c2dfd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bee1cc53-8d97-49a8-8acf-bb213d00a153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3d6d2e09-d2f2-4fac-a92d-a26b24c70f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_928be568-3974-496d-ab0d-d4db329c2dfd" xlink:to="loc_us-gaap_Assets_3d6d2e09-d2f2-4fac-a92d-a26b24c70f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_431e979b-4116-4fd2-b668-829211cdcc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1cb8222d-2d0e-4f28-96d5-a9612edd9b45" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_431e979b-4116-4fd2-b668-829211cdcc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_382736b7-8735-4535-8682-0b9cbf57d6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_431e979b-4116-4fd2-b668-829211cdcc78" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_382736b7-8735-4535-8682-0b9cbf57d6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e954b579-a639-49a4-8d6c-2fc1d9b86013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_382736b7-8735-4535-8682-0b9cbf57d6a9" xlink:to="loc_us-gaap_AccountsPayableCurrent_e954b579-a639-49a4-8d6c-2fc1d9b86013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d6abfdae-491c-4ce6-b816-3ab439b0b76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_382736b7-8735-4535-8682-0b9cbf57d6a9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d6abfdae-491c-4ce6-b816-3ab439b0b76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_73d6a5da-a8ce-42d9-a966-c62fc7abd980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_382736b7-8735-4535-8682-0b9cbf57d6a9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_73d6a5da-a8ce-42d9-a966-c62fc7abd980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d883a7bf-66df-4b24-886d-5546cba10d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_382736b7-8735-4535-8682-0b9cbf57d6a9" xlink:to="loc_us-gaap_LiabilitiesCurrent_d883a7bf-66df-4b24-886d-5546cba10d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3d307a8b-08dc-4602-b3c3-dfef12c3a701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_382736b7-8735-4535-8682-0b9cbf57d6a9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3d307a8b-08dc-4602-b3c3-dfef12c3a701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3307fde0-f3e7-45f9-95ff-82683a1695e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_431e979b-4116-4fd2-b668-829211cdcc78" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3307fde0-f3e7-45f9-95ff-82683a1695e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cfb20ecd-a078-4eca-a19b-3d9e5ac9c34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_431e979b-4116-4fd2-b668-829211cdcc78" xlink:to="loc_us-gaap_Liabilities_cfb20ecd-a078-4eca-a19b-3d9e5ac9c34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_37c54b0c-e12f-49d8-9f8e-4c33e2df3913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_431e979b-4116-4fd2-b668-829211cdcc78" xlink:to="loc_us-gaap_CommitmentsAndContingencies_37c54b0c-e12f-49d8-9f8e-4c33e2df3913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c4d383ea-fb4b-4c06-8f40-d4099ed9113d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_431e979b-4116-4fd2-b668-829211cdcc78" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c4d383ea-fb4b-4c06-8f40-d4099ed9113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_d2354f0b-d5be-4451-ab19-f364f752db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c4d383ea-fb4b-4c06-8f40-d4099ed9113d" xlink:to="loc_us-gaap_CommonStockValueOutstanding_d2354f0b-d5be-4451-ab19-f364f752db6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_002839f1-adf6-4e09-8116-9b3ecece2231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c4d383ea-fb4b-4c06-8f40-d4099ed9113d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_002839f1-adf6-4e09-8116-9b3ecece2231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5345f541-4b09-47a6-9ae7-7ed44fde3024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c4d383ea-fb4b-4c06-8f40-d4099ed9113d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5345f541-4b09-47a6-9ae7-7ed44fde3024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51dc318e-4d10-43e4-8828-0e70958feb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c4d383ea-fb4b-4c06-8f40-d4099ed9113d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51dc318e-4d10-43e4-8828-0e70958feb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2fc17ea6-5087-4c53-aaa4-742a03b9d3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c4d383ea-fb4b-4c06-8f40-d4099ed9113d" xlink:to="loc_us-gaap_StockholdersEquity_2fc17ea6-5087-4c53-aaa4-742a03b9d3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ffcbfc91-e370-494e-b2d2-02b92b15c818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_431e979b-4116-4fd2-b668-829211cdcc78" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ffcbfc91-e370-494e-b2d2-02b92b15c818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="plrx-20211231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7544dacb-d778-4083-9d82-e7f5b4a8454b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d1240186-f3f8-431a-8727-37ced750d284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7544dacb-d778-4083-9d82-e7f5b4a8454b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d1240186-f3f8-431a-8727-37ced750d284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e503343b-99d4-4cf5-af69-228148363d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7544dacb-d778-4083-9d82-e7f5b4a8454b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e503343b-99d4-4cf5-af69-228148363d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bf710ba2-dfff-4ab8-8bef-8b1d66545259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7544dacb-d778-4083-9d82-e7f5b4a8454b" xlink:to="loc_us-gaap_CommonStockSharesIssued_bf710ba2-dfff-4ab8-8bef-8b1d66545259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3df7b95f-0125-408d-b58d-a9735b6857ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7544dacb-d778-4083-9d82-e7f5b4a8454b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3df7b95f-0125-408d-b58d-a9735b6857ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="plrx-20211231.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5112b754-b163-42f0-9701-4ea991fbb756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5112b754-b163-42f0-9701-4ea991fbb756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_efdb28d8-24a4-470f-927a-ed62dd26e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_us-gaap_OperatingExpensesAbstract_efdb28d8-24a4-470f-927a-ed62dd26e30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5eab61a2-e3cb-4b77-a73a-4d666e872644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_efdb28d8-24a4-470f-927a-ed62dd26e30f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5eab61a2-e3cb-4b77-a73a-4d666e872644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_19facbb5-3878-4ad3-8324-4ef70c544ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_efdb28d8-24a4-470f-927a-ed62dd26e30f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_19facbb5-3878-4ad3-8324-4ef70c544ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_91452f22-e5ff-488c-b51c-cf99cdd62208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_efdb28d8-24a4-470f-927a-ed62dd26e30f" xlink:to="loc_us-gaap_OperatingExpenses_91452f22-e5ff-488c-b51c-cf99cdd62208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0edc324a-21ca-4eb4-b7cc-be5674dbf095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_us-gaap_OperatingIncomeLoss_0edc324a-21ca-4eb4-b7cc-be5674dbf095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_InterestAndOtherIncomeNet_f89d8acf-8e7d-42f0-9130-dcd9275c1be1" xlink:href="plrx-20211231.xsd#plrx_InterestAndOtherIncomeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_plrx_InterestAndOtherIncomeNet_f89d8acf-8e7d-42f0-9130-dcd9275c1be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c1fd2783-dae6-44c8-ab10-ca7f79797d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_us-gaap_NetIncomeLoss_c1fd2783-dae6-44c8-ab10-ca7f79797d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_341644f1-bdae-4c0e-bdfa-d4d3acbc29c4" xlink:href="plrx-20211231.xsd#plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_341644f1-bdae-4c0e-bdfa-d4d3acbc29c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fef19410-e6ed-4c1b-901a-67930c12cec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fef19410-e6ed-4c1b-901a-67930c12cec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cb60334f-4295-42d1-84a9-2a99d4f9ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_us-gaap_EarningsPerShareAbstract_cb60334f-4295-42d1-84a9-2a99d4f9ff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3f5b3ea0-c0ed-450d-9164-392ab3716959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cb60334f-4295-42d1-84a9-2a99d4f9ff2c" xlink:to="loc_us-gaap_EarningsPerShareBasic_3f5b3ea0-c0ed-450d-9164-392ab3716959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ebf98352-7643-4e58-8b77-361665217d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cb60334f-4295-42d1-84a9-2a99d4f9ff2c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ebf98352-7643-4e58-8b77-361665217d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_364016ee-e053-42bb-8ff8-db3e48695358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_364016ee-e053-42bb-8ff8-db3e48695358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_acebe304-3601-47de-88bf-d92170c1c6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_364016ee-e053-42bb-8ff8-db3e48695358" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_acebe304-3601-47de-88bf-d92170c1c6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64c7df5b-9938-4702-8f77-ad883de9998c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_364016ee-e053-42bb-8ff8-db3e48695358" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64c7df5b-9938-4702-8f77-ad883de9998c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d57c97b0-f033-4393-88e8-52d252985527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_db947100-a673-470a-9309-e87f4bd26cbf" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d57c97b0-f033-4393-88e8-52d252985527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fdedc808-abad-4393-88b9-e6965f72034e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d57c97b0-f033-4393-88e8-52d252985527" xlink:to="loc_us-gaap_NetIncomeLoss_fdedc808-abad-4393-88b9-e6965f72034e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_47c1d0ea-0b1d-439b-9682-d1eb1da00c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d57c97b0-f033-4393-88e8-52d252985527" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_47c1d0ea-0b1d-439b-9682-d1eb1da00c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d139c379-5fd3-47bb-bd94-1f2f0c8cbf13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_47c1d0ea-0b1d-439b-9682-d1eb1da00c2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d139c379-5fd3-47bb-bd94-1f2f0c8cbf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d91b2179-3075-44dc-9bb6-40c826321075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_47c1d0ea-0b1d-439b-9682-d1eb1da00c2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d91b2179-3075-44dc-9bb6-40c826321075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ff983038-a92c-4e27-ae33-d206fe6ce338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d57c97b0-f033-4393-88e8-52d252985527" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ff983038-a92c-4e27-ae33-d206fe6ce338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="plrx-20211231.xsd#StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7c9d4dda-a290-4455-8a0c-2b8ef68316ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7c9d4dda-a290-4455-8a0c-2b8ef68316ef" xlink:to="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d9072601-215c-4338-adae-e8c1e600c19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d9072601-215c-4338-adae-e8c1e600c19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9072601-215c-4338-adae-e8c1e600c19b" xlink:to="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesARedeemableConvertiblePreferredStockMember_feb46cf0-d296-4396-a484-dd7487a3ee70" xlink:href="plrx-20211231.xsd#plrx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:to="loc_plrx_SeriesARedeemableConvertiblePreferredStockMember_feb46cf0-d296-4396-a484-dd7487a3ee70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesBRedeemableConvertiblePreferredStockMember_fb1ac43d-0498-40f7-a422-6d58a26b4250" xlink:href="plrx-20211231.xsd#plrx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:to="loc_plrx_SeriesBRedeemableConvertiblePreferredStockMember_fb1ac43d-0498-40f7-a422-6d58a26b4250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_SeriesCRedeemableConvertiblePreferredStockMember_18a59419-7925-4896-aa98-7fbe433dc52c" xlink:href="plrx-20211231.xsd#plrx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c74077f5-0433-4762-9dab-453edf54e946" xlink:to="loc_plrx_SeriesCRedeemableConvertiblePreferredStockMember_18a59419-7925-4896-aa98-7fbe433dc52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_484ad698-da0c-42da-b215-1547df9d2fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_484ad698-da0c-42da-b215-1547df9d2fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_484ad698-da0c-42da-b215-1547df9d2fea" xlink:to="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c0423a75-f90c-416b-ae06-c526c4d26d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:to="loc_us-gaap_CommonStockMember_c0423a75-f90c-416b-ae06-c526c4d26d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5bf7020f-1745-4825-bc24-3baf9ac6a11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5bf7020f-1745-4825-bc24-3baf9ac6a11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8c9feb1-2261-46f5-98b0-1202205fadb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8c9feb1-2261-46f5-98b0-1202205fadb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a34cb84a-a68b-463e-b1f2-b9faf7abeec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eff67f53-5a6f-4ec9-9207-85f403090dc2" xlink:to="loc_us-gaap_RetainedEarningsMember_a34cb84a-a68b-463e-b1f2-b9faf7abeec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_383cb10d-4912-4805-8203-67fe5859c1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_383cb10d-4912-4805-8203-67fe5859c1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4e0806-167b-41d6-8d1d-50b40fdad91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_383cb10d-4912-4805-8203-67fe5859c1d4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4e0806-167b-41d6-8d1d-50b40fdad91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_218bedd5-454a-4bb7-a86d-129553f853a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4e0806-167b-41d6-8d1d-50b40fdad91c" xlink:to="loc_us-gaap_IPOMember_218bedd5-454a-4bb7-a86d-129553f853a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_12c255ea-b0b7-4a03-bfed-bea49ae461d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4e0806-167b-41d6-8d1d-50b40fdad91c" xlink:to="loc_us-gaap_PrivatePlacementMember_12c255ea-b0b7-4a03-bfed-bea49ae461d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8042b61c-686a-47a0-9a16-11abcf27aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aefc07fa-7c46-4078-97c5-1c9053e9bcd4" xlink:to="loc_us-gaap_StatementLineItems_8042b61c-686a-47a0-9a16-11abcf27aa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8042b61c-686a-47a0-9a16-11abcf27aa1f" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_75a5d04b-4a75-4d62-b381-6d27489dda04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_75a5d04b-4a75-4d62-b381-6d27489dda04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f8d18651-3f0f-451e-acab-a45d39100e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f8d18651-3f0f-451e-acab-a45d39100e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c119d7af-7e0c-463a-9245-d1325d1e72b6" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c119d7af-7e0c-463a-9245-d1325d1e72b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_aeb4cd91-5afb-441f-b4af-7429feb1412f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_aeb4cd91-5afb-441f-b4af-7429feb1412f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fd645ed7-ae11-4ba1-98f6-fbde792aba51" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fd645ed7-ae11-4ba1-98f6-fbde792aba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_569c185f-3958-4361-9d8a-960259c98a4a" xlink:href="plrx-20211231.xsd#plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_569c185f-3958-4361-9d8a-960259c98a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_5e7f60e0-0541-4ee9-a896-518ad1951403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_5e7f60e0-0541-4ee9-a896-518ad1951403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b918d44f-8b3a-4207-b4ba-cc7d06b30d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_83012165-01ac-4285-98c7-21a4fe7af3fd" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b918d44f-8b3a-4207-b4ba-cc7d06b30d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8042b61c-686a-47a0-9a16-11abcf27aa1f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_776e9ad3-ebc9-4e7d-ac51-74f2eaf0b7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_776e9ad3-ebc9-4e7d-ac51-74f2eaf0b7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_08776307-831c-4280-86a4-388115b0dd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockholdersEquity_08776307-831c-4280-86a4-388115b0dd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88dc3ab6-46b2-4335-9b1b-c2e7379b84dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_88dc3ab6-46b2-4335-9b1b-c2e7379b84dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_04f9ab5b-ae08-4e0f-a45c-398493697629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_04f9ab5b-ae08-4e0f-a45c-398493697629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28765ab5-05d3-467b-9c54-5e596bf593ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_28765ab5-05d3-467b-9c54-5e596bf593ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_24dfd55d-971b-4ccd-b3b2-80ceb948d9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_24dfd55d-971b-4ccd-b3b2-80ceb948d9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_42501b71-4445-4b11-8f1c-0dd68696c2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_42501b71-4445-4b11-8f1c-0dd68696c2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c93f7e45-56ac-4357-9844-6d4d839aac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c93f7e45-56ac-4357-9844-6d4d839aac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b8ac214f-b2a4-4d97-b2b4-e6e29e9f0a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b8ac214f-b2a4-4d97-b2b4-e6e29e9f0a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_13c0228c-4ca7-4671-b34d-1b33aa464150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_13c0228c-4ca7-4671-b34d-1b33aa464150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_576f6b2f-d2cd-4d9e-bf02-b240d8c302bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_576f6b2f-d2cd-4d9e-bf02-b240d8c302bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c5e48325-e0e0-432f-a73d-0b29bbce0320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c5e48325-e0e0-432f-a73d-0b29bbce0320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_49176d17-9094-46a4-8d98-6a445cb24269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_49176d17-9094-46a4-8d98-6a445cb24269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock_27c4f896-2c49-4a57-992f-396905f189ae" xlink:href="plrx-20211231.xsd#plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock_27c4f896-2c49-4a57-992f-396905f189ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_860edc62-4f8c-4f17-aab8-fbed495e5dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_860edc62-4f8c-4f17-aab8-fbed495e5dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ddffe590-341b-4f4a-854a-a47a57d7769d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ddffe590-341b-4f4a-854a-a47a57d7769d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15243171-5d1d-4f61-b860-31a9a05d9b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_NetIncomeLoss_15243171-5d1d-4f61-b860-31a9a05d9b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a1e50c0d-be05-4121-adc6-e76d9ddefc58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a1e50c0d-be05-4121-adc6-e76d9ddefc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ae533004-2093-4c1f-ad65-cb299b57171b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eb20b342-bf5d-432f-9ae7-b9ed6183eb22" xlink:to="loc_us-gaap_StockholdersEquity_ae533004-2093-4c1f-ad65-cb299b57171b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="plrx-20211231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_17b1ec18-5800-42c2-876d-fc4f75a82075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4647c6-9899-4044-a09c-dc31e0ab6695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17b1ec18-5800-42c2-876d-fc4f75a82075" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4647c6-9899-4044-a09c-dc31e0ab6695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_04b9df0d-00d9-4524-a77b-1d19fe9c5d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4647c6-9899-4044-a09c-dc31e0ab6695" xlink:to="loc_us-gaap_ProfitLoss_04b9df0d-00d9-4524-a77b-1d19fe9c5d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c124afa2-09f0-4ae8-b414-4227fc9f0ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4647c6-9899-4044-a09c-dc31e0ab6695" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c124afa2-09f0-4ae8-b414-4227fc9f0ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a3f2e49a-21cc-4b2c-80cf-560dd0487716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c124afa2-09f0-4ae8-b414-4227fc9f0ee0" xlink:to="loc_us-gaap_Depreciation_a3f2e49a-21cc-4b2c-80cf-560dd0487716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_44b34482-05f8-4dcb-afb8-76bf41a6afc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c124afa2-09f0-4ae8-b414-4227fc9f0ee0" xlink:to="loc_us-gaap_ShareBasedCompensation_44b34482-05f8-4dcb-afb8-76bf41a6afc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_365ad5d1-3b0f-4b1b-ac55-b58ca39367a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c124afa2-09f0-4ae8-b414-4227fc9f0ee0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_365ad5d1-3b0f-4b1b-ac55-b58ca39367a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_OtherLosses_7a52e94b-0a71-4ad2-9d5e-4cd596aad922" xlink:href="plrx-20211231.xsd#plrx_OtherLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c124afa2-09f0-4ae8-b414-4227fc9f0ee0" xlink:to="loc_plrx_OtherLosses_7a52e94b-0a71-4ad2-9d5e-4cd596aad922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4647c6-9899-4044-a09c-dc31e0ab6695" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_181a7ee0-4327-4c17-a18d-f95b93829431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_181a7ee0-4327-4c17-a18d-f95b93829431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7bd0719f-27a7-49b7-917c-b467816735cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7bd0719f-27a7-49b7-917c-b467816735cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0f7e9f9e-47f9-41da-8835-1dc4dadd6e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0f7e9f9e-47f9-41da-8835-1dc4dadd6e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4380faea-151a-46e0-b3e3-e70c1e26cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4380faea-151a-46e0-b3e3-e70c1e26cc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c6ff8cb-ccc4-40ea-b5e1-cb92bff34aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c6ff8cb-ccc4-40ea-b5e1-cb92bff34aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_080028f5-ebd7-400b-b6b6-ebf35e97c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_080028f5-ebd7-400b-b6b6-ebf35e97c3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_621c8f2a-39de-4baf-a9d4-20b40c88f606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_621c8f2a-39de-4baf-a9d4-20b40c88f606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_f44f6a47-c932-44f9-929e-fc7dcd850893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7fcce2f6-af91-44d3-bb28-eff0f4c42a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_f44f6a47-c932-44f9-929e-fc7dcd850893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a65be06-ee23-4169-b461-9b24a9be17bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4647c6-9899-4044-a09c-dc31e0ab6695" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0a65be06-ee23-4169-b461-9b24a9be17bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_98dd045f-24a2-41bc-b4aa-ce7a3611004e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17b1ec18-5800-42c2-876d-fc4f75a82075" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_98dd045f-24a2-41bc-b4aa-ce7a3611004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7436dae2-21da-41a8-a7b6-d6e22d835fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_98dd045f-24a2-41bc-b4aa-ce7a3611004e" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7436dae2-21da-41a8-a7b6-d6e22d835fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionOfShortTermInvestments_b853b746-a5ee-48ed-a781-cc931a530272" xlink:href="plrx-20211231.xsd#plrx_AccretionOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_98dd045f-24a2-41bc-b4aa-ce7a3611004e" xlink:to="loc_plrx_AccretionOfShortTermInvestments_b853b746-a5ee-48ed-a781-cc931a530272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_b9bc5a5d-7973-46d9-8a92-6116a721f34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_98dd045f-24a2-41bc-b4aa-ce7a3611004e" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_b9bc5a5d-7973-46d9-8a92-6116a721f34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8e526073-6ae5-48e5-8682-02b0cae434e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_98dd045f-24a2-41bc-b4aa-ce7a3611004e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8e526073-6ae5-48e5-8682-02b0cae434e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cca029b3-8439-4f54-92d8-49ab20d8bebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_98dd045f-24a2-41bc-b4aa-ce7a3611004e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cca029b3-8439-4f54-92d8-49ab20d8bebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdd3a099-13e6-495d-bdbc-00dfe0177465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17b1ec18-5800-42c2-876d-fc4f75a82075" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdd3a099-13e6-495d-bdbc-00dfe0177465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_482d8924-9475-462b-8b7a-9037e5d6ca62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdd3a099-13e6-495d-bdbc-00dfe0177465" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_482d8924-9475-462b-8b7a-9037e5d6ca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_913f29c9-51e7-433f-8b7a-fba78d8eaa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdd3a099-13e6-495d-bdbc-00dfe0177465" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_913f29c9-51e7-433f-8b7a-fba78d8eaa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4d89407b-9ddf-41bb-9dcc-09a0ff5ac152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdd3a099-13e6-495d-bdbc-00dfe0177465" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_4d89407b-9ddf-41bb-9dcc-09a0ff5ac152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fc9e8cc6-2327-494a-9ed9-4c6ca5e5f21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdd3a099-13e6-495d-bdbc-00dfe0177465" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fc9e8cc6-2327-494a-9ed9-4c6ca5e5f21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e452f3e8-31ef-4799-b4e2-e0cca74d1446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdd3a099-13e6-495d-bdbc-00dfe0177465" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e452f3e8-31ef-4799-b4e2-e0cca74d1446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c3e94b-abf3-4976-9563-489bfa1ee827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdd3a099-13e6-495d-bdbc-00dfe0177465" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9c3e94b-abf3-4976-9563-489bfa1ee827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ed678d20-afae-4c67-9136-e443d4e376b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17b1ec18-5800-42c2-876d-fc4f75a82075" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ed678d20-afae-4c67-9136-e443d4e376b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c264f5a-5160-4970-a683-22c45bcc5b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17b1ec18-5800-42c2-876d-fc4f75a82075" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c264f5a-5160-4970-a683-22c45bcc5b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad48f86f-c12f-4520-95c1-390dfcc51faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17b1ec18-5800-42c2-876d-fc4f75a82075" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad48f86f-c12f-4520-95c1-390dfcc51faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cff6d6f4-fbd8-4823-848b-47a3e2e35ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17b1ec18-5800-42c2-876d-fc4f75a82075" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cff6d6f4-fbd8-4823-848b-47a3e2e35ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bbb4318c-76df-46e0-ab84-2ea37d1e596a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cff6d6f4-fbd8-4823-848b-47a3e2e35ab4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bbb4318c-76df-46e0-ab84-2ea37d1e596a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting_3556c46c-f7e8-4322-b4e7-c145b20d1091" xlink:href="plrx-20211231.xsd#plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cff6d6f4-fbd8-4823-848b-47a3e2e35ab4" xlink:to="loc_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting_3556c46c-f7e8-4322-b4e7-c145b20d1091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_d658f270-82d8-4ab7-aa58-806c1a839a8e" xlink:href="plrx-20211231.xsd#plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cff6d6f4-fbd8-4823-848b-47a3e2e35ab4" xlink:to="loc_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock_d658f270-82d8-4ab7-aa58-806c1a839a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_fd002b89-fb02-4fa6-9ca3-52d67d02a158" xlink:href="plrx-20211231.xsd#plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cff6d6f4-fbd8-4823-848b-47a3e2e35ab4" xlink:to="loc_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_fd002b89-fb02-4fa6-9ca3-52d67d02a158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_6b31cefa-afae-475b-83b5-baf8b3323c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_cff6d6f4-fbd8-4823-848b-47a3e2e35ab4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_6b31cefa-afae-475b-83b5-baf8b3323c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="plrx-20211231.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0cc7b01-6410-438d-8410-4986e5914a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e0bfedae-1019-4f0f-93ba-3c9ba467234d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0cc7b01-6410-438d-8410-4986e5914a69" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e0bfedae-1019-4f0f-93ba-3c9ba467234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail" xlink:type="simple" xlink:href="plrx-20211231.xsd#OrganizationandDescriptionofBusinessAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_287bf12b-87cb-4c60-a4dc-5ce0b6b6e276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_287bf12b-87cb-4c60-a4dc-5ce0b6b6e276" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f583307b-7626-437f-8e0d-77545e310370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f583307b-7626-437f-8e0d-77545e310370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_189d08c8-eaef-48f1-b833-d26dc8ae329e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f583307b-7626-437f-8e0d-77545e310370" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_189d08c8-eaef-48f1-b833-d26dc8ae329e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_12ccf3fe-11a9-4768-9bfa-bbe8922a4ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_189d08c8-eaef-48f1-b833-d26dc8ae329e" xlink:to="loc_us-gaap_IPOMember_12ccf3fe-11a9-4768-9bfa-bbe8922a4ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_18eddc1e-9249-4c2b-b0bb-ecfd76651547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_189d08c8-eaef-48f1-b833-d26dc8ae329e" xlink:to="loc_us-gaap_PrivatePlacementMember_18eddc1e-9249-4c2b-b0bb-ecfd76651547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56e66939-dc94-4300-b04d-10e290b5f675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_56e66939-dc94-4300-b04d-10e290b5f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_94d75752-7f10-4fe4-93c9-5663839c4062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56e66939-dc94-4300-b04d-10e290b5f675" xlink:to="loc_us-gaap_EquityComponentDomain_94d75752-7f10-4fe4-93c9-5663839c4062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bd377b4d-a2b5-4555-aee5-356d0efeec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94d75752-7f10-4fe4-93c9-5663839c4062" xlink:to="loc_us-gaap_CommonStockMember_bd377b4d-a2b5-4555-aee5-356d0efeec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2ab8c093-0924-4f10-abf8-4add2d4acb4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_srt_CounterpartyNameAxis_2ab8c093-0924-4f10-abf8-4add2d4acb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6db6baa-6b9c-4176-b2c8-eb3aa2fd599e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2ab8c093-0924-4f10-abf8-4add2d4acb4a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6db6baa-6b9c-4176-b2c8-eb3aa2fd599e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UnderwritersMember_41aaee7f-c867-4015-9915-c151d539bdbf" xlink:href="plrx-20211231.xsd#plrx_UnderwritersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6db6baa-6b9c-4176-b2c8-eb3aa2fd599e" xlink:to="loc_plrx_UnderwritersMember_41aaee7f-c867-4015-9915-c151d539bdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_13d29649-3b53-4852-91d3-ca65dbb1923f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_srt_OwnershipAxis_13d29649-3b53-4852-91d3-ca65dbb1923f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2efa8450-dc3c-4b21-b389-26e6735e8417" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_13d29649-3b53-4852-91d3-ca65dbb1923f" xlink:to="loc_srt_OwnershipDomain_2efa8450-dc3c-4b21-b389-26e6735e8417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PliantTherapeuticsIncMember_36e7c4fc-a3dd-41c1-83ed-26b702ed9d31" xlink:href="plrx-20211231.xsd#plrx_PliantTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2efa8450-dc3c-4b21-b389-26e6735e8417" xlink:to="loc_plrx_PliantTherapeuticsIncMember_36e7c4fc-a3dd-41c1-83ed-26b702ed9d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1254e746-1290-462a-9fff-d11972e4bdc2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_dei_LegalEntityAxis_1254e746-1290-462a-9fff-d11972e4bdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8a62be9-4ab1-44a2-8b16-82a83bb68293" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1254e746-1290-462a-9fff-d11972e4bdc2" xlink:to="loc_dei_EntityDomain_e8a62be9-4ab1-44a2-8b16-82a83bb68293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisMember_49d79acd-5407-48bd-b673-483201b08d57" xlink:href="plrx-20211231.xsd#plrx_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e8a62be9-4ab1-44a2-8b16-82a83bb68293" xlink:to="loc_plrx_NovartisMember_49d79acd-5407-48bd-b673-483201b08d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0affe69a-8b2f-4d30-82ae-e9260d4f48b4" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_274dee9e-7848-43cb-93a7-2c9913aa2ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_274dee9e-7848-43cb-93a7-2c9913aa2ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_89f35451-6112-4ab0-81a9-2895b838a664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_89f35451-6112-4ab0-81a9-2895b838a664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0e7daa16-e04e-4ab0-81a6-2b990035a956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0e7daa16-e04e-4ab0-81a6-2b990035a956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8678c4b5-039e-48e7-a54e-e74e0df650f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8678c4b5-039e-48e7-a54e-e74e0df650f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_debd16d3-be78-47f5-a440-baa9f4dc542c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_debd16d3-be78-47f5-a440-baa9f4dc542c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b53226e0-dc63-41fd-81be-554ded333eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b53226e0-dc63-41fd-81be-554ded333eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_ef139771-8e76-4be5-8176-b865da466ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_ef139771-8e76-4be5-8176-b865da466ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_953be374-b268-435a-900e-587754ddac2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_CommonStockSharesIssued_953be374-b268-435a-900e-587754ddac2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0ed75829-257d-4a04-bfbe-b53c7e44e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_SharePrice_0ed75829-257d-4a04-bfbe-b53c7e44e0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_794cd013-567e-4099-a59c-09783beef554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_794cd013-567e-4099-a59c-09783beef554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3df96a2a-8bf7-4655-a072-017080d2b398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_c96bedb4-842a-415d-9c37-a7c21efb7fec" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3df96a2a-8bf7-4655-a072-017080d2b398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="plrx-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5d8fd65e-1471-446e-acd6-8f78cc831b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_464019a7-6587-44d9-b04e-eeb263bfbf15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d8fd65e-1471-446e-acd6-8f78cc831b7a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_464019a7-6587-44d9-b04e-eeb263bfbf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="plrx-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_89d5ee39-2f2a-4f9b-a49a-ab206d6d18be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_89d5ee39-2f2a-4f9b-a49a-ab206d6d18be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ff63cad8-2c24-42fe-90d9-c3b88496fac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_UseOfEstimates_ff63cad8-2c24-42fe-90d9-c3b88496fac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_172ec737-303a-49fb-92c6-14c94e534455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_172ec737-303a-49fb-92c6-14c94e534455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_cc6bf1c1-3ee1-4467-ae45-db545931137c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_cc6bf1c1-3ee1-4467-ae45-db545931137c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9528056b-6e2d-4cfe-a15b-26987aad6324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9528056b-6e2d-4cfe-a15b-26987aad6324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d5c9a2e5-1826-4133-9b5b-9b635a2039fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d5c9a2e5-1826-4133-9b5b-9b635a2039fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b083c4ef-99a1-4c53-9a8b-2fe221d78c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b083c4ef-99a1-4c53-9a8b-2fe221d78c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_2b874c27-4c14-4435-9857-a7f6dbe7f5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_2b874c27-4c14-4435-9857-a7f6dbe7f5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4702ada2-d909-4d96-8a85-14e686c3375a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4702ada2-d909-4d96-8a85-14e686c3375a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_372a1e4b-7a84-4a11-a5f9-44937f1fb3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_372a1e4b-7a84-4a11-a5f9-44937f1fb3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ee9c1d1a-c2ba-49de-bbe9-53109f249b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ee9c1d1a-c2ba-49de-bbe9-53109f249b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock_da000d4f-5a0e-4325-bb64-4f905e7c573e" xlink:href="plrx-20211231.xsd#plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock_da000d4f-5a0e-4325-bb64-4f905e7c573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_76add0ac-3ed1-4568-836a-e1e7d500cdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_76add0ac-3ed1-4568-836a-e1e7d500cdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_29d55c2e-3808-4f06-85f1-46cece0aac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_29d55c2e-3808-4f06-85f1-46cece0aac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9cc78a62-7481-47be-be85-8a6e894c3194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9cc78a62-7481-47be-be85-8a6e894c3194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_90a812b6-0617-429b-bb14-193f8f8b14e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_90a812b6-0617-429b-bb14-193f8f8b14e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_41d46af7-6c2e-438b-85f9-31936b2b1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_41d46af7-6c2e-438b-85f9-31936b2b1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_52702ca2-a6ff-4eb0-8874-a148c831f947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a36ee014-106f-41a3-a2be-0e9e04dd1c3e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_52702ca2-a6ff-4eb0-8874-a148c831f947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8246f87a-941f-44dd-9fe1-7bde503228c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock_5e9e03ec-6566-4a39-b5d9-62bfec809d14" xlink:href="plrx-20211231.xsd#plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8246f87a-941f-44dd-9fe1-7bde503228c5" xlink:to="loc_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock_5e9e03ec-6566-4a39-b5d9-62bfec809d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a575aa7e-d3e0-438a-9bcf-01658670bd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:href="plrx-20211231.xsd#plrx_AccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a575aa7e-d3e0-438a-9bcf-01658670bd94" xlink:to="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_bed2d048-13de-4efa-88cf-d675a134d610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_bed2d048-13de-4efa-88cf-d675a134d610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_24991256-8d18-43ec-a23e-d13c26005efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_bed2d048-13de-4efa-88cf-d675a134d610" xlink:to="loc_us-gaap_TypeOfAdoptionMember_24991256-8d18-43ec-a23e-d13c26005efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_e049289a-d69d-4e2a-b7f0-e5794345a6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_24991256-8d18-43ec-a23e-d13c26005efc" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_e049289a-d69d-4e2a-b7f0-e5794345a6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ab6e54fc-db23-402a-9518-68eb897d52cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ab6e54fc-db23-402a-9518-68eb897d52cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e9fa71e-8855-4313-b555-63a26d3fc144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ab6e54fc-db23-402a-9518-68eb897d52cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e9fa71e-8855-4313-b555-63a26d3fc144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementMember_6a8b86ea-51b6-4a48-ac7b-498731ce9102" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e9fa71e-8855-4313-b555-63a26d3fc144" xlink:to="loc_plrx_NovartisAgreementMember_6a8b86ea-51b6-4a48-ac7b-498731ce9102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:href="plrx-20211231.xsd#plrx_AccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesTable_50cf80c1-807a-4bde-af05-6e360460652e" xlink:to="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_5da56f52-994a-45d4-a87b-42b2c4321309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_5da56f52-994a-45d4-a87b-42b2c4321309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PercentageOfRevenueContributedByRelatedParty_7825fd2e-c333-4e0f-b8c1-3b0d46b7ae45" xlink:href="plrx-20211231.xsd#plrx_PercentageOfRevenueContributedByRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_plrx_PercentageOfRevenueContributedByRelatedParty_7825fd2e-c333-4e0f-b8c1-3b0d46b7ae45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_917c3f9f-54f5-4369-b3cf-202f30bd2e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_NumberOfOperatingSegments_917c3f9f-54f5-4369-b3cf-202f30bd2e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_27a6160b-51d5-4935-bd4a-0f26f39bb453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_NumberOfReportableSegments_27a6160b-51d5-4935-bd4a-0f26f39bb453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase_44f45264-a671-425f-a659-14bfc66f7b9f" xlink:href="plrx-20211231.xsd#plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase_44f45264-a671-425f-a659-14bfc66f7b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_42bba2b6-5f08-4a47-a59c-3c7d50559cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_42bba2b6-5f08-4a47-a59c-3c7d50559cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9b93bcb2-48ae-4c72-afee-b6ebd4851cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9b93bcb2-48ae-4c72-afee-b6ebd4851cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_82241340-d7cd-460c-9d28-4e4e527b5980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_82241340-d7cd-460c-9d28-4e4e527b5980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_748b77a6-a0c3-480b-a0e2-baad363036cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_OperatingLeaseLiability_748b77a6-a0c3-480b-a0e2-baad363036cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_d631d415-497f-403a-b208-4f3645f451ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_AccountingPoliciesLineItems_552a0627-b7e0-41d8-8695-d409da446f62" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_d631d415-497f-403a-b208-4f3645f451ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9aa855be-f343-4f9b-98c7-e6af6536e00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb2be8fc-4dbc-4684-8e15-f9e9c01fa047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9aa855be-f343-4f9b-98c7-e6af6536e00d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb2be8fc-4dbc-4684-8e15-f9e9c01fa047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb2be8fc-4dbc-4684-8e15-f9e9c01fa047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ddf8970-73ad-47ff-89f7-09645cc60b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_04f6eb53-6488-4aa7-a7fd-50df5d4ae10c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ddf8970-73ad-47ff-89f7-09645cc60b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f02ac652-a1da-4bcd-af5f-900bfa5faf72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ddf8970-73ad-47ff-89f7-09645cc60b17" xlink:to="loc_us-gaap_EquipmentMember_f02ac652-a1da-4bcd-af5f-900bfa5faf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ComputerEquipmentAndSoftwareMember_2bdaa9c2-eec7-4320-9f5f-0f8e7dfc64c5" xlink:href="plrx-20211231.xsd#plrx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ddf8970-73ad-47ff-89f7-09645cc60b17" xlink:to="loc_plrx_ComputerEquipmentAndSoftwareMember_2bdaa9c2-eec7-4320-9f5f-0f8e7dfc64c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6446ff12-c8a3-45fb-a9e2-a1d69363a5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb2be8fc-4dbc-4684-8e15-f9e9c01fa047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6446ff12-c8a3-45fb-a9e2-a1d69363a5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_56447ec1-851c-43d4-9619-5359b4290088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6446ff12-c8a3-45fb-a9e2-a1d69363a5de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_56447ec1-851c-43d4-9619-5359b4290088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/FinancialInstruments" xlink:type="simple" xlink:href="plrx-20211231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_190ff832-1125-40bc-9cc1-7704c144c207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a8e642ee-c9b4-4a02-9d63-6de105fc84dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_190ff832-1125-40bc-9cc1-7704c144c207" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a8e642ee-c9b4-4a02-9d63-6de105fc84dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1b9ae89f-3a3f-4184-b21b-2fee4f6d1b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_f6942888-bda8-4127-a33a-9f9865f4949c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b9ae89f-3a3f-4184-b21b-2fee4f6d1b59" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_f6942888-bda8-4127-a33a-9f9865f4949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7f632c88-17bd-498a-babd-ffb1500b7e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1b9ae89f-3a3f-4184-b21b-2fee4f6d1b59" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7f632c88-17bd-498a-babd-ffb1500b7e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_90555aed-ac37-417d-b2c3-5129ec4beb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_90555aed-ac37-417d-b2c3-5129ec4beb46" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e549c7af-88da-49d9-af24-4bd76e87bcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e549c7af-88da-49d9-af24-4bd76e87bcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f8469a2-b658-44c4-9d00-b9917010187f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e549c7af-88da-49d9-af24-4bd76e87bcd3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f8469a2-b658-44c4-9d00-b9917010187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_34ae936a-1be8-41a4-b1dd-391f21f18814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f8469a2-b658-44c4-9d00-b9917010187f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_34ae936a-1be8-41a4-b1dd-391f21f18814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e68bdba2-b57a-4886-8ceb-09abbedb290b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f8469a2-b658-44c4-9d00-b9917010187f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e68bdba2-b57a-4886-8ceb-09abbedb290b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3efcab56-8111-4903-be8b-2e022f997242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3efcab56-8111-4903-be8b-2e022f997242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3efcab56-8111-4903-be8b-2e022f997242" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5305a226-a434-4c36-b29a-c7d54c2e3512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5305a226-a434-4c36-b29a-c7d54c2e3512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7da54301-13ff-4cd0-8efe-ad0814c45458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7da54301-13ff-4cd0-8efe-ad0814c45458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9229cf88-b682-45cd-b8f3-b4e434ea55c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_64f0954f-eff0-46e0-a9f8-fc6aa9a2895a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_9229cf88-b682-45cd-b8f3-b4e434ea55c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6766ebb7-990e-4594-b333-ecf9666622a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:to="loc_us-gaap_InvestmentTypeAxis_6766ebb7-990e-4594-b333-ecf9666622a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e041ca76-4742-45f8-9c4a-306e26c42b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_6766ebb7-990e-4594-b333-ecf9666622a9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e041ca76-4742-45f8-9c4a-306e26c42b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_82a10e0c-1959-4bb9-982e-03334d21aa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e041ca76-4742-45f8-9c4a-306e26c42b81" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_82a10e0c-1959-4bb9-982e-03334d21aa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b12cc59d-8879-4392-b7b9-2196e484c7ec" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3eafd2f4-7584-428a-9d46-d04388ca4a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3eafd2f4-7584-428a-9d46-d04388ca4a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_c50f77d4-bf2d-45cb-ae62-9d8114403127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_c50f77d4-bf2d-45cb-ae62-9d8114403127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_12c89797-e9c1-4e04-a732-911f83329fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_12c89797-e9c1-4e04-a732-911f83329fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_75d4b10d-d75f-4e11-a738-7c21ee631fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3ae2b1e-4038-4782-8f1d-9b759746961a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_75d4b10d-d75f-4e11-a738-7c21ee631fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_cec98594-ed7e-49c7-aae1-7b269ac05baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_cec98594-ed7e-49c7-aae1-7b269ac05baa" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:to="loc_us-gaap_InvestmentTypeAxis_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3f8938bb-6ee3-4af7-8c3a-126454370d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_84e6f4fa-c240-4227-b3bd-2f1e3d8d6689" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3f8938bb-6ee3-4af7-8c3a-126454370d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_d56a21b9-7d1a-47b8-bbdb-ce54d312503b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3f8938bb-6ee3-4af7-8c3a-126454370d89" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_d56a21b9-7d1a-47b8-bbdb-ce54d312503b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_5d43777c-b05e-4fe3-ab36-a96e395faef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_5d43777c-b05e-4fe3-ab36-a96e395faef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_31130fa2-c203-4706-b099-c2f65580becc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_5d43777c-b05e-4fe3-ab36-a96e395faef0" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_31130fa2-c203-4706-b099-c2f65580becc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MatureInOneYearOrLessMember_178202bd-beff-4dbb-87fd-861d769fe5d5" xlink:href="plrx-20211231.xsd#plrx_MatureInOneYearOrLessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_31130fa2-c203-4706-b099-c2f65580becc" xlink:to="loc_plrx_MatureInOneYearOrLessMember_178202bd-beff-4dbb-87fd-861d769fe5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MatureInOneToTwoYearsMember_535d868d-9a1a-4b1d-bd37-138853e62e6b" xlink:href="plrx-20211231.xsd#plrx_MatureInOneToTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_31130fa2-c203-4706-b099-c2f65580becc" xlink:to="loc_plrx_MatureInOneToTwoYearsMember_535d868d-9a1a-4b1d-bd37-138853e62e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d3c6100d-7339-4637-84b5-532d69cb25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c980eae-d04a-4071-af13-fd655cbbe908" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d3c6100d-7339-4637-84b5-532d69cb25bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_36dd176d-f9c5-4996-8012-03954981f4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d3c6100d-7339-4637-84b5-532d69cb25bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_36dd176d-f9c5-4996-8012-03954981f4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2de7b15-4f41-487c-a65b-8f9af58760ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d3c6100d-7339-4637-84b5-532d69cb25bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2de7b15-4f41-487c-a65b-8f9af58760ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06a8a1c3-25ad-42ab-8136-7e5b6969da5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2e473d9e-bebf-423d-a55a-10b1fcda7bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06a8a1c3-25ad-42ab-8136-7e5b6969da5e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2e473d9e-bebf-423d-a55a-10b1fcda7bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2e473d9e-bebf-423d-a55a-10b1fcda7bd3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_98ba8f07-6901-447f-9d60-a23eb9d64e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd0f2e35-ce3b-4bf0-b44d-dfd9de24ab8a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_98ba8f07-6901-447f-9d60-a23eb9d64e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a6a45c93-51b1-4a32-b5e5-957cdad25a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_98ba8f07-6901-447f-9d60-a23eb9d64e13" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a6a45c93-51b1-4a32-b5e5-957cdad25a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_f3a1a02f-1c2a-47e4-a47b-31f5073808a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_98ba8f07-6901-447f-9d60-a23eb9d64e13" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_f3a1a02f-1c2a-47e4-a47b-31f5073808a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0175b69-4ecd-4b66-83f5-d894f1ab1e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2e473d9e-bebf-423d-a55a-10b1fcda7bd3" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0175b69-4ecd-4b66-83f5-d894f1ab1e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_012aa7e7-2d46-4137-a105-416bc1b0c7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0175b69-4ecd-4b66-83f5-d894f1ab1e98" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_012aa7e7-2d46-4137-a105-416bc1b0c7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_bb54a168-264a-41c9-9db7-3c0f350e89c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0175b69-4ecd-4b66-83f5-d894f1ab1e98" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_bb54a168-264a-41c9-9db7-3c0f350e89c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="plrx-20211231.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_99b5eccb-21dd-4817-8609-3ec9cedd451a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_670533c8-3606-4e46-a2e2-7b8cfe646e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_99b5eccb-21dd-4817-8609-3ec9cedd451a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_670533c8-3606-4e46-a2e2-7b8cfe646e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_34eedab1-05bc-4e8a-a0da-b9ade6e33ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5dfc104e-e814-4d55-91d0-141fe7b6354e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_34eedab1-05bc-4e8a-a0da-b9ade6e33ce4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5dfc104e-e814-4d55-91d0-141fe7b6354e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b6148261-cf65-468d-8944-e3ee173925b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ed8e4128-6a48-4add-9450-c1b69eaba0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b6148261-cf65-468d-8944-e3ee173925b4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ed8e4128-6a48-4add-9450-c1b69eaba0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f76e90-51a3-4424-91bb-878d8f5c9509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ed8e4128-6a48-4add-9450-c1b69eaba0be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f76e90-51a3-4424-91bb-878d8f5c9509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_25f76e90-51a3-4424-91bb-878d8f5c9509" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_0d6372f1-cd0a-4d04-8c19-f98de0ae7422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:to="loc_us-gaap_EquipmentMember_0d6372f1-cd0a-4d04-8c19-f98de0ae7422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_67c54a41-9219-4788-8a12-e56dc92463a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_67c54a41-9219-4788-8a12-e56dc92463a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a41d8528-9777-4608-939e-df794ff18e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:to="loc_us-gaap_ConstructionInProgressMember_a41d8528-9777-4608-939e-df794ff18e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ComputerEquipmentAndSoftwareMember_18fbe9cb-047e-430f-8670-9e32ae38abd2" xlink:href="plrx-20211231.xsd#plrx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5901991a-ff1f-4911-85e3-0f03823ea410" xlink:to="loc_plrx_ComputerEquipmentAndSoftwareMember_18fbe9cb-047e-430f-8670-9e32ae38abd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ed8e4128-6a48-4add-9450-c1b69eaba0be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2283667d-5c6c-46d8-9ca0-0f2321903e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2283667d-5c6c-46d8-9ca0-0f2321903e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7596c86d-ee79-47ac-a4d0-371e08770a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7596c86d-ee79-47ac-a4d0-371e08770a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1b9510f9-dd90-4ea3-bd8e-efda9f337b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2203ed8f-9463-4ee8-98df-8ec59076a6e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1b9510f9-dd90-4ea3-bd8e-efda9f337b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PropertyandEquipmentnetAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#PropertyandEquipmentnetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/PropertyandEquipmentnetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ffe1a66f-3b3a-4f21-bf89-dddb1a08be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_26e5fa1f-e286-4d57-978c-3b262b291e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ffe1a66f-3b3a-4f21-bf89-dddb1a08be8e" xlink:to="loc_us-gaap_Depreciation_26e5fa1f-e286-4d57-978c-3b262b291e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/Prepaidexpensesandothercurrentassets" xlink:type="simple" xlink:href="plrx-20211231.xsd#Prepaidexpensesandothercurrentassets"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/Prepaidexpensesandothercurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bd7c2234-c1cb-4152-8b14-a275f220df9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_f10f17ee-7309-48db-979e-865c47f78b1e" xlink:href="plrx-20211231.xsd#plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bd7c2234-c1cb-4152-8b14-a275f220df9e" xlink:to="loc_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_f10f17ee-7309-48db-979e-865c47f78b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#PrepaidexpensesandothercurrentassetsTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_57bf1efd-2400-465e-9b71-420cb1a0be90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_f7fa9bb9-fc32-4b55-a9db-7788f06504b3" xlink:href="plrx-20211231.xsd#plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_57bf1efd-2400-465e-9b71-420cb1a0be90" xlink:to="loc_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_f7fa9bb9-fc32-4b55-a9db-7788f06504b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#PrepaidexpensesandothercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_017c0d34-5e65-401a-bfc2-945f31c8715a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PrepaidResearchAndDevelopmentCurrent_9f2e3def-b1be-46c7-a743-0ff5da982531" xlink:href="plrx-20211231.xsd#plrx_PrepaidResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_017c0d34-5e65-401a-bfc2-945f31c8715a" xlink:to="loc_plrx_PrepaidResearchAndDevelopmentCurrent_9f2e3def-b1be-46c7-a743-0ff5da982531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_d0d0bb2e-0d90-4e87-916f-2f1c6b16ac5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_017c0d34-5e65-401a-bfc2-945f31c8715a" xlink:to="loc_us-gaap_PrepaidInsurance_d0d0bb2e-0d90-4e87-916f-2f1c6b16ac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PrepaidLicensesCurrent_37c32df3-43c7-4f6c-9f57-12ed8b179ac6" xlink:href="plrx-20211231.xsd#plrx_PrepaidLicensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_017c0d34-5e65-401a-bfc2-945f31c8715a" xlink:to="loc_plrx_PrepaidLicensesCurrent_37c32df3-43c7-4f6c-9f57-12ed8b179ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInterest_0b4dd647-5e4b-4865-929f-13e8fff65e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_017c0d34-5e65-401a-bfc2-945f31c8715a" xlink:to="loc_us-gaap_PrepaidInterest_0b4dd647-5e4b-4865-929f-13e8fff65e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_0bae361f-71fe-4cb0-a87d-c7b392d90b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_017c0d34-5e65-401a-bfc2-945f31c8715a" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_0bae361f-71fe-4cb0-a87d-c7b392d90b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9f44c64d-81b5-41c9-88c1-aa55eba4f72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_017c0d34-5e65-401a-bfc2-945f31c8715a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9f44c64d-81b5-41c9-88c1-aa55eba4f72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilities" xlink:type="simple" xlink:href="plrx-20211231.xsd#AccruedLiabilitiesandOtherLongTermLiabilities"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_7ba4f0cf-2f81-4c5c-8db9-79f7809fd244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f1e01728-efe9-4c44-9975-f4ea4bad2dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_7ba4f0cf-2f81-4c5c-8db9-79f7809fd244" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f1e01728-efe9-4c44-9975-f4ea4bad2dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#AccruedLiabilitiesandOtherLongTermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_e9fee921-25ba-4b63-996f-7d3a2bb6b108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e45bebd8-6e60-4a86-ba64-397d2a8989e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_e9fee921-25ba-4b63-996f-7d3a2bb6b108" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e45bebd8-6e60-4a86-ba64-397d2a8989e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_2dd18518-ccc0-4f7f-80fc-5a4dc22ec952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_e9fee921-25ba-4b63-996f-7d3a2bb6b108" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_2dd18518-ccc0-4f7f-80fc-5a4dc22ec952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_75a683be-8094-45ee-b1fc-c7f02a2ada60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccruedResearchAndDevelopmentExpensesCurrent_7b56dfde-02d4-4846-9556-dd7b6ec334a3" xlink:href="plrx-20211231.xsd#plrx_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_75a683be-8094-45ee-b1fc-c7f02a2ada60" xlink:to="loc_plrx_AccruedResearchAndDevelopmentExpensesCurrent_7b56dfde-02d4-4846-9556-dd7b6ec334a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_548daf3e-b551-4f40-bece-508f5cf26359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_75a683be-8094-45ee-b1fc-c7f02a2ada60" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_548daf3e-b551-4f40-bece-508f5cf26359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_57627cbb-9a21-4003-afbf-feb3fa8dd9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_75a683be-8094-45ee-b1fc-c7f02a2ada60" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_57627cbb-9a21-4003-afbf-feb3fa8dd9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent_f49bd3f6-bd57-4a3e-92f7-43c8a91662b3" xlink:href="plrx-20211231.xsd#plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_75a683be-8094-45ee-b1fc-c7f02a2ada60" xlink:to="loc_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent_f49bd3f6-bd57-4a3e-92f7-43c8a91662b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7e5ddd80-73ef-4fc3-bfd8-73f4aa8fe1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_75a683be-8094-45ee-b1fc-c7f02a2ada60" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7e5ddd80-73ef-4fc3-bfd8-73f4aa8fe1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_ca62e88c-77c2-4cef-9fa7-0ba70a4c67d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCredit_44d69337-8004-4236-a07c-2275ebd9f928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_ca62e88c-77c2-4cef-9fa7-0ba70a4c67d3" xlink:to="loc_us-gaap_DeferredRentCredit_44d69337-8004-4236-a07c-2275ebd9f928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor_6a231009-fd82-4c0c-8f47-5f9f0bac4ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveFromLessor"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_ca62e88c-77c2-4cef-9fa7-0ba70a4c67d3" xlink:to="loc_us-gaap_IncentiveFromLessor_6a231009-fd82-4c0c-8f47-5f9f0bac4ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_edbd5307-02f6-4ac3-8e94-b842a79cdf83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_ca62e88c-77c2-4cef-9fa7-0ba70a4c67d3" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_edbd5307-02f6-4ac3-8e94-b842a79cdf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6c0d76d1-b4c7-4361-8657-f97f0ffebbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_ca62e88c-77c2-4cef-9fa7-0ba70a4c67d3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6c0d76d1-b4c7-4361-8657-f97f0ffebbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreement" xlink:type="simple" xlink:href="plrx-20211231.xsd#NovartisCollaborationandLicenseAgreementtheNovartisAgreement"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8dbc257-2156-4582-84df-0a201907ed2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_42b46e34-b84c-463a-b44d-eed3595ba9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8dbc257-2156-4582-84df-0a201907ed2d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_42b46e34-b84c-463a-b44d-eed3595ba9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6f20b511-0d67-4c03-8b29-3e0c3d97336a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6f20b511-0d67-4c03-8b29-3e0c3d97336a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ce48235c-6de7-4156-b7ef-f128d6ee0503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ce48235c-6de7-4156-b7ef-f128d6ee0503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce48235c-6de7-4156-b7ef-f128d6ee0503" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementMember_c96051ad-0779-415b-9e6d-721edf48a31d" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:to="loc_plrx_NovartisAgreementMember_c96051ad-0779-415b-9e6d-721edf48a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementRDForPLN1474Member_a58d20b2-d315-4bfe-a34f-8aad5044383f" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementRDForPLN1474Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:to="loc_plrx_NovartisAgreementRDForPLN1474Member_a58d20b2-d315-4bfe-a34f-8aad5044383f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember_82b9b5bb-087d-4052-bbb9-60be72fa18aa" xlink:href="plrx-20211231.xsd#plrx_NovartisAgreementRDForIntegrinResearchTargetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3771a49-ae20-477f-8488-b55582292559" xlink:to="loc_plrx_NovartisAgreementRDForIntegrinResearchTargetsMember_82b9b5bb-087d-4052-bbb9-60be72fa18aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_785aa916-88e4-44b9-b591-5ec296cc3bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_785aa916-88e4-44b9-b591-5ec296cc3bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a9db8a5a-6961-448b-90ab-133fd5ed1464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_785aa916-88e4-44b9-b591-5ec296cc3bba" xlink:to="loc_us-gaap_RelatedPartyDomain_a9db8a5a-6961-448b-90ab-133fd5ed1464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NovartisMember_faa39aac-e892-4d06-8244-985420ba8317" xlink:href="plrx-20211231.xsd#plrx_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a9db8a5a-6961-448b-90ab-133fd5ed1464" xlink:to="loc_plrx_NovartisMember_faa39aac-e892-4d06-8244-985420ba8317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_srt_RangeAxis_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2591859a-5bd3-4fb9-b2bf-392565505b66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fa87a6ba-0306-4c9e-83cd-3e0d79b466cc" xlink:to="loc_srt_RangeMember_2591859a-5bd3-4fb9-b2bf-392565505b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6d9d61f1-8604-46c9-977e-f3d6cab0b682" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2591859a-5bd3-4fb9-b2bf-392565505b66" xlink:to="loc_srt_MaximumMember_6d9d61f1-8604-46c9-977e-f3d6cab0b682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0a82b2a3-c96e-43e6-8a5e-9f1fb5e5f905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b26f70d-457d-4f63-ac53-7fa7bb4f7f0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0a82b2a3-c96e-43e6-8a5e-9f1fb5e5f905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e6b7973-4896-454c-8e44-46c512cc87a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a82b2a3-c96e-43e6-8a5e-9f1fb5e5f905" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e6b7973-4896-454c-8e44-46c512cc87a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseFeeMember_f455e8fd-6801-4bfd-a4ca-683a136d0022" xlink:href="plrx-20211231.xsd#plrx_LicenseFeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a82b2a3-c96e-43e6-8a5e-9f1fb5e5f905" xlink:to="loc_plrx_LicenseFeeMember_f455e8fd-6801-4bfd-a4ca-683a136d0022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_39e26c01-309d-4e0e-b01f-af2e5edb1c02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_srt_ProductOrServiceAxis_39e26c01-309d-4e0e-b01f-af2e5edb1c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b6ff19fe-d564-44b8-922c-e817534761cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_39e26c01-309d-4e0e-b01f-af2e5edb1c02" xlink:to="loc_srt_ProductsAndServicesDomain_b6ff19fe-d564-44b8-922c-e817534761cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AchievementOfFirstPatientDosingMilestoneMember_e4fe580e-4d28-466b-9ddd-664921b00cc8" xlink:href="plrx-20211231.xsd#plrx_AchievementOfFirstPatientDosingMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b6ff19fe-d564-44b8-922c-e817534761cd" xlink:to="loc_plrx_AchievementOfFirstPatientDosingMilestoneMember_e4fe580e-4d28-466b-9ddd-664921b00cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39976489-172b-45bc-8a32-3aea4de162f0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NumberOfIntegrinResearchTargets_1e276c49-d2d7-4a0d-89dc-0f94c06f1080" xlink:href="plrx-20211231.xsd#plrx_NumberOfIntegrinResearchTargets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_plrx_NumberOfIntegrinResearchTargets_1e276c49-d2d7-4a0d-89dc-0f94c06f1080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ProceedsFromUpfrontNonRefundableLicenseFee_98b0fb4b-716e-40cb-b53d-2eefc41ae66d" xlink:href="plrx-20211231.xsd#plrx_ProceedsFromUpfrontNonRefundableLicenseFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_plrx_ProceedsFromUpfrontNonRefundableLicenseFee_98b0fb4b-716e-40cb-b53d-2eefc41ae66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount_f2168ef8-69a3-44bd-8366-183df605be6a" xlink:href="plrx-20211231.xsd#plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount_f2168ef8-69a3-44bd-8366-183df605be6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1277df23-03d6-49be-bf72-f2274a6b987d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1277df23-03d6-49be-bf72-f2274a6b987d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_4912d975-ccd5-4c5f-a062-455761eddcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_RevenueFromRelatedParties_4912d975-ccd5-4c5f-a062-455761eddcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_51e4e40f-1f73-4c90-82b9-6140e828f187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_51e4e40f-1f73-4c90-82b9-6140e828f187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_983956d3-e7e7-4544-8712-bde7a736bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_983956d3-e7e7-4544-8712-bde7a736bd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_307e31a2-6bad-486d-bc30-77c829745352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b1fc2f6e-7e2f-4e1e-ae9b-3c21104567b9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_307e31a2-6bad-486d-bc30-77c829745352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement" xlink:type="simple" xlink:href="plrx-20211231.xsd#RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsAbstract_4c4a4aa1-6b5a-4c7a-ae73-27b97f337980" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsTextBlock_9578d1d4-2ac9-4245-8b4d-0a52eafb7fb2" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_LicenseAgreementsAbstract_4c4a4aa1-6b5a-4c7a-ae73-27b97f337980" xlink:to="loc_plrx_LicenseAgreementsTextBlock_9578d1d4-2ac9-4245-8b4d-0a52eafb7fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsAbstract_a64b62ab-eccb-488f-b6ef-97cd402a3c00" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_LicenseAgreementsAbstract_a64b62ab-eccb-488f-b6ef-97cd402a3c00" xlink:to="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_01d2686f-ab06-4966-90ce-6787a5908742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_01d2686f-ab06-4966-90ce-6787a5908742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6cf7d2db-c4ca-4917-aba5-950ac3d613c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_01d2686f-ab06-4966-90ce-6787a5908742" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6cf7d2db-c4ca-4917-aba5-950ac3d613c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_7cce4e22-548f-4fdf-9275-167d20043aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6cf7d2db-c4ca-4917-aba5-950ac3d613c9" xlink:to="loc_us-gaap_LicensingAgreementsMember_7cce4e22-548f-4fdf-9275-167d20043aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd0f2138-eecc-4f8a-bb15-c1ec66734285" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:to="loc_srt_ProductOrServiceAxis_bd0f2138-eecc-4f8a-bb15-c1ec66734285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88f742b1-8d2e-4b47-9d1a-f1a930725862" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bd0f2138-eecc-4f8a-bb15-c1ec66734285" xlink:to="loc_srt_ProductsAndServicesDomain_88f742b1-8d2e-4b47-9d1a-f1a930725862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UCRegentsMember_a080de4c-61b3-4e08-94a7-8406a4598049" xlink:href="plrx-20211231.xsd#plrx_UCRegentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_88f742b1-8d2e-4b47-9d1a-f1a930725862" xlink:to="loc_plrx_UCRegentsMember_a080de4c-61b3-4e08-94a7-8406a4598049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LicenseAgreementsLineItems_d58b336c-2355-4380-9673-66a5f08e7936" xlink:href="plrx-20211231.xsd#plrx_LicenseAgreementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_LicenseAgreementsTable_5beedc7e-1228-44d7-b93e-32113729c7b6" xlink:to="loc_plrx_LicenseAgreementsLineItems_d58b336c-2355-4380-9673-66a5f08e7936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_MilestoneAndAnnualRoyaltyPaid_af36a3e3-4653-4bf5-8df5-5962a0a54793" xlink:href="plrx-20211231.xsd#plrx_MilestoneAndAnnualRoyaltyPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plrx_LicenseAgreementsLineItems_d58b336c-2355-4380-9673-66a5f08e7936" xlink:to="loc_plrx_MilestoneAndAnnualRoyaltyPaid_af36a3e3-4653-4bf5-8df5-5962a0a54793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreement" xlink:type="simple" xlink:href="plrx-20211231.xsd#AdimabDevelopmentandOptionAgreementtheAdimabAgreement"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_7bdd99bb-9ab7-40a0-96fa-846cde66659b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_32090448-1229-4f59-a9f9-ffd7cc81100d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7bdd99bb-9ab7-40a0-96fa-846cde66659b" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_32090448-1229-4f59-a9f9-ffd7cc81100d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_ac42c991-1522-49f8-a728-17c6b5575eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_ac42c991-1522-49f8-a728-17c6b5575eb1" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_719269f5-3c29-4f33-9f6a-f88479ea7f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_719269f5-3c29-4f33-9f6a-f88479ea7f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_c459bac3-e97e-443b-bca6-f8fd37a059a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_719269f5-3c29-4f33-9f6a-f88479ea7f75" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_c459bac3-e97e-443b-bca6-f8fd37a059a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_FullTimeEmployeeCostMember_9eb73d65-c8fa-438e-8c06-6f6493205862" xlink:href="plrx-20211231.xsd#plrx_FullTimeEmployeeCostMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetTransactionDomain_c459bac3-e97e-443b-bca6-f8fd37a059a5" xlink:to="loc_plrx_FullTimeEmployeeCostMember_9eb73d65-c8fa-438e-8c06-6f6493205862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_40b6b6b1-123d-40d6-af72-ea548d8d0a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_40b6b6b1-123d-40d6-af72-ea548d8d0a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f38b826d-b429-4fd2-9bce-36e5c5487beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_40b6b6b1-123d-40d6-af72-ea548d8d0a67" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f38b826d-b429-4fd2-9bce-36e5c5487beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AdimabAgreementMember_016e26a0-dfd2-449f-993d-e665d36e9b98" xlink:href="plrx-20211231.xsd#plrx_AdimabAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f38b826d-b429-4fd2-9bce-36e5c5487beb" xlink:to="loc_plrx_AdimabAgreementMember_016e26a0-dfd2-449f-993d-e665d36e9b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ffb4f1a-9c99-4909-8d66-a6db8596524a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dc7a15e8-174d-4d0c-b65e-b365d870a467" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ffb4f1a-9c99-4909-8d66-a6db8596524a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7fb48263-21d3-4246-ac6f-e39b0c126921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1ffb4f1a-9c99-4909-8d66-a6db8596524a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7fb48263-21d3-4246-ac6f-e39b0c126921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="plrx-20211231.xsd#RedeemableConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_7762879f-dac2-4503-8140-76a931261c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RedeemableConvertiblePreferredStockTextBlock_2a9aefb5-4e49-459f-9275-83271d62f23d" xlink:href="plrx-20211231.xsd#plrx_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_7762879f-dac2-4503-8140-76a931261c14" xlink:to="loc_plrx_RedeemableConvertiblePreferredStockTextBlock_2a9aefb5-4e49-459f-9275-83271d62f23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#RedeemableConvertiblePreferredStockAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_6318eb05-0324-4964-9457-fbb4e3a6ac60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_7d7aa398-1093-4ed8-a8cc-87c62b177610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_6318eb05-0324-4964-9457-fbb4e3a6ac60" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_7d7aa398-1093-4ed8-a8cc-87c62b177610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b266464f-8171-4687-a24c-8640683f9cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_7d7aa398-1093-4ed8-a8cc-87c62b177610" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b266464f-8171-4687-a24c-8640683f9cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6433a8a3-d98f-496f-9c07-f32666a0582c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b266464f-8171-4687-a24c-8640683f9cb8" xlink:to="loc_us-gaap_ClassOfStockDomain_6433a8a3-d98f-496f-9c07-f32666a0582c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_4f89f244-b015-4119-aa49-ee7483cd6db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6433a8a3-d98f-496f-9c07-f32666a0582c" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_4f89f244-b015-4119-aa49-ee7483cd6db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_5ec7fec3-defc-4821-a7e5-4877b2374a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_7d7aa398-1093-4ed8-a8cc-87c62b177610" xlink:to="loc_us-gaap_TemporaryEquityLineItems_5ec7fec3-defc-4821-a7e5-4877b2374a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7573d7cf-7cf1-49df-8881-f2c0cad4441e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_5ec7fec3-defc-4821-a7e5-4877b2374a8f" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7573d7cf-7cf1-49df-8881-f2c0cad4441e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/CommonStock" xlink:type="simple" xlink:href="plrx-20211231.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_43637750-b3cb-4ebf-b5f8-7fab7764e9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_89413c65-1abd-4d1b-9056-119dd3332427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_43637750-b3cb-4ebf-b5f8-7fab7764e9de" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_89413c65-1abd-4d1b-9056-119dd3332427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/CommonStockTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8f584497-f4ec-421d-982e-924f5464efe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_88debd0d-3afd-458f-9631-3305a85a952e" xlink:href="plrx-20211231.xsd#plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8f584497-f4ec-421d-982e-924f5464efe3" xlink:to="loc_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock_88debd0d-3afd-458f-9631-3305a85a952e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#CommonStockAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_16c3c2cc-2a0f-4e6d-aeb7-abb3c9ef8a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1da1feb6-6ab1-4560-88c7-451cfc76447b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_16c3c2cc-2a0f-4e6d-aeb7-abb3c9ef8a93" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1da1feb6-6ab1-4560-88c7-451cfc76447b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_115d9c8e-d96a-4c14-86f3-05628c499b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_16c3c2cc-2a0f-4e6d-aeb7-abb3c9ef8a93" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_115d9c8e-d96a-4c14-86f3-05628c499b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NumberOfVotesPerShareOfCommonStock_fdaf1edb-6880-4172-a997-a704a0059c5b" xlink:href="plrx-20211231.xsd#plrx_NumberOfVotesPerShareOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_16c3c2cc-2a0f-4e6d-aeb7-abb3c9ef8a93" xlink:to="loc_plrx_NumberOfVotesPerShareOfCommonStock_fdaf1edb-6880-4172-a997-a704a0059c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_8cc31132-e2de-4e8d-96b6-5bae1fb2c7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_16c3c2cc-2a0f-4e6d-aeb7-abb3c9ef8a93" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_8cc31132-e2de-4e8d-96b6-5bae1fb2c7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#CommonStockScheduleofSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7365c7ea-b70e-489a-84a2-7e0ec2ae959d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7365c7ea-b70e-489a-84a2-7e0ec2ae959d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c5126dd9-0782-4330-84f0-3bdab7a89f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:to="loc_us-gaap_AwardTypeAxis_c5126dd9-0782-4330-84f0-3bdab7a89f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f217149-885a-4cfb-b210-ce2759af8836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c5126dd9-0782-4330-84f0-3bdab7a89f83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f217149-885a-4cfb-b210-ce2759af8836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_45faba43-b36c-4151-a3cd-dddf983d990d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f217149-885a-4cfb-b210-ce2759af8836" xlink:to="loc_us-gaap_EmployeeStockOptionMember_45faba43-b36c-4151-a3cd-dddf983d990d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7380bd69-7599-4520-81b6-763cd1de3338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:to="loc_us-gaap_PlanNameAxis_7380bd69-7599-4520-81b6-763cd1de3338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c58d61ef-08d4-4cb4-b801-ea788d92fc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7380bd69-7599-4520-81b6-763cd1de3338" xlink:to="loc_us-gaap_PlanNameDomain_c58d61ef-08d4-4cb4-b801-ea788d92fc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember_ffe8a30f-2507-4c1d-9750-23fbdfecbf2c" xlink:href="plrx-20211231.xsd#plrx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c58d61ef-08d4-4cb4-b801-ea788d92fc5e" xlink:to="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember_ffe8a30f-2507-4c1d-9750-23fbdfecbf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_cb4f9f6d-367a-4fef-98a7-70fbd1f34ac5" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c58d61ef-08d4-4cb4-b801-ea788d92fc5e" xlink:to="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_cb4f9f6d-367a-4fef-98a7-70fbd1f34ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_32bd6c49-e181-43c7-a897-d433beec6dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ce21a1bc-e8e5-4822-a625-16d36a8f3924" xlink:to="loc_us-gaap_ClassOfStockLineItems_32bd6c49-e181-43c7-a897-d433beec6dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60381ac4-b8cd-4ecf-abf9-0034d2fcb0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_32bd6c49-e181-43c7-a897-d433beec6dcc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_60381ac4-b8cd-4ecf-abf9-0034d2fcb0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0101795-94f8-4204-bcbd-09e15f08a6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1929ddcc-706d-4f6e-878c-ae5d5e8296db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0101795-94f8-4204-bcbd-09e15f08a6a5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1929ddcc-706d-4f6e-878c-ae5d5e8296db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25fba028-b1a6-40b5-ad77-ae01757e28a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_06be027d-8fb4-4b1d-b23e-813952248be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25fba028-b1a6-40b5-ad77-ae01757e28a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_06be027d-8fb4-4b1d-b23e-813952248be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fdf7d445-cd3a-4fed-bb3c-ee9243cb445a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25fba028-b1a6-40b5-ad77-ae01757e28a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fdf7d445-cd3a-4fed-bb3c-ee9243cb445a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d72d67b4-6b2d-4b70-9f3b-d976a163f0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25fba028-b1a6-40b5-ad77-ae01757e28a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d72d67b4-6b2d-4b70-9f3b-d976a163f0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_53bc3f74-4937-4683-922e-0e96b37f1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25fba028-b1a6-40b5-ad77-ae01757e28a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_53bc3f74-4937-4683-922e-0e96b37f1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_11228f51-0988-4c78-9603-8df9caded515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25fba028-b1a6-40b5-ad77-ae01757e28a2" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_11228f51-0988-4c78-9603-8df9caded515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c7f0124-f44c-4143-b824-4f8f96d302c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c7f0124-f44c-4143-b824-4f8f96d302c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b2d917a1-7056-4712-93e0-c085ee93a356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_us-gaap_PlanNameAxis_b2d917a1-7056-4712-93e0-c085ee93a356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b2d917a1-7056-4712-93e0-c085ee93a356" xlink:to="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember_e04fd3b2-09a0-4c54-8c03-5817c0a66c19" xlink:href="plrx-20211231.xsd#plrx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:to="loc_plrx_TwoThousandTwentyEquityIncentivePlanMember_e04fd3b2-09a0-4c54-8c03-5817c0a66c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedCommonStockAwardsMember_73e8a30b-9de3-4065-ab31-e595abbb8b2a" xlink:href="plrx-20211231.xsd#plrx_RestrictedCommonStockAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:to="loc_plrx_RestrictedCommonStockAwardsMember_73e8a30b-9de3-4065-ab31-e595abbb8b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_2b07c4f2-6df0-4995-9c78-cf20ce4edd98" xlink:href="plrx-20211231.xsd#plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_63f092dc-a75d-4ab9-9df5-60d106655aa6" xlink:to="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_2b07c4f2-6df0-4995-9c78-cf20ce4edd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_srt_RangeAxis_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6015452d-53f6-4677-bd4a-2d7f3c4e0f76" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8c128e6b-7cc8-4e93-b48d-ceb510b60b3e" xlink:to="loc_srt_RangeMember_6015452d-53f6-4677-bd4a-2d7f3c4e0f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1df1d71e-6364-4b5b-96c6-69c2b6612cff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6015452d-53f6-4677-bd4a-2d7f3c4e0f76" xlink:to="loc_srt_MaximumMember_1df1d71e-6364-4b5b-96c6-69c2b6612cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_306ce66a-656b-4299-9f46-6911eac93a14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6015452d-53f6-4677-bd4a-2d7f3c4e0f76" xlink:to="loc_srt_MinimumMember_306ce66a-656b-4299-9f46-6911eac93a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c57f326-cb73-40fb-807d-b5e4d3aee722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c57f326-cb73-40fb-807d-b5e4d3aee722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cc4b0abc-b759-4ccf-9ada-a5825944a0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c57f326-cb73-40fb-807d-b5e4d3aee722" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cc4b0abc-b759-4ccf-9ada-a5825944a0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AccruedExpensesAndOtherLiabilitiesMember_ae274914-1357-49b3-834d-a8c34631da12" xlink:href="plrx-20211231.xsd#plrx_AccruedExpensesAndOtherLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cc4b0abc-b759-4ccf-9ada-a5825944a0f0" xlink:to="loc_plrx_AccruedExpensesAndOtherLiabilitiesMember_ae274914-1357-49b3-834d-a8c34631da12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_52ef8111-b8b5-4cf1-85c7-25f143712442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_us-gaap_AwardTypeAxis_52ef8111-b8b5-4cf1-85c7-25f143712442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_52ef8111-b8b5-4cf1-85c7-25f143712442" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_36a6c34a-a2aa-4562-a0ae-622fc0daeae0" xlink:href="plrx-20211231.xsd#plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:to="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_36a6c34a-a2aa-4562-a0ae-622fc0daeae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedStockAwardsMember_8088fb6a-1aac-40e4-a522-b9966aa9c0e8" xlink:href="plrx-20211231.xsd#plrx_RestrictedStockAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:to="loc_plrx_RestrictedStockAwardsMember_8088fb6a-1aac-40e4-a522-b9966aa9c0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a2f90cd7-da18-4c82-bd0d-25fed200ccd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45eac83e-71cd-4540-84dc-82bf572179bf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a2f90cd7-da18-4c82-bd0d-25fed200ccd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1278efcc-7e46-47af-b120-9439fab45175" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a2a305a2-f2b3-4bac-8dbb-dd3f75fa01ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a2a305a2-f2b3-4bac-8dbb-dd3f75fa01ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63ae3e14-2bc5-462f-aec2-6f044590e2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63ae3e14-2bc5-462f-aec2-6f044590e2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods_964f3ffb-fad0-4fc4-8a63-355d0bcfc629" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods_964f3ffb-fad0-4fc4-8a63-355d0bcfc629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders_f06758d4-d261-48f5-a940-6855fa45be14" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders_f06758d4-d261-48f5-a940-6855fa45be14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bad2d9d7-c9b3-4c63-804b-67e088f4b322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bad2d9d7-c9b3-4c63-804b-67e088f4b322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9221158f-b3aa-4d3b-aa18-dc3e1a411bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9221158f-b3aa-4d3b-aa18-dc3e1a411bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_3713764e-d979-4863-8a39-e96b3d642330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_3713764e-d979-4863-8a39-e96b3d642330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_147b3dea-9b6b-4dd1-9d62-91d327ebc7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_147b3dea-9b6b-4dd1-9d62-91d327ebc7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_f0638c6c-3dec-4fb6-91db-d8d390f84e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_f0638c6c-3dec-4fb6-91db-d8d390f84e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d0f1fed5-cfa6-42d8-9034-dafdd1c7af53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d0f1fed5-cfa6-42d8-9034-dafdd1c7af53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8feb47d0-f2dd-4382-95a6-e2671178eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8feb47d0-f2dd-4382-95a6-e2671178eae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5afaba1d-060c-4e27-9226-33f6f1bc994f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5afaba1d-060c-4e27-9226-33f6f1bc994f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_49881ecf-b50a-45d2-bbd1-cf29fd441a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_49881ecf-b50a-45d2-bbd1-cf29fd441a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eb674acb-5fe2-4781-a323-2315f6a84be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58780afd-390c-476f-abc0-ed0f6c25e84e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eb674acb-5fe2-4781-a323-2315f6a84be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79ae2789-ede8-427a-bc27-92d20703fd65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f1bab86-c3fe-4a36-8ed7-f2e3912d4da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79ae2789-ede8-427a-bc27-92d20703fd65" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f1bab86-c3fe-4a36-8ed7-f2e3912d4da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2f32049c-92d4-482f-b423-d9b497f6ce48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f1bab86-c3fe-4a36-8ed7-f2e3912d4da4" xlink:to="loc_us-gaap_PlanNameAxis_2f32049c-92d4-482f-b423-d9b497f6ce48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3a629f38-a06f-4240-b7d6-8ac602ac5c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2f32049c-92d4-482f-b423-d9b497f6ce48" xlink:to="loc_us-gaap_PlanNameDomain_3a629f38-a06f-4240-b7d6-8ac602ac5c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedCommonStockAwardsMember_1ab87a5e-ce65-4205-a292-f0a17926c44f" xlink:href="plrx-20211231.xsd#plrx_RestrictedCommonStockAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3a629f38-a06f-4240-b7d6-8ac602ac5c1c" xlink:to="loc_plrx_RestrictedCommonStockAwardsMember_1ab87a5e-ce65-4205-a292-f0a17926c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f1bab86-c3fe-4a36-8ed7-f2e3912d4da4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39f573c9-afb3-459c-a946-debb16650bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_39f573c9-afb3-459c-a946-debb16650bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31d652b4-dcb1-4471-8398-7aab3a498aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31d652b4-dcb1-4471-8398-7aab3a498aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_04e4d234-84ed-4bee-acc9-f565aa405237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_04e4d234-84ed-4bee-acc9-f565aa405237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod_a5c00f37-1187-4a19-a341-eee974f6f11d" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod_a5c00f37-1187-4a19-a341-eee974f6f11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cd1702c0-ffdd-4fe0-ba7d-1fdf2fdb6b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cd1702c0-ffdd-4fe0-ba7d-1fdf2fdb6b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f166f3f-ba33-493c-92c3-add2a70e8a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f166f3f-ba33-493c-92c3-add2a70e8a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_faf5d4dd-aacc-4ac9-b99e-20aecbf2457b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_faf5d4dd-aacc-4ac9-b99e-20aecbf2457b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_36c0f19b-e1e1-4815-925a-900ebca124b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_36c0f19b-e1e1-4815-925a-900ebca124b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue_80151e5c-c565-489a-aefb-5ec85596d052" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue_80151e5c-c565-489a-aefb-5ec85596d052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6cfbdc37-fdf3-499e-9ef7-849bc1510235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dfcbb0c-4082-460c-aa27-3048becfd4d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6cfbdc37-fdf3-499e-9ef7-849bc1510235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be706448-2da8-4c65-ab99-feb2926d8067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be706448-2da8-4c65-ab99-feb2926d8067" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:to="loc_us-gaap_AwardTypeAxis_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce5c9a50-5e13-4c75-9135-e112fefba982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9cc55a00-463e-4a52-bcc5-aeea0c97ec3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce5c9a50-5e13-4c75-9135-e112fefba982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_ee11ef15-c39d-4fa4-a3b3-6dd3197b9944" xlink:href="plrx-20211231.xsd#plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce5c9a50-5e13-4c75-9135-e112fefba982" xlink:to="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_ee11ef15-c39d-4fa4-a3b3-6dd3197b9944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_9e00cb26-71b3-40e1-8830-aef460f8ea86" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce5c9a50-5e13-4c75-9135-e112fefba982" xlink:to="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_9e00cb26-71b3-40e1-8830-aef460f8ea86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:to="loc_srt_RangeAxis_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c846fdb9-73c5-4ca7-88e1-b1db9451c34e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_15b2b267-bc08-4cb9-a5d9-2caa5f0502c8" xlink:to="loc_srt_RangeMember_c846fdb9-73c5-4ca7-88e1-b1db9451c34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff120b46-b9d2-4a74-977d-1450f475e79f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c846fdb9-73c5-4ca7-88e1-b1db9451c34e" xlink:to="loc_srt_MinimumMember_ff120b46-b9d2-4a74-977d-1450f475e79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce483d4a-9eef-48e8-afbf-5f4697ca5aca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c846fdb9-73c5-4ca7-88e1-b1db9451c34e" xlink:to="loc_srt_MaximumMember_ce483d4a-9eef-48e8-afbf-5f4697ca5aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c349f8e-d99b-4448-bc15-17270f9fce8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9c609348-90c0-4c06-846c-493eb9dc12e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9c609348-90c0-4c06-846c-493eb9dc12e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0d4202f7-9e34-4911-adca-fe722cab9bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0d4202f7-9e34-4911-adca-fe722cab9bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e9bbb331-2130-4abd-a44d-dea7e2e7abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e9bbb331-2130-4abd-a44d-dea7e2e7abd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d9ddac86-cf5c-43f5-b6cf-8b8972a5046b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d9ddac86-cf5c-43f5-b6cf-8b8972a5046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_82514061-6093-4849-8d21-67a090666dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_82514061-6093-4849-8d21-67a090666dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1e37824-b85b-4bff-a34b-0cdcb5eefcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1e37824-b85b-4bff-a34b-0cdcb5eefcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UnderlyingCommonStockFairValue_aefb884c-b31b-4510-b31d-9ff78363c02c" xlink:href="plrx-20211231.xsd#plrx_UnderlyingCommonStockFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a7ff6c1-d0e5-4b76-8de2-d2c2b3e8badb" xlink:to="loc_plrx_UnderlyingCommonStockFairValue_aefb884c-b31b-4510-b31d-9ff78363c02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a26e31a-8f0e-4d80-9496-fb9ac7a93258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a26e31a-8f0e-4d80-9496-fb9ac7a93258" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7a8694b8-8b61-4884-9f2d-72ee1361dfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:to="loc_us-gaap_PlanNameAxis_7a8694b8-8b61-4884-9f2d-72ee1361dfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d116b46b-597e-4cb0-b2d4-8f01c6b7d1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7a8694b8-8b61-4884-9f2d-72ee1361dfa5" xlink:to="loc_us-gaap_PlanNameDomain_d116b46b-597e-4cb0-b2d4-8f01c6b7d1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_a23b9b59-fcf1-4219-bd1d-13fde3807a38" xlink:href="plrx-20211231.xsd#plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d116b46b-597e-4cb0-b2d4-8f01c6b7d1f8" xlink:to="loc_plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember_a23b9b59-fcf1-4219-bd1d-13fde3807a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:to="loc_us-gaap_AwardTypeAxis_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a23aaf17-e519-4280-bbef-f5cddd7257cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7043bb07-6430-4ab0-b3a0-a3f8a6f4ec70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a23aaf17-e519-4280-bbef-f5cddd7257cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_4c3a57e9-a249-4f10-9c19-f15c0f1a1625" xlink:href="plrx-20211231.xsd#plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a23aaf17-e519-4280-bbef-f5cddd7257cf" xlink:to="loc_plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_4c3a57e9-a249-4f10-9c19-f15c0f1a1625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea1f458-78e8-4abf-bc8a-5be94ae235ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d472d2e-afb1-4c75-866d-09e35bc66877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d472d2e-afb1-4c75-866d-09e35bc66877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96e7eaed-80a2-48f9-a358-389c64b9ac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96e7eaed-80a2-48f9-a358-389c64b9ac3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d8b8b55-b863-429c-99a4-f4b731c87052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d8b8b55-b863-429c-99a4-f4b731c87052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_426f459b-2a98-4e86-b2ab-cbeebbf543dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_426f459b-2a98-4e86-b2ab-cbeebbf543dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc6b7d23-cae4-4d8e-9650-098679ba8637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc6b7d23-cae4-4d8e-9650-098679ba8637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_be3f086e-c5d7-46c0-b58f-50cfe721ce4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_be3f086e-c5d7-46c0-b58f-50cfe721ce4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e139db35-f7b7-4502-a66e-734d1553f5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e139db35-f7b7-4502-a66e-734d1553f5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_07827de6-2944-4f2f-94aa-671976635e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_07827de6-2944-4f2f-94aa-671976635e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8adf0c65-3c73-4d5d-a46e-5d881d10158c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8adf0c65-3c73-4d5d-a46e-5d881d10158c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4b6e0f71-29d3-441c-8269-8ee8b896af66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4b6e0f71-29d3-441c-8269-8ee8b896af66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f44d9caf-544c-4fca-87d4-011d3a2cdda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f44d9caf-544c-4fca-87d4-011d3a2cdda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2fd87be0-31fe-44bf-9592-1132df25d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2fd87be0-31fe-44bf-9592-1132df25d24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17e8615d-705c-4282-9282-e5fbbeddc2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17e8615d-705c-4282-9282-e5fbbeddc2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9e387ce7-a4d1-4ec6-94e0-356eb22d79c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9e387ce7-a4d1-4ec6-94e0-356eb22d79c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d24dc97e-0ee3-4c60-88f5-b85e983458d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d24dc97e-0ee3-4c60-88f5-b85e983458d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9c9251e6-4c21-4f42-af97-a0db9a2c4d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9c9251e6-4c21-4f42-af97-a0db9a2c4d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8252dcc8-c543-4eec-a32a-d34f287dec96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8252dcc8-c543-4eec-a32a-d34f287dec96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_566a3821-9fc7-4b77-a376-00e51b4d4ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_566a3821-9fc7-4b77-a376-00e51b4d4ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f0071503-2d7d-4aca-8b83-849ab9ca547a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f0071503-2d7d-4aca-8b83-849ab9ca547a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_449b0df2-8c2a-4c12-9f13-3eb8d360953e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_334a4d6f-5c4a-45c8-8569-8dd6955026c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_449b0df2-8c2a-4c12-9f13-3eb8d360953e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b00cb2d6-30e5-4182-a675-e4cb07ab4d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d65d3692-ec40-4f6a-bd7d-979bb0a41806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b00cb2d6-30e5-4182-a675-e4cb07ab4d9b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d65d3692-ec40-4f6a-bd7d-979bb0a41806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_656891af-7972-4cc6-a348-65a6cca528e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d65d3692-ec40-4f6a-bd7d-979bb0a41806" xlink:to="loc_us-gaap_AwardTypeAxis_656891af-7972-4cc6-a348-65a6cca528e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e57eb61-3b64-4f1a-bdd3-d72af88225c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_656891af-7972-4cc6-a348-65a6cca528e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e57eb61-3b64-4f1a-bdd3-d72af88225c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_3550f19a-5ba1-494a-ae6e-aaf5d58ba721" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e57eb61-3b64-4f1a-bdd3-d72af88225c1" xlink:to="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_3550f19a-5ba1-494a-ae6e-aaf5d58ba721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d65d3692-ec40-4f6a-bd7d-979bb0a41806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6810eb7d-5489-4f4d-a609-4d386dab3398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6810eb7d-5489-4f4d-a609-4d386dab3398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_84ba75e7-08a4-46d3-a636-e8808d861844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_84ba75e7-08a4-46d3-a636-e8808d861844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_ce5d510e-d17c-4e38-8918-ac4ee3bae87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_ce5d510e-d17c-4e38-8918-ac4ee3bae87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8910fb81-185f-4407-8a73-9fb86bf20308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8910fb81-185f-4407-8a73-9fb86bf20308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_EmployeeStockPurchasePlanOfferingPeriod_6ae39765-ae48-457e-b18a-b95866647e38" xlink:href="plrx-20211231.xsd#plrx_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_plrx_EmployeeStockPurchasePlanOfferingPeriod_6ae39765-ae48-457e-b18a-b95866647e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_CommonStockFairMarketValuePercentage_58b63aac-297d-46d4-b7b6-8465cca7b69e" xlink:href="plrx-20211231.xsd#plrx_CommonStockFairMarketValuePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_plrx_CommonStockFairMarketValuePercentage_58b63aac-297d-46d4-b7b6-8465cca7b69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_34cf7edd-5116-4f50-8637-1aa8e3c0800c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_34cf7edd-5116-4f50-8637-1aa8e3c0800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f971be40-081f-4058-b9b7-3a544307c748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b3cf5d2-9b57-46e5-8f5b-925648358483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f971be40-081f-4058-b9b7-3a544307c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a548f18e-6df2-4117-abf4-df08fef08187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a548f18e-6df2-4117-abf4-df08fef08187" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:to="loc_us-gaap_AwardTypeAxis_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cfd8ef-7700-4b84-b278-bd62749e0478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b4dd3acb-e081-40ed-b558-6f3fdf6b76ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cfd8ef-7700-4b84-b278-bd62749e0478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_ab2c58f3-9157-4601-af1e-142c6665e26d" xlink:href="plrx-20211231.xsd#plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99cfd8ef-7700-4b84-b278-bd62749e0478" xlink:to="loc_plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_ab2c58f3-9157-4601-af1e-142c6665e26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_380db0e2-9a0f-4857-9ff5-f34a8e290ac1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:to="loc_srt_RangeAxis_380db0e2-9a0f-4857-9ff5-f34a8e290ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e95f0906-d9f5-49c2-a542-31f898d9cfd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_380db0e2-9a0f-4857-9ff5-f34a8e290ac1" xlink:to="loc_srt_RangeMember_e95f0906-d9f5-49c2-a542-31f898d9cfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_218515a4-01b6-435b-8f20-8ae8372c5ecb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e95f0906-d9f5-49c2-a542-31f898d9cfd2" xlink:to="loc_srt_MinimumMember_218515a4-01b6-435b-8f20-8ae8372c5ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a3fcc40b-3e82-4145-ac19-89631ed573ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e95f0906-d9f5-49c2-a542-31f898d9cfd2" xlink:to="loc_srt_MaximumMember_a3fcc40b-3e82-4145-ac19-89631ed573ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8eea8770-93c1-4f87-b2d0-8773536ec395" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb3ebcda-ca68-4dee-abcd-a16cb0bb36a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb3ebcda-ca68-4dee-abcd-a16cb0bb36a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ad6e3b1f-8795-49c9-8870-10863d88f43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ad6e3b1f-8795-49c9-8870-10863d88f43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35906f0e-6c0d-4ad3-8fe1-15a111966ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35906f0e-6c0d-4ad3-8fe1-15a111966ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1da5a2f5-5abe-429a-abab-573c1bf8de7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82635c53-6cb8-4bc7-8165-62ec6abaab6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1da5a2f5-5abe-429a-abab-573c1bf8de7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab9d0425-dd10-4925-9376-ea3131b160ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81d5a4fd-2bdf-4725-aa15-eb7f280fa18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab9d0425-dd10-4925-9376-ea3131b160ff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81d5a4fd-2bdf-4725-aa15-eb7f280fa18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_452418a3-519a-4af3-9c07-4ea4fb9b99e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81d5a4fd-2bdf-4725-aa15-eb7f280fa18a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_452418a3-519a-4af3-9c07-4ea4fb9b99e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fc432aa9-c028-44c4-b789-da9cee25e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_452418a3-519a-4af3-9c07-4ea4fb9b99e1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fc432aa9-c028-44c4-b789-da9cee25e36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fae1a122-9022-442d-8d3a-0d6d5bf7a382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fc432aa9-c028-44c4-b789-da9cee25e36c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fae1a122-9022-442d-8d3a-0d6d5bf7a382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4eb28dbd-5622-40db-9783-3d3483888c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fc432aa9-c028-44c4-b789-da9cee25e36c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4eb28dbd-5622-40db-9783-3d3483888c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fb19074-2b22-4c87-8fe5-06650fa58278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81d5a4fd-2bdf-4725-aa15-eb7f280fa18a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fb19074-2b22-4c87-8fe5-06650fa58278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18de7fcb-10f6-4cf8-a78c-95b996c26401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fb19074-2b22-4c87-8fe5-06650fa58278" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18de7fcb-10f6-4cf8-a78c-95b996c26401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_25d961fd-941c-463e-826a-a9ddc8fc514e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c52feed6-3b64-41b3-8120-246390ee0630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25d961fd-941c-463e-826a-a9ddc8fc514e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c52feed6-3b64-41b3-8120-246390ee0630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c811bd33-befc-46e9-b514-0705ec0b2e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_eb40cf25-a2cd-4bf0-a915-d28e9d5d2aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c811bd33-befc-46e9-b514-0705ec0b2e04" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_eb40cf25-a2cd-4bf0-a915-d28e9d5d2aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d40fc774-0341-4b8c-8f0b-dab664283e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c811bd33-befc-46e9-b514-0705ec0b2e04" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d40fc774-0341-4b8c-8f0b-dab664283e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock_6ba5abb3-8c68-42b9-a9dd-5b7250600db4" xlink:href="plrx-20211231.xsd#plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c811bd33-befc-46e9-b514-0705ec0b2e04" xlink:to="loc_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock_6ba5abb3-8c68-42b9-a9dd-5b7250600db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_323a0b05-62bf-41d1-a839-b61d7323234b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c811bd33-befc-46e9-b514-0705ec0b2e04" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_323a0b05-62bf-41d1-a839-b61d7323234b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_3295dc29-ffb2-4a7a-b0f6-ce2254dcb7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c811bd33-befc-46e9-b514-0705ec0b2e04" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_3295dc29-ffb2-4a7a-b0f6-ce2254dcb7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c8575853-970d-4c3f-a223-b07449698bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1caefe63-15b5-49fe-9a3e-3a1655f27dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8575853-970d-4c3f-a223-b07449698bb3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1caefe63-15b5-49fe-9a3e-3a1655f27dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets_ae179927-61bd-40a3-b18a-b278cc24afb0" xlink:href="plrx-20211231.xsd#plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8575853-970d-4c3f-a223-b07449698bb3" xlink:to="loc_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets_ae179927-61bd-40a3-b18a-b278cc24afb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_IncomeTaxExaminationNumberOfExaminationsPending_f11d6a97-d667-4b21-adf9-a5a695440884" xlink:href="plrx-20211231.xsd#plrx_IncomeTaxExaminationNumberOfExaminationsPending"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8575853-970d-4c3f-a223-b07449698bb3" xlink:to="loc_plrx_IncomeTaxExaminationNumberOfExaminationsPending_f11d6a97-d667-4b21-adf9-a5a695440884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_cfc412d4-73a9-4996-b75a-a035bebb934f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8575853-970d-4c3f-a223-b07449698bb3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_cfc412d4-73a9-4996-b75a-a035bebb934f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_256eb6ee-6ce7-47b7-ae54-b8824119441c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8cb334c9-5fa6-4486-b8bc-e0f34db9e1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_256eb6ee-6ce7-47b7-ae54-b8824119441c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8cb334c9-5fa6-4486-b8bc-e0f34db9e1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6c470bb8-f597-47a2-a588-f7b405d87dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_256eb6ee-6ce7-47b7-ae54-b8824119441c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6c470bb8-f597-47a2-a588-f7b405d87dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal_10199aec-1e7f-4ed4-bbc7-f16b137065e9" xlink:href="plrx-20211231.xsd#plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_256eb6ee-6ce7-47b7-ae54-b8824119441c" xlink:to="loc_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal_10199aec-1e7f-4ed4-bbc7-f16b137065e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_e29a775e-f182-4f07-8437-415765c6b2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_256eb6ee-6ce7-47b7-ae54-b8824119441c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_e29a775e-f182-4f07-8437-415765c6b2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_9f2a7eec-f6a2-4e81-aa19-0edfcf26a427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_256eb6ee-6ce7-47b7-ae54-b8824119441c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther_9f2a7eec-f6a2-4e81-aa19-0edfcf26a427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_31e75730-efd3-4903-a61c-e605906a7e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_256eb6ee-6ce7-47b7-ae54-b8824119441c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_31e75730-efd3-4903-a61c-e605906a7e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8396cb28-aeea-4175-8836-088858eb282c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_256eb6ee-6ce7-47b7-ae54-b8824119441c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8396cb28-aeea-4175-8836-088858eb282c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a04fcd82-5e7e-43ba-af34-bdd9f2c49574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a04fcd82-5e7e-43ba-af34-bdd9f2c49574" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0ae06265-14c5-4a11-82c1-f1c459e72a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0ae06265-14c5-4a11-82c1-f1c459e72a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_66f69147-5ea0-4960-86ad-446bccd8c2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_66f69147-5ea0-4960-86ad-446bccd8c2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_eb5728f3-5ffc-4bf4-8b6d-54fe1a6144fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_eb5728f3-5ffc-4bf4-8b6d-54fe1a6144fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_1c8c8145-587e-4d08-8831-f9449771be97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_1c8c8145-587e-4d08-8831-f9449771be97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_b3fa49c5-1d5a-4f09-954f-f30705c43d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_b3fa49c5-1d5a-4f09-954f-f30705c43d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxAssetsLeaseLiability_89bf2e11-eff3-465f-9c72-e21ec4e2d32b" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:to="loc_plrx_DeferredTaxAssetsLeaseLiability_89bf2e11-eff3-465f-9c72-e21ec4e2d32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b0274130-35ff-40e1-9af2-056861968438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b0274130-35ff-40e1-9af2-056861968438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_07707562-12ea-4701-8334-7dffcbc1e163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7294831e-4815-46ef-a1d1-8c3be84c9978" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_07707562-12ea-4701-8334-7dffcbc1e163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1fb63ecc-94bb-46f6-9b56-7ffeb8a6bdac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a04fcd82-5e7e-43ba-af34-bdd9f2c49574" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1fb63ecc-94bb-46f6-9b56-7ffeb8a6bdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxLiabilitiesFixedAssetBasis_71edb290-06c6-43b1-a656-3487d7a170d8" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxLiabilitiesFixedAssetBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1fb63ecc-94bb-46f6-9b56-7ffeb8a6bdac" xlink:to="loc_plrx_DeferredTaxLiabilitiesFixedAssetBasis_71edb290-06c6-43b1-a656-3487d7a170d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_a386803e-b5c7-423c-b82d-190c57ba407b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1fb63ecc-94bb-46f6-9b56-7ffeb8a6bdac" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_a386803e-b5c7-423c-b82d-190c57ba407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_DeferredTaxLiabilitiesRightOfUseAsset_1bd31f9a-ff65-4317-a6b5-e00ff84cb301" xlink:href="plrx-20211231.xsd#plrx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1fb63ecc-94bb-46f6-9b56-7ffeb8a6bdac" xlink:to="loc_plrx_DeferredTaxLiabilitiesRightOfUseAsset_1bd31f9a-ff65-4317-a6b5-e00ff84cb301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_021b80fe-9f79-4a80-856f-9fc0d68c8474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1fb63ecc-94bb-46f6-9b56-7ffeb8a6bdac" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_021b80fe-9f79-4a80-856f-9fc0d68c8474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_40faf3c0-d8e5-4963-b236-afce661cf10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a04fcd82-5e7e-43ba-af34-bdd9f2c49574" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_40faf3c0-d8e5-4963-b236-afce661cf10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_eb367873-b452-4bfd-a2f6-a0dacc7e4745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a04fcd82-5e7e-43ba-af34-bdd9f2c49574" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_eb367873-b452-4bfd-a2f6-a0dacc7e4745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_23e77b35-92c6-4fc0-a6b5-ebe90b13f25f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_23e77b35-92c6-4fc0-a6b5-ebe90b13f25f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5b0269c8-4547-40c8-8c47-5c3d5c720179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b7fa6bca-92b4-4ec5-8d5b-a3890ff81c04" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5b0269c8-4547-40c8-8c47-5c3d5c720179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bb0a78f0-f8bb-42e5-9cfb-64e787274067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5b0269c8-4547-40c8-8c47-5c3d5c720179" xlink:to="loc_us-gaap_DomesticCountryMember_bb0a78f0-f8bb-42e5-9cfb-64e787274067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9f8b967e-3ee5-4db5-aa83-13c337612185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5b0269c8-4547-40c8-8c47-5c3d5c720179" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9f8b967e-3ee5-4db5-aa83-13c337612185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_aab1c74c-1280-48b4-b89b-abc553c51476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:to="loc_us-gaap_TaxPeriodAxis_aab1c74c-1280-48b4-b89b-abc553c51476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_aab1c74c-1280-48b4-b89b-abc553c51476" xlink:to="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_StartingFromJanuary12018Member_a8e1c9f8-7452-49ed-b6a6-ca5569775456" xlink:href="plrx-20211231.xsd#plrx_StartingFromJanuary12018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:to="loc_plrx_StartingFromJanuary12018Member_a8e1c9f8-7452-49ed-b6a6-ca5569775456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_BeforeJanuary12018Member_5cedaf78-7e5a-4ee0-8918-6b77ce7d8b23" xlink:href="plrx-20211231.xsd#plrx_BeforeJanuary12018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:to="loc_plrx_BeforeJanuary12018Member_5cedaf78-7e5a-4ee0-8918-6b77ce7d8b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarliestTaxYearMember_d2aa3ceb-f415-45fc-9b9c-b1878f184b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:to="loc_us-gaap_EarliestTaxYearMember_d2aa3ceb-f415-45fc-9b9c-b1878f184b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LatestTaxYearMember_10ee1b11-7b69-43e2-8f6f-e3f1b347c99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_82227f2d-d501-419a-9ab3-4bd6e153f86c" xlink:to="loc_us-gaap_LatestTaxYearMember_10ee1b11-7b69-43e2-8f6f-e3f1b347c99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_dfce12ca-6ce4-468c-8184-c6859b5a5d12" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ff9763ac-0cbe-40bf-91bd-cd04c17dd727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ff9763ac-0cbe-40bf-91bd-cd04c17dd727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7e681765-58e9-4447-93d4-f825dcfbc9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7e681765-58e9-4447-93d4-f825dcfbc9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_OperatingLossCarryforwardsExpirationYear_da0e6008-c10f-4f5a-9226-2d950323f5b2" xlink:href="plrx-20211231.xsd#plrx_OperatingLossCarryforwardsExpirationYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_plrx_OperatingLossCarryforwardsExpirationYear_da0e6008-c10f-4f5a-9226-2d950323f5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_TaxCreditCarryforwardsExpirationYear_ba0402b5-d449-4517-b2b9-f47c6ecc980b" xlink:href="plrx-20211231.xsd#plrx_TaxCreditCarryforwardsExpirationYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6e552946-32cc-4449-94bf-84a09e690580" xlink:to="loc_plrx_TaxCreditCarryforwardsExpirationYear_ba0402b5-d449-4517-b2b9-f47c6ecc980b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceAbstract_e6947b3e-fcb2-4fc3-875e-650ed4fd6308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dcbd744d-9948-416d-9e94-70dad7b40b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_e6947b3e-fcb2-4fc3-875e-650ed4fd6308" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dcbd744d-9948-416d-9e94-70dad7b40b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cff1354a-0c2f-4390-8fff-973ef5452b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_e6947b3e-fcb2-4fc3-875e-650ed4fd6308" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cff1354a-0c2f-4390-8fff-973ef5452b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d86c91ce-f89c-4d55-9130-8bbe2cc63674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_e6947b3e-fcb2-4fc3-875e-650ed4fd6308" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d86c91ce-f89c-4d55-9130-8bbe2cc63674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_f50a24a8-b440-4c55-b66f-72b3802ab734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a7c9af43-ac0f-45ad-8b93-173ab9281619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_f50a24a8-b440-4c55-b66f-72b3802ab734" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a7c9af43-ac0f-45ad-8b93-173ab9281619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_af6b40f9-1e02-4e55-87fe-b9c637f9bcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_f50a24a8-b440-4c55-b66f-72b3802ab734" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_af6b40f9-1e02-4e55-87fe-b9c637f9bcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_bd2a686f-a365-4292-87ad-90f73ba40ea9" xlink:href="plrx-20211231.xsd#plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_f50a24a8-b440-4c55-b66f-72b3802ab734" xlink:to="loc_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_bd2a686f-a365-4292-87ad-90f73ba40ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a497d0eb-1e59-49ea-8c8e-6adad1e13263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_f50a24a8-b440-4c55-b66f-72b3802ab734" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a497d0eb-1e59-49ea-8c8e-6adad1e13263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="plrx-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b388621b-a5b7-41b7-905d-177d442181cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5e978e2a-f606-4185-907b-2c0b41ab2839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b388621b-a5b7-41b7-905d-177d442181cd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5e978e2a-f606-4185-907b-2c0b41ab2839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15ffee35-8d0a-4ed7-b70f-55d64c53b2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ContractualArrangementsCancellationPeriod_813245c2-d4d0-4f6c-b39a-19a0ab0ebd79" xlink:href="plrx-20211231.xsd#plrx_ContractualArrangementsCancellationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15ffee35-8d0a-4ed7-b70f-55d64c53b2f5" xlink:to="loc_plrx_ContractualArrangementsCancellationPeriod_813245c2-d4d0-4f6c-b39a-19a0ab0ebd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/Leases" xlink:type="simple" xlink:href="plrx-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6cd24a9b-09fa-4b87-9d09-4bd9a40821c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fbae94b4-7761-410b-b8e1-5dd88a4c43be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6cd24a9b-09fa-4b87-9d09-4bd9a40821c7" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fbae94b4-7761-410b-b8e1-5dd88a4c43be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_faba557c-165a-4ae5-b27b-659c9e4f487d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10c78a83-d0f6-4723-9dcb-2cbc4c8b68af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_faba557c-165a-4ae5-b27b-659c9e4f487d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10c78a83-d0f6-4723-9dcb-2cbc4c8b68af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_AssetsAndLiabilitiesLesseeTableTextBlock_64e087ca-1a7c-46c7-9ca4-c51f50beb565" xlink:href="plrx-20211231.xsd#plrx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_faba557c-165a-4ae5-b27b-659c9e4f487d" xlink:to="loc_plrx_AssetsAndLiabilitiesLesseeTableTextBlock_64e087ca-1a7c-46c7-9ca4-c51f50beb565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_6d606d2e-94ff-4bba-928d-ee4583b4df28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_faba557c-165a-4ae5-b27b-659c9e4f487d" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_6d606d2e-94ff-4bba-928d-ee4583b4df28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e007eb52-ebaf-4ee3-b04c-2723e08651ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e007eb52-ebaf-4ee3-b04c-2723e08651ff" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd893cf2-eb38-43b1-8fe1-e003f5ede3da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:to="loc_srt_StatementGeographicalAxis_cd893cf2-eb38-43b1-8fe1-e003f5ede3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ac5c3c8f-9096-48cc-9758-2bff9b83ab16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cd893cf2-eb38-43b1-8fe1-e003f5ede3da" xlink:to="loc_srt_SegmentGeographicalDomain_ac5c3c8f-9096-48cc-9758-2bff9b83ab16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_ce720db3-15c4-4947-9426-34f5156cdcc3" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ac5c3c8f-9096-48cc-9758-2bff9b83ab16" xlink:to="loc_stpr_CA_ce720db3-15c4-4947-9426-34f5156cdcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4aac1fae-303b-4e5e-897c-fdc27f319fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4aac1fae-303b-4e5e-897c-fdc27f319fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_36c655c0-d204-4387-97fb-d35f91b3abe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4aac1fae-303b-4e5e-897c-fdc27f319fbd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_36c655c0-d204-4387-97fb-d35f91b3abe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_4d475f99-6799-4cee-9355-e4c5a8401711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_36c655c0-d204-4387-97fb-d35f91b3abe0" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_4d475f99-6799-4cee-9355-e4c5a8401711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c74250e-58b5-44ec-a373-fe5175e06188" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:to="loc_srt_RangeAxis_3c74250e-58b5-44ec-a373-fe5175e06188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85257a69-857a-4f1a-981f-863304043169" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3c74250e-58b5-44ec-a373-fe5175e06188" xlink:to="loc_srt_RangeMember_85257a69-857a-4f1a-981f-863304043169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_54de6567-753d-4e47-857d-4a1c715dc15b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85257a69-857a-4f1a-981f-863304043169" xlink:to="loc_srt_MinimumMember_54de6567-753d-4e47-857d-4a1c715dc15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e7ed3c8-3bd3-42ac-af1d-4f76136ea062" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85257a69-857a-4f1a-981f-863304043169" xlink:to="loc_srt_MaximumMember_1e7ed3c8-3bd3-42ac-af1d-4f76136ea062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d4adbb6f-8d5a-4e4a-9dec-c5e2c91eb289" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LeasedSpaceUnderNonCancellableOperatingLease_cac58fa0-724a-4d52-b0cb-3a94733c2628" xlink:href="plrx-20211231.xsd#plrx_LeasedSpaceUnderNonCancellableOperatingLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_plrx_LeasedSpaceUnderNonCancellableOperatingLease_cac58fa0-724a-4d52-b0cb-3a94733c2628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3972be56-43ef-4af0-8654-a9ca651c82bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3972be56-43ef-4af0-8654-a9ca651c82bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_PeriodOfBaseRentAbatement_0a4a8cf3-3f7a-4045-b5b5-4d4ccfd82813" xlink:href="plrx-20211231.xsd#plrx_PeriodOfBaseRentAbatement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_plrx_PeriodOfBaseRentAbatement_0a4a8cf3-3f7a-4045-b5b5-4d4ccfd82813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_BaseRentAbatedAmount_1fb827ef-ec14-4a53-a211-12cc30dcb30d" xlink:href="plrx-20211231.xsd#plrx_BaseRentAbatedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_plrx_BaseRentAbatedAmount_1fb827ef-ec14-4a53-a211-12cc30dcb30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_2eb2e69d-1db5-4ef2-921a-8099405011ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_SecurityDeposit_2eb2e69d-1db5-4ef2-921a-8099405011ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_de61a875-2ad4-43d2-a6cf-993c5fc9b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_de61a875-2ad4-43d2-a6cf-993c5fc9b8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_LeaseTermExtensionNoticePeriod_40780eaf-dc9c-4367-97aa-edc102bd942c" xlink:href="plrx-20211231.xsd#plrx_LeaseTermExtensionNoticePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_plrx_LeaseTermExtensionNoticePeriod_40780eaf-dc9c-4367-97aa-edc102bd942c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_50cf32f8-9726-4d9c-b6e8-d0f4d193772b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_OperatingLeaseCost_50cf32f8-9726-4d9c-b6e8-d0f4d193772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_13f41126-c9c6-4048-99ec-d33368b85f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_VariableLeaseCost_13f41126-c9c6-4048-99ec-d33368b85f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_66b09e0f-c56b-4630-a8f8-2600682e4fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_LeaseAndRentalExpense_66b09e0f-c56b-4630-a8f8-2600682e4fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a390012b-3d03-40a0-af14-32909c6a134e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_32de4d9f-80e0-49a9-9d3f-36ba7d36fc5f" xlink:to="loc_us-gaap_OperatingLeasePayments_a390012b-3d03-40a0-af14-32909c6a134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesScheduleofOperatingLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9f237a76-d10c-4d9b-8567-51731a2891b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9f237a76-d10c-4d9b-8567-51731a2891b9" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a0de1e92-eab7-41a5-8089-77538942a9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a0de1e92-eab7-41a5-8089-77538942a9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dec0e91d-a2b6-41be-82fe-a24b6cc84e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dec0e91d-a2b6-41be-82fe-a24b6cc84e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8fc6348-5819-43ff-8d76-035fd4873c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8fc6348-5819-43ff-8d76-035fd4873c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_40725638-862d-4dd6-9bc2-5f419155aae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_40725638-862d-4dd6-9bc2-5f419155aae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d3186949-c6c6-45c3-b05a-159a1920f75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d3186949-c6c6-45c3-b05a-159a1920f75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b8b3746-8aaa-4b50-915d-b020265e503e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b8b3746-8aaa-4b50-915d-b020265e503e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a1caf8b4-9f67-44ee-89fa-77a957dc0488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a1caf8b4-9f67-44ee-89fa-77a957dc0488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5d6d9c3e-370f-445f-a737-dc2945e3dfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4277f431-64f6-4ee5-aafc-7ca4bd8dd024" xlink:to="loc_us-gaap_OperatingLeaseLiability_5d6d9c3e-370f-445f-a737-dc2945e3dfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_abd7f99e-4e45-48b7-983f-c27ed959acb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_596154fe-a4fd-4432-8f5a-5946d28d69a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_abd7f99e-4e45-48b7-983f-c27ed959acb2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_596154fe-a4fd-4432-8f5a-5946d28d69a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_da37f75e-b88c-485c-97d0-48fa5dabf7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_abd7f99e-4e45-48b7-983f-c27ed959acb2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_da37f75e-b88c-485c-97d0-48fa5dabf7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2bc902e6-a0be-4352-98ad-3e654c9136ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_78d48a04-07ba-4438-86b1-2256208dc1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2bc902e6-a0be-4352-98ad-3e654c9136ab" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_78d48a04-07ba-4438-86b1-2256208dc1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_78d48a04-07ba-4438-86b1-2256208dc1d1" xlink:to="loc_srt_StatementGeographicalAxis_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cdc9dbd6-af9f-44ce-9809-c5cd105b0a73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7cb6f76d-a0dc-4e74-b9c9-b9f9fe31b193" xlink:to="loc_srt_SegmentGeographicalDomain_cdc9dbd6-af9f-44ce-9809-c5cd105b0a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_41270be1-0516-499b-9c6d-a613760ee91f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cdc9dbd6-af9f-44ce-9809-c5cd105b0a73" xlink:to="loc_stpr_CA_41270be1-0516-499b-9c6d-a613760ee91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_78d48a04-07ba-4438-86b1-2256208dc1d1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_812823ad-e1d6-4030-bea1-0ace9c7d0a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_812823ad-e1d6-4030-bea1-0ace9c7d0a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_525bc8e0-0434-4957-bd4c-8925010e07ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_525bc8e0-0434-4957-bd4c-8925010e07ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_890b1ec2-8c92-4d3b-9939-1c1cda78e1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_890b1ec2-8c92-4d3b-9939-1c1cda78e1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4a1d185c-649b-431d-8933-e32730676054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_4a1d185c-649b-431d-8933-e32730676054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e1cef70e-e010-437e-93d6-0809fd9ff8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_53c9bb09-0c37-4c6a-b042-5f4bf39d77fa" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e1cef70e-e010-437e-93d6-0809fd9ff8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="plrx-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_489cc7c0-c519-45c4-b2c7-33556459de35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5bc8ce3e-c3d0-48cb-9637-dacceb004185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_489cc7c0-c519-45c4-b2c7-33556459de35" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5bc8ce3e-c3d0-48cb-9637-dacceb004185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a186b8c8-fe42-47f0-8470-4098667d193d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a186b8c8-fe42-47f0-8470-4098667d193d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e9eded6c-3a90-4bde-b478-73034df03632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e9eded6c-3a90-4bde-b478-73034df03632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5eefda44-8115-4b7d-a048-0303d40a33f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9eded6c-3a90-4bde-b478-73034df03632" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5eefda44-8115-4b7d-a048-0303d40a33f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d9fe87b6-6e47-4db3-83b3-3dee0b974494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5eefda44-8115-4b7d-a048-0303d40a33f0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d9fe87b6-6e47-4db3-83b3-3dee0b974494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c45c4a07-a7ef-4b46-99c6-49ab8f34d456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c45c4a07-a7ef-4b46-99c6-49ab8f34d456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_916820b5-fe54-4bcb-9b14-9e1cb048a8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c45c4a07-a7ef-4b46-99c6-49ab8f34d456" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_916820b5-fe54-4bcb-9b14-9e1cb048a8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ThirdRockVenturesMember_45405ac3-3a27-4c44-b695-e24001b80f49" xlink:href="plrx-20211231.xsd#plrx_ThirdRockVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_916820b5-fe54-4bcb-9b14-9e1cb048a8f0" xlink:to="loc_plrx_ThirdRockVenturesMember_45405ac3-3a27-4c44-b695-e24001b80f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5fa4f65a-6988-4ba6-b098-c18e4315324a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_srt_TitleOfIndividualAxis_5fa4f65a-6988-4ba6-b098-c18e4315324a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1dcc73bd-9190-4afe-b014-bdec15d2274b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5fa4f65a-6988-4ba6-b098-c18e4315324a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1dcc73bd-9190-4afe-b014-bdec15d2274b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_NonemployeeDirectorMember_b1008310-26fe-4ba8-bb4f-7e37de233ca2" xlink:href="plrx-20211231.xsd#plrx_NonemployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1dcc73bd-9190-4afe-b014-bdec15d2274b" xlink:to="loc_plrx_NonemployeeDirectorMember_b1008310-26fe-4ba8-bb4f-7e37de233ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f69d8ef5-036d-471a-b277-9480ec24cf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_us-gaap_AwardTypeAxis_f69d8ef5-036d-471a-b277-9480ec24cf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2734e6-d733-4780-a0a0-530a190c3b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f69d8ef5-036d-471a-b277-9480ec24cf6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2734e6-d733-4780-a0a0-530a190c3b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_374c38b1-169c-4ec7-aa48-58d5e3e8c885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd2734e6-d733-4780-a0a0-530a190c3b54" xlink:to="loc_us-gaap_EmployeeStockOptionMember_374c38b1-169c-4ec7-aa48-58d5e3e8c885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_be6897e2-7782-4902-a23c-96be55b5f3e8" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f3bdeb70-4c56-4744-9a3c-9aafb7510a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f3bdeb70-4c56-4744-9a3c-9aafb7510a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b370498d-0021-4087-a226-82712cfab7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b370498d-0021-4087-a226-82712cfab7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_ca2cf4e7-16b2-4433-803e-3e13c89c8168" xlink:href="plrx-20211231.xsd#plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_ca2cf4e7-16b2-4433-803e-3e13c89c8168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e8ae3505-44d3-48ce-897c-95ca110e036d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e8ae3505-44d3-48ce-897c-95ca110e036d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_32904dae-9b20-4287-8ca7-35eaae2a105d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_32904dae-9b20-4287-8ca7-35eaae2a105d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_167b6a33-4fb5-47b9-a32d-b4d37e738091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_85990f1e-7e5c-41bd-8d23-938ad8823cbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_167b6a33-4fb5-47b9-a32d-b4d37e738091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/DefinedContributionPlan" xlink:type="simple" xlink:href="plrx-20211231.xsd#DefinedContributionPlan"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/DefinedContributionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ee5c967a-3ea2-4e0e-8d14-784a8ff432b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_304cebe2-3b4b-4e82-adc3-f74bed041e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ee5c967a-3ea2-4e0e-8d14-784a8ff432b0" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_304cebe2-3b4b-4e82-adc3-f74bed041e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/DefinedContributionPlanAdditionalInformationDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#DefinedContributionPlanAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/DefinedContributionPlanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bfe0843b-5853-4141-8314-d2c08e502e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_b7989fc9-3597-456b-86ff-35a5302ce735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bfe0843b-5853-4141-8314-d2c08e502e30" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_b7989fc9-3597-456b-86ff-35a5302ce735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanPlanNameExtensibleList_1443d66c-d40e-482c-8279-5093c7ebe8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanPlanNameExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bfe0843b-5853-4141-8314-d2c08e502e30" xlink:to="loc_us-gaap_DefinedContributionPlanPlanNameExtensibleList_1443d66c-d40e-482c-8279-5093c7ebe8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="plrx-20211231.xsd#NetLossPerShareAttributabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c9f94bef-65e9-4739-bcfc-d770bfdb294b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a5e9b7ee-5237-4b41-8e7d-095e595df648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9f94bef-65e9-4739-bcfc-d770bfdb294b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a5e9b7ee-5237-4b41-8e7d-095e595df648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="plrx-20211231.xsd#NetLossPerShareAttributabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3d593856-fa0b-4756-8605-d3b53cfe75ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5a6150d7-1de2-42e7-bbbe-edd47ef10e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d593856-fa0b-4756-8605-d3b53cfe75ee" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5a6150d7-1de2-42e7-bbbe-edd47ef10e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f41a3843-0e78-4e99-9988-75a78a887ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d593856-fa0b-4756-8605-d3b53cfe75ee" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f41a3843-0e78-4e99-9988-75a78a887ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_72ee13da-ece7-4153-a914-7f884dde2bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_72ee13da-ece7-4153-a914-7f884dde2bd4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_48673178-1af7-4783-ada5-8c16dac407ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_48673178-1af7-4783-ada5-8c16dac407ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a5d782cc-7cca-4d36-b981-1cf8c37dda4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_48673178-1af7-4783-ada5-8c16dac407ab" xlink:to="loc_us-gaap_ClassOfStockDomain_a5d782cc-7cca-4d36-b981-1cf8c37dda4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7ae3fcb7-7745-41ff-934d-c335dd7fce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a5d782cc-7cca-4d36-b981-1cf8c37dda4b" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7ae3fcb7-7745-41ff-934d-c335dd7fce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbadd256-1938-4ef2-a359-c4e71d0313e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbadd256-1938-4ef2-a359-c4e71d0313e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fbadd256-1938-4ef2-a359-c4e71d0313e8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40f31879-518a-4093-a0cf-b5a3cd6b19ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40f31879-518a-4093-a0cf-b5a3cd6b19ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember_639f9121-def3-42b4-b2e3-9abb59774ac3" xlink:href="plrx-20211231.xsd#plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:to="loc_plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember_639f9121-def3-42b4-b2e3-9abb59774ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1d93158f-2892-4667-a084-d576e9031a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a1ff62e-7841-44ce-bbd2-c18ab34a0aef" xlink:to="loc_us-gaap_RestrictedStockMember_1d93158f-2892-4667-a084-d576e9031a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cef095e6-70bc-49ec-b834-1ba9be8182f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0e7d46d1-276d-41c1-b10b-80e109e085e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cef095e6-70bc-49ec-b834-1ba9be8182f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_790e10cf-7626-4a74-a171-0f9e5ef676f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cef095e6-70bc-49ec-b834-1ba9be8182f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_790e10cf-7626-4a74-a171-0f9e5ef676f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="plrx-20211231.xsd#NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_a188d80c-6828-425b-b894-5d3e3a86f7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0b4e0e84-cbb3-420a-bd37-694fb12c6cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_a188d80c-6828-425b-b894-5d3e3a86f7c0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0b4e0e84-cbb3-420a-bd37-694fb12c6cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e666b0d9-2aec-4b3c-9d62-9e89fac17214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0b4e0e84-cbb3-420a-bd37-694fb12c6cba" xlink:to="loc_us-gaap_NetIncomeLoss_e666b0d9-2aec-4b3c-9d62-9e89fac17214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_63ad8e44-fbf8-4915-b7a2-25cbbcd09e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0b4e0e84-cbb3-420a-bd37-694fb12c6cba" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_63ad8e44-fbf8-4915-b7a2-25cbbcd09e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ba26a926-50b1-494b-9118-25b677817123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0b4e0e84-cbb3-420a-bd37-694fb12c6cba" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ba26a926-50b1-494b-9118-25b677817123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6c02f6a-5971-4541-af1e-3892e2978cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_a188d80c-6828-425b-b894-5d3e3a86f7c0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6c02f6a-5971-4541-af1e-3892e2978cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_57328e40-6b44-4db4-bf2b-d57b43ed5ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6c02f6a-5971-4541-af1e-3892e2978cf5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_57328e40-6b44-4db4-bf2b-d57b43ed5ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9e893346-c775-40b1-9ca4-791e4b188f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_57328e40-6b44-4db4-bf2b-d57b43ed5ab4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9e893346-c775-40b1-9ca4-791e4b188f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dfd06063-e992-4b8e-ba17-c93d8efcadab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_57328e40-6b44-4db4-bf2b-d57b43ed5ab4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dfd06063-e992-4b8e-ba17-c93d8efcadab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_715e0cdb-6bf0-4cb9-8ed0-88135ac02170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_a188d80c-6828-425b-b894-5d3e3a86f7c0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_715e0cdb-6bf0-4cb9-8ed0-88135ac02170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_acc3330c-50d2-4886-85ac-6d51a9a3aa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_715e0cdb-6bf0-4cb9-8ed0-88135ac02170" xlink:to="loc_us-gaap_EarningsPerShareBasic_acc3330c-50d2-4886-85ac-6d51a9a3aa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_effd014f-f4f7-48fc-9ed3-9dad11c22a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_715e0cdb-6bf0-4cb9-8ed0-88135ac02170" xlink:to="loc_us-gaap_EarningsPerShareDiluted_effd014f-f4f7-48fc-9ed3-9dad11c22a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>plrx-20211231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T(%!E
M=&5R<P    60 P "    %   $*:0!  "    %   $+J2D0 "     S(T  "2
MD@ "     S(T  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M ("+1_PT'X]_Y_+/_P !%KS&BCV-/L%V>G?\-!^/?^?RS_\  1:/^&@_'O\
MS^6?_@(M>8T4>QI]@NST[_AH/Q[_ ,_EG_X"+1_PT'X]_P"?RS_\!%KS&BCV
M-/L%V>G?\-!^/?\ G\L__ 1:/^&@_'O_ #^6?_@(M>8T4>QI]@NST[_AH/Q[
M_P _EG_X"+1_PT'X]_Y_+/\ \!%KS&BCV-/L%V>G?\-!^/?^?RS_ / 1:/\
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ML:?8+L]._P"&@_'O_/Y9_P#@(M'_  T'X]_Y_+/_ ,!%KS&BCV-/L%V>G?\
M#0?CW_G\L_\ P$6C_AH/Q[_S^6?_ ("+7F-%'L:?8+L]._X:#\>_\_EG_P"
MBT?\-!^/?^?RS_\  1:\QHH]C3[!=GM/A'XV>--<\21V-[>VXA:WN)#Y=J@.
M4@=U[>JBL3_AH/Q[_P _EG_X"+7-?#C_ )':'_KSO?\ TEEKEJGV4.9Z#NST
M[_AH/Q[_ ,_EG_X"+1_PT'X]_P"?RS_\!%KS&BJ]C3["NST[_AH/Q[_S^6?_
M ("+1_PT'X]_Y_+/_P !%KS&BCV-/L%V>G?\-!^/?^?RS_\  1:/^&@_'O\
MS^6?_@(M>8T4>QI]@NST[_AH/Q[_ ,_EG_X"+1_PT'X]_P"?RS_\!%KS&BCV
M-/L%V>G?\-!^/?\ G\L__ 1:/^&@_'O_ #^6?_@(M>8T4>QI]@NST[_AH/Q[
M_P _EG_X"+1_PT'X]_Y_+/\ \!%KS&BCV-/L%V>G?\-!^/?^?RS_ / 1:/\
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M,ZKM) 4YQC)' Z5TVI_$CPO/XK^(%];:L3#J^ABUL)!;R@RS"$KM^[E?F[G
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M-'V_P-_T =:_\&D?_P 9JN9]@.6HKJ?M_@;_ * .M?\ @TC_ /C-'V_P-_T
M=:_\&D?_ ,9HYGV Y:BNI^W^!O\ H ZU_P"#2/\ ^,T?;_ W_0!UK_P:1_\
MQFCF?8#EJ*ZG[?X&_P"@#K7_ (-(_P#XS1]O\#?] '6O_!I'_P#&:.9]@.6H
MKJ?M_@;_ * .M?\ @TC_ /C-'V_P-_T =:_\&D?_ ,9HYGV Y:BNI^W^!O\
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M01\RM\V3R!678)I?B73[73_!:>'9+A]+9)M%U73MEUYRIEWCN@N7<G<R_O%
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M8'[Q6R%+#"A2&)(Z5?'&NVEAH/Q2LEU.WM]0NM0MEBM_/5994(A5]JYR1MW
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M5'_"F? 7_0OQ?]_I/_BJ/K<.S#E9\?45]@_\*9\!?]"_%_W^D_\ BJ/^%,^
MO^A?B_[_ $G_ ,51];AV8<K/F?XD_P#)0M2_[9?^BDKEJ^R+SX5^#-7NWOM0
MT6.:XEQOD,KC.!@=&] *@_X4SX"_Z%^+_O\ 2?\ Q5*.*@DE8.4^/J*^P?\
MA3/@+_H7XO\ O])_\51_PIGP%_T+\7_?Z3_XJG];AV8<K/CZBOL'_A3/@+_H
M7XO^_P!)_P#%4?\ "F? 7_0OQ?\ ?Z3_ .*H^MP[,.5GQ]17V#_PIGP%_P!"
M_%_W^D_^*H_X4SX"_P"A?B_[_2?_ !5'UN'9ARL^/J*^P?\ A3/@+_H7XO\
MO])_\51_PIGP%_T+\7_?Z3_XJCZW#LPY6?'U%?8/_"F? 7_0OQ?]_I/_ (JC
M_A3/@+_H7XO^_P!)_P#%4?6X=F'*SX^HK[!_X4SX"_Z%^+_O])_\51_PIGP%
M_P!"_%_W^D_^*H^MP[,.5GQ]17V#_P *9\!?]"_%_P!_I/\ XJC_ (4SX"_Z
M%^+_ +_2?_%4?6X=F'*SX^HK[!_X4SX"_P"A?B_[_2?_ !5'_"F? 7_0OQ?]
M_I/_ (JCZW#LPY6?'U%?8/\ PIGP%_T+\7_?Z3_XJC_A3/@+_H7XO^_TG_Q5
M'UN'9ARL^/JZGP7_ ,@_Q7_V I/_ $?!7TQ_PIGP%_T+\7_?Z3_XJK%I\*O!
MEAYT=IHL<:WD1MYP)7^>,D,5Z^JJ?PI2Q4&K6#E/C:BOL?\ X4KX _Z%Z+_O
M])_\51_PI7P!_P!"]%_W^D_^*I_6X=F'*SXXHK['_P"%*^ /^A>B_P"_TG_Q
M5'_"E? '_0O1?]_I/_BJ/K<.S#E9\<45]C_\*5\ ?]"]%_W^D_\ BJ/^%*^
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M^ /^A>B_[_2?_%4?\*5\ ?\ 0O1?]_I/_BJ/K<.S#E9\P_$/_D9X?^P98_\
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M_P"*H_X4KX _Z%Z+_O\ 2?\ Q5-8JFMD'*SXXHK['_X4KX _Z%Z+_O\ 2?\
MQ5'_  I7P!_T+T7_ '^D_P#BJ/K<.S#E9\PR_P#)(;;_ +#LW_HB.N6K[-/P
MG\%FQ&EG1(_L:2&X6+S7P)"-I;[V>B@?A4/_  I7P!_T+T7_ '^D_P#BJ2Q4
M%T#E/CBKVEZU?Z-]L_LV?R?MUJ]G<?(K;XGQN7D'&<#D8/O7US_PI7P!_P!"
M]%_W^D_^*H_X4KX _P"A>B_[_2?_ !5/ZU!] Y6?'%;K>-?$#>)+K7VO\ZG=
MQ-#-/Y,?SH4"$;=NT?* .!7U5_PI7P!_T+T7_?Z3_P"*H_X4KX _Z%Z+_O\
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MJC_A2O@#_H7HO^_TG_Q5/ZW#LPY6?'%%?8__  I7P!_T+T7_ '^D_P#BJ/\
MA2O@#_H7HO\ O])_\51];AV8<K/CBBOL?_A2O@#_ *%Z+_O])_\ %4?\*5\
M?]"]%_W^D_\ BJ/K<.S#E9\<45]C_P#"E? '_0O1?]_I/_BJ/^%*^ /^A>B_
M[_2?_%4?6X=F'*SXXHK['_X4KX _Z%Z+_O\ 2?\ Q5'_  I7P!_T+T7_ '^D
M_P#BJ/K<.S#E9\<45]C_ /"E? '_ $+T7_?Z3_XJC_A2O@#_ *%Z+_O])_\
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M,KCY4&Q1P>RJ!^%+ZU"][!RGQE17V/\ \*5\ ?\ 0O1?]_I/_BJ/^%*^ /\
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M75G96'@^XU-=ULBW._Y-^W,K -CO@D'\*;?IJUQH=].FKVWB*P8[FWR.TUL
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M** "BBB@ J.+HW^^:DJ.+HW^^: ,C6?^/Q/^N8_F:SZT-9_X_$_ZYC^9K/H
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MV;9Y^HM?;_,SMW*1LQCWZ_I47_"-:[_T!=1_\!'_ ,*/^$:UW_H"ZC_X"/\
MX5#=)OF;7WCU+6L>*)M:T&PT^ZA_>V9.;C?DRC&!D8ZX YSS5+5M5_M06(\G
MROLEHEM][=OVD_-T&.O2G_\ "-:[_P! 74?_  $?_"C_ (1K7?\ H"ZC_P"
MC_X5,?8Q^%K[^X:ES5M:TG6-4FO[K3+U99B"PCOT"C  XS$?2JT&KPBQDTZ]
MM9+FP\PRP*)@LL!/7:^T@@C@@K@]1@TS_A&M=_Z NH_^ C_X4?\ "-:[_P!
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M5I3[@\A?YUZTB+&BHBA548"@8 'I7DXW'<O[ND]>YI&'5@B+&BHBA548"@8
M'I2T45X!L%%%% $8_P"/D_[@_F:DJ,?\?)_W!_,U)0 4444 %%%% !1110 4
M444 %%%% !1110!'/_JO^!+_ #%25'/_ *K_ ($O\Q4E !116!XXUR[\-^#+
M_5=.6%[FW">6)U+)EI%7D @GAO44TKNP&_16';V_BB*X22_UC29K93F6.#2)
M4=E[A6^T-@_\!/TI8/&.A75OITUO?&0:G<-;6J+#(9'D7.\%-NY=NT[BP 7'
M.*?*^@&Q*GFPO'G&Y2N?3-<U;>![9?AM;^$+V[DFBAMTB^U1*(VW(P97 .0"
M& /?I4FF_$#PUJ\ULEAJ#R+=2>5!,UK,D,DF"?+$K($+X!^7.[@\5/+XST&'
M5'L)+UA)'.+:246\I@CF(&(VF"^6K\CY2P.2!U(IVFM .<\3>$M5O/#NL:AK
M.H+K.HV^AWEI80V5B81NDB(9MF]R\C;548('4!>:N:'X3U.>'1KKQ'JPN_[-
MM<6ENMGY+1N\>PO*2YWN%)7@(.2<>FMJ7C;0-)O9K6^O75K?8+B2.VEDBMMY
M^42RJI2/L?G(P"#T(-9NE?$&RNKCQ*VIJ]A::)=>5YTMO*@9 B<DLH!<LQ 0
M?,1MP#D$U>;6PM#.C^%GEZ(NG_VQG;X>DT3S/LO]]@WFXW]L8V_K6YJ/@R'5
M+S1I+NXW0:=9W%I+#Y?_ !\+-&L9YS\O"^_6KEMXMT6YL[ZZ^V-;1Z> UVMY
M!);/ I&0S)(JL%(S@XP<$#)!K(L?'<6K?$"VT/3E;[,^GRW4PNK2:WG5E>,+
MA9 IV$.>=IR1P>#1>;#0GTOPKJ]DVG6UYXDDGTS2S_H\,-N8)I@HVQK/*'(D
M55/("(&(!/3!L^)O#EWK5_H]]IVH0V5SI5P\\?GVIG23=&R$%0Z'HQ/6LK7?
M&U[HOQ+TO0C;02:9>0(9ICD21222F-"#G!4MM7&,Y;.>,5/K?C"YL/B%H?AZ
MR@ADAO'(O)GR6CS'*R*N#C/[HDYSP1QSFBT[W G7PE<:AJ;:AXGU.._G6UDM
M+=+2V-M% D@ D8*7=BY  W;L #@=2<N/X?ZJUOX=M+SQ%#):>';B&6UBBT[R
MS*L:[ )#YARVPD J% ))(;@#7M?&>E)HFGWESJ'VYK\R"#[#I\Y>?82&*P*'
MD 7 !)XSCD;@*/!'B=_%FDWM^3 T,>HW-O;O I DA1R$8Y)Y*X)Z?047FE<-
M#)@^'M]826DVG:W;QRZ=?W5W9&6P+JJ7!<R1R 2C>?GX92F,=#FM;POX6N=!
MU36M0O=4&H3:O-'/)BW\H1NJ;2%^8_+@  'D <ECS5#Q#KGBG1M/UC7#!IMO
MIFEDNEI.C/->1)@LPE63;&6Y"@HQX&>N MSXDUS4]3U2+PPEBD.DV\4DJWT3
ML]S+)'YHB4JX$>$*_,0_+?=XY/>:W [*BN2MM9\1>)K6SOO#*6%AIUQ81W27
M.H1-<&:209\L(DB% @'S,<Y+# X),6D>(O$7BS2=)OM"M['3[:ZM6FN+NZ0W
M*B0,5\M$5XV/0MO)QC'!)XGD8SLJ*PO!^OR^(_#PN[J*.*YBGEM9Q"28VDB<
MHS(3SM)7(STSCG&:W:EJSLP"HX?]7_P)OYFI*CA_U?\ P)OYFD!)1110 C,%
M4LQ 4#))/2O(M8\:1ZMK$LL+_P"CH2D/NH_B_'K^5=C\1T\0WGA=M,\*637%
MU?'RI9?,5%AB_B.21R>GXFO,M,^"_B^7:;_4=/LE_NJS2L/R 'ZUZ>#C2BG4
MJ22.7$0E4CRQ.]\#J=5O)+QAF&WX!]7/^ Y_*M'4?'$MEJ>KV]MX?O[Z#1MI
MO+B"6$!08Q)\JLX9L*>PK7\-:%%X<\/VVF0OYIB7]Y*1@R.>K8^OZ8KD/[!U
M[4_%GC2"RU"+3+"^D@C=Y;!I7D!M45FC<NJ\<CHV"/PKCQ%15*C:VZ%X>E[*
M%NIUEEXEL]0UQ--M [F33H]12; V-'(Q5??/RYZ=ZF.MPKXI30O+D\][)KP2
M<;=H<)CUSEJY![BP\'_$6);E+J/3X_#T%I!)':RS E)7^4E%/.W!Y]:U 6E^
M*-MJ4<4ILV\/OB8Q,!DS(P'(X..<=:P-R];^+[*X\<7/AA(9A<6\/F&<@>4[
M (6C!SG<%D1CQT:G6/B[3K_Q/K.@Q^8E]I"QO*C@ 2(Z!@R>H&X ^AQZBO/H
MI[C3]+T'7KG3-135+C6SJ,P%G(X\FY)C9"5!VE(FC)#8YBK4O-#U%]?\4ZSI
M5J_]IV.H1SV892HNXS:1++#GN& (!Z!U4]J -J]\?M;>%--\16N@WMY87\,,
MFY)85:(RLJHK!G&3EQTR!73Z=<7%W81S7EE)8S-G=;R.KLG) R5)!R.>#WKS
MX6-V?@#H-I]DN!<I#IF^ Q'S$VSPE@5ZC !SZ8->E4 %%%% !4<71O\ ?-25
M'%T;_?- &1K/_'XG_7,?S-9]:&L_\?B?]<Q_,UGT %%%% &MI7_'JW^^?Y"K
MM4M*_P"/5O\ ?/\ (5=H **** *]YI]GJ$>R^M8;A>PD0-CZ9Z5COX&\..Q9
MM-4$_P!V60#\@U=!15*<H[,YZF%H5G>I!/U29SW_  @?AO\ Z!W_ )'D_P#B
MJ/\ A _#?_0._P#(\G_Q5=#15>TGW9E_9^#_ .?,?_ 5_D<]_P ('X;_ .@=
M_P"1Y/\ XJC_ (0/PW_T#O\ R/)_\570T4>TGW8?V?@_^?,?_ 5_D<]_P@?A
MO_H'?^1Y/_BJ/^$#\-_] [_R/)_\570T4>TGW8?V?@_^?,?_  %?Y'/?\('X
M;_Z!W_D>3_XJC_A _#?_ $#O_(\G_P 570T4>TGW8?V?@_\ GS'_ ,!7^1SW
M_"!^&_\ H'?^1Y/_ (JC_A _#?\ T#O_ "/)_P#%5T-%'M)]V']GX/\ Y\Q_
M\!7^1SW_  @?AO\ Z!W_ )'D_P#BJ5/ WAQ&R--4G_:ED/\ -JZ"BCVD^[#^
MS\'_ ,^H_P#@*_R*]GI]GI\?EV-K%;KW$: 9^OK5BBBL[M[G7&,8KEBK(***
M*"@HHHH 9#_JA3Z9#_JA3Z .7^)?_)+_ !%_V#Y?_0:G\-^';*QLK"\@GU)I
M?LZ?+/JES-'R@_Y9O(5_3CM70T57,^6P'A\<^FVNL6$^N;!91^-]3=VD7*HP
M#E&;T"MM)8\ #)QBI_&3V^JZ5XZU/2&CGT6ZCTZ(SQ$&*YN%G =E(X;"E%+#
MO@<XX]IHK3VNM[?U<5CA-?FM-%^*6BZIK;16ND+IT]O;7,I"0V]T64G<QX0M
M$I4$XS@@5S4=M8S6^H:K_;+>'[%O$!N]$U![??;!O)V.[!AL$;DR8)*Y."IY
MY]@HJ54L@L>-:MJ[ZMH-[NBTN=(O$=AMU72H3'#?DR)D\ELLN I.YAT&>*L:
MQJ5KX?EU=-&U;2]:$VJ+-)X7U.S_ -*>=I07$/(8DE@REHW  4@X&:]=HJO:
M+L%@HHHK$84444 %%%% !1110 4444 %)_RUB_WOZ&EI/^6L7^]_0T 6:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MCA_U9_WV_P#0C4E1P_ZL_P"^W_H1J2@ HHHH **** "BBB@ HHHH **** "B
MBB@ J.;[J_[Z_P ZDJ.;[J_[Z_SH DHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH C'_'R?]P?S-25&/\ CY/^X/YFI* "BBB@ HHHH **** "BBB@ HHH
MH **** (Y_\ 5?\  E_F*DJ.?_5?\"7^8J2@ KD_BA9SW_PVU6VM;66[ED$6
M((8C(S@2H3A0"3P#VKK**<79W XG3/\ A![/4H)]+\)R6=VK8BGC\*W$+(2,
M??\ (&W@D9R*P-!L-1L?B WC&YT*:.PUR>2VCM5MI/.T_.T+</'SM\WR_G^4
M%?D)/WJ]5HJ^>PCQGPS-+XB^%_AOP]I^F7\=U'>P2R7#6CK!%''/YK2B8C8Q
M(& H);<V".#0V@ZK%X;U3PU>/XDFN[B^GVV=I;0I:W*R3&19?M1MWV##9.Y]
MX*D ?=%>M:3I-EH>E0:;I</D6EN"L<>]FV@DGJQ)/)/>KE4ZNNB"QP>BWL_A
M&\UVRU'2M4NY[S5)+VT>RLGF2Y27&T&11L1@05(D9<  ]"#7.ZKHFJ2/XABM
MK+48GA\0VVKA8+4%I;98X@WE,ZF)Y%()"9))3&.E>O45*J6=PL>1:MH6IZ\^
MI:AIO]O:HUO;6RK)JL$=I]I\NY2<PI#Y$3'A3\[<9;:,\D;UG=RZY\7K'4[7
M2=3@L8='G@>ZO+&2W!D,D;;,.H/ []#SC.#7?T4>TT"QYSXS\.WNN^+=42W@
MF59/#12WN1&2BW*7'F1@-TW!E4XZ]ZI:;8:S?ZAX1UW4],N(+V^U>XO;Z+R6
M_P!$0VSQQJ^1E0%5!SCDGUKU.BCVCM8+'DO@NTU#PO\ V#JFK:7J'V5]-N+&
M58;*66:VE^TM*I:)5+A77/S $95<XR*U_ ]CXD_L.^DLE@T)I]8O9S;:GIKR
MMM>7<FW;+& ,9YY!['U]#HH=2X6/-=8U5_$/B6;3O$-EK%OH&FSK^XAT:[E_
MM25#G<S)&P$*L!A<G<1DG& ;;W-QX<\1>)IUTC4KR/6TANK$VMG)('D$(C:-
MR!^Z.54Y?:,,>>#7?T4<ZVL!Y3,=2TO0M&\#30ZK:65OIL2ZGJ=EIMQ<&3Y0
M&@A:-& )YRYZ#ISTT]>UV6WL=*T#PM8ZMI>FSV^)=1AT:Z=K.%24$<<8C+"4
M[3@L!M'S<Y6O0Z*.==@,GPO%IEMX=M;70[:XMK&V7RHH[FVE@<8ZDK(JL<GG
M)'))-:U%%0]6,*CA_P!7_P ";^9J2HX?]7_P)OYFD!)1110 4444 %%%% !1
M110 4444 %%%% !1110 5'%T;_?-25'%T;_?- &1K/\ Q^)_US'\S6?6AK/_
M !^)_P!<Q_,UG,RHI9R%51DDG  H 6BL2'QGX:N;T6D&O:=).6VA%N4))]!S
MR:VZ;36X&MI7_'JW^^?Y"KM4M*_X]6_WS_(5=I %<U;>-([G25U5=%U1=-8;
MFNBL+!$!P6*+(7P,$G"DX'2NEKCO"%Y;:?\ "BUN[]E6WBMY&DW' (WMQ^/3
M\:I;">YUT,T=Q!'- ZR1R*'1U.0P(R"*?7GGA""73M?T."__ '4J^&\%7."/
MWJG'/<#MVK*T(IJUIING6]O;W[NU_<Q1WTH%H?WQ4.4",96&[(&1@9Y&<A\H
MN8])U#6+?3;W3[:=)&>_F,,10 A6"EOFR>F!VS5^O*-$DW7&CQ+/%-#;^);J
M*$P#$001L0$&3A>20,GKUKL?%FEMJ=]I2QR:=/)%([C3-1/[N[7 #$#GYE!.
M#M;&ZAQL[ F=-5'4M6@TN2Q2X21C>W2VL>P X=E9@3DCC"GUKSM+E=1O-%TN
M#2+=+&*XNXGT^[O2;=YXRN%#[&W* Q*J5 SD#[M31B6&:PMBUL((/%"+%!;2
M.Z6Q\ERT09D48#9.%&!G':GR"YCTRBO*-.2ZE\-VFLM!IMOJCWZ[]2>[D:Z,
MQEVF$HL))!'R>6&P!@]JW="L=(U'3+_5/$8A6_AU.42WDTGER6S+)B-!)D%
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M=W81;_/LUC,P(X4N"0,]S@9].1SUQ<KRS4[=+*;Q7=V<*6\FVP$EQ$H5XXI
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M7_[^-_C4E% $?DKZO_W\;_&CR5]7_P"_C?XU)10!'Y*^K_\ ?QO\:/)7U?\
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MR_WU_C;U^M3U'-]U?]]?YT 'DKZO_P!_&_QH\E?5_P#OXW^-244 1^2OJ_\
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M_P#OXW^-'DKZO_W\;_&I** ()H5$?5_O#^-O4>]/\E?5_P#OXW^-$_\ JO\
M@2_S%24 1^2OJ_\ W\;_ !H\E?5_^_C?XU)10!'Y*^K_ /?QO\:/)7U?_OXW
M^-244 1^2OJ__?QO\:/)7U?_ +^-_C4E% $?DKZO_P!_&_QH\E?5_P#OXW^-
M244 1^2OJ_\ W\;_ !H\E?5_^_C?XU)10!'Y*^K_ /?QO\:/)7U?_OXW^-24
M4 1^2OJ__?QO\:/)7U?_ +^-_C4E% $?DKZO_P!_&_QH\E?5_P#OXW^-244
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M -^T_P#BZ/J>(_D8<R.YHKAO^%LZ%_SZ:C_W[3_XNC_A;.A?\^FH_P#?M/\
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M;AH+J[^U;9FV-ME>.+80RH<Y)=2=K8!XSV2LKJ&0AE89!!R"*AQ:W&+4</\
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M3G4(=/\ (GDB#%YK8-N:6, +M8GE0>A/3BNOMO$5G=^);C1(%D:>WM8[MI<
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MW_H"ZC_X"/\ X4?\(UKO_0%U'_P$?_"CVD.Z"S,RBM/_ (1K7?\ H"ZC_P"
MC_X4?\(UKO\ T!=1_P# 1_\ "CVD.Z"S,RBM/_A&M=_Z NH_^ C_ .%'_"-:
M[_T!=1_\!'_PH]I#N@LS,HK3_P"$:UW_ * NH_\ @(_^%'_"-:[_ - 74?\
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M4?\ P$?_  H]I#N@LS,HK3'AO7#TT;4#_P!NK_X4?\(UKO\ T!=1_P# 1_\
M"CVD.Z"S,RBM/_A&M=_Z NH_^ C_ .%'_"-:[_T!=1_\!'_PH]I#N@LS,HK3
M_P"$:UW_ * NH_\ @(_^%'_"-:[_ - 74?\ P$?_  H]I#N@LS,HK3_X1K7?
M^@+J/_@(_P#A1_PC6N_] 74?_ 1_\*/:0[H+,S**T_\ A&M=_P"@+J/_ ("/
M_A1_PC6N_P#0%U'_ ,!'_P */:0[H+,S**T_^$:UW_H"ZC_X"/\ X4?\(UKO
M_0%U'_P$?_"CVD.Z"S,RBM/_ (1K7?\ H"ZC_P" C_X4?\(UKO\ T!=1_P#
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MRL%#'"GC'8^F:;X7\1IXFL[VYBA6*.UU"XLU*R^8)1$Y4.#@?>QG'/U-%Y6
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M44 %%%% !1110 4444 %%%% !4<WW5_WU_G4E1S?=7_?7^= $E%%% !1110
M4444 %%%% !1110 4444 %%%% $8_P"/D_[@_F:DJ,?\?)_W!_,U)0 4444
M%%%% !1110 4444 %%%% !1110!'/_JO^!+_ #%25'/_ *K_ ($O\Q4E !7&
M_%O;_P *LUCS&VKB+<V[&!YR=^U=E13B[-,#B=,U#P';ZE!)8>,(Y[@-B.*3
MQ1-<*Y(QCRWF96Z]"#7)^&Y;.V^(<6OS0/#X8U&[N(="D:7]U#<O@22!2!M6
M8J^PY/\ %P-XKV*BK4[7$>'^';[2-1^&/AC0]"DA.OQZI;S_ &:,?OH66;=)
M.X'(7RMWSG@A@!U ICM=+X7UG0]1UBQM=6GU::1M.32VFU*68S;HIHLW"!_E
M\LJX4*%7!/RDU[#X>T.V\-:!:Z18O+);VJE4:8@N023R0 ._I6E5NKKH%CS;
M2]2T#1[CQ3IWC9K1+R^U5YOLMW%O>^@;:(3'&03*,+M"J&PRD8S7.ZT7*>*K
M2*6,>5XEM;Z]@FB:5EL_+A)E>$,KO&#M+=.%;G@U[714JI9W"QXMKIN=;DUR
M_P!/U2UU^$6=JFH'1K I;3QI<J[(7\Z3S)!$9,J!]UL$\@'H+'5]#UKXX6%W
MX?N+>\4:%-'+<VI#(2)8BJ;AP64'D=1N&>M>DT4>TT"QY=X[TZ?4O'&HQV7%
M[!X:%U:-W6:*Z$B$?\"053L;MM<U[P=XGFA:%M:UBXFBC<Y:.!+61(U_$*7^
MKFO7:*/::6L%CQGP)?6NBGPSJ?B">*TTQM+N[>UO+EPL,5P;IF==QX1G0#&<
M9",!TK:^&]QJ$?AF^/A32K&6S;6KXI'>7<EH8D\WY%"B%^W8XQBO3**)5+WT
M"QY?XC\7:-XIUJZ\+WVN:9I6D6,JQZK)<WL<<EW(IR;>,,00@(P[\9Y4=S5E
M-;TOPIXE\6'4[I(8]36"[TX$_P#'VOV=8]D./OL&4#:N3AEXYKT>BESJUK >
M21^)O^$=\,:#X%_M:QT35ETN$W]]>W"1"P0J 0H8C?+UP.@^\>,9TM2\8Z%X
M6T71O#'@_5M)@:XML6U]<W<?V:V@4E3,S9Q(Q8, H^\P;. #7I-%/G3Z 87@
MRUT:Q\+6UKX<OX=1M(BP:[BF67SI"<NS,O!8L23]:W:**S;N[C"HX?\ 5_\
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M/^- #Z*9B7^\G_?)_P :,2_WD_[Y/^- #Z*9B7^\G_?)_P :,2_WD_[Y/^-
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MT8F_O)_WR?\ &@ A_P!6?]]O_0C4E00B7RSAD^\W\)]3[T_$W]Y/^^3_ (T
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M>OYUS5<,K7@>_EG$-2514L5JGU_S/6J***X#[@**** &0_ZH4^F0_P"J%/H
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M R?X4?\ "/Z-_P! BP_\!D_PH^MQ[!_JM6_Y^+[F>%45[K_PC^C?] BP_P#
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M_P")?F>5T445^6'Z0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M82!MAXW^85#_ ";PFW(/..:H22M\0]<M?L:E?#.D7HG>\/\ S$KF)OE2(?\
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MPM-/A\FPM8+6(?P01A%_(58JI24N@C6TK_CU;_?/\A5VJ6E?\>K?[Y_D*NU
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MU/1Z*H:'>3:AH-E=W1@,\T"O(;<DIN(YQGM[9..F3UJ_6+T=BPHHHI %%%%
M!1110 R'_5"GTR'_ %0I] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !5:^LK?4;<6MY'YD,C#<NXC..1R.>HJS2?\M8O][^AI2BI)QDK
MICC)Q::T:,G_ (0CP]_T#_\ R/)_\51_PA'A[_H'_P#D>3_XJM^BN3ZCA/\
MGU'_ ,!7^1T_7,3_ ,_)?>S _P"$(\/?] __ ,CR?_%4?\(1X>_Z!_\ Y'D_
M^*K?HH^HX3_GU'_P%?Y!]<Q/_/R7WLP/^$(\/?\ 0/\ _(\G_P 51_PA'A[_
M *!__D>3_P"*K?HH^HX3_GU'_P !7^0?7,3_ ,_)?>S _P"$(\/?] __ ,CR
M?_%4?\(1X>_Z!_\ Y'D_^*K?HH^HX3_GU'_P%?Y!]<Q/_/R7WLP/^$(\/?\
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M 4444 %%%% !1110!&/^/D_[@_F:DJ,?\?)_W!_,U)0 4444 %%%% !1110
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M1?SJ2B@"/SXO^>B_G1Y\7_/1?SJ2B@"/SXO^>B_G1Y\7_/1?SJ2B@"/SXO\
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M7T,LVHRQ,@D(P&00-TQSAJVO"GAT^'-+GBGN!=7M[=2WMY.$V"2:0Y)"Y.
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MQ(%1!Z #@#VI3AR@34445F,*Y7XD_P#(@WW^]%_Z,6NJKE?B3_R(-]_O1?\
MHQ:YL7_N]3T?Y'1AOX\/5?F>%T445\"?;!1110 4444 %%%% !1110 4444
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M;+$4C!C$G ,@9L*<\*?QJJD84*EM[&-.52O3=]+G._V2MY,(K8>8['@*,_\
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M=7_D%%%%?0GA!1110 4444 1P_ZL_P"^W_H1J2HX?]6?]]O_ $(U)0 4444
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MIW>BZB?$7BK6]*MG.I6-_'+:JRE1>0FTA66'/<-C@]G53V->E44 >:"RNS\
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M^^#_ (4>>G^U_P!\'_"@"2BH_/3_ &O^^#_A1YZ?[7_?!_PH DHJ/ST_VO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M F'_ .>K_I1A_P#GJ_Z4M% "8?\ YZO^E&'_ .>K_I2T4 )A_P#GJ_Z48?\
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M_/5_S'^%244 1^4?^>K_ )C_  H\H_\ /5_S'^%244 1^4?^>K_F/\*/*/\
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M"/RC_P ]7_,?X4>4?^>K_F/\*DHH C\H_P#/5_S'^%'E'_GJ_P"8_P *DHH
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M **** "BBB@ HHHH **** "BBB@".;[J_P"^O\ZDJ.;[J_[Z_P ZDH ****
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MERQ/>RWAY8>:JXAW:V2V_P""%%%%<9]8%%%% #(?]6/J?YT^F0_ZL?4_SI]
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M?E%V;PUJDFJZ1KD^CZK(JZ4NF75A9ZH+6XA9&++*&CF5'4DD$%\C*G'4!\L
MU.G_ .$[TM])M[N&&\EN;BZ-E'IRQ 7/V@?>B*DA5*@$EBP4 9W8(S5\+>)+
M[6O&WB.RNX;FT@L8;3R[.ZC17A=Q+O\ F0D,#M4@AF'ICD5B6?A#5M-.G:]:
M:8J7=MJDUY+IOVUYII898A$=TTLC!I@H!^\J'&,]SN^&+76)/&GB'6-6TI]-
MM[Z"TCM8Y)HY)"(_.#;MC, ?F!X)&".<Y 344G;^M0.MKD/BI_R3C4?]Z+_T
M:M=?7(?%3_DG&H_[T7_HU:5'^+'U1SXO_=ZG^%_D?/5%%%?1GY^%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&*U\KQ/J^K:#XAEG=8[BY>9;8LI!!10?):, @8/7OU!-)7$W8]*HK N=>O\
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M"[LF]/.9RP()9B"I&WGGT+P[J-MJ_AO3[^QNI;NWGMT9)YU"R2<=6   ;/7
M STI2C8#2HHHJ!A1110 5R'Q4_Y)QJ/^]%_Z-6NOKD/BI_R3C4?]Z+_T:M:T
M?XL?5'-B_P#=ZG^%_D?/5%%%?1GY^%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#;,D=JBJ8B23&0!]W+,=O3+'UK1HIW8&79>&-!TUHSIVB:;:&-F9#!:1IL+
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M_OD444 'D0_\\D_[Y%'D0_\ /)/^^1110 >1#_SR3_OD4>1#_P \D_[Y%%%
M!Y$/_/)/^^11Y$/_ #R3_OD444 'D0_\\D_[Y%'D0_\ /)/^^1110 >1#_SR
M3_OD4>1#_P \D_[Y%%% !]GA_P">4?\ WR*/(A_YY)_WR*** #R(?^>2?]\B
MCR(?^>2?]\BBB@ \B'_GDG_?(H\B'_GDG_?(HHH /(A_YY)_WR*/(A_YY)_W
MR*** #R(?^>2?]\BCR(?^>2?]\BBB@ \B'_GDG_?(H\B'_GDG_?(HHH /(A_
MYY)_WR*/(A_YY)_WR*** #R(?^>2?]\BCR(?^>2?]\BBB@ \B'_GDG_?(H\B
M'_GDG_?(HHH /(A_YY)_WR*/(A_YY)_WR*** #R(?^>2?]\BC[/#_P \D_[Y
M%%% "^1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110
M >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%
M_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \
MD_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y
M%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1
M?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 GD0_P#/)/\ OD4OD1?\
M\D_[Y%%% !Y$7_/)/^^11Y$7_/)/^^1110 >1%_SR3_OD4>1%_SR3_OD444
M'D1?\\D_[Y%'D1?\\D_[Y%%% !Y$7_/)/^^11Y$7_/)/^^1110 >1%_SR3_O
MD4>1%_SR3_OD444 'D1?\\D_[Y%'D1?\\D_[Y%%% !Y$7_/)/^^12>1#_P \
MD_[Y%%% "^1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^
M1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110
M >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%
M_P \D_[Y%'D1?\\D_P"^1110 GD0_P#/)/\ OD4OD1?\\D_[Y%%% !Y$7_/)
M/^^11Y$7_/)/^^1110 >1%_SR3_OD4>1%_SR3_OD444 'D1?\\D_[Y%'D1?\
M\D_[Y%%% !Y$7_/)/^^11Y$7_/)/^^1110 >1%_SR3_OD4>1%_SR3_OD444
M'D1?\\D_[Y%'D1?\\D_[Y%%% ">1#_SR3_OD4OD1?\\D_P"^1110 >1%_P \
MD_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y
M%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1
M?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D
M_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%'D1?\\D_P"^
M1110 >1%_P \D_[Y%'D1?\\D_P"^1110 >1%_P \D_[Y%)Y$/_/)/^^1110
MOD1?\\D_[Y%'D1?\\D_[Y%%% !Y$7_/)/^^11Y$7_/)/^^1110 >1%_SR3_O
MD4>1%_SR3_OD444 'D1?\\D_[Y%'D1?\\D_[Y%%% !Y$7_/)/^^11Y$7_/)/
M^^1110 >1%_SR3_OD4>1%_SR3_OD444 'D1?\\D_[Y%'D1?\\D_[Y%%% !Y$
47_/)/^^13E54&$4*/0#%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>plrx-20211231_g10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #, CD# 2(  A$! Q$!_\0
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MK^5)8QK$URB#:JR\#T^5: +5%%% !5>U_P!;=?\ 77_V1:L57M?];=?]=?\
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MC<?B:P/'VF^%K+18WT5K+SOM*+:-:7+2R7%J807DN%).QQ)QC"]QC S7'1^
MO$HQGP_J(_[=F_PJY%X&\1KUT+4!_P!N[?X4 >I+!X=1-._M.WLKFVCTO2%L
M8[F9D7;+*WVIQM89()<D]L55>3P;;V4UGIS:>-:CN'CMKF:VG;!$I".TID\H
MC;@[BF,=JX7_ (1'Q+)'$DFD:DZ1+MC5H7(0$Y('H,DGCUJ:/P;KPZZ+??\
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MEC%)CU"GT-9_Q#^,:^ -9>P7POK.O+;::VKWUSIK6P2TME8J782S(S'Y6.U
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M+\HRI&<S6'P;\.ZXMOJLFJZSJUPUFUDU]>S_ +V=3'<0LS@H/FQ<2=  ,+@
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M-<2<J,G%8_5\J;FE15XZ6ZO5K377;\A\U334]3C_ ."D7Q,;KHOAC_P&N/\
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MK_[*M %BBBB@ JO:_P"MNO\ KK_[(M6*KVO^MNO^NO\ [(M %BBBB@ HHHH
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M92<H1@]E.G4<4XLQE**=FCV+P+\%/#W@'PMI&B6(F==.E$ZW!81O(XF><Y5
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M]D6K%5[7_6W7_77_ -D6@"Q1110 4444 %%%% !1110 4444 %%%% !1110
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M0FW;3&B;>1YDA:< X^?;C@"M(XM\D)2I.\K[=+"Y=7J?*/\ ;&H_]!*]_P#
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M.Q_B)Y: D\CJF<CC(K]1K6ZAO;:*XMY8Y[>9!)'+$P9'4C(8$<$$<Y%?S[Y
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M'_II_P!^F_PJS10!6^WP_P#33_OTW^%'V^'_ *:?]^F_PJS10!6^WP_]-/\
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MX_YF'+3[GYQ#]D?XT?\ 1-->_P"_2?\ Q5._X9)^-'_1-->_[])_\57Z-_\
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M?;X?^FG_ 'Z;_"BS;>UPX#!6DR-RD9^51WJS10 4444 %%%% !1110 4444
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MK"W$]S/'!"S(@DD8!2SL%49]2Q 'N15BO9/("BJ[786^CMMO+H7S]"!_6K%
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M-=9X?N]"\-:+::9:W^ZWMDV(TK;F(R3R<>]5.J[-*5Q**WL=+6=JO_'QIO\
MU\?^RM3/^$HTK_G]C_7_  JO<:M9ZE>6"6TZS.L^XA<\#:W-<IH;E%%% !11
M10 4444 %%%% !1110 4444 )2U7O+Z"PC\RXD$2=-S53_X2C2O^?V/]?\*
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M,\F,\F-3^ I]% $?D1_\\U_[Y%'D1_\ /-?^^14E% $?D1_\\U_[Y%'D1_\
M/-?^^14E% $?D1_\\U_[Y%*L2*<A%!]A3Z* "BBB@ HHHH **** "BBB@ HH
MHH **** $90PPP##W%,\B/\ YYK_ -\BI** (_(C_P">:_\ ?(H\B/\ YYK_
M -\BI** (_(C_P">:_\ ?(H\B/\ YYK_ -\BI** (_(C_P">:_\ ?(IZJ%&
M,#VI:* "DI:* (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\
MGFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\BI** &K&J?=55^@IU%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>plrx-20211231_g11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $Q 74# 2(  A$! Q$!_\0
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M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*/\ P7Q__':/^'H'PE_Z!OBC_P %\?\ \=KT?['S#_GRR/:0[GU]17R18_\
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MI$]._P"R7S?^G5*ZL/\ ;_PLRJ=/5'T?1117*:A1110 4444 %%%% !1110
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M?Q6\,_LW_"NT.J+%K&GBZURZ>.%9,21R"#S?*5\$'A1@]AC _1CXM:E<:/\
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ME6"IX2K.%))J+:^X(5).239^OU?F_P#\%7/^1R^'?_7A>?\ HR*OT@K\W_\
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M""=SM==_Y >H?]>\G_H)K\F17ZS:[_R ]0_Z]Y/_ $$U^3(K[?@'X,3ZQ_\
M;CR<YWI_/]!:***_6#YL^P?V!?\ D&^-/^N]K_Z ]?65?)O[ O\ R#O&G_7>
MU_\ 0'KZRK^<^*O^1S7_ .W?_24?<Y=_NL/G^;/QG_;B_P"3K?B#_P!?-O\
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MVY\._@SI/@Z7QQ+J.GW_ (CTB+5H8+'3I;I55E4D%D!P03CFO*O@G^T%X/\
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M08K_ '>IZ/\ (_/&BBBOZ?/SX*_1;]D__D@?A?\ W)O_ $<]?G37Z+?LG_\
M) _"_P#N3?\ HYZ_.N.O^1=3_P :_P#29'N91_'?I^J/3]=_Y >H?]>\G_H)
MK\F17ZS:[_R!-0_Z]Y/_ $$U^3(KS. ?@Q/K'_VXZ,YWI_/]!:***_6#YL^P
M?V!?^0=XT_Z[VO\ Z"]?65?)O[ O_(-\:?\ 7>U_] >OK*OYSXJ_Y'-?_MW_
M -)1]SEW^ZP^?YL_&?\ ;B_Y.M^(/_7S;_\ I+#7AE>Y_MQ?\G6_$'_KYM__
M $EAKPROTC ?[I1_PQ_)$3^)A7T;_P $]?\ D[#PK_UZW_\ Z3/7SE7T;_P3
MU_Y.P\*_]>M__P"DSU&9?[E6_P ,OR"G\2/U^K\W_P#@JY_R.7P[_P"O"\_]
M&15^D%?F_P#\%7/^1R^'?_7A>?\ HR*OS+AW_D8P^?Y,[ZWP,^%****_7SS3
M2\,_\C1H?_81MO\ T<E?OS7X#>&?^1HT/_L(VW_HY*_?FOSOBSXJ/_;WZ'9A
M^H4445\ =@4444 %%%% !1110!S'Q0TF\U_X:^+-,T^SM]1O[S2;NWM[.\_U
M,\CPLJH_(^5B0#ST)K\IH?AW\--:^%_A[X?^'_V=?%L7QVBEM(;JXU339EM%
MN5E3[1+/*7V&W8!_EV@!6X(QFOU=^).L7WA[X=^*-4TN2VBU.QTNZN;62\<)
M"LJ1,R&1F( 7<!DDXQFOSP^'OB+6/'7@_0_$&L?MW6V@:MJ5O'<WFC&"SC-I
M,P!>##2J?E.5^Z <9'&*]O 2E&$FGI=?S;^=D]#EK6;L?2_[%_PQNOAKJWQ?
MALO"UYX*\$7/B7;H&C7;,1LBA6*>XB#$D12R*67/4 5]-U#:?\>L/[WS_D7]
M[_?X^]^-35Y56HZLW-G1&/*K'"_$;X/Z1\2;S3=0N+_5]"UG3DEBM]6T&^>S
MNEAEV^;"77[R,50X(."BD8(S7-:Y^ROX&UBQTNQ@&KZ)866F+HDMMI&IRVZ7
M]@&+?9KG!S*N6<DD[CYC_-\QSZ_11&M4BDE+83C%[H@AL;:WMX8(X(TAA01Q
MQJ@"HH&  .P KYUN(UC_ ."B6GA%51_PJ^;[HQ_S%4KZ1KYPN_\ E(GIW_9+
MYO\ TZI6N'^WZ,FIT]4?1]%%<;KWQB\&>%]6GTS5?$-K97\&/,@DW;ER 1G
M]"*YXQE-VBKF>(Q5#"Q4\144$]+MI*_S.RHKSW_AH#X>?]#78_\ CW^%'_#0
M'P\_Z&NQ_P#'O\*T]A5_D?W,X/[9RS_H)I_^!Q_S/0J*XW0?C%X,\4:M!IFE
M>(;6]OY\^7!'NW-@$G&1Z FNRK.4)0=I*QWX?%4,5'GP]136UTTU?Y'R)^WF
M ;SP5D9^2\_G#7RCM'H*^KOV\O\ C\\%_P"Y>?SAKY2K]<R+_D74OG^;/Y;X
MV_Y'^)_[=_\ 2(B;1Z"IK%5^W6V0/]:O;_:%15/8_P#'];?]=5_]"%>Z]F?%
M0^)'ZOK]T?2O'/VO/^2#:_\ ]=+?_P!')7L:?=7Z5XY^UW_R077_ /?M_P#T
M<E?CF2_\C/#?XX_FC^U\5_N\_1_D?GC1117]/GY^%?HM^R?_ ,D#\+_[DW_H
MYZ_.FOT6_9/_ .2!^%_]R;_T<]?G7'7_ "+J?^-?^DR/<RC^._3]4>GZ[_R
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M?-O_ .DL->&5[G^W%_R=;\0?^OFW_P#26&O#*_2,!_NE'_#'\D1/XF%?1O\
MP3U_Y.P\*_\ 7K?_ /I,]?.5?1O_  3U_P"3L/"O_7K?_P#I,]1F7^Y5O\,O
MR"G\2/U^K\W_ /@JY_R.7P[_ .O"\_\ 1D5?I!7YO_\ !5S_ )'+X=_]>%Y_
MZ,BK\RX=_P"1C#Y_DSOK? SX4HHHK]?/--+PS_R-&A_]A&V_]')7[\U^ WAG
M_D:-#_["-M_Z.2OWYK\[XL^*C_V]^AV8?J%%%%? '8%%%% !1110 4444 <]
M\1+#1M4\ >);+Q%<+:>'[G3+F'4;AGV"*V:)A*Q;MA"QSVQ7YA6VB:/J5Y)X
M=U[]JSX>WGPYGTW3M"NS;QJFIW>E6,SR6]NW\",?,*LX))&.#W_3KXE:;=ZU
M\.?%.GV#VL5]=:5=06\E\H:W61HF"F0-P4!(SGC&:_-2'X;ZCKWPN\._"_2?
MV4+K0_B3:R6<4WC6]M8&L(YHY$,UZUS@^<CA6)0DJ0^!D8%>WE[2C*[MJNVG
MGKV\CDK;K0_2_P "^./#/Q!\.6^K^$M;T_7]%;]W'=Z;<+-%E>"N5)P1QP>:
MZ"OG7]DOX2ZI\-_$GQ>U"?PM;>"?#^N>(Q)HVAVC+Y8@AA6%KD(O$8G92X7@
M@8XZ5]%5Y5:,83<8.Z.F+;5V%%%%8E!7SA=_\I$]._[)?-_Z=4KZ/KYPN_\
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MYWI_/]!:***_6#YL^P?V!?\ D'>-/^N]K_Z"]?65?)O[ O\ R#?&G_7>U_\
M0'KZRK^<^*O^1S7_ .W?_24?<Y=_NL/G^;/QG_;B_P"3K?B#_P!?-O\ ^DL-
M>&5[G^W%_P G6_$'_KYM_P#TEAKPROTC ?[I1_PQ_)$3^)A7T;_P3U_Y.P\*
M_P#7K?\ _I,]?.5?1O\ P3U_Y.P\*?\ 7K?_ /I,]1F7^Y5O\,OR"G\2/U^K
M\W_^"KG_ ".7P[_Z\+S_ -&15^D%?F__ ,%7/^1R^'?_ %X7G_HR*OS+AW_D
M8P^?Y,[ZWP,^%****_7SS32\,_\ (T:'_P!A&V_]')7[\U^ WAG_ )&C0_\
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M]"%0U/8_\?UM_P!=4_\ 0A7NRV9\7#XD?J^GW5^E>.?M>?\ )!=?_P"NEO\
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M_-GXS_MQ?\G6_$'_ *^;?_TEAKPRO<_VXO\ DZWX@_\ 7S;_ /I+#7AE?I&
M_P!TH_X8_DB)_$PKZ-_X)Z_\G8>%?^O6_P#_ $F>OG*OHW_@GK_R=AX5_P"O
M6_\ _29ZC,O]RK?X9?D%/XD?K]7YO_\ !5S_ )'+X=_]>%Y_Z,BK](*_-_\
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M#/\ R-&A_P#81MO_ $<E?OS7YWQ9\5'_ +>_0[,/U"BBBO@#L"BBB@ HHHH
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M<8*&P4445S&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>plrx-20211231_g12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #A :(# 2(  A$! Q$!_\0
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MH\I/[B_E3J* &^4G]Q?RH\I/[B_E3J* (G\F,@/Y:D]-V!FA_)CP'\M2>F[
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M_P _H_\ @2_S#V<^QX'17OG_  PA\<O^A+7_ ,&EK_\ '*/^&$/CE_T):_\
M@TM?_CE']HX+_G]'_P "7^8>SGV/ Z*]\_X80^.7_0EK_P"#2U_^.4?\,(?'
M+_H2U_\ !I:__'*/[1P7_/Z/_@2_S#V<^QX'17OG_#"'QR_Z$M?_  :6O_QR
MC_AA#XY?]"6O_@TM?_CE']HX+_G]'_P)?YA[.?8Y?X=_&U/ 'P9^(?@N/3IY
MM1\3W%C<6VHI*JQVC6\@?YEZL21QBO;M=_;\@\0?%>T\6S^%;U;&#PM<Z";%
M;J/>;B=U9Y\XQM^51CKQ7G/_  PA\<O^A+7_ ,&EK_\ '*/^&$/CE_T):_\
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MF7OB[49OLVG:@+6\MF+R.K X(*D91@1R&R.<5P'_  PA\<O^A+7_ ,&EK_\
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M$X7OQ CU7[/-IUQ<21Q?8IHFW?-M5248A<XYQNQUJ#_AA#XY?]"6O_@TM?\
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M4MJ^HW*3-+:QH3 D>Q$18P'+<+R6)))KYK^%?PB\3^%?'VEZGKNGZUH7P_\
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M5N!^(YJG\0/%7@CX4Z39WGB9++3+>ZQI5I#'IQGFN 06^S10QHSNN 6**NT
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MN/\ XNC_ (6/XO\ ^AN\0?\ @VN/_BZ/]5*G_/Y?=_P0^L+L?N7]GE_YY/\
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M  L?Q?\ ]#=X@_\ !M<?_%T?\+'\7_\ 0W>(/_!M<?\ Q='^J=3_ )_+[O\
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MH! D3(^5@"?F'/)K\/?^%C^+_P#H;O$'_@VN/_BZ/^%C^+_^AN\0?^#:X_\
MBZ/]5*G_ #^7W?\ !#ZPNQ^Y?V>7_GD__?)H^SR_\\G_ .^37X:?\+'\7_\
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M$BB1"&1P".&4@$'J".*L^1*>3'(3_NFOPT_X6/XO_P"AN\0?^#:X_P#BZ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/QM_Z)MK'_?4/_QROV5HH_UJQ7_/N/X_YA]7CW/QJ_X8Y^-O_1-M8_[ZA_\
MCE'_  QS\;?^B;:Q_P!]0_\ QROV5HH_UJQ7_/N/X_YA]7CW/QJ_X8Y^-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>plrx-20211231_g13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g13.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 4/#A0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+N[D[L]\^9CVV_E](_\ !$^YD;]G'QG;D_NH_%DLBC'=K.U!_P#010!\%?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 97BKQ':^#_"^L:]?+(UEI=G-
M?3K"H9S'$A=@H)&3A3CD5^,_[6/_  5F\8_&33[SPS\-[*X\ ^%Y]T<VH-,#
MJEW&1]W<GRP*><A"S'^_@D']A_B=X<NO&/PV\6:!8M$E[JNDW=C TS%4$DL+
MHI8@$@989P#7QE^RC_P2=\$?!74;+Q-\0+R'X@>*K=EEM[5H2FF6<@_B$;<S
ML#T:3 Z'8" : /Q6UC1=1\.Z@]AJMA=:9?1JCO;7D+12JKJ'0E6 (#*RL/4$
M'H:_H-_X)T?\F4_"O_L'R_\ I3-7X_\ _!2G_D][XH_]?5K_ .D5O7[ ?\$Z
M/^3*?A7_ -@^7_TIFH ^CZ_G _;$\6R_$K]K+XH:I"AG,_B*YL[98B7,D<,G
MV>+&.I98UX'KBOZ)?&WB:#P7X-U[Q#=%5MM)L+B_E+= D4;.V?;"FOYD?"_C
M"?P_\0-)\57,"ZK<V6IPZG+!.Q5;EDE$A5B.@8@@X]: /T?@_P""'>LR0QM)
M\6[**1E!:/\ L%CM..1G[1S6EH7_  1*U;1M<T[4#\6[.46EQ'/Y?]@N-VU@
MV,_:.,XKP;4/^"OO[0EYJPO(;WP[86^<_P!GV^D*8?IEV:3_ ,?[5]C?L9?\
M%7-+^-GB;3O _P 2]+L_"OBK4)!!8:K8LPT^]F)PL+*[%H9&R N696/&5)4$
M ^S_ ([?$J/X.?!GQIXV=%E;0M)N+V*)^DDJH?+0_P"\^U?QK^=#X>^$/$'[
M1GQNT?0/MK7'B'Q=K*I<:A.-Q\R:3=-<.,C.,NY ZX.*_;?_ (*H:A-8_L/^
M/EA<I]HETZ%R"0=IOH"1^.,'V)K\KO\ @F':QWG[<_PQCE&5634)!_O+IUTR
M_JHH ^\OC=_P2(^%EK\#]6_X01-8MO'.DV#W5KJ%S?F7^TIHXR?*FC(V*'QC
M,83:=IY (/YI?L;?&J\^ ?[2'@KQ5!=-;V'VZ.QU1=Q"2V,S!)@P[X4[QG@-
M&I[5_1_7\M7BBQATOQ-J]G;J4M[>\FAC4G.%5R ,_04 ?TE?M*?%;_A1_P !
M?'7CE/+^U:-I<LUHLHRC7+#9 K>QE= ?K7\]'P:^'6L?M'?'7P[X3^W22:KX
MHU4+=:A.WF2 ,QDN)VR?F8()']R/>OV!_P""EVNW=Q_P3SFG=\R:E_8_V@\_
M-F2*0]_[RCK7YZ?\$H]/AO?VW/!DLH):TM-1FCP>-WV.5.?P=OTH ^SOVC/^
M"2OPOT7X!:W>_#V+5[3QKH.GO?0W5U?&?^TS"A9XY4.$5G56P8P@#%?X<BOS
MS_81^-%Y\#/VI/ ^MPSM%IVH7L>C:I'G"R6EPZH^[U"-LE'O$M?T2W5O'>6L
MUO*-T4J&-QG&01@U_*]%,\$J2Q.T<B,&5U."I'((/8T ?TU_';XE1_!SX,^-
M/&SHLK:%I-Q>Q1/TDE5#Y:'_ 'GVK^-?SH?#WPAX@_:,^-VCZ!]M:X\0^+M9
M5+C4)QN/F32;IKAQD9QEW('7!Q7[6?\ !3C6KG_A@GQC.K>7)?#2UE*9'#7E
MNS <]#C'T)%?ES_P3#M8[S]N?X8QRC*K)J$@_P!Y=.NF7]5% 'WE\;O^"1'P
MLM?@?JW_  @B:Q;>.=)L'NK74+F_,O\ :4T<9/E31D;%#XQF,)M.T\@$'\TO
MV-OC5>? /]I#P5XJ@NFM[#[='8ZHNXA);&9@DP8=\*=XSP&C4]J_H_K^6KQ1
M8PZ7XFU>SMU*6]O>30QJ3G"JY &?H* /Z2OVE/BM_P */^ OCKQRGE_:M&TN
M6:T6491KEAL@5O8RN@/UK^>CX-?#K6/VCOCKX=\)_;I)-5\4:J%NM0G;S) &
M8R7$[9/S,$$C^Y'O7[ _\%+M=N[C_@GG-.[YDU+^Q_M!Y^;,D4A[_P!Y1UK\
M]/\ @E'I\-[^VYX,EE!+6EIJ,T>#QN^QRIS^#M^E 'V=^T9_P25^%^B_ +6[
MWX>Q:O:>-=!T][Z&ZNKXS_VF84+/'*APBLZJV#&$ 8K_  Y%?GG^PC\:+SX&
M?M2>!];AG:+3M0O8]&U2/.%DM+AU1]WJ$;9*/>):_HENK>.\M9K>4;HI4,;C
M.,@C!K^5Z*9X)4EB=HY$8,KJ<%2.00>QH _JFHJII%T]]I-E<R8\R:!)&VCC
M)4$X_.OR6^-W_!7;XP_#7XT>/O".F>&_ \^FZ!X@U#2K66[L+QIGB@N9(D9R
MMVH+%4&2 !G. .E 'ZZ45^*W_#ZOXW_]"M\/_P#P77W_ ,F4?\/J_C?_ -"M
M\/\ _P %U]_\F4 ?M317XK?\/J_C?_T*WP__ /!=??\ R97[4T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'DW[5GQIB_9]_9^\:>.#(B7NGV+)IZR8(>\DQ';K
MCN/,921_=#'M7\VES<RWEQ+<3RO-/*YDDDD8LSL3DDD]237ZB_\ !:SXY?:-
M0\&_"73[C*6Z_P!OZJB-QO;=%;(<=POG,0?[Z'TK\Z/@W\*]8^-_Q0\-^!=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$LN[L P78"?XG4<YQ0!_19HMO)9Z/8V\HVRQ01QN,YP0H!K\XOBQ_P $:_\
MA:'Q4\9>,O\ A;_]F?\ "1:U>:O]B_X1GS?L_P!HG>7R]_VQ=VW?C=M&<9P.
ME?I510!^5?\ PXQ_ZK9_Y:G_ -VT?\.,?^JV?^6I_P#=M?JI10!_*O7]5%?R
MKU_510 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*H+  9X '- ']"]%>9?LX_#OQ1\,OA'HFD>-O%5_XR\7M']HU74[ZZ:<?:'
M+1Q%L8B3[J\#."Q +$5Z;0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.X)% ']1E%?-_P"S7^WI\*OVBO"MI<P^(M/\-^)UA5M0\/:M<K!-!)T;RV?
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MR9".ZQL*_GS\.>'O&/Q^^*%MI>GI=^*/&GB2];!FEW37,SY9W=V/' 9F9C@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X _\ !4?_ )/L
M^)O_ '#/_37:5^_U?@#_ ,%1_P#D^SXF_P#<,_\ 37:4 ??_ /P14_Y-9\4_
M]CG=?^D-C7W_ %\ ?\$5/^36?%/_ &.=U_Z0V-??] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!SOQ"^'WA_P"*G@S5?"GBK3(=8T#5(?(N
MK.;.'7((((Y5@0&# @@@$$$5^*_[6G_!+?XA_!/5-1UOP'8W7CSP&&,L;6:^
M;J-E'UVS0J,N%_YZ1@C RP3I7[E44 ?RMW-M-9W$D%Q$\$\;%7CD4JRL.H(/
M0U'7]._C/X,^ /B-<+/XL\#>&_$\Z@!9=9TBWNW&!@8,B$CBN1TW]CWX&:1<
M">V^$/@H2C!#2:%;2;2#D$;D.#[B@#^>SX4_!/QW\;]>31_ WA;4O$=Z75'-
MG"3%!GHTLIPD2_[3D"OVI_8%_P""?>F_LI:=)XF\23V^M_$F_A,,MS;Y:VTZ
M$G)B@) )9L#=(0,XV@ 9+?7FD:+I_A^Q2RTNPM=-LX_N6]G"L4:_15  J[0
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M&OQ=;^ O@[XX\1W4ODP:5HEY>,_!/R0NP !ZDD  =R17\RVDZ3=Z]JUEIEA
MUS?WDZ6UO F,R2.P55&>Y) _&@#^FCX)>?\ \*9\ _:O,^U?V!I_F^=G?O\
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M").#&G.[)QR3DT ?LU1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?@#_P %1_\ D^SXF_\ <,_]-=I7[_5^ /\ P5'_ .3[/B;_ -PS_P!-
M=I0!]_\ _!%3_DUGQ3_V.=U_Z0V-??\ 7P!_P14_Y-9\4_\ 8YW7_I#8U]_T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK?W0-\C'T!P">*_HO^(7P(^'7Q:U"UOO&G@G0_%-W:Q&&";5K&.X:)"<E5+
MX&3GBH/ /[/?PQ^%>M2:OX/\ ^'?#.JR0M;M>Z7IL4$QC)!*;E4':2JDCV%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^5>OZJ*_E
M7K^JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M017IO_#6/QO_ .BR?$#_ ,*B^_\ CM?M3_PZX_9B_P"B9_\ E?U3_P"2:/\
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M[/Y<4:A$7<Q).% &22?6@"_1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?@#_P5'_Y/L^)O_<,_]-=I7[_5^ /_  5'_P"3[/B;_P!PS_TU
MVE 'W_\ \$5/^36?%/\ V.=U_P"D-C7W_7P!_P $5/\ DUGQ3_V.=U_Z0V-?
M?] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\J]?
MU45_*O7]5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ ?\%6OV6_B?^TI
M_P *N_X5QX9_X2/^Q?[4^W_Z?:VOD^=]C\K_ %\J;L^5)]W.-O.,C/P!_P .
MN/VG?^B9_P#E?TO_ .2:_?ZB@#\ ?^'7'[3O_1,__*_I?_R31_PZX_:=_P"B
M9_\ E?TO_P"2:_?ZB@#\)OAE_P $T/VDO#WQ(\)ZKJ'PX^SV%CJUI<W$W]N:
M:VR-)D9FPMR2< $X )K]V:** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OP!_X*C_\ )]GQ-_[AG_IKM*_?
MZOP!_P""H_\ R?9\3?\ N&?^FNTH ^__ /@BI_R:SXI_['.Z_P#2&QK[_KX
M_P""*G_)K/BG_L<[K_TAL:^_Z "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /Y5Z_JHK^5>OZJ* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K\ ?^"H__)]GQ-_[AG_IKM*_?ZOP
M!_X*C_\ )]GQ-_[AG_IKM* /O_\ X(J?\FL^*?\ L<[K_P!(;&OO^O@#_@BI
M_P FL^*?^QSNO_2&QK[_ * "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /Y5Z_JHK^5>OZJ* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K\ ?^"H_P#R?9\3?^X9_P"FNTK]_J_
M'_@J/_R?9\3?^X9_Z:[2@#[_ /\ @BI_R:SXI_['.Z_](;&OO^O@#_@BI_R:
MSXI_['.Z_P#2&QK[_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /Y5Z_JHK^5>OZJ* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\ ?\ @J/_ ,GV?$W_ +AG
M_IKM*_?ZOP!_X*C_ /)]GQ-_[AG_ *:[2@#[_P#^"*G_ ":SXI_['.Z_](;&
MOO\ KX _X(J?\FL^*?\ L<[K_P!(;&OO^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /A+]N[_ )*[I'_8#A_]*+BOKWX._P#)(O __8#L?_2=*^0OV[O^2NZ1
M_P!@.'_THN*^O?@[_P DB\#_ /8#L?\ TG2OS_)_^1[COD?E^0_\E)F/R_,[
M"BBBOT _4 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /Y5Z_JHK^5>OZJ* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#8YW7_ *0V-??] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"7[=W_)7=(_
M[ </_I1<5]>_!W_DD7@?_L!V/_I.E?(7[=W_ "5W2/\ L!P_^E%Q7U[\'?\
MDD7@?_L!V/\ Z3I7Y_D__(]QWR/R_(?^2DS'Y?F=A1117Z ?J 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'\J]?U45_*O7]5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-2\K[7>_9XH/,\N)(D^2)5082-!PHSC)Y)- 'Z__ /!%3_DUGQ3_ -CG=?\
MI#8U]_U\ ?\ !%3_ )-9\4_]CG=?^D-C7W_0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'PE^W=_R5W2/^P'#_ .E%Q7U[\'?^21>!_P#L!V/_ *3I7R%^W=_R
M5W2/^P'#_P"E%Q7U[\'?^21>!_\ L!V/_I.E?G^3_P#(]QWR/R_(?^2DS'Y?
MF=A1117Z ?J 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '\J]?U45_*O7]5% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-_"KX^:+KOAFQM])@\5Z<UY>V-K$(XQ=QR%9)E X'F*T9( 'S*S')<U]K?\
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M_/\ )_\ D>X[Y'Y?D/\ R4F8_+\SL****_0#]0"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E7K^JBOY5Z
M_JHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"7[=W_ "5W
M2/\ L!P_^E%Q7U[\'?\ DD7@?_L!V/\ Z3I7R%^W=_R5W2/^P'#_ .E%Q7U[
M\'?^21>!_P#L!V/_ *3I7Y_D_P#R/<=\C\OR'_DI,Q^7YG84445^@'Z@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!_*O7]5%?RKU_510 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?@#_P %1_\ D^SXF_\ <,_]-=I7[_5^ /\ P5'_
M .3[/B;_ -PS_P!-=I0!]_\ _!%3_DUGQ3_V.=U_Z0V-??\ 7P!_P14_Y-9\
M4_\ 8YW7_I#8U]_T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\)?MW?\ )7=(
M_P"P'#_Z47%?7OP=_P"21>!_^P'8_P#I.E?(7[=W_)7=(_[ </\ Z47%?7OP
M=_Y)%X'_ .P'8_\ I.E?G^3_ /(]QWR/R_(?^2DS'Y?F=A1117Z ?J 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '\J]?U45_*O7]5% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17">//CEX(^&>KPZ7X
MEUO^S;Z:!;E(OLD\N8RS*&RB,.J,,9SQ7-_\-;?"C_H:_P#RG7?_ ,:KSJF9
M8&C-TZE>":W3DD_S/)JYMEU";IU<1",ENG.*:^39Z_17D'_#6WPH_P"AK_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7X _\ !4?_ )/L^)O_ '#/_37:5^_U?@#_ ,%1
M_P#D^SXF_P#<,_\ 37:4 ??_ /P14_Y-9\4_]CG=?^D-C7W_ %\ ?\$5/^36
M?%/_ &.=U_Z0V-??] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"7[=W_ "5W
M2/\ L!P_^E%Q7U[\'?\ DD7@?_L!V/\ Z3I7R%^W=_R5W2/^P'#_ .E%Q7U[
M\'?^21>!_P#L!V/_ *3I7Y_D_P#R/<=\C\OR'_DI,Q^7YG84445^@'Z@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!_*O7]5%?RKU_510 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH/\ 5;)_^?/_ )-+_P"2/J/]3,A_Z!__ ":?_P D?(/_  []_P"I\_\ */\
M_;ZV/!W[#W_")^+M#US_ (37[5_9E]!>_9_[*V>9Y<BOMW><<9VXS@XSTKZF
MHJX<,Y33DIQHZK^]+_Y(NGP?D=.:G"AJM5[T_P#Y(****^H/L@HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH _E7K^JBOY5Z_JHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KR#]K;_DWSQ7_P!NG_I7#7K]>0?M;?\ )OGBO_MT
M_P#2N&O*S;_D78C_  2_])9XF>?\BK%?]>Y_^DL\@_X)^_\ ,^?]N'_MS7U]
M7R#_ ,$_?^9\_P"W#_VYKZ^KR>%O^1/1_P"WO_2I'B\&?\B'#_\ ;W_I<@HH
MHKZL^U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *_ '_@J/_R?9\3?^X9_Z:[2OW^K\ ?^"H__ "?9\3?^
MX9_Z:[2@#[__ ."*G_)K/BG_ +'.Z_\ 2&QK[_KX _X(J?\ )K/BG_L<[K_T
MAL:^_P"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /A+]N[_DKND?]@.'_ -*+
MBOKWX._\DB\#_P#8#L?_ $G2OD+]N[_DKND?]@.'_P!*+BOKWX._\DB\#_\
M8#L?_2=*_/\ )_\ D>X[Y'Y?D/\ R4F8_+\SL****_0#]0"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "ORY_9C_X*5_%GXP?M9>'_ (;:Y9>&H_#]
M_J-Y:2R6=C*EQLBAF=<,9B <QKGY?6OU&K\"_P!@_P#Y2)>#O^PUJ7_I-<T
M?OI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!_*O7]5%?RKU_510 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E7QN_:D^%W[.]CYW
MCSQ?8Z/<LF^+35)GO9AT!2",%R,\;L!1W(J']K'4_&^D?L[^-KGX<)?2>-Q:
M)'I:Z;;^?<>8\R(2B8/.UFYQQUXQFORS^&__  2/^.'Q>U*37_B3X@L_!\E\
MS37,^JW#:IJDKD_?=4;:21R2TP;ID=< 'N/Q"_X+=>&K&9X?!'PVU/6$R0+O
M7+Z.R'L1'&LI(/NRFO+&_P""W'Q$^U%E^'GA@6V_/EF:Y+[<]-V[&<=]OX5]
M%>#/^"+_ ,&]$6*3Q!XA\5>);A5PZ?:8;2W8\<A$C+C_ +^'K7H,/_!*']FV
M.)$;P=?RLHP9'UN\RWN<2 ?D* /G?P-_P7 TR:98O&7PNN[.+^*ZT/4UG;\(
MI43_ -&5]F_ K]N+X-?M$3067A3Q?;QZY+C&AZLIL[TMC.U$?B4@=?++CCK7
MA7BS_@C;\"]<B)TF^\5>&YP/E-KJ$<T>?]I9HV)_!A7S7\5/^"*OC?P_')??
M#OQQIOB?RV+I8ZK"VGW  Y 20%T9LXY;RQ]* /V"HKY,_P""<-K\8]$^$?B'
MP]\:4UI=>T763:6!UPB60VGV>%EV3C(G0.S@.&?!!7/RX'UG0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^ /\
MP5'_ .3[/B;_ -PS_P!-=I7[_5^ /_!4?_D^SXF_]PS_ --=I0!]_P#_  14
M_P"36?%/_8YW7_I#8U]_U\ ?\$5/^36?%/\ V.=U_P"D-C7W_0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7BGQ$_:R\(
M_#/QCJ'AK5-.UN>^LO+\R2T@A:([XUD&"TJGHXZ@<YKVNOSC_:V_Y.#\5_\
M;I_Z20U\GQ+F6(RO"1K8=J[DEJKZ6;_0^(XNS;$Y-@88C"-*3FEJKZ6D_P!#
MZ._X;N\ _P#0(\2?^ UO_P#'Z/\ AN[P#_T"/$G_ (#6_P#\?H_X81\ _P#0
M7\2?^!-O_P#&*/\ AA'P#_T%_$G_ ($V_P#\8KR_^,H_N?@>-_QF7_3O\ _X
M;N\ _P#0(\2?^ UO_P#'Z/\ AN[P#_T"/$G_ (#6_P#\?H_X81\ _P#07\2?
M^!-O_P#&*/\ AA'P#_T%_$G_ ($V_P#\8H_XRC^Y^ ?\9E_T[_ /^&[O /\
MT"/$G_@-;_\ Q^C_ (;N\ _] CQ)_P" UO\ _'Z/^&$? /\ T%_$G_@3;_\
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MW=X!_P"@1XD_\!K?_P"/T?\ #"/@'_H+^)/_  )M_P#XQ7A'[4/P(T#X)_\
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M&/'UQ\._V,_B5?V;;+N]LH])C^;!VW4R028/J(Y)#^%?C;_P3_\ AS8?%/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O(/VMO^3?/%?\ VZ?^E<->OUY!^UM_R;YXK_[=
M/_2N&O*S;_D78C_!+_TEGB9Y_P BK%?]>Y_^DL\@_P""?O\ S/G_ &X?^W-?
M7U?(/_!/W_F?/^W#_P!N:^OJ\GA;_D3T?^WO_2I'B\&?\B'#_P#;W_I<@HHH
MKZL^U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /@K_@I%^W!\0_V3?%W@O3?!5KH=Q;ZQ8SW%P=6M))F#)(JC:5D3 P3US7UE
M^SSX]U+XI? GP#XPUA+=-5US1;74+I;5"D0DDB5F"*22%R> 2:_,K_@N!_R4
M;X7_ /8*N_\ T<E?HE^QA_R:7\(/^Q6T_P#]$)0![-1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^ /_  5'
M_P"3[/B;_P!PS_TUVE?O]7X _P#!4?\ Y/L^)O\ W#/_ $UVE 'W_P#\$5/^
M36?%/_8YW7_I#8U]_P!? '_!%3_DUGQ3_P!CG=?^D-C7W_0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YQ_M;?\ )P?B
MO_MT_P#22&OT<K\X_P!K;_DX/Q7_ -NG_I)#7Y_QM_R+H?XU_P"DR/R_Q#_Y
M%5/_ *^+_P!)F?HY1117Z ?J 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5\@_P#!0+_F0_\ M_\ _;:OKZOD'_@H%_S(?_;_ /\ MM7R
MG%/_ ")ZW_;O_I43XKC/_D0XC_MW_P!+B>O_ +)/_)OGA3_M[_\ 2N:O7Z\@
M_9)_Y-\\*?\ ;W_Z5S5Z_7K93_R+L/\ X(_^DH]K(_\ D587_KW#_P!)0444
M5ZI[84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'D'[37[4?@G]E/P''XE\8SSR-=2FVT_2[% ]U>S!2Q5 2 % &6=B%
M&0,Y90?@'4/^"Y%W]LD^P_!^$6H)"&X\0DN1G@G%M@$^G./4UB?\%OX]3'Q&
M^%\DI?\ L9M)NUM@3\OGB9/.Q[[3!G\*]7^"/_!'WX2:O\,_#FM>*?$7B'7-
M8U33K>]FDTV]AALE,B!\0CRBQ7# ;F8YQG SB@#SO_A^/JW_ $2"R_\ !^__
M ,CUZA^S'_P5@U']H3XZ>%/A[-\-K70XM;EEB;4(]8:=H=D$DN0AA7.?+QU'
M6NQ_X<Z? '_GIXL_\&J?_&J[/X-_\$S?@]\#/B5HGCGPT_B(ZWH\CR6WVS4$
MDBR\;QG<HC&?E=N] 'UC1110 4444 4=<T6R\2Z)J&D:E!]IT[4+>2TN82Q7
MS(I%*NN001E21D$'FLKP'\.O"_PM\.PZ%X1T#3_#FCP\K9Z;;K"FX]6(4?,Q
M[L<D]S71T4 ?SX?\%*?^3WOBC_U]6O\ Z16]?L!_P3H_Y,I^%?\ V#Y?_2F:
MOQ__ ."E/_)[WQ1_Z^K7_P!(K>OV _X)T?\ )E/PK_[!\O\ Z4S4 <!_P5Q_
MY,QUO_L*Z?\ ^CJ_.K_@DS_R>MX8_P"P?J'_ *3/7Z9?\%2O#,_B;]B?QR;:
M(S3:=)97^Q3@[$NHQ(?P1F;\*_+#_@F#XFB\,_MM?#UKAXXX+\WE@S2?WI+2
M81@<]3($7\30!_0!7\J]?U'>-O$MMX+\&Z]X@O)4M[32;"XOYI9" J)%&SLQ
M)(& %)ZBOYAO"?AVY\8>*M&T&S&;S5+V&QAP,_/+(J+QWY84 ?N/_P %./\
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M",;YI7X503W9L"@#]I/^"DW_ "CKL/\ N"_^R5\'?\$F?^3UO#'_ &#]0_\
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M._: ^$$'Q\^#OB?P!<ZE)H\&N0+ ]]#$)6B"R(^0I(!^YCKWKX(_X<>>'/\
MHJ^J?^">/_X[0!U/_#[+X3?]"1XS_P"_5I_\?H_X?9?";_H2/&?_ 'ZM/_C]
M<M_PX\\.?]%7U3_P3Q__ !VC_AQYX<_Z*OJG_@GC_P#CM 'R-_P4,_;"\+_M
M?>*O!^J>&-&U?1X=%LI[:9-66(,[/(K KY;MQ@=\5^QG[&'_ ":7\(/^Q6T_
M_P!$)7Q9_P .//#G_15]4_\ !/'_ /':_0KX/_#N+X1_"SPGX*@O7U*'P_ID
M&FI>21B-IA$@0.5!."<9QF@#KZ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OP!_X*C_\GV?$W_N&?^FNTK]_
MJ_ '_@J/_P GV?$W_N&?^FNTH ^__P#@BI_R:SXI_P"QSNO_ $AL:^_Z^ /^
M"*G_ ":SXI_['.Z_](;&OO\ H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K\X_P!K;_DX/Q7_ -NG_I)#7Z.5^<?[6W_)
MP?BO_MT_])(:_/\ C;_D70_QK_TF1^7^(?\ R*J?_7Q?^DS/T<HHHK] /U *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^0?^"@7_ #(?
M_;__ .VU?7U?(/\ P4"_YD/_ +?_ /VVKY3BG_D3UO\ MW_TJ)\5QG_R(<1_
MV[_Z7$]?_9)_Y-\\*?\ ;W_Z5S5Z_7D'[)/_ ";YX4_[>_\ TKFKU^O6RG_D
M78?_  1_])1[61_\BK"_]>X?^DH****]4]L**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU!DG/^IEF:/'MMP!QTKZ*TG2+#P_I=KINEV5OING6L:PV]G:1+%#"@& B(H
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ML!)J*J:ORE_D8UO#/BRA3E5J8.T8IM_O*6RU?VS[1HHHKVS\P"BBB@ HHHH
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M?PI_:Q^+WP/TL:7X)\?:OH>E!F==/619K9&;)8K%*&12223@#)YZU^P_AO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!?P-\$?&C_A.?^$RT3^V/[-^P_9/]+G@\OS/M&__ %3KG/EIUSC''4U]9_\
M##/P1_Z$G_RK7W_Q^O"/^"7?_-3/^X9_[=U]WUQY/A,/5P-.=2G%MWU:3ZL^
ME\1^(<YP/%.+P^$QE6G"/):,:DXI7IP;LDTE=MOU/!_^&&?@C_T)/_E6OO\
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MZJ*_E7K^JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#YQ_;N_Y)%I'_ &'(?_2>XH_81_Y)%J__ &')O_2>WH_;
MN_Y)%I'_ &'(?_2>XH_81_Y)%J__ &')O_2>WK\__P":H_[<_0_+_P#FLO\
MN'^A]'4445^@'Z@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?G'^R3_R<'X4_P"WO_TDFK]'*_./]DG_ ).#\*?]O?\ Z235^?\ $G_(
MQR[_ !_^W0/R_BW_ )&N4_\ 7S_VZF?HY1117Z ?J 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.#EV^;!  !T7_!8C7H-7_:^%I%,99-+\.V5G,I.?+8M-,%'I\LRG_@5?<O\
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M7OV??MW^7YJ-MW;$SC&=JYZ"N5_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>#_MS?
M\FL^-O\ MQ_]+K>O>*\'_;F_Y-9\;?\ ;C_Z76]<./\ ]TK?X9?DSZKA/_DH
M<N_Z_4O_ $N)X1_P2[_YJ9_W#/\ V[K[OKX0_P""7?\ S4S_ +AG_MW7W?7!
MD?\ R+Z?S_\ 2F?5^*/_ "5^-_[A_P#IJ 4445[I^5!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7YQ_M;?\ )P?BO_MT_P#22&OT<K\X
M_P!K;_DX/Q7_ -NG_I)#7Y_QM_R+H?XU_P"DR/R_Q#_Y%5/_ *^+_P!)F?HY
M1117Z ?J 4444 %%%% !1110!Q'Q(^,OA7X3R:>GB2]ELVOA(8/+MWEW;-N[
M[H./O#K7%_\ #8GPN_Z#5S_X 3?_ !-:OQP_9_T_XWRZ.]]JUSIATU9E06\:
MMO\ ,V9SGTV#\Z\O_P"&!]!_Z&K4O_ >.OD<=6SZ.(DL'2@Z>EF]]E?[2ZWZ
M'PN98CB6&*G' 482I:6;WV5_M+K?H>*?M6?$SP_\4_'6EZGX=NI+NS@TU;:1
MY(6B(<2R-C# 'HPKZ ^&/[5'PY\,_#GPQI.H:M<17UCIMO;3HME*P5TC56&0
MN#R.U?-'[0_P?L_@MXNT_1[+4)]2CN;%;LR7"*I!,CKCCM\@_.O9/ /[%6B^
M,/!&@ZY-XDO[>74K&&[>%($*H70,0">PS7P^!JYRLSQ$J%.+JOXD]EZ:_JS\
MYRVMG\<XQ<L-2@Z[^-/9;;>]^K/6?^&Q/A=_T&KG_P  )O\ XFO9K6ZCO;6&
MXB.Z*9%D0XQE2,BOE[_A@?0?^AJU+_P'CKZ>T^S&GZ?;6JL76")8@QZG: ,_
MI7Z-E=3-:CG_ &E",5I;E^=^K\C]8R6KG51U/[6IQBM.7E^=[^\_(L4445]
M?4!1110 4444 %?(/_!0+_F0_P#M_P#_ &VKZ^KY!_X*!?\ ,A_]O_\ [;5\
MIQ3_ ,B>M_V[_P"E1/BN,_\ D0XC_MW_ -+B>O\ [)/_ ";YX4_[>_\ TKFK
MU^O(/V2?^3?/"G_;W_Z5S5Z_7K93_P B[#_X(_\ I*/:R/\ Y%6%_P"O</\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!\X_MW?\DBTC_L.0_\ I/<4?L(_\DBU?_L.3?\ I/;T
M?MW?\DBTC_L.0_\ I/<4?L(_\DBU?_L.3?\ I/;U^?\ _-4?]N?H?E__ #67
M_</]#Z.HHHK] /U **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *_./]DG_ ).#\*?]O?\ Z235^CE?G'^R3_R<'X4_[>__ $DFK\_XD_Y&
M.7?X_P#VZ!^7\6_\C7*?^OG_ +=3/T<HHHK] /U **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\@_\% O^9#_[?_\ VVKY3BG_ )$];_MW_P!*B?%<9_\ (AQ'_;O_ *7$]?\
MV2?^3?/"G_;W_P"E<U>OUY!^R3_R;YX4_P"WO_TKFKU^O6RG_D78?_!'_P!)
M1[61_P#(JPO_ %[A_P"DH****]4]L**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'SC^W=_R2+2/^PY#_Z3W%'["/\
MR2+5_P#L.3?^D]O1^W=_R2+2/^PY#_Z3W%'["/\ R2+5_P#L.3?^D]O7Y_\
M\U1_VY^A^7_\UE_W#_0^CJ***_0#]0"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OSC_9)_Y.#\*?]O?_ *235^CE?G'^R3_R<'X4_P"W
MO_TDFK\_XD_Y&.7?X_\ VZ!^7\6_\C7*?^OG_MU,_1RBBBOT _4 HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_)K/BG_L<[K_ -(;&OO^O@#_ ((J?\FL^*?^QSNO_2&QK[_H **** "BBB@
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MSZOQ1_Y*_&_]P_\ TU ****]T_*@HHHH **** "BBB@ HHHH **** "BBB@
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M\]_Z#OP#^P>)/^AC^#/D+_AN[Q]_T"/#?_@-<?\ Q^C_ (;N\??] CPW_P"
MUQ_\?KZ]_P"%.^ ?^A'\-_\ @IM__B*/^%.^ ?\ H1_#?_@IM_\ XBC^Q\]_
MZ#OP#^P>)/\ H8_@SY"_X;N\??\ 0(\-_P#@-<?_ !^C_AN[Q]_T"/#?_@-<
M?_'Z^O?^%.^ ?^A'\-_^"FW_ /B*/^%.^ ?^A'\-_P#@IM__ (BC^Q\]_P"@
M[\ _L'B3_H8_@SY"_P"&[O'W_0(\-_\ @-<?_'Z/^&[O'W_0(\-_^ UQ_P#'
MZ^O?^%.^ ?\ H1_#?_@IM_\ XBC_ (4[X!_Z$?PW_P""FW_^(H_L?/?^@[\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G']N[
M_DD6D?\ 8<A_])[BC]A'_DD6K_\ 8<F_])[>C]N[_DD6D?\ 8<A_])[BC]A'
M_DD6K_\ 8<F_])[>OS__ )JC_MS]#\O_ .:R_P"X?Z'T=1117Z ?J 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^<?[)/_)P?A3_ +>_
M_22:OT<K\X_V2?\ DX/PI_V]_P#I)-7Y_P 2?\C'+O\ '_[= _+^+?\ D:Y3
M_P!?/_;J9^CE%%%?H!^H!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %(0&!!&12UG^(O$&G>$]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&?\ R(<1_P!N_P#I<3U_]DG_ )-\\*?]O?\ Z5S5Z_7D'[)/_)OGA3_M[_\
M2N:O7Z];*?\ D78?_!'_ -)1[61_\BK"_P#7N'_I*"BBBO5/;"BBB@ HHHH
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M45X/_P -S?!'_H=O_*3??_&*/^&YO@C_ -#M_P"4F^_^,4?7\)_S^C_X$O\
M,/\ 5/B'_H75O_!4_P#Y$]XHKP?_ (;F^"/_ $.W_E)OO_C%>TZ!KMCXHT+3
M=9TR?[3INHVT=W:S;&3S(I%#HVU@",J0<$ C/-;4L11K-JE-2]&F>;CLFS/+
M(QGCL-4I)Z)SA*-_2Z5R_11170>.%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7@_[<W_ ":SXV_[<?\ TNMZ
M]XKP?]N;_DUGQM_VX_\ I=;UPX__ '2M_AE^3/JN$_\ DH<N_P"OU+_TN)X1
M_P $N_\ FIG_ '#/_;NON^OA#_@EW_S4S_N&?^W=?=]<&1_\B^G\_P#TIGU?
MBC_R5^-_[A_^FH!1117NGY4%%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** /Y5Z_JHK^5>OZJ* "BBB@ HHHH ****
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M*** "BBB@ HHHH **** "OP!_P""H_\ R?9\3?\ N&?^FNTK]_J_ '_@J/\
M\GV?$W_N&?\ IKM* /O_ /X(J?\ )K/BG_L<[K_TAL:^_P"O@#_@BI_R:SXI
M_P"QSNO_ $AL:^_Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBO5/;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M))J_/^)/^1CEW^/_ -N@?E_%O_(URG_KY_[=3/T<HHHK] /U **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^>/VX?BMXI^#_ ,)]
M)UGPCJG]DZE/K<-I)-]GBFW1-!.Y7;(K ?,B'.,\?6OB#_AN;XW?]#M_Y2;'
M_P",5X.,SG#X*K[&I%M^5O\ -'ZOPYX;9OQ/@%F.#JTXP;:M)R3T](27XGZS
M45^3/_#<WQN_Z';_ ,I-C_\ &*/^&YOC=_T.W_E)L?\ XQ7%_K)A/Y9?<O\
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M"QN;8O 5)R4*6S35_G[MOP1\)_\ #)/Q7_Z%3_RHVG_QVC_ADGXK_P#0J?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#S:_\ [C?J?6=%%%?5GX %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S?\
M\%&/#^H^)OV*?BI9Z67%S'I\5Z^PD'R;>YAGGZ=O*BDS[9KZ0IDT*7$3Q2HL
MD3J59'&0P/!!'<4 ?G5_P2+_ &AOAJOP>TKX3I?1Z7\1?MU[</82VY1M3!W2
MB6.0#:Y6%=I#$,!$>-H!.?\ \%&O^">!UZ&?XM_!O2&LO%ME(;W5]%TG,;WN
M"7-U;(H_X^%;YBJX+\E<N,/]#_#G_@G;\+/A%^T':?%CP<FH:+?6_P!I*Z&K
MI)I\;31/&S1*4WQ<2-@!RH!P !Q7U#0!_/I^TU^VMJ7[4GP3^''A[Q592?\
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M '\J]?U45_*O7]5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7Y,_L,_P#)TW@G_M^_](;BOUFK\F?V&?\ DZ;P3_V_
M?^D-Q7RF<?[W@_\ %^L3]_\ #C_DGN(_^O/_ +96/UFHHHKZL_  HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^<?V[O^21:1_P!A
MR'_TGN*/V$?^21:O_P!AR;_TGMZ/V[O^21:1_P!AR'_TGN*/V$?^21:O_P!A
MR;_TGMZ_/_\ FJ/^W/T/R_\ YK+_ +A_H?1U%%%?H!^H!1110 4444 %%%%
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M;CC9&S!0HM^NXYW]L<_1U !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_H:_P#RG6G_ ,:H_P"&MOBO_P!#7_Y3K3_XU7S_ /KMEW\D_NC_ /)'R_\
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MG'_PUM\5_P#H:_\ RG6G_P :H_X:V^*__0U_^4ZT_P#C5?4?Z[9=_)/[H_\
MR1]E_P 1#RK_ )]U/NC_ /)GZ.45^<?_  UM\5_^AK_\IUI_\:H_X:V^*_\
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MPM_V.=K_ .D-]0!]W>&_^1=TO_KUB_\ 0!6C6=X;_P"1=TO_ *]8O_0!6C0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '\J]?U45_*O7]5% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:_\ QROJ/K%'^=?>C\(_LG,?^@>?_@,O\CO**X/_ (7Y\,?^BC>$O_!Y:_\
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M\DBU?_L.3?\ I/;T?MW?\DBTC_L.0_\ I/<4?L(_\DBU?_L.3?\ I/;U^?\
M_-4?]N?H?E__ #67_</]#Z.HHHK] /U **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_./]DG_ ).#\*?]O?\ Z235^CE?G'^R3_R<'X4_
M[>__ $DFK\_XD_Y&.7?X_P#VZ!^7\6_\C7*?^OG_ +=3/T<HHHK] /U ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?@#_ ,%1_P#D^SXF_P#<,_\ 37:4 ??_ /P14_Y-9\4_]CG=?^D-C7W_ %\
M?\$5/^36?%/_ &.=U_Z0V-??] !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R9_P4
ML_Y(5H7_ &,D'_I+=4?\$T_^2%:[_P!C)/\ ^DMK1_P4L_Y(5H7_ &,D'_I+
M=4?\$T_^2%:[_P!C)/\ ^DMK7RG_ #._^W3]_P#^;7_]QOU/K.BBBOJS\ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .#^/G_ "0KXC?]
MBWJ7_I+)7PA_P33_ .2ZZ[_V+<__ *56M?=_Q\_Y(5\1O^Q;U+_TEDKX0_X)
MI_\ )===_P"Q;G_]*K6OE,P_Y&>&/W_@_P#Y(;._E^2/TKHHHKZL_  HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M._Z#OA+_ ,#+K_Y&K]*Z*]3_ %?P/9_>?"_\1>XH_GA_X C\U/\ AVG\3O\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_./]DG_DX/PI_V]_\
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M(V/5FA+'U+$]Z_1W_@D[XZD\9?L:>'[6:<W$_A_4+S2&9G#$*)/.13SQA)T
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MMU1_P33_ .2%:[_V,D__ *2VM?*?\SO_ +=/W_\ YM?_ -QOU/K.BBBOJS\
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MO;[:<B*:X<81#@ [2Y*Y *G##]6((8[6&.&&-8H8U")'&H554#   Z "I**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /Y5Z_JHK^5>OZJ* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O!_VYO^36?&W_;C_P"EUO7O%>#_ +<W_)K/C;_MQ_\ 2ZWKAQ_^Z5O\
M,OR9]5PG_P E#EW_ %^I?^EQ/"/^"7?_ #4S_N&?^W=?=]?"'_!+O_FIG_<,
M_P#;NON^N#(_^1?3^?\ Z4SZOQ1_Y*_&_P#</_TU ****]T_*@HHHH ****
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M /P;^)'[7UU\,_VQO''C+]G>";P_I^J7$EI>6<@%W:ZU,LC&2X%OM^17?YU
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M(6*O'(MN[*RD="" 0?:NRJ.>&.ZADAFC66&12CQR*&5E(P00>H(H _EM\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** /Y5Z_JHK^5>OZJ* "BBB@
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MK_T*:G_DW_RL_1RBOSC_ .&2?BO_ -"I_P"5&T_^.T?\,D_%?_H5/_*C:?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !%HUP2(K[3+E)X6(.&7<I(R#P1U!X- &[1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
M*O7]5%?RKU_510 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X/\ MS?\FL^-O^W'
M_P!+K>O>*\'_ &YO^36?&W_;C_Z76]<./_W2M_AE^3/JN$_^2AR[_K]2_P#2
MXGA'_!+O_FIG_<,_]NZ^[Z^$/^"7?_-3/^X9_P"W=?=]<&1_\B^G\_\ TIGU
M?BC_ ,E?C?\ N'_Z:@%%%%>Z?E04444 %%%% !1110!6U*Z:QTVZN$ 9H8GD
M ;H2 37R!^S/^VOXI^-OQ8LO"NJZ%H]A9SV\\S368E\P%$+ #<Y'Z5]<Z_\
M\@'4O^O:3_T$U^7W_!/_ /Y.3TC_ *\KO_T4:^>S'$5:.+PU.G*RD]?/5'['
MP;DV S'A_.L7BJ2E4HP3@W?W7RS=U]R^X_5"BBBOH3\<"BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /DS_ (*6?\D*T+_L9(/_ $ENJ\T_8>_:0^'7
MP?\ A/JVC>+O$7]DZE/K<UW'#]BN9MT300(&W1QL!\R.,9SQ]*]+_P""EG_)
M"M"_[&2#_P!);JO#_P!D/]D/P=\?OAMJ7B'Q#J6N6=[;:M)8)'ID\*1F-887
M!(>)SNS*W?& .*^)Q3Q$<WOADG+EZ[']09#3RBKX=J.=SG"A[5ZPMS7OINFK
M=]#ZK_X;F^"/_0[?^4F^_P#C%'_#<WP1_P"AV_\ *3??_&*X3_AVG\,?^@[X
MM_\  RU_^1J/^':?PQ_Z#OBW_P #+7_Y&KTO:9S_ "0_'_,^)^I^&W_05BON
MA_\ *SN_^&YO@C_T.W_E)OO_ (Q1_P -S?!'_H=O_*3??_&*X3_AVG\,?^@[
MXM_\#+7_ .1J/^':?PQ_Z#OBW_P,M?\ Y&H]IG/\D/Q_S#ZGX;?]!6*^Z'_R
ML[O_ (;F^"/_ $.W_E)OO_C%'_#<WP1_Z';_ ,I-]_\ &*X3_AVG\,?^@[XM
M_P# RU_^1J/^':?PQ_Z#OBW_ ,#+7_Y&H]IG/\D/Q_S#ZGX;?]!6*^Z'_P K
M.[_X;F^"/_0[?^4F^_\ C%'_  W-\$?^AV_\I-]_\8KA/^':?PQ_Z#OBW_P,
MM?\ Y&H_X=I_#'_H.^+?_ RU_P#D:CVF<_R0_'_,/J?AM_T%8K[H?_*SN_\
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MG_!0NRU7P]_I.G:U\4%O;%HQPT,NJ^8C<=!L8'V% ']#]%%% !1110 4444
M%%%% !7SK\7/^"@/P1^!OC_4O!?C#Q3<:?XBTX1&ZM8M+N9Q'YD2RI\Z1E3E
M'4\'O7T57\W_ .V-XND^(_[6'Q1U6)?.\[Q#=6EOY9+F2.&3R(B/7*QJ<#UQ
M0!^PO_#UO]FO_H=;W_P1WO\ \:J[H?\ P5"_9V\1:UI^DV'C&\FOK^XCM;>,
MZ+>*&D=@JC)BP,DCDU^97_#IG]H[_H6-+_\ !U;?_%UT?PW_ ."6?[0GAOXB
M>%M7OO#6FQV6GZK:W<[+K%NQ$:3*S$ -R< \4 ?N!7B/[17[97PK_9=AAC\;
M:_C6+B/SK?0M-C^T7TJ9(#^6" BDJP#2%5)4@$D&N_\ B]\1K+X0_"WQ7XVU
M",S6F@Z9/J#0J<-,8T++&#V+L H]V%?SE7%UXT_:F^.B/<3-K'C7QEJR1"23
M<$\V5PBCOLB1<#T1$]%H _6;1?\ @M)\%M0U:.VO?#GC+2K21]OVV:SMI$C&
M?O.J3EL8_NAC[&OM#X6?%KPA\:_!]KXH\$Z]:^(-$N/E6XMF.8WP"8Y$(#1N
M 1E' 89''-?DO\?/^"/^L_"'X)ZKXTT7QXGBC5M#LWO]3TMM,-NCPH-TK0/Y
MC$E%#'##Y@"?E.%/DG_!,W]HS4/@;^TEH6CRWC+X4\87$>CZE:L3Y8ED;;;3
M = RR,H+?W'?Z@ _?&O"?VCOVUOA5^RVL=OXRUN277)HO.AT#28A<7TB<X8I
MD+&#@@&1E!P<$X..[^.WQ4M?@C\'?&'CN\C6>/0M-ENXX';:)I@,119[;Y"B
MY_VJ_G7T?3O&W[5/QRMK-KMM;\;>,-4"M=7CD*9'/+L0#LC103A1A43 & !0
M!^L_A_\ X+0_!75-6CM=0\/^,=%M9&V_;I[*WECC'JZQSL^/]U6/-?:?PS^*
M'A7XQ>#['Q3X,UNUU_0;Q<Q7=JQX. 2CJ0&1QD91@&'<"OR)_:4_X)'ZO\#_
M (*ZGXZT'QN/%MUH=O\ :]5TU]-^S9@&/-EA;S6R(URQ5@,JK$'("G@?^"6?
M[1NH_!S]H_2/"MS>N/"?C29=+NK1W_=I=MQ:S*,??\S$?;*RG.=HP ?N[7B/
M[17[97PK_9=AAC\;:_C6+B/SK?0M-C^T7TJ9(#^6" BDJP#2%5)4@$D&N_\
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M?;*RG.=HP ?N[1110 4444 ?RKU_517\J]?U44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>#_MS?\ )K/C;_MQ_P#2ZWKWBO!_VYO^36?&W_;C_P"EUO7#C_\
M=*W^&7Y,^JX3_P"2AR[_ *_4O_2XGA'_  2[_P":F?\ <,_]NZ^[Z^$/^"7?
M_-3/^X9_[=U]WUP9'_R+Z?S_ /2F?5^*/_)7XW_N'_Z:@%%%%>Z?E04444 %
M%%% !7YC>(/V_/BUIVO:E:0WFE"&"YDB3=IZD[5<@=_05^G-83^ _#4CL[^'
M=)9F.2S6,1)/K]VO*QV%KXE15"KR6W\S[WA7/,JR659YI@%BE.W+>WNVO?=/
M>Z^X_,^Z_P""@'Q;O+:6"2\TDQRH4;&GJ#@C![UXW\+_ (G:Y\(?%T'B3P[)
M#'J<,<D2-<1"1-KKM;Y3[5^PNN^ _#*:'J++X=TE6%O(018Q9'RG_9K\TOV#
M]-L]6_:*TJVOK6"]MVLKHF&XC$B$B(X.",5\?C<%BJ6(H0J5W)R>C[;>9_2'
M#'$V1X_)LTQ.$RR-*G2@G."M:HK3=G:*[-:I[FA_P\(^+W_/[I/_ (+E_P :
M][_8Q_:F\=_&[XH:IH7B>XL9;"WT:6]1;:U$3>8L\" Y!Z8D;BOK#_A ?#'_
M $+FD_\ @#%_\35O3/#&CZ+<-/I^DV-A,R[#):VR1L5R#C*@<9 X]J^BP^7X
MRE5C.IB')+IKK^)^,YQQAPUC\!5PV$R:%*I)64TXWB^^D5^9IT445]&?C 44
M44 %%%% !1110!^3/_-]7_=2/_<G7ZS5^3/_ #?5_P!U(_\ <G7ZS5\ID/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\F?\
M!2S_ )(5H7_8R0?^DMU1_P $T_\ DA6N_P#8R3_^DMK1_P %+/\ DA6A?]C)
M!_Z2W5'_  33_P"2%:[_ -C)/_Z2VM?*?\SO_MT_?_\ FU__ '&_4^LZ***^
MK/P **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X/X^?\D*
M^(W_ &+>I?\ I+)7PA_P33_Y+KKO_8MS_P#I5:U]W_'S_DA7Q&_[%O4O_262
MOA#_ ()I_P#)===_[%N?_P!*K6OE,P_Y&>&/W_@__DAL[^7Y(_2NBBBOJS\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O!_VYO^36?&W_;C_P"EUO7O%>#_ +<W_)K/C;_MQ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7X _P#!4?\ Y/L^)O\ W#/_ $UVE?O]7X _\%1_^3[/B;_W#/\
MTUVE 'W_ /\ !%3_ )-9\4_]CG=?^D-C7W_7P!_P14_Y-9\4_P#8YW7_ *0V
M-??] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'R9_P %+/\ DA6A?]C)!_Z2W5?(
MGP/_ &O/&/P!\)W?A[P]INAWEE<WKW[R:G!,\@D:.-" 4E0;<1+VSDGFOU7\
M3>$="\:6,=CXAT73M=LHY!,EOJ=I'<1K( 0'"N" P#,,]<,?6N:_X4'\,?\
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M\,?^B<^$O_!':_\ QNC_ (4'\,?^B<^$O_!':_\ QNC^S\S_ .@D/]<.!O\
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M_P#02'^N' W_ $)/Q7^9\(?\/+/B=_T O"7_ (!W7_R31_P\L^)W_0"\)?\
M@'=?_)-?=_\ PH/X8_\ 1.?"7_@CM?\ XW1_PH/X8_\ 1.?"7_@CM?\ XW1_
M9^9_]!(?ZX<#?]"3\5_F?GUXN_X*#?$3QIX3UKP]?:-X8BLM6LI[">2WM;D2
M+'+&R,5)G(# ,<9!&>QK6_X)I_\ )===_P"Q;G_]*K6ON_\ X4'\,?\ HG/A
M+_P1VO\ \;K6\,_#'P=X+OI+[P]X3T/0KV2,PO<:9IL-O(T9()0LB@E254XZ
M94>E%+*L7]9IUZ];FY0QW'V0?V+B\IRG+W0]NK-IJU^[.FHHHKZL_  HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KP?\ ;F_Y-9\;?]N/_I=;U[Q7@_[<W_)K/C;_ +<?_2ZWKAQ_^Z5O\,OR
M9]5PG_R4.7?]?J7_ *7$_//X"_M+>)_V=_[<_P"$<L-)O?[8\CS_ .U(99-O
ME>9MV;)$QGS6SG/0=._K/_#RSXG?] +PE_X!W7_R36]_P3C\ ^&/''_"PO\
MA(_#FD^(/LO]G>1_:EC%<^5N^T[MF]3MSM7..NT>E?:/_"@_AC_T3GPE_P""
M.U_^-U\AEV#QU7"PG1K\L7>R^;/Z*XSXDX5R_/<1ALRROVU:/+S3NM;PBU]R
M:7R/A#_AY9\3O^@%X2_\ [K_ .2:/^'EGQ._Z 7A+_P#NO\ Y)K[O_X4'\,?
M^B<^$O\ P1VO_P ;H_X4'\,?^B<^$O\ P1VO_P ;KTO[/S/_ *"3XK_7#@;_
M *$GXK_,^$/^'EGQ._Z 7A+_ , [K_Y)H_X>6?$[_H!>$O\ P#NO_DFON_\
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M$O\ P#NO_DFON_\ X4'\,?\ HG/A+_P1VO\ \;H_X4'\,?\ HG/A+_P1VO\
M\;H_L_,_^@D/]<.!O^A)^*_S/RO^&/B:Z\:?M0^$_$-]'#%>ZMXQM+^>.W!$
M:R2WJ.P4$DA06.,DG'<U^QE?DCI^GVND_MN6UC8VT-G96WQ#6&"WMXPD<4:Z
MD J*HX50   . !7ZW5'#R:C64G=\QT>,,Z=2MELZ4>6+I72[*ZLOD%%%%?7'
M\\!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_F5?]>5^@4445]6?@ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7X _P#!4?\ Y/L^)O\ W#/_ $UV
ME?O]7X _\%1_^3[/B;_W#/\ TUVE 'W_ /\ !%3_ )-9\4_]CG=?^D-C7W_7
MP!_P14_Y-9\4_P#8YW7_ *0V-??] !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !117,_$CXD>'/A%X+U'Q;XM
MU'^R?#^G^7]IO/(DF\OS)%B3Y(U9CEW4< ]<GC)K6C1J8BI&C1BY2DTDDKMM
MZ))+5MO9";25V=-17S1_P\B_9T_Z*)_Y1-1_^1Z/^'D7[.G_ $43_P HFH__
M "/7TO\ JGQ#_P!"ZM_X*G_\B8^WI?SK[T?2]%?-'_#R+]G3_HHG_E$U'_Y'
MH_X>1?LZ?]%$_P#*)J/_ ,CT?ZI\0_\ 0NK?^"I__(A[>E_.OO1]+T5\T?\
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M3S;/=XX\.<^S[B#$YC@HQ=.?):\DGI",7IZIGZ5T5^:G_#RSXG?] +PE_P"
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MPX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7X _P#!4?\ Y/L^)O\ W#/_ $UVE?O]7X _\%1_^3[/
MB;_W#/\ TUVE 'W_ /\ !%3_ )-9\4_]CG=?^D-C7W_7P!_P14_Y-9\4_P#8
MYW7_ *0V-??] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 45\T?\/(OV=/^BB?^434?_D>C_AY%^SI_T43_ ,HFH_\ R/7U
M7^J?$/\ T+JW_@J?_P B8>WI?SK[T?2]%?-'_#R+]G3_ **)_P"434?_ )'H
M_P"'D7[.G_11/_*)J/\ \CT?ZI\0_P#0NK?^"I__ "(>WI?SK[T?2]>9_M(_
M!G_AH3X+^(O ']L?V!_:_P!G_P")C]E^T^5Y5S%/_J]Z;L^5M^\,;L\XQ7FG
M_#R+]G3_ **)_P"434?_ )'H_P"'D7[.G_11/_*)J/\ \CUUX3AWB? XBGB\
M/@*T9TY*47[*;LXNZ=G%IV:ZJQ,JU&2<7)6?F?-'_#F7_JL'_EL__=E'_#F7
M_JL'_EL__=E?2_\ P\B_9T_Z*)_Y1-1_^1Z/^'D7[.G_ $43_P HFH__ "/7
MZ5_K+XH?\^ZW_A,O_E1Q^QP7=??_ ,$^:/\ AS+_ -5@_P#+9_\ NRC_ (<R
M_P#58/\ RV?_ +LKZ7_X>1?LZ?\ 11/_ "B:C_\ (]'_  \B_9T_Z*)_Y1-1
M_P#D>C_67Q0_Y]UO_"9?_*@]C@NZ^_\ X)\T?\.9?^JP?^6S_P#=E?#O_"F?
M^,E/^%3?VQ_S-O\ PBW]L?9?^GS[-Y_D[_\ @6S?[;N]?KS_ ,/(OV=/^BB?
M^434?_D>ORL_X61X<_X;>_X3_P#M'_BDO^%B?V[_ &AY$G_'E_:7G^;Y>WS/
M]7\VW;N[8SQ7Z?P/F_&6-^N_VY&HN6G>GS4E#WM=O<CS/RU]#BQ-/#QY?96W
MUU/KS_AS+_U6#_RV?_NRC_AS+_U6#_RV?_NROI?_ (>1?LZ?]%$_\HFH_P#R
M/1_P\B_9T_Z*)_Y1-1_^1Z_,/]9?%#_GW6_\)E_\J.WV."[K[_\ @GS1_P .
M9?\ JL'_ );/_P!V4?\ #F7_ *K!_P"6S_\ =E?2_P#P\B_9T_Z*)_Y1-1_^
M1Z/^'D7[.G_11/\ RB:C_P#(]'^LOBA_S[K?^$R_^5!['!=U]_\ P3YH_P"'
M,O\ U6#_ ,MG_P"[*^XOV;O@S_PSW\%_#O@#^V/[?_LC[1_Q,?LOV;S?-N99
M_P#5[WVX\W;]XYVYXSBO-/\ AY%^SI_T43_RB:C_ /(]'_#R+]G3_HHG_E$U
M'_Y'KY_.J_'_ !%AXX3-,-6J0C+F2]ARZI-7O&FGLWUL:TUA:+YH-)^O_!/I
M>BOFC_AY%^SI_P!%$_\ *)J/_P CT?\ #R+]G3_HHG_E$U'_ .1Z^*_U3XA_
MZ%U;_P %3_\ D3I]O2_G7WH^EZ*^:/\ AY%^SI_T43_RB:C_ /(]'_#R+]G3
M_HHG_E$U'_Y'H_U3XA_Z%U;_ ,%3_P#D0]O2_G7WH^EZ*^:/^'D7[.G_ $43
M_P HFH__ "/7TO7E8[*<QROE^OX>=+FO;GC*-[6O;F2O:ZO;:Z-(U(3^%W"B
MBBO*+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$WPQ\'>-+Z.^\0^
M$]#UV]CC$*7&IZ;#<2+&"2$#.I(4%F..F6/K63_PH/X8_P#1.?"7_@CM?_C=
M=Y16+HTI.[BK^AZ-/,L=1BH4Z\TELE)I?F<'_P *#^&/_1.?"7_@CM?_ (W1
M_P *#^&/_1.?"7_@CM?_ (W7>44OJ]'^1?<C3^ULQ_Z")_\ @4O\S@_^%!_#
M'_HG/A+_ ,$=K_\ &Z/^%!_#'_HG/A+_ ,$=K_\ &Z[RBCZO1_D7W(/[6S'_
M *")_P#@4O\ ,X/_ (4'\,?^B<^$O_!':_\ QNC_ (4'\,?^B<^$O_!':_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH _E7K^JBOY5Z_JHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *_)G]AG_ ).F\$_]OW_I#<5^LU?DS^PS_P G
M3>"?^W[_ -(;BOE,X_WO!_XOUB?O_AQ_R3W$?_7G_P!LK'ZS4445]6?@ 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X _\%1_^3[/B;_W
M#/\ TUVE?O\ 5^ /_!4?_D^SXF_]PS_TUVE 'W__ ,$5/^36?%/_ &.=U_Z0
MV-??]? '_!%3_DUGQ3_V.=U_Z0V-??\ 0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?SW_LW?!G_AH3XT>'? ']L?V!_:_V
MC_B8_9?M/E>5;2S_ .KWINSY6W[PQNSSC%?<7_#F7_JL'_EL_P#W97S3_P $
MW?\ D]'X=_\ <1_]-UU7[B5_6GBAQGGO#N<TL)E>(]G"5*,FN6$M7.:O>46]
MDNMCP<%AZ5:FY35W<_-'_AS+_P!5@_\ +9_^[*/^',O_ %6#_P MG_[LK]+J
M*_(/^(H\7_\ 0;_Y3I?_ "!Z'U'#_P OXO\ S/S1_P"',O\ U6#_ ,MG_P"[
M*/\ AS+_ -5@_P#+9_\ NROTNHH_XBCQ?_T&_P#E.E_\@'U'#_R_B_\ ,_-'
M_AS+_P!5@_\ +9_^[*/^',O_ %6#_P MG_[LK]+J*/\ B*/%_P#T&_\ E.E_
M\@'U'#_R_B_\S\T?^',O_58/_+9_^[*/^',O_58/_+9_^[*_2ZBC_B*/%_\
MT&_^4Z7_ ,@'U'#_ ,OXO_,_-'_AS+_U6#_RV?\ [LH_X<R_]5@_\MG_ .[*
M_2ZBC_B*/%__ $&_^4Z7_P @'U'#_P OXO\ S/S1_P"',O\ U6#_ ,MG_P"[
M*/\ AS+_ -5@_P#+9_\ NROTNHH_XBCQ?_T&_P#E.E_\@'U'#_R_B_\ ,_-'
M_AS+_P!5@_\ +9_^[*/^',O_ %6#_P MG_[LK]+J*/\ B*/%_P#T&_\ E.E_
M\@'U'#_R_B_\S\T?^',O_58/_+9_^[*/^',O_58/_+9_^[*_2ZBC_B*/%_\
MT&_^4Z7_ ,@'U'#_ ,OXO_,_-'_AS+_U6#_RV?\ [LH_X<R_]5@_\MG_ .[*
M_2ZBC_B*/%__ $&_^4Z7_P @'U'#_P OXO\ S/S1_P"',O\ U6#_ ,MG_P"[
M*/\ AS+_ -5@_P#+9_\ NROTNHH_XBCQ?_T&_P#E.E_\@'U'#_R_B_\ ,_GO
M_:1^#/\ PSW\:/$7@#^V/[?_ +(^S_\ $Q^R_9O-\VVBG_U>]]N/-V_>.=N>
M,XK^A"OP[_X*1?\ )Z/Q$_[AW_INM:_<2OM?%+%5L=DV0XO$2YIU*4I2>BNY
M0HMNRLE=OHK'-@8J-2K%;)_YA1117\ZGKA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!_*O7]5%?RKU_510 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5^3/[#/\ R=-X)_[?O_2&XK]9
MJ_)G]AG_ ).F\$_]OW_I#<5\IG'^]X/_ !?K$_?_  X_Y)[B/_KS_P"V5C]9
MJ***^K/P **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"*YN8;.WDGN)4@@C4N\LC!551R22> *\)\0_MZ?L^^%[]K.^^*_AY
MYU)5OL,S7: CJ-\*LOZU^8G_  50_:\USXG_ !@UKX7:+J<MKX%\,3_8KNUM
MI2%U"^0@RM-C[PBD&Q4.0&C+=2,>:? __@FM\:OCWX"MO&.BZ=I>D:'>*9+&
M37+PV\EX@)&^-%1B%)!PS;01R,@@T ?N)\,OCW\.?C,LO_"#^-M$\3RPJ'EM
M]/O4>>)3T9XL[U!P>2!G%=[7\SGBSPE\0_V5?B^=/U%;WP?XXT&9)X;BUF =
M,C*212(2&1E/4$@@D'N*_>;]AS]HV;]J#]GC0_%^H)!%X@ADDTS6([<C8+N+
M&7 P-N]&CDV_P^9CD#) /?&8(I9B%4#))Z"O"O%/[='P"\&ZO)IFJ?%3P^M[
M&YCDCM9VN@C X*LT2LJD'@@GC!]*^&/^"OW[7&KV?B&+X(^%M2DL+*.U2Z\2
MRVTA62=I5W16C$'(3RRLC*?O>8G8'/R+^SY_P3]^+_[2G@FY\6^%--T^VT%'
M:*VNM6O!!]ND4D.L( 8G:1@LVU<\ DAL '[U_#KXM>"_BYI,FI^"O%.D^*;&
M)MDLNEW:3^4V,[7"G*-CG# '!S765_-;\//B%\1?V//C<;^P:Z\.>*] O&M-
M2TR<_NYU5L2VTR@E7C8#J,_PNI!"L/Z*/A5\1M,^+OPW\->--&W#3-=L(;Z%
M'QOCWJ"8VQ_$IRI]U- '4LP12S$*H&23T%>%>*?VZ/@%X-U>33-4^*GA];V-
MS')':SM=!&!P59HE95(/!!/&#Z5\,?\ !7[]KC5[/Q#%\$?"VI26%E':I=>)
M9;:0K).TJ[HK1B#D)Y961E/WO,3L#GY%_9\_X)^_%_\ :4\$W/BWPIINGVV@
MH[16UUJUX(/MTBDAUA #$[2,%FVKG@$D-@ _>OX=?%KP7\7-)DU/P5XITGQ3
M8Q-LEETN[2?RFQG:X4Y1L<X8 X.:ZROYK?AY\0OB+^QY\;C?V#77ASQ7H%XU
MIJ6F3G]W.JMB6VF4$J\; =1G^%U((5A_11\*OB-IGQ=^&_AKQIHVX:9KMA#?
M0H^-\>]03&V/XE.5/NIH ZB21(8VDD94C4%F9C@ #J2:\)\1?MW? #PKJ[Z9
MJ'Q5\/\ VR-MCK:SM<HK X(+Q*R@@]<GBO@3_@KU^UQK-UXV/P3\-:A)8:+I
M]O%/X@DMI"CWD\J;TMFQUC6-D8C.&:3!'R"OF#X#?\$\_C%^T7\.W\:^%=-T
MV'0F:1+.34[X0/?-&Q5Q",'@,I7<^U<@C/!P ?O5\/OBAX0^+&BG5O!OB;2O
M$^G*VQ[C2[M)UC;&=K[22C8_A;!]JZBOYM?@[\8/'_['7QL;4]-^T:3KFCW;
M6.L:+<-M2Y5'VS6TR\@C((SR5(#+R :_HJ^'WCC2_B9X%\/^+=%D:72=;L(=
M0M688;RY4#J&'9@#@CL010!T%%%% !7X _\ !4?_ )/L^)O_ '#/_37:5^_U
M?@#_ ,%1_P#D^SXF_P#<,_\ 37:4 ??_ /P14_Y-9\4_]CG=?^D-C7W_ %\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/@?_ ,*.S_\ CE'_  T[\'?^BL^!_P#PH[/_ ..5^:7_  Z%^,7_ $,O@?\
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M .7'ZS45^3/_  PS\;O^A)_\JUC_ /'Z/^&&?C=_T)/_ )5K'_X_1_;&+_Z
MY?C_ /(A_P 0XX>_Z*.C_P"2?_+C]9J_)G]AG_DZ;P3_ -OW_I#<4?\ ##/Q
MN_Z$G_RK6/\ \?H_X89^-W_0D_\ E6L?_C]>5C,5B\76HU?JTE[-WV>NJ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY-?SV_'*&:W^-?Q BN 1.GB'4%D#')W"YD!R?K7]''P'_P"2&_#O_L7-._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /Y5Z_JHK^5>OZJ* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#\._^<E'_ '5K_P!S-?N)7X=_\Y*/^ZM?^YFO
MW$K]_P#%C_F5?]>5^AY6 ^WZA1117X >J%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M,FE6&)Y'SM12QVJ6.!Z <G\* /A'_@I=^WG)^SSH@^'O@:[V_$75[;S;B^09
M_LBU;(#@]/.?!VC^$#><93=^=/[$_P"S/X?_ &CO'UWK/Q(\;:7X:\&Z;.)-
M0;4-6BM[[5)F^;RH_,8, >KR^^!\QRO+?&CX?_&CXS?%CQ9XWU+X8^-S=:YJ
M,UX$DT&[8Q1LW[N+/E]$0(@]E%<7_P ,X_%G_HE_C/\ \)^[_P#C= ']"/@[
MXC?!?X>^&=/\.^&O%_@G1-#T^(0VMC9ZO:QQQ+UX ?J2223R2222237>^&_%
MVA^,K&2]\/ZUI^NV<<AA>XTVZCN(UD !*%D) ;#*<=<$>M?S8_\ #./Q9_Z)
M?XS_ /"?N_\ XW7Z_?\ !'_P5XA\"?LT^);#Q+H.I^'K^3Q=<SI:ZK9R6LK1
MFSLE#A9%!*DJPSTRI]* /RQ_;F\#R_#W]KKXJZ5*C1K+KD^HQ CCR[H_:4Q[
M!9@/PK]N?V#_ !YI_P 0OV0_A9>Z=,DHL=#MM'G5>#'-:(+=U8'D',>?<,".
M"*^=O^"GG[!NL?M +8?$;X>VB7GC/3;?[)J&E;PC:C:KN9&CSP9D)(P<;E.,
MY15;\HM"^)/Q8_9_FU;P]I7B+Q9\/9KC(OM*AN;C3V+8QN>+*D/@8W8W 9&:
M />O^"KGQ LO'?[9'B"WL)%GA\/V-KHKS1L"K2HIEE''=7F9"#T*&OTG_P""
M4?@&7P/^QKX<N;BW-M<>(+V[UET9-K%6D\J-CZ[HX(V!]"*_*W]D_P#8A^(7
M[5_C:SGDT_4M*\&23"?5/%5[$RH\98EQ [C]]*W/W<@$@M@=?W_\,^&]-\'>
M'-+T'1[2.PTG2[6*RM+6(86*&-0B(/8* * /YWOVYO \OP]_:Z^*NE2HT:RZ
MY/J,0(X\NZ/VE,>P68#\*_;G]@_QYI_Q"_9#^%E[ITR2BQT.VT>=5X,<UH@M
MW5@>0<QY]PP(X(KYV_X*>?L&ZQ^T MA\1OA[:)>>,]-M_LFH:5O"-J-JNYD:
M//!F0DC!QN4XSE%5ORBT+XD_%C]G^;5O#VE>(O%GP]FN,B^TJ&YN-/8MC&YX
MLJ0^!C=C<!D9H ]Z_P""KGQ LO'?[9'B"WL)%GA\/V-KHKS1L"K2HIEE''=7
MF9"#T*&OTG_X)1^ 9? _[&OARYN+<VUQX@O;O671DVL5:3RHV/KNC@C8'T(K
M\K?V3_V(?B%^U?XVLYY-/U+2O!DDPGU3Q5>Q,J/&6)<0.X_?2MS]W(!(+8'7
M]_\ PSX;TWP=X<TO0='M([#2=+M8K*TM8AA8H8U"(@]@H H _G)_; \$W'P[
M_:C^*6A7$0A\KQ#=W$*C_GA-(9H#T'6*1#^-?O+^QS\0;+XG?LN_#+7;*>.<
MMH5K:7/EYPES!&(9TP>1B2-^O;'7K7R9_P %0/V!]<^-EY!\4OAQ8_VCXJM;
M9;75]%BP)=0A3_5S19(W2HORE.KJ%V_,H5_RST'XH_%;X%1:OX7TGQ-XJ\!K
M<N3?Z3!=7%@2^ I9X\J0V !G .!CI0![/_P4^^(5E\0OVR_&CZ=-%<V6CI;Z
M,LT+!@TD,2^<#CNLS2H?]S\*_5+_ ()A^!9_ O[%_@5;N+R;O5_M&KNI7'R3
M3.86]\Q")OQK\I?V/_V$?'O[4OC73[R_TS4=$\ >:MQJ7B2\B:,3QYW%+8N/
MWLCCC<,JN=S=@W[[Z+H]CX=T>PTK3+6.QTVQ@CM;6UA7:D,2*%1%'8!0 /I0
M!=HHHH *_ '_ (*C_P#)]GQ-_P"X9_Z:[2OW^K\ ?^"H_P#R?9\3?^X9_P"F
MNTH ^_\ _@BI_P FL^*?^QSNO_2&QK[_ *^ /^"*G_)K/BG_ +'.Z_\ 2&QK
M[_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /P[_P"";O\ R>C\._\ N(_^FZZK]Q*_G*^&_P -_$?Q=\::=X2\):=_:WB#
M4/,^S6?GQP^9Y<;2O\\C*HPB,>2.F!S@5[C_ ,.W?VB_^B=_^5O3O_DBO[.\
M0N$\JS[-:>)QV;4\+)4U'DGRW:4IOFUJ0=FVUMT>O;YW"5YTH.,:;EK_ %T/
MW$HK\._^';O[1?\ T3O_ ,K>G?\ R11_P[=_:+_Z)W_Y6]._^2*_,/\ B''#
MW_11T?\ R3_Y<=OURM_SY?X_Y'[B45^'?_#MW]HO_HG?_E;T[_Y(H_X=N_M%
M_P#1._\ RMZ=_P#)%'_$..'O^BCH_P#DG_RX/KE;_GR_Q_R/W$HK\._^';O[
M1?\ T3O_ ,K>G?\ R11_P[=_:+_Z)W_Y6]._^2*/^(<</?\ 11T?_)/_ )<'
MURM_SY?X_P"1^XE?"?[0'_!+_P#X7I\8/$OCK_A9?]B?VS-'+_9_]@_:/)VQ
M)'CS/M*;L[,_='6OB?\ X=N_M%_]$[_\K>G?_)%'_#MW]HO_ *)W_P"5O3O_
M )(KZ').&,!P[7EB<KXHHTYR7*WRTI:73M:55K=+S,JE:59<LZ#?W_Y'TM_P
MYE_ZK!_Y;/\ ]V5\._\ "F?^,E/^%3?VQ_S-O_"+?VQ]E_Z?/LWG^3O_ .!;
M-_MN[UZ9_P .W?VB_P#HG?\ Y6]._P#DBO#O^%;^(_\ A97_  @']G?\5;_:
M_P#87]G^?'_Q^^=Y'E>9N\O_ %GR[MVWOG'-?L?#U;$U/K'M<^IXNT=.6%)>
MS_OODD[KR=D>=62TM2<?OU/T'_X<R_\ 58/_ "V?_NRO0OV?_P#@E_\ \*+^
M,'AKQU_PLO\ MO\ L::27^S_ .P?L_G;HGCQYGVE]N-^?NGI7Q/_ ,.W?VB_
M^B=_^5O3O_DBC_AV[^T7_P!$[_\ *WIW_P D5\-BI8G&4*F&K\747":<6O9X
M=735FKJ=]NVIU1M%J2P[NO-_Y'[B45^'?_#MW]HO_HG?_E;T[_Y(H_X=N_M%
M_P#1._\ RMZ=_P#)%?FG_$..'O\ HHZ/_DG_ ,N.SZY6_P"?+_'_ "/W$HK\
M._\ AV[^T7_T3O\ \K>G?_)%'_#MW]HO_HG?_E;T[_Y(H_XAQP]_T4='_P D
M_P#EP?7*W_/E_C_D?N)17X=_\.W?VB_^B=_^5O3O_DBC_AV[^T7_ -$[_P#*
MWIW_ ,D4?\0XX>_Z*.C_ .2?_+@^N5O^?+_'_(_<2BOP[_X=N_M%_P#1._\
MRMZ=_P#)%'_#MW]HO_HG?_E;T[_Y(H_XAQP]_P!%'1_\D_\ EP?7*W_/E_C_
M )!_P4B_Y/1^(G_<._\ 3=:U^XE?SE?$CX;^(_A%XTU'PEXMT[^R?$&G^7]I
ML_/CF\OS(UE3YXV93E'4\$]<'G(K^C6O0\6,-3P>59'AJ-15(PIRBIK:24:*
M4E9M6DM5J]]V1@9.4ZLFK7?^84445_.![ 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?RKU_517\J]?U44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQT'Y58HH **** "J]SI]K>/&]Q;0SO']QI(PQ7Z9'%6** "BBB@ HHHH *_
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M  0^O_W&?N)17X=_\9B_]5Q_\K%'_&8O_5<?_*Q1_P 0F_ZFM'[_ /@A]?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
M*O7]5%?RKU_510 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?AW_ ,Y*/^ZM?^YF
MOW$K\._^<E'_ '5K_P!S-?N)7[_XL?\ ,J_Z\K]#RL!]OU"BBBOP ]4****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "OP!_P""H_\ R?9\3?\ N&?^FNTK]_J_ '_@J/\ \GV?$W_N
M&?\ IKM* /O_ /X(J?\ )K/BG_L<[K_TAL:^_P"O@#_@BI_R:SXI_P"QSNO_
M $AL:^_Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OP[_YR4?\ =6O_ ',U^XE?AW_S
MDH_[JU_[F:_?_";_ )FO_7E_J>5CO^7?J?N)1117X >J%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '\J]?U45_*O7]5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^'?\ SDH_[JU_
M[F:_<2OP[_YR4?\ =6O_ ',U^XE?O_BQ_P RK_KROT/*P'V_4****_ #U0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M_*O7]5%?RKU_510 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >>_M$ZI>:)^S]\3M1TZ[GL-0L_"^IW%M=VLC1RPRI:2LCHZ
MD%64@$$'((!K\,?^&G?C%_T5GQQ_X4=Y_P#'*_<3]IS_ )-K^+/_ &*6K?\
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M,OCC_P #[/\ ^1*/^'0OP=_Z&7QQ_P"!]G_\B4?\1(X&_P"?7_E)!]3Q/?\
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MS7*X+6ZMM3ZGZCF&%KRX,P5)4WS*H]+.^]7H>X45RW_"U/!7_0X:#_X,X/\
MXJC_ (6IX*_Z'#0?_!G!_P#%5^C_ %W"_P#/V/WH_+OJ&+_Y\R_\!?\ D=31
M7+?\+4\%?]#AH/\ X,X/_BJ/^%J>"O\ H<-!_P#!G!_\51]=PO\ S]C]Z#ZA
MB_\ GS+_ ,!?^1U-%<M_PM3P5_T.&@_^#.#_ .*H_P"%J>"O^APT'_P9P?\
MQ5'UW"_\_8_>@^H8O_GS+_P%_P"1U-%<M_PM3P5_T.&@_P#@S@_^*H_X6IX*
M_P"APT'_ ,&<'_Q5'UW"_P#/V/WH/J&+_P"?,O\ P%_Y'4T5RW_"U/!7_0X:
M#_X,X/\ XJC_ (6IX*_Z'#0?_!G!_P#%4?7<+_S]C]Z#ZAB_^?,O_ 7_ )'4
MT5GZ+X@TOQ):M<Z3J5GJELKF-IK*=)D#  E25)&<$''N*T*ZHRC-*47=,XYP
ME3DXS5FNX44451 4444 %%%% !1110 4444 %%%% !1110 445PWQL^+VC?
M;X8ZSXZ\06U]>:1I7D^?#IL:/.WFSQPKM5W13\TBDY8< ]>E=&'P]7%UH8>A
M'FG-J*2ZMNR7S8FU%-L[FBOAW_A[U\'?^A:\<?\ @!9__)='_#WKX._]"UXX
M_P# "S_^2Z^X_P!0.*/^@"?W+_,YOK5#^8^XJ*^'?^'O7P=_Z%KQQ_X 6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:2<Y173=)RC?[SR<7SQK0G&+=C]Q**_#O_AV[^T7_P!$[_\ *WIW_P D4?\
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M "MZ=_\ )%'_  [=_:+_ .B=_P#E;T[_ .2*/^(<</?]%'1_\D_^7!]<K?\
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MQGXU_P"@IH/_ ($3_P#QFC_AC/QK_P!!30?_  (G_P#C-?9E%'^H^3_RR_\
M @_XB!G?\T?_  $^,_\ AC/QK_T%-!_\")__ (S1_P ,9^-?^@IH/_@1/_\
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M)Z\7.N$LLP.7UL313YHJZU/=R'C3-LPS.AA:\H\LW9VB'[&?_)+]4_[#$O\
MZ(@KWJO!?V,_^27ZI_V&)?\ T1!7O5?9\-?\B?#?X3X7BO\ Y'>*_P 7^044
M45]*?)A1110 4444 %%%% !1110 4444 %%%% !7#?&SX0Z-\>OACK/@7Q!<
MWUGI&J^3Y\VFR(DZ^5/',NUG1U'S1J#E3P3TZUW-%=&'Q%7"5H8BA+EG!J2:
MZ-.Z?R8FE)-,^'?^'0OP=_Z&7QQ_X'V?_P B4?\ #H7X._\ 0R^./_ ^S_\
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MIQ/G.=45A\QQ,JD$^9)][-7^YO[RX4:=-WA&P4445\N;A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,&<'_Q5?+G_  QGXU_Z"F@_^!$__P 9H_X8S\:_]!30?_ B?_XS1_;G$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_ '_@J/_R?9\3?^X9_Z:[2OW^K\ ?^"H__
M "?9\3?^X9_Z:[2@#[__ ."*G_)K/BG_ +'.Z_\ 2&QK[_KX _X(J?\ )K/B
MG_L<[K_TAL:^_P"@ HHHH **** "BBB@ HHHH *^,_VS/^2H:7_V!XO_ $?/
M7V97QG^V9_R5#2_^P/%_Z/GKX'C?_D3R_P 43])\/_\ D=Q_PR.-TK]HGXA:
M)I=GIUEX@\FSLX4MX(_L5NVR-%"J,F,DX ').:M?\-.?$O\ Z&7_ ,D+;_XW
M572OVB?B%HFEV>G67B#R;.SA2W@C^Q6[;(T4*HR8R3@ <DYJU_PTY\2_^AE_
M\D+;_P"-U^20S3EBE]?KKR2T7I^^1^TU,HYIN7]FX=W>[EJ_-_N'K\V'_#3G
MQ+_Z&7_R0MO_ (W1_P -.?$O_H9?_)"V_P#C='_#3GQ+_P"AE_\ )"V_^-T?
M\-.?$O\ Z&7_ ,D+;_XW5_VK_P!3"O\ =_\ =C/^Q_\ J68;_P "_P#N ?\
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MM:P(L<4,>GVH5% P% \K@ 5/_P -.?$O_H9?_)"V_P#C='_#3GQ+_P"AE_\
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M_P D+;_XW1_:O_4PK_=_]V#^Q_\ J68;_P "_P#N ?\ #3GQ+_Z&7_R0MO\
MXW6!XS^,7B_XA:7%IVOZO]OLXIA<)']FACQ(%90<H@/1FXSCFM__ (:<^)?_
M $,O_DA;?_&ZP/&?QB\7_$+2XM.U_5_M]G%,+A(_LT,>) K*#E$!Z,W&<<US
M8G,?:T90^NUIWZ26C]?WLOR9UX3*_8UX5/J%"%G\47[R\U^YCK\T?3/[&?\
MR2_5/^PQ+_Z(@KWJO!?V,_\ DE^J?]AB7_T1!7O5?O7#7_(GPW^$_G+BO_D=
MXK_%_D%%%%?2GR84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH/\ X#S_ /QZC_ALSQK_ - O0?\ P'G_ /CU'^O&3_S2_P# 0_XA_G?\L?\
MP(^S**^,_P#ALSQK_P! O0?_  'G_P#CU'_#9GC7_H%Z#_X#S_\ QZC_ %XR
M?^:7_@(?\0_SO^6/_@1]F5\%_M.?\EP\2_\ ;M_Z315U'_#9GC7_ *!>@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\ ?^"H__)]GQ-_[AG_IKM*_
M?ZOP!_X*C_\ )]GQ-_[AG_IKM* /O_\ X(J?\FL^*?\ L<[K_P!(;&OO^O@#
M_@BI_P FL^*?^QSNO_2&QK[_ * "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"*>U@NMOG0QS;>GF*&Q^=.CB2&,)&BQH.BJ, 4^B
ME97N/F=K7"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO\3['RG$G&/^L.$CA?J_L[24K\W-LFK6Y5W"BBBOOC\V"BBB@ HHHH ****
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M;'8BIB\1+FG4DY2>BNY.[=E9*[?16.R,5%**V04445R%!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^ /\ P5'_ .3[
M/B;_ -PS_P!-=I7[_5^ /_!4?_D^SXF_]PS_ --=I0!]_P#_  14_P"36?%/
M_8YW7_I#8U]_U\ ?\$5/^36?%/\ V.=U_P"D-C7W_0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[THH_P!0,K_Y^5/OC_\ (A_Q$G-_^?5/[I?_ "9\%_\ #,?Q+_Z%K_R?MO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7\.OV3?@OK7A'Q=HOBC4=2O?$$VJQRZ):VTL(B>VMH@I,EQ&=VZ%^,8P1SU
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ML?\ Y,KX _X=<?M._P#1,_\ ROZ7_P#)-'_#KC]IW_HF?_E?TO\ ^2: /O\
M_P"'U?P0_P"A6^('_@NL?_DRC_A]7\$/^A6^('_@NL?_ ),KX _X=<?M._\
M1,__ "OZ7_\ )-'_  ZX_:=_Z)G_ .5_2_\ Y)H ^_\ _A]7\$/^A6^('_@N
ML?\ Y,H_X?5_!#_H5OB!_P""ZQ_^3*^ /^'7'[3O_1,__*_I?_R31_PZX_:=
M_P"B9_\ E?TO_P"2: /O_P#X?5_!#_H5OB!_X+K'_P"3*/\ A]7\$/\ H5OB
M!_X+K'_Y,KX _P"'7'[3O_1,_P#ROZ7_ /)-'_#KC]IW_HF?_E?TO_Y)H ^_
M_P#A]7\$/^A6^('_ (+K'_Y,H_X?5_!#_H5OB!_X+K'_ .3*^ /^'7'[3O\
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M^E__ "30!]__ /#ZOX(?]"M\0/\ P76/_P F4?\ #ZOX(?\ 0K?$#_P76/\
M\F5\ ?\ #KC]IW_HF?\ Y7]+_P#DFC_AUQ^T[_T3/_ROZ7_\DT ??_\ P^K^
M"'_0K?$#_P %UC_\F4?\/J_@A_T*WQ _\%UC_P#)E? '_#KC]IW_ *)G_P"5
M_2__ ))H_P"'7'[3O_1,_P#ROZ7_ /)- 'W_ /\ #ZOX(?\ 0K?$#_P76/\
M\F4?\/J_@A_T*WQ _P#!=8__ "97P!_PZX_:=_Z)G_Y7]+_^2:/^'7'[3O\
MT3/_ ,K^E_\ R30!]_\ _#ZOX(?]"M\0/_!=8_\ R91_P^K^"'_0K?$#_P %
MUC_\F5\ ?\.N/VG?^B9_^5_2_P#Y)H_X=<?M._\ 1,__ "OZ7_\ )- 'W_\
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M ,%UC_\ )E'_  ^K^"'_ $*WQ _\%UC_ /)E? '_  ZX_:=_Z)G_ .5_2_\
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M2_\ Y)H ^_\ _A]7\$/^A6^('_@NL?\ Y,H_X?5_!#_H5OB!_P""ZQ_^3*^
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MK?$#_P %UC_\F5\ ?\.N/VG?^B9_^5_2_P#Y)H_X=<?M._\ 1,__ "OZ7_\
M)- 'W_\ \/J_@A_T*WQ _P#!=8__ "91_P /J_@A_P!"M\0/_!=8_P#R97P!
M_P .N/VG?^B9_P#E?TO_ .2:/^'7'[3O_1,__*_I?_R30!]__P##ZOX(?]"M
M\0/_  76/_R91_P^K^"'_0K?$#_P76/_ ,F5\ ?\.N/VG?\ HF?_ )7]+_\
MDFC_ (=<?M._]$S_ /*_I?\ \DT ??\ _P /J_@A_P!"M\0/_!=8_P#R91_P
M^K^"'_0K?$#_ ,%UC_\ )E? '_#KC]IW_HF?_E?TO_Y)H_X=<?M._P#1,_\
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M3/\ \K^E_P#R30!]_P#_  ^K^"'_ $*WQ _\%UC_ /)E'_#ZOX(?]"M\0/\
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M'7'[3O\ T3/_ ,K^E_\ R31_PZX_:=_Z)G_Y7]+_ /DF@#[_ /\ A]7\$/\
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MP0_Z%;X@?^"ZQ_\ DRO@#_AUQ^T[_P!$S_\ *_I?_P DT?\ #KC]IW_HF?\
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M]%GB>-9?#>K(ZAT:TF#*PR""AX-?RVP3R6LT<T,C0S1L'22-BK*P.001T(-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO_<,_P#37:5]_P#_  14_P"36?%/_8YW7_I#8U\ ?\%1_P#D^SXF_P#<,_\
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M_*_JG_R37U510!\J_P##KC]F+_HF?_E?U3_Y)H_X=<?LQ?\ 1,__ "OZI_\
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M_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\
M*_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_
M ,DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/
MV8O^B9_^5_5/_DFOJJB@#Y5_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5
M_5/_ ))KZJHH ^5?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_
M .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y7]4_^2:^JJ*
M/E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S
M%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__
M "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\ ROZI
M_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-'_#K
MC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
ME?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4
M_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_ ,DT?\.N/V8O^B9_^5_5/_DFOJJB
M@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/V8O^B9_^5_5/_DFOJJB@#^5>OW^_
MX=<?LQ?]$S_\K^J?_)-?@#7]5% 'RK_PZX_9B_Z)G_Y7]4_^2:/^'7'[,7_1
M,_\ ROZI_P#)-?55% 'RK_PZX_9B_P"B9_\ E?U3_P"2:/\ AUQ^S%_T3/\
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MC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
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M31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\
MHF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_
M .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y
M)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5
M?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%
M_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S
M_P#*_JG_ ,DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_
M\DT?\.N/V8O^B9_^5_5/_DFOJJB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ /VI/^"4O
M_#2GQV\3?$?_ (6C_P (Y_;7V7_B6?\ "/?:O)\FUB@_UOVI-V?*W?=&-V.<
M9/O_ .Q3^RE_PQ[\*]5\&_\ "4_\);]NUJ75_MO]G_8MF^""+R]GFR9QY&=V
MX?>QCC)^@** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\J_\ AQC_ -5L_P#+4_\
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M[+_Q+/\ A'OM7D^3:Q0?ZW[4F[/E;ONC&['.,GW_ /8I_92_X8]^%>J^#?\
MA*?^$M^W:U+J_P!M_L_[%LWP01>7L\V3./(SNW#[V,<9/T!10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S;^T]^P'\*_P!J
M:[_M?7K*ZT/Q4$"?V_HKK%<2J  JS*RLDH  &6&X 8# 5])44 ?FSHO_  1%
M\!VVK++JOQ'\0W^FALFUM;2"WE(ST\P[QT[[:^Z_@S\$?!?[/_@N#PMX%T.'
M1-)C;S9 F6EN)2 #++(?F=R% R3T  P  .[HH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYK/VL?^3IOC
M)_V.>L_^ETU?TIT4 ?*O_!+C_DQ/X9?]Q/\ ].EW7U5110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?RKU_51110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?*O_  5'_P"3
M$_B;_P!PS_TZ6E?BM^R=_P G3?!O_L<]&_\ 2Z&OZ4Z* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KX _X+5_\FL^%O^QSM?\ TAOJ^_Z* /P!_P""7'_)]GPR_P"X
MG_Z:[NOW^HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM$?#S]HCP_)K'P_\36NO6T)"W$*J\5Q;,<X$D,@5TS@X)&#C()'->CU_-_\
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M(_%'XM^#O@KX3N/$OC?Q!9^'-%@X-Q=,<NV,[(T4%Y'.#A$!8X/%==7\_/\
MP4=_: U#X[?M.^)H_M<DGAOPO<RZ'I%KO/E(L3[9I0,XW22JS;L9*B,'[@H
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MS@X506/85Y3^PC\;M3_:"_9>\'>+-=?S?$'ERV&HS!<>=-!(T?F\ #,BJCG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!PT2JA#3.O(8AE53QEB& ^-X?^"O'[0T6JB[;4] FMPV[[ ^CH(2/3((?'_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?B)_V+FH_P#I-)0!_.K^SC_R<-\+_P#L:=+_ /2N*OZ9*_F;_9Q_Y.&^%_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\$Z_ /P@\!_ >*/X3>)H?&:7DRS:UKA3RKF>[V#Y983\T"J#\D3= <Y8L78
M\-_X*^> /BI\6-*\ ^'_  -X/USQ-X?L6NM4U+^R+1K@?: JI!E5!8LJ&?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!2UJWDO-&OX(EWRRV\B(N0,L5( YK\#O^'7'[3O\ T3/_ ,K^E_\ R37[
M_44 ?@#_ ,.N/VG?^B9_^5_2_P#Y)KYAUK1[OP]K%_I6H0_9[^QGDMKB'<&V
M2(Q5ERI(."",@D5_4Y7X3?$W_@FA^TEXA^)'BS5=/^''VBPOM6N[FWF_MS35
MWQO,[*V&N01D$'! - 'T;_P3._8K^,W[/O[1%[XG\?\ @W^P=#DT"YLENO[4
MLKG,SRP,J[89G;D(W.,<=>E?+/\ P5.^'\_@7]LWQ;<.FRT\006NM6O7YD>(
M1.?^_P!#-^5?OE7R_P#MW?L4Z=^V!X!M$L[N'1?'.B[WTC4YP?)<,/GMY]H)
M\MB%.X E",@$%E8 Y3_@EC\<M$^(O[*OA_PX=4M?^$D\(K+I^H6)<++'")':
M"783G88F5=W0LCCMBOSI_P""K/QFT?XO_M431^']1BU32?#>E0:,+FVE$D$D
MZO)+,4(.#AIO+)'4Q>PKS+QU^P?\?OA_JTEC??"OQ)J15RJW&A6+ZE#( >&#
MVX? /7YL'U /%>S_ +,?_!*GXI?%3Q58W?Q!TFX^'_@N&5)+M[\JM]=QAOFA
MAA!+(Q QOD "[L@/C;0!]Z?\$C_AK<> ?V1;+4[N-XKCQ3JMSK*I(,,L6$MX
M_P "L&\>HDS7VG6?X?T#3O"F@Z;HND6<6GZ3IMM'9VEI N(X88U"(BCL H '
MTK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\+_;F\/WWBC]D/XKV&G>:;O^PYKA5A!+NL6)74 =<JC#'?->Z4
MV2-)HVCD17C8%65AD$'J"* /YUOV"_B5HGPC_:X^'/BCQ'=Q6&BV]Y-;7-W.
M0L< N+:6W$CD\*JM,&+'@ $GI7]$=SJ%K9V,M[<7,,%E%&9I+B1PL:1@9+EC
MP% YSTQ7Y#?M@?\ !)'Q7H_BG4/$OP5M(M=\.7DC3MX::=(KJP).2L)<A98A
MS@;@X&!AL9KYLD^#/[6U[HL?@&7PQ\69?#J*($T:6+4/[+50,A0#^X"@=.W:
M@#SC]ISQUIWQ,_:(^(_BG2&\S2=5UZ\N+.7_ )Z0F5O+?H,;E ;';.*_>73_
M (.W^M_L/6'PNO4\G5YOA]#X?<,,>7<C3EA!_"0 \^E?"O[#?_!*?Q'I?C72
M?'OQHM;?3;/2Y4N[#PJLZS33SHV4>Z*$HL:D*PC#,7/#[0"K?K!0!_,C\&/'
M$GP=^-G@SQ7=03(?#NN6M[=6^S$A2*96ECP>A*AEQ[U_13XP_:!\!^#?@_=?
M$RY\2:=-X32R-[;WT=RI2[&W<D<1_B=SA0H!.2!C-?GM^WY_P2[\0>+O&VJ_
M$CX/6EO?R:I(;G5/"WF+!+]H9B9)[=W8(P<G<T9*D')7=NVK\&V_[%OQYN=:
M_LI/A!XR%SOV>9)H\R6^?^NY41XYZ[L4 <+X5\/ZQ\;/BQI>C6Y\W7/%.L)
M'"EAYUQ, 7(ZX!<D^P-?TX:7IT&CZ;:6%LNRVM84@B7T55"@?D!7YZ?\$Y_^
M";NK? GQ)'\3?B<+9?%L<+1Z3H=O*LRZ=O7:\TT@^5IMI9 J$JH9CEB1L_16
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.?[S,2<= ,*,  4 >A4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7XF?$?_ (*H?M(>$?B%JGA_4YM TBZT/4Y+*^L['25
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M4;]F%0 /B9@?]@#4_P#Y&K\K/^'7'[3O_1,__*_I?_R31_PZX_:=_P"B9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+.Z79<1^%=-WIW4FVC;:?<9Q^%>M57T^Q@TNPMK*UC$5M;Q+#%&.BHH 4?@
M*L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?S6?M8_\G3?&3_L<]9_]+IJ_I3K^:S]K'_DZ;XR?]CGK/\ Z734
M ?O]^R=_R:S\&_\ L3-&_P#2&&OE#_@M5I<]U^S1X5O8EW0VGBJ'S<?PA[6Y
M ;Z9 '_ A7U?^R=_R:S\&_\ L3-&_P#2&&LS]L;X&R?M%?LX^,O!%H575KJV
M6YTQF(4?:X7$L2DG@!V3RR>RN: /P\_88_9^T[]I;]I#P[X.UR26/P\$FO\
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M#2CZ*>IKV+_@K'^U9J'P3^%FG^!/"][)8^*/&"R+/>0'$EIIZX60J?X6D+;
M1T428P=IK\:/ /B2Q\'^,M(UO4M LO%%G8SB=]'U(N+:Z*\JDFT@E,X)7."!
M@\$T ?9_["/_  30UG]H!]-\<?$%;C0/AQN$T%I@QW>M*.0$/!C@/>7JP!"8
MSO7]J?#OAW2_".@V&B:)86^E:1I\*V]K96L8CBAC48554<  5^/T'_!;#XD6
ML,<,/P]\(Q0QJ$2.,W*JJ@8  $G  KUW]E'_ (*J>._V@/V@O!_P_P!6\'^'
M=-T_6IIHY;JS:<RQA+>24;=SD=8P.1WH \Q_X+=Z9-#\6_AOJ+#]Q<:'/;H<
M'[T=P6;GITE6O5_^"(.HPR?#'XFV"MFX@UBUG=?17@95/YQM^5=K_P %A?@;
M?_$KX!Z1XSTBT:\O_!5Y)<72("66PF0+.X '.UXX&/HH=L\5^>G_  3\_;)@
M_9!^)6K7>M:==ZKX1\06R6VI0V!7[1$\;,T,R*Q"N5WR*5++Q(3G(P0#]/O^
M"LVH0V?[%/BB&0X>[U#3X8NG+"Y23_T%&Z5^:?\ P2GT6YU3]N#P-<P!3%IM
MMJ5U/D]$-C/",?\  Y4KM?\ @HS_ ,%!M%_:IT30/!O@;3]2LO"VGW9U&]NM
M4C6*6[N A2)517;"(KR9W'+%AP-N6]B_X(J_ N]BOO&/Q;U"UDALI+?^P-)D
MD! G)=)+EU!'(4QPH&'<R#J#0!^K-%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-M],?:<9[9S[X[5]O?LK_L6_#O\ 9+TBY3PM;3ZCK]\@2^\0:F5>ZF4'(C7
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MT8'D?HYX3\)Z-X$\-:;X>\/:;;Z1HNG0K;VEC:IMCBC'0 ?J2>222>36O10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFO!?BCQE\0Y=-718;Q-.TF*PL?L[2R(N^>1B2=RC?$HQQD2 ]*^R: "BBB@
MHHHH **** "BBB@ HK\Z_P!KG]N;XJ_LB_M6:/I&LV^GZQ\*-36&_BCCL0MV
M;4YCG19=V#)&X9@"!D% ?O9K]!= U[3O%6AZ=K6D7D.HZ5J-O'=VEY;MNCGA
MD4,CJ>X*D$?6@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@$$!E95]JK\-O^"0'Q#N?"G[6UOX>6X=;+Q3I5W9R6^3L>2&,W*.0.-RK#(
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MUS&*_+G_ ((P^*)])_:@US1Q,PM-6\-W :'LTL4\#HWU"^:/^!&@#]KZ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R:_X+C_ /(Q?"#_ *]=
M4_\ 0[:O3_\ @C7XNT+0/V8?$]OJFM:=IMPWC"ZD6*[NHXF*FRL@& 8@XR",
M^QKI/^"FG[&OQ%_:LU?X?W'@6/3)(]$@O8[O^T+SR#F5H2FWY3G_ %;9_"OB
M3_AS]^T%_P ^_AK_ ,&W_P!A0!^O/Q,_:D^%'PC\/7.K^)?'FA6L4,32I:PW
MT4UU<8_ABA5B\C$\<#ZX'-?@7XDO/$7[8O[46H3Z59L=;\<:\WV6V;+"WCD?
M"!R!]V*(#<W94)KZ-T'_ ((V_';4[Z.*_OO">CVVY0\\VHRRD+W*JD1R1CH<
M9)'(Y(_0S]C+_@GKX._9)>377OI/%GCNXA,$FLSPB*.VC;&Z.WBR=H. "Y)8
MX_A!*T :7[9WP-&O?L(^+/ 'ANUDE_L/0K5M-MH$+.R6!BD6-4'WF:. J%&>
M6&!G%?F7_P $G?CUHGP9_:,N],\2W\.EZ/XKT[^S$O+AML<5V)$>#>Q.%5L2
M)D_Q.O(&:_=&OS?_ &K?^"0>E?$KQ+J'BOX4:U9>$=0O6::X\/:A"PT]I3R6
MA>,%H 3DE-CKD\; ,4 ?H%XX\=:!\-?".I^)_$VJ6^D:%IL)N+F\N'PB*/3U
M). %&220 "37\\OA/0[O]K7]L41:;ITA7QKXNFU&:WP";>UFNFGG9N<8CB+L
M>OW3C/%?2-O_ ,$E?VC_ !(;'1-:\3:%#H-DX6'[7K=Q<00(."8HA&<''087
MT)%?H1^QC^P;X/\ V0M-NKZWNF\2>-M0A$-[KUQ$(]D?!,-NG/EQE@"<DLQ
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M$*JJ,[(ERVU,G&YB222:]ZH *_GGM;0^ ?\ @HM:PW:-&FD_%*,MYQVDHFK
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_)K_@N/_R,7P@_Z]=4
M_P#0[:OUEK\FO^"X_P#R,7P@_P"O75/_ $.VH ]5_P"")O\ R;SXW_[&E_\
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M?1'PG_X+)_%_PC<6T/C72]&\>:<N!+)Y/V"];D<B2(>6.,_\LO3I7MW[)/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOA'X.\/ZI/I&C%8&U)K286/VRYV-+*\H7:8XHECRW)4^:!SD5^EGP9^%.C?
M_P"%OAGP)H"D:7H=FMK'(RA6F?EI)G XWR.SNV/XG-=I10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?//[57[#_@7]KZ\\-W/C+5O$6FR:#'/';#0
M[F"(.)C&6W^;#)G'EKC&.IZU]#44 ? '_#E3X(?]#3\0/_!C8_\ R'6EH/\
MP1I^ VCWHGN]1\9:Y$/^7:_U2!8S^,-O&W_CU?=M% '#_"7X(^!?@5X;&A>
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M^9XUW;<_>X4ZWQL_X(IVVJ:Y=ZC\+/&L.CV$Q+1Z'X@ADE2W)).U+E"6*<@
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MU '7445D^)O%VA>"M+DU+Q#K6GZ#IT8+/>:G=1VT* <DEW(  ^M &M17Q_\
M\%(/%VA^-?\ @G_\2-3\/:UI^O:;*-+:.\TRZCN87!U.T((="0?SKVO]D[_D
MUGX-_P#8F:-_Z0PT >JT444 %%>/_LO_ +4'A7]K+P#J'B[PCI^L:=IMEJ<F
ME21:W#%%,94BBE+ 1RR#;MF3G.<@\="?8* "BBHKJZALK=Y[B:."",9>25@J
MJ/4D]* ):*X31_CU\,O$&O3:)I?Q%\)ZEK4+,LFG6>N6LMPA5MK!HUD+ AB
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MU^L% 'E7[6/_ ":S\9/^Q,UG_P!(9J_/K_@GS^Q1IW[2/P/\.^*?B]?WVO\
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M@X215?+;Q&&+,2QKY)_9Q_9MM_VE_P!KW]J+1?$VL:A#\.[#QE<W>KZ#83M
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M9O[*VAZ;=:CJ'P\BLK&UB:>>XG\0ZFB11J,LS$W7  !.:XCQ9\'_ (1^._\
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MP_)K,1O2Q?1U7S?+W!G;RSF$(0I"MYT;;1V_1>@#X _X+5_\FL^%O^QSM?\
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M<\4:='X>^(_PQ"Z+J6E+"8EEMD)2"ZC_ +X90-S#[S$/P)%R ?7%>5?M8_\
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M??LX?LU^)O%VC^7_ &^QBT_3#*>%GF<+OQW*)O<#OLQ7RG_P50\%_P#"M_V
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M?L^?V=X9^S_\+*\9W'_"5_Z?=-_:/FWUCYGWI3Y6?M,_^JV8W\8PN/7?VW/
M]K^Q;^P_XCTKX%Z-<>$]-U;7(/[6N+349Y);2*=%CDF62:1W&\PV\&%(P)"1
MCDU7_P""CW_)TW[%_P#V.;?^EVE5]1_M4?%[PA\$?@OK'B/Q[X;OO%7A!FCL
M=1TZQM(+K=',WECS(YI$1D+%5/)^\..N #Y.^"/['_[#7Q3\*Z;;>&[G3_%^
MIFTB,LUQXFNH-28E0-\MLLR>6Q.<KY8 .1BO</V2/V8?%_[+?C#QYH%MXCAU
M?X-WLD=UX9TRZO))K[3)3S,C*8@@1F9ONN<[%8C<[FO-O%7_  2J_9T^,6CV
MGB'PC_:7AFUU1%U"VO/#FI>=:SQR+N4JDPD4(0P(";1C &!Q7'?LTZ?\0OV4
MOVWK3X!W/CS4/B7X'UKP_)K,1O2Q?1U7S?+W!G;RSF$(0I"MYT;;1V /T7KX
ML_X*=W[:]X5^$'PT,I6R\=>.]-TW4(%.&N+4.-R<?,!YCPME<$%1SS@_:=?"
M7_!1[0W3XW?LD>*'D5++2_'T%I,N.29KFRD!ST&!:O\ G0!]UQHL:*B*$11@
M*HP /05^66O?"F_^-7_!6CXP>$HM>O\ 0-"O- LFU^32Y6AN;FP2TTMVMTD7
ME!)*(%8CJF\=Z_4^O@#X-_\ *9+X[?\ 8F6W_HG1J .._;F_86^%G[.G[/NH
M_%/X5:;J'@CQAX2O+&ZM[ZSU:ZF:7?=108(FD?:090X*;>5QT)%>E?!O]A_P
M1^TK\.] ^+'QU2^^(GCKQCIT&KM-)J-Q9VVGV\R"2"VMHH)$"HD;KP=V6+GO
M7>?\%1_^3$_B;_W#/_3I:5ZK^R=_R:S\&_\ L3-&_P#2&&@#Y)_8?L&_9]_;
M@^-_[/FB7EY=^!K+3H?$&FPWMP9#9NRVC%%&.<K?!2V<GR%SDG->P_M!?LD>
M(_VH/CEH[>.-?C3X&:38%E\,Z7J%Q!=:AJ!8'?<J$">6!T(<L-O&-[$>5?!O
M_E,E\=O^Q,MO_1.C5=^.WB3QW^TI^VE<_L]Z%X^U3X8^#] \/KK>JWFBH8;[
M5)&,)\N.;(.P+/&!M^7*R[@^ % .A^(7_!+G]F-?"-_&F@-X+N&@;RM:&OW6
M;=@.'(N)GC(!Y(*XQZ5%_P $K?B)J7QK_8_GT_Q<[:VFD:K=^'6?4'\\W5KY
M$,H1]PY 6X,>#GY4'TK'UK_@F3\ /A_I&L>-/B;XB\5>,;6QM?/NK[Q5KQ1(
MXXPQ(#0K&_.<8+-R!C&><[_@BI_R:SXI_P"QSNO_ $AL: $^#VN/_P $]_V@
M-0^$7BF[-M\$_%\TNJ>#=<OKAFCTRX(!DL9';[H)R!SR=C<F5]MWX(Z5??MX
M?M"'XW>(H6_X4[X.N)+3P+HMU$5%]=(V'U"5">JNI(R,@A!P8VW9'[<,E_\
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M7&F+#+COM<JV/:NB_P""</\ R=-^VA_V.:_^EVJT?\%'O^3IOV+_ /L<V_\
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M*^$[*Z^+5A>?$;XAW48GUK6[K7;[;+<L!O$922-F0= SC<0,G'0=;:_%V\^
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MOAGP'X+_ ."G'Q?T'X9B,>"]-\)R6EGY5T]TOF)-IBW&)79BW[\3<Y([#C%
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MBBB@ HHHH **** "BBB@ HHHH *^ ->_X)A^./\ A:GC_P 9>#?VD?$'P_\
M^$PUJYU>[LM"TV>W_P!9/+*D<CQ7T?F^7YS@,5'5B ,D5]_T4 ?!>E_\$V_B
M?<7)C\3?M=?$C6M*92'M+6:ZMW8_[TEY*N,9&-G?\#])?LX_LH_#_P#9=T6]
MM/!UC<2ZCJ+*^I:YJ<WGWU\PZ&23  &23M4*N23C))KV*B@#B_C%\(?#/QV^
M'>K^"O%UDU[HFI(%D$;;)(W4ADDC;^%U8 @\].01D5\@Z+_P3&\4Z'<#2;7]
MI[XE6G@&&)8+7P[97<L+0Q@* GF"?RMHP< 0  8].?O*B@#Y)\-_\$Y? WPS
M^+WPJ\;_  [ND\)CP4EU%>6DEF;N76A,CJ6EG,BE7 EE&XJPP5 "J@%>@_M;
M?LHZ5^U=X.TC3+KQ!J'A/6]#O?[1TC6]-4-);7&PJ"RD@LN=K85D;*+AA7NM
M% 'SAX'_ &-HA^SSK_PK^*WCS7?C!'K5Z]Y/K6M2R+<P$K&L2P&265HQ&8@X
MRQ&YG.,-BO'-%_X)C>*=#N!I-K^T]\2K3P##$L%KX=LKN6%H8P% 3S!/Y6T8
M. (  ,>G/WE10!\D^&_^"<O@;X9_%[X5>-_AW=)X3'@I+J*\M)+,W<NM"9'4
MM+.9%*N!+*-Q5A@J %5 *^MJ** /*OVL?^36?C)_V)FL_P#I#-7P3^Q_^PGI
MOQB_9-^'?C[PAX]\2_";X@75OJ%M>:UX;N71+U4U*Y6,SQJZ,Q5551M=> ,Y
MP,?I!\6/ O\ PM#X5^,O!OVW^S/^$BT:\TC[;Y7F_9_M$#Q>9LW+NV[\[=PS
MC&1UKE?V6_@7_P ,U_ GPS\./[;_ .$C_L7[5_Q,_LGV7SO.NI9_]5O?;CS=
MOWCG;GC.  >6_ 7]@+PY\*/'=M\0/&/B_P 0?%SXAV\"PV^N>*IS,MH1G+01
MLSLIRS8WN^W/RX))/3_MK?LI?\-A?"O2O!O_  E/_")?8=:BU?[;_9_VW?L@
MGB\O9YL>,^?G=N/W<8YR/H"B@ KP3]IS]C'P)^U$VD:AK<NI:!XJT8@Z;XDT
M.X\F[M\.'V\@JP#*",C<IR5*Y.?>Z* /A"S_ ."7^K^)9I+#XG?M$_$+XA^$
M!-')'X>GNYHHF5'W!)3)/,&'"C**A&"1@XQ]J:#X+T'POX1M/"VDZ3:V/AVT
MM190Z;%&!"L.W;LV]P1G.>N3G.:VZ* /A?Q%_P $OCH.H:A-\&OC=XV^#MCJ
M%T;J?2-,N9I;,$K@A%CGA;LN"[-@#'3&/4_@#^PMX4^"_CC_ (3S6?$?B'XF
M?$)8#;0^(O%EX;F6TC((80*<["06&XEF 9@" S _2M% 'D/[2G[+7@3]JKP;
M%H'C2SGW6KM-8:G8R^5=64A4J61L$,"#RKAE. <9 (^:F_X)B^*-6GN])\0?
MM._$G6/ <\1@/AXW<H8QD %'D>=XF4C<,>2!R/3G[SHH Y#X4?"?PO\ !/P)
MIG@_P=I<>D:'IZ;8X4Y9V/+22,>7=CR6/)KR[]G']E+_ (9]^*GQH\9?\)3_
M &]_PL?6AJ_V+^S_ +-_9^)[N7R]_FOYO_'UC=M3[F<<X'T!10!Y5^U)\"_^
M&E/@3XF^'']M_P#".?VU]E_XF?V3[5Y/DW44_P#JMZ;L^5M^\,;L\XP=[X?_
M  OM?!OP5\-_#J^N?[9LM*\/6WA^>Y,7D_:XXK98&?9N;9N"D[=QQG&3UKMZ
M* /CO]G'_@G[JO[-OQ2T[6-'^-OBW5/A_IIN'M/ MT72U,DL31EIBLWE289V
MD&(%.X(<\<^D_M.?L8^!/VHFTC4-;EU+0/%6C$'3?$FAW'DW=OAP^WD%6 90
M1D;E.2I7)S[W10!\(6?_  2_U?Q+-)8?$[]HGXA?$/P@)HY(_#T]W-%$RH^X
M)*9)Y@PX4914(P2,'&/MKPKX5TCP/X;TW0- TZWTG1M.@6VM+*U3;'#&HP%
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M&Z=H?[/.B_";Q1-#XOTBRT2/0KJ62U^SI=P)&(P3'O8H=H7HQ((R"*^7)O\
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ML;HS(@9HVP2-RL2IP3RIKRWP;^RE_P (C^V3X[^/7_"4_:_^$HT:/2/^$?\
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M5X\DKR%F+.[ #?M4%F(55&3BN[HHH ^?_P!G']E+_AGWXJ?&CQE_PE/]O?\
M"Q]:&K_8O[/^S?V?B>[E\O?YK^;_ ,?6-VU/N9QS@'[:W[*7_#87PKTKP;_P
ME/\ PB7V'6HM7^V_V?\ ;=^R">+R]GFQXSY^=VX_=QCG(^@** "OG_\ 9Q_9
M2_X9]^*GQH\9?\)3_;W_  L?6AJ_V+^S_LW]GXGNY?+W^:_F_P#'UC=M3[F<
M<X'T!10!X)^TY^QCX$_:B;2-0UN74M \5:,0=-\2:'<>3=V^'#[>058!E!&1
MN4Y*E<G/A=G_ ,$O]7\2S26'Q._:)^(7Q#\(":.2/P]/=S11,J/N"2F2>8,.
M%&45",$C!QC[OHH RO"OA72/ _AO3= T#3K?2=&TZ!;:TLK5-L<,:C 4#^O4
M]37R/\3O^":^EZIXRUKQ9\)OB9XJ^".MZTXDU"/P[<2?8YWW%F8Q)+$X)+-P
M)-H)R%'(/V;10!\!_$+_ ()(^'O''@"33Y/B3KE_XZNM4@OKWQMXFMSJMW)!
M%#-']DC4RQF.,M*')+L28U!R NWZG_:D^!?_  TI\"?$WPX_MO\ X1S^VOLO
M_$S^R?:O)\FZBG_U6]-V?*V_>&-V><8/JM% 'GOA7X,Z3I?P#T+X5:]Y?B31
M;'P[;>';MI83$M[%%;I SE Q*;@N<!B5SU.,U\FV?_!+S7/".HII_@7]I#XB
M>#/ 09V_X1NRNI05W,S,$ECGCC )8=823SDG/'WI10!\7:I_P2]\!V,/@.]\
M(:S<Z+XM\-^)8?$E[XHU>W.IWVL2(RNT<[&2/ 9T1AM^53O.TEV->H_MK?LI
M?\-A?"O2O!O_  E/_")?8=:BU?[;_9_VW?L@GB\O9YL>,^?G=N/W<8YR/H"B
M@ KY_P#!O[*7_"(_MD^._CU_PE/VO_A*-&CTC_A'_P"S]GV;8EDOF?:/-._/
MV/.WRU_UG7Y>?H"B@ KRG]I+]FKP=^U)\/7\)>,(;A88Y1<V=_9.$N;.8 @/
M&2".02""""#]"/5J* /A32?^"9GB2^DNM-\:_M+?$CQ9X,E.P>'EO9H(W@R0
M896>>57!4A3B-._ SQZC\*_V%?"WP._:,B^)/@.[M_#NA?\ "-+X>F\+Q6!<
M2D,A^T?:3+G>?*BW;D8L0Q+$MQ]-44 ?/_C+]E+_ (2[]LGP)\>O^$I^R?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>plrx-20211231_g14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T(%!E
M=&5R<P    60 P "    %   $*:0!  "    %   $+J2D0 "     SDQ  "2
MD@ "     SDQ  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&!*D X)'!]*
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MP1+;>)X-5MM8D6*!%BCM7@#!(QU"G/!/<XJ;T/P\^W^8_>.MHHHKB+"BBB@
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MB:Y^(F@6>FVEY<32HEV6"(4PPVG!)&>@J?5/%]GI5U$T[J;)[)[LNH)8J&0
MC_ONL1OA;9O96L?]I2-/;O)OE>(.&#G)4*3\OMUK6UGP3;:NL:FZD@6.R-H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-/GAU.\MFN7,*QQ7$4,>0"V69_I6[\/K:&U\$V26Q)0@MDS++DDY)W+P?PH
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MG7#-<0+))MU%P,D<X%7[?X?Z;:QF.UU+6H$+%BL=^R@D]3@=ZN>"O^1'T?\
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MZUU&>_MK&WBN[C_73I$ \GU/4T ><:EXEGUWX@^#HIM!U/3!'>S,'O82BO\
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ME6-(QG&26.*?IGQ!M]0\62Z0]C-;P;YH[>\D9=D[0MMD&,Y&#W(YH B\9?\
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MZ1]T\5Z.XS&P W<'C/6O$X?"^K6'CV'6O$.B?8K 7FRV6VU+Y,L3AW!.6)]
M !0!L?&31+>YN='OR;JWD65HWNK9)93&I0\;$=1R<#-=GX!MH[3P3I\,#M(B
MIP[P&%F]RI)(/U)K'^)ME%J<>DV)U=M-N);AC"S#]VQ5&;YSN&.!D<]<5K^
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MJFN:+KME=-%+8S6;_9(;<LLID"G 8],$T ;\FM:9%]F\V_MT^U?ZC=*!YO\
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M%>?Z;\39-4U6P2#2B+"X,,,T[2C=%-)'Y@7;W '>O0* "BBB@ HHHH ****
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MUZX]J $\/^'=/\.:>MKIMND(P-Y7/S$#'<G ]JU:*Y;Q;XWM/#B-;P-#<:@
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>plrx-20211231_g15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g15.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9U#*D# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **BNKJ&RA::
MXFC@A7[TDK!5'U)K#M_B)X5O+MK6W\3://<KUACOXF<?\!#9H Z&BD5@R@@Y
M!Y!%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 51US6K/PWHNH:MJ,WV?3["WDNKF;:S;(D4L[84$G
M!. ":O5Q/QP_Y(MX_P#^Q?U#_P!)I*ZL+25?$4Z4MI-+[V*3LFSQ[_AY%^SI
M_P!%$_\ *)J/_P CT?\ #R+]G3_HHG_E$U'_ .1Z_#NBO[*_X@KP]_S_ *W_
M (%#_P"5GSO]I5NR_'_,_<3_ (>1?LZ?]%$_\HFH_P#R/1_P\B_9T_Z*)_Y1
M-1_^1Z_#NBC_ (@KP]_S_K?^!0_^5A_:5;LOQ_S/W$_X>1?LZ?\ 11/_ "B:
MC_\ (]'_  \B_9T_Z*)_Y1-1_P#D>OP[HH_X@KP]_P _ZW_@4/\ Y6']I5NR
M_'_,_<3_ (>1?LZ?]%$_\HFH_P#R/1_P\B_9T_Z*)_Y1-1_^1Z_#NBC_ (@K
MP]_S_K?^!0_^5A_:5;LOQ_S/W$_X>1?LZ?\ 11/_ "B:C_\ (]'_  \B_9T_
MZ*)_Y1-1_P#D>OP[HH_X@KP]_P _ZW_@4/\ Y6']I5NR_'_,_<3_ (>1?LZ?
M]%$_\HFH_P#R/1_P\B_9T_Z*)_Y1-1_^1Z_#NBC_ (@KP]_S_K?^!0_^5A_:
M5;LOQ_S/W$_X>1?LZ?\ 11/_ "B:C_\ (]'_  \B_9T_Z*)_Y1-1_P#D>OP[
MHH_X@KP]_P _ZW_@4/\ Y6']I5NR_'_,_I"\&^,-(^('A72O$F@7?V_1=4MU
MNK2Z\MX_-C895MK@,,CL0#6S7CG['/\ R:Q\+?\ L 6O_H KV.OX\S+#0P>.
MKX:F[QA.45?>R;2N?00ES14GU"BBBO.+"BBB@ HHHH *^)/V\/\ @HYIG[,<
MC^$/"%M:^(/B%+&&D%P=UKIJGH90I!9R.0F1V)/:OKWQ]XG7P3X%\1>(602#
M2M.N+[8?XO+C9\?CMQ7\U&J:EK/QR^+LES>74EWK?B?5U4SS?,QDFE"@G'IN
M'Y4 >C>(/VDOVAOVBO$,L(\7>,O$=Y,2XTG0'G6)03_#;V^% _X#4&K7/[27
MP3:/6-4D^)W@H##+>WIU"S0^@+-@'Z&OW?\ V;_V<_!_[-OP[T_P]X8TF"TN
M?)0ZAJ&P?:+V;'S/*^,GG.!T Z 5Z7JVD6.OZ9<Z=J=G;ZAI]U&8I[6ZC62*
M5#U5E(((/H: /R$_9$_X*W>*O#>NV'AOXR3CQ%X>G=85\1+$J7EGDX#2[<+*
M@[G 8=<MTK]?=+U2TUO3;74+"YCO+&ZC6:&XA8,DB,,A@>X(K\%?^"E'[,>E
M?LU_'81>&XQ;^&?$%N=2LK-1\MI\Y5X@?[H8''L17Z!?\$?OB]?^/OV>;[PU
MJ=P]Q-X6OOLELTAR?L[*'1?HN2H]A0!]Y5\[_ME?MF>&OV1?!$=Y>1+K'BK4
M%8:5HBR;3*1P9)#_  Q@]^I/ [D>_:IJ5MHVFW>H7DHAM+6%YYI&Z(BJ68_@
M :_G)_:?^,VM_M/?M!ZUKSE[DWM[]ATJS4\1PAMD4:C/?CZDT =1\1/VT/VA
M/VD_$[6<?BGQ 3=L5M_#OA/S8(MN>$$4'S28]7W&L76=/_:7^$=DNNZK#\4O
M"%FNT_VC=C4;2)3V#2-@ ^Q-?M/^Q/\ LE^'/V7_ (4Z;;P6$$OB_4+=)M8U
M9D!FED89,:MC(C7. OXG)YKZ&NK6&^MI;:YACN+>92DD,JAD=2,%2#P01VH
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M 6D4?++CMO7!KZ8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWB?;-(O9<;I;<G&UL?Q*?E/':OK_ /X(?_\ (V?%#_KRM/\ T8] 'ZUT444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;;),]?D]R#_1!7\K&<<C@U_3O\&?%1\=_"#P/XE8EFUC0['426ZGS;=).?\
MOJ@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKTWQQ_P3_P#V?O'FDRV-U\,-#TLNN%NM#@&GS1G& P:';DC_ &@1Z@U]"T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML_\ WTO^%'_$(>*/Y(?^!H/[0H>9Q]%=A_PA]E_SUG_[Z7_"C_A#[+_GK/\
M]]+_ (4?\0AXH_DA_P"!H/[0H>9Q]%=A_P (?9?\]9_^^E_PH_X0^R_YZS_]
M]+_A1_Q"'BC^2'_@:#^T*'F<?178?\(?9?\ /6?_ +Z7_"C_ (0^R_YZS_\
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M "'1_P .5/@A_P!#3\0/_!C8_P#R'0!^*U%?M3_PY4^"'_0T_$#_ ,&-C_\
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M /(= 'XK45^U/_#E3X(?]#3\0/\ P8V/_P AT?\ #E3X(?\ 0T_$#_P8V/\
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M _\ !C8__(=?BS5G8]$_%:BOVI_X<J?!#_H:?B!_X,;'_P"0Z/\ ARI\$/\
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MT?\ "@/#W_/YJ?\ W]C_ /C='^L&![O[@_XA#Q1_)#_P-'@-%>_?\* \/?\
M/YJ?_?V/_P"-T?\ "@/#W_/YJ?\ W]C_ /C='^L&![O[@_XA#Q1_)#_P-'@-
M%>_?\* \/?\ /YJ?_?V/_P"-T?\ "@/#W_/YJ?\ W]C_ /C='^L&![O[@_XA
M#Q1_)#_P-'@-%>_?\* \/?\ /YJ?_?V/_P"-T?\ "@/#W_/YJ?\ W]C_ /C=
M'^L&![O[@_XA#Q1_)#_P-'@-%>_?\* \/?\ /YJ?_?V/_P"-T?\ "@/#W_/Y
MJ?\ W]C_ /C='^L&![O[@_XA#Q1_)#_P-'@-%>_?\* \/?\ /YJ?_?V/_P"-
MT?\ "@/#W_/YJ?\ W]C_ /C='^L&![O[@_XA#Q1_)#_P-'@-%>_?\* \/?\
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MM<_[_P /_P :H_UOROO+[@_U[R;^:7_@)\AT5]>?\,A>#O\ H):Y_P!_X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+Q'82V_AC0&8:+YR;5O[X@J9%SU2(;N>F\J 3L85^R5 !1110 4444 %%%%
M'\K$G^L;ZU^TW_!%/_DUWQ7_ -CE=?\ I#8U^+,G^L;ZU^TW_!%/_DUWQ7_V
M.5U_Z0V- 'Z T444 %%%% !1110 4444 ?A[_P %)/\ D\_X@_33O_3=;5\S
M5],_\%)/^3S_ (@_33O_ $W6U?,U?Z4<)_\ )/9=_P!>:7_I$3X[$?QI^K"B
MBBOJS **** "BBB@ HHHH **** "BBB@ HHHH **** "OW!_X)M?\F8_#_\
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M^Y_ZZM_,U7JQJ'_'_<_]=6_F:KU_*TMV?Q9+XF%%%%22%%%% !1110 4444
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M[5Z-10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0_QK_P!)D?F'B%_R*J?_ %\7_I,CQVBBBOQ,_GD**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#[H_8/_ .25ZU_V&I/_ $1#7TG7S9^P?_R2O6O^
MPU)_Z(AKZ3K^BN'_ /D5T/0_JSA?_D2X;_#^K"BBBOH3ZD**** "BBB@ HHH
MH **** "O#_VE/O:!])O_9*]PKG_ !5X%T?QG]F_M6W>?[/N\O;(R8W8ST/L
M*!HXG]G/_D3M0_Z_V_\ 1<=>K5C^%_">F^#[&2TTN%H8))#*RLY?YB ,Y)]
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MU.ZHHHK]B/WL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOM4 9]ZW*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^5B3_6-]:_:;_@BG_R:[XK
M_P"QRNO_ $AL:_%F3_6-]:_:;_@BG_R:[XK_ .QRNO\ TAL: /T!HHHH ***
M* "BBB@ HHHH _#W_@I)_P GG_$'Z:=_Z;K:OF:OIG_@I)_R>?\ $'Z:=_Z;
MK:OF:O\ 2CA/_DGLN_Z\TO\ TB)\=B/XT_5A1117U9@%%%% !1110 4444 %
M%%% !1110 4444 %%%% !7[@_P#!-K_DS'X?_P"]J/\ Z<+FOP^K]P?^";7_
M "9C\/\ _>U'_P!.%S7X#XU?\D[1_P"OT?\ TBH>KEO\5^GZH^FJ***_BH^C
M"BBB@ HHHH **** /"OVXO\ DUOQM]+/_P!+8*_):OUI_;B_Y-;\;?2S_P#2
MV"OR6K\XXD_WN/\ A7YL_M/P5_Y)ZO\ ]?I?^D4PHHHKY,_H **** "BBB@
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M_P"B(:^DZ_HKA_\ Y%=#T/ZLX7_Y$N&_P_JPHHHKZ$^I"BBB@ HHHH ****
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M_P#75OYFJ]6-0_X_[G_KJW\S5>OY6ENS^+)?$PHHHJ20HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_4'X%_\D:\%?\ 8)MO_18K\OJ_4'X%_P#)&O!7
M_8)MO_18K])X(_WJM_A_4_6O#K_?:_\ A_4[JBBBOV(_>PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _E8D_UC?6OVF_X(I_\FN^*_\ L<KK_P!(;&OQ9D_UC?6OVF_X
M(I_\FN^*_P#L<KK_ -(;&@#] :*** "BBB@ HHHH **** /P]_X*2?\ )Y_Q
M!^FG?^FZVKYFKZ9_X*2?\GG_ !!^FG?^FZVKYFK_ $HX3_Y)[+O^O-+_ -(B
M?'8C^-/U84445]68!1110 4444 %%%% !1110 4444 %%%% !1110 5^X/\
MP3:_Y,Q^'_\ O:C_ .G"YK\/J_<'_@FU_P F8_#_ /WM1_\ 3A<U^ ^-7_).
MT?\ K]'_ -(J'JY;_%?I^J/IJBBBOXJ/HPHHHH **** "BBB@#PK]N+_ )-;
M\;?2S_\ 2V"OR6K]:?VXO^36_&WTL_\ TM@K\EJ_..)/][C_ (5^;/[3\%?^
M2>K_ /7Z7_I%,****^3/Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKN/@7_R6[X>_]C%I_P#Z4QUP]=Q\"_\ DMWP]_[&+3__ $ICK>A_%AZK\SR\
MT_W#$?X)?^DL_::BBBOVP_S "BBB@ HHHH **** "OSF_:Z_Y.!\3?[MK_Z2
MQ5^C-?G-^UU_R<#XF_W;7_TEBKX#C7_D70_QK_TF1^8>(7_(JI_]?%_Z3(\=
MHHHK\3/YY"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^Z/V#_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK\]_^"@7_  4FU/\
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M\3_V:_V@-5\#>&="\(WVDVEK;S)-JUG=23EI$W,"T=RBXST^6O!?^'U?QO\
M^A6^'_\ X+K[_P"3* /VIHK\5O\ A]7\;_\ H5OA_P#^"Z^_^3*N:?\ \%L/
MB_'G[=X,\$W'/'V>WO(N/QN&H _9VBOR_P#AC_P6XT>]O([;X@?#JZTN!B V
MH:!>"YV^YAD"''T<GVK]!/@[\<O!'Q\\*1>(O VOVVN:>W$BQG;- W]R6,X9
M&]B/I0!WE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '\K$G^L;ZU^TW_!%/\ Y-=\5_\ 8Y77
M_I#8U^+,G^L;ZU^TW_!%/_DUWQ7_ -CE=?\ I#8T ?H#1110 4444 %%%% !
M1110!^'O_!23_D\_X@_33O\ TW6U?,U?3/\ P4D_Y//^(/TT[_TW6U?,U?Z4
M<)_\D]EW_7FE_P"D1/CL1_&GZL****^K, HHHH **** "BBB@ HHHH ****
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M?\F^_$[_ +%?5/\ TDEK^>>OZ\\$/]PQO^./_I+/ S+XHA1117]+GC!1110
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M9J_THX3_ .2>R[_KS2_](B?'8C^-/U84445]68!1110 4444 %%%% !1110
M4444 %%%% !1110 5^X/_!-K_DS'X?\ ^]J/_IPN:_#ZOW!_X)M?\F8_#_\
MWM1_].%S7X#XU?\ ).T?^OT?_2*AZN6_Q7Z?JCZ:HHHK^*CZ,**** "BBB@
MHHHH \*_;B_Y-;\;?2S_ /2V"OR6K]:?VXO^36_&WTL__2V"OR6K\XXD_P![
MC_A7YL_M/P5_Y)ZO_P!?I?\ I%,****^3/Z "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KN/@7_ ,EN^'O_ &,6G_\ I3'7#UW'P+_Y+=\/?^QBT_\
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M" ?TK^=?XW7$-W\8O&LUNH2%M7NBJ@Y'^M:OZ OV(;&73?V2?A5;39\V/0X
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MR9)$+$\89E'/6OV3HH _EG\0>']3\)ZY?:-K-C/IFJV,S6]S9W2%)(9%."K
M]"#7[6_\$B_V@[CXL? &Z\%ZM<&?6? LL5E&S Y;3Y%8VW. /D\N6/ SA8TS
MU&?DS_@M!\-]+\,?'CPMXJL(H[>[\2Z2WV]8PH\R:W<()3CDL4>-<GM&*L?\
M$3?$5W:_M ^.-"39]AOO##7LN0=WF07<"1XYQC%Q)GCTZ<Y /V6HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_%AZK\SR\T_W#$?X)?\ I+/VFHHHK]L/\P HHHH **** "BBB@ K\YOVNO\
MDX'Q-_NVO_I+%7Z,U^<W[77_ "<#XF_W;7_TEBKX#C7_ )%T/\:_])D?F'B%
M_P BJG_U\7_I,CQVBBBOQ,_GD**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#[H_8/_Y)7K7_ &&I/_1$-?2=?-G[!_\ R2O6O^PU)_Z(AKZ3K^BN
M'_\ D5T/0_JSA?\ Y$N&_P /ZL****^A/J0HHHH **** "BBB@ HHHH *\D^
M/'BK5O#;:-_9E]+9>=YOF>61\V-F,_F:];KP_P#:4^]H'TF_]DI%+<ZKX&^(
M-1\1>%[VXU*[DO)DO&C5Y#R%V(<?F3^=>C5Y3^SG_P B=J'_ %_M_P"BXZ]6
MIB>X4444""BBB@ HHHH **** "BBB@ HHHH \\_:*_Y-]^)W_8KZI_Z22U_/
M/7]#'[17_)OOQ._[%?5/_226OYYZ_KSP0_W#&_XX_P#I+/ S+XHA1117]+GC
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?THZ7_P @RT_ZXI_Z
M"*M55TO_ )!EI_UQ3_T$5:K_ "OG\3/MUL%%%%0,**** "BBB@ KX8_X*@_\
M@_X=?]=;_P#E;U]SU\,?\%0?^0?\.O\ KK?_ ,K>O#SO_D7U/E^:/U+PP_Y*
M[!?]O_\ IN9\$4445^4'^@(4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 5RGQ9_Y)7XR_P"P+>_^B'KJZY3XL_\
M)*_&7_8%O?\ T0]95?X<O1G?E_\ OE'_ !1_-'XF4445^(G^H@4444 %%%%
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M\Q  !]0JD_\  J /VDHHHH *Y?XI_P#),?%__8'O/_1#UU%<O\4_^28^+_\
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M3R.A\N:Z_P"64>>AQ]XCM@5^Y] 'X-?\%8O^3S?$7_7A9?\ HJOT!_X(]_\
M)IJ_]ABZ_P#0J_/[_@K%_P GF^(O^O"R_P#15?H#_P $>_\ DTU?^PQ=?^A4
M ?<E%%% !7P/_P %COB)%X;_ &<=-\-),BWFOZHGR;OF\N(%FX]#D<^U?<WB
M/Q)I7A#0[W6=;U"WTK2K*(S7%Y=2"..)!U))K\ ?V^OVJO\ AJ;XU3ZEIHDB
M\*Z0AL=)C<\R(&^:8CL7//L,4 ;_ /P2U\"MXT_;"\+W&QC%HD4VILV. 57:
MH/UW&OWQK\[/^"//[/-SX%^&6K?$G6+7R+_Q.5BL X^86:'AO^!-DCVK]$Z
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M HHHH **** /N7_@E_\ \A/XB?\ 7&P_]"GK[YKX&_X)?_\ (3^(G_7&P_\
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M (C?EW_0'/\ \"B?B[17[1?\*#^&/_1.?"7_ (([7_XW1_PH/X8_]$Y\)?\
M@CM?_C='^K-;_GXON8?\1OR[_H#G_P"!1,S]F+_DWOX??]@:W_\ 0:]/JKI>
MEV6B:?;V&G6<%A8VZ".&UM8ECBB4=%55   ]!5JONZ,/9TXP?1)'\H9AB5C,
M96Q,593E*5NUVV%%%%:GGA1110 4444 %%%% !7X)_\ !5C_ )/2\6?]>EE_
MZ(6OWLKYE^-G_!.[X/?'_P"(5]XT\6V6KS:Y>)''*]IJ+0QX10JX4#C@4 4O
M^"9/_)F?@;_=F_\ 1AKZGKB_@]\(_#WP,^'^F^#?"T=Q%HFGAA MU,99!N.3
MECUY-=I0 5^./_!3[]@_5/!/BK4_BSX&TLW/A/4'\_5[.T7+:?.3\TFP#_5,
M><CA2<''&?V.ILD:31O'(BR1N"K*PR"#U!% 'X4?L<?\%,?%_P"S+I4/A77M
M/;QIX(C;$%J\_E75@O<0N005_P!AN/0BOLO5_P#@M=\)8-#:;3/!GC&\U;;\
MEG=16L$.[T:43N0/<(?I7J/QH_X):? OXP:A<:I!I-[X)U>X<R2W'AN=88I&
M)Y)@=6C'_ %6O';'_@B/\.8[S=>?$+Q1/:9_U4$-M&__ 'V48?\ CM 'YW_M
M+?M0^/\ ]M#XD65SJ=LWEJ_V;1_#>F*\B0[C@!5ZO(W&6QD]@!Q7ZP?\$UOV
M-)OV:OAS-K_BFS6'Q[X@57NHF(9K* <I!D<;N<MCN<9XKU/]G_\ 8<^$'[-L
MD5YX4\-+<Z]&NW^WM8<75[[E6("QY[^6JYKWR@ K\=/^"K'[%NH^#_&5Y\7?
M".EM-X7U0A]9BM5S]BN2<&4J.D;]=W0$XXXS^Q=07EE;ZE:36MW!%=6LR&.6
M&9 Z.I&"K*>"".QH _$#]BO_ (*<Z[^S7H</@[Q;I5QXO\%0M_HOD3!;VP4G
ME8]WRR)Z(Q7'9@.*^J_''_!;#X;6?A^5_"'@KQ/JFN,G[J'6$M[2V1L=7>.:
M1C@]@O/J*](^+G_!)?X&_$S5+C4]+M]5\"WT[F21-!N%%LS'J?)E5PH]DVCV
MKS32_P#@B1\.8+Z-]1^(/B>\LP<M#;PV\+M[;RKX_P"^: /S0\<>-_B1^V9\
M;%O+N.?Q%XMUN=8+2PM$/EPK_#'&O\"*.I/8$DU^ZO[%_P"S/9_LL_!/3?"X
M:.XURX/VS5[N,<2W+#D#_9484>PK7^ /[)?PP_9GT]X? WAR.SOIDV7&K73F
M>]G'HTK<@?[*[5]J]AH **** "N7^*?_ "3'Q?\ ]@>\_P#1#UU%4M:TFWU_
M1[_3+L,;6]@DMI@IP2CJ5;!['!- '\T/PA_Y+QX*_P"QELO_ $J2OZ:Z^/=!
M_P""4_P%\.^)M.UVST_75U"PNX[Z%GU5V42(X=21CD9 XK["H *_%;_@LY_R
M<AH7_8$C_P#0S7[4U\]?M ?L)_"O]ICQ;;>(_&UIJD^IV]N+5&LK]H$V Y&5
M Z\T >,_\$=?^35IO^PQ<?SK[KKS7X"?L^^$?V;?!3>%?!<-W!I+7#W)6\N#
M.^]NOS$=*]*H ^:_^"CG_)F'Q+_Z\H__ $<E?DI_P3%_Y/+\$?6;_P!%FOW0
M^+/PMT+XT_#_ %CP9XECGET358Q%<K;2F*0J&####IR!7AWP=_X)Q_!KX%_$
M#3O&7A:RUB+6[#=Y+76I-+&-PP<J1SQ0!]&^)O#>G>,/#VHZ'J]JE[IFH0/;
M7-O(,AT88(K\ _VS?V,?%W[)OC^:XCM[F\\&7,YETG7K=&V)SE8I&'W)%]">
M<9&:_>7XD?%/PG\(= 37/&>NVOAW2'G2V%[>L5B\QL[5+8XS@]?2LK0?B/\
M##XZ:7>:5H_B7PKX\L)XL76GVM[;WZ-&>HDB#-Q_O"@#\CO@-_P6!^)/PM\.
MVFA^+]!L_B)9VB".&[GNVL[[:!@*\H1U?'J4SZDUL?&#_@L]\0O&F@W&F>"?
M".G^ I+A"C:C)>MJ%U&".3&3'&BGW*-CMSS7W;XR_P""8'[.7C*]FO&\"?V+
M<R_>.C:A<6T8/JL0?RU_!0*V_A?_ ,$[_@#\)=4AU32? -K?ZG"P>*ZUJ>2^
M,;#HRI*Q13GG(7- 'X;_ !%^"?C_ ,-?#[1/B;XQM;BUL_%E],EG)J#-]JNB
MJAVG*GG:=W!/7MQS7W9_P1 _Y&[XH?\ 7C:?^C'K;_X+>:]9_9?ACH2R(+R-
MKF\\D$9$9"H#CTRIJ?\ X(A^&I$TOXE>(#&1%)-;V(DQU*@OC_QZ@#]2J***
M "BBB@#YM_;6_8N\/_M<>!TADD32?&.FHS:5K&S.">?)EQR8V/Y'D>_X=?$;
MX5_$W]D_XDQ6NN6FI>$?$=C+YMEJ5I(R+)CI)!,APP^A[X/I7]*]<[XZ^'?A
MCXG:!-HGBW0-/\1:3+]ZTU&W69,^HR/E/N,$4 ?C_P#!W_@LM\3?!.GV^G^-
M_#FF>/X(5V"\$QT^]?W=U5XV/_;,$]S7K&N?\%M/#>K:'-:2_!FXU+ST*2V=
M]K,1MW![-_H[;A[%:]@^(O\ P1W^!_B^XFNM!N/$'@N>1MRP:?>+<6R_\ F5
MFQ]'%<%%_P $0_ BR*9/B3XB>//S*MG I(]CSC\J /R[^-?Q(T;XJ>.KO7]#
M\"Z/\/[.X.?[+T5Y6BW$Y+'>Q4'V147_ &:X55\MHVE1O+)S@?*6'?!Q7[R_
M"[_@E3\ /AK=0WESH-_XSO8B&23Q+>>=&"/^F,:QQL/9E:O7/CE^R1\,?V@/
M!,/AKQ)X:M8(;.+R].O--B6WN-/]/)91PO\ L$%3Z4 >)_\ !/#]I;X&>)?A
M;H?@'P,\?A'7+&$";0-5D5;FYFQ\\J2<"<L<G(^;U K[0K\,OVAO^"5/Q<^"
M]Q<ZOX/C/Q!\.PL9(Y])4KJ$*@Y!>W^\2/6,MTSQ7ZP_L:^"/%/@#]G/P?IG
MC35M2U?Q(UJ+BZDU6X>::$OR(=S'.$&  >E 'Y#?\%8O^3S?$7_7A9?^BJQ?
MV;?^"CGQ*_9=^'@\&^%=#\*ZAIGVF2Z\[6+2YEFW.<D9CN(UQ_P&OUG^-W_!
M//X0?M!_$"[\9^+K/5YM;NHHX9&M-1:&/:BX7"@>E<%_PZ&_9Y_Z!WB#_P '
M#_X4 ?%?_#ZOXW_]"M\/_P#P77W_ ,F5G:Q_P68^/&I0E+?3/!>DL5QYEGID
M[,#Z_O;AQG\,5]R_\.AOV>?^@=X@_P#!P_\ A5S3O^"2O[.5BQ,WAW5]0&0=
MMQK5P!]/D9: /Q[^-'[5_P 6?VA62/QSXSU#6+-6S'IL82WM%/8^1$JH3_M$
M$^]?2/[#O_!-'Q5\:M<T[Q7\0M,NO#7@"%UG6WO(S'<ZJ.H5$/*QGNY'(Z9Z
MU^K/PT_8[^"OP@NH[KPI\-]#T^]CYCO9X#=W">ZRS%W7\#7L= %/1]'LO#^E
M6FFZ;:Q65A:1+#!;PKM2-%& H'H!5RBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A?
MC%\#_!'Q\\)R>&_'?AZUU_3"Q>(3 K+;R8QYD4BD-&V#U4CC@Y!Q7YS_ !:_
MX(D^=>75W\-/B"D$# F'2_$UN3M;)X-S""=N,#_5$\=3FOU/EE2&-Y)'6.-
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MM-'<02#<DL3!E8>H(X(J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^
M5B3_ %C?6OVF_P""*?\ R:[XK_['*Z_](;&OQ9D_UC?6OVF_X(I_\FN^*_\
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M/^N-A_Z%/7WS7ZKD?^X4_G^;/X$\4_\ DKL7_P!P_P#TW ****]X_)PHHHH
M**** "BBB@#\C-0_X_[G_KJW\S5>K&H?\?\ <_\ 75OYFJ]?RM+=G\62^)A1
M114DA1110 4444 %%%% !1110 4444 %%%% !1110 5^H/P+_P"2->"O^P3;
M?^BQ7Y?5^H/P+_Y(UX*_[!-M_P"BQ7Z3P1_O5;_#^I^M>'7^^U_\/ZG=4445
M^Q'[V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _E8D_P!8WUK]IO\ @BG_ ,FN^*_^
MQRNO_2&QK\69/]8WUK]IO^"*?_)KOBO_ +'*Z_\ 2&QH _0&BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH @OO^/*X_ZYM_(U^(C_ 'F^M?MW??\
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MHHHK]L/\P HHHH **** "BBB@ K\YOVNO^3@?$W^[:_^DL5?HS7YS?M=?\G
M^)O]VU_])8J^ XU_Y%T/\:_])D?F'B%_R*J?_7Q?^DR/':***_$S^>0HHHH
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M 4444 %%%% !1110 4444 %%%% 'W+_P2_\ ^0G\1/\ KC8?^A3U]\U\#?\
M!+__ )"?Q$_ZXV'_ *%/7WS7ZKD?^X4_G^;/X$\4_P#DKL7_ -P__3< HHHK
MWC\G"BBB@ HHHH **** /R,U#_C_ +G_ *ZM_,U7JQJ'_'_<_P#75OYFJ]?R
MM+=G\62^)A1114DA1110 4444 %%%% !1110 4444 %%%% !1110 5^H/P+_
M .2->"O^P3;?^BQ7Y?5^H/P+_P"2->"O^P3;?^BQ7Z3P1_O5;_#^I^M>'7^^
MU_\ #^IW5%%%?L1^]A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_!:#2=8^'=]IWPH\-:UI/BN\'DIJVOQ6XCLD(.Z6-$DDWR#^$-A03D[L;2
M?/?_  5X\6:/XG_:^N;?29DGFT;1;33=0:,' N0TLI7/0D)-&#C."".H('KW
M_!$?X:W=QX^^(/Q!DCFCL;/3$T*&3CRY9)I4GD'3)9!;Q?02=\C'Y]>!/#,O
MQ:^(UKI^K^*-/T-]4N6EO_$/B.]$<46XEI)I9'.78Y)QRS$^^:_H'_8ZT?X3
M^#_@U8>$_A%XETWQ3HFBN8KR_L;M+B26Z<!Y))BIX9R<@=  %'"@  ]RHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBBOVP_S "BBB@ HHHH **** "OSF_:Z_P"3@?$W^[:_^DL5?HS7YS?M=?\
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M_P#75OYFJ]6-0_X_[G_KJW\S5>OY6ENS^+)?$PHHHJ20HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_4'X%_\D:\%?\ 8)MO_18K\OJ_4'X%_P#)&O!7
M_8)MO_18K])X(_WJM_A_4_6O#K_?:_\ A_4[JBBBOV(_>PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"-5VW@WX?^%_ASI;:;X3\-Z1X7TYG,K6>C6$5I"7/5BD:J,^^* -^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /Y6)/]8WUK]IO^"*?_ ":[XK_['*Z_
M](;&OQ9D_P!8WUK]IO\ @BG_ ,FN^*_^QRNO_2&QH _0&BBB@ HHHH ****
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M?.G9)M[2['YUQUA<1C,LA3PU-SESIVBFW;EEKH?*]%>O_P##)/Q7_P"A4_\
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M/^'7_76__E;UX>=_\B^I\OS1^I>&'_)78+_M_P#]-S/@BBBBOR@_T!"BBB@
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MWBR[\+_ME^!X;61D35C-ITX!X:-HF<@_C&* /W_K\KO^"IW[=FIZ3JUY\&_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW_!!)/\ PD_B#\X/_C=?JW N?99DBQ/]HOX^6WNWVYK_ )HX<32G4MR'P?\
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M_GG_ . ,_-2NX^!?_);OA[_V,6G_ /I3'7WG_P .T_AC_P!!WQ;_ .!EK_\
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M]I3[V@?2;_V2@:/4O!_C*P\;Z=+>Z<LRPQRF%O/0*=P /8GC#"MZO*?V<_\
MD3M0_P"O]O\ T7'7JU ,****!!1110 4444 %%%% !1110 4444 >>?M%?\
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MX#_63D ;%_V%'RCZ9H YS_@IIXDD\._L:^.!&_EM?K#99[X:0$@?]\U^4/\
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M2T2SL/%BO]KBC&%^V)C>P'^TI!/N:[C_ ((@?\C=\4/^O&T_]&/0!^ME%%%
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M_P"+_C2WMVWPIJ]T%;_MJQK^@']AN267]D7X4/,,2G0H-WZT ?D;_P %8O\
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M!KV7_@B'X+^U_$KXD^+6AD']GZ3;Z5'-R$/VB;S77T)_T5#[9]Z /UZHHHH
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M7[.?_(G:A_U_M_Z+CKU:O*?V<_\ D3M0_P"O]O\ T7'7JU,3W"BBB@04444
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M/@BBBBOR@_T!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^Y?\
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MH*_INMX?L]O%$.B*%_(8K^9CX0_\EX\%?]C+9?\ I4E?TUT %?BM_P %G/\
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MFOIN,_NT1LG\R*_H4K\E/^"+?P4EO/$GBKXGWL#+;V<7]E6$C# 9W^:4CU&
M!]:_6N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0D/7.5=80.V/F.<GICD _.W3=-N]9U&UT_3[6:^O[J58+>UMHS)+-(Q"JB*
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M\B^I\OS1^I>&'_)78+_M_P#]-S/@BBBBOR@_T!"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^Y?^"7_ /R$_B)_UQL/_0IZ^^:^!O\ @E__ ,A/
MXB?]<;#_ -"GK[YK]5R/_<*?S_-G\">*?_)78O\ [A_^FX!1117O'Y.%%%%
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M_DT/_DCY"HKZ]_X=^_\ 4^?^4?\ ^WT?\._?^I\_\H__ -OH_P!5LX_Y\_\
MDT?_ )(/]3,^_P"@?_R:'_R1\A45]>_\._?^I\_\H_\ ]OH_X=^_]3Y_Y1__
M +?1_JMG'_/G_P FC_\ )!_J9GW_ $#_ /DT/_DCY"HKZ]_X=^_]3Y_Y1_\
M[?1_P[]_ZGS_ ,H__P!OH_U6SC_GS_Y-'_Y(/]3,^_Z!_P#R:'_R1\A45]>_
M\._?^I\_\H__ -OH_P"'?O\ U/G_ )1__M]'^JV<?\^?_)H__)!_J9GW_0/_
M .30_P#DCW_X!?\ )%O!?_8,A_\ 0:[^L#P#X5_X0?P7HOA_[5]M_LVU2V^T
M>7Y?F;1C=MR<?3)K?K]VPD)4L/3IS5FHI/Y(_I/ TY4<+2IS5G&,4_5)!111
M74=H4444 %%%% 'DO[5'P-@_:*^!?B;P1(R1WEY!YMC,XXBN4^:-O;)RI/8,
M:_GX\,Z[XR_9;^-UIJ*V\VC^+/"^H?O+6X4H25)#HP/.UER/H<U_3#7S%^UU
M^P'X!_:QMQJ-XS^&?&<*;(?$%C$&:10.$GC) D4=N0P[''% "?L[_P#!0[X/
M?'GP[;2R^*-/\'^(@JK<Z+X@NH[202$<^2SL%E7/3:2?4"O2?B%^U1\(_A;H
MDNJ>(OB'X?M(%4LL,-_'/<2X[1Q1EG<_05^1/C[_ () _'SPM?2IH-KH?C.T
MR3'-I^I);.1GC<EQY85O8,1[UB^'/^"3?[2&N74<-[X5TWP_&S8-QJ6MVKHH
M]2('E;'T!- &/^WM^VY>_M;>-K:#2X)M+\"Z.S#3;.8XDF8\-/*!P&( PO8>
M^37V[_P2+_9/U'X>>'=0^*WBBQDLM4UR 6^DVTZX>.T/)E(ZC><<'LH-:_[+
M?_!(GPG\+-4LO$GQ,U2'QQKULPEATNWB*Z9"XZ%@PW3$'IN"CU4U^@\<:0QK
M'&BI&H"JJC  '0 4 >5?M1?'2Q_9S^"/B3QM=E&N+2'RK""3I-=/D1)[\_,1
MZ*:_G.\5>+M3^)/C:_\ $'B34GGU+5KLSWE]*"Y!=OF; Y(&>@]*_=K_ (*&
M?LM^.OVKOAWX>\->"]6T72Q9W[7=X-;N)H8Y!M 3;Y4,A)!W=<=:^!/^'*GQ
MO_Z&GX?_ /@QOO\ Y#H ]Z_9D_;K_94_9B^%VG^$O#]WKS3*HEU#4&T5O-O+
M@CYI&.?P [  5ZU_P]Y_9Y_Z"/B#_P $[_XU\5_\.5/C?_T-/P__ /!C??\
MR'1_PY4^-_\ T-/P_P#_  8WW_R'0!]J?\/>?V>?^@CX@_\ !._^-=1\+_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!]<445^ 3?\ !4;]IT,0/B9W_P"@!I?_ ,C4 ?O[17X _P##T;]IW_HIG_E
MTO\ ^1J/^'HW[3O_ $4S_P H&E__ "-0!^_U%?@#_P /1OVG?^BF?^4#2_\
MY&H_X>C?M._]%,_\H&E__(U 'RM)_K&^M?M-_P $4_\ DUWQ7_V.5U_Z0V-?
MBP3DY-?M/_P13_Y-=\5_]CE=?^D-C0!^@-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7Q%_P4\_Y%WP#_P!?5Y_Z!%7V[7Q%
M_P %//\ D7? /_7U>?\ H$5>)G7^X5/E^:/T[PS_ .2MP7K+_P!-R/C[]GS_
M )+M\/O^P]9?^CTK]GJ_&']GS_DNWP^_[#UE_P"CTK]GJ\CAG^#4]?T/T7QN
M_P"1E@_\#_\ 2@HHHK[(_FP**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _)_QQ_P CGKO_ %_3_P#HPU]D?L&_\DUU
M[_L+M_Z)BKXW\<?\CGKO_7]/_P"C#7V1^P;_ ,DUU[_L+M_Z)BK\.X8_Y'7_
M ($?SCP;_P E!_X&?3%%%%?N)_1P4444 %%%% !1110 4444 %%%% !1110
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M8+_M_P#]-S/@BBBBOR@_T!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^Y?^"7_ /R$_B)_UQL/_0IZ^^:^!O\ @E__ ,A/XB?]<;#_ -"GK[YK
M]5R/_<*?S_-G\">*?_)78O\ [A_^FX!1117O'Y.%%%% !1110 4444 ?D9J'
M_'_<_P#75OYFJ]6-0_X_[G_KJW\S5>OY6ENS^+)?$PHHHJ20HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_4'X%_\D:\%?\ 8)MO_18K\OJ_4'X%_P#)
M&O!7_8)MO_18K])X(_WJM_A_4_6O#K_?:_\ A_4[JBBBOV(_>PHHHH ****
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M,!Z$\ GG %?HC_P22^"^H?#']G&77-7M'L[[Q3>&_2*9=KB!5"1GZ,!N_&O
M/V1?^"0NJ0ZY:>)OC:UO;VELRS0>%[&X69YF'(%S(N5"_P"PA.>Y'2OU:M;6
M&QM8;:WB6&"%!''&@PJJ!@ #T H EHHHH **** "BBB@ HHHH **** .;\??
M#?PK\4M!ET3Q?X?T[Q'I4G6UU&W650?[RY&5;_:&#[UL:/H]EX?TFTTS3;6.
MRT^TB6&"WA&$C11@*!["KE% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7Y[_P#!:O2;FZ_9P\(WT43R06GBB(3,JDA ]K< ,Q[#( SZL!W%?H17
MD/[6GP0'[1/[/?C'P+'Y2ZC?VGF:=),Y1$O(F$D!9@"0I=55C@_*QXH _!G]
MCGXF:7\'OVGOAWXNUQC'I%AJ86[FXQ%'*C0M(<]D$FX^RFOZ/K.\@U"T@NK6
M:.YMIT66*:%PZ2(PRK*PX(((((K^6_Q+X;U3P=X@U'0]:L9M-U?3YWMKJTN%
MVO%(IPRD?6O=O@'^WW\:/V==/CTGPYXF&I>'HAB/1==B^UVT7  $>2'C48^Z
MCJO).,F@#^B"BOQ47_@M5\<%4 ^%_ #$#&XZ=>Y/OQ>5YO\ %K_@J-\??BSI
M,NEGQ!9>$=.GC:*XA\,VGV9YE8 <S.SRKQG[CKU.<\8 -?\ X*S?%'1?B9^U
MI<1Z'>QZA!X;TB#0KB>%@T?VB.6:65 1UV-.4/HRL.U=[_P10TJZF_:2\8ZD
MD6ZQM_"<UO++N'RR27EJR+C.>1%(>!CY>>HK\]J_:7_@CK\!KWX>?!36O'VK
MVCVE]XSN(S9)*&5OL$ 81OM(&-[O*P(R&4(P."* /T#HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^4/^"DO[1GC+]F+X&:'XI\#SV<&K7?B.#3)6O;8
M3IY+VUU(P"D\'="G/U]:^KZ^4/\ @I+^SGXR_:>^!FA^%O \%G/JUIXC@U.5
M;VY$">2EM=1L0Q')W3)Q]?2@#\VO^'O'[0W_ $$O#_\ X)T_QH_X>\?M#?\
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M_P#X,;[_ .0Z/^'*GQO_ .AI^'__ (,;[_Y#K]J:* /Q6_X<J?&__H:?A_\
M^#&^_P#D.C_ARI\;_P#H:?A__P"#&^_^0Z_:FB@#^5=AM)%?M/\ \$4_^37?
M%?\ V.5U_P"D-C7XLR?ZQOK7[3?\$4_^37?%?_8Y77_I#8T ?H#1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA?P/^UUH\4^I,^@>,K*$Q6'B*SC#.%SD13IQYL><D#(*DG:PR00#\S_V%/\
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M $.FM?\ @8_^-?2&N?L(?VSK-]?_ /"<>3]JG>;R_P"R=VW<Q.,^>,]:H_\
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MKZI_Z22U_//7]>>"'^X8W_''_P!)9X&9?%$****_I<\8**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#^E'2_^09:?]<4_P#015JJNE_\@RT_ZXI_
MZ"*M5_E?/XF?;K8****@84444 %%%% !7PQ_P5!_Y!_PZ_ZZW_\ *WK[GKX8
M_P""H/\ R#_AU_UUO_Y6]>'G?_(OJ?+\T?J7AA_R5V"_[?\ _3<SX(HHHK\H
M/] 0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /N7_@E_P#\A/XB
M?]<;#_T*>OOFO@;_ ()?_P#(3^(G_7&P_P#0IZ^^:_5<C_W"G\_S9_ GBG_R
M5V+_ .X?_IN 4445[Q^3A1110 4444 %%%% 'Y&:A_Q_W/\ UU;^9JO5C4/^
M/^Y_ZZM_,U7K^5I;L_BR7Q,****DD**** "BBB@ HHHH **** "BBB@ HHHH
M **** "OU!^!?_)&O!7_ &";;_T6*_+ZOU!^!?\ R1KP5_V";;_T6*_2>"/]
MZK?X?U/UKPZ_WVO_ (?U.ZHHHK]B/WL**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MS/$WB73/!OAW4]>UJ\BT_2-,MI+N[NIFPD42*6=B?0 &M.OB/_@KY\0[KP7^
MR1)I5GN5_$^LVNE3.DA0I"JR7#GCJ";=4(XR'/T(!\$_M.?\%3?BE\9-<O;/
MP1J=Y\._!N7B@M]/D"7]Q'GB2:=?F1B!]V-@!DC+=:^6[CXU?$*[F::?QYXF
MFE8Y:236+AF/U)>LSP#X%UOXG>--%\*>'+&34M<U>Z2TM+:,?>=CC)/\*@99
MF/"J"3@ U^CWAK_@AWKEYI5M+K_Q:L-*U%HP9[;3]#>\BC?NJR-/$6'7G:/I
M0!^>'_"X?'O_ $._B/\ \&UQ_P#%T?\ "X?'O_0[^(__  ;7'_Q=4/B%X4_X
M0/Q]XE\-?:OMW]C:G<Z=]J\OR_.\F5H]^W)VYVYQDXSU-?IF?^"&)VDK\:P6
MQP#X4P/_ $MH _-O_A</CW_H=_$?_@VN/_BZ_3O_ ((K_$+Q-XND^+5AKFOZ
MCK-K:C3)X$U"Y>?RG?[4KE2Q)&0B9_W17YO?&SX*^(_V:?BY?>#O&&FQ7%YI
MLR3*)!(+74;<G*2(RE6,;@$$JP((9<AE./VW_P""=^B_!2?X+MXN^#?AY/#R
MZY(D>N6DEY+=7%O=PK@P2/*[, OF%E&0"LH;'S4 ?5-%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?RL2?ZQOK7[3?\$4_^37?%?_8Y77_I#8U^+,G^L;ZU
M^TW_  13_P"37?%?_8Y77_I#8T ?H#1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7FWP)UN_UWPK>SZC>37LRWK(LD[EB%V(<9/;)/YUZ30(**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KYT_;&_:+\2?L]Z5X8N?#MEI5[)JDT\<P
MU2*60*$5"-NR1,?>.<Y[5]%U\S?MM? 7Q9\==(\*6_A6&UEDTZ>XDG^U7 B
M#K&%QGK]TUYV8NLL+-X>_/I:V^Z/M.#8Y;//L-'-^7ZO>7-S:1^&5K_.WS/F
MW_AY9\3O^@%X2_\  .Z_^2:/^'EGQ._Z 7A+_P  [K_Y)K!_X=[_ !>_Y\])
M_P#!BO\ A1_P[W^+W_/GI/\ X,5_PKX7GSK^_P#<?U5]5\,N^'_\"7^9O?\
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M45]"?CX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MX?\ M*?>T#Z3?^R5[A7A_P"TI][0/I-_[)294=S:_9S_ .1.U#_K_;_T7'7J
MU>4_LY_\B=J'_7^W_HN.O5J8GN%%%% @HHHH **** "BBB@ HHHH **** //
M/VBO^3??B=_V*^J?^DDM?SSU_0Q^T5_R;[\3O^Q7U3_TDEK^>>OZ\\$/]PQO
M^./_ *2SP,R^*(4445_2YXP4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ']*.E_\@RT_ZXI_Z"*M55TO_D&6G_7%/_015JO\KY_$S[=;!1114#"B
MBB@ HHHH *^&/^"H/_(/^'7_ %UO_P"5O7W/7PQ_P5!_Y!_PZ_ZZW_\ *WKP
M\[_Y%]3Y?FC]2\,/^2NP7_;_ /Z;F?!%%%%?E!_H"%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!]R_\$O\ _D)_$3_KC8?^A3U]\U\#?\$O_P#D
M)_$3_KC8?^A3U]\U^JY'_N%/Y_FS^!/%/_DKL7_W#_\ 3< HHHKWC\G"BBB@
M HHHH **** /R,U#_C_N?^NK?S-5ZL:A_P ?]S_UU;^9JO7\K2W9_%DOB844
M45)(4444 %%%% !1110 4444 %%%% !1110 4444 %?J#\"_^2->"O\ L$VW
M_HL5^7U?J#\"_P#DC7@K_L$VW_HL5^D\$?[U6_P_J?K7AU_OM?\ P_J=U111
M7[$?O84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN^*_^QRNO_2&QH _0&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:*_Y-]^)W_8KZI_Z22U_//7]>>"'^X8W_''_ -)9X&9?%$****_I<\8****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^E'2_^09:?]<4_]!%6JJZ7
M_P @RT_ZXI_Z"*M5_E?/XF?;K8****@84444 %%%% !7PQ_P5!_Y!_PZ_P"N
MM_\ RMZ^YZ^&/^"H/_(/^'7_ %UO_P"5O7AYW_R+ZGR_-'ZEX8?\E=@O^W__
M $W,^"****_*#_0$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[
ME_X)?_\ (3^(G_7&P_\ 0IZ^^:^!O^"7_P#R$_B)_P!<;#_T*>OOFOU7(_\
M<*?S_-G\">*?_)78O_N'_P"FX!1117O'Y.%%%% !1110 4444 ?D9J'_ !_W
M/_75OYFJ]6-0_P"/^Y_ZZM_,U7K^5I;L_BR7Q,****DD**** "BBB@ HHHH
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MX_\ !3I__P CT?\ #S7]IC_HI]Q_X*=/_P#D>K7_  ZX_:=_Z)G_ .5_2_\
MY)H_X=<?M._]$S_\K^E__)- %7_AYK^TQ_T4^X_\%.G_ /R/7Z%_\$I?VKOB
M)^T=8_$;3OB'K/\ PD-WHDEE<6E\UM# ZI.)E:,K$B@@&$$$C/S-[5^?W_#K
MC]IW_HF?_E?TO_Y)K]"_^"5_[(OQ!_9GTOQ_J7Q#TZ+1-1U^2SAMM-2[AN72
M.#SBTC/$[I\QF  !R-ISUH ^\Z*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M _E8D_UC?6OVF_X(I_\ )KOBO_L<KK_TAL:_%F3_ %C?6OVF_P""*?\ R:[X
MK_['*Z_](;&@#] :*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME_\ (,M/^N*?^@BK5?Y7S^)GVZV"BBBH&%%%% !1110 5\,?\%0?^0?\.O\
MKK?_ ,K>ON>OAC_@J#_R#_AU_P!=;_\ E;UX>=_\B^I\OS1^I>&'_)78+_M_
M_P!-S/@BBBBOR@_T!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW5HK \ ^.M$^)W@O1O%?AN^74M"U>U2[L[I 5WQL,C*GE6'0J0"""" 16_0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?RL2?ZQOK7[3?\ !%/_
M )-=\5_]CE=?^D-C7XLR?ZQOK7[3?\$4_P#DUWQ7_P!CE=?^D-C0!^@-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>'_M*?>T#Z3?^R5[A7A_[2GWM ^DW_LE)E1W-K]G/_D3M0_Z
M_P!O_1<=>K5Y3^SG_P B=J'_ %_M_P"BXZ]6IB>X4444""BBB@ HHHH ****
M "BBB@ HHHH \\_:*_Y-]^)W_8KZI_Z22U_//7]#'[17_)OOQ._[%?5/_226
MOYYZ_KSP0_W#&_XX_P#I+/ S+XHA1117]+GC!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?THZ7_P @RT_ZXI_Z"*M55TO_ )!EI_UQ3_T$5:K_
M "OG\3/MUL%%%%0,**** "BBB@ KX8_X*@_\@_X=?]=;_P#E;U]SU\,?\%0?
M^0?\.O\ KK?_ ,K>O#SO_D7U/E^:/U+PP_Y*[!?]O_\ IN9\$4445^4'^@(4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'W+_P $O_\ D)_$3_KC
M8?\ H4]??-? W_!+_P#Y"?Q$_P"N-A_Z%/7WS7ZKD?\ N%/Y_FS^!/%/_DKL
M7_W#_P#3< HHHKWC\G"BBB@ HHHH **** /R,U#_ (_[G_KJW\S5>K&H?\?]
MS_UU;^9JO7\K2W9_%DOB84445)(4444 %%%% !1110 4444 %%%% !1110 4
M444 %?J#\"_^2->"O^P3;?\ HL5^7U?J#\"_^2->"O\ L$VW_HL5^D\$?[U6
M_P /ZGZUX=?[[7_P_J=U1117[$?O84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G/[1GQ.
M;X,_ GQUXUB$9NM%TF>YMEE.%:?:5A4_60H/QKT:OD3_ (*M74EO^Q#XVC0X
M6>ZTZ-_<?;86_FHH _!F^O[G5+ZXO;VXEN[RXD:::XG<O)*[$EF9CR6))))Y
M)-?5G[-?_!-#XL_M'>';/Q- MAX1\*W?S6^H:VTBR7,?_/2&%5+,I[,Q4'J"
M:^>/A%X4M_'GQ8\%>&KO=]EUG6[+3I=IP=DTZ1M@]CAC7].>FZ=;:/I]K864
M"6UG:Q+!!!&,+'&H"JH'8  #\* /QK\;?\$6/BOHNGBY\-^+/#/B6959I+25
MIK.5B,;1&65D8GG[S(!@<G/'P=XS\%Z[\._%&I>&_$NE76B:[ITODW5C>1E)
M(FP",CN"""".""""00:_J.K\L/\ @MO\+=/CL?AY\1+:&*#4GGFT2]D6,;[A
M"GFP$MG^#9,.A_UG48Y (_\ @BK\=KNXD\8?"/4;II;:&+^WM(C?<WE#<L=T
M@). I+0N% '+2GG)K]4Z_ C_ ()9>(+S1/VW? <%M*8X-2BO[.Z0 'S(_L4T
M@7D<8DCC;C!^7'0FOWWH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /Y6)/]8WUK]IO^"*?_ ":[XK_['*Z_](;&OQ9D_P!8WUK]IO\ @BG_ ,FN
M^*_^QRNO_2&QH _0&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&4@-L\K2 3VSF\Q_7]: /U=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^
M5B3_ %C?6OVF_P""*?\ R:[XK_['*Z_](;&OQ9D_UC?6OVF_X(I_\FN^*_\
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M@RT_ZXI_Z"*M5_E?/XF?;K8****@84444 %%%% !7PQ_P5!_Y!_PZ_ZZW_\
M*WK[GKX8_P""H/\ R#_AU_UUO_Y6]>'G?_(OJ?+\T?J7AA_R5V"_[?\ _3<S
MX(HHHK\H/] 0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /N7_@E
M_P#\A/XB?]<;#_T*>OOFO@;_ ()?_P#(3^(G_7&P_P#0IZ^^:_5<C_W"G\_S
M9_ GBG_R5V+_ .X?_IN 4445[Q^3A1110 4444 %%%% 'Y&:A_Q_W/\ UU;^
M9JO5C4/^/^Y_ZZM_,U7K^5I;L_BR7Q,****DD**** "BBB@ HHHH **** "B
MBB@ HHHH **** "OU!^!?_)&O!7_ &";;_T6*_+ZOU!^!?\ R1KP5_V";;_T
M6*_2>"/]ZK?X?U/UKPZ_WVO_ (?U.ZHHHK]B/WL**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K+\3^%](\:^'[_ $+7M-MM7T>_B,%U8WD0DBF0]593U_\ K5J44 ?)C?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O#_P!I3[V@?2;_ -DKW"LK7/"VD^)/
M)_M.PBO?)SY?FC.W.,X_(4#6AY]^SG_R)VH?]?[?^BXZ]6K/T7P_IWAVV>WT
MVTCLX7?S&2,<%L 9_(#\JT* "BBB@04444 %%%% !1110 4444 %%%% 'GG[
M17_)OOQ._P"Q7U3_ -)):_GGK^AC]HK_ )-]^)W_ &*^J?\ I)+7\\]?UYX(
M?[AC?\<?_26>!F7Q1"BBBOZ7/&"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _I1TO\ Y!EI_P!<4_\ 015JJNE_\@RT_P"N*?\ H(JU7^5\_B9]
MNM@HHHJ!A1110 4444 %?#'_  5!_P"0?\.O^NM__*WK[GKX8_X*@_\ (/\
MAU_UUO\ ^5O7AYW_ ,B^I\OS1^I>&'_)78+_ +?_ /3<SX(HHHK\H/\ 0$**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[E_X)?_ /(3^(G_ %QL
M/_0IZ^^:^!O^"7__ "$_B)_UQL/_ $*>OOFOU7(_]PI_/\V?P)XI_P#)78O_
M +A_^FX!1117O'Y.%%%% !1110 4444 ?D9J'_'_ '/_ %U;^9JO5C4/^/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBLW5_$FEZ!Y7]I7]O8^;G
M9Y\@7=C&<9^HH TJ*HZ3K=AKUNT^G7D-["K;&DA<, V <<=\$?G5Z@ HHHH
M**** "BBB@ HHHH **** "BBB@#SS]HK_DWWXG?]BOJG_I)+7\\]?T,?M%?\
MF^_$[_L5]4_])):_GGK^O/!#_<,;_CC_ .DL\#,OBB%%%%?TN>,%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!_2CI?_ "#+3_KBG_H(JU572_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]>'G?_(OJ?+\T?J7AA_R5V"_[?\ _3<SX(HHHK\H/] 0HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?RL2?ZQOK7[3?\ !%/_ )-=\5_]CE=?^D-C7XLR?ZQOK7[3?\$4_P#D
MUWQ7_P!CE=?^D-C0!^@-%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_'_ '/_ %U;^9JO7\K2W9_%DOB84445)(4444 %%%% !1110 4444 %%%%
M!1110 4444 %?J#\"_\ DC7@K_L$VW_HL5^7U?J#\"_^2->"O^P3;?\ HL5^
MD\$?[U6_P_J?K7AU_OM?_#^IW5%%%?L1^]A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU^TW_!%/_DUWQ7_V.5U_Z0V-?BS)_K&^M?M-_P $4_\ DUWQ7_V.5U_Z0V-
M'Z T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6O#K_?:_^']3NJ***_8C]["BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#^\CA7!]5% '\]W[+/[3_BK]E?XG6?B;P_<R2Z;*Z1:OH[-^YU"VW?,C#H'
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M/_!5CX0V7Q*_9,US6C;HVL^$9H]6LI]HWB,NL=PF[J%,;EB.YB3T% 'Y]_\
M!,W]M+4_@7\3M-\!>(]39_ASXBN1;F.X;*:9=N<1SH3]U&;"N.!AMW5>?W*K
M^5=6*L"#@CD$5_2C^RC\3)_C#^SC\//%]V_F7^I:1";N0'.ZX0>7,WXR(YH
M]7HHHH **** "BBB@#^5B3_6-]:_:;_@BG_R:[XK_P"QRNO_ $AL:_%F3_6-
M]:_:;_@BG_R:[XK_ .QRNO\ TAL: /T!HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQG]H;5K[3&T
M/['>7%IO$V[R)63=C9C.#S7LU>'_ +2GWM ^DW_LE(J.YT7P U"[U+PG?27=
MS-=2+?,H>:0N0/+3C)/3FO3J\I_9S_Y$[4/^O]O_ $7'7JU,3W"BBB@04444
M %%%% !1110 4444 %%%% 'GG[17_)OOQ._[%?5/_226OYYZ_H8_:*_Y-]^)
MW_8KZI_Z22U_//7]>>"'^X8W_''_ -)9X&9?%$****_I<\8**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#^E'2_^09:?]<4_]!%6JJZ7_P @RT_Z
MXI_Z"*M5_E?/XF?;K8****@84444 %%%% !7PQ_P5!_Y!_PZ_P"NM_\ RMZ^
MYZ^&/^"H/_(/^'7_ %UO_P"5O7AYW_R+ZGR_-'ZEX8?\E=@O^W__ $W,^"**
M**_*#_0$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[E_X)?_\
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MH **** "BBB@"O?Z?:ZI:26M[;0WEM(-KPW$8=&'H5/!KYD^*W_!-/\ 9_\
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MO<*\U^,7P]U3QTVE_P!FM;K]F\S?Y[E?O;<8P#Z&D-;E/]G/_D3M0_Z_V_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M77-#\:7CV'@SQ/'&'OMC2)97<1;RY&502$9796('!V$\ D???[6G_!2#X5>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#SS]HK_DWWXG?]BOJG_I)+7\\]?T,?M%?\F^_$[_L5]4_])):_GGK^O/!#
M_<,;_CC_ .DL\#,OBB%%%%?TN>,%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!_2CI?_ "#+3_KBG_H(JU572_\ D&6G_7%/_015JO\ *^?Q,^W6
MP4445 PHHHH **** "OAC_@J#_R#_AU_UUO_ .5O7W/7PQ_P5!_Y!_PZ_P"N
MM_\ RMZ\/._^1?4^7YH_4O##_DKL%_V__P"FYGP11117Y0?Z A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?<O_  2__P"0G\1/^N-A_P"A3U]\
MU\#?\$O_ /D)_$3_ *XV'_H4]??-?JN1_P"X4_G^;/X$\4_^2NQ?_</_ --P
M"BBBO>/R<**** "BBB@ HHHH _(S4/\ C_N?^NK?S-5ZL:A_Q_W/_75OYFJ]
M?RM+=G\62^)A1114DA1110 4444 %%%% !1110 4444 %%%% !1110 5^H/P
M+_Y(UX*_[!-M_P"BQ7Y?5^H/P+_Y(UX*_P"P3;?^BQ7Z3P1_O5;_  _J?K7A
MU_OM?_#^IW5%%%?L1^]A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D%_P5K^!WQ'^
M)'[3&CZIX2^'_BGQ3ID?AFUMWO=%T6YO(5D%Q<DH7C1@& 93C.<,/6OU]HH
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MK$;67/\ $"1[T?#_ .#OCKXJZE%8>#_".L^([F3H-.LI)5 SC<S@;57/\3$
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M2&MSM_A'XRO_ !OX?NKW45A6:.Z:%?)0J-H13W)YRQKN:\I_9S_Y$[4/^O\
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M17[$?O84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3?\ !%/_ )-=\5_]CE=?^D-C0!^@-%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>'_ +2GWM ^DW_L
ME>X5XS^T-I-]J;:']CL[B[V";=Y$3/MSLQG XI%1W-#]G/\ Y$[4/^O]O_1<
M=>K5YC\ -/N]-\)WT=W;36LC7S,$FC*$CRTYP1TXKTZF)[A1110(**** "BB
MB@ HHHH **** "BBB@#SS]HK_DWWXG?]BOJG_I)+7\\]?T,?M%?\F^_$[_L5
M]4_])):_GGK^O/!#_<,;_CC_ .DL\#,OBB%%%%?TN>,%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!_2CI?_ "#+3_KBG_H(JU572_\ D&6G_7%/
M_015JO\ *^?Q,^W6P4445 PHHHH **** "OAC_@J#_R#_AU_UUO_ .5O7W/7
MPQ_P5!_Y!_PZ_P"NM_\ RMZ\/._^1?4^7YH_4O##_DKL%_V__P"FYGP11117
MY0?Z A1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?<O_  2__P"0
MG\1/^N-A_P"A3U]\U\#?\$O_ /D)_$3_ *XV'_H4]??-?JN1_P"X4_G^;/X$
M\4_^2NQ?_</_ --P"BBBO>/R<**** "BBB@ HHHH _(S4/\ C_N?^NK?S-5Z
ML:A_Q_W/_75OYFJ]?RM+=G\62^)A1114DA1110 4444 %%%% !1110 4444
M%%%% !1110 5^H/P+_Y(UX*_[!-M_P"BQ7Y?5^H/P+_Y(UX*_P"P3;?^BQ7Z
M3P1_O5;_  _J?K7AU_OM?_#^IW5%%%?L1^]A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7SG_ ,% OCI=_L^_LN>*O$&E7:6?B&^\O2-*E9PK+<3D@NF>KI$)9 /^
MF?H#7T97YW?\%LKAU_9[\$0 _NW\4(Y'NMI< ?\ H1H _&BO0/#O[/7Q4\8:
M;;ZCH/PT\8:WI]PGF0W>G:#=7$4B'^)72,@CGJ#7K/\ P3C^$FF?&3]KCP;I
M6N6MO?Z+I_G:O=VEP3MF\B,M$N ,,/.,1*MP5# YZ'^@U56-555"JHP% P /
M2@#^6'4-/NM(U"YL;ZVFLKVUE:">VN(S')%(I*LCJ1E6!!!!Y!%>F-^RC\;E
M4LWP<\?A0,DGPO?8_P#1597[0G_)?/B5_P!C-J7_ *525_3-#(LT*2(=R,H8
M'U!H _EDM[ MJD=E=S)IA,PAFFND?;;_ #89G559\+R2%4MP< GBOV\_X)C_
M +'/B7]F'1_&.M^(M?T+6T\5QV+6!T">2>'R(EE82&1T3.[SQ@ =%SGG ^6?
M^"Q7[-&C?#_QAH/Q4\/6RV,?BB>2TUBWC.$-XJ!DF5<8!= ^[! )C#8RS$^R
M_P#!&+X\:KXP^'_BOX::Q<R7:>&'AO=)DE?<R6LQ</ !C[J2)N!)/^N(X"@4
M ?I'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '\K$G^L;ZU^TW_!%/_DUW
MQ7_V.5U_Z0V-?BS)_K&^M?M-_P $4_\ DUWQ7_V.5U_Z0V- 'Z T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '*_%;PK=^.O
MA;XQ\-V$D,-]K&C7FG6\ERQ6)9)H'C4N0"0H+#. 3CL:_+#_ (="_&+_ *&7
MP/\ ^!]Y_P#(E?KS17W?#G&F;<+4JE++912FTW>-]5H<M;#TZ[3GT/R&_P"'
M0OQB_P"AE\#_ /@?>?\ R)1_PZ%^,7_0R^!__ ^\_P#D2OUYHKZ__B+W%'\\
M/_ $8?V?0\S\AO\ AT+\8O\ H9? _P#X'WG_ ,B4?\.A?C%_T,O@?_P/O/\
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M $,O@?\ \#[S_P"1*/\ AT+\8O\ H9? _P#X'WG_ ,B5^O-%'_$7N*/YX?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *9+,D$;22NL<:C+,QP /4FGU\B?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?RL2?ZQOK7[3?\$4_P#DUWQ7_P!CE=?^D-C7XLR?ZQOK
M7[3?\$4_^37?%?\ V.5U_P"D-C0!^@-%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>'_M*?>T#Z3?^
MR5[A7A_[2GWM ^DW_LE)E1W-K]G/_D3M0_Z_V_\ 1<=>K5Y3^SG_ ,B=J'_7
M^W_HN.O5J8GN%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@ HHHH ^Y?^"7_ /R$_B)_UQL/_0IZ^^:^!O\
M@E__ ,A/XB?]<;#_ -"GK[YK]5R/_<*?S_-G\">*?_)78O\ [A_^FX!1117O
M'Y.%%%% !1110 4444 ?D9J'_'_<_P#75OYFJ]6-0_X_[G_KJW\S5>OY6ENS
M^+)?$PHHHJ20HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_4'X%_\D:\
M%?\ 8)MO_18K\OJ_4'X%_P#)&O!7_8)MO_18K])X(_WJM_A_4_6O#K_?:_\
MA_4[JBBBOV(_>PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZEH6FZUY?]H:?:W_EY
MV?:8%DVYZXW XZ"KU% %33=)L='A:&PLK>QB9M[1VT2QJ6P!D@ <X _*K=%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\_\
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M 4444 %%%% !1110 4444 ?<O_!+_P#Y"?Q$_P"N-A_Z%/7WS7P-_P $O_\
MD)_$3_KC8?\ H4]??-?JN1_[A3^?YL_@3Q3_ .2NQ?\ W#_]-P"BBBO>/R<*
M*** "BBB@ HHHH _(S4/^/\ N?\ KJW\S5>K&H?\?]S_ -=6_F:KU_*TMV?Q
M9+XF%%%%22%%%% !1110 4444 %%%% !1110 4444 %%%% !7Z@_ O\ Y(UX
M*_[!-M_Z+%?E]7Z@_ O_ )(UX*_[!-M_Z+%?I/!'^]5O\/ZGZUX=?[[7_P /
MZG=4445^Q'[V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 445\W_$?_ (*(? 3X3^-M6\)>
M)?&SV>O:5+Y%Y;PZ5>3K%)M!*[XXF4D9&<$X.1U!H ^D*\#_ &YO@;XA_:+_
M &;?$?@CPM+9Q:Y=S6L]O]OE,<3>5.DC*6"G!*J<<8SC..HX?_AZE^S/_P!#
M_<?^"+4/_C%'_#U+]F?_ *'^X_\ !%J'_P 8H ^"_@C_ ,$J?CQX>^,/A76-
M:L-#TO2=%URSO)KJ354D\Z&*6.5VC6,,Q. 5 8*<CL.:_:BODO\ X>I?LS_]
M#_<?^"+4/_C%'_#U+]F?_H?[C_P1:A_\8H ^M**^2_\ AZE^S/\ ]#_<?^"+
M4/\ XQ1_P]2_9G_Z'^X_\$6H?_&* /K2BODO_AZE^S/_ -#_ ''_ ((M0_\
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M_P#MT?\ )NNM?]?-M_Z,%?0%?/\ ^W1_R;KK7_7S;?\ HP5])PW_ ,CK!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7\TO[46_\ X:8^+?F[O,_X
M2[5]V[KG[;+G/O7]+5?/OQ,_8%^ GQ@\97_BOQ7\/H-0U^_(:ZNX=2O+3SF
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M^]H'TF_]DKW"O#_VE/O:!])O_9*3*CN;7[.?_(G:A_U_M_Z+CKU:O*?V<_\
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M=NWYH_0O#_'X7*^)<)B\944*<>>[>RO"27XM(_+&BOK/_AVG\3O^@[X2_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6*_2>"/]ZK?X?U/UKPZ_WVO_ (?U.ZHHHK]B/WL**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/C)\0_$V]@NFZ!'IQ4#Y2;FX60$^X^R''U- '[$4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!_*Q)_K&^M?M-_P13_ .37?%?_ &.5U_Z0V-?BS)_K&^M?
MM-_P13_Y-=\5_P#8Y77_ *0V- 'Z T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445XE^TA/)"V@^7
M(R9$V=K$?W*!K4]MHKRS]G>9YO!]^9'9S]O898Y_Y9QUZG0 4444""BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG_P#;H_Y-UUK_ *^;
M;_T8*^@*^?\ ]NC_ )-UUK_KYMO_ $8*^DX;_P"1U@_^OD?S1C6_AR]#\O*_
M:WPG_P BOI'_ %Z1?^@"OQ2K]K?"?_(KZ1_UZ1?^@"OV'Q5_A8/UG_[:<&!W
MD:U%%%?ST>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?DU^W'_R<UXM^EM_Z3QUZ1_P32_Y*IXD_[!0_]&+7F_[<
M?_)S7BWZ6W_I/'7I'_!-+_DJGB3_ +!0_P#1BU^98?\ Y'/_ &^_U/[DS?\
MY-JO^P>E^4#]':***_33^&PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /R,U#_C_N?^NK?S-5ZL:A_Q_P!S_P!=6_F:KU_*TMV?Q9+XF%%%%22%
M%%% !1110 4444 %%%% !1110 4444 %%%% !7Z@_ O_ )(UX*_[!-M_Z+%?
ME]7Z@_ O_DC7@K_L$VW_ *+%?I/!'^]5O\/ZGZUX=?[[7_P_J=U1117[$?O8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?RL2?ZQOK7[3?\$4_P#DUWQ7_P!CE=?^D-C7XLR?ZQOK
M7[3?\$4_^37?%?\ V.5U_P"D-C0!^@-%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>'_M*?>T#Z3?^
MR5[A7A_[2GWM ^DW_LE)E1W-K]G/_D3M0_Z_V_\ 1<=>K5Y3^SG_ ,B=J'_7
M^W_HN.O5J8GN%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#*C:?_ !VOT<HH_P!2<N_GG]\?_D0_XAYE7_/RI]\?_D#\X_\ ADGXK_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4D9!(&00:_:C_@C[\0KCQC^R:=&NMQ?PQK5SIL+-(7+0N$N%Z],-.Z@>BCZ
M ^XJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E8D_UC?6OVF_X(I_\FN^
M*_\ L<KK_P!(;&OQ9D_UC?6OVF_X(I_\FN^*_P#L<KK_ -(;&@#] :*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***\N^-7CK6/!C:3_95PL'VCS/,W1J^<;<=1[F@9ZC17 _!KQ9J
M7C#PW=W>J3+//'=M$K*@3Y0B'& /4FN^H$%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5R_Q(^(^C?"GPI<>(M>>:/38'1':",R-EC@<?6NHKY_
M_;H_Y-UUG_KYMO\ T8*]C)\+3QV8X?"U?AG**=M[-V,ZDG&#DBE_PWU\)O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\A?\%79GC_8C\9*IP)+O3E;W'VR(_S KZ]KX_\ ^"L'_)DOB[_K]T[_ -*X
MZ /Q(^#.C6GB+XP>!=)OXEGL;_7K&UN(F (>-[A%92#Q@@D5_3O7\PGPA\06
M7A+XL>"M<U.1H=.TS6[*]N9%0L5BCG1W( Y.%4\"OV[_ .'L'[-W_0W:A_X)
M+O\ ^-T ?8%%?'__  ]@_9N_Z&[4/_!)=_\ QNC_ (>P?LW?]#=J'_@DN_\
MXW0!]@45\?\ _#V#]F[_ *&[4/\ P27?_P ;H_X>P?LW?]#=J'_@DN__ (W0
M!^6W_!333TTW]N+XGPQJJJTUC-A?62PMG)_-C7V5_P $.O$,MSX5^+>A&,"&
MRO=.O5DW'):9+A&&/86Z_G[5\(?MU_%CPW\<?VJ/&WC;PA>27_A[5/L/V6XE
M@>%F\NQMX7RC@,,/&PY';-?;/_!#'[WQL_[@G_M_0!^JM%%% !1110 4444
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M%2?XT?\ "6:Y_P!!G4/_  *D_P : /ZDZ*_EL_X2S7/^@SJ'_@5)_C7ZX_\
M!%'5+S5/AC\26O+N>[9=8MPK3R,Y \@],F@#](J**_,'_@I/_P %&];\ ^)K
M[X3_  JU$Z9JMF FN>([<@RPR$9^S6Y_A901OD'S*?E&TJ30!^COB?XB^%/!
M+(OB+Q/HV@LXRJZIJ$5L6!SR-[#/0_E2^&/B%X6\;>9_PCOB71]?\L;G_LN_
MBN=HSC)V,<<U_,#JFJ7NMZA/?:C=SW][.VZ6YNI6DDD;U9F))/UI=)UB_P!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH *^/_\ @K #_P ,2^+^/^7W3O\
MTKCK[ K&\9>#=$^(7A?4O#GB33+?6=#U&(PW=C=)NCE3(."/8@$$<@@$<B@#
M^7"BOWT;_@E;^S.6)_X0"<>PUW4/_C]'_#JW]F?_ *$"X_\ ![J'_P ?H _
MNBOWT_X=6_LS_P#0@7'_ (/=0_\ C]'_  ZM_9G_ .A N/\ P>ZA_P#'Z /P
M+HK]]/\ AU;^S/\ ]"!<?^#W4/\ X_1_PZM_9G_Z$"X_\'NH?_'Z /P+K]5_
M^"&=M,L'QHN&B<02-HT:2E3M9E%\64'H2 RY';</6OIW_AU;^S/_ -"!<?\
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MPW_!+K_D^OX9?74__39=U^_]?@!_P2Z_Y/K^&7UU/_TV7=?O_0 5^4?_  7
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MTW_!%/\ Y-=\5_\ 8Y77_I#8U^++'+$CIFOVF_X(I_\ )KOBO_L<KK_TAL:
M/T!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KR#X^^'-4U]M%_LW3[B^\H2[_ "(RVW.S&<?0UZ_1
M0-:'FWP)T2_T'PK>P:C9S64S7K.L<Z%25V(,X/;(/Y5Z3110(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \U_:1_Y(?XM_P"O5?\ T8E?F=7Z8_M(_P#)#_%O_7JO
M_HQ*_,ZOQGC;_?:7^']6?S_XB?\ (PH_X/\ VYGZD_!G_DDW@_\ [!5O_P"B
MQ795QOP9_P"23>#_ /L%6_\ Z+%=E7ZW@_\ =J?^%?D?N6 _W2C_ (8_D@HH
MHKK.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /%I/VT_@-%(R/\7/""
MNIP5.K19!';K3?\ AM;X"?\ 17O!_P#X-HO\:_G-UC_D+7O_ %W?_P!"-5*
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MX5U*#)]9+9XP/S<4 ?S<5^Y?_!'V21OV/8 X^5==O@G&./W9_F37X:5^]/\
MP2BT&;1?V*?"4\R[#J-Y?WBCOM^TR1@GZ^7GZ$4 ?7]?RL2?ZQOK7]4]>5?\
M,G_!#_HC?P__ /"7L?\ XU0!_-917]*?_#)WP0_Z(W\/_P#PE['_ .-4?\,G
M?!#_ *(W\/\ _P )>Q_^-4 ?S645_2G_ ,,G?!#_ *(W\/\ _P )>Q_^-4?\
M,G?!#_HC?P__ /"7L?\ XU0!_-97[3_\$4_^37?%?_8Y77_I#8U^++_?;ZU^
MTW_!%/\ Y-=\5_\ 8Y77_I#8T ?H#1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117%?$;XE1_#TV(
MDL&O?M6_&V4)MVX]CGK0!VM%<M\/?'*>/M(GOX[-K(13F#8TF_.%5LYP/[WZ
M5U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'FO[2/\ R0_Q;_UZK_Z,2OS.K],?
MVD?^2'^+?^O5?_1B5^9U?C/&W^^TO\/ZL_G_ ,1/^1A1_P '_MS/U)^#/_))
MO!__ &"K?_T6*[*N-^#/_))O!_\ V"K?_P!%BNRK];P?^[4_\*_(_<L!_NE'
M_#'\D%%%%=9W!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'X:_L5_!3X/^,K'Q7X/\!6>B>(+(2+;WT5U<.T8=&C? >0KRK,.1WKVZBB@
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M/[/7CK]H[QI!X;\#Z+-J5P67[5>,"MK8QDX\V>3&$4<\=6QA0QXK^@3]EO\
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M-]:_:;_@BG_R:[XK_P"QRNO_ $AL:_%F3_6-]:_:;_@BG_R:[XK_ .QRNO\
MTAL: /T!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G'_ ,%;OC_\
M0/@3XD^#-[X&\37WA]FDU*ZGBMGQ%=-']F5%F3I(@$C_ "MD?-GK@C]'*\,_
M:[_9,\-?M=?#=?#NM7,VE:K8R-<Z3K%NN]K2<KM.Y"1OC;C<F1G P00#0!XK
M^Q7_ ,%-?"?[17V'PGXS%OX/^(A1416?98:H_(_T=F)*.>/W3G/(VE^<?;M?
MS>?M+?LG?$#]EGQ4^E^+],+:;-*R:?KMJ"UG?*!D%&_A;'5&PPP>".3]7_L7
M_P#!5[6OADMEX0^+[WGB7PL@2"UU^,&6_L1D#]]DYGC .<C]X O&_(  /V4K
M\^?^"S'Q>N_!?P)\.>"K"Z:VF\7ZB_VI5#9EM+4([IN' !DEM\@]0".F:^[O
M"/C#0_'WAVQU[PYJUIK>C7T8EM[ZQF$L4B^S#OV(Z@@@U^<W_!;WP3>:E\/O
MAAXLBW-9:/J-[I\ZK&2 ;J.)T8M_"!]D8<CDL/Q /A_]D_\ 8$^(O[6MG=ZQ
MH<MAH'A:TN/LLNLZJS[9) H9DAC129"H*YSM4;A\V<BOJQ?^"'&K>0Q;XOV8
MF[(/#[E3_P "^T?TK%_X)L_\%#? /P%^&5Q\.?B.;K1K2"]FOK#6K6U>XB*R
M;2T4J1[G#!MQ#*I!'!P1\WW6O_!2#]FYM ;6!\4]/^R*<&,V5V+G[VWBW\GS
M3R?[G3GIS0!^47[5_P#P39^(7[+/A67Q=<:IIGBKPC#-'!/?V.^*:W9VVH98
M7Z*6*KE6;EAG%?7W_!%+XP:EKG@OQQ\.+^9IK+0IH=3TS>V?*CG+B:,#'"AT
M5_K*U<S_ ,%#_P#@H]\+_B_\"=6^&OP[GO/$L^NRV_VK5)+26TM[6*&>.?@2
MJKN[-$HQM  ).<@ Y?\ P0]T6ZD\8?%35O*<645C8VIDVG:9&DE; /J AX]Q
M0!^MM%%% !1110 4444 %%%% !1110 4444 %%%% !7G?Q!_9V^&/Q8UN/6/
M&7@/0?$VJQP+;)>:I8QS2K$K,P0,PSM!9CC_ &C7HE% 'E_@S]E[X1_#OQ)9
M^(?#'PX\-Z#KEGO^SZA8:='%-%O1D;:P&1E693[,:]0HHH **** /&?BC^QO
M\%/C->S7WB[X<Z+J.HSG=-?V\;6=U*?5YH&1V/N6-</I?_!,W]FG1[I;B#X7
MVTCJ00+K5;^X3@Y^[).RG\N:^GJ* ,3PCX)\/?#_ $>/2?#&A:;X>TN/[EGI
M=I';0CWVH ,^];=%% !2,H=2K ,I&"#T-+10!\_>//V _P!GWXDZG)J&M_"_
M2/MDAW22:8\VG;SZL+:2,$GN2,GO2^ _V!?V??AOJ$=]HGPNT<W<9W))JC3:
MCL/4%1<O( 1V(Y%?0%% "*H50 , < "EHHH **** "BBB@ HHHH _E8D_P!8
MWUK]IO\ @BG_ ,FN^*_^QRNO_2&QK\69/]8WUK]IO^"*?_)KOBO_ +'*Z_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S7]I'_ )(?XM_Z]5_]&)7Y
MG5^F/[2/_)#_ !;_ ->J_P#HQ*_,ZOQGC;_?:7^']6?S_P"(G_(PH_X/_;F?
MJ3\&?^23>#_^P5;_ /HL5V5<;\&?^23>#_\ L%6__HL5V5?K>#_W:G_A7Y'[
ME@/]TH_X8_D@HHHKK.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116'XE\;:
M+X/^S_VO>_9/M&[R_P!T[[L8S]U3CJ.M &Y163X<\4Z7XMLY+K2;K[7;QR>4
MS^6Z88 '&& /0BM:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S7]I'_ )(?XM_Z
M]5_]&)7YG5^F/[2/_)#_ !;_ ->J_P#HQ*_,ZOQGC;_?:7^']6?S_P"(G_(P
MH_X/_;F?J3\&?^23>#_^P5;_ /HL5V5<;\&?^23>#_\ L%6__HL5V5?K>#_W
M:G_A7Y'[E@/]TH_X8_D@HHHKK.X**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO@'^TI\1/V6_&;:OX-U62PE#&.]TB]5GL[K'!6:'(R1C[PPR]B.:_;[]CO\
M;H\$_M=:-);:>&T+QM8VRSZEX=N6W,JY"F6!^/-BW$ D %=RA@-RY /I.BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /Y6)/]8WUK]IO^"*?_)KOBO_ +'*
MZ_\ 2&QK\69/]8WUK]IO^"*?_)KOBO\ ['*Z_P#2&QH _0&BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O#_VE/O:!])O_ &2O<*\/_:4^]H'TF_\ 9*3*CN;7[.?_ ")VH?\ 7^W_
M *+CKU:O*?V<_P#D3M0_Z_V_]%QUZM3$]PHHHH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!YK^TC_ ,D/\6_]>J_^C$K\SJ_3']I'_DA_BW_KU7_T8E?F=7XSQM_OM+_#
M^K/Y_P#$3_D84?\ !_[<S]2?@S_R2;P?_P!@JW_]%BNRKC?@S_R2;P?_ -@J
MW_\ 18KLJ_6\'_NU/_"OR/W+ ?[I1_PQ_)!11176=P4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7?%?_8Y77_I#8T ?H#1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .(G_(PH_P"#_P!N9^I/P9_Y)-X/_P"P5;_^BQ795QOP9_Y)-X/_ .P5;_\
MHL5V5?K>#_W:G_A7Y'[E@/\ =*/^&/Y(****ZSN"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH _E8D_UC?6OVF_X(I_\FN^*_P#L<KK_ -(;
M&OQ9D_UC?6OVF_X(I_\ )KOBO_L<KK_TAL: /T!HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /-?VD?^2'^+?^O5?_1B5^9U?IC^
MTC_R0_Q;_P!>J_\ HQ*_,ZOQGC;_ 'VE_A_5G\_^(G_(PH_X/_;F?J3\&?\
MDDW@_P#[!5O_ .BQ795QOP9_Y)-X/_[!5O\ ^BQ795^MX/\ W:G_ (5^1^Y8
M#_=*/^&/Y(****ZSN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!YK^TC_P D/\6_]>J_^C$K\SJ_3']I
M'_DA_BW_ *]5_P#1B5^9U?C/&W^^TO\ #^K/Y_\ $3_D84?\'_MS/U)^#/\
MR2;P?_V"K?\ ]%BNRKC?@S_R2;P?_P!@JW_]%BNRK];P?^[4_P#"OR/W+ ?[
MI1_PQ_)!11176=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '\K$G^L;ZU^TW_!%/\ Y-=\5_\ 8Y77_I#8U^+,G^L;ZU^TW_!%/_DUWQ7_
M -CE=?\ I#8T ?H#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7A_[2GWM ^DW_LE>X5P'Q3^&US\0
M#IQM[R*T^R^9N\Q2=V[;TQ]*!K<R/V<_^1.U#_K_ &_]%QUZM7'_  Q\#S^
MM#N;&XN8[IY;@SAXU( !55QS_NUV% ,****!!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M:_M(_P#)#_%O_7JO_HQ*_,ZOTQ_:1_Y(?XM_Z]5_]&)7YG5^,\;?[[2_P_JS
M^?\ Q$_Y&%'_  ?^W,_4GX,_\DF\'_\ 8*M__18KLJXWX,_\DF\'_P#8*M__
M $6*[*OUO!_[M3_PK\C]RP'^Z4?\,?R04445UG<%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#S7]I'_DA_BW_KU7_T8E?F=7Z8_M(_\D/\
M6_\ 7JO_ *,2OS.K\9XV_P!]I?X?U9_/_B)_R,*/^#_VYGZD_!G_ ))-X/\
M^P5;_P#HL5V5<;\&?^23>#_^P5;_ /HL5V5?K>#_ -VI_P"%?D?N6 _W2C_A
MC^2"BBBNL[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y6
M)/\ 6-]:_:;_ ((I_P#)KOBO_L<KK_TAL:_%F3_6-]:_:;_@BG_R:[XK_P"Q
MRNO_ $AL: /T!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KROXW^-M:\'MI']D7OV3[1YOF?ND?=C
M;C[RG'4]*]4KP_\ :4^]H'TF_P#9*0UN=?\ !;Q3JGBWPW>76K77VNXCNVB5
M_+5,*$0XPH ZDUZ#7E/[.?\ R)VH?]?[?^BXZ]6I@]PHHHH$%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M5=2U2ST6QFO=0NX+&SA&Z2XN9%CC09QEF8@#GUKF?^%Q> ?^AX\-_P#@VM__
M (NL3]I/_DAOB[_KU7_T8E?F?7PV?\0U<GKPHTZ:E=7U]6C\WXFXJK9#B84*
M=)24HWU;[M?H?J7_ ,+B\ _]#QX;_P#!M;__ !='_"XO /\ T/'AO_P;6_\
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M\23^]!1116QT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\K$G^L;ZU^T
MW_!%/_DUWQ7_ -CE=?\ I#8U^+,G^L;ZU^TW_!%/_DUWQ7_V.5U_Z0V- 'Z
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5X?^TI][0/I-_P"R5[A7DGQX\*ZMXD;1O[,L9;WR?-\S
MRP/ESLQG\C2*6Y+^SG_R)VH?]?[?^BXZ]6KSGX&^']1\.^%[VWU*TDLYGO&D
M5)!R5V(,_F#^5>C4Q/<****!!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR^&G_0G:;_WRW^-'_#.7PT_Z$[3?^^6_QKTBBC^S\%_SYC_X"O\ (/[*R_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#^5B3_ %C?6OVF_P""*?\ R:[XK_['*Z_](;&OQ9D_UC?6OVF_
MX(I_\FN^*_\ L<KK_P!(;&@#] :*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X/XG?$J7X>G3Q'8)>
M_:M^=TI3;MV^Q]:[RO#_ -I3[V@?2;_V2@:W/0OAKXYD\?:+<7TEFMD8K@P;
M%DWYPJMG.!_>_2NNKRG]G/\ Y$[4/^O]O_1<=>K4 PHHHH$%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '\K$G^L;ZU^TW_!%/_DUWQ7_ -CE=?\ I#8U^+,G^L;ZU^TW
M_!%/_DUWQ7_V.5U_Z0V- 'Z T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[E'\@*^V: /Y=_B%X?7PGX^\2Z(F=FFZG<V:YZXCE9/_ &6OU2_X(@>+FNO
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M\)3\0/\ P8V/_P AU]_T4 ? '_#E3X(?]#3\0/\ P8V/_P AT?\ #E3X(?\
M0T_$#_P8V/\ \AU]_P!% 'P!_P .5/@A_P!#3\0/_!C8_P#R'1_PY4^"'_0T
M_$#_ ,&-C_\ (=??]% 'P!_PY4^"'_0T_$#_ ,&-C_\ (='_  Y4^"'_ $-/
MQ _\&-C_ /(=??\ 10!\ ?\ #E3X(?\ 0T_$#_P8V/\ \AT?\.5/@A_T-/Q
M_P#!C8__ "'7W_10!\ ?\.5/@A_T-/Q _P#!C8__ "'1_P .5/@A_P!#3\0/
M_!C8_P#R'7W_ $4 ? '_  Y4^"'_ $-/Q _\&-C_ /(='_#E3X(?]#3\0/\
MP8V/_P AU]_T4 ? '_#E3X(?]#3\0/\ P8V/_P AT?\ #E3X(?\ 0T_$#_P8
MV/\ \AU]_P!% 'P!_P .5/@A_P!#3\0/_!C8_P#R'1_PY4^"'_0T_$#_ ,&-
MC_\ (=??]% 'P!_PY4^"'_0T_$#_ ,&-C_\ (='_  Y4^"'_ $-/Q _\&-C_
M /(=??\ 10!\ ?\ #E3X(?\ 0T_$#_P8V/\ \AT?\.5/@A_T-/Q _P#!C8__
M "'7W_10!\ ?\.5/@A_T-/Q _P#!C8__ "'1_P .5/@A_P!#3\0/_!C8_P#R
M'7W_ $4 ? '_  Y4^"'_ $-/Q _\&-C_ /(='_#E3X(?]#3\0/\ P8V/_P A
MU]_T4 ? '_#E3X(?]#3\0/\ P8V/_P AT?\ #E3X(?\ 0T_$#_P8V/\ \AU]
M_P!% 'P!_P .5/@A_P!#3\0/_!C8_P#R'1_PY4^"'_0T_$#_ ,&-C_\ (=??
M]% 'P!_PY4^"'_0T_$#_ ,&-C_\ (='_  Y4^"'_ $-/Q _\&-C_ /(=??\
M10!\ ?\ #E3X(?\ 0T_$#_P8V/\ \AT?\.5/@A_T-/Q _P#!C8__ "'7W_10
M!\ ?\.5/@A_T-/Q _P#!C8__ "'1_P .5/@A_P!#3\0/_!C8_P#R'7W_ $4
M? '_  Y4^"'_ $-/Q _\&-C_ /(='_#E3X(?]#3\0/\ P8V/_P AU]_T4 ?
M'_#E3X(?]#3\0/\ P8V/_P AT?\ #E3X(?\ 0T_$#_P8V/\ \AU]_P!% 'P!
M_P .5/@A_P!#3\0/_!C8_P#R'1_PY4^"'_0T_$#_ ,&-C_\ (=??]% 'P!_P
MY4^"'_0T_$#_ ,&-C_\ (='_  Y4^"'_ $-/Q _\&-C_ /(=??\ 10!\ ?\
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M ^ /^'*GP0_Z&GX@?^#&Q_\ D.C_ (<J?!#_ *&GX@?^#&Q_^0Z^_P"B@#X
M_P"'*GP0_P"AI^('_@QL?_D.C_ARI\$/^AI^('_@QL?_ )#K[_HH ^ /^'*G
MP0_Z&GX@?^#&Q_\ D.C_ (<J?!#_ *&GX@?^#&Q_^0Z^_P"B@#X _P"'*GP0
M_P"AI^('_@QL?_D.C_ARI\$/^AI^('_@QL?_ )#K[_HH ^ /^'*GP0_Z&GX@
M?^#&Q_\ D.C_ (<J?!#_ *&GX@?^#&Q_^0Z^_P"B@#X _P"'*GP0_P"AI^('
M_@QL?_D.C_ARI\$/^AI^('_@QL?_ )#K[_HH ^ /^'*GP0_Z&GX@?^#&Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:2H!P<XH ^]Z_&G_ (*X?LFZAX)^)4OQ@\/V$L_A;Q$5_MAH5++87P 7>_\
M=28;2#TW[P<;E!_9:J6M:+I_B32;O2]6L;?4],O(FAN+.\B66&:-A@JZ,"&!
M'8T ?S/?!7XV>+_V??'UEXQ\$ZF=,UFV5HB60213Q-]^*5#PR' X[$ @@@$>
MV?M#?\%)/C%^TAX*;PEKD^CZ#H$^W[9:>'[62#[;M(($KR22,5R =JE5/<'
MK[Z^,/\ P1F^&?C;5+C4?!/B;5/ $MQ(7:Q:!=0LH\]HT9DD4>QD('8 5YQX
M=_X(<P1WR2:]\79)[-9/FM].T$1R.GM(]PP4]?X&H _-;X1_"?Q'\;OB'HW@
MSPK827^L:I.L2!5)2%,_/+(1]U$&69NP%?T@_!/X4:7\#?A/X8\":,S26&AV
M:VRS.H5IGY:24@="[L[GW8UR7[.?[)/PU_9;T66S\#Z*8[^Y4)=ZU?N)K^Z
M(.'DP,+D [$"KD9QGFO9* (;RTAU"TGM;F)9K>9&CDC<95U88((]"#7\[W[;
M'[*NK_LJ_&34M%:UN)/"5_*]SH&IN"4GMR0?++=Y(]P1AUX#8PPK^B>N.^*W
MPA\'_&[PC<>&/&^@VGB#1ICN\FY7YHGP0)(W&&C< G#*0>3SS0!_/U^S)^V9
M\2?V3KW46\%7EG/INI,KW>CZM 9[25U!"OA65T;!QE&7(QG.!B+]IC]L3XD?
MM7:I87'C:_M8M/T\LUGH^E0F"S@9OO.%+,S,0,;G9B!P,9-?H/X^_P""(?AC
M4;^:?P;\3-3T.U;+)9ZQIJ7^#_=$J218'U4GZTGP_P#^"(?AC3=0BN/&?Q,U
M+7;1=K-9:/IJ6!)'4&5Y)LJ>G"J?<4 ?$7[!7[*.H_M1?&S3;:YLYO\ A"-&
ME2\UV^V?N_+4Y6W#=-\I&W'4+N;^&OZ$54(H51@ 8 %<E\+?A-X1^"O@^U\+
M^"="M?#^B6Y++;VP.7<XR\CDEG<X&68DG YXKKJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#^;C]L?_D['XP?]C7J7_I2]?<W_!#;
M_D,_&+_KWTG_ -"NZ^&?VQ_^3L?C!_V->I?^E+U]S?\ !#;_ )#/QB_Z]])_
M]"NZ /UAHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYF-O!JE[:R6[>;!)"V]4MD8_+*Q&&'('7I7V#0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 2EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ@;F*X2P5EA+17$D6Y58DC(0'&3R:]SH **** "BBB@ HHHH **** "BBB@
MHHHH 2EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N?^('CO1?AAX)UKQ9XBNQ8Z)H]J]Y=SX+%449P .68\  <DD
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M]>4W_H!K^6^;_72?[Q_G0!^]O_!*C_DQ_P #?]?&I?\ I=/7UQ7P/^PG\>O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$B_AKX<\-_LIZ7XML-,BB\1>([JZ.I:@?FEF6&YEBB3)Z(JK]T<9+'J:^WZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=-)\9ZWJ[7D.L72(]O90F"./<J$_/+E#@,-HX)W=* /WSFGCMTWRR+&O3<Y
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MSC(PKR\ \YYZ#'[45_-)^S7\<-1_9U^-GA?Q[IZM.-,N<7=JI(^TVK@I-'U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5S'Q,^&OAWXO^!=7\(>*].CU70=5A\FYMI..X*LIZJZL RL.00".E=/1
M0!^)OQ__ ."0?Q5\ ZQ<7/PY\GXA>''D)AC$\5KJ$"$M@2)(RH^!M&Y&R2<[
M%'3YRD_8K^/46O#2&^$/C$W>X+YBZ1,UODC/^O"^5C'?=@'CK7]']% 'X9?!
MG_@DA\;?B-J43>*K:S^'.B[OWMUJ4J7-R5QUCMXF.3G P[Q]^>,']?/V=?V<
M?!O[,7P]M_"?@ZS:.'=YUY?7!#7-]/M ,LK>IP,  *!P *]1HH HZ[9R:CH>
MH6D6/-GMY(DW' W,I S^=?@?JG_!,#]I:SU*Y@3X<-=HDC*MQ;ZQ8&.09X9<
MS@X/7D ^H!K]_J* /GW]@OX.^)O@/^RWX0\&^,+:&R\0VANIKFU@G680^=<R
M2JA=<J6"N =I(SG!/6OH*BB@#\:OVV?^"?/QW^(G[3'C;Q9X5\%KK^@:U=BZ
MM;NVU.TCXV*"K)+*C!@1Z8]":^G/^"5/[*'Q(_9KL/B'??$/1X-"D\0&P2SL
MQ>17$P$!N=[/Y3,J@^<F/F)X.0._WS10!YQ^T=X&U3XF_ 7Q]X3T18GU?6=&
MN;*T6=]B&5XR%!;L,GK7X@_\.Q?VF?.\O_A6,N[.W/\ ;.G;?S^T8Q7] M%
M'GG[/'@74_AC\"/A_P"$M9\G^UM$T*ST^[^SOOC\V.%4?:V!D9!YQ7H=%% !
M1110 4444 %%%% "4M)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W%Q%9V\L\
M\J001*7DED8*J*!DL2>  .]?BA_P4C_;]D^/>JW'P[\$7,D/@'3KG_2KV*0@
MZO,AX)P<&%3RH/4@,>@Q^CW_  4>U_4?#?[%OQ+N],F>VN'M8+9Y8QDB*6YB
MCD'T9'9?^!5_/90!ZS^S/^S7XL_:C^)5IX3\,0>5%D2ZCJTL9:#3X,\R/CJ3
MR%3(+'C@9(_H!_9X_9X\(?LS_#FR\(>$++RH(_WEW?2@&XOIR &FE8#ECCIT
M      K^<[P=\5O&WP[M[B#PIXQU_P ,P7#!YH]'U.>T65@, L(V&3CN:Z+_
M (:<^,7_ $5CQQ_X4=Y_\<H _I=JKJEF=0TR[M0VTSPO%N]-RD9_6OYK/^&G
M/C%_T5CQQ_X4=Y_\<K]?_P#@DA\6/%?Q5_9QUF3Q;K=[X@O-)\036-O?:E<2
M7%PT1AAFP\CL6;#2L!SP,#M0!^:^O?\ !-G]HVWUO4(XOAK=W<2W$@2X@O;4
MQR#<<,N90<'W JC_ ,.W_P!I'_HEFH?^!EI_\>K^A2B@#^>2^_X)V_M%:98W
M%Y=?##4(;:WC::60WEJ0J*"2>)>P!KYS=&C=D8893@BOZAOB)_R3_P 3?]@N
MZ_\ 135_+_??\?UQ_P!=&_F: /8_AC^Q?\:/C+X1M/%'@SP)=ZYH-T[QPWL5
MS;QJ[(Y1AAY%(PP(Y':OZ'/AWH=QX7\ ^'=(NL?:;'3X+:7;TW)&%/ZBOF#_
M ()/_P#)D_A'_K\U#_TKEK[!H _FC_:;_P"3BOB7_P!C%??^CWK]1O\ @B9_
MR07QS_V,K?\ I+!7Y<_M-_\ )Q7Q+_[&*^_]'O7ZC?\ !$S_ )(+XY_[&5O_
M $E@H _1:OP]_P""Q'_)V2_]@2U_]FK]PJ_#W_@L1_R=DO\ V!+7_P!FH M_
M\$9/^3LM7_[%2\_]*;6OVD\3_P#(MZM_UZ3?^@&OQ;_X(R?\G9:O_P!BI>?^
ME-K7[2>)_P#D6]6_Z])O_0#0!_+IJO\ R%+S_KL__H1K]W/^"3O_ "93X2_Z
M_-0_]*Y:_"/5?^0I>?\ 79__ $(U^[G_  2=_P"3*?"7_7YJ'_I7+0!]A444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 E+24M !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &9XE\-:5XQT&_T36["#5-(OHC!=6=R@>.5#U5AW%?-+?\$N?V8F8D
M_#(9)SQKVI@?^E-?5-% 'RK_ ,.N/V8O^B9_^5_5/_DFC_AUQ^S%_P!$S_\
M*_JG_P DU]544 ?*O_#KC]F+_HF?_E?U3_Y)KW7X1?!GP;\!_!L/A7P+HB:#
MH,4KS+:K/+.=[MN9B\K,[$GU8X& .!7:T4 %%%% $5U:PWUK-;7$2S6\R-')
M&XRKJ1@@CT(-?+.I?\$O/V:M4U">\D^';1R3.9'C@UF_CCR3DX43X4>PP!VQ
M7U710!R_PU^&/A?X/>#-/\)^#M'AT+P_8*5M[. LP7))8EF)9F)))9B2222:
MZBBB@#YI\=?\$XOV>_B+XJU+Q'K7@(/J^HS-<7<UMJEY;K+(QRS[$F"@D\G
M&3S7J_P8^ _@3]GOPJ_AWP!X?B\/Z5).US+&DLDSRRD %WDD9G8X ')X  &
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M)2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y)^T!^U/\
M#K]F*VT2?X@ZM<:5%K#S)9F"REN=YB"%\^6IQCS%Z]<T >MT5\?_ /#V#]FW
M_H;]0_\ !)=__&Z/^'L'[-O_ $-^H?\ @DN__C= 'V!17Q__ ,/8/V;?^AOU
M#_P27?\ \;H_X>P?LV_]#?J'_@DN_P#XW0!]@45\?_\ #V#]FW_H;]0_\$EW
M_P#&ZW/ _P#P4L^ ?Q%\8:-X7T+Q1?7.LZO=1V=I"^D74:O*[;5!9D ')ZF@
M#ZDHK&\9^+M,\ ^$=9\2ZU,UOI&D6<M]>3)&SE(8T+N0J@DD '@<U\L?\/8/
MV;?^AOU#_P $EW_\;H ^P**\U^ W[1'@?]I3PI>^(_ 6I3:II-G>MI\TL]K)
M;E9EC20KMD4$C;(ASTYKTJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **^+/CS_P %5OA?\"?B?K'@BXT77O$E_I+B&[NM)$!@
M2;&6B!>1264\'C@@CM7OG[,_[05A^TU\,8/'.DZ!JF@:3<W,L%K'JOE^9.L9
MVM(NQF&W>&7DYRIH ]7HKPWX]?MI?"C]FGQ)I^A>/M<NM+U*^M!>P1P:?/<!
MHB[)G=&I ^9&X//%<#X>_P""H7[/7BCQ!IFBZ=XKOY=0U&ZBL[:-M&NE#22.
M$0$F/ R2.30!]844BMN4$=#2T %%%% !17FG[1'QOM/V=?A7J7CS4=#U+7M,
MTUXQ=0:7Y?FQH[!!)AV4%0Q4'G/S?6OFOX,?\%:/A9\8_B9H?@Q-"\0>'+G6
M)OLUO?:H(!;B8@[$8I(2"QPHXZD#O0!]OT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1244 +1244 +1244 +1244 +1244 +1244 +1244 +12
M44 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +124M !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH?Y2FW.=W&,YKY^_X1/]CW_H#? __P !='_PH \-_P""*/\ R;/XO_[&^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\0?]ZP_]+8*\E_X(H_\ )L_B_P#[&^?_ -(K.O6O^"HW_)D/Q!_WK#_TM@H
M_ 2OK;XL?\%!/%VO? GP'\)?!%U=^%_#NC>'[33=7NX7\NYU*98561-XY2$$
M%=H(+C);@A1\DU^F?_!(O]D7PU\1+?6?BOXRTJ#6X=-O?[/T:PO8Q) )E17D
MN&1AAR-ZJF> 0QQD*0 ?FU-H6IPZ<FHRZ==I82'"W;P,(F/!P'Q@]1W[BJD,
MTEM-'-#(T4L;!TD0D,K Y!!'0U_4QJ>C6&M:3<:7J%C;WNFW$1AFL[B)7BDC
M(P49",$8[&OYP?VM_AE8?!W]I#X@>$=*0Q:5I^J2"SB)R8X'^>-,]\*P&?:@
M#ZU^#'_!77Q1\/\ ]GO5_#GB2TN/%/Q!L]MOH.LW1#1M$P(W71SN=HL#!Y+[
M@&(P6/P[XV\<>-?CGXTO->\1:AJ?BWQ%=?/)-(&FD"@_=55&$09X50%'8"JW
MPO\  -]\5/B-X:\'Z8P2^US4(+".1AE8_,<*7(]%!+'V!K^CGX#_ +/W@O\
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M!&OOFOGS_@G_ .&8O"O['/PLM(5"K<:1'?G']ZX)F8_G(:^@Z /QJ_X+9?\
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M96OW;_X)*^+7\2?L=:+9R2>8^C:A>6&2>0/-,JC\%E ^@% 'V;1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4B?R45^#E?O7_P $H_\ DR/P7_U]:C_Z6S4 ?7M?SY_\%+/^3U_B5_U\6_\
MZ2Q5_097\^?_  4L_P"3U_B5_P!?%O\ ^DL5 $7_  3:TZ/5/VV_A?!* 5%U
M=3<CNEE.X_517]"-?S\_\$Q_^3Y?AA_UUO\ _P!-]S7] U 'QE_P5N_Y,VUC
M_L*V7_H9K\)*_=O_ (*W?\F;:Q_V%;+_ -#-?A)0!_0M_P $Y?\ DR_X8_\
M7C)_Z.DK\@_^"D^JR:Q^VI\2I9"Q,5U!;C=V$=O$@_#Y:_7S_@G+_P F7_#'
M_KQD_P#1TE?E!_P50\)3>%_VS_&$SJ1;ZM#::A V,;E:!%8_]]HX_"@#YL^&
M_P 1-;^$_CC2/%WARXCM=<TF;S[2::%9E1]I7)1@0>">HKZ;_P"'L'[27_0W
MZ?\ ^"2T_P#C=>,_LGZ?X3UC]HWP#IGCFPM]3\*ZAJ2V5[:W4K1QL)5:-"S*
MP(P[(V<CISQ7[=#_ ()O_LVGD?"W3R/^OV[_ /CU 'Y5_P##V#]I+_H;]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;<P5B/E0]NM '\Y-?O7_ ,$H_P#DR/P7_P!?6H_^ELU?G[_PYM^/?_/YX/\
M_!I+_P#&*_4/]AOX(>(OV=OV;_#O@7Q4]E)K5A-=R3-I\S2PXDN9)%PQ52?E
M<9XZT >^5_/G_P %+/\ D]?XE?\ 7Q;_ /I+%7]!E?E/^V)_P3*^+WQV_:-\
M8>./#=SX:CT75I87MUOK^2.8!88T.Y1$P'*GO0!\H_\ !,?_ )/E^&'_ %UO
M_P#TWW-?T#5^5?[&7_!,WXN_ 3]I;P7X\\37/AN30](>Z:Y6POY))CYEI-$N
MU3$H/S2+W'&:_52@#XR_X*W?\F;:Q_V%;+_T,U^$E?T0_MX? ;Q+^TA^SWJ'
M@KPG)8QZQ/?6UPC:C,T46U&);+!6.>?2OS'_ .'-OQ[_ .?SP?\ ^#27_P",
M4 ?I;_P3E_Y,O^&/_7C)_P"CI*\$_P""O7[,-]\3/A[I7Q-\.V4EYK'A:-X-
M2@@C+R2V#'=O ')$3;B?]F1CT6OJW]D;X4ZU\$/V=_!G@CQ$UJ^LZ1;-#<-9
M2&2$L9&;Y6(!(PP["O7G19$9'4,C#!5AD$>E '\K2L48$$JP.01U%?J/^S#_
M ,%C+7PSX/LO#WQAT/5-5O+&-8(?$&AI'+)<(  #<1R2)\_'+J3N_NCJ?1OV
MI/\ @C_X=^(FKW?B/X3ZM;>#-4NG:6?1-05FTUW.23$R O ,_P (5EYX"@8K
MXD\2_P#!+']I+P]<S)#X%@UJWC.!=:;J]FR/SC*H\J2?FE 'N_[97_!6:Q^+
MGPYU/P+\+]#U72;/5XFMM2UG6ECCF,!R'BABC=P XX+LV<$C;SD?FLJM(P50
M69C@ #))KZT\)_\ !*_]H_Q/=)'/X+MO#]NS;3=:MJUJJ+[E8W>3'T6OO_\
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M,4SE(,[IGX_NQJ[?A7],6FZ?#I.G6ME;QK%;V\2Q1HHP%50  /P% %FBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ \-:]X0L=&U1+188-5O+J.X7RK6*%MRQVSJ,M&2,,>".G2O#_\ ARI\;_\
MH:?A_P#^#&^_^0Z #_A]7\;_ /H5OA__ ."Z^_\ DRC_ (?5_&__ *%;X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M->Q?%7XM?#7X?Z'=P?$'Q5X>T;3[F%HIK/6;R)3<1LI#((F.Z3(S\H!R,\4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO&.-88TC0;44!0!V K^;#]K"_O-2_:<^*D]_-+-=?\)-J"LTQ.X;;AU"^P
M '8 "@#0^(7[8WQO^+5PP\1?$OQ%=I+\IL[*Z-G;MGMY$&Q#_P!\U6\%_LE_
M&OXF3J^A_#+Q3?K,=PNY].D@@;/?SI0J?^/5]Y_\$7]0^%T.G^*[;41I,?Q6
M:_S:27RJ+IM/,48"V[-_TU$A<)SRF[C;7Z"_'O\ :7^'_P"SAX1O=<\9:]:V
MLL,3/;Z3'*K7UZX'$<,.=S$D@9X5<Y8@<T ?S<:[HE[X9UJ_TC4H/LVH6,[V
MUQ#N5MDB,59<J2#@@\@D5^XG_!(?_DSO3?\ L+7W_HROQ%\9>))/&'B[6M=F
MC$4NIWDUX\:]%,CEB/UK]NO^"0__ "9WIO\ V%K[_P!&4 ?5OQ2^']A\5OAO
MXF\'ZF!]BUO3YK&1L9\O>A <#U4X8>X%?S,^,_"M_P"!?%VM>'-5A^SZGI-[
M-8W,6<[)(W*,,^Q!K^H^OQ%_X*_?!3_A7O[1=MXQLX?+TOQE:"Y+#@"[AVQS
M*![CRG)]9#0!]A> _P!K\6__  2[F\?27I/B72=';PYO\P&7[>"+:*0_[1#)
M-CTK\7]%T>^\5>(+#2K"%KK4M2NH[6WA7K)+(X55'U9@/QKHK3XL>(+/X1W_
M ,.([@#PU>:Q%K<D/(;[0D319SGD%6&0>Z+7TM_P2G^"I^*O[4VFZQ=V_G:/
MX0@;5YBZ!D,_W+=#Z'>3(#_TQH _:?X&_#*S^#7PA\(^"K'#0Z+IL-HTG>61
M5&^0^[-N8^YKN:** "BBB@ K\[_^"S?QB;PK\%O#G@"SF*77BB^-Q=JIZVMO
M@[6]FE>,C_KD:_1"OPU_X*^>/F\5_M;7&BK*7@\-Z3:V"J#\H9U-PQ^O[X _
M[N.U 'F'_!//X1K\9/VLO!&F7,'VC2],G.M7HSP([<;TSZ@R^4I'HQK^A@ *
M !P!7Y+_ /!$7P"EQXD^)/C2:%=]K;6VDVLNWG]XS23+GM]R'_(K]:: "BBB
M@#\H_P#@N)_Q_?"7_KGJ/\[>O!?^"1:D_MB:?@9QH]X3^25ZM_P6X\31W7Q5
M^'GA]7W/9:-+>LN>%\Z9D''8_N?Y5A?\$6/!TNJ?M!>+?$F,VVDZ ;9N#Q)/
M,A0YS_=@DX/K[4 ?L[1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML8M!NO"7A<M^_P#$&N6SPQ*O',4;;6F.#QM^7(P66OZ#Z* /P'_:G_8"\?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>plrx-20211231_g16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g16.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 4C#SP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO3X-!T*ZA26'3M/FB<962."-E8>H('-:<,,=O$L<4:Q1J,*B   >PH ^"_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@ HKS[X[_&_P -?L]?#/5O&GBBZ6&QLH_W5N&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/+^UA\56=V=O[?N1ECDX#8 _*OTG_P""):C_ (43X[.!G_A(P,_]NT5?F_\
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M_@%:?_&:_1[_ (<P_ S_ *#?C;_P8VW_ ,C4?\.8?@9_T&_&W_@QMO\ Y&H
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M..37[%?!_P"&.D_ OX3^'_!FD.\FG:%9" 32#YI2 2\A'JS%CCMG% 'Y&_\
M!1KXI^)?VGOVNM/^#WAZ5WTO2+^+1[.S5L)-?2;1),W.#C<%!/0*WK7Z"_!7
M_@G#\%/A/X/L]-OO"5CXMUKR56]UC6$,KSOU8JA.U%SG  SCJ37YQ_L%P_\
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MN2>@KP[4/VZ/@'I>K-IMQ\5?#8N5;8Q2\#QJV<$%QE1CZU^7_P *?B=\=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF."-@"21QO(VC.1GI7[I>&O#FF^#_#^FZ'H]I'8:5IUNEK:VL(PL<:*%51^
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MZ(?X-_84^)OCCPKIFOV2:5;V>H0K<0QW5V4DV-RI("G&1@]>AK:_X=U_%?\
MOZ%_X'-_\17Z;VEI#86L-M;1+!;PHL<<2#"HH&  /0 5-7Z''AW!I+FO?U/X
MZK>,?$4JDG25-1N[+E;LNBO<_,+_ (=U_%?^_H7_ ('-_P#$5]$?L8_LP^,O
M@/XJ\0:AXE;3S;WUFD$7V.X,AW!\G(*C Q7UK175A\EPN&JQK4[W7F>%G'B;
MGV=X&KEV+Y/9U%9VC9[I[W\@HHHKWC\F"BBB@ K,\3>(+/PEX;U77-1D\G3]
M,M);VYD_NQ1H7<_@%-:=<=\9?"]UXX^$'CGPY8E1>ZOH5]I\&[IYDMN\:Y_%
MA0!^+/@G2?'7_!4K]JZZ37M:GT[PY;^9=RJC%XM,L%8!88$QM\QLJ,D<G<QS
MC%?J%X7_ ."<G[/7A?0$TM?AU8ZD FV2[U*22>XD.,%BY;@G_9P!V K\XO\
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M=.^ 'Q(NKA_+@A\.:A)(^"=JBW<D\5^9/_!$2%V^)'Q+E"DQKI=JI;' )E;
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M?LG_ ! ;XJ?\%)]"\7,I7^V?$-S>*IZA660KGWVXH _>*BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPM=/110 4444 %%%% !1110!^"/_  5:_P"3WO&O_7KIO_I%#7VG_P $2?\
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M_P#$4 ?0=%?/G_#P+]G?_HJ^A?\ ?4G_ ,11_P / OV=_P#HJ^A?]]2?_$4
M?0=%?/G_  \"_9W_ .BKZ%_WU)_\11_P\"_9W_Z*OH7_ 'U)_P#$4 ?0=%?/
MG_#P+]G?_HJ^A?\ ?4G_ ,11_P / OV=_P#HJ^A?]]2?_$4 ?0=%?/G_  \"
M_9W_ .BKZ%_WU)_\17O]O<1W5O%/"XDBD4.CCH5(R#^5 $E%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7$>._@GX&^)C>9XD\,Z?J=P!@7,D($H'LXY_6NWHJ)PC47+-
M77F=6&Q6(P=15L-4<)+K%M/[T>-^'?V0?A)X9NA<6W@ZSN)5;<IO2UP%/L')
M'%>OV]M#9P)!!$D$,8VI'&H55'H .E2T5%.C2HJU.*7HK'1C<SQV924L;7E4
M:VYI.7YL****V/-"BBB@ HHHH **** "BBB@#\W/VZ/^"6]Q\4O%=[\0OA++
M:Z?X@O9#<:EH=P_E17,Q.3/"_1'/)*G@GD$'.?F[0[C]O?X9Z;'X=M+7QL+:
M-!%"DJQW?EJ. $D); _&OVTHH _%WX:?\$V_C[^TKX^A\1_&C4;_ $.P9U%Y
M?:U=_:=1EC7&$B3)"Y' )( ]#7Z^?#;X<Z!\)? ^D>$O#%BFG:)I<(@MX5ZX
M[LQ[L3DD]R:Z:B@#Y-_;R_85T[]KCPY9:AIEY%HGCK2(V6RO95S%<QGGR)L<
MXSR&_A)/4$U^>7A?X>?MO_LQQR^&O#5CXHAT>)F6*&P=+VRYZM$"2%S]!7[?
MT4 ?BK\.O^"=?[0G[4WQ C\0_&._U'P_I[.OVK4M=G$]])%D'9!%D[>,@;L!
M3V/2OV+\ ^!=%^&?@W1_"WAZS2PT72;9+6U@3LBC&2>Y/4GN236_10 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!^"/_!5K_D][QK_ ->NF_\ I%#7VG_P1)_Y(=X__P"QC7_TFBKXL_X*M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /P1_X*M?\GO>-?\ KUTW_P!(H:^T_P#@B3_R0[Q__P!C&O\
MZ315\6?\%6O^3WO&O_7KIO\ Z10U]I_\$2?^2'>/_P#L8U_])HJ /T;HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^
M73QY_P CSXB_["-Q_P"C6K^@W]@;_DS?X3?]@6/_ -":OY\O'G_(\^(O^PC<
M?^C6K^@W]@;_ ),W^$W_ &!8_P#T)J /?J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ***P]=\=>&O"]TEMK/B'2M(N9$\Q(;Z]B@=ER1N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** /P1_X*M?\GO>-?^O73?\ TBAK[3_X(D_\D.\?_P#8QK_Z315\6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,>'<5A\;D^$KX5^XX1M;I9)6^35OD%%%*H+, .IKAWT/H=M3]9/V'M>N]?\
MV:_"TMX_F/;&>SC/I'%*R(/P4 5[S7GG[/\ X#@^&OP=\+:# \,S0V:2336[
M;HY97&]W4^A9B:]#K]LHQ<:48RW27Y'^9.>UZ6*S7%5Z"M"52;7HY-H****V
M/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAX5#,6"W=X!D]!YQXH _*;_@HUXJD\6_MF?$FX:?SHK6\CL8AG(18H40J/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4;9))'P /D+ *#G)&1BOQS^'?@74_B;XZT'PIHT+3ZGK%Y'9P(J[CEFP6QZ
M9)]@: /WU_X)TZ"?#_[&OPU0HL;75@;P@#'^L=F!/N1BOH/7-"TWQ-I%WI6L
M6%KJFF7<9BN+*\A66&9#U5T8$,#Z$5G> ?"-MX!\#Z!X;LU5;;2;&&S38, [
M$"Y_$C/XUOT >6_\,K_!C_HDW@G_ ,)ZT_\ C='_  RO\&/^B3>"?_">M/\
MXW7J5% 'EO\ PRO\&/\ HDW@G_PGK3_XW1_PRO\ !C_HDW@G_P )ZT_^-UZE
M10!_/W_P4Q\(Z'X&_;$\7Z/X<T:PT'28;:P:*QTVV2W@0M:1,Q5$ 49)).!R
M2:^Z?^")/_)#O'__ &,:_P#I-%7Q9_P5:_Y/>\:_]>NF_P#I%#7VG_P1)_Y(
M=X__ .QC7_TFBH _1NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /Y=/'G_ "//B+_L(W'_ *-:OZ#?V!O^3-_A-_V!
M8_\ T)J_GR\>?\CSXB_["-Q_Z-:OZ#?V!O\ DS?X3?\ 8%C_ /0FH ]^HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\2_
M^"SW_)UVB_\ 8J6G_I3=5^VE?B7_ ,%GO^3KM%_[%2T_]*;J@#Y7_9A_Y.2^
M%/\ V->E?^E<5?TIZCI]KJ^GW-C>P1W5G<Q-#-!*NY)$8$,I'<$$BOYK/V8?
M^3DOA3_V->E?^E<5?TN4TW%W6X'X;_MJ?LRW_P"RW\6V?2EF_P"$3U1VN='N
M\'Y!G+0,?[R9Q[J0:XKPKXJA\0V^UL1WB#YX_7W'M7[7_M&? G1OVB?A9JOA
M'5U6.65?-L;W&6M;E0=D@]L\$=P37X.>-_!NO_!SX@:EX>UFW>PUO2+EH94/
M0X/# ]U88(/<&OZ0CE>7^,>0?4\9)0S/#*T:G62Z.7>+VE_++WEO9_6<'<:X
MW@/,/:4[SPM1^_#]8]I+IW6C[K]#_P!CO]L27X=SVO@SQG=-+X7D8)9W\A+-
MI[$_=;UB_P#0?I7Z/6]Q'=01S0R+-#(H=)(V#*RD9!!'4$5^%^EV9U_P9;^)
M]/!FT_S/LUVHY:TGQG8_LPY5N_3J*^L_V.OVQ)/AW-:^"_&ETTOA>1@EGJ$A
M+-I[$_=;UB)_[YZ]*_D6,\9P_CJF2YQ!PJ4WRZ]/GUB]T]K>1^\<8\'8+BK!
M+BGA9J?.N:48_:[M+I-?:CU_Q;_I#14<$\=U#'-#(LT,BATDC8,K*1D$$=01
M4E?4G\N;:,****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7XP?\%KO^3D/!W_8J1?^
ME=U7[/U^,'_!:[_DY#P=_P!BI%_Z5W5 'QE\ ?\ DNWPX_[&33?_ $JCK^FR
MOYAO@[K5EX;^+G@C5]2G%KIVGZY8W5S.REA'$EPC.V "3A03P,\5^[__  \J
M_9K_ .BHV?\ X+KW_P",4 ?35%8?@?QMHGQ(\)Z7XF\-WZZIH6J0BXL[Q$9!
M+&>C , PZ=P*W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "D9BJD@;B!P/6EHH _$SXR?\ !-O]
MH[XH_%?Q=XLN-$T^=M7U.XNU>34HPWELY\L'Z)M'X5QO_#I_]H?_ *%[3/\
MP9QU^\M% 'X-?\.G_P!H?_H7M,_\&<='_#I_]H?_ *%[3/\ P9QU^\M% 'S=
M_P $^O@OXI^ /[-6D^#_ !C:PV>N6]]=SR10S"5=LDI93N'M7JGQP^"GA?\
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M":OY\O'G_(\^(O\ L(W'_HUJ_H-_8&_Y,W^$W_8%C_\ 0FH ]^HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#\$?^"K7_)[WC7_ *]=-_\ 2*&OM/\
MX(D_\D.\?_\ 8QK_ .DT5?%G_!5K_D][QK_UZZ;_ .D4-?:?_!$G_DAWC_\
M[&-?_2:*@#]&Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _ET\>?\ (\^(O^PC<?\ HUJ_H-_8&_Y,W^$W_8%C_P#0
MFK^?+QY_R//B+_L(W'_HUJ_H-_8&_P"3-_A-_P!@6/\ ]":@#WZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_D][QK_UZZ;_ .D4-?:?_!$G_DAWC_\ [&-?_2:*@#]&Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ET\>?\ (\^(
MO^PC<?\ HUJ_H-_8&_Y,W^$W_8%C_P#0FK^?+QY_R//B+_L(W'_HUJ_H-_8&
M_P"3-_A-_P!@6/\ ]":@#WZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OQ+_X+/?\G7:+_P!BI:?^E-U7[:5^)?\ P6>_
MY.NT7_L5+3_TINJ /E?]F'_DY+X4_P#8UZ5_Z5Q5_2Y7\T?[,/\ R<E\*?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7XP?\%KO^3D/!W_ &*D7_I7=5^S]?C!_P %KO\ DY#P=_V*D7_I7=4
M?&7P!_Y+M\./^QDTW_TJCK^FROYD_@#_ ,EV^''_ &,FF_\ I5'7]-E !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\$?^"K7_)[WC7_ *]=-_\
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M8H_X= _&_P#Z"G@S_P &DW_QB@#W/_A^3_U1W_RX_P#[EH_X?D_]4=_\N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_$O_
M (+/?\G7:+_V*EI_Z4W5?MI7XE_\%GO^3KM%_P"Q4M/_ $INJ /E?]F'_DY+
MX4_]C7I7_I7%7]+E?S1_LP_\G)?"G_L:]*_]*XJ_I<H **** "BBB@ KR/\
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M(-?Q+FN51QD7":Y:D?ZL_P"M#]KX(XVQ7"6*ZSP\W[\/_;H]I+\5H^C7P/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\8/^"UW_ "<AX._[
M%2+_ -*[JOV?K\8/^"UW_)R'@[_L5(O_ $KNJ /C+X _\EV^''_8R:;_ .E4
M=?TV5_*_IVHW6CZA:W]C<2V=[:RK/!<0.4DBD4AE=6'(((!!'3%>J_\ #7WQ
MR_Z*]XV_\'US_P#%T ?TET5XK^Q;XBU7Q;^RK\,M8UO4;K5]6O-'BEN;Z]E:
M6:9R3EG=B2Q]S7M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNI+.R,,ODEL?,Q09&[WH ]OHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#-IJ:YIQC]KO**Z27VH[OUO?]#**;'(LL:NC!T895E.00>XIU?;G\N!1110
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MH6XV$CH-T94K]>:_1JO//B3^T)\./@_J%I8^,O&&FZ!>W2[X;>ZD.]ESC<5
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MR;NGM_D?9=%%%?CIZ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P $-_\ 7?&#_=TO^=U0!^J]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?B7_ ,%G
MO^3KM%_[%2T_]*;JOVTK\2_^"SW_ "==HO\ V*EI_P"E-U0!\K_LP_\ )R7P
MI_[&O2O_ $KBK^EROYH_V8?^3DOA3_V->E?^E<5?TN4 %%%% !1110 4444
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M:Q&G:CJVG17,\"C"[B.64?W6^\/8BO0JBM;6&QMXK>WACM[>)0D<42A510,
M #@ #M4M?Q7BJE.MB*E6C#DC)MJ/9-Z+Y+0^CBFDDSBO&GQJ\!_#O5+;3?$W
MBW2=$U"Y&8K:\NE21AZX)X'UKHM%\3:/XDA\W2=5LM3BQG?9W"2C'_ 2:_(S
M]O/]E?XKR?'KQ9XOMM U+Q/X>U2;[5;7]C&TX@BV@")P,E=N, =,#BODFSU/
MQ3X!NB;6ZU?P[<;LGRI);9L_ABOZ'RKPIR_/,MHXK YDG4E%.2LI)-J[5E)-
M6VUU]#R:F.G3FXRAH?T>45^%?P]_;[^-WP]N;4Q>,[G6;* @?8=75;B-E[C)
M&[]:_:WX7^,F^(?PY\->)WM&L'U?3X+UK9N?++H&*Y[C)X/I7YKQ=P+F/!ZI
MU,5.,X3;2<6]UW32M^)V8?%0Q%U%:HZ>BBN=UKXB^%O#>K0:9JWB+2]-U&;F
M.UNKM(Y&_P" DYK\]ITJE9\M.+;\E<ZVTMSHJ*@M+ZWU"(2VMQ%<Q?WX7##\
MQ4]9M-.S&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M\8/^"UW_ "<AX._[%2+_ -*[JOV?K\8/^"UW_)R'@[_L5(O_ $KNJ /C+X _
M\EV^''_8R:;_ .E4=?TV5_,G\ ?^2[?#C_L9--_]*HZ_ILH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*^J%C(W_ *+%?8]?E[_P6[\8^3X=^&OA>.=E::YNM0FA!X=5540D>Q+_ )T
M?GK^R?\ !6']H3X^>%/ UW--;Z=J4[?;)[;'F1PJA9BN>,\#\Z_4+_ARS\*/
M^AK\3?\ ?47_ ,37Y>?LQ?M$:A^S!\2)/&VD:-:ZSJZ6$]G:I?2,L4+2 #S"
M%Y; '3(Z]:]]_P"'OG[0/]H?:?M7ASR]V?LO]E'ROI]_=C\: /L;_ARS\*/^
MAK\3?]]1?_$U]P_"WX?67PI^'?A_P?IL\US8:+9I9PS7!!D=5& 6QWKX7_9-
M_P""M_A_XJ:U8>%?B?IMOX/URZ98;?5[:0G3[B4X 5PW,))/&2R^K"OT0!#
M$<B@#\2_^"Q'Q;G\9?M(VG@Z*YW:9X3TZ.,P \"ZG ED8^^PPCVP?6K'_!(?
M]G70?BY\5O$GBSQ1I<.KZ7X6MX1:VEY&'@>ZF+;693PVQ8VX/&74]J^>_P!N
MS6)=<_:]^*EU*,.-:D@ZYXC"QC]%%?HA_P $2=/CC^#?Q!OA_K9=>2$\?PK;
MH1S_ ,"- 'O/[>G[+/A+XQ?L\^*IX- T^T\3Z'82:CIFH6UND<J&%2[1DJ 6
M5D#+M/&2#7X'^'=?OO"NOZ=K.FS-;:AI]Q'=6\JD@K(C!E/YBOZ@O%EE_:7A
M76;38)/M%E-%L;HVZ-A@_G7\O.M0_9]9OXL!?+N)%P.V&(H _IM^$'CN#XG_
M  L\)^++=Q)'K&FP7FY>FYT!;'XYKKZ^9/\ @FSKW]O?L9_#MM^\VEM)9\@C
M&R5AC\*]L^+GQ*T_X.?#/Q)XVU:VN;S3="LWO;B"S"F9T7J$#$#/U(H Z^BO
MSS_X?8?"'_H3/&W_ 'XL_P#Y(H_X?8?"'_H3/&W_ 'XL_P#Y(H _0RBOSS_X
M?8?"'_H3/&W_ 'XL_P#Y(H_X?8?"'_H3/&W_ 'XL_P#Y(H ^'?\ @JU_R>]X
MU_Z]=-_](H:^T_\ @B3_ ,D.\?\ _8QK_P"DT5?G'^VE\=M%_:2_:&\0>/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*4=F<_X\\!Z)\2O"][X?\0V27^F7:[71OO(>SJ?X6!Y!%?E'^TA^S?K?[/\
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M)_I_DS]/XZX+P><8-\5<-M2A).4XK9KK)+HU]N/J][I_>]%%%?;'\PA1110
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M9\,/^"@/P3^)6DQ7+>,+/PQ>E TUAX@<6CQ-W7>WR-]58UEXAXK/>),/2Q&
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MWW,PQ&'6(BHMV/YT_"_Q3\<_#N=!H7B?6M":,Y$-O>21J/JF<'\17T%\,_\
M@IE\:? ^HVAU?68?%VF)(OGV^IVZ>8\8/*K(@!!QW.:_6_QC\"?AW\0(Y$\0
M^"=#U5I/O2S6,?FG_MH &'YUY-;_ /!.SX#6?B:VUF#P;Y;6\BRK9&\F>V+
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MO3Y'CO,>63C*!_0?17Y!_!__ (*I_%#P]KVF6WC./3_%.AM,J74GV807@0D
MLK(0N0.<%>?45^O$$RW$,<J<I(H9<CL1FOR/B?A#,^$ZM.GF"34[\KB[IVM?
MHFK76ZZG?1Q$*Z;AT)***B-U LOEF:,2?W-PS^5?%6;V.DEHHHI %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5^,'_  6N_P"3D/!W_8J1?^E=U7[/U^,'_!:[_DY#P=_V
M*D7_ *5W5 'QE\ ?^2[?#C_L9--_]*HZ_ILK^9/X _\ )=OAQ_V,FF_^E4=?
MTV4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNT8DC;<I9(T1^?\ ?5J_0W_@B7I-U;_!WX@:C(F+2ZUF&*)_5HX<N/PWK^=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7\0^RV[?],H3D9!_B;)],5]6:AJ%EH>FSWM[<0V%A:QF26>9Q''$@&2Q)X
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MV?K\8/\ @M=_R<AX._[%2+_TKNJ /C+X _\ )=OAQ_V,FF_^E4=?TV5_,G\
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M;/Q!%"I9T5.(KC _A"_(Q[84U^IU175K#>V\MO<1)/!*I22*10RNIX((/!%
M'\U/[/?[1'C']FCX@6_BSP=>+#=!?*N;.X!:WO(<Y,<J@C(]P00>0:^O_B;_
M ,%F/B+XO\%2Z/X<\+Z7X4U2Z@,5QJT<KSR1DC!,*MPIZX+;L?7FOKWXT_\
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M1110 4444 %%%% !1110 4444 ?C=_P5^_Y.GTO_ +%:R_\ 1UQ7N7_!#?\
MUWQ@_P!W2_YW5>&_\%?O^3I]+_[%:R_]'7%>Y?\ !#?_ %WQ@_W=+_G=4 ?J
MO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#MM24D_[M?G/_P $_?VVA^R'XPUF'6=/N-5\'Z\D8O8;4CSH)8]VR5 >#PS
MCN#[5^[WBOPGIGC3PGJOAO5;9;C2-3M)+*YMR.&B=2K+^1K\"_VJOV!_B/\
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M_P#)#O'_ /V,:_\ I-%7Q9_P5:_Y/>\:_P#7KIO_ *10U]I_\$2?^2'>/_\
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M$"PR#Y?)1BT<&>C22-\SXZ#(]*_2;5?@]X%UR/9?^#M#NEQCY]/B_P#B:TO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M; >/<2>N1DXSTK]1?VM/V4?#'[67PW?P]K9%AJUJ6FTK68XPTMG*0,\?Q(V
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MS_@JU_R>]XU_Z]=-_P#2*&OM/_@B3_R0[Q__ -C&O_I-%0!^C=%%% !1110
M4444 %%%% !1110 5\A_\%6_^3(?&G_7UIW_ *6PU]>5\A_\%6_^3(?&G_7U
MIW_I;#0!^,G[+'_)R_PJ_P"QHTW_ -*8Z_HAD_UC?4U_.]^RQ_R<O\*O^QHT
MW_TICK^B&3_6-]30 VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _&[_ (*_?\G3Z7_V*UE_Z.N*]R_X(;_Z[XP?[NE_SNJ\
M-_X*_?\ )T^E_P#8K67_ *.N*]R_X(;_ .N^,'^[I?\ .ZH _5>BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKT55D=P#[ED_(5\8?\%(O^3V_BE_U^6__I)!7WQ_P1-_Y(KX\_[#B?\ HA:
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M3XN>39Q!TZM-\KOO?L^C\FM&K>I^F\;\#X3.,)_K1PO:=.:YI1CU7645T?\
M-'>]]+W1][T4@(8 @Y%+7TI_,@4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV5]J(8<XGE><?I(*]_JKI>F6NBZ9::=8PK;65I"EO!#&,+'&BA54>P  JU0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI%DCD4]"K*2"/<5:H **** /(/VP;>:\_95^+D$$3S3R>%M15(XU+,S&W?
M'4U_.G_P@_B;_H7]6_\  .7_ .)K^HI@&!!&0>QJ/[-#_P \D_[Y% '\O/\
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MADZ3>I:"%;O[1YFY-V[.U<>G2@#\GO\ @J5X<?P_^VCXSE9&4:G%:7RYSR#
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M>5N&[;G&['7&>]?&G02T444@"OQ#_P""D'CJY\:_M7>*(9=ZVVBI#I=O&_\
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M6/T/8U\9E>9SH3^I8W1K1-_D_P!&?IG'7 V&S3#?ZS<,VG3FN:<8]>\HKO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG/-?J517WD?%3BM4W3>)3OI?DA?\(HY?J-"]^4BM;>.SMH;>)=L42"-%SG
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MH0"->O)Y/'0?=?\ P2)\#07FC^/OB'>@76L7E\NFI<2<NJA1++S_ +;.A/\
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M) OT!)Q]:^V*^$XBRK^P\VQ.77NJ<FD^ZW7X6.FC4]I34^X4445\Z;!1110
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M "9?H/\ V%-0_P#1QK[,KY&_X)6Z#/H/[%_A(3@@WES>7B97'R/,V/Y5]<T
M%%%% !1110 4444 %%%% !1110 4444 17-M#>6\MO<1)/!*I22*10RNI&""
M#P01VKX>^//_  20^$_Q6U2;5_"US=?#S4YGWS1:>@FLG);+$0L1L)&1\K!1
M_=KVW]J_]L?P/^R7X6CO?$,C:EK]XC'3= M' GN2/XF)_P!7'G@N1] 3Q7Y:
M_$S_ (*__'#Q??RGPR^D^"-/WGRXK.S2ZFV=@[S!@3[JJT ?MAX9T"V\*^&]
M+T:R01VFGVL=K$JC "HH4?RK3K\!-&_X*B?M'Z1?1W#>/%OT5@6M[S3+5XW
M/0XC!'X$&OMC]EW_ (+!:)X[U:R\.?%G2;?PMJ%RXBBUW3RQL68\ 2HQ+1Y_
MO9(Y["@#W+]J?_@GIX5_:N^*_A[Q=X@UV\TFTT^Q-G=V>G1*)KS#[D/FMD(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(# \>AKWO]J7_@D/>_"GX?ZEXN^'GB:\\40Z5"US>:3J%NJW+1+RSQ,F VT
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M%?D9\=/^"-_Q!\.:]=77PSU2Q\4>'W9GAM=0F^SWL([(<C9)_O97MQ7[+44
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M 4444 %%%% !1110 4444 %%%% !5?4=0@TK3[F]NI!%;6T332R-T5%!)/Y
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M_@B+#>'XJ?$:5=_]GC185?\ N^89P5_' :OU_H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y>_P""@WPO\!?&/X+MX9\6
M^*-(\):VTANM U'5IQ$B72+R,G^%@=K8['/:OR@_8W_:TUC]A[XL:W:ZA9KK
MOAN]?[)JUC9SJP+1D[)X7^ZQ&3CL5;M7UU_P6_Q_8?PO]?M-W_Z"E?D[0!^_
M7A;_ (*@_L[^)K-9W\:-HS;<F'5+.6)P?3@$?D:W/^'C/[.O_13=-_[]3?\
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M>:?XELKAAEX/L22;#Z;@^#7BO[07_!9I-8\,ZAHWPJ\-7>FZA=(T(U[5G7=
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MO:/]6AXRQYP3@5^S5E9P:;9P6EK"EO:V\:Q10QJ%5$4850!T   Q0!/1110
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M26)@R,#T((X(H FHHHH **** "BBB@#\$?\ @JU_R>]XU_Z]=-_](H:^T_\
M@B3_ ,D.\?\ _8QK_P"DT5?%G_!5K_D][QK_ ->NF_\ I%#7VG_P1)_Y(=X_
M_P"QC7_TFBH _1NBBB@ HHHH **** "BBB@ HHHH *^0_P#@JW_R9#XT_P"O
MK3O_ $MAKZ\KY#_X*M_\F0^-/^OK3O\ TMAH _&3]EC_ ).7^%7_ &-&F_\
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ME?\ 9A_Y.2^%/_8UZ5_Z5Q5_2Y7\T?[,/_)R7PI_[&O2O_2N*OZ7* "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7%MJ#^9>PQ]VBG/S$CKAR0>F1UK]LOAK\1M ^+G@71O%WAB^74-#U:!;BWF
MP<'JK#JK Y!!Z$&@#IJ*** "BBB@ HHHH **^._V^/V_K']DVPM/#^@64&N?
M$#4H?/AM[@GR+*') EE Y8D@[4!&<$Y'?\LO%7_!2#]HCQ9>SSR?$6\TR&7.
M+73+>&") >RX3=^9)H _?Z\\,Z/J$OFW6DV-S)TWS6R.?S(J_;V\5I"L4$20
MQ+T2-0JC\!7\X_\ PVQ\=O\ HJ7B+_P*_P#K4?\ #;'QV_Z*EXB_\"O_ *U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"<<G@5SC^*/".@W4^_
M5M%TZYN'\R;-S#$\C=-S<@D^YK\H_P#@J)^W-XLF^)VI_"CP-KD^AZ!HX6#5
MKK3Y3'/=W.,O&9!RJ)PNT8R0<Y'%?FW-/->3O+-(\\TA+/([%F8]R2>IH _I
MUU;QAX#\0:;<:=JFM^'=1L+A=DUK=W<$L4B^C*Q((^M>)#]EK]E,:]_;(\*^
M"/M^_P S=]L7R]WKY?F;/_':_GT\MO[I_*CRV_NG\J /ZA?#/B#PGY=MH_A[
M4M&\N%-L%AIL\6$0=EC0\ >PKHJ_"7_@DBA'[9FADJ?^07?]O^F)K]VJ "BB
MB@ HHHH R/%GA'1O'GAO4- \0:;;ZOHU_$8;FSNDW1R(>H(_KU%?F%\=_P#@
MBW)<ZM<ZE\*/%4%O92,SC1=>W9B]%CF4'<,Y^\!CU-?4W[47_!1;P+^RG\0+
M?PCXD\.>(M5OIK-+U9M+C@:((Q8 ?/*IS\I[5X]_P^R^$G_0D^-/^_-I_P#)
M% 'Q=>?\$E?VC+>ZDBB\.:5=1J<+-'K-N%;W 9@?S%>N_"?_ ((K^--4U&WG
M^(/BW3-"TP',MKI(:YN6]@Q 09Z9R<>E>Z?\/LOA)_T)/C3_ +\VG_R11_P^
MR^$G_0D^-/\ OS:?_)% 'V;\#?@-X,_9U\#6_A3P3I8T_3HSYDLTAWSW4F,&
M25\#<QQ[ =@*]"K\];;_ (+6_"&:X1)/!_C*WC8X,C06I"^Y G)_*O:O@[_P
M4B^!7QFU:UTC3_%+:)K-R0L5EKD#6N]CT59#^[+>P;- 'U!12*P8 @Y!Y!%+
M0 5\Z_M[_L_7W[1_[-^O^&]&C67Q#:LFHZ9&<#S9HCGR@20 77<N?<5]%44
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MXKL9KUCA+6=C#*_^ZKX)_"N"\*?L%_"3P[9)%>Z1<^()\?//?W3@DXYP(RH
M]JY#XH?\$[O!^M6,MUX)O+KPUK$8W0Q2RF6V=@. <_,O/\0)^E<;J9K%<[A!
MKLF[_?L?21PG 6(E]6AB<13ELJDHP<+]W%>]8^N:*^)?V6?VA_%/@GX@/\'O
MBBTW]HQ2?9M/OKIMTBN!D1NY^^K#&QOH,G(K[:KT<)BX8RGSPT:T:>Z?8^,X
MAX?Q/#N,^K8AJ49)2A..L9Q>TDPHHHKM/F HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M59_#>V21F'_$P/0DG^Y4/_#G/XZ_\]_#?_@P/_Q% 'T)_P /OO#W_1,]3_\
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M,JY^CFOZB?$%U]AT'4KC;O\ )MI9-N<9PA.*_EV\02>=KVI28QON9&QZ9<T
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MG_L:]*_]*XJ_I<K^:/\ 9A_Y.2^%/_8UZ5_Z5Q5_2Y0 4444 %%%% !1110
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M>EEF'G1PJC56KNW\SXKCC-J&9Y[.K@)7ITU&$)=U!6O\W>WE8_.SQ)HOB_\
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M2ER<]^5W33MOJF]KHDHHKSKQ-^T1\-O!OB"70]9\8:;8ZK#_ *VW=RQC/HQ
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M_P"3D/!W_8J1?^E=U0!\9? '_DNWPX_[&33?_2J.OZ;*_F3^ /\ R7;X<?\
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MX\F//L>5/LQK^=?QEX-UOX>^)]0\/>(M-N-(UG3Y3#<6ERA5T8']1W!'!'-
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M7[2WP)TGQWJVF6ND7MY/-$UK9LS1J$?:""Q)YK\8O^':?[1G_1.;G_P+@_\
MBZ_7C_@GK\*_%'P:_9AT+POXPTMM'URWNKF26T=U<JK/E3E21R/>@#Z3HHHH
M **** "BBB@ HHHH **** /YE?V@?^2\?$;_ +&/4?\ TIDK]E/^"1'_ "9W
MIW_86O?_ $97XU_M '/QX^(V.?\ BH]1_P#2F2OV4_X)#_\ )G>G?]A>]_\
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M3_R0[Q__ -C&O_I-%7Q9_P %6O\ D][QK_UZZ;_Z10U]I_\ !$G_ )(=X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ_%GQ=J5K+XUO],\&:.=KR[9?M5WMR,J$7Y0V,\EL ]C0!QG_!*7X5ZEX_\
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MM7L'PO\ V??AQ\%XV7P5X,TCP](XP\]G;*)7XQ\SGYC^=>A4 %%%% !1110
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M:-81"&VL[5 D<2#L /\ )K7IJ.LB*Z,&5AD,IR"/6G4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $+WMO'=1VSSQI<2 LD+. [
M=2!U->+?M$?L;_"[]IRW5_&.@J=8C3RX=:L6\F[C49PN\?>7GHP-?#?_  6D
MU#6M%\3?#/4-(N=0L&BM;H-=V+R1[/G7JZXP?QKXW^&__!0KX]_#'R(]/\?7
MNI6<(VI9ZPJW<6/^!C=^M 'Z!0_\$3?AJFI+,_COQ-):!]QM?+@&5_N[]N?Q
MK["^ ?[+_P .?V:M$ET_P+H$>GR3_P#'SJ$S>;=W'.</*>2/88'M7YO?#?\
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M^L;ZF@!M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^-W_!7[_DZ?2_^Q6LO_1UQ7N7_  0W_P!=\8/]W2_YW5>&_P#!7[_D
MZ?2_^Q6LO_1UQ7N7_!#?_7?&#_=TO^=U0!^J]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!^#W_!5+7-2A_;$\96,>HW263VMD&M5G81'_1T."N<>]?'EO=36<HE
M@ED@E'1XV*D?B*_I7\:?LR_"OXC>(KC7O$W@/1=<UFX55EO;RV#R.%&%!/L.
M*P_^&+?@9_T2WPW_ . 0H _G8_X33Q , :[J0'_7Y)_C2_\ ":>(?^@[J?\
MX&2?_%5_1+_PQ?\  L=?A;X;'_;F*7_ABWX%_P#1+?#?_@$* /R>_P""3WB3
M5M3_ &Q=$@O-5O;J$Z9?'RI[EW4D0GL3BOW*KS7P/^S;\+OAGX@CUSPKX%T;
M0=7C1HTO+*V"2*K## 'T(KTJ@ HHHH **** ([BXBL[>2>>5(((U+O)(P554
M#)))Z 5XYXH_;-^!W@V^:SU?XH>';6Y4[3&MV)<'_@&:_.__ (*^?M3>()O'
M\/P?T'49M.T&QMH[K5OLTFTWDT@RL;D<[$7^'H2W/05^;.GZ1?ZO(R6%E<7K
MKU6WB:0CZ@"@#^AS_AO[]GC_ **QH'_?;_\ Q-'_  W]^SQ_T5C0/^^W_P#B
M:_GX_P"%>>*O^A9UC_P E_\ B:/^%>>*O^A9UC_P E_^)H _HA\%_ME?!3XB
M>*-/\.>&_B-H^KZYJ#F.UL;=W,DK!2V!E?0$_A7L]?S_ '_!/CP7XATS]LKX
M7W5YH.J6MM'J$A>::SD1%'V>49)*X%?T T %%%% !7C?[6G[1-E^R_\ !/6O
M&]Q;+?WL.VWT^Q9L"XN7X16(Y"@\L1S@&O9*^"_^"R7@G4_$W[,NEZO8*TEK
MH.MQ7=ZJ D^6\;Q!N.P9UYH _-SQ[_P42^/_ (]UJ>^D^(>I:)#(?EL=&86L
M$8SP %&3]22:Y?\ X;4^.W_15_%'_@P>ON+_ ()9_L7_  K^+WP?U/Q[XWT>
M#Q9J<FIS:='8W;MY%HD:1MDJ",NV_.3VQ[U]Z?\ #%OP,_Z);X;_ / (4 ?A
M3_PVI\=O^BK^*/\ P8/7ZL?\$D/BKXP^+7P1\7ZEXR\1ZAXEO[;Q$UO#<:C,
M97CC^S0-L!/098G\:]^_X8M^!G_1+?#?_@$*[[X=_"OPA\)=+N=-\'>'K'PY
M87,WVB:WT^(1H\FT+O(]<*!^% '5T444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME5@1N)8#/H*^.O\ @I)J,^H_MF_$4SL&,-U' F!C"K$H K]0_P#@DGIPT_\
M8UT9@^\W.J7LYXQC+A<?^.T ?+G_  6._9S\->"?^$2^)'AO2K;1Y]3N7TS4
MX;*$1QS.$+QRD#@-A64GOQ5+_@BC\4KG3OB-XU\ 3S_\2[4[!=4MXV/2XB<(
MVT=LHY)_W!7T?_P6.LHKC]E6UG<$R6^N6S1D'H2&4_H37P)_P2?O9K7]MGPC
M%&Y6.XLM1CE7^\HM)6 _-0?PH _>BBBB@ HHHH **** (KFZALK>2>XEC@@C
M7<\DC!54#J23P!61_P )QX<_Z&#2_P#P-C_^*KS+]M**>?\ 9-^+,=LDDD[>
M';P(D()<GRS@ #G-?SP_\(_XL_Z!FL_]^)O\* /Z:_\ A./#8Z:_I?\ X&Q_
M_%4O_"<>'/\ H8-+_P# V/\ ^*K^9/\ X1_Q9_T#=9_[\3?X5GWW]KZ9(([S
M[;:2'HL^]#^1H _I\_X3CPY_T,&E_P#@;'_\51_PG'AS_H8-+_\  V/_ .*K
M^8K3[/Q!JT+2V,&I7D2MM9[=))%!ZX)'>K/_  C_ (L_Z!NL_P#?B;_"@#^G
MZPU*TU6W%Q974-Y 20);>0.I(ZC(.*LU\>?\$H;6\L_V.=#BOX;B"Y&J7Y*7
M*LK\S''#<U]AT %0W=K#?6LMM<1+/;S(4DCD&592,$$=P14U4]8U:UT'2;S4
MKZ4065G"\\\IZ(B@EC^ !H X?_AG7X7?]$^\-_\ @LB_^)H_X9U^%W_1/O#?
M_@LB_P#B:\I_X>2?L[?]%%L_^_,O_P 31_P\D_9V_P"BBV?_ 'YE_P#B: /0
M]>_90^#GB>U^S:G\-/#5U#V4Z?&N.G< 'L*_+?\ X*%?LDZ9^QMXZ\)_$_X:
MP1PZ#>WKJVDWT8N8+2Y4;@N'SNB=21M.<;2.F*^_[S_@I9^SM9V[S'X@V\P7
M^"&VE9CSV&WFOSG_ ."DW[>GAS]J"UT'PEX%M[IO#.F3M>SZC?0F)[F8KM55
M0\JJ@MR>I/3B@#]-_P!AWXP>$OC=\!=,\1^%=#L/#4C2-#JFDZ?$L<<%XH&_
M"CLW# GG!%?0-?F5_P $0A>_\('\3"<_V=_:=MM]/-\HY_\ '=OZ5^FM !11
M10 56U+4+?2-.NKZ[D$-K:Q-/+(W144$L?P -6:\[_:,CNYOV??B8ECN^VMX
M9U(0>7][S/LLFW'OG% '\_?[4G[0'B#]ISXTZSXJU.6=[>:X:WTG3=Q9;2V#
M8CB11W(P21U8DU]'_!S_ () _%CXC^'[?6/$6IZ9X$BN462&TOU>>YVG^^B8
MV'V)S7S?^R%<:+9_M0?#*;Q$T":3'KMN9FNO]6K;OD+>V_;UK^DF@#\E-2_X
M(@:\MJ38?$_3GN<\+<Z;(J$?4,2.W:OBG]IC]DOQ_P#LJ^([?3O&-E$UE>[C
M8:M9OOMKH+U /4,!@E3R,]Z_I!KX!_X++Z[X?MOV;](TJ]FMCX@NM9AET^%L
M&;8JMYK+W P0"??% &I_P29_:2U3XR_!?4/"GB*\:^UOPC)';PW,SYEFLW!\
MO=W)0J5R>VVONJOQ]_X(BV]R?BS\1IPK_8QHD*,W\/F&=2H^N U?L%0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=8T+3?$-FU
MIJNGVNIVK=8+R!94/U5@17@/Q(_X)[_ 3XG?:)-1\ 6.FWLWWKS1BUG(/H$.
MW_QVOHRB@#\T?B-_P1.\):@9Y_!'CO4M'?'[JSU:!;F//O(NUO\ QTU\N_$;
M_@D9\=O!9EETBUTGQC:1C/F:7>!)#](Y=K$_3-?NA10!_,QXM^#?Q-^#NI(V
MO^$_$7A6]C.4FFM982/<.!_(UVGPY_;B^.?PM\N/1?B+K#VL;9-IJ,OVN-L=
MCYH8X^A%?T775K!?6\EO<PQW$$@VO%*H96'H0>#7BOQ#_8G^!_Q0WMKOPWT4
MW# _Z180_8Y ?7,)7)^N: /S@^'7_!:GXA:/LB\9>#M&\1Q[@&N+!WLY OJ%
M^92?RK[;_9;_ ."D'P]_:C\81^$M+TG6="\1R0/<+;7T2O&RH 6(D0D=^^*\
MA^(G_!%KX9Z[OE\(>+-<\+S')$5VJ7T6?0?<8#\35+]CC_@FUX[_ &6_VE+'
MQA?Z[HVO^&TL;JV,MFTD<ZEPNW=&ZCT[$T ?H]1110 4444 %%%% '\Y_P"W
M9XPN/&_[77Q1O[B4RF#69M/3)X5+?$( ^GEU]*_LC?\ !*%_CU\)M+\>>+?&
M%QX:M=7!FT_3[&T661H<D"1V9@!NP"  >#VKY,_:XT^;2_VHOBQ!.K+(?$^H
M2_,,':]P[J?R85^Y?[ GC/1_&G[(OPRDT>YBG&GZ/#IMU'&>8KB%?+D5AV.Y
M2?<$&@#\%[OX;1>%?C@_@3Q3<2V$%GKO]D:A<PJ"\2B;RWD /' YK]+]<_X(
MD>&KO1WF\/\ Q.U%;UHB\'V[3XVA<D97<58$#W&:^3O^"IW@'_A!?VQ/$]S#
M 8+77(;?58F QO9T D/_ '\5J_8[]DCXI6_QC_9S\">)X9XYII],BANA&V?+
MN(U"2(?<,IH _!'7_AG)^S7^T!%X8^*_AR34[+2+U#J.GV\YB%Y;'D/%(!T9
M3N!]L''-?T%?L_Z1X#TCX1>&_P#A6=E;:?X+N[9;RPAM22NV3YB222=V<YR>
MH-?E9_P6JU#1+KXZ>#;:QD@?6K;1&&HK'C>H:4F$/[[=Q&>Q%?5G_!'GQQ=^
M)OV7;C1[N5IO[!U>:W@+'.V)PL@4>P);\Z /NJBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _!'_ (*M
M?\GO>-?^O73?_2*&OM/_ ((D_P#)#O'_ /V,:_\ I-%7Q9_P5:_Y/>\:_P#7
MKIO_ *10U]I_\$2?^2'>/_\ L8U_])HJ /T;HHHH **** "BBB@ HHHH ***
M* "OD/\ X*M_\F0^-/\ KZT[_P!+8:^O*^0_^"K?_)D/C3_KZT[_ -+8: /Q
MD_98_P"3E_A5_P!C1IO_ *4QU_1#)_K&^IK^=[]EC_DY?X5?]C1IO_I3'7]$
M,G^L;ZF@!M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!^-W_  5^_P"3I]+_ .Q6LO\ T=<5[E_P0W_UWQ@_W=+_ )W5>&_\
M%?O^3I]+_P"Q6LO_ $=<5[E_P0W_ -=\8/\ =TO^=U0!^J]%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% $%[>V^FV<]W=S1VUK!&TLLTK!4C11EF)/0  G-?F-^TI_P62M
M_#^MWVA?"'0K?64MRT1\1:MN\AW&/FBA&"RYSRQ&<<#!S7JW_!7KXT7?PW_9
MSL_#&F7;6FH>,+XV<C(<,UI$H>90?<M$I]F([U^3O[,G[,WBS]JCXC)X3\+"
M&W\N(W%[J-WN$%I""!N8@$DDG 4<D_0T ?M[^P#\>O$_[1_[.]EXR\7FT;6Y
M-1NK9VLH?)BV(^%PN3C@XZ]J\R_X*'?\% /^&7K.W\(^#X[:_P#B!J,'G,]P
M-T6FPG(61E_B=L':I[<GT/LW[*_[/]M^Q[\#9?"USXE?7[.QEN-3FOI+86XC
M##<X"AFX&T\D_E7X(_M#?%2\^-?QJ\7^,[R0R-JFH220C<65(0=L:KGH H'%
M $WC3]I;XK?$+5I=2U[X@^(;VZDZ[=0DBC'T1"JC\!74?"#]MGXS?!/5H;O0
MO'&I7=LK[Y--U>9KRVFXQM97)('^Z17V?_P3 _8+\%?%#X>77Q+^).BC7H;N
MY:VTC3+EG2$)&1NF8*1O);@9., \56_X*8_\$]_"'PG\!_\ "T/AI8G0]/LY
MHX-6T1'>2$*[!5FBW$LOS$!E)Q@Y&,8(!]V?L8?M?:%^UU\.)-7M8$TGQ+IK
M+#J^C^9N,#L#M=#U,;X.#[$'I7T)7X0?\$G_ (E77@7]KK1-*21AI_B:UN-,
MNH\\$[#+$<>H>-1GT)K]WZ "BBB@ HHHH _!C_@JQX'U#PE^U_XAO[J.3[)K
MEO!?VLS+A778$95/?:RX/UK]8OV&O@WX-^%_[./@=_#>FVHN=4TR#4;W4O+5
MI[F>5 [%I.I"D[0.@"_6OE/_ (*U?%+X17LEG\/_ !GH/B#_ (3.TLQJ.D>(
M-'AMW2#>2/*DWR*S(Q7D <<$<BOG']C7_@J)KW[.'@^W\$^*=";Q;X4LR?L$
MEO,(KNR4DDQC(VNF3D X(R>2.  ?M_17YV0_\%L_A2T:F7P-XQ23NJ):,!^/
MG#^5/_X?9?";_H2?&?\ WZM/_C] 'Z(45\4?!'_@JQ\./CM\5?#O@/1_"GBF
MPU/6YV@@N+Z.V$*$(SY;;,3C"GH#7VO0 4444 %>"?MR?&%?@9^S;XF\42>'
M+#Q9;AH+*?2-3)%O<13RK$X; /9C7O=>5?M.? &P_::^$&I^ -2U6XT6TOIK
M>9KRUC61U\J59  "0.2N/QH _#+X%_MK^,_V:?'&NZK\.K>WTKPUK$WFS>%K
MZ1KJU3!R-K'#!ER0&ZX.#G%?4-O_ ,%NO'$<*++\-]!ED ^9Q>S+G\,<5ZO_
M ,.1?!/_ $4G7/\ P B_^*H_X<B^"?\ HI.N?^ $7_Q5 'EG_#[WQK_T3/0?
M_ ^;_"ON/]@O]K/5?VOOAMK_ (FU;0;/P_/INK'3D@LYGE5U$,<FXEAUS(1^
M%?-__#D7P3_T4G7/_ "+_P"*KZR_9!_9-TK]D/P-K/AG2->N]?@U+4CJ+3WD
M*Q,C&)(]H"DY&(P?QH ]XHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *_$O\ X+/?\G7:+_V*EI_Z4W5?MI7XE_\ !9[_ ).NT7_L
M5+3_ -*;J@#Y7_9A_P"3DOA3_P!C7I7_ *5Q5_2Y7\T?[,/_ "<E\*?^QKTK
M_P!*XJ_I<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX!_X*
MK?%C4X-%\(_"?0W=;SQ/.L]VL9(,D0<)%'D=FD)R.^T5]_5^9G_!025-!_;9
M^#NJZE_R#-MFP9ONJ%NR&Y]B0:_3_#?#TJW$-.I4CS.G&<XKO*,6X_CK\CBQ
MC:I-+KH?:G[+O[/6B?LY_"S3/#^GVT9U62)9M4O]@\RYN",L2>NT'@#L!7PG
M_P %CO\ D>?AM_V#KO\ ]&QU^I2L'4,I#*1D$=#7@/[47[&GA']JC^R[G7=2
MU+2M4TN&2"SN;%T**'()WHP^;E1W%+A'B:G@.*(9WG$VT^=R=KN\HM;=M>FR
MV#$47*A[.FCP7_@ES\%]+OOV</%5_P"(--AU"R\6WS6TMK=1ADDMX5VCKV+.
M_P"(S7F/P+6]_8G_ &^+OX9_:I'\&>*I$@MDE8D%)<FU?_?63,1/<;J_1+X,
M_"^Q^"_PO\.^"M.N'N[31[;R%N)$"M*2Q9G(!."2Q-? '[:-Q'KW_!17X0:;
MII\S4;9]+28Q\E";MG /IA?F^AK[;)<ZEQ-GN<4*CYL-B:=25GLN1?NY^322
M_I'/4I^QI4VMTU^.Y^FE>5?M1>.A\//@1XMU17"7,EH;.WYP3)+^[&/<!BW_
M  &O5:^'_P#@IEX\^SZ+X4\'PR?-<2OJ5PG^RH*1_J9/RK^:,RK_ %?"5*G6
MUEZO0_3."LJ_MGB'"81J\>92E_AC[S^]*WS/D'X!^#YO'WQF\(Z-$2#-J$<D
MC>B(?,8_DI_.OV=4;5 ]*_.G_@FQX#_M7XA:_P"*IHR8=*M!;0L1P993SCW"
MK_X]7Z+UY'#M#V>%=1_:?X+3_,_1/&3-%C,]A@H/2A!)_P"*7O/\.4S_ !!H
M.G^*M#O]'U6UCO=-OH'M[BWF4,LD;#!!'T-?A5^V'^S/J'[,_P 5KK2-LD_A
MN_+7.CWK#B2'/,9/]],X/X'O7[RUX]^U/^SOI7[2GPIO_#5Z$@U2(&XTN^(R
M;:X ^4_[K?=8>AK]^\/>,)\*YDE6?^SU;*:[=IKS77NK];'\[8O#^WAINCYJ
M_P""97[6W_"P/#:?"[Q1>AO$6D0YTFXF;YKNU7K&2>KQC\U_W:^]J_G54^+/
M@'\4?^7C0?%OAN_]U:*5&_53^1!]#7[E?LL_M$:3^TI\*;#Q-9&.#5(\6^JV
M"GFVN .1C^ZWWE/H?4&OJO%+@^.6XA9YEROAZSN[;1D];K^[/==+W75&&!Q'
M.O93W1[!1117X">J%%%% !1110 4444 <3\7OA#X?^-7@^Y\/^(+;?&V6M[I
M /-MI,<.A]?4=".#7Y-_&SX)^(O@/XRDT;68V,1)DLM0B!$=S'GAU/8^HZ@U
M^S5<1\7OA#X?^-7@^X\/^(+;?&V6M[I /-MI,<.A]?4=".*\#-,KACH<\-)K
M9]_)GZYP'QY7X4K_ %?$7GA9OWH]8O\ FC^JZ^I\M_L:_ME+KBV7@3QW>A=1
M4"'3=7G; G["*4G^+L&[]#SU^VZ_&7XV?!/Q%\!_&4FC:S&QB),EEJ$0(CN8
M\\.I['U'4&OL;]C7]L9/$<-EX$\<7@35D AT[5)FP+D#@1R$_P ?H>_UKS,J
MS2<)_4\9I):)O\G^C/N>/> \/B</_K)PW:=&:YI1CM;^>*[?S1Z;]TOM2BBB
MOLC^:@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I7VB:
M=J8(O+"UNP>OGPJ_\Q6'_P *K\&?;(KO_A$]$%S&=R2#3X@P/K]WK74T5#A"
M6Z.JGBL115J=1I>3:$I:**LY3YO^.7[#WA/XS>*Y_$BZG>>']7N@/M3V\:RQ
MS,  &*DC!P!G!YQ7C&K_ /!,6Z7=_9?CB&3^[]LLBO?OM8]J^]Z*\BME."KR
M<YT]7ZH_1<N\0N)LKHPPV'Q;Y(*R34962V5VF[+U/SAD_P"":/CI;I$'B707
MA)&Z4&;Y1GTV<U][_#+P+;_#/P#H7A>UG>YATNU2W\^08,A Y;';)R<5T]%:
M83+</@I.5%:OS.3B'C3.>)Z-.AF51.,'=)12UVN[>05^87[=GA'QQ-\;-1U'
M4+*_O="D1!IL\4;O D>T948X5LYSZU^GM%&88%8^C[)RY=;D\'\43X2S%X^%
M%5;Q<;-VWL[IV=GIVV/PYM]:U_0<>1?:EIV/^><TD6/R(KIM"^/GQ&\-S)+I
M_C36HG0Y'F7;RC\G)%?L5J'A'0M7S]NT73[W/7[1:QR9_,5S4_P(^'5S>173
M^"-"\^-MRE;"-1GZ 8/XBOF?]7J]-_NJ_P":_4_<?^(PY3BHM8[++W\XR_.*
M#X%^+-6\=?"+PKKVNP?9]6OK)9;A-NW+9(#8[;@ WXUW=,BC2&-(XT6.- %5
M%& H'0 >E/K[6G%P@HR=VEOW/YAQ=:&(Q-2M2AR1E)M16T4W=)>FQ\J_M$?M
MT6GP7\?2^%-,\/?V[>V:HU[--<>2D9=0P1<*23M(/IS7'Z3_ ,%.-$95_M/P
M7J$1[_9+E'_]"Q7HW[0'[$.@?'#Q=)XGAUNX\/:Q/&J7)2 3QSE5VJQ4LI4X
M &<] .*\+U;_ ()D>(8\_P!F>,],G]/M=O)'_P"@[J^3Q3SF%:3I:QOIMM^9
M_0>14_#3$Y;0IY@W"ORKG;=1/FZZKW;7VMTW/8=#_P""C'PQU*1%OK?6-(#'
M!::V$@7Z[":^F-!U[3_%&C6>K:5=QWVG7D2S07$+961",@@U^;EU_P $XOB;
M!=+'%?:'<Q%L&9+EPH&>N"@/Z5]^_!KX<K\)_AGH/A47?VY]/@"27&,!W))8
M@=ADG%=^65\PJSE'%PLEUVU/D>-\JX1P.'I5N'<3SSD]8\W,E&V^UT[V5F]?
MD=K45Q=06H!FFCA#=/,8+G\ZEK\T_P#@H##XW7XQ&6\%^?#?V>/^S6A#_9QQ
M\X&.-^<Y[]*[\PQGU&C[7EYM3Y7A#AM<59E_9[KJE[K=VKWM;1*ZN]>^R9^E
M$4\<RYCD60>JL#4E?B%9>.O%6B$"T\0ZQ8$<#R;V6/'Y,*ZS1?VF?BGH#*;/
MQSJXV]/.F\X?^/@U\]'B:E]NFU\_^&/V'$>"&.BKX?&PEZQ:_)R/JW]ISXZ^
M*_BU\2Q\&OABTJMYIMM2O+=MK2N/OIO'W(D&=Q[D$=N?@S]O[P%J?[+/CSPK
MX3TO6VNYK[08]3O;I8@/W[3S(RIG/R 1C&>3R:^^O^";'A**\L/&/C>\_P!)
MU6YNA8K<2<N!CS)#G_:+)G_=KX]_X+7?\G(>#O\ L5(O_2NZKNP.&CCE]=Q2
MYG+9/9+IH?*\5YW7X7J?ZL9%-TJ=%)5)QTG4J-)R;DM;*]DOTM;XKTGXM>*K
M6[3%ZU^6(40S1AMQ)Z# SFO4+C1X/BSX<E>]TFXT?6(!A9)H&3:W;#$#<I].
MU>;_   S_P +X^&^.O\ PDNFXQ_U]1U_0Q^T]X'MOB!\#/%FG7$:O)#9O>V[
ML,F.6(%PP]\ C\371C,OI\CK8=<E2.J:T^3]3R.&N,<;]9CEN<U'B,)6:C.,
MVY6N[<T6[M..^C_&S7\XEQX+UZWGDB.CWSF-BI:.V=E.#C@@<U^LW_!$W2[W
M2_A_\3TO;.XLV;5+,J+B)DW#RGZ9'-?0'_!.OQ9<Z]\$KK3+B0RC1]0>"(L2
M2J. X7Z DXKZHKTL)7^LT(5NZ/BN(<J>1YMB<NO=4Y-)]UNG]U@HHHKK/GC,
M\4?\BUJW_7I-_P"@&OY<+S_C\G_ZZ-_.OZC_ !1_R+6K?]>DW_H!K^7"\_X_
M)_\ KHW\Z /ZA/ /_(B^'/\ L&VW_HI:^-O^"Q=G)<?LDQ3)RL'B"S9^.Q64
M9_,BOLGP#_R(OAS_ +!MM_Z*6O*_VVOA3<?&;]E_QYX:L81/JCV)NK)"NXF:
M$B0 #U(4J/=J /R$_P""5.I?V=^V=X5^56\^UNX/F.,;HCR/?BOWL)V@D\"O
MYG_V??B?+\"OCGX0\9R0,_\ 8>I)+<6YRK&/)61<>NTMQZU^V7Q:_P""C'P3
M\-_!?5/$NA^.M+U[5+BQ86&BV4X:]:9U(17A^]'@GYBP &* /PX^-%PMY\8O
M'<Z?<EUZ_=?H;B0U^^GP1T&Y;]AGPOI9 6YG\%J%X)'SVQ*_HPK\#/AKX+UC
MXT?%C0_#MC']KU?7]32+H<%I'R[''0 $D^@%?TPZ#X=M/#OAC3M"M4"V-C9Q
MV42XQB-$"*,?0"@#^6^W.VXB/HX_G7]2GAV\_M#P_IEU@#S[6*7"G(&Y >#^
M-?S=_M1?">]^"/Q^\;>$KNV^S1V>I2R6>%VJ]J[%X67VV,O3N".U?K[^R#_P
M4&^$_B+]GWPU'XQ\<:5X8\4:)81V&I6>KW"P22O$NT2Q!O\ 6!U4-\N<$XZB
M@#XF_P""S5]'=?M0:- F=]MX>@1_J996'Z$5]'?\$1[.2/X._$.Y88BEUZ)%
M/J5MU)_]"%?G9^VQ\=;/]HO]I#Q7XSTKS/[%F>.TT\R*59K>%!&CE3R-V"V#
M_>K]C?\ @FC\([OX1_LF>%X-2M_LVJ:RTFL3QLA5U$QS&K \Y"!: /R<_P""
ME6E3:3^V=\0A,0?M%Q%<I@$?*T2D5^GO_!)#4CJ'[&^D(45/LNJWL'!SG#AL
MGT^]7QM_P6<^$MUX?^-6@>/HK=SIGB#3UM)9P/E6X@XV_4H5/X5T'_!)W]L;
MP9\*?#_B'X=>/M?M?#5I-=?VCI=_J#B*VW%<2QO(>%)PI&[ /(H ^A_^"R.I
M16O[+-C;.#YEUKMNJ?55=C^@KX+_ ."3>FSWW[:OA:XB7,5G8ZA-,?13:R(/
M_'G6O3_^"L_[6WA#XV77A3P/X&UBU\1:7H\TFH7NIV3[X&G9=B)&XX<!2Q)'
M&2*ZW_@BA\(KN;Q)XW^)5U 5L+>U71;*1UX>5V624J?]E40'_KI0!^M%%%%
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M)?\ [+>J?L[_  6N]3\36[6?BGQ3*EW/92?>M(%4B*-AV<[F9A[@=J^S:**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&[NX-/
MM9KJYFCM[:%&DEFE8*B*!DL2>  !G-?D)^V%_P %:O%&M>)+_P ,_!FZ70M
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MBOZ ?V:/VD_"?[4/PUM/%GABX"28$6H:7(P,]A/C)C<>G4JW1ASZ@ 'Y@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS2-(V=J@#@9QU) K\7_V\/\ @H)J?[6DUIX>T33Y_#W@*PF\^.UGD!N+V4#
MDFV\  $X0$@$YR3C !YU^P3#//\ MA?"I8 Q<:U$S;3_  @$M^&,U_177XD?
M\$@?@K>^./VC'\<2V\@T3PC:R2&<CY'NID:..//J%9W_ . #UK]MZ "BBB@
MHHHH _+K_@I=^Q;\8?V@_CS8>(_ ?A1=:T>+2(;5K@ZC;08D5W)7;+(IZ$<X
MQ7R3_P .M_VEO^B>)_X.K#_X_7[]UEZCXHT;1Y!'?ZO8V,AZ)<7*1G\B10!^
M#'_#K?\ :6_Z)XG_ (.K#_X_1_PZW_:6_P"B>)_X.K#_ ./U^[G_  L#PO\
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M7VG1117V1_-84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO87/Q+\97>G\M=13:]=/&T>.58&3!!Z8/7-<YIOP'UZZF NYK:SBSRV\NWX
M#^M?7WP(_81^(7C3P;>7'@O3;/3@RC9JOB*22WCN6/=-L;,P'7@;?>ML5F4*
ML70P;YYRTTV7FV>;D/!>*P%>&;<11^KX6BU)\^DIM:J$8[MM^6Q^@G_!/?P7
M<>&?@6-2N4:)]:O'NT5AC,8 16_'!KZ=KS7]FWX>ZS\)_@3X*\(>(;BVN];T
MC3TMKN>S=GB>0$DE695)'/<"O2J];"T%AJ$**Z(_/<^S26=YIB,QFK>TDW;L
MNB^2L@HHHKJ/!*>L6;ZAI%]:QE5DG@DB4MT!92!G\Z_&J?\ X(L?&66:1QXK
M\$X9B?\ C[N^Y_Z]Z_:&B@#,\,Z;+HOAO2=/F97FM+2&!VCSM+*@4D9[9%:=
M%% 'YM?ME?\ !)F+XG>*-0\:_"B_LM$U:_D:XOM!OLQVLLIR6>%U!\LD]4(V
MY).1TKX[T_\ X)1?M'7FL)93>$K&RMV;:=0FUBV,*C^]A7+X_P" YK]Z:* /
MC#]A?_@G1I'[*]PWBOQ%?P>)/'\T1B2X@0BVL$8898=PRS'D%R!QP *^SZ**
M /EK]MC]@WPU^UWI-K?I=KX<\;Z=&8K/6%BWI+'G/DSJ,%ESG!!RI)ZY(K\P
M?$G_  2;_:*T35GM++PUIVO6X.!?6.K6Z1$>N)61O_':_>.B@#\K?V4?^"/^
MH:)XLT_Q/\9+ZPGL[*19XO#.GN9A.XP5$\F -H/5%SN[D#(/ZGQ1)#&D<:+'
M&@"JBC 4#H /2GT4 >??'3X&^%OVA_ASJ/@SQ;:&XTZ[&Z.:+ FMI1]V6-B#
MAA^O(K\B/BY_P1\^,?A#6)AX*;3O'6D,_P"XD2ZCL[D+V\Q)650?]UC7[<44
M ?B?\'O^"._Q<\6:U:-X[GT[P3H@?-SBZ2[NROI&L9*9/J6&/?I7Z^?!SX0^
M&_@3\.='\%>$[/['HVFQ[$WG=)*Y.7ED;^)V)))_ 8  KM** "BBB@ HHHH
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MS.$16=ST51DF@#]NC_P64^ H)_T'QB?^X7#_ /'Z/^'RGP&_Y\/&7_@KA_\
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M/+$$4G(R<G+FO ?^"WW_ "3WX8?]A.\_]%1UT'_!$W_DWWQQ_P!C0W_I);T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,^%U_WY;_"@#^C?Q%^V-\$?"NGO>ZA\4/#2P*"3]GOEN'X]$CW,?RK\I?\
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M/L=F?J*_4VN.^$7PH\._!'X>Z/X,\+6GV/1M,B\N,,<O(W5I';^)F.2378T
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M /GPM?\ ORO^%<3H_P"T1\+]>MQ/8?$#PY<Q8#;EU*(<'IU:K_\ PNKX??\
M0[^'O_!I#_\ %4 =/_8NG_\ /A:_]^5_PJS#;Q6T8CAC2)!T5% 'Y"N/_P"%
MU?#[_H=_#W_@TA_^*KI=%U[3?$FGI?:3J%MJ=DY(6XM)5EC8CJ RDB@"_111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH @O+*WU"W>"Z@BN8'&&BF0.I^H/%>0_$+]CGX+_%#S'\0
M?#K0[BY=2OVJ"V$$RY]&3!%>RUYE\8_VE?AI\ K>*3QSXML-$FF!:&S=]]Q*
M!W6-<MCWQB@#Y,\>_P#!&7X0Z^N[PSK>O^%90"0OG+=QD^XD&<?C7S+\0O\
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MNGFCT^Z69HU,: %MIX!(KTS_ ((F_P#)OOCC_L:&_P#22WK\O?\ AE7XP_\
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M7:;_ ,-&?MWKH&IYF\/Z VQH&.4:.%=[KC_;<X/M7WX1'9VN$14BA3Y408
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8STQTK]%J^9_VGO^"@/PN_9?NI-)U>[FU[Q6J!_["TK#2H#T\US\L>1Z\^U
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MPN/_ (NO>?A/\)?"WP2\%VWA3P=IO]E:%;N\D=MYC289SECEB3R: .PHHHH
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M^,'^[I?\[JO#?^"OW_)T^E_]BM9?^CKBO<O^"&_^N^,'^[I?\[J@#]5Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,X^T6K^4X+*/XXB3PX]<'!R* /%_^"1__)YFB?\ 8+OO_1)K]VJ_"7_@D?\
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M$CAC49+,37Y=_'3_ (+37$.KW>G_  H\*6\]A'E8]:\0;\RG/WEMU((7O\S
M^H% 'ZL45^,O@C_@M/\ %+3-25_%/A3PYKM@2-T5@LMG(H[D,6D!/X5^G/[,
MO[4G@O\ :H\"CQ%X3N&BN(2([_2;H@7-E(?X7 /(/9AP: /8:*** "BBB@ K
M\2_^"SW_ "==HO\ V*EI_P"E-U7[:5^)?_!9[_DZ[1?^Q4M/_2FZH ^5_P!F
M'_DY+X4_]C7I7_I7%7]+E?S1_LP_\G)?"G_L:]*_]*XJ_I<H **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_ /0CX)4(*];,K?]N+]9G[)WGQN^'^G[?M'C/1(=W3=?1\X_&L.Y_:D^$MJ
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M^"G.F@M]C\$73#;\OGW:CGWP#Q6#=?\ !3S5-W^C>!+,#'674'Z_@G2F6/\
MP3'UEO+^V^-K&/GY_(M7;'TR16[9_P#!,&RVJ;KQ_<9SRL.F+T^ID_I1_P +
MT_+_ ,!"WA/AM'[W_@Y_D<5>?\%+O&DVW[/X8T>WXYW/(^?Y5@77_!1CXIRD
M>3;Z% ._^ALV?_'Z]PL_^"9OA&$?Z3XLU:X.[/R0QIQZ=_SK>M?^"</PPCSY
M]_X@G.>-MW&@^G^K-'U7.Y[U+?-?H']N^%V&_AX7F_[AR?\ Z4SY7O/V^OB_
M>  :M8V^&S^YL4'X<YXK O/VSOC%=Y_XK.Y@RV?W,$2_A]WI7W%9_P#!/_X1
M6N[=I^I7&?\ GM?,<?D!6]:?L3_!NU)SX/CN.,?OKN<_CPXYH_LO-I_%7_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !117PS_ ,%-OVV]5_9L\,:9X0\%3I;^-]?B:9K]EW'3[4$KO0$8,C,"!GH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKG#7#+TW/@'V&!FOK_\ X*V?MF_989?@CX0OOWSA7\2W<+?=4@,EH"/7AG_
M<<U\B?!_]D&?Q%^RK\3OC5XDAFM]*TFR\K0(=VW[5<>:BO,<<[$!('8DGKB@
M#S+]E7_DY'X:_P#8>M/_ $8*_I4K^:O]E7_DY'X:_P#8>M/_ $8*_I4H _,'
M_@M%\>+S1]#\*_"K2[IH$U0'5=6$;X+Q(VV&-A_=+[F^L8KXA_8;_9&N/VNO
MBK/H<]_-H_AS2[;[9JE_#&&<+N"I$F>-[DGD] I.#C%=A_P56\5'Q+^V;XH@
M,F\:1:6FG ?W<1"3'3UE/YU]<?\ !$+P^EOX#^)VMX4R76HVEIG/($<<C8_.
M7]/:@#R;]NS_ ()@:#^S_P#":7X@?#W6=6O[#2Y$75;'6'2601NP198W1$X#
M,H*D=&SGBOF_]@7X\7WP$_:6\*ZA'<.FC:Q<II&J6X8[)(9F"JQ&<91RK9[
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M@XW?O%1/_0F%;EE^Q#\9KPKGP>UNK#.Z:]MU_#'F$@_A1_:^:3^"A_Y+(/\
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ME.[E8=+SD?4RC!_"MRS_ ."9/AF//VGQEJD_/_+.UC3CTZFOM&BMXY+@(_\
M+O\ %_YGEU/$SBRIOC6O2,%^43Y,M/\ @FS\-X]WVC6?$4Y[;+B%,?\ D(UN
M6G_!/7X26N[?;ZQ<Y&/WM]T]^%%?2]%;QRO!1VI(\NIQUQ-5^+'U/D[?E8\&
ML_V'/@U:G+^%#=<8_?7T_P"?RN.:V[+]D?X0:>5,/@73B0-H\QI)/_0G->O4
M5O'!86.U*/W(\JIQ1GM;X\=5?_<2?^9Y]8_L^_#33MAA\":#\@P/,L(Y/SW
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MTG_Q5?JA_P +"\+?]#+H_P#X'Q?_ !5'_"PO"W_0RZ/_ .!\7_Q5 'Y0ZO\
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M ((+K_XBOZ3G=8U+.P50,EF. *H_\)!I?_02L_\ O^G^- '\W_\ PR3\;O\
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M'\N3VK\=_B7_ ,%=OCCXNUF[?PY=:;X.T=V(AL[6SCGE5<\;I9 26QUQ@>U
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MUH==GVF,Y7/&['_ LU^F'_!%RUGB_9W\3SR',$VNL(ACIB)=W\Q0!^@]%%%
M!1110 4444 %%%% !1110 4444 %>3?%C3?@AKC2K\1T\#W,GW)/^$B>TW\<
M 'S3GC'Z5ZS7X/?\%4_A#J'PU_:GUK5VAD&B^*E75;28L65I",3+Z AP>/0@
M]Z /V8^ ]C\+-+\(W%K\)(]!C\.QW3^:/#Q0P><<%LE>">G>O1IH4N(GBE19
M(W4JR,,A@>""/2OQ"_X)C_MM:+^S7XBU;PCXVD>U\':_,DXU)5+BPN0-N]U
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M9#:N2<YD"Y<Y[_,6KO: /'?^&-_@3_T1_P $_P#@BMO_ (BC_AC?X$_]$?\
M!/\ X(K;_P"(KV*B@#QW_AC?X$_]$?\ !/\ X(K;_P"(H_X8W^!/_1'_  3_
M ."*V_\ B*]BHH _GW_X*4>"?#_P[_:^\7:%X7T6P\/:+;VU@T.GZ;;K!!&6
MM(F8A%  RQ)/N:^[?^")/_)#O'__ &,:_P#I-%7Q9_P5:_Y/>\:_]>NF_P#I
M%#7VG_P1)_Y(=X__ .QC7_TFBH _1NBBB@ HHHH **** "BBB@ HHHH *^0_
M^"K?_)D/C3_KZT[_ -+8:^O*^0_^"K?_ "9#XT_Z^M._]+8: /QD_98_Y.7^
M%7_8T:;_ .E,=?T0R?ZQOJ:_G>_98_Y.7^%7_8T:;_Z4QU_1#)_K&^IH ;11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?C=_
MP5^_Y.GTO_L5K+_T=<5[E_P0W_UWQ@_W=+_G=5X;_P %?O\ DZ?2_P#L5K+_
M -'7%>Y?\$-_]=\8/]W2_P"=U0!^J]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%?#/_  44_;@\=?LC^)?!]GX5TC1]0LM8M)III-22
M1F61'  7:PXP: /N:BN1^$?BC4?&WPN\*>(-6AA@U+5-,M[RXB@!$:O(@8A<
M\XYKKJ "BBOFS]OC]H[Q/^R[\$[;QEX5L+#4+TZK#931ZBCM&(G20DC:0<[E
M7OW- 'TG17S[^PU\??$7[2WP$LO''B:RL;#4+F]N+=8M/5ECV1OM!PQ)SG/>
MOH*@ HHKS[]H'QYJGPO^"GC/Q;HEO!=ZKH^FRWEM#= F-W09PV.<?2@#T&BO
MBS_@G7^V9XW_ &N/^$RE\5:5I.GVVC>0L#::CJ6=]Q(;<Q[+7VG0 444V1BL
M;%>2 2* '45^=W[(O_!0;XD_'K]J*Y^&NOZ'H5EI=JMZTTUE'()AY)VCDN1U
MQGBOT1H **** "BBB@#\^?\ @J7^UM\3_P!F;7/AW;_#W7H=&AUBVOI+Q9;"
M"Y\QHVA"$&5&Q@.W3'6O"O#/_!2;XY?%OX8>'O /P]L+CQ3\8=0>XEU/6;;3
M8E%M;A\1K'&%$:G;C,C  9 ')XT_^"XW_(S?"+_KSU/_ -#MJ]0_X(J^ M*L
M?@EXO\9) AUK4=;;3))R,LL$,,3JH/8%IB3ZX'H* /C?QM\<_P!LC]EGQ39:
MCXX\1>+=+EO',D,.MW*WUC/@Y* ;GB[_ '1@@>E?J%^PC^V?8_M>?#VYFN[6
M'2O&>BE(M6T^%OW;[A\D\0))"-@C!Z$$9/!JQ_P49\ Z9X^_8_\ '\>H1(9M
M+M5U2SG*!FAFB=6ROIN7<A]G-?F#_P $C?%]QX<_:\L=.261;;6M+NK26)<[
M7*@2*2/;8<'W/K0!^Q7QB_:.^&_P%TUKOQQXMT_1&V[DLWDWW4OILA7+G/KC
M'O7YR?'[_@M%J%[]JTSX1>&5T^'E4U[7E$DQX^\EN#M4@Y^\6SZ5\_\ _!4'
MX<^+M%_:F\8>)-2T'4X/#NH21-9:I)$S6TB^6JX5^5'S C:2#[5>_8,^/'[.
MWPJU6T'Q/^'C3^(5ES%XJF)OK>$A@4/V9N(R.<NN?I0!F>$?V<_VF_V\-<B\
M0:T^JWFFS-N76_$T[P6<:,<X@C(Y7G@1KMXZBOU)_95_99B_8B^!OBNS7Q%)
MXAU*XCEU2ZN?($4221PM@1KDG& .IY/I7O'PY^)/A#XH>'8-6\&:]IVO:2R+
MLDTZ56" ] RCE#[, :I_&RUEOO@[XVMX?];)HUV%R<<^2W>@#^>;]G_3U^+'
M[4G@6VUP+=CQ!XHMC>B0960RW +Y'H2QK^C#QUX7L/&7@?7O#^HVZ7&G:E83
M6<\+KE6C>,J1CZ&OYV_V+_\ D[3X0?\ 8TZ?_P"CUK^CR\8+:S$] C']* /Y
MN?V6O%%U\.OVH/AQJD6;>6T\16L$HDRI6-Y1%*#Z'8["OZ2^O(Z5_,]X+F76
M/VB-"EM/WZW7BF!HL?QAKM2OYY%?TOQ K$@/! % #Z_ 7_@J!XPE\6_ME>,T
M>1VBTL0:=$C'A!'$N0![DD_C7[]5_.C^WE9S6/[8?Q82;[SZY-*N#GY6PR_H
M10!^XG[%_A&W\$?LL_#32K<+A=&AF=U4#>\@WLQQU.6K\9/^"E_@^U\&_MD>
M.([*+[/%?M#J.Q4V@-)&"Q'L2"?Q-?MU^S1_R;W\.O\ L!6G_HI:_&[_ (*W
M745U^V5K(C??Y6E6,;^S!#Q^M 'V?^T)\7[V^_X)):3KUM/_ *5K&C:=I$LF
M<[E,BP2@G/4JCY]S7RG_ ,$;?"MGKW[5&H:C<PI+-HOA^YO+=G&2DC210EAZ
M';*P_$UZC\9M,N8_^"-7PY9D\L0W%O(ZL<':]Y-M/OG<#^-<1_P11_Y.0\8_
M]BI+_P"E=K0!]R_\%5/"-GXF_8P\77<]J+BZT6XL]0M6V;FC?[0D3,/3Y)7R
M?3-?!?\ P1E\87&C_M,:WH(D"V>L:#*SJ3]Z2&1&3]&D_.OT<_X*-7L5C^Q9
M\4))GV(UC%$#_M/<1*H_$D#\:_+G_@D;!)-^V-IA1"PCTB]=\=AM49_,C\Z
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M-?S7_#/_ ).2\-?]C1!_Z5"@#^EJEI*6@ HHHH **** "BBB@ HHHH ****
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ML_X)4_M$_$_XK?M#ZCI/C'Q[KWB72X]&FF6SU*^>:(2!T ;#'J,G\Z /EO\
MX*1?\GM_%+_K\M__ $D@K[X_X(F_\D5\>?\ 8<3_ -$+7QG_ ,%7O"Y\-_ME
M^(Y]BH-6L;/4 5&-V8_+R??,7Z5]7?\ !$'Q+'<>"_B=H!<"6VOK.]5,<E9$
MD4G\#&/S'K0!^@OQL94^#7CQF(51H-^26Z ?9WK^8Q_OM]:_I+_:ZUR#P[^R
M[\5;RX=4C_X1N^@W,<#=+"T:_P#CSBOYN;&RFU*]M[2VC,MQ<2+%%&O5F8@
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M3%U\MYKX91YFGTDVDN7M?6ZVT[G$^,OBQXP^(5Q%-XA\1ZAJKPJ$C$\[%4
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M>T;?*/ZA_9GA3A_XE?F_[>JO_P!)+MY_P4ZOFV_9? UNG//G7S-_)16%=_\
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M:3/URW-;UC^R;\([!4">!-)EVG(,\1DS]<GFC^Q\SG\=?_R:0?\ $1N",/\
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MTZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1V)8_4DU_0=_P3X^#<_P1_97\(Z/?V[6VKWZ-JU]$W599L,%/T0(,=J_/?\
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MOBS_ (*M?\GO>-?^O73?_2*&OM/_ ((D_P#)#O'_ /V,:_\ I-%0!^C=%%%
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M_P 31_P]:_:#_P"@UHG_ (([?_XFOJ/_ (<Q^!O^BE^(?_!;!_\ %T?\.8_
MW_12_$/_ (+8/_BZ /ES_AZU^T'_ -!K1/\ P1V__P 31_P]:_:#_P"@UHG_
M (([?_XFOJ/_ (<Q^!O^BE^(?_!;!_\ %T?\.8_ W_12_$/_ (+8/_BZ /ES
M_AZU^T'_ -!K1/\ P1V__P 31_P]:_:#_P"@UHG_ (([?_XFOJ/_ (<Q^!O^
MBE^(?_!;!_\ %T?\.8_ W_12_$/_ (+8/_BZ /ES_AZU^T'_ -!K1/\ P1V_
M_P 31_P]:_:#_P"@UHG_ (([?_XFOJ/_ (<Q^!O^BE^(?_!;!_\ %T?\.8_
MW_12_$/_ (+8/_BZ /ES_AZU^T'_ -!K1/\ P1V__P 31_P]:_:#_P"@UHG_
M (([?_XFOJ/_ (<Q^!O^BE^(?_!;!_\ %T?\.8_ W_12_$/_ (+8/_BZ /ES
M_AZU^T'_ -!K1/\ P1V__P 31_P]:_:#_P"@UHG_ (([?_XFOJ/_ (<Q^!O^
MBE^(?_!;!_\ %T?\.8_ W_12_$/_ (+8/_BZ /ES_AZU^T'_ -!K1/\ P1V_
M_P 31_P]:_:#_P"@UHG_ (([?_XFOJ/_ (<Q^!O^BE^(?_!;!_\ %T?\.8_
MW_12_$/_ (+8/_BZ /ES_AZU^T'_ -!K1/\ P1V__P 31_P]:_:#_P"@UHG_
M (([?_XFOJ/_ (<Q^!O^BE^(?_!;!_\ %T?\.8_ W_12_$/_ (+8/_BZ /ES
M_AZU^T'_ -!K1/\ P1V__P 31_P]:_:#_P"@UHG_ (([?_XFOJ/_ (<Q^!O^
MBE^(?_!;!_\ %T?\.8_ W_12_$/_ (+8/_BZ /ES_AZU^T'_ -!K1/\ P1V_
M_P 31_P]:_:#_P"@UHG_ (([?_XFOJ/_ (<Q^!O^BE^(?_!;!_\ %T?\.8_
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M^/UWKOQ(L/$NH^#-4L)K=[K4+<V]G92 B2,QQD*!DKM^4?Q5\W_'#X/>,?\
M@F'\=O"'BWPG=MJFC7EJA%Q>1*\4\@4"ZM9.. 3DJ>N"#VK]??V=?CUX?_:2
M^%.D^-_#I=+:Z!CN+64$/;7"X\R(^N">HX((H W?B]JVO:'\+_%5]X6TR76?
M$D.FSMIMA#C?-<;#Y:C) ^]BOQ\\#_MH_M7_ ++&I"Q\=:)K7B#1X3^^L_%%
MC(Q50,82Y RN/3)'M7[95^9/_!4_]N1_#D-[\$_ \F[6+I!'X@OO*R8(W (M
MH\C[[ @LPZ @#DG !\0? 3]KJ7X&_M">-OB=HGA1-5U+78KV+3M-N)3LMFN+
MA)<MM&7VJI7 QG-?1'P*_:3_ &LOC9^T1X/\17>E>(]2\+V>HQF^TJQL6M-/
M6V<F-V8$!7*JY.22<J*\S^+W[#WC?]EGX&_#3XTZ;=7,7B!'2YUJW$:DZ3*[
M;[9L$'(P0CYX#8'>OTV_8)_;(T[]J[X:%;J..P\;:(B1:Q90Q[8FSD+/'V"O
M@_+V((Z8H ^HZ*** "BBB@#\E_\ @N-_R,WPB_Z\]3_]#MJZ#_@B_P#'C0[/
MPWXI^%>IWL%CJSW_ /;&FI-(%-V'18Y43/5E\N,XZD,?0US_ /P7&_Y&;X1?
M]>>I_P#H=M7F/[)/[ L'[4O[+MQXO\-ZZWAGXAZ5XCN;6"[D9O(GA6&V=4;;
M\R,"[D,O][F@#[^_X*<?&[0OA?\ LN^*=$N;Z#_A(?$T TW3]/W R.&=?,DV
M]0JH&Y]<"OS^_P"".OPZO/%'[3=YXE%ONTSP[I,KRSD<+-,0D:CW($A_X#5_
M3?\ @DC^T#XX\41KXPUS2[6R4[#JMYJC7K[ ?X5Y;\#CK7ZD_LN_LP^%?V5?
MAM%X5\-JUU/*_P!HU'59U FO9\8WMCH !@*. /?)(!ZIK&BZ?XAT^:PU2QM]
M1LIAMDM[J)9(V'NI&*^(_C[_ ,$D/A1\3EN+_P &&7X>:VP)5+(>98LV. 83
M]T9Y.PBONFB@#\&?'7[(O[2G[$_B"7Q#X;;5#8P$[=?\)S/)&4S@>;&/F7([
M,I&.]?HY_P $[OVD?%_[6WP3\6?\)V+*34M/N3I9N[6+RC.DD1.70<!AG''6
MOLE@&!!&0>"#6)X=\$>'_"%QJ,^AZ-8Z1+J,BS79LH%B$S@8#,% !..] '\Y
M=DU[^S'^T];O>6LJW7@SQ*LAA?Y798)P5/\ P)0"#[BOW,^+7[9GPP\)_ '6
M/'NG>,-)U-)=+>73;.WO$-Q<SNA\J,1@[E8L0#D?+SFO+?VXO^";FB_M1:D/
M%WAK4(?"_CH1B.>::,M;7ZC 7S0O(<#@,.V >E?"%C_P1Z^/-QKBVEP/#UKI
M^_:=0.I!U"_WM@7=^&* /(OV!OAG<_%K]KCX?V$5O)-;6&HKK-XZ=(HK<^;N
M;_9+JB_5P.]?O7\5/C7X&^".DV>I^.O$MGX9L+R;[/!/>%@LDF"VT8!YP":\
M<_8G_8?\._LA^%[EUN4UWQGJ:*NHZSY>U=HY$,(/*QYYYY8@$]!7,?\ !2O]
MFGQS^TY\+_#.A>!;2SN[^QU4W<ZWEVMNHC\IER">IR1Q0![]\*/V@OAU\<CJ
M(\!^++#Q.=/V?:A9%OW._.W.0.NT_E7XX?\ !6[X;77@O]J^]ULP;-.\26,%
M];R=F=5\N4?7<N?H17W-_P $Q_V1_B+^RV/'0\>65A:#5_LIM?L=ZMQNV;]V
M=O3[PKW[]J_]D[PG^UGX!70/$)>PU*S<S:9K%NH,UG(<;N#]Y&  *GT!ZB@#
MRG]@?]J[P%XJ_9:\,0ZQXMTO2M:\-V2V&J6^I7<<$BF,';( Q&Y2@!!'N*_)
M/]L#XG0_M&_M4>*]=\.^9?V&HWZ6.EX0[I8T"QH0/]H@D>Q%>Y^+?^".GQQT
M?6GMM$G\/^(=/_AOEOOLV?JCC(_6OK#]BC_@E?!\#_&5CX[^(NJ6FO\ B'3S
MYNFZ79*3;6LO:5V8?.Z\X & <'DB@#T[]H[]GJYN/^"<M[\/+:V:75-"\.VM
MPMO!\S/<VP25U7'7+*X]\U^97_!,7XY:+\#?VGK&Z\1WB:;HFN6,NCSWTS;8
MX&<J\;.?[IDC1<]MV>U?ODZ+(C(ZAD88*L,@CTK\P?VKO^"0,GBWQ9J'BCX0
MZG8Z4E\[3S>'-0S'%'(3D^1( =JDY.UAQG@XH [C_@J]^TOX-@_9OG\#:)X@
MT[7=;\37<"F#3;M)_)MHI!,TCE"0!N2-0#R=V>U>#_\ !%'X7W.I?$WQMX_E
MMY%L=+TY=)@G(^1YIG5W4>ZK&A/H''K7'_#_ /X(W?&37M:CB\4W^A^%]+#*
M9+A+K[7(5S\P5$'7'3) S7ZV? 7X%>%_V=/AKIO@OPG:F&PM07EN),&:ZF;[
M\LA'5CC\  !P* /QZ_X*\_#>Z\'_ +5D_B QD:?XFTZWNX7 XWQJ(9%SZY0-
MC_:%??W_  3X_:H\!>)/V5_"UAJOBK2](UGPQ9+IVHVVI7B0R*(P0L@#$;E9
M0#D9]*]C_:I_97\)_M7_  \/ASQ&'L[VV<S:;JUNH,UG*1@D _>4@8*GKQW
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"J/[#.@?"O3;;XK_  ^TY-*T:XNA:ZWI-N,0P2O_ *N>,?PJQ!5EZ!BN.IH
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MI]D?(/H),]J_//\ 9"_:IUS]DKXICQ5I=HFJZ?=0&SU/2Y7*+<PDAN&_A=6
M(/U!X)K^B_4M-M-9T^YL+^VBO+*YC:&>WG0/'(C##*RG@@CL:_.WX[?\$:?!
MWC+6+W5_ASXCD\&27!WC2+J(W%E&QR3L;.]1TXYQ0!\P?MI_\%/KW]IKX<+X
M&\->&9O"FAW<B2ZI)=7*S37(1@R1C: %3< Q[DJ*\U_X)R_L[WWQZ_:0T"62
MUD;PWX;G35]3N=IV#RV#119Z;G<+QZ!J^I/!/_!$/4!JJMXO^)5J=-')31;)
MC*WMF0X'Y&OT:^!/P \%_LY>"(O"_@G2UT^R#>9/.YWSW4F,>9*_\38_ =J
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M;(8[."'/EP1Q_P"Z@%34459RMM[A1110(**** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 ?@C_P %6O\ D][QK_UZZ;_Z10U]I_\ !$G_ )(=X_\
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M *.N*]R_X(;_ .N^,'^[I?\ .ZKPW_@K]_R=/I?_ &*UE_Z.N*]R_P""&_\
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M%%% 'Y2?\%MM$U'5_$OPF-C875Z([34MYMX6DVY>WQG XZ5[?_P1PTV[TO\
M98UJ&]M)[.;_ (2JZ;R[B)HV(^S6O.".GO[5]V44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <[X^^'OAOXI>%;SPWXLT>UUW1+P8FL[M-RG
MT([JP[$8(K\]?BC_ ,$4_">KWUQ=^ _&]]H$;_<T_5(!<QH>_P"\!#8]B#]:
M]K_;S_;^T_\ 9)M;#0M%TZ'Q!XZU*(SQVL[E8+.'D"67'))/1!C."20,9_.G
M4O\ @KI^T'J%QYD>HZ#8K_SRMM+&W_QYB?UH ]0B_P""(_Q#^U*)?B'X9%MN
MY=8;@OM]=NS&?QKVWX1?\$7_  +X9U*WO_'GBJ^\6^65<Z;:1"TMV8$'#-DL
MRGICCCO7QQ_P]E_:'_Z#ND_^"M/\:ANO^"KW[1%U;O$OB/38"PQYD6F1AE^F
M<T ?NAX3\)Z+X$\.V.@^'M,M='T>QC$-M96D82.-1V '\^IZFM>OQP_X)U_M
M*?$[XZ?MG:#_ ,)SXTU37H$TV^*6DDHCMP?).#Y2!4)'8D9K]CZ "BBB@#\\
M_P#@M-HL]Y^S_P"$]23_ %-CKH63C_GI$P'_ *":^5_^"-GB&STO]I[4].N'
MV7.I:),EOGHS(RNP^N ?RK]3/VQ/@@?VA?V>/%O@V!(VU2>W^TZ<T@R!=1'?
M']"<%<_[5?SX^"/&/B?X"_%+3]=TTR:3XG\.W^[RYEP4DC8AXW7N#@J1[T ?
MT[45\A?LZ_\ !3;X0_&C0+-->UZT\"^*=BK<Z;K,HAB:3H3#,WRNI/09W>HK
MZ9L_B5X1U"W6>V\4:-/"WW9$OXB#_P"/4 =)7R1_P52U6ST[]B?QM!=2(DU[
M/8V]LK$9>07<3X'OL1S] :]5^)'[8'P:^%%C/<^(OB'H=O)"A?[';W:W%S)C
MJ$BC)9C]!7XZ?\% /VZ[K]K;Q-9:1H=M-I?P^T61I+.VN !->3X*FXD Z?*<
M*O8%L\M@ '-?\$W=.GU+]M;X8B",OY-Y//(0.%1;:4DG]!]2*_H2K\E_^",O
M[.]]/XBU[XP:K:20Z=! VDZ.T@P)Y&(,\BY'(4*J CC+..U?K10 4444 ?+O
M[0W_  3M^&/[2WQ&D\:>*[G7(M6>UBM"MA=K'%LCSMX*'GGUKK-:_8X\#:]^
MS18_ ZYGU4>#K,1B.1+A1=?).9AE]N/O'TZ5\[?MI?\ !3#7OV5_C9-X&T_P
M1IVOVR:?;WHO+J]DB<F3=E=JJ1@;:\(_X?@>+/\ HENC?^#2;_XB@#Z(_P"'
M-OP+_P"?[Q3_ .#"/_XW1_PYM^!?_/\ >*?_  81_P#QNOG?_A^!XL_Z);HW
M_@TF_P#B*/\ A^!XL_Z);HW_ (-)O_B* /HC_AS;\"_^?[Q3_P"#"/\ ^-U]
M'?LS_LN^$?V4_".J>'?!TVHS6&HWQU"8ZE.)7$AC2/@A1@805^=/_#\#Q9_T
M2W1O_!I-_P#$5]O_ +"'[6FI?M?_  WU_P 3:GX>M?#DNFZL=-6WM+AIE=1#
M')N)8#!S(1CVH ^EZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OQ+_X+/?\ )UVB_P#8J6G_ *4W5?MI7XE_\%GO^3KM%_[%2T_]
M*;J@#Y7_ &8?^3DOA3_V->E?^E<5?TN5_-'^S#_R<E\*?^QKTK_TKBK^ER@
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M/X:_1JOY^XEX?Q/#.95,NQ/36+Z2B]I+]>SNNAZM&K&M!3B%%%%?+&X4444
M%%%% !1110 4444 5-3TBPUJV-OJ%E;W]OG/E742R)^3 BJ&F^"O#VC7(N-/
MT'3+&X7I+;6<<;C\0H-;5%2XQ;NUJ;QKU8P=.,VHOI=V"BBBJ, HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\8/^"UW_ "<AX._[%2+_ -*[JOV?K\8/^"UW_)R'@[_L5(O_ $KN
MJ /C+X _\EV^''_8R:;_ .E4=?TV5_+)H>M7WAK6M/U?3+AK34M/N([NUN%
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MH_X2#2_^@E:?]_U_QK^7;_A(M5_Z"=Y_X$/_ (T?\)%JO_03O/\ P(?_ !H
M_J)_X2#2_P#H)6G_ '_7_&C^W],Z?VC:?]_U_P :_EV_X2+5?^@G>?\ @0_^
M-:'AWQ#JC>(-+#:G>%?M46<W#_WQ[T ?U#@Y&1R*6L[PX<^'M+/7_18O_0!6
MC0 4444 %%?,O[4/_!07X7_LMZA_8NL3W7B#Q5M5SH>D*KRQ*>AE=B%CXYP3
MDCD"O"? ?_!:3X9Z]KD%EXC\*:[X:M)G"_VAF.YBB'JZJ=V/]T&@#]#V4,I5
M@"I&"#T-?D7_ ,%EO@OX+\#ZCX(\8>'],M=%U[6)9[:_AL46))UC5664HO\
M%DX+ <]^:_6+PUXETKQCH-AK>B7\&J:3?0K/;7EJX>.5&&0P(KXV_:Z\*?LT
M_M#_ !FLOAS\2O$UUX=^(FG6D8L)DN6MD*3?,L:NX,3$D@[>&/'- 'F?_!'W
M]ISQ7\2M/\2_#?Q1?SZS%H%I'>Z9?73%Y8H2XC:%F/+ $J5ST&1TQC]**^7?
MV+?V%]&_8\E\5W%EX@D\3W>MM$L=W-:K \,"9(CX9LY8YSQT'%?45 !1110
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M@G_P6W/_ ,DUQ>G_ /!*/]HR\D19/"MA9AER6GU6#"\=#M8\UH_\.C_VA/\
MH$Z+_P"#5/\ "@#H_P#A\Y\=?^@/X)_\%MS_ /)-?6W_  3H_;P^(O[5_P 1
M/$VA^,K'0+6STW3ENX6TBTEA<N9-N&+RN",>PKXF_P"'1_[0G_0)T7_P:I_A
M7V)_P31_8H^)W[,?Q*\4ZSXXLM/MK'4-,2U@:TO%F8N)-QR .!B@#]%:***
M"BBB@ HK\H/B;_P4X^(/[./[67Q$\+ZG:6_C'P/9ZL8X=/GQ#<VL>Q"1#,!T
MR2<.&_"ON#]G?]N/X3?M*V\,/AOQ EAX@8?/H&K$07@/H@)Q)_P GWQ0![_6
M/XQ\2V_@SPCKGB"[4M:Z38SW\RKP2D4;.P_)36Q7(_%[PO/XX^$_C/P[:_\
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MZKT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX&CA&Y0NY/=O5G@9[Q7F7$$84<0XPHP^&G!<L(^B77S=_(****]$^."BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU)0J5R>Q7TK[MK\>O^"(UU*OQ@^(EL'/D-H44A3MN%PH!_)C^=?L+0 4444
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ME\(_A+X8^!_@'2_!WA'3ETW1=/3:B Y>1C]Z1VZL['DDUV-% !1110 4444
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M%'>3(B+JDP"J'(  W=*_8:OGZ^_83^#VHWMQ=SZ#=M//(TLC#4IQEF.2?O\
MJ:\#-L%B<8H+#RM:]]6NW8_7/#[B7)>'*F)EG%%U%-1Y;1C*UN:_Q-6W6Q^<
MW_#17Q2_Z*'XF_\ !K-_\51_PT5\4O\ HH?B;_P:S?\ Q5?HG_PP/\&?^A?O
M/_!G<?\ Q='_  P/\&?^A?O/_!G<?_%U\[_8N9?\_5_X$_\ (_9O^(G<$_\
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M\_5_X$_\A?\ $3N"?^@&7_@JG_\ )'YV?\-%?%+_ **'XF_\&LW_ ,54EO\
MM$?%%KB,'XA^)L%@/^0I-Z_[U?H?_P ,#_!G_H7[S_P9W'_Q=*O[!/P:5@P\
M/WF0<C_B9W'_ ,71_8N9?\_5_P"!/_(3\3N";?[C+_P53_\ DCZ"MV+6\9)R
M2H)_*I*:JA%"CH!@4ZOT$_C][A1110(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGKU9P8&NXOV%3=;?Y'UU1117\TGLA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^CTK^G%?NBO$=-_8B^ ^CZC:W]E\+/#EM>6LJSP31VN&C=2"K YZ@@&O;Z
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M )(=X_\ ^QC7_P!)HJ^+/^"K7_)[WC7_ *]=-_\ 2*&OM/\ X(D_\D.\?_\
M8QK_ .DT5 'Z-T444 %%%% !1110 4444 %%%% !7R'_ ,%6_P#DR'QI_P!?
M6G?^EL-?7E?(?_!5O_DR'QI_U]:=_P"EL- 'XR?LL?\ )R_PJ_[&C3?_ $IC
MK^B&3_6-]37\[W[+'_)R_P *O^QHTW_TICK^B&3_ %C?4T -HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /QN_X*_?\ )T^E
M_P#8K67_ *.N*]R_X(;_ .N^,'^[I?\ .ZKPW_@K]_R=/I?_ &*UE_Z.N*]R
M_P""&_\ KOC!_NZ7_.ZH _5>BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** .,^-7_)'/'?\ V ;_ /\ 2=Z_%2OVK^-7
M_)'/'?\ V ;_ /\ 2=Z_%2O@.)OXM+T9_7G@A_N.-_QQ_)G[G>'?^1?TS_KU
MB_\ 0!6A6?X=_P"1?TS_ *]8O_0!6A7WL?A1_)-;^)+U844451B%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME?\ :6_99^.&E>)CX,:3P]=$66M6D=]$?-M68;F"AN60@./=<=Z /V!HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /DG_@H=
M^TAX(^"OP]L?#?CWP7=^,]!\7+-:2V]K.D1C" '<"W1@2"".A%?B=X'^+^L?
M!/XH-XL^&6JZAH36\S?9&N"K2- 3_JIE'RN".".AZ\5^LW_!6#]GOX@_'G2/
M $/@3PU<^(9-/GN6NEMRH\H,JA2<D=<&OSH_X=T_M$?]$SU/_OJ/_P"*H ^C
M/#'_  6Q^(>FZ?'%K?@/0-:NE7#7$-Q+:[CZ[0& ^E;/_#\+Q3_T2O2/_!K+
M_P#&Z^6O^'=/[1'_ $3/4_\ OJ/_ .*H_P"'=/[1'_1,]3_[ZC_^*H ^I?\
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MQ"2-O?!Z$=B.1VKX^\9?\$A?@-XHU"2[T^'7?#6]MQMM.OPT 'H%D5B/^^J
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M22>  2:_&?XO_P#!4KXZ_$S69IM)\0+X&T@EA%INBQKD*>@>5P68CU&WKTH
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M8QD#KF@#ZQC_ ."WVC^6N_X8WV_ W;=03&>^/EIW_#[[1/\ HF-__P"#!/\
MXFO!?^'-_P <?^?WPU_X'-_\11_PYO\ CC_S^^&O_ YO_B* /MK]E/\ X*<:
M;^U!\8++P':^"+O0Y;FVGN?MDUVLBKY:%L;0.]?<%?F5^PC_ ,$Z/B?^S?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?_M
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MZ5_Z5Q5_2Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX.9Y".1N/\Z_I5_:BUR#P[^SC\3+^Y94A3P[?1DL<#+PL@_5A7\T] ']$?\
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M\9]4_:*\+VD?@[7O#$ND:I#<WFJWUG);PVB1R LPD8!6/! "DYSQQ7] E%%
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MDEDZ1J,$Y)[<9-?2/_!7[_DZ?2_^Q6LO_1UQ7N7_  0W_P!;\81VVZ5_[=4
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M!>^WUQ7Y_P#_  3(_9C^*MK^TUHOBR]\-ZUX4\/Z$)6O[K5+22T$X9"H@57
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M26DL_BSX=ZBK>5\LLULKD=E8':X&?X210!_2=3719%*NH93U5AD&OP \.?\
M!3K]HSPU:QV\7CYKY4&-^I6-O<N?JSH2377Q_P#!7G]H-8U5M1T)V P6.DQ@
MGWH _=%5"J H"@= *9<7$5G \T\J0PQC<\DC!54>I)Z"OP*U[_@J-^T;KUO)
M"_CB.Q1@1FPTVW@89]&5,_K7E\OCGXX?M+:K'IC:SXP\?WA< 6RS3W(0G(&0
M/E4=>N!0!^],G[7'PD;XDZ)X"L?&VFZSXJUB?R+:QTJ3[4 VUF.^1,HN IX+
M9]J]@K\I_P!@C_@F7\0_A_\ %+PQ\4/']U;>&AH\INK?0D(GNI6*.F)2#MC
MW9P"Q/M7ZL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M; ;W]=H "J.RJ* /9J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGT3PA9N]S<E7O]6N\-<WC@<%F X4<X4<#- 'KMM;QV=O%!"@CAB0(B+T50,
M#\*EHHH **** "BBB@#\$?\ @JU_R>]XU_Z]=-_](H:^T_\ @B3_ ,D.\?\
M_8QK_P"DT5?%G_!5K_D][QK_ ->NF_\ I%#7VG_P1)_Y(=X__P"QC7_TFBH
M_1NBBB@ HHHH **** "BBB@ HHHH *^0_P#@JW_R9#XT_P"OK3O_ $MAKZ\K
MYE_X*.?#SQ)\4_V2?%?ASPEHUUK^NW5S8M#8V:[I'"743L0/95)_"@#\*/@;
MXNT[P#\:/ OB;5S*NEZ/K=G?W1@3?((HID=]JY&3A3@9K]=F_P""L/P 9B?M
M?B?D_P#0&'_QVOS-_P"&"_VA/^B3>(__  ''^-'_  P7^T)_T2;Q'_X#C_&@
M#],/^'L'P _Y^_$__@F'_P =H_X>P? #_G[\3_\ @F'_ ,=K\S_^&"_VA/\
MHDWB/_P''^-'_#!?[0G_ $2;Q'_X#C_&@#],/^'L'P _Y^_$_P#X)A_\=H_X
M>P? #_G[\3_^"8?_ !VOS/\ ^&"_VA/^B3>(_P#P''^-'_#!?[0G_1)O$?\
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M.2-NJL#@@^X(KU_PG^QO\;/'7AO3_$&@?#;7=5T74(A/:WMO #',AZ,ISTH
M_4?_ (>P? #_ )^_$_\ X)A_\=H_X>P? #_G[\3_ /@F'_QVOS/_ .&"_P!H
M3_HDWB/_ ,!Q_C1_PP7^T)_T2;Q'_P" X_QH _3#_A[!\ /^?OQ/_P""8?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?#/_  5W^-%[\-?V<;7PYI=TUI?^+[[[%*Z-AC:1KOF48]28U/LQ'>OR
M7_9F_9G\6?M3?$1/"GA588#'%]HO=0NLB"TA! +MCJ<GA1R37WU_P7%,O_%I
M =WD?\3+;_=W?Z/G\<8_2H/^"'OV3[9\5<>7]O\ +L<_W_+S+C\,YH ^Y?V4
M_P!G^W_8_P#@6WA:[\1'6[6QDGU*XOI(!"L>X;I,#)^4;2>3FOP4_:+^*U[\
M;/C9XP\97LID.I:A(\ W$A(0=L2KGL$"U^ZG_!0CXJ)\)?V3?'.HK<"WO]1M
MO[)L\_Q2S_*1_P!\;S^%?STVEK+?74-M ADFF=8T0=68G 'YF@#]./\ @F#^
MP3X/^*'@.Z^)OQ)T===M+J=[72-)NMP@V)P\S@8WY)PO8;35;_@IG_P3[\(_
M"/P*?BC\-[(Z-I]O<QP:MHRNS0HLC!$EB!R5PQ52O3G/K7Z5_LW?#F/X2? ?
MP+X22,Q-IFE0QRJ>HE9=\F??>S5YA_P4AU6RTG]C+XCO>RK$L]I';Q;AG=*\
MJ*@'N210!^7/_!)[XE77@7]KK1=*21AI_B:TN-,NH\\$A#+$<>H>-1]":_=Z
MOYT_V"H9I_VPOA4L"NSC6HF;8>=HR6/TQFOZ+* "BBB@#YY_;T^"'B+]H/\
M9KU_PCX56WEUR2:"[@ANGV++Y;[B@;LQ'3/&:_%OPU\=/C]^Q[XJET"+7-?\
M)7MG)F;0]4S);L0,9,3Y1E]".*_HJKS_ .,'P$\ _'C07TGQQX9LM<@VD1S3
M1XG@." T<@^92,GH: /S(^&/_!;#Q/I=O%;^// MCKFQ K7FCSFUED;NQ5@R
MCZ#%?0?AW_@LI\$]2M$?5M,\3:/<$9:(6:3A3Z;E<9_*O*/C-_P13MKBYGO?
MACXS-I$Q9ETK7T+A1CA5F09/U85\F>,O^"8G[0_@TMCP3_;B X#:-=QW&1ZX
MR#^E 'Z<1_\ !63]G=T5O^$@U5=PSM;2Y,CV-<WK?_!8SX%:?"YL(/$NJ2KD
M!5T]8E;\6?\ I7Y8M^P_\>UD*'X3^)MP.#_H1ZUV7@[_ ()G_M$>,)"B^ IM
M& .-^L7,=L/U)- 'U7\0?^"W5S)&T?@CX<1POD@7&N7AD&.S!(P.>G!-?)/Q
M*_;>_: _:8U!= ?Q%J+Q7S&*/0O#<)@68$Y"E8_F?'J2:^LOA%_P10O9+B&[
M^)/CB&&WPK-IV@Q%G)SRK2OP![@&OT$^!O[*?PP_9UL$A\$^%K6PN]NV35)Q
MYUY+U^]*W/?H,#VH \$_X);?LW^.?V?/A3XD;QY9+IFI^(=0COHK%Y-\\2+'
MM_>]@Q.3C)]Z^UJ** "LKQ%X5T7Q?I[V.N:39:O9NI5H+V!94P1@\,#6K10!
M\Q^-/^";/[//C9F:?X?6NE.Q!+:/-):?HA _2N';_@D/^SR9"W]F:\!G.T:O
M)CZ=*^U** /E[P?_ ,$T?V=_!K%HO $&K,?^@Q<278_)VQ7T-X5\$^'_  /I
M\=CX>T33]$M(U"+#86R0K@=!\H&:VZ* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K\2_\ @L]_R==HO_8J6G_I3=5^VE?B7_P6
M>_Y.NT7_ +%2T_\ 2FZH ^5_V8?^3DOA3_V->E?^E<5?TN5_-'^S#_R<E\*?
M^QKTK_TKBK^ER@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#\LO\ @I]^R1_PC6K2_%SPK9[=*OY NNVL*\03
MMP+@ =%<\-Z-S_%7E_\ P3P_:S;X#_$$>%_$%T5\$^()E25I&^6QN3PDP]%/
M"M[8/:OV+\2>'=.\7:!J&B:O:1WVEZA ]M<VTRY62-A@@U^$W[7G[->H_LS_
M !7O-$=9+CP_>%KG2+YAQ- 3]TG^^A^4_@>]?UAP%GF%XQR>IPGG3O-1]QO=
MQ6UO[T.G=>C/"Q5.6'J*O3_K_AS]Z8Y%D171@Z,,AE.01ZBG5\(?\$S_ -K;
M_A9'A=?AGXHO0WB;1H<Z;<3/\U[:K_#D]7CZ>ZX]#7W?7\X\09'BN'<QJ9=B
MU[T7H^DETDO)K[MMT>O2J1K04XA1117SIL%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%1374-NI:66.)0,DNP 'YTTF]@):*R;GQ=H5GN^T:UI\
M&T9/F74:X'KR:Q[_ .+W@;2PQN_&.A0;5W'=J,/3U^]73#"UZFD*;?HF3S);
MLZZBO*=1_:L^#^D\7?Q'\/0_+NYO5/'KQ7/7G[='P(L]N[XE:/+D$_N6=_Y+
M7IT\AS>M_#PE1^D)?Y$.K36\E]Y[O17S!?\ _!23X"V.S_BK)KC=G_CWL97Q
MCUXKG;O_ (*I? R!1Y5UKMR2<'9IC+CWY85ZM/@WB.K\& J_^ 27YHAXBBOM
M(^P:*^%]2_X*Y?"ZU'^B>'O$-Z=V/]7''QZ\M7.7O_!8KPDJL+3X>ZU(V[@S
M7D2@CUX!KU*?AWQ55^' R^;BOS:(>+H+[1^A=%?F?JG_  6,D_>?V=\.%SN^
M3[5J!^[WSM7K7-7W_!8CQE)Y@M/ &B0 GY&ENIG('OC%>K3\*^+*F^&2]9P_
M^2,WCJ'\Q^JM%?D+JG_!6[XKW?F_8]%\/V&[[G[EY-OYMS7-WW_!4[XZW6\1
M7^B6BL, 1Z6I*^X+$UZE/P>XFJ?%[./K/_),AYA1\S]GJ*_#W4O^"CGQZU+?
M_P 5@MKN7;_HUG$F/<<=:YJ\_;B^.U\<O\2]:C&W;B%U0?HO6O5I^"N>2_B8
MBDOG)_\ MIF\RI=$S]YZ*_GUU#]J+XMZM@W7Q$\0RX4J/].<<'Z&N8O/BMXU
MOR#<>+M<FQTWZC,?_9J]2GX'XU_Q<=!>D6_U1#S*/2)_1+<ZQ86>/M%[;P9.
M!YDJKG\S61=?$CPE9#-QXIT6 9V_O=0A7GTY:OYY/[4\3:I_R]ZM=[3_ ,]9
M7P3^/6G)X)\4Z@24T#6+D@\[;.5N3_P&O0CX)T(?Q\RM_P!N)?G,C^TGT@?O
MUJ/[0GPQTE2;KQ]X=C ;9QJ,3<^G#&N8U#]M#X'Z67%Q\2]#4JVTA)F<Y_X"
M#7XD:?\  ?XCZKN^R^!O$$VT G&G2CK]5KJ+']CGXV:CS;_#/Q XP&R;4KP?
MJ:O_ (A1PWA_]ZS2WSIQ_.X?7JS^&'YGZW:E_P %!O@)IJR'_A/K6[*8&+:W
MF<GZ?(*Y?4O^"GWP(T]I NLZI>%,?\>VFN0V?3)%?FUIO[ ?QYU)@!\/KZVR
MF_-S)&@^GWNOM74:?_P3'^/6H*A/A_3[4,N[_2-2B7'L>3S1_J'P!AOX^:7_
M .XM/]$'UK%2VA^#/MO4O^"LGP:ME?[)9^(KUE&5'V)8PQ].7XKE]2_X+ ^
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MBRL.1Y\HXV]/E7K@@G% 'IO_  1W^ NH_#WX/ZWX[UJT:TNO%DR?88Y5*O\
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M85GM[B%LI)&PRK ^X-7J_C^47!N,E9H^@"BBBI **** "BBB@ HHHH ****
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M^'UK<;L?ZZ[N#CZ8D%=#I_[&/P0TLDV_PUT-21M.^)GX_P"!,:/^(E<%T/\
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M_P %#_XU^6FH?L#_ +04VH74B?"O7RK2N0?('(R?>J__  P'^T'_ -$JU_\
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MX?(7/IG[1G'X5\N_M3_\$X_B5^R_HLGB.ZDL_%/A)) DFJ:6&#6^>%,T3#*
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M^$GC?6/+^P^$-<N_,^YY.GRMN^F%KI=/_9;^,&K!#:_#'Q7*CG:)!I$X3/\
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M#I+[9G/VG4;@[L^NUQ^E?3E%>55XRXCK?'CZORG)?DT6L/17V4>#:?\ L)?
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M<9% 'Z8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@C_ ,%6O^3W
MO&O_ %ZZ;_Z10U]I_P#!$G_DAWC_ /[&-?\ TFBKXL_X*M?\GO>-?^O73?\
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M\9CL)3J2O.\I0C)V4GU:OHCV;_ANSXT_]#7%_P""RU_^-T?\-V?&G_H:XO\
MP66O_P ;K2_X9F\/_P#06U+\H_\ XFD_X9F\/_\ 06U+\H_\*XO^%+_G[+_P
M)_YGTW_&$?\ 0#2_\$Q_^1,[_ANSXT_]#7%_X++7_P"-T?\ #=GQI_Z&N+_P
M66O_ ,;K1_X9F\/_ /06U+\H_P#"C_AF;P__ -!;4ORC_P */^%+_G[+_P "
M?^8?\81_T TO_!,?_D3._P"&[/C3_P!#7%_X++7_ .-T?\-V?&G_ *&N+_P6
M6O\ \;K1_P"&9O#_ /T%M2_*/_"C_AF;P_\ ]!;4ORC_ ,*/^%+_ )^R_P#
MG_F'_&$?] -+_P $Q_\ D3._X;L^-/\ T-<7_@LM?_C='_#=GQI_Z&N+_P %
MEK_\;K1_X9F\/_\ 06U+\H_\*/\ AF;P_P#]!;4ORC_PH_X4O^?LO_ G_F'_
M !A'_0#2_P#!,?\ Y$SO^&[/C3_T-<7_ (++7_XW1_PW9\:?^AKB_P#!9:__
M !NM'_AF;P__ -!;4ORC_P */^&9O#__ $%M2_*/_"C_ (4O^?LO_ G_ )A_
MQA'_ $ TO_!,?_D3!US]M3XO>(M%U#2;_P 3QS6-];R6MQ&-.MEWQNI5AD1Y
M&03R.:\.KZ/_ .&9O#__ $%M2_*/_"C_ (9F\/\ _06U+\H_\*YJN'QE=IU9
M<UN[N>Q@,YX;RN,H8"DJ2EOR4^6_K9(RK?\ ;D^,UK;Q01>*HECC4(H_LVU.
M !@?\LZD_P"&[/C3_P!#7%_X++7_ .-UH_\ #,WA_P#Z"VI?E'_A1_PS-X?_
M .@MJ7Y1_P"%='_"E_S]?_@3_P SQW_J2W=X*G_X)C_\B9W_  W9\:?^AKB_
M\%EK_P#&Z/\ ANSXT_\ 0UQ?^"RU_P#C=:/_  S-X?\ ^@MJ7Y1_X4?\,S>'
M_P#H+:E^4?\ A3_X4O\ G[+_ ,"?^8?\81_T TO_  3'_P"1,[_ANSXT_P#0
MUQ?^"RU_^-T?\-V?&G_H:XO_  66O_QNM'_AF;P__P!!;4ORC_PH_P"&9O#_
M /T%M2_*/_"C_A2_Y^R_\"?^8?\ &$?] -+_ ,$Q_P#D3._X;L^-/_0UQ?\
M@LM?_C='_#=GQI_Z&N+_ ,%EK_\ &ZT?^&9O#_\ T%M2_*/_  H_X9F\/_\
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M5C;VZ*%2&-8U4=   ,4 3U^"/_!5>Z>Z_;6\8;L#R[6QC&/06T=?O=7X:_\
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MAQI4NPY'VC?+GZ[F.?QKWJBO+J<4Y]6_B8ZJ_P#N)/\ S-%0I+:*^X\IT_\
M92^#>F;3;_"_PHK*VY7;2878'ZLI-=)8?!GP#I8 L_!>@6H#;_W6FPK\WKPO
M6NRHKRJF:8^M_%KSEZRD_P!2U"*V1GVGA_2[!66VTVTMPQW$10*N3Z\"K:VT
M2?=B1?HHJ6BO/E.4M9.Y84445 !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&_B=CU/T'  %=Q110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?@C_P5:_Y/>\:_P#7KIO_ *10U]I_\$2?^2'>/_\
ML8U_])HJ^+/^"K7_ ">]XU_Z]=-_](H:^T_^")/_ "0[Q_\ ]C&O_I-%0!^C
M=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?D/^UU_P %
M*OC;\'/VD/'?@SPYJ.CQ:'H]\L%JEQIB2.$,2-RQ/)RQKR#_ (>[?M$?]!;0
M?_!/'_C0!^Z]%?A1_P /=OVB/^@MH/\ X)X_\:/^'NW[1'_06T'_ ,$\?^-
M'[KT5^%'_#W;]HC_ *"V@_\ @GC_ ,:/^'NW[1'_ $%M!_\ !/'_ (T ?)?C
MS_D>?$7_ &$;C_T:U?T&_L#?\F;_  F_[ L?_H35_.]J>H3:OJ5W?7!4W%U,
M\\A48&YF+' [<FOJ+X9_\%,?C?\ "7P#HG@_P]J.CQ:+H]N+6T2?2TD<("2,
ML3R>>M '[^T5^%'_  ]V_:(_Z"V@_P#@GC_QH_X>[?M$?]!;0?\ P3Q_XT ?
MNO17X4?\/=OVB/\ H+:#_P"">/\ QH_X>[?M$?\ 06T'_P $\?\ C0!^Z]%?
MA1_P]V_:(_Z"V@_^">/_ !K]R=#NI+[1=/N9B#+-;QR.0,#<5!/ZF@"]1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'QI_P4V_Y)SX/_P"P
ML_\ Z):OA/X8_P#)0_#O_7]%_P"A"ONS_@IM_P DY\'_ /86?_T2U? _@G5K
M?0_%^CZA=EEMK6ZCED*+N(4')P.]?F.=.V9-O^Z?W-X91<^"XQBKM^U_-GVG
M17G'_#07@S_GYO?_  %/^-'_  T%X,_Y^;W_ ,!3_C77]8H_SK[SYW^Q<R_Z
M!Y?^ L]'HKSC_AH+P9_S\WO_ ("G_&C_ (:"\&?\_-[_ . I_P :/K%'^=?>
M']BYE_T#R_\  6>CT5YQ_P -!>#/^?F]_P# 4_XT?\-!>#/^?F]_\!3_ (T?
M6*/\Z^\/[%S+_H'E_P" L]'HKSC_ (:"\&?\_-[_ . I_P :/^&@O!G_ #\W
MO_@*?\:/K%'^=?>']BYE_P! \O\ P%GH]%><?\-!>#/^?F]_\!3_ (T?\-!>
M#/\ GYO?_ 4_XT?6*/\ .OO#^Q<R_P"@>7_@+/1Z*\X_X:"\&?\ /S>_^ I_
MQH_X:"\&?\_-[_X"G_&CZQ1_G7WA_8N9?] \O_ 6>CT5YQ_PT%X,_P"?F]_\
M!3_C1_PT%X,_Y^;W_P !3_C1]8H_SK[P_L7,O^@>7_@+/1Z*\X_X:"\&?\_-
M[_X"G_&C_AH+P9_S\WO_ ("G_&CZQ1_G7WA_8N9?] \O_ 6>CT5YQ_PT%X,_
MY^;W_P !3_C1_P -!>#/^?F]_P# 4_XT?6*/\Z^\/[%S+_H'E_X"ST>BO./^
M&@O!G_/S>_\ @*?\:/\ AH+P9_S\WO\ X"G_ !H^L4?YU]X?V+F7_0/+_P !
M9Z/17G'_  T%X,_Y^;W_ ,!3_C1_PT%X,_Y^;W_P%/\ C1]8H_SK[P_L7,O^
M@>7_ ("ST>OF+]HW_DH@_P"O*'^M>K?\-!>#/^?F]_\  4_XUXC\8O%FG>-/
M& U'2WD>U^S1Q9E38=PSGC\:\_'5J<Z-HR3=SZ_A;+L9A<P]I7I2C'E>K378
M^Q/^"8/_ "!/B#_U\67_ *#-7W#7P]_P3!_Y GQ!_P"OBR_]!FK[AK[C)?\
M<*?S_-G\N>)O_)6XWUA_Z;@%%%%>V?EX4444 %%%% !1110 4444 %%%% !1
M110 4444 17-O%>6\MO,@DAE0HZ-T92,$?E7RE\(?^";_P ,O@O^T%=?$[0Q
M<NBQ,=.T6Z(DAT^X<D/+&QY/RDA0?N[CSTQ]944 ?._[7W[%?A/]KS2] BUJ
MZFT;5-)N0\>J6:*TQMS_ *R#GC!X(ST(]S7JOP?^$/AGX%_#_3/!OA&R:PT3
M3U/EQR2-([,QRSLQY+$DDUV=% !7R3\5/^":_P ,?BA\>M(^)TXN+.X2\%YK
M&E*=]MJCJ!L+!CE.0-V."*^MJ* /,/VB_P!G_P ._M(?"75? VO1B&"Y0-:7
MD: O93K_ *N5/<>G<$CO6#^RO^R9X-_9-\%RZ+X8$]W?WI234M5NW)ENY%!
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M;V[E6>:5?X6;:H"]0H.?O8K]![;P=H%GJ!O[?0]-@OB<FZCM(UESZ[@,UL4
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M,[AQNR/RA^%O[2'QR_8LN=9\.Z-<7GA0W<I-SI>L:>'02K\I=$E7 ;@#<O4
M5_1-65K'A/1/$$B2:IHVGZE(@PK7EJDI4>Q8'% 'X#? 7]FGXI?MO?&8ZKJD
M&HRV&H7@O-<\4:A$RQ",MEMK$ ,Y (55Z<=!7[\^%?#5AX-\,Z5H.E0BWTW3
M;:.TMXA_#&BA5_' J]9V-OI]NEO:6\5M G"Q0H$4?0#BIZ "OYG_ (U,%_:.
M\>,2 O\ PE=^<]O^/R2OZ8*YZ;X=^%+BX>>7PQHTD[L7>1]/B+,Q.22=O)SW
MH T]#_Y FG_]>\?_ *"*O4BJ%4 # '  I: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /SP_:Z_X)<Z_^TM\=-:\?67CW3=#MM0B@C6RN
M-/DE=/+B5"2P< Y(ST[UXU_PX^\4_P#14]'_ /!5+_\ '*_72B@#\B_^''WB
MG_HJ>C_^"J7_ ..4?\./O%/_ $5/1_\ P52__'*_72B@#\B_^''WBG_HJ>C_
M /@JE_\ CE'_  X^\4_]%3T?_P %4O\ \<K]=** /GS]B/\ 9BO_ -D[X0W'
M@S4=>MO$,TFI2WPNK6W:%0KJ@VX9CR-O7WKZ#HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BN;^)7CRP^%_P_P#$?B_54FDT
MW0K";4;E(%W2&.)"[!1W. :^+/\ A\M\%O\ H%>)/_ 5/_BJ /O>OS?_ ."V
MGBA]/^#_ ,/]!5L)J6L37++SSY$0 /\ Y&_6NI_X?+?!;_H%>)/_  %3_P"*
MKQK_ (+(>*K7QY\*?@/XEL(Y4L-5%]>PB9<,J20VK*&]#@T ?%W[#GCKPG\+
M?VC- \:^-+QK/1?#T-Q?YC3>\DHB98T5>[$OQ7U+X_\ ^"U?CS4-=F_X0_P;
MH^DZ,K_N1J1>XN'7'\9!"@YST%?GQX,\(ZIX_P#%FD>&]$MC=ZMJES':6T(X
MW2.P R>P]3Z"OUK\'_\ !%7P-'X'2#Q+XQUB?Q3-$IDO+!46W@DP,A$(RR@]
MV.3[4 1?LU_\%C-&\::]:Z!\5M"M_"LMU((HM<TYV:S4G 'G(Q+)DY^8$@>@
MK]);>XBO+>*>"5)X)5#QRQL&5U(R""."".]?S8?M-?L]ZY^S'\7-4\#ZY-'>
M/;A9[6^A!"7-N_*. >AQP1V(-?K+_P $A_CG??$WX W_ (4U>Z>[O_!]TEK!
M))][['(I,2Y[[2KCV&T=J /SU_X*D>(WU_\ ;2\:Q.S$:;':6*[AT @1\#\9
M#7V;_P $1='AM_AC\2-44+Y]UJMM;N<<[8XF*\_61J^&/^"DBE?VVOBCD$9O
M+<C(Z_Z)!7WO_P $3?\ DBOCS_L.)_Z(6@#[0_::TPZS^SG\4+-83<22^&=2
M$<8ZLXMI"H'_  ("OYH^5;C@@U_3A\<KF*S^"GQ N)Y%B@B\/Z@[R-T51;2$
MD_A7\Q[\LWUH _IZ^$>L'Q!\+/"&I,0S76DVLI*MN!)B4DYKB?VKOVD++]E?
MX2R^.K_1+CQ!;QWL-D;.VG6%\R9PVY@1@;?3O6Q^S38RZ9^SW\.;68*)8=!L
MU8*<C/DKWKY]_P""M&C:AKW[(MU::9876HW1UNQ80VD+2O@%\G:H)Q0!XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#U!'44 2T444 %%%% !1110!^"/_  5:_P"3WO&O_7KIO_I%#7VG_P $2?\
MDAWC_P#[&-?_ $FBKXL_X*M?\GO>-?\ KUTW_P!(H:^T_P#@B3_R0[Q__P!C
M&O\ Z314 ?HW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MP5\>?^"3/ASX[?%[Q/X]O/B%JFE7.N7(N7LX=/BD2(A%7 8L"?N^E<#_ ,./
M_"?_ $5+6?\ P5P__%U^F=% 'YF?\./_  G_ -%2UG_P5P__ !='_#C_ ,)_
M]%2UG_P5P_\ Q=?IG10!^9G_  X_\)_]%2UG_P %</\ \71_PX_\)_\ 14M9
M_P#!7#_\77Z9T4 ?F9_PX_\ "?\ T5+6?_!7#_\ %T?\./\ PG_T5+6?_!7#
M_P#%U^F=% 'YF?\ #C_PG_T5+6?_  5P_P#Q='_#C_PG_P!%2UG_ ,%</_Q=
M?IG10!^9G_#C_P )_P#14M9_\%</_P 71_PX_P#"?_14M9_\%</_ ,77Z9T4
M ?F9_P ./_"?_14M9_\ !7#_ /%U^E6FV8TW3K6T5S(+>)(@Q&"=H S^E6:*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /C3_@IM_P D
MY\'_ /86?_T2U?GG8V-QJ5Y#:6L+3W,S!(XHQEF8] !7Z&?\%-O^2<^#_P#L
M+/\ ^B6KX3^&/_)0_#O_ %_1?^A"OS#.X\V8N/>WY']U>%U1T>#J=1;Q=1_=
M)DG_  JKQ?\ ]"YJ'_?DT?\ "JO%_P#T+FH?]^37V'14?V;3_F9M_KMC/^?4
M?Q_S/CS_ (55XO\ ^A<U#_OR:/\ A57B_P#Z%S4/^_)K[#HH_LVG_,P_UVQG
M_/J/X_YGQY_PJKQ?_P!"YJ'_ 'Y-'_"JO%__ $+FH?\ ?DU]AT4?V;3_ )F'
M^NV,_P"?4?Q_S/CS_A57B_\ Z%S4/^_)H_X55XO_ .A<U#_OR:^PZ*/[-I_S
M,/\ 7;&?\^H_C_F?'G_"JO%__0N:A_WY-'_"JO%__0N:A_WY-?8=%']FT_YF
M'^NV,_Y]1_'_ #/CS_A57B__ *%S4/\ OR:/^%5>+_\ H7-0_P"_)K[#HH_L
MVG_,P_UVQG_/J/X_YGQY_P *J\7_ /0N:A_WY-'_  JKQ?\ ]"YJ'_?DU]AT
M4?V;3_F8?Z[8S_GU'\?\SX\_X55XO_Z%S4/^_)H_X55XO_Z%S4/^_)K[#HH_
MLVG_ #,/]=L9_P ^H_C_ )GQY_PJKQ?_ -"YJ'_?DT?\*J\7_P#0N:A_WY-?
M8=%']FT_YF'^NV,_Y]1_'_,^//\ A57B_P#Z%S4/^_)H_P"%5>+_ /H7-0_[
M\FOL.BC^S:?\S#_7;&?\^H_C_F?'G_"JO%__ $+FH?\ ?DT?\*J\7_\ 0N:A
M_P!^37V'11_9M/\ F8?Z[8S_ )]1_'_,^//^%5>+_P#H7-0_[\FL/6="U#P[
M>?9-3LYK&YVA_*F7:VT]#BOM^OF+]HW_ )*(/^O*'^M<N*P<*%/GBSZ'(^),
M1FN+^KU()*S>E^ECZL_X)@_\@3X@_P#7Q9?^@S5]PU\/?\$P?^0)\0?^OBR_
M]!FK[AK]!R7_ '"G\_S9_'WB;_R5N-]8?^FX!1117MGY>%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45_/+KWQF^(,6N:BB>.O$RHMS( HUBXX
M 8_[=4?^%U?$/_H?/$W_ (.+C_XNOZ9CX(8N45+Z]'7^X_\ Y(\;^TH_RG]%
M%%?SK_\ "ZOB'_T/GB;_ ,'%Q_\ %T?\+J^(?_0^>)O_  <7'_Q=5_Q _%_]
M!T?_  !__)"_M*/\I_1117\Z_P#PNKXA_P#0^>)O_!Q<?_%T?\+J^(?_ $/G
MB;_P<7'_ ,71_P 0/Q?_ $'1_P# '_\ )!_:4?Y3^BBBOYU_^%U?$/\ Z'SQ
M-_X.+C_XNC_A=7Q#_P"A\\3?^#BX_P#BZ/\ B!^+_P"@Z/\ X __ )(/[2C_
M "G]%%%?SK_\+J^(?_0^>)O_  <7'_Q='_"ZOB'_ -#YXF_\'%Q_\71_Q _%
M_P#0='_P!_\ R0?VE'^4_HHHK^=?_A=7Q#_Z'SQ-_P"#BX_^+H_X75\0_P#H
M?/$W_@XN/_BZ/^('XO\ Z#H_^ /_ .2#^TH_RG]%%%?A9^RG\6?'&K_M*?#*
MROO&?B&\LY_$%G'-;W&JSO'(IE7*LI?!!]#7[IU^3<9<'U>#\32PU6LJCG'F
MNE:VMN[._#XA8B+:5K!1117YZ=84444 %%%% 'D'[1_[+/@?]JC0M(TCQPFH
M/9Z7<M=6_P#9]UY#;V7:<G!R,4S]F_\ 94\"_LKZ/K.F>!DU%+;5IX[BY_M"
MZ\\[D4J-O P,$U[%10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME6J*#1^A]%%%?SB>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY//K7UG10!\$^#_^"-?P9T'5HKS6-6\1>(H8FW?8IKB."*3V?8FXCZ,*^V/
M_@7P]\-?#-EX=\+:/::%HEFNR"RLHPD:>I]R3R2<DGDFMZB@ HHHH **** "
MOQ+_ ."SW_)UVB_]BI:?^E-U7[:5^)?_  6>_P"3KM%_[%2T_P#2FZH ^5_V
M8?\ DY+X4_\ 8UZ5_P"E<5?TN5_-'^S#_P G)?"G_L:]*_\ 2N*OZ7* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\8/\ @M=_R<AX._[%
M2+_TKNJ_9^OQ@_X+7?\ )R'@[_L5(O\ TKNJ /B7X.Z+9>)/BYX(TC4H!=:=
M?ZY8VMS Q*B2)[A%=2001E21P<\U^\'_  [7_9K_ .B767_@PO?_ (]7X6?
M'_DNWPX_[&33?_2J.OZ;* ,/P1X)T3X;^$]+\,^&[!=+T+2X1;V=FCLXBC'1
M06)8]>Y-;E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGQ\^&,OQH^#/C#P-!J":5+KVG26*WLD1E6$L/O%01GZ9% 'Y/?\ #Z[XP_\
M0G^"?_ :[_\ DBC_ (?7?&'_ *$_P3_X#7?_ ,D5VW_#CG7/^BMZ?_X(Y/\
MX_1_PXYUS_HK>G_^".3_ ./T <3_ ,/KOC#_ -"?X)_\!KO_ .2*/^'UWQA_
MZ$_P3_X#7?\ \D5VW_#CG7/^BMZ?_P"".3_X_1_PXYUS_HK>G_\ @CD_^/T
M?!/[0_QVUO\ :2^*VJ^/O$-E8:?JNHQP1RV^FJZP*(HEB7:'9FY" G)ZU^HO
M_!$G_DAWC_\ [&-?_2:*OS)_:B^ =Q^S+\:-9^'MSK,>OS:;%;RF_AMS K^;
M"DH&PLV,;\=>U?IM_P $2?\ DAWC_P#[&-?_ $FBH _1NBBB@ HHHH ****
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M (UT'P#\'Z3XZ^(D&E:U;M<V+6TTAC21HSN5<@Y'/6OI;_AF7X=_] :X_P#
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M_P"&9?AW_P! :X_\#I?\:/\ AF7X=_\ 0&N/_ Z7_&C_ %IR;_GP_P#P&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5^)?_  6>_P"3KM%_[%2T_P#2FZK]M*_$O_@L]_R==HO_ &*EI_Z4W5 '
MRO\ LP_\G)?"G_L:]*_]*XJ_I<K^:/\ 9A_Y.2^%/_8UZ5_Z5Q5_2Y0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?C!_P6N_Y.0\'?]BI%
M_P"E=U7[/U^,'_!:[_DY#P=_V*D7_I7=4 ?&7P!_Y+M\./\ L9--_P#2J.OZ
M;*_F3^ /_)=OAQ_V,FF_^E4=?TV4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#XT_X*;?\DY\'_P#86?\ ]$M7Y\:1JMQH>J6NH6C!+FVD66-F4, P.1P>
MM?KU^T-^SWIO[0V@Z5I>I:M=:3'I]RURLEJBL7)0K@[NW->$?\.R/"O_ $.>
ML?\ @/%7PN:Y7B\5BW6HQTTZH_JO@'CWA_(^'Z>79C5:FG.ZY)-6<F^BML?'
M'_#07C/_ )_+;_P$C_PH_P"&@O&7_/Y;?^ D?^%?8_\ P[(\*_\ 0YZQ_P"
M\5'_  [(\*_]#GK'_@/%7G_V5FO]27^9]?\ Z_<!=E_X*E_\B?''_#07C+_G
M\MO_  $C_P */^&@O&7_ #^6W_@)'_A7V/\ \.R/"O\ T.>L?^ \5'_#LCPK
M_P!#GK'_ (#Q4?V5FO\ 4E_F'^OW 79?^"I?_(GQQ_PT%XR_Y_+;_P !(_\
M"C_AH+QE_P _EM_X"1_X5]C_ /#LCPK_ -#GK'_@/%1_P[(\*_\ 0YZQ_P"
M\5']E9K_ %)?YA_K]P%V7_@J7_R)\<?\-!>,O^?RV_\  2/_  H_X:"\9?\
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MX[AKB:G4JY92C)0:3O"VK]4CTC_AH+QE_P _EM_X"1_X4?\ #07C+_G\MO\
MP$C_ ,*^OM-_X)I>%K[3K6Y/C'6%,T2R$"WBXR ?ZU9_X=D>%?\ H<]8_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MXE_\%GO^3KM%_P"Q4M/_ $INJ_;2OQ+_ ."SW_)UVB_]BI:?^E-U0!\K_LP_
M\G)?"G_L:]*_]*XJ_I<K^:/]F'_DY+X4_P#8UZ5_Z5Q5_2Y0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?C!_P6N_Y.0\'?]BI%_Z5W5?L
M_7XP?\%KO^3D/!W_ &*D7_I7=4 ?&7P!_P"2[?#C_L9--_\ 2J.OZ;*_F3^
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MH5G^'?\ D7],_P"O6+_T 5H5]['X4?R36_B2]6%%%%48A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5^>'_!8W_D0_AO_P!A*[_]
M%)7Z'U^>O_!86TGN_ OPX$$$DQ74KHGRT+8_=)Z5^E^&S2XLP3?>7_I$CCQG
M\"7]=3\_OV</$&F^&OB=;WVK7T.G6:VLZ&>X;:H8I@#/O7U;_P +C\"_]#;I
M?_?[_P"M7P=_8VH?\^-S_P!^6_PH_L;4/^?&Y_[\M_A7]K9KP_A<VQ'UBI5<
M79+2W2_^9\Y3K2IJR1]X_P#"X_ O_0VZ7_W^_P#K4?\ "X_ O_0VZ7_W^_\
MK5\'?V-J'_/C<_\ ?EO\*/[&U#_GQN?^_+?X5X_^IF!_Y_R_\E_R-/K,^Q]X
M_P#"X_ O_0VZ7_W^_P#K4?\ "X_ O_0VZ7_W^_\ K5\'?V-J'_/C<_\ ?EO\
M*/[&U#_GQN?^_+?X4?ZF8'_G_+_R7_(/K,^Q]X_\+C\"_P#0VZ7_ -_O_K4?
M\+C\"_\ 0VZ7_P!_O_K5\'?V-J'_ #XW/_?EO\*/[&U#_GQN?^_+?X4?ZF8'
M_G_+_P E_P @^LS['WC_ ,+C\"_]#;I?_?[_ .M1_P +C\"_]#;I?_?[_P"M
M7P=_8VH?\^-S_P!^6_PH_L;4/^?&Y_[\M_A1_J9@?^?\O_)?\@^LS['WC_PN
M/P+_ -#;I?\ W^_^M1_PN/P+_P!#;I?_ '^_^M7P=_8VH?\ /C<_]^6_PI'T
MF^C1G>SN%11DLT3  >IXH_U+P7_/^7_DO^0?69=C[R_X7'X%_P"AMTO_ +_?
M_6H_X7'X%_Z&W2_^_P!_]:O@*KG]C:A_SXW/_?EO\*I\%8..]:7X?Y!]9EV/
MO'_A<?@7_H;=+_[_ '_UJ/\ A<?@7_H;=+_[_?\ UJ^#O[&U#_GQN?\ ORW^
M%']C:A_SXW/_ 'Y;_"I_U,P/_/\ E_Y+_D'UF?8^\?\ A<?@7_H;=+_[_?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^,'_!:[_DY#P=_P!BI%_Z5W5?L_7XP?\ !:[_
M ).0\'?]BI%_Z5W5 'QE\ ?^2[?#C_L9--_]*HZ_ILK^9/X _P#)=OAQ_P!C
M)IO_ *51U_390 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!^"/_!5K_D][QK_ ->NF_\ I%#7
MVG_P1)_Y(=X__P"QC7_TFBKXL_X*M?\ )[WC7_KUTW_TBAK[3_X(D_\ )#O'
M_P#V,:_^DT5 'Z-T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<9\:O^2.>._^P#?_ /I.]?BI7[5_&K_DCGCO_L W_P#Z3O7XJ5\!Q-_%I>C/
MZ\\$/]QQO^./Y,_<[P[_ ,B_IG_7K%_Z *T*S_#O_(OZ9_UZQ?\ H K0K[V/
MPH_DFM_$EZL****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J&XLX+Q0)X(Y@IR!(@;'YU-133:U0%+^Q=/\ ^?"V_P"_*_X4
M?V+I_P#SX6W_ 'Y7_"KM%7[2?=@4O[%T_P#Y\+;_ +\K_A1_8NG_ //A;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\2_\ @L]_R==HO_8J6G_I3=5^VE?B7_P6>_Y.NT7_ +%2T_\
M2FZH ^5_V8?^3DOA3_V->E?^E<5?TN5_-'^S#_R<E\*?^QKTK_TKBK^ER@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_&#_@M=_P G(>#O
M^Q4B_P#2NZK]GZ_&#_@M=_R<AX._[%2+_P!*[J@#XR^ /_)=OAQ_V,FF_P#I
M5'7]-E?S)_ '_DNWPX_[&33?_2J.OZ;* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P1_P""
MK7_)[WC7_KUTW_TBAK[3_P"")/\ R0[Q_P#]C&O_ *315\6?\%6O^3WO&O\
MUZZ;_P"D4-?:?_!$G_DAWC__ +&-?_2:*@#]&Z*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBOQ$\8:M?+XNUL"\N !?3@?O6_YZ-[UXF9YE_9R@^3FYK];;?)GZ
M?P/P2^,YXB"Q'LO9*+^'FOS7_O1M:WF?MW17X6?VO??\_MQ_W];_ !H_M>^_
MY_;C_OZW^->%_K.O^?/_ )-_P#]7_P"(&S_Z&*_\%?\ W0_=.BOPL_M>^_Y_
M;C_OZW^-']KWW_/[<?\ ?UO\:/\ 6=?\^?\ R;_@!_Q V?\ T,5_X*_^Z'[0
M?&G_ )(YX[_[ -__ .D[U^*E6FU2]D4JUW.RL,$&5B#^M5:^?S/,?[1E&7)R
MV\[_ *(_7^!N#'P;0KT7B/:^T:=^7EM96_FE<_<[P]_R -,_Z]8O_0!6A7X6
M#5KX<"\N /\ KJW^-']KWW_/[<?]_6_QKWUQ,DK>Q_\ )O\ @'Y%/P/G.3E_
M:*U_Z=?_ '0_=.BOPL_M>^_Y_;C_ +^M_C1_:]]_S^W'_?UO\:?^LZ_Y\_\
MDW_ )_X@;/\ Z&*_\%?_ '0_=.BOPL_M>^_Y_;C_ +^M_C4EOJU\;B(&]N,;
MA_RU;U^M'^LR_P"?/_DW_ $_ V?_ $,5_P""O_NA^Y]%16W_ ![Q?[@_E4M?
M<'\MO1A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7!K]!J**^-SSB/,^)*L*^:5>>4%9>[&.E[_92.BE1A15H*P4445\T;!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?B7_P6>_Y.NT7_ +%2T_\ 2FZK]M*_$O\ X+/?\G7:+_V*EI_Z4W5
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M/X4?]$^\/_\ @$G^%>G44?5:'_/M?<@_MW-O^@NI_P"!R_S/,?\ AF/X4?\
M1/O#_P#X!)_A1_PS'\*/^B?>'_\ P"3_  KTZBCZK0_Y]K[D']NYM_T%U/\
MP.7^9YC_ ,,Q_"C_ *)]X?\ _ )/\*/^&8_A1_T3[P__ . 2?X5Z=11]5H?\
M^U]R#^W<V_Z"ZG_@<O\ ,\Q_X9C^%'_1/O#_ /X!)_A1_P ,Q_"C_HGWA_\
M\ D_PKTZBCZK0_Y]K[D']NYM_P!!=3_P.7^9YC_PS'\*/^B?>'__  "3_"E_
MX9E^% Y_X5]X?_\  %/\*]-HH^JT/^?:^Y"_MS-O^@NI_P"!R_S$50J@ 8 X
M%+1172>(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7XE_\ !9[_ ).NT7_L5+3_ -*;JOVTK\2_^"SW_)UVB_\ 8J6G_I3=
M4 ?*_P"S#_R<E\*?^QKTK_TKBK^EROYH_P!F'_DY+X4_]C7I7_I7%7]+E !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^,'_!:[_DY#P=_V
M*D7_ *5W5?L_7XP?\%KO^3D/!W_8J1?^E=U0!\9? '_DNWPX_P"QDTW_ -*H
MZ_ILK^9/X _\EV^''_8R:;_Z51U_390 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^"/_  5:
M_P"3WO&O_7KIO_I%#7VG_P $2?\ DAWC_P#[&-?_ $FBKXL_X*M?\GO>-?\
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M[6S7FGRB2,2J 63/J R_F*ZFOAC_ ((X_P#)HMQ_V,M[_P"BX*^YZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^BEK@_VK_BS)\$/V>/''C&W.+ZPT]UM,, ?/D(CC(SW#,&_X#0!\V_MA_\
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M &J/ '[4GA636/!>I,\]MM6^TJ[7R[NS8C(#IGD>C*2IP<'BO7Z_FZ_9+_:
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M?AII-U9EAN6UU"2*11GD@E&!.*_0/]E_]LKX=_M7:-/-X4O9;36K10U[H6H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\2_\ @L]_R==HO_8J6G_I3=5^VE?B7_P6>_Y.NT7_ +%2T_\
M2FZH ^.?@_XPM/AY\6?!7BJ_AFN;'0]:LM2GAM\>;)'#.DC*F2!N(4@9(&:_
M6O\ X?9?"7_H2?&G_?JT_P#C]?C-10!^S/\ P^R^$O\ T)/C3_OU:?\ Q^C_
M (?9?"7_ *$GQI_WZM/_ (_7XS44 ?LS_P /LOA+_P!"3XT_[]6G_P ?H_X?
M9?"7_H2?&G_?JT_^/U^,U% '[,_\/LOA+_T)/C3_ +]6G_Q^C_A]E\)?^A)\
M:?\ ?JT_^/U^,U% '[,_\/LOA+_T)/C3_OU:?_'Z/^'V7PE_Z$GQI_WZM/\
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M -"3XT_[]6G_ ,?K\9J* /V9_P"'V7PE_P"A)\:?]^K3_P"/T?\ #[+X2_\
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M ,?K\9J* /V9_P"'V7PE_P"A)\:?]^K3_P"/T?\ #[+X2_\ 0D^-/^_5I_\
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M -"3XT_[]6G_ ,?K\9J* /V9_P"'V7PE_P"A)\:?]^K3_P"/T?\ #[+X2_\
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M ,?K\9J* /V9_P"'V7PE_P"A)\:?]^K3_P"/T?\ #[+X2_\ 0D^-/^_5I_\
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M -"3XT_[]6G_ ,?K\9J* /V9_P"'V7PE_P"A)\:?]^K3_P"/T?\ #[+X2_\
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M ,?K\9J* /V9_P"'V7PE_P"A)\:?]^K3_P"/T?\ #[+X2_\ 0D^-/^_5I_\
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MVVY] M?AY>_\?D__ %T;^=?U'^*/^1:U;_KTF_\ 0#7\N%Y_Q^3_ /71OYT
M?U"> ?\ D1?#G_8-MO\ T4M?'O\ P6#U:?3_ -D5K>%V07FNV<,FT_>0"1L'
M\5'Y5]A> ?\ D1?#G_8-MO\ T4M?&7_!8^%W_9-M9%&43Q#:;CZ927% 'Y[?
M\$L])&K?MG>$,HK_ &:&ZN1N/3;$>1[\U^^;*'4J1D$8(-?@S_P2AO8[/]L[
MPUY@8^;8WL2[1W,1Q7[ST ?S#_&2U6P^+WCFV3!2'7;Z,8&.!<..G;I7[_?
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M"9IB/T(KZ&_X(BQL/A)\1Y"IV-KD*ANQ(MQD?J/SH _2:BBB@ HHHH ****
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M_/+_ ,%$/&$WC3]L;XE7$K;ULM0_LV,Y_@@41C_T&OZ&J_FY_;%_Y.H^*O\
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M;]CVU!8D+K=\ #V^937M'[<TKP_LA?%F2-VC== N"K(2"#@=#0![G17\LO\
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MM[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\
M;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_
M -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*
M_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?
M_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z
M"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /
MZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\
MH(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^W
MM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O
M\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[
M4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\
M&C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]
M_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_E
ME_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?
M]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@
MC=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZF
MJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=
M_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3
M_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P :
M /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_
M^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C
M^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V
M_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_
MM[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\
M;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_
M -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*
M_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?
M_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z
M"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /
MZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\
MH(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^W
MM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O
M\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[
M4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\
M&C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]
M_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_E
ME_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?
M]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@
MC=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZF
MJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=
M_P#?]O\ &C^WM3_Z"-W_ -_V_P : /ZFJ*_EE_M[4_\ H(W?_?\ ;_&C^WM3
M_P"@C=_]_P!O\: /ZFJ*_EE_M[4_^@C=_P#?]O\ &C^WM3_Z"-W_ -_V_P :
M /ZFJ*_FC_9_UO49/CU\-D>_NF5O$NF@J9F((^U1\=:_I<H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\2_^"SW_ "==HO\ V*EI_P"E-U7[:5^)?_!9[_DZ[1?^Q4M/
M_2FZH ^3?V==+L]<_: ^&>G:C:0W^GW?B;38+BUN4#Q31M=1JR.IX92"00>H
M-?T'?\,E_!+_ *)'X)_\$%K_ /$5_/W^S#_R<E\*?^QKTK_TKBK^ER@#R?\
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M]$C\$_\ @@M?_B*]8HH \G_X9+^"7_1(_!/_ ((+7_XBC_ADOX)?]$C\$_\
M@@M?_B*]8HH \G_X9+^"7_1(_!/_ ((+7_XBC_ADOX)?]$C\$_\ @@M?_B*]
M8HH \G_X9+^"7_1(_!/_ ((+7_XBC_ADOX)?]$C\$_\ @@M?_B*]8HH \G_X
M9+^"7_1(_!/_ ((+7_XBC_ADOX)?]$C\$_\ @@M?_B*]8HH \G_X9+^"7_1(
M_!/_ ((+7_XBC_ADOX)?]$C\$_\ @@M?_B*]8HH \G_X9+^"7_1(_!/_ ((+
M7_XBC_ADOX)?]$C\$_\ @@M?_B*]8HH \G_X9+^"7_1(_!/_ ((+7_XBC_AD
MOX)?]$C\$_\ @@M?_B*]8HH \G_X9+^"7_1(_!/_ ((+7_XBC_ADOX)?]$C\
M$_\ @@M?_B*]8HH \G_X9+^"7_1(_!/_ ((+7_XBC_ADOX)?]$C\$_\ @@M?
M_B*]8HH \G_X9+^"7_1(_!/_ ((+7_XBC_ADOX)?]$C\$_\ @@M?_B*]8HH
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M06O_ ,11_P ,E_!+_HD?@G_P06O_ ,17K%% 'D__  R7\$O^B1^"?_!!:_\
MQ%'_  R7\$O^B1^"?_!!:_\ Q%>L44 >3_\ #)?P2_Z)'X)_\$%K_P#$4?\
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M_P#B*/\ ADOX)?\ 1(_!/_@@M?\ XBO6** /)_\ ADOX)?\ 1(_!/_@@M?\
MXBC_ (9+^"7_ $2/P3_X(+7_ .(KUBB@#R?_ (9+^"7_ $2/P3_X(+7_ .(H
M_P"&2_@E_P!$C\$_^""U_P#B*]8HH \G_P"&2_@E_P!$C\$_^""U_P#B*/\
MADOX)?\ 1(_!/_@@M?\ XBO6** /)_\ ADOX)?\ 1(_!/_@@M?\ XBC_ (9+
M^"7_ $2/P3_X(+7_ .(KUBB@#R?_ (9+^"7_ $2/P3_X(+7_ .(H_P"&2_@E
M_P!$C\$_^""U_P#B*]8HH \G_P"&2_@E_P!$C\$_^""U_P#B*/\ ADOX)?\
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M>O:G\D,7S,TDTO0>O+5_3!X,\%P>$_AKH?A-0KV^G:3#IGLRI"(_UQ7YT_\
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MJ*** /YE?V@?^2\?$;_L8]1_]*9*_93_ ()$?\F=Z=_V%KW_ -&5^-?[0/\
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M\,2? /\ Z)%X1_\ !7'_ (4?\,2? /\ Z)%X1_\ !7'_ (5[;10!XE_PQ)\
M_P#HD7A'_P %<?\ A1_PQ)\ _P#HD7A'_P %<?\ A7MM% 'B7_#$GP#_ .B1
M>$?_  5Q_P"%'_#$GP#_ .B1>$?_  5Q_P"%>VT4 >)?\,2? /\ Z)%X1_\
M!7'_ (4?\,2? /\ Z)%X1_\ !7'_ (5[;10!XE_PQ)\ _P#HD7A'_P %<?\
MA1_PQ)\ _P#HD7A'_P %<?\ A7MM% 'B7_#$GP#_ .B1>$?_  5Q_P"%'_#$
MGP#_ .B1>$?_  5Q_P"%>VT4 >)?\,2? /\ Z)%X1_\ !7'_ (4?\,2? /\
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M\%<?^%>VT4 >)?\ #$GP#_Z)%X1_\%<?^%'_  Q)\ _^B1>$?_!7'_A7MM%
M'B7_  Q)\ _^B1>$?_!7'_A1_P ,2? /_HD7A'_P5Q_X5[;10!XE_P ,2? /
M_HD7A'_P5Q_X4?\ #$GP#_Z)%X1_\%<?^%>VT4 >)?\ #$GP#_Z)%X1_\%<?
M^%'_  Q)\ _^B1>$?_!7'_A7MM% 'B7_  Q)\ _^B1>$?_!7'_A1_P ,2? /
M_HD7A'_P5Q_X5[;10!XE_P ,2? /_HD7A'_P5Q_X4?\ #$GP#_Z)%X1_\%<?
M^%>VT4 >)?\ #$GP#_Z)%X1_\%<?^%'_  Q)\ _^B1>$?_!7'_A7MM% 'B7_
M  Q)\ _^B1>$?_!7'_A1_P ,2? /_HD7A'_P5Q_X5[;10!XE_P ,2? /_HD7
MA'_P5Q_X4?\ #$GP#_Z)%X1_\%<?^%>VT4 >)?\ #$GP#_Z)%X1_\%<?^%'_
M  Q)\ _^B1>$?_!7'_A7MM% 'B7_  Q)\ _^B1>$?_!7'_A1_P ,2? /_HD7
MA'_P5Q_X5[;10!XE_P ,2? /_HD7A'_P5Q_X4?\ #$GP#_Z)%X1_\%<?^%>V
MT4 >)?\ #$GP#_Z)%X1_\%<?^%'_  Q)\ _^B1>$?_!7'_A7MM% 'B7_  Q)
M\ _^B1>$?_!7'_A1_P ,2? /_HD7A'_P5Q_X5[;10!\J_'[]COX(>'_@3\1]
M4TWX5^%K+4;'PWJ5S;74.FQK)#*EK(R.I X(8 @^U?@#7],'[2W_ ";G\5/^
MQ4U7_P!(Y:_F?H _HH\,?L6? >[\-:3/+\)/";RRVD+NS:9&26* D]*T_P#A
MB3X!_P#1(O"/_@KC_P *]6\'_P#(I:)_UXP?^BUK7H \2_X8D^ ?_1(O"/\
MX*X_\*/^&)/@'_T2+PC_ ."N/_"O;:* /$O^&)/@'_T2+PC_ ."N/_"C_AB3
MX!_]$B\(_P#@KC_PKVVB@#Q+_AB3X!_]$B\(_P#@KC_PH_X8D^ ?_1(O"/\
MX*X_\*]MHH \2_X8D^ ?_1(O"/\ X*X_\*/^&)/@'_T2+PC_ ."N/_"O;:*
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MK&V=OA%X1+-&K'_B5Q]P/:OYSX/]='_O#^=?U-Z7_P @RT_ZXI_Z"* /'/\
MAB3X!_\ 1(O"/_@KC_PH_P"&)/@'_P!$B\(_^"N/_"O;:* /$O\ AB3X!_\
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M!G /'L?2@#]D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^4/^"I7_)COQ"_W]/\ _2^WKZOK
MY:_X*;:3?:Y^Q7X]LM-LKG4+R1[#9;VD+2R-B^@)PJ@DX )^@H _G\K][_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHJY.,DM@ >]?IA^P'_P3)G^"GB*U^(?Q/-K=^*;8;M,T>W?S8K%SQYLC]&D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0/F0R/\ -M"97/'''-;OC7XZ?#GX;ZLFE>+/'?ASPUJ;Q+<+9ZMJD%M*T9)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\_\
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MB@ HHHH **** "O/_&7[07PR^'=P+?Q/X_\ #>@SD[?+U#5(8FSZ89J_-_\
MX*F_MU>)]&\<W/PA\ :S+HEG8Q+_ &[J%BY2XEF<!A;JXY154@MMY);&< @_
M"_P9_91^+?[2$-]J/@;PE>:_:P2E9]0EFC@A,AY*^;*RJS<@D D\C/6@#^A?
MP/\ &3P)\2UW>$_&.A^(Q_U#+^*<]<=%8]Z[&OYG/B+\*?B3^S-XVM;3Q-I6
MJ>"_$,7[^TN(Y2C''&^&:-L-CIE6K]?O^"8/[:.J_M'^#M4\)>,[@77C3PY'
M&XOR &O[5B5$C ?\M%(PQ'7*GJ30!]RT44V218T9W8(BC)9C@ >IH 9<74-I
M'YD\L<*9QND8*/S-,MM1M+QBMO<PSLHR1'(&(_(U^'G_  4W_;,;]H+XC'P9
MX8O'/@/PW.T8>-L)J-T.&F([JO*KGW/>O0_^"(__ "6;XA_]@"/_ -*4H _8
MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\YOCI_P5V'P7^,'B
M[P,?AL=4_L'4)+'[9_:OE^=M/WMOE'&?3-<+_P /Q%_Z).?_  <__:: /U3H
MK\K/^'XB_P#1)S_X.?\ [373>%_^"W7@Z^OXHM?^&VL:3:D@/<6>HQW17U.P
MHG\Z /TMHKS[X*?'OP-^T)X3'B'P+KD.L6*L$GC *36SD9V2QGE3^AP<$UZ#
M0 45^7WB3_@M8/#WB+5-*/PK,QL;J6V\S^V,;MCE<X\KC.*^X/V3OV@?^&G?
M@GI/Q _L;^P/MT]Q#]A\_P [9Y4K1YW;1G.W/2@#V&BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHKXC_;(_X*2?\,F_%2#P<? I\1^;81WOVO\ M#R,
M;RPV[=C=-O7/>@#[<HKX^_8C_P""@'_#8GBWQ'HH\&_\(S_8]E'>>=]N^T>9
MN?9MQL7'K7V#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 44R::.WA>65UBBC4L[N0%4 9))/05\-?&[_@KM\)/ACJUUI/AFRO\ X@W]
MLQ22;3W6WL]P)!59F!+8P>0A!XP30!]T45^6EG_P7$L_M:_:_A/.+8GYC#K0
MW@>HS#@_3BOK;]FK_@H#\*/VF[Y=(T749M#\3E<KHNLJL4LW&3Y+ E9,>@(;
MOC% 'TK1137D6-&=V"(HR68X 'K0 ZBOA_X_?\%:/A5\']<N]#\/V=Y\0-7M
M',<[:?*L-FC X*B<AMQ!_NJ1[UX[H/\ P7 TB;4HX]9^%MY;6+, \UGJRR.@
M]=C1 -],B@#]0J*\K^ /[37P]_:7\-MJ_@;6UOC#C[5I\Z^5=VC$=)(R>.OW
MAE3V->J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 45P'QX^,FC? 'X4>(/'.N$-9Z7;F1+?>%:YE
M/$<2D_Q,V!7P'X-_X+1#Q=XNT70Q\+3;G4KV&T\[^V-VS>X7=CRAG&<]: /T
M[HHHH **Y#XI?%SPC\%?"=QXD\::[:Z#I$/'G7+_ #2-C(2-1\SL?[J@FO@;
MQY_P6T\%Z7J+P>$OA_JVO6HZ7FH7B6>?I&%<X^I% 'Z445^<WPQ_X+3> /$>
MK0V7C/P=JGA*"1@G]H6MPM]$N3U=0J, .^-WTK] _"GBS1O'/AZQUWP_J=MK
M&CWT8EM[RTD#QR*>X(_EU'>@#6HHKR3]H?\ :F^'O[,/AV/5?&^K_9YK@'['
MI=JHEO+LCKY<>1P.[$@#UH ];HK\O-<_X+@:3%J,B:1\++NXL58A)KO5UC>1
M>QV+$0OTR:]G_9[_ ."L/PI^,VM6^A^(+>X^'FLW+[(/[4G66SD8G 7[0 H4
MG_:4#WH ^W**16#*&4@J1D$=#2T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!0U[_D!ZC_ ->TG_H)K^7#5O\ D*7G_79__0C7
M]1^O?\@/4?\ KVD_]!-?RX:M_P A2\_Z[/\ ^A&@#],_ ?\ P6BM_!?@K0M
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MJ>4D3C.".584 ?77[3G_  2>\8? /X<WWC31/%=KXVTW35\W4+=+%K2XABR
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M\3_;5\;7'P\_95^)FN6F/M46D20QY]92(OY.:]LKY5_X*>9_X8P\=?\ ;O\
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MTWWQ$^(NHI$LVFQPZ9;7%P %A5P9)7#'[IPB@GT)K[^^)FK_  A_:.\%Z_\
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M$FD^,/#FFZWH-];ZEHU_ L]I=6K!HY(V&5*D?R[=*U: "BBB@ HHHH ****
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M2-=U673=/@E0B2=8XP[3#_8R=H]2#7VW_P $1_\ DLWQ#_[ $?\ Z4)7I?\
MP67\-Z9X-^!OPBT/1K..PTK3]2FMK6VA&%CC6W 4#\!7FG_!$?\ Y+-\0_\
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M_%&WM=)\37K"&PUJU7R[:\DQPDBYQ&['@$?*3@<$T ?HO7XD?\%DO^3IM/\
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M^?+XE?\ !1;]H#XD:M+J1\<:AX=L6<B.RT+_ $6"/G(7(Y8@=R23BND^!?\
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M?,['@<>HSBN\K^;W]KCQ%KGB[]I3QZFI:C?:O-'KES;VR3RM*442%51%[#
M 'I0!Z%^W)^W5KO[6WB6*RM(I=$\!:;(6L-*9\O,_3SYB."Q'0=%!_&O"O@O
M_P E>\%?]AFT_P#1RU[9XG_86\5?#/\ 95U3XO>.8YM!NI;NS@TG174"9HY7
M(:6<'E.,;5Z]S7B?P7_Y*]X*_P"PS:?^CEH _IUJMJ.H6^DZ?<WUW*L%K;1-
M-+*QP$1022?H!5FOFO\ X*,>.Y_A]^QO\1KZV+"XO+1-*4JVT@7,JPL0?978
M_A0!^-'[9_[56M_M4?%[4=:GN9H_"UE*]OH>EL<);VX. Y7_ )Z/C<QZ\XZ
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M_"^Q\8ZWXKL_"']JP?:-.T^2T:>5HV ,<DI# *&&2%&3@@^U?(?QT^"GB/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(D)R3[D"OV)^!/P1\-_L\_#+2/!'A:!H]-L%)>:7!EN9FY>60]V8_D, < 4
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M^"BG[(WQB^*_[4WB'Q%X2^'^K:[HD]O;)%?6JH8W*Q@-C+ \&@#ZD_X(V_\
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MA[3$,>G:39PV-LIZB.- BY]\** -:BBB@ HHHH **** "BBB@ HHHH ****
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M'A_4_L4P\)>%[N/4]4ORN(]T9WQ0 ]V=PO Z+N-?OU0 4444 %%%% !1110
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M4/,/R7MD\U^47P5^,_B'X!^/+;QAX533_P"W+6)X[>;4+-+E82V 716X#XR
MW4!CZU](_P##V_\ :*_Z#NB_^":'_"@#]W**_)/]BO\ X*,?&OXW?M)>$/!O
MBC5]+N-"U&25;F.#2XHG8+$S##+R.0*_6R@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _F5_:"_Y+W\2O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!_.;^W7_R>%\6_^P_<?S%=+^R#^W9XC_8^
MTGQ'8:%X;TS74UJ>*>5M0DD0QF-64!=I[[JYK]NO_D\+XM_]A^X_F*]>_P""
M??["GAO]L#0?&%_KOB/4M#DT6Y@@B2QB1Q()%9B26[C;0!Z)??\ !;'XDSVY
M2V\"^&[67M)YLSX_ FOD?]HC]K#XC_M0:M:7?CG6%N;:RS]DTVTC\FU@)X++
M&#]XC +')K]*E_X(E_#P,"?'_B C/(^SP\UW?@__ ((_? OP[J$-WJ3:]XB,
M3[A;WEZ$A<?W65%!(_X$* /S7_8%_9-U?]IKXT:6;BQF3P1HL\=[K.H/&?*9
M5;<ML#T+R$;<#H-Q[5_02JB- JC"J, "L7P7X'\/_#GP[::#X8T>ST+1[5=L
M-G8Q".->,9P.IXZGDUMT ?R^_$S_ )*-XI_["EU_Z-:OW!_X)._\F3^$_P#K
M^U'_ -*I*_#[XF?\E&\4_P#84NO_ $:U?N#_ ,$G?^3)_"?_ %_:C_Z524 0
M_P#!0+]B[QQ^U])X7M] \7Z9H6C:-'+(]AJ$4A\ZX<@;]R ]% '/OZUX]^QG
M_P $J9_A'\5+KQ-\5!HOBFTT^-3I%K 6DA:XSS))&ZX.T= >YSVKZN_:X_;$
M\(?LC^#X-1UQ9-3US4-RZ9HMLP$MPP'+,3]R,'&6/T&37Y7?$[_@KI\</'$U
MS'H,VF>";"3_ %::?;B:>/\ [:R9S_WR* /V5\8?"#X?^*O#=YI?B#PIH=SI
M$L)CE2>SB550C'#8&WZ@C%?S??&3PK8>!_BQXQ\/Z5<)=Z7INK7-K:31R;PT
M*2L$^;^+Y<<]Z](O/&'[1G[25_\ 9WO_ !QXSED&W[/;"=HV#=BB *?RKQ;7
MM!U'POK5[I&KV4VG:I92M!<VEPA22&13AE8'H0>U '[G_P#!)769M5_8UT2&
M4DK8:G>VL>3G"[Q)QZ<R&OB'_@L7\;+SQA\>K'X>V]TW]B^%+2.26V4_*U[.
MH=G/J1$T0'IEO6OL[_@D#_R9[;?]AV]_E'7Y>?\ !0Z2:3]LSXH&<L7_ +14
M#<,':(8POZ8H ]6_X)7_ +*>@_M"?%#6]?\ &%E_:/AKPM%%(+&0'RKNZD+;
M%?U50A8KWRO:OV2UGX*> /$'AV?0;_P9H4^D31-"UI_9\2IM(P<84;3CN,&O
M@3_@B'C_ (5Q\2?7^UK?_P!$U^F% 'X=_%K_ ()4_%R'XO>)]/\  /AL7O@]
M+QCI=[>7L<0,#<JI+$$E<[2?:OTH_P""?/PI^)OP1^!8\%_$R&UCN=-O'_LP
MV]ZMSBU8!MA(X4*V[ ]#7TY10!^"G_!43XX7OQ:_:BUS25N&;0_"A_LJRA5\
MIO&#+(/=F./^ BO?/^"1W[(?A;XA:7J_Q6\8Z9;ZXME??V?I%C=*)(4E10TL
MKH>&(WH%SP/F]J_/[XZ74]Y\:_'TUR[23MKU]N9^I_?N/Y5WWP=^,W[0?@?P
M:NF?#;5_%-CX:%Q)((M'M6>#SCC><A#EN%SSZ4 ?NU\8OV7?AO\ &[P/>^&=
M>\+::D,T)2WO+6U2*>T?!"O&Z@$%>N.GJ*_G5^(?@W4/A7\1_$/A>ZE8:EH&
MI36+3QY0EXI"N]>XSMR/J*^B/^&E/VP?^AC\??\ @$__ ,;KQ7Q1X#^*7C3Q
M#J&NZYX:\2:GJ^H3-<75Y/ITI>61N2Q^7J: /WS_ &)_C)/\=_V9/ _BR]F:
MXU62S^R:A*PP7N86,4C$?[13=_P*ORY_X+)?\G3:?_V ;?\ ]">OM?\ X)$6
M>L:/^S%J&E:S8W^FW%EKUPJ6]_;M"55DC?*A@,J2QY]<U\4?\%DO^3IM/_[
M-O\ ^A/0!XG^PG^S?;_M/?M Z5X8U-I(_#UK$^H:HT60S0QX_=ANQ=B!GTS7
M[V^'O@E\/_"OAV'0=*\%Z%::1%&(EM5L(F4J.S94EOJ<U^6'_!$<Q_\ "WOB
M(&V^9_8L.S/7_7\XK]A: /Q)_P""J7[(.@?L_P#C+0_&'@NR72_#/B1I(9M-
MC_U=K=H Q\L=E9><=B#CK7/?\$G?B_=?#K]JC3= :XV:/XL@?3KF%B=IE"EX
M& _O;QMSZ.U?:'_!:1%;]G7PNQ52R^($VDCD?N9.E?F/^Q46'[6_PAV;@?\
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M ,F_?#?_ +%VP_\ 2=*]&H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUB#7=/TN?Q%XCA'[K4M:<3&%N?FCCQM1N>N"?>OJ.B@ HHHH **** "BBB@
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MWU2&^U*U%G<&^OC.IC#A^ 0,'('->^T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '\YO[=?_)X7Q;_ .P_<?S%?>__  0__P"1-^*7_7_9_P#H
MN2OF;]L+]D/XS^-OVH?B9KNA?#?Q!JFD7VM33VMY;VA:.:,D893W%?9W_!(K
MX+^.?@WX6^(MOXV\+:EX9FO;VU>V3483&956-PQ7/4 D4 ?H-1110 4E+24
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MRX_;1_X)+W?B/Q!J?C7X,&W6:]E:XN_"EQ(L*"1LEFMI&.T GGRVP!DX.,*
M#[Z_9]_:&\'_ +1WP]T[Q3X5U*&<31J+JP+C[19S8&^*1,Y!![]",$<&N5_:
M]_:J\,?LP?"O5=7O]2MV\2SV\D6CZ2LBF>XN",*VS.=B%@S$\8&.I%?A/J'P
MA^-7P0UJ9I/#/C'PC?J3$US:V]Q!N'HLD> P^A(J3P]\!/C5\<_$"2V?A'Q5
MXGU&Z;8U_>03.../GGEX 'JS4 >8[;WQ-KF(H7NM1U"X^6*%26DE=N H]23T
MK^C+]CGX,O\  /\ 9R\&>$+J%(=4M[3[1J CZ&YD.^3\03C\*^7_ -@W_@F+
M%\#=7M/'OQ+DM=5\90C?8:5;D2VVG,1]]F(^>4=L?*O8GK7Z$4 %%%% !111
M0 4444 %%%% !1110!^+O_!9[P!J6C_M">'O%LD9.D:UHL=K#* <":!WWJ>P
M^61"/QKA/^"87[5>A?LV_&+4K'Q=.+'PMXH@CM)]0*Y6SG1B8I'/:/YG5CVW
M G@&OV%_:8_9O\,?M1?#&\\'^)E:$%A/8ZC"H,UE< $+(F>O!(([@D5^)?QW
M_P""=?QI^!VK7"-X6N_%FAJY$&L>'X6NHW3G#.B@O&<==PQGH30!^Y/B?]H;
MX:>#_!\OBC5?'&AV^AI%YPNEOHW$@QP$"DEB>@ Y)-?S[?M8?&N/]H;]H#Q?
MXZMX9+>QU&Z"V<<OWQ;QJ(XMWH2BJ2.V:XRU^%?C2]OA96_A+7)KPML$$>G3
M%]WIC;G-?6?[+/\ P2U^)?QAU^RU#QWI=WX#\&(RR3R7Z>7>W*YYCBA/S*2/
MXG  !R,]* /L?_@C+\.KWPS^S_XA\37L/E)XBU8M:%A@M#"@CS]"^_\ *OG7
M_@M%\)IM"^,'ACQ_!;O]AUZP^Q7%QGY1<0<*OMF,K^1K]=O!OA#2? 'A72O#
MF@V::?H^EVZ6MK;1CA(U& *XS]HCX ^&_P!I3X6ZIX)\3(R6UT!);7L('FV<
MZ\I*F>X/4=P2.] 'XV?\$M_VCM$^ /Q\N+;Q1>Q:9X=\36?]GS7]PVV.VF#!
MHG8] I.5+'@!LU^J7[6O[77@;X(_!37]43Q+IE]KM[820Z/I]K<I+)<S.A5"
M%4D[ 2"6Z "OQW^/W_!/OXQ_ 77+F&?PO>>)]"5S]GUS0X'N89$[%U4%HSCL
MP'/0GK7CNA?!KQ[XGOULM(\%Z_J5VQP(;;39G;\@M '+6%C<:MJ%O9VL3W%W
M<RK%%&@)9W8X  [DDU_2M^S7\,/^%,_ 7P+X,>-(KG2=*ABNEC^[]H8;YL>O
M[QGYKX'_ .">O_!,O6_ OC#3OB9\6;2&TO+ ^=I/AMB))(YL_+/.0=H*]509
M.<$XQ@_J%0!^&_\ P6$_Y.Y?_L!V?_L]>I_\$/\ _DH'Q3_[!=E_Z-DJ'_@J
M%^S/\4_BO^TTVM^$/ FM>(=(_LBUA^V6-L9(]Z[MRY]1D5Z+_P $B_@'\1/@
MWXV^(MSXW\'ZKX9M[[3[2.VDU& QB5ED<L%SU(!'YT ?IM7\U?[57_)R/Q*_
M[#UW_P"C#7]*E?@?^T9^QQ\;?$_QX\?:MI7PR\0WVFWFLW,]O<PV;%)49R0R
MGN"* /T*_P"".O\ R:0__8?O/_08Z^K?CI_R1?QS_P!@6[_]$M7SQ_P2W^&?
MBKX4?LSOHGC#0;WP[JW]M74_V._B,<GEL$PV#V.#^5?2'QBTVZUKX4>,+"QM
MWNKVZTFZAA@C&6D=HF"J!ZDF@#^8>OZ3?V1_^37_ (5_]BW8_P#HE:_"3_AA
MOX^8S_PJCQ-_X!-7[U?LS:#J/A;]GGX<Z/J]G+I^J6.@V=O<VLZ[7BD6)0RL
M.Q!% 'Y#?\%=?@W=^ ?VFI/%J0,-&\86D=U%,%P@N(D6*:/Z_*C_ /;2IO\
M@EE^U[H/[//CK7/"_C2_&F>%/$OENFH2G$-G=)D!I/1'4X+=MJ]LU^M7[2G[
M.7A;]J#X97G@_P 3QM&&/G6.HPJ#-8W !"RIGKUP5Z,"1Z$?C1\8/^"6_P =
M?ACK%S'I7AW_ (3?1U.8=1T-U=G7/&Z%B'5L8R,$>A- '[3^+OVBOAGX%\(O
MXGUGQQH=MHJQ><EPM[')YHQD"-5)+L>P )-?@C^VE^TB?VI/CMJWC"WMY;+1
M41;+3+:8C>ENG"LP'1F.6([9KN?A9_P3&^/?Q)UB"WNO"3^$=.9L3:CKTBPK
M$N>2(P2['T 7\11_P4"_9?\ #G[*/B7P#X4T*::_NY]#-UJ>I3D@W=P9G!8)
MDA%   4=AR2: /4_^",'_)Q_B'_L R?^C$K]IZ_%K_@B]&[?M&>)'56*KH+[
MF X&94QFOVEH **** "BBB@ HHHH **** "BBB@ HHHH **** /B[_@KI_R9
MGJW_ &%[#_T8:_%OX+_\E>\%?]AFT_\ 1RU^XW_!3?X=>)OBE^RKJ6@^$M$O
M/$&LR:I92K96,9DD*+)EFP.PK\H_A3^Q;\<]'^)WA.^O?A=XCMK2VU6VFFFD
MLV"HBRJ68GT % ']!=>=?M$?"]?C/\#_ !MX*RJS:QI<UO;NPR$FVDQ-^#A3
M^%>BT4 ?RQZOI-[X?U:\TS4+:2SU"RF>WN+>92KQ2(Q5E([$$$5^\O[#/[;G
M@GXZ?"70-,U3Q!8Z3XZTNSCM-2TV^F6!YFC4+Y\08_,C  \9P3@UY'_P4"_X
M)F2?&K6[WXC?# 6]KXOG7?J>BRL(XM2<  21L>$E(&"#A6X.0<EORI\8?L__
M !*\ ZC-8^(/ GB#2[B)RA$^G2A202,JVW# XX()![4 ?IS_ ,%;/VL?!]U\
M*8OA9X9URUUO7M1O8Y]2^P2K*EI!'\P1V!P'=BI '.%.>HKX&_8/^%MU\6OV
MJO 6DPP&:UM+Y=3O& !$<,!WECGW"C\:P_A;^Q]\8OC%JEO9^'/ .L/'+@F^
MO;9K:U13_$TL@"].<9R>P-?L]^PK^P[I/[(?A.[GO;N+6_'.KJO]HZE&I$4*
M#D00YYV@\ECRQ[  "@#TG]KCX82_&+]G#Q[X4MDWWUYIDC6HV[CYR?.@ ]25
MQ^-?S?*USH^I*2C07=K+DJZX9'5NA'J"*_J?K\LOV_/^"7NK^)?$VI?$7X06
M4=W-?.UQJGAE"L;>:>6EM\X!SR2G7/(SG% 'V1^RW^USX%^-7P1T3Q#-XGTN
MQU:SL(TUJSN[N.*2UG1<2,RD\*Q4L#TP:_)C_@IQ^TAHG[1'[0$;>%;]=3\+
M^'K(:=:WD8_=W$I8M-(A[H3M4'OLR.#7SGKGP;\>^&;XV6K>"]?TZ[!P8;G3
M9D;\BM>R_L__ /!/GXQ?'K7K:"+PQ>^%]!WK]IUO7+=[:&-.Y16 :5O90>>I
M% 'T_P#\$4OA%<7WCCQI\2;F!EL=/LQHUG(P^5YI6627'NJH@_[:5].?\%?/
M^3/+K_L.67_M2OI;X"_!'P[^SQ\+=%\#^&8=MAI\?[RX<?O+J9N9)G_VF;GV
M& . *\-_X*>?#?Q1\5/V7;G0O"&AWGB'6&U>TF%G8QEY"B[]S8]!D?G0!^(W
MP#_Y+K\.?^QDTW_TJCK^FVOY^_@S^Q?\<=#^,/@74K_X7^([6QL]>L+BXN)+
M-@L<:W$;,Q/8  D_2OZ!* /R7_X+?_\ (S?##_KSN_\ T-*\(_X))_\ )Z7A
MW_L&:A_Z(:OK3_@KI\!_B%\9/$'P]E\$^$=4\3165K<I<OIT!D$19U(#8Z9P
M:\;_ .":/[+_ ,5_A;^UAH>O^+/ .MZ!HT6GWT<E]?6I2)6:$A03ZDG% '['
MU^!?_!4W_D]+QG_UQL__ $0E?OI7XO\ _!13]E?XM_$O]J_Q5K_A;X?ZYKFB
MW$5J(;ZSM2\3E85#8/L010!Z=_P0V_U?QB^ND_\ MW7VI^W=\(+GXW?LM>./
M#NGPF?5H[8:A8QJNYFF@82;5'JRAU'NU?,G_  2#^!WC[X,Q_%(>./">I^&/
M[0.F_9/[1@,?G;/M._;GKC>N?J*_1F@#^6?1=6O?"^OV&IV;&WU'3KJ.YA9A
MRDL;AE)'LP%?T+_LQ_MG?#O]HCX?Z;J5KXBT_3O$*6Z_VEH]]<I%<6\H #G:
MQ&4)SAAP:^1?VW?^"4=YXY\5:GX\^#S6D%[J#M<W_A>X<0H\Q)+26SGY5W$Y
M,;8 .<'!P/A23]@']H./5CIY^%NN&;=M\Q8U,7_?S=MQ[YH _0S_ (*;_MT^
M#=+^%.L?"WP9K-KXA\2:ZGV;4)M/E$D-A;[@75G4X\QL8VCH"2>U?CC7Z-?#
M/_@E3JW@KX4^,O'OQ@,,-UI^BW5QI_ANSN=[),L;%9)Y$.W@@$(A.>Y'2OSE
MH _IB_9O_P"3?OAO_P!B[8?^DZ5Z-7G7[.:-'\ /ANKJ5;_A';#AA@_\>Z5Z
M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@ HHHH *1E##! (]Z6B@!  HP!@4M%% !1110 C*&X(!^HH50HP  /:EHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** &^6@;(50?7%.HHH **** $I
M%C5>54#Z"G44 %%%% !1110 4444 %%%% !1110!^7O_  4J_:R^.?[-/Q\T
MRU\'>)6TGPGJ6E0W5O!)I\$\4DJNZRKNDC)SPN0".&'K7G'[.?\ P5Z\>?\
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M*K?>4'ZBG44 ( %& ,"EHHH **** &M&K<LH/U%+2T4 %%%% !1110 4444
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MM/!_AZ+PCX2T30H#NATNQ@LD/JL<:H/T6M>BB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ JGK&LV'A[2[G4M4O;?3M/MD\R>ZNI5CBC7U9F(
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M1N,] ^-A^JGM7[<4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQY_P4;\%?M37I\/75F_A+QI'"TW]G7,H>&Z55R[0R<9P,DJ0#@$U\S_MR?\
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MO!OQT\6:SI=YX8O/"&G:3HUSK5WJM_>1R11Q0E PP #D[QC\N]<3_P %L/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?S]?\%-/^3T?'_\ UTM__1"5]B?\
M$.?^19^+O_7YIG_H%S7QW_P4T_Y/1\?_ /72W_\ 1"5]B?\ !#G_ )%GXN_]
M?FF?^@7- 'Z@UYG^T]_R;;\5O^Q4U7_TDEKTRO,_VGO^3;?BM_V*FJ_^DDM
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MX;_:..A>,[+2[G3?$EDUC;R:M;QRQI=!@T:C>I"EOF7/'.!WK]L/^%.^ ?\
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MRO(UEM_[5,Q5ER"8XI)%_P#'D%?HA_P6P_Y(?X'_ .PZW_HEJ^&/^"8,:O\
MMI>!-RAMOVHC(S@_9WYH _?ZBBB@#\B/^"X"C_A8GPN..?[*O!G_ +;)3O\
M@B'=2CX@?$JW#GR6TRWD*=MPEP#^1-4/^"W&K17/Q:^'=@A!EM='G=QW&^88
M_P#0:[+_ ((@>%SY?Q0\1,A 4V=@CE3\V?,=@#[;5S]10!^J5%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M!O\ P4H\,ZQJ'[97CV>UTF^N86D@VR0VSNI_<IT(%?7G_!$G1[_2?#?Q:6^L
M;FR+W>F[1<1-'NPEQG&1SU'YU^F+VL$C%GAC9CU+*":6.&.'/EQK'GKM4#-
M$E>:_M,0R7'[./Q3BB1I97\*ZHJH@)9B;24  =S7I5(RAE((R#P0: /Y</\
MA#/$&,_V%J6/^O.3_"OZ;OARK1_#WPPK JRZ7:@J1@@^4M;?V&V_Y]XO^^!4
MPXX' H _G@_;>\*ZW>?M<_%F:WT>_GA?Q!<E9([5V5ANZ@@5^HO_  2&T^ZT
MW]DOR;RVFM)O[=O#Y<\91L83G!K[5:S@=BS01LQY)*#)I\<20KM1%1?11@4
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M*OZ3:_GQ_P""A7[/4G[._P"TEKEI8VK6OAO6G.K:0RC"+'(Q+1K_ +C[E]<
M'O0!_08CK(BLI#*PR".A%?F!_P %K]'O]6L?AD+&QN;TK+=[A;PM)CA.N!7V
MG^QC\9H/CQ^S?X,\4+(KWWV-;*_501LN81LD'/N,_C7M4D$<V/,C63'3<H-
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M'XH?LFP^*-#\6:GHVI>&=4:.[MTT^9VD@N0-K'#*/E9=O3NM?:5%% !1110
M4444 %%%% !7S3^WG\#OB)^T5\([?P-X#U#3=+@O+M9=5GU"9XR\*#*QKM!R
M"V"<^E?2U% 'QE_P3V_8-E_9-L]=UOQ1<V.J^--3/V=)[/+1VUJ.=JE@#ECR
M>/X0*^S:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHJ"^OH-,L;B\NI5M[6WC:66:0X
M5$4$LQ/H ": *6L>*-&\.M&NJZO8Z89 2@O+E(MP'7&XC-6KC5+*ST\W\]Y;
MP6*H)#=22JL04]&W$XQSUK\1-5\2ZC_P4<_X* :592"23PA!>F.WM6(*P:7
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^3_\
M@IY\6+CX4_LD^)/L,[6^HZ_+'HL,D;8=5ER92/;8C*?]ZOK"OS-_X+?:A<0_
M#[X7V22%;:XU.]DD3LS)%$%_+>WYT <?_P $2?AG#=:K\0?'T\:O):I#I%LS
M)RA;]Y(0?<!!7VW_ ,%"/^3,_BI_V"O_ &HE>'?\$:--@M?V8]6NHUQ-=:[,
MTK>I5$4?H*]Q_P""A'_)F?Q4_P"P5_[42@#\E?\ @E;_ ,GJ>#O^O>]_])WK
M]\:_ [_@E;_R>IX._P"O>]_])WK]\: /S8_X+6?##3]0^%W@WQ[%:QC6-.U/
M^RYK@8#-;2QNX4_WL2(,>F]O4UP/_!$3QU<Q^(/B5X/DN)&LYK:VU2"W/W$D
M5FCD8>A8-&#_ +@]*]P_X+,7\%K^RSI,$K[9;GQ';)$N"=Q$4S'Z<*:^:/\
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M"P=67!7(/'45^"_[0_CKQ_\ $CXJ:IXA^)EM<6?BR\2)IH+BS-J4C" 1@1D
MA=N,9ZCN:_?[]D6.67]EOX9I>*[R-H%LLBS9)(*=#GVH _-S_@GY_P % ?BA
MXN_:3T/PI\2?&5QX@T/7DDL(8[J&&/RKHC,14HBG)8;>3_%7Z_W5S'9VTMQ,
MP2&)#(['H% R3^5?ST_M=_#2_P#V5_VN];@TQI+6*VU)-<TB9&VGR7?S$P1T
MPP9?^ U^K'[6'[5%C:?L W/Q"T>[6*\\7:3#9V'DOADGN5V2!<]3'^\S_N4
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M''K_ (FOVEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@J#^S5#"SK\11,5&1''I%]N/TS"!^M?(O\ PXWU/_HL-I_X3S?_ "33H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>plrx-20211231_g17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g17.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 8+"%<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF61#WR[ X<8PO^":O['I_:5^+0UWQ!:&3X?^%Y4N+\2+\E_<?>BM!Z@XW/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$MZC%O,\*Z8&).3O6UC5AG_>!H ]7K^6+6/^0M>_]=W_ /0C7]1GB/5T\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&OZ:+_[?U^5S_>;ZU^J/_!#'[WQK^FB_^W] 'ZK4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!_*P_WF^M?JC_P0Q^]\:_IHO\ [?U^
M5S_>;ZU^J/\ P0Q^]\:_IHO_ +?T ?JM1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!_*P_P!YOK7ZH_\ !#'[WQK^FB_^W]?E<_WF^M?J
MC_P0Q^]\:_IHO_M_0!^JU%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '\K#_>;ZU^J/_!#'[WQK^FB_P#M_7Y7/]YOK7ZH_P#!#'[WQK^F
MB_\ M_0!^JU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M\K#_ 'F^M?JC_P $,?O?&OZ:+_[?U^5S_>;ZU^J/_!#'[WQK^FB_^W] 'ZK4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M77]NW$$NSR/-V>7Y4,>,^<^<YZ#&.<@'T#1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\K#_>;
MZU^J/_!#'[WQK^FB_P#M_7Y7/]YOK7ZH_P#!#'[WQK^FB_\ M_0!^JU%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?BS_P6L_Y.@\)
M_P#8G6W_ *6WM?M-7XL_\%K/^3H/"?\ V)UM_P"EM[0!\G_LJ_\ )T'P?_['
M'1__ $MAK^E:OYJ?V5?^3H/@_P#]CCH__I;#7]*U !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?RL/]YOK7ZH_\$,?O?&OZ:+_ .W]?E<_
MWF^M?JC_ ,$,?O?&OZ:+_P"W] 'ZK4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5^+/_!:S_DZ#PG_ -B=;?\ I;>U^TU?BS_P6L_Y
M.@\)_P#8G6W_ *6WM 'R?^RK_P G0?!__L<='_\ 2V&OZ5J_FI_95_Y.@^#_
M /V..C_^EL-?TK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%]?
M6VF65Q>7EQ%:6EO&TLUQ.X2.-%&69F/   ))/  H GHK\E_VLO\ @L!K4FN7
MWAOX(Q6]AI]K(T+^++Z%9Y;DC(W6\+@HJ9Y#.&+#'RKW^%_$?[6GQK\674D^
MI_%?QC.7?S#%'K=Q%"&YY6-'"+U/0#K0!_2A17\ZGP[_ &]/C[\,M0BN=,^)
M^O:C$A4&SUZZ.I0,H_@VW&_:,<?)M/H17ZN?L,_\%'-!_:FE7PGXDL[?PO\
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M^#__ &..C_\ I;#7]*U?S4_LJ_\ )T'P?_[''1__ $MAK^E:@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^#?^"P'QRNOAK^SWI_@W2[C[/J'C:[:U
MG96PWV&$*\X'^\S0H?568=Z^\J\^^*W[/WPX^.,5LGCSP;I7B9K5&CMYKV#,
MT*L06"2##J"0.A'2@#^9_3]/N=6O[:RLK>2ZO+F5888(5+/([$!54#DDD@ >
M]?KQ\"?^",W@JW\%V-Y\5-:UC4/%-U"))]/T>XCM[6R++_J]VQFD=3U?(4G^
M$@9/ONC_ /!,?X!>&?B!H'B_0?#=_HNHZ+J$.I6]O;ZI-+;M-$X=-Z3%R5W
M' (Z>G%?5E 'X5_\%!_^"?47[),.D>*O"VKW>M>"-5N_L&W4MGVJQN2C.B,R
MA1(KJDA#!1C80>H)^/\ PKXHU3P3XETOQ!HEY)IVL:9<QW=I=0G#12HP96'T
M(%?K/_P6A^-OA^#X:^'/A;:WD-UXFNM4BUB[MTPYM;6..5%+_P!UG>0;1U*H
MW8C/Y%V-C<:I?6]G:027-W<2+###$I9Y'8@*J@=220 />@#^F_X-?$!?BM\)
M?!OC)(A!_;VD6NI-"N<1M+$KLGX$D?A5/X]_%2U^"/P9\8^.KL1NNAZ;+=11
M2'"RS8VPQD_[<C(O_ J;^S[X!G^%GP+^'_A"[1$OM%T*SLKH1G*^>D*B4@]P
M7W'\:^3?^"ROC)M _98TS18IBDFO>(;:"2,'&^&*.69L^H#I#^E 'XP>,/%N
MK>//%6K^(]=O)-0UG5;J2\N[F3K)*[%F/MR>@X XK[7_ ."?/_!..U_:B\/W
MGCGQQJE_I'@V*Y:SLK73"B7-_(@_>/O=6"1J2%X4ECN&5VY/PC7]&_[#_A.+
MP7^R+\)M.AC$8D\/VM^Z@8_>7*_:'_'=*U 'YO?MZ?\ !,'2/@#\-IOB)\-]
M5U34-$TUXUU?2]6=)988W8(L\4B*N5#,H92"1NW9P"!^>&GZA<Z3?VU[93R6
MMY;2K-#/"Q5XW4@JRD<@@@$'VK^FWXU>#X?B!\'_ !OX:N(A-%JVBWEEM(!Y
M>%U4CW!((]"!7\Q= ']'O[&GQT?]HK]G'P?XTNI(GUF>W-KJBQ#:%O(6,<IV
M_P .XJ' ]'%=E\<OBA:_!7X/^,/'-XJ/'H6FS7B12' FE"XBB_X'(47_ (%7
MP+_P1!\9->?#_P")OA5YF(T_4[74HXF/ \^)XV('_;LN?PKT;_@LAXT;P[^R
ME9Z+%*5D\0:_:VLD8.-T,:23DGU >*+\2* /Q>\:>,=7^(7B[6/$VOWCZAK6
MK74EY=W,G5Y'8LQQV'/ '   ' K[/_X)[_\ !.FU_:FT74/&WC;4[_2/!=M<
MM96EOIA1+F_F4 NV]U8)&I*C(4ECN *[<U\+5_1=^P?X5B\'?L>_">QAC$:S
MZ%!J+ #JUR#<$_B9: /SL_;Q_P""7NC_  %^&<_Q#^&VJ:IJ&D:8T8U?2]6=
M)I8HV8()XG1%RH8J&4@D!BV< BOSIL[R?3[N"ZM9I+>Y@=98IHF*NCJ<JRD<
M@@@$&OZ=_BUX1A\?_"WQAX:GB6>+5](N[$QLN<^9"R#CUR1CWK^8,]30!_1I
M^Q/\=IOVC/V;?"7C"_ECDUQHFLM5\L;?]*A8H[$=!O 63 Z"05[I7YC?\$/_
M !BUUX*^*'A5Y#ML=0L]3BC)X_?QO&Y _P"W9,_45^G- !1110 4444 %%%%
M '\K#_>;ZU^J/_!#'[WQK^FB_P#M_7Y7/]YOK7ZH_P#!#'[WQK^FB_\ M_0!
M^JU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?BS_P
M6L_Y.@\)_P#8G6W_ *6WM?M-7XL_\%K/^3H/"?\ V)UM_P"EM[0!\G_LJ_\
M)T'P?_[''1__ $MAK^E:OYJ?V5?^3H/@_P#]CCH__I;#7]*U !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6/B3=<[8]%MXCR,?-/G_ -DKT3_@N):;_"?PENMO,=[J,>[/3=';GI_P#]*
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MJ/\ AZ-^T[_T4S_R@:7_ /(U>J_\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\
MT-/P_P#_  8WW_R'0!Y5_P /1OVG?^BF?^4#2_\ Y&H_X>C?M._]%,_\H&E_
M_(U>J_\ #E3XW_\ 0T_#_P#\&-]_\AT?\.5/C?\ ]#3\/_\ P8WW_P AT ?
M'7FOU2_X(8_>^-?TT7_V_K\K2,$BOU2_X(8_>^-?TT7_ -OZ /U6HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\6?^"UG_)T'A/\
M[$ZV_P#2V]K]IJ_%G_@M9_R=!X3_ .Q.MO\ TMO: /D_]E7_ ).@^#__ &..
MC_\ I;#7]*U?S4_LJ_\ )T'P?_[''1__ $MAK^E:@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLK@HR>;!+=221MM8 C*L#@@$9YKZJ_X(V_\ )W%Y_P!BS>_^C;>@#]OZ***
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M4_Y!C:9<K=?]<C$V_P#\=S7\NYZU^L7[>G_!43P=XB^&>K?#[X0:C<:U>ZY
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M?_(U '] %%?S_P#_  ]$_:<_Z*:?_!%IG_R-1_P]$_:<_P"BFG_P1:9_\C4
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MT_\ @BTS_P"1J/\ AZ)^TY_T4T_^"+3/_D:@#^@"BOY__P#AZ)^TY_T4T_\
M@BTS_P"1J/\ AZ)^TY_T4T_^"+3/_D:@#^@"BOY__P#AZ)^TY_T4T_\ @BTS
M_P"1J/\ AZ)^TY_T4T_^"+3/_D:@#^@"BOY__P#AZ)^TY_T4T_\ @BTS_P"1
MJ/\ AZ)^TY_T4T_^"+3/_D:@#^@"BOY__P#AZ)^TY_T4T_\ @BTS_P"1J/\
MAZ)^TY_T4T_^"+3/_D:@#^@"BOY__P#AZ)^TY_T4T_\ @BTS_P"1J/\ AZ)^
MTY_T4T_^"+3/_D:@#^@"BOY__P#AZ)^TY_T4T_\ @BTS_P"1J/\ AZ)^TY_T
M4T_^"+3/_D:@#^@"BOY__P#AZ)^TY_T4T_\ @BTS_P"1J/\ AZ)^TY_T4T_^
M"+3/_D:@#^@"BOY__P#AZ)^TY_T4T_\ @BTS_P"1J/\ AZ)^TY_T4T_^"+3/
M_D:@#^@"BOY__P#AZ)^TY_T4T_\ @BTS_P"1J/\ AZ)^TY_T4T_^"+3/_D:@
M#^@"BOY__P#AZ)^TY_T4T_\ @BTS_P"1J_?RW8O!&QY)4$_E0!)1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)\LW<7[F<#J8I5RD@]T8BOK#_@C;_P G<7G_ &+-[_Z-MZ /V_HHHH ****
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M2/#^E^'X?*TO3;/38L >79P)$N!G PH'J?SK0H **** "BBB@ HHHH ****
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M&;P+_P"!][_\B4?\.=_C-_T,W@7_ ,#[W_Y$K]AJ* /QY_X<[_&;_H9O O\
MX'WO_P B4?\ #G?XS?\ 0S>!?_ ^]_\ D2OV&HH _'G_ (<[_&;_ *&;P+_X
M'WO_ ,B4?\.=_C-_T,W@7_P/O?\ Y$K]AJ* /QY_X<[_ !F_Z&;P+_X'WO\
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MK)"%;*1J> S=^] 'ZNT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4=K_ ,>T7^X/Y5_*Y7]4=K_Q[1?[@_E0!+1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTT7_ -OZ /U6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_%C_@M9_R=%X4_[$VV_P#2V]K]IZ_%C_@M9_R=%X4_[$VV_P#2V]H
M^2OV8?\ DY7X3?\ 8W:3_P"ED5?T25_.W^S#_P G*_";_L;M)_\ 2R*OZ)*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_,O_ (+3?\>_
MP?\ ]_5_Y65?II7YE_\ !:;_ (]_@_\ [^K_ ,K*@#\PZ_JCM?\ CVB_W!_*
MOY7*_JCM?^/:+_<'\J ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;J^$9!\IKIHO+C8]FVP!\'M(I_BKY_\ ^"8^M7>C?MN?#?[+O9;J2\M9HT.
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MTT7_ -OZ /U6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_%C_@M9_R=%X4_[$VV_P#2V]K]IZ_%C_@M9_R=%X4_[$VV_P#2V]H
M^2OV8?\ DY7X3?\ 8W:3_P"ED5?T25_.W^S#_P G*_";_L;M)_\ 2R*OZ)*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_,O_ (+3?\>_
MP?\ ]_5_Y65?II7YE_\ !:;_ (]_@_\ [^K_ ,K*@#\PZ_JCM?\ CVB_W!_*
MOY7*_JCM?^/:+_<'\J ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ;G; ]@     !W\<:0QK'&JHB@*JJ,  = !3J "BBB@ HHHH **** "BBB@
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M%7]$E?SM_LP_\G*_";_L;M)_]+(J_HDH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K\R_^"TW_'O\'_\ ?U?^5E7Z:5^9?_!:;_CW^#_^
M_J_\K*@#\PZ_JCM?^/:+_<'\J_E<K^J.U_X]HO\ <'\J ):*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJVI:E::/I]S?W]U#8V-K&TT]U<R".**-1EG=B0%4 $DG@8JS7YI_\%FOVAM0
M\)^$/#?PGT:Y-L?$2-J6LLAP[6D;A88L_P!UY%=C_P!<0.A((!T/Q@_X+-?#
M?P3KEWIG@KPMJ7C[[,YC.H-=+I]G*0<$Q.4D=E]R@SVR.:\CE_X+C:RTCF/X
M16*1Y.U6UYV('8$_9QD_@*_+ZB@#]/O^'XVN?]$DT_\ \'DG_P 8H_X?C:Y_
MT233_P#P>2?_ !BOS!HH _2C7_\ @MYXXN;=UT3X:^'].G*X62_O9[I0WJ54
M19'3C/XUUO\ P3N_;)^+'[3/[6]Q;^-_$SSZ/%X>O)H=%L8EMK*-Q+  WEK]
M]ADX9RQ&3@\U^52J68 #)/  K],/^"2?[.?Q-\%_':Y\<>(O!.KZ!X7DT*YM
M([[58/LOF2/)"R!(Y,.P(1CN"E>.M 'Z\4444 %%%% !1110 45X!^TE^W%\
M*?V7[=X/$^M_VAXCV[HO#FC[9[ULC@NN0L2GUD*Y'3/2OR]^//\ P5T^+OQ,
MFN;+P4+?X;Z"_P J_8<7%^Z_[5PZX4_]<U0CIDT ?L_XU^(GA7X;Z7_:7BSQ
M)I/AFPYQ<ZM>QVR''8%V&3TX'/-?.?C/_@J)^SEX-F: >.7UVX7K'HNG7$Z]
M>TA01G\&/3Z5^#'B/Q1K/C#5I=4U_5[[6]3E_P!9>:E<O<3/WY=R2>I[]ZS*
M /VIU#_@M1\$[;S5M?#'CJ\=?N-]@LTC?\3=;@/^ T:;_P %I_@G=>4EWX9\
M<V3M]]OL-I)&GXBZW'_OGO7XK44 ?OMX/_X*D_LX^+6$;^-YM!G/2/6-,N(@
M?^!JC(/Q85]%>!OBEX-^)UG]K\(>*]%\3VX7<TFD7\5R%'^UL8[3['H:_E_J
MYI&LZAX?U&#4-+OKG3;^!MT5U9S-%+&?564@@_2@#^IRBOP<^!__  53^.'P
MDF@M]9U>/XB:(N UIXBR]P!W*72_O-WO(7'M7Z6_LU_\%,OA%^T&UMI=W?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG7&\0>#[JTN6@CU/,UQ8^3"TBK#*3N"?*%V-N4#[H6OV#KXZ^$O_  34\%_
M/]H[1?B=X#UJ_L--M([J*;P[?_Z2@\V%XP89R0X"EA\K[R>?F[5]BT %%%%
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M#^5?RN5_5':_\>T7^X/Y4 2T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ8_X+6?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLNF:'I\&G6V[[Q2*,(&;U8XR3W)-=%110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '\K#_>;ZU^J/_!#'[WQK^FB_^W]?E<_WF^M?JC_P0Q^]\:_IHO\ [?T
M?JM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^+'
M_!:S_DZ+PI_V)MM_Z6WM?M/7XL?\%K/^3HO"G_8FVW_I;>T ?)7[,/\ R<K\
M)O\ L;M)_P#2R*OZ)*_G;_9A_P"3E?A-_P!C=I/_ *615_1)0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7YE_P#!:;_CW^#_ /OZO_*R
MK]-*_,O_ (+3?\>_P?\ ]_5_Y65 'YAU_5':_P#'M%_N#^5?RN5_5':_\>T7
M^X/Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?/'[<'[)UA^UI\'9M"1H+/Q7IC->:#J,V0L4^,-
M$Y SY<@ 5NN"%;!*@5]#U\;_ /!2C]LR\_9;^&^GZ/X5=4\>^)Q(EC<LJNNG
MP)M$EP5.06RP5 1C.X\[-I /Q[\">-/B)^Q;\?$U&*SDT'QEX<N&M[S3;],I
M*C##PR 'YHW4@AE/(*NI^Z:_6#X5_P#!8;X*>+M)MV\8)JW@+5<8GAFM)+ZV
M#?[$L"LS#_>C4^U?BEK_ (@U/Q5K5[K&LZA<ZKJM[*9KF]O)6EFF<]69F))/
MUJA0!_0A#_P4F_9LGA21?BE8A7 8!["\5N?4&$$'V-/_ .'D/[-O_14M/_\
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MH _,.OZH[7_CVB_W!_*OY7*_JCM?^/:+_<'\J ):*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+O\ 2,U^S] 'YRVO_!$GX9+ HN/'WBR6;^)XEM44\]E,9Q^=2_\ #DOX6?\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ8_X+6?\G1>%/\
ML3;;_P!+;VOVGK\6/^"UG_)T7A3_ +$VV_\ 2V]H ^2OV8?^3E?A-_V-VD_^
MED5?T25_.W^S#_R<K\)O^QNTG_TLBK^B2@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OS+_X+3?\ 'O\ !_\ W]7_ )65?II7YE_\%IO^
M/?X/_P"_J_\ *RH _,.OZH[7_CVB_P!P?RK^5ROZH[7_ (]HO]P?RH EHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %.[U)M#2"2ZDN;*2V4K+O"E-X!/,; \#''K0!D_\,!_L\_]$G\/_P#?I_\
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M7WMH7AV1Y);C!^Y).RJ(U/?8&)!X93R/U>M[F&\A2:"5)X7&5DC8,I^A%2T
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M%+$%)DBD&W;,W&,Y YZ@_,'_  Y4^"'_ $-/Q _\&-C_ /(=??\ 10!\ ?\
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M?\>_P?\ ]_5_Y65 'YAU_5':_P#'M%_N#^5?RN5_5':_\>T7^X/Y4 2T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_P1M^)S>$_VFM1\)2R$6GBS2)8DC'>YMOWZ$_2(7 _X%0!^V=%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P %</B9_P )U^UQ?Z/#/YMEX5TVVTI54Y3S6!GE/US,$/\ USQVKXK52S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /!C??\ R'0!\ 45]_\ _#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\
M_P &-]_\AT ? %%??_\ PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\
M\&-]_P#(= 'Z/?\ !/'_ ),M^%7_ &#&_P#1\E?1=>4?LK?"C5_@;^SYX*\"
MZ[<65WJ^B6;6]Q-ISN\#,9';*,Z*Q&&'517J] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?RL/]YOK7ZH_P#!#'[WQK^FB_\ M_7Y7/\ >;ZU^J/_  0Q^]\:
M_IHO_M_0!^JU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7XL?\%K/^3HO"G_ &)MM_Z6WM?M/7XL?\%K/^3HO"G_ &)MM_Z6WM '
MR5^S#_R<K\)O^QNTG_TLBK^B2OYV_P!F'_DY7X3?]C=I/_I9%7]$E !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?F7_P6F_X]_@__ +^K
M_P K*OTTK\R_^"TW_'O\'_\ ?U?^5E0!^8=?U1VO_'M%_N#^5?RN5_5':_\
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M^E/H K:;IMIH]C!8V%K#8V5N@CAM[:,1QQJ.BJH   ]!5FBB@ HHHH ****
M"BBB@ HHHH **_+G_@HK_P %+/$'@?QIJ/PN^$M_'IMYIK>3K7B6(++*L^/G
MMH P*J4SAWY8-E1M*DG\V->^/?Q,\4W37.L?$/Q5JD[$DR7>LW,AYQD#+\#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=FMD=WX[LS,Q]R: /YU_BS\+]=^"WQ&U[P1XEBCAUO1KC[/<B%BT;':&5T)
M)5E96!P."*]_^!O_  39^*W[0WPSTKQUX3O_  PVBZBTJ1I>:A)'/&T<C1LK
MJ(C@Y4GKR"#WKU/_ (+.?#M/#?[2&@^*8(?+A\2Z)&9GQ]^YMW:)C_WZ-N/P
MKZ'_ .")?Q!_M;X1^/O!DLNZ71=7BU&)6ZB*YBVX'L&MF/U?WH _.[X^_L2_
M%_\ 9KL$U/QGX79-"=EC&L:=,MU:*Q. KLAS&2>!O"Y/3-'[&OP2\"_M!?&2
MR\&>./&5WX.COEQ8-;6R/]NGS_Q[B5VQ$[#.TE&#$;>"5#?T.>+O">D^//"^
MJ^'=>L8M2T;5+:2TN[28966-U(8>W!ZCD'D5_-3\7?!-W\$/C;XL\+VMW.MS
MX8URXM+6]!V2D0S$13 CH2%5N.F: /Z/?A#\+=&^"?PUT#P/X?>ZDT;1;?[-
M;/>R"29EW%B78!022QZ #VKL*\>_9#^-#_M ?LY^"/&]S(CZG?67E:CY8"C[
M7$QBF.T?=!=&8#T85[#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\K#_ 'F^
MM?JC_P $,?O?&OZ:+_[?U^5S_>;ZU^J/_!#'[WQK^FB_^W] 'ZK4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?BQ_P %K/\ DZ+P
MI_V)MM_Z6WM?M/7XL?\ !:S_ ).B\*?]B;;?^EM[0!\E?LP_\G*_";_L;M)_
M]+(J_HDK^=O]F'_DY7X3?]C=I/\ Z615_1)0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7YE_\%IO^/?X/_[^K_RLJ_32OS+_ ."TW_'O
M\'_]_5_Y65 'YAU_5':_\>T7^X/Y5_*Y7]4=K_Q[1?[@_E0!+1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117
MYY_\%3/VY-2^"NFV_P +_ 5^]CXPU:V%QJ>JV[8DT^T;(5(S_#-)@G=U10".
M75E /H;XZ?M\?!3]GO49M*\2^+%O?$$/^LT718C>7,9[K)M^2-O]F1E//2O!
MK7_@M1\$YKPQR^&/'5O =H69K"S..N=RBZ) ''3.<]!7XL22/-(TDC,[L2S,
MQR23U)--H _HO^"/[<?P6_:!O8--\)^-+7^W)A\NC:I&]G=LW]U%D $I]HRU
M>\U_*PCM&RLK%64Y#*<$'UK]"_V)O^"J/B+X7WFF>#?BU=W'B7P82((=>EW2
MW^F*> 7/)GB'<'+J.A8 )0!^SE%4=#US3O$VC6.KZ1>V^I:7?0K<6MY:R"2*
M:-AE75AP000<BKU 'P;\2/\ @K]\-OAG\1/%/A"^\&>*KJ^\/ZK=:3//;BV\
MN22"9HF9,R@[24)&0#@UV7[,_P#P4*^'?[7GQ1B\(Z1X-UBQU6QLY=5@O-8A
MMV2+8R(=A5V96/F#D#L>:_&S]K'_ ).F^,G_ &.>L_\ I=-7TI_P1M_Y.XO/
M^Q9O?_1MO0!^W]%%% !1110 4444 %>?_M">"Y?B-\"/B'X7MXVENM7\/WUG
M;HO4RO XCQ_P(K7H%% '\J[*58@C!'!!K]E?^";7_!0+PAXH^'OA#X1>,KTZ
M+XTTR.+1M)DE1F@U2%?DMT5P"$D50L>UL!MH()+%1\C?\%)OV(=;^!/Q(UCQ
M[X=TV2[^&^O737?G6L9*Z3<2-EX)<?=0N3L;@88)U'/%?\$Q?!?_  FG[:?@
M$/'OMM*-SJLW^SY5O(8S_P!_3%0!]V_\%J_AZ^N? WP9XOAA,DGA_6FM96 _
MU<-U%RQ]O,@A'U85\$?\$]?VI+']E?X\)J^O^<?"6M6C:7JK0*7:!2ZO'<!!
MRVQEY YVL^ 3@']O_P!I3X-6_P"T#\#/&'@&XD2!]8LBEM/(,K#<HPD@<^PD
M1"<<XS7\W7C#PCJ_@'Q5JOAS7[&73=:TNY>TN[288:.1"0P]QQP1P1@CB@#]
M_P#XB?\ !0_X"?#_ ,$S^(8_B%I'B240E[;2=#N5N;RX?G:GEKS&21UDV@=3
M7X(_%+X@7WQ6^)'BCQGJ<:0W^O:E<:E-#&24C,LA?8N?X5SM'L!7+UI^&?#.
MJ^,_$6FZ#H=A-J>L:E<):VEG;KNDFE<A54#U)- '[=?\$?\ [3_PQW;>><Q?
MV[??9_9/DS_X_OK[;KRK]EGX+Q_L]_ 'P9X"#K+=:799O94Y5[J1FEG(/=?,
M=P/]D"O5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E8?[S?6OU1_P""&/WO
MC7]-%_\ ;^ORN?[S?6OU1_X(8_>^-?TT7_V_H _5:BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K\6/\ @M9_R=%X4_[$VV_]+;VO
MVGK\6/\ @M9_R=%X4_[$VV_]+;V@#Y*_9A_Y.5^$W_8W:3_Z615_1)7\[?[,
M/_)ROPF_[&[2?_2R*OZ)* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0#P3_@G3^W]=_LXZ_!X'\:W<UW\,M1GPLCY=M%F8\RH.ODL3ET'3EU&=P?\
M;^PO[;5;&VO;*XBN[.YC6:"X@</'+&P!5E8<$$$$$=0:_E?K[T_X)^_\%)+K
M]GJ.W\!?$-KG5?AXSXL[V,&6XT=F/("]7@R22@Y4DE<_=(!\P?M8_P#)TWQD
M_P"QSUG_ -+IJ^E/^"-O_)W%Y_V+-[_Z-MZ^6_VD=>T_Q5^T1\4M:TB[CU#2
MM2\5:I>6=W"<I/#)=RO&ZGN&5@1]:^I/^"-O_)W%Y_V+-[_Z-MZ /V_HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK\R_^"TW_'O\'_\ ?U?^5E7Z:5^9?_!:;_CW^#_^_J_\K*@#\PZ_JCM?^/:+
M_<'\J_E<K^J.U_X]HO\ <'\J ):*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *_GX_X*2?!6[^#7[6/C F!DTCQ
M+.WB#3YMN$=;ABTJCM\DWFKCT"GN*_H'KY]_;0_9"T+]KSX9C1KJ==*\3:8S
MW&B:QMW""4C#1R#J8GPH8#D;589*X(!^#/P-^.WC+]G7Q];>+_!&I_V=JL2&
M&1)$$D-S"Q!:*5#]Y"0#V((!!! -?K3^Q7_P4^U;]I[XJ:3\/=8^'MKI6HW-
MK<7,VLZ?J3&%?*C+_P#'N\98 D ?ZPXW"ORK^.G[+OQ+_9SUR:P\<>%[S3[=
M7V0ZM"AEL+D=C'.!M.1SM.&&>5!XKZB_X(PZ%_:7[4^N7[+\FG>%[J16]'>X
MMHP/^^6?\J /VQHHHH _*+_@I)_P3?>UDU7XM?"C2R\#%KK7_#5G'DQGJ]U;
M(/X>I>,=.67C('Y:5_517YO_ +<G_!*RS^)5WJ'CKX/0VNC^)I=T]]X:8B&U
MOWY)>!ONPRD]5.$8G.4.2P!^.]?=/_!&W_D[B\_[%F]_]&V]?&?C7P'XC^&_
MB"XT+Q5H6H>'=8M_]99:E;/!*!V;# 94XX8<'L:^S/\ @C;_ ,G<7G_8LWO_
M *-MZ /V_HHHH **** "BBB@ JMJ6I6NCZ;=W][.EM96L3SSS2'"QQJI9F/L
M "?PJS7CG[9-Y<V/[)_Q>EM!F;_A%M13CLK6[JY_!2Q_"@#\&OVK/VCM=_:?
M^,>L^,-6GF73VE:#2--=R4L;,']W&HZ!B/F8C[S%C[#Q^BOU^_8+_P""9?P\
MOOA#X?\ '_Q1T@^*M<\16D>HVFF7$SI:65M( T.51AYCLA#'?P-X7;E22 ?D
M#17]'<7[$OP#AC2-?A%X1*J H+:7$QX]21DGW-._X8I^ G_1(?!__@IB_P *
M /YPJ*_H]_X8I^ G_1(?!_\ X*8O\*/^&*?@)_T2'P?_ ."F+_"@#G_^">/_
M "9;\*O^P8W_ */DKZ+K)\*^$]&\#>'[+0O#VF6NC:-8IY=M8V40CAA7).%4
M< 9)/XUK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!_*P_P!YOK7ZH_\ !#'[
MWQK^FB_^W]?E<_WF^M?JC_P0Q^]\:_IHO_M_0!^JU%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7XL?\ !:S_ ).B\*?]B;;?^EM[
M7[3U^+'_  6L_P"3HO"G_8FVW_I;>T ?)7[,/_)ROPF_[&[2?_2R*OZ)*_G;
M_9A_Y.5^$W_8W:3_ .ED5?T24 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5^9?_!:;_CW^#_^_J_\K*OTTK\R_P#@M-_Q[_!__?U?^5E0
M!^8=?U1VO_'M%_N#^5?RN5_5':_\>T7^X/Y4 2T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU_31?_;^@#]5J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OQ8_X+6?\ )T7A3_L3;;_TMO:_:>OQ8_X+6?\ )T7A3_L3;;_TMO:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_\ @IB_PH _G"HK^CW_ (8I^ G_ $2'P?\ ^"F+_"C_ (8I^ G_ $2'P?\
M^"F+_"@#^<*BOZ/?^&*?@)_T2'P?_P""F+_"C_ABGX"?]$A\'_\ @IB_PH _
MG"HK^CW_ (8I^ G_ $2'P?\ ^"F+_"C_ (8I^ G_ $2'P?\ ^"F+_"@#G_\
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M %%%% !1110 4444 %?F7_P6F_X]_@__ +^K_P K*OTTK\R_^"TW_'O\'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-BI/)DDQRV.B+ECV& 2/WQ_9F_9Q\,_LN_"NP\%^&E:;:WVB_P!2E4"6_NF
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M-?TT7_V_H _5:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV>GW]]IL\@[/<1PR1@_A;2U^G=>)?MF? /\ X:2_9V\5>"[?:NLR1+>:5(Y
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M /!)7XH_%6ZM=2\>J?AOX9+!GCO%#ZG.O<)!_P LSU&92".NQJ^N?VZOV??
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OS+_P""TW_'O\'_ /?U?^5E7Z:5^9?_  6F_P"/?X/_
M ._J_P#*RH _,.OZH[7_ (]HO]P?RK^5ROZH[7_CVB_W!_*@"6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0!^ /[$W@KP1\2OVEO"'A'XA:=)J7AS7));%DBN9+=DG:-C P9&!YD"KC/\
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M&"#7]45?/O[1'["?P@_:6:>]\3>'1I_B.5<?\)#HK"VO<@8!<X*RX&!^\5L
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MS-?J-7YF_P#!<#2Y)OA[\+M1"GR;?5+RW9NP:2*-@/RB;\J /R)K^G+X'_\
M)%O '_8OZ?\ ^DT=?S&U_3-^SOJ"ZM^S_P##.^0@K<^&-,F!7IAK6,\?G0!Z
M%7\L6L?\A:]_Z[O_ .A&OZE=0O4TW3[F[E.(K>)I6R<<*"3_ "K^6*>5YYI)
M'.YW8LQQU).30!^CW_!$:1U^,7Q$C'W&T&)CQW%PN/YFO1O^"XTTB^&?A%&
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M G[1'A6U\-_$+0O^$@T6UO4U"&U^USVVV=4DC5]T,B,<+*XP3CYNF0,>*_\
M#KC]F+_HF?\ Y7]4_P#DF@#\ :*_?[_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\
MHF?_ )7]4_\ DF@#\ :*_?[_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7
M]4_^2: /P!K]4O\ @AC][XU_31?_ &_K\KFX8CWK]4?^"&/WOC7]-%_]OZ /
MU6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_%C_
M (+6?\G1>%/^Q-MO_2V]K]IZ_%C_ (+6?\G1>%/^Q-MO_2V]H ^2OV8?^3E?
MA-_V-VD_^ED5?T25_.W^S#_R<K\)O^QNTG_TLBK^B2@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OS+_X+3?\>_P?_P!_5_Y65?II7YE_
M\%IO^/?X/_[^K_RLJ /S#K^J.U_X]HO]P?RK^5ROZH[7_CVB_P!P?RH EHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *_)'_@MI\)[JW\8^ OB5;P.]A=V+Z#>2JORQ2Q2/-#N/JZRRX_
MZY5^MU<5\9/@_P"&?CQ\.=8\$^+;+[;HVI1[6VG;+!(.4EC;'RNC8(/M@@@D
M$ _FV^%_Q0\3?!GQUI7B_P (:I+I&O:;)YD%Q'@@@C#(ZGAD8$@J>"":_H*_
M8I^.7B/]H[]G?P]X^\3Z78Z5J6HR7$?EZ=O$,JQ2M$9%5R2N61^,G&.M?D!^
MTU_P35^+/P!UB\N=)T:[\>>#@[-;ZQHMNTTJ1]?](@7+QD#JP!3_ &NP_9/]
MC_P0?AU^R[\+M >+R+BWT"UEN(R,%9I4$TH_[[D:@#\'/VR/AC)\'_VGOB/X
M8,)AMH=7FNK-<8'V:<^?#CUQ'(H^H-?0'[,'_!5SQO\ L^_#FS\%:QX:M?'6
MD:;$8=+EGO6M+BUB PD1<(X>->P(! ^7=@#'V3_P4^_87U/]H+2;'XA> K);
MOQSHUO\ 9KS35;:^IV8)90G8S1DM@<;E8C)*HI_%O5=)OM!U*XT_4K*XTZ_M
MW,<UK=1-%+$PZJRL 0?8B@#V3]JK]KCQK^UMXSMM9\4FWLM/T]'BTS1K$$6]
MFC$%CDG+NVU=SGKM&   !WG_  2_\+3^)_VV/ +1)N@TW[9J%PW]Q$M90I_[
M[:,?C7S+X?\ #NJ^+-:M-(T33;O5]5NW\NWL;&!IIIF]%1023]!7[>_\$T?V
M(;W]F/PCJ'BOQE#&GQ \0PI$]JK!_P"S+0$,(-PX,C, SX)'R(!]TD@'VW11
M10 4444 %%%% !1110 4444 <K\2OBEX3^#OA.Z\3>-->L_#NB6^ ]U>.1EC
MT1% +.Y[*H+'L*^%_'W_  6J^&.AZA);>%?!WB'Q3'&VW[9</%80R?[29WOC
M_>13[5\$?\%#/VE]4_:(_:$UZ,7KMX2\-W<VEZ+9J^8@D;;)+@#NTK)NSUV[
M%_AKR'P+^SS\4/B=8"_\)_#WQ-XAT\YQ>Z?I4TL!P<8$@7:3[9SP: /TEL/^
M"XVCR3L+WX0WUO#YF%>WUY)6*?WB#;K@^V<>]?2OP!_X*8?!3X^ZQ:Z';:I>
M>$O$5T_EV^F^)(5@^T/_ '8YD9HR2> K,K,> M?CGJ'[#_Q]TR$2S?"+Q8ZE
M#)BWTUYFP!G[J G/MC/M7D7B#PWJ_A'5I=,US2[[1=3A_P!99ZA;O!,GU1P"
M/RH _J6HKXH_X)5?M,:I\>O@7>:%XEO7U#Q-X-GCL9+R9]TMS:2*3;R2'NXV
M21D]2(P22237VO0 4444 %%%% !1110 4444 %%%% !7R!_P5@_Y,E\7_P#7
M[IW_ *5Q5]?U\@?\%8/^3)?%_P#U^Z=_Z5Q4 ?@M7]"?_!-W_DR7X6_]>5Q_
MZ5SU_/97]"?_  3=_P"3)?A;_P!>5Q_Z5ST ?2M?&7_!6KX>W'CK]CW5+ZUC
M\V;PUJEKK)4#YO+&^!R/HMP6/LIK[-K&\9>$M,\?>$=:\-:U!]JTC6+*:PNX
M<X+PRH4< ]CACSVH _EPK^@K_@FS\3[7XG?L>^!&BE#7F@VYT&\CR"8WM_E0
M'ZQ>4W_ J_$O]IK]GCQ%^S+\6M7\&Z];S>3%(TFFZ@R8CO[0L?+F0]#D<,!]
MU@P/2K?[.?[67Q'_ &6=8OKWP)J\=O;Z@%%[IE]")[2YVYVED."&&3AE*GG&
M<<4 ?O+^V!\3+7X1_LR_$;Q+<S"&2'1Y[:TR>6NIE,, 'K^\D3/L">U?S<U[
MM^TA^VM\4_VIX;&S\:ZM;IHUD_G0:/I=O]GM1+@KYK#)9VP2 68XR=H&3GS_
M ."_P?\ $?QX^)6B>"O"]F]UJFISK&7"$I;19&^>0CHB+EB?;'4@4 ?KC_P1
MC^'-QX9_9SU_Q5=0^4WB;6G-LV/]9;VZ"(-_W],X_"NY_P""LGP[G\>?L>:S
M>6L7G3^&]1M=:V@$ML4M#(1]$G9C[*:^F?A%\,=)^#/PR\->"-##?V9H=E'9
MQ/)C?*5'S2-CC<[%F..[&MCQ?X5TWQUX4UGPYK-N+O2-7LYK"\@)QYD,J%'7
M/;(8\T ?RW5_0)_P31^*%K\3OV/?!'E2A[[P_$V@WD>03&\!Q&/QA,+?\"K\
M5OVH/V<O$7[,/Q:U;P?KMO,;1)&ETK4G3$>H6A8^7,I'&<8#*#\K CM4O[.?
M[5_Q&_9:UJ]O_ FK1V\&H!1?:;>PB>UNMN=A=#@AEW'#*5/)&<$B@#][_P!K
M'XD6GPE_9M^(OB>[F6$VNC7$5ON_BN94,4"_C+(@_&OYL*]Y_:0_;;^*G[4U
MK8V'C/5K:+1;-Q-%H^E6_P!GM?- (\UAEF=L$@;F(&3@#)SYW\&?A#XD^.WQ
M(T7P5X5LGO-5U*98]P4F.WCR-\TA'W8T&6)]L#)(% 'ZV?\ !%_X<S^&_P!G
MSQ)XMN8O+/B;62MLW_/2WMD\L-_W]:<?\!K]!ZXWX._"[2?@I\+_  UX&T,,
M=,T.S2TCDD^]*PY>1O\ :=RS''=C794 %%%% !1110 4444 ?RL/]YOK7ZH_
M\$,?O?&OZ:+_ .W]?E<_WF^M?JC_ ,$,?O?&OZ:+_P"W] 'ZK4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?BQ_P6L_Y.B\*?]B;
M;?\ I;>U^T]?BQ_P6L_Y.B\*?]B;;?\ I;>T ?)7[,/_ "<K\)O^QNTG_P!+
M(J_HDK^=O]F'_DY7X3?]C=I/_I9%7]$E !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?F7_P %IO\ CW^#_P#OZO\ RLJ_32OS+_X+3?\
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M\/SO^J)_^77_ /<5 'ZJ45^5?_#\[_JB?_EU_P#W%1_P_._ZHG_Y=?\ ]Q4
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M;_L;M)_]+(J_HDK^=O\ 9A_Y.5^$W_8W:3_Z615_1)0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7YE_\%IO^/?X/_P"_J_\ *RK]-*_,
MO_@M-_Q[_!__ ']7_E94 ?F'7]4=K_Q[1?[@_E7\KE?U1VO_ ![1?[@_E0!+
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5^2/_!7CX)_$3XE?M"^%M2\(> O$_BK3H?"
MT-O+=Z)HUS>1)*+NZ8HSQHP#;64X)SA@>]?K=10!_-9_PR=\;_\ HC?Q _\
M"7OO_C5'_#)WQO\ ^B-_$#_PE[[_ .-5_2G10!_-9_PR=\;_ /HC?Q _\)>^
M_P#C5'_#)WQO_P"B-_$#_P )>^_^-5_2G10!_-9_PR=\;_\ HC?Q _\ "7OO
M_C5'_#)WQO\ ^B-_$#_PE[[_ .-5_2G10!_-9_PR=\;_ /HC?Q _\)>^_P#C
M5'_#)WQO_P"B-_$#_P )>^_^-5_2G10!_-9_PR=\;_\ HC?Q _\ "7OO_C55
M=4_9B^,>AZ9=ZCJ/PF\<:?I]G"]Q<W=UX;O(XH(D4L[N[1@*J@$DDX !-?TN
MUYE^U!_R;3\6O^Q1U?\ ](Y: /YI*[3P3\$_B)\2M,FU'PAX"\3^*M/AF-O+
M=Z)HUS>1)*%#%&>-& ;#*<$YPP/>N+K]H/\ @BC_ ,FT^,/^QNG_ /2.TH _
M+3_AD[XW_P#1&_B!_P"$O??_ !JC_AD[XW_]$;^('_A+WW_QJOZ4Z* /YK/^
M&3OC?_T1OX@?^$O??_&J/^&3OC?_ -$;^('_ (2]]_\ &J_I3HH _FL_X9.^
M-_\ T1OX@?\ A+WW_P :H_X9.^-__1&_B!_X2]]_\:K^E.B@#^:S_AD[XW_]
M$;^('_A+WW_QJC_AD[XW_P#1&_B!_P"$O??_ !JOZ4Z* /YK/^&3OC?_ -$;
M^('_ (2]]_\ &J/^&3OC?_T1OX@?^$O??_&J_I3HH KZ<K1Z?:JP*LL2@@C!
M!P*L444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML,R%'1A)< JRGD$'L:_62@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y6'^\W
MUK]4?^"&/WOC7]-%_P#;^ORN?[S?6OU1_P""&/WOC7]-%_\ ;^@#]5J*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ8_X+6?\G1>
M%/\ L3;;_P!+;VOVGK\6/^"UG_)T7A3_ +$VV_\ 2V]H ^2OV8?^3E?A-_V-
MVD_^ED5?T25_.W^S#_R<K\)O^QNTG_TLBK^B2@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@#+M?"VC6.OWNNVVDV5OK5]$D%UJ$5NBSW$:9*+(X&Y@NYL DXR<=:U***
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MF_[&[2?_ $LBK^B2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_!:S_DZ+PI_V)MM_P"EM[7[3U^+'_!:S_DZ+PI_V)MM_P"EM[0!\E?LP_\
M)ROPF_[&[2?_ $LBK^B2OYV_V8?^3E?A-_V-VD_^ED5?T24 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5^9?_  6F_P"/?X/_ ._J_P#*
MRK]-*_,O_@M-_P >_P '_P#?U?\ E94 ?F'7]4=K_P >T7^X/Y5_*Y7]4=K_
M ,>T7^X/Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF5\E_P##-WQ&_P"A=_\ )ZV_^.4?\,W?$;_H7?\ R>MO_CE']K9=_P!!$/\
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MK^-__0K?#_\ \%U]_P#)E'_#ZOXW_P#0K?#_ /\ !=??_)E?)?\ PS=\1O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@#XW^!/B33?!OQP^'GB#6+G['I&D^(M.O[RXV,_E017,;R/M4%FPJDX4$G'
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M_P#HHW_E#U+_ .1J_"NB@#]U/^'EG[-__11O_*'J7_R-1_P\L_9O_P"BC?\
ME#U+_P"1J_"NB@#]U/\ AY9^S?\ ]%&_\H>I?_(U'_#RS]F__HHW_E#U+_Y&
MK\*Z* /W4_X>6?LW_P#11O\ RAZE_P#(U'_#RS]F_P#Z*-_Y0]2_^1J_"NB@
M#]U/^'EG[-__ $4;_P H>I?_ "-1_P /+/V;_P#HHW_E#U+_ .1J_"NB@#]U
M/^'EG[-__11O_*'J7_R-1_P\L_9O_P"BC?\ E#U+_P"1J_"NB@#]U/\ AY9^
MS?\ ]%&_\H>I?_(U'_#RS]F__HHW_E#U+_Y&K\*Z* /W4_X>6?LW_P#11O\
MRAZE_P#(U'_#RS]F_P#Z*-_Y0]2_^1J_"NB@#]U/^'EG[-__ $4;_P H>I?_
M "-1_P /+/V;_P#HHW_E#U+_ .1J_"NB@#]U/^'EG[-__11O_*'J7_R-7PQ_
MP4\_:8^&W[0\/PW7X?>)/^$@.D-J)O?]!N;;RO-%MY?^NC3=GRW^[G&.<9%?
M"5% !7]4=K_Q[1?[@_E7\KE?U1VO_'M%_N#^5 $M%%% !1110 4444 %%%%
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MZ]9HH \F_P"&1_@=_P!$<\!?^$U9_P#QNC_AD?X'?]$<\!?^$U9__&Z]9HH
M\F_X9'^!W_1'/ 7_ (35G_\ &Z/^&1_@=_T1SP%_X35G_P#&Z]9HH \F_P"&
M1_@=_P!$<\!?^$U9_P#QNC_AD?X'?]$<\!?^$U9__&Z]9HH \F_X9'^!W_1'
M/ 7_ (35G_\ &Z/^&1_@=_T1SP%_X35G_P#&Z]9HH \F_P"&1_@=_P!$<\!?
M^$U9_P#QNC_AD?X'?]$<\!?^$U9__&Z]9HH \F_X9'^!W_1'/ 7_ (35G_\
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MP._Z(YX"_P#":L__ (W7K-% 'DW_  R/\#O^B.> O_":L_\ XW1_PR/\#O\
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M  R/\#O^B.> O_":L_\ XW1_PR/\#O\ HCG@+_PFK/\ ^-UZS10!Y-_PR/\
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M /1,5?%\7_\ (JEZK\S\]XZ_Y$LO\4?S/=****_"#^; HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]1?^"&O_ "%/C)_UQTG_ -"O*_JJ.R/[3CLC]7Z***904444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH _-:Y_X^)?\ ?/\ .OU%_P""&O\
MR%/C)_UQTG_T*\K\NKG_ (^)?]\_SK]1?^"&O_(4^,G_ %QTG_T*\K^JH[(_
MM..R/U?HHHIE!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7F'[4?_)LOQ<_[%#5_P#TBEKT^O,/VH_^
M39?BY_V*&K_^D4M '\TU?7/[(/\ R3O5?^PJ_P#Z)BKY&KZY_9!_Y)WJO_85
M?_T3%7Q?%_\ R*I>J_,_/>.O^1++_%'\SW2BBBOP@_FP**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#\UKG_ (^)?]\_SK]1?^"&O_(4^,G_
M %QTG_T*\K\NKG_CXE_WS_.OU%_X(:_\A3XR?]<=)_\ 0KROZJCLC^TX[(_5
M^BBBF4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5\T?M[?M;0_LF?!MM3T\07/C/6G:RT.TFY4.!F2X=>Z1 J<
M=V9%/#$CZ7K\2?\ @LGXWN]?_:BT[P^\I-AH&A6Z10]A+,SRR/\ 4J8A_P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7F'[4?_)LOQ<_[%#5__2*6O3Z\P_:C
M_P"39?BY_P!BAJ__ *12T ?S35]<_L@_\D[U7_L*O_Z)BKY&KZY_9!_Y)WJO
M_85?_P!$Q5\7Q?\ \BJ7JOS/SWCK_D2R_P 4?S/=****_"#^; HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /S6N?^/B7_?/\Z_47_@AK_R%
M/C)_UQTG_P!"O*_+JY_X^)?]\_SK]1?^"&O_ "%/C)_UQTG_ -"O*_JJ.R/[
M3CLC]7Z***904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[S?6OU1_X(8_>^-?TT7_ -OZ /U6HHHH **** "BBB@ HHHH **** "BBB@
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MOYX?=_P _MKAO_GY3^Y?Y'F?_"SO&/\ T-FN?^#*;_XJC_A9WC'_ *&S7/\
MP93?_%5Z9_PR%XQ_Z"6A_P#?^;_XU1_PR%XQ_P"@EH?_ '_F_P#C5']J9%_/
M#[O^ ']M<-_\_*?W+_(\S_X6=XQ_Z&S7/_!E-_\ %4?\+.\8_P#0V:Y_X,IO
M_BJ],_X9"\8_]!+0_P#O_-_\:H_X9"\8_P#02T/_ +_S?_&J/[4R+^>'W?\
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M],_X9"\8_P#02T/_ +_S?_&J/^&0O&/_ $$M#_[_ ,W_ ,:H_M3(OYX?=_P
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M<O\ (\.)+$DG)-?J3_P0U_Y"GQD_ZXZ3_P"A7E?EO(IC=E/53BOU(_X(:_\
M(4^,G_7'2?\ T*\KZL^U/U?HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K\=O^"W'_ "6CX>?]B_)_Z4O7
M[$U\O_M9_L!^#_VO/%6B:]XD\1:YHUQI5DUC%'I9AV.ID+Y;>C'.3VH _GWH
MK]D_^')?PL_Z'KQA_P!]6O\ \9H_X<E_"S_H>O&'_?5K_P#&: /QLHK]D_\
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M$_\ RZ__ +BKU;_@M5_R:OX7_P"QRM?_ $BOJ_%6@#]5/^'YW_5$_P#RZ_\
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MT()&0 03\!_\%>/V<_'+?&Y/B7I^D7VM^%-4L+>V>YLX6F%C-$NPQR!0=BL
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MN;P!^UU#J-MX>CO-%\1Z<@FNM$U0()?*)QYL;*2)$R0">""1D#(S]&5^/_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/UC7X6?\%-OV;_'G@_\ :2\3^+WT6_U7PQXCG^VV>J6L+S1H2H#0N5'R,IX
M/48(H _6/]EG]K[P+^UKX7O=3\)O=65_I[K'J&CZBJK<VQ;.UCM)5D;!PP/8
M@X((KW"OR\_X(Y?L\^-?!>H>+/B%XBTN\T'1M2LX]/T^WOHVBDNR'+-+L8 [
M5P &[[FQTK]0Z "O+OVB?VCO!O[,7P_E\6>,KJ5+8R>1:V5H@>YO)B"1'&I(
M'0$DD@ =3R,^HU\!_P#!7KX ^,?B]\+/"FO^$M/N=:_X1>YN9+[3;-3),T,R
MQ_OE0#+;#%SCD!\XP"0 =7^SG_P5/^&/[0'Q"M?!LFE:MX0U>_;R].?5#&\%
MT_:/>C?(Y[ C!Z9R0#]HU_/-^QA^S3\0/BO^T!X/_LS0-2LM.T?5K;4-1U:>
MW>*&TCAE60Y=ACS#MPJ]23TP"1_0PJ[5 SG QDT +5;4M2M=&TZZO[^XCL[*
MUB:>>XF8*D4:@EF8GH  23[59K@OCYX#OOBC\%?&_A+3+A;74=9TBXL[:5FV
MJ)'0A0QP<*3@'V)H ^/-8_X+.?"+3?'$FDVWA[Q)J.A1S^2VNPQ1*K#=@R+"
MS!RG?G#8_ASQ7W1X/\7:/X^\+Z7XBT"^BU/1=3MTNK2[A^[+&PRIYY'!Z'D5
M_-=K'P!^)&@^.)/!]YX'UY/$:S_9QIZV$KR.V[:"F 0RD]&&0>N:_?G]BGX2
MZW\#_P!F7P/X/\1M_P 3NRM6DNH]X?R7ED:4Q9'!V;]O''RT >X4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O,/VH_P#DV7XN?]BAJ_\ Z12UZ?7F
M'[4?_)LOQ<_[%#5__2*6@#^::OKG]D'_ ))WJO\ V%7_ /1,5?(U?7/[(/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M &FC_ALW_J3_ /RI_P#VFOFFBC_5;)_^?/\ Y-+_ .2#_4S(?^@?_P FG_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E8?
M[S?6OU1_X(8_>^-?TT7_ -OZ_*Y_O-]:_5'_ ((8_>^-?TT7_P!OZ /U6HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\R_:@_P"3
M:?BU_P!BCJ__ *1RUZ;7F7[4'_)M/Q:_[%'5_P#TCEH _FDK]H/^"*/_ ";3
MXP_[&Z?_ -([2OQ?K]H/^"*/_)M/C#_L;I__ $CM* /T(HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH _E8?[S?6OU1_X(8_>^-?TT7_V_K\KG
M^\WUK]4?^"&/WOC7]-%_]OZ /U6HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;/\ RU/_ +MH_P"'&/\ U6S_ ,M3_P"[: /RKHK]5/\ AQC_ -5L_P#+4_\
MNVC_ (<8_P#5;/\ RU/_ +MH _*NBOU4_P"'&/\ U6S_ ,M3_P"[:/\ AQC_
M -5L_P#+4_\ NV@#\JZ*_53_ (<8_P#5;/\ RU/_ +MH_P"'&/\ U6S_ ,M3
M_P"[: /RKHK]5/\ AQC_ -5L_P#+4_\ NVC_ (<8_P#5;/\ RU/_ +MH _*N
MBOU4_P"'&/\ U6S_ ,M3_P"[:/\ AQC_ -5L_P#+4_\ NV@#]2M+_P"0;:?]
M<4_]!%6JBM8?LUM%#G=Y:!-V,9P,5+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?RL/]YOK7ZH_P#!
M#'[WQK^FB_\ M_7Y7/\ >;ZU^J/_  0Q^]\:_IHO_M_0!^JU%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '\K#_>;ZU^J/_!#'[WQK^FB_
M^W]?E<_WF^M?JC_P0Q^]\:_IHO\ [?T ?JM1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!_*P_WF^M?JC_ ,$,?O?&OZ:+_P"W]?E<_P!Y
MOK7ZH_\ !#'[WQK^FB_^W] 'ZK4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?RL/]YOK7ZH_\$,?O?&OZ:+_[?U^5S_>;ZU^J/_!#'[WQ
MK^FB_P#M_0!^JU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '\K#_>;ZU^J/\ P0Q^]\:_IHO_ +?U^5S_ 'F^M?JC_P $,?O?&OZ:+_[?
MT ?JM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_*P_WF
M^M?JC_P0Q^]\:_IHO_M_7Y7/]YOK7ZH_\$,?O?&OZ:+_ .W] 'ZK4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?RL/]YOK7ZH_P#!#'[W
MQK^FB_\ M_7Y7/\ >;ZU^J/_  0Q^]\:_IHO_M_0!^JU%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 7([&1&CD(Z R$#BO<_$.O6/A70-3UK4YUMM-TVVEO+J9ND<4:%W8_103^%
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M:_5'_@AC][XU_31?_;^@#]5J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJV^D2>+O$T.&36/$6R<PN.=T,041QG/1MI<?WJW?^"AO_)E_Q5_[!B_^CXJ
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M\H&E_P#R-1_P]&_:=_Z*9_Y0-+_^1J /W^HK\ ?^'HW[3O\ T4S_ ,H&E_\
MR-1_P]&_:=_Z*9_Y0-+_ /D:@#]_J*_ '_AZ-^T[_P!%,_\ *!I?_P C4?\
M#T;]IW_HIG_E TO_ .1J /W^HK\ ?^'HW[3O_13/_*!I?_R-1_P]&_:=_P"B
MF?\ E TO_P"1J /W^HK\ ?\ AZ-^T[_T4S_R@:7_ /(U'_#T;]IW_HIG_E T
MO_Y&H _?ZBOP!_X>C?M._P#13/\ R@:7_P#(U'_#T;]IW_HIG_E TO\ ^1J
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MH&E__(U'_#T;]IW_ **9_P"4#2__ )&H _?ZBOP!_P"'HW[3O_13/_*!I?\
M\C4?\/1OVG?^BF?^4#2__D:@#]_J*_ '_AZ-^T[_ -%,_P#*!I?_ ,C4?\/1
MOVG?^BF?^4#2_P#Y&H _?ZBOP!_X>C?M._\ 13/_ "@:7_\ (U'_  ]&_:=_
MZ*9_Y0-+_P#D:@#]_J*_ '_AZ-^T[_T4S_R@:7_\C4?\/1OVG?\ HIG_ )0-
M+_\ D:@#]_J*_ '_ (>C?M._]%,_\H&E_P#R-1_P]&_:=_Z*9_Y0-+_^1J /
MW^HK\ ?^'HW[3O\ T4S_ ,H&E_\ R-1_P]&_:=_Z*9_Y0-+_ /D:@#]_J*_
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M (>C?M._]%,_\H&E_P#R-1_P]&_:=_Z*9_Y0-+_^1J /W^HK\ ?^'HW[3O\
MT4S_ ,H&E_\ R-1_P]&_:=_Z*9_Y0-+_ /D:@#]_J*_ '_AZ-^T[_P!%,_\
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MIW_HIG_E TO_ .1J /W^HK\ ?^'HW[3O_13/_*!I?_R-1_P]&_:=_P"BF?\
ME TO_P"1J /W^HK\ ?\ AZ-^T[_T4S_R@:7_ /(U'_#T;]IW_HIG_E TO_Y&
MH _?ZBOP!_X>C?M._P#13/\ R@:7_P#(U'_#T;]IW_HIG_E TO\ ^1J /W^H
MK\ ?^'HW[3O_ $4S_P H&E__ "-1_P /1OVG?^BF?^4#2_\ Y&H _?ZBOP!_
MX>C?M._]%,_\H&E__(U'_#T;]IW_ **9_P"4#2__ )&H _?ZBOP!_P"'HW[3
MO_13/_*!I?\ \C4?\/1OVG?^BF?^4#2__D:@#]_J*_ '_AZ-^T[_ -%,_P#*
M!I?_ ,C4?\/1OVG?^BF?^4#2_P#Y&H _?ZBOP!_X>C?M._\ 13/_ "@:7_\
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M]$S_ /*_I?\ \DU^_P!10!^ /_#KC]IW_HF?_E?TO_Y)H_X=<?M._P#1,_\
MROZ7_P#)-?O]10!^ /\ PZX_:=_Z)G_Y7]+_ /DFC_AUQ^T[_P!$S_\ *_I?
M_P DU^_U% 'X _\ #KC]IW_HF?\ Y7]+_P#DFC_AUQ^T[_T3/_ROZ7_\DU^_
MU% 'X _\.N/VG?\ HF?_ )7]+_\ DFC_ (=<?M._]$S_ /*_I?\ \DU^_P!1
M0!^ /_#KC]IW_HF?_E?TO_Y)H_X=<?M._P#1,_\ ROZ7_P#)-?O]10!^ /\
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M]$S_ /*_I?\ \DU^_P!10!^ /_#KC]IW_HF?_E?TO_Y)H_X=<?M._P#1,_\
MROZ7_P#)-?O]10!^ /\ PZX_:=_Z)G_Y7]+_ /DFC_AUQ^T[_P!$S_\ *_I?
M_P DU^_U% 'X _\ #KC]IW_HF?\ Y7]+_P#DFC_AUQ^T[_T3/_ROZ7_\DU^_
MU% 'X _\.N/VG?\ HF?_ )7]+_\ DFC_ (=<?M._]$S_ /*_I?\ \DU^_P!1
M0!^ /_#KC]IW_HF?_E?TO_Y)H_X=<?M._P#1,_\ ROZ7_P#)-?O]10!^ /\
MPZX_:=_Z)G_Y7]+_ /DFC_AUQ^T[_P!$S_\ *_I?_P DU^_U% 'X _\ #KC]
MIW_HF?\ Y7]+_P#DFO*OCG^RU\3_ -FM=%/Q'\,?\(X-:\X6'^GVMUYWD^7Y
MG^HE?;CS8_O8SNXS@X_I3K\KO^"YO^I^"O\ O:U_*QH _*BOJE?^"7/[3C*"
M/AGP>?\ D/Z9_P#)-?*U?U2P_P"IC_W1_*@#\!/^'7'[3O\ T3/_ ,K^E_\
MR31_PZX_:=_Z)G_Y7]+_ /DFOW^HH _ '_AUQ^T[_P!$S_\ *_I?_P DT?\
M#KC]IW_HF?\ Y7]+_P#DFOW^HH _ '_AUQ^T[_T3/_ROZ7_\DT?\.N/VG?\
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MO_1,_P#ROZ7_ /)-'_#KC]IW_HF?_E?TO_Y)K]_J* /P!_X=<?M._P#1,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KYU_X*&_\ )E_Q5_[!B_\ H^*OHJOG7_@H;_R9?\5?^P8O_H^*
M@#^>&OW=_P""27_)E^@?]A/4/_1YK\(J_=W_ ())?\F7Z!_V$]0_]'F@#[+K
MSO\ :&^%L7QL^!_C?P/(JM)K6ES6]N7QM2X"[H'/^[*J-^%>B44 ?RPZKI=Y
MH>J7FFZA;26=_9S/;W%O,I5XI$8JR,#T((((]J_2G_@D_P#MJ>$_A?H.K_"S
MX@Z[;>';"6[;4=%U;4I1':HSA1+;O(?EB&5$BLQ"DLX)!V@^A?\ !1__ ()N
M:I\2->O_ (J_"FQ^V:_='S-;\.1E5:Z8+C[3;YP#(0/G3JY^8?,2&_)75M(O
M]!U*XT_4[*XTZ_MW\N:UNXFBEB8?PLC $'V(H _<G]N3]OKX=?#7X)^(M(\'
M^,M)\3>.-;LY-/L+?0KV.[^R>:A5KB5XRRQ[%8LH)RS;<#&2/PKHK[4_8;_X
M)R^+/VA/$FF^)?&>F7GASX9P,MP]Q<H8IM5 .?*@4_-L;O+C &=I)Z 'WK_P
M2-^"\OPT_9C_ .$EU"U:WU7QG>MJ0\Q2K_8T'EVX(]#B20'N)@:^G_V@/A?#
M\:?@GXU\$3!2=:TN:V@9^B3[=T+_ / 9 C?\!KN;&QM]+L;>SM(([:TMXUAA
M@A4*D:* %50.    ![5/0!_+%K&DWOA_5KW2]1MI;+4+*=[:YMIE*O%*C%71
M@>A!!!'M7Z2?\$G_ -M3PG\*]%UCX6_$'7+?P]IUQ>'4='U;491':H[JJRP2
M2'Y8@=H=68A<E\D$C/I7_!1[_@FYJOQ.\07WQ4^%=F+SQ#= /K?AU65&NV50
M/M%OG \P@#<A/S=1\Q(;\DM8T74/#NIW&FZK87.F:C;.8YK2\A:*6)AU5D8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7*^,_A3X)^(_E_\);X.T#Q1Y8VI_;6EP7>T9S@>8K8&>:ZJB@#SGPO
M^S?\)_!-]#?:!\,O"&C7\)W1WEEH=M%.ASG(D";OUKT:BB@ HHHH *Y?QG\+
M/!?Q'6-?%OA#0?%"QC:@UK3(+L*,YP/,5L#/-=110!YQX8_9M^$O@N^AOM!^
M&/@_1[^$[H[RST*VCG0YSQ($W#\^*]'HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\KO\
M@N;_ *GX*_[VM?RL:_5&ORN_X+F_ZGX*_P"]K7\K&@#\J*_JEA_U,?\ NC^5
M?RM5_5+#_J8_]T?RH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '\K^I?\A"Z_P"NK?S-?J'_ ,$-?^0A\9O^N6D?SO*_+S4O
M^0A=?]=6_F:_4/\ X(:_\A#XS?\ 7+2/YWE 'ZNT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7*^.OA/X(^*'V(>,O!OA_Q:+'?]E_MW2X+W[/O
MV[_+\U&V[MB9QC.T9Z"NJHH \J_X9.^"'_1&_A__ .$O8_\ QJO5!QP.!2T4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5M
M^RC\$78LWP<\ ,Q.23X7L<G_ ,A5U'@7X2^!OA>UZW@WP9X>\)->A!='0M*@
MLC/LW;-_E(N[;N;&<XW''6NLHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBJ^HZA;:3I]U?7L\=K9VL33SSRMM2.-069F/8  G\*
M +%%>*_\-K? 7_HKW@__ ,&T7^-)_P -K? 3_HKW@_\ \&T7^- 'M=%>*?\
M#:WP$_Z*]X/_ /!M%_C6S8?M5?!;5&B2T^+O@6>64;DB7Q)9[SQG[OF9SCMC
MB@#U*BL[0O$6D^*-/2_T;4[/5[%_NW5C<)/$WT920:T: "BBO+O&'[4GPB^'
MOB.\\/\ B7XD>&]"UNS*BXT^^U&.*:+<H==RDY&593]"* /4:*\P\%_M/?"3
MXC>([7P_X7^(OAS7];N@Y@T_3]0CEFDVJ7;:H.3A5)/L#7I] !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M N803D*3PR\[21SAEK\./BY\+];^"WQ*\0^"/$42Q:OHMVUM-L.4D Y21?\
M9="KCV85ZG^P/\3;OX5_M;?#C4K>9HK?4-3BT:\4?=DANF$)##N SJ_U0'M0
M!_1/7\_/_!3C_D^+XF?]=;'_ -(+>OZ!J_GY_P""G'_)\7Q,_P"NMC_Z06]
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MS#NP.[$]Z /THK\S_P#@H]_P4BU;X8^(KWX6_"N\6SUZU'EZUXA0*[6K,O\
MQ[P9R!( ?F?JIX&&!(_03XM>.4^&/PM\7^+G19!H>DW6HK&YP)&BB9U3_@1
M'XU_,EX@UR\\3:[J.KZC.]U?W]Q)=7$\ARTDCL69C[DDT &N^(-4\4:M<:IK
M.HW>K:E<-OFO+Z=III6]6=B23]35"OT*_P""57[%OACX\76N?$+QYIT>M>'=
M%NUL+'29B?)N+H*LCM,O\2*KQX4\,6.00,']4->_9A^$/B;P^VB:C\,?"<VF
M&-HU@31X(O*!&"8V1 T9_P!I"".QH _G-^'/Q0\6_"/Q)!K_ (-\07_AS5H2
M"+BPF*;@#G:XZ.OJK @]Q7[@?\$^?VZ[?]K#PO=:+XAC@T_XB:-$)+R"W7;#
M>P9VBXB!)QR0'7L2".& 'Y/_ +>/[-ME^R]^T'J?A;1YI)?#UY!'J>EB9BTD
M4$A8>6Q/78ZNH/.0H)Y)K/\ V%?B%>_#7]K/X::E9RM&MYJ\.E7"[L*\5RP@
M8-Z@>8&Y[J#VH _HPKY(_P""A'[;4?[)O@6UT_0DAO/B!KT;C3HYL,EE$.&N
M9%_BP>%4\,P.<A2#];U_.3^VQ\9Y/CO^TOXV\3+=-<Z6MZUCIGS$JMI"?+C*
MCL&"[R!W<GO0!Y?X_P#B+XF^*GBB[\1>+M<O?$&M71S+>7TID?'95SPJCLHP
M . !7.U]7?\ !-_]E_3?VFOCP;;Q);M<^$?#]M_:.HP!BHN6W!8H"1R QW,<
M=1&PXS7[,>.OV0?@Y\0/ L_A2_\ AYX>M-->$Q02:=IL-M/:'& \,B*"C#KZ
M'N""10!^"W[.?[4WQ _9A\61:OX.UB:*R>16OM%G<M97RC&5DCZ9QP'&&'8]
M17[_ '[.7Q\T#]I3X2Z-XY\/YA@O5*7-E(P:2SN%.)(7QW!Z'C(*GH17\[7Q
ML^&%[\%_BQXJ\$:@2]QHFH2V@E(QYJ*QV2 >C+M8>QK[?_X(Q?&27PW\8O$?
MP[N[IAIWB*Q^VVD+-\HNX.NT=BT3,2?2(>E '[)T444 %%%% !1110 451UG
M7-.\.Z=-J&K7]KI=A",R75Y,L,2#U9F( _&N.TG]H+X7:]J7]GZ9\2?"&HZA
MO$?V6TUVUEEW'HNQ9"<^V* ._HI*6@ HK@M8^/WPP\.ZH=-U7XC^$M,U'>8_
MLEYKEK#-N'5=C2 Y'IBNMT/Q#I7BC3TO]&U.SU:QD^Y=6,Z31-]&4D&@#0HH
MHH ***YWQ;\1O"?@%(W\3^*-&\.)("R-JVH0VH8#J1YC#(% '145R/A'XO>!
M/B!-Y/A;QKX=\2S;=WEZ1JL%TVWUQ&YXX-==0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7Y6"D!=Q&?R&H _JF5A(H92&5AD$=#3J^(/^"3?[1-W\9/@!-X7UFYDN]?\
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M_P"S5_-W0!^M/_!#_0TA\*_%+6=O[RXO;*T+>T<<CX_\BU^G]?G%_P $2?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KB_C9_R1GQ[_ -@"_P#_ $GDKM*XOXV?\D9\>_\
M8 O_ /TGDH _F,;[Q^M>O?L^_LH_$C]I]M>'P]TBWU4Z'Y'V[S[V&V\OSO,\
MO'F,-V?*?ITQ[UY"WWC]:_5#_@AE_K/C5]-%_P#;^@#YM_X=/_M)?]"AI_\
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M/7=)U#2;DV=L][/:D7:%)%8-#(C$^6LPVY(YSCB@#T3_ (?)?'O_ )\_!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ_P)10!^C7B[_@L!\!=#\/2WFC3ZYXDU/RRT6FP:<]N2_&%>27"J.>2-V,'
M/ /Y*?M1?M+>)?VJ?BI=^,O$21V:",6NGZ9 Q:*QME8E8@2 6.69F8@99B<
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MC>1ZJH"QJ>,J@.,DU[A110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN>"/<'()! /YS?@)\<O$O[.OQ/TGQQX5EC74;$E)+><$PW4+</#( >58?B"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KD_BUX=O/%_PJ\9Z#IS,FH:IHM[8V[*Y0B22!T0AATY8<]JZRB@#^:G3
M/VCOC)X!O9K/3OB9XSTA[>1HGM4UNZ158$@AHR^,@YZCBOJ3]C__ (*A^./
MWQ0MX_C%XOU7Q-X%NK=[>7?;QRRV<I8%)\JHD8##*5!/#9 ) %?2O[=7_!+.
M7XP>*-2^(/PKN;/3_$=\QGU+0;QO*@O9CRTL4G2-VZE6^4DD[E[_ )I>.OV0
M?C7\-KB:+7_A?XGMDB.UKJWTZ2ZML^TT0:,_@U '[=I_P46_9QDL%O!\5-*$
M3'&UH+D2?C'Y6X?E7Y[_ /!2;_@H7X5_:&\)V/P\^'(NKO0([Q;W4-9NH&@%
MRR!A''$C8;9\Q8E@"2%P.,GX2/PT\7K="U/A36Q<E=XA_LZ;>5Z9V[<X]Z[[
MX>_L>?&OXI7$<?AWX9^([B*1@HN[JQ>TMLY_Y[3;$X[_ #<4 >5:'HM[XDUK
M3])TVW>[U&_N([6VMXQEI978*BCW+$#\:_IF^"O@%?A9\(?!OA!2K?V)I-M8
M,Z]&:.)5+?B03^-?%O["?_!+^/X#^(+3Q]\2;RSUKQA; MI^EV>9+33V(_UC
M.P'F2@9 P-JY)&XX(_0>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>plrx-20211231_g18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g18.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9>#L\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[,T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8(FE?8"0"VU#@9'/>O)/V'OCS>_M'?LU^%?&.KF,Z^RR6.J&)0JM<0N4+X'
MWJ$DP.!OP.!72?M8_P#)K/QD_P"Q,UG_ -(9J /FK_A\E\!/^?/QA_X*XO\
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M6H _#BOTX_X(?^)+B'QM\4O#^_-K=:?9W^P]GBDD3(],B;GUP/2OS'K]2O\
M@A]X.N6U/XI^*Y("MFL-EI<,YZ.Y:2211] (B?\ >% 'ZO5Q_P 4?C!X+^"O
MAI]?\<>)+#PUI2G:LUY)AI6QG9&@RTC8_A0$^U:7CSQMI/PW\%:YXJUVX^RZ
M/HUE+?74O4B.-2Q '=CC '<D"OYS?VF/VDO%?[4'Q.O_ !;XFN76$LT>FZ4L
MA:#3K?/RQ1CUP 6;&6;)/8  _5#QM_P6@^#N@W<MMX?\/>*/%&QL"Z6WBM+>
M09ZJ9)/,_P"^HQVKEE_X+>>!MPW?#7Q %SR1>P$U^6_PI^"'CSXY:U+I7@/P
MKJ7B>\A4/.+*+,<"G.#)(<)&#@XW$9(P*]3\1?\ !._]HOPMIKW]]\*]6DMT
MC$K"PFM[R3:1G_5PR.^?]G&1Z4 ?J/\ #+_@KI\!_'VH0V.JW&M>![B5MBRZ
M[9*;?)/'[V%Y-H_VG"@<Y..:^S=+U2RUO3K;4-.NX+^PN8UE@NK659(I4(R&
M5E)# CH17\L<T,EO*\4J-'*C%61Q@J1P01V-?H=_P2#_ &F-=\+_ !@B^$.H
MWK77A7Q%%<36%O,Q/V.]CC:4F,D_*LB1N"O=@A&#G< ?LQ7SA\>OV_OA+^S?
MX\/A#QG>:M!K(M8[S;9Z>TR>6^[;\P/7Y3Q7T?7X;?\ !87_ )/ ?_L7['^<
MM 'Z/_"O_@I9\%/C)\0M$\%^&[[6I=<UB8P6J7&F-'&6"EN6)XX4U<_:>_X*
M&?"O]EW56T'5Y[SQ%XL5%=]$T5%>2W##*F:1F"1Y'.W);!!VX(-?A5\&/BIJ
M/P3^)FB^-](@BN-5T<RRVBS\QB5H71&8=PK.&V]\8R,YKG=8U;5_&OB*]U/4
M;BZUC6]2N'N+BXE)DFN)G8LS$]22230!^QW@O_@M)\)-<U**U\0^%_$WAF&1
M]OVT1Q7<,0X^9PCA\=?NHQZ<>GHWQ"_X*D? /PCJ%YHLVMZI?3-9PSQW%CID
MCPR1SVZ31LK'!Y25<Y (.1VK\0/AK\/=3^)WQ*\.>"].1DU36M2ATV/<I_=M
M)($+,.P7))] #7T5_P %!/@KK&@_M8>+]+\,>%=7G\.Z99:/8V,EK82RQ^3#
MI-I& '5<'&S!]P: /DVOL7_@FC^T_P"!OV7?B1XNUKQU/?06.I:2EG;FQM3.
MQD$RN<@'@8!YKXZK2T/PUJ_B::2'1]*OM5FC7>\=C;O,RKG&2%!P,T ?T%?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9;XQ:HRYE4:5;(V.@/VMF&?P3\J /U-ATVTM=/2PAM88K%(_)6U2,+$L>,;
MH& N.,=*S?"/@CP_\/\ 26TOPSHMAH&FM/)<FSTVW6"+S)&W.P10 "2<UMT4
M ?EK_P %RO\ D%?!O_KMJW_H-G7Y0U^KW_!<K_D%?!O_ *[:M_Z#9U^4- ']
M+O[,O_)MOPH_[%+2?_2.*O2Z\T_9E_Y-M^%'_8I:3_Z1Q5Z70 4444 %%%%
M!7YU?\%M/^2!>!?^QF'_ *2SU^BM?G5_P6T_Y(%X%_[&8?\ I+/0!^-E?T9_
ML*_\F?\ PD_[%^W_ )5_.97]&?["O_)G_P )/^Q?M_Y4 >ZT444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#^'SX"RD^V8"/J17X[T ?TN?LQL'_9K^$S*0RGPEI)!'0_Z'%7IE?AS\'?\
M@K9\4/@_\)-&\#P^'?#NN_V):)8:=J6H).'2!!MC21$D4/L4*H(V_*HSDY)_
M5W]C7XQ:K\??V:_!7CO7#;_VQJL-Q]K^R1^7$)(KF6$[5R<#]WZT >TT444
M%%%% !7YU?\ !;3_ )(%X%_[&8?^DL]?HK7YU?\ !;3_ )(%X%_[&8?^DL]
M'XV5_1G^PK_R9_\ "3_L7[?^5?SF5_1G^PK_ ,F?_"3_ +%^W_E0![K1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MX _\%1_^3[/B;_W#/_37:5^_U?@#_P %1_\ D^SXF_\ <,_]-=I0!X5\$?\
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MUZ:WGU"WBDC:5,,K2*"#\O<&@#^@^BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;]I+X:ZG\8O@/XY\$Z-/
M:6VJZYI<ME;37SLD".PX+E59@/HI/M7I-% 'XK?\.5/C?_T-/P__ /!C??\
MR'7VI_P3>_8I\<?L>_\ "Q/^$RU7P_J?_"1?V=]D_L*XGEV?9_M6_P SS88\
M9\],8ST;..,_:M% !1110 4444 %>(_M5?LD^"_VM/!$>B^)DDL=4LBTFEZY
M:*/M%E(PYZ\/&V!N0\' P00&'MU% 'X<?$;_ ((__'?PGJ,Z>&X=%\<6 ;]S
M-9:A':2LO8O'<% I]@[#W-8_A'_@DK^T7XBU"*#4O#ND^%H&;#76J:S;R(@X
MY(MVE8_@.W:OW?HH ^+/V0_^"87@7]G*^L_%'B2Y7QUXYA7=%<W$(6QL7/>"
M$YRXZ"1R3QE50U\B>.?^"+OQ3O/&FO3^&/$G@F#PW+?SR:;#>WMXD\=L9&,2
MR*MJRA@A4'#$9'4U^QU% 'Y__P#!/?\ 87^+_P"R#\2]=U#Q%KGA'4O"FN:>
M+:\M=)O;I[@3QMN@D59+9%.-TJG+#B0GG&*^R_C=X)OOB5\%_'WA'3);>#4O
M$'A_4-*M9;MF6%)9[:2)&<JK$*&<9(!.,X!Z5VM% 'XK?\.5/C?_ -#3\/\
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M# )8\U^N%% '\^*_\$U/VE6NOLX^%UYYF_9N.I603.<??\_;CWSBOH3X#_\
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M3_PYM^/?_/YX/_\ !I+_ /&*_;^B@#\0/^'-OQ[_ .?SP?\ ^#27_P",4?\
M#FWX]_\ /YX/_P#!I+_\8K]OZ* /Q _X<V_'O_G\\'_^#27_ .,5J^$_^"0'
MQUT7Q3HVH7%WX1-O:7L-Q)LU.4MM1PQP/)ZX%?M510 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ!O* ;ZC(K\'_%WC+7?'WB&\U[Q)J]YKFLWC^9/?7\S2RR'W8GIZ#H!P*QZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]P/^"9_A&Y\&_L4_#F"]A,%U?0W.IE3WCGN99(F_&)HS^- 'U!1110 4444
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M*,?(>_>L[]E']J[PY^UQX*U;Q-X9TG5-(L]-U Z=)%JRQB1G$:2;AY;L-N)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#>$]4U2Y\0:KYWV:*XTR2&,^5"\SY<\#Y(V_E7TW7X _\$N/^3[/AE_W$_\
MTUW=?O\ 4 %%%% !1110 4444 %%%% !1110 4444 %0W=TEE:S7$N1'"C2-
M@9. ,FIJSO$G_(NZI_UZR_\ H!H ^=?@Y_P44^#'QV^)&D>!O">J:I<^(-5\
M[[-%<:9)#&?*A>9\N>!\D;?RKZ;K\ ?^"7'_ "?9\,O^XG_Z:[NOW^H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF/X=0ZAXJT;3;SXH7TTLE[J0V7!LX@Y$4%O(5&U=BJ[8Y+N020JX /S!N_\
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MMCB5G:5AV#[!GD[@,$ _/S]IJ.+3?VO_ (DKX4;:T/C&]^Q>4!A)Q=MPN1C
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MP-:7OPTM/B&WA*:20V[^'KFZCM&<.5D*B-@N=P(/'45VG_"K/VU_^?/XO?\
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MKVF^(K);S2=1M=3LV^[<6<ZS1GZ,I(J]0 4444 %%%% !1110 4444 %%%%
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MOWOCD61%=&#HPR&4Y!'J*AU#4+72;"YOKZXBL[*UB::>XG<)'%&H)9V8\
MDD] * /YU?A[X-^*6L_M">%_%NL^%_$LFKW/B>TU.\U*;2)D+3&Z21YF/EA0
M2V6)^IK^B'Q)_P B[JG_ %ZR_P#H!KXY^&O_  5D^$GQ-^)ECX)T[0_%@O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVV>W2[MTY_B,3&3TZ1GO^/VSX%^(7AGXG>'+?7_"6NV'B+1KC_5WFG3K+'G
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MVU/1]&\-:KIMRN^"\L;6WFAE7^\KJ"&'N#0!T/AO_D7=+_Z]8O\ T 5^%/\
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M#X-^$?@3X'LO"7@K1X=&T:U^;9'S)/(0 TLKGEW; RQ] .  !VM%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8U_X)U^"OV4V7Q!=W \7^/WCV'6;B )%9!AADMH\G9D$@R$EB,CY02M?6U%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KRC]I[]H;1/V8?@[K/CK6D^U-;[;>PT]7"/>W;Y$<2D]
M!P68\X5&.#C%>KU^0'_!;3XE76H?%#P%X!CD(T_3-)?6954\/-<2O$NX>JI;
M\?\ 74^M 'PM\9/C1XU_:-^(ESXG\7:C-K.M7C^5;V\8/E6Z%OD@@C&=J#.
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MPC^'N@>#-#:X?2-$M$LK5KMP\IC7IN8  G\!0!U-%%% !1110 4444 %%%%
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M'^"?Q!MCCRH_$*2+QSEK:,'_ - %?H[7P!_P1;T"?3?V8_$FI3Q&-=2\43M
M2!\\<=M;IN!]-_F#_@)]:^_Z /YK/^&L?C?_ -%D^('_ (5%]_\ ':/^&L?C
M?_T63X@?^%1??_':_?[_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\P/^
M"+O_ "-7[0O_ %^Z5_Z,U&OT_K\P/^"+O_(U?M"_]?NE?^C-1K]/Z "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^?']LCX
M]?$R;]H+XP>%)/B+XLD\+CQ'J5D-$;7+HV7V<7#J(?(W[-@  VXQ@=*_H.KX
M1^*'_!(GX<?%3XC^)_&6H>,O%-I?:_J5QJ<]O;&V\J-YI&=E7=$3M!8XR2:
M/Q%J_:^(-5L(%@MM2O+>%<[8XIW51DY. #7["?\ #DOX6?\ 0]>,/^^K7_XS
M1_PY+^%G_0]>,/\ OJU_^,T ?D#_ ,)9KG_09U#_ ,"I/\:/^$LUS_H,ZA_X
M%2?XU^OW_#DOX6?]#UXP_P"^K7_XS1_PY+^%G_0]>,/^^K7_ .,T ;W_  1A
MU"[U+]EWQ1+>7,UW*/&-TH>>0N0/L5B<9)Z<G\Z^]Z\7_91_9;T#]DGX=ZCX
M0\.:MJ6L6-[JLFK//JAC\Q9'AAB*C8JC;B!3TSDFO:* "BBB@ HHHH ****
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MW[$.H0ZE^R)\(I8&WHOANSA)_P!J.,(P_!E- 'QK_P %P_\ D2OA1_V$+_\
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M: /Z%/V3O^36?@W_ -B9HW_I##7JM>5?LG?\FL_!O_L3-&_](8:]5H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4R:9;>&25SA$4LQ]@,T^JFK?\@J]
M_P"N+_\ H)H ^2O^'L'[-O\ T-^H?^"2[_\ C=?17PO^,?A;XQ?#&Q^('A>]
MDO?"]['/)!=26[Q,RPRR12?(P###1..G./>OYC:_>C_@G+_RCI\&?]>6M?\
MIPO* #_A[!^S;_T-^H?^"2[_ /C='_#V#]FW_H;]0_\ !)=__&Z_!>B@#]Z/
M^'L'[-O_ $-^H?\ @DN__C='_#V#]FW_ *&_4/\ P27?_P ;K\%Z* /WH_X>
MP?LV_P#0WZA_X)+O_P"-U]/_  ]\>:-\4/!.B^+/#UP]WHFL6RW=G/)$T;/&
MW0E6 (^A%?R\5_1G^PK_ ,F?_"3_ +%^W_E0![K1110 4444 %%%% !1110
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MH **** "O*OVL?\ DUGXR?\ 8F:S_P"D,U>JUY5^UC_R:S\9/^Q,UG_TAFH
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MZEH6M?$S1-.U?3;B2TN[2:1P\,R,5=&^7J""/PKY#_X(A_\ )+/B7_V&;?\
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MX9[^%G_1-/!__@AM?_C='_#/?PL_Z)IX/_\ !#:__&Z_-7_A^-KG_1)-/_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\62V+X[';OQGIQN_&O>_@O\ \%)_@1\;+^WTVR\4/X8UFX*K%IWB>$63NQ.
MBR;FA+$X 429)(P#0!]14444 %%>3_M#?M/>!/V7]#TK5_'EW>6=EJ=RUI;M
M9VC7!,@7<00O08'6O"?^'N'[.O\ T&];_P#!--0!]G45\8_\/</V=?\ H-ZW
M_P""::N@\+_\%1OV;_%%Y!:_\)X^DSS':HU32[J% <G[TGEE%'&<LP'/6@#Z
MNHK*\+^+-$\;:);:SX>U>QUW2+D;H;[3;E+B"0?[+H2#^=:M !1110 4444
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M $2'QA_X*9?\*/\ ABGX]_\ 1(?&'_@IE_PK^CZB@#^<'_ABGX]_]$A\8?\
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M1*"\C8[*":ZS7=:M/#>AZAJ^H2^186%O)=7$N,[(T4LS?@ :_GO\3:[\2_\
M@HQ^U"L5H/M&L:U.\6G6=Q,PM-(L4RP#, =L<:9+,%RS$D LP! /TOUC_@LQ
M\!]-U+[-;Z;XSU:'C_3+/3(%BZXZ2W"/[_=[U[K\!_VY/@W^T9?QZ7X1\61K
MK[KN&B:I$UI=M@$D(K_+*0 21&S8 )-?+_A?_@B7\,[?08H_$7COQ9J&M>7^
M\N-+-M:V^_':-XI6QG_;KXB_;1_89\4?L3Z]HFOZ=K\FM^%[Z[(TW7+=&MKF
MSND_>)'(%8[9-J[E=6^;RV.%QB@#]]Z*^8_^"=_[2=]^TS^SGI^L:[)YWBG1
M;AM&U:?:%^TRQHC)/@<9>-T)QQO#X &!7L7QR^+>E? GX1^*?'FL_-8Z)9-<
M>3N"F>4D+%"">C/(R(/=A0!E_'#]I7X;?LY:1!?_ ! \4VNA_: 3:V>&FNKG
M! /EPH"[ $@%L;1D9(KY=?\ X+-? A=6-F-*\:O;[L?V@NF6_DXQG.#<>9CM
M]S-?F[\,?AK\3_\ @I%^T9JEQ>:HIU"ZS>ZKK-RCM:Z9:AL+'&F>@SMCB!&<
M') #,/OUO^")?PL_L$PKX[\8#6MF!>$VIMM^.OD^3NQGMYGXT ?8OP-_:9^&
MO[1VDRWW@#Q3:ZTT #7-B=T-W; G ,D#@.H)! ;&TXX)KU"OY[/B?\,?BG_P
M3>_:&TNYM=36+4+?-YI&N6:N+34[7<59'4^H 62$D[=PY(*.?W5^ WQ@TOX]
M_"#PMX]T<;+36K-9F@W;C!,"4FA)[E)%=<]]N: .^HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBO//C]\;M _9V^$VO\ CWQ&7>PTN(&.VB_U
MEU.Q"Q0IP>7<@9Z*,L> 30!K?$WXM>#O@SX9E\0^-_$=AX:TB,[1<7TNTR-@
MG9&@RTCX!(1 6..!7PS\0O\ @M5\,M!NI[?PCX-\0>+#'D+<W3QZ?;RG'!4G
MS),9XRR ]>#W_/#5M;^,/_!1?]H*&V7S=;UZ^9C;6:NR:?HUF"-S<Y$4*#;N
M;EF8C[[L ?T@^#/_  1M^%7A/2(I/B%J.I>/-:<9F2&=["QC/7"+&?,/7&YI
M.<9VKTH X'P__P %QM%N;T+KGPCO].M,C,NGZZEW)WS\CP1#T_BKZV_9[_;Z
M^#?[25W!IGASQ$VE>))A\GA_7HQ:7CG!.V/YC'*<*3B-V( R0*X?Q1_P2<_9
MOU[3);6P\*:CX;G92%O=,UJZ>5">X%Q)*F1[J17YM_MI?\$\_%W[(<L'BS0]
M1G\3> VN%5-8AC,=UIDI8>6MP%X7)P%E7"EA@A"4# '[S45^>/\ P2Z_;MU/
MXV6L_P ,/B%J1O\ QGI\+7&E:M-Q+J5JN-\<AZ--'UW=73DY*,S?H=0!\O\
M[4'_  4+^'7[)OC[3_"/B[1?%&HZE>Z9'JL<NB6MM+"(GEEB"DR7$9W;H7XQ
MC!'/4#R#_A]7\$/^A6^('_@NL?\ Y,KY5_X+5_\ )TWA;_L3+7_TNOJ]0_91
M_P""5WPG^.O[//@OQYKWB'QE::OK5J\]Q#IM[:);JPF= $5[5V P@ZL><T >
MM?\ #ZOX(?\ 0K?$#_P76/\ \F5WW@7_ (*N?L\>-;Z&TN/$6H^%YIF"H==T
MUXX\D#[TD?F(HYZL0..M< ?^"*GP1P<>*OB #_V$+'_Y#KR'XV?\$4Y--\/7
M.H?"WQK<:KJ<"%UT7Q#%&AN<8^5+A-JJV,X#)@DC++UH _4[P_XBTKQ9HUIJ
M^B:E::QI5Y&);>^L)UF@F0]&1U)##W!K0K^?[]D']K;QM^Q+\6I=%UR*_7PF
M]]]E\1^&+P,K6S!@KSQ1G[DZ8Z<;PNUOX67]]-%UBQ\1:/8:KIEU'?:;?01W
M5K=0MN2:)U#(ZGN"I!'UH NT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!^8'_!%W_D:OVA?^OW2O\ T9J-?I_7Y@?\$7?^
M1J_:%_Z_=*_]&:C7Z?T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?SI_MH>&=8NOVLOBW+#I5]+$_B6^99$MG96'FMR"!S7]%E%
M '\MG_")ZY_T!M0_\!9/\*/^$3US_H#:A_X"R?X5_4G10!_+9_PB>N?] ;4/
M_ 63_"C_ (1/7/\ H#:A_P" LG^%?U)T4 ?RV?\ ")ZY_P! ;4/_  %D_P *
M/^$3US_H#:A_X"R?X5_4G10!\$?\$8=/N]-_9=\417EM-:2GQC=,$GC*$C[%
M8C.".G!_*OO>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K^:S]K'_ ).F^,G_ &.>L_\ I=-7]*=?S6?M8_\
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M4K;6-/MKZRF6YL[F)9H9HSE71AE6'L015FOTY-25T?L2:DKK8****8PHHHH
M**** "BBB@#\8_\ @JY^V!K/Q!^)]]\'O#&H36_A'P_,L&JQVKX_M._ !9'(
MY9(B=@0\>8K$@[4(Z+X!_P#!&/6O%WA:QUSXF^+I?"=Q>0^:OA_3;19;F ,
M5\Z5VVJX'5 K8S]X$$5]:-_P2U^$\?QPL?B?#J?B1M6AUL:]-I]U=136=Q<"
M;SOF!B#X+\D;R#C'KG[&H _%G]K+_@DQKOP-\!ZMXX\%>*#XPT/286NM0T^\
MM1;WEO;J,O*K*Q655 +-PA !(!KVK_@D%^UQKGC)]3^#GB[4;C5I-/LSJ'A^
M\NG,DD=NC*LMJSGDJNY63/W5WKG:$4?=7[3'Q?\ #'P1^"OBKQ)XIN[>&S6P
MFA@M)2-]].\;!+>-2?F9R<8[#). "1^2/_!'CP'JGB/]JI_$5M"W]E>'=(N)
M+RXV_('G7R8H\]F;+L/:-J /V\N+B.UMY)YI%BAC4N\CG"JH&22>P K\ _VI
M/VB/'G[>WQ_@T+PU;WNI:*U^UCX6\-VN0&7) N'4D 2.HWN[8"+D$A5)K]XO
M'WA;_A.? OB/PV+Z;2SK&FW.G_;K< R6_FQ-'YB \%EW9&>,BOCC]D'_ ()D
MV_[*?QQE\=OXVC\7VJ:9<6EG;RZ5]EFMII'CQ)N\UPV(A*A("YW^G% 'B?PY
M_P""(L,FBP3^._B3-%JDD8,ECH%BIB@?C(\Z4YD'7G8M>._M8?\ !)WQ9\"_
M">H^,O!>O+XX\-:=$UQ?VLMM]GO[2%1EI H++,B@$L058#^$@$C]LZJZI+9P
MZ7>2:@T26"0NUPT^/+$84[RV>,8SG/:@#\N/^"17[8VL:UK4OP3\8ZI)J4?V
M5KGPQ=7<A>:,1+NEL]Q.601@R(/X1'(,XV!?U09@BEF(50,DGH*_G[_X)XVQ
MO_V\OA[_ &"K16JZE>2Q @DK;+;3D@YS_P L\C)]>M?LO^VS\0)?AA^R?\4/
M$%M.UK=Q:-+:6\Z-M:.:X(MXV4^H>92/<"@#\A_VTOVC_&'[</[1$7@WP:+K
M5?"]KJ/]F^&=#LF&V\ER4-V_.UF<[B'8@)&1T^=F^F/A_P#\$1;63PS%+XV^
M)%Q!K\L89[;0[)6M[=B/N[Y#NEP>^U,^G>O+O^"+WPSMO$_Q^\3^,;N&.=?"
M^C^7:[U!:*YNG*+(I['RH[A?I)^?[/T ?@%^U1^Q3\1?V%_$FB>)K37#JFB&
M[4Z7XKTI&M9;>Z7YU61-S&&3Y2RX9@0IP<@@?K1^P%^U,W[5'P)M=8U1HQXO
MT>7^S=;CC 422A04G"@ !9%(; & P<#@5V'[8WPRMOB]^S#\1_#<\*33R://
M=V>\?=NH%,T!SU'[R-02.Q/TK\PO^"+GCZYT']HCQ-X5,H73_$&A-,T?=KBV
ME5HS^$<MQ^?Y@'[14444 %%%?G_XP_X*8:_X7_;-@^":>"=,FTV3Q18Z =7:
M\D$HCGEB0R;-N,J)2<9QQ0!^@%%?F=^U;_P6"MO OB:_\+?"#1['Q%<V,K6]
MSXBU;>UF9%;#+!$C*T@&"/,+!21D!EPQ^?\ P?\ \%F?C3H^L0RZ]H_A?Q%I
MF[]]:BTDM92OHDBN0I]RC#VH _;&BOGKPG^W3\+/$O[-LOQHGU9M,\.6A^SW
MUG, ]W;WOR_Z($'WY#N4KC@JP;@9(_.OXH?\%H?B=K7B"?\ X07PWH7AG058
MB!=2A>\O)%R<-(V]4&1@[57CD;FZT ?LS17Y'_ 7_@M#XCB\36.G?%OPYI=S
MH$\BQ2ZUH,4D-Q: _P#+5X69UE4'&0FP@9(W$!3^L^FZE:ZSIMKJ%C<1W=E=
M1)/!<0L&26-@&5E(Z@@@@^] %FBN.^+7Q<\+? _P'J7C#QCJD>DZ)8+EY&Y>
M5S]V*->KNQX"C^0)K\J/BS_P6I\>ZMK$\/PZ\(Z/X?T57817&MJ]Y>2+_"Q"
MNL<9/4KA\<#<<<@'[$45^,_PQ_X+1_$_1==MQXY\,Z#XET)FQ.-.B>RO%!(^
M9'WM&<#/RE.>!N7K7M?QU_X+'Z;X1U?PV_PV\.Z?XOT/5=%CU">34+I[>ZL;
MHSSQO:RQJ#M=1$C=>1(&!*E20#]+:*R_"NL/X@\,:1JDD:PR7UG#<M&IR%+H
M&('TS6I0 4V21(8VDD94C4%F9C@ #J2:=7R5_P %0OC3<_!O]DW75TVX>UUC
MQ/<1^'[:6/[R+*KM.?;]S'*N>Q=: /SK_;^_;W\0?M*^-KOP)X$O+RT^'%I<
MFTAAL2PEUZ4-M\V0*<M$6_U<7<;68;B GJ'[-?\ P1KU;Q=H]KKOQ?\ $%UX
M6AN8Q)'X>T4(U\BD @S3.K)&W7,81SR,LI!6L'_@CC^SU8^/OBGKWQ+UJU%S
M:>$%CATN.090W\P;][UY,4:G (X:5&'*BOV7H ^([K_@C]^S[<:6]I';^);6
M=DVB^BU;,RG^\ R%,_5,>U?&W[6G_!)7Q-\&_#]]XM^'&K3>-_#=E&TUYIMS
M"%U.VC'5U"#;.H&2Q 1ACA6&2/VEHH _'/\ X)I_\%"=8\$^*=%^$_Q&U674
MO"6H.ECHNIW;;Y-+F8XCA9SR8&)"C.?+.W&$SC]C*_!G_@J-^SO9? ?]I*>]
MT.T6S\->+;?^V+6&(!8X)RY6YA4=@' D Q@"8 =./UN_8;^,5Q\=/V6O ?BB
M_F>XUC['_9^HRRXWR7-NQA>1L<9?8)/^!]NE 'RI_P %NO\ DC_PZ_[#TO\
MZ3M7S'^P/_P3V\,_M>?#/7_$^M^*M6T&XTW5VTU(-/BB='40Q2;B7&<YD(_"
MOIS_ (+=?\D?^'7_ &'I?_2=JT_^")O_ ";SXW_[&E__ $DMZ ,S_AR+\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*_HL_8W^+ES\<OV9?A_XROI?/U2]TX07TF>7N8':"9SZ%GB9L?[5 'LU%%%
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M7XKVWA'PSX,T/P_<:Q<7^E6ES'-O26&-(QYEQ(&+F7:$"[F8J!UP?TI\2?\
M(NZI_P!>LO\ Z :_FE^ _P ++[XW?&#PGX"L)S:RZ_?QVDDXY\J'.Z63'?:B
MLV.^V@#["^.7_!8KXJ^,-<NH?AM;67@+0$DQ;336L5[J$J@G#2&4-$NX8^14
M.W)&]NM5O@M_P6%^+WA'Q%8CXA"P\=^'FD"WFVRBL[Y8R>6B:$)'N /W63#8
MQE<[A^N/P:^ ?@/X ^%[;0O!'ARRT:WBC5);F.)3<W3  &2:7&Z1SCDD^PP
M!7YY_P#!9SX ^%M#\)^$_BEH^E6NDZY<ZM_8VI26<*Q?;@\$DL4DH ^9T%NR
MANI# $D*N #Z9_:5_P""C/P_^!OP@\,^+=%/_"7ZKXNLA>Z!I<+B+="1_K[@
MGYHD4_*1@L7!4 8=D_,WQ)_P5D_:0US5C>67BK3?#MN3G^S]-T2U>$>V9TED
M_P#'Z]"_X)3_ +*.@?M!>)-;\8^/[/\ X2#PUX2$5CINCWI,EM+<2,\K!T)P
M8TR6\O&UFFR<\@_L9=>#]!OO#KZ!<Z)IT^A21F%M,DM8VMC&1C:8R-N,=L4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?F!_P1=_Y&K]H
M7_K]TK_T9J-?I_7Y@?\ !%W_ )&K]H7_ *_=*_\ 1FHU^G] !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'QD^,_A'X!^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MREH ^BOV3O\ DUGX-_\ 8F:-_P"D,->JUY5^R=_R:S\&_P#L3-&_](8:]5H
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M +!^G_\ I,E?KI\4KJ[LOV)O%UQ8%A?0_#V\D@,:[F\P::Y7 QR<XXK\B_\
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M=S 85<DU^(G[">L7?B+]NCX<:K?R>=?7VNR75Q)C&^1TE9C^))H _H5HHHH
M*_#?_@L)X+D\-_M=/K'D,D'B'1+.]$PCPKO&&MV&['+ 0)GN R]L5^Y%?$?_
M  58_9AN_CI\#K;Q3X?M&N_%7@II;Q+>)2SW-BZC[3&H!Y9=D<@ZG$;JHR]
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MHGF#O^]K[,H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_FL_:Q_Y.F^,G_8YZS_ .ETU?TIU_-9^UC_ ,G3?&3_
M +'/6?\ TNFH _?[]D[_ )-9^#?_ &)FC?\ I##7JM>5?LG?\FL_!O\ [$S1
MO_2&&O5: "BBB@ HHHH **** "BBB@ KYS_;,^$MQXT\'VOB32X&GU+0PWG1
M1C+26K<L?<H1N^A>OHRD//!Y%>?C\%3S##3PU7:7X/H_DSR\SR^EFF$J8.MM
M)?<^C^3/R\^$/Q:U?X/>*TUC3 L\+KY5W92,0EQ'G.T^A'4-V/J"0?MWPG^U
MQ\./$EC%)<ZNVAW9'SVNH0N"I]G4%2/Q_ 5POQH_8QL_$UY<:SX*G@TB]E.^
M72Y@5MG;N48 ^6?]G!7_ ':^<-8_9M^)>BW#PS>$;^?:<;[,+.K>X*$\5^5T
M99YPVW0A3YZ?31M>JMJO1_<?BN'EQ'PE*6'A2]I2OIHY1]4UJK]G]W4^I_B1
M^VEX0\/:;+'X69_$>K,N(SY3Q6T9QU=F +8]%'/3(KXGU"^UKXA^+)+F<S:K
MKFJW/11EY9&. H _  #@  5Z'X7_ &4_B5XFNEC.@-I,)QNN-3D6%5S_ +/+
MG\%-?6_P-_9ET+X/D:E<2C6O$;+C[=)'M2 $<B)><>A8\GV!(IO"YQQ-6C]:
MC[.DO*R^2>K?X>A4L'G_ !?7A]=A[*C'R<4O1/63_#T.K^"/PW7X5_#?2M!8
MA[Q5,]Y(N"&G?E\'N!PH/HHKO***_7*%&&'I1HTU:,4DOD?NF'P]/"T84*2M
M&*27H@HHHK<Z HHHH **** "BBB@#\6/#_\ P4D^.'@/]JBQTOXI>+ _A;1/
M$$FF:YI-II=O;Q)$KM!*XVQ^8VSF0 L3E17[065[;ZE9P7=I/'<VMQ&LL,T+
M!DD1AE64C@@@@@CUK\Y/^"DG_!.75_C%X@N/BG\+[:.Z\3RQ(NL^']RQM?[%
M"K/ QP/-"@!D) 8*"/FR'^$_AC^VE^T-^R6A\&PZK?Z99V0*CPWXJT[?]EST
M"K*HEB YPJL%Y/% '] &N:YIWAG1K[5]7OK?3-+L87N;J\NY!'%!$@+,[L>%
M4 $DGTK^>#XS>()OVPOVRM;NO#$#X\8>(8['3/W;$^3E((977 (_=HLC _=^
M;)XS6U\1/VH?VB/VU;A/"%Q>ZIXFM)I%D'AOPWIVR%B&!4R)$NYU#8.9"P4@
M'C&:_1'_ ()R_P#!.FY_9_O(_B/\1XK>7QY)"4T[2XV$JZ.CJ0[,X.UIV4E?
MERJJ6 +;C@ ^_+2U2RM8;>($1PHL:Y.3@# K\;O^"DG[?.I?&/Q-?_"'X;74
MO_"'VMS]BU&\L=QDUNY#;3$F.3 K\ #_ %A&>5VY_2+]N#QQXC^'O[+/C[5/
M"%G>7OB66S2PLDT^-WGC:XE2%I4" G<B2.X('5!TZU^"W@WP3\6?A_XHT[Q%
MX?\ "7B?3=:TZ43VEXFBS,T,@'#*&C(R,\''!Y'- 'ZA?L"_\$P;'X:KI?Q#
M^+EC%J/C!2MSIWAV7$D&EL,[9)L$K+-T('W8R,\L 5_1ROP._P"&H?VRO^@Y
M\0/_  3O_P#&:/\ AJ']LK_H.?$#_P $[_\ QF@#]\:\Z_:,^&[_ !?^ _C[
MP9"J&[UG1KFUM?,^Z+@QDPD^PD"'\*_+7]C_ /:"_:B\5?M+> -)\:ZOXSG\
M+76H;+^/4-,:*!H_+<X=O*&!D#N*_8^@#\+O^"4_QMM/@G^U!)H'B.8Z9IOB
MNU;19&N<1K!>K('@\S=@C+*\6/[THSW(_=&OR,_X*/?\$X?$D/C;6/BI\*]'
MGU[2M6E>\UG0+"/?<V=PW,D\,8^:2-VRS*H+*S$@%3\GSYX#_P""F?[1'PIT
M'_A&?^$FCU..Q!MH_P#A(;!+BZM=N5V&1@'8@_\ /0L1C'M0!^JO_!1WX[:=
M\$OV6O%L;WBPZ_XFM)="TJV5\2R-,NR:1>X$<3.V[L=@R"PKXH_X(F_"NXO_
M (A>._B+/%(MCING)HEM(1\DDTTBRR8_VD2%,^TP_#YA\+^ _C[_ ,%#OBA;
MWEW+JGBJY9A!/X@U"/R=-TV($;AE56*,#.[RXQN8YPI.:_<C]F_X!Z!^S3\(
MM%\">'_WT-FIDN[YDVR7MT^#+.XR<%B, 9.U0JYP!0!Z=1110 5_/Q^VA_RD
M$\;_ /8S6W\H:_H'K\'?VP/AEXQU7]O#QGJ5EX3UR\TZ3Q';R)>6^FS/"R@1
M98.%P1P><]J /WBKQG]L_P#Y-+^+_P#V*VH?^B'KV:O(/VP+"ZU3]E?XL6=E
M;37EW/X9OXXK>!"\DC&!@%51R23V% 'Y:_\ !%3_ ).F\4_]B9=?^EUC7[4U
M^.O_  1S^'_BCPI^TUXFN];\-ZOH]H_A"ZB6?4+"6!&<WMD0H9U )PI./8^E
M?L50!^5?_!<[_FB?_<;_ /;"OIG_ ()2?\F0^"O^OK4?_2V:OG[_ (+6>#/$
M'B[_ (4W_86A:EK7V?\ MGSO[.LY+CRMWV';NV XSM;&>N#Z5]'?\$O=#U+P
M[^QCX.L-6T^ZTN^CNM0+VMY"T,JYO)2,JP!&00?QH _,S_@I1X%U?X&_MMZM
MXGLD:WAUB>V\3:5=%25,@V^9ST)6>-R1UPRGN*_9;]GGX^>%_P!I+X6Z1XT\
M+7L4\-U&$O+,.#-870 \RWE7JK*3QD892K+E6!/$?MH?LAZ'^UY\,ET6ZGCT
MGQ-ICM<:)K31;_LTC8WQN!@F*0*H8 \%4;DJ ?QXU+]GW]J#]CSQE<RZ+HWB
M[1)\A3K'A+SKBRNT!.W<\(*LIR2$E (SRHH _?[5M7L?#^EW>I:G>6^G:=:1
M-/<7=U*L<4,:C+.[,0%4 9)-?SQ_MW_'RS_:._:7\3^*M(=I/#T'EZ9I4CKM
M,EO"-OF8]'<R2#.#AP" <UU\_AS]K[]KJZM_#VJ6WC[Q%I[LNZ/58Y;+3%PP
M(:4N$AR",C=EN..E>7?M1?LZWW[+WQ&M/!.JZK;ZOK"Z5;7U])9J1#%-+N)B
M0GEE4 #<0">N!G% ']$OPU_Y)SX5_P"P5:_^B4KI*YOX:_\ ).?"O_8*M?\
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M56_;-T7X\>)-)^'G@?4(M6\(>';AKR[U6V</!?7^UHQY1'#1QHS@.#AC*^.
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M4 9^O:!IOBG1[O2=7LH=1TV[C,4]K<('213V(/\ D5\,_%[_ ()MW/VR>_\
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M HHHH **** "BBB@ HHHH **** /S _X(N_\C5^T+_U^Z5_Z,U&OT_K\P/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPUZK7E7[)W_)K/P;_P"Q,T;_ -(8:]5H **** "BBB@ HHHH **** "BBB@
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M'! 5!T(R6/- 'YG?\%7/VHK_ .+/QRO?A[I6H2#P=X.E-I);Q.1'=:@.)Y'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!K'P?\-Z3\,O!FIR:9XC\0V[7>IW]K)MGM;')140CE6E8.-PP0L9 ^]D:_\
MP3%_8=D^!'AVP^*FNZQ>'Q7XGT8)_8T05+:UM)FBF19 1N:;Y$)Y4+EEP>M?
MF3^W=\4F^+W[6/Q&UQ9C-8P:D^EV1SE?(ML0*5]F,9?_ (&30!X*S%V+,2S$
MY)/4UZC^SS^TEXX_9F\=6WB3P;JDEN-Z_;=+E=C::A&#S'-'G!&"<-]Y<Y4@
MU])?\$O?V.?"?[3GBCQ?K'C^PGU/PMX?A@ACL8KF2W6XNIBQ&YXV5]J)&V0"
M.9%YXQ7)?\%)/V3=#_97^,&EP>$1/%X1\0V)O+.UN)C*]K*C[)80[?,RC,;
ML2?GP2<9H _;?X'_ !?T7X]?"GPWX\\/EAINLVPF$+D%X) 2DL+8_B1U=3Z[
M<CBNZK\Y/^")OC2XU3X+^//#$SM)%H^MQW<.YL[%N(0"H]!N@9OJQK]&Z "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OYK/VL?\ DZ;XR?\ 8YZS_P"ETU?TIU_-9^UC_P G3?&3_L<]9_\ 2Z:@
M#]_OV3O^36?@W_V)FC?^D,->JUY5^R=_R:S\&_\ L3-&_P#2&&O5: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSR>%=3,:+U9EMI&"CZD8_&O6JK:EI]OK&G75A>1+/:743031-T=&!5E/U!-
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MI%E>S%A7U/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5_-9^UC_ ,G3?&3_ +'/6?\ TNFK^E.OYK/VL?\ DZ;X
MR?\ 8YZS_P"ETU '[_?LG?\ )K/P;_[$S1O_ $AAKU6O*OV3O^36?@W_ -B9
MHW_I##7JM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M11Y&=B]<#<6(!KZ K\>?B!_P6T\>:S830>#_ (?:+X8FD!476HWDFI/'D=5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S
M _X(N_\ (U?M"_\ 7[I7_HS4:_3^OS _X(N_\C5^T+_U^Z5_Z,U&OT_H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-OCU
M^SSX&_:2\$R>&/'6D+J%F&,EM=1-Y=U9RXQYD,G56]1RK=&!'%>DUROQ,^*G
MA+X-^$[GQ-XUUZT\.Z';D*]W=L<%CT1% +.QYPJ@DX/'% 'YO:S_ ,$-[.;5
MG;2?C!/:Z8S';%>>'Q/-&N. 76Y17/OM7Z5];_LG_L$_#C]DWSM2T5;GQ!XM
MN(O)F\0:IM,JH<;HX44;8D..<98]"Q& /,]>_P""PW[/^CW$T=H?%&N(@RLM
MAI*JLG7A?.DC.?J!UK#A_P""T_P.FF1&\->/858X,CZ=9%5]SB[)_(4 ?5/[
M4GPPO/C-^SQ\0/!>FI')JFK:3-%9),X1&N%&^$%CP 75>3TKX^_8Y_X),Z9\
M(_$6G^-/BGJ5EXJ\0V3K/9:)8JS:?:R@@K)([@&9U/1=H4$9^?@CJ6_X+)_
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M89# _P!.HZ&OP/\ ^"A'[(MI^R3\7K/3]!NKF]\(:]:&^TQKPAIH"K;98&8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOL3]DW_@GI\-OV6[>VU1+<>+/'(4&3Q%J42YA;&"+:+D0CD\Y+G)RV.!]24
M<M\-?A;X3^#OA.U\,^#-!L_#VB6WW+6S3&YN[NQRSN<#+,2Q[FNIHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*^(/^"PO_)G[_P#8P6/\I:^WZ^(/^"PO_)G[_P#8P6/\I: /HK]D[_DUGX-_
M]B9HW_I##7JM>5?LG?\ )K/P;_[$S1O_ $AAKU6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?QAXFM/!/A'6_$5
M^<6.D6,]_<$?\\XHVD;]%-;%>._MC7$MK^R?\8'A!+GPIJ2?+_=:V=6/Y$T
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M7\_7[8'['?B_]AOX@:'J5AK<^HZ%>3&?1/$EFC6\T,T9#>7)M)\N5<JP(.&
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MY,APBKSM<J!A2< '[#T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?F!_P1=_Y&K]H7_K]TK_T9J-?I_7Y@?\ !%W_ )&K]H7_ *_=*_\
M1FHU^G] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHKYU_:H_;J^&W[*>GR6^M7W]M^+WCWVWAC37!N6
MR/E:5N1 AX^9N2,[5;!% 'OVL:Q8>']+NM2U2]M]-TZUC::XN[N58HH4 R6=
MV("@#N37YN?M.?\ !5^74-9/@']G?2YO%'B*[D^R)XA^R-.ID.1ML[?&9FST
M=QMX.%<$&O'+70_VD_\ @JIX@CO-2G_X0CX1Q7&8_E=-.C /6./(>]F&/O$[
M0<C,><5^CG[,?[&/PV_95T58_"VE?;/$$L82\\1Z@!)>W'J V,1)G^!,#@9W
M'F@#XQ_9U_X)8^(OB1XB_P"%C?M+:W?:KJEZXN&\._;6EN)CV^UW )VC'_+.
M(\# W+@K7Z8>&/"^C^"M!LM$T#2[/1='LHQ%;6-C"L,,2CLJJ !6I10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7Q!_P6%_Y,_?_ +&"Q_E+7V_7Q!_P6%_Y,_?_ +&"Q_E+0!]%
M?LG?\FL_!O\ [$S1O_2&&O5:\J_9._Y-9^#?_8F:-_Z0PUZK0 4444 %%%%
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M?60+.IB'\4D;,_R]65R!DJ%/XQZEIMWH]]/8W]K-8WMNYCFM[F,QR1L.JLI
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M ,51_P +.\'?]#9H?_@RA_\ BJV^J8C_ )]R^YBYEW/D[_@H=^VM=? 73(/
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M$ZY'I7CCPY=:%<S M!))MD@N ,9,<J$H^,C(!R,C.*_?K_A9W@[_ *&S0_\
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M'C?18+2ZU70]-DO+:&_1W@=UQ@.%96(Y[,/K7IE>#?MX?\F=_%K_ + ,W]*
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MQ#!6(VXQ7V1\0/A?X3^*GA*Y\,>+- L-<T.XC\MK.[@5E3C 9.,HPX(9<$$
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M@CQ5H?A33]*;3;F\,VCVES'/OCV[1F2XD7'S'/R_C7Z05^&7_!'[_D\2W_[
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MPB0;E8@Y5B,BOBK_ (+%_#P^%?VJ;?Q%''BW\4:+;W328X,\.;=U^H2.$_\
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M9U55@!'!\M%13C(+;R#@BOI6@ HHHH **** "BBB@ HHHH YOXE?\DY\5?\
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M0[KPW\.K"9+IX=3A,4^L;3D0QQ,-WE-@;Y" "I(7).5_<!5"*%4!5 P !P*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA7"(.!T'.,G)YKF?!?C_ ,3?#G6$U;PKX@U/PYJ:8Q=:7=R6\G'8E",CV/%
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MLD[VO;=/:[,:E&%6W.KV/SW_ .'.O@[_ **%KG_@'#1_PYU\'?\ 10M<_P#
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M8Z@#\FO^"X__ ",7P@_Z]=4_]#MJ^N_^"7'_ "8G\,O^XG_Z=+NOD3_@N/\
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M-_\ 8F:-_P"D,->JUY5^R=_R:S\&_P#L3-&_](8:]5H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM:>)?B"UMX_\;J1*J31EM-LGZYCC8?O7!S^\D'H0BD9K[GZ<#@4M% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?FS7T+^P%_P3'\3>(/&&E?$#XNZ+-X?\-Z;*EY8>'K]-EUJ,JD,AFB/,42D
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MK2_@_P#M@?!TMX=\/Z!\6_#]KNR;;PT;_P"R$DG)W6Q,1YR3SWSWKT7X:_\
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MK(RG@@@D$>]?DA^UK_P2"\0:'JMUXB^!ZKK>ARL7;PM=W(2\M,D?+!+(VV9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^8'_!%W_D:OVA?^OW2O\ T9J-?I_7Y@?\$7?^1J_:%_Z_
M=*_]&:C7Z?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?CI_P %C_VBM3\0_%.Q^$6G73P:!X?MXK[4X8W(%S>S('0..XCB9"H]
M96/85^Q=?SK?M^:C+JG[9/Q8FEY9=:> <Y^6-$C7]%% 'A>D:/?^(-2M].TN
MQN=2U"Y?RX+2SA:665O[JHH)8^P%;WC7X4^-OAJ+<^+O!^O^%A<Y$!UK3)[/
MS<#)V^8J[N/2OU,_X(F_"W1U^'?CCXBRVD,VNS:O_84-TZY>""."&9U0]@[3
MKG'7RU]*^_/C5\)=#^./PO\ $/@KQ!9PW=CJEJ\*M,N3!-M/ES*>S(V&!'I0
M!_/!%^TCXTC_ &=[CX,&_+^#Y=7CU948GS$VAMT .<>4TA27;CATSW-6/V=O
MV6OB'^U%XDN=(\":0MTEFJO?:E>2B&TLU8X4R2'/)P<*H9C@D# )'E$\+6\T
MD3_?C8J<>H.*_=K_ ()*^"[+PS^QGX>U6"!8[OQ#J%]?W4F/F=DN'MER?0+
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MX-_]B9HW_I##7JM>5?LG?\FL_!O_ +$S1O\ TAAKU6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHJMJ6I6FCZ?<W]_=0V-C;1M-/<W
M,@CBB11EF9B0% '))X% %FO*/V@OVH/AW^S+X9_M?QSKL=G+(I-II5OB6^O"
M.T46<D9X+'"CNPKXS_:B_P""L5O;:H_@7]G_ $YO&'BBYE^R)K_V9I[<2$[0
MMI"!NN'ST8C9D# D!KE/V??^"7OC#XR>)1\2?VF=>U&\O;UEG/A]KLO>3CC:
MMU,#^Z3''E1\@$#<A&V@#@O%WQZ_:*_X*;>)+SP?\--(F\'?#4.8;UUF:*W\
MOUO;L#+D@_ZB,<Y^Z^-U?;7[)7_!.7X<_LPQVFLW,2^,O'B .=>U"$!+5\?\
MNL7(B_WR2_7Y@#BOICPAX-T+X?\ AVRT'PUI%GH6BV:;+>QL(5BBC'LJCJ3R
M3U)))YK9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB#_ (+"
M_P#)G[_]C!8_REK[?KX@_P""PO\ R9^__8P6/\I: /HK]D[_ )-9^#?_ &)F
MC?\ I##7JM>5?LG?\FL_!O\ [$S1O_2&&O5: "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJW_ ""KW_KB_P#Z":MU4U;_
M )!5[_UQ?_T$T ?RQ5_1A^PC&L/['OPE5!M!T&!OQ.2?U-?SGU^E?P#_ ."O
M&D?!?X,^#_ TWPSO=5ET'3H[%KV/5TB68H,;@IA.,^F30!^B7[:W_)H_Q>_[
M%F^_]%-7\X5?IC\<O^"OVD?&#X.^,O!,/PROM,EU_2Y].6\?6$D6$R(5WE1"
M-V,],BOS.H _J/\ !<*VW@[0H4SLCL($&>N!&HJ#XA?\B#XF_P"P9<_^BFK\
MU='_ ."V^B:7I-E9GX3:A(;>!(2XUM!NVJ!G'D>U0^)/^"V&B:]X=U33%^%%
M_"UY:RVPD.MH0N]"N<>1SC- 'Y3U_1G^PK_R9_\ "3_L7[?^5?SF5_1G^PK_
M ,F?_"3_ +%^W_E0![K1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7E7[6/_)K/QD_[$S6?_2&:O5:\J_:Q_Y-9^,G
M_8F:S_Z0S4 ?@#^R=_R=-\&_^QST;_TNAK^E.OYK/V3O^3IO@W_V.>C?^ET-
M?TIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?G9^V5_P $G;+XS>+M1\<?#'6+'POX@U%VN-0T?4486-U.
MQRTR.@+0LQW%AM8,QS\O.?T3HH _ [6/^"5'[2VF7A@MO MKJT0&?M-GKEBL
M9Y(QB69&[9^[WKUOX-_\$8_B/XAUBWF^(^O:7X2T-6!FM]-F^V7T@!Y5<+Y2
M9&?F+-CCY37[+44 <=\)/A+X7^!_@'2_!W@_34TO1-/3:D8Y>5S]Z61NKNQY
M+']!@5V-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5D>)O&&@^"[%;WQ#K>G:%9,VP7&
MIW<=O&6/;<Y S[5\'_\ !0G_ (*4'X$W]W\.?AF]O=^.U0?VAK$BK+#I.1D1
MJA!62?&"0WRID9#'(7\@_%WC?Q;\6O%#ZIXCUC5/%6O7;X\Z\F>XF<D\*H.<
M#L%7@= * /TE_P""/?Q \+^%_%_QSBUGQ)I&D2ZG>Z9]A2^OHH&N\27^?*#,
M-^-Z?=S]]?45^KJL&4$'(/((K^7K7?AOXN\+V"7VL^%M:TBR< K<WVGS01D$
MX!#,H')XKV']F?\ ;E^*7[,.K6BZ'K<VK^%ED!N/#&J2M)9R)_$(\Y,#8_BC
MQR!D,!B@#^B6BO,/V<_VAO"O[37PQT_QIX4G/D3'R;RPF(\^QN% WPR =QD$
M'HRE6'!KT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7&&!Y^5Q0!^G=?S@_MK?\G<?%[_L9K[_ -&M7ZT_\/>?V>?^@CX@_P#!._\
MC7XZ_M*>.]*^)_Q^^(/BW0WEDT?6M:NKZT:>/RW,3R%E++V.#TH _6#_ ((J
ML3^RQXH!.<>,[H#_ , ;&OO^O@#_ ((J?\FL^*?^QSNO_2&QK[_H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_F
ML_:Q_P"3IOC)_P!CGK/_ *735_2G7\UG[6/_ "=-\9/^QSUG_P!+IJ /W^_9
M._Y-9^#?_8F:-_Z0PUZK7E7[)W_)K/P;_P"Q,T;_ -(8:]5H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HK'\7>,-#\ ^';W7O$>K6>AZ-9)Y
MEQ?7TRQ11K[L3U/0#J20!7YE?M"?\%1O%OQ>\2_\*W_9FT+4+V^O7,"^(1:&
M2[G'1C;0$?NE Y,LG(&3M3&Z@#[._:A_;:^&O[*FEL/$FI?VEXFDCWVGAK36
M5[R7/1G[1)_MOC(!VAB,5^=?F?M*?\%5O$&%_P"*'^$45Q@X+IIL>T]#T>]F
M'_?*G_GEFO;?V7O^"3L4>J+XZ_:"U%_%WB6ZD^U/X?\ M+30K*3G==SYW7#Y
MZJ#LR#DR U^CNFZ;::/I]M86%K#8V-M&L,%M;1B.*)%&%55  4 < #@4 >#_
M ++O[$/PU_94TM'\/:=_:OBB2/9=>)=257NY,CYEC[0H?[J=1C<6(S7T#110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q!_P6%_Y,_?
M_L8+'^4M?;]?$'_!87_DS]_^Q@L?Y2T ?17[)W_)K/P;_P"Q,T;_ -(8:]5K
MRK]D[_DUGX-_]B9HW_I##7JM !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 54U;G2[P#D^2__H)JW10!_+9_PB>N?] ;4/\
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MH:_I3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTV?XU:7+IGC@75QYC3B!)+B!GWQ2-'"=L1 ?R]A"D>7DCGFC^WQ<6%M^QO\
M%E]2*+;G1)$7S",><S*L/X^84Q[XH _*W_@DU\=KOX7_ +35GX3GNBGA[QK&
M=/GA=OD6Z16>VD _O;MT?_;8^V/W0K^;#]D>.XD_:H^#XM3B;_A+M*(.,C:+
MN(MGVQFOZ3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=,\(^&='\*Z;-,;F2ST2PBLX7E*JID*1JH+%40;L9PH'85T% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\UG[6
M/_)TWQD_['/6?_2Z:OZ4Z_FL_:Q_Y.F^,G_8YZS_ .ETU '[_?LG?\FL_!O_
M +$S1O\ TAAKU6O*OV3O^36?@W_V)FC?^D,->JT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?S6?M8_\G3?&3_L<]9_]+IJ_I3K^:S]K'_DZ;XR?]CGK/\ Z734 ?O]
M^R=_R:S\&_\ L3-&_P#2&&O5:\J_9._Y-9^#?_8F:-_Z0PUZK0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9^R=_P G3?!O_L<]&_\ 2Z&OZ4Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQYSP\C \<5]I^$_!N@> ]%AT?PUHFG^']*A_U=CIEJEO"ON$0 9H _*S0/\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q!_P6%_Y,_?\
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M&20'U"QGWK]+J* //?A/^SW\-_@98_9? G@S2?#8*['N+6#=<RCTDG;,C_\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\UG[6/\
MR=-\9/\ L<]9_P#2Z:OZ4Z_FL_:Q_P"3IOC)_P!CGK/_ *734 ?O]^R=_P F
ML_!O_L3-&_\ 2&&O5:\J_9._Y-9^#?\ V)FC?^D,->JT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK&(K>SLXEBAA0=%1% "@>@%7:** "BBB@ HHHH **** "BBB@ HHHH ****
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M,?*V&&>0#Q0!SUO_ ,%0/VF[>%(D^)KE5& 9-#TUV_%C;$G\:D_X>C?M._\
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M;:PZC(.#WKZ:^*'C"+X>?#/Q;XJG8I#H>D7>INP7<0L,+R' [GY>E?S)^']
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MPF_:CO/[*\-:G=:1XFVL_P#PC^N1+!=2*H)+1E69)1@$X1BP R0*_+_X'_\
M!)WXH?&KX2V/CD:YH?AN/5K5;S2=.U$RM+<Q,,QR2,BD1*XVLN-QPP) KY/U
MS1O%GP+^)UWIMT;OPWXQ\,Z@8V>"0I+;7$3<.CKU&0&5@<$$$$@T ?T^45XU
M^R!\=/\ AHW]GCPAXXGV+JMU;&WU2.-=JK>1$QS$+V5F7>H[*ZU[+0 4444
M%>5?M8_\FL_&3_L3-9_](9J]5KRK]K'_ )-9^,G_ &)FL_\ I#-0!^ /[)W_
M "=-\&_^QST;_P!+H:_I3K^:S]D[_DZ;X-_]CGHW_I=#7]*= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC?\ I##7JM66%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M G:BG'&=H(- 'Z"K_P %M/A;_:GEMX$\7C3MV/M %J9MOKY?G8S[;_QK[ ^
M?[3WPX_:6T.;4O 7B*+4WM@IN]/F4PWEINSCS(FY )! 894X."<5^4WQ3_X(
MW_%?P/X5N-9\.Z]HOC6:UB:6;2[19+>Z< 9(A#@K(<9X+*3T ).*^/O@I\9/
M$OP#^)6C>-O"EZUIJFG2AFCR?+N8B1YD$H_B1QP1]",$ @ _HE_:8\47/@G]
MG7XG:]9OY=[I_AK4;BV?&=LRVTAC/4<!MM?S5Z5ITFL:I9V$+*LUU,D"-(2%
M#,P4$X'3)K^@G]J3QE:_%#]@'QQXLT3S&L-<\''5+<=&$,D*R8;W"DY'L:_
M?P/_ ,CKX?\ ^PA;_P#HQ: /Z@M)TNWT/2K/3K.,16EG"EO#&.BHBA5'X "O
MPX_X*]>&K70?VQKZ\MT5)-8T2QOY]O>0!X,GWVP+7[I5^(O_  67_P"3M--_
M[%:S_P#1]S0!]._\$2O$TM[\%?'^@N[-'I^O1W<8;HOGVZJ0/Q@SCW]Z_1VO
MRQ_X(9PSK9_&>9E;[,TFCHC'[I<"]+ >^&3/U%?J=0!Y5_PUC\$/^BR?#_\
M\*BQ_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM?@#_PR=\;_P#HC?Q _P#"7OO_
M (U1_P ,G?&__HC?Q _\)>^_^-4 ?O\ ?\-8_!#_ *+)\/\ _P *BQ_^.UYI
M^TU^TW\'M>_9M^*^F:9\5_ ^HZE>^$M6MK6SM/$=G+-/*]G*J1HBR$LS,0 H
M&22 *_$S_AD[XW_]$;^('_A+WW_QJJFK?LR_&'0=*O-3U/X3^.-.TVRA>YNK
MR[\.7D4,$2*6>1W:,!55026)P "30!;_ &3O^3IO@W_V.>C?^ET-?TIU_-9^
MR=_R=-\&_P#L<]&_]+H:_I3H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$6B+LM W/#7+X4K_ +48DZ_6OER?]L#]L/\ ;,FDL_A'X/G\(>&YF,?V_28
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7PI_P %DO\ DT>R_P"QGL__ $3<5]UU\*?\%DO^
M31[+_L9[/_T3<5$MON(GM]WYGTM^R=_R:S\&_P#L3-&_](8:]5KRK]D[_DUG
MX-_]B9HW_I##7JM66%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%8/C/QYX:^'.BR:QXJU_3?#FEQ\->:I=);Q9QG 9R 3[#
MDT ;U%?!'QK_ ."Q'PF\!?:++P/I^H_$34TR%FA!LK#/O+(N\_\  8R#C[W>
MOGO_ (7#^V_^VY\O@[2;KP!X/N>EWIJ'2K<H>C?;)3YTGOY)QS]WT /TP^+W
M[2GPP^ UJ9O'?C72M EV[ULI9O,NY!ZI;H&D8>X7'(KX3^+7_!9RTNKXZ)\&
M_ %YXAU*9O*M[_7595=^0/+M829) >,9=#[5/\(?^",.D)>#6/B]XZO?$VHR
M-YL^GZ&6BA=\\[[F0&20'V6,^]?=GPE_9Y^&WP+L?LW@3P9I/AS*['N;>#=<
MRKZ/.^9'_P"!,: /S)'P%_;8_;:Q+X^URZ\!^$+KEK'5)#IT'EG^'[#"/,<@
M'CSP/]ZOHOX*?\$?OA!\/?(O/&=UJ'Q&U5,$I=L;.Q#>H@C;<>>SR,#Z5]WT
M4 8OA+P7X?\  .BQ:1X9T/3O#^E1?<LM+M4MX5]PB #/O6U110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#$C6-/^%?Q6ODG\03 0Z)XCE(5KYQTM[CL92/NO_&>#\Y!;]+Z_ECCDO\
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M._Y.F^#?_8YZ-_Z70U_2G0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"JW7&Y,$D99>M?F+KNAZEX4UR^TC5K.?3-6T^=[:ZM+A"DL$J,59&!Y!!!%
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MO_B-=VNUDL;V!+73V<$'<\"EF<9'W&D*D$A@U?>4,*6\211(L<2*%5$& H'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFFQ6TTJ])9\;II![-(SM_P "H ] HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KRK]K'_DUGXR?]B9K/\ Z0S5ZK7E
M7[6/_)K/QD_[$S6?_2&:@#\ ?V3O^3IO@W_V.>C?^ET-?TIU_-9^R=_R=-\&
M_P#L<]&_]+H:_I3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT+_U^Z5_Z,U&OT_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !7\UG[6/_)TWQD_['/6?_2Z:OZ4Z_FL_:Q_Y.F^,G_8YZS_Z734
M?O\ ?LG?\FL_!O\ [$S1O_2&&O5:\J_9._Y-9^#?_8F:-_Z0PUZK0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Y@?\ !%W_ )&K]H7_ *_=*_\ 1FHU^G]?F!_P1=_Y&K]H7_K]
MTK_T9J-?I_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_I=-0!^_P!^R=_R:S\&_P#L3-&_](8:]5KRK]D[_DUGX-_]B9HW_I##7JM
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV4AHY-JA<C(( W*VT8^Y=$_X+AZ!-;K_ &O\*-2M9]OS?8=8CG4M[;HD./\
M/O0!^GE%?G/#_P %M?A@T*&7P%XN24@;E0VK*#W )E&1^ I__#[3X6?]"+XP
M_P"^;7_X]0!^BM%>+_LH_M2:!^UM\.]1\7^'-)U+1[&RU6327@U01^8TB0PR
MEAL9AMQ.HZYR#7M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7\UG[6/_)TWQD_['/6?_2Z:OZ4Z_FL_:Q_Y.F^
M,G_8YZS_ .ETU '[_?LG?\FL_!O_ +$S1O\ TAAKU6O*OV3O^36?@W_V)FC?
M^D,->JT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %4]8UBP\/Z7=:EJE[;Z;IUK&TUQ=W<JQ10H!DL[L
M0% '<FO OVI_VZ?AK^RII\EOK=]_;?BUX]]MX9TUU:Z;(^5I3TA0_P!YN2/N
MJV,5^>MKH_[2G_!53Q EU?S?\(1\)(YR4^5X]-0*W\"9#7LPQ]XG:I!YCSB@
M#V;]IS_@J]+?:R? /[.^ES>*/$=W*;1/$'V1IT,AXQ9V^,S-GH[C;QPK@YK&
M_9U_X)9^(_B9XB_X6/\ M+:W?:IJ=ZZW+>'?MC2W,Q["\N ?E ''E1'@8&Y<
M%:^SOV8_V+_AK^RKHX3POI?VWQ#+'LN_$>I!9+V?CYE5L8BC)_@3 X&=QYKW
MB@#*\+^%=&\$Z!9:'X?TNST71[*/RK:QL85AAB7T55  _P#KUJT44 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7PI_P62_Y-'LO^QGL_\ T3<5]UU\*?\ !9+_ )-'LO\ L9[/
M_P!$W%1+;[B)[?=^9]+?LG?\FL_!O_L3-&_](8:]5KRK]D[_ )-9^#?_ &)F
MC?\ I##7JM66%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ"KU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'Y@?\ !%W_ )&K]H7_ *_=*_\ 1FHU
M^G]?F!_P1=_Y&K]H7_K]TK_T9J-?I_0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 445^6WQ._P""Q?B'X9_''QOX83P)HWB7PSHN
MKW&G6DT%Y+:7$JPN8V9I")%.65B"$ P1P: /U)K^<G]K[PSK%Q^U5\7I8M)O
MI8G\5ZFRNELY5@;F3!! Y%?T"_!OXAGXM?"GPEXU_LU]'7Q!ID&II8R2B5H5
ME0.JEP!NX(YP.M>%^-_^"EWP"^'?C+6_"^N>*+ZVUG1KV:PO(4TBZD5)HG*.
MH94((# \CB@#\$?^$3US_H#:A_X"R?X4?\(GKG_0&U#_ ,!9/\*_IF^%/Q2\
M._&KX?Z3XT\)W<E]X?U19&M;B6%X6<)(\;91P&'S(PY':NMH _EL_P"$3US_
M * VH?\ @+)_A1_PB>N?] ;4/_ 63_"OZDZ* /@C_@C#I]WIO[+OBB*\MIK2
M4^,;I@D\90D?8K$9P1TX/Y5][T44 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?S6?M8_P#)TWQD_P"QSUG_ -+I
MJ_I3K^:S]K'_ ).F^,G_ &.>L_\ I=-0!^_W[)W_ ":S\&_^Q,T;_P!(8:]5
MKRK]D[_DUGX-_P#8F:-_Z0PUZK0 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[_DZ;X-_]CGHW_I=#7]*= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?E!_P %8/\ D[OX%_\
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M_P#@COXC\<:M_P )'\=?B;=ZCJ5P0]Q::1,]W<R=\/>7 //J!&PZX;O7W/\
M!?\ 8]^#_P  5AD\&^!].L]2C _XFUVINKXGN1-*69<^B%1[5[+10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!^8'_!%W_D:OVA?^OW2O_1FHU^G
M]?F!_P $7?\ D:OVA?\ K]TK_P!&:C7Z?T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHK$\7>-O#WP_T675_$^N:=X>TJ+[][JETEO$OMN<@9]J -NBO@[XU
M?\%@_A#\/_/L_!5IJ'Q&U1,A9+539V(8=C-(NX\]TC8''6OG8_'+]MK]MS]W
MX%T2Z\!>#[KA;W3(SIL!C/1OMLQ\V0@=?(/_  &@#]-/BY^T5\-/@38FY\=^
M,]*\/-LWI:3S;[J5?5($S(X_W5-?"GQ<_P""SFEF];1?@_X#O?$VI2MY4&H:
MV&CB=^WEVT1,D@/NT9]J9\)/^",>GRWPUKXQ>/;SQ)J<S^=<6&ALR1R.>3YE
MU*#)("<YPB'WK[L^$?[./PR^ ]F(/ G@O2O#S[-CWD,.^[D7T>X?=(X]F8T
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MZ)816<+RE54R%(U4%BJ(-V,X4#L*Z"BB@ HHHH **** "BBB@ HHHH ****
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M.[T*UCU&;3C:WEW=R.6C5&+95\8/F#\J]F_X=-_&_P#Z+Y_Y'OO_ (NO:_\
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M +Y)?K\P!VU]9T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%?C/_P4J_;^\2>-/B%K?PO\ :S<
M:+X/T69['4KS3YC'+JERA*RJ77!$*ME-H.'*DG(*@ 'ZVZE\6/!&CZD-.O\
MQEX?L=0)"BTN=4@CER3@#87!SGCI736]S#>01SP2I/#(-R21L&5AZ@CJ*_EX
MTKP+XEUW0=0US3?#VJZAHNGY^V:E:V4LMM;8&3YDBJ53@@\D<5[+^R7^V?XY
M_93\8V=SI=_<ZIX0DE_XF7AF>8FVGC)^9HP>(Y1U#J.H ;(R* /Z)Z*Q/!/C
M'2OB%X/T7Q/H5R+S1M8LXKZTG QOBD0,I(['!Y'4'(K;H **** "O*OVL?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:_EO\5>%]9^'OBS4] UNTFTK7M(NWM;JV<C?#-&Q5AD'!P1P0<'@@XK^B?\
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MK!_R=W\"_P#KC;?^G"OU?H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX*@?%/\ 9V_:3\8?#WPWH'@^]T71_L?D3ZI9W4EPWFV<$[;V2Y13AI6 PHX
MZGD@'Z?U^5/_  5T_;'U"RU-O@=X1OFM8/(CG\3W5NQ$DF\!H[/(Z+L*N_\
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MDW+ZC:3D5I4QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?/\ ^WY_R9M\6/\ L#/_ .AI7T!7S_\ M^?\F;?%C_L#
M/_Z&E 'BO_!&W_DT>\_[&:]_]%6]?=5?"O\ P1M_Y-'O/^QFO?\ T5;U]U4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN]/_  K\CUL#_NM+_#'\D%%%%=9VA1110 4444 %%%% !1110 4444 %%%%
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MC!EZJ:]@_9S_ ."E?Q@_9R\,P>&;"?3?%7AJV4)::?X@A>4V:_W89(W1PO\
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M]G_P#J.H_$73=/U_QOXDMA;ZA87")=6EA:[@XM0""LC%E5I&Y7*JJY"[G?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !17SA\1_V[_ /PO\;ZMX6U72/$EQ
MJ&F2B&:2SMK=HF)4-\I:=21@CJ!7-_\ #RSX8_\ 0"\6_P#@':__ "37F2S/
M!PDXRJ*Z/N:' _$F)I0KT<%-QDDT]-4]4]^Q\Y_\$7?^1J_:%_Z_=*_]&:C7
MZ?U^,/\ P3+_ &H/"WP%U_XQ7'B"PUB\37;FPDMAIL,3E!&]X6W[Y4Q_K5QC
M/0_C]U_\/+/AC_T O%O_ (!VO_R35U<PPM&;IU*B31SX'@_/\SP\<7@\)*=.
M5[-6L[-I]>C31]9T5Y]\$OC9H?QZ\(S^(O#]KJ%G90WCV31ZE'&DF]41B0$=
MQC$@[YX/%>@UV4ZD:L%.#NF?,XO"5\!7GA<5!QJ0=FGNF%%%%:'(%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5_+_\5-3N-:^*'C#4+LN;
MJ[UB\N)3(<MO>=V;/ODFOZ@*_G6_;N^#-]\$/VHO'.CW%J\&G:A?RZQI<A'R
MRVMP[2+M/<*Q:,^\9H _<']C#PQHGA/]E/X56>@1Q)8S>';*]>2)0OFSS0K+
M-(?]II'<G/(Z=J_)/_@KQ_R>3J7_ &!K#_T!JV/V)?\ @I_JO[-GA2#P-XRT
M2X\6>#;9G:QFM)@M]8!OF,:ASMDCW9(4E2NXX8@!1XU^W?\ M!>&_P!IOX_7
M/CCPK:ZE9Z3/IUK:B'5H4BG5XU(;(1W7'/&&- '[;?L4_P#)H_PA_P"Q9L?_
M $4M?FK_ ,%KM,T6S^/'@JZM(HXM<O- WWYC4!I(UG=87;U/$BY/9 .PQZ!\
M,O\ @K1X ^"O[-?@KP?I/A?7O$/C#1-"MK%UF6*VL//2,*<R[VD*@CM'SZCK
M7YS_ !P^-7B?]H+XEZOXX\6W2W&K:BX_=P@K#;1*,)#$I)VHHX R2>22222
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MLNR5NN3Z=:^DH_CY\:/@Q(D'CCP\VK6"';]HNH=A/LMQ%E"?J&->J^"/VS/
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MX'?'3QOIW@_PEXMFO/$VHF46FGSZ3=PF7RXGE<[VB"#"1N?F89VX')&34/\
M@GK^SKJ2@3?"G14PV[_1VFA_] D''M5CX:_L%_ SX/?$+2_&_@WP1_8?B737
MF>VNX]5O957S8I(G'ER3,F"DK#[O'&,8H ^@*J:MJUCH.E7FIZG>6^G:;90O
M<W5Y=RK%#!$BEGD=V("JJ@DL3@ $FK=<Y\2/!-K\3/AWXI\(7T\UK8^(-*NM
M)GGM\>9''/"T3,F01N <D9!&10!E:?\ '3X;:L2+'XA>%;PA=Q%OK5M)QZ\/
MTKJ--\1:5K)4:?J=G?%D\P?9KA),KQ\PP3QR.?>OSFU/_@B'X&E\W^SOB5XA
MM00/+^U64$VT]\[=F>_I7,:E_P $-8FWMI_QD=/E^6.Y\-ALM[LMT,#_ ("?
MQH _5"BOR?7_ ((X_$[063^P/C9;0B./:A$%U:E3S\HV2-@=/\*2/_@FK^UM
MX?\ (_L'X]V\(B#;=GBC5K8H3GA=D1ZY/IUH _6&BOR=C_9+_;Z\.^1]C^+E
MUJ.&+?-XNN)MO^]YZ\@^G/2A/ /_  4E\.K']CUFZU+$F_#:IH\V",=?//*\
M=.1[4 ?K%17Y.GX@_P#!23PZI^V:)=:EB7;G^R](F/T_< ?+P>??KTHD_:V_
M;Y\/+-]L^$5UJ.&"Y7PA<3$?[OD-R/?F@#]8J*_)Z7_@I=^UGH)G.N_ 2UMU
MCP#N\,:M;>63_>WS-UR/2AO^"R'Q,T!I?[?^"EK"(D!<&XN;4H3CD[XVP/\
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M=WI4$(?FQ"@RPR"LF*^S_P!D?_@FK\//V:Q9Z]K"1^-_'L>'&K7T(^SV;_\
M3M"<A2/^>C9?N"H.V@#Y)^%_[#_QO_;J\6V_Q&_:!\0ZIX=\-R'?:V$R^7>/
M"W(2VMR-EK&>/F9=QX.UL[J_3_X0?!/P3\!O"4/AOP-X?M-!TQ,&3R%S+<.!
MCS)I#EI'_P!IB3V&!Q7<44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*_(]; _[K2_PQ_)!11176=H4444 %%%% !1110 4444 %%%% !1110 4444
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MZN1XL\?SQ>7)K,T(2*S4CYH[:/G:#T+DEF']T$K7UG7BG_#:WP$_Z*]X/_\
M!M%_C73^%OVC/A5XXN(K;P_\2O".M74NT);6.MVTLQ)Z#RP^X$X/&,\4 >B4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S#^V1^P3X*_:[L;>_
MN;E_#'C6QC\JU\06D"R&2/J(KB,D>:@))'S*RDG!P2#]/44 ?BIJG_!%OXU6
MVJ/!8>(_!=[8EL1W4E[<Q';G&73[.2#CD@%O8FOJ?]D;_@DSX?\ @KXHL/&/
MQ%UBW\:>([!UFLM-M82NG6LP(*RG?\TS*1E<A5!YVD@$?H)10 4444 %%%%
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M*]+HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC@!QTR$ K6H KZ?I]KI.GVUC96\=I96L2P06\*A4BC4!550.     /2K%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%(2%!). * %HKA?%'QR\!>#=XU7Q5IT4J?>@@E\^4?5(]S#\J\A\4?MV>$]
M-WIH>BZEK,B]'F*VT3?0G<WYJ*\?$YQ@,'_&K13[7N_N5V>#B\^RS W6(Q$4
M^U[O[E=_@?3%%?&G_#0WQM^)GR^$/"AT^U?[ES;6+2X^LTO[O]!2_P##-_QG
M^)7S>,O%WV&V?[]K<7KSX^D4?[O_ ,>KRO\ 6#V^F!PTZGG;EC][_P CQ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M N.?]KUKUGPS_P %EO@9K.U-3TSQ=H#_ ,37.GPRQCKT,4S,>W\(ZU]K>(O
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M&I1K9:>)I69II$$6X@L6"1@\[22P &X ^#?^%L>-_P#H<O$'_@TG_P#BZ/\
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MB@ HHHH *_FL_:Q_Y.F^,G_8YZS_ .ETU?TIU_-9^UC_ ,G3?&3_ +'/6?\
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M.#\PZ5])_M;?L$_#W]K.V6_U-9/#GC*"+R[?Q'IT:F1E'W4G0X$R#L"0P[,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5C^)(KB^I8S#_P"[5[KM/7\=SZ7_ %FX:S?3.LK5.3^WAWR/_P  ?NOYLV?
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MVS3332%8H+:%%R2>@554?I0!_-#\:/A'K_P)^)FL^!O% MAKVE&'[4+.4R1
MRPI,H#8&?ED7/&,YQGK7[%_\$J_@[\.V_9A\'^.X/!ND_P#":W$MXEWKDUN)
M;HO'=RHA21\F,;%CX3 R,XS7Y&_M/?%Q/CM\?_'/CN%&CM-8U)Y+19!AQ;(!
M'!N'9O+1,^^:_=#_ ()[?#V[^&?['/PTTB_3R[ZXL'U252N"OVJ:2Y12.Q"2
MHI]Q0!]$T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1:_._P#X(J^")]&^ OC'Q-/"T0US7?)@9AQ)%;PJ-P]M\LJ_537Z(4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_-9^U
MC_R=-\9/^QSUG_TNFK^E.OYK/VL?^3IOC)_V.>L_^ETU '[_ '[)W_)K/P;_
M .Q,T;_TAAKU6O*OV3O^36?@W_V)FC?^D,->JT %%%% !1110 4444 %%%%
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M/_)%#_V$K?\ D]>'GG_(LQ'^%GSG$?\ R)\5_@?Y'IOP=_Y)%X'_ .P'8_\
MI.E=A7'_  =_Y)%X'_[ =C_Z3I785Z.$_P!WI_X5^1ZV!_W6E_AC^2"BBBNL
M[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /E/]MC]@'PK^UQI\6K0W0\,^/[&#R;364CWQW" Y6&Y0<LH).&!W+G^(
M?*?R<^*'_!.']H'X6ZA/#+X!O?$]G&?DO_"X.H1S#U5$'FCZ,BGVK^@^B@#^
M9=OV>?BJC%6^&?C!6!P0= N\C_R'7JGPO_X)T?M _%.^ABMOA]J'ART<C??>
M)E_LZ*('^(I(!(P_W$8^U?T*44 ?)?[%/_!/7PG^R;"VNWETGBOX@W$9CDUF
M2'9%9HPPT5LA)V@\@R'YF''R@E:Y?_@J-^SW\3?VD/ _@3P[\.O#ZZXEKJDU
M[J#/?6]LL&(@D1/FR*6SYDGW02,>XK[<HH _-#]BO_@DW-\-?%VF>.OB]>6&
MI:GITJW.G>&]/<RP13*04DN)" '*D9$:@KD EF'RU^E]%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5?M8_P#)K/QD
M_P"Q,UG_ -(9J]5KRK]K'_DUGXR?]B9K/_I#-0!^ /[)W_)TWP;_ .QST;_T
MNAK^E.OYK/V3O^3IO@W_ -CGHW_I=#7]*= !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'RI^W1XX^.'PS_P"$(\3_  @TVYUC3K'[=_;]
ME#9K>1R*?LY@\R(?O,#;-\T>"O.2,C/G?P3_ ."L'@GQ4\&F?$C2+CP1JN?+
M:_MPUS8%NA+ #S(N>Q5P.["ON^O&?C9^R#\*_C]'-+XH\,0)J\BX&MZ;BVO5
M/J9%&),=A(&'M7Z1E&<</5,%3RW/,%\-[5J3M45VW[R>D[7LK[))),XZE.JI
M.=*7R>QZ=X5\8:%XZT6#5_#NL6.N:7,/W=YI]PLT3>VY21GVZBMBOS!\5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KP+]MG_DBA_["5O_ ">O?:\"_;9_Y(H?^PE;_P G
MKP\\_P"19B/\+/G.(_\ D3XK_ _R/3?@[_R2+P/_ -@.Q_\ 2=*["N/^#O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^'_ /@F
MU_R'OB]_U\V'_H5Y7W!7P_\ \$VO^0]\7O\ KYL/_0KRON"O$R7_ '"G\_\
MTIGZ?XF?\E7B_2G_ .FH!1117MGY@%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=E'>VZS##A'&0#[UU5=46I)-'9&2DE)=0HHHIE!1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6!\0/!]K\0_ ?B3PK?,T=EKFF7.F3LHR1'-$T;$>^&-
M;]4]8OCI>DWMX$\PV\#S!"<;MJDXS^% '\TW]AZI^SW\>K2P\5:<\&I^$]>@
M>]M&7.[R9E<[<XW*R@%3T(8'H:_I4\.^(M-\7:!IVMZ/>1:CI6HVZ75K=P-N
M26)U#*P/H017\_G[87[76A_M;:A8:[/\,K7PEXNM@L,NLV.J--]K@ .(Y8S$
MH8K_  OD$#@Y& ,S]GW]NWXP_LUZ6-'\)^(H[CP\&9UT75X!=6L;$DDQ@D-'
MDDDA& )))!- ']$]%?BI'_P6I^."QJI\,> 7(&"S:=>Y/N<7F*=_P^K^-_\
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MV]P!>6X] ,E7'U+M]*\\_P"%2_M1_L__ #^&-<F\4Z/".+>TN1>1A/06\XW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>)_V5=#_ .$1U71E\8>!_.::"S-P8+FP9R2_DN0RE&8EBC#[Q)!7)S]JZ?\
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ME_\ 5;)_^?/_ )-+_P"2/CO]3,A_Z!__ ":?_P D?(/_  []_P"I\_\ */\
M_;Z/^'?O_4^?^4?_ .WU]?44?ZK9/_SY_P#)I?\ R0?ZF9#_ - __DT__DAD
M,?DPQQYSM4+GZ"GT45]6?:A1110 4444 %%%% !1110 4444 %%%% !1110
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MR);Z-!C\%-5O^'GVE_\ 1/[O_P &B_\ QJI_MK ?\_?P?^1M'PSXMDKK!/\
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MVUANBE_X"Q+PSSRS<I4EZU8_YGWU17P3=?M4?M/W"J(_A++;$'DQ>%M1)/\
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MK7/CSPS;JQP#+K%NH/YO7S-;_P#!,GPFLH,_C'6I(^ZQP0H?S(/\JM_\.S?
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M54 ?#WP]QQS81G^E2V_[.'PKMI1(GP\\-%AVDTR%Q^3*13]EFG_/R/W,2QW
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M^5C>2L,]CCRAD?C5>W_X*(?$"ZD$<'PTMYI#T2/[0Q/X 5]]44_J.-ZXI_\
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M110 4444 %%%% !1110 5_-9^UC_ ,G3?&3_ +'/6?\ TNFK^E.OYK/VL?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Q/QP\
M93?#OX+^/?%-NP6YT30;_482?^>D5N[K^JB@#\XOV\/^"IOB;PC\0M4^'WP=
MNK73ET>9K;4?$S0QW,DMPO#Q0(X9%5#E2Y!)8';@#+?#VI?MT?M :I<F>;XM
M^*$<]K:^:!.I/W4PO?T_E7B*K<:E>  275U/)@ 9=Y'8_F22?QS7WIKO_!(/
MQWX3^ ^O>/-:\6Z?!KVEZ3+JS>&+2S:9F$:>8\33EU <(&X5&&X;03G- 'S?
M_P -K?'O_HKWC#_P;2_XT?\ #:WQ[_Z*]XP_\&TO^-9O[+?P/LOVCOC9H7P]
MO/$Q\)MK"SK!J7V'[8!+'$TH0IYD?W@C '=UQQS7V)\2O^"*?CWPWH-Y?>#_
M !SI7C"]@#.FFW-DVGRSJ.@1C)(N\^C%1_M4 ?#7CCXY_$;XFPF'Q;X\\2>)
M;<G/V?5-5GN(@?9&8J/P%?OY^PK_ ,F?_"3_ +%^W_E7X3_L]^'OA_;_ !XT
MSP]\;+35].\-_:VT[4!:SBUEL;C?L!G#(6\M6!#J-K#KGY=K?T7> _!.B?#?
MP9HWA?PW:"QT'2;5+2RMQ*TNR)1A1O8EF^I))H WZ*** "BBB@ HHHH ****
M "BBB@ HHHH ***_&[XK?\%??C#X;^*/C#2/#UCX1FT#3]8O+33Y)]/G>1[:
M.=TB9F$X!8H%)( !)/ Z4 ?LC17XB_\ #Y?X\?\ 0-\&?^"R?_Y(H_X?+_'C
M_H&^#/\ P63_ /R10!^W5%5-(NGOM)LKF3'F30)(VT<9*@G'YU\4_MX?\%)M
M._9AU%O!/@VQM?$GQ",:R77VIB;32E9=R>:%(9Y&!5A&"N%8,3R P!]PT5_/
M_J?_  5 _:5U+4VO%^(S60W;DM[72+$1(,Y VF$Y'^\23W)KZH_9#_X*]ZGJ
M?BBP\+?&Y+!+&\80Q>+K.(6_V>0X"_:HE^383UD0*%XRI&64 _5BBD5@ZAE(
M92,@CH:6@ HHHH *\J_:Q_Y-9^,G_8F:S_Z0S5ZK7E7[6/\ R:S\9/\ L3-9
M_P#2&:@#\ ?V3O\ DZ;X-_\ 8YZ-_P"ET-?TIU_-9^R=_P G3?!O_L<]&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2V\47&IZK)K3WEG 8H4\R""((A+$NN( V_C._IQD_1E !1110 4444 %%%%
M!1110 4444 %%%% !17R[^T[_P %$/AO^RC\0+/P?XLT?Q/J>J7.FQZFLFAV
MMM+"D;R2QA6,EQ&0^8F.,8PR\\X'D7_#ZOX(?]"M\0/_  76/_R90!]_T5\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT]NC29'JWRN?=R>]?K3_ ,$\?B->?%#]COX<ZMJ,S3ZC;6DFESR.Q9F^S3/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI.C:?H-FMIIEC;:=:KT@M(5B0=ONJ *X*V1NM2HTIU-(76V]_P C[/!>)_\
M9.,S#,*&$O+%2BTG+2/+&VME>6_2Q\O_ +(_[&J?!^:+Q9XN\F\\7LA%O:QD
M/%IP88.&Z-*1P6' !(&<YKZLHHKW\-A:6$IJE25D?CF>9YCN(<;+'YA/FF_N
M2Z)+HE_P7=ML****ZCP0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N"^(GQZ^'?PE(3QAXST;0+@X(M;J[
M47# C.1$"7(]P,<CUKX=_;Z_X*$:AX7UK4?AI\+M0^R7]J3!K'B*W;]Y!*#A
MK>W/\++T:3J#E1@@FOSDT+PUXI^*/B22VT?3-6\5Z[=,99$M(9+NXD)/S.V
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M.*E'9A1117"4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5BA4K_>9)RC#W !]LU^GO_#R']FW_HJ6G_\ @%=__&:/^'D/[-O_ $5+3_\
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MOV:_@'?+_P $Y=&^%^J!K74-<\*7T3B4 -;OJ'GS*"".&0W Z]"M?@E)'?\
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M>/-$****^0.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M> H)90?K2P_X(=Z])X?$U[\6M.M];V9-G;Z))+;;\=//,RMC.>?*_"KW@/\
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MAX@T6Z_L[R-1TO0;JYMYMNG6J-LD2,JV&5E.#P5(ZBOV_HH _FL_X9.^-_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  KUCPWX:TKP=H-CHFAZ?;Z5I%C$(+6RM(Q'%#&.BJHX 'I0!IT444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN/@I;3-$_P 5/"193@F/5X77\"K$'\*AE_;"^",,;R-\4_"Y506(74HV/'H
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MA_\ ?M__ (JK=G^QK\#K&,QQ_"[PTRD[OWUBLI_-LG'M1]<X!2TPN)?_ &_
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M'_M:I[7_ ((W^'UF!N/B;J4L7=8M*C1OS,A_E7Z*T5@_$SBUZ?77_P" 4_\
MY ?U.A_+^9^>_P#PYU\'?]%"US_P#AJY9_\ !'KX?QQD77CGQ+-)GAH8[>,8
M],%&YZ]Z^_**QEXC<5R5GCI?='_Y$?U.A_*?!7_#GWX:_P#0Z>*OSMO_ (U6
MDO\ P2$^#VT;O$OC@G')%]9C_P!M*^XZ*PEX@\4RWQT_P_R']4H?RGQ%:_\
M!(OX-6\P>37?&ERH_P"6<NH6H4_]\VP/ZU>_X=-_!+_GZ\5?^#*+_P",U]GT
M5C+CSB>3N\?4^\?U6C_*CX[L_P#@E3\#+:,K)#XBNV)SOFU3!'M\J*,?AWJ?
M_AUC\"/^@?KG_@U?_"OKVBL7QMQ*W?\ M"K_ .!L?U:C_(CY47_@F-^S^J@'
MPO?L<=3K%US_ ./U-:_\$S?V>[>8/)X.NKE1_P LY=9O I_[YE!_6OJ6BL'Q
MAQ&]/[0K?^#)?YC^KT?Y%]Q\T?\ #MW]G3_HG?\ Y6]1_P#DBKEG_P $\_V>
MK&,QQ_#BV92=V9M1O93^;3$XXZ5]%T5C+BKB"2L\PK/_ +BS_P#DA^PI?R+[
MD?/?_#O_ /9^_P"B;6/_ (%W7_QVM)?V'O@0J@#X8Z'@#'*.?_9J]RHK&7$F
M=R^+'57_ -Q)_P"8_8T_Y5]QXG:_L4_ NSF$J?"_P^S#M+;&1?\ OEB15W_A
MD'X)?]$L\*_^"N+_  KU^BL)9]FTG>6+J/\ [?E_F/V5/^5?<>66?[*OP9L8
MS''\*/!C*3NS-H-M*?S9"<<=*G_X9C^#O_1)O __ (3=G_\ &Z],HK%YOF+=
MWB9_^!R_S'[.'9'"K\"/AHJA5^'GA0 #  T2VX_\<J>U^"OP\L9A-;^ _#-O
M*.DD6CVZL/Q"5V=%8/,,8]'6E_X$_P#,?+'L<S_PK'P=_P!"GH?_ (+8?_B:
MN6?@GP[I\9CM= TNVC)W%(;.- 3ZX"]>!6U16,L57DK2J-_-E<J[&9_PB^C?
M] FQ_P# 9/\ "M)5"J%4  #  [4M%8RG*7Q.XPHHHJ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KE/BM\/;+XL?#7Q+X/U$[+36K"6S:7;N,3,I"R
M>JMM8>ZBNKHK:C6J8>K&M2=I1::?9K5,32:LS^<WQ=X5\1_!?XC7VB:DDVC^
M)?#]]M+1DJT<L;!DEC;N#A75AU!!'6OUB_9?_P""E/@/XF>&[+3?B'JMIX+\
M90HL=Q-?'RK"\(P#*DI^6//4HY&,\%AT[K]L#]B/PW^U'IJ:E#,GA_QS9Q>5
M::PJ%DF0$D0SJ/O)DG##YESQD94_E3\5/V+?C)\(;V:/5_!&HZA91L0NIZ+$
MU[:NH_BW1@E!_OA3[5_8$,PX9\4<NI4,RJ*CBX>:C)/KRWTE&5KVW7EN_G^2
MM@IMP5XL^VOV(/C)X'^$<WQ7U/QCXITOP]9W$]FUNUY< /<!6NRWE(,M(0&7
M(0'[P]:^>_V\OVYA^TA<6_A+PE%/9^ ]/N!<&:X79-J4X!"R,O5(URVU3R2=
MS8. OA_B;P1XB\;2:1:>'= U37KI0RM#IEG)<."P7 (121G!Q]#7T-^SO_P2
MZ\?_ !"U*TU'XAHW@?PRKAI;9V5M1N%[JD8R(L\C=)R/[AK\]\*\JX8X?X?P
MW$^;8A>V_><L6UHXU)QO&"]Z4FE?K:][=3]6\5:E:KQ=C*%-:6I?^F:9J_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MYO\ M&_\D/\ &/\ UXM_Z$*](KS?]HW_ )(?XQ_Z\6_]"%>?F/\ N5;_  R_
M)GEYK_R+\1_@E_Z2SA?V'_\ DC,W_85G_P#0(Z^@J^??V'_^2,S?]A6?_P!
MCKZ"KBR+_D68?_"CSN&_^1/A?\*"BBBO=/I0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^5?_  5<_9SO
MM%\;V_Q;T>S>;1M6CBM-9>,9%M=(!'%(WHLB!%STW)R<N ?&OV*OVW-3_9:U
M2[TK4[.;7/ NI2^==6$+ 3VLV /.@W$*20 &4D!MJ\@CG]I_$?AS2_%V@WVB
MZU80:II-]$T%S9W2!XY488*D&OS)_:&_X)-ZY8:G=:M\(]0AU73)7+CP_JDX
MAN+?/.V*9CMD7L-Y4@8R6.37]/<'\9Y+F^3+AGBBRC%<L92TBXKX;R^S*/1Z
M*R6M]_%Q&'J4ZGMJ!]?^'_\ @H+\ O$&E"^7X@VMAA=SVVH6T\,R'&=NTI\Q
M_P!TD5\Z?M3?\%3- @\.7WA[X/27&HZQ=(T+>))X&A@M5(P6@1P'>3T+*%'!
M^;I7YW?$#X)^.?A7XDL= \5^&;[1=7O@#:VLR@M/E]@V%20V6&.#7O?PI_X)
MF_&CXB7T!UC2(? ^DLV)+W695,H7OM@0ER?0-M!]:^EI\!<#Y!.&:8W%\]+>
M*G.#C*W912<[=E?LTS%XK$U?<C'7^ON/"O@K\(]?^/?Q0T?PAH<4D][J,X-Q
M<[2RVT.X>;/(?[J@D^YP!DD"OZ!/!/A'3_ '@_1/#.DQF+3-'LH;&V5L;O+C
M0(I)'4D#)/<DUYE^S+^RCX-_9>\+O8>'XFO]:NU']HZ[=(/M%T1R%&/N1@]$
M''<ECS7M%?C?B+QM'BS%PI81-8>E?EOHY-[R:Z=HK=+?>R]#"8;V$;RW8444
M5^0'H!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M./!>G>#O"]Y8:#J]QI\%Q="Y\V1(W*AFVR@9('8"@#]5:_G5_;J^".H? ?\
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M<FJ7B0>8?1 QRY]E!- 'Y@?\..=<_P"BMZ?_ .".3_X_1_PXYUS_ **WI_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$WAW6+GQ1<7T5K/+'(6@:TM$5\QLPP6C<=<_+7V1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_-9^UC_ ,G3
M?&3_ +'/6?\ TNFK^E.OYK/VL?\ DZ;XR?\ 8YZS_P"ETU '[_?LG?\ )K/P
M;_[$S1O_ $AAKU6O*OV3O^36?@W_ -B9HW_I##7JM !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _,C_@IQ_R=-\&/^N-O_Z75^F]?F1_P4X_Y.F^#'_7&W_]
M+J_3>OUCBO\ Y)S(O^O=7_TM'#0_C5?5?D%%%%?DYW!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*OVL?\ DUGXR?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?B[_P %8OV0KWX;_$JZ^+7AO3BW
M@[Q+*'U3[.ORV&HM]]F Z),?G#?\]&<'&5S\-> ?B%XD^%OBJR\2>$M:O- U
MRS;=#>V4A1QZJ>S*>A5@01P017].7BCPMI'C;P]J&@Z_IMMK&C:A$8+JQO(Q
M)%,AZAE/^00#7Y2_M0?\$<=;L-4O]=^"E]!J6E.3*OA?5+CR[F$]T@G;Y9%]
M!(5('5F/) .<^&O_  6J^(_AVQAMO&?@O1?&+QC!N[2=]-GE]WPLD>?]U%'M
M7J,?_!<;13&I?X17ZOCY@NNH0#['R!FOS9\??L]_$WX6RNGBSP#XBT%%.//O
M--E6%O\ =EV[&'N":\^H _2GQQ_P6Z\::I921>$OAMHOAZX9=HGU34)=1*>X
M54A&>N,Y'3@U\*_&CX]>._VA/%A\1>//$%SKM^H*0))A(+9#_!#$H"QKP,[1
MR>3D\UB>#?AGXO\ B)=K:^%?"VM>)+AC@1Z3I\MRWY(IK[3_ &<_^"1'Q,^)
M%Y9ZG\1I$^'OAO>&DM9&674YTSR$C&5BSR,R'(Z["* /&_V$/V2]4_:H^,EA
M:SV<@\#:/-'=>(+XY5/)!R+=6_YZ2XVC'(&YOX>?Z$+6UAL;:*WMXD@MX4$<
M<4:A510,!0!T ':N.^#_ ,&?"'P&\#V?A+P3H\.C:-;_ #E4RTD\A #2RN>7
M<X&6/H ,  #MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O*OVL?^36?C)_V)FL_P#I#-7JM>5?M8_\FL_&3_L3
M-9_](9J /P!_9._Y.F^#?_8YZ-_Z70U_2G7\UG[)W_)TWP;_ .QST;_TNAK^
ME.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#VD+_]G']HK0+Q[V2'PKKL\>E:[:[R(FAD;:DS+TW0LV\-C.W>HX<Y_?\
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MQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\
MCM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM '
MJM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>
M5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\
M#6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P
M0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+
M)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_
M /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ
M+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X
M[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_P
MUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$
M/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR
M?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__
M ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*B
MQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\
MCM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM '
MJM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>
M5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\
M#6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P
M0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+
M)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_
M /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ
M+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X
M[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_P
MUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$
M/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR
M?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__
M ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*B
MQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\
MCM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM '
MJM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>
M5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\
M#6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P
M0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+
M)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_
M /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ
M+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X
M[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_P
MUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$
M/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR
M?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__
M ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*B
MQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\
MCM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM '
MJM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>
M5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\
M#6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P
M0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+
M)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_
M /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ
M+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X
M[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_P
MUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$
M/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR
M?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__
M ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*B
MQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\
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M-/:O)_\ @B_XZN-#_:/\1>&3)BQU[09)&CSC,]O*C1M^"/./^!4 ?M-1110
M4444 %?S6?M8_P#)TWQD_P"QSUG_ -+IJ_I3K^:S]K'_ ).F^,G_ &.>L_\
MI=-0!^_W[)W_ ":S\&_^Q,T;_P!(8:]5KRK]D[_DUGX-_P#8F:-_Z0PUZK0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&9AQZ&<J?<$4 ?27_!#.&=;/XSS,K?9FDT=$8_=+@7I8#WPR9^HK]3J_._\
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MU1_PR=\;_P#HC?Q _P#"7OO_ (U7]*=% '\UG_#)WQO_ .B-_$#_ ,)>^_\
MC5'_  R=\;_^B-_$#_PE[[_XU7]*=% '\UG_  R=\;_^B-_$#_PE[[_XU1_P
MR=\;_P#HC?Q _P#"7OO_ (U7]*=% '\UG_#)WQO_ .B-_$#_ ,)>^_\ C5<_
MXV^"/Q%^&NE1:GXN\ >*/"NFS3"VCO-;T:YLX7E*LPC#R(H+%4<[<YPI/8U_
M3G7P!_P6K_Y-9\+?]CG:_P#I#?4 ? '_  2X_P"3[/AE_P!Q/_TUW=?O]7X
M_P#!+C_D^SX9?]Q/_P!-=W7[_4 ?@#_P5'_Y/L^)O_<,_P#37:5X5X)^"/Q%
M^)6E2ZGX1\ >*/%6FPS&VDO-$T:YO(4E"JQC+QHP#!70[<YPP/<5[K_P5'_Y
M/L^)O_<,_P#37:5]_P#_  14_P"36?%/_8YW7_I#8T ?E7_PR=\;_P#HC?Q
M_P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\
M)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"
M7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_
M^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_
M (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?
M\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1
M_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?
M&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,
MG?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\
MZ(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&_
M_HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\
M0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?
MQ _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\
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M?_T1OX@?^$O??_&J/^&3OC?_ -$;^('_ (2]]_\ &J_I3HH _FL_X9.^-_\
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MOX@?^$O??_&J_I3HH _FL_X9.^-__1&_B!_X2]]_\:H_X9.^-_\ T1OX@?\
MA+WW_P :K^E.B@#^:S_AD[XW_P#1&_B!_P"$O??_ !JC_AD[XW_]$;^('_A+
MWW_QJOZ4Z* /YK/^&3OC?_T1OX@?^$O??_&J/^&3OC?_ -$;^('_ (2]]_\
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ML6>1W8DLS,22Q.222:_?3_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\
MY7]4_P#DF@#\2])_:;^,.@Z59Z9IGQ7\<:=IME"EM:V=IXCO(H8(D4*D:(L@
M"JJ@ *!@  "K?_#6/QO_ .BR?$#_ ,*B^_\ CM?M3_PZX_9B_P"B9_\ E?U3
M_P"2:/\ AUQ^S%_T3/\ \K^J?_)- 'XK?\-8_&__ *+)\0/_  J+[_X[1_PU
MC\;_ /HLGQ _\*B^_P#CM?M3_P .N/V8O^B9_P#E?U3_ .2:/^'7'[,7_1,_
M_*_JG_R30!^*W_#6/QO_ .BR?$#_ ,*B^_\ CM'_  UC\;_^BR?$#_PJ+[_X
M[7[4_P##KC]F+_HF?_E?U3_Y)H_X=<?LQ?\ 1,__ "OZI_\ )- 'XK?\-8_&
M_P#Z+)\0/_"HOO\ X[1_PUC\;_\ HLGQ _\ "HOO_CM?M3_PZX_9B_Z)G_Y7
M]4_^2:/^'7'[,7_1,_\ ROZI_P#)- 'XK?\ #6/QO_Z+)\0/_"HOO_CM'_#6
M/QO_ .BR?$#_ ,*B^_\ CM?M3_PZX_9B_P"B9_\ E?U3_P"2:/\ AUQ^S%_T
M3/\ \K^J?_)- 'XK?\-8_&__ *+)\0/_  J+[_X[1_PUC\;_ /HLGQ _\*B^
M_P#CM?M3_P .N/V8O^B9_P#E?U3_ .2:/^'7'[,7_1,__*_JG_R30!^*W_#6
M/QO_ .BR?$#_ ,*B^_\ CM'_  UC\;_^BR?$#_PJ+[_X[7[4_P##KC]F+_HF
M?_E?U3_Y)H_X=<?LQ?\ 1,__ "OZI_\ )- 'XK?\-8_&_P#Z+)\0/_"HOO\
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M-_\ T63X@?\ A47W_P =H_X:Q^-__19/B!_X5%]_\=K]J?\ AUQ^S%_T3/\
M\K^J?_)-'_#KC]F+_HF?_E?U3_Y)H _%;_AK'XW_ /19/B!_X5%]_P#':/\
MAK'XW_\ 19/B!_X5%]_\=K]J?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
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M-_\ T63X@?\ A47W_P =H_X:Q^-__19/B!_X5%]_\=K]J?\ AUQ^S%_T3/\
M\K^J?_)-'_#KC]F+_HF?_E?U3_Y)H _%;_AK'XW_ /19/B!_X5%]_P#':/\
MAK'XW_\ 19/B!_X5%]_\=K]J?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
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M -%D^('_ (5%]_\ ':_:G_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\
MY7]4_P#DF@#\5O\ AK'XW_\ 19/B!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\
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M?_':/^&L?C?_ -%D^('_ (5%]_\ ':_:G_AUQ^S%_P!$S_\ *_JG_P DT?\
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MD_8_*_U\K[<>;)]W&=W.<# !\J_\-8_&_P#Z+)\0/_"HOO\ X[1_PUC\;_\
MHLGQ _\ "HOO_CM?57_!*7]EOX8?M*?\+1_X6/X9_P"$C_L7^R_L'^GW5KY/
MG?;/-_U$J;L^5'][.-O&,G/W_P#\.N/V8O\ HF?_ )7]4_\ DF@#\5O^&L?C
M?_T63X@?^%1??_':/^&L?C?_ -%D^('_ (5%]_\ ':_:G_AUQ^S%_P!$S_\
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M )7]4_\ DF@#\5O^&L?C?_T63X@?^%1??_':/^&L?C?_ -%D^('_ (5%]_\
M':_:G_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DF@#\5O\
MAK'XW_\ 19/B!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\ QVOVI_X=<?LQ?]$S
M_P#*_JG_ ,DT?\.N/V8O^B9_^5_5/_DF@#\5O^&L?C?_ -%D^('_ (5%]_\
M':/^&L?C?_T63X@?^%1??_':_:G_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)
MG_Y7]4_^2: /Q6_X:Q^-_P#T63X@?^%1??\ QVC_ (:Q^-__ $63X@?^%1??
M_':_:G_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DF@#\5O^&L?C
M?_T63X@?^%1??_':/^&L?C?_ -%D^('_ (5%]_\ ':_:G_AUQ^S%_P!$S_\
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M9/\ @H'\;OCMX!3P;XI\4QMH;HJWL5A916S7Y4@@S,BC/*YVKM4GJIP,=O\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E7_P7._YHG_W&_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]]455TW5+/6M/M[_ $^[@O[&X020W-M(LD4J'D,K*2"#ZBK5 !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7Y5_\ !<[_ )HG_P!QO_VPK]5*Y3QU\)_!'Q0^P_\
M"9>#?#_BW[#O^R?V[I<%[]GW[=_E^:C;=VQ,XQG:N>@H _('_@BI_P G3>*?
M^Q,NO_2ZQK]J:XKP3\$?AU\-=5EU/PCX \+^%=2FA-M)>:)HUM9S/$65C&7C
M125+(AVYQE0>PKM: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI.KV,IANK&\U:&.6%QU5E+9!'H:]+TW4K76=-M=0L;B.[LKJ))X+B%@R2QL
MRLI'4$$$'WH LT454U75K'0M/FOM2O;?3[*$;I;FZE6*-!ZLS$ ?C0!;HKR
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MC/ !H NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\_P#_
M ,%#OVD=<_:*_:,UW38KF:3PMX;OYM'T338F+(3&_ER3A1]YY74MG&=NQ>U?
MT 5_./-KUS^S;^V5=:QK.D?VG<>$?&$MS/83';YXBNF;Y6(."0 RM@CE3S0!
MO>%?^"=/[1OC&QBN]/\ A9JD,,B;U_M*YMK!\<=4N)48'GH1FLOXA?L(?'SX
M6Z/=ZKXB^&>K0:;9H9;BZL7AODA0#<SL;=WPH')8\#!ST-?K;X9_X*P?LWZ[
MI<5U?>+M0\.7#*"UEJ6B7;RH3U!,$<J<>S5F?$/_ (*X?L_>%]!NKC0-8U+Q
MMJ(B)@L+'2[BV61\'"O)<)&%7.,D!L \ GB@#X>_X))_M*:Q\//CM9_#.]OI
M9O"'B[S(X[21\QVM^L9>.5 >A<(8R!]XLA/W17[:U_//^P/HM[XZ_;:^&QLK
M81,NLMJDJ6ZD1PQ1*\SCV7"[1]0.]?T,4 >+?M"?L>_"S]IK3W3QGX;A;5MF
MR'7M/Q;ZA!CIB4#YP.RR!EYZ5^5_[2/_  20^)OPI^U:OX!D_P"%D>'$R_D6
ML?EZI"OH8,D2XX&8B6/78*_;FB@#\;O^"-WBKQ7I?[1?B3P1>ZGJEKH<6@75
MU+H%S*ZPQ727-LN\PMPD@#N"< \\U^R-<\/A[X97QN/&*Z#I\?BK[(UBVL1V
MZK=/;LR,8FD RRY1" <XQQCFNAH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^"'G_(E?%?\ ["%A_P"BYJY/_@N/_P C%\(/^O75/_0[:NL_X(>?\B5\5_\
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M ,?:#\4?!>C^+/#&HQZKH&K6ZW5I=Q@@.A[$'!5@05*D J000""* .@HHHH
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MJOH-UJ3@=W)[U^E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXP$S'NQ@G+MSSQZW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB,,^/XO*CA'/8+0!^G7[#'[4:_M8? NS\3WD$-GXFT^=M-UJUM\B,7"*K"1
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M(>#-0!TRSD#>*+N'GSYU*M'9JV?NH0&DQU?:N1L8'YN_X)<?\GV?#+_N)_\
MIKNZ\)T_X:^*O%_@/Q7\13#)/H6C74$6H:I=NQ,US<.0J*Q!WR=7;G@8).67
M/NW_  2X_P"3[/AE_P!Q/_TUW= '[_4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/%7P@_99U7Q)X-UJXT#7(=1LXDO;7;O5'DPPY!'(]J^IJ^,?^"N/_)F.M_\
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MT*]Y.N<>80Q CC!!R[$9P0H8C%?!M]_P7$UUM2+6?PGT^.PW<1SZU(TI7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#2ZQK]J: /%_VL?VHO#O[)WPIN?%VN0OJ5[-)]DTK2(7"27UR5)";B#L0
M%F?!V@<!F*J?QL^)_P#P4\_:"^(^JW,UOXR;PCIKL3%IOA^!+=8ESP/-(,K'
M&.2_;H*]]_X+>ZG?2_%+X::?)N_LVWT:YN(?E.WS9)PLF#Z[8HOT]:V/^",O
MP)\&^+K;QMX_U[2+76M=TN[ATW3A?1++'9JT>]Y$5LCS&RJ[L9 4@$;FR ?)
M_@W_ (*,?M$>"M0BNH/B7J6JQJ^][764CO8I!QE3YBE@#C^$@CG!%?K3^P=^
MW5I?[7WA>\LM1LX-"^(&CQ+)J.FP,3#<1$A?M-ON);9N."I)*%E!)W GS_\
MX*Q? GP3J_[+NO>//[#L;+Q7X=GLGM=2M8$BFECENHH'A=@ 73;*6 .<%>,9
M.?ST_P""6FMZAI/[;W@&"Q=A'J$=_:7<2D 2P_8II"#[!HT?ZH* /WXHHHH
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MB%\/[R9Y;;2+JWU:P5W+;%G#I,B@_=4-#&V!QF1SU)S@_P##C'_JMG_EJ?\
MW;7T?^Q'_P $]Y/V-_&GB'71\0V\71:QIZV36?\ 8YL5C*R!Q(3]HDW$8(Q@
M?>/- 'V+1110 4444 %%%% 'F?[3VH2Z3^S7\6;Z#:9K;PEJTR;AD;ELY2,^
MV17\T=?T]?&#0#XK^$OC;1%C64ZEH=]9B-U#*WF6[I@@\$'=TK^86@#^I?PW
M_P B[I?_ %ZQ?^@"OR"_X+;?\ER\ ?\ 8N-_Z4RU^N7@74X=:\$>'M0MFW6]
MWIUO<1MD'*O$K \>QK\??^"UNLPW7[1G@_38^9;/PO')(P/0R75QA?KA ?\
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MP Y3S .P<5^._P 4/V4_VNOC3XD37_&_@?Q)XBUA+=;5;R[,&\1*694^5@,
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M4K*5EM]2U.'1+Z(?=EMKIUA8,.^TLD@'K&M ']%%%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M59QB*VL;"!8(($'141 %4>P% 'Y_?\%LO^3>?!'_ &-*?^DEQ7S-_P $5/\
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MP9UWX>R:]/X<MM7:#S[ZV@$SA(YDEVA2R\,8P#STS7PO_P .//#G_15]4_\
M!/'_ /': /B#]FW]O'QY^RKX3OM"\#Z%X5"7]S]JO+_4;&::ZN&QA0SB91M4
M<*H  RQZLQ/KW_#Y?X\?] WP9_X+)_\ Y(KZ!_X<>>'/^BKZI_X)X_\ X[1_
MPX\\.?\ 15]4_P#!/'_\=H ]<_X)I_MF>//VN/\ A8W_  FUMHMO_P (_P#V
M;]D_LBUDASY_VK?OW2/G_4)C&._6OMVOF+]BO]AW3?V,_P#A,O[/\5W7B?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OC'_@KC_R9CK?_ &%=/_\
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M*S_;G^&,DSB-&?4(P3_>;3KI5'XLP'XU^EG[/O\ P2F^%GP=T?56\0S3>/\
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M3P.Y))))Y))))))H _!O_@J/_P GV?$W_N&?^FNTK]5/^"7'_)B?PR_[B?\
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MR!G:   "6 /L2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4D<@]".037CGQ&_X*8?!+X4^.M;\(>);_7+#7='N6M;N#^R)6 8=U8<,I!#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **S-8\4:-X>:)=5U:
MQTQI03&+RY2(OCKC<1G&1^=9W_"RO"'_ $-6B?\ @QA_^*H Z2BN;_X65X0_
MZ&K1/_!C#_\ %4?\+*\(?]#5HG_@QA_^*H Z2BN;_P"%E>$/^AJT3_P8P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB_XL^%?@A=Q_!GPW?:[XPU*<6ANK *TFFVY5FDG1#]]^ B@#@ON_A /Y,?\
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M'J8Y8U=<^^&%?BY_P5@^/VJ>+/VIKOPWHVKWEII7A&QBTTI:SF-'NG'G3O\
M*<DCS$C.>\/'J?K'_@E_^TYIUI^Q=XKC\0W.?^%7BZN)P9-TAL&22YB/KG<)
MXU'/$:@>@_.C]F+X?ZC^US^V'H=KK2+=_P!N:W+KNOOY9,;0B1KFY!ZX#\Q@
MG/,B]: /V;_8!^$]_P#"/]EGP=9:U)/-X@U:$ZUJ+718R+)<8=(VW<@I%Y49
M![H>G2OHJJFIW)TW2;NXB1<V\#NJXX^520/IQ7X^?\/MOB9_T('A/_OJY_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .2^+?@6+XG_"SQ?X0F;9'KVD76F[_[AEB9 WX%@?PK\.?^":?B
M>X^%O[<7A+3M40V#WTEYH%Y#, K)*\3A(SGHWGI&N*_?.OQ*_P""F?P9U/\
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M7YN_\%MO'D>F_!_X?^#UE=;G5]:DU)E0D!HK:$H0WMNND(![K[<?I%7XB_\
M!1#Q9JW[6G[<5E\./!8&J'1VC\,V,<;9B:[+%[J5B =H1B4<]EMR>U 'US_P
M1C^&TGAC]G/7O%MQ$$F\4:R_D,!]^VME\I23_P!=3<#\/<U^@-<E\)?AOIOP
M?^&7ACP5HX)T_0["*QC=AAI"B@-(W^T[;F/NQKK: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\L_\
M@M-X)\1>+M?^$[:%H.IZTL%KJ0E.GV<DXCR]MC=L4XS@XSZ&OS4_X4S\0?\
MH1?$O_@HN/\ XBOZ=Z* /Y9=:T+4O#>H/8:MI]UI=]& 7MKV!H95!&02K $9
M!S5GP]X/U_Q<TZZ%HFI:TT !E73[22<Q@YP6V XS@]?0U]7?\%9O^3UO$_\
MV#]/_P#29*]^_P""''_(Q?%__KUTO_T.YH _.W_A3/Q!_P"A%\2_^"BX_P#B
M*_8K_@CGX9UCPI^S+XFM-;TF^T>[?Q?=2K!J%L\#LALK(!@K@$C*D9]CZ5]V
MT4 ?S;?%[X0^/+OXL^-IX/!/B*:"76[UXY(]*G974SN000G(([U^U?\ P30T
M74/#W[$OPXT_5;"YTR_A_M+S+6\A:*5,ZE=,-RL 1D$'GL17/:]_P56_9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y_?\%H/!4^
MN_LV^'O$%O'O_L+Q!$;@X^Y#-%)&6S_UT\H?\"KE/^"(?BJ"Z^&/Q+\-!O\
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M'- 'CO\ P2'_ &5=0^%_@?5?BEXGL&L=:\4P);:5;SIMEATX,',A!&5\YPC
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M:KJ>KV%[JDFK//JK1F59'AAB*CRT4;<0*>F<D\T >S5^./\ P6T\61ZA\;O
M7AQ"S-IF@/>N=P*@W%PZ[<=CBW!/LRU^QU?@C^TE+J'[:/\ P4,U;0/#LS7$
M.I:W%X?L957<L-K;*(I9P.Z 1S3GV)^E 'ZG_P#!-+P3-X'_ &+?AW!<ILN=
M1@GU9^.JW$\DD1_[]&.OI^L[PWX?L?"?AW2]#TR$6^FZ;:Q65K".D<4:!$7\
M%4"M&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;;VC&9YB44%ERR(.V5D[CC\>/VA/C!K7[3OQY\0>,)H9Y+K7+X1:=IX^9H8
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M[3VK:9JGCS2+N\U+3H#:V]S:7TMNRQ%BQ4A3@\DGD9KW*B@#Y\^#'[!/P/\
M@/KT&O>%_!<+:_ =T.J:I<2WDT)YPT8D8K&W)^9%!YZU]!T44 %%%% !1110
M 4444 -D4R1LH9D+ C<O4>XKY_\ @G^PK\)?@#\0+GQMX8TJ_E\3SPRPG4-5
MU"2[=?,8&1UWGAVQ@OUP6&<,<_05% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X.?\
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ML_P_^"7P1\%^!7^'VNS3Z%IL5I/-:30+%-,!F6103GYG+-S_ 'J /+OVS/\
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MZD\VYN)6FED( W.Q)8X''))K^D;]D6U2T_94^#J1@A3X/TF0Y.>6LXF/ZDT
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M/C&X3[!IHTR9YH;2U.UI'W.B_O'8!>!\JH<'YV ^[J* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *^,?^"N/_ "9CK?\ V%=/_P#1U?9U?&/_  5Q_P"3,=;_ .PKI_\ Z.H
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MO&?!'CSQ1\)_%EMKWA?6+_PWK]C)\EU9R-%(I# E&'\2DC#(P(/0@CBOZA
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M/VI/@O='Q-<17'C?PU<+9:I-&BI]IC=2T%R47A2X5U.  6B8@ ' ^M:_(_\
MX(>WTL?C?XK68/[F73K"5A_M)+,%_1VK]<* /P__ ."Q'P]7PG^U9#K\%OY=
MOXGT6VO9)1T>XB+6[CZA(H2?][ZU]1_\$5?BM+X@^$/C/P%=2M(_AS4H[ZT#
M?PV]TK91?82PR-]9?I7$_P#!<?0?W?P@UI H(.J6<I[G/V5TQQTXD[]Q7E7_
M  1;\23:;^TQXETCS,6NI>&)F:/=C,D5Q;E#CN0K2?\ ?1H _:BBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3H_Y,I^%?_8/E_\ 2F:O5?CQ_P D-^(G_8N:C_Z325Y5_P $Z/\ DRGX5_\
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M4 %%%% !1110 5\8_P#!7'_DS'6_^PKI_P#Z.K[.KXQ_X*X_\F8ZW_V%=/\
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MH?LO_'#2OB!<?$.V\0Q65O<P&PCTEK=G\V)DSO,S8QG/2OOZB@ K\ZOVG/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!*X()^<%_P""X'A3[9M/PMUD6N_'F#5(M^W/7;LQG';=^- 'Z9T5\P?LS_\
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M_:,^)U]\&/@;XU\<:;:6]_?Z%ITE[#;76[RI&7'#;2#CGL:]'KCOC!\,M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S%_P4L\67
M'@_]BGXDW%J66>\M[?30R_W)[F**3/L8V<?C7YA?\$CO#,7B#]LS1KR6/S#H
MNDW]^G. K&/[/G&>>+@^O4'MD?HO_P %9-.DOOV)_%4R9VV=_IT[X7/!NHX^
M?3F0<_AWKX$_X(V3QP_M;WJNP5I?#%XB _Q'SK=L?D"?PH _;ZOP!_X*C_\
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MJ:26Y\2Z_P#9["9H2<1PQ)+(Q1< $JK'<Q)YX ^?O^"K?[;WC'X>^,+;X2>
M-7N/#;+91WFMZM8N8[IS+DQV\<@YC4* [,N&.Y1D ,&^2_V9/^">_P 5/VO=
M)E\9V^I6&C>'9KIXGUK79Y9)KN13B1HD56:3#<%F*C.0"2"* /5_^"I?QE_9
M_P#B_;^&I?AE=Z?JGC;3[R2/4-0TK3G@BEM60G:\Q15F(<*5(W ;GP1DBNP_
MX(>WDR>.OBK:JY$$FFV,CIV+++*%/X!V_.O'?VV/^">^F_L=_"7PYK[^-I_%
M.O:KJ_V%XA8K:0)%Y,DA95WNQ(*H,[@.>E>N?\$/_P#DHWQ0_P"P5:?^CGH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF7U1[=U;]#79UP'[07BJW\#_  )^(>OW7,&G>'[^Y*Y WE;=RJ#)ZL< >Y%
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M(_Q"EU3X:?$;P5,[LNCZI;ZG!O;("W4;(RJ.P#6N2.F9,]2:Z?\ X+76J/\
MLR>$;DY\R/QA;QCTPUE>$_\ H KP[_@A_*Z_$+XI1AV$;:79L4SP2)9,''J,
MG\S0!^NU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y/^U=\-7^,'[-WQ&\(P1>=
M>:AHT_V.,YPUS&OFP#C_ *:QI7XE_P#!-?QVG@']M#X=3SSB"TU.XFT>7<V
MYN(7CB7\9FB_'%?T&5^ ?[=GP<U7]D_]KV_U/1$DL],O=03Q1X>NMOR(3+YI
MC! Q^ZF#*%SG:(R?O4 ?OY7X _\ !4?_ )/L^)O_ '#/_37:5^Z'PC^).F_&
M#X8^&/&ND,#I^N:?%>QKG)C+*"\9_P!I&W*?=36!XQ_9D^$OQ"\27?B#Q/\
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MGA^)M,TF21 5DO95_?.ISG,<+;3QS]H&#P10!^P,<:0QK'&BI&H"JJC  '0
M4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>plrx-20211231_g19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T(%!E
M=&5R<P    60 P "    %   $*:0!  "    %   $+J2D0 "     S$V  "2
MD@ "     S$V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ+$K[540KYB\YW,0>3QP,V8?'EXMEI>KZCH:VFB:K/'%;S_:]\Z"4XB>2+8
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MU6#PMHEOJ,6E2&WFENK\VWFSA=S1Q@1OG&5!+%1D^@)KEO%_B6X\0V?@74=
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M,TQMS*!9",3 &0KU\W/&[IMS0!TE%<]H_C"/6WM9;/1]4_LZ\9A;:B\2>3*
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M[";;%+?)%)]MEA4CY2I^0,0,%A^5>BVEK%8V4%I;+LA@C6.-?15& /R%2T4
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M710 4444 %%!.!D\"J.GZWI6K231Z7J=G>O <2K;7"R&,^C!2<?C0!>HHHH
M**YRZ\0W<'Q*L/#R1PFTN=.ENG<J?,#HZJ #G&,$]JO7'BCP_:#-UKFFP#SF
MM_WEW&O[U3ADY/W@>HZB@#5HKE_%OCS2_"5QI$-W/:%]1O(X6$EVL1AA8-F<
M@YR@*@9X'/6MHZYI*Z2NJMJED-.89%X;A/)(Z9WYQV]: +U%5M/U*QU:U%UI
M=[;WMN3@2VTJR(3Z94D5F-XV\*K<?9V\3:.)MVSRS?Q;MWIC=G- &Y16;/XB
MT2UF:&ZUC3X95F$!22Z16$A&0F"?O$$''7FJFG:G<KJ6O/J^IZ0;"RD4Q"WE
MP]K&$W-]H).%/?Z<T ;M%9L?B+1)M0CL8=8T^2\E0/';K=(9'4C((7.2".<T
M[4M?T?1I(TU?5K&P>7_5K=7*1%_IN(S0!H44B.LB*Z,&5AD,#D$>M5M0U.PT
MFU-SJM[;64 .#+<RK&N?JQ H M45!97]IJ5HEUIUU!=V[_<F@D#HWT(X-4HO
M%&@3W,UO#KFFR3VZLTT27<9:,*,L6&<@  YSTH U**Y+PK\0M)\62W]M9WEA
M'>6][/;6\ O$D:X2,\3*HP=K#GC(QW-7O#6M-/HFEKKFL:/=:I?"4QMITX,5
MR$8D^5DY;:N-V.AS0!OT57>_LX[^*QDNX$NYD+QV[2 2.HZD+U('K5:S\1:+
MJ%^]C8:Q875W'G?;PW2/(N.N5!R* -&BN1TSXCZ%J/C'4]!-_I\36C01VTWV
MY#]L>0'*(O\ >4@*0"3DCI6[?^(=%TJZCMM4U>PLIY/N17%RD;/] Q!- &C1
M0#D9'(K \1+XP-Q#_P (G)HB0[#YW]IQS,V[/&W80,8]: -^BO-_!GBKQIK?
MA^S\4:W)X<MM">*2>X$44ZSI&F[)!+E?X<_2I-,\2^/?%MJ-6\,Z9HNG:1*<
MVO\ :[2M-<)V?$?" ^^?QH ]$HKBO$GB?Q'X>^&%UK5YI]A!K5O)''Y/F-+
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M *UH)9(1)GKN5& ;/?(YH X'4=:U+Q)^S5>WNM7AN;Q[Q(FN%C1"0MZB@X4
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MN<8H ]"HKBO OB'Q)XHM;35[J;0'TJZBWF&R,AGMV(R$9B2I(Z,,+@^M=K0
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MV,WF28)QP#C@'DX%%IK-A?:KJ&FVL_F7>FF-;J/8P\LNN]>2,'*\\$UYS?\
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M*\/^'+C1H;<W_B15:T6]FV0P+L#NTC#DA00,#J: .YHKB/#7C'4I_&$GAOQ
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M3);WJ_8KEL !SE'/LW]#7!B*;O>*T(Y;-LZVBD!S2UQ#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0G%(K!URI!'M7+^/+
MC58-#"Z/(D<DTBQ'GYVW' ">_P#2KW@Z&YM_"EE!?1/%<1(4=7ZY!-:.G:GS
MW,^?W^2Q%=:;=?:I"D1=68L"#ZUG3^&Y;B7S#!(K'K@CFNRHK#D1T*HT<M!H
MEQ&BPQP;$]21Q[U(^E74;%%BWJ. 0>HKI:*.5"YV<:?##F3?]F;KG&X8JX-(
MNI<(T?EKD98D<5TU)BCD0_:,Y>YTBY97A>%G1N,KWJG:^'+BVN/-$<K'& ,
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M]2%& 35RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^1B21N)W=SSG-;%% &/JGA31=9\-IH&IV(GTQ$1%@,CKM"8VX8$-Q@=ZEO\
MPYI6I>&SH%Y:!]+,20_9U=D&Q<;1E2",;1W[5IT4 49-&L)=>AUF2#.H00-;
MQS;V^6-B"1MSCJ!SC-5-?\(Z'XG,#:W8+<26Y/DS+(\4D>>N'0A@#Z9K9HH
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M;JQ8*\SRG)ZDLY)/YU?HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR0+M'X&O-_B1I5CI5U8S65V99+J(K(HY! /WLCZXQ[5ZEX.N%N?!NER*2?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMP7G'TH LT5YB=>^)H\:)X;W>$_M+:>U^)?(N=FP2"/;]_.<G-:D'B/5]/\
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M46U'3%:<;;F%C#<)_=D7@_X_C5M7C=="$[2LS5HHHJ"PHHHH **** "BBB@
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M.DQVE\9%E6"641 I#*5W;&P<CZXQ[UUM !1110 4444 %%%% !1110 4444
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M@.,84YQE@6X'3O7=MX>NS\4(_$8DA^QKH[6!3<?,\PS+)G&,;< ]\Y[5T=%
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M"V,:['F>+K -TCAD<<]^E;0K+N4_XJ*SD'_/-Q6F#FG+9$QW8M%%%26%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#3NZ@(PE5F7:<Y. ISD#\:U: "BBLW1?$&G^(([Q]+E:5;*[>SF+1LF)4QN
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M=0R%P2@20'=CKC'6I8IXYPQAD5PK%25;.".H^M #R,TH&*** "BBB@ HHHH
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M]G%MZG0 TM8?A*2YG\-V]Q?2-)/,6=F;KUX%;@K6,N97-(NZN%%%%4,****
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MM#T77-;36;37H;G9FS2 V\L*ASMV]5(.,,2?>@#OZQ_"_B6S\6Z&FJZ;'/'
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MEDTWH=04444@$)P#7/6Y_MGQ5)<YW6FF PQ?[4Q'S'\!@?B:NZ_J3Z=I4CP
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M+\O=YVZ,IC.1MZYS@UN444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-<FZ:SAV-,1C<<DG [#)P/;%;5 @HHHH **** "BBB@ HHHH **** "BBB@
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M\MH;@V\HFA,L8;RY!D!UST89/(YYJ>BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "H);*UGO(+N:VADN;8,()GC!>(, &VMU&0!G'7%3T4 %
M%%% !1110 4444 %%%% %<6%FNHM?K:0"\:,1-<B,>84!R%+=<9YQTJQ110
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MN*GW#UKAM'NKOPCJ46AZF/,L)W(L[KT)/W36UI]Q=77B;4C)/BVM0D,<'J2
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MJY./?!QFN1NM4O;V6:2XN9#Y[;Y%#$*Q^G2AR1Z>'RV<M6U;=,]4TO4KK1O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HKS.S^)NJ,\M_J6D01Z''JC::US#
M.3)&X?:K%"/NYQT-6X_'/B#4+F[O=#T&.^T6SOC9N5F/VB4J0'=%QC )[GM0
M!U'B'0%U^S2"2ZFME1]V8C][ZUREK<:AX&U:.UU2X>ZTBX.$G;)\H_T^E=?J
M^NVVC6\3W2S2-,VU$BC+,Q^E<YXE\4Z)>^&[RWE9Q</&0D$T15P_8X/H:EV/
M0PSJ22@XWB_ZN<_XZ\60:NR6.G8>&%Q(9Q_$WM7)&]NVF>4W,QD?[S[SEOK4
M%+63=SZBCAZ=&"A%%N+6K^+3'TM'86<L@>11@%O7FO7XM5EL-+C(TB2*UBC&
M'\^,*%QUSFO%*[WPJVCZGI$46NZK(9(WP+6:XVQD#[O'<41OW/.S'#IQ4EM?
M70VW\:W<-[LGT>40MRA0Y)'J.Q_"H6\>7+?ZK2I N\+N))X].G6NHL]5TVXO
M#86<\<DL,88I'R%7H.>E7]JGJH//I7.Z%=[5/P/!<H1=G Y>T\?Z9*SK<QS6
MQ49^89S[<=ZV]-UJQU>(O8S!]OWE/!7ZBLSQ5HD%[H\QACABG4B02$!<X[$U
MQ'AS45T/5C+=!P&C* *,\GH3[5R2Q=;#UXTJK33ZFBHPJ4W."V.D\:V^@-=V
M]SJNGM<W-MB821'#!5.<'^\..E8NEZW=^+-5U?3UD0V>H6^ZWBN2<(F-I"X[
MCK5ADN]8FDG;YQC#R.P"J/J:Y>01^#_B%;26$C7-I$JR2L"-JK(<,!CL,U]7
M3@G%QZGBXG]VU+I?4[;PWX5MO!4;SQ:6US<%</=+*';'H <8'TJ[-XGO+PJN
MDVC\'YB1N/TXK7O[EYREA9M^]N%R[CGRX^[?4]!5ZSLH+&W$-M&$0=O6N1SO
MK)79UPC&"M%$J9:-2PP2 2/2G8I0**Q*"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** $-<WK4FG-J2QZMHLMTFSY+@0>:O^[@<BNAGF2")I
M96VHBEF)[ =:X^\\3W&NW(T[PD=Q/^NO60[(E]L]329T4(2<KK;OM8\OUWRX
M-0OS:PM!&C.8XG7:5'4<&N4LM8OHX;&XU!HI8;Q6*B--K(P&<>XXKUGQ=X"N
M(-/FOX+R2\8H3<M+C=T^\/\ "O,;+0([9H?/NI+E;="L,;@!4!&#TZUG:VY]
M+"I*M&+HO;\QNFW&JW<=M>L\+VUQ\S0A<&-3T(/>NIT25(=;M6FEFBB+A9&@
M)# 'TQS7-V>B/;S0(E[/)! V8K< <9Z D<GKTKTCX?6MM;^)'&IJ8+M4_P!'
MCE7;DGJ1GOBDM67.;I4)<^]CMM!U*!IS86,5_- @+F[N0<9S]W+<FNB%( /2
MG5L?)3DI.Z04444$!1110 4444 (PR*Q-!M(H+W59(UPSW;!CGL #_4UN51T
M^TDM9;LR$'SKAI5P>Q ']*SE%.2;6Q2>C1%KT0ETJ0,<8*GCZBM!!A<>E5]1
MMWN;-XH\;F*]?8@U: I**4W(&_=L+1116I(4UNAIU(1D4 ?,>I/_ &QXZN/[
M4N?)6>]*2RM_RS7=C] *^AO#6BV.@Z-'9:4SO; EE+2;\D]3FN*\1_""+6?$
M$E_97XM(KA]\T1CW8)ZE?K7>Z-I-OH>D0:=9*1# NU<G)/J3[DUV8BK&<(J+
M^1Y^%HSISDY+YE^BBBN,] #7!^/?#]Q=[;RSN+G>Y\MXR[&-$QR=H]\>U=Y2
M$>E7";A+F1$X*:LSQZ#PUI$6EJ4B<W,;@2,96'FCL=O3BO2?#%N\6BH9'8ES
MNPW\/M4SZ!ITDPE>U0MG/4\FM(# K2I6<U8(PA!6BK"T445@6%8VL>&=,U=9
M6NK=5FE4*UQ& LF!V#=:V::RY!IIM.Z)E%25F<A?^*_#_A'35M+(+.85P(+;
M#;>V6/0?4USMG=ZOXHU:VO?$.FR1Z3&^XQ2D10*O9F+??^G2NQG\$:+/=PS?
M8UC6)S(8H_E25O5QWK8NK"WOK1K:[@CF@8 &-URI_"NA5(16BU?4YG2J2?O/
M1=#B]=^(EM98L?#=JVH73?)$8U_=Y'88^]CT%6O!$>LO=7M[K<-TKW 4AYW"
MCC^%8Q]T>]:^G^$],TS59=0MH?WSC:@8Y6$>B#^&MP#VJ93@H\L%\RH4ZCES
M3?R 4M%%8'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >8V7PRUG]]INI:I9G0Y-5;4GB
M@B;SI27W*A8G &0,X%7+?P7XGTJ>[T_0=9M;/1KN^:\,AC)N8=Q!>-?X2"1U
M/3->A44 1[0%&X9(]:XKQ1K-IJMG?Z=IVGS:A.B%&EBCRL3?[WM[5W##BN2U
M;Q%I/A9I;&SM6:[DS((8D.&9NY/UI,ZL-?GT5V>1="0>#Z45U<GP_P!<GLOM
MZK"9929&M\X89Y^E<W_9][F8?99CY!(EPA^0CKGTK%IH^OIXBE47NR6A !G^
M(#ZFN\T%-%LO#L=MXDTV023.71V@)W@],,*Q-)\)M<36XU>?[!%=Q[K9S@^8
M>P]O6N_LKK6-&FMK/688;FT8B&.[MQRIZ#<O;ZBDHR[GF8[$1DE"#_&WW$.E
MW.GZ0K)HVBS1M(2.G+8Z9)J__P )%=1KON-+G5-H)([&MY5&,XIQ4'M6#H8A
M_P#+W\$>'*M"3NXW^;.&O=9O=;5[2&W^4G=M4'=@>M)IO@XW\GG:FDD2+]U0
M<%OK7;);11L62-5+=2!C-2@5R4\KO55:O/FDON-IXRT/9THV1P]]X5NX)MED
M#-#C<,G'X5AIX,;7=6<3-+;?N&C<E. >Q^N:]4Q1@5]#'$3BM#S9QC-6D9/A
MW1Y-'TF.WN9Q<W '[RXQ@R>GY#BM<445BVV[L:22L@HHHI#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** $90PP1D>AJ*.WAMTVPQ)&I.<(
MH _2IJ1AF@+G SR7OC3Q%=:9'.UMI5DVV8)PTI]/T-7?%&C:58>%3;0V<,;.
MZ0Q/M&58D#);K73VFFV=E//-:P)%)<-NE91]\^II;[3[;4;9H+V%9HF()5O4
M4K'9]8M*/+I%'.:KX8$%G8W.A6< O+%U<* %\T8P035C6] D\26-E,R_8;R"
M1906^8IZKD5T:J%4*!@ 8%*!CI18S^L3NGU0B JN#3J**9SA1110 4444 %<
MZWC/3+?Q#J>EW\@LQIT<+R7,[A8V\TD* ?7BNBKR[Q;X$UG6M>UZYMH(7@OC
MI_E!Y -PA<F3(^A_&@#J-6^(GAO2M/M[QM3@N(+BZ%LK02*V&/4GGH.IK877
M]);5!I@U*U-^5W"V\T>81C/W>M><:KX"UA9M:N-.T^VD677+74+6W$BH'CC4
M!AZ*2:JI\-]:;QI<SW44AM9M2-_'=Q7:((LKT*["Y8=, X(H ]*3Q9X?DNI+
M:/6;%YXMV^-9U++M&6R/853/C72Y=3MH;*[M+FTEBEDENTNDQ%Y8#'Y>IX/;
MI7CNA6-Q?ZQI.@65E9O<:=8ZA!+=VS[O-+J55GX!7)/\7-=?/\.M333]"AL;
M.VA:TT.YM+D(RKF>2(*#QUR1R: /0K;Q1H-W%<26NL64L=LH:=DG4B,'H3SP
M*M:;JMAK%K]HTJ\AO(<X\R%PPSZ<5Y=>?#?4FMQ'#IEI)&V@064L2S>5OG20
M,>5'7C(8\9ZUU?P\T75]'M-0_MN%(VN+C?#NV&8IM _>L@"LWH?2@#=\1Z]:
M^&M"N-5O][10X&R,99V) 50/4D@5G:%XJFU2_GLM2T6]T>XAA$X^T[61T/<.
MO&1W'6E\>Z!<^)?"4]CI[QK=K)'/!YAPI>-PP!]CC%<9-H'C>]N]<U""S.G2
M7U@;9+634C,GG,P#2J.B@+G % '1:7\2]*U?P_K>K6L,_EZ/O,L38#2* 2'7
MV;!Q5>+XI6PA=M2T74-/<V#ZA;I+L/VB)1D[2"<'!'!KG?\ A6GB/2(KRVL+
MNWU&"_T5M.D'EK;^4RC]T<#[W4@GKS1'\,M6TZ*Z2SC^UB]T V9:ZNB[6MQC
ME4+=$;VZ8H ZW0OB#%J^J6-A>:1?:7+J,!N+)KC8R3J "<%2<'!S@UV5<9X.
M^']EH,6GWUX;JYU6WM%AW7-TTJP$@;A&#PH^E=G0!BZOXBAT?6-'TZ:&2235
MIV@B9<80JI8D_@*LZAK^DZ3)%%JFI6MI),<1K-*%+?3-<YXYTC6KW6/#NIZ#
M917KZ5=2320RS"+<&C*CDY]:Y;QIX9\9>+',KZ1;P"?3Y+<PQ7: QR;L@NY7
M+*1_".] '=VGCC1+SQ)J6C1WB+<:;&))F=P%*D9.#G^'OZ5:7Q;X>:Q6\76K
M$VS2>4)A.NW?UVYSUKS?4OA[XAO(]:M(;>&--2TNSC6X\X#;+"JAHV&,X;'6
MF:=\.-7:XL[FZT\QG^U[:YN8KFZCE#1QJ03A5"]\8[B@#O+WX@>'K2\TB :C
M#,-6D:."6&1608[DYZ9X^M=/7E$'@?6]-O--NK?3K>9;/Q!=7A@655Q;R@A2
M.W&<[:]7% !7,ZIXXT[2O&FG^&YUE:YOER)% V1$YVACZMM./I72G/:O(];^
M'GBO6KS7-:2^@M+V>[CFL[38KY6'_5?O/X,\Y ]: /2KCQ#I%KJ T^YU.TBO
M2NX0/* Y'7.*Y_3_ (D:5J\=K-II62&:\DM96EG1#%L!.[;_ ! @9 '..:Q;
M7PMK<7B:YDO- T^^BU#4(;]KZXF&ZUPBAD ')*D';CCFJ>D>!M=M[O2H;JP@
M2WT_7;F\>59E/FPR*V"!UR,@8- 'HZ^(='98V74K4K);FY0^:,-$/X\_W?>I
MM-U;3]8M3<:5>P7D(;:9() P!],BO)$^%&MMH/B.SDFB\UU6UTG+\?9EE,FU
MO3.0/PKL/AQX:O=!34KC4K::UFO9(R8Y;E)<[5QGY%4"@#MZ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 48HHH ,5%):PRSQS211M)%GRW9063/7![444 2XHHHH *,444 &*,444
=0V]K#:HRV\4<09B[!% RQZGCO4U%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>plrx-20211231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,/!ED# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN=H.3S7T;X:UR'6=,CE1AO  ->-7H<KN;QD;^0**:.G-.KE98M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M$XI:B<X- #M_-+O%0DBDW4 3[A2;Q4.ZFEZ5QD^\4;ZK%Z-]%P+6\4;Q5;?2
M[Z+A8L;A2[A5??2AZ+A8L;J,U"&IVZBX6),BC(J+-&: L2;J-U19HW4!8EW"
M@L*BW4A:@+$N^EW"J^ZE#4 3[Z-XJ+-,+T")P].!JLK<XJPM,!U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !24M)28!29I:2FA,,TUI%4<FF.VTY/2L#6=76%&1&Y/%<
MU>NH(VI4G-V)=6UN.V!56R:X^]U&XNI#SA3[U7DF>:3+DFFG!/%?/5\9*3LC
MV:&&4(W8NT$9ZFF;MHQ@5<*J+8MWJD.3S7GU9R;U.VDHO1"CIFC!WT=\>E3^
M7^Z#^M:4XIJ[)FFI$.>V*3O2]Z0]:B=GL:6T'QINS3"!DYXJU:ID$^U5WX8B
ME'FB3:+W'0S20G=&QKI=)U\A@DQQ7+[L+@"C<>".&%=-+$RC(PKX:,EH>IPS
MK*@93D5,&S7":+KCQN(93Q7:0SK*@93FOI<+B(SCJ>'6H.#+'%%'44M==CG"
MEHHH ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %(:6B@!*2G4E "5A>*=832=+DE+ -MR*W&ZY]*\5^*N
MO>9-]C5N@*]:UP]/FD3)GG.J:A)J>J2S2L3\QQFJJCC+'-,"D_-G%.'79MZ]
MZ]VE&R.=[B,^/E J>TMGNY5A12SL<<5"01.(@-Q/3%>K_#CP:7E_M"Z3&<,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$>EZ4Z(_[QN/SKY\N9&FN'D/)<UWX:F]S-L]3^$VI*DCVQ;L *]ER#UKY?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX;?4M12X=#Y:''->E4J\D+$\MSUKP3HR:5H\?'S,,G\174@]JBAB$,*(!C:
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MUU/-&D8_V>CO1XEL>N\_E0/$ME_?/Y5P./<_G2X]S2>:2'_9R.^_X22R_O\
MZ4O_  D=GC._]*\_P?4_G2G.,9_6A9I(/[.1WY\2V0'#G\J0^([0J,/^E<#_
M  XR:3##'/'UI2S1A_9R.XN]?M'MV4.<D>E<7,WF7#LOW2:82">2:&Z#;7+5
MQGME9G10POLV*>G'6CM2=,49 7)ZDUPQ3E+E.UR447M'MS-? 'H,&O1H$\N(
M+Z5RWAJQ)_?,.U=;C(KZK+Z/)$^>QE7GF*OM3Z8HQ3A7ILX1:**3O0 M%%%
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M"T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXL37Y4:]A;+;6X0#&!5I>E(>!Q0#Q7U,(J*2/ E/FE<4=:?48ZT^K$%%%+0
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M3 I:2@!& QS4$D:R1E'4,AXYJQBDXH3:8FCS;Q9\.X-05[BSC"OUPHKQ[5-
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M:EH[858S6@\&BD[9%.[5)6XG-+1FEICM8**** "BBB@ HHHH **** "BBB@
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M'6FC.<4HP*E@+U-(:#G/%*:2=P "EI,T9S30#J*;FEH 6BBB@ HHHH ****
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MS7E_A7Q:\<JV]TQQG&37I4$T<\0D1@01FLI(^HPV(56),*6FT[-0=0M%%%,
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13=U+D4
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MO=).H*L/SK>-2YSN#1:HIH-.XK6Y%@YS2TF*6@ HHHH **** "BBB@ HHHH
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MM(*6@ HHHH **** "BBB@ HHHH **** "DI:2@ I:2B@ HHHH @NI!%"S$X
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M6&:U4S*4;%S-+3.O.:7M5K4@=12#/>BA@+1110 4444 %%%% !1110 4444
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M \<'TKJ-/M?LL 3/05G@J#C*[-<764XV1<I:2BO9L><%+24M !1110 4444
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M!7F8RKI8]G T6W=DX/.*DIH':G5Y9[O06DI:* "BBB@ HHHH **** "DI:*
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MQ1>02/M;"M4[K+)"RQL2*FO=#25/-MR<]:R(Y;BPFVR<C/<UV4ZT&SQZV&E
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M6&HZK*"N^*/OCO6E8Z)%"0\I+N?6MA(T1<(H ]J ,VQT:WML/M#/W)%:0''
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M8!%$8*.P-MF\.:*9G:<9&/<T<GH0?QIL:)**:#SCO3J "BBB@ HHHH ****
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M47WW3_NS_#T-;]M9PVD8C1.* ,>UT225Q+=L2>N U;B0Q0KA4 ^@J4+Q@=*
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M:SJ7AN[A_M)U:.?D;#G K0\7^*Y=,L8);8$^:H(XSUJK=:%)J=U!]LO(71.
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M<J\) JNZM'T%=T9Q:.3DG#1B?4\T<@]:;O7N>::9!VJE**):DR3<WH306/\
M$A^M.CCFD&54FKMOH]]>,%\MAFIE742X8>4B@ 2V-V1Z5;M-,GO9E2.,X]:Z
MG2O!,BL&N2V/0BNRL=(MK)1L1<COBN&MC+K0[J.7MN[,/0?"L5HHDE +]>E=
M8H5%"KVI0%[4< UYLYN3U/;HT535D.YQ0#2]:3%9FC%HH%% PI:2EH ****
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M 4444 %)CI2T4 (1FC I:* &[12XXI:* &E 1CI2@8&*6B@!,4M%% !1110
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M4;O4/$AARWEAC4JFVKE.O9V/3VEC099P!ZYI@O+;_GJGYUQWBN^GM+94C)'
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M<5XAH?A;6/#VN"_G#R)(0,8Z5[59W!N+=7*E"1WH L+DT^FC@_6E% "T444
M%%%% !1110 4E+3?K0 ZD--Z=!06[XH #1WIH;)Z4_G% 6 F@&H6E1>78 TU
M)D;)1P3[4[$.:N6*2F\[:1B5&<TBGMJ.&<]:4\_2H?M$2_><9IZN&&5.0:=B
M5.*Z@<YPIQ]:7:.]1F6(/@R 'TJ0#/?(H&U%C3$IZBF&UA/5%_*IF;;U/%1K
M-%(<*P)IW9#IT[V8PV<'_/-?RIJV5OGB-?RJP#USQBH3=0QD[Y5%,F5.$79H
M>((DZ*OY4_ 7TJ-98Y/N.#FI>IP>E*Y:45L)MP,T#I37E53@\"HOM4&<"5<T
MK#]I#:Y8P3WIU1AU9<J<TCR(OWG H&FK7)<BES40=67(.13N-U <PZFD#UJ-
MYXU.TL!3#<0DX,BT[$\\;[DXQZT^JJ/&6VI("35C!]:1I9=!]%%%( HHHH *
M2EI*3 .U!HI#TI] ZB#I6?JW_'C-_NFM 5G:M_QXS?[IJJ/Q&&)^$\X\.X_X
M2%SG^(5ZLGW!7E'AXC_A(&Q_>%>K1\QCZ5T8A-,Y\*]+&%XK'_$ID/?(KD/!
MP!U1OH:[#Q9_R")/PKD/!PQJC$^AJZ3_ '9%2-JAM>,K$/9B<+\U4O VH\>0
MW7 %==JUH+NP=".BYKSC1Y1INOM&W W8IP?/3<2*D73J*3.W\6W9MM+D*G#%
M>*Y_P59>=<F\9>AIGC#4?M#0PQG(<'-=1X8L!::8OJ^&J7[E/E9<)<\[HP_&
M^,8]A5+PIJMM86VV9P.O6KOC@?+^597AS0X]3M@\CLOTK>#7L;,YYMJL=E::
M_97<XAC=22<4GB8;='F]-M5M/\+0V5TLZR.2IS@U<\3 ?V/,3V6N2-N=';)?
MNV<+X9N(H=2)9@.373>(=3M/[.*EE8D=*X?3;*6^O&2 D-D]#4FK:9=Z=.AN
M78QY'4YKME&+FCS$VD[&CX1M));_ ,Z-2J9[5Z@3R*YKPM-:2V2B #<!SQ71
MCH">M<6(?O'JX9>X29Y%.%,)/RU)7,=8E+24M, HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $/ KSSQO>EI5A4]#7H,APC'VKRCQ/+YNK2C^ZU)E1,^W'[L>]74
M&!56$<(:N+C;61I$EC&34[8 J*WY;GI5?4;Q8%8 \XXK%)N1T1B97B"Z1-JY
MSS7.VUD]V\DW.U34E[(UY<JN>2:Z**T6RT23CYF7->CADHR.?%5&URHYT+UC
M]ZT8055(5[D5FP M<'ZUOZ7!Y^H*#T S3QKN=. C[.-SIM/M!:VJ #FKV 3]
M*:/N!?2@9!/O7E\P56W)F?J$Y.$%6+) B#/4\U!<6S22;NU6XAA /05:9-M#
M'UIM\GED<&J-OI,L1\Z/.*MZA('O GTK7@_<PA< YXYK.<F9):E*+5UBC,4H
M ;&.:P[VZW3$ELJ36]J6CBXBWQ9$GH*Y*[M+BV?;*II1DI'2M":-=[97I6A!
M%T^;%5;1/E!'([UIQPL>0*V4$5SHMVT;\8SBM4%!'\QK,B\P_**;=>8@P6(/
MUJTK&<M2Q-?_ &;_ %9J :U=..,X^M4Q&6.6)-7XHQLP%%%TB+%>>\N'3.#6
M7+=3IG@UNLHQAE%03P0E:M5K$NG<YB>XFE/.:IM'(W7-=#+ G4 53D5<'BK>
M(NA1HVD8LD;(.:H,Y$J_6M6YS67)@2 ^]%.5V;3I>[<ZJU;_ $0'VK!U2Y;S
M2JGO6G'.$L_PKGYF\^[Z]Z[G5<(Z'!A</&O5Y636MM)*=S9Q5S[.B<8JY B0
M6F[OBLF]O2'^6O+J5G)GT_U:-&*1.CF*8;:ZO3YEEC564<UPUH[SS#ZUV6GC
MRXQ41D[G%B(Q>Q>N])_Y:Q=>O%-M+RXMVV2 X]ZNVUP['#?=IE[$91E5P!W%
M:RDV<2BBS]H++NJI-+N.":+?<$VD4YHP6YK%W-%%%<Q(>>]59@O=!5^2/:.*
MJRH6Y(HN.R,^2%&'  K/N+<@':>*U77'0&H'BD8[0G!IW"R,50(O8YKK?#]V
M6C"%JQ?[(N)Y/E0UO:1HTULX9\@=ZQD4K&Z\885$MH2>IJQ, OW3FFQ,<XK%
M2U(:$%H >:6>!&M6CP"2*G(]305[UM%CA*S.%,#073P$?+VJE?.UHDD9^ZPP
M*ZG5[,"7SE'-8&KP;K5),<GK73AW[YU5ZW-2L8,$A1&XSNI8)'M)_-'#'D4Z
MS&;N.-A\IZUT^JZ)&+6.:/.=OI7L3FFK,^85%N;DC0T/5?MUN%=OW@/Z5N8V
MG Y KS+3;J6RN\]#G&/:O0[*[6>S1U.<UYF(I>S]Z)WPJ\RY69/B'2A<K]HC
M7D<G%8.E7[V5X%<X4&N[(R&1QPW%<5KVFM;S&2,?*><U>&J^T]UA4I<NJ.SA
MD%U&LR'@#FI#R:YGPWJ6\BW8_+WKJ'XZ#-<V*I\LK&M.>@T8IVTCI0#V(I5/
M-<JBS?=&]HTAQ@FML=:YC3'VW &>]=,IR :[*+T.2HK,=2TF:*V,A:*** "B
MBB@ HHHH **** "BBB@ HHHH **** #M40SEB1@5+3"/FH BDAAF&)%#CWI8
MK:& 'RHU3/I3_+&X-GIVI2,\4 1RQ0SIME0.OO3(X((?D2)4'M4Q3\,4CR(B
M;WP!0 BPHC$K& 3WIDMM!<<3PJX'K3UG1U#*<ANA%/[#- %>.UMXC^YB53[4
M\IAP5C&[UJ7'I3!A226_.@!60DYS^%5WLK5V#R6Z%SW-3JZ2<*V<4[///44
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MK+!]T K2BS"JBU3A11718YA:***8!1110 4444 %%%% !1110 4444 %%%%
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MY=N*Y8>()7.7'.?6M>TOA>QX;K2E2ZFU&M&1+(489XXIN]=F1VILL6P$9ZU
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MH*ZC:*"#3L4&L*<8K0=1114FP4444 %)2T4 )12TE !12T4 )24M%%@$JAK
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M* &8(;(H.><#K4E)T% # #CFCC:<TZD(!&* $ZCCI2L,@8I 6!P<8I<!><T
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M''45F+1116IF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E
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M49H WUSCI2C.>:JVU_;W*[HGX]^*L[MWW2#0 ZEIH/KUI: %HI,TM !1110
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MH **** "BBB@ HHHH **** "BBB@ HHI* %I#TI:0]* &@FE%'05&\R1#+L
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MY\!*:K#=3Y$+)GM7G5G[QV4UH+IVLS6,GRDE<UV>F>*8)0HDX8^U>?!1YFT
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M7'>B@!,@TTL0>*?@48% #0<TIXI0 *.* &[J,YZ4[ Z4  4 ,[C%24F *6@
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MP!T%'2@!A#4N2>V*=@^M+0 S%+MI<48H !2T44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (
MV<<5QGCU1_9@8#^(5V?>LS5])74K?RF]<T <[HV/^$#;CL]4OAXNUIR%ZJ*Z
MRTT=+?2/L/\ "<_K3-(T9-*=Q$.#QTH XC0@/^%A7QQC_2/Z"J^DRI:?$!FF
M/EJ6;D_A7;VOAV*'6IK]>&=]W2J7B'PBFHRB>V8Q3#^)1S0!RGQ U.UNM7M(
M(I5D;S(SQ]176:]HMEJ^GP1M(D<RJ"">QQ5)? ,!FBN)FWRH1R1SQ6QK6@RW
MR(;:9HF& 2HH XW2]6U#1M3;29)6N$SL##I4.@W$=GXVN&NF$9>;(W?A77:/
MX36SN6N+J4SRCD%QSFC7/!L.HR_:(3Y4W4,HYH UKO4K:>W>..178C@"N%\*
MW5O;>*9O,<1?*QY_&NHT/PU)IS$W$K3'L6%5=5\%QW%]]JMY#$QX.T4 <WK&
MH6MSXS41.K-E>15C7]W_  DEHN#@R\FMZT\$6T%TMS(0T@Q\Q'-:5YH$=U=1
MW&<E&R#B@#E=:U^ZDOK;2+:4V^_Y3)VKF/$EM=6E];";41<,<' 'O7HVL^$X
M[]8YH3Y=P@X=1SFJ*^!A-L>YF:21>C,.10!B^,/F@T_(VG$7]*]"TU<Z=",X
M( _E6?J/AZ*_$._YO*VXX]*VH8O*C50. ,4 /%.%&*,4 +1110 4444 %%%%
M !1110 4444 %%%% "8YI<444 )BEHHH 3%+110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 F*6BB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ I,4M% #3UH(##IF@TFTYH AEM()UVN@_*LNXT
M!!DP,5/;'%;F*0YH Y5EU+3 &&9/]XU;MO$(P/M:;#["MXJI7[H/U%5+K3;>
M\3#(!]!B@!8=1MKA<QO^=1ZG>I963R[@<BLNX\/.AS;2$ >K5Q7B/4KVW/V7
M<&_'-)@D9MY,U_J$DQ^Z>E3Q8VX-9UK=X^608_"M*.1&3<I%0]S2.Y5N4+@U
MB*H$K*>I-;V69STQFL690&=^X-#;;L>A@XJ+<AUS,8X?+4\FKWARS\RY+,.
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M@8ZT +12"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX#TIM/T[S6',BUV&#^= #^U% HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHI* $SAJAN)Q!"\C< 5*>2,5S_BN_P#LVGO&.K"A@C@=9NC>ZHW.0"::
MJ@* *K6R&2=I&]:M8/F8[5C-FT4/!P*:D>]C@T$Y;%6(DP01WZUG%ZE./,[&
M;J[>39E.["N=0$1')YS6YXFD"M"@/4<UBP12/$S8^45Z-&R1G7;BN4Z_PU,L
MEMM(]:V##&ZD% :Y/PS=^7,8S[UUN_:"WM7+B%K<K#ZJQAZI96XC90HW8KF;
MBWGMX_W9-=->2^9.3_#FLT1--=!0,KFN9,]2/N*XW3[EH8,O']36]X?G@N-0
M7YQNS565$2#;L%:OAW0%G8SQLP;GI6\#S\1.[.E\56@N-)##G:,UY2/]97HF
MKV6I)9R DE I_BKS(S/%<$,O2MGL<R-,?=Q21/L>H4N8RO7FI47S 2/6O*Q$
M;L[Z3LC;L9LX]*WUT^*ZM_NC)%<G;RF #(KH=/UA$0*2*BG%H5[LP-3\(RR3
M%DS@'L*QY-(EM6V["<5Z5YXG4L"*SKCRB6R@)^E:RD=E*2B<"(G5\;:T;:U:
M3&16S_9Z2RYQ6G!IR(!67)=G4\1IH9MMIHP,BKPLE X%:26ZJ*<8P*UC"R.>
M=639CO9#TJ/[*J]16M+@"L^>4#-3)!&394DC116;<[1FK-Q<<&LFYN,YK-G7
M"Y!._%46?FG2RDU6+<UFSH41S/3&;L*0G--SS0KFO-RHFLY##<!O>O0M*NI+
MBVQC(Q7G."9%/3FO1O#FU=-!/7;3W.#$RYD.U&(FU= .2*X%[9VNF##H>*](
M93/(..!7+ZW MK<94<FK4;'/AWJ1Z;$@P&'2M5I@%*XX K AN-C#FKS3\?6D
MSJG!ME:];+8%4?*R,U9F8L]/2,E:FQM'W49S(4:IXKG8,5+-%M'2J#_*U%F.
M,T2W%P6!JA';>=)NQ5N-/-< 5O66F*(MQ':MJ<78YJDM3GRCJP4"KT=C+.H"
MJ:O36JB3ITK:T,Q;MC*/RK5,Y:FJ,>RT.3=^]4X]ZZ&TTJ*$@B,9K96)"XPH
MQ4TCQ1KT&:M,X9.S,B]1U3:HQ]*JPQ!%+2=?>M&YF#MP*S+ZX"QX'%8565$Q
MM3D#R<=JO6?%J#6+<$R2]>];=N,6@%33W"6Q7N^=I]Z[WPF!_9J''5:X)SYD
MBI[UZ+X=A\G3HQCM7?3.2H;%)R32]**W,A.G%5-0M%O+*2)AG@XJS@TH8-P*
M$!X?J]F=,U-X67OBJP7.<]#7=^.-(#*;I!SR:X&#?@Y'2BP)DL;!7Q6G:L2>
M*RPRJV34R7PCX09-0T:J1T]OD#FI&N8HS\SXKGXI+NX^[QGWK2MM,:0YF=JA
MHM,LOK"_<A0$^HH6"^NF#!W ]JTK6SMH0,*&/N*T(PJCY1BIL%S/MM&3AK@[
MC[BM2*"*$ )$IJ15##.:<!3L(D0 '/3VJ3ANVVHUXJ2BPRW:8!XYJZ5!-4[3
M^M7:TB8R%Z4#I12U9(F.:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH IZE8IJ%D]NXR&%>=Q>%M;TRXEBM+F=87).!C'
M->H4F 3DB@#SSPUX-N['56O[N>1G88^84?%*RBNM+C^;$RYV>N:]"/TK$US0
MDUB6V+L0J-D@4 8OP[TQK70HVDSYC*#DU!K.F:[/=-'%+,86)Z=*[.TMX[.%
M8(QA5&!Q4S'##@&@#D?#'A5]-AE><DR.&'(]:QH_"NJV'B22\MII1$^ 0.F*
M]*I, G- '%ZKX9GO[^TN\MN1]S<=:Z>?3TNM+^QR_=*X(J\*,4 >8CPQK>CW
M<HL+B9;>1B2%Z5J^'O"=S#J)U'49'DEVD#>*[DX/!&:0\G;VQ0!XIKMI>WGQ
M*N$LI7C98T/R=^M="_A36=5OH#?7$S1Q-G:W2NK'AR(:_)J/\3*!^5;_ $Z"
M@#CO$WA.34].MK:!F41)M^45M2:4TGAN/3RQW*@7-;('%''2@#E_"6@OH5A/
M;2DD.[-R/7->=>(-(^U_$(06Q/EH58@?6O:RF48'N*YVW\-1IK#W[$ER* -R
MR@%M:I#C[HJP.M-Y)IU "T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 44E&: "EI,TTO0 ZEI@?-&<F@!]%)D 4FX4!8=13-P]:4'- [#J
M*3-)F@0ZBF9I<T@'44W-+3 6BD%+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4E+24 -^Z">U><^,[WSKI8U/3(
M->@74GEVLA]!7D>HRM<:I,2<@-Q2;*B@@!6/BI<[1DT18"]*5QNK%FR$09;-
M78AQDU5B7M5J1O+MG;T%3RZEP?O''Z_.9+O&?N'%;NE6 ETP\<GFN9O,S7K9
M_B->@:,BQ:<H(Z@5UJ7*A5X7=SE(8#::CD<#-=/-<C[,/]KBJ.H6PCD,F*KK
M,9DVGHO-95I7B&'A9W&SGY HZU:L8A$F]AS4<$/FR$GD"KDF!$5':N6*.VM+
MW2"8LS8&,$UWWANW,5@& &37!6<37-^B 9%>HV$ M[1$'H*Z8H\VH[H;?1B6
MRD5AU4UXQJ]LL5_(F.]>W2KNA<>HKQSQ+'LUB8?[56]C)&2+/*94_K0C3VS
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MI,T4P%HI*6D 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9(0WS@8->76HV=T<\X6-_G=ST[5)4:CUJ2N=F04M)2T %%%% !1110 4444
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MAZBJ4Y)7FMSPI!NN=WL:TIJQPS>AVBY*CZ4Y013@,"EKIB<S"BEHJA!1110
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MCEFK,=F@4W%**AZ$CJ*2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2+I4M1IQ4E42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !24M)0 TC+"O._B7JOD:<T$;89L=*]$/%>&_$6[:36!%GY<&MJ$;R+@
MM3BP 22>IYKH?!VB-J^J@,"53#5SYY7/>O5?AA9@P?:",,1BNZ<N6)N]COK;
M1[6&%56)59>^*T%4(@ [4[%)G')KRY2;.5LI7^H)I\>]@#QWKB]5\13ZN7L[
M08<J>%-=[)!'*/WB!ACN*\\UFYATGQ1YD<:CY.0!Q6E):E0/,-6TJ^L[QFNE
M;D]ZH.ZLH &#7J>JZYHFH_+<D*Q'9:XK6++3D3S;.1FQSR*]*E(ZHF"O3!-
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MC9M?N[K7PTP;9TQBO1M-@\[%SC@@<4XZ&4X3I+WCSCQK'/'J<A?[K-\M<QR
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M!$6_!/X5*5S-S4'8SX9H ?E49J];WA.0(S6=#;>7=[2.,UU.GV4+ ?*,FG&
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M0!*M/IB=*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@J)\K-@_F*S?AO"MS>&9AEO6N.3W,I'H>B>'GT^&,F<$CVKHEYX)S2X' ]*
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M,5H+*AZ.I^AH DSF@C-,Z\K3AGO0!"X[BD4CO3Y$W<U%G!Q0!86GU%&,"I*
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH
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M)6&,D@CE&UT4@^U8EWX4TZ\W$Q#)]JWV) XH&,5:DUL.[/.[SX9V\Y)3C/\
MM8K+;X2\Y#G_ +[KUG%)QTJ_:R*4VCR,?"8D_?/_ 'W5ZW^%<<; NQ/_  .O
M3B *0XQFG[63'SLY;3_ ^G6JC=&"1Z\UOVVF6UH,1Q*/^ BK@P133N[5FY-D
M.;%P .,"@D 4F!WI<\=*1-VPQQFDSSQ3O:F_=YI,+"CWI<4W.[FG9I)6&+F@
M4E*II@+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #:
M6BEH 2DI:* &\4F!G-*>M9^I:C%I\#22,!@=ZF4K(N$>9VB7F8 =<5&;F/.T
MD5Y?JGC.\O+HPV"D]OE-4O,\4']X4FQUZU+J:'8L)_,['L(=6Z,*4G'6O+]!
M\0ZE%>K#>JW)Q\QKL?$5_+;Z+)-"Q#!<C%$9W,9X;EDHHW@P)IXKS/P9KU]?
MWQ2YD<C=CDUZ8I^454'=$5J3INS"EHHIHQ$ZT$XI#QS2'YQP:: ?GVHIJJ5'
M+9I:8"TM- (]Z7-(!:*3-&: %HI,T9H 6BDHH 6BBDS0 M%)10 9I:2B@!:*
M2EH **3-&: %HI,T4 +2444 %->G4UJ5QD+5"PJ<\U$RT@(2IQ496I\#'WJC
M8#^]2&5)!VJC<<5H..>N:S[D$O@46 JV\!N+I1CC-=A#$(8E4#I65I-GM)9A
MVK:XQBFA,#U%+Q0#250A:*** %HI** %HI** %KF/&47F:>#Z UTU<SXRG$5
M@ >X- =3RU>&8>AJY$>!5-3^\8^IJRC8(S61KT++-_*L^*!GN78>E:& RYS4
M,$D:2G+=:QJ)LZ*#29F74L\4NT9ZTQ)[HMRK5H7$8DN@PY!-;%M8Q,BDJ*XV
MFF>S":L<A,9M^2"!5D#S(PN*W=0L(\?*!63@1/C'>J92DGL4-3LO*@#BJ6G3
M2;@5!-:NKS![<*M5-"MW,ZY7()JK&<G8T4:6:15.5S6@VC3&,.Q)7Z5->V)@
MV3CC S5^#7XGM?(\M68=\T6,O:6*4&E!5\QUX%7+2P-WTX6JT]W=7 \J*(@'
MTJ>TCO;2+:68&GRDRG<?-I,$#?.5*U-']@2+;&BEO:L.66]GU$0.6VEL5O?9
M8;")6?!8C/-78E-E:>*(VS$)@YJ32X-]NXQZTV:X26([% ^E.T2[ E9)!@'-
M1*(*3N<[JMGY=R6'7--CO)88@K,:Z/5[$22;UZ5S=\BHZ*3WK/E.A2NA_FM-
MSL)J>VM9K@XV$"M>P@M%LU8[2V*FDO88AB)5'TI<AG*?0;;0+8IN;&<54N=9
MN)69$SM%075V]S*$!/)JU);Q6EL&8#<:UBA+70H)=NS?,2I]ZV;&_"[=[9%8
MY,4J<X5C4*R-'E<TVRTDM#K94BE^92.16!'"L5^6(S4*WLJ)PQJ-+S#[I#^=
M0V)0L[C]3D#2_*,5B71V3Q-_M5<O+P._R5E:D[$1E>N:ALU2.RL=5$=J 6[4
MV6\65P<UR-N]P\7>KUHTK.-V>*5R)([6Q(*"K^<"LK3VQ$*TP>*W@<-7<44&
MD%!-.VIDMAK=*@X!(J1FXJ%OO9JF"V+>E1[[L#T-=PG"UR_A^ -,7]JZD=*Z
M:>QR5-P%%%%:F8M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %)CTHI: & &EP:=10 TCTINS-244 1[<=*KW.G6]XN)T#_ %JW1^E '/R>
M'?+)-HXA^@J%CJ.G]=]P1Z5TW;K32 ><9H P;;Q#SMNHC#_O&M:"_MYQ\DRM
M]*;<Z;;7(_>0JQ]36;-H3(I^S2%#_LB@#>SQUHZ5RZMJ>G'YM\X_VJLP^(5S
MBZ00_C0!O$COVH!'K5.'4;2X!\N0,!U-9]WXGTNRG$<MPJD=J=A&[GBCM56T
MO+>^BWP2!E/I5H#'% PX%%'6CO4@1N_EJSMT%<G)XYM(]5%GP6)QUKI=1)^Q
M2?2OGZY5AXS4[C]X_P Q711I\Z*C&Y]!^:OD>>>!MW9]L5RT_CJS2^^S(P+9
MQP:S_%WB7^R=!CBC;,K(HQGU%<AX'\.3:QJ!O[G.W.1D4<EEJ-QL>N3ZO';Z
M;]JDXXS63HOB^#5KTP1$$[L=:9XOB2#P\\8XPAKS;X9$CQ-("V1YO^%$8)QN
M'+H>NZWKD&C6QEEQ^=<VOQ)L6&1C'UK/^*;E=-(S@'%<YX)\)PZQ8%W;G<>U
M7&G'DNRK*QZ!9^/]-N9-K2HGU-=+9ZA;7L8>"17'M7EVO?#=HK1I;.1E91GY
M16#X.\27>C:JNGW4C$9"_,:GV::T):5CVW4+Z.PMGGE/RJ,\URL?Q#T][KRB
M5 SCK5KQA,)_"\DJG[R9KP::"8^9<1DY1NU.E233N5&-T?3UO<QW4*R1,"",
MY%9FL^(;?1@/.(R3CK7(_#CQ%]KLA:3/^]7U/:JGQ._@Y_BJ/96E8GEU.^TC
M6(=7M_-0@J!GK65JOC2STNX,4C#@XZUE_#K/]A=/X*\]\>@G7=G3<QJH4U?4
MI1/1#\2;$'/&/]ZKVF>-K35+KR8P#\N>M8>C^ K.[TN&60 ED!Z5N:/X)M=+
MN_.0#ICI1.,!-#+WQO:Z;J M9@!D@#)KJ+.[CO+5)D((89%>4?$S02LZWL0(
MVG/ ]*U_AWXB%SI;12O_ *I,]:'33C= HW.LU[Q+;:)&#*XW$9 S4F@Z\FM0
MF6,?*#CK7C?C#4)=>\2_8XF)57*X%>N^$=(73-)C7&&8 FHG#EB)HZ*BBBLB
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M #T7_ON@#I]R_P!X?G1N7^\/SKF/['U?_GJO_?=']CZO_P ]5_[[H Z?<O\
M>'YT;E_O#\ZYC^Q]7_YZK_WW1_8^K_\ /5?^^Z .GW+_ 'A^=&Y?[P_.N8_L
M?5\?ZQ?^^J/[(U;'^L7_ +ZH Z?<O]X?G7 >/+T-MA4CY2>]:S:3JR(6,JX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6Y'69I":XO2O']M>W@MYAL8GCY<5O:SK*Z7;K+MW;NG&: -BL_4]5ATM \K
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M%+110 4E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=5Q_9
MES_N5=JM?PM/831+]YEP#0!YQX#)^VZSZ"4?R%0^$=+MY?$UU-*-^)6X/(K?
M\*>';G2YM2:5A^^D##CV%+X:T"[L-5N+AW78TA(XH PO$=LMM\0H# !&IC7A
M>/2I?&42-JUMNC3EEY*UKZWH%U>^+8KY2-BHHZ>E/\8Z!=ZA;12VK 2(<]*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH ;0!1BG 4
M+1110 4444 %%%% !1110 4444 )2TE+0 T^E<AXXO/(L?+SU(KL#P,UYEX[
MNO-N1$#TQ2&CE81Q^-7(A56(8J[&*SDS5$R#FK"5"HJRBUFV6D2JM3**:HJ5
M147+2'*,FGM"&4T(.:G&.E)LJ+.<U"TQGBL"6(JQ%=M>0;ATKGKJT(8G%2SJ
MA(R([8L>E:%O8 CD5)"@4\BM6W5<4D6Y7,F2T\L<"HXG,39Z5LW(3%8\XR_R
MT"3+$A,T><UG)'ND(-68=Y^6K4.GL26YH*<BM$&ADQ_#5IXQ( R=:62V=>"*
M8FZ(T7,)2N2+))$1G.!4WVQ&'*\TT$,N6%*OD>@IW&A#=J/X:<M^N.%YIRK;
M_P 0%.VVP/ 6BXFRL[RW!QM.*?%"EMRW4U:,\*+\JBJ<TGFF@$QEPQ<_+52:
M/:A)]*N !5R:HW,OF'8M2:*1E/+(&PN<5)%&\Y YJR+-@>14UNABF''>DF#D
M TU F2!NIT"-!)[5M1PB1 :JW5N0>*JY/,6$V2ISBJL\*@X%-A9DX-6-I=JE
ML'(2SMR7S6[$FU,53M8B!TJ\ 0*:,I,,4]5I .:G1>*LS&@4I7BG$4A/%%QD
M+"HG%6#4;+2N,JL*A(X(]:LLM0'O33U#H=#X9N -\7O75#D5P&D3_9[U"3P3
M7>1-NC5AW%=,&<E1:D@I:04M:W,@HHHH **** "BBB@ HHHH **** "BBB@
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M8VCB@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH S->?9I,IKQP_--(V>=Q_G7K
M7BAV&ER(H))KR:&WF,KDQM]XU,AHL1+5N.H(X9=^/+-6EAD_N&L9(UBR9!5J
M,5!'%)_<-6HXWQ]PU%F:IHE5?>I-O'6D6-_[AI^QO[AI<K+4D- IR]:0HX_@
M-*JR?W31RL7,B=.E.)XIBK(/X34FQS_":7*PYD(.E&!BDV2?W31LD_NFFHLE
MR(G3)Z4PIQBK/ER8^Z:B:*3/W33LQ*14DA!%5B@5NE:#12G^$U";>7/W319C
MYQ(QQ4=PN5-6EAD_NFFRPN5^X:+,:DC$\K]Y5Z%0HILENZG[AIB^8I^X:7*R
M^=%P\CK36 Q3 9"/N&F-YN/N&CE9+DBK< 9J&%&W\5=AMGEF&Y#UK5BTU1SL
MI<K*50R5MI)33_L#)SBM]+4(.$H:,_W#1R,'4,$6K9!P:L):;F&16J8C_<--
M*,/X#2Y&B?:%58 O:G!.:D(?^Z:3;)_=--)D\X$@#I30":=LD_NFE"-_=-5R
ML.9"JE/QM%( W]TTNUST4T6870W-+NI0C_W304?^Z:3BRU)$;'FBE\N3^Z:/
M*D_NFERL:DA**<(Y/[IH*2#^$T<K!R1&XJG+QD5=*R8^Z:JRQ.?X32LR>9%8
M<JPKI?#<ASM]ZYWRY!T4UN>'1()OF!'-:Q3(J--'7"E%(M+70CE%HHHI@%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 (>E-%/ZTW&* ,_6?M TV;[,P#;>
MXKQC26\0?\)1,8I4#B3C*5[A=DBSE)_NUYUX=<-XNE^;/[WI0!#I.OZVOB>.
MRU%D.X$@A,53\8W-Q:^+8G@!,IC7&!6AJSG_ (3VU ?G8W\Q5;Q!=Q6WC:W-
MP1CRDY/X4 /FU_Q+I(AN+F0&W<@8"<UO:WXKGMO#,.HVQ^9U)Z5#XVU:PET6
MVC21)&9L!0?85@:I&8?!=H)!A64X4T :?AW6O$6I^3=2N! PSRG:I=3\3:G=
M:DEEIK8;!W';D9K?\-J&\(VJQ#&8AC%<CX6N8=.\27*WTBH[2L5W>E $L'B/
M7M(U!$U60-"Y X3'6M3Q)XJGM1'%9N$+X 8C(YK/^(=_;7T4%M:,)9O-1OE]
M,BKT^B6E]HD$=U,D5PO(+=>E %C0+C7'(>]G26(]"JTR#7)6\3?92!LWXZ5A
M:9KM[INL+HS3FXB+; 1T%2VI"^.HPQR/-Z4 3ZEXIU*XUG['93+%C(PXSFNJ
M\/OJGD_\3!P^>F%Q7.Z]H-BURVH6=Y%#<1@_6I? WB.[U3S+>[9I"C,H<^U
M'<YW-@BGTT#'4TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :>
MPH^M.Q28H 9M4=*</I2X%&* $(&.:3'. .*=BEH 9SG!'%!( YXIV.<T$ T
M,.%[4W<=W R*EQ1@4 ,/S=L>E'([9I^!1B@!N"*;A=W'%2TF!0 W;@9QDT@S
MU8<5)28H 8,<G%*PXR.M.P,8I: (RFY>:0!DX'2I:3% " =6[FD..F.M/HQ0
M!'M[4H&T=*?BB@!@)/48I&4'@'FGXI: (]N4V@X-*BX[YI]% !1110 4444
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M.5"NRE_9\/\ =%+]@@_NBKF**.5!=E3[#!_=%+]A@_YY+5JBGRH+LJ_8H/\
MGFM(;"$]$ JW12Y4',RH+&'^Z*3[!#_=%6\4M'*A\S*GV"'^Z*/L,/\ =%6J
M,4<J#F94^Q1?W12?88?[HJ[BC%'*@YF4_L$/]T4TZ; W\(J[11R(7,S/_LNW
MS]T5/#910ME !5G'-%-)#<F%%+13)"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!#Q3233L9I: (9E#QE&_B&#6)9>&8+'4FO(CEF;<1BN@(!HQ0!
MSTWAN"35DU$MF5 0!CUJGJ_@RUUB\%S)+B0*%''2NMP*-HSTH X2'X=1BZ66
MXO7E13D(PXK?U+P[;:A:16I 6.+H,5NT4 4;.R2PM(;>(?)&N.*P-8\$VVJ7
MBW23>3(!U45UF*6@#CM-\"PV5X+FXN3.P& &%6M<\+/JD@>*[>''91738XH
MQ0!R.E>"XK"X^U32F:;J"PYS5Y/#$ U3^T-_[S=NQBN@Q1CC% '':CX):\G:
M1-0DC5CRH K3T'PU;Z%$51][$DEL>M;V*,4 1#=NP>@[U-28%+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>plrx-20211231_g20.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g20.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M9%@C3C$  Z8X$&D :SVQ"2^P P.9%^[P#>DI.,98@Y>Q#"\0GP4PGP=!#VD
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M]#! <=H2#?B U;JKNZJK]FJO]4JO#ZBO^+JO]\JO /NO INO ^NO!'NP5%H
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M#M_@#J+<%.94.#(QM(T\L1[QT& X@'<G"9H0V(I\2O1<&+1+L-?:T#EQGMF
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M!M?V=J19-8MGP%F3L+A.1\3Q#>'VU)/G-A0L(5*;<=DV%QH4D"^;%%8]-M'
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MR5!BR:Q(H';4V1S=0=Y4M&SMSDE#1S& B'"]&+%D635IVP<:1+3)3!@ 2
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M:%@#HZJ05\1( I1%A9C%8KS'Z?!%DI3'D4R9DBQ&? S)8<1%6O0*#G.=W#@
M%8B!Z8N+:,#"V/K($HG&AOQ)J+B=@SF0%>"U-)F0_W'&GZP'-VO%-%/#H42_
M7'3)F#3)>7S'A[!'7?Q%7S2/=P1+>@Q+C=L*M3@ 28B, .@)_N&+6TE(JK00
MAI1+!4$-(/&O1@,2$$S"#6FXNJ0);.&;CKQ(P'2]8(Q'KFS)7&3)LFQ)7AS&
MEJ3%R)P.K.1+?:O)#R0&!+E,FNO)R3-,,WR!C%+_QM#L"FXL$64)0L.TBJA,
M,P$\KH/;"C#I3(;[D;/JC&H\BX\SRRWR#$U PJP)N'M<3/TX27^TS,3<1Y$T
MSN)427V41:_8N32 1!6ZC14(L[NPC+@T306AR^YL,K3YR]#<A!>(/<)<S4%"
MDO&$"JHBRBSIB7$*BCP)-!J:CL/(*\<S"_]B&VBXQ["\Q<E43'L,R0(529>4
MS*PLT,H4R>#,BL(BEWC93S!\Q)YL2O"<BJ#$4"9#F_24RTI8 ->4R@ME&T6\
M*7830TU,C"W[2\^@C:1ID8$)'Z&80?2Y@<80 TF4B4E D+&K31-!#0)=3,C$
M1WD<RUI,SIA<3.241UKL_\VLT <<D!?L5!+="A*^B 81W-"XL+PO$,HM%8K2
M5!"+]-"A7 9/^M*L\$B9 )"9:-/$8*X7.0Y*&CN?$!(P\PG;0*$=(8P3&L4Q
MD*K\I G>>*5#ZXPG&2LDT0\0BR(9DH2<PYHB94ZKM,IA],IW7,D"G<P ;<?%
M#,NOR OL#))).  >49#*T1 2!=.F@):,2M-5):N]?-(&&4-5+<=-J LQ?0MU
MW,;H-$79D G:S*5;Q#1:Y4\Q?#S:0J:0Z0UWT0V=0$7CX+7>:#V:@"@EX<0P
MS0VSR, M,C8\<ZE_$8M779!NT47*+%!^9-!?]%1X7%=VC<RR;+\;B[A9?0O(
M2?\V6'6+$K1$?1T6BID3^:204V1/N7R0%UB&F5N0-?7/L, EQ[@SV*"'9A(#
M30 LV/"OL]!5M'!8:T4,%+I+A?#$AL&8:@4.Q[!"!"R3'6D1G,N,_AF,9W6,
MD/&KW E8+H*2$@U)(SU06G32D712=;W*,\G46@S0! 76BEH&"_77K["\\VS:
MJ/@?[,+"*TT6<RG3CUR&""%7J6B[S7G4WAB8^4J<8&)6U)F3,'C6@KV+XV@\
MF7BR.MJ0+]&)@]&70[LS5>&PBP&B1J,2GX B)-D1U @91ZR)V)DR'\DOR1"8
MS5-$2'46U,!4 R7.K417).W');U<Q_S1KT%('8W:K?C_SM!]BKSP"<]ABU)<
M$((%3[<142"LB8^K6Z2I![9JEW;K26*H-(GQM&2Q$IJPDQT9 RBZ#+5LD]_P
MH-U1FVO" 9F0'2=2ALN9J=O('$T0L(I-K3/I.33@P-\8F!_*G7\Y#-45EG<Z
M4*%-S+*LS,J$SL<D266H7<;LV:T\T*X=$!)AQEPA7:V(QHW=W\7H#1##PDGP
M7Z] &UN%Q66H@24K$5X%#=X( Q>*WO"Q#8B94='3$K9M6W\1D$+]%S19!KH:
M#*3A(Z'3DP_*M&0"$]T0H3$8D3D1F#L1V<8AX=YE+_ARP1_Q%[&AH=Q9(JMB
M&\E%4/>%Q_5;*P%=*WA,XEGD_PC+'%(DU=ZN*+AY/56K0>#_C8G1Q6)?0[8#
M<5D2(=/N!*H"0"0365.<^!&-T=-L@I5] "NV C /TQC<9) P(8Z0H1<.W T<
MT0>=")D]H<[<^.,+@R.I&8Z<5$18D03L\6-FG02+":%8?58M:16X0B:L"M^Q
M(]]@00W%A$R>K93YL[FQ2)G!X(BQ0X-3GA.O-%H%?4P'G0K3A:@F(1_X59#\
MO6(LUM M9HKFHE8JJY":REJ%/%C[]=JIC(GI^"O86(P_,T1EUH?,B)7.!=7X
M#!FQJE/H+3N(:@M&ZPEL@J1HQN-,D 3=U81_$8.\VN:Q931Q!68NP>.*]<\=
M6Z;O8:N2)2E@$HD:EGQ??SP,9",BX   I_KG'8D=S !EXNS96NPILB$[FJ7F
MIX@&1E B7HX*+;;HSK#CB#14"@&1:#7,3D)#]&P6>C 3DT;I_UB*B56(9  %
M91"73CZAAYC8['4,L% ,H=NB'=F+F7H(SI"T<#L[%#4.56D2XPC$B/X0Q6S.
M]H5'D/!C]L/" _#>TZU8L%O73UY7]?6*,<R0 X"! ,@VAGE$^,GHI^C_W[.F
M42SDD!!A"Z4V&G/)Y36\EA#5%0<&EGIH!W,X![XVAUZ 96!I+@^!HF]DDM:
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MTY$N-!HQ]+S&D54,H;&" 0%P:R],]B[#>DI#M\28WK7C5,]69=@^MZX^MP6
MD\Q!!?SNS2VS!E<>/QER\3-!/O))T;"NC\.3&[V/]2 Y'/;1*2XT$&FSA0BU
M:%)#9&CFZ$8J5K4P$!D#&KA&'EU>"(H)6$G+>-T\_S!%PU,EMM>_A]7% *B[
M&/Z:@R^Y#= [X_E4E?"VJP92,$C*Z8A%WG6BJ&W(>_%2C?@\=Q 5.255%SM
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M"I90TC4!M.9K6<A-##V\4+3ABW003P"6Y9C.>/2#! !5_:I5ZPUP00.R?DU
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MKCE)TB"<'DV:2YH^AO\ .-/OR=O:Q.&Y*/^HOT\_9>CGYV[0>,*.R>"UDC5
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M&,F@=^-YE^0D,!D#0^@AU[T)C6>  N4'^2$=,( $.V* #M#W_Y/-R_/^CVK
MJ #6X,DJJ=LTPD^*H1)>K PPQRYH1U%L@1>&81@PX1,83 _23\E*:\'H8/\\
M  GHP/Y$0AD<CW=*80!9<+N<KP6?1OH*P.'_?BXZ@DXCEB$4'!!D8FP?5@BK
M?"T;K"4;:@$3>$> ? >EJ@Y_GF&(]B$:EBW2[&: 2*+0K+!^. P&M="6E('*
M!' +(2;T2LV?<NGZNJP8U. + D4-BF&CSL@6O(5VJF47C(UWN$GE^NTB4I!W
MLA ,_?#)/NP/_27N-F'NMJON."(K)&H''(8--ZI]WJT6(N$2(J$6>NT5+-$<
MG/# ]L$$!?$3K>SE0#%=0F_T>JKT$K$8RN!#=J 2B*'<ZJP67*9ND@ 3(F'W
M;A$29&84>9'Y#*X7B840QW">E&DCJ&H5XZ(2NB,P,/$,A$ (1HH4E $*U\\#
MK-$#2A 8M;'L1'$;_SGE-@[PX;SD(H9N 6C "WP!C6IA$<Q "/+-AYY0B8P/
M?TH!%+SQ'EGN%_%13N*.!B=,&<* J11B&7;0!;P@%N!0$EVF#;C.%&3*WQ#B
M(/)P'RG2RO2JRBI22LS'Y]"+A?;$\/9A$?/N"FP!#A<A$MK #;I.(C.R)</.
MP\C.):-$&">,1QIA!@B !ARA%XBA(*^ $6SA)"\ANTQ.)HTR'_GI**,D]"BL
M'0[!!5Z@ %S !;J@!O*N"QB!$80A ]UJY93R*Z/L!<%20OK1$%.+&+Q@[S#D
M!5Q@#,9 &(3!_!YR+.F2VKH0(^O2.,#1%/U)$Z*23<A@&-(J+PESX/8I)@8+
MLSC>XH3_*(P8B(X&$BHQ)3,LDW(RB\/3QDVUB $+U!(JO" R+3,TN6OL,DTT
MO;$]7(#O&.$]3+,U7; R77,;Z4$8&$$,9F ,>$$8,B\V>7.0]+$WM5"+M"=T
M)&$?^!(XD=-OH $YC@HC+O(+D]/_*D8,0--4S.P&HS,[_682H@- ,$(LM9/Y
M, 8GBH*\3BP\T3-SV&L26F*2 A#FTC/F)@A4C@DC1"@^\9-JPL(L]M/? C$_
MPVXQ""<^;BHY##0^(F=B/L5 .8=!';1!(?1!)31"*71"+;1",?1".6=#F:-#
MF\-#.?1#131$211$371$3[1$471%5;1%4_1%611&731&412O_P"T*ZQF-(A!
MJ1!"014T( %@"RAF03.T2"_T2(TT29%T296T29GT29TT2J%T2J6T2J>T.B<'
M&AK!  CG28R"&!CC  J$,_ZC(1Q$3,\4!M(T -14!<243=>T3=]43F$ 3MVT
M3NG43N<T3OGT3O443_OT3.]T3]444 L53@^U4 EU40V541'5416U427U42<U
M4BGU4BTU4]&T4C<54SM54Q/U4SOU^F[4)/:S/W#".,TL!MB43 '@ %9@(EH+
M(@Q@!1BC5F_55LU,5W%U5W/U5WTU6'MU6'FU6(&56(_56(5569%U69/U69TU
M6IMU6IFU6J&56J_56J556WNU4%>U5_\; E=U-5QU50'[AF8(U#H[R,P:0B(<
M0R+<M3'D-5[IU3'>52SFU5[S=5_KE5_O]9 2I(/N%5[G]3$&]F#7U;4*=F$)
MMF$15F!;:RR.Q6#7]6$I%F(Q-F';U6(9EF,=MH-@HP]+]23ZTVK$9!_>U3$D
MEE_A-64OMF5?=F 5%F8+UF5K-F9?EBQH=F=MEF=?-F+;U6=O=FB%5BP:HF>1
M%F>)]EY#1V&3EFC7E5X9-@8<) T.:(((1Y),Y<) 81@TP3^H\ZZ\-DON2L,P
M3!,N#&V1@VS9=FV]]FSA5L.2P34 8'#*]F[;%F_7=F_UMF^SQ$7"PDSXEFVQ
M9&V30340]W"OWU83%#=Q$==K#S<3(.>N*+=%UO:N '=M,Q=S+]=R*W=SD6.I
MT*!S.?=S.Q=T4?=TD:,_H$AS5==T8==U8Y=SAP'B=G-D1P(ZD(8[9R1M,>PF
MO <H'A=QT[9XQ_9XT19YC3=Y5:-K-<$+*W=PI==OIS=OR;8_)F)THY=ZN==Z
M!Q=4[LH-QN(&)J%ZS;=[S==%)B(RO!=]W9=M065M&8)\S[=]B<%YEW=M\1=\
M-T=-L?^S;ZS&9W#"/ /27)F"*+#F-0Q8*8AA+"Z#7Q8X*1@*2[NB-& +=YGB
M7AY"$YRD++#&>[QR*6P0:[B'ERP#XB[##5; A"M#&7   (HS>PS)DBX"%2OC
M->"S6$:X,G8BISJ%7_YW*3)AA2FX*<0'@YN"&.(C!G;1(M3B &*8,G;B $1V
M*>IA(CZ',L T<HJ8*;#X,B;H@K7X!E0@@JEF;5DI:ZQV=32ABAD8!V!@C7FX
MBS-X+)IS,E)$2RP#A]T8B45"'Z81/O 2+50$,[+W.)$B2_H8*>HA.L0@A),B
M7RZ&:N58ACEB>S#!:9(A8S+99@#'C#4%XA#9CR/F/[5CDBG_8I&1 I*3 AJ^
MV&F@HXR%R84%LF9BQ  J&6* >)3E1+#$F)3IPK<\V&E0^&8B:2UX64ZZ2)A8
MZ(YK!AHVS&DH1I4S976!V3*8DYHS96*T64ZNZ&GT(9JO>9S).3^2N07-LIS5
M>9W9N9TMK9O=>2/J 1K.N4KHF3X@9I[I@Y6KQ#RYD#7@64J6D\PDAH[1))L3
M J'/9:'PBJ$#.IZ=F&*&$4TD)B$VQYEGY:)#I3^X&5V4836<XX$^18^EZ)X&
M&&)T]RRPUR% F48J!B<(A[V*PJ"GA*'D1:5;HCPA.B5\ZS&B>,S"XH*?9$_0
M98E/@W XZ#30Q::ITU0$BXCKF6I\3CD,:'BAP?8LRG %?AEG6N(GS&0A3J.K
MS<53BB(ZZ"6L&VJG<]<AV/, :+J?GZ1N$0),(^,AWMJE(>(3!.NN6H(]TWI3
MQ(!='N(EYG,QS/]"BF9"14YZJ5L+:>HA$[@4K%MZ0GSB3NX)&I1*L;<:9^BY
M)33[0*!3K44B77=BLJ-DJ"&B1Z7C2=Q@K$=7)U;@4R)$&?H%7;QK&)9!#&"@
M*A;[B##&GECEH27D0+C3GM) !>Q1MSGX7*!AB#_H-.AELS>ED?NE9%-5M$O"
M2W5"EL<,>T\6#40G7=-EKTM6J9F;C]EK/EKBKOT&08"[O?PE3)1!'Q8C*.;3
MMNT:&@:8O=C;I=<[I<=3N.,Y78<A $@U34QV/DI[7$IS5ACB@YXD)]Q[S'*+
MH,YBL)/HM^DE# 1<0E(%::8L ,Y"D&:%H2KBBA^9O3K<Q!3\S"+<.G/_&+LY
M0KL7_%_"I(  8$"K6E8\92TV*$+H^EQ>1'>5. 96Q8>1: MN ,-P8J*G1"::
MNK0;&9_,I6*<X[NRI+<YA2708#EYHIZ0P[QE7"2*FQ@$%*4A0L'+LSW'>H@'
M1\%A>HA-6T*69G<'>#XU7(I:(KS^FEB"&JL?(CZD6T[4HB@F9A\:X30>(HBG
MY)Y^0CX$'</'_ 0#=M!+7%5,Y2&Z>L6-8XMQ8G1-^B$XO3@B2;QNH"*".CKF
MG&]8(@S$(%DH_+#'I57ZF[)9!2><IQ.;1];]G%7DY2"4^-.C6K1CA(EJO=%_
M(J%9Y;6)93F;Q[!,Y2=08Z$)RSG8DWQ''6*62N&NLOUOR.P)K=E<6*@U[DJ)
MD&/8)61M%:*B)[T*A=-F;-14OIU85*3>3US>N]TXWCTB5P3=V_W? 3[@!7[@
M";[@#?[@$3[A%7[A_QF^X1W^X2$^XB5^XBF^XBW^XC$^XS5^XSF^XSW^XZMG
M/M(93>X9Y)$B7^)WWD_B0#9,7U#"/%N^:UU>)?)=:?S=Y/M&8C)A-;C]*)B3
M8D EVSD:Z->VYC&>O8Z&.OD9(UK]!D@%)^9<8B (51,D#$AEVE>>&'+9BK$$
MYV\I$^"851L#UA4H/F(U5H_:)/8](<+B[&G5(= ]18Q>B52>G:,A(+D'7QF=
M(U[X0<1"=$@"050 @J:,>Q)KJ':\:F( !HS^GE;=Z_U&)OZC5D,V)?@%\<<W
MGUB)@&)DA!C* '1VA3?1)#K?Z)W]\?&3'EC5KKBS(9+F0/19WM?]@9SXM?\4
MU)'7W3Q56HDFR*TM I!9@RA&>O>5(4#J7O;M8Z=\>*/7G>G;;O;IN>1U B)0
M'_+U<T\6ZC4B&ROR9:-M-%^ 1BWL2?DQI=YCW]P).G#)/HO\ ]2+'_8)NMZ=
M6/[GVI%C>HL:&O9SGZ3E_?X!0AF]?<LRQ0 P2=F^A0P;.GP(,:+$B10K6KR(
M,:/&C1P[>L2X+,R!80R)W0"0:>$D,3=NB"&V3YE+A?LRB4%#<V&]&S%2[JN7
M"4",A<ILQKB1D.%*GFA@*CLH-%/.AIE4W*"I#(U+ELJ*BHDA1JI.-%]OX*P)
MM:?-FU^;IFF+=5)+,23WT7L["0T7I-"4B0$ 8,7_V8^$"QL^C#BQXL6,&SM^
M#)EJC)X,]>$ (*FKW!4&8J !ZA+F/I,QID)KR_ IRIB3)A\5K4QNC!6>NT(%
M\!*B7P.3&!ID^9H8FH-\?]KL;.#E:<"X,PT7\S6YT>2POZY JE"92$DX8,1(
MH\PD\ZN1RYL_CS[]19DK?,9$LZ*W0;#$NZX H+ >&@"?&[(/Z]Q!:/ST%7V>
MV1745M?9!H *8DQ%50 W5-<@#CBU!A9//L'GDH#AG218;,1])=0-800 PR31
M*"-) & !,.&*?QWU%P#$[':=>^KMR&.//OX(9)#FS:>C&"%F8N(DDQP P#!/
M'9!2;+@YY)=0:*QT4 PW1@[GV8PI88@&DNWIQYERNOW5VT)!X=:446$=E$D]
M,L6@Y$F?&01C)L(!=J4!90Z77$PQ&'#E9"D1D^5*!ZB0T"0 P)";D)+_3DKI
M>3NUUY"C Q(C55&3P;3?)-"0IN-/)PU*6U1HW2"5F"FET5Q1-]8$P %=1114
M&#01\]>#<MYP0&88*L2I9K@1 XVC$Z)%9U: (=MK>),YN5\:^NSVH'CR&5I/
MI=Y^"VZXXH[[D":&4@4 #@)I,HES*@"0QCYHJ(#3;FDRI!]@G %V()'U)(N;
M,FY<EU!XV<$I494#J@E80LEVIJ>C#XZ:22:M";7/<@GE^^ ^,]XXR8)!];3G
M@ZJ)JAU_T0P30P"ED@MSS-]"<RY1H69<U$JJ$A/P;Q!"PT6)6XFV7W_YQNOH
M9&&1!)10$&8J(58GQ3N:"@&$P9+3&7,J5\#Y_PZU3QHP+*MLMV(D5U2MT)WD
M*T^2[!/-7W<>];+,=M^-=]YZ,ZNCQ.%QR1-"T)C[TGP05@D6=&%VRR%-(TLK
MU$U8U0R128+I]#B! !C04I::\734E#L)7J48"Q6MT'XWU#-CA\>J)IK<]&AR
M@PIU[XU[[HC5<Z)[](@1[&@L14?9/H9^9;I#.WE&S(TYH0F-76\X&),D/,%P
M@!B:T%J:1,, $$9U]"XTS $PX,!64FL%?L/V(T??VK+OR^M@42BR)49O?GVW
MCSZ]]D4YW0EP@ 0L8&+F<R^/\2<K1VG7220AIS!X!@V0>DB^KM*5G"@+*YN#
MB4U AQ1!\29A-[@<P_^6):_(Y25_G@*+<S"FP,_$)E#[\%M-%C2C1J!AA_4:
MU(:R9QN7&7"(1)R(3&RW#'IX"C\>DPZ&MI?"LHBF(30KGD/@<Q9[$85=7X%!
M2D8VD4Q$;2$F"=X^S-63KMPH&O00$*\"1H^1=2LH)BN;QP* DZI,*(/9.5MO
MEM&K>@R#)U,LHB$/B4C=(5"-F?#3,(B! Q7$2QDR0$@TPN::&$#1/V=K!$0P
M)!J_99 871L*HJSXD"JY9X/O65!XPK(_7^W'=#)!2$QZ=;H%<LQ95P%*6.1T
MD-@Y:%0^3*0Q"5B/R]SD+0<)PS+V44*W>,<G3S% P"Q8N[J=<A*<.E<FTN#_
M)"0%0']P>IJ:5-"]F)PH>?2X 6]R%J7 Z&E>R])$!Y/U&N[E,EN&*DI3;IFB
M_OTE#"N*ICF/B="$*I1'+(/1V@ZBKM)9[%UHT,<^&IHNBU)IEKKA"8#\^+=V
M[6D%?;'3K%(IMVYQSW&3:9<?:PBQ4BZD5_.DH0T?QS.U?(6<JPD;VDSBH$(N
M=*CB@L:)&F0 %Z&P0, IWJ50F1H<0'4AT!B.2WB2)H-LQ24D>4I0+_F0)77L
ME@=2B=*P&A-@A0$'/%D6RP+PH-9,3&+10YXR\&D@9.TO)<O@J%\.$ 85$76P
MA"WL83(1R:3"X'ZBF4]; R")9\9-* G$UW 6]A"C_X"N8YH%74I8-YG!4&FG
MOEG!6$44.LX6"'3=XU*80K:PYR@D?C/-Y%E(0Y.V+",KUQFK87\+I'JL$#J2
M2PU9KF23NM0P3Q&11*0@LI:P1$]-9!&#)#;IG+ ,!*5)B8E-=)3=_$V75SB0
MQ"32<%TUB4%7SDF*7_KSW6YY!3KNL<GV]/'=9_)*N\#MKW__2Y3S.G>'W?4N
M(\(DG'MAXCK*I:)P;L>:FR204]!I5TF^:TZ@A,FX<6((-+);8.%<B6OY:>\\
M?6*Q#J?8<601BW?'FF*+9D6\ *[Q>:#QKXQ5!*RWY,UV'\+CC@1Y(<\THO*F
MNQ&-PHV*.G$(DCU\9'P]V8G&5*ZRE1FBQ,N@8<A7[K*7P643H6SRRV0NLYD'
MBX9%3?7,;&XS9(#B0B6[><YTKO/=5O)/.^MYSQ^Y*Y__K!N&+$.C@RZR/G),
M&#[JYE:I(0:B8\+HU,0$T)2NM*4OC>FAAF?%P[#8C2JFIYQI@AY<QDA1=-CA
MU-C$O-FQ"8)C(AP69BK5F:ZUK?]OC>M<>VLMK;H)*(:QDDE\@E>L,J=&LP.1
M.;:I74@FI9[>H+^F9*53(G5.JVNCZVQK>]O<[G9'_O9+G\4&.W[)'T2649!V
M<1/)7>F4<GS9D"M%SR9>45,C_$DLU6+'V_SNM[__;>NB5&PT%5.&/C11<*"\
MP4D0:6-8=NB4\(C4+RCV;5CTRXB*)8_B2NICE!)\4("+?.0D+SF E2$G^<:D
M'FR4$U%<KIN>R*E=?WNU7QH[UM-DPJ*:>.W"..X&^8;%-P4VN=&/CO2D7_DI
M-,D+A2>1XZP@2WC/ZW""\T*4L* WZZL4K=*_#O:PBQV1,J&)),#SX;S$B>+J
M;0@L+YK_!HV3L4W@N>44.S[VO"NFU(*6,]Q4JO? "YXB3XD2>@'O[&EK1K1X
MMS:OE%T42<#$)#EQ0]$'?_)1=N5?,-<)COEH,*)DT(*' [R1(:*/(J<R)PKY
M<4/DVQ75=X74F*]][9^RA14>E%=Y^6=X;GFEW)PF3+^,S94VK!2OVQZXL1Q>
MJ\JZ$)=D=S);Z<M*WIX:L&@PA!19R90),O2'F.1>YS6G7[;2U0\J?_GL__I.
MTG"ED!.\NT4)\,")?';EPM,A-S)]^PMK?)D%%K#Q*61D83/E0>%'%!IB,] G
M$4CB?Z<S":Y'1H-"-)D!$62Q)2:3&WCW$*HG:!_X$*GG$-&@_U+10&C_IX)G
MABC$H ]\!V44R!!LY! DZ!\_L8(VQG8.P6OJ11XUD6?6ED&F=WY6QQ)I@F<=
M%AO$U3%X-@G7HH -\0GTM1!I4# &,RN,]F VH5ZLYQP#5F*2 '$UL1(N!FL2
MIA 6(X:9P @K$7?.988Y*(<U5E7R-X>85FZ@)A6^A'PK!!L'&&S(-15^H4-I
M2!;R(0;#!DO6YC.9<%W#$'?Z(5C\%Q;:HP]Y$5($-A7VA76WU#=I%'_*$'<4
M-BK%YA_2%FYAT4U2@345<R5W"(O^U7FQB&OEIB0B51-A43"5R&)$DT:>YA^L
MPDTY(V_AIW:-X!-B@ .\TBGT]HJ912\7FI 9Z*4,NZ5HOF%= 6AWJ2$7W2(<
M%#8,T< K%#85<I()*\,73I<L.# 0DB.)W_]'B_$HC_-H'EE1+^$Q;P"B)QI'
M30=(%ODA;ZFACZ"6%SO16,>'8L27/]F58'YW2]O3%/&G1 9#$QH66?7FB8+&
MA9Z(!CB@))CP48>C;MAA,=6XD5>R6P5)CRO)DBV9&#M(%=QD,3(Y&-^H$OV1
M+ ET<S,Y3Z*B)2J1%]S4/V5X$_NX)95%/F*0#&2('5R38O_R39/P3)>X,#:Y
M$'&T<6$!AZ 6>2#H%7HB7B5YB<DC7G?Q-BZ)EFFIEA7A%Z+2+3A60]+F$J,2
M*0^6=2@W;<&X@5+QBK"4%>V"7KN% [I"<QFT#&=G@PP!"MIC5B8#:L.@"0>7
MC32H"8XI6LDR5W3_1Q++D( 04I#18!;"52^()8%W57YKB9JIJ98S!FJ< H1=
M 1W[,(58D6?)4C&X6!(= QT@(Q^O-0DDX1P6 Q:#8UXKMCA3QQ##H)1J<@-U
M]Q#KU2Z0>2U.]UP$(0D'\)M#9WP:]S>N]Y5KD3,H=Y(;8UZJ:9[G28\S&92=
M,BNN&7J0MHDTEUG9,74N1DH) 5;$( F@UBV@H"1BX3QYMA#1D FJ1PP-1A7H
M985BD2Q-,663$ ;?Y!X%P6JPQF4I5BR_YUT+H0FP 6'H":(A*J*1$8>.L80C
MBJ(IJJ)ZHZ'E<7\K"J,Q*J-$!8,S:J,WBJ,YJJ,[RJ,]ZJ,_"J1!*J1# TJD
:119JI$>*I$FJI$O*I$WJI$\*I5'J& $! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>plrx-20211231_g21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g21.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #/ B@# 2(  A$! Q$!_\0
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MGA_P_I5M#<^&X]4L?#_A[34O8=/*,+S3]5:\GN0P&X&6,B,-][(Y.*T-6_;
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MKJ]U;VVGR7^O6DS:#/\ Z#JD<>G6TT;2*DLJ%HI)'48D< C^%MR@ ^U****
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M[^?-9PPJK1V:*4B!8;79<ID LP!]2T444 %%%% !1110 44U]Q1@I"MC@D9
M/TKXOU?Q!\:=*.BI<7?B77IK;QKJT,L%KILMI_:ELES;K:QB6*-DMX?+:=U:
M3]VRQG+YY(!]I45\#/XR^/JZ>Q2;QLSB;S$8Z.H=M=\M2;(CRN--WEL/_J_^
MFN*^F-6^)_Q"\-_%S0-#U;P9H<7@K7-5DTNSURVUV22]W"TGN$9[4VX49^SL
MIQ(<9!YH ]AHHHH **** $50O0 =^*:L*+C"*,=,#I3Z* &>4G'R+\HP..@/
M:DCMXH6+1Q(C'J54 FI** ,OQ)X9T_Q;H6H:/J<4DEA?Q&&X6">2W=T/4"2-
ME=?J"#3]!\/:9X8T/3]&TFQ@L-+T^W2TM;2! L<,**%5%'8  #\*T:* .&/P
M2\%M\05\;/HWF^)$E^T)<2W4[Q1S>48?-6 OY2R>62F\(&PQ&>37;^6@Z*HY
MW=._K3J* &>4@VG8N5^[QT^E'E("I"+E?N\=,^E/HH :R*QR5!/N*/+7CY5X
M.1QT/K^IIU% #?+7=NVKN_O8YI%B1=NU%7;TP.E/HH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN;:&\MY;>XB
M2>"52DD4BAE=2,$$'@@CM4M% '$^+/@WX4\::78Z5J&F^5I%KJ,6JMIUB[6U
MO=7$;B1#/''@2J'5'VMD%D4G.*ZG5M$T[Q!9_9=4L+74K7<&\B[A65,CH=K
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MMZ* *#Z!IDFK#5'TVT;4Q'Y0O6@4S!/[N_&<>V:B7POHL:JBZ18*JA%51;(
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MX2F\/VKHLMK>Q:M9:G8WJ,6&8+BUE<-@J0<A>HQGG'I% !7EWQD_Y''X._\
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M*Y2S_9_\$V^L6VI7&DQZI-:S75Q!'J2K<1PO/)#(2BNIV^7]GC6/&-BY ZT
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M^6&154#]X9+!P8R?ND<Y/R_0]SX>TN\CU!+C3;2=-0 %XLD"L+@!=H$F1\V
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M\#21I,H4',;N%;H: /5/A?\ #_P[\-?"[Z3X8&=.EO;F_=_-$F^:>9I93D<
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MYY('XUMU\S_$C]AOP]XZ\2Z;J=IXAU73((OENX+B:2]>5=Y;]W)*Y:,\D<9
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MVZ /G,/^>< 8^I6OGSX\_L)ZE\6/%FG>(/'GQ$U_7/$EY;K:7DFC^'"UE9P
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M2QXXW#VYJMJ4_A7P7X9U+5+M--TO0X;<"[F6)%B\I%\L*P4?, H"!>>R@=J
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MHQV! ]J]]KR2'_D[&\_[$F#_ -+Y:];H **** "BBB@ HHHH **** "BBB@
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M/H>M:.?".MV]NTLNFZA= W!8%FVHFT%@(@LC'MYBXR.: $A_Y.QO/^Q)@_\
M2^6O6Z^?_A[\2/#?Q,_:@U:^\-:D-3M;;P=;PS2"&2/:YO92!AU4GCTKZ H
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>plrx-20211231_g22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g22.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +1 [8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^ #GSO\ ?JCH?F/\/Y5*$.(QQBK_ ("CDC$GF*1\_I0!W:CKFG#I2'I2KTH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *2EI* %I"*6D[4  JO=VR74+(Z@YJ<4R1
MQ&A8]J%N!XOXX\*I92&XC& QQT]:M>!_!R3A;J09^HJS\0O$-NX^SJP)!!JS
MX"\2V_DK;%@#74V^4#TBUMTM81&@  JQVIBD.H8'@T\=*Y6 M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI:J::[3:?$[_ 'B*M]JY6-"BEI.U% "TE+10 F:*6DH **6B@ HHHH ****
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M+B]J7O4?F+G!89^M*IS1RLGF'FCZ4GUH+;12*%HIJD-3LTP"EI,TM !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !24M)0 4W-.--YP*+@8WB>.231YDC!W%>U
M?.^K0RVU]()%;DGM7T^X5UV.,@UY-X[T>WAO5(4#=S6M.0'(>![.=]46158+
MGT-?0EHK"U0-UQ7+>#M"M;>P254&XUU_3@=*520#NU I.U K(!:6DI,TP'44
M44 %%%% !1110 4444 %%%% !1110 4E+10 E&:*2@3"EI*6@$-I12FBBX[B
M4@'%.HH#43%(> 33J:W0T"=['EGC^]$5Q@CT[5Q]F(KR96!&0:ZOXBQ>9(<
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MP.>*X+3KF6UN4!R>:[%\!Y\TN<]Y\*Q>5IB#'\-=!VXKGO"<_G:4A/\ =KH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4
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M !=P/QJ2"[BN4WQL"/8T 3TM4GU.VCDV,X#?6K4;B1=RG(- #Z*** "BBB@
MI*6B@!*,4M)P32L 9II. 2*Q=<\00:3$6=AD#UKC'^)D$CL@SZ9S6B@P1I^-
M?$-IIULT3*ID(],UYUX;\3K::L9I57:W'W:S_%NJ-J5_YN25(%<\&R%VYSGB
MM[6B2J:<CZ>TC4X=5MA+%C&,\5I<-QZ5P'PS\_\ LE3(#C:.37:7VH0:?$9)
M6 '7DUSM:EV2+G%**XS_ (3^P-UY0<8]<UU%A?PW\(DA8,#Z&E8FY<HI.:6D
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:>F:=3#Z4
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MCS9?F)/>@"SK]G++IR2#*MWJSX2WBPV,V2%J]K>9=.&P=?2JOA6&2*)M^>E
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M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3%+10 4444
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M*0DXXJG:ZI;7@Q%("?:K@!!ZT/0!PZ4"CM0*+@+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,)X%4]4
MO5LK!Y2>0,BK@X !ZUC>(+&2^MS$F<$8H X":=;FX>]8?,K8'%="==,VEJ(>
MN0IK0MO"\2Z>T;#YCSUJE%X8>-&1,]21S0 EII$SPI<&5OF/K67J6G$ZL@9V
M^]6K:P:E'<"W(_=J<BK&HZ3/+-'*!\P.: *<H: 1Q@GD5"^H/82A7<Y89&:U
MK32YI+F-IAPM1:SX>>[NXY$Z*,=: ,:\U&:"WW$GYF_G5:UFNHKF.5"6#L!R
M:ZG4?#YN+- H&5 _2LW3["Z%PL3QC:ISTH [&S+-:J[<$BIQ38UV1*M/[4NH
M=""\/^C/]*\QNE(O'R.YKU*9=\1%>=Z[:/;7I?'RFN+%IM'?@96D9^1C H )
M-*I39N')IJL\@.Q3^5>73IOF/;JU%R7*=_<^3A1WK)VF3+%CUJ?4(Y!<+Y@(
MJ)OW>,=#7O82@MV?'YEBI7LF(J\8R<U)%/<6DBR1NW!]:,9?/M3 Q8,/:O7E
M"*B>+"M)L]0\+:S]MM0DC?-BNG45Y7X-D9;S:"<9%>J)R@S7G31[%";:'444
M5*.A!1FBB@ I:2EH **** "BBB@!#12TE)@%,!^8BG4@'>A!8:QV_,W %<1X
MMU*.YC:U0YSU-=+K-W]GM')..*\Z<^?.\C$GFN/%5+:'H8*@V^83PZL>E3,T
MP&U@>OO63K;17.M2/"WR8'%:\J>?&5Z?2N:EADM[QR<XQ6>$ES,>:0<(7)7C
M7;M'>J$7AU[V=F9C@'UJVUW'M//(IEI?W D8)T)KW(Q31\C"M-$-M8+;.R-U
M!XJ]LP.!51_-#L[=SFI8;C=\IJE3AV,YSG-W;)?+4\$4U6>!LJQQ4F,<T[:&
M3FIK4(R1M1Q<Z;W-&RO1(,.>:O$YZ<5S,;F&;VKH+9_-B!KY[%4;/0^QRS&*
MHO>)L[A@T*0H*]<^M)E%/)_6@21$XR/SKCBI+H>I5JP6ER2TN)+.X5D/&>:]
M%TRZ%S:(^<G'->:R#Y"0<XKKO"MT3;LI[5Z.&;BM3S,93BXW1N:A=I:V[,QY
MKRG6(SJ.J"<#A3_(UU'BN_9KI(D;@CFL55$:Y'.:BM53=BL)A[QNR;4;ZW;1
ME@&!(,]JY.&,%=QYK1U6W9DW1DYSZUFQ.88\25Z&!Y;:GC9JG&1%<6AN&V@U
M7D\.^0RR%CZU++=E9 4JU-<S3P#V%=TJ29XD:DGU"&(! N!Q4I50-N*I1R/&
M?FJY&ZO6T81L82J2ON1M"H^920:GMKR2!@&Z>]-(PU,F3<,CM7-5PL9QN=N%
MQTZ4TKG0PR+-&"#3MV#@5CZ7<%7\LFMIU7@YQ7S.(HN$[(^WPF(C.%V-^Z<Y
MIDJ^:=RC!'I3F* <L/SH5D)7:1S[T1ISB;2K4FFCHO#>IE'$$A[XKM4.5!]:
M\MLG,.JQGL37IEI)OMT/M7IX=NVIX6)2YKHL44E+78<FXM%%% !1110 4444
M %%%% !113<4 *1Q7->,KV2RT:1T^]MKH\8K+U_3!J>GO$>XQ5+<+'S;?WD]
M[<.[2-][UJQ8I+>RK;EB?QK:UCP5=VUS(\:'9DFL.SFETV^WL!E>.171 &;T
M_@&^G*O$#M/H:[KP7X,_L_:\Z_,,5B:%X\!G2"4+CC^&NTU'QA:V=D)$9<X[
M8HJ.X)LU]>O!I^ER,O\ "O%>!ZQXAN[R^D42LH!/0UUNJ^/5U&VDASUXZ5PL
MUC-<RM+"A.3V%)120G<WO"GB.ZM=12.21BI..37O=G,9[2.3U%> ^%O#5W=Z
MC&TB,,'/3'>O?[&#[/:I%Z"LIC1/FG#I333A65@ 4M)13 6BDI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &8YR
M:7C/2EZT8H 3H:3']W%.(S2 $&@!N #T&[UQ2XXY -.(S1B@!O ' HP,<C-.
MQ1B@!ISG Z4@"[N% /KBGXHH 2CK2T@H#4;(0J<FN-\4W<3VK!<%L]JU_$&H
M?9;=@.IKAMSW$C&4Y!K@Q-5+0]'!T&]1V@VGVL8<_G7:Z?H4$8R0#7$02O:R
M[HL@#TKO-!O_ +7;Y)YQ4X=QDS7&<\5H<GXVTP(%>%#P#TKC0V4PPY%>TZEI
MZ7UN48#)%>=:GX7GAE8HIVYSP*]BFTMCY;%4I2=SG.<4W:57&>35LZ;=*6RC
M#%9BS.E\%D!P#WKHE*Z.-47'5G=>"=.82^<P]#7HU<-X?U^TMX5CX!(QUKM+
M>YCN(0Z$'([5QS1ZV&:Y2>EIN:3=61U#J* <T50@I:3%+0 4444 %%)0:  T
M44TT"N.II]J44'K4]0>QR?BZ1EM=H/)%<E$G[G/<UU'B_(VGVKF1D(".E>5C
M'J>]@U:GH+QL/M7/WUVLMR\..W6M_'F1L.G%<S,JKJ#[AVX-:9?;F.7-Y/V1
M5:R"HQ[@5+9# P!S5O<N&[DBJ<$<\<S/M(4FOH[I(^+BV7#ACM(JE,GDR9%7
M%8,_H:BG7<V!R33YD2U)L=%)O2I.F!4<-G<I\PB;%2%)<_ZLTG45K&L:+L17
M)5 ":M6U^$@PIYK(OC*3MVD5)90.%R]<DZ,9O4ZJ%>=%:%QKR61SUIIDE!R#
M3U4#I0..M-8.%A3S&K)DUKJ#JPC?H>*])\.Q(--:12,D9KRYTR,K72>%M?D@
M?[),2$)QS7/+#\J9VX;&SJ249"Z@6GU)V8Y"DBD!P>>F*+@[[J0K_$V12DC(
M^E?/XCFC,^OH>[%6*6H2B*'<.]<_(CW7.<"MK54/E[A]WTK,MV^0 \5[. NU
MJ?,YTWS%%X!"PW<UH!E$2[?2H9T,S[4&:6(-&VV1#CWKV&SYVG)CYXMZ9%5X
M6*O@U;W@D@'BH%@DFE/EJ3]*:DK$\C;+0 *TU!G(H^SW$:@,C8J*0RQ*2$(J
M)U%:R-(TG>XD,P@NLDU<N-29P!&:P8A+-=?/FM5(EC(KC>'4W<[XXV5*-A1-
M.PY-"7,L!#9.!4A)/0TTX*;6&<5<L&C*.8RYC>\/3IJ-\@DXP>]>H6R^7$JC
MD 5XC%/+I\BS1$C'.!7K/AO51J%@I8_, !4^P4#TX8I5%J;HIU(.G%**EE"T
M444 %%%% !112=Z %HII.*:9%498[?K0 ^D+ =3BLJ_URVL^-X9OK6!<>))I
MCMBC8Y]#04E<Z\SQIDLX ^M5GU.W7/S@@>]<H$U*\4Y9PM/71KAT.9>?I0B^
M0OZIJMD]I(NP%CWKP_6K2>74':.,[23VKVA?#\;Q8<@GOQ4@\,66.44FM8RL
M/E/!HM,NEF\Q8V!'M5F[%_-&$8/CZ5[E_P ([8 X$2U&_A:P<8V+FAR#E/G^
M2TGA7.QORKU'P%:VT\:_:E'XUT\W@ZPDCP47/TJ)/#9LA_HWR_04<[%RG46E
MI80-OA"@_6M >H.:X?R-0M&SN8U/!X@NK<[9E8#WJ&0XG9BEZ5BV>OV]P%#$
M!CZFM=76105((-(5A]+3>W6DR >:0A]%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 )3>H-./2FCY:35PN<=XN#E.!Q7.*1L&.N*[G7K/[5;L!UKA)4-L2'X
M(->3BZ=V>U@9Z 7"*=PZUU'A0,T>1P,5S,,1O)%45WFA6/V6W ([4\)#E'CJ
MBL:XSQ398$D^\H-/Z]*7M7J)L\1V9A:S:VL%B[B-0<5Y/=K'+=LP ZU[!KL6
M[3GQSQ7CTB'[9(IXKJ@[H\S&OE6@W#1G]VQR*ZWPKX@EBG6"=CC..37*;=KG
M)XI;>9HKGS!QM-:2IW.;"XAK<]RCD$J*XZ$4[ KBM.\76Z6BI(_S@8K<TW7[
M>_;:KC-<TH6/5A73-D"G4U3D<4[-0;WN+1110 4444 %(:6B@!*0TM% F)VI
M.F*=32:2W!Z(YGQ7;F6U+ =!7&0O\I!Z#BO2]5MQ<V+KCG%>:S1/:W+HXP":
M\S&4[L]C 55RV%)).4X'>L#5FC-P0F-_M6[*W[HB#YF(Z5S9@=;YFFR&(Z56
M IOF(SBI'V9607 >,D';GFO3=#L=.U+3%CVIYI7!XYK@9!\A["NF\"2N+_;D
ME=U>Y.Z1\IAU&3)=3\&3I,7@#8]A4>F>#[EIPTRM@'N*]/PK#D T;5'0 5AS
M,[U1@9$.A6L=N$>)<^XI/^$=LC_RS7\JV" PYI5X&*GF9?LXGE/C#2X+*3,:
M@=>E<^.(017<>.[8M'NYZ&N$C<F/;Z5U4]3S<8N78?C(HZ'!H))7'0T#CKUK
MI2/-BVP7N.PH5BDZ,G!%+_#@=:2$>;>1Q+RQ/2LJFS.K#RE&HC;RQ>,="5S4
MC-EL"MC5=(>+3X9T'S!!FL:&150A_O5\QBH^^??8.JW35R'455+3>3QV%<O(
M99%!C!Q[5LZHMQ)#P#MS5*V CB /)KU,!'W3P,XJ)RU-+PP+?[8HNL=>]=Q?
M^%[6\M/,ME&2.,"O-XR5NU*G!SVKV#PZS-IRE_05W578\S"QC(\[?P=>B0A0
M_7TKJ= \)BU3=<)D^XKL=B9SM%.(XXK#G9V*C RGT.RD_P"6*?E5#4O#]B+-
MRL*!@/2NB'RXJ"^C\RU<#N*E[C]DK'B,D"QWDH QAB*48+<U-J2&VU*53_$Q
M-1-A6!]17;2T1X^)C9B=#1TP,9S2XW-Q0>H ZUK&5SE22&NNX;2:[#P%<L9'
MBSP&KCW;8I)ZUUOP_MG$[2D<%JYZK1VX6[9Z2K<4ZDQ2BN6Y[4=$.HHHI#"B
MBB@ IG>GGI52\NDM8&=CC XH&A+N\BLHB\K#\:X^^UVXOY#';@A0<9!JM<O=
MZ[?; 2L(.,@UO/80V.D,(U#28Y)%!?*8=O:QSS@W$N?4&NBM[&S7F-%;CBN.
MTFSDN5N)S*P*EL#/IFI=.UZ:VA82C@$C-!21VZ?)@;<+2.RQ/NW?+7(7'B&4
MVWF1\@BJUUK%Q<Z;\IPVWL:8[G=*RR'*MQ2(0K'<:X2UUBZ@B"MR?K5PZY/(
M!M'UIA<Z\ [RW\)IK.L.7+<5RK^)CY?DC[PJA-KEPT91N* N=Q#,+DG8>E2J
M2I);H*X6PUF2T4NQXZ\U9F\2228"=Z07.O7]\"=N<&H)[&VN5VF-0:PTU2XA
MCR0 "N>M9D/B<QW4B2'H.* -B[\//G=:N05YX%5K75[O2IQ'= E0>K&J'_"0
MW8G,JC]T?>NGCAM]5T]'D4!G7.0*";&KI^I0WZ;XW&?05=(!;FO/U2YT"_W<
MF GN:[6QO([Z%94;/%(AQ+OM2TP'-/H)"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-
M%% #.<T=<TIZ4W.!3"YS'B'5VM/W:CD^U<??,U]T(!ZUWFLZ*M^N1@-ZFN&U
MFT?3OEC8%L]J\O%IW/6P4E:PRPG:QSNY(%=CX<UEKL%7';TKE-)LC?1@2.-Q
M[5VVC:,EBH;N:>$3%C6C<'0GUIW:DQD4'I7HL\HCN(A+ R-W%>3^)]+>QO&E
M53M)["O6^HK.U/2X=0A977G%:PE8PKTE.)XRC;^5Z#UI),$''6NEU3PE=6[L
M;?[OTKE+M'L[M8YD;KS74I7/)E1<'H,@1G<EF8<\8-7K2[ETZY1T=L;AWJO-
M/&CIY:D CFGLX(7D9-3,4)OF/8]$OUO;"-LY;O6M7(>"$D%GN?ICBNMS7++<
M]JE\(\4M,4T^I- HHHH **** "DHHH ;2-SBG4AYXI1W%+4C=>,=JXCQ?%"(
M6,>/,]JZ_4;C[/9NV<$"O-KJ:6\O&+G*YKBQ4E<[\%!W&>%-K7FVZZ'(YJQX
MUTF&TVW<)&">@-5I(_)7?%PPYXK&O]6N=1<6TI)5#FG@IKF,\V@W RS>-.47
M& Q]*]4\&Z1%!;)<9!9@#UKS:6VCV_NQ@K79^!=3GDG%L[?*"!7L57H?/8-*
MYZ1BG4VG5R7/6LA,4$9'%+BDZ"@>AC:_IPOK)AC) KR.\A>QO6C9"!D]J]R(
M&#D9K UCPS;:BI94 D]:UA.QQUJ7.>58)^;(H!.<\5MWGA"]M7./F7/855C\
M/ZA,VU4*_5:Z54T.#ZNTS,=P#QUKI/!^@R7-^MU,ORALUH:1X);<KWF&^G%=
MS9V4%C"$B7;@5A.MN=5'#OFN1WT<0M=KXV@8YKR36&D750(,[-W./K7:^*M6
MD$PM(B?F%<X(D3[XW,1G->)B)IR/J,'3DHG2V>G6M[HGS%=X4GK7F^I2?8+V
M2(#.#CCFMFZU2YTY2(V.T\8K)^6[?SIA\S5Z>!DN4\'-XM2U+GANR_M6_4N0
M,'N<5['8VZVULD:]A7BEE<2:?>J\)PN<U[!H=TUU8+(_7 KHKLYL$E:YJ=Z=
MVIN13JYT=^@F!CFD8!D(IU)3'8\Q\7Z#(DYNT4D#TKDXYO,^5QC''/%>Y75I
M%=Q&.5<@UPVM>!]S-);8'>NBG4MH>?7PKEJCB\XY4C%)E7!;O5]_#6H0G:%)
M_"K-IX4OKB1 1M&><BM7-'"L')LQ(8WU"3R(T;/3.*];\-:6NGV"#&&(!-0Z
M'X8@T\!W4%_6NC50HP.@KFG*YZ5##\@O:D7I3L\XI!UK-([!U%%% !24&B@
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MHSZ=*Y;3?$AEO1!,1\QQTIE[XJ,=W]GC4GZ+0,ZS)[T \>]<[IWB%9U8/D$
MGI5-_$SO=XC^[GTH [ >]+52QN?M, <]Q5J@0M%(*6@ HHHH **** "BBB@
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M?SI?^$HM\?>7\Z.41T-)WKGCXHMPF=R]?6C_ (2BVXY7\Z+#.A_"D'+5@?\
M"46V<;E_.D7Q/;8<[EX]Z%$70WI>(V^E>-^)U/\ ;Z''\0_G7HS>);9H&;<O
M'%>8^(+Q;K6$E1OE##I]:YJBU.S"=3UO03G3(ATXKS3XKC]_&0?XC77Z1X@@
MBLTC+#(%>>_$C5([ZX7RR/E8]*VI+0X\5NSL?AKD:6/<"O0*\M\!:NEGIJA\
M=!UKL6\3VP/WE_.M6C*&QT0I:YX^)[;(^9?SH/B>VW8W+^=38U.AH[YKGO\
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M"N'TW57LT C0D9[5J'Q%(S@[&Z^M$%H%3<Z3Y@I-!9]M<X?$D@5OW;?G3?\
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MV+7Q%#*BK-PW?-9%&J%0MD$TK%8P3(0 !FL^76;*!"5.3]:Q;S5)]4;R[=6
M/'2@$1ZC<R:SJ(MX<[%(SBNQTJR6RLUC ^8#FL[0M$6S7S9!ES6^!R351*2
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M!4C-930W"Q=HI!1VK-$"BEI!2T#"BBBD 4444P"BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% !1110 F:6DQ2T %%%% !124M !124M
M!1110 4444 %%%% !1110 4444 %%%)0 M%%% "&L'Q!>F" PJ<,PR*WC7)^
M(R1J$1[;::*1R5A=+:ZBTEP<CG[U:Z:G-J%_MMD'E#'(KD_$]O)J5\L-H2K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH@PS 9J,SQ*V,_K1=@6" >H%-V#L!0-I&:7W%, P!VHP/2EHH .*;M7TIU%
M#?+7^Z/RH"*.B@?A3J* $P,TO&:** #(IIQW%.HH$-PI_A'Y4 +_ '1^5+11
M< POI1D>E';% %%QBXS3=B_W1^5.HH ;L7^ZOY4>6G]Q?RIW-'- !@#H*6DI
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*0TZ
MD(H \P^)-W<1KY4#D;R1UKF]-\)ZP^DC4$N&.%W >8?\:Z#XDX$T>!_$:Z/P
M[*D?A6)F==OEC.: ,+PAXPE_>6=X3YD;8Z>E=9I?BBUU"X>%6^903^5>6Z)$
M+[Q9.$!V[FY%175V?"VNR[B0'0XY]: /4F\76JZE]C#988SBH=6\;V>G7'DJ
MVY@<$#FO/_!>G2:QK%W?2$E6C^4^_-4K[2IK7Q+=33*TT1;HO:@:5SU*S\86
M5W TB[MR]1BO++_X@7D7B1H8V/E[CQBM30[K3$GN$.0S-]TMTKC3:1WOB_:@
MXR<?G2-XQMJ=;=^)X[N1/M9(! ]JZ7PSJUAO8Y^4+G)K@?$^D(+RV@^[G9W^
ME=+J>AIH7AN.6$G=(,$@^U Y5K*QU=]\0-.L9_*!)&<9 S6SIWB"UU*U,T3#
M@=#7FWAOPQ8ZIH,EU=9:4)G.ZJ.C3R6=_<6L,G[M7QC-!R:L[VY^(%C:W+0L
M22#C@5:T[QA8ZNKQQN0VT]>*\RT72;?5?$$BW))RS=ZEU+3X]"UM4LGP"!WS
M5%W2&ZO>#3_%PDFE?8&! #5Z%8>/=/N+A+7<0Q.!D8KSFZLX-4UZ%+D$L2O0
MXJ;QAH5MHVHV<EIE&,G][VH8KG9^-/LDKV[32$*P)!#5H_V_9>'](A9W.TJ,
M<YKS_P 62-<:7IV]CN\KKGW--\8()/#]FA)^X@ZT@.Z;XCZ<LB*2V&QSBNLL
M;V&_MEN(&!5O>O(-9\+64/A**] (D 4YW>U=;\+99)/#$;R-GYF'- '>@TM,
M4T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3%&*6B@!**6B@!
M*,4M% "8HI:* $Q1BEI#0 UCM!)Y'>O.?%ES//?*MM+PN00*[K5)V@T^0H,L
M5XKSZTT>_O9Y[@[^6R!0!V.B:JLFD!Y6_P!4 I)]:RG\2W$]QF"-FC#8X/O6
M-IZ7MFD]A(C?O&+9-7="O+2VA>*55W[SUH C\0:O>^?$T6Y06'%7H-0;9"TZ
MG<3WJ+60&CAN!$-N^J\A^U"%T& ISQ0!H7/B22)Q%'&Q^AJ]H_B W<GENI!S
MCDUB6,(?4!YB9&>]2V2&'6,!,*2: .X!!QCO3J8@RJGVJ2@!,48I:* "BBB@
M I,4M% "8HQ2T4 )BC%+10 F*,4M% !1110 4444 %%%% "9HS2TE !FC-%%
M "T4E% "TE%%&X"T4E% !1110%A:*2BE<!:0FEI#3N F:7-)29H"X[-%(#0>
MM%T O:FDTZFT6N!YY\0='NM0B!M@=P)Z"N/L[7Q,;+[$#,(P-O2O<'BCDSN4
M&L^2XLH)/+ 4,:$F)RL<]X.\)KI2&YN #,W))%<7\6+*UN[N,6^TR[E!Q]17
MK)OX)(659!G%>8ZE8&Z\0AI&)0$'GZU5F*,KG2^!M':R\, J=LC*1G%<KJ[Z
MKI]]<EB\L;>E>AIJ%M8:>L2D<#I7&:KJ#7UU(BI\IJ6=5.E?4XK2-->YUIIV
M&TN^>:NCPQJ5AX@CNHE<J<G(%>C:'X:B$,5PR\D9Z5U:V46%W(#@4BY3BE8\
MLU?0;V_O[:9T8[=F>/3%=KJ6BF_\/BW(^8+Q^5=']GC;K&..E.5<<8XH..>K
MT/$X[/7]'1[.#S?+(V\"MC0?#$T4$U[=*=['<<BO4&LX'8LT:DTR[MA)9/#&
MN,C'%,:V/ H9KR'Q!*++<"&(^6NBTK0-3U/4?M%YOZ<;A75:/X-^R:L]S*N0
MS$\BNU2VCCQL4# [4$26IY:WABZ3Q)',H.Q2O:KOC;0;G4;RT:-2=CDG KT<
MPQYW;1GUI6CC."R@F@L\K\0^&[NYTVR1%8LD>#Q1XA\.7=SI%J@4DHJ@\5ZH
MT4; 90''2D:".1=K*"* .%U?1KFZ\)1VH!W!1QCVJY\/=-FT[0$@G4@AF/-=
M<Z+L"E1CTI4C1!M10H'I0 ]0 .*=2#@49H 6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 03P+.FUNE)!;1VZ8
M11BK%% %%["%I?-*#=TZ51N/#]N\@D4;3G/ K;Q1[4 4)M.BFMUC91@>U-AT
MJWC0*%Z>U:.*"* *:Z?"D@<*,CVIPL(/,\P*-WTJWVI * $Z<4ZBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*2C- !11F@T %%)1F@!:*
M3WHS185Q:*3.:08!H"]QU%%(2*+#L+25#/<+#&79A@>]8X\36QF*;NE-19+E
M8WJ6J,.I6\PW;Q^=5Y]:MHI,>8/SI\C&G<UJ0G%<U=^)X8G&UABH9?%<0C#
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M6EHHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3- "T4F:3<.E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IM.IIZ4@(;B401-(>
MPKB;WQCY=X8QC@XZUVEW&9+1U[D5Y7K&G207COLZFM8*YFTSM=-\3V\Z_O7
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M@4YVC\JMT4<S$1+;QIR$'Y5)M7J !^%+12&%&,T49I!83;1BEHHL 8HHHHL
MF*6EI*+ %%%%,+"44M% !1110 4M%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>plrx-20211231_g23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g23.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )T W$# 2(  A$! Q$!_\0
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MD\R9NB_*#CZGBHOC'\0-0^&/P]U+Q#I?AN]\67UJ$V:5IXS-+N8#(X/ !R<
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M'U#XV_ '1;74+:?5;?Q)'<3VL4@9HHS)&%+ =,D&MG]JW6O@WJWCVRT#XO\
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M(MEG=2/* "98')Q79:AX?L]4\.W&B3QEK">U:T>/<03&5VD9^E '@G_!//\
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MCG*D9' X]J /F_X7W]O\-_V]OBEIFN3I92>*K&VO-,FN6"+.$'S(A/4]>/\
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M#]D]I<:_>&^OV:9G\R8Y^8 GCJ>!Q7=4 ?(__!3G_DW.V_[#MG_[/7U/X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I*6B@"E>:3::A 8;JWBNHCU29 X/X$466D6>FP
M>3:6T-I#_P \X8PB_H*NT4 (HVJ!2T44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;S3;;
M48'@NH([F!_O13(&0_4'BK5% $%M:Q6<210QK%$@VJB*  !T ':H=2TFTUFS
MFL[ZVBO+29=DMO.@='4]F!ZBKM% &=HWA_3?#ME'9Z78V^FV<?W+>UB6.-?H
M ,5HT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4E+7-^/O'6E?#GPGJ?B'6IOL^FZ?$9)7[GT4>I)P />A)
MMV0'1;AZT!AZU^:OC#_@HQX]U36'D\.Z;IFC:8KXCBGB,\K+VW,3C\@*^@_V
M6/VS(_C5JS>&?$.GPZ5XE\LR6[VS'R+I5^\ "<JP'..01GTKMJ8.M3ASR6@'
MU3135^Z#[4ZN( HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8TBKU.*R=
M8\9:!X>FCAU76]/TR63[B7ETD1;Z!B*\T_:H^+4_P8^$6JZ]9X_M:8I96&1D
M+,_\1_W0&;\*_);7-8U'Q-J4VHZO?7&I7TS;I+BYD9V8D^I->AA<%+$)R;L@
M/W%ANH;B%)8I4EB<95T8$,/45./F%?E[^Q+\>-8\"_$[2O"=[>SW?AS6I/LB
MV\TA<6\Q^XZ ],G@X]?:OU CX0"N?$4'AY\K ?1117. 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?T:7=;S?*\;_ 'X9!U1AZBNP7M7S'^PGX9U/1?ACJ5_>PR06VI7GGVD;C!9
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M]CK5P][J&C3+$+J0Y:2-@2FX]R,$9^E?+U_^R'\4+/7#IT>A+>1[]J7T,ZB
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F-W]:?3&H _*_\
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ME#C&0OKBOTGC_P!6*>:<KJIQ)R?$O$TI.4;-.SZ?>24445XQ[X4444 %%%%
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M%O%.G?"77K;6M:BT_7M:M_[+DT:3RUN'=&(2X!_Y9X!W#U%8/[,^T?!_XH\
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M#%5FCBZJ<2<IQ%7$4G[:-I+1DM%%%>*>\%%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIQFO+Q]>CEM94J\[-GJ87+<5C*;J4(<R1]#T#/6N8\$^/]#\>:6+_1[Y9X^
M\;<21'^ZZGD&NG4Y7(Z5I"I&I%2B[IGG3A*G)PFK-#Z***T("BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **2C- "T444 %%)N'J*6@ HHHH **** (9)0O7H.IKYK^*?QTU'4M
M6N-%\+3FQLK60Q7.IJ 7E8=5B]AT+>W%>H?'CQ6_A+X>ZA);R^3?7NVSMV7J
M'?C(]P,G\*^4K6U2SMXX8QA(P%%?&9]F4\,E0HNS>Y]]PQE-/%MXFNKQ6R(K
MC3X;R>2>[\R]N';+374C2,3Z\FO./C1\/9=?\-++I$&;BS?S?LZL2'4CYMJY
MQGI7J6VDP.>U?$X/,*V#Q,<3%W:\S]*Q67T<5AWAW&R?8^'H]/NYKD6L=I<2
M7).!"D3%R?\ =QFO</%G[*GBSPG\ ]+\:7FG7"WS7;27>GA29+>U90(W91WR
M"3Z!A7O_ (0OD\/^/O#FJI!"76^2WE8QKEDE.PY..Q((]Q7VSY<<\3+(BR(^
M0589!![$=Z_:LOXD>94^>,.6SUZGXGF^52RJJJ;=TS\+EF#8 ();@8YR?3%?
MI]^P'\.=6\!_!Z>?6K:2QN-9NS>Q6THPZQ;0JDCL3C/T(KU^S^ _P[L->_MN
MW\&:/%JF[?\ :5M5SNZY Z?I7>)&L8PJA>U>IBL=]8AR15CPQP %+117E %%
M%% !1110 4444 %%%% !1110 4444 >=_&_X+Z/\<_ ]SX=U@M%DB:UNXQ\]
MM, 0'7UX)!'<$U\--_P3>^(/]KFW&MZ,VG;L?;<OG&>NSKG%?I349B7TKJHX
MFI05H,#Y.\9?L+Z'<? FR\':+?B'7M.F:_CU:Y7 N)V4"0.!T0@ #'3 KY+\
M#_L^&/4+E_$4L,Z6T[0B.TDWQRE3C<&[KZ5^B7[1'BJ7PO\ #Z:&T;;?:G*M
MC$R]5#??;\$#5\Q0VZ6\4<48"H@"KCT'%?&9_GV)P\/JM&5G+5L_0>%\IIXJ
M^*KJZ6B1EZ?X5TC2;=8;6PABC'\(''U^M:^AW5_X3N_M>@:A<:3<]<1N3$^.
MSH>"*3;2[:_-HXBM&?M%-W]3]/EA:%2#IR@FGY'U+\&_B@?B%I#I>QQ6FM6;
M!;F"-LJX[2+[']#D5Z4*^+_AGJC:#\3?#EVC,AEN?L<FTG#+(, 'U^;!K[.S
M\U?JN3XV6-PRE/XEHS\2S[+XY?BW"G\+U1)13,]Z=7NGS@M%%% !1110 444
M4 > _M;?LWC]H#PM9C3IHK3Q)I99[.6;A)%;&^)CV!P"#V(K\Z_B%^SM\0?A
M7I<VI>)]!_LW3HYE@%T9T9)'.<!,')SC/3M7['M&K8)'-?,'[?W@+5/&7P52
MYTJ&6ZDT>^6]GMXE+,8MK*Q '7&[/TS7J8/%3IRC2OH!\0?"_P#:B\??!O18
M='\,W=E;Z9',T[V\UJK^:S'DLW4\8'X5]P>"_P!N/PUJGP2O?&^M6KV6J:=*
MMG<Z7"<M-.PR@BS_  M@G)Z8-?F(9%Q][CUZ8_PKT*7X2^*(/@K_ ,)S+9W$
M>@2:DL&UE(! 0XFQ_=R=N[WKV,1A:-2SEHV![SKG_!1;Q'XB:^L+WPAI;>'+
MV-[>6U69_M'E,"#\_3=@_2OE9]#N9D>YL;.XGT\R,D<H0MT/"MC^("L_C;_6
MOHC]FK3;JW\.:G=3JRVUQ./(#C[VT8+#V_PKR\VQD,DPKQ%.*O=:=SVLIR_^
MT<2J#=M'KV.0^"OPQU*\\16VM:C;26=A9G?&)1AY7[8'H.M?1_WLT;11C'-?
MA&;9K5S>O[:KI;9+H?M&69;2RRBZ4'>YH>%?%,_P_P#$D/B"T0R&,;+J%>//
MA[@^I'4>]?:FCZA%JVE6E] <PW,2RH?9AFOAB508V#=,'-?6GP)FFF^$/A9I
M]P;[&JC=P2HX7] *^CX9Q$Y\]%NZ6I\/QAA:=/V>(BK-Z,]!HIF31GWS7WA^
M:CZ*2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ2.]>PQ_*@ K]"RZ.(C02Q/Q'Y;FLL)/$MX-6B*?6N0^*7@6U^)7@75_#EV
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MC/(]Q0!HT5Q^H>*M8L_'5AI0TJW.@S6,ES<ZL]XB-!*K +'Y1Y((R=W056\
M_%S0?B3/KT&C77F3:-J,NF7"R%07DC"EF0 _,GS#YNAH [FBH]S?Y%% $E%%
M% !1110 4444 %%%% "4C84<TM-DY XI ?*W[1VO_P!M?$J#2U;=;Z/;!RO8
M3R'KCUV ?]]&O-YHUGBDCD4,C@JP/<'C^5;WQ,9S\8/&A<9;[3"!G^[Y*8K#
M-?C>:U95,94;Z,_?,EHQI9?2BENOS/IO]FW7WUKX9VUO/(TUQI<SV#,QRVU#
M\F?^ E:]47YLUX'^R6S_ -E^*U_Y9#4E*_4PIFO?ATK]2RVHZN$IR?8_&<VI
M1HXZK".R84M%%>F>2,VCTYKYY_;6L;R;X8:;=PJYL;'5(Y[S:,[8]KJ';V#%
M:^A_YU6U"QAU*UDMKF*.X@E4I)%*H964C!!!ZUI3E[.2EV.;$T?K%&5*]KGY
MAM(D<)F9U6'&[S"?EQ]:^BO@#^S#X,\7_"?2-6UW2I!?7+33'[+=-&)(FD8Q
MAP#C[N/3@UY;^U%\*?"/AGXD6FAZ)I3:;8I9_;;J&.=_+F>1V"KM)X4;6X'K
M7+^#O&VI_![4H==T&ZN((;4J;G3_ #F:"XA!^9"A)&<=".AKZ&KSXJE[2GH?
MFN$6'RO&2H8CWKZ'Z.^%]!T_PMH]MI.DVL=CIUJ@CAMXEPJ#^OK6U6?I-TFH
MV-O=Q?ZJ>-94!Z@, :T*^;=^I^HQLDK!1112*"BBB@ HHHH **** "BBB@ I
MDO\ JS3Z9)G:<4 ?)7QZ\03:]\4I[(MNL=%MUAC4?\]I!N=O^^=H_.N!FA2Z
MMWAD4%9%*G\:WO'S,WQ(\7E_O?VA^GEIBL6OQG,JDJF,J2?<_?\ )Z,*> I0
MBM+'U)^SWXFG\3?#337O'\R]LB]C,YZL8SM!/N0 :],KQ#]E4M_PBNN#^ :I
M)M_[X3^M>W_6OU7+ZCJX6G.79'XGF=.-+&581V38M%+17HGF#2!W%?,/[<&E
MWTWA3POJ42,^E6.ILUZ%Z1[HV5)&]@3C/^U7T]6=J6E6NK6-Q9W]O%=VDZ%)
M8)DW*Z'L0>M:4Y^SDI]CDQ5!8FC.BW:Z/S*GFBAMI)I758 NYI&^[MQU^E?2
M_P #/V6O _B3X5^'-4UO294OKB(S2QPW+(KJS$H'4'KMVUXK^TC\,_".@?%/
M^P-$TE["PL[1+BXMQ.YCDDD)( 4G[J@=/<^E9WPZ\<:I\(_$5EJFCWEQ%8B:
M-+[3VE:2"XA+ ,-K$[6 .01Z5]#6]IBJ2J0T/S? _5\LQ;P^(7-T]#]%M!T&
MR\-Z;::;IEI'8Z?;((X;>%=J1J!P,5JXIL;B1%;LPS3Z^:/U&*26@4444%!1
M110 4UJ=36ZT ?/?[5VH2&'PII8.(KB]>X<>HCC.,_BU>*U[+^U;;,EWX.OO
M^6:W$UNQ[9:/(_/::\9S7Y3Q Y?77?LC]JX64?[.C;NSN_@#J!T_XN6T7\%]
M8S1'W*E6'_LU?6:U\B_ NQ:]^,&EN!Q:6<\S?CM4?S/Y5]= YKZ_A[F^I*_=
MGPG%*BLQ?+V0^BBBOISY :36=KFDP:YI=YI]U'YMK=PO;RKZJP((_*M.FCO1
MYH4HJ2LS\Z?B?\&?%OP7M;RYO-+EU;PY:Y,>JV; D1YPHD4\AN0..IJW^SE\
M:K3X3ZEJ^KZ_X<OW_M'RX5FM75VMK=<GE.I)))./05](?MD:=>7WPA:>V1Y+
M>QU""ZNTC!)\H$@MCT!(8_2OC/SHS 9@Z&(C=YF[Y<?6OH\/?%T7&HS\SS&*
MR?&*IAHZO4_3+P[KEAXHT6TU;3;E+VPNXQ+!/&<AE-:OM7@?[&<LL?P6MEEN
M(YHY+RXGMH5E#-% SG;D#IDY('H17O@.Y0?:OGZD>63B?HF'JNM2C4>ET.HH
MHJ#I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBFLVWMQ0 O>DW"L?Q!XHL?#.FW-[>2'9;P27!CC^:1T09;8O5C
MCL*X7X/_ +0/ASXSW>L0:,SQR6,@"QSC:\L1Z2!>N,Y'M6D:4Y1<TM$3S).Q
MZG1[4FXU2U75K;1;&XO;R9;>TMT,LLTAPJ*!DDUFDV[(HNY&>M+7DGPI_:/\
M*_%J>^ATQY[>>T+-(+F,HGE[]J$,>,MP<=:]7CF#G@5I4ISI/EFK,F,E+8\D
M_:M\9:GX#^ _BW5M'F:VU+R([:&X4\P&618O,'^Z')_"OG?]HC]GSPI\)/@W
MX:U3PZE]:ZNVM:5%?7WVV5VU#=.A8SY8ACNPP/8U]B^.O!.F?$7PIJOAW6HC
M/I6I6[6\\8X.#W![$'!!]17A/B+]CW6/&7@]/#?B+XL:]JEAI[12Z,3:Q(]I
M)&08WE(_UQ7&!NQZUF4?14Q;[&5C<1/Y> YZ*=O!-?G_ *EX%T_P/IM\?BUH
M'BC3O$TVH274?Q;T*X>\@CW3;HG)5OW2*I52A7  -?>UAH<L>@6VG:C>-J<R
MVRV]Q<N@0W!VX9B!T)Y/'K7A$_[(=_\ \(_<^#;;XF:Y!\.+EF\SP\\$<D@B
M9MS0+<M\X0DD=,@'% &=;W&[]M[PN5OFU"%O 4K"Z!^6?]^F),#C)Z_C67K#
M'_A9G[4HW$H/#5E@$G _T*7H*]-^('[.*>(=>\->(?"GB:\\$>(]!LCI=M>V
ML"3I):';F&2-^"/E!!SG-1>$OV9;?PZOC^:]\6:MKVI>-+%+/4;V^";E*QO'
MO0#@</PO08% 'S[_ ,*#\,:/^QUI_P 0[![^S\=:;X>BUBUU_P"W2>=%*D89
M4 SM\OC;MQC%>C>"O$-UXJ_:@^'&L7FY;G4/APUU,F2%\QIHRQQ]3^M::_L<
M7;>%=-\$3_$W7KKX=6T<<4_A^6&/?<*I!\LS_>$9(^[^%=I\2OV?F\5Z]X<\
M0^%_$]UX(\1Z#:M86MY9VZ31M:MC,+QMP5X!'H: /(M9D9?C%^T\ S#;X6M"
MHW' _P!%DY'I7GMY\%_#FA_L7:!\2K07Z^.K#2['4+;7&O93-&^^,!!\V!'@
M[=N.E?1WA/\ 9=M_#]QX[O=0\6ZKKVJ^,M/6QU&]O$0$%49=Z*. ,-PO08K=
MU#]G_3K_ . $'PI;5+I-,BL(; 7ZJOG;8V4AL=,G;0!P7BRQM_$G[6'@RPU*
M(7-E?>"[Y+BW9CLD5I(PP./8D?C65^R!\+_"GAGQ%\4-3TO0[>RO['Q7>Z7;
MSQEMT=L%C(B&3TSS7M,WPDM+CXI:%XW:_G%[I.E2:3':A1Y;H[*2Y/7/R_K6
M1X%^"EU\/_B-XGUW3_%-T^@:]<2:A/X>EMT,<=VX4/*LOWL$*/EH ]2W44[;
M[T4 .HHHH **** "BBB@ HHHH *1EW4M% 'R9^T'H)T/XK27P7;#K-FDBMV,
ML?RL/^^=I_.O/RP12Q("J,DGVKZQ^,/@'3?'GAN2.^N5L)[/_2+:_/\ R[N
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MC"V,I="T&L272R2WPWL"60 ;,8 ]Q0!]"4E+10 4444 %%%% !1110 4444
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MB!XWMY#*^ 21@YP>E?1\=M#$BHD:HBC"JHP!]!2+;PQR,ZQHLC'+,J@$GU-
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MRHN _-#=*9Y@'\)/X4GF<9V\4 4-<_Y!%[_U[R?^@FOC/]AG_DHGB/T^Q_\
MM2OLW7&_XD]^,<^0_;_9-?&?[#)Q\1/$?'_+G_[4KPL9_OE#YGTN7_\ (OQ7
MHCZX\9^#K7Q9INQXX5U"!6:QNYHA)]EF*D+*JG@L,Y_"OGWX(_LDR^'O&-]X
MI\;W/]MZC%>2-9)*=PDPWRW$F?XCC(7MFOJ3?T^4\TN_G[K?E7T]/%5:4'3@
M]&?*RIQE+F?01%&U>!4G%,\P8Z''THW_ .R:YC4?Q1Q4?F#KM/\ A2^8..*
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MC-,W_P"R?RH\SK\O0XI@<5\8OAO;_%[X=ZYX1O+F2S@U.#8+F$9:)PP9&QW
M8 X[UXKX@_9O^*'Q#C\+0^,?B/IUS;>&]3M=0M;?3=*,2W)A8'=,Q8DM@8XX
MR2:^GO,'4 X]:7=GC:12 \X\+?"F3P[\9/&7CLZAYX\0VEG;"S$>/)\@,,[N
M^=WZ5A:/^S^MGX<^*NC76J-<6_CJ]NKIGCCPUJL\83:/4C&:]D\SJ<4;^>AY
MI@?/O_#/OBSQ!\'] \%^)O%%A<SZ'J=C<VEY8V;1A[>V92B.I/WR%Y8>M7_&
M'P1\82_%W4/B-X.\80:-JESIL&FG3K^S,]K,B,Q/F8(;.2,$=.?6O=%<9Q3Z
M / _"'[,<;>%?'EGX[U9O%.N>.#G6+^*/R4553;''"O\*H.F>]85Q^SG\0_%
M/AW3O _BWXA6NJ^ +22,316^G&+4-0@C(*0S29V@<#)49.*^F:* /$OB-\%=
M?U#QUH_C;X?Z];>&/$=E8_V7/#?6IFM+VTW;ECD4$$%3R"*I?#?X5W_P>\8>
M./B1XW\:PZK+K%I ;ZX:U^S06@AW9V\G" ' SSQFO>JJW^GP:G9SVMW;PW5M
M,NV2&9 Z.IZAE/!'L: /F/\ 94\#Z5JWQ6^*7Q0T<R2Z!K6H&UT9V!"/&,/<
M2Q _P/*3SWVYKZD7[O JOI^GPZ;;QVUM##;VT2A(X8$"(BCH HX ^E6J "BB
MB@ HHHH **** "BBB@#S[XW6VNW7@2Y'A^:2*[616D\E]KM'W"GUZ5XG>:#\
M4_L/AO\ T^Z+2_ZD+<8:(EACS3WZCK7TMXF3S-)>(#F5TC&/=A7,SR;X=.&U
MC]E5W;VVRJ/Z&NNE4Y(VLBUL>.1Z#\53XMUJ%-3E\](7+2^=^YD&.!&.@;D?
M2LE='^)P\$B?[;>BV%US"9_W_3KG.=OM^->_R7'DZMJ-X5)1XYU'OM5/\#5;
M[/(VD'3MI\TW!_+R=W\ZU]L^R'?R/'[C0_BI'XNTB.35)?->!=LPF_<*-I)#
MCH3P?K7F?@31=:75-8_X1T?9=3>RD>5X2%>2,2(756]<L#7UN[?;+ZRN%!VQ
M+"&X[LCC'_CPKYZ^ [K-\0O$$0*O]G6>T.WW> #]0:XZV)M."Y5J>CAJ;E2J
M-/9&C>:+\4#I?ALC4;DAC\BK-\T9W@#S3W[=?I6BN@_%/_A+]94:FZGR)&\X
MR?N'&!@1KV;D?2O89U/V2WC"_P#'OYA/_ 95_H*LR3>7J%U.1E7690?HJ_X&
MNOVS[(\^Y\^G1_B?_P (*LIOKPQ-=\0>=_I'3KNZ[<]JU9M!^*8\7:-&=4=I
M3!&WFB4>2HQR''<\'ZU[(UL6T]+/:=RS>G819_G4L<HDU>TNV'RK'"F?<J_^
M(I^W\D+H>!V>C?%$Z;XD==0NE2,XE5[C+2$,<^5Z=#TQ27NB_%)=+\.DW]V_
MF,1$B7 #QG=P9#GD<CKVKW"W4I8WL94AKK8R_P# IF_Q%)=,TEK8J$.ZU\UV
M_P" RJ/Z4U6U^% >0P:#\56\8:K NIR"<0.?.:;]PPV\;!T!Y'T[UE?V1\3S
MX)DF%]>?9UN\&'S_ -_T^]NSG;GM7OK3>5KEU>8.PI-&#]%0_P!#4$5JW]FO
M8E3O:=>W8Q9_I2]L^R"YY!<Z'\4O^$JT%6U20NT,>V19?W2?+R)%Z$\'GO52
MQT3XI+I_B;_B87"E/OJ\V6E^8Y\H]NAZ5[HK>=>:=.!\L*0;OQ##'ZBF1J?)
MN_EQ]I1<?C*P_K2]MY(#PJ^T/XHC1/#K?VA<L&=MB)/AXCNX\T]Q_*O(/C;X
M?/P>\61^(]3L%L]2EU57@U/3(PA:9^68$=B"<CWK[5N%_P!%A3:<VYE;'TD%
M</\ &WX66/Q;\,ZEI5XNR3SC<V<^/]5-&$(/XX8?0FM(U]=D8UHMQNEJ>9:;
M;?$?5/ !O+35+J>QDO-JHD_[\L,@G=U W<$5NOH/Q43Q9H<,FJ2&9H4(D$W[
MJ,8Y#KW/!^O:N _9G^*VH7GBZ_\ !-^"+.Y$NHV?F?*T,J3RI)&<]"<*<?6O
MJAIO,UBRN\?NT2!3]7W?RR*<ZG*[60J-558W/!K;1/BD;?Q+C4+H"+B96N,F
M0[N1%Z< ]/I3+K1?BBNBZ _V^Z*22%8HUN,/&=PP9#W'UKW&!F2WU7(.;SE.
M.N967^HIEPK&PM857Y[7SW8>RR#G\JCVS_E1N>1C0?BH?&NI0C4Y%N/L[MYQ
MF_<,-O 5>@;D?2LF/1_B>W@JXD%]>>0MV UOYY\\\=0V<[>G%?033!->N;PC
M]SMDCS](T/\ 0U!;VS+9FT(YDGC/X>4#_2A5O)!\CQJ30?BC_P )%X>#:I)N
M:"/;)YN8H_42+_$?YU6L]%^**V_B@G4;A2J_/OFR92&_Y8G^'@'I]*]TC;SK
MC3Y]O^J2 -^.X4S9_H]X,$?:(R!^,K#/Y$5/MO[J&>%7FB_%%/#_ (?_ .)A
M=$-*RI&L^)(SD8,A[CZ]*U!H?Q3;QQJ$:ZH_F"!R9O, MV&S@*O8Y(^F:]@O
M$+6L"[3FW,TI'T?']:F=O)UJ[NMOROYB X](U/\ 0T_;>2"Y\\3:3\3#\/-1
MG>_NQ:^>-T+3_OB,<D'KMY'%>+?LXV?B.^\?-%X<F>WOMHWR;\(J[N=_J*^V
M;Z!T\*W&GLN925)XY_U.XG]#7RK^Q>WD_$+5I>HCB0'\9-O]:^=Q]6^-H.RW
M9]/E[_V#$_(])L="^*G_ !5 34;A'B4F;?/GS/FY\KTX!Z?2J][H_P 45\-Z
M%*;^[:)I65(UN,21G(QYA[CKUZ5[M#<>6VK2,#MNHV"?]_&7_P!F%,N(V;2X
M;;:2]NUPY&.NU\C^=?1>V?9'RYY*N@_%1O&U[&-4;S_LS'SC*/LY&SH%[-DC
M^=8L.A_%!O!EY(+Z\$'VI0T!G/VALCJIZA<D<>]?01F"Z]+=8^3:\>>W^K4_
MTJ*UC/V,6I3[T\1Z?],P2?TH]O\ W4.YXQ)HGQ1'B#PT&U.0[H8SYBR_NHQG
MD2#^(X_.JUKHOQ1_XJ@G4IU"(WF%YO\ 68;_ )9?W> >GTKW./\ >26$A7_5
M1P@_B2#43*5@U!0I+7,;!?\ OZP_J*/;OL@/"+[1OBB/#NA$W]TP>=A'&L^)
M8SV\P]QUZ]*UET'XJ-X[NXQJK>:MNS&?S<0$;. %]<D?CS7KUXI:QAC49-NT
M\C#Z-Q_.K'G>3KUQ=G)C<O$#VXB5OZ&CVVFR"Y\_PZ3\3V\%WTPO[P6ZW*AH
MC<9G;W5NH7)'%:%QHOQ3_MKPTK:G,6DB38RS#RX_42?WCC'UKV"UMW71Q8%2
M))986Z=B@/\ [*:F$QFFTF< _P"C0P;N/[S;2/TI^VUT2 \3L]#^*9D\3*NH
MW"O&A,I>?(D^;_EEZ< ]*^-?BQX+\4_L_?$31_%]NEQIB:E(UU;2POR'#8EC
M)'0G.<=P:_3>-C')JLI!VW43A/?$C 8_[ZKR_P#:0^$:_%OX17^AQH%U2Q>X
MOK%\<^9'D[?HP./QH]M?2R1P8RDZM.\=UL<]X&OO'WC;6;'6]-US[38:A8>?
M#=K)FWVM'PNW^^&X/<$5##HOQ1_X1/4'^WW@C^TJ&A,_[YCZHV?N\CBO*/\
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M;CS?[W4<GZ5[99;O[-G@8%3<F!UX_O-S_*G;2UGIJ;>;-%+?A*H_]E-/V_\
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M@]]Q44Y-S-#K2U&C9I]><=0M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_ <_E7K%-:-77##(Z8JZ=1TYJ:Z$RCS1<3SOP;XML/''ANPUK3I ]O=1AB
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M_#$':1I90_G,<Y 4CTQ6M.#E))(J,)-W.\_9%ROP\UJWC):TMM=O(K8]O+W
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MP.58=5.#G!KJJ^</@?8V^D_M4_'&RL88[2S,>ES^1 H5/,:)]S;1P">]?2%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ_V57"JOMS7N.*/PKD=>I:R9SNGS.\VV4-)TFUT>Q@L[2!+>U@0)'&@P%4=
M*O!%]*=QZ45AOJS1*P8HQ2T4#$HI:* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!*Q]?\)Z5XHMU@U2SCO(U.Y1(.A^M;-)CTH3:=T-.VQ1T_1[/2K.*TLX
M$M;:,82*(;5'X"K8A ((/2I**=R>MQ-H]**6BD,**** "OD'XW>!]9\>_M4+
M)X7U.32O%OAOPBFHZ3,'(A>4W3!H95_B1U!4^F0>U?7U?)7B;X<R_%7]L7Q5
M:3ZWKFB:99^%K.*8Z+<&V-SNFD/EM(!D#G.%(- &UXJ^,EU\6OV5_'NH:%!-
MH_B_3;&:TU32-_\ I-A.@_?+Z_=#%6[\5IZ3X'^#=G\%_"?C9=&L+30/#]G%
MK-KJ5DNR:(J@8G>GS,Q.<J2<GK1IW[*=G\-_'6B>(?AM/'H$; VOB&QOC)<Q
M:O:G)R^XY\T'HQ/?FM"W_8]\ 6^H*535QH0N_MR^&CJ,O]EK-NW9\C.W&>=O
MW?:@#B_%7B:;X/\ Q^L_B7;:-K&J>#/'&B0V]ZNEV3SRPWD9S \D:C(W(^W)
MZ8KH=*^ -Q??\+@T"[2*#P-XWVWUD,YFM;J6/$S&/MAPKCGKFOHA8D155455
M48  X ]*78O]T?E0!PL?PJTK6?AOHWA#Q4J^);6Q@MXY)KA2GGR0[=LA /!R
MH/6NWA@6$ +T P/I4FT>E+0 4444 1R0K(N"..AK"TWP'H.CZI)J-GIEO!>R
M#!F5.0#U ]/PKH:*=VMAW:(?LRYSGFG+$$SSGZU)12$)M'I1M%+10 E+110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !5&!$6\9@BAVX9@!D_4T44 7:*** %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>plrx-20211231_g24.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g24.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M6JM?<CZUNM;PC$-NHA9CY',K,7Q/2)RJSO3TU2C:!8Z$Q/C</DAU _0=2E4
M* B;9O>:",4@728<3X/.8S7?58Y>)RK3=C)QHEY)+TH'4Y&1@J.R%0IJ?Q:"
MAH8\5SJUN6=C$@+/$;U&0O19R#R4^Z%Q!#:ZJ+GJ>'<ZSQGK0ZRYF7!V#"..
MTJ(FGDF9BQ@ FI.04B6I+*H(56=KSX"V-2#VJ$P\4CR-E33U1$*][C*?<E/\
M7K:X 1$1@ (AW7C$L,#V/,R"*,ID[KS$A3""ZT]D%%LE4^2O>;G)A\/R8=.
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MN%3"'=US??6F*L]9G\&G5ZB+PC:LRAHL&#FR*>;9R#],O;JLN(^Q&FNF(EQ
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M@6)H_@0:5.A0HD%=PBR:=*A-GDV=YO0Y<Q* &!D]6N7X#B,QCA>5>=6ZT0
M8DK-GA4:XR7_6K8LF3Z%ZS1JTJ]?,WVEF(DB,6*?^-JMV%;P8*)J,Q%&O/!M
M7,90:384T_&C5<J2*W,46#;QYK8N#W-.O+CQZ)YFB:%!,RDUZM5B5JM^?1?T
M[*42#]9%>''D4=J$19-N/#?FU*J5)W?DB-5RQ!4 /O>&_E,MTNAH?P./:S I
M-&*9O'__'D,,>/*:JY\_>7H2M'VG78O,A&9\O873T9^]COVI=ID-'TY.;CGD
M+LLHI/L./(DW!(O*3[^FA!LL-9$6I) D9<0P0 R(T+A!F1@F(>;#3,2@#B$%
M*PRJ00=W@G EX@2\2CGC8M3(,!11M/%&H%1<T;'$4F-/QQMCN&$%732X(W$?
M^3BD2(P;$*)OGQR%G(G''F]J427(,N(J(J^ZI/&J "O+C$H$Q2C(S"JOC"M+
MME*+4DT$(;I!PPL/R^2&22)31KY]?N-/3I6L9+,TJ:@B,,R,QAS0(VB:>_].
M4.CLDW300O?;;+P)*T7OPB.)&6^?/?>,R,_?2N2T)$(+#90E_SAB]#BOZNJ*
MRZW&VC15T#S3M:9+Y=H,SEZK4Z9.B%S;1XSQ8KA+V8.\FG)8Q7Y]D*87C1L3
M5LN2TU:B,J7=C%)P%5J533?1 G)<VBX4@[U)8F@H(F65_:2^M=1-J-PKSSUI
MRVZYG3%@RK[%5[ 3"]:W1W[-DK!@T+R[;9),UOMSXDA-O-?AA%=<N*1K!3X.
M8#$GB];ALTI6=V,'6Q5L/I,WBY.D(.V].&5J>6)92X<"9#1;D&DT\&6T7,H9
M7)7UZSBIAH6^D>B7C\8NZ9$^#DN9L";"J&H C\/_Z%'GF#XY8X1O9C%8BL&N
M4-RQR?:Q/P#X_-E6+^7^B)BQS$.;*%Y-AAHXJ8D2-N\%]]:8[;:'0U3DK1M5
M/+E]"!8\+;'Q[9NTHM'2-'($U:;<<)PN[]>A1"F+53*+M@I:<Z,FM]ES@OX>
M:FG5SSNX<]<'@CVAAK@8>5$8%941Y=EC$M[HVW$W>WCTBI>V\M%R1VBJ#DF?
ML=O?02)+^9]J;_UXZ(&277O:N!_7^> > X!WKDW_&:)NF1??),Z[OQUTLS*/
MG[;YRS]>(/M+\D^82L<^B@R0*;G*7TI<XH:G]>]M-,D$D21X@PD2B0L4%(-X
M*!@##6;P!A>L( 5%2"2\T25P)N0S7O^^)ZKTT0TL%?D2U[P"*\B9\"3[2Z'W
M:.*D2?30AS]\31!5,\37_-"(#<F>#6D"OUZ9CS$K#."_!&2]C\0J=4HT"0J;
MY\ 5DBIN7S0.I+!XPC3QC8O6:F'[1B<CCS!QC&Y,E1.S\QBX)4I;4@39%<>H
M$AQNL7__(TD >P<\ 6(+>R7<HT*T."PYP@6*=5S?%ZD($3@F$F,UXY\*T1@#
M \9H@%2LB$ P:4DIL2Z3.IR)L@;9J)!-L4!))"5*^LC(,\Y$D*OD&BBS9A4]
M_\9R'X1;&RK[ TF0*>YGE23E(IM82YF\J&?7FUM$M!8CM2 REK-<YA^M!;<[
M+LZ.K.RE+VG60&W:\FUTJ\M6K*?+CXA2G EQFADU:<L.E6Z %SE=]90AQG>V
MQ)0YO%T7$55%;T:30&.Z6S\/@DQ)-?(I7:PCU@P*)O<E:IH1J:%"$8)-73D4
M6.;\#_5$:DR1-@>!OE1F1YD9$_D8\G<D!5!"-;J0E,9QI2SYF#U=ZCLR?4VA
M'+5I.8?I23!^\Y4GG2E#!>71I@!R)%OBJ4C7Z!%MA3.9/BW</(?J2L85E#+\
MG"D\RYA582*N.#XKI*)*Y[516A*HG&(J3U;8B.E%5?\RLR*D]:SZTW_ZL:RN
MVME6!&M0JX IAE["#"S?65.XWG0E+8T56F,4PUK5"*MA/0@P;?=7%PV4H$3%
MVC,'60^9]E.I<HKK3IRZ$"]:K:BL-$Y&D]I76@J5I><D9&X[B3VD7G6U#76L
MEH@II@+R]).2 2MF?TG;;')6)1]CHU2[&J/DBO.ME4JM3AX)6S;.BIT>V:MI
M+[O9@**/3Y-<WVXU$MX]:I9^KMLN9< $/)W2B+3C#2MCL1O<E$"WF#MEU./P
M>TWFJM2V..6FP-:IX$,J=Z,%#NKQ?JN[P!*5JWGEI6+%J5_@:I6ED>'9UO"Z
MN&F61;8:Y?!2^8L2Z!I6L/F'I*]Q2_O.TZHINX=CB2JG"J,1AXF]UATP0.%K
MWN5T$I_%/2Q& =!;2Z88M2ON%R1%JYP0L['&6(PG6<M[J.+H$X\!"U!U?7G=
M#DO86B%EU S3:]?U:CBL9%;Q@1];85RZE*2)M>95&2A/YZ:DI85=97)Z;-=Z
MN-/!RVUK;?O,XH%&UKAK'-.5_[4'YR=[V%41E:17,\QD\:+JO9Z#(FXC>=SH
M)I;3[84P2Z"Q8/9IQ"PWQ@E$MS6@XJX/R6*:,6:=;&,HF\2_;+9PW,1,X$3+
MI![D07:ROW/J-<E9N*_=\9A^/.8@^[5^Z/N/1"6*V,%Z4Z]+1G&J5S(O<L]K
M!>(I][R*W>Q%1UF=K>Y=97\W['![^I1;;J9GU2JC .$SG6)Q,X'M/;1UTZ77
M)5%E)TF];R7GF:\#M_:0S3E<]?H[NDQQ>"+=RY90A>;@)&EMR'H\7X:WL=K]
MW+698(VE3:XYWI&D'KW=*NZT%)Q!#IPP0O[<;[0J/+;@/K2DA;1R@N3\(*\"
M]DY'>__4<!N=)C>P.5&(CCQ;2EFZ4A4M6P^]7*=3:>J&<IOZ+O[=BWOHY'L4
M.O$R_NJ//W6X=K;,"VTU;8&3L]V^%EV:Y5WK8!_GQ/&SS6YHKG,G%;Y.=2I\
MNM'40<7/Z_"&I\G7'R@5- ^HW_H4J8#7;D.(D&3C0@8U^L3^E9ZK\=_OT+H2
M^Q2^!T-<?NB>%P[$$ ;9T_[QB$_\[9V$ ]J36RT B#S.Z6CZD9%<EW]78GQ8
M7TK7-_?:($WK2#5B_($!W8:CJM-)=UTG97M'$]W_?K*'D>RI )_=^/[P5:HV
MY:)2\NP)9)>R:I9RK[>=M6F$D7KMF.O\P4L9I!HGF1 /39#_&(FAA&$(OTQ
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*M*,M[6FS+"  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>plrx-20211231_g25.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g25.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M59%F,U0,?GE@Q1 *]L@0&!DT5&(SY"D1K-$;-[ [W.B@F5!?Y7@8^;1OC4
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M:\H3&5TF2L;6!00P!NS6#H!U7"<5EQ!!.H*PL8*0!060!1PK"+Y0%6NH#+.
M"VI"C4:X(JC_VC3JXR=(\B*XLP](0A^\LZD @AK(U!@L!5SLT)8!10"!F'*;
MH .Y5ZL+40R^\ M,2P-P^0M+^PO8:A2^>5.8! Z(@ B,J$KN]G4WV;(40UC9
M,;:@F#TB<ASR 1[R,:$(D9Y]H0_#, 9H%X65H F9]0*G5Y@-D2G+)E93^U<#
MP0X?MPNQ$ N%&)RL":-DZI4"TAO,LR<9*Q\3HA[@@223"[DMIH2.D9#L(+=T
M]69:50DMRU(P9JA4@6^XI _N@ BR0 SY\%20R7F0&C1-I#GAN*Q?YQS7PZGU
MP!L3PJEMNSF).Q;]%5@/,;S#Q0ZE)%^S50 +4 ;;9KH6P9R3J17%_Y +\RJ]
M*XN$0-,=(L0=89F=^9$=WI(?"[HFCZ.W7Q%[AZ*'ZGL01Y4M&4<.K=J'+K )
MO?J3!E&Z74$/P(JT#8&/V$F[K0&V&7$IR!L6?]NK>RA(@KL.CK  $!F%V)@1
M<92BBI2_2%$/B8 +[G"1BXLS"/*@^H&I*F%O9J'!#J&ZP> -?EI6?5@ %8QT
MTKN?7N&_N0# !OJU1',[ZJ&O&DDJ$T86^61^@G7$1OR^F38/-!A'E7!5(?@"
MF%@1FS8^^K4&G,9I^.H4]2 +V6L1Q!I-5W*=SX.Y)U&A8+%F0=9"+41#T;L0
MB=9E\R" 2R80Q3!7=&5Z.KRWFJ #_Y->9);@Q_>4%<7@"+/0LIS'B]U;/>,9
MF]81J2%Q*5O\%1MH07/;4Q)9J++7#L;&#ME""5_P6LW[ EA #"I<$)MP5?7W
MEC#I8%,\%5W\Q47X$&&<,Y6SL"_A*:=L%532!5XP!EX04%[PRUU !L*J2*'$
MM05!";AG4E$XJ,3PMPFQ2=&@6IOF"(A0"5K,>U&Q?P0AK_3:4+TJP ;_O##.
M(:PD(<EHD6CS '5C0 ",L);9I[^Q([@HA\HU8(?%4 D@^'J37!&_( N_L,M"
ML0P![0BX@ N(T H(C;TN^G4AC#.\X:- 7,Y$I;EG 5B-%HMC4  VU8A>EBUY
M]F<LQ5.4X% MV9P:$5<*_0M:X0N", @RS0J#0-."(-#6&286;3 (8JUFG$5#
MG!:(E%\$H GII[*4N0ZZ8'68QE-KL$WU0'Z3J<1$M@^Y, LCFQ7UX BL( @T
MW=4UG0BQ&]$SDZ"R:9ZRF:;DN"II$41DD(X(T64EJ0P>YZ>]24@$\-0#$0UF
MN1']U=+:VQ+Y-#'>XBUQO->:_ LQ;=.M@)=9__UUCPK))N,M.NI>R@ ANYH2
M;JL5:U  6$I]KL8.R99/Q; #!)"4 Q%!*OT1 ?W8+Q&_!)$MLLUM*X:6F88+
MC<T*B4#3N!#.7,FR/!,AY]MDYHO.N_0X<O'6V B4A"=L=IW:=GO:=39^O442
MN) (+DW0%\& &7$H]"!M]+ ,[R!>:J:T2HL(,;W0@H#5%4'.T60>8C">E?J/
MORB08VFD;*%?;(<0+)4,PU;'WZQ?.Y"<O2G5'P'>&Y0+B#"RTN9>KVUGAU(/
MX%T,I$.5:I:N4/L+N/ (N) +N" +LC +K)L(LE#3@R (N+#'N$:F429'^(%I
M^+&5>E>+5%TM$G*3/O^:XS?YH*3BD6ZA2,K-$&JY2M784,10:=!+5<O&G]L]
M>U'K"R6."QGN"\ZFW?3LW1).6*1#.N6-X;[@"QZ.O0HN"R0^"+)PTR0^XL#:
MT%*."R:.TQ51@3 P9*A!3\0P"<-0$+<Q*;=AW-H2(>;1/,7A&CO=$)N=%9W]
MV7&-I)#6M=^\5SJ OTXX>_'EDX"5$<O0U8R]L8TM"UFJG(@MSJ,3#9MDI^W%
MG83U#EA)#*?VY1KNX1TLXJR "%V-"(.0M2-.Y@FMX4SK"Q8NX>V5+<MPEX(0
MK+$#T<#-.S1Z VF0'\HN(2$"'GX3 +[CC]O1XO>"'YXHV:G"UG$1Y+&=VLG_
M?,]Z_M9D5!!I"'WLZ52T*'T5T64"40^^,-."T-B-/0BN#5@]&WZ:=F:K)N'?
M#>Q8297HNK0=GNOHW=4QO;'H3>NL*^:YL+0#3^'2;! !C>^.FB>20B%A$ -A
M,"'[ -_7,R%-=#TPP#B\@0/7<[!ILRZ%3A6I6 EMIX<//,]GMG.1;A!S#'*,
M$+'L!@SM$'[:_:7U;NM?[0C.=BB#)>%1>>$&S^'H?>8AR[$GOK%D#J8=GJZG
M]@[2EMF:3!'O@ @I#L+)'K<W*1LE'R:N05A7<@"<8R7&FAIJXV)K >1P/9'
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M$(=JTZ$MQ3FH>J !=J7+!.V$@C=$ 4L?F]++G6@($WHHB!T/HH'4-+$,2M0
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M7Q@$7,@0TS*+=C '&]S!&JS!'6P'KU &>K!#6\ &<+!#.RP^11E"]6H@(SQ
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M79 2!ZFB'= +>GB$&!$FTG0-7IB&U&P-<,"&<\!*ER$&&[107_23RCQ/'C*
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M]XT6G2.7H4,=7V)I3,/(I9@#=.155(=/C^QSGAE,@V#08)+@Z: &!:5,07=
M U5FC2&4J$P!K!G1&A#OEU89QCJ^(0R'C;.<90M@1(CAI51\:R?>0044U>1/
M^3A3GA!1!DQC"K8WR91.'HEI1'"JS/O0J9@/408Q,I$)8A#-/3I=J6WZ9A^0
M/(\&-7 J09SJU!="I!(251 /']*>9T6K/?3(!2)P08S^F I/:G"!&O!D4Y%\
M@Y#F2&9,%NA.GK@4J6=I2++44 8R5&(_56%,X90AAL$2%@W"BO_&,' 0AL'B
M8+"96$X]H$'8QS8$&L1  V&'4:AE8&*2F1!#)N!:66(,]@8QN($8AN%3GG '
MJ**]Z21 :]?:8 )W NTB,391C$U08@$ZJ(1N%7-*O);!,I:L0?TX(I*%A7(?
M#T-$+LJICV&\[6U>(  BW.8V";FLI#XYXFQS-<+A!HA@$]T!X6+"00/$0# Q
MD"T]WH"4]L8 !@=(K4..@A1"L8\8-P! # Y@ !P(2QGMW<=__P:2>F3"M 88
MK&!P0*Z["I8P,?%O##(1WL"9I('(?(DR-+<8H;6G$@,R;@%JP-!A<;4=1'N8
M('+QL?:DR$)7<($5+%*15XC*8T !!TK_XU77#;.TFI:IP7ZZ T*(9&(% )B$
M4-$0T/M, L!"S812T? 8- #8R@R!QE%B .4M).4^Q'CP/L109E$2 Z;[<+-@
M5Y!AH&HQF3!M,]AB&I5XP1FH#0FS,I9R'YF*TK7<\>\*-$QDG13&LD(E*F2@
MH0RANODCDB0FTEZ[#\1M!2'+\JA(U+&+AC7DN;D(YC<LE*$;<T$L=D$B3VQA
MFD7CJC_+$&-$D5,#Y[CD*#<0UCXD<8 8$+7*,7#(#520AJDHP\F9",.3[U./
MV"I:#/>]3R94H&$U3\+,;G L,;J]#REG.+^@G9&@8RL&-(16E)]UK+25 >7+
MKEO#I 6  ;8H_V\LHT'<6$;M)"#=X'+3>G48?F^[ZT'N7XOVPRY9!@'*>+$E
M/T^B!EG#3-NABW60FB$PQH4IPW815%R! ($8.0*+ZA,1T:K@?@+8,I2QC!I8
MTYJ:6*;,<QEF8!L8 )E@L)6#VC>"[R/,RT##"GY=V89P61)U0D, [J-F?:OY
MM#'PE5*XS%\?#JWJ_Q7SFXUMVJ6>>3#M!<"OZV-E90"XO6(@AG\!_'5[WR#1
M+G?@?M7\:V@86^_ AHB.>/028AATM?K8A&4((O%A"8,<^>,/,1 18Y"$Q2+9
ML *.8601T"DY)N-1C2U02H\YO>GN-EJ&)LB@UZSDNM-D7 ,F5]OD&%!\ J\Q
M4,$D^(X4?.]>*:*<^CZ&85I%\V?V&A;LL=,<[5X1>]+.%FP'AZ$)Z1/C09-&
M>YO[ML6R_[S!/-*O0.L36F/_O.R@E;2:)XG\MQN8Z/^F1XEEGUP8;F/X/ER>
MQ.^6EAF'HT09"U"(,.V0"PQ$1+E0^B@#.SC>/#A$,<A"IX"/N&@>R1$ ((Q<
MQ_$$=<'-A)"%+7R#+9S#A+U??%1<1%F<<1T'#31.0^47>P&;?QG LAU%TI46
M@.'?FPD&4=4##BS5G^5&&C $,9P60TR=,FA=0_Q7:*5?82C#CLP7\0VAX+T9
MWW10DQ'*F:U H?S7)!0= *Q %L6 W15=>Q6*@1G 4-7=$XK@2;26&&18$":?
MCDC"8DP:E-4AM$6A?Y1:IOE'-%1"P11#@!" &FG5)P5#N-2#\B3"_T0$T53>
MJM' R5T$]F@&18R<)69#2JG_87@ C"8 XB:8($$0 /UTHLS=!H#Q&1ABPKBA
M'7^@@0'\6C14V6 ,5FXHW10&0"8TQE%LH?)U6QO>5B\J'W_5 PT2FT- 'R_B
M%9<!8Z\P'( 51CT(AH:%66&<60P4"J")$AB>H?MIXH(Q!-+= $P!V!?RERSN
M'@#@#@^B!.$MGD=L @W00/3L0S5M0KS@4CGL @UAC2\D@BPLXI(]!)#IV(WE
MF(Z-S$ZXBNFXPSRD"SVX0SNX@Z9Y8VTL@WF%XE9X5!4%A@$ 6V!D&- E']^T
M5Q*BX^[!P ]RX0V0B\(1'!$:(4-HX:2Q%_'IPT>F(;?=AV7!5)7= -.]%U 9
M !9"_V'X =A2?*2P7&&AU,,-F"&BI2%%+DH;*IVO3>$6K:))]AY,A (!$,]'
MP"-R=<2M0<6PM%&T'*(O#((LU%$7T4,ON,)%I$)!8D0F0DCG@5%4VL@G&I<"
M;$X_<>&<!97?*$,L EB;!57ZM9FOS)M0[: 8Z(,FJ   X "4I8%FB<$-3$5.
M5MG;Z9[/P53Z'1\Q[& ,3-CU7:.\ 24Q=.'/]5SNK:8!")H6%MT*&("9L1<9
M3EUDB<$*$,K 065>/H24[=T-7N,^X$8:D(G020*6#=Q@S)4H&=3?.016),0O
M$,,[! ^#% ,Q<.<N.,V#@)4L$,-R*,I$K)-%3(-%E-PA8/_$,$!G<-[,0]6<
M5\*$?M&78-R ;^B#+%K=UVV1L145;HA9&NR>>_6;:34$$0H6>W'!V/E>?<1
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M#O];[%V'\4)BB0LXQ)=B? FGEAWG]3'GG#X%28TF.QY;[[WY[MMOEHCIQ<5
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M)20@HTP]H!''&[JDC7$4D$GLR#T-SJ0+0YS-,/8H( 60P8L/:1.[7H0V BR
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M$!FG#,=,HBX(F0BM<M:_D[1$5X3B&,'T-)%@[81Z"5199$8"L@IN9"J<(@_
M6B42Y'6$*-T924Y:DN4Z#::,&,-[E(-4")7Z6 Q*H^H2 F'X$>[@!QI!04I(
M,&.RW6#+=SC<R)A>"!\)"9%=C@E0$17T-,2 YHD7X4].%"0:%YWM)/"1(C&&
M8T4JGLH\%Q+C3OA4DDD,[T+_,^-)!C@[%$DK)Y7YB5?<Z+UF301WIJL9TYYF
MDQNF9'!X+*0A#VDKB    $U"I )OLDBE36F1B[RB(R^BJ*&\99$ W*2>P(?'
M!4K/-0"(R7 46<FT7'*5K&RESHAQ&&40TI46X8]A3%*?6]*2(J*1E"U]>1A+
MLE)S%(G6) 1$D8<8!I2[;*8S_Y^)DN&T#)H7(6(#J5E-5;($FQ.)WT6\R<UP
MBG.<Y"RG.<^)SG2J<YWL;*<[WPG/>,ISGO2LISWOB<]\ZG.?_.RG/_\)T( *
M=* $+:A!#XK0A"ITH0REI38;"M&(2E2?F1.DPAXGGF5@5(%?"M^7>/8E:UYR
M)G\!$DM"FA&23G2E+/4440Q 2>0I0Q/$\%@,F .58=P !\Q$&]&8 I6UK(!I
M3$/#0Q&IDW=EXDU5F1CX6L*NEDIUJN-!4K42,YF?9/4&89BF4W0(RC 9)U )
M*X\B;6(3+:'DJ!YAJX+&! "DZ$L]DP1:1O1(U;SJ-263Z.%,U.@J?0UC1/5!
M5F:(H?]$LBD$&F#B4MYL,HR)4&ALA!H@T"@$%L7B\B\SDM!1[<,6GKU#(8?M
MJ&)KB=C,D+:CC%4IVCPK69.2C;%<@@])@41;0IF4)2(AGEJW\Q*DM/:C/^WI
M7H^KUYJDX; -66HIF9*J:- #,9.0S@W2(*UJV84U"G'1O/1E%W4Q%9",+(EH
M+":R-SGL+]7-K@CW$:V7//1IVV)(M-0%U.U8=UM C<Z6;*F>0!G%45"M+DG6
M^[1[<>%PB"'M:L#R$ @*\3T4:0Q]HH,Q]?Y%@LCML(=_ J/QZI>3$8)I07!P
M'Q?%0 5):E12*+R/<X5)-N!9#:2.0J.(2(4D2"$A8EHU"2#_Q:9*7K*(?7 2
M(< ]:F8XUM; 2C8M)07M-GQJ;@CWHE:(! 4Q+C[(I2"UF7X9<'@5@6M3IK(4
MPW"9-%D4""?UDD$/RWFO4HG,(E6  T?92$OT.#*IZN+<&\3/2D]2VCY0% VP
MSJAN6)90;&!G@ L+Q*BODG1=^%16M$42K=EJ%&PN[9*\#.R+-,H+DNPBD-.$
MNC00/+)G@"*3R\ .NC8R#HIJR;^IE+)!G&3N35QUG-G->=A4349UW4SA,H("
M9[PST#ZF*[OH10M*$<2)Q&S2%AR]2&EMW(<;+@5(8!>J)8T,VGN/?(,W:;=G
MA(J-V49#G8),"7J*QM(*W'#HB/0JE3@S6:2\5RTWS@J/-,IHE:ELN!VFK08-
MC?BU>I[6'1T=S[C$KOA!ZS,B?8BFDJ_BZ3Z&L<B)W+HEG*OV:9 TKWP;JH?0
MT!1:;S1)X\#Q:2]12#T0(J%4[U$WW504,8#D8 G'BB3I=E&,5X N_ORGC*+<
M!TS37?2\V,=5L8H04*JBD'YU&UPP3<M4IC.K^^2KJ!51XWLM_XYVA4),E6^1
MQ(PM1YL)$;HEV*%.F&!\KD1C.X!P&= 7+6O 0(9K(I^@"L!TU%>[#J7FM;21
MCLB-&2 I\<:9"4[07%6ATUCIHTH$K4[&!"M(H2N)IU1-7(F(\$(WE?$T$N$!
MTPY[A?))2\N@.0 T,:.@X%Z1#AFY&.A7;4-U!N+6/C7?67V;F<]J*8YN(;_M
M+2J>PU=1.>/3*)F_0"L3*!-D7\M7 -L0?C.HN2'/CDPLRVHGT8;QN);5\L%N
M8<2>*3,5EG#L[V]0$)=R!8O$@8;T7Q+^EF]YP6YV!U>+Q'\&,BXP!TDO\1*F
M1DG$\&U TR64A'FA9D#WH2;U<&0Y$_]S7$)*P14U"/A<#M& 3"-A#7@?H2&
MS4: (0AC!1(>%R$W^E(5 T0:I-0@KF(:^.>#!:4,8\ PU7(U@2()/K(:"B,)
MDS$N1V% 1T%89!5%-75>F5%=YQ=5](4954@XJP$V4A%5,P(:\Y6$41$HOD16
M8#-]P80[E;4M.!*&6G@W94A?#X<K:F@0 OA-\".&6W2&4>0BU$* Z?&#A3A0
MCZ,,].!5%+$,&B)=7)),T8 L^B")R:0/TT0/U).)9=:( A=;UP2)".0[NU5+
M;.56\7-4F;$5LP-.#E%%\Y5,HPA&+ %O*=5;W91-L<A8M'40F6:(OPB,;E2
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F<2NW<TNW=6NW=XNW>:NW>\NW?>NW?PNX@2NX@TNXA6NX)!D0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>plrx-20211231_g26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g26.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "H EL# 2(  A$! Q$!_\0
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MKX@N;[_D&Z7-<1]I[D_9XS[C(W'_ +YJI>ZSJ%B2+S4]&L&_N-O=O_0ES^5
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MR1FM#X=?M/>%OB1XPM?#UGIGB#2[B]2\;3KO5M.,%KJ!M9?*N5@DW'>48C/
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M*/&DTA(:#3=+0(9/O;YI7W%?PAP3[XH&GY'76NDR:W"MQ?ZG)=QR<B"T8PP
M>G'S-_P(_@*U+'1;'3>+6S@@]XXP"?J>IJ#9_9^K(R<07A(9>PD R#^(!S]!
M6I02Q:*S?$FN1>&] U#59T:2*S@>=D3[S;03@>YZ5RGPE^*T7Q4TF[NUTFXT
M:6WD"FWN75V*D<-D=L@C\*JSM<FZO8[VBDI:0PHHHH **** /G+XP_'KX@>!
MOB#!H.D:!HD\4D?VA()(M2O[J6WW[!*WV6W9( S @!BQX)[5[UX<NM2O='MI
MM7L(M,U)E_?6L%QY\:-_LOM7<._*@\]*^7_VLM+O;SXG>%KRP\!_\)+*MH(8
M[Z)+QVG<7 S9M);S1K:J ?,\V4,O48X-?5N]8(=[%8T5<DLW &/6@":BH6NH
MHY(DDE1'E.$5F +G&< =^*FH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $S2;AZUXY^
MT##KUG#:ZJOB[Q/H7A:+;%=VG@W2(KF^W$L3/)*ZNR0J ,B-,C)))'2G^SCX
MNTWQ=)JDWA_XRQ_%+08XU5+6[A@&H:?)DY\QXU1BI'&)(P00>>U '7:)\</#
M6OZ?XZU"W^W167@V:6'49KJV:$$QPB9VB#8+)M/#8 .#C(YJ?PW\:/"VM>$=
M.\17NK:?H%AJ!*V_]I:A;H6( )7(<KN /*YR.XJS=_"?1+J_UJ\$NH6TNLW/
MVJ^^S7CQB9A:_9@#@_=$8!Q_>4-U%</\1?A_\,/AG\*]:N_%.BP:UIJ3RWTM
MSJVFMJ\YO)E6+S=HC=@QPBDJH  YP,F@#V2ROK?4K.&[M)XKJUF0213PN'21
M2,AE8<$$=Q4]>1?LAKL_99^$RXQCPQIXP/\ KW2O7: "BBB@ HHHH **R?%'
MBC2_!>@WNMZU>QZ=I-E&9KFZE!VQH.I.!FIM!UZP\3Z/::KI=TE[I]W&)H+B
M/.V1",@B@#0HHHH **** "BBB@#EO'7@U/%=A$RO)!?VK>9#-#)L?W7/H>#S
MQD"DT7PQJVF6J6XUZ4VP5<!K=#(IQR,G(Q^%=310!BS:9J]O&S6NK^>X'$=[
M I5CZ$H%(^O-)I?B>.8BWU&%M)U #+6]PPPWO&_1Q].?4"MNN%\<>=)X@TNU
MO8YI_#]Q&Z206ZEF>7DY( W8 &,#J6[8H [H,#1N%<#'X56>.*+2=,N]&MXR
M"))[Z6(''3]TCDG_ ($15Z'P5JOFQO+XPU0QJVYH85C4-[996;'XT =AN%&X
M5BKX8\M0(]7U13_$QN-Y;_OH$#\,4?\ "*6LW_'[<7FHC.=MS.=G_?"X4C\*
M &>)M>TVSTJX:?4+6(1@.X>91A0P)[^@->;:CX[NKC6I+W1_#NJ:CX;<-+/K
M$,16-1CEPDFUG7@\QAO:O65T:PAA:..RMXHV&"(XE7C\!5>QNC9R+8W;'S5X
MAE8\3+VY_O#N/QI%+8\IUZYT^XT);NVNHA;38$,J."LA;G<#WXJAX=UBV\(^
M,8-1MK$W-E=6BV4[02@F,[]P8 XSDG&/I7HFJ_!_PSJ$KSVUF^C7;G+3Z6_D
M[B3D[DYC;)_O*:X*PT5?$=]J-BOB#[3X(LHV>]U6/3X+8R3*PQ$DZ !@FTLS
MHHP0!N)) RE&4FFG8]##XBC3IRA.#DWYG=ZI\3/#GG6<37TD<RW(W(]K*"NT
M'(^Y5EOBQX8CF\LZ@X&T.9&MY%106"Y)*CN1^>>E+\.;S5/$'AG1M6UI'AO9
M+-,QLNPLQ',A7^$L #CMFNL:-9/O*&P<C(SBM4>?+L<;XJ\1:1X@TDZ5#=K*
M]Y+'!LV,,@L,CD>@K$^'^FQZ#X\OK&$!(FT\,5'3*R<'_P ?-==\0+K^S_"&
MHWP_Y<T%U^"$,?T!K@_@WX@C\:>(-2UN [H4M(X-WJS.3_)1^=:KX69/='KU
M%%%9EA1110 4444 ?"?[47A73M%^,6I3ZI?>&H-)72H]7M;2Y\-PW%XKO>!)
M_(>6X3SIF9FEP%; 3&W)7=]0?'[X6R?&#X3:GX;M9/+O)/*FM2]Q)!&948,O
MF;.648SM(() R.*\:_:PU/7[CXH>&].T#X@>$O"^H6-I#J-MIOB."T628M<&
M.2:*>XB?:5 3"QD,<-G&5-?5T7^K7G/'7U]Z /"OB9\(/%GQ ^(VDZYMTRWM
M+%XK:%WNG,MK'%?6]S]IC 3_ %LB1/$5R,9'S$$BJVKZAX^\#?M*^ ]+N_']
MQKWA3Q;-J['0Y]*M(5LUAM_-A1)HT$C;20,L22!S7T!7S_\ %+7M/O/VLO@?
MI4-U')J-FNMRSVRGYHT>Q7:Q^N* ,/5OA7\7_!?C;QWXUT?QKIUQI]Q!=36F
MEZD]Q,L<>=X4)E4C90N PR/4<DUXKX7_ &O/B/8_"G4M0FGBU&Y-X$M]6N8U
M8H2$S$4X!'7G&?FK] Y(4FC9)%#HPVLK#((/4&O(/V@OA1%XL^$&H^'_  _I
M,,-PT\=Q#!8PI'EPPR<< 9'!/I76L5))<T$[6Z=%TT_KR.JC-2FE4V?]=>WK
M8X!OVP+;38?AS%=07$4^M"/^TYM1TYX-JL OFQD,%*%F!!7=P#7K^@_%O1/$
MOQ*U3PGI^JVUY/;6$-V@MQOR2S[SO!VD &'\6-?-'Q8\">)?!]]\*]+0+K&B
MVX1FM=0C0R6[@ 2H"0<*5R1S@$>V:7PYX1\.:U^TMXBB\.;K>]_L[?##JQF(
M$@5?, D1E93MVX8,PZ_>R*QI8C"5E)2]R27=/6^FFCV^9VRP7M%[2A)26K?1
MQ2_FM?\ R\SZ+M-;\1V_PY\5:G-K4%WJ>GS7WV>5[%50+;NZA2BMSN$?)R,;
MJT=:\5:[X?TWPEY<%EJL^JW45I<33R-;A&="^Y456XPK<9]*^-?#'A\^&_V>
M_B';ZAXAUO3IVU":-+BQ=I[.X9"JF-]C=7P<EBN0V?FZ5Z!KMMXLL?AY\%)]
M'^),*6UQ=VOEC7(41M^P[6'&YHU!92K,?O+S7J/#4G+22M?LUTN>9+#UX;Q^
M[4^F%\4:H?B4WAPV-I_9PT_[>+S[0WG8W[-NS9C.X?WNGY50T;XBZA>Z'XIU
M*\\/^4-#N9K86]G>+/)<^4,N1N5 O!& 3ZUYK#XH^)-E^TE+9W/A;3M1L$T(
M#[18W7E;X?-R) 9#PV\E=A],YK$\&_&R6T\&?%:;Q-X;U#PU;PZE?&*YGBDD
MA:1UVF%W13M<';S]T[A@UA]5?+S))Z+9ZZ^5SGYUL]#VF\^)4EOX5\/ZY%X=
MU"X76)88DM?-A66$S$",OE]N#D="<9K7F\7)!XPM?#QTR_::XMFNA>*J&W5%
M(#9.[=D%E'W?XA[UXK-\7/#MY\'_ (:W=OXAT: M?:7$Z7%QS&T;*'RN01M*
MG.1CCKT-:>I?M >&XOCYH^BVL-_J[/I$\8N],MFN(BSNC_*%R6 $)RR@@%@/
M7&?U:<KI0>E_P_R&Y)*]STS0]:URXG\3BZ@L[L:;<^1:PV>Z-Y?W22_,SMM!
MQ(H[#()[\4-1^(>I0^!=,\1V7AQKEKZ6W5;*XOHXF1)F58W+@,.KKD=LGTKR
MSP?^TQ9W5U\3)4\'>)I/[.O6G5(;%G9PL"1[7 '[ILPDX;H&'H:QYOVCM"L_
MV=_"VIZII&M:=BXL+81/8R%'\B9&9DE(",I6)B.<GIBM%@ZO,KPZI?>K]R/:
M);L^B;KQGIFG^(-.T&[DEBU>^C,L,"V\KHP'WOW@7:,<9R1U'J*N1^(M)FDN
MDCU2S=[4%KA5N$)A ZEQGY<>]<!-\0?#>O?$[P0NGZ]87+W5A?F*&.X4R-GR
M"!MSD'Y6X//RGTK3\&V5K_PL+XA 00Y:YLP^$7+ VJ$@^N?>N25/E6JMI?\
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MLW8P.N,X% '(_LA_\FM?";G/_%,:?_Z3I7KE>1_LAX_X9:^$V.G_  C&G_\
MI.E>N4 %(3CDTM0WDC16<[KPRHQ'U H EW"C(KY9^!^A_&/XN?"'PCXSNOCG
M?:;<:YIT5])9P>&--:.$N,E5)CR0/4\UV_\ PI_XN?\ 1P&J?^$MI?\ \:H
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M_3=-L['3TO+E;B2",6>;I8A<W:R6TS36Q+JGEHT9#!FS@$K]5Q_=['W7ITH
M?7AWQ;_Y.:^ ?INU[_TA6O<*^?\ XI?VI_PUE\$#<-9G2MNM_95C5_/#_81O
MWDG:5Z8P,T ?0!I-IZTM+0!ROBCPU>ZUK6@WEN]A'%IMR;B1;JW,DCY1DPK
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MDZOX2M]0FD,JW6J:7<,T#,T6R5@&0;-@^<J<Y'0U1L/%%NW[)\4ZW$EVWFI
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M%% "$XHW"AAE<5\P?#?Q9\1;K]IC6+#6/%^DWO@Z>\OTL;>"]A;SA JJ;:&
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M>4.T,F VU@.APPH VJ*** "ODJ]2RD_:86^7X-0W'B^/Q&EJNN#2[@Q?V5Y
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MQCWQ77USWC_5CHG@[5;H65[J!6!U\C3XO-F.X$9"Y' SD\]!0!X7\,O&E_\
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MJ,GJ/H/]H3XB:S\/?"^B7.DW,6GI>7K6]UJD\'VA+55M)Y4)7I^\EBBBR?\
MGIQR17#?'#3_ (::#XOTV/Q5XJ\>V5^^^_==#U/4C;6<#S9\ZY,&4A@#Y12^
M% ! X%?2,:J54 Y4#CG- 'SUX@^/.M1ZS\/_ "R+:UO(DBUS3[-$:]%^\ELG
MV>.*1266/SG+[?F"\YXI/B'J^H:A^U9\$[:ZT*[TNWMY-?$%Y// Z70^Q 91
M4=F7C!^<+U]:^B-@KP_XM#'[37P#_P![7O\ TA6@#W&EHHH **** "DI:* .
M7^RZA_PL!KLV)&F_8/LXNO.3[V_=]S.[':N,;P'I^H> ?B#I=LOV!;^\O!+,
MH,A!P.0&/7K^=>L'O7)66B:AHVA^)?MUQ;W(NVN+I/L\3)LW*<@Y)ST%<DZ:
M;UU6OXF=YPTB]'OV^?<\@\16.M_#3X;_  [MM*^W>)H%O[!WMWB+% I#C:PR
M5!X7!R/3'2O1;;Q79ZA\8-+L91+8ZE_8MR39W2[7YFA(P1\K#"MR">AK0N!_
MQ1OA(G@_:-._FE5=>^'_ (>UKXH:?JE[I<,VI?V;-B[RPD7:\84@@\$!VP1S
MS7+&G.'\-Z>[H_T-(UNC\_Q_+\?0VO#(#7WB]2 5.IG@C(/^BP5Q&N:#IFM?
M!7PG'?Z?:WL<;Z642:%65=TL2L0".ZL0?4$U!X8U'Q;X&_X3O4=>2TU?18+Q
MIP;24_:XT6%.H90)#Y8C[@D[JPV^+?AMO@?X:N+FXGTV-)].A)O;=X@7BGCW
M@,1M. C'KT!IRK4W#EGH[/1^IZ-&LE43IRZQ_)[&MXT^"_AC5OC5X0U)[62U
ME^R7!,=E)Y"9@,9C/R8(/[ULD'L/2N,\'_!?Q-H/CCXI7&@>+)8]1*&&U65-
M^]Y4$T>]GW?=R%W 9XSTXKV/4-5LM4^)?@V6RNX+J)K/42KP2*X/_'N>H-2^
M#?\ DHGQ _Z^;/\ ])4J/J]*52Z7VNG^$]6GG&,IT%#GYH\B5I)25E.]M3Y;
MU;2/B)9_LLVMK-%:ZEI\VI!U\M?,F@@#\ \!<&4>Y^;T/':^(/B=KVD?%+X.
MZ9K6@7%AJ*6ZI.H>/:SW"B%BH4-M"X)*D@_3K79=?V7X.WRQ_P#I:*[3QIIU
MI<_%#X?SS6T,LR/>[9'0%EQ!D8/L>:Y8X=QC%QFUI#SZ_>>E+-:-6I/V^'B]
M:KTO'5Q];61WP6JNK6=Q?VOE6U]+ITN0?.A1';'IAU(Y^E6O8<TLLBQ+N=E5
M?5CBOH+V/ASS/1?A%JNC^,]:UT>-]8D6^5!';N(W2(]7(1E*#) QM48Y]:W?
MBEX/O_&WPI\4^&K.XC.HZII-Q8PSW7RH9'B*AGV@X&3S@?05T,.O:=<7<]K%
M?6[W,./,B60;ESTR,UE_$;Q@/A_\/_$7B<VWVY='T^>_-NK[?-$:%]N[!QG'
M7%'ME6UNG;T-)\]_?/&_B%\(_B!\1K/2O-MM(TY[+2KG2X;4ZQ.Z6ES(L7DZ
MG&R0KF6$HX"$#AN'7)KDK3]DGQY;_%"WU23QND_A.+5$1]/:>8/-I8E%\Z%0
M-HF:^SSG'E'&><5WL'[6GA^;QY/HDBV]II5K:6UW<:M<W#(JK+:W-PP"%.2B
MVQSR,AN.1@VM4_:X\$6&O6-JMQ</II%T-2OI+2>-M.:&WAN!YD1CW;6BG5MW
M0 =>:9F9/B[X%^+/$_B/QY91S:;9^'_%&O:5K(U1;EVN[5;-+7*+!Y>TNSVO
M#;\ -G&1BN"US]DWQ[K'A6:Q75[*TN1!:Q2I;ZI/Y>J7D33%]1N!)"P+R>8@
M:(@Y"G]X"$(]P\??&#4?#?B<Z3HFAV^M^5X>N/$;R27OD>9%%(B>7'\C LV_
M()P./QJ*S_:A^&]QHXU.?Q%'I]HMDU[+-=Q.L<82!9Y8S)C898XW5F16+#GC
M@X .2^%OP(\:>$_B\_BG7O$,>HVS0,&:UN742!K>"-;<Q-&6,<;Q.REICC=D
M*"6)]_N(%NH7B<9C=2K#)&01@UY]#^T%X#FN='M_[>2.;5M@MEF@E3[\IACW
MDKA-\@**6P&(XS7?WUP]K9SS1Q^=)'&SK'DC<0"0,@'K]#0!P<'[/_P]M=*T
M[38?"EC'I^G7AU"TMUWA(+D[<S(-W#_*#NZYR>K$G?\ "_P[\.>#=4UC4M%T
MBWTZ_P!8F^T:A/#G==298[WR>6^8\^F!T  \RTOXY>.K[1_#-U<?"K4K2YU'
M5)+._M7F;=I]N#\EPW[OE2'B/'/+<?*0)]4^-7CFUTKQE/:_"[4+N\T>_2UT
MVV6=O^)I"QVF:,^7T!5R0<<!3W!(![515/2+Y]2TJSNY(&M9)X5E:!\[HRP!
MVG(!R,XZ"KE &+XTU"]TCPAKU]IL7G:C:V$\]M'L+[Y5C8H-HZY('%?,7PA^
M+'@/QY\68]9U[P"+#QE+;:;%8^(6\,7<4UQ=26^+D-(T6(_+?]V')'RG&<5]
M;8HVT >(?M?76LV?PA=]$\27?A>?[=%YU]:I=!?+VOE99K5'EMX\[2954XVA
M3PQK>_9PFU.[^&-K>:MXNTWQG<WES/<K?:3>M>6L*,Y(MTF8!I G(RP!'3 Q
M6+^UIX@M_#OPSLVN6FC@O-5M[-I3KDNC62;P_-[=Q O%;<8;;U)5>]6/V4]6
MT#5/@_:-X;\,Z7X5TRWO+FU^S:%*)]/N)(Y"KW%O-M4S1R$;A(1EN<T >Q[A
M7(_%C6-:T7P!K%UX?\/_ /"3:FL)5=.^VQV>]6X=O-D!4;5);'?&*\6\!^$/
MBCH&D>+;+4H-3N+[5M/DLA?KJ$<H^WEKU_MT:O)A$*/:1A1M^91D *36AI/A
MOXMZ1\'6TW1YO#NA75M-<J[^)+*:ZFN;(1 )(ZPW.$G+;MWS,I !P"2* .3L
M?^49^C8Y'_"!V?\ Z(CKT6]_9Q\(?%!O _BG6HKLZAING6@\N"8)%<*BJRK(
M,$D YZ$9!Q7G5CC_ (=GZ-C@?\('9_\ HB.OI?P/_P B5H'_ &#[?_T6M>A&
MI.EAXRINSN_R1BXJ51I]E^9QWPK_ .2@?%C_ +#L'_I!;5M?%;Q#IOA/P;=:
MQJVIZAI5E;,N9].SYFYCM48 .1DBL7X6_P#)0/BQ_P!AV#_TWVU?/7C?X8^,
M?'WQF\93+;7.O>%K'4 MUIZZL+8$&%9$"AC@8#*>!VKQ<QKU**7LX\S=EZ:;
MNQ]+D.!P^.K2>*K*G""YG>R;UV5[*[Z7T/HSX&^*;+QMX%M]7L-5U'5]Y$-S
M)J!(*SHH\P*"!A<GZ5Z(WTKX6\/?"WQIX1\6>"-6L[>YT#PKJ&HV,<=O_:_G
M;I) &9F53T?:QP1QD U]U,H8$=CUKGP->I6@U5C9KUU\U?4Z<_R_#8*M&>$K
M*<)W:VO'79M:77D<7H_PS\/Z+XSO/$]JUP=7N]PF=KIF1@V,C9G&.!CTQ79M
M]TUP^B^%='M_'FKM%IMK&;>"UDBVQ@>6Q\S++Z$X'-=Q_":ZZ*5G96U9\A1B
MHI\JMJSX%U;Q!;Q^'/!7ACPOX(T^^\2R6Z7MW/<:3',]YERRE3C)7Y<,2><D
M=J]K^ -O=2>/-%U/4/#^E>&[_4?#-Q.]KI5G]F!C%W$$,B_WR,GV! KNO@%X
M9TR;X=^#M>>SC.KQ:4;-+PCYUA,A8H/;(K2F7_C(*QQ_T*]Q_P"E<5>Y6KQE
M>G&-K7U/9JUHR3IJ.U]2M?+)+\:]1CBB\]I/#JIY?F>7G,Q!^;'%<[<?#X>!
M/A[KZO:#S[B:)VO'N!*Y7[0FU/NC&!U/<\UT\DCP_'2]>.,S.OAY2(U(!<B8
MX&3ZUDZMXKU;Q=\*];N=6T=]'ECNHXD5L_.HG3L>>.A/0XXK\WE3H2G4E-/G
M3J<NFG2^MM#V%.M&,(P?N-4[ZZ^6G4]>YVTZD_AI:^R6Q\J<3\7[>.Y^'7BJ
M*7?Y;Z1=!O+7<W^J;H.YSVK\Q_#>N3Q^,K#4[*1A>Z?:I?3VD@=)3^YVR0YP
M1O)50%]37ZL:U9QZ@KVLZ[[>>)HI$_O*P((_(U\A?!3X5Z7XV\3ZW8ZKJM_+
M;V+LUO9PK'%NC69H\.X4D\@=,5\QC(PJ2J4Y[,ZZ-65&<:D-SY=M?BM^T+XC
MUR9](M7TZTD)9;>;38XTA7L-\N"3[^U7M6UGXTVL7_$^^)&E>'DD&2\T\"LO
MT"IG\JH_'RVDOOCUK>@Z)XDDN/"VFRJMLEE,3&S; 7C<YP2C%E/NO05G:IX+
MTWQ!JEYKJ:?'!8-Y27*1R&413HN'7//EJ\@W8X]!Q7I8?*J=2E&;A%)^5SS\
M1FLZ-1QYFVOD.UC0M.N+=+G6_B=K_B*]">8TFGB:="OJ/G5%^K5W4?[,_AS1
M-#&I)HDVKW-Q&C_:-:OA%(6<C:F(U)R20.IJK\/M%AUWQ!I=GM%U"UPOF@QY
MC6)3O(8=\JN/QKZ-\7:S%:V*EH?,$,;7(..C#Y5 'KDUYN826#K4\/1>^KVV
M.K U)XRE.M56BT1Y5\-?@'I>GZI-?6^DZ?H\<,R!FM5DFDN6498&65B54,<?
M*H)YY%?25Y=:CXDA>UU*\DNK:5#&]L<")E/9D'!'L:Y73)K30])MX%R/*3+[
MCGYC\S$GZDUTGAGPEX@\82B>-O[+TSM=3(=[C_IFO?ZGCZU\C4Q%7%5G;5'T
ML:,*%-<VC\RLOAQ-.D26P;[%>1-YBO"H W_3OGOGK3O&7QST3P79PZ]XIL5M
M3I\;*)(4W7%Q(_RK#%QP#RQW, "H]*[C6/AW_8>EK-I+W5[+&2T\<TF]Y!W*
M^A']T5PNN:-IOBZPEMKNWANH959)(9D#9!Z@@UZ5'$UL"VHO1]/\CA=.EB;<
MZ^:W/./AE\1-=_:0^(T9N+M;'P[EIK?P['&L\#V\ 5G:9R/F+RM F<$8+@"N
MS^'/A.T\0?LW^%=)>_M=2TFZLS!;:3#I""83K(PD"'S%*LD@;+\8P22*3]GU
M?#_PY\:77A73;,2HL"VD$L+AVL57?/)$P/S%3O5V<DX,D2]QCN=2^'_B;P%X
MNU+Q+\/(--U6WUB02ZEX=UBY>WC20_?GM)E5O*+X&^(KL9OFR#G/MRJRK14Y
M7UVOU//J*$9N,-D>>_ 6U^(6BZMK>D_$3Q#8ZQ?Z/J(L--UIK;SHHE:-62-U
MW)MD(V@2D$GE=WKUOP'+/\8/CJ8[B*ZMAK=@DLL,7EHUT+"+SN-S?P^4,YZB
MN'TE?&]Q\1O%4MYHMOX?\.:I>17WB"&XOTNS:1PJAV1O$-I>7 ^7J!Z5UWPO
M\3>-U\,F^\-?#S0+O2M4O+C45OH_$*0O=&65F\R1!"VUR,97<=N,=L4YQ?*Y
M/J1L[,^@+/\ X^4_'^5:E>:^#/$/CN_\10P:[X*T_1]-8-NO+?7!<NF%)'[O
MRESDX'7C.:]*KU,O5J37F9U-PHHHKU#(**** "BBB@#YE^-/PE\5?$OXK1W\
MB?#2\T+3HH5TV378;I[Z%]Y:5)%CE5)5!PRH^4SCY<Y)^EX\[<$YKX)_;-\&
M_#'PW\9-)>\AM]%U'7[-KC4WCTFTFDN,3[A+;O+*C?:V*LN4#G&SC)4-]ZPX
MVC'3 QQCM0 \U\__ !2TDVW[67P0O_MMY+]I76X_LDDH,$6VQ'S(N.&/<YKZ
M )P*^?\ XI:Y:77[67P/TR-I#>VBZW+*K02*@5K%=N'*[6/LI)'>@#Z %+2#
MI2T %%%% !1110 56O[*#4+62VNH5N+>4;7C<95AZ$59I",T <CXET6>STS2
MK/0M*CF@M[V&<PQRK$L:(^XXSZ^@JW<9_P"$ZT\XQ_Q+;C_T9#71;0*RYO#>
MG2ZW#K#P9U&-/+2;>W"GJ,9Q^E8.G;6/E^!BX6U7D4]!57NO$JLH93?\JPR#
M_H\-<OJ>AZ;K'PM\.07VGVMY"IL&6.>%74$R1J3@CN&8?B:Z7PZM_'?:^UWI
M[V<4]UYT+M*C[U\I$Z*3CE,\^HK(_P"::>'>/^@=_P"C8JSDE*+NNC_,R?PZ
M]G^9C>*/A3H6K?%7PYJTB3V\\=K.HCM)C#'A"F.%QUWG//.U?2LOPOX#\0>&
M?&'C_4M*\37%[--)%)#IMY KQ%A$#&A=FW8"X3.1P,UZ-JG_ "/&@?\ 7M>?
MSBJ/P\/^*L\5?]=[?_T2M8>P@ZC:5G?_ -M-5*7,XWZV_"_YGA%Q>>-M-_9O
MBLYO#D%\YE2)?LMSA]HN ^]E(P!D%>N<D5V?B/XBA?BG\-;75-$U#2;FY-RV
MV1%E6/S8MBAF0D [N#G&*W]O_%F(S[+_ .E KIM>4?\ "7>%U[%[G_T56,:4
ME&-IO:';N:0Q-3XIZM_G+1^7W)'1K45Y9P7T/E7$*319SMD4$9_&I57M3J]=
MJ^C*V.>M_ 7A^UU"XO8M'M%N;@ 2OY8^;'MTJ?Q9X3L?&GA/5O#FH"1=-U.T
MDLIQ;ML<1NI5MI['!XK:VT5G3I4Z7P12OV-)U)U/C=_4\>\=?LQ^%/&FH:CJ
MUQ%/<:I<:>MBL=Q<,+9@EM<6\>]5PV-MR^2"#G!'2N9\'_LGQ30^)[GQOJUS
MJFI:X)[=OL=TS"&WEL;:S=/,9068K;!@=HV[L<]3]$45J9GG7BCX(:/XIO(;
ME]1U;3G31GT"3[#<+'YUFY4LC$J2"2@^92".<&L:+]EWP3:W+FUBO[.Q#W$]
MMIL-SBVL[B: 6\L\2$'#F/(^8E?G<X^8UZ]10!XKX9_9(\!>$=2TZ]TR&\@E
MLW$A3S4,4N)S.JE-FU%5V.%C"  XKVJBB@ HHHH **** "BBB@#QCX_?&+6_
MAC=:/8P_#I?&&CZW-'8+<S:U:6<7VE]Y6!DGZ@JA;=T[=:Z'X#_$H?%+P3+J
M)\/IX8EL-0N=*ETN.\ANTA>!]A"R0_(1QQMKA/VM(=4'A^U#:M8W.A:C)'IJ
M>$Y_"<6N2ZI>,6=%199HT!VJ3\V -A.172_LMWMO=?":U@@>WC:QN[BREL;?
M0DT;[!)&Y#VS6J.Z*R'J58ALY!YH ];KD_BMX<N_%7@'5].L=?U/PS<O"774
M=(\K[0NWYBH\U'7# ;3\N<$X(/-=;7GWQZT_P=J7PKUN#QY=VEEX<**TLU]J
M#6,0D# Q RAT()<* -W)..<XH \+L^?^"9VCG_J0[/\ ]$1U],>!_P#D2= _
M[!]O_P"BUKYHL\G_ ()GZ/GK_P ('9_^B(Z^E_ __(DZ!_V#[?\ ]%K76_\
M=H_XG^2,_P#EX_3]3COA9_R4#XL?]AV#_P!-]M61X?\ $^D^&?%?Q5DU;4(;
M".;5H8T:9L;C]AAX K7^%O\ R4#XK_\ 8=@_]-]M7AWQ$_9]U3XV_$SQM<:=
MJMGIRV&II$ZW4;,6+6D!R-OTKRLPG4I\LJ4>:6FGR/H\BH87$5)T\;5]G3MK
M*U_M+\]BEX)^/\_Q/OO!7AB71X;!-'UC32EQ'<%S)M+1\J5&,]>M?2_Q%^(0
M\ KHX&G-J,VJ7@LHHQ<)"JN5)!9FX XQ7&^-O"-AX4TCX;V]O96<-W#XATRW
MFN+>!8VE*JX)) R<D9YK&_:_'_%*>'L;O^0B?]7][_5MT]Z\R,JV%H5)5)7D
MK=+&'%.,P_U=8G 4_9P5[*]^JN[OON7-%^)WB>7XE:] / UX6:WB0QO<+&L?
ME;\L96&PAMQQCKM->K>#?$B^+O"^FZU';M:I?0B80NP8IGL2.M>8FVN?'?AS
M4],T?Q';K<ZCI6GQG4+A<-*A$F_Y%;(<C@\\9-==\#5DC^$OAI)-A*VF%* X
MV@D#\<=:Z<+*?/RMW3N^G?R/C\)*JJO)*3E%IN^G?;3^NQ#^S[_R1?PI_P!>
M?_LS4EQ_R<)8_P#8KW'_ *5Q4[]GS_DC'A/_ *\__9FIMQ_R<)8_]BO<?^E<
M5>[+^+/YGOOXY?,6#_DO=S_V $_]'FM'XN?\D_U/_?@_]')6=;_\E[N?^P G
M_H\UH_%O_DG^I_[\'_HY*^6I_P"[8G_%,]*I_O%#T@=E_#2TG\-+7OK8\8S[
M\XG0^W]:^$/B=XFUOX5ZIXYMO#D?E7VH3WFG+/OV&")Y/-\Q?]K!(&.YSVK[
MNU#_ %R_2OAK]IB2*X^(GBF">\MM*BL[RS;SKE@D;^9;!@&8_=W,2,^U?+XO
MF=6HH[G72<5*#GM<^0+6SNK/Q4UOY+VXU"W$JW$G.TJ=I/UZ?7FO7/ ?AX^#
M=+,4%S,7FRT\B2?ZW><MZC:3V/%5=3\ :EKVGVT\2*\UNQ>WN;&='*Y';'!7
MVIL>F:ZDT:7;M$54#FQDP3Z\$C\J]'!YI&GAXTZZ:E'R;//S+*ZF(Q,JN&DG
M&7G;\STK^U+W3]0T[6X0MP;9&@E@2)1F G+[ @'SC P>^,5M:]XMMH+&QU"Y
MDEG2^F1HH8(RS.B#(7'8%NI/%>=:?_:MHJ2RWU]*%("QV]L\:'GN2O\ 6NC\
M7Z@]F\L:VQDDL($CBCZY< %LGZGT[5X&9UL/6;KTT^:UM5:YZ^5X;$T.7#U6
MN7?1W_JY]+_L\^'M/\<>"['Q;JEE_I,\TR)8NX>*'RY&3)QPY.W//2O<>!@#
M@#I7C_[)JE?@=HX\Q)!]HN2/+^Z/WK9 _'->P5A1A&G!**L:8B<IU97=]0%<
MOXI\ V7B"WN9+5AIFJM&PAO(TR%D(X9TR X!QQQGUKJ**U<5+=7,%)QU3/+/
MA3\'S\.[C4-0U&7^U-4FW0Q7A(D>. MN<;B Q:1_WCGV11\L:U<^)GB33]!C
MTUY/%']A"UNDN;J!'&7M?F23S5ZK'\WW^ &"\YXKT>O*OVBOAAH?CCX9^)KJ
M\AEM]1M=/ENH[RS?RY7:&-WC20C_ %D8;G8V1WZ\UZ\<<Y0]G.*9RQP\5/F;
M9X9XT^.%QXFT_7O#/PQLH;F26TD^Q-.-L^J7<GRH(]V-N6.[>W]PGI7T7\"/
MAG9_!_X0^%O"=G&T9L;-#<M(<O)<O\\SL>Y+LU>$?L2_"^]T?^UM;U"_L[\0
M7CPAA;%9_,\F/9A\G"*LDOR]R_M7UI7+7JRE[C.AQII_N]OS\R>S_P"/A/\
M/:M2LNS_ ./A/\]JU*]?+?X3]?\ (YZFX4445ZID%%%% !1110!\C?M(^+-1
MNO'"SZ-K6KZ?+#9/I]A:2^"+O5+>*\%PZ2W0E2!C X7R_+D5L':20RX(^M+;
M/DID[CM&2>_'6OA_]L'0].\"_$?3;[1M \"^?JA2\NO[>NV6^O)VGV.T:FXC
M"J@V$G!SN;'*X/W##_JDQC&!C'3I0!)7AWQ;_P"3FO@'_O:]_P"D*U[A7@'Q
M2CU%?VL/@=)/<VTFFL-<%O;QV[++&XL5W%Y"Y# ]@$7'J: /H"BD%+0 4444
M %%%% !1110 4E+10!7O+47EK- S21B12I>)RKKGN".AKGKKP2?^$=M-'L-1
MN+."VDCD227$[X1@RKE^P('X#%=3142@I;DRBI;G,:C;:D?&6BW$=B9[&W@F
MCFN_.1=K/L_@ZG[G;UJ+PS<,_BSQ.6M;J&.2:$QRS0LB2!8PIVL>O(-=74-Q
M;I=0R0R F.12K $@X(YY'2H]G9W3\_PL1R:W3\_PL>=?\T8B&.<+_P"E KIM
M>8?\)AX7]GN?_152+X#T--"71_[/5M,5_,%NSNP#9SG).>M5=7LKR/Q-X;:S
MTZ2:QL_-66994 B5DV 89LG'M6')*,5?^[^#,>648I/^[^#.JIU,4YZ\4^NT
MZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6/VKOC=X3\+:YJ'@KQ_I
M&GZGH$^F:?J-A#<?:(YI[EKUXIBDT0)0PQ 2 KANO.#7LOP+OOA_>?#NR_X5
MG):R>$H9)(H6M!)M,@8F0LTGSLQ8DEFR23R32_$3X2R^.-4M]5TWQGXF\&:M
M##]G^T:%>((I$W$@26\R21.02<,4W#)YI_P[^%+> [V[U&^\7>)/&&K7<2P2
M7>O7JNB("3B.")$BCR3R53)P.: .]W"N5^)UUHUKX%U>37;>.ZTX0D-'+9M=
M+NQ\A\M58G#8.<<=:\$\*?M'>+)/#/C6ZU..WN==AT^6?3-,6S=#;ZDIO2=.
M(',C+%:Q2X.&(D]&6NX^'_Q&\2>*OAKJDS:==>-)6OKO3K34]*CM[5;F%4&R
M<B65%QN9DS&2"4SB@#SBQ_Y1G:,._P#P@=G_ .B(Z^F/ _\ R)6@?]@^W_\
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MD?)?_"@OB++Q+K,VWGA=8?G_ ,=J)OV;_&_WAJ3[L?\ 05<_J5KZYHH^HO\
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MKW;!+Y66?;+L(( 5@#G!H ^H:6J>C:DFM:/8ZA&ACCNX(YU5NH#*& /YU<H
M\.^,GP&UKXO>-H9KO5K.T\)PZ9<6T5G"C)=+>RPRPB[=P/WGE1S,(XR0H+NQ
MR<8[/X._#J]^'>BZK%J-W:W5]J5_]ME%C$8X(L0Q0JJ@G)^6%6)/=C7?44 %
M-89IU% 'SWXB_9V\0>+/%_C#6M9O=(OX[^6W71[5&N+6.RMH;F.X,;>258R2
M2)O>;<3E4&-JXKV3P'H6I>&?!^D:5K&KR:]J5I;+%<:E,N&N''\1Y)]LDY.,
MGFN@HH **** "BBB@ HHHH **** "BBB@ HHHH **** &22)&K,[!%49+-P
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M:** ,[P7X.T_P'X:T_0],^T&QL(O(M_M<[3R)$"2J;V)8JH. ">  .U;M%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>plrx-20211231_g27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g27.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .^ WX# 2(  A$! Q$!_\0
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MP/ZU%\6-%?2O$<5_!D)O7)%2_!8!-5;!SG=_6O2/BKHL>H>'#(%)D7)R![4
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M\'?#:PU#P^MQ?.S2,H*Y&>U>7^*]*'ACQ1"MD[+^]7IQQN%?1?@D >%H,?\
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MQKWC2*P61O(DFVX![<TGPMTJ34=6NI$4X93SCW-5/%%N-&^(D'G9PD_7MT-
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M5;<!P!7=XYI2* /&?'7PMFU"].H:>RI*.:Y0^%O&%Z@L);C]V.,[3T_.OI'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]:P/C?\ Z]/]VM_X'?\ (&/^\W]: /7^]%'>B@!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!#1W%!H[T > _&__7I_NUO_  ._Y Q_WF_K6!\;
M_P#7I_NUO_ [_D#'_>;^M 'K_>BCO10 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)FC- "T4F:
M-U "T4W=S3J "BBB@ HHHH 0T=Z#1W% '@/QO_UZ?[M;_P #O^0,?]YOZU@?
M&_\ UZ?[M;_P._Y Q_WF_K0!Z_WHH[T4 +1110 4444 %%%% !1110 4444
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M-4TJ&Y4YW"M): %]*6BB@ HHHH 0T>E!H[T > _&_P#UZ?[M;_P._P"0,?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 9T;IUKPWXHZ?<V&N0:HL99$RQKW+/S5S7B34M C
MC,.JLO([J#0!X5XB\>QZM#:*%4&%0IP?2K>J>*#XP%GI=K$'9#'D@^F*W[W0
MO!-W<>?%>,H_NA!C^=;GAQO!6D2J\4P:7.T$H,_SH [SPMIQTS0X;=QA@,D5
MM8Q5>TN(;B!9(3E".#5@$F@!:*** "BBB@!#1W%!H[T > _&_P#UZ?[M;_P.
M_P"0,?\ >;^M8'QO_P!>G^[6_P# [_D#'_>;^M 'K_>BCO10 M%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$^@KI>]8UOB92%[T4G>EK,84444 %%%% !1110 4444 %%%% !1110 4444
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MULT4 111B)%11A5& *4J6'''-244 ( <<TM%% !1110 4444 %%%% !1110
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M@C#X&&KF%^*OB!=Q^T2\_P"U7T/J'@;1]4N3/<1*SYSDKFJW_"MM!)SY"_\
M? H ^8M9\3:AK[>9>.S8XY->W? PDZ,Q/]]OZUQGQ:\.V.B2H+-0H*\@#%=I
M\#?^0*?]YOZT >OFBCVHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HI,XJ.
M:;R8C(>@H\@)**Y5O&MBDKQLX!4XZ4?\)OIW_/4?E6GL9"YD=517*_\ ";Z>
M3Q*/RH_X3C3O^>H_*CV,A<R.JHKE?^$XT[_GJ/RH_P"$XT[_ )ZC\J/93#F1
MU5%<K_PG&G?\]1^5-_X3C3_^>@_*CV4PYD=4WW#7BOCO_D-)]37H)\;:>4.)
M!7F/BK4X;_4UE1N 3711A*+)<CU/P=_R"4^@KI:\Z\->*[.ST]8W<#&*W#XW
MTX?\M1^59U*<G*X*1U6.:*Y3_A.-/_YZC\J7_A.-/_YZBH]E(KF1U6*,5RO_
M  G&G_\ /44?\)QI_P#ST%+V4@YD=5BBN5_X3C3_ /GJ*/\ A-]/_P">@H]E
M(.9'54M<G_PG&G?\]!^5:>CZ_;ZKO\ML[3@4G2DE<=S9HI,TM0,**** "BBB
M@ HHHH **** "BBB@ HHHH ***2@!:*2B@!:*2B@!:*2B@!:*2EH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/B#!JLFGK-I1Q+'DGGK7SIK
M$_B(ZI')=I)]H4_+A3BOKYE!!! (]Q61=^&-+OYUN)K<&1>A&* /GF'4/'#6
MZ;$8*!Q\IH32_%?B74(8KY&"*RGH1T-?2T=E;11JHA3"C ^45(MO"K;DB0'U
MVB@#,\.6#:7HL-LWWE'-:ZYQF@ YYQ2Y[ 4 ''I4;Q18SY2$_P"Z*DX%( <Y
M)XH X;Q3X BU_4X[L*HV[> <=*ZK2M.33+!+5% V^@J_SG@T'(.: $3C(I_
MIO<FEZT >!?'#_6I_NUO_ W_ ) I_P!YOZU@?'#_ %R?[M;_ ,#?^0*?]YOZ
MT >O]Z*.]% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG=#0*6BBF@"BBB@ HHHH **** "BBB@ HHHH 0T444 +2444 %%%% !2TE%
M"TE%% !2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 <5K'C>#2]?
MCTV5>7DV YJUJ7C:QTVXM8'PWGC(.>E<!\5?#>HS:BNHV,+.ZN6!%>1ZG?:X
M;J!;SS!,G" F@#Z]@N([B!)0PVN,BGB1%;&\5\R6VO\ CJ*WC1(K@ICY3N[5
M=LM=\;M=1>;'<!2XSEO>@#Z0SCGKFGBLK0)+B32HFN@?,(YS6J* #:*6DI:
M&@<TZBB@!#1WH-'<4 > _&__ %Z?[M;_ ,#O^0,?]YOZU@?&_P#UZ?[M;_P.
M_P"0,?\ >;^M 'K_ 'HH[T4 +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24@ =*I
MZG_QX2_2K@Z53U/_ )!\OTJH_$A,\*L/^1ID_P"NI_G7O5G_ ,>D7^X/Y5X-
MI_\ R-,G_74_SKWFT_X]8O\ <'\JZ*^R)6Y/WHHI*Y;W-!:*2EH *3%+10 8
MHQ244 +BC%)10 M%)10 M%)2T %%%% F>>_$;_CU7\:S_AC_ *R;_>%:'Q'_
M ./5?QK/^&'^LF_WA7;_ ,NC-;GJ5%%%<?0T%HI*6D@"BBBF 4444 %%%% !
M1110 4AI::2 .: "C-56U"V1BK2 $4S^U+3_ )ZBCE8^5EW/M2_A5+^U+3_G
ML*/[4M/^>PI\K#E9<I:I?VI:?\]A2?VI:?\ /84*+#E9>[4=.]4AJ=I_SU%+
M_:=I_P ]12<6%F6\TF:J?VE:#_EJ*5=2M6(59 2:.5A8MTZHE.2"#P:D%&PK
M"T4E+0 4444 %%%% !1110 4444 %%%% !1110!4DB69RKQJZ]]U<CXIT3P[
M9[=2OE2,Q#( 4<UVJKMSGO7A?Q3U&74]:@T=6=4DRI.2* )[CXMZ#:2""&TB
M=4X!\NNF\*^.] \23B%88DD[?)BJ.A?!_1SIT4MP&9W4'.[-<IXN\*)X)U""
M]T]RJF1!C=ZD4 ?0$84*%0 +CC%/'%8GA>^;4-$AN&^\1@UMK0 M%%% !111
M0 AH[T&CN* / ?C?_KT_W:W_ ('?\@8_[S?UK ^-_P#KT_W:W_@=_P @8_[S
M?UH ]?[T4=Z* %HHHH **** "BBB@ HHHH **** "DS0>E(,YH 4'-+3 ><4
MX=: %HHHH ***2@!:3-%)GM0 ZBFC.*7F@!:**2@!:*** "BBB@ HHHH ***
M* "DHHI  JGJ?_(/E^E7.E4M3.=/E^E5#XD)GA=A_P C3)C_ )ZG^=>]6G_'
MI%G^X/Y5X!;RI;^(YIG)PLA_G7J]MXTT]+>-2_(4"NNO%M*Q%]3K\T5RW_";
M:?\ WZ/^$XT[^^:Y_92[%\QU-%<M_P )QIW]\T?\)OIW]\T>RGV%S'4T5RW_
M  G&G?WS1_PF^G?WS1[*?8.8ZFBN6_X3C3O[YH_X3C3O[YH]C/L/F.IHKEO^
M$WT[^^:/^$XT[^^:/8S[!S'4T5RW_";Z=_?-'_"<:=_?-'LI]A<QU-%<M_PG
M&G?WS1_PG&G?WS1[*78.8ZFBN6_X3C3O[YH_X3?3O[YI^REV"YC?$?\ X]5_
M&L[X8<R3?[PJ#QKX@M=1MP(R3UJQ\+CEIR!_$*Z7&U(E'J5%%%</0T"EHHI(
M HHHI@%%%% !1244 +1244 +4%R"8'QUQ4U)1>P7L>1:]%K']HOY(?;N]36:
ML&M@?Q_F:]L:"$G)B0GW44GV:'_GC'_WR*U54U52QXH(=<]'_,T-%K@Z!_S-
M>U_9H?\ GC'_ -\BD-O#C_4Q_P#?(I^U#VAX;--JMN 9F=0?>EADU6Y&86=O
M^!5W'C^.)+%2J*IYZ#%5OA^B-&=Z!N1U%:\ZML:.>ARGE:YV#_F:/)US_;_,
MU[8+>#_GC'_WR*=]G@_YXQ_]\BLG5\B'4/$O*UP_W_S-7=)CU@:A'YH?;N]3
M7L/V>#_GC'_WR*06\(((B0'V44G4N0Y7([('[-'NSNQS5FDQ@XQQ2BLF2PI:
M2B@0M%)10 M%%% !1110 4444 %%%% !1110!&0!C->/?%GP]=B2/5-/C)EC
M!;@9YKV''.3UJ*>&.=3',NY3ZT >%:1\8KC3-/6UOX)?.C 4<8K/N-:U+XA:
MK%$L;B .IY7T->KW_P ,O#^H71GEM8R3ZBM;0O">F:$,V<"I]* +F@Z>-,TJ
M&V'51S6H*8HYW$T\=* %HHHH **** $-'>@T=Z / ?C?_KT_W:W_ ('?\@8_
M[S?UK ^-_P#KT_W:W_@=_P @8_[S?UH ]?[T4=Z* %HHHH **** "BBB@ HH
MHH **** "L37/$5GH*;KDXXSG.*VZ\Z^)GA2]\26H2UD*X&, 9H L'XJZ)V/
M_CPI3\4M&'5O_'A7C@^#NL[<>:V<_P!VG?\ "GM=V?-,W_?- 'L/_"T]$_O?
M^/"C_A:>B?WO_'A7CO\ PI[6R !,P_X#45W\)-:M+=IGE8JH_NT >S_\+3T3
MU_\ 'A1_PM/1/7_QX5\Q+IUPVK#3MQ\PG'2NWB^$6M30+*DS88 _=H ]G_X6
MEHGK_P"/"FCXIZ+N;YO_ !X5X\OP>UQNDS#_ (#2'X.ZV!S,W/\ LT >Q'XI
M:,1][_QX5TNC>(+76H?,MONCCK7SR/@[KN!^^;'^[7L/P\\-W7A^R\JY8LV>
M#B@#O*6BD[4 +1110 4444 %%%% !1110 4E+24@#M5'4^-/E^E7JI:H,Z?+
M]*J/Q(3/G^2VDO-8N8XV )E-=#'X#U*6)7$F,CT-96G?+XID'_34_P Z]YM.
M;6+_ '!_*NVK4Y4C.USQS_A -5_YZC\C2_\ " :K_P ]1^1KVG HP*R^L-="
MN4\6_P"$ U7_ )ZC\C1_P@&J_P#/4?D:]IP*7 I_67V#E/%?^$ U7_GJ/R-'
M_" :K_SU'Y&O:L>U&*/K+[!RGBO_  @&J_\ /4?D:/\ A -5_P">H_(U[3BC
M%'UF0<IXM_P@&J_\]1^1H_X0#5?^>H_(U[3@48%'UF0<IXM_P@&J_P#/4?D:
M/^$ U7_GJ/R->TX%+CVH^LL.4\5_X0#5?^>H_(TG_" :K_SU'Y&O:\>U)BCZ
MR^P<IXK_ ,(!JO\ SU'Y&C_A -5_YZC\C7M6*,4?67V#E/ =7\-7VFQDSR @
M>U=;\+R0+A3UW"M#XC?\>B_C6?\ ##[\W^\*V<^:D*)ZB.E+117G6T-!:***
M8!1110 4444 %)FBFYR<4 .S124M @I.:6C'O0-"9I:,45.H:"<TAZ4ZFMTJ
MDAJQPGQ#_P"/&/\ &JWP^Y3\15CXA_\ 'A'^-5OA]PGXBMGL;/8]%'M2TF<4
MN:PDF8,**6BE8 ZT4450@HHS3=U Q]&::3QUI*!,?12"EI7&%%%%, HHHH *
M*** "BBB@"/!*Y[U7EO+>$XFD /O5G/<=.]>+?%R?4+.1&M)G7<"0 V* /6O
M[4LBW$X'M3O[3M =OG"OF2QM?%E[&'5YL8R#O-1^;XFBO/(FEE5NWSF@#ZD6
MXCN,+"^['7%6$7 ZU\SV.O\ BCPQJ$,EZ&,#L!DN37T)X=U9-8TJ&[4_?&30
M!K"EI >32T %%%% "&CN*#1WH \!^-_^O3_=K?\ @=_R!C_O-_6L#XW_ .O3
M_=K?^!W_ "!C_O-_6@#U_O11WHH 6BBB@ HHHH **** "BBB@ HHHH *2EI*
M &X7N*7KP12D44 )@ =*S];_ .01-QGBM''%9^N?\@>?Z4 ?*\1_XN,,CC>W
M\Q7U7I>W^SH /[B_RKY3AY^(RC_;;^8KZMTK_D&P?]<U_E0!;Z=J7:#U%(<Y
MI>] "=\8I>!110 M)TI:* "BBB@ HHHH **** "BBB@ I*6D-( JGJ?_ "#Y
M?I5SM5/4_P#D'R_2G'XD)GA6G_\ (TR?]=3_ #KWJS_X]8O]P?RKP73_ /D:
M9/\ KH?YU[U:?\>D7^X/Y5TU]D2B>BBBN8L****0!1110,****8@HHHH ***
M*0!1110,****8CSWXC?\>J_C6?\ ##[\W^\*T/B/_P >J_C6?\,/OS?[PKM7
M\(A;GJ5%%%<70T%HHHH0@HHHH **** &-G Q4#W<,;;6<!JG;I7D?BW5;BWU
M=U21@ QZ&KC&Y<8W/4OM]MG_ %@IWVZWQ_K!7B:7.J2+O1Y"#[FE^TZQZR?F
M:;C8IQ/:OMUO_P ]!2_;[?\ YZBO%?M&L>LGYFD^T:QZR?F:?(F'(CVO[?;_
M //04?;K?_GH*\4^T:QZR?F:/M&L?]-/S-6J2[AR(]K%[;_\]!2->V__ #T%
M>*BZUD=/,_,TOVG6C_ST_,TO9KN"@CL_'DT<UBH1LD9JMX!ECCC/F-@@BN/G
M35+@8D5R/?-$$>IVP_=*Z_3-:<BL:M*Q[?\ ;K?_ )Z"E^W6W_/05XK]HUG_
M *:?F:3[3K/_ $T_,UFZ:,^1'M?V^W_YZ"C[?;?\]!7BOVC6?^FGYFD^T:Q_
MTT_,TO9H3IH]K^WVW_/04&_MO^>@KQ3[3K'_ $T_,T"XUDG_ ):?F:7LT'LT
M>U?;[?\ YZ"D^W6__/05XMY^L_\ 33\S33=:NB;F,@_$T_9HKV:/;8[N"1MJ
MR FK&,FO'O"FHW<NKJDLK'YAP37KR$^6#Z5$HV,I*Q-12#I14$BT444 %%%%
M !1110 4444 19P^>S5X3\3[F:+Q+;M< _9E)SQVKW91SDURWC/P=:^)K%E8
M 2!<!B: (O#>OZ!/H\.PVZE$ ;=M%<!X^U^PO=3@BTQ$,HD3)11TR,]*YZY^
M%>NPS-%:WZ+%GIS_ (UU/@WX9#3[KS]4N$E8 XP>] &+X_\ $-K-I=IIGE 7
M2L"2$]0*]-^&,+Q>$[57SG9WKGM2^&2ZKXI^WL1Y(VX7Z5Z;IUA%IUHEO$N%
M48H MT4F*6@ HHHH 0T=Q0:.] '@/QO_ ->G^[6_\#O^0,?]YOZU@?&__7I_
MNUO_  ._Y Q_WF_K0!Z_WHH[T4 +1110 4444 %%%% !1110 4444 %)BEHH
M 3%%+10 E9^N?\@B?Z5H5GZY_P @B?Z4 ?*T/_)1U_WV_F*^K-*_Y!L'^XO\
MJ^4X?^2CK_OM_,5]6:5_R#8/]Q?Y4 7J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "D-+2&D HZ52U/\ Y!\OTJZ.E4M3_P"/"7Z54?B0F>%Z?_R-4G_7
M0_SKWFT_X]8O]P?RKP;3_P#D:I/^NA_G7O-I_P >L7^X/Y5TU]D2B>BBBN4L
M**** L%%%% 6"BBB@ HHHH **** "BBB@+!1110%CSWXC_\ 'JOXUG_##[\_
M^\*T/B/_ ,>J_C6?\,/OS_[PKM7\(A'J5%%%<70T"EI*6DA!1113 **** &'
MH17C/C,C^V9..C'M7LQ%>->,B1K,G^\:VI&M(] \*VT#Z0A,2$X'516\+*V_
MYX1?]\"L;PD/^).F?05T(J)NS)F]2O\ 8K;_ )X1?]\"E^PVW_/"/_O@58HJ
M;D\S*_V&V_YX1_\ ? H^PVW_ #PC_P"^!5BBCF8<S*_V*V_YX1?]\"E^Q6W_
M #PB_P"^!5BDHNPNRO\ 8;;_ )X1_P#? H^PVW_/"/\ [X%6**%)A=E?[%;?
M\\(_^^!1]AMO^>$7_? JQ2T7"[*WV*W_ .>$7_? H^PVW_/"+_O@59HHNPYF
M5OL-M_SPB_[X%'V*V_YX1?\ ? JQ2&ES,+LK_8;;_GA'_P!\BLK7;2!--<B&
M,<'^$5N]163XA_Y!;CV-7&3N4I,\M\-X'B3 Z!Q7LL7* 5XSX;X\2'_>%>SQ
M?ZM?I6E5#F/'2B@45@9AWI:** "BBB@ HHHH **** (\'C]:\L^)7CZZT3_1
M-.#F=@0-AYS7J"LV]F_A/2O%_BCIBV&JP:K(-T8RS ]* .4A\6^-[A=\<=U@
M\]O\:M6?B'QE+?1++%<[=PR3CU^M=SHGC[PHVFQ*RVZ2*H##_)K4MO&WA:><
M)&+?>3QB@#KM#EN)=,B:<$28YS6H#FJ=E<Q7=NLD&-A]*NT %%%% !1110 A
MH]*#1Z4 > _&_P#UZ?[M;_P._P"0,?\ >;^M8'QO_P!>G^[6_P# [_D#'_>;
M^M 'K_>BCO10 M%%% !1110 4444 %%%% !1110 4444 %%%% "5GZY_R")_
MI6A6?KG_ "")_I0!\K0?\E&'^^W\Q7U;I7_(.@_ZYK_*OE*#_DHP_P!]OYBO
MJW2O^0=!_P!<U_E0!<'2EI!TI: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!*IZF?\ B7R_2KE4M3Q]@E^E./Q(3/"]/Q_PE4F3_P M#_.O>K3_ (]8
MN?X!_*O!K''_  E$C>DA_G7NUFZFUBP?X!_*NFO=I$+<M44W<OK2[U]:Y;,T
MN+12;U]:3>OK19@.S1FF[U]:-R^M%@'=:*;O'K1O&>M%F ZC--WKGK1N [T6
M87'44W>OK2[U]:+,!<T4F]?6DWKZT68#LT4W>OK1O7UHLQ,\_P#B,<6R\>M9
MWPQ'SS'_ &A6C\1<-9\'IFL_X7LI\\'J&%=J5J1*9ZD.E%(.!UI:X7L6+111
M30!1110 4444 (:\8\9_\AF7_>->SFO&/&?_ "&9?]XUM0W-J.YZ-X1_Y R?
M05T KG_"/_(&3Z"N@%95/B,Y_$+1112)%HHHH **** "BBB@ HHHH **** $
MHHHI, [5D>(?^09)]#6OVK'\0_\ (-D^AJX;HJ.YY;X;_P"1D/\ O"O9XO\
M5+]*\9\-_P#(R'_>%>S1?ZM?I6M;<J9)124M8&84444 %%%% !1110 4444
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M6BDS14M$V%I:2BE8!:*2BBP"T4446 ****+ )0*6DH *2BCM2:&+VK'\0_\
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M_P (?K'J_P"5'_"'ZQZO^5'LX=PY4>E?\)18?WA_WU1_PE%A_>'_ 'U7FO\
MPA^L>K_E1_PA^L>K_E1[.'<.5'I7_"46']X?]]4?\)18?WQ_WU7FO_"(:QZO
M^5'_  B&L>K_ )4<D.X61Z3_ ,)18?WQ^='_  E%A_?'_?5>;?\ "(:QZO\
ME0?!^L$8R_Y4G"'<.5'I1\46']\?G69K6OV4VG.JN"2#WKB?^$/UC/WG_*H;
MCPKJ4$1>4M@=<BG&,4RHQ0OA=P^OE@.-PKV:(YC7Z5XOX5!BUM4]&%>S0\QK
M]*584T34M(*6N<R"BBBF 4444 %%%% !1110!'C).1]*\3^+]QJEI(GV2YEC
MW X"U[86 VKZUX1\3[U[;Q);-=J?LRD\XSQ0!R6GZ%X[OX%FAN[PH1G(Q_A5
M>6#QC;W8M)KZZ#'IDC_"O>- \6^'6TB!8Y$4*@#?*!7"_$#Q#I]]J=O%I>&E
M$B$E1VR,T <K:ZEXI\*WD$NH3SO$[@9<U]!^&]676M)AN@?O#->*>/\ 7[27
M3K33I% N@PZ#GD"O3OAE#)#X4M5?.0G>@#M>M+3<]<49.* '44W<*6@ -'<4
M<T4 > _&_P#UZ?[M;_P._P"0,?\ >;^M8/QO_P!<G^[6]\#O^0,?]YJ /7^]
M%'>B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** $K/US_D$3_2M"L_7/
M^01/]* /E:#_ )*,/]]OYBOJW2O^0=!_US7^5?*4'_)1Q_OM_,5]6:5_R#8/
M]Q?Y4 71TI:2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *2EI,4F <^E% XI:-0&XHQ3J3-%PL)CWH_&EHIZ %)BEHHT 2C'?%+1B@
M _"BEHI %%)2TP"BBB@ HHHH **** "BBB@ HHHH :2/SKQGQKN_MB3;_>->
MS$5XSXS.-9D/^T:VHNS-:>YZ+X0!_L="WH*Z'C%8'A YT9?H*WN]9U&^8B;?
M,&T9ZTNT4&BHNR;L-M)MI:*=QW$VTNVBBBXKB;:-M%'%&H7#;1MI:,4787#;
M1M%&**87$VT< TM)4ML+@5[UC^(%']FR'/8UL+63X@_Y!DGT-7"]RHO4\N\-
M_P#(R'/]X5[+%C8N/2O&O#;C_A(S_OBO98L>4/I6E4J9)2TE+6",PHHHI@%%
M%% !1110 4444 1YP #UKE/&/A/3_$UH8[AT23& 2P6NLX;ZUY)\2(_$+S_\
M2QB.O12: .3N?A3?P2M':7Z",GC_ $C_ .O73^$?AC;6,HNKZZ224=,S!OZU
MPBP^.\<RG_OV?\:AM[_Q5;ZK#%=3%%+#.5([_6@#U/4?A?!J_B0:A(<QKM(
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M'68=;L1<P,"O'2M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!.,<U ]
MO"W+*#4U)^%%Q7*XL[=O^68I?L,'_/,5/TZ<4[FGS#YBM]B@_N"E^QP#_EF*
ML44<S'=E?[)!_P \Q1]B@_YYBIZ3-%V&I!]BMS_RS%!LX!_RS%3YXIN:+L%<
MX+X@PQQV<>U?6H? ,:2(-R^E6?B&?]!CX]:@^'QS'T]*Z/L&C6AWOV2 _P
MH^R0?\\Q4F?2ES6&I!%]C@_YYBC['!_SS%39I<\4KBO8@^QP?\\Q2?8H/^>8
MJP#11<.8@^Q0?\\Q2?8X/^>8JQS2T[L.8KK:01MN5 #4WWNE'/I2BI$**6D%
M+0 4444 %%%% !1110 4444 >8>.XM?MKTW>F[F16R5W$"N4MOBYJ>FL(;ZU
M 9>"<$_TKV?5+VSLK5Y+PILQ_%BO-]2U_P #W4I651O]0HH BA^--J4_>+A_
M3;4%W\:61#Y5NK9Z84UJ6GP^\-ZX@N;1\J>P<5LZ;\-='LWW-&6Q_>YH \\B
M\6>*?%5SM@M_*B)X*L1_2O7O"MG>6>D11WCLTNWDL<U?M-+L[% (+>-1VP@J
MZ/0XX]* &R1B5"C#@UQ=[\-]-O;QKB1!N)/\-=OU_"E.<4 <!_PJS23R1S_N
MBNGT'0;?1+80P?='M6Q3<?-0 Z@44>E '@/QO_UZ'_9K?^!W_('/^\W]:P/C
M?_KT_P!VM_X'?\@8_P"\W]: /7N]+1WHH 6BBB@ HHHH *3O2TE 'GOQ=P/"
M$YS@Y'/YU\\^%/"\WB*^:)6)Y/>OH;XNG_BC[A?4C^M>4?!DG^VV!]6_F: -
M,_!.Z8 [GY]Z3_A25U_>?\Z^A5 P..U.P/2@#YX_X4E=?WG_ #H_X4E=?WG_
M #KZ'P/2C ]* /GC_A25U_>?\Z/^%)77]Y_SKZ'P/2C ]* /GG_A2=UC&Y_S
MI/\ A25UC&]_SKZ'P/2C ]* /GG_ (4G<XZO^='_  I.ZS]Y_P Z^AL#THP/
M2@#YX_X4E=?WW_.C_A25U_>?\Z^A\#THP/2@#YX_X4E=?WG_ #H_X4E=?WG_
M #KZ'P/2C ]* /GC_A25U_>?\Z/^%)76/OO^=?0^!Z48'I0!\[K\$;M2&\R3
M!Z\UYSXGT!] U-[=F;AB.:^S0!Z"OECXN@?\)/+_ +YH ]O^%7_(JK_P'^5=
MU7"_"K_D5$_X#_*NZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3%%%%
M !11118 I,TM,D<(C-Z"E8+"\FC%<E?^-(+.Y:%CR#CI58>/;?L?TK10D6H,
M[;(%&,BN('CZ#U_2D/C^#U_2CD8<CN1_$7BQ3'O5?X>$>4/PK(\4^(TU6!57
M!Q[4SPSXCBTM K<?A6_)+E-.1V/7L<T$5Q!\>0@]?TI/^$^A]?TK'V<B'3D=
MQ2]L&N(_X3V#U_2I+;QM!=7*1 ]3CI2<&MQ<C6YV8H%1PRB2-6'<4\"HL0T.
MHHHH .<4G2ES10 "EI!2T %%%% !1110 4444 %%%% 'A7QAU.\:]33X)"H=
MRM<[:?"2XNO#K:@\I\PIN')K9^*\JP>*[2:3B,3$L3]#79V/C_P_'X=BMVOH
M=P3!7=0!P7PEU*]T[Q ^F3R$H'(P?:OH0-N0'UKYCT+Q!8VWCEKLRHL)=CG/
M'6O;(?B+H$GEQK>0EC@8W4 =C_D4 8Z\FH;>XCNX5FB<%&Z8JP* # HQS2T4
M )VHI:* $H]*#1WH \!^-_\ KT_W:W_@=_R!C_O-_6L#XW_Z]/\ =K?^!W_(
M&/\ O-_6@#U_O11WHH 6BBB@ HHHH *;3J0T >>?%W_D4)S[C^M>4_!H$ZVQ
M]V_F:]7^+FW_ (0^X!ZY']:^>O"OBF;PS=M-%$['<?NF@#[&7[H^E+7SM_PO
M6^P!]EFX_P!H?XT?\+UO_P#GVF_[Z'^- 'T317SM_P +UO\ _GVF_P"^A_C1
M_P +UO\ _GVF_P"^A_C0!]$T5\Z_\+TO_P#GVF_[Z'^-+_PO2_\ ^?:;_OH?
MXT ?1-%?.W_"]+__ )]IO^^A_C2?\+TO_P#GVF_[Z'^- 'T517SM_P +UO\
M_GVF_P"^A_C1_P +UO\ _GVF_P"^A_C0!]$T5\[?\+UO_P#GVF_[Z'^-'_"]
M;_\ Y]IO^^A_C0!]$T5\[?\ "];_ /Y]IO\ OH?XT?\ "];_ /Y]IO\ OH?X
MT ?1-&*^=O\ A>M__P ^TW_?0_QH_P"%ZW__ #[3?]]#_&@#Z(.!BOEKXO\
M'B.3 YWFMT?'*]?K;2Y7_:'^->=>*/$4WB*_:[D1E).>30!]*?"G/_"*)G_9
M_E7=UPOPK_Y%5.<_=_E7=4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "44M% "5'*F^-E]14M% ' ZIX$^W7;3[@,G/6J2_#LCC</SKTJBM%4:-
M%4:/-A\.>/OC\Z!\.>/O#\Z])I:'48>T9YL/AT<\NN*:WPZ!/# ?C7I=%/VT
MK6#VC/-?^%<GNX_.C_A7//WQ^=>E4E+VL@]HSS4_#H_WQ^=6;#P!]ENEFWCY
M3GK7H.:*'4;%SMD%M#Y,*I_=&*G HI:ALEL3%&*6BD(3%+110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#U_O11WHH 6BBB@ HHHH **** "BBB@ HHHH .U>7?%>75$@7^SPV=O8XKU
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!#1W%!H[T > _&_P#UZ?[M;_P._P"0,?\ >;^M8'QO_P!>
MG^[6_P# [_D#'_>;^M 'K_>BCO10 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 AH[B@T=Z / ?C?\ Z]/]VM_X'?\ (&/^\W]:P/C?_KT_W:W_
M ('?\@8_[S?UH ]?[T4=Z* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)Q2TW(H
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M%4_[4LO^?F+_ +[%)_:ME_S\Q?\ ?8H NTE4_P"U+,C/VF'_ +[%']JV>?\
MCYA_[[% %VDS50ZI98_X^8?^^Q2'5;(#_CYB_P"^Q0!=HJD-5LC_ ,O,7_?8
MI?[4L_\ GYA_[[% %RBJ?]J6?_/S#_WV*/[4L_\ GYA_[[% %RBJ?]J6?_/S
M#_WV*/[4L_\ GYA_[[% %RBJ?]J6?_/S#_WV*/[4L_\ GYA_[[% %RBJ?]J6
M?_/S#_WV*/[4L_\ GYA_[[% %RBJ?]J6?_/S#_WV*/[4L_\ GYA_[[% %RBJ
M?]J6?_/S#_WV*/[4L_\ GYA_[[% %RBJ?]J6?_/S#_WV*/[4L_\ GYA_[[%
M%RBJ?]J6?_/S#_WV*/[4L_\ GYA_[[% %RBJ?]J6?_/S#_WV*/[4L_\ GYA_
M[[% %RBJ?]J6?_/S#_WV*/[4L_\ GYA_[[% %RBJ?]J6?_/S#_WV*/[4L_\
MGYB_[[% %RDR*J?VI9?\_,7_ 'V*3^U;+_GXB_[[% %VBJ0U2R;I<Q?]_!2?
MVM9;L?:8O^^Q0!>HJG_:ED/^7F+_ +^"D_M6R)_X^8O^^Q0!=HJG_:ED/^7F
M+_OL4?VI9_\ /S#_ -]B@"Y15/\ M2S_ .?F'_OL4?VI9_\ /S#_ -]B@"Y1
M5/\ M2S_ .?F'_OL4?VI9_\ /S#_ -]B@"Y15/\ M2S_ .?F'_OL4?VI9_\
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M_P"?=: /E+^TO%7_ #QN/^^31_:7BK_GC<?]\FOJW^P--_Y]UH_L#3?^?=:
M/E+^TO%7_/&X_P"^31_:7BG_ )XW'_?)KZM_L#3?^?=:/[ TW_GV6@#Y2_M'
MQ3_SQN?^^32_VAXHSS#<_P#?)KZM_L'3O^?=:0Z%I_\ S[K0!\HMJ'BIVXCN
M%'NIJK/XBURT8)+*ZMZ'-?6DF@::4;_1EZ5\U_%&VBM/$:QPIA=QX% &*FJ^
M);A0\7G.OL#4W]I>*-N/)N"?]TU[Q\.-%L)_#\<DD"LV!79C0=,SQ;+0!\I#
M4/%7_/&X_P"^32_VEXJ_YXW'_?)KZN_L+3SUMUI/[ TW_GW6@#Y2_M+Q5_SQ
MN/\ ODT?VEXJ_P">-Q_WR:^K?[ TW_GW6C^P--_Y]UH ^4O[2\5?\\;C_ODT
M?VEXJ_YXW'_?)KZM_L#3?^?=:/[ TW_GW6@#Y2_M+Q5_SQN/^^31_:7BK_GC
M<?\ ?)KZM_L#3?\ GW6C^P--_P"?=: /E+^TO%7_ #QN/^^31_:7BK_GC<?]
M\FOJW^P--_Y]UH_L#3?^?=: /E+^TO%7_/&X_P"^31_:7BK_ )XW'_?)KZM_
ML#3?^?=:/[ TW_GW6@#Y2_M+Q5_SQN/^^31_:7BK_GC<?]\FOJW^P--_Y]UH
M_L#3?^?=: /E+^TO%7_/&X_[Y-']I>*O^>-Q_P!\FOJW^P--_P"?=:/[ TW_
M )]UH ^4O[2\5?\ /&X_[Y-']I>*O^>-Q_WR:^K?[ TW_GW6C^P--_Y]UH ^
M4O[2\5?\\;C_ +Y-']I>*O\ GC<?]\FOJW^P--_Y]UH_L#3?^?=: /E+^TO%
M7_/&X_[Y-']I>*O^>-Q_WR:^K?[ TW_GW6C^P--_Y]UH ^4O[2\5?\\;C_OD
MT#4?%6[_ %-Q_P!\FOJW^P--_P"?=:7^P--_Y]UH ^4EU'Q3GF&X_P"^335U
M'Q3O.8+G'^Z:^KO[!TW_ )]EH_L+3O\ GV6@#Y+FUKQ!:L3,98Q_M BG6WB#
M7KEL0^=)[J":]2^-.FVUC8(\"!,YZ54^#%E!>)F>,-R.M 'GIO\ Q5G_ %-S
M_P!\FC[?XI'_ "QN/^^37U=_8>G'C[.M)_86G?\ /NM 'RE_:7BD_P#+&Y_[
MY-']I>*O^>-Q_P!\FOJW^P-._P"?=:/[ TW_ )]UH ^4O[2\5?\ /&X_[Y-'
M]I>*O^>-Q_WR:^K?[ TW_GW6C^P--_Y]UH ^4O[2\5?\\;C_ +Y-']I>*O\
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MVJ_H7Q&UG0=0CMK_ 'JI(!W+B@#Z4/(Q2XXQ69H>K1:SIL5W&>'&>M:6 30
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M72H[@??VC.:Z89[T +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M);:%I:WVGMLD0%LJ* /4O"?A[3M$L\:<4,;8(V5TU>-_!SQ'>7UN+:Y=GVX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH **** "BBB@ HHHH **** "BBB@ HHI,XZT +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%(3@9H ._M17-ZIXTTO1[O[-<N ^,\MBM32]6M]6M1<6Q
MRA]Z -&BF*^:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 444E "TE!Z5@ZQXLT[0Y52[<!B,CYL4 ;U&:RM'U^SUR+S;1MR],@
MYK5&<\T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^-5OM]K_ ,]!1]OM?^>@H L_C1^-5OM]K_ST%'V^U_YZ"@"S^-'XU6^WVO\
MST%'V^U_YZ"@"S^-'XU6^WVO_/04?;[7_GH* +/XT?C5;[?:_P#/04?;[7_G
MH* +/XT?C5;[?:_\]!1]OM?^>@H L_C1^-5OM]K_ ,]!1]OM?^>@H L_C1^-
M5OM]K_ST%'V^U_YZ"@"S^-'XU6^WVO\ ST%'V^U_YZ"@"S^-'XU6^WVO_/04
M?;[7_GH* +/XT?C5;[?:_P#/04?;[7_GH* +/XT?C5;[?:_\]!1]OM?^>@H
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MY7_M#Q7_ ,])_P#OHT?VAXK_ .>D_P#WT:^J/^$=TW_GVC_[X%'_  CNF_\
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M'_WP* /E?^T/%?\ STG_ .^C1_:'BO\ YZ3_ /?1KZH_X1W3?^?:/_O@4?\
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M .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'/M2;>H[&@#@YXI+_P 2KY<>(T*GI@5V\MO'*I5U!4=.*:EC#"Y>-<,>IJP
M10!%%"L485!@5@VFA26]_-<L>')Z'UKI"H-(0<<4 <KI'AZ:PEN&R-LF_OZY
MJK'X2N KX8?-G'S5V04YR32X..M ''R>%YMNG\C= V6YJQ?^'Y;O5K*Z)^6#
MKS74;?E]Z3:2IR>: ,%+"_=FCD9?+[<U2/AN<V<D0(&6)ZUUF#C%*5XXH Y>
MUT"2/P^+,GYLGOZUS]SX)U + 8Y.$.<!Z]( P,4!0* . TOPG?V,-VRE-\QR
M/FI+?P5+97BW5N0)B<L=U=_MRV3VZ4A3YLB@#$UK1Y=1M(D0C<NW//I6;?\
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E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>plrx-20211231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +)!F # 2(  A$! Q$!_\0
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MX;>'NILHRWTIK?#;0\_);QJ/3%==<2B"U>5NJJ3^E<3I>O7VJ:A.T8;RXQG
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M3M]C1S 0ZQJ^H?VXENN4C+8R#BNQT-)1:_O9-V><YS7+>*+ZSN(VCDMYQ*O
M:.,_S%7_  -'>QVDGVC=Y9;*;NN*.9@/\7:U-9LMG:_ZY\=\=:HZ=I^N0$7,
M[ML'S$;^U+XUL)_M<>IPJ6V%00!GI[4ZQ\7/J$/V5K:568;,F(@?RHY@,RYU
MVYU?6;F&VD*I;G)P<5;\/:Y=I=7-O.2PW84DYK _LM=)\17CW23E9S@&,$UU
M>@164IE$,,P(/5U-',!SL5SKNLZC<+ Q$<;$</6CX>U74;Q;JQF/[Q4?G=Z
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M\:/QI:*+@)^-'XTM%%P$_&C\:6BBX"?C1^-+11<!/QH_&EHHN GXT?C2T47
M3\:/QI:*+@)^-'XTM%%P$_&C\:6BBX"?C1^-+11<!/QH_&EHHN GXT?C2T47
M 3\:/QI:*+@)^-'XTM%%P#\:***+L I*6BB[ 2EHHHU ****+: (>A^E<!9
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M4H4"@"O);QS+B4!B?44+:P@#$:C'M4^P9I<4 0+ BON50#CK4A48_G3\48H
MC$:)]U0,^U(J@,<*!^%2=Z"!0!%Y<:MO"#=ZXJ.6QMY>7C![]*M8%(10!6CA
M1 0B )Z8IOV*V?Y_)49Z\5; I=HH KK D:[54;#VQ2^3$T97RQM],5/M%&!0
M!4CM+9#@0K^(%2-;Q%-K(&7T-3[12;!0!7CM(HUVH@"^F*3[%;AMWE+GZ"K(
MXS28R#0!&8D9=FT%?3%28"K@#%*JXI2* (F"@9(SFJYL+4R^;Y0W$\\5=VBC
M:* *YA3^!0,=L4]% &0H&/05)M%+@4 1E$[C.:00QH,!1@^E2$"F]* &+#&
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M9ESP :?UJ8<AX'_PJK5^N9?RI!\*=7QUE_*O??.']T4GG#/W11]:F+D/!/\
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MS3@H]*?UJ8<A\]_\*KU?_IK^5'_"K-7_ .FOY5]"[%]!1L7T%+ZW(.0^>O\
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MJ">E2L5(.0\>\'?#_4-&U 2SF3'N*Z+Q%\NLVRYY#K7?[><XK@O$I']O6_\
MUT%1[5R921W4'^I6I.]1P?ZE*DR,UB,=12"EH ***;NH =2'I2!E)X.<4C'C
MB@ ;:!Q3'Z#G&:?U&#7$>(_%36VJG2[4!I^.#[T =NH*CKFER,\UYK8^+[W3
MM:33=155=FVC!S7H\;K+&KC^(9% #SR,4UL@8 I3UXJ*[N%M[625CC:I/Z4
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M*!BBCF8K@:!112YF 444478!1111J%PHS11S0%PI:3FB@=PQ1110%PHHHHL
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M_P J[T_=/TK@K3_DJW_;J?Y5K'9D]3KFHH:BLAB4444 %%%% !1110 4444
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M(JY'K4[Z#;2)&I4?)C'X5K=J0^U '/:AX5MK^<RN%R1CD59C\/6L6FK:(@
MQFMFCUH YRP\)6MG<^<0K'.>E3ZMX9L]5"[T4%1@$UMCZYI2...* ,&S\+65
MJ5947>O>GZIX;M-3;+HH<=S6UUHZ_P"-(#"TCPW#I4K.A7GT%;F"<TOXTHHZ
M@(?NGZ5P5I_R5;_MU/\ *N]/W37!6G_)5O\ MU/\JUCLR>IUS44-160Q****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "CO12'Y10 O>CG%)D%:</E&>U FP&,5%)((H&D8
M\ 4]L*A?/ KG=;U=&M&B1L'FBYO2HN9C:QXDN)G>WMP-O0-GFN7CT^2>YW3N
MS,3TZUJV-KYI#MDY]*ZC2?#B+*+J3.WK@FH>IV<RPZT(]#T)8]KR)D>XKJMH
MCC"**,*%"J!P.,5#<7<-K"9)' ([$T)6.6<_;O09J-XFGV@E<\DUPNL^*6N5
M,:' ]J3Q)XB&H)]GC/0\5FZ3HDFH*JN#GN:ILWIT%37-(H6=K/JMZ$7)R>37
MI>A^'XM*B5\9<C/(I^C>'H=,B#;1O]:V$)S@_A4V,ZF*<_=#DC%)CUIW4TQO
ME&7.!5(Y''E=QS'@$4F%W*78C--6ZMB-BRIG_>%/ 5B#^5,!54>9CM[US7B2
MYUB!\6,2G_@6*Z5@Q&Y^,=,4FP.,R >V: /-QJ7BW_GTC_[[/^%']I>+?^?2
M/W^<_P"%>B[%!RRICZ"E6.-_F0)@]>!0!YU_:7BS(_T6/'^^?\*/[2\6_P#/
MI'_WV?\ "O1A%%YH78.?:D:)%?E%V_2@#SDZEXM[VJ?]]G_"L[Q%J/BDZ-)Y
MMNBQX.2'/^%>KNT$2Y81@'UQ5.]M;/4K-K=BI#@@[2* /FC0]5UR&]C-DTKG
M/().*^A?"UQJEUIT<FHQ*C;>,'-+HGA'3=%4I%"K-C&64&M\J(T& !CH *
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MI2#FD')X%9#$HH/7%' H **.310 44E+0 4444 %%%% !1110 4444 %%%%
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MY=)N'N;8JIQ&F#Q0 GBRY\B:)#G8VW@'UIUA-;V:,XW E> 35G5]*DOKB R
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MU1(8-L8[U;)P!NXH ?1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC1N 6/K6CK7B@V[+;V@$DS8X!]:XG7!L>TW2N[LZ$]^I%76!M?&GGW )@,:
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M3QA91'N)/6FW?B2\N=5^SV$1=!C)!JE<K_Q61WYVF/!.*;J^G0V4[ZC8SN9
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MIW9[8HX/ &*=C(YH 6BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
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M %=;&ZN3F20I]14Z:=%'Q*0_O3&O;BX'^CQ[OI1'9WUQQ)NCS0!:Q:VHW*5
M':H7U8/\L41)]0:FBT$JV9;AG'H16C%86T8^6)<^M S"#7UP_P B.JU.FA22
MD-+*/H16^J*@^4 4I^M %*'3+>%1E Q'>KB!5X6G8I,#M3 #F@8%*!ZT;: #
MBBC%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %(WM2TAI,!/YUY]XLF%KJD,L@R!(.:]"%8^L:'!JBYD4
M$@Y&16E-V HV_BVP\@?O%X'K4G_"6Z>PSO7CWKFK_P *W$61;6F[Z5SMYH6N
MP@[--8UHHQ8CTG_A+;'^^OYTG_"66/\ ST7\Z\@G.M6H_>Z81CU-9<OB*[@;
M$FG@8]ZM4HL5SW/_ (2ZQ/\ $OYT'Q98_P!Y?SKP;_A+6'6T4?C2?\)D>UJO
MYU:PZ>PKGO'_  E]ATWJ/QI3XNL!_&I_&O!QXK8\FS7\Z#XM.?\ CS7\Z?U4
M7,>\?\)=8_WE_.C_ (2VQ_O+^=>$?\)<?^?1?SH_X2YO^?1?SI_51<Y[Q_PE
MMC_?7\Z/^$NL?[Z_G7@__"6M_P ^B_G2?\)<_P#SZ+^=+ZHP]H>\_P#"6V/]
M]?SH_P"$ML?[Z_G7@P\7,>MHOYTO_"6G_GU7\Z?U0?,>\?\ "6V']]?SI?\
MA+;'^^OYUX+_ ,)@?^?1?SH_X2Y_^?1?SI_4PYCWG_A+;#^^OYT?\);8?WU_
M.O!O^$N;_GT7\Z/^$O/_ #Z+^=+ZH',>\_\ "6V/]]?SH_X2VQ_OK^=>#?\
M"7'_ )]%_.C_ (2X_P#/HOYTOJH<Q[S_ ,);8_WU_.E_X2VP_OK^=>#?\)<W
M_/HOYT?\)<W_ #Z+^=/ZH',>\?\ "6V']]?SI?\ A+;#^^OYUX-_PES?\^B_
MG1_PES?\^B_G0L(',>\_\);8?WU_.D_X2ZQ_OK^=>#_\)<?^?1?SH_X2X_\
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M%_X2X_\ /HOYT?\ "7'_ )]%_.CZF'.>]?\ "6V']]?SH_X2VP_OK^=>"_\
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M+S[UDZ*0[GNO_"6V /\ K%/XT?\ "76']]?SKQV"75[D#R=+W9]ZU[71=?F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 '%'%'%'% !Q1Q1Q1Q0 <4<4<4<4 '%'%'%'% !Q1Q1Q1Q0 <49'I1Q1Q0
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MQ2L 448HQ3 **,4E%D 4N!1BEI<J 3&>M& .E&*,4]$ 8]::54_PC\J=12;
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M)FC- "T49%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !112'I0 4@I-X4?,<?6D\Z/^
M^/SHLP'T9J/S8_[Z_G0)8_[Z_G2LP)*.:C\V/^^OYT>='_ST7\Z=F!)S1BH_
M.C/_ "T7\Z/.C_YZ+^=%F!)BC%,\V/\ OK^='FQ_WU_.E9@245'YT?\ ?7\Z
M/.C_ +Z_G3LP'T8J/SH_[Z_G1YT?]]?SHLPN245'YT?=U_.CSH_[Z_G1J%R2
MBF>='_?'YT>;'_?7\Z-0'XHQ3/-C_OK^='G1Y^^OYT68#\48J/SH\X\Q?SI?
M-C_OBBS ?13/-C_OC\Z3SHO[Z_G18+DE)3?.C_OK^='G1YQO6BP7'4G%-\Y.
MF]:/-3^^M'*%Q]+@4SS8_P"^/SH\Z/\ OK^=%F@T%*(>J*?PJ)[6"3AHDY_V
M13_-3^^M'FIW=?SIZBT,V?P_87'WX$_[Y%9UQX(TB92! H/^Z*Z/S8_[XH\V
M('[X_.J4YBLCSV]^%]I.3Y8V_CBL*Z^#N06C8_\ ?=>O^='_ 'Q^='FQ_P!]
M?SK15JB#E/ KWX87]OGRAG'O6%<>!M:@.X19_ U],^9"?XD--;[*PP?+_(5K
M'%3CN'*CY8FTG4K;B6!N/1#5&1)8S\T,@_X":^J+C2=,N/\ 6HG/TK-G\'Z!
M,,M",_45LL:R7$^9MV>J./J*7@=_UKWZ\^'.D7&?)"K_ ,"KGKOX1Q2$M'<1
M#TR:U6,1/*>1!@>E*/K7H-Y\+;JW&8YHV^E8Y\ ZGYNWM_NULL2A<IRQ]S33
MACP:]!LOA?=7!!EE1?K6U!\(D0AFN(C^-3+%I#43R4N0,;&/T%*BR2'"PR?]
M\FO=['X:Z9!CSBC8]#6]#X-T"$<0C/\ O"L98WL5RGSO#HU]<?ZN%OQ4UH0^
M#=;G((AP/]TU]$V^BZ5;8,4:CZXJ^JVR#"B/'T%82Q<GL'*CP*S^&FHW*CS5
M S[XK<M/@Z[ &1__ !^O9-\ _B2E$L/]]?SK)XB;'RH\XL?A39VY'F9;ZMFN
MBM? NE6X'[E3CU KI?-B/\:_G1YT>/OK^=9NK-E61F1>'=.A^[ G_?(J_':6
M\0PL*?\ ?(J3S4[.OYT>;'_ST6H;DQZ!Y:CHBC\*=R!P!3?-B/\ &/SH\Z/^
M^M39AH.[<T+CM3?-B_OC\Z3S8NSC\Z+,-"0C-)31-$/^6B_G1YL?]\?G0%R3
M%%,\Z/\ OC\Z3S8_[X_.BP$G6C%1^;&/XU_.CSHSTD7\Z+,+DF*6HO.C_OK^
M=+YL?]]?SHLP)*2F>;'_ 'Q^='G1_P!\?G19@/HJ/SH_[XH\Z/\ OBBS DHI
MGG1_WQ^='G1_WQ^=%F%Q]%1^='_?'YT>='_?'YT68$E%1^='_?%+YT?]\?G1
M9@/HIGG1_P!\?G1YT?\ ?'YT:A<?13/.C_OK^='G1_WQ^=%F%Q]%1^='_?'Y
MT>='_?'YT[,"2BF>='_?'YT>=%_?'YTK,!]%-$L;<!P:7- "T4"B@ I:2B@!
M:*** "BBB@ HHHH R=<OS9V^%X8]#6''9:JNVY%T64L#M [5NZSIYO8#MY8=
M!6#Y^K&$6_D-& V-P/:@"Y<^(9;:Y\I8'<*!N(-$GB8F#?% SG'0&LR>TOH+
MN0>29!(NW<>U26.B75OL+!B.X- $L/BN>5MJVKEAU&:?_P )5*Y*10/))W4'
MI4D>EO\ :&9(MA)[5S5LMUI6KR$Q%V9B0#0!L:CK\DUG&NXP3^:,H>N,U/=>
M+4L'2$(9&XR0:S;_ $>ZU)$N1 8Y-PX'I2RZ--;722&V^T X!W4 ;*^*H_+\
MQD*J>A)ZUKZ9?G4(C)L*KV/K7)ZII$VI(B0P>0J= O>NBT&*:&Q6WECV&,8!
M]:-!7-CD"@ CO0.F#2@T!<7IT%+3<^E.HV&)112T7 2EHHH **** "BBB@ H
MHHH 0FF?>Z]*>1FFXYQF@#"URQEN5$B(6*D$ >U84QU*25)!:R*5/6NXSCJ?
MPHVJ5PR@9H8&=I=S<3*?.1AQWK.\3P!H=VX#BNA0)&N!C-8?B9"UID<\5RXF
M_LC2GHSE-+*_;5W,#@UZ-"1Y*X'85YC"5CG5EX(/->AZ7<"2T4L:X<#**=F:
MUE=&@.G%)U/2C(]:0N%'/%>K*<4CFL5K^01P,?:N*FDW3L/4UT^M3A;?KVKE
MT7S+A<=Z\+&U.>=D=E'1'4:'$([?/<U?O+47EOY;]_6H]/BV0+]*N@EJ];"1
MM35SGJ:LR=/T&TL.0BE_6K%SIL=P0S <=JNY]LTH.:ZC,IM9+)9M;C"@U0TW
MPY9V.[**[,Q.16TV>RTWE5_K2 HG2E^T;P0(QT3TJ[\B#[P"CM6#KGBVRT9?
M*\Q9+GLAKEPVO^)I-\9ELHV_N'-,#L[SQ-I=CD2W<:D=B:SQX\T8GBZBQ]:I
MV7@2';F_?[4QZF05H_\ "$:)MVBPA'OB@!\'C#2)Y J749SWS6S%=17"AHG#
M*>XKF+GP+I[*1:HL+>JBL"XTC7?#\GFVMS/<1KSY9X% 'I>T]2<T[H.#BN1\
M/^-(=0D%M>!8+GIY>>]==D'\>E "CI2T@^E+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36Z
M=:=2'GM0!P/Q%UN[T;3?.MY&4[@.*\K'Q!UOK]IDKT7XMC.D[0/X@:\-CW$8
M/K7HX:GS(SFSK3\0-9_Y^WI?^%A:R!D73_G7);?G.>E+E1P!DUV/#P1FI'5C
MX@ZW_P _,AS[TI^(.M'@W$@%8UGX>U/4!NM[9F'M4&H:9>Z1*%O("N?[U2J-
M,?,;_P#PL'63\J7,E-/Q!UQ3C[1)DURSX#!E'6IH86NYDB4?,QQ3="F',=+)
M\0];V#;<R%A[T?\ "PM;.";F0?C63JNA3Z/'#)*#^]7(R*RAS&W')-+V%,.9
MG5_\+!UH'/VIZ7_A8.M$?\?3UR8&5QBFC([=*I4*8<QUO_"?ZTN,W3_G2-\0
M=<882YDXKEXT,YP.IIT<,IN!!$FYR<8H]A3%S'3-\0-9.W_2GX'-./Q!UD-Q
M<OTK$U+0[W2XDDGA90XW#-9SG."$QQ2]A3'S,ZL?$+6S_P O,E+_ ,+"UKC-
MS)^=<ETZFCMG-/ZO3#F.L/Q#UP<_:)/SI3\0=;!5A<R=/6N>TVQEU.[2WC!)
M8XXJ35M)GTJ98YLC(SS25"GS#YC;;X@:VK;OM,E*?B'KF<BXD_.N3Z]32@@,
M10J$+BYCK%^(>MC.;F0;O>D7X@:TI.;B3!]ZR-)T*?65E,0/[L9XJA<6[VMT
MUO)G*G'-/V-(.8Z7_A8.MAMQN9,4I^(>M%]RW$GYUB:5I,^L2F.('CTJ&^LG
MTN8P2 [O>DJ-(.8Z)OB%K>[<+F3GWH_X6%K9R/M,E<DN<9-*.I-5[&G839UG
M_"PM;X_TF3\Z3_A8&M,>;MQ7)%N#6U8>'KK4K1I88RP7J14NA3"YI_\ "Q-:
M)YN)#CWH_P"%@ZVYR+F0>V:Y:4B*1DV_,IVD5I6GAZ_OK#[;%$WEC.<>U+ZO
M =S8/Q!UP<_:9*/^%A:WU^TR?G7*,I1V0GI3>QJEAH!S,ZW_ (6#K74W,F/K
M21_$'6G)!N7Q]:Y//%.E=5P$49-+ZO$.=G4_\+!UE7*BY?\ .G'Q_K( _P!(
MDS]:Y79EE55R[' K6C\*:S)&'6U<@]*)X>"6H*5S4'Q$UD@AIY#CWH_X6%K1
M;_CZ?;63-X5UF&(RM:.%'6JEMIEY>S>1#;G?TP*R]C =S?\ ^$_UM3E;J3%/
M/Q"UAUQ]J?/UK,D\(ZY;H6DLG"8SDUFP6%Q-=&WB@S(.U7[*&XFSI1X_UP
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ML6=^U>E31></!:+?8\S>/O=::G)#LCD].^'+7^FQW1D90QYYJA_PA32:T]A
M[.B-@MFNUU*^GL_!$36[!2SL.OTJEX!F-Q87C,P:Y,8P2<\Y%6JDA<J,]_AK
M:B)TANG:X7C;D=:3PCX2A763#>$\$_*:G\,0ZG'XWF:Y,GE&;N3CM6LUP/\
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M#2\-^'(M)M5=U!N&Y9CZUT#!BN :4=<YIU $:KMIXI:* "BBB@!I!S2YI:*
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M:QAMZGJ*0;F?<%) JHTTB36T'69-%O5FBRM;NL>,8]2,<PB82H0<_2N.^_\
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M9K9TYI6A#RX''K0!H9QUI<5S6I^(A:W?DJ <#-:NCZC_ &C9K-ZF@#1HHHH
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M.N58=*7[-'Y/E;1M]*E@<18E+F3S;_S1V&,BC5;&(W<$D8<H'&,UV$VEVUR
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M(;=(%"Q#&* )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI+%3#E1X,?A#J&?^/G_QVE/PAU#@BZ&1_LU[Q1^-#Q4PY4>#'X0Z@3DW7/\
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MA5%Z 4]5P*KV<ZSVR,O.15@'M7ERT>ING="=Z6G4E(-!:0TZD- #>].%%+0
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MHQ2T4 )12T4 )12T4 )12T4K )12T4P$HI:*5@$HI:*+ )1BEHI@)BC%+10
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M **** "BBB@ HHHI@%%%%( HHHH **** "BBB@ HHHH ****8!1110 4444
M%%%% !1110 4444 %%%% !1112 **** $HI:*8!1110 4444 %%%% !1110
M4444 %%%% #:,5$;N!>KBE%U">CB@"0THZ5";F'^^/SIAOK=1]^@"=N:SKC1
M[:Z?>Z+N^E+)K5K&<;OTJN_B*T7^(_E0 [_A'K8_PC\J4Z!;$;2H_*HAXDMC
M_%^E._X2*VQU/Y4 .ET6VBMW^4< GI5'0+:-W=BH('2KUQK%O+:N%;DJ>WM5
M?PT#]G)(X)- &V(HQR(Q3@JD_=%.Q322#Q0!C>(2JV+*H^8L*L:5;(+-=R Y
M&:I:[:33E6BR0!R*K66M-:J([A=N..*0CHFM82/]4M5VTJVD.2B@_2FV^KV\
M_1JMBZA89#C\Z!H9;V,-J=R*,U84Y-1_:(O[X_.C[3"/XA^= $I..U'!%1?:
MH2/OBGHZ,,@YI@8^H:.;MRP)S67<:-=6\1<2. M==G(.*RM<NA!9,IZD4 <]
M;1WLF=K,<&K:QZE&,_/5O0KB 1$,>2<\UO85NPQ0!RC/J;#&'I%TN_N^7=UK
MJ]B#^$8IV, ;0!0!P]WIUS9R(6D8KWS6U:Z);W$"R-@DCTJ_J\(DT^0XY X-
M8EAK M8VB8DG- &HGAVT4Y**?PJ4:):CCRUQ]*S)O$$AXC3/X55;5-3<_+$,
M?6@#:?0+1QC8HQ[5$_ARV(& ./:L>35M0@&7C )]Z7^V-1(4K$"#[T(#JK6W
M6WA\L=*FY]*Y=-;N5&7CI?[>GSPG%+J%CHY85GC*LH(-<+XA\+@.9X.,<X K
M3EUN[8 1QTSS-1O5V-$,'WK:%3D9+B<"[$,8I%P5XS6]X6U25;Y8=Q*9K<3P
MH9WWRKC/I6QIWARUL9!(!\P]JJ=3F0)&RK#:ISU%.HVC&/2E(K H!2T@I: "
MBBB@ HHHH **** $-(*#1B@ S28YI<4M)CN0SPK/&589&*X36]">.4R1(=I-
M=^:C:))1M=0:2;1+29Y!=:7YD;+Y0#$5Y[K.G36-V^$/7K7T9J&A0S!G08..
MPK@=6T<+<D3P@H3UQ5\TF3&FDSS#3O%&H:6-L<[@=AFO2?!OQ&>ZN$L[U_F;
MH6-7;GX;Z?<Z-]I@),CKD#%>17EE<:3JFTAHV5\*1Z9I)&MU8]\\;:&-?T?S
M(1N; (P/:O%="AO-*\5107&Z+]X /?FO>_",CR^'H3-\Q('7GM7-_$#PRCQ)
MJ=K&%EA;><#'2ADH[*YM!>:84;ERO!K'\/73VUW+93G[K;5S1X$\0+K6B1"0
M_P"D(N7'I2ZW!]@OH[R//JU%@.I(':E'3FLQ+E[K3]\'+[?6N9T_4-5N=7>!
ME&U03][TH [CD=!1DCC%<F^K7L]Y);0J,QKD\TV;6;F"W1&QO;CK0!US' Z9
MIAW%>16!I-S=S'=(5*_[U6-9U0VD06/!8CO0!L!3M]:53G@C%<WH6J7,^H&W
MG Y4L,'-,UK5KB&^^SP ;^.IQ0!TC!MV0:<.G-<MI^O217+P7F 4]#FK]MXE
MM+FZ>%3]TX)(H W 01Q1@XK#_P"$DM_M/EK]W."<4^\\26MI*D9;);'0>M &
MQCF@@GD5B7'B>TAD"*V6[C%5;[Q5'!'&8QDL>>* .C#X.*?]:P3XB@CMHY''
MSN,@ 5+)K]N+3SPW((&,4 ;0%+5:VNA<1*Z]"*L9YH 44M%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5QBC/M0<TGF1C^(?G2>8I_B%-"'<TM-!S2T,!12T@I: "BBB@ HHHH ****
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MF:6DP%I***8"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"08*J#0!6B\00Y"LN"?>M"&\AGY$@^E<OJ5M"+Y8H2.0.E2OI%Y;H)(G<^U
M'6Y';FD8!A@UR<.K7MK(%F0[?4FMB#7+:0 %E#4 :"0I&WRKUJ1<C(Q4:74+
MC<&%2!E;H: *]Q90W"8=1S67)X<AZQX'X5NY7H:0, 3Z4 <GJ.BK!:/)O (%
M4; V>TK*H9^QKJ[VS%V0ID(0]:I1:-90L26!(/I0!2M]0AMFVB+Y?K5M=>MU
MZI@?6K#V^G(OS;*S=233Q;,8]F?:@"ZOB6V)X _.E7Q':EB#C\ZS-'M+&XMD
MWE=Y%:?_  C=JQW CGVH !XDM^F!^=(WB.,CY$_6GCPY:CKC\JFCT.V3^$'\
M* ,R37;@_<C:H3J&HS\!7%=&EA;(/]4M3"WA7[L8H Y80ZG)SEQ^%+Y.J1\[
MG_*NK QT%!P1R* .375-1AD",CD9KH[*=YX0SJ0?>IC;PMR8P33U4(,*N!0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX6CLKY;FWO6DCV],<5VV.![5G.-F%QPH[T"EJ2@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *_V6W8Y,2_E3OL\(^[$OY5+
MQ28- #%4+T4"GB@ T8-  031V]Q3J:5&<YH 3DC%+CC%!XY)X%1B2-CC>/SH
M @FLHKKEZ=#800+@(I^HJP/E7BC/:@",0P]D /TIQABQRB_E3^@S2 G&3TH
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MN/7[8R_\M!^%6%UFWDN-H8CGO0!.]A!YF[[/'D^U59]&MY#O"A6]A5PZA!N
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M 'T4@I: "BBB@ HHHH **** "BBB@!.<UFZUD:5<8_N-_*M+M6=K7_()N/\
MKFW\J</BL!Y_\-C_ *3,,#J?YUZC@>E>7?#;_CYF^I_G7J-75W$@I.W-*:#6
M8R+Y]W!I7Q@9Y-",6!^M9FLZW;Z/!OF(SV&: -3'R@4HX'-<)%XSNII1(MO)
MY+'CFNMTZ_%] )"N..] %_MS2&HA<0LVP2!CZ5@>+]<FT2RCFA1F+2*G'N:
M.CH&[UK$CUL0Z$E]<=6SU-9VC>,4U:^,"+@9QUH ZTD]C0OO2,0HW'@#O3%G
MBD;"N"?2@![87FE!W#(JCJFIQ:=;M+(,[1G%8?ASQ=%K]U)#$NS8,]: .I(R
M>HIX'%1\%JE[4 )M'I1@>E+10!7ND0VTF5'W3VKRK051?'M\%&/G%>KW/_'M
M)_NUY3H9'_">WO\ OBMZ7PL#UI>F*44BGBEK![@+1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !111WH 0\#-9\^I)"^#6@W0_2N2U/FZ:@
M#9_MF#_)I?[:@]#^=<OL ZT86F!U']M0>A_.C^VK?T/YUR^!Z4A''RC% '4?
MVU!Z'\Z/[9@'8_G7,_*JYQS0H\T@ 4 =+_;,/8'\ZFBU%).=I%84-B1AC6DD
M9"85>* -%KF,CO31>QKP:AAM]R[JR[Z:&!RTLJICUH V&OTSQ2_;5QG!KAM3
M\7V5DI\ME=O8USS_ !!G8_*&V^F: /6Q>*U-^WQ;L#K7F6G^/DED"2@KGU-=
M1:7=O=J)8Y%!- CJEF23@BE>94Z"LRSG4 *S U?*JW>@!XE0CY@*C:Z55.%Q
M5>>014U9X73! H MB]C*Y*T@O4(Q51_*"\8I(TA(SD4 7/M*''RD^XIWG)(=
MNW'UJNLD:C"BC:7;CBA 7LHJY 'Y57:^B4X(HV,HPQRM4+I8\G:O- %\W$9Y
MP/RI?MD2X!ZFL6*3DAWVCWILLULARTZB@#<%Y#NP,9I?/C;G XKFQ>6@/RW2
M59CN%8?),&]A0!N?:H@.%_*C[4O7L:RX=TG!4U,T;*N"* +AO%4=#4#ZLB'D
M&JY!Z8Z5&]M$ZY;&:!EG^VX>_P#.D_MJ#T/YUF2Z;&>4 JG)9.IX4T ="-9M
M\=#^=']M0>A_.N8,17JM)E: .H_MJ#T/YT?VU!Z'\ZYG;1@>E '3?VU!Z'\Z
M/[;M_0_G7,[1Z4QU]J .I.L1'. <5SFH?$"RT^5XI8WRIQG--C8 ?,*YCQ;X
M>AU"S>:% 9 .U 'IVDZG%JUDMQ$"%([U?'7K7-^"+9K70EB88( KHU&#2 D%
M+110 4444 %%%% !1110 4444 %%%% !1110 4F.E+10 PH&!W#(J'[';$_Z
MI35FDQQ0!&(HQ'MV +GI08E/\(^M28I: (O)0@Y4&A88D^Z@4GTJ6C% $2PH
MK9"#/K2&"-SET!;WJ7%!% # B[<8P.PI'AC; 90:DQ1B@!@A0$84#%--O$3G
M8,U-10 PJ..*#&I.2*?10 P@8QVI&B0KMVBGXHQQB@!@B15P%%*(T!X49IV*
M,4 -*@GYA2&.,E<J..E/ Q2T )B@48I: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***:6XSVH 6C-)GY<TH(H 0MBFAZ<Q '-8VI:W;V*D!L
MR'@#%(#4GNH[=,R,!BN9U/Q$\K>39#<QXR#5/R[_ %=_-D)2/KP:U;+2XK8
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M.Z4WIUZT *WI0#MI,DBC&: %/-(,YS1MYI:  \G-*>1TI**  =.E*"%[4E%
M P#<D9'I56XT^TG;+0(#ZU:/(I<_+C H Y^Y\.OYOFVTK#'0 54FN-1LG'FH
MV!ZFNI&1T-#QQRC$R _A0!C6NO0N@WL%85J),LRAU?-4KW1;>Y'[OY#_ +(K
M(:QO].?="6=1_>- '3-&7'R+SWJE>:7!<K_JP)/[U4K773Y@CG&T^U:\=Q'.
MV%;M0!@_9K[33NA9Y%'45HV'B5&/E3X60<<FM!E4_*O)/7-9]SIL4C<(%]6
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M>*3'SY% $,EI"\(A**4'8BJ0T#3E<.+>,$>B"M3CK2=#Q0!6ET^WGB$;QJ5
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M!SF@#3W9.,<&HW<*^2VU?>L^'7K&6;R1,N[I6-X[U"73])ADA8C=*HR/0D4
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M6HVXD7RA@YXIS2M+,J[<C.*M7D MHE=1DT ==X)\1R"Y^P73D@G"YKT@$D
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MR=4T*#5,;Q@@YR!6KB@94&CD3*A6=/8P+3PG:6=PLV-Q!SR*WBJ!0$&W'84
MMC%)G'6IY4$J\I;CP0?E-(6V_*4!4^M)L5AD'FE!(&&I\HMS(U3PQ8:FC.$"
M2$<$"N,DM]:\)W'FQ%IK?/S!VZ"O2>0V12301W*E95#*W7BJ2L19O<R="\1V
MNM0*%VK-CYEQCFM@G^$UYYK^@76B7AU+32VP'<5S_2NH\/Z['K%HH8@3)A2#
MQ058W'^Z AI,<9I0,'%( 2=OI2L)A1110 4444 ';%%%% !1110 4F*6B@ H
MHHH **** "BBB@ HHHH **** "BBB@! /FS5Z+E:HCK5Z'[M,9)WI:.]% !1
M110 4444 %(:6D- !6?K7_()N/\ KFW\JT*S]:_Y!-Q_US;^55'XD!Y]\-?]
M=-]3_.O4:\N^&O\ KIOJ?YUZC55MQ(#37&X8IQIK<'-9C$X4Y)XZ5Y?XA;_B
MO]DQ_<_+M^O->GNFY< ^]<7XO\/2W+)?VXS,C9'X4 =C"L:Q*$^[VKB/&>H3
M2W<.GQ.8Q)D$J<52M/$GB-(DA>!,CC_5U9US2;_4;"/4 H%S&N0!ZT 0ZOX:
M>RT%;J&>3S1M.<U1U;4)K[PG#YP!=)U7D^A%2W.I:_J.EKI_DJ,$ DICI6AJ
M_ANX_P"$9@MXA^]\U7;],T ;>F3W,/AF)[6)7DYX)K@=5DU,ZY#<ZK$$@\S)
MP<BNR^T:GH^C0PVT:LX/.5S7.:BVL^)9(K6>!$3.&*IMH ZV^DLY?#\4AF:.
M QY!7TKA=5O+*WN89M/N9BRX!R,9K>U_1K^VT.UAMLL((]I&<YK"N].U'4((
M42W5=N,G9B@#TG3S]HT4RRJ"_E=?PKB_"$>?%-VW3Y>WU-=++)>Z=H:QPH&D
M,>WIGM7"Z#_PD%EKLMPT*[).#\GO0!Z[D[_:I,U4M'DGM5:488CZ5:084 T
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MDG+_ '?2AY([B4N#@C@"@"57 MRC'O59HVV[LT^2"3R-_;-0H6,>,T ,7>7
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MEUB_RV?)4XKJ(8DMT$:#@"@0Y42-!&@  '2E!^7!ZT#@YH[YH ","B@<'-%
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MR9R1.:UCT-95Q_K2: *ZI^^+5Y=X]F\[4 ,_<)%>J_=5S[5XYXJF\W5;A?\
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MRLLC$1]!UIH*L<@C/I7'>&]9FC^T0WC$-\Y4D_7%5]*U2ZDUN;S)6$*C(YH
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M]%I//AS_ *Q:\5^P^,?[UQ^='V+QC_>N/SI^QCW#F9[3]HAS_K5JY%<P[?\
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M:U6)]KV<IR?2IIO#.HVT EDMW"_2NQ;XE6SG+6<1_$U#<^/XKE0K6R;3T&:
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MI.&Y/6E'3FN=:,WN%%%(:8"T4F:44 'X4'-+G%(<D9H 7Y0,]Z2(@%B>F#2
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MQ*HK@?AE;NL<DC#AE%=_-_K: -:V_P!54PJ&V_U0J:D M%%% !1110 4444
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MAI>G7"7$-NBR+SD5>N-$L[K4([R6(&:-<*3Z4 5].\.Z?IRI);HP;:.K9K7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<$4NX8ZC-  <]N*7]:0'CWI <]#0 XX[T4#%'>@!:*** "BBB@"&Y_X]I/\
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M/W!]ZOWAPAR.&JDBD)2 V;/_ % JQ4%J,0BIQ0 M%%% !1110 4444 %%%%
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MC:7=V7M76Z39Q);AT0KD=#0I)@:EMJ8;Y''/TKSCXH_-=V[+_?3^8KO3;@3
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M,?WFJUXEO+6/2Y%:52Q!Z,*S? VH6L>B+&\J@[F_B%8NYTP7,==P.O6HY_\
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MT 7(G5)7"=*B9G,N"< FIH((_/;! JE="07F#+\N>E %I;$.VY2!]:ANY#
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3O2T44 %%%% !1110
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M0 G.?:FF-2V2H_*GT4 ,\I,_=7\J3R4S]T?E4E% #=B_W1^5)Y:YS@?E3Z*
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<2 8I:* "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>plrx-20211231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #X HP# 2(  A$! Q$!_\0
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M (_\*]!HH^LUOYW]X<L3SW_AGGX8_P#0@>'O_ "/_"E_X9Z^&/\ T3_P]_X
M1_X5Z#11]9K?SR^\.6)Y]_PSU\,?^B?^'O\ P C_ ,*3_AGOX8_]$_\ #W_@
M!'_A7H5%'UFM_._O#EB>??\ #/7PQ_Z)_P"'O_ "/_"C_AGKX8_]"!X>_P#
M"/\ PKT&BCZU6_F?WARQ//O^&>OAC_T3_P /?^ $?^%)_P ,]_#'_HG_ (>_
M\ (_\*]"HH^LUOYW]X<L3SW_ (9Y^&/_ $('A[_P C_PI?\ AGKX8_\ 1/\
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ME/C#Q-\4/@%?>%]:\1^,+7QEH.JZA'8:C8-9+;O;.Y 4Q$$Y4$]ZT5\8>/\
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M/!K?V&*CRR]II+?5^HO:1?F>E?\ #/?PQ_Z)_P"'O_ "/_"C_AGOX8_]$_\
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MMZ+W<U\C^./VJOBCXJ<R7?C#5+9B>(M/D-H@'IB/'ZUUTZ=>HKF<N6)^DJ_
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M640, 3U?)'IS7J4<#CZRYHQLO,XZF*H0ER-ZGW4WP)N^!_PL7Q5D_P#3TO\
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MN$\4?$35/B#J4+7+QVTMO@V5O:IMCB4= !Z]*PA[M)OJ:5I.I-0E*\$S[?\
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MIK(\=%WBDGZB^L4^K/4O&/\ P3"\-7NH/>>%/%6H:,23BVOHUN8U] &X<_\
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M?[3) $M"<#:,\YKZ*P:\6K1E1FX3W1O&2DKH?111611\,?\ !4\?\49\/_\
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M7[7)N:$]4)SDKR>.G-<LJA5"CH.!7H8>G6I-RG*^QG+WM$>I_LP?\ER\,_\
M71__ $&OV4\,_P#(OV'_ %Q7^5?C7^S!_P ES\,_]='_ /0:_93PS_R ;#_K
MDO\ *OB^)/\ >$WO8]#"V<;FH.]+2#O2U\D=@4A7-+2-THV :P(%?B!\=O\
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M7WE_P3;_ .05J'_89;_TG2O@W 7A>GUS^M?>7_!-W_D%WW_89;_TG2LLZ?\
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M[8K[@\"^ _">EV/@RVL?#$AG@U+6M-;Q%!.A,;QL=OG H5.]<  ].<5PU]\
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M@>E9%MJ5U9*Z6MY=6L<@VLD,S1A\=R 1G\:^U/\ AVCN+#_A:-B#WQI3Y_\
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M^@Z!8VS^8LP-O;!3O0DJPXZKD_B35I?#>EQ6D%LFFVT5G#*9X81$ D<NXL6
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MH-S9:3>213.42(:@_FQ0VXF65H$48PK,.I)/3TKZ,_X5_<?]#!??^._X4O\
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M%%% #<'.?RI?>EHH 1>E+110 4444 %%%% !1110 4444 %%%% !2?CQ2T4
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MD_\ PT7I'_0N>*/_  3S?X4?\-%Z1_T+GBC_ ,$\W^%'LI=@YD>L<T<UY/\
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M7_0N>*/_  3S?X4O9S'S(]8P:-IKR=?VC-);IX>\4'_N#S?_ !-'_#16D_\
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M@_L>;_"CV4NP<R/6.>](X#+@G]*\H_X:*TANGASQ0?\ N#S?_$TG_#16C_\
M0N^*!SCC1YO_ (FCV-3H@YD:>L:=>C5)VBTRZF1VR'CD5?TQ53^SM1(8?V/=
M_-U E '\JK_\-$Z0HR?#GBG [_V/-_A1_P -%:1G \.>*"?^P/-_A6BIU7TO
M\Q73)_[-U!N&T:ZY&"1(/Y4OV#4<D_V->-QC!E7GMQQZ=?6JZ_M$:0V,>'/%
M!ST_XE$W^%'_  T5H_\ T+GBC_P43?X4_9UOY?Q#W2P=/OV7!T:\(Z#,@.SV
M'M0NGZBK IHMT.W^L VXST_&JQ_:+T=>OAWQ0/\ N$3?X4O_  T3I&<?\(YX
MHS_V")O\*/9U?Y?Q'[I8;3]1;(.C7A/4;I5(SCC/'K2M8:AT.B717&W;YBD;
M0<]/7-5_^&B=(_Z%WQ1_X*)O\*7_ (:)TG_H7?%/_@GF_P */9U/Y?Q#W27^
MS]2P,Z-=NV<G,@QSWQW-*NFZAR!I%YM[*\@(^I]Z@_X:'TC_ *%WQ1_X)YO\
M*/\ AH?2/^A=\4?^">;_  H]G5_E_$/=)_[/U!MI_L:Z!W#.YU/'KG'%-&FZ
MCLYT:[+==IF4C\<CFHO^&A](_P"A=\4?^">;_"E_X:(T?_H7/%'_ ()YO\*7
MLZJUM^(>Z/AT>[M8TB@T*ZCA081$D10I)R3C'>G_ -GZBV1_8MYSQ_K%/]*A
M_P"&B='_ .A>\4?^">;_  I#^T3H_;P[XI_\$\W^%*U8F\35\/:/?#Q)8W4F
MGRVD,$;QEI&!SD\=!7H7F+ZUY.O[1&D_]"[XH_\ !1-_A3K']HCPG??:!*^I
M:9-!*87@N[-XI,@ Y*D9YR*3I5):I%*2.<^"[L/A[" Q ^U77?\ Z;-7=F1_
M[S?G7!_!?_DG\/\ U]77_HYJ[JBM_$D$/A'>8W]X_G1YC?WC^=-HK H=YC?W
MC^='F-_>/YTVB@!WF-_>/YT>8W]X_G3:* '>8W]X_G5?4+Z2QL;FX6&XNVBC
M9Q!:C=*^!T0=V]JFI4;;(C9 (88+ X'N<54;-VEL)WMH>6^$?VAM/\6:QJ-I
M-HFMZ(FG.(;^^U2)8X;60J&".^>"01\OKBN\;QMH<>G07_\ ;=B+&4$Q7#72
MA6V_>YSR1Z5XEK'PU\9V=E\1)-+TVTNY-6\007UO#<+',SVJQH'*!P5\WCY=
MPKGO!/[/6NK-X4B\0:+#<Z;8^([_ %6XM;MHY%6*6/$995"JQSU  &:];V%"
MI%-2L8\TXZ,^D%\9:(-1&FIK=FU^V&%L+H%WR,C'/7VK+U[XK>%O#V@ZIKEW
MKEM+I^F\7<EM*)9(CG&,9YYKY%\&V,/B#XE7EB]K_I]YJ&LVVD36RIYUC-*&
M43SH5#JNT *2?E!XZUU6A_LV:[<> _$5A>Z)<0ZZV@#2X3=7%O):W$BNK*42
M-%(Y7/F,=PR:TE@Z,&VZ@N:3/J:T\4:;=Z;9ZA;ZE;M9WI AG,@VRD] #G&:
MBU+QIH>B[OMNMV=D8G\M_,N@#&WH1G_]6:\\\4_#Z_\ &GP'M]#@T2'P]KUJ
MD-W9:?&R*D%U"P92"O&"0?SKS"_^#/C^X\'V"W&CVE]K&N2ZA=Z_Y8@:>&XE
M 6!4DD5@(PJ@-M&[BN:&'HRE>4RW*1[/XB^-5KH/B;5M%CTNYU-['2H=7$EK
M<H(Y5>41[58]SG=5KX@?&+1_A_!:+=3+?:A=7=M:'3H+A/.7SG"J[#J,5X3>
M? /QG/X5ELWL(YKEO!UEI!W3*2]U'<AV0GL HZT[Q)\"/%MUXFU*,>&;/43-
MXFL];3Q/+<)Y\-M'Y0>W'&[C:<=JZ/88=NW.3S3[7/I:;QIH4-[>6AUVS-W9
M(\MS''=*TBHH.21GMBN5\._'+P_XQN/#R>';C^UX-8$C-)%*J&T"J.95SG#'
M(_"O)+/X0^,]5^,%GK.LZ-:1Z=%=ZDDLD"P+;O;S1,D9VA0S$Y^8R$\]!6=X
M3_9]\2VNF^![7_A';#PWJ>B'4[6[U6$QB2=98=L,Q9>2-Q/!Z#D5"PV'Y?C$
MIS_E/I>S\::)>F]2TUFRE_L\;KI8KE3Y '!!YZ#/6IM+\2:9KLD\>F:K:Z@U
MN0LJVMP)&4GD$X/%?+>F_ 7Q;=:&EJOA6S\.3Z7X6O='FDMIT)UBYE&%=BO)
M7(+9;G)KI=)\(:I\"-2O/$VG^&HKFW_X1JPTP:?8XC:\U 2\AMHSG!)WGL*B
MIAJ*@W">I:E*^L3Z$U36K/0[7[7J6H0:?;!@GG74HC3<> "3[UPG@WXW6GC1
M=,EL],NH;6]O;VR^T2W";8/LW61O[RMVQ61\;/!.M^*KCP-JMEH5MXD31[TW
M-]X?GE79.&B=5QY@VL4+=^OUKS?P?\!O$NF:=X4MK[1+>.WLKC6Y;FR@NL".
M.Z4B)$8=,YQQT^E*CAZ+I?O):DN4[Z'T<OC;09-/N=037;%K""012W0G C#'
MH"<]32WGC;0[&SM+J[UVQM[:Z_X]Y)KI0DO.,J<\C/>OE^/X%^.V\,Z7;QZ>
M\&E:+K"75II#&U6^>W$.T!G"-%(RD_+O!]^:G\3?!'Q=_P (/I&@Z-H,LFG2
MV=]Y\=W+;2WMO<3-E5+LFU(C@DK$!@U7U6C9?O!\\_Y3Z@D\3:;'J=OITFJ6
MRZC< -!;?:!YDH/3:,]#18>*-,U:\GL[+5+:\N[;_6V\,H9H\<<@&OG>Q^$/
MB_3/&WAF]T[34MKK^R[:PUG4KF2.6 [("H:/(WQRQL<94C=UJ?\ 9_\ @GK?
M@?Q1IEUK=AJ,5[I5K<V_]HK=6YM;OS'R<*J*['.&/F'([5,L/1C"4N<.>?\
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M7M/-'F* ,DGGBOE7Q-\ _B'-X5T;PVEC:7\=EI-G%#?6_DYCF20,ZRR.#(0
M,+Y9 XKH]:^#/B[4/%OBM=%LETG3M=L+A;R\OI8YA+</"J*\$@42QEB,,I)
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MM>SUNSN5M"1<F&Z4K'CNV#Q]:^:],_9Z\8PV>BVR1PZ8?L^O*T=O-^[TQKS
MAA4]< \DIP"37+>-OACXAT#P)J6L7/A:U\+0:9X970YHK.4'^U)S*#Y[A!T7
M&=S=<\\53PU*;45(7-*.I]2ZA\3]-1-.?2)TU[[3>I9O]@N5)MMP/[QN>0,=
M.]:G_"9Z)%+?1#7K%9+%=UV!<J#![OSW-?*_P[\'/XTM0-%TY6U+3_%EGJNJ
MZI"(OLTL8@9 8F3:I"<951P2:Z'1_ACXX\._#[5_#]KX(TAM>BN&)UUS#+)J
M,;7/F-@..24.07. 11+"TH2Y7/4I2E+4]LU[XM:5I-]X3CLV&LP^(=3_ +,@
MN;&X!2-MA;)^F*Z/5/$FG:'-!#J6KV]I+,1'&L\X4R-GG )_6OF[P%\$?%^C
MWFC375B+>WM?&3:RR/+&6CM6M@N2$4#=N)X4 >E:WQT^#.N^,OB5<ZO#I]YK
M.@:AHZ:9]GT^X@CDA96RS'S4;;NXY4@\5G&C1YXKVG<.:?8][D\1:?##-,^I
M0;(9OL[N91B.0](CS]XUS]M\4M-'A$ZYJA_L5=\\:6E]<()9#&6 "'..<?AF
MO(;OX#Z\OQ>M8[9(Y/A_>7%OK.H":4,\EY;Q>6@([[CR2 ,US4?P%\7Z;:Z)
M)<>%K'Q/$D&J6CZ=>SKMM9+B8M'/SP1CN.15T\-ATK.8^:7:Q]!^%/BMHOB;
MP?X>\07-[#HT6N0>=9VU]<HK\D_X5N77BS1[6^2PN-;L8;UG$*6K72ARQY'&
M<U\IR?LY^+%T_P .0:EIM[JUG_PC4&C75GIMS;J]G*DF7(,J'Y3P=T9#9%=!
MX@_9YU:^O/%M_'H\%UJ,VK:1<:;>3.K3""W6(28;LPVG/K52PM"/_+P.:717
M/I!?$VFKJ\NEG6+4:E&A>:S%ROFQ@#.6&>!CFC1_$6G>(+>233=1M=2BB.UW
MM90Y0^G!KYX_X4_XJ:R^(.@'P]8+J6LSW]S:>-#,HEVS+A(CP7']WTP<@UUO
M[/7PUOO!=]JU_J.D:EI5_=6EM:NEW<V[1-Y6?]6L*A>_WCR<^U82HTHQNI7*
M4I/=6/:O,?\ OL:/,;^\?SIO^>**\_?5&O0=YC?WC^='F-_>/YTVBE=B'>8W
M]X_G1YC?WC^=-HH =YC?WC^='F-_>/YTVBF@'&1O[S?G7S=\1&;_ (6%XC^;
M_EZ7_P!%1U]'U\W_ !$_Y*%XC_Z^E_\ 14==V#W9C4W/5O@O_P D_A_Z^KK_
M -'-7=5POP7_ .2?P_\ 7U=?^CFKNJYJW\61I#X0HHHK H**** "BBB@ HHH
MH **** (DL[>.=ITMH$G;[TRQ*'/U8#-2CY>G%%%.[ ****0!1110 >H['K1
M110 48'< \YZ?K110 =>O-%%% !1Q_%G'?'6BD;[IH ;-+':PR32RI&B\O(Y
M58U]"68XS7,>)OB5H_A>Z\.P3/\ :8]<NVL[>YA=#%&50NS,<X_A/YURW[0G
MA+5O%WAW0UL-+DU^RT_5H;W4=%B=5-]:KD%<-P>2"0>N*\:O/@WXDDTO2[J3
MP++/HB^*IM5'A/S$#6EHT)0(PW;1N;'R#@9'/->GAZ%.I'FG(QE*2^$^G-4\
M<:!H^I:-IUUJMO!=:M(XL@)@1+M&3ALXP.F>_2K-YX@M+.TU"6.:.ZFL8'N'
MM[256E&P%MN,_>X(&> 3S7R]HOP/UW2X?A]JE_X%_M!-/UB^GET6-HY)=-L9
M3N@1BQP55OF*@G;U%-M?A;XYO/&UYJ+^$?[)FDL]8M;A[2***"=I4;R KJ2T
MP;@EGZ$]!6KPM'F^,.:1]0Z7XFLM2T>QOW=--^UQ+(EK>E4FAW<_,N>"?:K]
MQ>6MO=16\MU''<,-PCDD <KZ*N<FODV^_9]UW6=%U7^T?#CW-]:^!K6STL32
M+F+4HVY"X/##^]5B^^#/BR^^) O-=TW5KN*:33)[?4]/6!S:>4B"2-G<[XQN
M5B=F<@U*PM%M^^'M'_*?1/BSXB:5X2U;0=-NV,UWJ^H#3DBMF5C!*8V8-(N<
M@8&/QJIXH^*&G>&?&VA>$C;R7FL:L&F$=O(H2WC3K(V>V?X:^?\ 0/@[XGM?
M'VASWO@F<ZE8>++C5+[Q5YJ-]LM7R(MGS9.W*C!'&*],^(GPMG\1_'#3?$46
MA0WL-OX>U&W>\&WY+QD(A'/.XYX(Z4.E1B[7OI^H^:3U1ZVVKZ>L,L\FH6L<
M,;9<K.FV,D=FS@$^A]Z?-J-G;PJ\UW;01L X=YE6-U_O*<\_AWKY<T[X&W_A
M?P5\,))/!#:_#8),WB308F5Y)KAD*I*RN=LNS.!D\;N.E0Z%^SUKM[#X6M?$
M7A_[7I5MI.L'['+*&2SDED+6<&W.25X]@:'AJ3U4A<[6C1]5QWUK=221P7$,
M\BX+(DP9L'E<@'CBN)A^,&GW&O:MI$.G:C/-I>JPZ3</&B[1)*A<2#_9 &#7
MF7P-^#^L_#_QQX1U2;19=+0>%Y+76)F=7+WOF*5#G/SG&[![ 8JMKGPG\477
MQ"UB^72I%L+CQKI^H+/N7!M8XR)'QGH,]*(T:7-*$I:6W$YNVQ]'_;8/W;BZ
M@82#Y?G#>9QV&<$X&>/6H[6_M=0C9K6YANHU)1FMYU<J>I&5Z?2OE2'X#^/9
MO^$IT6.U-AIN@V5];^$YGGV^<US-O.#G*E4 0$CO7H7[-_P]O?",VK7EYI.L
M:%)=6UO UMJ$-O#"\J+AWC2$X)ZY8\GO42PU*,4W.Y7/(]"\$^.]!^)>FO=P
MPP>9#=SVXM;[RVE#0N5+J#DXR,UT_P!LMY0N+F':060^<NTJOWFZ_,/ITKYB
M\(_ G7-%U#PCJZ>'FL=97Q)J<^J7@==_V.4,(P^#RARIP*S_  [\-?'TEGX3
MTB[\(W5C%X;TW6K%KZ2="EU)<AS$8USG!.W[V*T="$W=2)YWU1]4-K6FJKLV
MHV82,@./M*\9^[GG@U)+J%E'=1VD]Y;1W$A"I!).GF'/0@$YZU\EV_[,=TNF
MVL<OA,&<^"6ANSO5@VK[OE+C/S,%Z-VI?&7PM^(&N2>'[<^$3)<Z?:Z,8=4M
M8XGGW1E/M*23.VY&!#<*,&D\'1T]\?M'T1]9+J%HTRP"[@:Z+,%@:5=YQ][
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MY<$$5O'_ '(8PB_D!BI***0!1110 9]J*** "BBB@ _PQ1110 4444 %%%%
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M^!\7^-%%'U6/=_A_D'M)!_PT%\+_ /HH/A[_ ,#XO\:/^&@OA?\ ]%!\/?\
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MXT?\- _"_&/^%@^'O7_C_B_QHHI_5(=W^'^0<\@_X:"^%_\ T4'P\><_\?\
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2'D YHHKLPV&IQO9$\SEN?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>plrx-20211231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T(%!E
M=&5R<P    60 P "    %   $*:0!  "    %   $+J2D0 "     S(R  "2
MD@ "     S(R  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^^OYT>8G]]?SK-I*9R&GYB?WU_.CS$_OK^=9E% &GYB?WU_.CS$_OK^=9E%
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MX'/4(!U^M2^)]8_MJ^M]$TJ:0EF+2>4#F3 XY'\/O6SX:\,0:%"794,[9(P
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M_P 27VFV%BC)8WS6<W[\"6/:#F1HR/N$C ()Z]J;\5O$>I^%_A[?:GHXA\]
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M;XU-5K/M'_TE$4?@^_\ ,****XC4**** "BBB@ HHHH **** "BBB@ HHHH
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M$!V_-@<(".,@T =%J6AV.MSVL]T6DCA5P$1R%D#@ YQU&!TZ5IJ JA5   P
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MI6%8I#JZSF^:WW#J1MV>F=OZUSWPXT/4Y?'5A/LDL4@5YV,RE&E13M90._+
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M;^'_ #V6V-F@CCD9%.X,QR!R> ,>U8L>F^'I[4^'HHYY]=EU 0PZ@I_=%"V
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M444 %%%% !103@5YEX@^(OB'2OC%IOA>TT59M-N=F^8HQ=@WWG5AP O?([4
M>FT4@.>M+0 5EZOXET;0!$=:U*WL1,<1F=]H<^@K4KA?BX"O@B-HTWNNHVI1
M<XR?,&.>U '167BW0M1OH[.RU2WFN902D2M\S8&3CZ"M?=Q7.P7NK:AJRVU_
MH[:;$+=WCNO.CE9).%^7&0#ACU'-<EH^H^)&\8W'A/5O$<@NK:8WB7BPP#[5
M:XXB5=F X)RQZ@=.M 'I^ZC=7GLESXJU77?%-CI^NQ62Z8T;6I6S5N63=L;=
MGCU/7Z5EZ?XM\2>)]4\.VMEJ,>EC5M'GGF(MED\J:-E7<NX\C)/'I0!ZMN]J
M-U>77?B?Q5>6^HR>'X[ZZNM-N_LT,4=I'Y%T8\!S(Q.Y2QR1@C'O5W4O$6KP
M^)Q;7^H3:+YT\(L4D@1K6Y0[2Z&3!(DSN Y Z<&@#T0MBJ=GJUM?7EY:V_F&
M2RD$<VZ-E 8J&&"1AN#U&:XK^W]47QJEAJ.IS:=*^HE8+2>W3[-=VHZ>7)C)
MDQ@D;NH(Q5:^\:ZMHL'BPW4T5U)8ZE;V5CF((D?G(A!8=2!O[GM0!Z5NH#9K
M@[_5M;\.>+K#2I]3;4;;5K6<QRS0('MIHUW9 0*"A]#R/4UC:-XE\3OHWA'6
M[W58YX]5O!:7-I]F558,6P^[J&&WZ>U 'JU)NQ7.^-_$4WAW1();54^T7E[!
M91/(,K&TKA=Q'? YQWK*_M#6-)\?6GAR]U.6^M=6LY9(+IHHUFMI8^O1=I4@
MY&1P1SF@#>'BS2CJL=@DDSR22M"LB6[M$9%ZIY@&W(],UL;O45PGPFM)X?"L
MLTFH7,ZM?WBB&01A5(N'RPVJ#D]3DXYX I;JY\2:CX^U?0K#6TL8(;"&XAD2
MT5VC9F88^;(/W>__ ->@#N]WM1FO)K#QAXGUO_A&;6.^AL+B^EN[.\=;<.-\
M.1YBY^F<5NV%]KNM:QJNB0:XUM-HL443726R;KJ=ER796! 3H,+@]>: .\S[
M5G:KK]AH^P7C2M(ZLRQ00O-(57[S;4!.!D9/O7(^'_BCI4WA73[[Q+<+8WEP
M98V1(G97:-RC,, X!(SBF75I+=_&C3Y[;5KR))-#EF38L> OG1?(-R$[3U.>
M>.HH Z!?'F@-I+:D;J1+5;A;;?);R(3(<8 !7)ZCGI70[LC->3Z_JNIZGX#\
M4Q:E<).]EKZVL#"/8!&&B*C Z_>-:]UJOB/0?%ATR\U5+^VU#3Y[FVE-JJ-:
M2QC.,+]Y"/7GWH ]"W5CZQX5T37IX[C5M/CN)XAMCF!*2*/0,I!Q[9K@K'Q3
MXCMO!FBZ[?ZM%<3:ZUO90P&T54MY)'(,I(Y/RC[O3.*OZUJVMZ+KMWX?GU6>
MZAO=(GN[2]\N-)[>6('*_*NTJ>,'&1^M '8";2O#5C:PPQ>1;W$Z0Q"")GW.
M_ )*@^G+'\36J&S7EVC:AJVC_#3P'/;:K)(NH3V$,ZSQ(Q\N1!E%( P..IR>
M>M;4-_KWB>;69="U5--.FWIL[:%X5>.0I@L9<@MSD@;2,>] '<TF:SM8OKO3
MO#=[>VT NKNWM7D2%,_O'"YP/QKS_3M;UVY\1>&G7Q)+>6.H6$MY?6\,$/[D
MJH. =A8+DE<$YR.M 'J#'(K%U3PCH6M7J7FIZ='+=*NU9U9D?'H64@D>U<9I
MOBCQ5JO]C:MIUI?7$%Y<@75J]M&MO';L2-Z/G=N7CJ3GG@55N?$GBL>'?%&L
M1ZS"G]@ZI)%'"+1<3QKL^1B>0,,>G/OVH ]/M+*VL;1+6S@2"%!A4C& *HZ3
MX7T?0[RZNM*M#!-=MON'\UV\UO4[B>?>N1UGQ/KM_JNLV.@"^BFTR*(0_9;5
M)4DF>/?B4OT7! PN#U.>U1:MXGUZV^ROK5S/X=$]E&8Y1 DMN+DY#I,V#M&<
M8Y YZF@#TF2010M(^=J*6.!G@55TW4[?5M-@OK+>;>==R&2-HVQ[JP!'XTVZ
MEN%T.62&5%N!;EEDV[EW;<YQW%>>6WBCQ'=Z/X"=-2A2?7-R7DAM@=Q$;-N
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M7'^[G S7+6Q,JJLTCNP^#C0=TV_R^X]?HHHKE.T**** "BBB@ HHHH ****
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MTAMD02CT8 <BI]+T#2M$C>/1M-M+".0[G2VA6,,?4@4 : Z44 8%% !1110
M444A;% "T4FZEH **** "BBB@ HHHH **** "BD)QUI: "BB@G% !10#D44
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M$=Q9X77+(QKT^U6V7C_$?>7]:=P.AHJ*VNH+RW6>TF2:)AD.C9!J6F,****
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M7@6V@;,)DL]4154$R9X4CD;N",#K0,[;4O&FCZ3</'>RRJD3K'/.L+-% S=
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MYI=J_P!T?E2T4 (%48PH&.G'2@*H& H ^E+10 FQ<8VC'IBEP/2BB@!"H/4
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MLDBQ1L\AVJH)8GL!5/1]:L-?TY;_ $F<7%LS,JR!2,E3@]1ZB@"]136<+G)
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M[CE1N'YU:K$V"C..E%% &3(BZ#<?:[<;-.=\W4('RPDG_6J.PS]X=._8YI>
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MG,9D="IY))^;;ST]>@K*-13FH15[G=/ 5*5"5:JTN6VE]=3U$ # 4!0.  .
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>plrx-20211231_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g6.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '' D(# 2(  A$! Q$!_\0
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MSQMN,J1E>0.O P>]5&,I7I7_  _4-&[G=>*/$&IZOI=VT%O&\BNPMS$V[@G
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MVK7NA7['[5#+=%98-WWBC>GUKTKX:^ 3X3L9?M,CW$LI4+',Q?RU4= 3W/\
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MR[>V@D#AXMH^8\GG)(Z]JZ[7Y%^W;6.#MH-Z/Q%2VC58?F89QZ=:?M23>J$
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MC\);<ON0-\NT<@?UJ"0K*X=G+[3@Y.!_^JI[BU5K4S9PC8!Q[>@JG=)%-;C
M6)#QN8\\#K2!,I7&9+EMMMB(?>91G/'UJU\.9(O[=O5C.YE7!_,5GQ^=##\K
M-\QVG8QZ8ZGFM#X<VJQ>(+]Q]]XP2,\#D<5<-T34^!GJ&#13J*[3R#YR^/\
M^T5\/%\*^-/!3^-;?2O$9L[BRV%)/W<S1D!2P7'.<9SP":^9_@3<_LO2_#'1
M_P#A,H+>#Q.BE;_[>TY9I <EE*_+L(QC'I7T[^T%I_P=^'^F:KXB\4>'_#ES
MXANK>6ZMK>^"K-J$J ?*#C.22HR!WKA/!'BO]F7Q%X)TO5M5T[P9H>J75JLM
MQIDSH7MY"#E#QG(([CO0/H>W?L[_ /"MO^$)G_X5?]F_X1_[6WF?9M^/.PN[
M.[G.-M=_XA03:1?QL2 UNX)'7E2./>O'/V/_ (@>'_B!X!U>Y\-^%[7PKI]I
MJLUN+>RYBFP!B0$@')&,CMQ7MFJ#_09\\_(?Y&I?=$2V9\E:;X1U?P7I$=K9
M1_VM;Y9U=P=P#')#?0'MZ5C2:+XJTW5[C5-2OH;7PX,-]G2#! )Q\S>N37NO
M"]@!^E9OB"_L;?3WCN_+E20;1"Q&'YZ8KE]M)O8\3D2W9+X=,']E0"WE25 N
M"R<C/7FM=:YOP1H\FDZ?-O?*32F2./M&IQA?T[UTRUA)*^C-X[(\^^,'B"/2
M?"\\9LKB^FD4^6D)V_,.@S[U!\.;PZAI]O#>VLEL\\ *K)UX RI/J/Z5Z'<6
ML%RH$L22#_;4'^E9'BC299=*,NGA8[VW7="P&!QR5Q[BM5-."A;4?*[W8ZW\
M,:;IF9RN0IW?O#D#WQ7GOCGQ%>Z?K4E[##+<16O)AVG]ZAX4K]#_ "JU#XJG
M\5:A=V9=[6YMXPBQD\*Y7.YO;.*O#[3?6LIU2[AMG@7RA,'&TR'C R.YQ6L4
MZ;YJA$GS)1CH=5X;\3#6;=/W9BD*ABC## 8& 1ZUT*G/;%>0>#]6@\/ZD+BX
MOHYHG)A>3>"=P[8]J]-7Q%I_[L?:5)897!S6$X.+V-HO2S9L]>,9H'4TR.0.
MH93D'FG_ .>:5^YHA<T'VI0#FG4K]4.USA/C!']H\+I;J\T7GSQIYD*;MG/4
MCTJ_\,?$P\4>$;:]$4L14F+]ZH4MM.,@>A%=%J%H+VRFA90=ZE<,,@Y]J\6M
MY/$?PQTP:'IMK#/OOF:W"L2?).3L )ZX]3VKKCRU*?)U,'>,[GN$EU%#CS'5
M-QP-Y )^G-</\7O%%EI?A>[MIK:2_,R[&@AA,G7@%AGIG%)=?#6'Q!;RWNIR
M7+W\T!5$,[H(B1V .,@]P*J1>";+0M/M/ME[+/>PQ-##YDS2<DCDC/...M9+
MDB[WN7*4I*S1PGA_Q%K=I:V!U06< AD$5TL?$05E;85XX8$*/QKMM.U,^']>
M?[(F^&=?.FCZGDXW ?G53XA3>5X'LTEGBM+N:ZC <(H#;3DDC'8 _G4>BW'V
MK39O$MPD=M<LL<1+-D)$ARW_ 'T/YUT.*J1YCEUC.USN?$UC_P ))H:+;-O5
MCN!'3KGD>QJ]X7TEM'TF"V<*9%^\P'4YY/UJ'PC'_P 2<2AQ)%<.T\14Y7:W
M(Q[5N'*_E_2N)W2Y3OBK^\PW*V?7VIV,^U>:>*+[4M!\<+?#57CT];;YK)L>
M7P22Q..N*[?P[XCL_$VEQ7UC.DT4@SE&!'O^(JIPLU;8(RN:NWVJ.>%9X7C<
M?*PVG\>*D7..N:KWE]!9@&:98@?[S 5FM]"W:VIY-XCMM0T'Q986-@DL%NZ-
M+]NC. F&^X?8BO2/#NOQ:]:[UXD0[74'(R#@D?6L?Q1K>FWEF\'FQ_:'R(27
M(^;&?\*\C^'GQBAE\1SZ4+:2WEL9&COI",1JP)!QZY_K78Z4ZL;Q6VYS0FHO
ME3/HQ>GM0%'S&H;>=)X4DC8/&R[E(]#WJ;L:XNAU%W0_^0E%GU_I7:Q_=%<5
MH?\ R$8_\]J[2+_5BNRC\)K#8?37SM..M.HKH+/ECXU/^T3JGBCQ!I?AC0_#
M]_X+N5^SP"^*;Y(FC <,"W<ENU>9_##PM^U7\*?"-OX=T;2]#ETRU9C;1WD\
M;M$K'.P-G[H)/6O=?VOO&WCGPCX!EC\'^&_[:M[RUN8M1NP[J]E'Y9Q(NTCD
M9/.>U?/OP3^.7Q[TOX3^';/0?AFOB32X[7;;:O=23/+<+N)#$[^>I_*@#ZI^
M!=]\3;SPW>M\3[/3K/6%N<6RZ<P*F':.6P>N[-=;K\@&I1@J,,F=Q_'BO(_V
M0O!7CKPIX5\1WGC[S8-3UK57U"*QDG,OV>-E&5 R0H+9^4'@5ZWXAPUX@;IL
MZ4CHH+WK%/RLL"JX.,@FI85=220""<?_ %ZA@Q"&()(Q@9.:EC^;<#\HQR/\
M*Q.MHKR;OM14O]T9XYZFIS:CS [$?3O]:KPP,9')/ 4J1_*G>=Y<88Y= >O7
MZ"BX_)%QI&+9/S9[>E)'& R..,]C2*S2;&7C/)_PJ9FW2#:N%/Z4C/R(C")F
M9"<$'/H*E^RI&@ VM]*9&K-YH9_G7FE68C"JV]B.P_2@B[O8DP57IQTJ,HTC
M%!A4ZY)IWF-(N ?+(/?FF22;<%^1C\^*3#J+&!T!Y3FJ[,ZW!E#DHW 7%.A9
M6D*[AE^-O?ZU,8 N%ZA3G-279(BEF/G1CHA&2?Z5%M^T2$@M@'&#_GI5B1%W
MAQRHXYY'Y4Y6VL,KQZ]!6=GW!/L,SG##@#Y>/I38</N.<$=Z2+.UTQC<W&#D
M?6G^3L!;:6'>J41W[DD;*Q&5!QU)[U Q,DQWJ41>1CD?2F3>9&/-4<8QL]/>
MG[O,V88."N3@YQ0]!:;W&@B\4JR *GS*,5$T8<!B&W@9('7WJ=5*J3&-[CD[
MN*;)(F"2-LI';H14W*7<CC\DQEV3@\JS$9I&CSEC@;\G<.M))(&C08VG&&6J
MTL[2?N\'"\+C^M!=GT$:.XR(H\N@.=V>!4#R"W8Q,>(QR3GK[4K^?M1 [##9
M9>!D#M4SO;3J$GB\K>1ALY_ T6-(W2U(%!8EY+D#=]T;34\8\U@P*I@D9/M_
MC3[BV$+#_1P\8^ZR\CZTR%E>0(9%RQR,Y]: YE:R&[)%_P!8P$9/05#+'%N(
MV-LQV//6KDV(H6$B>8>S9Q5=9!)\GD9'4E6YJG:VAF4;B!8]A1LCT7^I_P *
MN> PJZY<@IB3:<XZ?>JC?*_EO#"!OSD#OC-:7@7Y]8N9-RG]WCWR" :(;HJI
M\#/1<BBDV^]%=IY!\A_M+?$C]G[QO?:AX8\<:J(O$.E+-:17(M9W:RD<#+#:
M-K$$*<$XXKR_PS>?L>Z/X>L+'49_[9O8(A'-J$MK=HUPW=BH.!GV%?7_ ,2/
MA_\ #G2-)UOQ=XA\*:3=?989+R[N);)'E<*I)Y(Y8@5\;M^T=X7OKNSCTO\
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MI8P:?;I#;Q)! G"QQJ%4<YZ?6GS;O*?;]_:=N3[<5YVCEIU.[9;FAH+ ZI&
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M#"D !NO/J/2I/.2[B$TBA) "#M&!]:<K64B?O;<B8\[E&5)__74$:R,$20$
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MZVOK*2WEU;"P-ND (@)RVT9]?:K7Q*\;V*W@\,S#?)>HPR<8XP=N?4BJFJ>
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M-G-,K12!@ 2J$<@-QGI7Q?K/A3]D[4-6DN[+XB^(](MG9C]AM;>8QH&ZJI:
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MUSPA>>#[BWNO(2UO-VZ1=H.\;E!ZDCI77:_^[U)'X_U>T_G0;T/C*L+!^!N
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M<TL2F1&RA*\J<=1[UZ)"<QJ>M?-OPU\5:GJGB+1-)EN?])L;AH[_ ,K'4 D
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M-OXAL;C1K/Y;F\#$1P< X;(X)##J.YK,D^//P[>UCOE\8:;]DD+K')YQ"R%
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M_"FRNM,^'VA6E]<F]NHK5%>9LY?  &?J *ZMONXS[5QOPW\2"^T&U@OYDBU
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M'"7($,A ZG% <K-C;[48]A6#-XLMHR56*25EQN55R1GUJPOB"#:"0P'3D?\
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M:I>0K7T*%WJ-_P#;2EBR/G]W\X)^;U)QTJMIMU')X@NA]MN;N[$8CD4J1$C
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M+/RV8JTC@G));(]\>U-O%\F:"1% DD*H2$!.WT/MR*M12B-Q$Z@%AN!4<?\
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MVF>*.=E-U+O:7O@#[OTQ6@TZ1QEF4;%&1\P!/_UZ5^PK:IA#,WFG(7R\8'/
M]!3)[=+I0S$!$.>.!]:21A!:I<R#;$Q&%R"1GN?6II)A!(?+@+[@I]N1Z4K,
M>A'-<VNFLQP%149R^W. ._UQ3-*F>_8SVY!LFY27D$Y[ >M/NM,DO(I"=T$3
MK^\; +;<'@#TZ5*LT=K90)"S(&&R/@GH,9/OBJ2MJ9WOL)<7<.GSQVF&\V5"
MRJJC &3DD^M#0D2))YQ0A,+'P1GGD_\ UZ+'3TMHRI=IW#,[22'<>>V:I7<=
MQ)KL1(Q;"#"L&(PQ/I]*&"WU*5UXTT^SD*37(=H_O%%R<CJ/K5"T^)%E<1RR
M1I*I7G:RYR.QK T>\L?#NLZ@NO0>:GG%O,5"4RQ)R1CDX]*[31;CPC>-YEE:
MP(;GCF'&[G'3%9\M];FTN6.R,8?%+3Y(C($G1%;!4ID-V&/QJQ'X5D\>Q17]
MT[6D8!$:8!R#W^M=O:^&=*ABV1V%OY8.?]6">M:D<<<:!50(HX  P/H!6RAI
MJ<_MDM(+4\\\06-SX#\+QG2Y^(GP_GL2<'N/Q-<_I7A;4/%EK]LU6[>.-22C
M*W)R.3UZ# KKOBM87E[X9(M%$@5PTBG^Z./YU)X-NXK[0HD18_*C4*=O]['(
M_,"HEI:QHIODYNI0T'PCI^CVOVF#S+R4]Y!SUK6OD_T6=KD(+=$4R1JH9C@\
MKM^A':K"S^<\L<3YN(\,PQZ]/PJ);.6XU"1V BC^]E6Y9AU##'3(%-'.Y-[C
M[.XD,0$=OLC>,-&0NU>OW<>PJ.V:19[@-;CRY,2L[R G<>JA?458C\^*Z$KN
MH@=%4Q[<'?GKFI5.V;:50)C!<<M^=7H20:>1=;Y8VN(T VE'48Z]1^50_P!G
MRW%W<-<BW2W&/LTL"D3+Z[C[^U6[B5[=7949T49Z\_3%-M;AKQW5HY(RJ@[N
M,<C(%1<!E]I\5[&$D<R$'=NQACVP"/3^M<U-IYTFSGLTU2>=(\S_ +Z9C*H)
M.T9_NY_2NE-J/M2W'G3<*5$>XE3GN1ZU5U#2DU#[3#=!O(F14\Q"5?Z$^@)J
MT[(:'6=P+.WQ<0022R#S-D2C.,<'..M5XM=O+YHE2U\J,MA]R@, .E4;>/7[
M?7(H3'8IH$<3(&C5C+D8"C.>!C/YU+<6+?VN;B.]D1S@&+.%/'4BEI>Y=A;O
M-NUP[SSE)5VXW8 SZ"CP/I\,&I1.A+[(&C#2-N;E@<$T:UI_]H613?LE4A@5
MSCCM5CPEE=4"LJB98N=G ZBI^T@>QWF#[44ZBMSF"BBB@ JO,&Y],58J"X^[
MCUYI,#YH^)FD7GB*R,>F:L=,U:*Y8Q3P$<,&)P>/;]:\RM?VA;W0M4.C^*K!
M;N.SC(GO[=3YA(X+*?;/I7T3K_A^R>\DDM2(+MG:7RU.!(PR,'CN:\_U+3?"
M^H.]QJ5C#]K\MH)"J\\<,N,>IZU*G[-6:NCR8VDW%[CX;>S\:>'4O[L_\)!X
M>D7S;=E7]\BX. 3GK]:\DE^"]_X@OKB[T"^$>GR9CBMKC="T8)&.?XL<]*O^
M$?&MQX#\3:_9QV\=CX?TFP:Z&F";<)LD!6R>A/H :V8/&WB#QB7U+2?#J?V<
M7C$MK.S;]I&2T9Z 8]!6SA;WGL.,JE-VBSG_ !!^R)J6J;U^UPRQB%0GS'.X
MD%L?A7,_$KX8>.+:ZT31M$MK[^SXXO(:.%QM+ #DX[9SUKUK2_CAH6FZK;6D
M5OKBSPKL:Q: N&)& -WH#71V?BCQ%9+<ZA?6$5I;7#?)-U\D'HSCOQ[]ZSE'
ME:YK6-_;5MV<SH?P&\.^'?!&E7WBA5M-0C3_ $J1I02?8>^#VK<T?P?X*^#<
M<EYHK,T]V,CS#OPIYP..IS6OXSU;1X?#]G<^(=5T^[2-@T2HXP7/(R,]?PK)
MMI-%UB2"[D5[B>,#R=/*G$@QD,3CA0*4;/7_ (8B3G):DVD^)(M7C3(6>VFE
M9.1M902.Q]/:C6[?3+>.>:^6ZECM TD4BE@%VCC: /Z>E:?AS5T\:P->?V?I
MA%C(RP[ 00X)!7W'2KOBCQ!X@TSP_=:@+>TNC N[[#&C$LHP2 ?7'M4*,7+1
M_H2Y6:5CSK3OB\WB;3].D,%S-:R,P2-U)8$'&2,=/K6-\4/"]S<;[O2O]!UB
MZV+]JC))=<C*NH/*G(Z>E>C6/B#7WTT/I'@VST^)FRHOI &Y/+$*/7M37U[Q
MY:RN%T?1',3 BX5F4L">0!V(^IK7V<:<[IK3I<KVO,[6/!;W]I"[\-M=:1JU
MO]IU:P_<K#;Q%8"RC + \G@CH:ZOPI^U5<F\M5\1:1#):,N$GL8")86/ 8#N
M #VI/$7C+P#XJ^(4L5YI9TCQ,VU6\Q5*7# =O?CJ36M=6^@>*+6W6'99W]DR
MG#H%(P<XS]16-1NG4]U:,[8JG*-I+4R?@O\ "^QU35M;\7ZXQU>X^TR&WDF1
M@=@).XJ?XNGY5V'Q2^+6C_"GPO%)# ))'DQ%;J!N]P?0$>W>M.'1]3L+[[/9
M:HULEQ'YD[NH9>1]X<]?K5[_ (0'PZL-M!);QZK/.K22W,\1<L03U/I]*52?
MM)\\]CF>FY\O2_$SXA:NHU[1[A[?2IIL6MDD18,0V, ^WJ:^B(_&VO?\(_%I
MP6.YUV6-?]4^U=Q&<$>H.>_:NFTO0M/MKAM-AAALHXQN2&- 1@C.X'U/M5R3
M3TL8IWN+2,%WQ!,BC.,=_>IYXO5HN=1-6BCA[SXL7'P^CTRT\6V%Q::C-"WE
M)''N$K#LI!ZBH=)^.UEX@D0/IFHP,LF%7:6W$] 1CI6;XUN-?M_$VD:V-6M;
MG0(SF?[8BM]G*D@!,\Y-5[S]H*7PUY&H'1K6YTZ:?[.FHI$$!)XP>.HSWIU(
MPW7YE4X\RU1I>-_CPVEK<6L=E<V#PM_KI(<JW< ''4UX;:_%3Q?H?C9_$6KB
M6YCD51'9(^W:K'"DC'7!KZ2L_B9X-TZW2'Q%J&GSO=MYH\N(.BLQR S=B >]
M?,7CJ[BT_P")6GWT>JP>)],FO6\F"!<$J3@(3]2!TXK-P;A>*.J@XIN,HGV=
MX*UYO%&A6VI?)BXC#+MYV\=_<&HM-O!IFN1V5_Y.+@'$\2X.[/0U1\(QQZ6M
MO#;Q/;6\D!>.U4$B,_Q*3Z@^U='I]O#J$8GFM/*=6)"R $Y]13A+E6IY51+F
M=BMXBT\6LB7D2(;A3L2=^0JGJ?\ ]55]'O9;D1N0)X&BPTZXR&!Y##TQ722S
M6\UF]M=1"6-^#G'YU1>.PTOR;>(I$LA_=JH W$#Z=:VD[Q21GL<S#:6GC2&X
ML-5T^.[&3MD\H[&4'CKW']*S&^$6DZ9?/?Z;8VMO=JF$9HPP'(YQ^%=Q+=-;
MW44<-J\CD[6(P H)Y-5M:EN8[K]Q)&B1HQ59&VAV.1@^PJ-=HLKF:1G6S26L
M<L)F6XN54LA*\ GHO';-+IUYK<UBYN8%M[D';L7(# 'J.3U'Y4UM(U-])BA9
M8;>65LRR0,20O)R/I[4V^CBM[*W6:6=R'#*Q8JSL.Q/H:N-K69$G*6I=M-6M
M=0C$4@;8XR4D4JV00",?6O9;''V.$ 8&T >W%>1P^1PT\2)&KJT9<Y&3@]<]
M<UZ[9,&M8S[9JTT]CKPR>K+-%%(QVC-4=HM%>6>//CMIO@WXH>$O B6%SJ6N
M>("S(D#!5@B7.9')[85C@>AKTRZ9H[=W1/,=1E4!QDCMF@">L;Q0S#33M&3O
M7^=<3\$?C=I_QITO5Y[6PNM)OM)OGT^]L+L@R12+[CC!Y_*NR\6M,FFJT(RP
ME0L,9^7//>@N'Q(YAKB7RYTCEC$^S*C[VS/1C[9I?M1B6WCDP\^-I8+D'CJ>
M>F/RJEX@U*PT'3YKNZ1Q"R^4[11%SST!*]JM6,MO=VEL8U\L[1M!7!'&>A_K
M63W/26UV6_.N+<SQ%  &_<XSCE<@G\<T64DJ+LNH<;?F,FX$'UP*@O[=I-A>
MYN!-%Q^[(&X$Y (QTJ4Z@C2)"8V7?&6DWX!4 =2:FW8S8Z\N/M#6;0*&B65@
MY;@].P]*NM%%*NV6-9 .@90:SEN(([<A/-DCZ!?+^;GNIQ6WIMFHM8I&W@ 8
M57Z].].S,VTM"-=+7RQY<:A!QM)XZ>E.C@FDN';RE$702.2<XZ\8IVH:K%:X
MW;EC9MH8+Q^=0ZK=7JI&;98I(\'S [%<<''YG^=58RO)Z$D]Y%<QA ^]&.,I
MT]_TKD]#DUO3+345U..*9A=/]BCAX(@ &W+>N<]:W+/5$%JIN42W<;58*N%W
M$X(!J>6Z#6+3QRQR!20=R[@,'GCUQ2-$N4J6]O\ :M2@O!)(ENL+1K$&PI)(
M.6'<Y!HU:.ZF9+>U0.,A@S,0W49'3IUIUI=!I%CMXI#;R1F7SU3"CG&WGOFH
M[":>Z=X[N5A<QL2FT !ESP#QUZ5&ZN)DLFF"99XIRLBR<@,H."!VX]:\_P!<
M\"ZE8WT<VD$N6.59I2!NR20!CBO0/L-P+^26,AX\@JC9!5B.<\]*O,CS0H"K
M1ECEE1@2I'4Y]*BSZ%1JN'F>86_C3QCHHF-Q%'(D9YW+D>F,^]=!:_%J>UDB
M75--:!60,9(R<<@8&/QKL)(8?L[^=&LH"\_*">.^/6LR:STO5K-HUC5]W3>N
MU@P]L>U4N;N'M*<MT:FD^(K#Q':M]GDWCHRL #[\5PZR/X#\5&UG;_B5ZG(6
MM\8 5^X/YU!KO@V\TO[/?:&[)/"Y9ES@MQR,>E:UOKVC^+K?[%JYCM]0MR"1
M+A2'(^\I-5'WEJ7R*/P:IG0R^9<W<$T*Q)"RDNYX?V /YU=D2;R2\(7S57 W
M_=^IK@=#OI+/6)]+_M$RSG_484,F,\Y.?2NXO )[.XAP2A7;P2#[D<TH^9SR
M7+H4](U8:TI&S]Y"Q5P4*C<IP<<]*T58M,4*J".N>_IBF6MO]A@BA4?=[]^@
M&3[U%=::MT$+3&)U8-N4<\=C[4V9]2":Q::\AG+O!Y+?*JMD/D<AAZ=*NLI;
MYB#O'&,$#\LU*RB8@/\ O2IR.@IBP@322LS MQMW9''I1T"P]$;RVVE20.-P
MS4#1CR1YJ&67;SM) /TIT@^3,8!?W(IK,<8 8<YP"#1?H%F4$V6,6U3(2>5$
MS9ZGI67K%U'+#<*T3072#*R;<@8[UK:@!.JK(N0ISP,L#VQ4<;)<1L-K*P7
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ML6]@MY)M'$GEMI<BJ0T9!!R?6NQ\+_$30M5^*6E:QX?BF&GZM;$S6!&#;R(
M"1ST/-<_L^5-IE2C4CK(^@='L388B5 R(-^X*,+D<@?E3M1U&>&2*"S"F9BL
MC>9D+LSR<^M,M9+'6=0CNK=IMX39N4D ,,[E(]1]*OG3([BW\F;$KYVLS<#
M.1T-1&+6K//;N]#$FDOFMYW<1+&C/&R@X,F "#GT'^-6=+\0--'(3:M&L<:C
MS(B&Y;@# [?YXI)]%BD62*XNEVLK1KSS'NX)/X>U/M[ZPT^$VUH&D>+; =H
M9N@!QW K2-K;:BD]=RW9*JV<MO<2-=2ALD/CA220"/PJNUG_ &Q.T,GFQ"UE
MW($& XP"#^']*AN+R*RNHH(8=MQ-\I."1@$\D_CW-,U".Z:YL"/.C'F9^T0D
M8&>Q&>A^E)!I:Y;738M3W37]LL<V2@.=Q90<@9XI8[<R1RQ-$L E^7 .2,#
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M;$(P <#(ZGT-2MU<U>D3N-P]**3+>U%;G*/HHHH *KW&>OH*L57N,[2>^,4
M>.ZA:W37$[>=%;(CN=PR%Y;OSU/]:GM[R*.R1S*",9+*V1[\YKYG\1_'#Q!!
MK&JZ58:6^J@W4T:1C<3PY&<UW'P>\=:W<0P6?BG3(=/DNMPM!DB0CIDJ?>LU
M#G3=SRJN'G3=VCV6UU(7%I]IMCYJ$?= ()YQ3M0M89)DOHQ^_1?F1<98'U]Z
M9ID9BMS$Z&(C(7//Z^E/M[Y8G6-X3&78JNX=<5";V1S]KC&NBUN6MPIEVY"'
M@]!Q6<T)\M+Z12"%PUNQ&W)(R>G8U:FAD60F!<RYW-GA6]L]L52U!TTV$2WT
MDC.VXJ8@,*#V(_#K0M[ [O8O:AI=MJ+Q)(SHRGS1M&1],XZ9KSKX@^&YH-)F
MDM]!M/$,$).+*[0%EXY9&]?_ *U>@V.O17&H?8F!1&A\Q96XR/KZU#-I266]
MBS/:2923<Y)PWIQZ_E6L;[,N+<6I6/F3X*^"]8\+^/I[VQD_L_1-8+[;=6RP
M?.2I7_9)ZU]/19TF%(7E,MVS95)6 +YZ@>U9>G^&],T;4Q) L,%P$)*N>".Q
M4D]>HJU>+91/#=7,ZSRELVQ<DJ#V&1V%*;YY7+E-3]XOW6AQZOI,B7%A#(P;
MS#;.Q 4]B#[8KD[;X0^%;K5?M\-G')+.-TTJ,S*6!((SGZUOZ#JEW:S"WU$2
M&YDW,)!@Q!0> #Z'WKH=A52\01,C "C SU)(^M3+EZBA4G%>ZSC)?AIH6CJW
M]GZ);N9I!YA9 V!DY(S6O:^"='M+=H#91M&QX5D7 R.@X]ZMV$\]LI:]G\^1
MF'RQK]W)QT]/<U8N)S?3/:VSM&\;9=I%(7;GG!]:7LU:R+=64G=L\/\ C/\
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M*ZO'';VZ1DB5" 0!R>,>_I2=I:/4:;331\X_&WX6:@EY+XO\&NUK?3KY,]F
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M*<,?X20:](L4\NSA0=%4 9]A44^:WO&E.2DVT6J***V.@**** $QS5#5H3-
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MSCI@>F/0U:\,7K7>L.[2H_R$[5 &.1P1ZT1>MBW\)V_/K13L_2BMSD%HHHH
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MN77@MKKR]UQS&P93M/4?C4__  BLG'[\9Z$[:GE:=P]E/:QR4VBB>9KNWNS
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+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>plrx-20211231_g7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #M =T# 2(  A$! Q$!_\0
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MUG3[+RG6.3[1=1Q[&;[JG)X)[#O4VJ^(-+T*UCN=2U*ST^WD8(DUU.D2,QZ
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M5\!?LJ_L ^&?$?PT^V_%;PSKD?B#^V[V=M&O=4GBLY(A.QA9K9'\LAEP>G-
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M&MU>3&?1-.O-.BL-B&&1;@Q[F?(R2!& !TY-=Y10!66R1(U1<*J@!548  Z
M#TJ>-=B@9S[XIU% $7DCMQ^%-^R]1OR#V(XJ>B@"'[/_ +1.>M'V?Y<;B1Z'
MI4U% $#6H8YW=L8QQ2BWQ_'T&!QR*FHH CBC\I2,YJ2BB@ HHHH **** "BB
MB@ HHHH 1AN&*:B%>^?PQ3Z* (WCWMG=BF_9_FSN)]?>IJ* (UAVL#NSBGD9
MI:* (VBW,#NP1TIOV?\ VR34U% $2P;?XC2?9_\ :_(5-10!";?)SN(-!M]P
MP78^M35F7NNV>GZA96=U?6]M=7TC16D$KA7N'52[*@)RQ"J6X[ F@"]Y/^U[
MBN=\!?#G1/AGX?.B^'H'L]/-U<7K(\C2%I9I6ED8EB2<LQ/MTKI%8MBGT 0?
M9^N#C/7BG+!MQ\YXJ6B@!LB^8I4]ZCD@WJ!NJ:B@"#[-QC<<?UI?LX P#@>G
M:IJ* (O([9X^E)]GZ?,:FHH :J[1BG444 %%%% !13'D$?6G*P89% "T444
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M &5= _9YUK6]2TR_DU6ZU94\R2YMU1H&W$NL1!^6)ODQ'_#LZ\U[U0 4444
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M]B?_ ";BH ^A+?\ U:_0?RJ2HK?_ %:_0?RJ6@ HHHH **** "BBB@ HHHH
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M =U^S;_R;[\-_P#L7K'_ -$)7H]><?LW?\F^_#?_ +%ZQ_\ 1"5Z/0 4444
M%%%% 'QQ^Q3_ ,G(?M4?]C7'_P"@R5]CU\<?L4_\G(?M4?\ 8UQ_^@R5]CT
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MX#=%;KCI7SY^WTV[]E;Q<1T\RR_]*XJ /H.W_P!6OT'\JEJ*W_U:_0?RJ6@
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MOL]ONFOCG]NW_DK/[+7_ &4&'^2T ?8D;%@<C'.*?34 7('K3J "OC']EO\
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MI^-+36Z?B/YT ?'G["O_ "6S]JG_ +'D_P#H+U]BU\=?L+?\EK_:H_['D_\
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MEBF!PK=?2OO.B@#Y-^&_[:G@CPS\//"NCWN@>.4O=/TJUM)U7PI>,!)'"JL
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M?$W[9WC_ ,(:IX@M;CX?:'>Q^&=;TW0-4^SZS(K2W-Y&"GV?='C8KGEGQQC
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MJ2_ZU&POS*^!N!X/>NSL;&'3X8X+>-(8(D$<<4:A510,!0!T ''X4 6:***
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>plrx-20211231_g8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #> ?0# 2(  A$! Q$!_\0
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M .">?_XFC_AYY\!_^@UJ_P#X)Y__ (FG_9&8?\^)?<P^M4/YU]Y]7T5\H?\
M#SKX#_\ 0:U?_P $\_\ \31_P\Z^ _\ T&M7_P#!//\ _$T?V/F'_/B7W,/K
M5#^=?>?5]%?*'_#SKX#_ /0:U?\ \$\__P 32_\ #SGX$?\ 0:U?_P $\_\
M\31_8^8_\^)?^ L/K5#^=?>?5U%?*/\ P\X^!'_0:U?_ ,$\_P#\32_\/./@
M1_T&M7_\$\__ ,33_L?,?^?$O_ 6'UJA_.OO/JVBOE+_ (><? C_ *#6K_\
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M_P"'EWP,_P"@SJW_ (*)_P#XFC^PLT_Z!I_^ L/KF&_Y^+[SZHHKY8_X>6?
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M445YYN%%%% 'Q7_P5H_Y-ETG_L9[3_T1<U^1%?KO_P %:/\ DV72?^QGM/\
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MA_0_ ^A^-- N(K2\^-FMZ/J>HPKA1;06GEFZ4D]FN3DGZUX/^W/\3M4\>?M
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M+VRD5A(Q!]Z]&\)^/(;QA!<L%8]*[,/BJ]6;A)I?+_@B>58;S^__ (!Q]O\
M [Q/<\1BQ)_Z^A_A3IO@3XK@.&CLOPN@?Z5[9;-R)(F^7VJZ]XS$9.>*X\;C
M,PPLKPY7'T_X)2RG"[._W_\  / /^%*^)LX\NT_\"!_A2_\ "EO$PX\NT_\
M @?X5] C;(P(ZD4\1CD5T4<TG*GS2M<EY3A[]?O/GF3X+>)6B<!+/H?^7@?X
M5^XW@2![7P/X>AE_UD>G6Z-@YY$2@\U^6]TH6-@.N*_5'PM_R+.D?]></_H
MK\^X]JRJT,+)]Y?E$];+L)2PKE[.^IJ4445^-GM!1110!\_?MM?\DCL?^PQ!
M_P"BY:^'8HLM_>]*^W_VWVV_"&Q_[#$ _P#(<M?&-C9^7&'D&6;M7Z[P_B(8
M7*%.3U<G^AP54Y5"D]NQ!+# ZU49TC0LSX'UK0\2:Q::/8F29U0MP%/4UY1K
MWBR:^D MB4@Z%O6OM\LQ5?$1<WI$PE'7ECN;^M>-8+)C' &E?/.WM7%:QJMW
MJDS"=RJ%OW>/7M6E)I?E6X!7)8>9O/OVK-M+A(-8MXYP-FX8+<G-;4\=AL=4
MEAX*YZM?*ZN%HJM,[OX:^&YK35H-4N9&\U1@KGK7T-IUJ+B%&)QQ7E/AC9(R
M@]*]8T=E,**&[5^%YQ#V>(E%=&94]4:4:>2N$&ZI6N0N-PVTJQE5)ZUGZEJ"
M0)M(]Z^?2YF;%;4[P)R#D=ZPKK5QNP*KZQJAY*].]8=GJ"SS,SYPO3ZUZ^'P
MDJBND92D;+73R#)8K52X:.1OF8FF&;SNAJ&3![XKVZ6$A#=&;D*;EH>8R2OH
M:Z#0M222/.[GTKE65MXJ[#-_9[I(#PW45&.P4%34H;A&3OJ=;<W7F-BO&_C'
M\+T\0QOJNG*%OT7+HO\ RT'^-=S_ &P9)"PZ5.+IIH22O?K7B1H5*5I-&M[G
MQ\D(M9I(KJ(QR+D'(Q@^AK,;[Q'&,^E>Z_%7X=C5%;4;%=ET@S(JC[X]:\1N
MHU5EV*R%>'5NN:]VE6459F319MM+$EF+CS5.24V9P:S&B=9MHXP:=NDW ;SS
MVS5RSCQ,I<??4XS7K\ZE#1:F94,:R#<#G!Q4J*83D%D?J".*LV=K!/9W1+&*
M91\GHQ]*=';G4;BQC>3'G+MW#H,5S<S<K,HZ;PO\6-<\,$(T_P!LMO\ GE*<
M\>QKU_P_\2=+\70",/\ 9[DCE&[&OG"[@6WFGB8_O(V*CT(I;61K?9+'(\<B
M\AD.#5T;1E=B9]-RHI8JQW'L:BVE>AS]:\FT#XL7-J$CU)//C''F#KCUKTW2
M=4M]8M5N+:42(W/7D5^F9+7>(O)O8Y*D>B+J2=1BK/EKLR#@U65LY%2?,5(!
MKZ:=.ZT=B824;\RN?4'["LQD\4>*U)SMLX?_ $-JY#]M/CXU+CK_ &9!_P"A
M/74_L(X_X2WQ:/\ IR@_]#:N5_;68+\:%XR?[,@_]">OS.A&GA^*ZSAI'DO_
M .2Q.GXJ&IX/-(6P%Y-6(+1X>6Y-6M%TUIG:=U^4=!6S-:(L)8XXKU:G$$8S
M]FE=,B,''WD[,YJ2]2S9_,X"C->;>*O&K:A.T,!_=YVY%=IKOF7\DOE#Y1A1
M[UA6_@6"&\D:0YC^]DBO$SK-L+@<1",E:;5VNQ^AY'EN+S#".I]FYS]GI\EP
M8F?(W'FNV&BV-G$S2/G: ^,57^T6D<B(FW .!Q52>662^D53O$AV 5^78_&/
M%UXU(:'Z?@L(L+1<):F9-X@DDO'E3_5Q<;>V*ZW1]4&N6+\?ZE=S5DZ3X0%Q
M-=(YP6.,5TFF>'CI*S1QJ2LHVDXH>84LLK0K4I^\+ZC4S"C*E5C[HW277SHV
M(#1N>#7HMOI]O>0JB<<=J\UCCDTYMCKPK<5WOARZ\Q5.<\<<U]]F*CC\'3S*
MGHY:/M?N?A.8X/\ L[%RPW8S=6T6:SG9=NY>H-2:'9D2%G3\ZZJXF613N4,?
M>H8X4:/(7:?2O ABI*GR-'G<NMS:TV\@AM0FU0<>E4;ZX6:0\ BEM+,R*,&K
MIT<"(DGG%>5[D)7N:',:K;Q7%NRD8XSQ6$NBB91@\GVKL;FQ1<[SQ1!#$K J
MHSVKT88J=-?NV1RI[F#9^%V$9#')["N9\6R6^AV\DDQ$9 KTUIEB7/2OEOXU
M>*I-2\0S6L;D0Q''!ZU>'J5JM923!I)'*>+?%DNL3,D;E8P<?*>HKEWC^Z6I
MTF>6'('6A;A9GP1CCBON_K%2,4VMCEY4.D"R; .E2_-!(K1,01Z4ME$+QP!P
M(P2U"L#M8'CFHIXJK&7M <5L>@^"_'QA9(+IR0>!FO3K>07*!U/#<BOG%5$<
MVY3CC(KV7X5:T^MVK6C\R1>OI7M5,S6(I235KBULH]CL87*-@FI_/[=ZT)-*
M4KD<&L^2$QRX(P:C*:D*TO9LF<7T(;IL1L?:OU4\*_\ (L:1_P!></\ Z *_
M+"[C"P/GGBOU/\*_\BQI'_7G#_Z *^?X^<94,+R]Y?E$WP\7"4DS4HHHK\;.
MX**** /G_P#;8 /PGT[(SC68#_Y#EKXIU;7H-'TZ2XDZ(N<5]I?MO$CX16&#
M@_VS!_Z+EK\ZO&5X;NZBM$D. WS*._M7ZWPYA*>(R^-2K\,7)LY>652LJ<=V
M<YJE[<>)[C[;=%C&W,2= HS2_P!BLT4?EN"C<\]C6Q>Z:]O;Q9VK&, %:K3:
M?M;=;2,&/9NF:]'%9I7E&T-(KIY'W6#RO#TK)ZLI-)<0'9,6PQV@MVQ67JD)
M:XCN(L%XSDE:Z.X;:$BD!WH<ECT-4&M8Y9I&B 56&'7^HK#+*BP];VRW9T9C
M3=>C[%[(V_!7C)UF6"Z;;(3E6[&O:_#NN;@A,F?2OF>$K87X4X;9T/KFO2/"
MOB99B(QDE>OM5\09/&M%8BBM]3\ZBW3FX2Z'T3:ZCNBSQT]:RK^,Z@[$_*J\
M9KG]&UU9+;:7[5I6^H![?Y6[]Z_+8X><*EFCJYM#)UFU41E1Q7/6<9CW@C^*
MM_4-\S$!LUC2;K>3+?=)P:^TP*4*=NIS2W+L.%7/2J]Q(VX;?RJ[;JKI5>XA
M&_(&:NE-*J[@]AB[67)^4U1O;EIGC56X]:+YS&A["H;"W:1BS<$\BO;IX.G[
M%UZC]#+F=[(UX;<>2,#FK=O(!'M;CZU5A#*HYXI7)S[5\[4IJ=XO8V3&3*)+
M@HXSG\B*\3^+G@$Z1='5;*(M92']ZJ\[37L]PKE@RGE>HJ.Y2&_MG@N$$D3C
M:RMW%>/6H<CTV-$SY*;'FEP N1P.U&GV\U_)]GB7,@RP'<UV7Q$\"?\ "*7S
M20%GL9"2O^Q[5QD%Y);W,1MCME5LJPZUZ^!3F[&<AOG/& F=K*WXYIZR2H%V
MEE.<BM&ZT^5[AI"J^8XW/SQD]:CM=+FNHVDBR_EGD#M[U[=+"<T]49.6A!<0
M%FYS)+W;WJ*0>3,(I#L/1O:K.FW0M;YV<\)DE6'6J=W<"ZG>4_?8Y-<\L&Z<
MVWL5S:$TD:^8(X\N,8W=C6GX7\3W7A6\#*Y>!C\\.?U%,\/:>+I9G=UA3:0&
M<XY]JSN8WG1U!_VJZ</C)X-ITV)QYMSZ&T/7;77+%;FV<,".1W%:5NKLW[L%
MZ^=M"\27GAN\$UJ^8\_-&>C"OI+X;:O:^*M%^VP<'.)$[J:^CQV?06'7)\3W
M,HP;=F?3'["Z[?%OBSY=I^Q09_[[:N2_;.95^-RENG]EP?\ H3UZ+^QI;K%X
MJ\3NHQNLX1_X^:\V_;4C,OQL51U_LR _^//7QN4R>9YY4YG;FA^D3>?N4UZG
ME:ZM%:V("XX&?K6-<:I<7Q*@[(^X%0S6\OE],KBK&F^4JA)"%+>M?5XS"X+(
M\)4QJ?.X_F=^4X.>:8R&&[FYH/A:35M/:>*/*+[=:XKQ==2Z/') R;'8XKV#
M3=4A\(^'1"Q!,AR"?>O(/&BR:_//.BY3/WAVK^3J>.Q>=9I.MB)>ZWNS^G,+
M'ZG1E3HPM3BK*W4XZRD$UQ'\WS;^E=/X=T&;^UI)Y=Q6,\ ]*Q=+T<1XF#9D
M4@A?6O5?"%C+=7T33Q>4C@,P^E>]G./6$2A2V2W(P=->SE7K(ROL4L%]&JJ0
M\I[5ZO!X%SX?M[N3C)YJOXFT&&$V]Q"H#!QC'I5^Y\4-;1I92/A% ;;FOS'%
M9EB<9&FJ73<SJXNK54?JRMKJ>9>)O#<\-W,VP^5_":S] DECD"*Q#9QMKW*[
MCT^]T%W8*[R1D@5XC#'Y/B9-O"%N?PK]OX(SRIFN!K9355I4_>3[VW7]=C\P
MXPP4:T5F4%:2?++Y[,ZB;SH6C#?Q5K6*B1@#S5M-/6ZCCD'.TYJ[9Z7Y<@8B
MO9E65FF?F-@:5+5?*0?/CKZ4^QOPVZ&3D]FI8--ENIY)2"%!Q40LS;W17'7O
M7G7YF65KY1)(WIFLU6RS!,G'I6Q=6Y56)XXK,TFU+PRNW<\?2NZ,[(DS+Z:5
M[=PJG/3.:^5?B-;"/Q-<C.3NKZ5\0ZXFEVMR\A"*N:^8?$E\NJ7UW<,<L7R*
M]S+.=U4K:&4]CFI-S*P5>GWJ9\JVL9QAP3FK\:IMDR<%A2W5G&MG;LAW,Q._
MVK[^LDZ:Y5H<JW*%G<&%)@O'F#%.AADD9449..*T+/3VO+&=84R\; Y]J:S'
M3;E R_,%S^=>=5]Z*BBT1VMN'5F9L;:[SX1ZM'I7B3;(0$F&*X*-QYC#.%)S
M_P#6JS8W#6>I1R1L<H<BNZAA(5H<C>Y#DT[GUS\LD>5Y&*Q-4@*L6'!K(\)>
M*6O-*A<G?QCZ5MSSK=QYZ UP8.AB,OQ5VM"Y24EH94S![=P3SBOU3\*_\BQI
M'_7G#_Z *_*FX4(KC/%?JMX6_P"19TC_ *\X?_0!6''CB\/A7#:\ORB7AY.4
MI.1J4445^.'<%%%% 'SU^W$VWX/V) R?[8@_]%RU^;ET&FN+MI?E<29#^F*_
M2;]MQ=WP@L_^PO#_ .BY:_.IM,=K>ZG=]Q9S^[[@5^LY-B/8Y)"/24Y7_ ]+
M*\/[;$2DMTC.6:211&[%U/S &K5I:73,9/+RG3:?YU2MX?L\P#9.#WK=6^::
M1<,J@#E0:]''893IKV)]%@\0X3?M3(O-03SPDT)C\L]QUJC8N)IGVKY:%LK[
M5N7EQ'?3I!)&KKGFH+>SMC<21PDQN <(>E*G16#I<U0<ZSQ=3EIF%-I3278&
MW:[ ^6V."?2I;%I=(D%SCY"WS'W[BNITV2"ZC^R7";'#;E?N#[&LW4=.N;62
M6VN%$EL[;Q)77A\TK0DJ;5Z?F<6)RNA5@Y/29U_AW6//CSRK'G%=?I=WNX/%
M<1X5C;[+#N )S@9%=G)((8<[0#ZBO$SK"PI5E.FM)*Z/C>65.3IRW1<N)OW@
M]*JWT:O#P15!KUY'P>1[5<6,-'N//L:\I148IK<16@NIH%VCYATJ>.XDF7[F
M#ZT^U5.> *G(16]*>L6T]P*<EIYAS(=U2*NWC@+5SRT;DU4FVJQ%=%.M*?N,
M5A3+@<<TOG[EX'-9\DR1]3WZYJ6,C&X'/I70Z46KHFY/(_!XYJD4);C.*E:8
M\\9I;>4'J.*B6'<J;NAWU,37M%AURSDM9EW*PQR.E>-WWPNU2QOI!;VS-&#\
MLGM7T-E=V0H'U%2L!(N#TK.E!X=J2&]3YMTW1TTV_%K?DHS<;6ZYKK;7PJ/#
MMXEPI5[2;AE_NDUUOCCPKIVIQ))<8AF0Y24<&L'7-;LK?P_) TZ_<\L29Z'M
M7W> <:Z2.66AQ7BGP6-/O+JX4XA==Z*/7TKCX[%WOHU,?EH2 Q/0"O85FV>&
MX)KG%PR1Y#-SNQWKRWQ!K U;+1H(<=0*\['+V;E"1<=2/7)E2Z%FA AAP-R]
M&]ZAL]/?49)HX6#R(N[;GDCVJJEN)O*_>?,W&/2E7?:[)(RZR9.&4U\?*3;.
M@B+,S$*,!>,&O3/@#XJ;0/%PL+A@+*^&TY/ ;L:\[41JP:;<7;D@=:07GV&Y
M6>!V1XV#K^%<M:,ZBLAK0_5C]C]=GBSQ0 05^R0X_P"^S7$?M<Z6;KXS>:!_
MS#81G_@3U:_X)^:\_B#5O$%PQ)W:;;L?KO.:3]KK4EL?BL03@G3H?YM7'AZ>
M)PN9.G2^-Q7XI%-J4+L\&U2)8$$:C+'BL[2]&?4=:ACR1$O):G7EZ)#YDDFT
MN<+4&E:P^FR$AMSGUK+C+%8FG@UE&'=YO67^7R/U?@K*XQC/,:KLWI&_YFUX
MW5L"V60G:.*XFVLKM%DA.XQYY:NHNK[[=()F^;/6L2^EDAAN8E<@D@AJ_-<N
MR>NJ/LX0U[GZG4QN'PJBG/1%GP_X;>;5(EC'F!3DK7J\;6_A^2#[0@5>%+&O
M']+U2?2M8AECF++QFO98;>W\0:,;F:0-O/RANQKY?/\ "XG!UXTL2O<:,98N
MGBE&5/X'OY,ZO[+#KVEM)&1PIVX_2N1OO"H\E+][@O(@(:,^U$-]<Z#:K:AV
MYZ?2L:\U"_CN,*6DA9AD9XKY7#X6K"H_9R]W]#GP^&JTYOV<O=_0ZG01_P )
M%H<\"_N;B,8"CKBO+FT^;2?$PM[K((E(#'O7T9\,_#MC\]U+*L7[L,RUX7\5
MKJ.X\:7$ELP,2S_*P]J^[\.<5.MQ%5PU/X7"5_N9\1Q!B%6P.+I=(\K^?,CT
MBVMHH;$'.5Q4,>H1+(%W5FZ*ES>Z?'\[%=O-+=:>R1LZM\RU^E\JYFI,_'SH
M+63<K^6,J3VJK=8%QUYJ;18WCMESU(IE\HCFYX-8+XK 4KIEV8;O67<7'DQ$
M1C\JGU28B10.1BLZ^N!#:EB,,>E=U-+2Y+/GGXS^)IO[8&FQL1N^9L&O*E3=
M,2QP#UKNOBNJMXTF?=EM@KD%:..X;/(V\"OT#+:2J4TTK,Y9NS*TMNANW9#F
M/M4S:5)'I:W.24DD(%27%JUG%$SC"R+N%5KC4I"(8=Q\B,[MG:OJ*]>-&BJ4
M5J^I@E=W(8)[BP9BA*@C#"IUMY-3BDGV[RN ?:IIX?MT-W=(-BK@[?PING:F
M=/M7C$>[>.3Z5X\Z4G=,TN98BS(IW87.#[5950LTFTYVG@TR2'<5(. W-7VT
M:9%& <MC%>CEJDIQ@NA,^YW7PYUH*39LWWN5KU&)2L((:O'/"6BR66I0O*QC
M*MQGN*]CCC=D!3YDQ7U=2M"-J=1I/SZD4^6_O(@N%W0N3U%?JKX5_P"18T?_
M *\X?_0!7Y67"GRW[<5^J?A7_D6-(_Z\X?\ T 5^:\=I*CAK::R_*)U4%:3M
ML:E%%%?CYVA1110!\_?MMMM^#]JQZ+JT)_\ (<M?GFEP6FE94^:09QZ5^@O[
M<^[_ (4Y9!3@G6( ?^_<M? D!^S7$H(5BP_*OT3#4Y2X>C*/2;_0^DX<G&..
ME&75&-<0%=Y<\GFN>FF-O(7+D'&*[&X@$UG)*#\^[!7VKGM5L1\KE00W4"OI
MLEQ"G%1J=#T,XP[C)R@9MO<%IBRL2<8SFNLM1#?6$88&.9>!*!S7/V.BM,Q\
MG..N6K9VW6E6#O/\T:#@#J:Z<TBZV(C!?"<^6R5+#RD_B)X[.>W5OEWCJ&K<
MAC35]* ?(VG\:Y:Q\1R3Q,)DVQ]5QZ5JZ+X@CGF:$ @'@ #O73@HTZM=4GLC
MGQDJE.BZJW9T&F_NY%4*1MZ<5TC1M-!@G%8T V[6/!^E:EO(S+C.:X,XG]8J
M72LHZ'Q<6WJ]V%O:B%CD9]ZMA<KUXJ"/Y6Y.!3FD"\ \5\[*'\IH"YC)(7(I
M0/,7D<TY67&",'KUJL]U\QVC(%$+U'IN&Q,MT(01VK.N]0,S%8QS275P/XV
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M62T9E).&5>GUKSV+Q%-#(-TFZ/\ E79:/XB6X5 6R"*PQ&7UJ,5.2'&:>A?
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M27T-6V-J:WT1M@V=N#+NVYSQC/6LOX=_%CP_\3O"=WXDTB:2+2;6\N[*6>\
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M:*7M9[7#ECV/.K[X%>'K_,+W6K+ITEY)?7.F+?O]ENI7N#<$R1G/20Y^7;P
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BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>plrx-20211231_g9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plrx-20211231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-C;W1T(%!E
M=&5R<P    60 P "    %   $*:0!  "    %   $+J2D0 "     SDU  "2
MD@ "     SDU  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?IOAXV/CG0]/M@[V^B:<RO*P.&)P!S^-9\E'E]U]/T_S#4]#HHHKA+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***KW.6DB0,5#-S@T 6**@^RC_GK)_WT:/LH_YZR?\ ?1H
MGHJ#[*/^>LG_ 'T:/LH_YZR?]]&@">BH/LH_YZR?]]&C[*/^>LG_ 'T: )Z*
M@^RC_GK)_P!]&C[*/^>LG_?1H GHJ#[*/^>LG_?1H^RC_GK)_P!]&@">BH/L
MH_YZR?\ ?1H^RC_GK)_WT: )Z*@^RC_GK)_WT:/LH_YZR?\ ?1H GHJ#[*/^
M>LG_ 'T:/LH_YZR?]]&@">BH/LH_YZR?]]&C[*/^>LG_ 'T: )Z*@^RC_GK)
M_P!]&C[*/^>LG_?1H GHJ#[*/^>LG_?1H^RC_GK)_P!]&@">BH/LH_YZR?\
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MQ#_T%9_TH ^@Z*^??^$Q\0_]!6?]*7_A,?$/_05G_2@#Z!HKY_\ ^$Q\0_\
M05G_ $I?^$P\0?\ 05F_2@#W^BO 1XO\0?\ 05F_2E_X2_Q!_P!!2;]* /?:
M*\$'B[7_ /H*3?I3AXMU_P#Z"DWZ4 >\T5X0/%NO?]!.;]*</%FO?]!.;]*
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MIU%8^@Z]%JT&QR$N%'S+Z^XK8H **** "BBH;HD0?*2"6 R/K0!-15?[*/\
MGK)_WT:7[*/^>LG_ 'T: )Z*@^RC_GK)_P!]&C[*/^>LG_?1H GHJ#[*/^>L
MG_?1H^RC_GK)_P!]&@">BH/LH_YZR?\ ?1H^RC_GK)_WT: )Z*@^RC_GK)_W
MT:/LH_YZR?\ ?1H GHJ#[*/^>LG_ 'T:/LH_YZR?]]&@">BH/LH_YZR?]]&C
M[*/^>LG_ 'T: )Z*@^RC_GK)_P!]&C[*/^>LG_?1H GHJ#[*/^>LG_?1H^RC
M_GK)_P!]&@">BH/LH_YZR?\ ?1H^RC_GK)_WT: )Z*@^RC_GK)_WT:/LH_YZ
MR?\ ?1H GHJ#[*/^>LG_ 'T:/LH_YZR?]]&@">BH/LH_YZR?]]&C[*/^>LG_
M 'T: )Z*@^RC_GK)_P!]&C[*/^>LG_?1H GHJ#[*/^>LG_?1H^RC_GK)_P!]
M&@">BH/LH_YZR?\ ?1H^RC_GK)_WT: )Z*@^RC_GK)_WT:/LH_YZR?\ ?1H
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M=73F*$P8&7/3&/3(I2P\/=M?7^NUOQ*ACZKY^9I.-_ZWO^!U46LV,]U<P1S
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M+$#U..E.F\1Z7;P6LTETOE73;8G'0G^E<UIFHV&C:[J1UMTA:=5>&2;HZ8Z
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MSD9R,U+_ ,(/KEK>6<EG+:O&VF-8W0D!R#G(*\UK#PG>BR\+0^9'NTAU,_\
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MJZY_Y_1_WQ7KGR>U'R>U 'D?_"KKG_G]'_?%+_PJ^Y_Y_!_WQ7K?R>U'R>U
M'DO_  K&Y_Y_!_WQ1_PK*Y_Y_!_WQ7K7R>U'R^U 'D__  K.Y'_+V/\ OBE'
MPTN?^?L?]\5ZO\OM1\OM0!Y2/AM<C_E['_?%+_PK>Y_Y^A_WQ7JOR^U'R^U
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M %%%% !1110 4444 %%%% !45O:P6JL+:%(@[;F"+C)]:EHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%Y_Q[GZU/4%Y_Q[GZT
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M$4<L<<5R=K8>*?#.I01PQ7.FW-ZPCC) R_/XU<*RG&ZM<&C&EL;RV7==6EQ
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M?3->B>$)=&_X1_4(+"%WO/L;//-)V/.%%9'A&,:GX<UO3)5#!(O/C)_A(/\
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MY8P&]?K3!I=@+TW@LK<71ZS>4N__ +ZQFK5%%V 4444@"BD# D@$$CJ/2EH
M**"<=: 01D'(]10 4444 %%%% !4%Y_Q[GZU/4%Y_P >Y^M $]%%% !4$W_'
MQ!_O'^53U!-_Q\0?[Q_E0!/1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!#_R^G_KF/YFIJA_Y?3_US'\S4U !1110 5\P_'#_ )*=<_\ 7"/_ -!%
M?3U?,/QP_P"2G7/_ %PC_P#017J97_'^1G4V//A2BD%**^D,112BD%** .L\
M'^*;3P]INM6]U%([:A (HRG\)YZUS,#>7/$[9(1PQ_ U&*=6:@DVUU"YZIK/
MC/X?>(KF*[UC1]0EN4B6/<LC*,#V!K!O/%U@O@L:+I$4\$D5\;B!V/W%W97G
MUKBZ>*QCAX126NGF5S,]$\7?$H>)-#TF.V6:WU*R<.\PX&[&,BL?1_&5V/%&
MG:EXDNKB_ALI/,5&.2#[5RHIXJHX>G&/*E_3%=G03^*;I/&EQXATUMD[RL\9
MD4-@'V-=.?BE<7'@R]TZ[AA.H7$N5=+9!'M(&<@#&>O->=BG"E*A3E:ZV_0+
ML]+A^(6BM>VFM75C<_VU:6Q@0(?W1.,9JGIOC33;G24L?$UK/(+>[-U ]N<<
MDY*GVS7""GBI^K4Q\S.WC\::??\ B74M0UNRE\N\39$\#%9(!VP15'Q9XFCU
M]K.WLXY([*RC\N+S6R['NQ/K7,KUIXJXT(1DI+H*[.I\+>)+32].U'2]6@DE
ML=00!S%PZD=,5KO\0(;75-)_LJVD&GZ;$8@DI^=PW7^5<$*D%*5"G*3D_P"N
M@<S.NUKQ+IC^'Y-(T"WGCAN+@SS-.><YS@>U5O"6OV^@R7[74;N+JW\I=G8\
MUS@IXI^QAR.'1A=[G5KXGM?^$8T73?*D\W3[L3R-V8;LX%=-I.LGQ+K.MK:V
M4D]A>PH)8@X648SR!WKS$5-#-+ ^^"1XV]4.*B>'BT[;_P#!N-2/0/&RP6/@
MC2-.C@>U=)&802G,@7GD_6J/@:=;C3M:T8_?N[??&/4KV_6N0DGEN'WSRO(W
MJYS2QR/$X>)V1O53@T+#VI<C>N_XW"^MSH9=?@;P;9Z,8Y!<6UP9')''WLXK
M1U+Q]<C7O[0T$F#=;K$_FH&SCZBN-SDY/))YI15_5Z;=VN_XBNSJ+KQSJFLH
MEIKDRRV+.#*D<2AB >Q K4\0^*/#^NVL4!%_!# F(X(P F<<$UPHI:7U:G=-
M*UNP<S.@\,Z[;Z*NHK<([_:H#$FWL>>M:7A%QIGAO6]4E.U6B%NF?XF8_P#U
MJX^GB63R_+WMY><[<\9ISHJ5_.U_D"8@I:2EK<0"EI!2TP"M;0- N=?OA# "
M(P?WDG912:!H%UKU^L,"D1@_O),<**]NT+0;71;%(+9  !R>Y/J:\W&8Q4%R
MQ^+\BXQN.T'1H-$TY+:V0* .3CECZFM2BBOFG)R=V;A4-W_J/^!+_.IJAN_]
M1_P)?YT@)ATHH'2B@ KDC\1M''Q#'@_][]O*;]VWY<XSC\JZVJ!T+2SK0U<V
M,/\ : 38+C;\^/3-5'EUYA._0OTC?=/TI:0C*D5(SQW0?B;I&F>#;K3K]]3D
MO$$R>8MI+(,X./G Q^M:'A?Q'::=I>B7>I?:)&32I;AKAIF("!WX*YY/'7&:
MZS0/"\NF>#I=*NO(>X=9 '49'S#CM7-R> YK71;==6G3[+:Z7-;7!@!9OF9V
MRH[\,*Z^:F[HRM)$MO\ $?6O[2TM-1\+S6EEJLWEV]PT@.!M)&X9X/'0UD:'
MXYU'0H;YY=*N;S38M4DCN+UI/]7D\;03D@>U8FGZOK.O>(?#NG'6++4K:SN@
MRI:PN)"H1ANDR,+UZ<]:[V3P3J#^#=2TD30>?=WCSHV3M"DYYXZTY*$-&MQ)
MM[&M\0)3'\/=6E1WCQ!G=&Q# 9&<$<YQ7C23^%6M[2+PE<^)#XE=4:"-Y;G#
M-QDD.=I7->Y>)=)FUCPK=Z;;LBRS1A59^@P0?Z5EZ_X/;4M!LAI[QVNL:>J-
M;7(& ' &0?\ 9.*BE.,59E2390\0?$"ZTG5ETC3["&]OX8EENO-N4A5 >P+$
M9//05%JOQ2@M?#NF7^GVBSW&HRM"D<LRQHCKC<&<D#N.]9WBSX<:IK&LIK5K
M:Z1=WEQ"B74%]N*(P Y1A_45<O/ 6J0^![32=,72II8W9Y[:XA(@D+8Z8)(Q
MCK32I60>]J7V^(,L'A6/4;O2)1?33BVAM(G#B:0G VL."O?.>E9M]XSU*[TC
M5M)UW29=&U(69G@VRAE=,X.&4]1_6JVF_##5+/PRZ)>V]KJ:W:WEM%"I-O P
M_@&><$<5;3P;XHUE[R_\4WMC]M:T:UM8;4'RT!.2Q)YR<#MVHM33T#WC7\-^
M)6>V.GO"S-8Z7#<&5FR9"8U./UKF?^$SUW4_&.FFWTXG3+K39I9$$X7@'!;K
MG(Q^M:%SX,\36E]'+H-_9QI<Z<EE>>>I)0J@7<GKT[XHM_ ^NZ<=#DLKFTDD
MM;.6SNQ*3AE<YW+QUH7(M1>\%IXTGMM&TJP\,:)-?WMU 9E@DGR(T!(RSL?;
MN:FG^)<T.@K<G19O[22]6RGL-PW(Y!((/<<=:KCP5XET:UTR\\-W=D-3M;<V
MTT=QGRI4R3G(&01GTJ:V\"ZL;6&XU&\@FU.;4DO;ME!" *K#:O\ WU1^[W'[
MQL^%/%=WK=_?Z;J^EMIFH6)!>(N'!5@"""/8BL%]#;X@>)M6_M>_O(M-TZ;[
M/!:6MP\.YN[L5()[?K746&AW%KXTU35W=#!=Q1HBC[P*@ Y_*L;6?#7B73]=
MN=6\$WMHAO<?:;2]!\LL.C@C.#R>U0FK^[H/6VH^S^'VW2;W1-2U2]N]*DD#
MVR_:76:$#'R^8"&(SGO7->#_  %HXU_5YYKO4B-+O=L'F:C,551GJ"V#^-=G
MX3T#5=/FNM2\1Z@+O4KS&]8@1%"HZ*H/\ZET7P[)976N&^\N6#4KDR*@S]TY
MX/YT_:-75PML87C_ %^);+2;K2+@WIBU*(-%9R[B_P P^7CUJSIGCJ^-S>V.
MO:'-87]O;FYBA1PXF0$#@C//(J/6_AY FG6T/@Z*VTJ6.\2Y9\$@E2#T[]*I
M_P#"$^)-;CU&[\3:C:QW\MJ;6U6T4^7&I8,22<$YV@?B::]FXV_X<7O7$T#X
MJMJ/B(Z5J>G1VSO"TT7D7*3-A1G#!2<'ZU)X4^)MQXEU*-1I"I83[O+GCN$=
MT &<N@.5Z=P.:R_#WP\\26?B'3K^_;2;6*RB>$)9HV6R,;R3U/M3;+X9:Y+X
MLM[_ %)M+M8[>4R&ZL499KD8(PR]!G.>IJFJ6HKR+\OQ:VWTTT.FQ/H\$IBD
MN3=(),@X)$>=Q'X5I:WXWOQJ<^G^&]%DU5;:$274RR!!&K#("YZGV%<I/\(+
M^/5Y8K6WT673YIC+]JN(V-PFXY(V@X/YBNFU+PKXET_6IKKP?>V<<-]&L=S'
M=*?W>T8#)CO[4FJ5U8/>ZF1HOB"_LO@VM[;O(+VXN7AC><EFC9G/7/I5J]^&
M*Z;I4VJ6.O:J-9MXVF^U/>2,LC*,D%"=N#CIBM;1_ \B?#P^'=:N%DF9G<SQ
M=F+$AA[\USNK^%/B9J4?V/\ MZQ6VBC:/SD#*]PI&,.N,#/KDTU).3Y7;4+.
MVITGASQG+JEQ9V4]O^\DTX73R@]2&92,?\!_6J5[\1[F+P]#?VFDB226>6("
M698XTV,1DNQ YQTS4-QX1\10W.E:EX?DL[.YCLOL=W!/ED"YX92!R>3Z=:RI
M_AIXAATK2_LUQI]]=V<LK217@;RGWL3OX_BYZ4DJ=[CO(TK?XKM>>&+34K+2
M6N;F:^-DUM%(&&_&<A@<$>]9OB/Q_P"(9?#%['!H[V&KV-[!'/%YPX5G7&&S
M@Y! _&KWA_X>ZSIMM;)>W%FSQZJ;YC""J[2H&T#\*O\ B'P3J6J2:]+9W$$<
ME\T$EMOS@/%M(#>Q*T_W2EH+WK'/>(O$VJV=CJ<NDZ?+'J2O:BY)NL@;MW"@
MG Z=O6MCQ1\2]0\-;!/HL:F*!9;DS721@$C)5,D;\=.,T77@;6[W3M7::XM$
MOKU;=X]I)021[LYXZ'=67K?P]\5:EJ=U=))I$CZC;JEQ+<*S-;ML"D1^HR,]
MJ:]FWK;^K![W0?)XSU;4O&D9MK%Y-$N-(:X(\X*0.,MUSGM^-=!X=\7V\5NE
MK-;/:VL6FK>Q/)*7+)CD$DDDC!K+@\!Z_92:6UK<6;>7IKV%X')'7!#)Q[5/
MJWP]O[_PWHEC!=10SV:B"[<$XDA/#J/P)J7[-Z N89=_%"X2*Q@LM*CDU"ZA
M^TM#-<I$L<><#+,0,GTKK/"OB6W\4:.+R!?+D1S%-%N#;''49'!KC_&OPUN-
M6U:WU31K?3;F6. 6[VVH*WE[1T(*]#^'>NG\$>&G\,:!]DF%LLTCF21;6,K&
MI/89//UJ)^SY+QW*7-?4Z.BBBL"PJ"\_X]S]:GJ"\_X]S]: )Z*** "H)O\
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M>D?_ 'T*/.@_YZ1_]]"E]?Q/\WX(.2)X1_PHBX_Z"Q_[]_\ UJ7_ (45<?\
M06/_ '[_ /K5[MYT'_/2/_OH4>=!_P ](_\ OH4?7\3_ #?@@Y(GA7_"B[C_
M *"I_P"_?_UJ=_PHVX_Z"I_[]_\ UJ]S\Z#_ )Z1_P#?0H\Z#_GI'_WT*/K^
M)_F_!!R1/#1\#[@?\Q3_ ,ATX?!&X_Z"A_[]_P#UJ]P\Z#_GI'_WT*/.@_YZ
M1_\ ?0H^O8G^;\$')$\0'P3N!_S%#_W[_P#K4X?!6X'_ #$S_P!^Z]M\Z#_G
MI'_WT*/.@_YZ1_\ ?0H^O8G^;\$')$\4'P7N!_S$C_W[I1\&;C_H)'_OBO:O
M.@_YZ1_]]"CSH/\ GI'_ -]"CZ]B?YOP0<D3Q<?!NX'_ #$C_P!\4H^#MP/^
M8C_XY7L_G0?\](_^^A1YT/\ STC_ .^A1]>Q/\WX(.2)XU_PIZX'_,1_\<I1
M\(+@?\Q _P#?%>R>=#_STC_[Z%'G0_\ /2/_ +Z%'U[$_P WX(.2)XZ/A%<#
M_F('_OBE'PDN/^?\_P#?%>P^=#_STC_[Z%'G0_\ /2/_ +Z%'U[$_P WX(.2
M)X__ ,*EN/\ G_/_ 'Q2CX37'_/^?^^*]?\ .A_YZ1_]]"CSH?\ GI'_ -]"
MCZ_B?YOP0<D3R'_A5%Q_S_'_ +XI?^%4W'_/]_XY7KOG0_\ /2/_ +Z%'G0_
M\](_^^A1]?Q/\WX(.2)Y'_PJJX_Y_O\ QRE_X57<?\_Q_P"^*];\Z'_GI'_W
MT*/.A_YZ1_\ ?0H^OXG^;\$')$\D_P"%67'_ #^_^.4O_"K+C_G]/_?%>M>=
M#_STC_[Z%'G0_P#/2/\ [Z%'U_$_S?@@Y(GDW_"K;C_G]/\ WQ1_PJZX_P"?
MT_\ ?%>L^=#_ ,](_P#OH4>=#_STC_[Z%/Z_B?YOP0<D3R;_ (5=<?\ /Z?^
M^*<GPNG+@->G&>?DKU?SH?\ GI'_ -]"@2PD\2)G_>%+Z_B?YOP0<D3,T'0K
M;1;!(+>,# Y/=CZFM>BBN)MR=V6%%%%( J&[_P!1_P "7^=35#=_ZC_@2_SH
M F'2B@=** "BBB@ HHH- &/X8UW_ (2+1_MWD^3^]:/;G/0UI&ZMR)<S1XB_
MUGS#Y/KZ5YQX#\;^'-(T$V&I:K%;W2W4@,3JV02?I63J?B&PTF7QQ9WKR+<7
MRB6U0(Q,RF%0"OX@UT>R;DU8CFT/3XSH6F.TT(L+1Y,%G140MGIDCKFKMQ>V
MMI;B>ZN(X8CT=V !_&O([#PSIGB#5[DZQ:FX$.A1&-7SA6V]?K5.$:4T?AT>
M-R[Z*EE(L)F#-'YHE<?-COM"XI^R3ZBYCVJ"Z@NE+6TR2J#@E&SBN$/C;Q5?
M:E?Q:#X62]M;.X,'G-=*FY@ >A/O47PA&FBSUP:'O_L_^T'\@."#MR?7M69X
M?\'W6MZKKUW!XCU33%&I,OD6S[4.$3FDHQBVGT'=NQV3^(M4L]*-UJ>F1V\D
M=D]Q-$)U9E=1G:,'D>]:>C:Y:ZM9P2++&MQ)$)6@#@L@/J*XCQ7 ]OX@GA,D
MDQC\/W"F1N2QP.3[URVEQ^&1!X</A=9/^$C$J>>0C!]G\7F$\8Z4U34HW%S-
M,]K34+.2<PQW4+2@$E XS@=>*+74+.]9Q9W44YC.'$;AMOUQ7C_]B11>"?$.
MK6EO(;R7494GFCR9!;^?\X7VVYJ335\+#Q5I(\ [D=H)!J+6Z, (\#E\_P 6
M<_K2]DM;,.9GK<.HV=Q=/;074,D\?WXU<%E^HJK::M_Q+Y+K53!9JLI3/G*5
MQVYSU]J\,\,FVT3QGIXL?L>L;[K9YL*R17B;C@F4%<$#//-7M9L[>Z\(VS7=
M]%:F+4[ADCO8F:WF^[PY7)'MQZU7L$G:XN<]UAFBN(5E@D62-AE64Y!%<W/X
MVM;;2;[5)H7^R6\WD0%>6N']%%<Y\+[QY_!VJ6]O91V_D.XC>V9C#*2"<Q[@
M"!D^E4U@D/PNT*_M87N1IUV+BXA099@-P;CN1D5"II2:97,[:&N?B!KFF;+O
MQ+X6FT_2I& ^TK*',0)X+J.0/6NDMO$:W/BV31HXLHMHMRLP/W@3TKA/&GQ3
M\/W^B7.CV#274FH6YB1Q&0L3-QA\_=QFI8-;TKPK\0D&M:A' C:1$B2,"0Y!
M[8!JG3NK\MF+FUW.L\8^);_P^NGQ:1IHU&[OIO*2(R!!]<FH-(UWQ7.UR=:\
M-1V,44)=&6Y5][#^' /IFL'QE<6?C-_#?]AZM+'%)?,HN[3(9" .F:ZOPWX;
MG\/I<?:M;OM5$N/^/Q]VS'I4M1C#5:CU;+$.NB^\+G5M.C25S&S+&[A1O&05
M)/3!!%6EU.VCMT>]GA@<A=RM(/E)Z#-><0*X^%OBW:&\DSW1AQZ<YQ^.:K+X
M>L-=UO5O[5MS<+;Z/$\2L3M5]I(;ZBG[-:BYF>K"^M3="V%Q$9RNX1[QN(]<
M4TZE9+>BT:[A%R>D)<;C^%>2:?X?L=/TWP?K,$4AU*6[5);@L2[INQM/M@8K
MB]1GM9]4CU**2WL[\:JG^CK$[W(!D .]\  8^M5&@I/1@YV/H^XU*RM)EBNK
MJ&&1QE4=P"1]*K_VFW]I^7B'[%Y'F_:/-&<Y';TYZUXSK2^%W7Q(WC82'6RY
M-J75BWE[%V^61QC.?QJXRL^A*OSX;PJHR,_WH_UI>Q5@YSV."_M+J5XK:YBE
MDCQO5'!*Y]:8=5T\7#6YO8/.4[6C\P;@?3%>6?\ "-VWAS4]"F\-6[6]W>:;
M*)2I/[U@JD%O?DUS#)X/&E^'#9K*/$OVZ#[675A+YFX;_,/3&<T*BGLPYVCZ
M%HI%^X/I2US&@4444 %%%% !1110 4444 %%%% !4%Y_Q[GZU/4%Y_Q[GZT
M3T444 %03?\ 'Q!_O'^53U!-_P ?$'^\?Y4 3T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 0_\OI_ZYC^9J:H?^7T_P#7,?S-34 %%%% !7R_\<M3
MU"V^)]S':W]U!&((\)%.RC[H[ U]05\K?'C_ )*I<_\ 7"+_ -!%=V!_B_(F
M6QPO]MZM_P!!:_\ _ I_\:/[;U;_ *"U]_X$O_C5&BO;LC(O?VWJW_06OO\
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MGTKH'\ >+(XFD?0;H(HW%LJ<#UZT-P6]@U,O^V]6_P"@K??^!+_XTHUO5O\
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M:ES^VM5_Z"E]_P"!+_XTO]M:K_T%+[_P)?\ QJA3JKE78"[_ &UJO_04OO\
MP)?_ !H_MK5?^@I??^!+_P"-4J*?*NP%W^VM5_Z"E]_X$O\ XTO]M:K_ -!2
M^_\  E_\:BDTV]BTZ*_EMG2TF8K',?NN1U JO32B]@+W]LZK_P!!2^_\"7_Q
MH_MG5?\ H*7W_@2_^-4JNZ9H^HZS<&#2;*6[D R5C'0>Y/%#44KL _MK5?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_U./Y]:S5.LG>[^_P _\AW1UMOX-\'Z=KV@^&]4LKFYOK^%)I;H2D#+#.W
M[=J\U\2Z?!I_BZ_T^S79!%<^6BDYP*]KT&Y$\_A_6-4_L2Y>UM@KZB+K#11A
M>A0@'=CBO$_$U]'?^+=1O;9MT<ER71O49JL-*;F[OI^-P=K'IGB73;.?Q7X)
M\)R1DZ>+>(RQ@D;B_)/'UHNO!_A"\F\3:5INGSV]WI*>8ER9BP/^SCTK/\1^
M)H/,\'>,+9(YY+2)8IX-X#;XSCD=1G%8MM\13;ZSX@OQI^?[9C*%-_\ JO\
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M[=I7&[<WH,C\ZP=>^&.JZKJ4>KM;Z'?7\T"1W4=]&S1JR@#<AVD]!TP*T_\
MA7VI:9I&E2>'[NRM]6TTO@&(K X?&Y< ''W1SCM3M2L@]X/ >JW^J>.O$;ZG
M:S6,J")6M9'+!#L7E?8]:R- \9:UH^FWLB:'<:AIUM?R_:;MI>47(^Z#U KJ
MO"'AK6]*UW5=5\07MO=3Z@$X@! 3"@8Y XXK$3P3XQ@M;K2K75K!-+OKAY)B
M58R1JQ!PO&#GZBB\&WMT#6Q=F\:Z;IFH:QJ*6D\I6W@==LA/GEU!557H#SVJ
M;3_'FI)J(LO$N@/I<D\+RVC"7>LFT9*D]CC^507GPYGN/[1CM[U($E@@2TD
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M]%_*C9<_\]%_*@">BH-ES_ST7\J-ES_ST7\J )Z*@V7/_/1?RHV7/_/1?RH
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M_+O\_P#Z]'_"@M)_Y_+O\_\ Z]/^TL/W?W!R,\$HKWO_ (4%I/\ S^7?Y_\
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M]]&@":BH=US_ '(_^^C1NN?[D?\ WT: )J*AW7/]R/\ [Z-&ZY_N1_\ ?1H
MFHJ'=<_W(_\ OHT;KG^Y'_WT: )J*AW7/]R/_OHT;KG^Y'_WT: )J*AW7/\
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M2"G'9ZGG3A*G-PEN@HHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&%U<QL,$ D8Y&>W-:]2TT[,84444@(H)Q,I(['%2U2TW_5O_ +QJ[0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11WHH
M***R_$TTMOX:OI8',<B1$JR]0::5W8#4HK!U+69M)\+6UX@CDF:-!^^? )*]
M??Z5@Q_$&YETZQNQ91QQS.R2RNQ" AL8!SP3UYJE"3U0KHWO$WAB+Q!"C*_E
M7$?W7QG(]#69X=\#?V7?+>7TRRR1_<51P#ZUH>&=5U'4)-5;41%Y,%T4@,9Y
MV[%.#^=<]<>,+]M7M;]H/+TQ#<; K_-*45L;A]17#+*\/4Q'MY1]Y';',*\*
M/L5+W3T*BN,D\9ZC!97/GZ:@NX?+<A"618WSACCTV\U#??$/[+#9&*WCFEFB
M\Z18VW J#@A<=_:N_P!G(X>9'<T4R"7SK>.4 J'4-@CD9I]9E!43S!)UC/5A
MFI:I3_\ (2A_W: +M%%% !1110 4444 %%<UX\FN(?#?^B-*)'GB3$+[&8%P
M" W:LV.YN_#>FS7:Z;>":21(DCN[TS!B<].>*M0NKDWU.WHKA;OQCJDUG<65
MM8Q+J48G67Y\(@0$%@<]<BM.#7)[#P/8WKH;BZF"QJ&/WG)/4_A3=-H.9%7Q
M%X&_M2_:\L9EBDD.75AP3ZUI^&?#$7A^%V,GFW$GWGQ@ >@KG4UG5=:\9:99
MS(MO';O(+E(Y2 SKD<8/(XZ&KWBZ._FU2,P_:+BSAA+/!93^7*C$\,0#EAQT
M]C7!#*\-3Q'ME'WF=L\PQ$Z/L7+W4=E17GEAXNU"V>5A*+ZPMK)7#2+LE+[@
MIW#C![5IWGC&Y^T2V-C9HUT75(M[84Y4DD_2N_V<KG%S(["BN"T#Q==VVBLN
MIQ&6XVR/$=V3(WF$;!]#Q7<P.\EO&\B['902OI4RBX[C3N25"LX-PT7=14U4
M8_\ D*2_[HJ1EZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYR2?4FK5%%9[E!1110!2TW_5O_O&KM4M-_U;_P"\:NT %%%% !1110 4444
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M:0%K[1#_ ,]4_P"^JJ7<B27-OL8-@G.#FE_LJ#^[4D.GPPMN5>: +0Z4444
M%%%% !33(B#YV"_4TZH)[6.X^^,T /\ M$/_ #U3_OJC[1#_ ,]4_P"^JJ_V
M5!_=H_LJ#^[0!:^T0_\ /5/^^J;));2QLDKQLC#!4D8-5_[*@_NT?V5!_=H
M=%;Z=!&T<,<"(_WE&,&J.I:-I^H6*V:S+;P;U:1(L#S #G:?:KG]E0?W:/[*
M@_NT[M:@6$EMXXU1)$"J  -PX%"R6Z9V/&N3DX(Y-5_[*@_NT?V5!_=I 6OM
M$/\ SU3_ +ZH^T0_\]4_[ZJK_94']VC^RH/[M %K[1#_ ,]4_P"^J/M$/_/5
M/^^JJ_V5!_=H_LJ#^[0 NF_ZM_\ >J[4<4*PKM08%24 %%%% !1110 4444
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M;_<&* )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849937910840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLIANT THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4272481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">260 Littlefield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-6770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751,814,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,113,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001746473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849937819240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936673192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,665<span></span>
</td>
<td class="nump">$ 50,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">148,931<span></span>
</td>
<td class="nump">226,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,998<span></span>
</td>
<td class="nump">9,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Tax credit receivable</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">6,764<span></span>
</td>
<td class="nump">4,498<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">209,441<span></span>
</td>
<td class="nump">290,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,606<span></span>
</td>
<td class="nump">4,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">221,215<span></span>
</td>
<td class="nump">295,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,971<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">11,991<span></span>
</td>
<td class="nump">9,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">1,869<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,831<span></span>
</td>
<td class="nump">11,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, non-current</a></td>
<td class="nump">5,325<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,156<span></span>
</td>
<td class="nump">12,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2021 and 2020; and 36,083,301 and 35,552,795 shares issued and outstanding at December 31, 2021 and 2020, respectively;</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">414,348<span></span>
</td>
<td class="nump">400,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(215,091)<span></span>
</td>
<td class="num">(117,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">199,059<span></span>
</td>
<td class="nump">283,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 221,215<span></span>
</td>
<td class="nump">$ 295,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849937848296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">36,083,301<span></span>
</td>
<td class="nump">35,552,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">36,083,301<span></span>
</td>
<td class="nump">35,552,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849939134392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 7,572<span></span>
</td>
<td class="nump">$ 41,817<span></span>
</td>
<td class="nump">$ 57,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(77,549)<span></span>
</td>
<td class="num">(66,193)<span></span>
</td>
<td class="num">(47,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(27,558)<span></span>
</td>
<td class="num">(17,269)<span></span>
</td>
<td class="num">(10,930)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(105,107)<span></span>
</td>
<td class="num">(83,462)<span></span>
</td>
<td class="num">(58,283)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(97,535)<span></span>
</td>
<td class="num">(41,645)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_InterestAndOtherIncomeNet', window );">Interest and other income (expense), net</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(97,263)<span></span>
</td>
<td class="num">(41,533)<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock', window );">Accretion to redemption value and dividends on redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,225)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (97,263)<span></span>
</td>
<td class="num">$ (41,533)<span></span>
</td>
<td class="num">$ (6,856)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share, attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (2.71)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (2.71)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing net loss per share attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">35,846,421<span></span>
</td>
<td class="nump">21,344,236<span></span>
</td>
<td class="nump">1,623,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">35,846,421<span></span>
</td>
<td class="nump">21,344,236<span></span>
</td>
<td class="nump">1,623,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,263)<span></span>
</td>
<td class="num">$ (41,533)<span></span>
</td>
<td class="num">$ (631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on short-term investments</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (97,432)<span></span>
</td>
<td class="num">$ (41,564)<span></span>
</td>
<td class="num">$ (632)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion to redemption value and dividends on redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_InterestAndOtherIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest And Other Income, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_InterestAndOtherIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849929918008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Initial Public Offering</div></th>
<th class="th"><div>Private Placement</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Initial Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Private Placement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Initial Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Private Placement</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A</div></th>
<th class="th"><div>Series B</div></th>
<th class="th"><div>Series C</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
<td class="nump">49,501,221<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,516<span></span>
</td>
<td class="nump">$ 70,587<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series C redeemable preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,360,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C redeemable preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
<td class="nump">49,501,221<span></span>
</td>
<td class="nump">26,360,745<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,468<span></span>
</td>
<td class="nump">$ 75,860<span></span>
</td>
<td class="nump">$ 47,947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (71,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (71,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of founders&#8217; common stock and restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of founders&#8217; common stock and restricted stock awards</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion to redemption value and cumulative dividends on redeemable convertible stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">$ 5,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock', window );">Accretion to redemption value and cumulative dividends on redeemable convertible stock</a></td>
<td class="num">(6,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on short-term investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">(76,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(76,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series C redeemable preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,527,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C redeemable preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A, B, C convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,000,000)<span></span>
</td>
<td class="num">(49,501,221)<span></span>
</td>
<td class="num">(54,888,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A, B, C convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (62,468)<span></span>
</td>
<td class="num">$ (75,860)<span></span>
</td>
<td class="num">$ (99,966)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering/private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering/private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,278<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,277<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A, B, C convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,432,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A, B, C convertible preferred stock to common stock</a></td>
<td class="nump">238,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of founders&#8217; common stock and restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of founders&#8217; common stock and restricted stock awards</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on short-term investments</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (41,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">35,552,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,552,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 283,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(117,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">2,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on short-term investments</a></td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">36,083,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,083,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 199,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (201)<span></span>
</td>
<td class="num">$ (215,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion to redemption value and cumulative dividend on redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period value conversion of convertible securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849938241704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (97,263)<span></span>
</td>
<td class="num">$ (41,533)<span></span>
</td>
<td class="num">$ (631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,437<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
<td class="nump">1,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Noncash lease expense</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_OtherLosses', window );">Other</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Tax credit receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">7,281<span></span>
</td>
<td class="num">(2,227)<span></span>
</td>
<td class="num">(7,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,266)<span></span>
</td>
<td class="num">(2,756)<span></span>
</td>
<td class="num">(1,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">2,695<span></span>
</td>
<td class="nump">2,689<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,754)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent and other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(75,443)<span></span>
</td>
<td class="num">(37,271)<span></span>
</td>
<td class="num">(2,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(219,887)<span></span>
</td>
<td class="num">(322,605)<span></span>
</td>
<td class="num">(51,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AccretionOfShortTermInvestments', window );">Accretion on short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturity of short-term investments</a></td>
<td class="nump">295,539<span></span>
</td>
<td class="nump">113,271<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,953)<span></span>
</td>
<td class="num">(1,532)<span></span>
</td>
<td class="num">(964)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">73,699<span></span>
</td>
<td class="num">(210,866)<span></span>
</td>
<td class="num">(17,931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,751<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock upon completion of private placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series C preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,019<span></span>
</td>
<td class="nump">47,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(457)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,582)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">213,212<span></span>
</td>
<td class="nump">45,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">783<span></span>
</td>
<td class="num">(34,925)<span></span>
</td>
<td class="nump">24,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">50,882<span></span>
</td>
<td class="nump">85,807<span></span>
</td>
<td class="nump">60,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">51,665<span></span>
</td>
<td class="nump">50,882<span></span>
</td>
<td class="nump">85,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting', window );">Reclassification of restricted stock awards from liabilities to common stock upon vesting</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock', window );">Accretion to redemption value and dividends on redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities', window );">Deferred offering costs in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized loss on short-term investments</a></td>
<td class="num">$ (169)<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_AccretionOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of short-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_AccretionOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion to redemption value and dividends on redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_OtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_OtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of restricted stock awards from liabilities to common stock upon vesting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936486104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pliant Therapeutics, Inc. (the &#8220;Company&#8221; or "Pliant" or &#8220;we&#8221; or &#8220;our&#8221; or &#8220;us&#8221;) is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis with an initial focus on treating fibrosis by inhibiting integrin-mediated activation of TGF-&#946;. Fibrosis refers to the abnormal thickening and scarring of connective tissue due to the production and deposition of excess collagen in the extra-cellular matrix. Fibrosis can occur in many different tissues including lung, liver, kidney, muscle, skin and the GI tract, and often causes severe and debilitating disease leading to organ failure. The Company is located in South San Francisco, California, and was incorporated in the state of Delaware in June 2015.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;22, 2020, the Company implemented a 1-for-7.15 reverse stock split of the Company&#8217;s common stock. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&#8217;s convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. As of June 3, 2020, all outstanding preferred stock had been converted into common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company completed its initial public offering (the &#8220;IPO&#8221;), in which the Company issued and sold an aggregate of 10,350,000 shares of common stock, which consisted of 9,000,000 shares of common stock and 1,350,000 shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares, at a public offering price of $16.00 per share. The aggregate net proceeds received by the Company from the offering were $148.3 million, net of underwriting discounts, commissions and offering expenses of $5.7 million. Upon the closing of the IPO, 160,389,279 shares of the Company&#8217;s outstanding convertible preferred stock were automatically converted to common stock on a 7.15:1 basis and the related carrying amount of $238.3 million was reclassified to common stock and additional paid-in capital within stockholders&#8217; equity (deficit). </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the completion of the IPO, the Company also issued 625,000 shares of its common stock to Novartis Institutes for Biomedical Research, Inc. (&#8220;Novartis&#8221;), a strategic partner and existing stockholder of the Company, in a private placement at a price of $16.00 per share for proceeds of $10.0 million, which resulted in Novartis owning approximately 6.1% of the Company&#8217;s outstanding shares of common stock immediately after the IPO.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936455368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Certain prior year reported amounts have been reclassified to conform with the current period presentation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development costs, fair value of assets and liabilities, stock-based compensation, income taxes and uncertain tax positions. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, however, actual results may differ from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topic 606). To determine revenue recognition for arrangements that fall within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, our revenues have been generated solely from the Collaboration and License Agreement with Novartis (the &#8220;Novartis Agreement&#8221;). The Novartis Agreement includes licenses of intellectual property, cost reimbursements, research and development services, upfront signing fees, milestone payments and royalties on future licensee&#8217;s product sales.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of accounting for this arrangement, we must apply judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the contract. To determine the stand-alone selling price, we rely on assumptions which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and license revenue in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development services </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to research and development services are recognized as the related services or activities are performed, in accordance with the contract terms. The cost associated with full-time equivalent researchers is estimated each period and billable to Novartis based at specified full-time equivalent rates.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales-based royalties, including milestone payments based on the level of sales, are considered to be predominately related to the license included in the arrangement, and we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue from the Novartis Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize contract assets when we have a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditional on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration (i.e., only the passage of time is required before payment becomes due). A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables cannot be netted against contract liabilities and would be presented separately from contract assets. Contract assets and contract liabilities are netted at the contract level. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The carrying amount of the Company&#8217;s financial instruments, including cash and cash equivalents, short-term investments, tax credit receivable, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short-term maturities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. The Company invests in money market funds, treasury bill and notes, government notes and corporate debt securities. The Company limits its credit risk associated with its cash and cash equivalents by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. However, the Company had deposits in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limit of $250,000. The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base. During the years ended December&#160;31, 2021,  2020 and 2019, Novartis accounted for 100% of the Company&#8217;s revenue and accounts receivable.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future results of operations involve several other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products, including those that may be developed or marketed by larger companies, securing and protecting intellectual property, strategic relationships and dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing novel therapies for fibrotic diseases. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. All long-lived assets are maintained in the United States of America.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in Money Market Funds, United States (&#8220;U.S.&#8221;) treasury securities, U.S. government agency securities and corporate debt securities and are stated at fair value.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investments consist of U.S. Treasury securities, U.S. government agency securities and corporate debt securities with remaining maturities beyond three months at the date of purchase. The Company has classified and accounted for its short-term investments as available-for-sale securities as the Company may sell these securities at any time even prior to maturity and such investments represent cash available for current operations. As a result, short-term investments may include securities with maturities beyond twelve months that are classified within </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current assets in the Balance Sheets. As of December&#160;31, 2021 and 2020, all of the Company&#8217;s short-term investments were classified as available-for-sale and were carried at fair market value with unrealized losses recorded in other comprehensive loss in the statements of operations and comprehensive loss. See Note 3 for further details.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are considered impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its short-term investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, the duration and extent to which the fair value is less than cost and its intent and ability to hold the investment. Once a decline in fair value is determined to be other-than-temporary, an impairment charge will be recorded to other expense, net, in the statements of operations and comprehensive loss and a new cost basis in the short-term investment will be established. As of&#160;December&#160;31, 2021, the Company had not recorded any impairment related to other-than-temporary declines in the fair value of short-term investments.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;) as of January&#160;1, 2021, which did not have a significant impact on its financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires the Company to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if the Company&#8217;s estimate of fair value for the investment increases. To determine whether to record a credit loss, the Company considers issuer specific credit ratings and historical losses as well as current economic conditions and its expectations for future economic conditions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost net of accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. The useful lives of property and equipment are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of remaining lease term or estimated useful life</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the balance sheets and the resulting gain or loss is recorded to the statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, Leases (&#8220;ASC 842&#8221;), the Company determines if an arrangement contains a lease at the inception of the contract and a records right-of-use (&#8220;ROU&#8221;) asset and lease liability on the balance sheet at lease commencement based on the present value of remaining lease payments over the lease term. The Company only considers payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases with an initial term greater than 12 months, lease liabilities are recognized based on the present value of the future minimum lease payments discounted by the Company&#8217;s estimated incremental borrowing rate. The Company measures ROU assets based on the corresponding lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred and (iii) tenant incentives under the lease. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the present value of future minimum lease payments using its estimated incremental borrowing rate when the discount rate implicit in the lease is not known. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. In determining its incremental borrowing rate, the Company gives consideration to its credit risk, term of the lease, total lease payments and an analysis of peer companies with profiles similar to its own.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the short-term lease practical expedient to exclude leases with a term less than 12 months from its ROU assets and lease liabilities. The Company records rent expense for short-term leases in its statements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of operations on a straight-line basis over the lease term and records variable lease payments as incurred. The Company has also elected to not separate lease and non-lease components and, as a result, accounts for any lease and non-lease components as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There was no impairment of long-lived assets during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All preferred stock was automatically converted into common stock upon the Company&#8217;s IPO in June 2020. Prior to this conversion, the Company classified redeemable convertible preferred stock outside of stockholders&#8217; equity (deficit) because, upon the occurrence of certain change in control events that were outside the Company&#8217;s control, including liquidation, sale or transfer of the Company&#8217;s assets, holders of the redeemable convertible preferred stock could have caused redemption for cash. At any time on or after December 19, 2024, the holders of a majority of the outstanding redeemable convertible preferred stock could also have required the Company to redeem the redeemable convertible preferred stock by providing the Company a written notice requesting such redemption. The Company recognized changes in the redemption value immediately as they occurred, for example changes in fair value of preferred stock, and adjustments in the carrying amount of the redeemable convertible preferred stock to equal the redemption value at the end of each reporting period up through December 19, 2019, when the Company entered into the Series C Preferred Stock Purchase Agreement. See Note 9 for further details. In the absence of retained earnings these accretion charges were recorded against additional paid in capital, if any, and then to accumulated deficit. The Company analyzed all embedded derivatives and beneficial conversion features for its redeemable convertible preferred stock and concluded that none required bifurcation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist primarily of personnel costs for the Company&#8217;s research and development employees. Also included are non-personnel costs such as fees paid to consultants and third parties for preclinical and clinical studies, research and development services, laboratory supplies and equipment maintenance costs, license costs, contract manufacturing costs and allocations of facility related costs. The Company estimates preclinical and clinical studies and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. We estimate the amount of work completed through review of detailed budgets and timelines included in our contracts and agreements, and update these estimates with information obtained from third-party service providers and internal personnel on a quarterly basis. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and are expensed as services are rendered.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are expensed as incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based equity awards include restricted stock awards, stock options and shares that will be issued under the Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). Stock-based compensation for awards that are granted to employees is accounted at fair value on the award grant date and the expense is recognized over the period the employee is required to provide service in exchange for the award, which is generally on a straight-line basis over the vesting period of the award. The expense is recorded in either research and development or general and administrative expenses in the statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model, used to estimate fair value of stock-based awards, requires the use of the following assumptions:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term for the Company&#8217;s stock options was calculated utilizing the simplified method, which represents the average of the weighted-average vesting term and the contract period of the awards. The expected term for the ESPP is the offering period.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Prior to the Company being public, the Company did not have any trading history for its common stock, the expected&#160;volatility was estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their size, stage in the life cycle or area of specialty. As the Company went public in June 2020, the Company will continue to apply this process for stock options and ESPP awards until enough historical information regarding the volatility of its stock price becomes available.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S.&#160;Treasury notes with maturities approximately equal to the expected term of the awards.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on the common stock and has no plans to pay dividends on the common stock.&#160;Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our IPO, the fair value of our common stock has been determined using independent third-party valuations based on relevant valuation methodologies as outlined in the American Institute of Certified Public Accountants (AICPA) Practice Aid,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Valuation of Privately-Held-Company Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Issued as Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. The Company also considered the amount of time between the independent third-party valuation dates and the grant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dates and used interpolation of the fair value between the two valuation dates to estimate common stock fair value at each grant date. This determination included an evaluation of whether the subsequent valuation indicated that any significant change in valuation had occurred between the previous valuation and the grant date. Following our IPO, the Company uses our stock price traded on NASDAQ to determine its fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax basis of assets and liabilities and net operating loss and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all the tax benefits will not be realized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with ASC No. 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes any penalties and interest expense related to income taxes as a component of income tax expense, as necessary.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's comprehensive loss represents unrealized losses on short-term investments. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss attributed to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the conversion of our preferred stock in our IPO, net loss or income per share attributable to common stockholders was calculated using the two-class method, which is based on an earnings allocation formula that determines net loss or income per share for the Company&#8217;s common stockholders and holders of participating securities. The holders of preferred stock were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on the common stock. Under this method, net loss or income is increased or reduced by the amount of any dividends earned and accretion of redeemable convertible preferred stock to its redemption value, if any, during the period. The undistributed earnings are allocated to common stock and each series of redeemable convertible preferred stock to the extent that each preferred security may share in the earnings as if all of the earnings for the period had been distributed. Net loss or income attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Diluted net loss or income per share is computed using the more dilutive of (a) the two-class method or (b) the as-converted method. The Company allocated earnings first to redeemable convertible preferred shares stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss or income gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalent shares are excluded from the computation of diluted net loss or income per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 842&#8221;), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. Subsequent to this, the FASB issued various amendments to ASC 842, which affected certain aspects of the previously issued guidance. One of the amendments included an additional transition option that allowed entities to apply the new standard on the adoption date and recognize a cumulative effect adjustment to the opening balance of retained earnings. These updates were effective for public companies for annual periods beginning after December 15, 2018, including interim periods therein. Because the Company lost its EGC status on December 31, 2021, the standard became effective for the Company for its annual period beginning January 1, 2021. Amounts prior to January 1, 2021 were not adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASC 842 and all related amendments effective January 1, 2021 using the modified retrospective transition approach. The Company elected the package of practical expedients upon adoption, which permitted the Company to not reassess under the new standard the Company's prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease exception policy, permitting it to exclude the recognition requirements of this standard from leases with initial terms of 12 months or less.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASC 842 effective January 1, 2021 resulted in the recognition of operating lease ROU assets of $8.0&#160;million and operating lease liabilities of $8.9&#160;million in the Company&#8217;s balance sheet. In connection with the adoption, pre-existing liabilities for deferred rent and lease incentives totaling $0.9&#160;million were reclassified as an offset to the operating lease ROU assets. The Company&#8217;s financial position and operating results for reporting periods prior to January 1, 2021 have not been adjusted and continue to be presented in accordance with the accounting standard in effect at that time. The adoption of ASC 842 did not have a material impact on the 2021 quarterly or annual results of operations or cash flows and had no impact on retained earnings. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires </span></div>allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2021. The adoption of ASU 2016-13 did not have an impact on the Company&#8217;s financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936310552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investments consist of U.S. Treasury securities, U.S. Government agency securities and highly rated, investment-grade corporate debt securities with original maturities beyond three months at the date of purchase. The Company has classified and accounted for its short-term investments as available-for-sale securities as the Company may sell these securities at any time even prior to maturity and such investments represent cash available for current operations. As a result, short-term investments may include securities with maturities beyond twelve months that are classified within current assets in the Balance Sheets. The Company&#8217;s short-term investments classified as available-for-sale are carried at fair market value with unrealized losses or income recognized in other comprehensive loss.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the Balance Sheets and assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for&#160;identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or&#160;no market data.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalent Money Market Funds are classified as Level 1 because they are valued using quoted market prices. The fair value of the Company&#8217;s U.S. Treasury securities, U.S. government agency securities and corporate debt securities are classified as Level 2 because they are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency and include U.S. government agency securities, U.S. Treasury securities and corporate debt securities. These Level 2 instruments require more management judgment and subjectivity compared to Level 1 instruments which include determining which instruments are most similar to the instrument being priced, determining whether the market is active and determining which model-derived valuations are to be used when calculating fair value. The Company performs its analysis with the assistance of investment advisors.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets or liabilities as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash and cash equivalents, Money Market Funds and short-term investments by significant investment category as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities included in cash and cash equivalents and short-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities included in cash and cash<br/>&#160;&#160;&#160;equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263,697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may sell certain of its short-term securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the remaining contractual maturities of the Company&#8217;s short-term investments as of December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mature in 1 year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mature in 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149,130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020. There have been no transfers between fair value measurement levels during the years ended December&#160;31, 2021 and 2020. In addition, there were no assets or liabilities measured at fair value on a non-recurring basis as of December&#160;31, 2021 and 2020.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had not recorded any impairment related to other-than-temporary declines in the fair value of short-term investments.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records interest income and accretion income earned on Money Market Funds and U.S. Treasury, U.S. government agency and corporate debt securities to interest and other income (expense), net in its statement of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936362360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,947&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,540&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,625&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,809&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,019)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,488)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,606&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,321&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense during the years ended December&#160;31, 2021, 2020 and 2019 was $1.5 million, $1.3 million, $1.1 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936325368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid expenses and other current assets</a></td>
<td class="text">Prepaid expenses and other current assets<div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849940016680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities and Other Long-Term Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities and Other Long-Term Liabilities</a></td>
<td class="text">Accrued Liabilities and Other Long-Term Liabilities<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits consist primarily of accrued bonuses and accrued vacation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-Term Liabilities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold incentive obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities &#8212; deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936342136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Novartis Collaboration and License Agreement (the "Novartis Agreement")<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Novartis Collaboration and License Agreement (the "Novartis Agreement")</a></td>
<td class="text">Novartis Collaboration and License Agreement (the "Novartis Agreement")<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into the Novartis Agreement, for the development and commercialization of our preclinical product candidate, PLN-1474 and up to three additional integrin research targets. PLN-1474 is an internally discovered small molecule selective inhibitor of integrin &#945;v&#946;1, currently being developed for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (&#8220;NASH&#8221;). Pursuant to the agreement, we received an upfront, non-refundable license fee of $50.0 million and were eligible to receive additional payments of $416.0 million contingent upon achievement of specified research, development, regulatory and commercial events and royalties on world-wide net sales thereafter. Additionally, Novartis agreed to fund up to $19.6 million associated with research and development services for PLN-1474 and up to $13.4 million for research and development services on the integrin research targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the Novartis Agreement in accordance with ASC 606 and determined that Novartis is a customer and identified the following performance obligations: (1) to provide worldwide license rights to PLN-1474, (2) to provide research and development services for PLN-1474, (3) to provide non-exclusive license rights to integrin research targets, and (4) to provide research and development services on integrin research targets.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the license to PLN-1474 was functional intellectual property and distinct as Novartis is capable to benefit from the license on its own or together with other resources that are readily available, and the research and development services we promise to deliver are not transformative in nature. Additionally, we concluded that the non-exclusive license rights to integrin research targets were not distinct in the context of the arrangement as the promised research and development services on integrin research targets were expected to significantly modify the license and Novartis could not benefit from the non-exclusive license without such services. Therefore, the non-exclusive license rights and research and development services on integrin research targets were considered a single performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the transaction price of the PLN-1474 research and development services and integrin target research and development services was $20.0&#160;million and $13.4&#160;million, respectively, as of December 31, 2021, and the performance obligations associated with the aggregate unrecognized transaction price of $2.0&#160;million would be satisfied in 2022. As of December 31, 2021, variable consideration associated with specified research and development milestones totaling $391&#160;million have been constrained from the transaction prices but remain eligible for achievement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are utilizing a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. We believe this is the best measure of progress because other measures do not reflect how we transfer the performance obligation to our counterparty. In applying the cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of third-party contract costs and internal full-time equivalent effort. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the performance obligations. The cumulative effect of revisions to estimated costs to complete the performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we recognized revenue of $7.6&#160;million which consisted of revenue generated from research and development services. During the year ended December&#160;31, 2020, we recognized revenue of $41.8 million, which consisted of $25.0&#160;million from the achievement of the first patient dosing milestone of the Novartis agreement in the first quarter of 2020 and $16.8 million of revenue generated from research and development services performed during the year.&#160;During the year ended December&#160;31, 2019, Company recognized revenue of $50.0 million related to the license fee and $7.1 million from research and development services.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, there was a receivable of $2.0&#160;million and $9.3 million, respectively, related to the Novartis Agreement. There were no contract assets or contract liabilities as of December&#160;31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936384184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Regents of the University of California License Agreement (the &#8220;UC Agreement&#8221;)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_LicenseAgreementsTextBlock', window );">Regents of the University of California License Agreement (the &#8220;UC Agreement&#8221;)</a></td>
<td class="text">Regents of the University of California License Agreement (the &#8220;UC Agreement&#8221;) In 2015, we entered into the UC Agreement to obtain an exclusive, worldwide license relating to the use of certain patents and technology relating to &#945;v&#223;1 compound in fibrosis indications. Pursuant to the UC Agreement, we made a $2.4 million milestone payment upon the close of our IPO in June 2020. Subsequently, we determined the licensed technology was no longer relevant to the development of our product candidates and, therefore, we exercised our right to terminate the UC Agreement which became effective in the first quarter of 2021. No further obligations or financial commitments survive the termination.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849939985400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Adimab Development and Option Agreement (the "Adimab Agreement")<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Adimab Development and Option Agreement (the "Adimab Agreement")</a></td>
<td class="text">Adimab Development and Option Agreement (the "Adimab Agreement")In 2018, we entered into a development and option agreement with Adimab, LLC (&#8220;Adimab&#8221;) for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the Adimab Agreement, we will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. We are required to pay Adimab an agreed upon rate for its full-time employees during the discovery period while Adimab performs research on each target under the applicable research plan. We have an exclusive option to obtain a worldwide, royalty-bearing, sublicensable license under Adimab platform patents and other Adimab technology to research, develop and commercialize up to 24 antibodies of our selection.During the years ended December&#160;31, 2021, 2020 and 2019, we recognized research and development expenses associated with full-time employee costs of $28,000, $0.2 million and $0.2 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936464072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_RedeemableConvertiblePreferredStockTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred StockUnder the Company&#8217;s Amended and Restated Certificate of Incorporation (&#8220;Certificate of Incorporation&#8221;), the Company is authorized to issue two classes of shares: preferred and common stock. The preferred stock may be issued in series, and the Company&#8217;s Board of Directors is authorized to determine the rights, preferences, and terms of each series. These rights preferences and terms could include dividend rights, conversion rights, voting rights, terms of redemptions, liquidation preferences and sinking fund terms. As a result of the IPO in June 2020, all then outstanding convertible preferred stock was converted into shares of common stock. There are no outstanding shares of preferred stock as of December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_RedeemableConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_RedeemableConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936319000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had 300,000,000 authorized shares of common stock, at a par value of $0.0001 per share. The common stock has the following rights and privileges:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of common stock are entitled to one vote for each share of common stock held at any meeting of stockholders and at the time of any written action in lieu of a meeting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of common stock are entitled to receive dividends, when declared by the Company&#8217;s Board of Directors. Cash dividends may not be declared or paid to holders of shares of common stock until all unpaid dividends on the Preferred Stock have been paid in accordance with their terms. No dividends have been declared or paid by the Company since its inception.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After payment of the respective liquidation preferences to the holders of shares of Preferred Stock, the holders of shares of common stock are entitled to share ratably in the Company&#8217;s remaining assets available for distribution to its stockholders in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or upon occurrence of a deemed liquidation event.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares reserved for future issuance</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,620,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock available for future grants under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,234,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,644,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">613,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,467,491&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,338,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936314152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Company's Board of Directors adopted the 2015 Equity Incentive Plan, as amended in 2018, 2019 and 2020 (the &#8220;2015 Plan&#8221;), which provided for the grant of incentive stock options, nonqualified stock options or other awards including stock appreciation rights and restricted stock awards to the Company&#8217;s employees, officers, directors, advisors, and consultants.  In May 2020, the Board of Directors adopted the 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;) and suspended the 2015 Plan. Awards outstanding under either the 2015 Plan or 2020 Plan that are cancelled, expire or otherwise terminated subsequent to May 2020 will become available for issuance as common stock under the 2020 Plan. Additionally, the 2020 Plan is subject to automatic increases on January 1 of each year beginning January 1, 2021. The number of shares added each January 1 will be equal to the lesser of: (i) 5% of the outstanding shares on the immediately preceding December&#160;31 or (ii) such amount as determined by the administrator of the 2020 Plan, which is the compensation committee of the Board of Directors of the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan provides for the grant of incentive stock options, nonqualified stock options or other awards including stock appreciation rights, restricted stock awards and restricted stock units to the Company&#8217;s employees, officers, directors, advisors, and consultants. As of December 31, 2021, the 2020 Plan had 4,234,213 shares of common stock available for future issuance.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Options under the 2020 Plan may be granted for periods of up to 10 years and at prices no less than the market price of the Company&#8217;s common stock on the date of grant, provided, however, that the exercise price of an incentive stock option granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant and the option is not exercisable after the expiration of five years from the date of grant.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Restricted Common Stock Awards</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted restricted stock awards under the 2015 Plan. The purchase price of the restricted common stock awards was the estimated fair value as determined by the Company's Board of Directors at the issuance date. The shares vest from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzM1NTY_17d5b407-5e02-4666-bc12-447640c0a66b">one</span> to four years and vesting could be accelerated upon a change in control. A holder of an award may pay a total purchase price or a part of the purchase price for granted shares at any time during the vesting periods. Upon termination of employment, the Company has the right to repurchase any unvested restricted shares. The repurchase price for unvested shares of common stock will be the lower of (i) the fair market value on the date of repurchase or (ii) their original purchase price. During the vesting term, holders of restricted stock awards are deemed to be common stock shareholders and have dividends and voting rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for restricted stock awards as early exercised options and recognized a liability in other liabilities when cash was received for the purchase of shares of restricted stock. As shares of restricted stock vested, the Company reclassified the liability to common stock and additional paid in capital. As of December&#160;31, 2021 and&#160;2020, the Company recorded a liability included in accrued expenses and other liabilities of $2,000&#160;and $10,000, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no grants of restricted stock awards during the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during the year ended December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested, as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(103,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested, as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate fair value of restricted stock awards vested during the years ended December&#160;31, 2021 and 2020 was $0.2&#160;million each year. Total intrinsic value of outstanding unvested restricted stock awards as of December&#160;31, 2021 and 2020 was $0.3&#160;million and $2.9&#160;million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Options and Nonqualified Stock Options</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued under either the 2015 Plan or the 2020 Plan generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzU0NDE_e2781c43-be0a-4144-b7b0-5f65f0005fa6">four</span> years and expire ten years from the date of grant. Certain options provide for accelerated vesting if there is a change in control, as defined in the respective plans.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for stock option awards with the following assumptions:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"/><td style="width:37.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.83%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.10%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.80%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.61 %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.39 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.27 %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.82 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underlying common stock fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.22</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the 2015 Plan and the 2020 Plan is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average&#160;Exercise<br/>Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(in&#160;Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,993,855&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.18&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.84</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,890&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,520,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(336,340)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.21&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(557,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,620,180&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.56&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.25</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,368,543&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.66</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,620,180&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.56&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.66</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the difference between the fair value of the underlying common stock and the exercise price as of December&#160;31, 2021 and 2020. The weighted-average grant date fair value of options granted during years ended December&#160;31, 2021 and 2020 was $16.94 per share and $7.27 per share, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, the Company adopted the Company's 2020 Employee Stock Purchase Plan (the "2020 ESPP"). The Company reserved 700,000 shares of common stock for future issuance under the plan. The 2020 ESPP provides that the </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">number of shares reserved and available for issuance will automatically increase on January 1 of each calendar year, beginning January 1, 2021, by the least of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) 700,000 shares or (iii) such lesser amount as determined by the administrator of the 2020 ESPP, which is the compensation committee of the Board of Directors of the Company.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2020 ESPP, eligible employees may purchase shares of our common stock through payroll deductions that cannot exceed 15% of each employee&#8217;s salary. The 2020 ESPP provides for a six-month offering period. At the end of the purchase period, eligible employees are permitted to purchase shares of common stock at the lower of 85% of the fair market value at the beginning of the offering period or 85% of the fair market value at the end of the purchase period, subject to tax limitations on the total value of the purchase. The 2020 ESPP is considered a compensatory plan, and the Company recorded $0.5 million, $0.5&#160;million and nil in stock-based compensation expense for year ended December&#160;31, 2021, 2020 and 2019. As of December&#160;31, 2021, 86,902 shares of common stock were issued under the 2020 ESPP. The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for the 2020 ESPP with the following assumptions:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.575%"><tr><td style="width:1.0%"/><td style="width:52.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.655%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.06% - 0.07%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.11%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term of options (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.16% - 89.51%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83.72%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense during the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"/><td style="width:57.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,928&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,719&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,437&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,895&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $37,000 of unrecognized compensation costs that is expected to be recognized over the weighted-average periods of 0.38 years related to restricted stock awards. As of December&#160;31, 2021, there was $24.2 million of unrecognized compensation costs that is expected to be recognized over the weighted-average periods of 2.5 years related to stock options.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849940004120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company had a pre-tax U.S. book loss of $97.3 million, $41.5 million, and $0.6 million for the years ended December&#160;31, 2021,  2020 and 2019 respectively. During the years ended December&#160;31, 2021, 2020 and 2019, the Company did not record an income tax provision. The Company will continue to maintain a 100% valuation allowance on total deferred tax assets. The Company believes it is more likely than not that the related deferred tax assets will not be realized.<div style="margin-top:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax computed at federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General business credit&#8212;federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(267.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,554&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,989&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,617&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">775&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">474&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(921)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(558)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,742)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(682)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred taxes</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Year</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal (starting from January 1, 2018)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,231&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Does not expire</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal (before January 1, 2018)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2035-2037</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,964&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2035-2041</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits, federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2036-2041</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits, state</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,069&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Does not expire</span></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating loss carryforwards and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code (&#8220;IRC&#8221;) and similar state provisions. Annual limitations may result in the expiration of the net operating losses and tax credit carryforwards before they are utilized. The Company performed a IRC Section 382 analysis through December&#160;31, 2021 and does not expect any previous ownership changes to result in a limitation that will reduce the total amount of net operating loss and </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax credit carryforwards disclosed that can be utilized. Subsequent ownership changes may affect the limitation in future years.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021&#160;and 2020, the Company recorded a full valuation allowance on federal and state deferred balances since management does not forecast the Company to be in a profitable position in the near future.&#160;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2021&#160;and 2020 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,684&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2017 through December 31, 2021. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entire amount of the unrecognized tax benefits would not impact the Company&#8217;s effective tax rate if recognized. The Company's accounting policy is to include interest and penalties as a component of tax expense. During the years ended December&#160;31, 2021,  2020 and 2019, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions (reductions) for tax positions of prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,355&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the "Cares Act") was enacted. The CARES Act changed net loss carryforward and back provisions and the business interest expenses limitation. The Company has evaluated the impact of the CARES Act and determined that none of the changes would result in a material cash benefit to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936397000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contractual arrangements with research and development organizations and suppliers; however, these contracts are generally cancellable on 30 days&#8217; notice and the obligations under these contracts are largely based on services performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential payments related to the Company&#8217;s license and research agreements, including milestone and royalty payments, are detailed in Notes 6 and 7.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of business. The Company record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. Management is currently not aware of any legal matters that could have a material adverse effect on our financial position, results of operations or cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936370648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 1, 2021, the Company adopted ASC 842 and the following disclosures as of and for the year ended December 31, 2021 are presented under ASC 842.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a non-cancelable lease agreement (the &#8220;Lease&#8221;) for premises consisting of approximately 32,974 square feet located in South San Francisco, California (the &#8220;Premises&#8221;). The Company moved into the Premises in July 2018. The Premises is being used for the Company&#8217;s corporate headquarters and principal operating facility. The term of the Lease is eighty-four months, which commenced on July 1, 2018. Base rent was abated for the first two months of the lease term and thereafter is $0.2 million per month during the first year of the lease term, with specified annual increases thereafter. The Company paid a refundable security deposit of approximately $0.4 million, which is included in other non-current assets in the Balance Sheets at December&#160;31, 2021 and 2020. The Company has the right to extend the lease term by seven years upon written notice not more than twelve months nor less than nine months prior to the expiration of the original lease term, with monthly payments equal to the &#8220;fair rental value&#8221; as defined in the Lease. The exercise of lease renewal options is at the sole discretion of the Company and is not included in the ROU asset and lease liability as it is not reasonably certain of exercise. This lease does not contain material variable rent payments, residual value guarantees, covenants, or other restrictions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, the Company recognized expenses associated with the operating leases of  $2.3&#160;million. Additionally, the Company incurred variable lease costs of $0.9 million which is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance. Short-term lease expense and variable lease payments recorded in operating expenses were immaterial for the year ended December 31, 2021. Cash paid for amounts included in the measurement of operating lease liabilities was $2.4&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maturities of the Company's operating lease liability as of December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The weighted-average remaining lease terms and discount rates related to the Company's operating leases were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total rent expense under ASC 840 was $2.5 million during each of the years ending December&#160;31, 2020 and 2019. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Future minimum lease payments under the Lease as of December 31, 2021 were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936307672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsIn 2019, certain employees of Third Rock Ventures, a stockholder of the Company, provided consulting services to the Company. Commencing January 2020, Third Rock Ventures ceased providing management consulting services to the Company.&#160;The Company recorded no consulting expenses for consulting services provided by Third Rock Ventures during&#160;the years ended December&#160;31, 2021 and 2020.&#160;The Company recorded Third Rock Ventures consulting expenses to general and administrative expense of $36,000 during the year ended December&#160;31, 2019.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2021, the Company granted 26,572 stock options with a grant date fair value of $0.5 million to partners of Third Rock Ventures who are also serving as non-employee directors on the Company's Board of Directors. The shares of common stock subject to these options ve</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">st 25% on</span> the first day of each calendar quarter for three quarters with the final vest date being the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting of Stockholders. In March 2020, the Company granted 26,573 stock options with a grant date fair value of $0.1 million to a partner at Third Rock Ventures, who is also serving as a non-employee director on the Company&#8217;s Board of Directors. The common shares subject to these options vest 1/12th on the last day of each calendar quarter over a three-year period and commenced vesting upon our IPO. In order to vest at each calendar quarter end date, the shareholder must be providing continuous service to the Company through such vesting date. The stock-based compensation expense related to these options was immaterial during the years ended December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936327336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">Defined Contribution PlanThe Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. The Company made contributions to the plan of $0.6 million, $0.4 million and $0.2 million during the years ended December&#160;31, 2021, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936260664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been antidilutive:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:57.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redeemable convertible preferred stock (on an as-converted basis)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,442,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,620,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,993,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,337,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards granted and not purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">302,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,642,021&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,124,572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,086,140&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net loss per share attributable to common stockholders is as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"/><td style="width:57.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(97,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accretion to redemption value and dividends on redeemable convertible preferred shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(97,263)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,533)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,856)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,846,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,344,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,623,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,846,421&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,344,236&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,623,358&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to common stockholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.71)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.95)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936544600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Certain prior year reported amounts have been reclassified to conform with the current period presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development costs, fair value of assets and liabilities, stock-based compensation, income taxes and uncertain tax positions. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, however, actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenues in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topic 606). To determine revenue recognition for arrangements that fall within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, our revenues have been generated solely from the Collaboration and License Agreement with Novartis (the &#8220;Novartis Agreement&#8221;). The Novartis Agreement includes licenses of intellectual property, cost reimbursements, research and development services, upfront signing fees, milestone payments and royalties on future licensee&#8217;s product sales.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of accounting for this arrangement, we must apply judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the contract. To determine the stand-alone selling price, we rely on assumptions which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and license revenue in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development services </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to research and development services are recognized as the related services or activities are performed, in accordance with the contract terms. The cost associated with full-time equivalent researchers is estimated each period and billable to Novartis based at specified full-time equivalent rates.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales-based royalties, including milestone payments based on the level of sales, are considered to be predominately related to the license included in the arrangement, and we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue from the Novartis Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize contract assets when we have a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditional on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration (i.e., only the passage of time is required before payment becomes due). A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. </span></div>Receivables cannot be netted against contract liabilities and would be presented separately from contract assets. Contract assets and contract liabilities are netted at the contract level.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The carrying amount of the Company&#8217;s financial instruments, including cash and cash equivalents, short-term investments, tax credit receivable, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short-term maturities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties Policy</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. The Company invests in money market funds, treasury bill and notes, government notes and corporate debt securities. The Company limits its credit risk associated with its cash and cash equivalents by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. However, the Company had deposits in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limit of $250,000. The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base. During the years ended December&#160;31, 2021,  2020 and 2019, Novartis accounted for 100% of the Company&#8217;s revenue and accounts receivable.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s future results of operations involve several other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products, including those that may be developed or marketed by larger companies, securing and protecting intellectual property, strategic relationships and dependence on key individuals and sole source suppliers.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing novel therapies for fibrotic diseases. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. All long-lived assets are maintained in the United States of America.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in Money Market Funds, United States (&#8220;U.S.&#8221;) treasury securities, U.S. government agency securities and corporate debt securities and are stated at fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term investments consist of U.S. Treasury securities, U.S. government agency securities and corporate debt securities with remaining maturities beyond three months at the date of purchase. The Company has classified and accounted for its short-term investments as available-for-sale securities as the Company may sell these securities at any time even prior to maturity and such investments represent cash available for current operations. As a result, short-term investments may include securities with maturities beyond twelve months that are classified within </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current assets in the Balance Sheets. As of December&#160;31, 2021 and 2020, all of the Company&#8217;s short-term investments were classified as available-for-sale and were carried at fair market value with unrealized losses recorded in other comprehensive loss in the statements of operations and comprehensive loss. See Note 3 for further details.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are considered impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its short-term investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, the duration and extent to which the fair value is less than cost and its intent and ability to hold the investment. Once a decline in fair value is determined to be other-than-temporary, an impairment charge will be recorded to other expense, net, in the statements of operations and comprehensive loss and a new cost basis in the short-term investment will be established. As of&#160;December&#160;31, 2021, the Company had not recorded any impairment related to other-than-temporary declines in the fair value of short-term investments.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;) as of January&#160;1, 2021, which did not have a significant impact on its financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires the Company to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if the Company&#8217;s estimate of fair value for the investment increases. To determine whether to record a credit loss, the Company considers issuer specific credit ratings and historical losses as well as current economic conditions and its expectations for future economic conditions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost net of accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. The useful lives of property and equipment are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of remaining lease term or estimated useful life</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the balance sheets and the resulting gain or loss is recorded to the statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases and Rent Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, Leases (&#8220;ASC 842&#8221;), the Company determines if an arrangement contains a lease at the inception of the contract and a records right-of-use (&#8220;ROU&#8221;) asset and lease liability on the balance sheet at lease commencement based on the present value of remaining lease payments over the lease term. The Company only considers payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases with an initial term greater than 12 months, lease liabilities are recognized based on the present value of the future minimum lease payments discounted by the Company&#8217;s estimated incremental borrowing rate. The Company measures ROU assets based on the corresponding lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred and (iii) tenant incentives under the lease. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates the present value of future minimum lease payments using its estimated incremental borrowing rate when the discount rate implicit in the lease is not known. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. In determining its incremental borrowing rate, the Company gives consideration to its credit risk, term of the lease, total lease payments and an analysis of peer companies with profiles similar to its own.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the short-term lease practical expedient to exclude leases with a term less than 12 months from its ROU assets and lease liabilities. The Company records rent expense for short-term leases in its statements </span></div>of operations on a straight-line basis over the lease term and records variable lease payments as incurred. The Company has also elected to not separate lease and non-lease components and, as a result, accounts for any lease and non-lease components as a single lease component.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There was no impairment of long-lived assets during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All preferred stock was automatically converted into common stock upon the Company&#8217;s IPO in June 2020. Prior to this conversion, the Company classified redeemable convertible preferred stock outside of stockholders&#8217; equity (deficit) because, upon the occurrence of certain change in control events that were outside the Company&#8217;s control, including liquidation, sale or transfer of the Company&#8217;s assets, holders of the redeemable convertible preferred stock could have caused redemption for cash. At any time on or after December 19, 2024, the holders of a majority of the outstanding redeemable convertible preferred stock could also have required the Company to redeem the redeemable convertible preferred stock by providing the Company a written notice requesting such redemption. The Company recognized changes in the redemption value immediately as they occurred, for example changes in fair value of preferred stock, and adjustments in the carrying amount of the redeemable convertible preferred stock to equal the redemption value at the end of each reporting period up through December 19, 2019, when the Company entered into the Series C Preferred Stock Purchase Agreement. See Note 9 for further details. In the absence of retained earnings these accretion charges were recorded against additional paid in capital, if any, and then to accumulated deficit. The Company analyzed all embedded derivatives and beneficial conversion features for its redeemable convertible preferred stock and concluded that none required bifurcation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist primarily of personnel costs for the Company&#8217;s research and development employees. Also included are non-personnel costs such as fees paid to consultants and third parties for preclinical and clinical studies, research and development services, laboratory supplies and equipment maintenance costs, license costs, contract manufacturing costs and allocations of facility related costs. The Company estimates preclinical and clinical studies and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. We estimate the amount of work completed through review of detailed budgets and timelines included in our contracts and agreements, and update these estimates with information obtained from third-party service providers and internal personnel on a quarterly basis. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and are expensed as services are rendered.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based equity awards include restricted stock awards, stock options and shares that will be issued under the Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). Stock-based compensation for awards that are granted to employees is accounted at fair value on the award grant date and the expense is recognized over the period the employee is required to provide service in exchange for the award, which is generally on a straight-line basis over the vesting period of the award. The expense is recorded in either research and development or general and administrative expenses in the statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model, used to estimate fair value of stock-based awards, requires the use of the following assumptions:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term for the Company&#8217;s stock options was calculated utilizing the simplified method, which represents the average of the weighted-average vesting term and the contract period of the awards. The expected term for the ESPP is the offering period.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Prior to the Company being public, the Company did not have any trading history for its common stock, the expected&#160;volatility was estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their size, stage in the life cycle or area of specialty. As the Company went public in June 2020, the Company will continue to apply this process for stock options and ESPP awards until enough historical information regarding the volatility of its stock price becomes available.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S.&#160;Treasury notes with maturities approximately equal to the expected term of the awards.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on the common stock and has no plans to pay dividends on the common stock.&#160;Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our IPO, the fair value of our common stock has been determined using independent third-party valuations based on relevant valuation methodologies as outlined in the American Institute of Certified Public Accountants (AICPA) Practice Aid,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Valuation of Privately-Held-Company Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Issued as Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. The Company also considered the amount of time between the independent third-party valuation dates and the grant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dates and used interpolation of the fair value between the two valuation dates to estimate common stock fair value at each grant date. This determination included an evaluation of whether the subsequent valuation indicated that any significant change in valuation had occurred between the previous valuation and the grant date. Following our IPO, the Company uses our stock price traded on NASDAQ to determine its fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax basis of assets and liabilities and net operating loss and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all the tax benefits will not be realized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with ASC No. 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes any penalties and interest expense related to income taxes as a component of income tax expense, as necessary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive LossComprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's comprehensive loss represents unrealized losses on short-term investments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss attributed to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the conversion of our preferred stock in our IPO, net loss or income per share attributable to common stockholders was calculated using the two-class method, which is based on an earnings allocation formula that determines net loss or income per share for the Company&#8217;s common stockholders and holders of participating securities. The holders of preferred stock were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on the common stock. Under this method, net loss or income is increased or reduced by the amount of any dividends earned and accretion of redeemable convertible preferred stock to its redemption value, if any, during the period. The undistributed earnings are allocated to common stock and each series of redeemable convertible preferred stock to the extent that each preferred security may share in the earnings as if all of the earnings for the period had been distributed. Net loss or income attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Diluted net loss or income per share is computed using the more dilutive of (a) the two-class method or (b) the as-converted method. The Company allocated earnings first to redeemable convertible preferred shares stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss or income gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalent shares are excluded from the computation of diluted net loss or income per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 842&#8221;), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. Subsequent to this, the FASB issued various amendments to ASC 842, which affected certain aspects of the previously issued guidance. One of the amendments included an additional transition option that allowed entities to apply the new standard on the adoption date and recognize a cumulative effect adjustment to the opening balance of retained earnings. These updates were effective for public companies for annual periods beginning after December 15, 2018, including interim periods therein. Because the Company lost its EGC status on December 31, 2021, the standard became effective for the Company for its annual period beginning January 1, 2021. Amounts prior to January 1, 2021 were not adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASC 842 and all related amendments effective January 1, 2021 using the modified retrospective transition approach. The Company elected the package of practical expedients upon adoption, which permitted the Company to not reassess under the new standard the Company's prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease exception policy, permitting it to exclude the recognition requirements of this standard from leases with initial terms of 12 months or less.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASC 842 effective January 1, 2021 resulted in the recognition of operating lease ROU assets of $8.0&#160;million and operating lease liabilities of $8.9&#160;million in the Company&#8217;s balance sheet. In connection with the adoption, pre-existing liabilities for deferred rent and lease incentives totaling $0.9&#160;million were reclassified as an offset to the operating lease ROU assets. The Company&#8217;s financial position and operating results for reporting periods prior to January 1, 2021 have not been adjusted and continue to be presented in accordance with the accounting standard in effect at that time. The adoption of ASC 842 did not have a material impact on the 2021 quarterly or annual results of operations or cash flows and had no impact on retained earnings. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires </span></div>allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2021. The adoption of ASU 2016-13 did not have an impact on the Company&#8217;s financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936328904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock', window );">Summary of Useful Lives of Property and Equipment</a></td>
<td class="text">The useful lives of property and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of remaining lease term or estimated useful life</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936429592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash and cash equivalents, Money Market Funds and short-term investments by significant investment category as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities included in cash and cash equivalents and short-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities included in short-term investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities included in cash and cash<br/>&#160;&#160;&#160;equivalents and short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263,697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summery of Remaining Contractual Maturities of Company&#8217;s Short-term Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the remaining contractual maturities of the Company&#8217;s short-term investments as of December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mature in 1 year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mature in 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149,130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936335448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,947&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,540&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,625&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,809&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,019)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,488)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,606&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,321&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936373496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936414040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities and Other Long-Term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Summary of Other Long-Term Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold incentive obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities &#8212; deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936473544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock', window );">Schedule of Shares Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares reserved for future issuance</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,620,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock available for future grants under the 2020 Stock Option and Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,234,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,644,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">613,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,467,491&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,338,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849937547544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock activity during the year ended December&#160;31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant Date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested, as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(103,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding and unvested, as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for stock option awards with the following assumptions:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"><tr><td style="width:1.0%"/><td style="width:37.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.83%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.10%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.80%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.61 %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.39 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.27 %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.82 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.44</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underlying common stock fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.22</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity Under the 2015 Plan and 2020 Plan</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the 2015 Plan and the 2020 Plan is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average&#160;Exercise<br/>Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(in&#160;Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,993,855&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.18&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.84</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,890&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,520,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(336,340)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.21&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(557,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,620,180&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.56&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.25</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,368,543&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.66</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,620,180&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.56&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.66</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan</a></td>
<td class="text">The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for the 2020 ESPP with the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.575%"><tr><td style="width:1.0%"/><td style="width:52.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.655%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.06% - 0.07%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.11%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term of options (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.16% - 89.51%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83.72%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Classification of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense during the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"/><td style="width:57.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,928&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,719&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,437&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,895&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849929843560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company&#8217;s Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax computed at federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General business credit&#8212;federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(267.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,554&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,989&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,617&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">775&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">474&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(921)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(558)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,742)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(682)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred taxes</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock', window );">Summary of Net Operating Losses and Tax Credit Carryforwards</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Year</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal (starting from January 1, 2018)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,231&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Does not expire</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal (before January 1, 2018)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2035-2037</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,964&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2035-2041</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits, federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2036-2041</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits, state</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,069&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Does not expire</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Changes in Valuation Allowance for Deferred Tax Assets</a></td>
<td class="text">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2021&#160;and 2020 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases recorded to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,684&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions (reductions) for tax positions of prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,355&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net operating losses and tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849937909640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Maturities of the Company's operating lease liability as of December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Weighted-average Remaining Lease Terms and Discount Rates</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The weighted-average remaining lease terms and discount rates related to the Company's operating leases were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Future minimum lease payments under the Lease as of December 31, 2021 were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936244856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been antidilutive:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:57.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redeemable convertible preferred stock (on an as-converted basis)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,442,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,620,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,993,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,337,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards granted and not purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">302,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,642,021&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,124,572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,086,140&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net loss per share attributable to common stockholders is as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"/><td style="width:57.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Numerator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(97,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accretion to redemption value and dividends on redeemable convertible preferred shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(97,263)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,533)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,856)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,846,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,344,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,623,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,846,421&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,344,236&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,623,358&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to common stockholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.71)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.95)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849932882968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 22, 2020</div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.13986014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,083,301<span></span>
</td>
<td class="nump">35,552,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Initial public offering, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price of shares issued in initial public offering (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from the initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts, commissions and offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,389,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Reclassification of convertible preferred stock into additional paid in capital upon initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Initial public offering, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Initial public offering, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pliant Therapeutics, Inc. | Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of noncontrolling ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177168-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=plrx_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=plrx_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plrx_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plrx_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=plrx_PliantTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=plrx_PliantTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849938262024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_PercentageOfRevenueContributedByRelatedParty', window );">Percentage of revenue contributed by related party</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase', window );">Debt instrument remaining maturity period at date of purchase</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 6,330,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 7,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember', window );">Novartis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of customer payment terms</a></td>
<td class="text">The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent and lease incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument remaining maturity period at date of purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_PercentageOfRevenueContributedByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue contributed by related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_PercentageOfRevenueContributedByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936614616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849935349256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">$ 183,958<span></span>
</td>
<td class="nump">$ 263,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">183,757<span></span>
</td>
<td class="nump">263,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">15,329<span></span>
</td>
<td class="nump">27,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">15,329<span></span>
</td>
<td class="nump">27,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities included in cash and cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">163,626<span></span>
</td>
<td class="nump">118,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">163,425<span></span>
</td>
<td class="nump">118,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities included in short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency securities included in short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">54,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">$ 5,003<span></span>
</td>
<td class="nump">$ 54,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849932771528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summery of Remaining Contractual Maturities of Company's Short-term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">$ 183,958<span></span>
</td>
<td class="nump">$ 263,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">183,757<span></span>
</td>
<td class="nump">$ 263,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">149,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">148,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short Term Investments | Mature in 1 year or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">114,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">113,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short Term Investments | Mature in 1 to 2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">35,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">$ 34,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=plrx_MatureInOneYearOrLessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=plrx_MatureInOneYearOrLessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=plrx_MatureInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=plrx_MatureInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849929815000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfers of assets between Level 1 and Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value Measurements, Non-recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849932789272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 9,625<span></span>
</td>
<td class="nump">$ 7,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(5,019)<span></span>
</td>
<td class="num">(3,488)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">4,606<span></span>
</td>
<td class="nump">4,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,947<span></span>
</td>
<td class="nump">6,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849941136232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
<td class="nump">$ 1,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936549624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_PrepaidResearchAndDevelopmentCurrent', window );">Prepaid research and development</a></td>
<td class="nump">$ 2,819<span></span>
</td>
<td class="nump">$ 1,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">2,585<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_PrepaidLicensesCurrent', window );">Prepaid licenses</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInterest', window );">Interest receivable</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 6,764<span></span>
</td>
<td class="nump">$ 4,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_PrepaidLicensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Licenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_PrepaidLicensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_PrepaidResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_PrepaidResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849940315128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities and Other Long-Term Liabilities - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 5,868<span></span>
</td>
<td class="nump">$ 3,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">5,216<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 11,991<span></span>
</td>
<td class="nump">$ 9,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses, current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred rent and leasehold incentive obligation-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849937398952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities and Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Leasehold incentive obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other liabilities &#8212; deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive received by lessee from lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123386226&amp;loc=d3e41620-112719<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849933049000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Novartis Collaboration and License Agreement (the "Novartis Agreement") - Additional Information (Details) - Novartis<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>research</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember', window );">Novartis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ProceedsFromUpfrontNonRefundableLicenseFee', window );">Proceeds from upfront non-refundable license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue recognized from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 41,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Receivable from related party transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember', window );">Novartis Agreement | Achievement of First Patient Dosing Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue recognized from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember', window );">Novartis Agreement | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue recognized from related party</a></td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember', window );">Novartis Agreement | License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue recognized from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember', window );">Novartis Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_NumberOfIntegrinResearchTargets', window );">Number of Integrin research targets | research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount', window );">Collaboration and license agreement, integrin research targets amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 416,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementRDForPLN1474Member', window );">Novartis Agreement RD For PLN-1474</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transaction price of Novartis agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementRDForIntegrinResearchTargetsMember', window );">Novartis Agreement RD For Integrin Research Targets | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transaction price of Novartis agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement integrin research targets amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_NumberOfIntegrinResearchTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Integrin research targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_NumberOfIntegrinResearchTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ProceedsFromUpfrontNonRefundableLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from upfront non-refundable license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ProceedsFromUpfrontNonRefundableLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plrx_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plrx_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plrx_AchievementOfFirstPatientDosingMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plrx_AchievementOfFirstPatientDosingMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=plrx_LicenseFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=plrx_LicenseFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementRDForPLN1474Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementRDForPLN1474Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementRDForIntegrinResearchTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plrx_NovartisAgreementRDForIntegrinResearchTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936414888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Regents of the University of California License Agreement (the &#8220;UC Agreement&#8221;) - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License Agreements | UC Regents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_MilestoneAndAnnualRoyaltyPaid', window );">Milestone and annual royalty paid</a></td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_LicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_LicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_MilestoneAndAnnualRoyaltyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone and annual royalty paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_MilestoneAndAnnualRoyaltyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plrx_UCRegentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plrx_UCRegentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849929825848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Adimab Development and Option Agreement (the "Adimab Agreement") - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 77,549<span></span>
</td>
<td class="nump">$ 66,193<span></span>
</td>
<td class="nump">$ 47,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=plrx_FullTimeEmployeeCostMember', window );">FTE costs | Adimab Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=plrx_FullTimeEmployeeCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=plrx_FullTimeEmployeeCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=plrx_AdimabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=plrx_AdimabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849929894824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849935434120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_NumberOfVotesPerShareOfCommonStock', window );">Common stock, voting rights | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_NumberOfVotesPerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Votes Per Share Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_NumberOfVotesPerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849939062936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="nump">8,467,491<span></span>
</td>
<td class="nump">7,338,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="nump">4,234,213<span></span>
</td>
<td class="nump">3,644,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="nump">613,098<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,620,180<span></span>
</td>
<td class="nump">2,993,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plrx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plrx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849934349704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,467,491<span></span>
</td>
<td class="nump">7,338,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember', window );">Incentive Stock Options and Nonqualified Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of stock option (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.94<span></span>
</td>
<td class="nump">$ 7.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_RestrictedStockAwardsMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,620,180<span></span>
</td>
<td class="nump">2,993,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Common stock shares outstanding percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,234,213<span></span>
</td>
<td class="nump">3,644,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders', window );">Exercise price as a percentage of estimated grant date fair value of shares</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period from date of grant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods', window );">Options under plan may be granted for periods</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders', window );">Exercise price as a percentage of estimated grant date fair value of shares</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_RestrictedCommonStockAwardsMember', window );">Restricted Common Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate fair value of restricted stock awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Total intrinsic value of outstanding unvested restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_RestrictedCommonStockAwardsMember', window );">Restricted Common Stock Awards | Accrued Expenses and Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_RestrictedCommonStockAwardsMember', window );">Restricted Common Stock Awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_RestrictedCommonStockAwardsMember', window );">Restricted Common Stock Awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember', window );">2015 Equity and 2020 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award exercise price with purchase price of common stock percentage of estimated grant date fair value for shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation options under plan may be granted for periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plrx_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plrx_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plrx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plrx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plrx_RestrictedCommonStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plrx_RestrictedCommonStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=plrx_AccruedExpensesAndOtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=plrx_AccruedExpensesAndOtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849937955432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Common Stock Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding and unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">126,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted during period (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested (in shares) | shares</a></td>
<td class="num">(103,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod', window );">Number of Shares, Repurchases (in shares) | shares</a></td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding and unvested, ending balance (in shares) | shares</a></td>
<td class="nump">21,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date fair value, Outstanding and unvested, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date fair value, Issued (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date fair value, Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">1.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date fair value, Repurchases (in dollars per share) | $ / shares</a></td>
<td class="nump">2.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date fair value, Outstanding and unvested, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were repurchased during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options repurchases weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plrx_RestrictedCommonStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plrx_RestrictedCommonStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849932912760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember', window );">Incentive Stock Options and Nonqualified Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">74.83%<span></span>
</td>
<td class="nump">72.10%<span></span>
</td>
<td class="nump">74.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">76.31%<span></span>
</td>
<td class="nump">77.50%<span></span>
</td>
<td class="nump">82.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.61%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
<td class="nump">1.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.39%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">2.59%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember', window );">Incentive Stock Options and Nonqualified Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 5 months 8 days<span></span>
</td>
<td class="text">5 years 3 months 3 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_UnderlyingCommonStockFairValue', window );">Underlying common stock fair value</a></td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="nump">$ 5.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember', window );">Incentive Stock Options and Nonqualified Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_UnderlyingCommonStockFairValue', window );">Underlying common stock fair value</a></td>
<td class="nump">$ 38.23<span></span>
</td>
<td class="nump">$ 28.79<span></span>
</td>
<td class="nump">$ 7.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months 29 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_UnderlyingCommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underlying common stock fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_UnderlyingCommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849933029448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Option Activity Under the 2015 Plan and 2020 Plan (Details) - 2015 Equity and 2020 Incentive Plan - Incentive Stock Options and Nonqualified Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">2,993,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,520,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised (in shares)</a></td>
<td class="num">(336,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited (in shares)</a></td>
<td class="num">(557,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance (in shares)</a></td>
<td class="nump">3,620,180<span></span>
</td>
<td class="nump">2,993,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable (in shares)</a></td>
<td class="nump">1,368,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">3,620,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Outstanding, Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 8.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Granted (in dollars per share)</a></td>
<td class="nump">26.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Exercised (in dollars per share)</a></td>
<td class="nump">5.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Forfeited (in dollars per share)</a></td>
<td class="nump">16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Outstanding, Ending balance (in dollars per share)</a></td>
<td class="nump">14.56<span></span>
</td>
<td class="nump">$ 8.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Exercisable (in dollars per share)</a></td>
<td class="nump">9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price per Share, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 14.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (in Years), Outstanding</a></td>
<td class="text">8 years 3 months<span></span>
</td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term (in Years), Exercisable</a></td>
<td class="text">7 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term (in Years), Vested and expected to vest</a></td>
<td class="text">7 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding balance</a></td>
<td class="nump">$ 16,735<span></span>
</td>
<td class="nump">$ 43,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">9,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 16,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139850032792200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,467,491<span></span>
</td>
<td class="nump">7,338,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,437,000<span></span>
</td>
<td class="nump">$ 3,895,000<span></span>
</td>
<td class="nump">$ 1,829,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Common stock shares outstanding percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Employee stock purchase plan, description</a></td>
<td class="text">The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1 of each calendar year, beginning January 1, 2021, by the least of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) 700,000 shares or (iii) such lesser amount as determined by the administrator of the 2020 ESPP, which is the compensation committee of the Board of Directors of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of payroll deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_EmployeeStockPurchasePlanOfferingPeriod', window );">Employee stock purchase plan offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_CommonStockFairMarketValuePercentage', window );">Common stock fair market value percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_CommonStockFairMarketValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock fair market value percentage .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_CommonStockFairMarketValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_EmployeeStockPurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_EmployeeStockPurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849933033416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months 29 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.72%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">67.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">89.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849934229784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Classification of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,437<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="nump">$ 1,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,928<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,509<span></span>
</td>
<td class="nump">$ 2,176<span></span>
</td>
<td class="nump">$ 1,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849940195480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>taxExamination</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Pre-tax U.S. book loss</a></td>
<td class="num">$ (97,300,000)<span></span>
</td>
<td class="nump">$ 41,500,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets', window );">Valuation allowance as a percentage on total deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_IncomeTaxExaminationNumberOfExaminationsPending', window );">Number of income tax examinations pending | taxExamination</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, income tax penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_IncomeTaxExaminationNumberOfExaminationsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax examination, number pending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_IncomeTaxExaminationNumberOfExaminationsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance as percentage on deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849934232312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company&#8217;s Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal', window );">General business credit&#8212;federal</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">295.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(50.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther', window );">Other permanent differences</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(33.20%)<span></span>
</td>
<td class="num">(32.60%)<span></span>
</td>
<td class="num">(267.70%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation general business tax credits federal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849932809128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 51,554<span></span>
</td>
<td class="nump">$ 27,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">13,989<span></span>
</td>
<td class="nump">7,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">70,426<span></span>
</td>
<td class="nump">36,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_DeferredTaxLiabilitiesFixedAssetBasis', window );">Fixed asset basis</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(921)<span></span>
</td>
<td class="num">(558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(1,760)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,742)<span></span>
</td>
<td class="num">(682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">67,684<span></span>
</td>
<td class="nump">35,441<span></span>
</td>
<td class="nump">$ 21,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_DeferredTaxLiabilitiesFixedAssetBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Fixed Asset Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_DeferredTaxLiabilitiesFixedAssetBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139850032791320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Operating Losses and Tax Credit Carry Forwards (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 14,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Starting from January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">155,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Before January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 29,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_OperatingLossCarryforwardsExpirationYear', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_OperatingLossCarryforwardsExpirationYear', window );">Net operating losses, Expiration year</a></td>
<td class="text">2037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 182,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 4,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_OperatingLossCarryforwardsExpirationYear', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_TaxCreditCarryforwardsExpirationYear', window );">Tax credits Expiration year</a></td>
<td class="text">2036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_OperatingLossCarryforwardsExpirationYear', window );">Net operating losses, Expiration year</a></td>
<td class="text">2041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_TaxCreditCarryforwardsExpirationYear', window );">Tax credits Expiration year</a></td>
<td class="text">2041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year that operating loss carryforwards expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_TaxCreditCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_TaxCreditCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=plrx_StartingFromJanuary12018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=plrx_StartingFromJanuary12018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=plrx_BeforeJanuary12018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=plrx_BeforeJanuary12018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849940365816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the beginning of the year</a></td>
<td class="nump">$ 35,441<span></span>
</td>
<td class="nump">$ 21,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases recorded to income tax provision</a></td>
<td class="nump">32,243<span></span>
</td>
<td class="nump">13,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the end of the year</a></td>
<td class="nump">$ 67,684<span></span>
</td>
<td class="nump">$ 35,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849939191912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract', window );"><strong>Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">January 1</a></td>
<td class="nump">$ 2,007<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Additions (reductions) for tax positions of prior year</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">December 31</a></td>
<td class="nump">$ 3,505<span></span>
</td>
<td class="nump">$ 2,007<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849932820248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ContractualArrangementsCancellationPeriod', window );">Contractual arrangements cancellation period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ContractualArrangementsCancellationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual arrangements cancellation period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ContractualArrangementsCancellationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849934133096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_PeriodOfBaseRentAbatement', window );">Period of base rent abatement</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_BaseRentAbatedAmount', window );">Base rent abated amount</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_LeasedSpaceUnderNonCancellableOperatingLease', window );">Leased premises under non cancelable operating lease | ft&#178;</a></td>
<td class="nump">32,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">84 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_LeaseTermExtensionNoticePeriod', window );">Lease term extension notice period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_LeaseTermExtensionNoticePeriod', window );">Lease term extension notice period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California | Other Non-current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Refundable security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_BaseRentAbatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base rent abated amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_BaseRentAbatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_LeaseTermExtensionNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease term extension notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_LeaseTermExtensionNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_LeasedSpaceUnderNonCancellableOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leased space under non cancellable operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_LeasedSpaceUnderNonCancellableOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_PeriodOfBaseRentAbatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Base Rent Abatement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_PeriodOfBaseRentAbatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849940191960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases, After Adoption of 842:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">2,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">8,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value discount</a></td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 7,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849940004680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-average Remaining Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849936660312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - California<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2023</a></td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2024</a></td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2025</a></td>
<td class="nump">1,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total lease payments</a></td>
<td class="nump">$ 7,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849933096568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">26,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Grant date fair value of stock option</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights, percent</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=plrx_ThirdRockVenturesMember', window );">Third Rock Ventures | Non-employee Director | Outstanding stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Grant date fair value of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The common shares subject to these options vest 1/12th on the last day of each calendar quarter over a three-year period and commenced vesting upon our IPO.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses | Third Rock Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting service expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grants in period fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=plrx_ThirdRockVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=plrx_ThirdRockVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plrx_NonemployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plrx_NonemployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849935329800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Payment made under defined contribution plan</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanPlanNameExtensibleList', window );">Defined Contribution Plan, Plan Name [Extensible List]</a></td>
<td class="text">Retirement Plan Name, Other [Member]<span></span>
</td>
<td class="text">Retirement Plan Name, Other [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanPlanNameExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates name of defined contribution plan designed to provide retirement benefits. Includes, but is not limited to, legal name of plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanPlanNameExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849932817208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,642,021<span></span>
</td>
<td class="nump">3,124,572<span></span>
</td>
<td class="nump">20,086,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,620,180<span></span>
</td>
<td class="nump">2,993,855<span></span>
</td>
<td class="nump">1,337,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember', window );">Restricted stock awards granted and not purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,195<span></span>
</td>
<td class="nump">4,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">21,841<span></span>
</td>
<td class="nump">126,522<span></span>
</td>
<td class="nump">302,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock (on an as-converted basis)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,442,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139849934239224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,263)<span></span>
</td>
<td class="num">$ (41,533)<span></span>
</td>
<td class="num">$ (631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: accretion to redemption value and dividends on redeemable convertible preferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,225)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (97,263)<span></span>
</td>
<td class="num">$ (41,533)<span></span>
</td>
<td class="num">$ (6,856)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">35,846,421<span></span>
</td>
<td class="nump">21,344,236<span></span>
</td>
<td class="nump">1,623,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">35,846,421<span></span>
</td>
<td class="nump">21,344,236<span></span>
</td>
<td class="nump">1,623,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share, attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (2.71)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (2.71)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>plrx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plrx="http://www.pliantrx.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plrx-20211231.xsd" xlink:type="simple"/>
    <context id="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0452ce794f54f2bb9a119d0f2ddb847_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8320fd52a1ae40e18b77aefd41de8571_I20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="i4c2aeb24bd264584a324aec3746051a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19974a4386bd4627a7211a58dab7ab17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id682893acc45496a970c56af4620e9fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8fad418d5e0c4442b3c947090aa4197d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1140261f7add41b5b728c3a650671ec6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e75b3a2844245b397c0918c42b28f6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id19e6266bc8b4ecca92ba96df80eff19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76c3089f6aa24936b58640c2e6b7da25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i105a9ac3dc914251920a2e0a79bd4eef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a323ae54ce842b387531c5805e9f231_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i352bc25f1a8b4f56a69867979fce6c4b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95bbcd616eec42679d3f2ba166e8427e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d5f0f71b08940e796377b4b0153bd67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaef884d5c4ad4ddc992fd9dc8a744804_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0ee10d79d854a2aa094cc081ddee51d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8427be0929874da48269b8a87d7e8ba7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dd41145a7974d92a2226a3fc35633a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25794e7f363a4bf1abd2e657b1000f09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife5a281e3e5b42d79b8b4f9a04af5d63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77ad7fa9b65442f2ba3cba3af87805a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb689d41a0fc49d096930b208671ff5a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc82fb340f724ed2902d29a505bc74c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i826b025c166f473987892842e39f1549_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6bbff1d55944244a3110049517d61da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffe3207e1e714584bed5756b07541340_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c41e7454f6a4547977cbf6b6a2349d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if537cc7d047f4502af240fda53df5d71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7fb96ee1b444920b7e071c2562a2d93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ac12187e1ff4ab9bc07add5cf0d39c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4029b81cb5354eb6ae5e85b44506260f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i763102559694449eb64cf66afe0a616f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6338bf9158f4706b6ad1a45102335fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f8cb5576bbf476b8d7705a54bb4ff2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53c7626359c74441b6a578b9d935f19c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8589e12213434e09abcb711b749141bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id52ffdf994934ba09ae03636d3857089_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8f4455a8e244490bb265a1a4f8a8cb0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ce83dd4cd2843efa13d02a41dcfe432_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5401e3f0f3d449e8847afa47baa6f9a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icbc20870287540578a9e62621b62c833_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i62be0d4030cf4d84a89b73f59b635fc1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iecc4ce257ab041eab3f3f31f4101a94f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie0e1e2bb434c4f519e0a4c7d227fc9d1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic95cde64854f441a96044b55c63e47c5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib3740b71577f46c7aa6db36ccc8e9008_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idcb6e46e8589417fbb6dce85ec4707e9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic7e2e2d92973409c98c50757da18b62d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic527f172d0e443c493b5b9528858fff0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i062d513c3af24fb8a871914681ad6ed0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic4f89da1832e4c048b3bf07808761b7c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">plrx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f4ededd465745ac8a09d27d629bf294_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61761cf5edab4bc4a348e46cd23dc2f4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1b3902b908614fb1b9c4a93bf96af64c_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iae29663b5db54f749ffcf7b5c72df914_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plrx:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i81a558379cd44a9ab226783aa88f48a7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibc3d94b8d41948578ccb00771371441d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plrx:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9550253bdd3e4a6da0f6c0d34c9b9d1a_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plrx:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib16143c3aac54e6ca3119c33948ae5eb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">plrx:PliantTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plrx:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia6f0aba9c8a241cea27a247b44371de6_D20200522-20200522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <startDate>2020-05-22</startDate>
            <endDate>2020-05-22</endDate>
        </period>
    </context>
    <context id="if4ff395e311847909da6a655116394ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97ba5b3806e14f8cb378e134282cefff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i72575f12fa974fe28bf756200624bdba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6401410f7ef49438a2f863fbc13df66_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4a0d9e0cac2348ca84c706c8288bceb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie79933d3e8de4b1dbcd02a40640ad95c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i502608fba6ca409d9d1c9db643401ed1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ccce3ad26234845a35af7149a3ec646_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iddc5aed3e7a8426487bf4c221631f7c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i771d84b1911848a9bbe7a4b3d4704f30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad109a114dc8411c89edb8c84d2b1e18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29ada465fe97416585c2b4b0679231ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95ed66f76be545c297192eb65c6e90ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i741c7a0fae7340c89c0beeec92183dff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c3fbf9468164232b5a4585f59962a25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fedf72de50140c3b7b150892abda892_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7be8fb727d34fd78dee97819061e39f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88eb8ff0e0954c70883407fca7e46607_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibbd310f10677481088f4abcc6a267dac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">plrx:MatureInOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i762f167b21754e29a50cab9db8dacfac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">plrx:MatureInOneToTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i788f10f5c97047c98f3a91d33d462adc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfb9d77c8aeb443b8744a5d136c48c67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad0147962f3a43ae98dc9257ca855342_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48f177c3974b433093600a48912c81ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb37502688b5432890a52460645ba22c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id16f08eb632f4af58a00d176e37ebf70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i604392abc5a0452d940c039026024807_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e78efdd427f4cb090c0239dd860231c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3ceadd77d9b4e6091731d2900ea887e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8691f274c844ea689788aa8180fc7ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icaafcff2da3c4e68a71fc38bc8eaeeef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8516b91fd4c4e219c9d323eabb5f186_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc186515959f44048d743426dc3fdbb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaac21b42661c400488b1fa60189baec8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a11a4aeb6da425289c1166b59fd1bef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icf4063173b5147aaa5ea48ffb9a0b41a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementRDForPLN1474Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id20b043448f24ec285209cd2157d817f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementRDForIntegrinResearchTargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i65678d1f069d4f07b494357695afab1c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementRDForPLN1474Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3487dc6202fc4061837be6f1764523cd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementRDForIntegrinResearchTargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f8872e361484321beb5a17ef1f8345f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d55eaa32322449995997cb4bfd779d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plrx:AchievementOfFirstPatientDosingMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7aab796f0bd54438a683ab44e486ff52_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac8fe1712787414792033f6f6a6693aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1401fc63110c46cca48abbee90d24210_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plrx:AchievementOfFirstPatientDosingMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8fd2e317fcf496da3fadf37239b10a7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia854acc757a14f42801309f5de85921c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">plrx:LicenseFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i935a529a108b4fe0854d7b486b19bf50_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief48b07f768842d19a26be0c2fdd1f5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1584a412397045a9b86f15e94c5effa9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plrx:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plrx:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia97bea2e62e046a3b667360c66ca83de_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plrx:UCRegentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i325f7f2d873247748a03caa8aa5d4255_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">plrx:AdimabAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis">plrx:FullTimeEmployeeCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d58d249d30a4738b31d13b2325bbf0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">plrx:AdimabAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis">plrx:FullTimeEmployeeCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92b24333fd1f4bc6a82043ff6caa6b4b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">plrx:AdimabAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis">plrx:FullTimeEmployeeCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i854a3335aa6a4adc9776beabc85e03a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39ce7df93a7d4382a3b7d79316b6d848_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d8e01ec8dfa4b258bddae261451f4ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id08bb42e6ee74106be86d58f7fcbc58f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d9b60a984584a44a4ee09a45e5275aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ff87434abfc452d80645776f0f00c77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cf105f8083b45429f14ea888203d42a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6f33d4df0354eefb5a56946ce9457da_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i978188554a324ce7b6a888947d74558d_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i290aba2015df4504b16ad472119c117d_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i2fc83290d82c40ddb10360a0b1a2183c_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i82f0177dc3e04d418b662056854c1e4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">plrx:AccruedExpensesAndOtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica5a99276a1147c19fe6753da55b633a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">plrx:AccruedExpensesAndOtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58ea8b06f17a484f9edfb9c294799d18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia016e7bdf0174df7a7fba019617bf8ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0866a31e05374ddab8c0a62345cc2249_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:RestrictedCommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i962e48e9796f47aeb0fff9145b63f53a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc0db696ccde415882e24106f2b32245_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d838bfb91454b308b74f37279c3dce3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f90bc5eed144f31928518fb768afba8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4dac08fa4ec49c8b7257c8ac25cdc21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idda313aa08fc4436871f7a8d1f6538ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96b95e5be86744cfb426abbbd9280039_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i93980ffa2b4c48c69c6aeaa148e56ca5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaee36529cae34a1880d776adf134e69e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib513e9b41ca0401988a6ebdb0da1f635_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie36ef4c5abf7430991b10fecc4a30686_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plrx:TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie08b0d8bbc764ddfa7bbdedd05be39a6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iff90f11d0095440091e5fe52c4904b74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i63754797203a4fa396889e7f6f569993_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c2c45617c474b8d8d2f5c5ec54bc1cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28a1619e7cc641e895b0a776ffb7951c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4dcffcd3361d45578bb203270ca62583_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d49e2ef8b934a9ca9872c2da4874dc1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0bc85e58f5bc489fbe3f59c43aa576af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8619df5f4bbc4c15a77403491fcf90bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9b2f94dc394411bb306ac98316895ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib90cfc2ccdd64c42ad8668e78941f9b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e35f96e1d3a4ff1b9a03fab757d000c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plrx:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8eb5094414c244a28314369adcc54cc5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31bce1e599344a70a32426478b95d1df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">plrx:StartingFromJanuary12018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73826d9211d549b896476358b41d3bde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">plrx:BeforeJanuary12018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff7f1036aa4b454fb82af94ab3f2ce41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a3ebd1303b143afb79b5a5535c7e658_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f33c2bafe3843d8bf470ed2c96ee5fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia814f0994a1449ce83dd2ebd288a95a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29fe77ab043541358883b2c7d9041522_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iddb8c639eb9a45ed83884b3db05c0ffd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6b323227a6846f1b65d034e58f88164_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i598f80db39ac4c599c0538ab9aae3c30_I20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="ib125d2281fd7483b97614c1e8f176399_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="ic31ace94ac1847898d10e8026fbd8b04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c910fd3e4444dd2b8564e3ace9a8326_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54765707cbc04888952c42feb9bd45de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i429668ed867b4b9eb0766f77046f00f3_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i339a84165f6b4c48adba2aba4271bc4a_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i7166be69743e4e60a692a5adc04dcd3f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">plrx:ThirdRockVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48fa76d3d2dd4c4c86df500aed228234_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">plrx:ThirdRockVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1f553a0f5fd4433b0cc4baba93fea24_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plrx:NonemployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">plrx:ThirdRockVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i342e8370c50840b5ab283afd24abbf11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plrx:NonemployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">plrx:ThirdRockVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47e995f177284199bb8b0695a7c9725d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c0035b443cb469b9de089f502f3e9c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18bd16bfffe94894922846cadcd48ed0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie24ad985733c48bfb53bfbd864d91f27_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68e2483823f6420cb6185c251c58ac55_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib34337582e984ae1ba7584d1346e1780_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id4eb9436dd324df99ee7f4d8e63df7e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plrx:RestrictedStockAwardsGrantedAndNotPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf1265c8744c461286d3671e01ec1cc8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plrx:RestrictedStockAwardsGrantedAndNotPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9964d5d87c0b4f47a4e7b2802949d585_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plrx:RestrictedStockAwardsGrantedAndNotPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i123f913abe274f3b80052d070e8729c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib31f0ac37c034f85b050eb91b4830b28_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a427494f6ff428e8b8a4b08835c85f7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001746473</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>plrx:segment</measure>
    </unit>
    <unit id="research">
        <measure>plrx:research</measure>
    </unit>
    <unit id="vote">
        <measure>plrx:vote</measure>
    </unit>
    <unit id="taxexamination">
        <measure>plrx:taxExamination</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N180L2ZyYWc6NjEwMmUwMzA3NmI1NGIwZWFjMDU5MDE1MjgxZmU3MWEvdGFibGU6ZTA2OTNmZWQwNmU4NDQ2OWEyNjlmNjAzY2FlNmU2YzMvdGFibGVyYW5nZTplMDY5M2ZlZDA2ZTg0NDY5YTI2OWY2MDNjYWU2ZTZjM18yLTEtMS0xLTEyNjU5_68444f7e-0299-4858-8e98-1dccdf47a348">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N180L2ZyYWc6NjEwMmUwMzA3NmI1NGIwZWFjMDU5MDE1MjgxZmU3MWEvdGFibGU6ZTA2OTNmZWQwNmU4NDQ2OWEyNjlmNjAzY2FlNmU2YzMvdGFibGVyYW5nZTplMDY5M2ZlZDA2ZTg0NDY5YTI2OWY2MDNjYWU2ZTZjM18zLTEtMS0xLTEyNjU5_d111b5ce-f34d-4dcf-82d4-dc41082bc4f9">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N180L2ZyYWc6NjEwMmUwMzA3NmI1NGIwZWFjMDU5MDE1MjgxZmU3MWEvdGFibGU6ZTA2OTNmZWQwNmU4NDQ2OWEyNjlmNjAzY2FlNmU2YzMvdGFibGVyYW5nZTplMDY5M2ZlZDA2ZTg0NDY5YTI2OWY2MDNjYWU2ZTZjM180LTEtMS0xLTEyNjU5_8cfe8b82-e290-4657-ad24-0b1379efa38f">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N180L2ZyYWc6NjEwMmUwMzA3NmI1NGIwZWFjMDU5MDE1MjgxZmU3MWEvdGFibGU6ZTA2OTNmZWQwNmU4NDQ2OWEyNjlmNjAzY2FlNmU2YzMvdGFibGVyYW5nZTplMDY5M2ZlZDA2ZTg0NDY5YTI2OWY2MDNjYWU2ZTZjM181LTEtMS0xLTEyNjU5_4c370458-89c0-4204-8403-67dad86dcbb8">0001746473</dei:EntityCentralIndexKey>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ia6f0aba9c8a241cea27a247b44371de6_D20200522-20200522"
      decimals="8"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzgxL2ZyYWc6MzkwZTg4OGVlOGE4NGRhZjk1MmFhYTk4MDI5MjA4N2UvdGFibGU6NmQ4ZjM4MTI2ZmZkNDk1NjhhM2FjZTg5ODMwYWM1YTYvdGFibGVyYW5nZTo2ZDhmMzgxMjZmZmQ0OTU2OGEzYWNlODk4MzBhYzVhNl8xLTEtMS0xLTI4ODcy_539f4045-4aa4-4e80-98c6-79465e1d5439"
      unitRef="number">0.13986014</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i290aba2015df4504b16ad472119c117d_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzM1NTY_17d5b407-5e02-4666-bc12-447640c0a66b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i962e48e9796f47aeb0fff9145b63f53a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzU0NDE_e2781c43-be0a-4144-b7b0-5f65f0005fa6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzg4L2ZyYWc6ZTZlNzBiN2FiNDAzNDQ5NDg3MTUzOGNiNzRmNjcwNGQvdGFibGU6MTgwOGVlM2FiMmFjNGI2ZGJlNWU0NjFjNTQ4MWJjYzUvdGFibGVyYW5nZToxODA4ZWUzYWIyYWM0YjZkYmU1ZTQ2MWM1NDgxYmNjNV8wLTEtMS0xLTI5MTE4_19bb4197-5d4e-4e30-8e1d-1f07af176d27">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i342e8370c50840b5ab283afd24abbf11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTQvZnJhZzpjMWJjY2ViYWVhZmI0ZjE1OGMwYzJjYThiMTBlNjIxYy90YWJsZTowNGI3YjBlMzNmMjE0YmJkODA1ZDE4MzQ1ZDcwNjIyNS90YWJsZXJhbmdlOjA0YjdiMGUzM2YyMTRiYmQ4MDVkMTgzNDVkNzA2MjI1XzEtMS0xLTEtMTI2NTk_9cae239d-06d8-4567-bd46-100e22c9650b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DefinedContributionPlanPlanNameExtensibleList
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjAvZnJhZzo3ODE2YmQ0ODM3ZWE0MWY0YmJmMzgxNjMxMGMwMGFjNS90YWJsZTpiNjJjMDJiNTlkOTk0ODcyOGIzZGJhOGFmZDIwNTY2Ny90YWJsZXJhbmdlOmI2MmMwMmI1OWQ5OTQ4NzI4YjNkYmE4YWZkMjA1NjY3XzEtMS0xLTEtMTI2NTk_8bef088e-aadc-4f23-8e2d-0ef293c964d4">http://fasb.org/us-gaap/2021-01-31#RetirementPlanNameOtherMember</us-gaap:DefinedContributionPlanPlanNameExtensibleList>
    <us-gaap:DefinedContributionPlanPlanNameExtensibleList
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjAvZnJhZzo3ODE2YmQ0ODM3ZWE0MWY0YmJmMzgxNjMxMGMwMGFjNS90YWJsZTpiNjJjMDJiNTlkOTk0ODcyOGIzZGJhOGFmZDIwNTY2Ny90YWJsZXJhbmdlOmI2MmMwMmI1OWQ5OTQ4NzI4YjNkYmE4YWZkMjA1NjY3XzEtMi0xLTEtMTI2NTk_a460edb0-8c21-4471-a022-a409c9f0d680">http://fasb.org/us-gaap/2021-01-31#RetirementPlanNameOtherMember</us-gaap:DefinedContributionPlanPlanNameExtensibleList>
    <dei:DocumentType
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDAx_d4800754-f591-45a9-9e00-8346608d0fc5">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6YWUzYTQ5NTY0ZjBhNDkwMDg1Y2VkZjdhOWIwZDM1NzcvdGFibGVyYW5nZTphZTNhNDk1NjRmMGE0OTAwODVjZWRmN2E5YjBkMzU3N18wLTAtMS0xLTEyNjU5_a158dc0e-9f77-433f-b9dd-cc19cc5efcb6">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8yMjA_6b4fe0e2-5568-4981-81fd-6a93521569c8">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8yMjA_56bd5d2d-47aa-4916-a0fc-daf8dda8e2cd">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6YTQ4YzM0NWE3N2M2NGQ4ODk3ZjNiNTUwOGE4MGMzNDkvdGFibGVyYW5nZTphNDhjMzQ1YTc3YzY0ZDg4OTdmM2I1NTA4YTgwYzM0OV8wLTAtMS0xLTEyNjU5_d282ec58-c0ad-4622-b713-34f63d8c256c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDAy_b23d0afa-adab-4b32-b2a2-0d4a3db0f063">001-39303</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDAz_abc6c56c-758a-4d1d-a42c-be56aa162cc8">PLIANT THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8wLTAtMS0xLTE5NDYy_cbe1feac-af77-47df-a603-4f0e09156c7e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8wLTMtMS0xLTEyNjU5_222e7dc2-ba43-4268-9538-a072a0972730">47-4272481</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8yLTAtMS0xLTEyNjU5_7ce98c30-4e3e-47ca-bcb1-c4bce9bb7cc3">260 Littlefield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8zLTAtMS0xLTEyNjU5_59f3bd92-449a-493f-a4be-1e398b48a5d9">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8zLTItMS0xLTEyNjU5_0fbc302f-9ed8-429a-bb26-9457709be03b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6NTkxYTI0YzcxYjIwNDhiNzlhNjZkNGZlZGM1MWQwZjQvdGFibGVyYW5nZTo1OTFhMjRjNzFiMjA0OGI3OWE2NmQ0ZmVkYzUxZDBmNF8zLTMtMS0xLTEyNjU5_3a72fa63-5eb5-434d-ad85-0031d0336c77">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDA0_eab2688a-532d-486e-9124-6e91130a8108">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zMzk3_239abe10-2342-40a6-99a3-67f7794a34a3">481-6770</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6ZDI1ZGZkOTVjNTMzNDc2N2IxNmU1MzdkZGRhODA3NjQvdGFibGVyYW5nZTpkMjVkZmQ5NWM1MzM0NzY3YjE2ZTUzN2RkZGE4MDc2NF8yLTAtMS0xLTEyNjU5_162eff64-018d-4109-9434-9e18c0dcaa14">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6ZDI1ZGZkOTVjNTMzNDc2N2IxNmU1MzdkZGRhODA3NjQvdGFibGVyYW5nZTpkMjVkZmQ5NWM1MzM0NzY3YjE2ZTUzN2RkZGE4MDc2NF8yLTEtMS0xLTEyNjU5_04fd1c7e-dd84-4019-aae9-9306dfa59078">PLRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6ZDI1ZGZkOTVjNTMzNDc2N2IxNmU1MzdkZGRhODA3NjQvdGFibGVyYW5nZTpkMjVkZmQ5NWM1MzM0NzY3YjE2ZTUzN2RkZGE4MDc2NF8yLTItMS0xLTE5NDY0_b916fde9-322e-4253-9a12-0d27c375f498">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xNDI5MzY1MTE2NDU3NQ_17bca756-fd1b-4fc6-831e-5f7194993a24">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xNDI5MzY1MTE2NDU3OQ_4bc90d9b-e8ed-44ab-953d-baf04a653e99">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xNDI5MzY1MTE2NDU4NQ_66bf38bf-98b8-4cdd-87f0-ed38995b39e1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xNDI5MzY1MTE2NDU5MQ_67ec24ea-b891-46fc-94ed-570d63e13ada">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6MDJjMDc4ZmE5MWI1NDU1OTlhMmFkYTkyMGQ5MmVhZWQvdGFibGVyYW5nZTowMmMwNzhmYTkxYjU0NTU5OWEyYWRhOTIwZDkyZWFlZF8wLTAtMS0xLTI4NDQ0_199342c4-b432-40d6-8c15-13881a699077">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6MDJjMDc4ZmE5MWI1NDU1OTlhMmFkYTkyMGQ5MmVhZWQvdGFibGVyYW5nZTowMmMwNzhmYTkxYjU0NTU5OWEyYWRhOTIwZDkyZWFlZF8yLTQtMS0xLTEyNjU5_e912b925-9a74-4bbf-b6de-f2945eb10e76">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGFibGU6MDJjMDc4ZmE5MWI1NDU1OTlhMmFkYTkyMGQ5MmVhZWQvdGFibGVyYW5nZTowMmMwNzhmYTkxYjU0NTU5OWEyYWRhOTIwZDkyZWFlZF80LTEtMS0xLTEyNjU5_727256ef-aa4b-4705-95e0-63d31c76d238">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV80Mzk4MDQ2NTE0NTEz_2a751655-6c9c-42ce-875e-0e9f17069a8c">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zMjk4NTM0ODg2NzYy_e22f25ee-f369-4132-b917-8f1a84b0c962">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ia0452ce794f54f2bb9a119d0f2ddb847_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8yODk5_eea67725-3c9c-4f5a-ab74-37613baf925c"
      unitRef="usd">751814002</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8320fd52a1ae40e18b77aefd41de8571_I20220225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8xMjY0NDM4MzcyMjk1NA_a96803c6-5764-4e70-981f-c8f929ad1514"
      unitRef="shares">36113521</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xL2ZyYWc6YzQ1NDdkOTljNDUxNGMwZjkwOTMzN2IzOWNhOGUyYTEvdGV4dHJlZ2lvbjpjNDU0N2Q5OWM0NTE0YzBmOTA5MzM3YjM5Y2E4ZTJhMV8zNDAw_ada5e995-3971-40b2-9bfa-29f394833761">&lt;div style="margin-top:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184Mi9mcmFnOjNkOWJkOTBhZWZkNDRmZGI5YmU4MGUzMWNiY2E5NDYxL3RleHRyZWdpb246M2Q5YmQ5MGFlZmQ0NGZkYjliZTgwZTMxY2JjYTk0NjFfMzI5ODUzNDkwNDAwMg_1a523547-3eef-4038-9a7c-dd3ca5025ea3">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184Mi9mcmFnOjNkOWJkOTBhZWZkNDRmZGI5YmU4MGUzMWNiY2E5NDYxL3RleHRyZWdpb246M2Q5YmQ5MGFlZmQ0NGZkYjliZTgwZTMxY2JjYTk0NjFfMTM3NDM4OTUzNjc4OTY_14b98500-dfe4-4a11-9cc3-f0c1f501bddb">34</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184Mi9mcmFnOjNkOWJkOTBhZWZkNDRmZGI5YmU4MGUzMWNiY2E5NDYxL3RleHRyZWdpb246M2Q5YmQ5MGFlZmQ0NGZkYjliZTgwZTMxY2JjYTk0NjFfMzI5ODUzNDkwNDAwNA_810cbe85-25af-466c-81da-54208d911ca7">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMy0xLTEtMS0xMjY1OQ_e7deb152-abee-44b4-b7fc-0b5cf7ab3641"
      unitRef="usd">51665000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMy0zLTEtMS0xMjY1OQ_08053b56-0e73-4cd3-a0af-8600aad70499"
      unitRef="usd">50882000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNC0xLTEtMS0xMjY1OQ_fa470899-ca96-48e2-8901-31cd19b125b6"
      unitRef="usd">148931000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNC0zLTEtMS0xMjY1OQ_6cfeac8b-dd56-429f-938c-98ba514a1587"
      unitRef="usd">226012000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNS0xLTEtMS0xMjY1OQ_76b2cd9e-a749-4ef6-831b-b7b290859374"
      unitRef="usd">1998000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNS0zLTEtMS0xMjY1OQ_e6b3b567-4360-40a6-a0ca-b7b997abffad"
      unitRef="usd">9279000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNi0xLTEtMS0xMjY1OQ_02dc2f80-9a18-4431-91ee-a03986e19ea3"
      unitRef="usd">83000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNi0zLTEtMS0xMjY1OQ_ff13470d-1483-4c8d-8240-bbd1f425635b"
      unitRef="usd">83000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNy0xLTEtMS0xMjY1OQ_ff8117c2-a332-4289-a672-6e6cc97fcb89"
      unitRef="usd">6764000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfNy0zLTEtMS0xMjY1OQ_16a5b38c-6395-43cc-8d8b-c2fc994b90b8"
      unitRef="usd">4498000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfOC0xLTEtMS0xMjY1OQ_935f263a-4714-41cc-aedb-f0eff95b7721"
      unitRef="usd">209441000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfOC0zLTEtMS0xMjY1OQ_cd851040-5e0c-486b-a09d-1dd58c57ef45"
      unitRef="usd">290754000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfOS0xLTEtMS0xMjY1OQ_33aa4132-e982-4e41-b4bd-7d200e0bdc5f"
      unitRef="usd">4606000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfOS0zLTEtMS0xMjY1OQ_028dfb27-8a7d-4703-b6ab-6e9baf5e53d4"
      unitRef="usd">4321000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTAtMS0xLTEtMTk3Mjc_5db5fdd6-5502-4b31-b6f2-bcae4d21edb7"
      unitRef="usd">6330000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTAtMy0xLTEtMTk3MzM_41064ec3-0ba6-461d-a784-d42e89ff9081"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTAtMS0xLTEtMTI2NTk_76df5775-505d-4c69-9fb3-ce272d606613"
      unitRef="usd">838000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTAtMy0xLTEtMTI2NTk_91c7252b-afd6-4111-aa13-30f196450721"
      unitRef="usd">451000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTEtMS0xLTEtMTI2NTk_1709e975-3a4c-4258-b6c8-6137edfdd191"
      unitRef="usd">221215000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTEtMy0xLTEtMTI2NTk_a8fe6f21-3607-45c5-9ff4-ca746f49c8bf"
      unitRef="usd">295526000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTQtMS0xLTEtMTI2NTk_76b4999b-5505-4a76-867a-33cc7c3a148d"
      unitRef="usd">2971000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTQtMy0xLTEtMTI2NTk_141a695e-b848-4034-b61f-6b0c3432ed7a"
      unitRef="usd">2023000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTUtMS0xLTEtMTI2NTk_1fe250eb-80db-4f89-a9f9-8a394dedb483"
      unitRef="usd">11991000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTUtMy0xLTEtMTI2NTk_655ba4c0-86cb-4ae2-b1d7-33f013aaaf9e"
      unitRef="usd">9576000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTctMS0xLTEtMTk3Mzk_c882a4bd-6a81-4d1b-9917-ac86358bcd14"
      unitRef="usd">1869000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTctMy0xLTEtMTk3NDU_dbcaa39b-48a6-4ae6-a6b5-d10bccfccd17"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTYtMS0xLTEtMTI2NTk_911cffa7-1c77-4f87-b956-4208c7379d8c"
      unitRef="usd">16831000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTYtMy0xLTEtMTI2NTk_333e9b42-8ed5-442b-9c6e-fcc19e180c1e"
      unitRef="usd">11599000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTktMS0xLTEtMTk3NjA_dbc176cd-221b-4eb9-9e22-2af9c04c0a95"
      unitRef="usd">5325000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTktMy0xLTEtMTk3NjY_7f1bd2a7-6f9a-4208-bf94-cb33b6ce2f2d"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTctMS0xLTEtMTI2NTk_731c7101-e59d-4f5e-a46c-f702b03b59de"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTctMy0xLTEtMTI2NTk_852e86e1-05f8-476b-ae87-dff66f024158"
      unitRef="usd">866000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTgtMS0xLTEtMTI2NTk_dd9fb72f-9640-400c-88fb-174669e245c9"
      unitRef="usd">22156000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTgtMy0xLTEtMTI2NTk_def455d4-65c8-4b82-9a9b-9fefc0e05e8e"
      unitRef="usd">12465000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTktMS0xLTEtMTI2NTk_617d5230-c2b7-4f07-98cc-2b1f14036d15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMTktMy0xLTEtMTI2NTk_32bf95a7-ef6f-468d-bdb8-23a81d5d7880"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDU3_06ec65b1-4e0e-4136-8ed4-4d266d613446"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDU3_a5dbced0-200d-4a5e-a7ca-dd841d2da932"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDQ3_039875d4-ad47-4614-8498-5e9f29f96071"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDQ3_74e28157-f445-4817-9ba0-e4359ea0bd44"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDIw_3b36e164-3130-4847-8679-38aa64344bf5"
      unitRef="shares">36083301</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDIw_c1cff679-d571-4b1d-bd95-e030bff1ae70"
      unitRef="shares">36083301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDMz_4a2060e6-c652-4a58-b8d8-cdb57393dd96"
      unitRef="shares">35552795</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjEtMC0xLTEtMTk1MjQvdGV4dHJlZ2lvbjo1NDUxMzQ0YzhiYWE0YzcxYjY2MDAyYjRmZTgwNjQwM184Nzk2MDkzMDIyNDMz_9a7a5254-5c80-4f72-9194-a65aaea50f4e"
      unitRef="shares">35552795</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjUtMS0xLTEtMTI2NTk_6d8aa990-5683-4a4a-b158-8ab3d8a4eb5d"
      unitRef="usd">3000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjUtMy0xLTEtMTI2NTk_8eaee3ad-dcdf-4a75-93e8-bab6daf2cf4f"
      unitRef="usd">3000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjYtMS0xLTEtMTI2NTk_cdec4b03-2266-4c18-840e-e53b1bf9ffbe"
      unitRef="usd">414348000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjYtMy0xLTEtMTI2NTk_78838422-686f-4f58-85c9-ae91a10cd6b4"
      unitRef="usd">400918000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjctMS0xLTEtMTI2NTk_c418c687-7ef8-4be5-9418-2c65d57864c4"
      unitRef="usd">-215091000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjctMy0xLTEtMTI2NTk_3f2d4caf-9b69-4f0e-a4f5-1fd5dba00c55"
      unitRef="usd">-117828000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjgtMS0xLTEtMTI2NTk_d48f1ddf-02e8-44cd-af7d-d0c77bf2c1d1"
      unitRef="usd">-201000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjgtMy0xLTEtMTI2NTk_1627e30b-c6fa-4e6d-9f00-80559956f1b5"
      unitRef="usd">-32000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjktMS0xLTEtMTI2NTk_7796c29a-ff8b-4250-84c5-0fa7a95d3eb6"
      unitRef="usd">199059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMjktMy0xLTEtMTI2NTk_ac681f87-168d-455a-8b97-bce75cf816ac"
      unitRef="usd">283061000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMzAtMS0xLTEtMTI2NTk_fe35aa22-96d6-4f44-9ad9-329e36839765"
      unitRef="usd">221215000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N184NS9mcmFnOjQ3NTBjYzE1N2ZkMTQ3YTZiNzA2NDY1ZmVlM2U2MjJkL3RhYmxlOmNlMTZmMmZkYjljODRjYzFhZmE2ODA1YmYzNWVkMzE0L3RhYmxlcmFuZ2U6Y2UxNmYyZmRiOWM4NGNjMWFmYTY4MDViZjM1ZWQzMTRfMzAtMy0xLTEtMTI2NTk_5c5196f5-92a6-4f27-a31d-86850ecce292"
      unitRef="usd">295526000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMi0xLTEtMS0xMjY1OQ_43709db1-a733-4215-a87e-85a4db810e25"
      unitRef="usd">7572000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMi0zLTEtMS0xMjY1OQ_8d8e731f-4216-4563-a8f3-e3c49dde5e10"
      unitRef="usd">41817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMi01LTEtMS0xNjQ5Mw_6509f84c-2b42-4ac9-9c2d-6850edc346e0"
      unitRef="usd">57052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNC0xLTEtMS0xMjY1OQ_a7f0b0e3-67de-4f89-aff2-1156b2e35afa"
      unitRef="usd">77549000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNC0zLTEtMS0xMjY1OQ_1cd8467b-858c-44d4-bc8b-36420d40970c"
      unitRef="usd">66193000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNC01LTEtMS0xNjQ5Mw_1fcc95b9-cf53-4654-8ee6-bba2e1130991"
      unitRef="usd">47353000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNS0xLTEtMS0xMjY1OQ_d5ef6fc7-1f7c-485b-bd50-c81193310b32"
      unitRef="usd">27558000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNS0zLTEtMS0xMjY1OQ_ac750d54-36e0-45ab-9611-23d8c6778658"
      unitRef="usd">17269000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNS01LTEtMS0xNjQ5Mw_549b3457-0671-480e-9075-cea7f5ce27d6"
      unitRef="usd">10930000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNi0xLTEtMS0xMjY1OQ_49166be8-5122-4dfe-b569-be637636cf37"
      unitRef="usd">105107000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNi0zLTEtMS0xMjY1OQ_3785fa9b-75c2-4a86-a3fb-a92ddec845e7"
      unitRef="usd">83462000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNi01LTEtMS0xNjQ5Mw_38e176b9-22c6-4e57-a116-1c81a4ad969f"
      unitRef="usd">58283000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNy0xLTEtMS0xMjY1OQ_f38d5948-f6d8-4f75-9ccd-2084737e0b4d"
      unitRef="usd">-97535000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNy0zLTEtMS0xMjY1OQ_e65e6b0f-422a-4d44-8eba-041cb1f70d09"
      unitRef="usd">-41645000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfNy01LTEtMS0xNjQ5Mw_795840a3-09e9-43da-8b31-99edf154eb06"
      unitRef="usd">-1231000</us-gaap:OperatingIncomeLoss>
    <plrx:InterestAndOtherIncomeNet
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfOC0xLTEtMS0xMjY1OQ_a6f12709-8801-4cab-8788-ff82e9f3c51f"
      unitRef="usd">272000</plrx:InterestAndOtherIncomeNet>
    <plrx:InterestAndOtherIncomeNet
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfOC0zLTEtMS0xMjY1OQ_43ccc982-5fdb-4a14-b22d-15b106bb8597"
      unitRef="usd">112000</plrx:InterestAndOtherIncomeNet>
    <plrx:InterestAndOtherIncomeNet
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfOC01LTEtMS0xNjQ5Mw_20834711-4f53-41f4-a166-1423acdcfe7c"
      unitRef="usd">600000</plrx:InterestAndOtherIncomeNet>
    <us-gaap:NetIncomeLoss
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTAtMS0xLTEtMTI2NTk_df162a57-2d70-4034-ac6f-f61210a5fc59"
      unitRef="usd">-97263000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTAtMy0xLTEtMTI2NTk_9caeafb3-9d8b-4a56-afd8-c3891c82bf7f"
      unitRef="usd">-41533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTAtNS0xLTEtMTY0OTM_e4ceb873-d4b9-4da2-b031-38e70d4e919a"
      unitRef="usd">-631000</us-gaap:NetIncomeLoss>
    <plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTEtMS0xLTEtMTI2NTk_fdd4dab4-dcdc-4c35-91ae-42357c2793d3"
      unitRef="usd">0</plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock>
    <plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTEtMy0xLTEtMTI2NTk_de64c902-fc2f-402e-a7ec-0fe07f75f99e"
      unitRef="usd">0</plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock>
    <plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTEtNS0xLTEtMTY0OTM_231dfe55-2309-48dd-aba6-e5ef6789c01d"
      unitRef="usd">6225000</plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTItMS0xLTEtMTI2NTk_c3f4e9ce-1e94-40b0-b9c4-97df27bca875"
      unitRef="usd">-97263000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTItMy0xLTEtMTI2NTk_487f266b-e7cb-484b-8451-47a031c90e5d"
      unitRef="usd">-41533000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTItNS0xLTEtMTY0OTM_26d10232-c1b4-4e4f-8c92-a4c2b1b02923"
      unitRef="usd">-6856000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTQtMS0xLTEtMTI2NTk_fba350fc-bb6b-460e-b303-15c4ff3ade47"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTQtMy0xLTEtMTI2NTk_fd5318b9-6efa-4991-bb83-170bf81e125f"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTQtNS0xLTEtMTY0OTM_1ec160aa-b579-48af-80c8-5394055bcb5d"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTUtMS0xLTEtMTI2NTk_d2e8ab20-b744-4b26-a366-cba978c03cbf"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTUtMy0xLTEtMTI2NTk_fc5b2c57-57b6-4861-90af-87407c3df2ff"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTUtNS0xLTEtMTY0OTM_d79744b6-848d-480c-b98a-8db51a281440"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTctMS0xLTEtMTI2NTk_9d10dc74-8372-4936-b4a3-aa35bdabd89b"
      unitRef="shares">35846421</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTctMy0xLTEtMTI2NTk_ac593688-8c97-4073-8ffb-c290805c8c8e"
      unitRef="shares">21344236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTctNS0xLTEtMTY0OTM_39295e0c-e1b9-43b7-bd52-3ce77bae651e"
      unitRef="shares">1623358</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTgtMS0xLTEtMTI2NTk_3301c863-8364-448b-bd79-cd06b80e275b"
      unitRef="shares">35846421</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTgtMy0xLTEtMTI2NTk_b87ea826-6c35-46b7-a500-147ffe3b4a01"
      unitRef="shares">21344236</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMTgtNS0xLTEtMTY0OTM_023c991c-ef55-417f-9385-d917a6131409"
      unitRef="shares">1623358</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjAtMS0xLTEtMTI2NTk_033a4c42-6fd8-46f7-adb2-c72eafaa02f1"
      unitRef="usd">-97263000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjAtMy0xLTEtMTI2NTk_1eb81e1a-8855-487f-b5ea-ef583f3f7286"
      unitRef="usd">-41533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjAtNS0xLTEtMTY0OTM_a841dcda-ee17-4ef9-9f33-4dda3a656166"
      unitRef="usd">-631000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjItMS0xLTEtMTI2NTk_a3ee09c6-2038-4e4d-ba1b-dde2fdf2f7d3"
      unitRef="usd">-169000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjItMy0xLTEtMTI2NTk_a7a77d9f-b29d-4538-89ec-050c4e9d1b09"
      unitRef="usd">-31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjItNS0xLTEtMTY0OTM_f18f50d2-1535-4d16-a530-897b5b257f07"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjMtMS0xLTEtMTI2NTk_b02b73c7-7846-49b8-a10a-2442a41065bb"
      unitRef="usd">-169000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjMtMy0xLTEtMTI2NTk_983ce3c0-fb00-4c6b-bbb7-99bcbb60db30"
      unitRef="usd">-31000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjMtNS0xLTEtMTY0OTM_522dd3fd-746e-4f73-9c94-8d152397f28d"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjQtMS0xLTEtMTI2NTk_ba94f668-be85-4fa3-8e11-e05214b1a8a1"
      unitRef="usd">-97432000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjQtMy0xLTEtMTI2NTk_f742d346-b000-468f-9395-54e5de67ecf1"
      unitRef="usd">-41564000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185MS9mcmFnOmFjYjQ4YTgyZjAyNjRmZGQ4M2ZmOGJjNWZhZmYxYTU3L3RhYmxlOmRjMDMwNGY4MmRlNzQzYTdhZWIxYWI3MGRjOTM0MzNiL3RhYmxlcmFuZ2U6ZGMwMzA0ZjgyZGU3NDNhN2FlYjFhYjcwZGM5MzQzM2JfMjQtNS0xLTEtMTY0OTM_6a7cc289-99ca-4a09-a7c0-cc9278fc5414"
      unitRef="usd">-632000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8fad418d5e0c4442b3c947090aa4197d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xLTEtMS0xMjY1OQ_74c1220b-1fee-4538-b57a-2c6cb09755af"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i8fad418d5e0c4442b3c947090aa4197d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0zLTEtMS0xMjY1OQ_8609d43c-20fe-4e36-842d-dc2ecba8e3a1"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i1140261f7add41b5b728c3a650671ec6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy01LTEtMS0xMjY1OQ_472db416-346a-447a-8c61-170b85405fe7"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i1140261f7add41b5b728c3a650671ec6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy03LTEtMS0xMjY1OQ_86979281-e67f-4edb-8dfa-f06489cbbbb2"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7e75b3a2844245b397c0918c42b28f6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy05LTEtMS0xMjY1OQ_946c1a04-d94b-4e94-8056-46fe0f572192"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7e75b3a2844245b397c0918c42b28f6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xMS0xLTEtMTI2NTk_384bd584-67be-4e11-804e-3f835e4aed1d"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xMy0xLTEtMTI2NTk_389baf30-53f9-4814-a0b5-73fcb75b5109"
      unitRef="shares">35552795</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xNS0xLTEtMTI2NTk_40f67bd8-387c-4b6f-bc5f-e38d94dcfd65"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id19e6266bc8b4ecca92ba96df80eff19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xNy0xLTEtMTI2NTk_a515ee42-0802-454a-bd20-84d117679a7d"
      unitRef="usd">400918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i76c3089f6aa24936b58640c2e6b7da25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0xOS0xLTEtMTI2NTk_fd3052f1-0a05-42d1-833c-b639cffa39f8"
      unitRef="usd">-32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i105a9ac3dc914251920a2e0a79bd4eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0yMS0xLTEtMTI2NTk_00e394e6-c743-420a-8830-bc455a6c2ad6"
      unitRef="usd">-117828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMy0yMy0xLTEtMTI2NTk_8ca3c0a6-6839-41ad-a0b0-2e39ff3defc5"
      unitRef="usd">283061000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i7a323ae54ce842b387531c5805e9f231_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOC0xMy0xLTEtMTI2NTk_1b5634c7-232f-4079-ad0a-cee5534b152d"
      unitRef="shares">103164</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i352bc25f1a8b4f56a69867979fce6c4b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOC0xNy0xLTEtMTI2NTk_7481d474-7c65-48c6-9405-4b742c74633e"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOC0yMy0xLTEtMTI2NTk_18764d74-654a-4649-befb-775a910b3003"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7a323ae54ce842b387531c5805e9f231_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOS0xMy0xLTEtMTI2NTk_15b0831d-edbc-4bee-85a6-e3fa1a977d6e"
      unitRef="shares">427342</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i352bc25f1a8b4f56a69867979fce6c4b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOS0xNy0xLTEtMTI2NTk_ea7bd513-ab60-4d8c-9e1d-54f189882897"
      unitRef="usd">2984000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfOS0yMy0xLTEtMTI2NTk_933c0f82-a254-46d6-882f-d016b0cb5530"
      unitRef="usd">2984000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i352bc25f1a8b4f56a69867979fce6c4b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTAtMTctMS0xLTEyNjU5_4e4d1c89-c4f5-42b7-8540-d693ee0b74ad"
      unitRef="usd">10437000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTAtMjMtMS0xLTEyNjU5_7a50b888-b5d3-46fc-ae2e-67b06ca85153"
      unitRef="usd">10437000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i95bbcd616eec42679d3f2ba166e8427e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTEtMTktMS0xLTEyNjU5_0840dac0-7141-4cb9-942b-adc5c16f767a"
      unitRef="usd">-169000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTEtMjMtMS0xLTEyNjU5_c11d7b31-5672-4ef2-b4da-e80867a87960"
      unitRef="usd">-169000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i1d5f0f71b08940e796377b4b0153bd67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTItMjEtMS0xLTEyNjU5_221cea42-96f9-4931-926c-06466d0973a6"
      unitRef="usd">-97263000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTItMjMtMS0xLTEyNjU5_2f9a88bf-ebfb-4b8d-9f7c-4ad7fd7fe150"
      unitRef="usd">-97263000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iaef884d5c4ad4ddc992fd9dc8a744804_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMS0xLTEtMTI2NTk_4041d095-be3e-456c-9109-82e628d6a831"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iaef884d5c4ad4ddc992fd9dc8a744804_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMy0xLTEtMTI2NTk_c2618104-ea96-410b-86bd-ce21b00ccb5e"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if0ee10d79d854a2aa094cc081ddee51d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtNS0xLTEtMTI2NTk_edbacc9d-cc43-4058-a9db-2952f4a0e714"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="if0ee10d79d854a2aa094cc081ddee51d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtNy0xLTEtMTI2NTk_3f45c628-be76-46d7-8b83-39b83610ace0"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8427be0929874da48269b8a87d7e8ba7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtOS0xLTEtMTI2NTk_beee8b4f-9d1f-42a8-b88d-f1b1c26a70ab"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i8427be0929874da48269b8a87d7e8ba7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTEtMS0xLTEyNjU5_6b11e280-b467-4f0b-a701-9577a1f33eb6"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9dd41145a7974d92a2226a3fc35633a9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTMtMS0xLTEyNjU5_6fc568f7-2924-4e84-b4df-abfe5a9542a7"
      unitRef="shares">36083301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9dd41145a7974d92a2226a3fc35633a9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTUtMS0xLTEyNjU5_d4fc6217-2bf3-4f9b-8ffd-96902c2180a4"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25794e7f363a4bf1abd2e657b1000f09_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTctMS0xLTEyNjU5_2f65ae20-5a5c-4026-9e97-af9c4f202f36"
      unitRef="usd">414348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife5a281e3e5b42d79b8b4f9a04af5d63_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMTktMS0xLTEyNjU5_48525e99-5b56-4d3d-824a-2092b7b20ed5"
      unitRef="usd">-201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77ad7fa9b65442f2ba3cba3af87805a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMjEtMS0xLTEyNjU5_678b5500-9897-4e07-a514-8e2a95b7841d"
      unitRef="usd">-215091000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmY5YjcwYjg2MzAxYjRhODk5Y2Y0YmQ3NDg1OWI5OTk2L3RhYmxlcmFuZ2U6ZjliNzBiODYzMDFiNGE4OTljZjRiZDc0ODU5Yjk5OTZfMTMtMjMtMS0xLTEyNjU5_df23b086-1bbe-45f7-becc-ed210c7a8042"
      unitRef="usd">199059000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="idb689d41a0fc49d096930b208671ff5a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xLTEtMS0xMjY1OQ_62ed75ca-0e62-4a67-8a80-50dd53ca8a23"
      unitRef="shares">56000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="idb689d41a0fc49d096930b208671ff5a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0zLTEtMS0xMjY1OQ_a16f9b3b-6bf1-4929-850e-0479bbd44405"
      unitRef="usd">62468000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ibc82fb340f724ed2902d29a505bc74c7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy01LTEtMS0xMjY1OQ_c665fb37-0bde-4b21-850f-e2b5136a7859"
      unitRef="shares">49501221</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ibc82fb340f724ed2902d29a505bc74c7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy03LTEtMS0xMjY1OQ_50da6a55-20c3-4614-86c7-a3e239f96350"
      unitRef="usd">75860000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy05LTEtMS0xMjY1OQ_3c52a9f8-31f9-4ab1-9ee3-b01b7ec58a78"
      unitRef="shares">26360745</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xMS0xLTEtMTI2NTk_4d29f2f5-6010-4656-8984-66a432f80313"
      unitRef="usd">47947000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i826b025c166f473987892842e39f1549_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xMy0xLTEtMTI2NTk_a09d8106-5510-47da-bbf5-d045731a6502"
      unitRef="shares">1846024</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i826b025c166f473987892842e39f1549_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xNS0xLTEtMTI2NTk_3b1b74b2-7b92-426c-9fd4-cee538093df1"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6bbff1d55944244a3110049517d61da_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xNy0xLTEtMTI2NTk_e589c622-a4a9-4f54-b553-c766c1f4e1c5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffe3207e1e714584bed5756b07541340_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0xOS0xLTEtMTI2NTk_6ef51cd1-5d5b-445e-b90b-542fb2d349cf"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c41e7454f6a4547977cbf6b6a2349d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0yMS0xLTEtMTI2NTk_a76a6963-c5a4-4d04-a5bd-c90485475c9d"
      unitRef="usd">-76295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMy0yMy0xLTEtMTI2NTk_1df113a7-cc9a-471a-bbb3-14d08b910149"
      unitRef="usd">-76295000</us-gaap:StockholdersEquity>
    <plrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="if537cc7d047f4502af240fda53df5d71_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNC05LTEtMS0xMjY1OQ_f947ddaa-33fe-4a28-97e6-1a0f24a14901"
      unitRef="shares">28527313</plrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="if537cc7d047f4502af240fda53df5d71_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNC0xMS0xLTEtMTI2NTk_9b80572e-7ddd-4a13-a79b-88d4ab1ef8d1"
      unitRef="usd">52019000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if7fb96ee1b444920b7e071c2562a2d93_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xMy0xLTEtMTY1OTI_eb09a541-aea8-4c7c-9d38-5eac2e586d9c"
      unitRef="shares">10350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if7fb96ee1b444920b7e071c2562a2d93_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xNS0xLTEtMTY1OTg_c0f4018b-10f5-4e20-bee0-410f6b93aa79"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9ac12187e1ff4ab9bc07add5cf0d39c5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xNy0xLTEtMTY2MDQ_61df1731-0ba3-4978-a99b-b87340bc15ac"
      unitRef="usd">148277000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4029b81cb5354eb6ae5e85b44506260f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0yMy0xLTEtMTY2MjI_1186da5c-be5f-46be-b2d6-7d71c89339f0"
      unitRef="usd">148278000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i763102559694449eb64cf66afe0a616f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0xMy0xLTEtMTY1OTI_473735dd-c5bc-4e74-8f17-375b676b3cde"
      unitRef="shares">625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic6338bf9158f4706b6ad1a45102335fb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0xNy0xLTEtMTY2MDQ_e13732db-3a7a-4fae-8d38-831ac0f7380a"
      unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2f8cb5576bbf476b8d7705a54bb4ff2a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0yMy0xLTEtMTY2MjI_d0ae5cc2-bc76-4498-bff9-3ac6e409d047"
      unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i53c7626359c74441b6a578b9d935f19c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xLTEtMS0xNjU1Ng_5ab8ba6c-17a1-41f5-9726-1021497a437b"
      unitRef="shares">-56000000</plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i53c7626359c74441b6a578b9d935f19c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0zLTEtMS0xNjU2Mg_60d0f6b6-96e8-4705-8d00-8aeda409866b"
      unitRef="usd">-62468000</plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i8589e12213434e09abcb711b749141bd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy01LTEtMS0xNjU2OA_6c547d5f-2d6e-4e8a-9bce-906916e22bc4"
      unitRef="shares">-49501221</plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8589e12213434e09abcb711b749141bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy03LTEtMS0xNjU3NA_e5ba5567-6631-4283-a30d-eee8beca6cf4"
      unitRef="usd">-75860000</plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="if537cc7d047f4502af240fda53df5d71_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy05LTEtMS0xNjU4MA_3b109066-396c-48f7-a4de-966f42823c6f"
      unitRef="shares">-54888058</plrx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if537cc7d047f4502af240fda53df5d71_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xMS0xLTEtMTY1ODY_0fd3c0a9-288a-4cca-bf8a-729091a2f261"
      unitRef="usd">-99966000</plrx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xMy0xLTEtMTY1OTI_6a6ebde5-0308-4ca6-9963-be267b5b0afa"
      unitRef="shares">22432029</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xNS0xLTEtMTY1OTg_d3be7632-6c2a-4110-abbf-bc972d1b6b7a"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id52ffdf994934ba09ae03636d3857089_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0xNy0xLTEtMTY2MDQ_a6e1b966-0263-4da3-a145-4b6e46dde1e9"
      unitRef="usd">238293000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id8f4455a8e244490bb265a1a4f8a8cb0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0yMS0xLTEtMTY2MTY_6877a44d-9bbc-4364-9155-8d48ab49bd59"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNy0yMy0xLTEtMTY2MjI_72522c3e-5f77-437e-b12a-014a8deb27a2"
      unitRef="usd">238294000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xMy0xLTEtMTI2NTk_df9a66e9-7d46-482a-ab9b-f2cabbfa6542"
      unitRef="shares">163544</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id52ffdf994934ba09ae03636d3857089_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0xNy0xLTEtMTI2NTk_2cfdab7a-0d24-4fe9-8789-e3fadc4c12e2"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNS0yMy0xLTEtMTI2NTk_a61bceab-2393-4db4-92b4-89fcca731419"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4324a45a54bc48deabad0c46f503ccd1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0xMy0xLTEtMTI2NTk_62a61122-288c-4de7-9a68-e4abb2429cf7"
      unitRef="shares">136198</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id52ffdf994934ba09ae03636d3857089_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0xNy0xLTEtMTI2NTk_3e82af2e-cc14-4a5f-907c-b4ff9edefd47"
      unitRef="usd">442000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfNi0yMy0xLTEtMTI2NTk_36bc4153-3bb6-4aa1-bb5e-8f20681ecbb4"
      unitRef="usd">442000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id52ffdf994934ba09ae03636d3857089_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfOC0xNy0xLTEtMTI2NTk_ced8ae3a-be59-4b11-a663-563b15669c6d"
      unitRef="usd">3895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfOC0yMy0xLTEtMTI2NTk_0469fa6a-7fdd-4853-8b58-49ccc70aa5ed"
      unitRef="usd">3895000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4ce83dd4cd2843efa13d02a41dcfe432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfOS0xOS0xLTEtMTI2NTk_6e40e117-77a2-4632-92a2-9fda757b3bc9"
      unitRef="usd">-31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfOS0yMy0xLTEtMTI2NTk_dac6e76b-d106-47eb-9b45-c25d0b6dd1ac"
      unitRef="usd">-31000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="id8f4455a8e244490bb265a1a4f8a8cb0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTAtMjEtMS0xLTEyNjU5_83153806-b257-4a01-a6d7-9ed50965aabc"
      unitRef="usd">-41533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTAtMjMtMS0xLTEyNjU5_d317b939-0c7d-4f20-91d8-9ad7c28b4d4f"
      unitRef="usd">-41533000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8fad418d5e0c4442b3c947090aa4197d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMS0xLTEtMTI2NTk_e5fd3b49-910d-4908-b92d-622bd89bcebf"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i8fad418d5e0c4442b3c947090aa4197d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMy0xLTEtMTI2NTk_f6b4138e-a03c-4605-a1d4-54f5bd2fd0c3"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i1140261f7add41b5b728c3a650671ec6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtNS0xLTEtMTI2NTk_11645f96-4f75-4147-9a27-0ff8f953c794"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i1140261f7add41b5b728c3a650671ec6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtNy0xLTEtMTI2NTk_23cedd57-ea26-4d4e-9d53-559c9bb970bb"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7e75b3a2844245b397c0918c42b28f6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtOS0xLTEtMTI2NTk_e16d3827-78f5-4126-894f-52980be36b52"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7e75b3a2844245b397c0918c42b28f6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTEtMS0xLTEyNjU5_4c279138-02d7-4e90-a89c-b6e2462da702"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTMtMS0xLTEyNjU5_1dab5505-3964-485b-96e7-be46efc5ab31"
      unitRef="shares">35552795</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i531a5827fe9b4d4cb9b6f497f726d0b7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTUtMS0xLTEyNjU5_3ea090eb-bcdc-4c0d-91e2-bbc827b2d285"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id19e6266bc8b4ecca92ba96df80eff19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTctMS0xLTEyNjU5_d5404b6e-2a87-4e7b-bcab-0d388eeb1e43"
      unitRef="usd">400918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i76c3089f6aa24936b58640c2e6b7da25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMTktMS0xLTEyNjU5_d4336ba7-e697-498c-9656-50c4f3757fa2"
      unitRef="usd">-32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i105a9ac3dc914251920a2e0a79bd4eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMjEtMS0xLTEyNjU5_63fb4249-a867-4076-b0a2-593bf245b7bc"
      unitRef="usd">-117828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOjIxZDc0Yjk4MmI5NjRjNTI4OWE5MmM0NTNjYTAwYjg3L3RhYmxlcmFuZ2U6MjFkNzRiOTgyYjk2NGM1Mjg5YTkyYzQ1M2NhMDBiODdfMTEtMjMtMS0xLTEyNjU5_f91f2096-79cb-4cae-8f87-cd34f541b2b2"
      unitRef="usd">283061000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ie5401e3f0f3d449e8847afa47baa6f9a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xLTEtMS0xODQ5MQ_fec2b7f6-a157-423a-bf6a-ae16b48d829c"
      unitRef="shares">56000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ie5401e3f0f3d449e8847afa47baa6f9a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0zLTEtMS0xODQ5MQ_867083d0-c600-4b45-ad5b-f545ca107ffe"
      unitRef="usd">61516000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="icbc20870287540578a9e62621b62c833_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy01LTEtMS0xODQ5MQ_3ec1b6da-6d54-4eea-ac34-5bc7d68f9d87"
      unitRef="shares">49501221</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="icbc20870287540578a9e62621b62c833_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy03LTEtMS0xODQ5MQ_b054b994-2e7f-46bf-b307-29af2838e1f1"
      unitRef="usd">70587000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i62be0d4030cf4d84a89b73f59b635fc1_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy05LTEtMS0xODQ5MQ_5e5c741b-72c3-45a5-b981-16c57e944a2d"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i62be0d4030cf4d84a89b73f59b635fc1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xMS0xLTEtMTg0OTE_241aed9a-1350-426a-a4ad-3301fb8b98c0"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iecc4ce257ab041eab3f3f31f4101a94f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xMy0xLTEtMTg0OTE_5547312d-239a-4107-afb8-d49351a7a120"
      unitRef="shares">1363000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iecc4ce257ab041eab3f3f31f4101a94f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xNS0xLTEtMTg0OTE_df729cad-ea7d-4aae-b564-738d9ae30b8d"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0e1e2bb434c4f519e0a4c7d227fc9d1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xNy0xLTEtMTg0OTE_85be2b46-5552-4a97-b669-e0a8583db3ed"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic95cde64854f441a96044b55c63e47c5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0xOS0xLTEtMTg0OTE_04d2db2c-806f-4d98-adc8-d5aeb4f7aefc"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3740b71577f46c7aa6db36ccc8e9008_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0yMS0xLTEtMTg0OTE_c9a87193-3593-44b5-a249-a1df593aff56"
      unitRef="usd">-71470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcb6e46e8589417fbb6dce85ec4707e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMy0yMy0xLTEtMTg0OTE_c55655bf-5a7a-4dad-8a09-6c496adbf848"
      unitRef="usd">-71469000</us-gaap:StockholdersEquity>
    <plrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ic7e2e2d92973409c98c50757da18b62d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNC05LTEtMS0xODQ5MQ_199a9ef7-2748-47f5-a055-047ce3fde498"
      unitRef="shares">26360745</plrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="ic7e2e2d92973409c98c50757da18b62d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNC0xMS0xLTEtMTg0OTE_5e9d0ae3-399e-4583-913f-18c2a53dc2c4"
      unitRef="usd">47947000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic527f172d0e443c493b5b9528858fff0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNy0xMy0xLTEtMTg0OTE_12e14df0-f4b5-40df-b309-59ebdd3b9316"
      unitRef="shares">440964</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNy0xNy0xLTEtMTg0OTE_7bfd44b6-cf61-482a-8e50-644b90fa919d"
      unitRef="usd">28000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfNy0yMy0xLTEtMTg0OTE_e7728967-86be-4c3f-96d6-dd486e377cbc"
      unitRef="usd">28000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic527f172d0e443c493b5b9528858fff0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOC0xMy0xLTEtMTg0OTE_353a3e7b-f3d3-4687-9721-e0549d14a931"
      unitRef="shares">42060</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOC0xNy0xLTEtMTg0OTE_d4aeec7b-d771-41f0-8bc0-6a52abd2fa2d"
      unitRef="usd">174000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOC0yMy0xLTEtMTg0OTE_9f9fa9cc-227e-4d82-b3ea-f0f8569371b0"
      unitRef="usd">174000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i062d513c3af24fb8a871914681ad6ed0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS0zLTEtMS0xODQ5MQ_dc17cd0b-8a41-4460-a865-b7fd498f7f3d"
      unitRef="usd">952000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="ic4f89da1832e4c048b3bf07808761b7c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS03LTEtMS0xODQ5MQ_602235ab-9d23-4d67-bf2d-bc3d7785cb1c"
      unitRef="usd">5273000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock
      contextRef="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS0xNy0xLTEtMTg0OTE_8067d1de-a480-4696-a70b-7231cffb454b"
      unitRef="usd">2031000</plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock>
    <plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock
      contextRef="i5f4ededd465745ac8a09d27d629bf294_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS0yMS0xLTEtMTg0OTE_3cc2eb2a-e3a4-48ac-9b7d-c200f4368008"
      unitRef="usd">4194000</plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock>
    <plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfOS0yMy0xLTEtMTg0OTE_cecff902-187d-493b-a66b-956fc456d87f"
      unitRef="usd">6225000</plrx:AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibe987c02641347c6962709f0ce68fe57_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTAtMTctMS0xLTE4NDkx_ab3129f1-17ef-4954-9fb3-43c81e4923d8"
      unitRef="usd">1829000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTAtMjMtMS0xLTE4NDkx_897c3d30-acf5-4489-b3f0-665f5a3d1064"
      unitRef="usd">1829000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i61761cf5edab4bc4a348e46cd23dc2f4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTEtMTktMS0xLTE4NDkx_350e4c4f-c022-4724-91e4-fcd529e87530"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTEtMjMtMS0xLTE4NDkx_10ea5fbe-33c8-491a-b901-cf35386329fa"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i5f4ededd465745ac8a09d27d629bf294_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTItMjEtMS0xLTE4NDkx_b11c6cc5-bb25-40e5-bb75-08ed4a4b4819"
      unitRef="usd">-631000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTItMjMtMS0xLTE4NDkx_7b06d43e-6b30-4d7b-ab66-6edbd9c72f98"
      unitRef="usd">-631000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="idb689d41a0fc49d096930b208671ff5a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMS0xLTEtMTg0OTE_f07faa90-955c-46b5-b6ef-28578f1b8608"
      unitRef="shares">56000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="idb689d41a0fc49d096930b208671ff5a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMy0xLTEtMTg0OTE_48b3d804-f3cc-4679-b588-ef02b138747d"
      unitRef="usd">62468000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ibc82fb340f724ed2902d29a505bc74c7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtNS0xLTEtMTg0OTE_22049891-36f0-4d9e-ad85-b259449d95a0"
      unitRef="shares">49501221</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ibc82fb340f724ed2902d29a505bc74c7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtNy0xLTEtMTg0OTE_d43a9e61-88fd-4098-b6da-bacbf6a8cf8e"
      unitRef="usd">75860000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtOS0xLTEtMTg0OTE_881a1ad2-d676-4ecf-8cf2-dfbd354d4c2a"
      unitRef="shares">26360745</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6ed0ae1a14084937b77c2c5adbfeaacb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTEtMS0xLTE4NDkx_365b6d5b-daee-4dbb-ad5a-ae6f732a6e44"
      unitRef="usd">47947000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i826b025c166f473987892842e39f1549_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTMtMS0xLTE4NDkx_91a4ac62-1fac-47f2-a09a-66a400e06e14"
      unitRef="shares">1846024</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i826b025c166f473987892842e39f1549_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTUtMS0xLTE4NDkx_b26042cf-2214-4f5c-b3c5-16a7222f5c85"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6bbff1d55944244a3110049517d61da_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTctMS0xLTE4NDkx_23217169-7d9b-4ff8-b90b-bf02f2586806"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iffe3207e1e714584bed5756b07541340_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMTktMS0xLTE4NDkx_2265fde7-ebd4-41b8-8a3d-16d0511bb071"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c41e7454f6a4547977cbf6b6a2349d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMjEtMS0xLTE4NDkx_0fc2f349-49ac-4132-be27-47e8b57d2c39"
      unitRef="usd">-76295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185NC9mcmFnOjEwNzEzZTE1N2ViZTQ0MWZhY2E1YjhmNWFmZGQ1OTE2L3RhYmxlOmI2ZTJmNWM4ZDhkNzQ5NmI4YjQ4NjFjMWFiZjlhMmUxL3RhYmxlcmFuZ2U6YjZlMmY1YzhkOGQ3NDk2YjhiNDg2MWMxYWJmOWEyZTFfMTMtMjMtMS0xLTE4NDkx_130dbf0d-6e65-4f12-a081-02d01232e853"
      unitRef="usd">-76295000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMy0xLTEtMS0xMjY1OQ_42d35e4e-f495-469e-b784-4cb9a40821af"
      unitRef="usd">-97263000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMy0zLTEtMS0xMjY1OQ_cb412252-6f9b-49b8-8581-6f256540decc"
      unitRef="usd">-41533000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMy01LTEtMS0xODQ0Nw_8061be47-ba31-4d74-9c42-db8bd2dabc10"
      unitRef="usd">-631000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNS0xLTEtMS0xMjY1OQ_75cbc93d-df99-4871-9cd8-08614ca9dbbb"
      unitRef="usd">1535000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNS0zLTEtMS0xMjY1OQ_9a56ea03-d4d6-41e2-8fcf-069ca6b007c5"
      unitRef="usd">1310000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNS01LTEtMS0xODQ0Nw_b2d99ae6-55b2-4169-9416-fc2f42e2ed55"
      unitRef="usd">1113000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNi0xLTEtMS0xMjY1OQ_678d51f7-1b8b-4274-bf90-42fb8793b411"
      unitRef="usd">10437000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNi0zLTEtMS0xMjY1OQ_a223ff3e-f2b0-4ad4-8d6e-d42cd1947fa9"
      unitRef="usd">3895000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNi01LTEtMS0xODQ0Nw_ba6908c2-a4a5-4237-bb6f-8c381767cc5f"
      unitRef="usd">1829000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy0xLTEtMS0xNTk2NA_70158265-33e0-459f-8012-4450451fec28"
      unitRef="usd">1669000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy0zLTEtMS0xNTk3MQ_3e9e4fb0-be83-448f-9cdb-c3b8533336a6"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy01LTEtMS0xODQ0Nw_1a11da20-773c-4be5-be27-1435a9743e80"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <plrx:OtherLosses
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy0xLTEtMS0xMjY1OQ_7b35be12-8be9-4c82-9cfa-0a9becca9c50"
      unitRef="usd">1262000</plrx:OtherLosses>
    <plrx:OtherLosses
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNy0zLTEtMS0xMjY1OQ_7fc43161-33a1-4235-80d0-9e46a337812c"
      unitRef="usd">266000</plrx:OtherLosses>
    <plrx:OtherLosses
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfOC01LTEtMS0xODQ0Nw_371e7a09-4667-430d-9f26-7496d7b9669f"
      unitRef="usd">0</plrx:OtherLosses>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfOS0xLTEtMS0xMjY1OQ_a3fa2b42-df1c-47f5-82c6-c89a3d3676e4"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfOS0zLTEtMS0xMjY1OQ_ba17bcda-75ab-4517-8c01-198cf25db4ac"
      unitRef="usd">-250000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTAtNS0xLTEtMTg0NDc_b0da2207-d07a-4d3c-b1eb-243dfb254ff6"
      unitRef="usd">-167000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTAtMS0xLTEtMTI2NTk_0d603106-91f8-4670-8fe4-407fd854c2be"
      unitRef="usd">-7281000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTAtMy0xLTEtMTI2NTk_a1e67a64-9f16-4be0-909b-5a2ef367b4e5"
      unitRef="usd">2227000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTEtNS0xLTEtMTg0NDc_c18ce9d0-a85a-41c9-ad81-77403baad318"
      unitRef="usd">7052000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTEtMS0xLTEtMTI2NTk_7bec9951-44c8-4ab5-b52d-17c3d6069208"
      unitRef="usd">2266000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTEtMy0xLTEtMTI2NTk_557d94a7-cb69-4fc2-9672-4bf02b1c005a"
      unitRef="usd">2756000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTItNS0xLTEtMTg0NDc_26645dff-1679-4a55-b349-16c798782139"
      unitRef="usd">1458000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTItMS0xLTEtMTI2NTk_51388638-43c2-4716-b3c1-0598816d0028"
      unitRef="usd">-70000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTItMy0xLTEtMTI2NTk_348da33c-8df6-4a02-9fce-a77963182633"
      unitRef="usd">70000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTMtNS0xLTEtMTg0NDc_f6cc81ff-9458-482a-bd73-bed8e0dd75a0"
      unitRef="usd">-232000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTMtMS0xLTEtMTI2NTk_9644e992-2c54-4288-9398-9a48ae2158a3"
      unitRef="usd">891000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTMtMy0xLTEtMTI2NTk_67efcc68-c679-4708-8f3a-fdfd0bf20d7f"
      unitRef="usd">922000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTQtNS0xLTEtMTg0NDc_6a78e463-32de-4d5d-9a86-ff0849a111ef"
      unitRef="usd">-1255000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTQtMS0xLTEtMTI2NTk_4e4ab3e0-edc5-4644-9e62-c5629a566a08"
      unitRef="usd">2695000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTQtMy0xLTEtMTI2NTk_e692ad84-1f9b-4fc3-956c-1b6e9b2ef79d"
      unitRef="usd">2689000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTUtNS0xLTEtMTg0NDc_c81045f2-c856-4ffa-b8b7-6d5a79f2022f"
      unitRef="usd">4255000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtMS0xLTEtMjA2NzQ_929e7683-8c10-469d-9976-0f70c203287c"
      unitRef="usd">-1754000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtMy0xLTEtMjA2NzQ_1ce30f18-0afc-4585-a6d8-e4010f0f2a6b"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtNS0xLTEtMjA2NzQ_75aafa8b-f3a3-409e-972e-e52663dc4b65"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTUtMS0xLTEtMTI2NTk_1bf17e4b-40da-4287-a8fa-0dd73ca0d419"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTUtMy0xLTEtMTI2NTk_9f7fdc87-93fe-468d-9ccf-4db5181cb27a"
      unitRef="usd">-17000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtNS0xLTEtMTg0NDc_617a1b73-a51e-4bf2-a1cb-35aebfc0572c"
      unitRef="usd">50000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtMS0xLTEtMTI2NTk_e558cd47-cdd0-4a34-ba26-95f7323ef66d"
      unitRef="usd">-75443000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTYtMy0xLTEtMTI2NTk_539612c0-87e2-486c-b5d1-e12061045b76"
      unitRef="usd">-37271000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTctNS0xLTEtMTg0NDc_f06b7fdc-905c-4fd3-8247-c52aa9915aaf"
      unitRef="usd">-2750000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTgtMS0xLTEtMTI2NTk_057f1727-7dcb-494d-a5b5-90c338e26499"
      unitRef="usd">219887000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTgtMy0xLTEtMTI2NTk_a5a3f421-9c76-46f7-94fe-2afe56930268"
      unitRef="usd">322605000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTktNS0xLTEtMTg0NDc_9766f0d6-678c-4962-b2b2-d137ddb38dcb"
      unitRef="usd">51713000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <plrx:AccretionOfShortTermInvestments
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTktMS0xLTEtMTI2NTk_7dd9e1f5-12c6-4883-b79b-d008df2d0a44"
      unitRef="usd">0</plrx:AccretionOfShortTermInvestments>
    <plrx:AccretionOfShortTermInvestments
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMTktMy0xLTEtMTI2NTk_ebefce8e-36ba-4a75-a0cd-f14d5c80f850"
      unitRef="usd">0</plrx:AccretionOfShortTermInvestments>
    <plrx:AccretionOfShortTermInvestments
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjAtNS0xLTEtMTg0NDc_17416340-7ac0-44a1-93bc-85b48f1e437a"
      unitRef="usd">254000</plrx:AccretionOfShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjAtMS0xLTEtMTI2NTk_40516cde-72ae-4190-9dec-7cacf9e72100"
      unitRef="usd">295539000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjAtMy0xLTEtMTI2NTk_eb734cc4-ea66-48af-8488-d81594d0fa85"
      unitRef="usd">113271000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjEtNS0xLTEtMTg0NDc_f0d9cae7-cf60-4de0-97e8-95273fd01256"
      unitRef="usd">35000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjEtMS0xLTEtMTI2NTk_99b11d9a-238d-43c5-998b-60d1b3d9bac6"
      unitRef="usd">1953000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjEtMy0xLTEtMTI2NTk_fcdb7ef9-8837-4831-ba00-b16f1dfe7c27"
      unitRef="usd">1532000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjItNS0xLTEtMTg0NDc_954bfc7a-fa85-448b-a001-721452d73f20"
      unitRef="usd">964000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjItMS0xLTEtMTI2NTk_2b0a1130-5930-46b9-b9dc-aaed913a644b"
      unitRef="usd">73699000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjItMy0xLTEtMTI2NTk_f99ecb31-67ee-4dfc-8061-c5b7590434cb"
      unitRef="usd">-210866000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjMtNS0xLTEtMTg0NDc_06170ad1-fcdd-4d38-97ca-517b94ffcfbc"
      unitRef="usd">-17931000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjQtMS0xLTEtMTI2NTk_b25a4afb-59cb-4761-a53b-fd6828c1282e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjQtMy0xLTEtMTI2NTk_145f39ba-0049-4af3-9bcc-462611fc0b21"
      unitRef="usd">150751000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjUtNS0xLTEtMTg0NDc_edfa8836-f802-423e-abdc-aacd6e417639"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjUtMS0xLTEtMTI2NTk_049d1749-3212-4d4a-b94a-e7629b7a5836"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjUtMy0xLTEtMTI2NTk_21f24b04-b8d6-4221-8442-1253dbe546b9"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjYtNS0xLTEtMTg0NDc_0793c9cc-aaa3-4646-8d39-c91737ae637d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjYtMS0xLTEtMTI2NTk_16dfc32d-9d05-45e9-913e-6d6236bc0257"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjYtMy0xLTEtMTI2NTk_df7cbdd3-b780-4107-8f64-5c2e289ef239"
      unitRef="usd">52019000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjctNS0xLTEtMTg0NDc_2fde7406-2394-4b88-bdd2-d5a3818b3967"
      unitRef="usd">47947000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjctMS0xLTEtMTI2NTk_7dd735d9-c77d-47cc-abcf-164c105cc022"
      unitRef="usd">2984000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjctMy0xLTEtMTI2NTk_dfcb656b-7e17-4547-ba47-c384bbd290e4"
      unitRef="usd">442000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjgtNS0xLTEtMTg0NDc_4b07be56-68fe-44c5-9b35-719691a8791b"
      unitRef="usd">174000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjgtMS0xLTEtMTI2NTk_a93f7f9b-38c0-4fb4-8522-c501ab6760fc"
      unitRef="usd">457000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjgtMy0xLTEtMTI2NTk_efc8f5a4-bb66-4b7a-977a-a8a657a91f83"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjktNS0xLTEtMTg0NDc_ec0c7736-e53f-43e3-b552-ce257a6eb6cf"
      unitRef="usd">2582000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjktMS0xLTEtMTI2NTk_889ab773-9dcd-415a-ba13-b00a117e1e70"
      unitRef="usd">2527000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMjktMy0xLTEtMTI2NTk_ed43c3ac-c8f4-4e1c-a749-754f168c5d91"
      unitRef="usd">213212000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzAtNS0xLTEtMTg0NDc_478c14bd-7d55-456a-9200-d098659183ab"
      unitRef="usd">45539000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzAtMS0xLTEtMTI2NTk_80fa12e2-58ab-4ae5-b2d6-db7c49ef43c9"
      unitRef="usd">783000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzAtMy0xLTEtMTI2NTk_eb27bfc7-5af5-4f39-94a0-89ca979eae12"
      unitRef="usd">-34925000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzEtNS0xLTEtMTg0NDc_203f8b33-3a38-476b-aa7e-5e13e1413d2e"
      unitRef="usd">24858000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzEtMS0xLTEtMTI2NTk_9c957a4b-00fb-41cb-8a6f-1a3d57c5144b"
      unitRef="usd">50882000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzEtMy0xLTEtMTI2NTk_47670a3f-39a3-47af-aebe-ba34a61be78c"
      unitRef="usd">85807000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idcb6e46e8589417fbb6dce85ec4707e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzItNS0xLTEtMTg0NDc_a30460a7-d121-4959-bc7c-703756f37bfe"
      unitRef="usd">60949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzItMS0xLTEtMTI2NTk_fb107b96-d32e-46e8-8610-ab779271592b"
      unitRef="usd">51665000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzItMy0xLTEtMTI2NTk_bd208a45-337f-457c-82f2-eb86c9ce1783"
      unitRef="usd">50882000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzMtNS0xLTEtMTg0NDc_6e2af041-6e4a-4de1-8181-c94079347e2a"
      unitRef="usd">85807000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzQtMS0xLTEtMTI2NTk_e5845180-47ce-4105-b191-34712b41e3ae"
      unitRef="usd">57000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzQtMy0xLTEtMTI2NTk_4bbf00e5-9f58-4e3b-bbb9-de1ed2b6bcaf"
      unitRef="usd">188000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzktNS0xLTEtMTg0NDc_699c4051-2fc7-4fe0-8e68-808f8cb8c0f0"
      unitRef="usd">159000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzUtMS0xLTEtMTI2NTk_f3618ef8-d7a3-4fe4-abd0-3680784b98f3"
      unitRef="usd">9000</plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting>
    <plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzUtMy0xLTEtMTI2NTk_1403d89d-a05f-43df-ba1e-372d427af70d"
      unitRef="usd">11000</plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting>
    <plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNDAtNS0xLTEtMTg0NDc_b7fba357-f4f8-441f-8eee-3fe70a07ee41"
      unitRef="usd">30000</plrx:ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting>
    <plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzYtMS0xLTEtMTI2NTk_4fdc42b6-29cf-441c-9f18-2046d28d4675"
      unitRef="usd">0</plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock>
    <plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzYtMy0xLTEtMTI2NTk_401d97f4-4e0e-4a84-95ca-dae4d07161b3"
      unitRef="usd">0</plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock>
    <plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNDEtNS0xLTEtMTg0NDc_bf17a2c3-d8ee-42f4-a70f-4ff83b5d4713"
      unitRef="usd">6225000</plrx:AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock>
    <plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzctMS0xLTEtMTI2NTk_8e1150dc-6253-463e-ad24-5b10a5d5e150"
      unitRef="usd">0</plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities>
    <plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzctMy0xLTEtMTI2NTk_5b0ac021-8408-4b5b-8101-3b51e9c25c50"
      unitRef="usd">0</plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities>
    <plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNDItNS0xLTEtMTg0NDc_1366bcb2-0264-48bd-b04c-ff01462fb836"
      unitRef="usd">230000</plrx:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzgtMS0xLTEtMTI2NTk_88dfb8db-8669-4369-9e64-680d36186363"
      unitRef="usd">-169000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfMzgtMy0xLTEtMTI2NTk_a5362efa-0869-425d-8c52-b2614b2eecd1"
      unitRef="usd">-31000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N185Ny9mcmFnOjdhMzEwNDZiNmNhMjRjNGQ5ODFiZDRiM2ZmMTIyOWQ4L3RhYmxlOmFmM2M1N2Q0ZWJlMjQ1ZGRiNTBjMWI0ZmExNTU0NjdmL3RhYmxlcmFuZ2U6YWYzYzU3ZDRlYmUyNDVkZGI1MGMxYjRmYTE1NTQ2N2ZfNDMtNS0xLTEtMTg0NDc_141359e7-0a40-4439-b498-f200157a0016"
      unitRef="usd">-1000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI5OTk_9b6aeebc-b13c-407e-aa24-dc98f10312de">Organization and Description of Business&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pliant Therapeutics, Inc. (the &#x201c;Company&#x201d; or "Pliant" or &#x201c;we&#x201d; or &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis with an initial focus on treating fibrosis by inhibiting integrin-mediated activation of TGF-&#x3b2;. Fibrosis refers to the abnormal thickening and scarring of connective tissue due to the production and deposition of excess collagen in the extra-cellular matrix. Fibrosis can occur in many different tissues including lung, liver, kidney, muscle, skin and the GI tract, and often causes severe and debilitating disease leading to organ failure. The Company is located in South San Francisco, California, and was incorporated in the state of Delaware in June 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;22, 2020, the Company implemented a 1-for-7.15 reverse stock split of the Company&#x2019;s common stock. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. All share and per share data shown in the accompanying financial statements and related notes have been retroactively revised to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company&#x2019;s convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. As of June 3, 2020, all outstanding preferred stock had been converted into common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company completed its initial public offering (the &#x201c;IPO&#x201d;), in which the Company issued and sold an aggregate of 10,350,000 shares of common stock, which consisted of 9,000,000 shares of common stock and 1,350,000 shares of common stock sold pursuant to the underwriters&#x2019; exercise of their option to purchase additional shares, at a public offering price of $16.00 per share. The aggregate net proceeds received by the Company from the offering were $148.3 million, net of underwriting discounts, commissions and offering expenses of $5.7 million. Upon the closing of the IPO, 160,389,279 shares of the Company&#x2019;s outstanding convertible preferred stock were automatically converted to common stock on a 7.15:1 basis and the related carrying amount of $238.3 million was reclassified to common stock and additional paid-in capital within stockholders&#x2019; equity (deficit). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with the completion of the IPO, the Company also issued 625,000 shares of its common stock to Novartis Institutes for Biomedical Research, Inc. (&#x201c;Novartis&#x201d;), a strategic partner and existing stockholder of the Company, in a private placement at a price of $16.00 per share for proceeds of $10.0 million, which resulted in Novartis owning approximately 6.1% of the Company&#x2019;s outstanding shares of common stock immediately after the IPO.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzE4OTM_2d106352-e177-4f0e-8568-a1635c919c4f"
      unitRef="shares">10350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1b3902b908614fb1b9c4a93bf96af64c_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzE5MzU_346b83fa-a7f2-4cc8-8161-b5bf648d8c5d"
      unitRef="shares">9000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iae29663b5db54f749ffcf7b5c72df914_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzE5NjU_aef584ec-5a42-4c93-abf4-84694eb87458"
      unitRef="shares">1350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i81a558379cd44a9ab226783aa88f48a7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzIxMTI_33049bdc-27ba-44f3-9d6d-80d45a5eebf9"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzIyMDA_9f22773c-8390-4f1d-934e-b2c0ab660e10"
      unitRef="usd">148300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzIyNzI_e146f029-4a6a-408b-822f-f78e7ad6e973"
      unitRef="usd">5700000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i81a558379cd44a9ab226783aa88f48a7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzIzNjY_3b874795-5e94-4627-b5a2-770db7f8ce01"
      unitRef="shares">160389279</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI0ODM_4cfcfa27-fe81-4d9d-be34-5fd68201d08f"
      unitRef="number">7.15</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI1Mjg_c8ff0c7b-6a25-46d8-9750-ce20718d4c1a"
      unitRef="usd">238300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibc3d94b8d41948578ccb00771371441d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI3MDE_3d492d95-e7cb-4da4-898a-299a49328acc"
      unitRef="shares">625000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="ibc3d94b8d41948578ccb00771371441d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI4NTU_705204b5-08c7-461f-b3ea-d4ec7549721b"
      unitRef="usdPerShare">16.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9550253bdd3e4a6da0f6c0d34c9b9d1a_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI4ODQ_1bee15ad-7b39-431b-b7af-a7764d810be8"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ib16143c3aac54e6ca3119c33948ae5eb_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDMvZnJhZzozNDEzYzM1MTlmNmY0OTZmYTg1Mzc3NTM0YjcxYmQ2Yy90ZXh0cmVnaW9uOjM0MTNjMzUxOWY2ZjQ5NmZhODUzNzc1MzRiNzFiZDZjXzI5MzY_e4e65ad7-9194-4385-b84c-3acb6b11864f"
      unitRef="number">0.061</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTA5_afdd737a-7695-4e50-8b46-28789ee935e8">Summary of Significant Accounting Policies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Certain prior year reported amounts have been reclassified to conform with the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development costs, fair value of assets and liabilities, stock-based compensation, income taxes and uncertain tax positions. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, however, actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Topic 606). To determine revenue recognition for arrangements that fall within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, our revenues have been generated solely from the Collaboration and License Agreement with Novartis (the &#x201c;Novartis Agreement&#x201d;). The Novartis Agreement includes licenses of intellectual property, cost reimbursements, research and development services, upfront signing fees, milestone payments and royalties on future licensee&#x2019;s product sales.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of accounting for this arrangement, we must apply judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the contract. To determine the stand-alone selling price, we rely on assumptions which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and license revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development services &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts related to research and development services are recognized as the related services or activities are performed, in accordance with the contract terms. The cost associated with full-time equivalent researchers is estimated each period and billable to Novartis based at specified full-time equivalent rates.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sales-based royalties, including milestone payments based on the level of sales, are considered to be predominately related to the license included in the arrangement, and we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue from the Novartis Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize contract assets when we have a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditional on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration (i.e., only the passage of time is required before payment becomes due). A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables cannot be netted against contract liabilities and would be presented separately from contract assets. Contract assets and contract liabilities are netted at the contract level. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The carrying amount of the Company&#x2019;s financial instruments, including cash and cash equivalents, short-term investments, tax credit receivable, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. The Company invests in money market funds, treasury bill and notes, government notes and corporate debt securities. The Company limits its credit risk associated with its cash and cash equivalents by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. However, the Company had deposits in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limit of $250,000. The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base. During the years ended December&#160;31, 2021,  2020 and 2019, Novartis accounted for 100% of the Company&#x2019;s revenue and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future results of operations involve several other risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#x2019;s product candidates, uncertainty of market acceptance of the Company&#x2019;s product candidates, competition from substitute products, including those that may be developed or marketed by larger companies, securing and protecting intellectual property, strategic relationships and dependence on key individuals and sole source suppliers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product candidates require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing novel therapies for fibrotic diseases. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. All long-lived assets are maintained in the United States of America.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in Money Market Funds, United States (&#x201c;U.S.&#x201d;) treasury securities, U.S. government agency securities and corporate debt securities and are stated at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term investments consist of U.S. Treasury securities, U.S. government agency securities and corporate debt securities with remaining maturities beyond three months at the date of purchase. The Company has classified and accounted for its short-term investments as available-for-sale securities as the Company may sell these securities at any time even prior to maturity and such investments represent cash available for current operations. As a result, short-term investments may include securities with maturities beyond twelve months that are classified within &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;current assets in the Balance Sheets. As of December&#160;31, 2021 and 2020, all of the Company&#x2019;s short-term investments were classified as available-for-sale and were carried at fair market value with unrealized losses recorded in other comprehensive loss in the statements of operations and comprehensive loss. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are considered impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its short-term investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, the duration and extent to which the fair value is less than cost and its intent and ability to hold the investment. Once a decline in fair value is determined to be other-than-temporary, an impairment charge will be recorded to other expense, net, in the statements of operations and comprehensive loss and a new cost basis in the short-term investment will be established. As of&#160;December&#160;31, 2021, the Company had not recorded any impairment related to other-than-temporary declines in the fair value of short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;) as of January&#160;1, 2021, which did not have a significant impact on its financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires the Company to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if the Company&#x2019;s estimate of fair value for the investment increases. To determine whether to record a credit loss, the Company considers issuer specific credit ratings and historical losses as well as current economic conditions and its expectations for future economic conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost net of accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. The useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the balance sheets and the resulting gain or loss is recorded to the statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon adoption of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, Leases (&#x201c;ASC 842&#x201d;), the Company determines if an arrangement contains a lease at the inception of the contract and a records right-of-use (&#x201c;ROU&#x201d;) asset and lease liability on the balance sheet at lease commencement based on the present value of remaining lease payments over the lease term. The Company only considers payments that are fixed and determinable at the time of commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases with an initial term greater than 12 months, lease liabilities are recognized based on the present value of the future minimum lease payments discounted by the Company&#x2019;s estimated incremental borrowing rate. The Company measures ROU assets based on the corresponding lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred and (iii) tenant incentives under the lease. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the present value of future minimum lease payments using its estimated incremental borrowing rate when the discount rate implicit in the lease is not known. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. In determining its incremental borrowing rate, the Company gives consideration to its credit risk, term of the lease, total lease payments and an analysis of peer companies with profiles similar to its own.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected the short-term lease practical expedient to exclude leases with a term less than 12 months from its ROU assets and lease liabilities. The Company records rent expense for short-term leases in its statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of operations on a straight-line basis over the lease term and records variable lease payments as incurred. The Company has also elected to not separate lease and non-lease components and, as a result, accounts for any lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There was no impairment of long-lived assets during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All preferred stock was automatically converted into common stock upon the Company&#x2019;s IPO in June 2020. Prior to this conversion, the Company classified redeemable convertible preferred stock outside of stockholders&#x2019; equity (deficit) because, upon the occurrence of certain change in control events that were outside the Company&#x2019;s control, including liquidation, sale or transfer of the Company&#x2019;s assets, holders of the redeemable convertible preferred stock could have caused redemption for cash. At any time on or after December 19, 2024, the holders of a majority of the outstanding redeemable convertible preferred stock could also have required the Company to redeem the redeemable convertible preferred stock by providing the Company a written notice requesting such redemption. The Company recognized changes in the redemption value immediately as they occurred, for example changes in fair value of preferred stock, and adjustments in the carrying amount of the redeemable convertible preferred stock to equal the redemption value at the end of each reporting period up through December 19, 2019, when the Company entered into the Series C Preferred Stock Purchase Agreement. See Note 9 for further details. In the absence of retained earnings these accretion charges were recorded against additional paid in capital, if any, and then to accumulated deficit. The Company analyzed all embedded derivatives and beneficial conversion features for its redeemable convertible preferred stock and concluded that none required bifurcation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of personnel costs for the Company&#x2019;s research and development employees. Also included are non-personnel costs such as fees paid to consultants and third parties for preclinical and clinical studies, research and development services, laboratory supplies and equipment maintenance costs, license costs, contract manufacturing costs and allocations of facility related costs. The Company estimates preclinical and clinical studies and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. We estimate the amount of work completed through review of detailed budgets and timelines included in our contracts and agreements, and update these estimates with information obtained from third-party service providers and internal personnel on a quarterly basis. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and are expensed as services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based equity awards include restricted stock awards, stock options and shares that will be issued under the Company&#x2019;s 2020 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). Stock-based compensation for awards that are granted to employees is accounted at fair value on the award grant date and the expense is recognized over the period the employee is required to provide service in exchange for the award, which is generally on a straight-line basis over the vesting period of the award. The expense is recorded in either research and development or general and administrative expenses in the statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model, used to estimate fair value of stock-based awards, requires the use of the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term for the Company&#x2019;s stock options was calculated utilizing the simplified method, which represents the average of the weighted-average vesting term and the contract period of the awards. The expected term for the ESPP is the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Prior to the Company being public, the Company did not have any trading history for its common stock, the expected&#160;volatility was estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their size, stage in the life cycle or area of specialty. As the Company went public in June 2020, the Company will continue to apply this process for stock options and ESPP awards until enough historical information regarding the volatility of its stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S.&#160;Treasury notes with maturities approximately equal to the expected term of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Expected dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has never paid dividends on the common stock and has no plans to pay dividends on the common stock.&#160;Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to our IPO, the fair value of our common stock has been determined using independent third-party valuations based on relevant valuation methodologies as outlined in the American Institute of Certified Public Accountants (AICPA) Practice Aid,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Valuation of Privately-Held-Company Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;. The Company also considered the amount of time between the independent third-party valuation dates and the grant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dates and used interpolation of the fair value between the two valuation dates to estimate common stock fair value at each grant date. This determination included an evaluation of whether the subsequent valuation indicated that any significant change in valuation had occurred between the previous valuation and the grant date. Following our IPO, the Company uses our stock price traded on NASDAQ to determine its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax basis of assets and liabilities and net operating loss and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all the tax benefits will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with ASC No. 740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company includes any penalties and interest expense related to income taxes as a component of income tax expense, as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's comprehensive loss represents unrealized losses on short-term investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss attributed to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the conversion of our preferred stock in our IPO, net loss or income per share attributable to common stockholders was calculated using the two-class method, which is based on an earnings allocation formula that determines net loss or income per share for the Company&#x2019;s common stockholders and holders of participating securities. The holders of preferred stock were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on the common stock. Under this method, net loss or income is increased or reduced by the amount of any dividends earned and accretion of redeemable convertible preferred stock to its redemption value, if any, during the period. The undistributed earnings are allocated to common stock and each series of redeemable convertible preferred stock to the extent that each preferred security may share in the earnings as if all of the earnings for the period had been distributed. Net loss or income attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Diluted net loss or income per share is computed using the more dilutive of (a) the two-class method or (b) the as-converted method. The Company allocated earnings first to redeemable convertible preferred shares stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss or income gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss or income per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 842&#x201d;), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. Subsequent to this, the FASB issued various amendments to ASC 842, which affected certain aspects of the previously issued guidance. One of the amendments included an additional transition option that allowed entities to apply the new standard on the adoption date and recognize a cumulative effect adjustment to the opening balance of retained earnings. These updates were effective for public companies for annual periods beginning after December 15, 2018, including interim periods therein. Because the Company lost its EGC status on December 31, 2021, the standard became effective for the Company for its annual period beginning January 1, 2021. Amounts prior to January 1, 2021 were not adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASC 842 and all related amendments effective January 1, 2021 using the modified retrospective transition approach. The Company elected the package of practical expedients upon adoption, which permitted the Company to not reassess under the new standard the Company's prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease exception policy, permitting it to exclude the recognition requirements of this standard from leases with initial terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of ASC 842 effective January 1, 2021 resulted in the recognition of operating lease ROU assets of $8.0&#160;million and operating lease liabilities of $8.9&#160;million in the Company&#x2019;s balance sheet. In connection with the adoption, pre-existing liabilities for deferred rent and lease incentives totaling $0.9&#160;million were reclassified as an offset to the operating lease ROU assets. The Company&#x2019;s financial position and operating results for reporting periods prior to January 1, 2021 have not been adjusted and continue to be presented in accordance with the accounting standard in effect at that time. The adoption of ASC 842 did not have a material impact on the 2021 quarterly or annual results of operations or cash flows and had no impact on retained earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires &lt;/span&gt;&lt;/div&gt;allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2021. The adoption of ASU 2016-13 did not have an impact on the Company&#x2019;s financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE1_5d33cfd3-19f1-4410-ac91-69470d749bab">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Certain prior year reported amounts have been reclassified to conform with the current period presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE2_836d4661-c21e-4386-83fd-a6ec6eefb6a3">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development costs, fair value of assets and liabilities, stock-based compensation, income taxes and uncertain tax positions. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, however, actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE3_edbabebf-8431-4c20-95fe-96c809c049a8">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenues in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Topic 606). To determine revenue recognition for arrangements that fall within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To date, our revenues have been generated solely from the Collaboration and License Agreement with Novartis (the &#x201c;Novartis Agreement&#x201d;). The Novartis Agreement includes licenses of intellectual property, cost reimbursements, research and development services, upfront signing fees, milestone payments and royalties on future licensee&#x2019;s product sales.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of accounting for this arrangement, we must apply judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the contract. To determine the stand-alone selling price, we rely on assumptions which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of an arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and license revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development services &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts related to research and development services are recognized as the related services or activities are performed, in accordance with the contract terms. The cost associated with full-time equivalent researchers is estimated each period and billable to Novartis based at specified full-time equivalent rates.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sales-based royalties, including milestone payments based on the level of sales, are considered to be predominately related to the license included in the arrangement, and we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue from the Novartis Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize contract assets when we have a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditional on something other than the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration (i.e., only the passage of time is required before payment becomes due). A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. &lt;/span&gt;&lt;/div&gt;Receivables cannot be netted against contract liabilities and would be presented separately from contract assets. Contract assets and contract liabilities are netted at the contract level.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE4_b479e59d-62ea-45b4-b5c2-6122a436ff7d">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The carrying amount of the Company&#x2019;s financial instruments, including cash and cash equivalents, short-term investments, tax credit receivable, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE5_3cf70967-62ad-4cb9-b6ba-6933136205de">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. The Company invests in money market funds, treasury bill and notes, government notes and corporate debt securities. The Company limits its credit risk associated with its cash and cash equivalents by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. However, the Company had deposits in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limit of $250,000. The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base. During the years ended December&#160;31, 2021,  2020 and 2019, Novartis accounted for 100% of the Company&#x2019;s revenue and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s future results of operations involve several other risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#x2019;s product candidates, uncertainty of market acceptance of the Company&#x2019;s product candidates, competition from substitute products, including those that may be developed or marketed by larger companies, securing and protecting intellectual property, strategic relationships and dependence on key individuals and sole source suppliers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product candidates require approvals from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms
      contextRef="if4ff395e311847909da6a655116394ff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTI2_f0273549-dbe8-437b-85c3-25eecc37af46">The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <plrx:PercentageOfRevenueContributedByRelatedParty
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2NDkyNjc0ODU0MjM_27ac5b90-af2a-4016-97ec-0df02ab96410"
      unitRef="number">1</plrx:PercentageOfRevenueContributedByRelatedParty>
    <plrx:PercentageOfRevenueContributedByRelatedParty
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2NDkyNjc0ODU0MjM_8be87384-311d-40e6-9f22-a1d0b343c2ce"
      unitRef="number">1</plrx:PercentageOfRevenueContributedByRelatedParty>
    <plrx:PercentageOfRevenueContributedByRelatedParty
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2NDkyNjc0ODU0MjM_9de788e7-ed1e-4f03-9c05-d35624466f36"
      unitRef="number">1</plrx:PercentageOfRevenueContributedByRelatedParty>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTEw_cbe5bc8a-560e-4e00-bfb1-b8922474c009">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing novel therapies for fibrotic diseases. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. All long-lived assets are maintained in the United States of America.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEyMTU5_26761c0b-f1e3-4916-a4cd-71ecec68b0b2"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEyMTU5_b5fad364-028c-4011-9dfb-6f2ce5e43d8c"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTI3_d5dd6f67-5c35-4eb4-a9d0-26a7163d308e">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in Money Market Funds, United States (&#x201c;U.S.&#x201d;) treasury securities, U.S. government agency securities and corporate debt securities and are stated at fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <plrx:DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEyNjY0_32b62ec9-ffc5-4101-a2f6-089db3dbc78a">P3M</plrx:DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTI4_566e4b31-5ace-4dac-ad27-ede84e50941e">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term investments consist of U.S. Treasury securities, U.S. government agency securities and corporate debt securities with remaining maturities beyond three months at the date of purchase. The Company has classified and accounted for its short-term investments as available-for-sale securities as the Company may sell these securities at any time even prior to maturity and such investments represent cash available for current operations. As a result, short-term investments may include securities with maturities beyond twelve months that are classified within &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;current assets in the Balance Sheets. As of December&#160;31, 2021 and 2020, all of the Company&#x2019;s short-term investments were classified as available-for-sale and were carried at fair market value with unrealized losses recorded in other comprehensive loss in the statements of operations and comprehensive loss. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are considered impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its short-term investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, the duration and extent to which the fair value is less than cost and its intent and ability to hold the investment. Once a decline in fair value is determined to be other-than-temporary, an impairment charge will be recorded to other expense, net, in the statements of operations and comprehensive loss and a new cost basis in the short-term investment will be established. As of&#160;December&#160;31, 2021, the Company had not recorded any impairment related to other-than-temporary declines in the fair value of short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;) as of January&#160;1, 2021, which did not have a significant impact on its financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires the Company to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if the Company&#x2019;s estimate of fair value for the investment increases. To determine whether to record a credit loss, the Company considers issuer specific credit ratings and historical losses as well as current economic conditions and its expectations for future economic conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTIw_de9e16df-6c86-42e9-8fae-c5404d508e7a">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost net of accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. The useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale of the assets, the cost and related accumulated depreciation and amortization are removed from the balance sheets and the resulting gain or loss is recorded to the statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <plrx:PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTEx_32996c9e-6690-4266-896a-0cda93e730b3">The useful lives of property and equipment are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of remaining lease term or estimated useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plrx:PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i97ba5b3806e14f8cb378e134282cefff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90YWJsZTo1MWM0MjgyMWExY2M0MDZjYTQxNTBlNzdhOWVjNGQ2Yi90YWJsZXJhbmdlOjUxYzQyODIxYTFjYzQwNmNhNDE1MGU3N2E5ZWM0ZDZiXzAtMS0xLTEtMTI2NTk_722a3183-375e-41e6-a3f4-e0c4c1525872">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i72575f12fa974fe28bf756200624bdba_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90YWJsZTo1MWM0MjgyMWExY2M0MDZjYTQxNTBlNzdhOWVjNGQ2Yi90YWJsZXJhbmdlOjUxYzQyODIxYTFjYzQwNmNhNDE1MGU3N2E5ZWM0ZDZiXzEtMS0xLTEtMTI2NTk_8f363407-eedd-465c-8214-5dada8bb9293">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzQzOTgwNDY1ODczNDE_f89dcb4a-567d-4dc2-8105-907b22cced83">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon adoption of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, Leases (&#x201c;ASC 842&#x201d;), the Company determines if an arrangement contains a lease at the inception of the contract and a records right-of-use (&#x201c;ROU&#x201d;) asset and lease liability on the balance sheet at lease commencement based on the present value of remaining lease payments over the lease term. The Company only considers payments that are fixed and determinable at the time of commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases with an initial term greater than 12 months, lease liabilities are recognized based on the present value of the future minimum lease payments discounted by the Company&#x2019;s estimated incremental borrowing rate. The Company measures ROU assets based on the corresponding lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred and (iii) tenant incentives under the lease. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the present value of future minimum lease payments using its estimated incremental borrowing rate when the discount rate implicit in the lease is not known. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. In determining its incremental borrowing rate, the Company gives consideration to its credit risk, term of the lease, total lease payments and an analysis of peer companies with profiles similar to its own.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected the short-term lease practical expedient to exclude leases with a term less than 12 months from its ROU assets and lease liabilities. The Company records rent expense for short-term leases in its statements &lt;/span&gt;&lt;/div&gt;of operations on a straight-line basis over the lease term and records variable lease payments as incurred. The Company has also elected to not separate lease and non-lease components and, as a result, accounts for any lease and non-lease components as a single lease component.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzQzOTgwNDY1ODczNDI_b84dcd14-a71e-4796-a9c5-b54fe79ea50e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon adoption of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, Leases (&#x201c;ASC 842&#x201d;), the Company determines if an arrangement contains a lease at the inception of the contract and a records right-of-use (&#x201c;ROU&#x201d;) asset and lease liability on the balance sheet at lease commencement based on the present value of remaining lease payments over the lease term. The Company only considers payments that are fixed and determinable at the time of commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases with an initial term greater than 12 months, lease liabilities are recognized based on the present value of the future minimum lease payments discounted by the Company&#x2019;s estimated incremental borrowing rate. The Company measures ROU assets based on the corresponding lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred and (iii) tenant incentives under the lease. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates the present value of future minimum lease payments using its estimated incremental borrowing rate when the discount rate implicit in the lease is not known. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. In determining its incremental borrowing rate, the Company gives consideration to its credit risk, term of the lease, total lease payments and an analysis of peer companies with profiles similar to its own.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected the short-term lease practical expedient to exclude leases with a term less than 12 months from its ROU assets and lease liabilities. The Company records rent expense for short-term leases in its statements &lt;/span&gt;&lt;/div&gt;of operations on a straight-line basis over the lease term and records variable lease payments as incurred. The Company has also elected to not separate lease and non-lease components and, as a result, accounts for any lease and non-lease components as a single lease component.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTIz_67f84f9d-dcfe-4160-aa5b-bc580b060a70">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There was no impairment of long-lived assets during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2MDA1_06119dd3-5df9-4c2a-87ed-f6ee23750962"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2MDA1_29adf15c-e3b2-4362-9ad4-18486440e01d"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzE2MDA1_86d3ef9f-a48b-4fd9-9b20-0ba284961118"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <plrx:RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTI0_7539af19-2a6e-41f9-9ffd-4ff49d24edfa">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All preferred stock was automatically converted into common stock upon the Company&#x2019;s IPO in June 2020. Prior to this conversion, the Company classified redeemable convertible preferred stock outside of stockholders&#x2019; equity (deficit) because, upon the occurrence of certain change in control events that were outside the Company&#x2019;s control, including liquidation, sale or transfer of the Company&#x2019;s assets, holders of the redeemable convertible preferred stock could have caused redemption for cash. At any time on or after December 19, 2024, the holders of a majority of the outstanding redeemable convertible preferred stock could also have required the Company to redeem the redeemable convertible preferred stock by providing the Company a written notice requesting such redemption. The Company recognized changes in the redemption value immediately as they occurred, for example changes in fair value of preferred stock, and adjustments in the carrying amount of the redeemable convertible preferred stock to equal the redemption value at the end of each reporting period up through December 19, 2019, when the Company entered into the Series C Preferred Stock Purchase Agreement. See Note 9 for further details. In the absence of retained earnings these accretion charges were recorded against additional paid in capital, if any, and then to accumulated deficit. The Company analyzed all embedded derivatives and beneficial conversion features for its redeemable convertible preferred stock and concluded that none required bifurcation.&lt;/span&gt;&lt;/div&gt;</plrx:RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTE0_8f563438-efe3-4c23-9d97-1aedd0c088fc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of personnel costs for the Company&#x2019;s research and development employees. Also included are non-personnel costs such as fees paid to consultants and third parties for preclinical and clinical studies, research and development services, laboratory supplies and equipment maintenance costs, license costs, contract manufacturing costs and allocations of facility related costs. The Company estimates preclinical and clinical studies and research expenses based on the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. We estimate the amount of work completed through review of detailed budgets and timelines included in our contracts and agreements, and update these estimates with information obtained from third-party service providers and internal personnel on a quarterly basis. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and are expensed as services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTIx_7e9297db-bf39-4a54-86ea-254591c35349">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based equity awards include restricted stock awards, stock options and shares that will be issued under the Company&#x2019;s 2020 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). Stock-based compensation for awards that are granted to employees is accounted at fair value on the award grant date and the expense is recognized over the period the employee is required to provide service in exchange for the award, which is generally on a straight-line basis over the vesting period of the award. The expense is recorded in either research and development or general and administrative expenses in the statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model, used to estimate fair value of stock-based awards, requires the use of the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term for the Company&#x2019;s stock options was calculated utilizing the simplified method, which represents the average of the weighted-average vesting term and the contract period of the awards. The expected term for the ESPP is the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Prior to the Company being public, the Company did not have any trading history for its common stock, the expected&#160;volatility was estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their size, stage in the life cycle or area of specialty. As the Company went public in June 2020, the Company will continue to apply this process for stock options and ESPP awards until enough historical information regarding the volatility of its stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S.&#160;Treasury notes with maturities approximately equal to the expected term of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Expected dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has never paid dividends on the common stock and has no plans to pay dividends on the common stock.&#160;Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to our IPO, the fair value of our common stock has been determined using independent third-party valuations based on relevant valuation methodologies as outlined in the American Institute of Certified Public Accountants (AICPA) Practice Aid,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Valuation of Privately-Held-Company Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Issued as Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;. The Company also considered the amount of time between the independent third-party valuation dates and the grant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dates and used interpolation of the fair value between the two valuation dates to estimate common stock fair value at each grant date. This determination included an evaluation of whether the subsequent valuation indicated that any significant change in valuation had occurred between the previous valuation and the grant date. Following our IPO, the Company uses our stock price traded on NASDAQ to determine its fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzIyMzkz_91b6a1db-9038-40ea-852e-4682baa56d3c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTMw_e7e04ef7-edef-4f66-b26c-6b11aea3a2df">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax basis of assets and liabilities and net operating loss and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all the tax benefits will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with ASC No. 740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company includes any penalties and interest expense related to income taxes as a component of income tax expense, as necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTIy_63c57716-96cb-408c-89db-9a088ae17838">Comprehensive LossComprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's comprehensive loss represents unrealized losses on short-term investments.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzMyMTMx_87cb7b60-2c40-4407-80b3-e3df71a2f22c">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss attributed to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the conversion of our preferred stock in our IPO, net loss or income per share attributable to common stockholders was calculated using the two-class method, which is based on an earnings allocation formula that determines net loss or income per share for the Company&#x2019;s common stockholders and holders of participating securities. The holders of preferred stock were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on the common stock. Under this method, net loss or income is increased or reduced by the amount of any dividends earned and accretion of redeemable convertible preferred stock to its redemption value, if any, during the period. The undistributed earnings are allocated to common stock and each series of redeemable convertible preferred stock to the extent that each preferred security may share in the earnings as if all of the earnings for the period had been distributed. Net loss or income attributable to common stockholders and participating preferred shares are allocated to each share on an as-converted basis as if all the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. Diluted net loss or income per share is computed using the more dilutive of (a) the two-class method or (b) the as-converted method. The Company allocated earnings first to redeemable convertible preferred shares stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss or income gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss or income per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzQzOTgwNDY1ODczMzg_54a365ea-dbc5-4718-a1ab-8f0b3dc5e946">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 842&#x201d;), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. Subsequent to this, the FASB issued various amendments to ASC 842, which affected certain aspects of the previously issued guidance. One of the amendments included an additional transition option that allowed entities to apply the new standard on the adoption date and recognize a cumulative effect adjustment to the opening balance of retained earnings. These updates were effective for public companies for annual periods beginning after December 15, 2018, including interim periods therein. Because the Company lost its EGC status on December 31, 2021, the standard became effective for the Company for its annual period beginning January 1, 2021. Amounts prior to January 1, 2021 were not adjusted and continue to be reported in accordance with previous lease guidance, ASC Topic 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASC 842 and all related amendments effective January 1, 2021 using the modified retrospective transition approach. The Company elected the package of practical expedients upon adoption, which permitted the Company to not reassess under the new standard the Company's prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease exception policy, permitting it to exclude the recognition requirements of this standard from leases with initial terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of ASC 842 effective January 1, 2021 resulted in the recognition of operating lease ROU assets of $8.0&#160;million and operating lease liabilities of $8.9&#160;million in the Company&#x2019;s balance sheet. In connection with the adoption, pre-existing liabilities for deferred rent and lease incentives totaling $0.9&#160;million were reclassified as an offset to the operating lease ROU assets. The Company&#x2019;s financial position and operating results for reporting periods prior to January 1, 2021 have not been adjusted and continue to be presented in accordance with the accounting standard in effect at that time. The adoption of ASC 842 did not have a material impact on the 2021 quarterly or annual results of operations or cash flows and had no impact on retained earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires &lt;/span&gt;&lt;/div&gt;allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2021. The adoption of ASU 2016-13 did not have an impact on the Company&#x2019;s financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib6401410f7ef49438a2f863fbc13df66_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEwOTk1MTE3MDM5NjA_0fe736a7-1f30-4cd5-8670-9c64050dcb8e"
      unitRef="usd">8000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib6401410f7ef49438a2f863fbc13df66_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEwOTk1MTE3MDM5Nzc_bdfe679f-442e-42ff-9d49-16742c4a60b6"
      unitRef="usd">8900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="ib6401410f7ef49438a2f863fbc13df66_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDYvZnJhZzpiYTRjNzYwYjNlY2Y0YTAwOWExZmJjZGVmZmY0ZTVmMS90ZXh0cmVnaW9uOmJhNGM3NjBiM2VjZjRhMDA5YTFmYmNkZWZmZjRlNWYxXzEwOTk1MTE3MDM5OTM_ef0e985e-dd84-4b6f-837f-5f59c84f7c40"
      unitRef="usd">900000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzUzMzQ_002e3832-a7c9-49ac-a7b5-8e6979b38b18">Financial Instruments&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term investments consist of U.S. Treasury securities, U.S. Government agency securities and highly rated, investment-grade corporate debt securities with original maturities beyond three months at the date of purchase. The Company has classified and accounted for its short-term investments as available-for-sale securities as the Company may sell these securities at any time even prior to maturity and such investments represent cash available for current operations. As a result, short-term investments may include securities with maturities beyond twelve months that are classified within current assets in the Balance Sheets. The Company&#x2019;s short-term investments classified as available-for-sale are carried at fair market value with unrealized losses or income recognized in other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the Balance Sheets and assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for&#160;identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or&#160;no market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash equivalent Money Market Funds are classified as Level 1 because they are valued using quoted market prices. The fair value of the Company&#x2019;s U.S. Treasury securities, U.S. government agency securities and corporate debt securities are classified as Level 2 because they are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency and include U.S. government agency securities, U.S. Treasury securities and corporate debt securities. These Level 2 instruments require more management judgment and subjectivity compared to Level 1 instruments which include determining which instruments are most similar to the instrument being priced, determining whether the market is active and determining which model-derived valuations are to be used when calculating fair value. The Company performs its analysis with the assistance of investment advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets or liabilities as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash and cash equivalents, Money Market Funds and short-term investments by significant investment category as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities included in short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities included in cash and cash equivalents and short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;183,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;183,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities included in short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities included in short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities included in cash and cash&lt;br/&gt;&#160;&#160;&#160;equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may sell certain of its short-term securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the remaining contractual maturities of the Company&#x2019;s short-term investments as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mature in 1 year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mature in 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no liabilities measured at fair value on a recurring basis as of December&#160;31, 2021 and 2020. There have been no transfers between fair value measurement levels during the years ended December&#160;31, 2021 and 2020. In addition, there were no assets or liabilities measured at fair value on a non-recurring basis as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had not recorded any impairment related to other-than-temporary declines in the fair value of short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records interest income and accretion income earned on Money Market Funds and U.S. Treasury, U.S. government agency and corporate debt securities to interest and other income (expense), net in its statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzUzMzU_193e1500-8ba5-4131-8782-f84266b5b13e">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash and cash equivalents, Money Market Funds and short-term investments by significant investment category as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities included in short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities included in cash and cash equivalents and short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;183,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;183,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities included in short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities included in short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities included in cash and cash&lt;br/&gt;&#160;&#160;&#160;equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4a0d9e0cac2348ca84c706c8288bceb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzMtMS0xLTEtMTI2NTk_2f13d16a-f78d-41a1-9ca6-3ac9e129624d"
      unitRef="usd">15329000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="ie79933d3e8de4b1dbcd02a40640ad95c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzMtMy0xLTEtMTI2NTk_bbaa59b1-0c16-415c-98c2-b11fa95df5d2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="ie79933d3e8de4b1dbcd02a40640ad95c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzMtNS0xLTEtMTI2NTk_66d7c58e-7a9f-468c-8298-4ae562590a64"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a0d9e0cac2348ca84c706c8288bceb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzMtNy0xLTEtMTI2NTk_2d859941-12be-4863-9543-d7882f592ac7"
      unitRef="usd">15329000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i502608fba6ca409d9d1c9db643401ed1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzYtMS0xLTEtMTI2NTk_2a76feb9-ac35-41b5-81bf-5fc5a2a47ae7"
      unitRef="usd">5003000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="i9ccce3ad26234845a35af7149a3ec646_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzYtMy0xLTEtMTI2NTk_7eea580f-0c65-4374-ae9c-a35fe145929f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i9ccce3ad26234845a35af7149a3ec646_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzYtNS0xLTEtMTI2NTk_dd2b3f59-92d5-49e2-a9f6-b8c40f21aa5b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i502608fba6ca409d9d1c9db643401ed1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzYtNy0xLTEtMTI2NTk_481456de-d1c9-41eb-8720-392a661277c1"
      unitRef="usd">5003000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iddc5aed3e7a8426487bf4c221631f7c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzctMS0xLTEtMTI2NTk_4f0ce7f4-b71c-4be9-a329-eb90b97d09a8"
      unitRef="usd">163626000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="i771d84b1911848a9bbe7a4b3d4704f30_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzctMy0xLTEtMTI2NTk_6c024407-9381-4dd5-a00d-453bdfd6aef9"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i771d84b1911848a9bbe7a4b3d4704f30_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzctNS0xLTEtMTI2NTk_76da95ce-2584-4f21-93df-e6e568081e36"
      unitRef="usd">202000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddc5aed3e7a8426487bf4c221631f7c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzctNy0xLTEtMTI2NTk_4cde4d71-e9be-48b6-89e6-d94a952b3117"
      unitRef="usd">163425000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzgtMS0xLTEtMTI2NTk_819f4dfc-4b04-41cb-9200-17a45156bb5b"
      unitRef="usd">183958000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzgtMy0xLTEtMTI2NTk_949b8c2b-8bde-45a2-a70f-58584b3c7bd9"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzgtNS0xLTEtMTI2NTk_ea55d99b-3d5d-40b8-a753-55ced7f8e56e"
      unitRef="usd">202000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZTplMzdlY2Q3YzcwMTQ0ZWUwODgxNDY0OTI0NWI2YTQ3Ni90YWJsZXJhbmdlOmUzN2VjZDdjNzAxNDRlZTA4ODE0NjQ5MjQ1YjZhNDc2XzgtNy0xLTEtMTI2NTk_2f7299e2-8a09-4ac7-946b-99639e564831"
      unitRef="usd">183757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iad109a114dc8411c89edb8c84d2b1e18_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzMtMS0xLTEtMTI2NTk_9566f6ff-a00f-49df-8a6d-ac54ef52a354"
      unitRef="usd">27686000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="i29ada465fe97416585c2b4b0679231ca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzMtMy0xLTEtMTI2NTk_6db50b19-ae16-4caa-b413-17e8bd313fe8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i29ada465fe97416585c2b4b0679231ca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzMtNS0xLTEtMTI2NTk_2d04174f-6241-413c-9e07-a31e92ec46af"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad109a114dc8411c89edb8c84d2b1e18_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzMtNy0xLTEtMTI2NTk_f1c7fd51-4756-404c-97c0-fcdbd13e9d8c"
      unitRef="usd">27686000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i95ed66f76be545c297192eb65c6e90ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzUtMS0xLTEtMTI2NTk_cd1e8a76-42f6-4ecb-a6e2-d9d5b40a14a1"
      unitRef="usd">63101000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="i741c7a0fae7340c89c0beeec92183dff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzUtMy0xLTEtMTI2NTk_0dabb25c-00f5-4944-80d7-34aac3fb7c3e"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i741c7a0fae7340c89c0beeec92183dff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzUtNS0xLTEtMTI2NTk_755743d6-3c99-4657-b884-e8da387b6952"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95ed66f76be545c297192eb65c6e90ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzUtNy0xLTEtMTI2NTk_9ba146ac-e885-44f6-8f71-d50c376a6efe"
      unitRef="usd">63104000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0c3fbf9468164232b5a4585f59962a25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzYtMS0xLTEtMTI2NTk_c2dd4305-1a25-4654-9b9c-856810bcba4c"
      unitRef="usd">54183000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="i0fedf72de50140c3b7b150892abda892_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzYtMy0xLTEtMTI2NTk_7d33b7bb-117b-4f09-bcc7-47da0ce1b10a"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i0fedf72de50140c3b7b150892abda892_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzYtNS0xLTEtMTI2NTk_ae007553-da3c-492d-91e8-2a9741e1e175"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c3fbf9468164232b5a4585f59962a25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzYtNy0xLTEtMTI2NTk_486dc19e-3bcc-4809-ab49-dee5b47a3c8b"
      unitRef="usd">54193000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia7be8fb727d34fd78dee97819061e39f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctMS0xLTEtMTgyMzQ_82d99c83-84c5-4d93-b76b-021443c36d2e"
      unitRef="usd">118759000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="i88eb8ff0e0954c70883407fca7e46607_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctMy0xLTEtMTgyNDA_1426d3af-26a0-4226-8fe5-c75ffab7e5a6"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="i88eb8ff0e0954c70883407fca7e46607_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctNS0xLTEtMTgyNDY_49c5d9dc-8918-46d8-a718-ad527f12421b"
      unitRef="usd">46000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7be8fb727d34fd78dee97819061e39f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctNy0xLTEtMTgyNTI_157e8055-ab77-4ef2-8f17-df7ab8e5f9ea"
      unitRef="usd">118714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctMS0xLTEtMTI2NTk_2ac248ab-f61e-4d67-9370-7f79fd2eb19d"
      unitRef="usd">263729000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctMy0xLTEtMTI2NTk_c688968e-f062-48e9-8d71-02d23075df5b"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctNS0xLTEtMTI2NTk_945b262b-fa00-4a63-9144-e68f22f7388d"
      unitRef="usd">47000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToyM2I4YzgyMDdjNjk0YmU2OGMzNDY2MTZhMmVmMThmMi90YWJsZXJhbmdlOjIzYjhjODIwN2M2OTRiZTY4YzM0NjYxNmEyZWYxOGYyXzctNy0xLTEtMTI2NTk_974772e1-a219-4472-89d3-47b8d317df7f"
      unitRef="usd">263697000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzUzMzY_03ed00ed-b8a2-4dcc-8af8-290f7846d046">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the remaining contractual maturities of the Company&#x2019;s short-term investments as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mature in 1 year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mature in 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibbd310f10677481088f4abcc6a267dac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzEtMS0xLTEtMTI2NTk_9097fc82-d230-4dc0-b870-fe064e4b2c6c"
      unitRef="usd">114076000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbd310f10677481088f4abcc6a267dac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzEtMy0xLTEtMTI2NTk_7907be7e-6dca-411d-aaed-efd5310d3e2e"
      unitRef="usd">113974000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i762f167b21754e29a50cab9db8dacfac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzItMS0xLTEtMTI2NTk_9ec246d9-d5dd-4e5c-87ad-0f5dcb47eadd"
      unitRef="usd">35054000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i762f167b21754e29a50cab9db8dacfac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzItMy0xLTEtMTI2NTk_b3ce58e0-d72d-45b9-95f3-91d8111c744b"
      unitRef="usd">34956000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i788f10f5c97047c98f3a91d33d462adc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzMtMS0xLTEtMTI2NTk_4421ddc4-918d-44f1-af80-eb5d107fea31"
      unitRef="usd">149130000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i788f10f5c97047c98f3a91d33d462adc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90YWJsZToxODQ4YTcyNWFlY2M0M2VlYWI5YzEyY2JiM2Y4ODUxNC90YWJsZXJhbmdlOjE4NDhhNzI1YWVjYzQzZWVhYjljMTJjYmIzZjg4NTE0XzMtMy0xLTEtMTI2NTk_8b93712d-3b62-473a-ab54-5ccfb9df1f29"
      unitRef="usd">148930000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ibfb9d77c8aeb443b8744a5d136c48c67_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQxMDg_22e1b2c9-84a2-43f7-8da6-aed4b2b0ba27"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="iad0147962f3a43ae98dc9257ca855342_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQxMDg_6c427bb8-bad9-4a31-8514-08999a79cc98"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQyMDA_7965b4ed-8d30-4358-8d83-626b2f6ac564"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQyMDA_ccd56b9b-3310-4749-a72f-f59d8c45167b"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i48f177c3974b433093600a48912c81ba_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQzMDk_87392369-a321-4a1d-b67a-9aa2c25ef43b"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="idb37502688b5432890a52460645ba22c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMDkvZnJhZzo1ZmYyZWEwZWFlYTU0YzdhYTZiYTk4MjcyNzA2OGUwMy90ZXh0cmVnaW9uOjVmZjJlYTBlYWVhNTRjN2FhNmJhOTgyNzI3MDY4ZTAzXzQzMDk_a23ceb6d-eaf8-4c30-824e-b8bb2aa2753b"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE4OA_1b07e4c4-dbce-4185-8dfd-e165fae909aa">Property and Equipment, net&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense during the years ended December&#160;31, 2021, 2020 and 2019 was $1.5 million, $1.3 million, $1.1 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE4OQ_b8a2f950-a77e-40d0-9bcc-0c8dcb3c12de">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id16f08eb632f4af58a00d176e37ebf70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzItMS0xLTEtMTI2NTk_11db932d-a9b0-4500-8be4-110c3fcc6cc1"
      unitRef="usd">7947000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i604392abc5a0452d940c039026024807_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzItMy0xLTEtMTI2NTk_1f9362b6-d113-4c5d-94c7-2155864a2667"
      unitRef="usd">6540000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6e78efdd427f4cb090c0239dd860231c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzMtMS0xLTEtMTI2NTk_97aa3802-e663-425d-8777-e2242b4acdf0"
      unitRef="usd">1618000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib3ceadd77d9b4e6091731d2900ea887e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzMtMy0xLTEtMTI2NTk_09bfe3a3-6a07-4560-a226-2b1d632297be"
      unitRef="usd">947000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id8691f274c844ea689788aa8180fc7ea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzQtMS0xLTEtMTI2NTk_edf4f3a1-7495-4f7d-8b2c-55385ac5c8dc"
      unitRef="usd">38000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icaafcff2da3c4e68a71fc38bc8eaeeef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzQtMy0xLTEtMTI2NTk_7b2549a7-34f4-4eec-98df-638a5e1e26b7"
      unitRef="usd">300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic8516b91fd4c4e219c9d323eabb5f186_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzUtMS0xLTEtMTI2NTk_40ba1f0d-69ac-4497-ae60-891311775739"
      unitRef="usd">22000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icc186515959f44048d743426dc3fdbb4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzUtMy0xLTEtMTI2NTk_d547d435-a97b-416e-bfda-59fd519a6424"
      unitRef="usd">22000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzYtMS0xLTEtMTI2NTk_0c8dc86f-a6dd-4f23-a252-ba15b8395bb8"
      unitRef="usd">9625000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzYtMy0xLTEtMTI2NTk_c610d476-57fb-49f7-a1ed-287e689def57"
      unitRef="usd">7809000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzctMS0xLTEtMTI2NTk_aff8c90f-2de9-42d0-8495-08d991e664d1"
      unitRef="usd">5019000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzctMy0xLTEtMTI2NTk_a3007d69-a29e-4a7b-8c66-d6a52fe46674"
      unitRef="usd">3488000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzgtMS0xLTEtMTI2NTk_ec5ed227-e365-4a40-88c7-e0af78c9aa85"
      unitRef="usd">4606000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90YWJsZTo0Y2FmYjM1ZGU4ODc0OTcyODc2ZTU4NDMzNGY3NDUxNS90YWJsZXJhbmdlOjRjYWZiMzVkZTg4NzQ5NzI4NzZlNTg0MzM0Zjc0NTE1XzgtMy0xLTEtMTI2NTk_977b3b88-0e72-455f-af13-b74ef895ea3b"
      unitRef="usd">4321000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE2NDkyNjc0NDE4OTg_0b62bd7a-de7e-4452-9e11-7cab089483e0"
      unitRef="usd">1500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE2NDkyNjc0NDE5MDI_877b2e45-add4-479f-ae13-5a1d3c05f593"
      unitRef="usd">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTUvZnJhZzo0ZjM5YjIxYzRmNDA0ZDdjYWQ2ODMzMDEyODhmMjEzYi90ZXh0cmVnaW9uOjRmMzliMjFjNGY0MDRkN2NhZDY4MzMwMTI4OGYyMTNiXzE2NDkyNjc0NDE5MDY_1db2a9e0-61e1-4812-9d0c-ab29e936af01"
      unitRef="usd">1100000</us-gaap:Depreciation>
    <plrx:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGV4dHJlZ2lvbjplMDg4MjIxYTA0N2U0NzI1YmY2NTU3NzQxYTM2ZTJkYl80Mzk4MDQ2NTExMjQw_d381c70a-de29-4a1c-b49d-0b90c00cad2c">Prepaid expenses and other current assets&lt;div style="margin-top:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</plrx:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <plrx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGV4dHJlZ2lvbjplMDg4MjIxYTA0N2U0NzI1YmY2NTU3NzQxYTM2ZTJkYl80Mzk4MDQ2NTExMjQx_b8b69808-9aca-4814-9dc1-624318d70225">&lt;div style="margin-top:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</plrx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <plrx:PrepaidResearchAndDevelopmentCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV8yLTEtMS0xLTI2ODk1_e3741363-6a0d-428d-b4c7-16d6e125c46d"
      unitRef="usd">2819000</plrx:PrepaidResearchAndDevelopmentCurrent>
    <plrx:PrepaidResearchAndDevelopmentCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV8yLTMtMS0xLTI2ODk1_bc4fa9dd-139b-43ac-b304-00a128cffcbd"
      unitRef="usd">1898000</plrx:PrepaidResearchAndDevelopmentCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV8zLTEtMS0xLTI2ODk1_2c5c688c-4c12-4650-aeb5-52ae223d2eaf"
      unitRef="usd">2585000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV8zLTMtMS0xLTI2ODk1_0ff0bd8c-e978-4da3-926a-e179b999fe07"
      unitRef="usd">1459000</us-gaap:PrepaidInsurance>
    <plrx:PrepaidLicensesCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV80LTEtMS0xLTI2ODk1_d2c4ad64-8318-4f5e-bfa5-abd2c41c1c60"
      unitRef="usd">819000</plrx:PrepaidLicensesCurrent>
    <plrx:PrepaidLicensesCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV80LTMtMS0xLTI2ODk1_16ba04f2-2d13-4b8d-8a9d-95a367f30acb"
      unitRef="usd">665000</plrx:PrepaidLicensesCurrent>
    <us-gaap:PrepaidInterest
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV81LTEtMS0xLTI2ODk1_1f428aaf-4333-4d44-9c3f-0727f4075007"
      unitRef="usd">385000</us-gaap:PrepaidInterest>
    <us-gaap:PrepaidInterest
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV81LTMtMS0xLTI2ODk1_079d66f4-0b4c-4cbb-b421-1dcd160ac32f"
      unitRef="usd">386000</us-gaap:PrepaidInterest>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV82LTEtMS0xLTI2ODk1_89ea7b5a-89fa-48c0-9b72-6aeea275a83b"
      unitRef="usd">156000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV82LTMtMS0xLTI2ODk1_6b2da7c6-f5d1-4a2e-93a9-b393458b2e04"
      unitRef="usd">90000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV83LTEtMS0xLTI2ODk1_227469e5-abb4-4078-a299-fa614690662c"
      unitRef="usd">6764000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNzM2L2ZyYWc6ZTA4ODIyMWEwNDdlNDcyNWJmNjU1Nzc0MWEzNmUyZGIvdGFibGU6NjdmMmEyYjM5N2YxNDcxN2E3ZDUwZjIwYzdmNjA5MTUvdGFibGVyYW5nZTo2N2YyYTJiMzk3ZjE0NzE3YTdkNTBmMjBjN2Y2MDkxNV83LTMtMS0xLTI2ODk1_47f87fa7-5280-4fe8-8e61-ddc539fdd4d3"
      unitRef="usd">4498000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90ZXh0cmVnaW9uOjc4YzQ1YzE1YTZmMTQ1YmFhYjJlODU1ZTMwYzBmYmUyXzMzOA_7e05c977-94c4-4fd2-b55e-e92ce29e3d17">Accrued Liabilities and Other Long-Term Liabilities&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation and benefits consist primarily of accrued bonuses and accrued vacation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-Term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold incentive obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities &#x2014; deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90ZXh0cmVnaW9uOjc4YzQ1YzE1YTZmMTQ1YmFhYjJlODU1ZTMwYzBmYmUyXzMzOQ_90180e94-e627-4321-b862-9659483f7f1f">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <plrx:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzItMS0xLTEtMTI2NTk_1286deb8-5178-4ae4-969f-e67213ac9eaf"
      unitRef="usd">5868000</plrx:AccruedResearchAndDevelopmentExpensesCurrent>
    <plrx:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzItMy0xLTEtMTI2NTk_c21c03f3-0a12-4656-851f-7057de4761f4"
      unitRef="usd">3274000</plrx:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzMtMS0xLTEtMTI2NTk_4a34c87b-5231-43c7-96dd-b60a8954e05e"
      unitRef="usd">5216000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzMtMy0xLTEtMTI2NTk_8f18fef6-58e6-4745-8611-4c9a5396fb0d"
      unitRef="usd">4542000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzQtMS0xLTEtMTI2NTk_cb41c97f-62a5-4bce-a9b2-c967f14ab218"
      unitRef="usd">907000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzQtMy0xLTEtMTI2NTk_d9e21c55-b064-4883-b472-b6863e34601d"
      unitRef="usd">1675000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <plrx:DeferredRentAndLeaseholdIncentiveObligationCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzUtMS0xLTEtMTI2NTk_3de26c56-3e23-4562-b4ab-2ceb8c8c0174"
      unitRef="usd">0</plrx:DeferredRentAndLeaseholdIncentiveObligationCurrent>
    <plrx:DeferredRentAndLeaseholdIncentiveObligationCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzUtMy0xLTEtMTI2NTk_96e73467-4b88-48ef-ab9b-cfa7bd741b78"
      unitRef="usd">85000</plrx:DeferredRentAndLeaseholdIncentiveObligationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzYtMS0xLTEtMTI2NTk_607173a7-2fab-40bf-8110-19e2d9b89a79"
      unitRef="usd">11991000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZTo3ZTM4OTAyMGRlZGU0NDVhODY0ZDJhZjdlZmExMjQyMC90YWJsZXJhbmdlOjdlMzg5MDIwZGVkZTQ0NWE4NjRkMmFmN2VmYTEyNDIwXzYtMy0xLTEtMTI2NTk_da82de78-8484-4771-8b1e-1c63d41db821"
      unitRef="usd">9576000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90ZXh0cmVnaW9uOjc4YzQ1YzE1YTZmMTQ1YmFhYjJlODU1ZTMwYzBmYmUyXzM0MA_515ef14b-b16f-46cf-8ad3-0f7f712a0ac9">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold incentive obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities &#x2014; deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:DeferredRentCredit
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzItMS0xLTEtMTI2NTk_3902768a-d128-4cea-846c-1f7b5436631d"
      unitRef="usd">0</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzItMy0xLTEtMTI2NTk_1d414265-e808-4357-9866-d93d442aa555"
      unitRef="usd">581000</us-gaap:DeferredRentCredit>
    <us-gaap:IncentiveFromLessor
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzMtMS0xLTEtMTI2NTk_65413f9e-9dfb-4276-a2c1-549c3690cc92"
      unitRef="usd">0</us-gaap:IncentiveFromLessor>
    <us-gaap:IncentiveFromLessor
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzMtMy0xLTEtMTI2NTk_c51e90e1-9f57-489e-a895-d0562f781478"
      unitRef="usd">283000</us-gaap:IncentiveFromLessor>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzQtMS0xLTEtMTI2NTk_e2a0d485-e72b-4659-b73a-79ae8c0e3349"
      unitRef="usd">0</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzQtMy0xLTEtMTI2NTk_7f23e8f0-ffc0-41df-bf0f-2251dada51e4"
      unitRef="usd">2000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzUtMS0xLTEtMTI2NTk_4b09dbca-0e0f-4ab4-84d9-c9b2d3a559e1"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMTgvZnJhZzo3OGM0NWMxNWE2ZjE0NWJhYWIyZTg1NWUzMGMwZmJlMi90YWJsZToxMjUxMmViNmNkYTg0YjBjYjlmMzNiZGY0NjQ2NGU5MS90YWJsZXJhbmdlOjEyNTEyZWI2Y2RhODRiMGNiOWYzM2JkZjQ2NDY0ZTkxXzUtMy0xLTEtMTI2NTk_c055235b-a323-4c5f-bc8d-8169c6616100"
      unitRef="usd">866000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzcxODU_98916e3c-a44b-4836-aab2-1bddbe6dadd3">Novartis Collaboration and License Agreement (the "Novartis Agreement")&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into the Novartis Agreement, for the development and commercialization of our preclinical product candidate, PLN-1474 and up to three additional integrin research targets. PLN-1474 is an internally discovered small molecule selective inhibitor of integrin &#x3b1;v&#x3b2;1, currently being developed for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (&#x201c;NASH&#x201d;). Pursuant to the agreement, we received an upfront, non-refundable license fee of $50.0 million and were eligible to receive additional payments of $416.0 million contingent upon achievement of specified research, development, regulatory and commercial events and royalties on world-wide net sales thereafter. Additionally, Novartis agreed to fund up to $19.6 million associated with research and development services for PLN-1474 and up to $13.4 million for research and development services on the integrin research targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed the Novartis Agreement in accordance with ASC 606 and determined that Novartis is a customer and identified the following performance obligations: (1) to provide worldwide license rights to PLN-1474, (2) to provide research and development services for PLN-1474, (3) to provide non-exclusive license rights to integrin research targets, and (4) to provide research and development services on integrin research targets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the license to PLN-1474 was functional intellectual property and distinct as Novartis is capable to benefit from the license on its own or together with other resources that are readily available, and the research and development services we promise to deliver are not transformative in nature. Additionally, we concluded that the non-exclusive license rights to integrin research targets were not distinct in the context of the arrangement as the promised research and development services on integrin research targets were expected to significantly modify the license and Novartis could not benefit from the non-exclusive license without such services. Therefore, the non-exclusive license rights and research and development services on integrin research targets were considered a single performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the transaction price of the PLN-1474 research and development services and integrin target research and development services was $20.0&#160;million and $13.4&#160;million, respectively, as of December 31, 2021, and the performance obligations associated with the aggregate unrecognized transaction price of $2.0&#160;million would be satisfied in 2022. As of December 31, 2021, variable consideration associated with specified research and development milestones totaling $391&#160;million have been constrained from the transaction prices but remain eligible for achievement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are utilizing a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. We believe this is the best measure of progress because other measures do not reflect how we transfer the performance obligation to our counterparty. In applying the cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of third-party contract costs and internal full-time equivalent effort. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the performance obligations. The cumulative effect of revisions to estimated costs to complete the performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, we recognized revenue of $7.6&#160;million which consisted of revenue generated from research and development services. During the year ended December&#160;31, 2020, we recognized revenue of $41.8 million, which consisted of $25.0&#160;million from the achievement of the first patient dosing milestone of the Novartis agreement in the first quarter of 2020 and $16.8 million of revenue generated from research and development services performed during the year.&#160;During the year ended December&#160;31, 2019, Company recognized revenue of $50.0 million related to the license fee and $7.1 million from research and development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, there was a receivable of $2.0&#160;million and $9.3 million, respectively, related to the Novartis Agreement. There were no contract assets or contract liabilities as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <plrx:NumberOfIntegrinResearchTargets
      contextRef="iaac21b42661c400488b1fa60189baec8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NDk0NTk_158c1bda-6d68-4ba8-896f-635e7b6d2f4e"
      unitRef="research">3</plrx:NumberOfIntegrinResearchTargets>
    <plrx:ProceedsFromUpfrontNonRefundableLicenseFee
      contextRef="i4a11a4aeb6da425289c1166b59fd1bef_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5MTc_9a3ee829-9792-4e3a-987a-5b3b7cd9cb85"
      unitRef="usd">50000000</plrx:ProceedsFromUpfrontNonRefundableLicenseFee>
    <plrx:CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount
      contextRef="iaac21b42661c400488b1fa60189baec8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5MjM_0c85a3da-2929-4be1-b921-c42666bdb25a"
      unitRef="usd">416000000</plrx:CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="icf4063173b5147aaa5ea48ffb9a0b41a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5MzE_18ac8592-9cd5-4c4f-aae3-a1157ae665c0"
      unitRef="usd">19600000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="id20b043448f24ec285209cd2157d817f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5Mzg_b0652a8a-cfb6-42d5-bd97-fbd5ba6e4ff8"
      unitRef="usd">13400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i65678d1f069d4f07b494357695afab1c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NzQ4MzA_b730288d-84be-45bd-a8b7-d89e8b6e0257"
      unitRef="usd">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i3487dc6202fc4061837be6f1764523cd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NzQ4NDU_583084f4-369a-43cc-b04d-467e767f9b6a"
      unitRef="usd">13400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i7f8872e361484321beb5a17ef1f8345f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NzQ4NjA_41d45a1e-acb3-4382-98f2-2c935dd66d3a"
      unitRef="usd">2000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i8d55eaa32322449995997cb4bfd779d4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzQzOTgwNDY1NzQ4NzQ_33c80521-30e5-4266-b082-2036afccd3a7"
      unitRef="usd">391000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i7aab796f0bd54438a683ab44e486ff52_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjU5NjM_0988e298-8dae-4129-a57f-816e8eea7666"
      unitRef="usd">7600000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="iac8fe1712787414792033f6f6a6693aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwMDM_52c4020a-e6d2-4966-ad77-11c6db876e9e"
      unitRef="usd">41800000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i1401fc63110c46cca48abbee90d24210_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwMTA_f38e5a33-1ce9-4566-840c-3e38ddb25d97"
      unitRef="usd">25000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ic8fd2e317fcf496da3fadf37239b10a7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwMTc_d18b527c-6f58-40e3-a671-1f56f4460ef2"
      unitRef="usd">16800000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ia854acc757a14f42801309f5de85921c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwMzk_9157af09-c664-4b2d-9ee6-7f392c03ee42"
      unitRef="usd">50000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i935a529a108b4fe0854d7b486b19bf50_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwNDY_9ab9b920-b47b-4f93-99ee-c46bfabf3cc7"
      unitRef="usd">7100000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ief48b07f768842d19a26be0c2fdd1f5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwNjU_56909548-b80f-4e8d-9e8e-0329e77c986d"
      unitRef="usd">2000000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i1584a412397045a9b86f15e94c5effa9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwNTg_25826552-5914-4e78-8d6f-c9def415bfb4"
      unitRef="usd">9300000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i1584a412397045a9b86f15e94c5effa9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwODU_05d70b5a-500e-4ab5-896b-5a03c852966f"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1584a412397045a9b86f15e94c5effa9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwODU_643c1056-4044-43ad-a6f8-7b4dc5f22435"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ief48b07f768842d19a26be0c2fdd1f5b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwODU_765f44ac-87c3-4692-a5cd-67356eea5e4d"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ief48b07f768842d19a26be0c2fdd1f5b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjEvZnJhZzpjMTJlNWY0YjIzZTU0NTQyOTNkYWVmMzc5MGU2M2Y2My90ZXh0cmVnaW9uOmMxMmU1ZjRiMjNlNTQ1NDI5M2RhZWYzNzkwZTYzZjYzXzEwOTk1MTE2NjYwODU_c906da23-1c0d-464e-b86c-77f4e6c3579c"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <plrx:LicenseAgreementsTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjQvZnJhZzoyYTE1ZmM5ZDZkNTE0YmIxYWRlMDgwZDgwNjFmMTQwYi90ZXh0cmVnaW9uOjJhMTVmYzlkNmQ1MTRiYjFhZGUwODBkODA2MWYxNDBiXzIzMjM_d2527c20-d05f-422b-bd66-a6cf3dd849c7">Regents of the University of California License Agreement (the &#x201c;UC Agreement&#x201d;) In 2015, we entered into the UC Agreement to obtain an exclusive, worldwide license relating to the use of certain patents and technology relating to &#x3b1;v&#xdf;1 compound in fibrosis indications. Pursuant to the UC Agreement, we made a $2.4 million milestone payment upon the close of our IPO in June 2020. Subsequently, we determined the licensed technology was no longer relevant to the development of our product candidates and, therefore, we exercised our right to terminate the UC Agreement which became effective in the first quarter of 2021. No further obligations or financial commitments survive the termination.</plrx:LicenseAgreementsTextBlock>
    <plrx:MilestoneAndAnnualRoyaltyPaid
      contextRef="ia97bea2e62e046a3b667360c66ca83de_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjQvZnJhZzoyYTE1ZmM5ZDZkNTE0YmIxYWRlMDgwZDgwNjFmMTQwYi90ZXh0cmVnaW9uOjJhMTVmYzlkNmQ1MTRiYjFhZGUwODBkODA2MWYxNDBiXzk4OTU2MDQ2NjA4ODU_fcad15b3-979a-4d10-b62e-36d5e20d7c09"
      unitRef="usd">2400000</plrx:MilestoneAndAnnualRoyaltyPaid>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjcvZnJhZzphNGVjZmYxM2QwYzM0MTQ3OWY5YjBiZjcxODk1NTg4NC90ZXh0cmVnaW9uOmE0ZWNmZjEzZDBjMzQxNDc5ZjliMGJmNzE4OTU1ODg0XzM0NjY_9568ccd3-0d45-4956-b576-d8053b8ff0ba">Adimab Development and Option Agreement (the "Adimab Agreement")In 2018, we entered into a development and option agreement with Adimab, LLC (&#x201c;Adimab&#x201d;) for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the Adimab Agreement, we will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. We are required to pay Adimab an agreed upon rate for its full-time employees during the discovery period while Adimab performs research on each target under the applicable research plan. We have an exclusive option to obtain a worldwide, royalty-bearing, sublicensable license under Adimab platform patents and other Adimab technology to research, develop and commercialize up to 24 antibodies of our selection.During the years ended December&#160;31, 2021, 2020 and 2019, we recognized research and development expenses associated with full-time employee costs of $28,000, $0.2 million and $0.2 million, respectively.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i325f7f2d873247748a03caa8aa5d4255_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjcvZnJhZzphNGVjZmYxM2QwYzM0MTQ3OWY5YjBiZjcxODk1NTg4NC90ZXh0cmVnaW9uOmE0ZWNmZjEzZDBjMzQxNDc5ZjliMGJmNzE4OTU1ODg0XzE2NDkyNjc0NDYxMDQ_daff8b00-848e-4332-82b9-6f9356b56e18"
      unitRef="usd">28000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5d58d249d30a4738b31d13b2325bbf0f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjcvZnJhZzphNGVjZmYxM2QwYzM0MTQ3OWY5YjBiZjcxODk1NTg4NC90ZXh0cmVnaW9uOmE0ZWNmZjEzZDBjMzQxNDc5ZjliMGJmNzE4OTU1ODg0XzE2NDkyNjc0NDU4Mzc_b779cf02-24c2-4ae4-ab2a-c6202fc57b48"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i92b24333fd1f4bc6a82043ff6caa6b4b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMjcvZnJhZzphNGVjZmYxM2QwYzM0MTQ3OWY5YjBiZjcxODk1NTg4NC90ZXh0cmVnaW9uOmE0ZWNmZjEzZDBjMzQxNDc5ZjliMGJmNzE4OTU1ODg0XzE2NDkyNjc0NDU5MTk_b2ed0ad4-5844-494f-8270-08a698ee115d"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
    <plrx:RedeemableConvertiblePreferredStockTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzMvZnJhZzozNmMzNGZhZmMwNjM0OGQ4OTA2OTc2NTUzNGQ1NTk1My90ZXh0cmVnaW9uOjM2YzM0ZmFmYzA2MzQ4ZDg5MDY5NzY1NTM0ZDU1OTUzXzc2MDI_10d2c34c-e3f4-4932-8dff-90168451928b">Redeemable Convertible Preferred StockUnder the Company&#x2019;s Amended and Restated Certificate of Incorporation (&#x201c;Certificate of Incorporation&#x201d;), the Company is authorized to issue two classes of shares: preferred and common stock. The preferred stock may be issued in series, and the Company&#x2019;s Board of Directors is authorized to determine the rights, preferences, and terms of each series. These rights preferences and terms could include dividend rights, conversion rights, voting rights, terms of redemptions, liquidation preferences and sinking fund terms. As a result of the IPO in June 2020, all then outstanding convertible preferred stock was converted into shares of common stock. There are no outstanding shares of preferred stock as of December&#160;31, 2021.</plrx:RedeemableConvertiblePreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i854a3335aa6a4adc9776beabc85e03a9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzMvZnJhZzozNmMzNGZhZmMwNjM0OGQ4OTA2OTc2NTUzNGQ1NTk1My90ZXh0cmVnaW9uOjM2YzM0ZmFmYzA2MzQ4ZDg5MDY5NzY1NTM0ZDU1OTUzXzEwOTk1MTE2MzU4MDU_8b4e83c4-94bf-4b96-8390-c56c5386af1f"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzI1NTQ_21dd2b76-9d17-4f0a-b083-4fa0a060f11f">Common Stock&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had 300,000,000 authorized shares of common stock, at a par value of $0.0001 per share. The common stock has the following rights and privileges:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of shares of common stock are entitled to one vote for each share of common stock held at any meeting of stockholders and at the time of any written action in lieu of a meeting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of shares of common stock are entitled to receive dividends, when declared by the Company&#x2019;s Board of Directors. Cash dividends may not be declared or paid to holders of shares of common stock until all unpaid dividends on the Preferred Stock have been paid in accordance with their terms. No dividends have been declared or paid by the Company since its inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After payment of the respective liquidation preferences to the holders of shares of Preferred Stock, the holders of shares of common stock are entitled to share ratably in the Company&#x2019;s remaining assets available for distribution to its stockholders in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or upon occurrence of a deemed liquidation event.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shares reserved for future issuance&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock option awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,620,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock available for future grants under the 2020 Stock Option and Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,234,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,644,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;613,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,467,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,338,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MDQ_2ccffb89-c00d-4b90-8a9d-9ab6243ccdb0"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MDQ_93313fe3-9f67-4f3f-9e2a-f0a486e31ddf"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MTI_ad34b9f4-fc04-4fa4-a594-e429436ed6e1"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MTI_e42bb063-e0b4-4dfd-9585-934eb0d6b3f1"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plrx:NumberOfVotesPerShareOfCommonStock
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzQzOTgwNDY1MTU4MzE_96e3709b-4b50-4dd7-81ad-5bc5b8435fb3"
      unitRef="vote">1</plrx:NumberOfVotesPerShareOfCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzE2NDkyNjc0NDQ2MTY_20aea35e-ac10-4274-81f2-2e76cf4b2f0c"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90ZXh0cmVnaW9uOjhkODM0ZGFhMDQ1MTQ5ZDViODE2MTM1M2ZmZGRlYWFhXzI1NTU_e26cd78c-f22f-4e6a-805f-23950ee55210">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shares reserved for future issuance&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock option awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,620,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,993,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock available for future grants under the 2020 Stock Option and Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,234,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,644,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;613,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,467,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,338,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i39ce7df93a7d4382a3b7d79316b6d848_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzMtMS0xLTEtMTI2NTk_618f22d9-5504-4e1a-9986-5cbcf42c2eeb"
      unitRef="shares">3620180</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2d8e01ec8dfa4b258bddae261451f4ff_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzMtMy0xLTEtMTI2NTk_de66bb72-2854-4487-b8a3-ec9b7b233775"
      unitRef="shares">2993855</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id08bb42e6ee74106be86d58f7fcbc58f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzUtMS0xLTEtMTI2NTk_53c9f35f-758d-4f0b-ac61-dda4149dada4"
      unitRef="shares">4234213</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3d9b60a984584a44a4ee09a45e5275aa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzUtMy0xLTEtMTI2NTk_19dd7b0f-d932-463d-bb31-322af7a293a3"
      unitRef="shares">3644459</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3ff87434abfc452d80645776f0f00c77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzYtMS0xLTEtMTI2NTk_6b6d1c99-4b15-46d4-bad6-3371be4258b1"
      unitRef="shares">613098</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2cf105f8083b45429f14ea888203d42a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzYtMy0xLTEtMTI2NTk_daadcb29-5b3b-4df0-a412-e4f6f9dee9e5"
      unitRef="shares">700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzctMS0xLTEtMTI2NTk_53b90144-a8d9-4273-bb4f-dee678d68d99"
      unitRef="shares">8467491</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xMzkvZnJhZzo4ZDgzNGRhYTA0NTE0OWQ1YjgxNjEzNTNmZmRkZWFhYS90YWJsZToyNTMyMDU1ODU3NmI0M2M3OWNlYmM4NDE1N2Y4MTNmZC90YWJsZXJhbmdlOjI1MzIwNTU4NTc2YjQzYzc5Y2ViYzg0MTU3ZjgxM2ZkXzctMy0xLTEtMTI2NTk_120425e4-fda7-4b36-b08f-b3c3d5b88ded"
      unitRef="shares">7338314</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjI_7dfefe51-639e-496e-bb2e-b2b9e9a7004d">Stock-Based Compensation&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, the Company's Board of Directors adopted the 2015 Equity Incentive Plan, as amended in 2018, 2019 and 2020 (the &#x201c;2015 Plan&#x201d;), which provided for the grant of incentive stock options, nonqualified stock options or other awards including stock appreciation rights and restricted stock awards to the Company&#x2019;s employees, officers, directors, advisors, and consultants.  In May 2020, the Board of Directors adopted the 2020 Stock Option and Incentive Plan (the &#x201c;2020 Plan&#x201d;) and suspended the 2015 Plan. Awards outstanding under either the 2015 Plan or 2020 Plan that are cancelled, expire or otherwise terminated subsequent to May 2020 will become available for issuance as common stock under the 2020 Plan. Additionally, the 2020 Plan is subject to automatic increases on January 1 of each year beginning January 1, 2021. The number of shares added each January 1 will be equal to the lesser of: (i) 5% of the outstanding shares on the immediately preceding December&#160;31 or (ii) such amount as determined by the administrator of the 2020 Plan, which is the compensation committee of the Board of Directors of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Plan provides for the grant of incentive stock options, nonqualified stock options or other awards including stock appreciation rights, restricted stock awards and restricted stock units to the Company&#x2019;s employees, officers, directors, advisors, and consultants. As of December 31, 2021, the 2020 Plan had 4,234,213 shares of common stock available for future issuance.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Options under the 2020 Plan may be granted for periods of up to 10 years and at prices no less than the market price of the Company&#x2019;s common stock on the date of grant, provided, however, that the exercise price of an incentive stock option granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant and the option is not exercisable after the expiration of five years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Restricted Common Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted restricted stock awards under the 2015 Plan. The purchase price of the restricted common stock awards was the estimated fair value as determined by the Company's Board of Directors at the issuance date. The shares vest from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzM1NTY_17d5b407-5e02-4666-bc12-447640c0a66b"&gt;one&lt;/span&gt; to four years and vesting could be accelerated upon a change in control. A holder of an award may pay a total purchase price or a part of the purchase price for granted shares at any time during the vesting periods. Upon termination of employment, the Company has the right to repurchase any unvested restricted shares. The repurchase price for unvested shares of common stock will be the lower of (i) the fair market value on the date of repurchase or (ii) their original purchase price. During the vesting term, holders of restricted stock awards are deemed to be common stock shareholders and have dividends and voting rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for restricted stock awards as early exercised options and recognized a liability in other liabilities when cash was received for the purchase of shares of restricted stock. As shares of restricted stock vested, the Company reclassified the liability to common stock and additional paid in capital. As of December&#160;31, 2021 and&#160;2020, the Company recorded a liability included in accrued expenses and other liabilities of $2,000&#160;and $10,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no grants of restricted stock awards during the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock activity during the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested, as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(103,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested, as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The aggregate fair value of restricted stock awards vested during the years ended December&#160;31, 2021 and 2020 was $0.2&#160;million each year. Total intrinsic value of outstanding unvested restricted stock awards as of December&#160;31, 2021 and 2020 was $0.3&#160;million and $2.9&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive Stock Options and Nonqualified Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options issued under either the 2015 Plan or the 2020 Plan generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzU0NDE_e2781c43-be0a-4144-b7b0-5f65f0005fa6"&gt;four&lt;/span&gt; years and expire ten years from the date of grant. Certain options provide for accelerated vesting if there is a change in control, as defined in the respective plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for stock option awards with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.83%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.61 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.39 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.27 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.82 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Underlying common stock fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the 2015 Plan and the 2020 Plan is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(in&#160;Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,993,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,520,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(336,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(557,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,620,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,368,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,620,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value represents the difference between the fair value of the underlying common stock and the exercise price as of December&#160;31, 2021 and 2020. The weighted-average grant date fair value of options granted during years ended December&#160;31, 2021 and 2020 was $16.94 per share and $7.27 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, the Company adopted the Company's 2020 Employee Stock Purchase Plan (the "2020 ESPP"). The Company reserved 700,000 shares of common stock for future issuance under the plan. The 2020 ESPP provides that the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;number of shares reserved and available for issuance will automatically increase on January 1 of each calendar year, beginning January 1, 2021, by the least of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) 700,000 shares or (iii) such lesser amount as determined by the administrator of the 2020 ESPP, which is the compensation committee of the Board of Directors of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2020 ESPP, eligible employees may purchase shares of our common stock through payroll deductions that cannot exceed 15% of each employee&#x2019;s salary. The 2020 ESPP provides for a six-month offering period. At the end of the purchase period, eligible employees are permitted to purchase shares of common stock at the lower of 85% of the fair market value at the beginning of the offering period or 85% of the fair market value at the end of the purchase period, subject to tax limitations on the total value of the purchase. The 2020 ESPP is considered a compensatory plan, and the Company recorded $0.5 million, $0.5&#160;million and nil in stock-based compensation expense for year ended December&#160;31, 2021, 2020 and 2019. As of December&#160;31, 2021, 86,902 shares of common stock were issued under the 2020 ESPP. The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for the 2020 ESPP with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.575%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.06% - 0.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term of options (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67.16% - 89.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83.72%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of stock-based compensation expense during the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $37,000 of unrecognized compensation costs that is expected to be recognized over the weighted-average periods of 0.38 years related to restricted stock awards. As of December&#160;31, 2021, there was $24.2 million of unrecognized compensation costs that is expected to be recognized over the weighted-average periods of 2.5 years related to stock options.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="if6f33d4df0354eefb5a56946ce9457da_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzk4OTU2MDQ2NjQ3NjU_a417b0c9-08b4-465e-80fd-b976e2f0bbdd"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id08bb42e6ee74106be86d58f7fcbc58f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzk4OTU2MDQ2NjU4NjE_53c9f35f-758d-4f0b-ac61-dda4149dada4"
      unitRef="shares">4234213</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <plrx:ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods
      contextRef="i978188554a324ce7b6a888947d74558d_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzI5MTg_79c7ab2b-51a1-4a34-ac3e-e8f96d03b2c9">P10Y</plrx:ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods>
    <plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders
      contextRef="if6f33d4df0354eefb5a56946ce9457da_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzMxMDI_49d1f026-1d7a-442b-ac63-db1b4973b1eb"
      unitRef="number">0.10</plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders>
    <plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders
      contextRef="i978188554a324ce7b6a888947d74558d_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzMxNDA_df8d02cd-5414-4e32-9a45-f70d0e95b194"
      unitRef="number">1.10</plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="if6f33d4df0354eefb5a56946ce9457da_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzMyNjQ_45618d20-1462-46d5-bc2d-a6cfa49851ac">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2fc83290d82c40ddb10360a0b1a2183c_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzM1NjI_02891c67-866b-41dd-9c27-96021fd20ea9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i82f0177dc3e04d418b662056854c1e4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NzI_6b91a4cd-6c91-421a-ace5-b4eca0e09c75"
      unitRef="usd">2000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="ica5a99276a1147c19fe6753da55b633a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5Njg_7e69ba1f-fc40-41ff-8178-3766e85ba34a"
      unitRef="usd">10000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzQ2NDg_5b94a3b1-514d-4dbd-bea1-4b30059c88c3"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjU_d4edb2b5-f7c6-4eec-8af5-c3c72c898eb8">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock activity during the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested, as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(103,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding and unvested, as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i58ea8b06f17a484f9edfb9c294799d18_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzEtMS0xLTEtMTI2NTk_0d42410d-2b35-48fa-a711-4731755bbbec"
      unitRef="shares">126522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i58ea8b06f17a484f9edfb9c294799d18_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzEtMy0xLTEtMTI2NTk_3b46ad5f-8a10-4ce6-91db-56d872f78cfa"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzItMS0xLTEtMTI2NTk_9901b1ae-3389-492d-9c83-c138ca6ec841"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzItMy0xLTEtMTI2NTk_dd488920-f3c1-40bd-a9e9-79825d8e1717"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzMtMS0xLTEtMTI2NTk_eefd8a81-9edf-4c19-a58f-b37675bacb85"
      unitRef="shares">103164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzMtMy0xLTEtMTI2NTk_7bde19db-84ca-42cc-988f-4b2619fa61d0"
      unitRef="usdPerShare">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod
      contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzQtMS0xLTEtMTI2NTk_fe0057f3-9b48-4270-876b-1ea2775da479"
      unitRef="shares">1517</plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod>
    <plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue
      contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzQtMy0xLTEtMTI2NTk_824a9964-5236-4ee8-964e-a241ee81321d"
      unitRef="usdPerShare">2.12</plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia016e7bdf0174df7a7fba019617bf8ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzUtMS0xLTEtMTI2NTk_c5e9ed11-6cb3-485a-8d5b-c8e934d5ed45"
      unitRef="shares">21841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia016e7bdf0174df7a7fba019617bf8ba_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTpkNmVjNjUyNDZhNDY0M2YzODMyNmI1NTZkNTJhMTU0Ny90YWJsZXJhbmdlOmQ2ZWM2NTI0NmE0NjQzZjM4MzI2YjU1NmQ1MmExNTQ3XzUtMy0xLTEtMTI2NTk_8512e126-471c-4c71-9427-64103bb2d6aa"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i0866a31e05374ddab8c0a62345cc2249_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NzY_c82d7df2-d143-422b-bd66-45de3a6c87de"
      unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ic13b457c597e4851b96cf2169f622cea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NzY_ed485ec2-9deb-465a-bdb3-b19d4b090c10"
      unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ia016e7bdf0174df7a7fba019617bf8ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2MzkwMjI_26817646-a094-4e16-8743-d712ad321c56"
      unitRef="usd">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i58ea8b06f17a484f9edfb9c294799d18_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2MzkwMTQ_fd860020-8c42-4714-87f1-11922647ad07"
      unitRef="usd">2900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i962e48e9796f47aeb0fff9145b63f53a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzU0Njc_15c3c7e8-ea76-4b87-9d9e-6c4e1e24381e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNTk_52617833-febd-4e10-b007-4db0408365e3">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for stock option awards with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.151%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.83%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.61 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.39 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.27 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.82 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Underlying common stock fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItMS0xLTEtMTI2NTk_60ae17c9-043e-4272-9515-171b37350371"
      unitRef="number">0.7483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItMy0xLTEtMTI2NTk_642b533f-32ba-422b-bead-269a22ba54c9"
      unitRef="number">0.7631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItNS0xLTEtMTI2NTk_823b962d-e410-41fc-9484-810e89444d93"
      unitRef="number">0.7210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItNy0xLTEtMTI2NTk_d48d3c1a-23e3-41f5-bb70-9fe163e09b80"
      unitRef="number">0.7750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ibc0db696ccde415882e24106f2b32245_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItOS0xLTEtMjE2MjE_189f9e81-41e1-4f8c-8e40-80f2b75271af"
      unitRef="number">0.7480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ibc0db696ccde415882e24106f2b32245_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzItMTEtMS0xLTIxNjIx_8b7109c8-142b-4b7e-b4e8-a3ee57bdf74b"
      unitRef="number">0.8253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtMS0xLTEtMTI2NTk_19c571d7-a44f-4118-bda4-59158aab7ed6"
      unitRef="number">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtMy0xLTEtMTI2NTk_5bc775bd-17c9-46a6-8cbb-7a7eb44b68d9"
      unitRef="number">0.0139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtNS0xLTEtMTI2NTk_e8d84e45-b51d-4ccc-83f2-27a687dd6aa6"
      unitRef="number">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtNy0xLTEtMTI2NTk_b9c7ec18-49fe-4e6e-bb15-340b216a4d3a"
      unitRef="number">0.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ibc0db696ccde415882e24106f2b32245_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtOS0xLTEtMjE2MjE_6bac2fe1-47a6-48e6-b9b1-4505edc74004"
      unitRef="number">0.0143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ibc0db696ccde415882e24106f2b32245_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzMtMTEtMS0xLTIxNjIx_017e90a9-836f-4fd2-a44e-7406a42cadde"
      unitRef="number">0.0259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzQtMS0xLTEtMTI2NTk_fc750bfc-56dc-47bf-b607-573c5083b5ea"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzQtNS0xLTEtMTI2NTk_5514d5fd-503e-4483-a717-d4c213288296"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzQtOS0xLTEtMjE2MjE_47751ba2-553e-41f8-a7c3-e3de1b685405"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9d838bfb91454b308b74f37279c3dce3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtMS0xLTEtMTI2NTk_e862fb8d-b22e-45ec-98a0-937f4c4f218f">P5Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4f90bc5eed144f31928518fb768afba8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtMy0xLTEtMTI2NTk_013ecd9d-ee15-4301-a89e-db1f5da5b293">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if4dac08fa4ec49c8b7257c8ac25cdc21_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtNS0xLTEtMTI2NTk_68baf194-8f23-4564-adbb-3cfa1e534492">P5Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idda313aa08fc4436871f7a8d1f6538ec_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtNy0xLTEtMTI2NTk_326abb99-8381-46a9-8e51-96998484c716">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i96b95e5be86744cfb426abbbd9280039_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtOS0xLTEtMjE2MjE_e709e27a-b273-464e-b92c-48b0927ab085">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i93980ffa2b4c48c69c6aeaa148e56ca5_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzUtMTEtMS0xLTIxNjIx_5273b47f-3899-4742-af08-58615593703a">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <plrx:UnderlyingCommonStockFairValue
      contextRef="i9d838bfb91454b308b74f37279c3dce3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtMS0xLTEtMTI2NTk_17b72188-7856-4cf9-8cbd-fb070399570b"
      unitRef="usdPerShare">15.2</plrx:UnderlyingCommonStockFairValue>
    <plrx:UnderlyingCommonStockFairValue
      contextRef="i4f90bc5eed144f31928518fb768afba8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtMy0xLTEtMTI2NTk_2e96038b-f105-41a1-bfd9-af9871e912cb"
      unitRef="usdPerShare">38.23</plrx:UnderlyingCommonStockFairValue>
    <plrx:UnderlyingCommonStockFairValue
      contextRef="if4dac08fa4ec49c8b7257c8ac25cdc21_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtNS0xLTEtMTI2NTk_c98d9be2-1cb8-483a-9ca2-ed4d4ce74286"
      unitRef="usdPerShare">6.22</plrx:UnderlyingCommonStockFairValue>
    <plrx:UnderlyingCommonStockFairValue
      contextRef="idda313aa08fc4436871f7a8d1f6538ec_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtNy0xLTEtMTI2NTk_f6556017-7301-4ce2-82e9-f39cd9708689"
      unitRef="usdPerShare">28.79</plrx:UnderlyingCommonStockFairValue>
    <plrx:UnderlyingCommonStockFairValue
      contextRef="i96b95e5be86744cfb426abbbd9280039_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtOS0xLTEtMjE2MjE_bfcac742-7cfc-4fbf-9e83-7cc43b625f92"
      unitRef="usdPerShare">5.15</plrx:UnderlyingCommonStockFairValue>
    <plrx:UnderlyingCommonStockFairValue
      contextRef="i93980ffa2b4c48c69c6aeaa148e56ca5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2MjAwYWM1MTBlNTA0YjU2YTlhMmY5YWNhMDQwZTdkOS90YWJsZXJhbmdlOjYyMDBhYzUxMGU1MDRiNTZhOWEyZjlhY2EwNDBlN2Q5XzYtMTEtMS0xLTIxNjIx_b0e61c87-1e55-42ab-86a4-ac7f2a79cf6c"
      unitRef="usdPerShare">7.08</plrx:UnderlyingCommonStockFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjA_61dd4013-81d3-4920-a642-4f4022aa7b25">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the 2015 Plan and the 2020 Plan is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(in&#160;Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,993,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,520,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(336,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(557,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,620,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,368,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,620,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaee36529cae34a1880d776adf134e69e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzEtMS0xLTEtMTI2NTk_ae169bdb-a8ef-45c1-ba74-7e8cd4ce69e2"
      unitRef="shares">2993855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaee36529cae34a1880d776adf134e69e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzEtMy0xLTEtMTI2NTk_3091000c-cc60-46ae-a3c2-dcb98013d510"
      unitRef="usdPerShare">8.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib513e9b41ca0401988a6ebdb0da1f635_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzEtNS0xLTEtMTI2NTk_28a5dbdc-5c5e-4f51-93f2-6478aeb9c6b5">P8Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iaee36529cae34a1880d776adf134e69e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzEtNy0xLTEtMTI2NTk_5e091356-8516-475c-b2a9-bc5da81a97a7"
      unitRef="usd">43890000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzItMS0xLTEtMTI2NTk_aa4ae01b-2f7f-45bf-800b-e5d7dd0a5f9d"
      unitRef="shares">1520391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzItMy0xLTEtMTI2NTk_e3094504-410e-4032-87f2-fd4f83393730"
      unitRef="usdPerShare">26.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzMtMS0xLTEtMTI2NTk_700a30aa-3690-4d7a-8981-3d50a1c313f5"
      unitRef="shares">336340</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzMtMy0xLTEtMTI2NTk_2b716fed-65b3-4a89-9b0d-d72e00cdd58f"
      unitRef="usdPerShare">5.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzQtMS0xLTEtMTI2NTk_8bd27a0d-7fb2-4642-a044-d8e8bb5d49ca"
      unitRef="shares">557726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzQtMy0xLTEtMTI2NTk_0a1083e6-522a-42ce-b061-b1001729f641"
      unitRef="usdPerShare">16.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzUtMS0xLTEtMTI2NTk_98e6b1a9-1ef9-44ea-8de1-ca485a105231"
      unitRef="shares">3620180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzUtMy0xLTEtMTI2NTk_b8d6ee86-6e80-4f9f-a4fb-f7efa24221c3"
      unitRef="usdPerShare">14.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzUtNS0xLTEtMTI2NTk_d69d1baf-d660-4ddc-940a-eff50f2fabd6">P8Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzUtNy0xLTEtMTI2NTk_f4293830-83d7-4b30-85f2-26c77fcba276"
      unitRef="usd">16735000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzYtMS0xLTEtMTI2NTk_7646a557-401e-4c46-8125-f07c9ffbb281"
      unitRef="shares">1368543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzYtMy0xLTEtMTI2NTk_2c9d4cbe-0625-47b6-aad4-997b0787cae9"
      unitRef="usdPerShare">9.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzYtNS0xLTEtMTI2NTk_305ea2aa-dcb3-4fb2-ab10-5e8cc85d7cab">P7Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzYtNy0xLTEtMTI2NTk_65770196-e25d-4c3f-99e6-2bceed8a6e46"
      unitRef="usd">9426000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzctMS0xLTEtMTI2NTk_b6def006-ef64-46b0-8c3a-9cc81846602b"
      unitRef="shares">3620180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzctMy0xLTEtMTI2NTk_b9e32694-c56f-4623-a84d-432e455fc88c"
      unitRef="usdPerShare">14.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzctNS0xLTEtMTI2NTk_1a1255f5-06c2-4261-a067-4c6d5601e193">P7Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ie36ef4c5abf7430991b10fecc4a30686_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo2ZTJjNzQxMGEwNGY0YmEyOTM2YzhmZGY0NzMzMWY3YS90YWJsZXJhbmdlOjZlMmM3NDEwYTA0ZjRiYTI5MzZjOGZkZjQ3MzMxZjdhXzctNy0xLTEtMTI2NTk_56d585fa-5961-4c43-88d9-aa0c60de0f43"
      unitRef="usd">16735000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5MjM_70ef29d0-b0c6-4794-ae4b-60d26858b9f3"
      unitRef="usdPerShare">16.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i521390118c2b4cca9acf12798fd9d5b8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5MTg_0bd68be1-e933-48b5-aae3-41d228f217dc"
      unitRef="usdPerShare">7.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie08b0d8bbc764ddfa7bbdedd05be39a6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5Mjc_9e41f2fe-a83e-4329-862b-4db2dd699eeb"
      unitRef="shares">700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjY_0f2c7ffa-6c3f-43c1-884f-bd55d5878975">The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1 of each calendar year, beginning January 1, 2021, by the least of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) 700,000 shares or (iii) such lesser amount as determined by the administrator of the 2020 ESPP, which is the compensation committee of the Board of Directors of the Company.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzY4MTc_6373db44-1fa7-49dc-accb-1867264fb054"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie08b0d8bbc764ddfa7bbdedd05be39a6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzY5MzA_ae9bd7f7-a54b-411f-8c5c-01ca977203cc"
      unitRef="shares">700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="iff90f11d0095440091e5fe52c4904b74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzcyMTA_b2426f0b-61ba-4a32-9719-f8865eee7a2d"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <plrx:EmployeeStockPurchasePlanOfferingPeriod
      contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzQzOTgwNDY1MjcyMjc_5131feda-1488-4dfc-8e8f-4e82be8cb4fb">P6M</plrx:EmployeeStockPurchasePlanOfferingPeriod>
    <plrx:CommonStockFairMarketValuePercentage
      contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzc0MTQ_0927e627-3301-4eaa-960c-02cc0aadbf45"
      unitRef="number">0.85</plrx:CommonStockFairMarketValuePercentage>
    <plrx:CommonStockFairMarketValuePercentage
      contextRef="iaf43394617f041c4be0bd92837a85e96_D20200601-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzc0ODU_cd49915a-0871-4c98-919c-2c3677b18c2b"
      unitRef="number">0.85</plrx:CommonStockFairMarketValuePercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzc2ODU_d5d7c2e5-1ae2-4b9f-97b4-61e40d464145"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzk4Nzc_b83af22d-1e76-45ce-b146-a62e63be23d1"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzk4NTM_b91b488e-224d-4422-8bca-fdce62135b4d"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1Xzc4ODc_ee002bbf-d5f7-41ba-a636-d64c918f71d3"
      unitRef="shares">86902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjc_1527d02e-d867-4f08-a353-1d24366d38e6">The Company used Black-Scholes option pricing model to estimate stock-based compensation expense for the 2020 ESPP with the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.575%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.06% - 0.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term of options (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67.16% - 89.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83.72%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i63754797203a4fa396889e7f6f569993_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzItMS0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpkNzVjMTViYzZjYzI0MDRiYTQ5NGY2MzA1ZmE0YmRiY184Nzk2MDkzMDIyMjIy_6a1f048a-0059-4ba8-89b5-5a49bd79c1c9"
      unitRef="number">0.0006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6c2c45617c474b8d8d2f5c5ec54bc1cb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzItMS0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpkNzVjMTViYzZjYzI0MDRiYTQ5NGY2MzA1ZmE0YmRiY184Nzk2MDkzMDIyMjI4_73aa175f-f8da-451c-adc5-6137458b3448"
      unitRef="number">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzItMy0xLTEtMTI2NTk_2e5bccff-4311-47f6-91cd-3e625b42d29a"
      unitRef="number">0.0011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzItNS0xLTEtMjE2OTU_b684448d-2451-4cac-b726-b3827b3d65d2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzMtMS0xLTEtMTI2NTk_1836f0df-2532-4466-9a3b-683001dcc372">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzMtMy0xLTEtMTI2NTk_0ca1aefc-8136-459b-8279-1d7d30f75bec">P0Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i63754797203a4fa396889e7f6f569993_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzQtMS0xLTEtMTI2NTkvdGV4dHJlZ2lvbjoxZDE0Yzk1Y2UwZWU0YjNmOGNkYWI5ZTk2MDM4MjM1NV84Nzk2MDkzMDIyMjEy_ff6f8fa0-1f8d-44f7-bdfa-8995050cca4b"
      unitRef="number">0.6716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6c2c45617c474b8d8d2f5c5ec54bc1cb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzQtMS0xLTEtMTI2NTkvdGV4dHJlZ2lvbjoxZDE0Yzk1Y2UwZWU0YjNmOGNkYWI5ZTk2MDM4MjM1NV84Nzk2MDkzMDIyMjE4_37803f02-9359-4920-b9a6-217f1ed73d00"
      unitRef="number">0.8951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzQtMy0xLTEtMTI2NTk_8686c4d9-5efa-4769-928e-defe20584ff3"
      unitRef="number">0.8372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzQtNS0xLTEtMjE2OTU_ae8582fd-c230-4002-b263-d61185ea1599"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3b3d5a2576be40ae8c5623b4794ba43b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzUtMS0xLTEtMTI2NTk_7a0584f6-9751-4b8a-8d52-3c64c15f1cb1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzUtMy0xLTEtMTI2NTk_eca17cb5-1bad-4495-adee-0d394d46ea8d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if94beea011984f7c80cc5fc14e3e6cc1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTo5ZGZjODMyZTMzNzc0ZmE0YjM2NmQ4YmY1YTcxZDljNy90YWJsZXJhbmdlOjlkZmM4MzJlMzM3NzRmYTRiMzY2ZDhiZjVhNzFkOWM3XzUtNS0xLTEtMjE2OTU_100431f8-1f87-4d32-bc18-477934fd4bed"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzgyNjE_805c50cc-8d79-4e15-b775-77fb4f7f0e14">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of stock-based compensation expense during the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i28a1619e7cc641e895b0a776ffb7951c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzItMS0xLTEtMTI2NTk_f634b582-9ecc-4572-adb0-b01ca0e8ce13"
      unitRef="usd">3928000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4dcffcd3361d45578bb203270ca62583_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzItMy0xLTEtMTI2NTk_47ee72b7-7d01-4a79-94cc-cc9971be2a3a"
      unitRef="usd">1719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d49e2ef8b934a9ca9872c2da4874dc1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzItNS0xLTEtMjE3MjU_dfbd0d61-2cd6-40b2-9c0f-d1f872a13b67"
      unitRef="usd">584000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0bc85e58f5bc489fbe3f59c43aa576af_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzMtMS0xLTEtMTI2NTk_9ce20751-a5fa-43be-b62b-dcfcf98f07a6"
      unitRef="usd">6509000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8619df5f4bbc4c15a77403491fcf90bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzMtMy0xLTEtMTI2NTk_1dee61d3-c893-4c7e-9540-07ac3f904cd0"
      unitRef="usd">2176000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9b2f94dc394411bb306ac98316895ab_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzMtNS0xLTEtMjE3MjU_d8a61ca2-a3b7-41ff-bbf7-11dd43e83616"
      unitRef="usd">1245000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzQtMS0xLTEtMTI2NTk_9b4ab56d-1ed3-4c67-907e-902c5237fba9"
      unitRef="usd">10437000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzQtMy0xLTEtMTI2NTk_2f146879-b2db-47d4-b402-7e31becf249b"
      unitRef="usd">3895000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90YWJsZTozNmE3YmE4Mzc5MmI0N2UyYjRhZjVmYmM4M2M4Y2VkYS90YWJsZXJhbmdlOjM2YTdiYTgzNzkyYjQ3ZTJiNGFmNWZiYzgzYzhjZWRhXzQtNS0xLTEtMjE3MjU_b6878444-3b77-4f37-8db5-ece34b7b6848"
      unitRef="usd">1829000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ib90cfc2ccdd64c42ad8668e78941f9b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NTE_99afcaa3-7c6b-44dd-90bf-03e2ef2eff5c"
      unitRef="usd">37000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6e35f96e1d3a4ff1b9a03fab757d000c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NTU_5363b5ca-944a-4176-802a-c792d6304596">P0Y4M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i39ce7df93a7d4382a3b7d79316b6d848_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NDA_f61a8914-cb27-487d-a269-2eb7c63c660c"
      unitRef="usd">24200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8eb5094414c244a28314369adcc54cc5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDIvZnJhZzoyMjcwNjMwZmY2Y2U0MTQ3YmQ5MjExYTk1OTk0MDlhNS90ZXh0cmVnaW9uOjIyNzA2MzBmZjZjZTQxNDdiZDkyMTFhOTU5OTQwOWE1XzEwOTk1MTE2Mzg5NDU_c673a3e0-b92b-42b1-aa56-8982e1790ac2">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTU_ee917d2b-fbc7-4113-80c2-a444b1d93074">Income TaxesThe Company had a pre-tax U.S. book loss of $97.3 million, $41.5 million, and $0.6 million for the years ended December&#160;31, 2021,  2020 and 2019 respectively. During the years ended December&#160;31, 2021, 2020 and 2019, the Company did not record an income tax provision. The Company will continue to maintain a 100% valuation allowance on total deferred tax assets. The Company believes it is more likely than not that the related deferred tax assets will not be realized.&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax computed at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General business credit&#x2014;federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(50.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(267.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets and liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed asset basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(921)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(558)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses and tax credit carryforwards were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expiration Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, federal (starting from January 1, 2018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Does not expire&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, federal (before January 1, 2018)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2035-2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, state&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2035-2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2036-2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits, state&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Does not expire&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the net operating loss carryforwards and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code (&#x201c;IRC&#x201d;) and similar state provisions. Annual limitations may result in the expiration of the net operating losses and tax credit carryforwards before they are utilized. The Company performed a IRC Section 382 analysis through December&#160;31, 2021 and does not expect any previous ownership changes to result in a limitation that will reduce the total amount of net operating loss and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tax credit carryforwards disclosed that can be utilized. Subsequent ownership changes may affect the limitation in future years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021&#160;and 2020, the Company recorded a full valuation allowance on federal and state deferred balances since management does not forecast the Company to be in a profitable position in the near future.&#160;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2021&#160;and 2020 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2017 through December 31, 2021. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entire amount of the unrecognized tax benefits would not impact the Company&#x2019;s effective tax rate if recognized. The Company's accounting policy is to include interest and penalties as a component of tax expense. During the years ended December&#160;31, 2021,  2020 and 2019, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions (reductions) for tax positions of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the "Cares Act") was enacted. The CARES Act changed net loss carryforward and back provisions and the business interest expenses limitation. The Company has evaluated the impact of the CARES Act and determined that none of the changes would result in a material cash benefit to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzY2_aa18a6e7-971b-44bd-8689-5f50d72ac983"
      unitRef="usd">-97300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzEwOTk1MTE2MzA5Mzk_0565c01a-11a9-4b68-991d-d543ac114eb0"
      unitRef="usd">41500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzE2NDkyNjc0NDUwNzA_ec922d02-c6bd-48c3-890c-e96800f84859"
      unitRef="usd">600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <plrx:ValuationAllowanceAsPercentageOnDeferredTaxAssets
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzI0NA_67512e77-0044-400a-921b-6c38d2306683"
      unitRef="number">1</plrx:ValuationAllowanceAsPercentageOnDeferredTaxAssets>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTY_0008fb0a-584f-4a75-b079-2194d4c18f5b">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax computed at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General business credit&#x2014;federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(50.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(33.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(267.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzItMS0xLTEtMTI2NTk_d5490ed9-b331-4ddd-9a3e-f67e502012ed"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzItMy0xLTEtMTI2NTk_c060bdec-8238-489d-b5c9-e954adf45d05"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzItNS0xLTEtMTc2MTM_f1b0b244-a128-4416-828f-c47f6cafa90d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzMtMS0xLTEtMTI2NTk_d97994b2-ab95-4d58-8e67-421a2e02c001"
      unitRef="number">0.077</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzMtMy0xLTEtMTI2NTk_90375e82-4fcd-4574-8b76-49f55133d4d5"
      unitRef="number">0.074</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzMtNS0xLTEtMTc2MTM_adefea75-485c-483c-9919-2a01563b65a9"
      unitRef="number">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzQtMS0xLTEtMTI2NTk_6e9e468f-33e9-4c58-ab59-0638d46bc401"
      unitRef="number">0.053</plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal>
    <plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzQtMy0xLTEtMTI2NTk_0c60dc6f-ae84-4c05-a6bc-479f7a319701"
      unitRef="number">0.053</plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal>
    <plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzQtNS0xLTEtMTc2MTM_ba005a10-d0c3-4f8d-a491-ed7aa5d2e0b8"
      unitRef="number">2.959</plrx:EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzUtMS0xLTEtMTI2NTk_1dcf2d00-8e94-44db-9188-0b1fefed48f4"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzUtMy0xLTEtMTI2NTk_6cb61e9a-ed94-4909-af9b-bc93a6a8a78a"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzUtNS0xLTEtMTc2MTM_6e99008d-e684-4002-8cb7-d494d72d40d7"
      unitRef="number">-0.500</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzYtMS0xLTEtMTI2NTk_0c83fe91-cdba-44da-8493-58c326c6a2d3"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzYtMy0xLTEtMTI2NTk_4791bc44-1df1-4b67-847b-14505889b3c0"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzYtNS0xLTEtMTc2MTM_e3ef0a6b-2a2f-49ef-a43c-ad5a7e2342b6"
      unitRef="number">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzctMS0xLTEtMTI2NTk_58b1b2a9-be85-4c7b-af3d-d06656e114b7"
      unitRef="number">-0.332</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzctMy0xLTEtMTI2NTk_5ce8d979-9456-4f76-8b91-44c62c238213"
      unitRef="number">-0.326</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzctNS0xLTEtMTc2MTM_951c7646-f2d0-450f-a203-d92ad4d159c0"
      unitRef="number">-2.677</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzgtMS0xLTEtMTI2NTk_4c2b2782-6743-44df-8f1a-149f50fdf224"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzgtMy0xLTEtMTI2NTk_3e55a4d9-00c0-4721-8106-f378e9248894"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTplODkyYWFkYzIwZTg0NjQ2YWRkMTBhMGQ2ZmYwOTYzMS90YWJsZXJhbmdlOmU4OTJhYWRjMjBlODQ2NDZhZGQxMGEwZDZmZjA5NjMxXzgtNS0xLTEtMTc2MTM_77be8c65-ea56-4773-ae37-cab10d5f2569"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTc_363a1479-3ee9-43fc-ab22-c986f383d4fa">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets and liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed asset basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(921)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(558)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzMtMS0xLTEtMTI2NTk_844ad894-c6ff-409a-9441-48ab7d053ced"
      unitRef="usd">51554000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzMtMy0xLTEtMTI2NTk_4189a5a6-55e1-4125-bb14-92376fe15391"
      unitRef="usd">27047000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzQtMS0xLTEtMTI2NTk_9735d55b-e0be-44c5-b9ab-e55a3c137cda"
      unitRef="usd">13989000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzQtMy0xLTEtMTI2NTk_22d24856-fb47-4fc0-8a63-9a03cef8a5b3"
      unitRef="usd">7617000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzUtMS0xLTEtMTI2NTk_a8f09584-f538-4af2-949c-2d8354dd5329"
      unitRef="usd">292000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzUtMy0xLTEtMTI2NTk_247c78d7-ceb0-4d0e-bae6-5da2e8c3f54d"
      unitRef="usd">291000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzYtMS0xLTEtMTI2NTk_ffc8d088-64c3-494e-84e9-60c053fd7e00"
      unitRef="usd">775000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzYtMy0xLTEtMTI2NTk_54a65d8e-1f50-4699-a406-d8b6810320b2"
      unitRef="usd">474000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzctMS0xLTEtMTI2NTk_2e956673-f040-4b9c-a408-662804da6242"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzctMy0xLTEtMTI2NTk_61a82152-8a54-4acb-a856-63a0b8ef23f5"
      unitRef="usd">266000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <plrx:DeferredTaxAssetsLeaseLiability
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzgtMS0xLTEtMjgzMTk_76af69ba-aa83-4435-a87d-4b57259fcf5c"
      unitRef="usd">2000000</plrx:DeferredTaxAssetsLeaseLiability>
    <plrx:DeferredTaxAssetsLeaseLiability
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzgtMy0xLTEtMjgzMjY_07d520c4-cb50-449e-a46b-05aba13a6f0a"
      unitRef="usd">0</plrx:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzgtMS0xLTEtMTI2NTk_f42b0e15-543f-4544-860d-8188f4c9ffc7"
      unitRef="usd">1816000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzgtMy0xLTEtMTI2NTk_d3639ee9-57fb-4150-8b3f-7e375fe77f87"
      unitRef="usd">428000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzktMS0xLTEtMTI2NTk_144a1131-c89a-4d96-a95f-e8577eff24f9"
      unitRef="usd">70426000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzktMy0xLTEtMTI2NTk_e86c860d-f67d-469b-a678-bbefaccc6c8c"
      unitRef="usd">36123000</us-gaap:DeferredTaxAssetsGross>
    <plrx:DeferredTaxLiabilitiesFixedAssetBasis
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzExLTEtMS0xLTEyNjU5_0f50fa2e-24bd-4750-8e76-dc9ecca2eb0e"
      unitRef="usd">61000</plrx:DeferredTaxLiabilitiesFixedAssetBasis>
    <plrx:DeferredTaxLiabilitiesFixedAssetBasis
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzExLTMtMS0xLTEyNjU5_73d54795-6a96-49d4-8274-c0e86df0f29d"
      unitRef="usd">124000</plrx:DeferredTaxLiabilitiesFixedAssetBasis>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzEyLTEtMS0xLTEyNjU5_916250b5-d282-4265-9d86-620fd72574a1"
      unitRef="usd">921000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzEyLTMtMS0xLTEyNjU5_765d5401-8fe1-430f-8092-7d04fa4d2700"
      unitRef="usd">558000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <plrx:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE0LTEtMS0xLTI4MzM3_0f6faefb-5c57-4f51-ad89-8aaa2e82f7f6"
      unitRef="usd">1760000</plrx:DeferredTaxLiabilitiesRightOfUseAsset>
    <plrx:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE0LTMtMS0xLTI4MzQ1_c1ef713d-177c-41b7-b07d-ca9aaae37972"
      unitRef="usd">0</plrx:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzEzLTEtMS0xLTEyNjU5_a2c2230b-e210-4131-8bbe-f597b5347956"
      unitRef="usd">2742000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzEzLTMtMS0xLTEyNjU5_326fcd22-20b9-4328-8f5f-b99301728f15"
      unitRef="usd">682000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE0LTEtMS0xLTEyNjU5_375484d2-1ce6-4254-95f6-1d5fa4e4c84c"
      unitRef="usd">67684000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE0LTMtMS0xLTEyNjU5_b3e06d91-0b6d-4dd4-8401-09042c110a11"
      unitRef="usd">35441000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE1LTEtMS0xLTEyNjU5_82fde880-6214-4528-9acd-a00695de2239"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTozNmExMTBhODgxZmI0Y2Y1ODk1NzA5N2Y2OWVkMmRmOC90YWJsZXJhbmdlOjM2YTExMGE4ODFmYjRjZjU4OTU3MDk3ZjY5ZWQyZGY4XzE1LTMtMS0xLTEyNjU5_9d7cc8e9-e79f-44fe-be5f-bf28372df7c6"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <plrx:ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTg_46066fd6-6407-4117-8678-5f892b8ae833">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses and tax credit carryforwards were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expiration Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, federal (starting from January 1, 2018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Does not expire&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, federal (before January 1, 2018)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2035-2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, state&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2035-2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2036-2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits, state&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Does not expire&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</plrx:ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i31bce1e599344a70a32426478b95d1df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzEtMS0xLTEtMTI2NTk_6c04f3cf-be48-4f5e-95ac-ce40a4ad655b"
      unitRef="usd">155231000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i73826d9211d549b896476358b41d3bde_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzItMS0xLTEtMTI2NTk_dd07a38b-f008-4a44-8ca6-ca149e6fd53b"
      unitRef="usd">29486000</us-gaap:OperatingLossCarryforwards>
    <plrx:OperatingLossCarryforwardsExpirationYear
      contextRef="iff7f1036aa4b454fb82af94ab3f2ce41_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzItMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpiM2IyZWVjMmY1ZDA0M2E4YmJkZWQ3NDlkZGQxMTZiZl80_f708323f-026f-485f-beeb-31380d5b32fe">2035</plrx:OperatingLossCarryforwardsExpirationYear>
    <plrx:OperatingLossCarryforwardsExpirationYear
      contextRef="i6a3ebd1303b143afb79b5a5535c7e658_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzItMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpiM2IyZWVjMmY1ZDA0M2E4YmJkZWQ3NDlkZGQxMTZiZl83_273d84bd-9377-47d1-b3b9-d17f35a8a9f4">2037</plrx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0f33c2bafe3843d8bf470ed2c96ee5fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzMtMS0xLTEtMTI2NTk_be59b562-7c97-484c-8844-c66433785127"
      unitRef="usd">182964000</us-gaap:OperatingLossCarryforwards>
    <plrx:OperatingLossCarryforwardsExpirationYear
      contextRef="ia814f0994a1449ce83dd2ebd288a95a6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzMtMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjo5YWJlNWM4OTU3YmE0Mjk1OGJhNDAwMTAwMzY0ZWNlNV80_9b595ce0-4d86-4996-91b8-6e7d006c0900">2035</plrx:OperatingLossCarryforwardsExpirationYear>
    <plrx:OperatingLossCarryforwardsExpirationYear
      contextRef="i29fe77ab043541358883b2c7d9041522_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzMtMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjo5YWJlNWM4OTU3YmE0Mjk1OGJhNDAwMTAwMzY0ZWNlNV83_75156977-bc36-479b-9b69-9d08caf9e5b8">2041</plrx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="iddb8c639eb9a45ed83884b3db05c0ffd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzQtMS0xLTEtMTI2NTk_5fc118d9-af95-46a3-b32c-d0fe3a2f454b"
      unitRef="usd">14094000</us-gaap:TaxCreditCarryforwardAmount>
    <plrx:TaxCreditCarryforwardsExpirationYear
      contextRef="ia814f0994a1449ce83dd2ebd288a95a6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzQtMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpjMzlmYTllYmM2MjU0ZTVjYmM4MDkyZTlhNzNlMWE4NV80_c8fd520c-5a17-4785-89ec-5d47e2de163c">2036</plrx:TaxCreditCarryforwardsExpirationYear>
    <plrx:TaxCreditCarryforwardsExpirationYear
      contextRef="i29fe77ab043541358883b2c7d9041522_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzQtMy0xLTEtMTI2NTkvdGV4dHJlZ2lvbjpjMzlmYTllYmM2MjU0ZTVjYmM4MDkyZTlhNzNlMWE4NV83_039b76e0-22ad-4cf8-baf2-ab1eead71735">2041</plrx:TaxCreditCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i0f33c2bafe3843d8bf470ed2c96ee5fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTo3ZjdkNDU5ZjAxYzE0YTc2OTVjMDA3ZTQ4ZWZlYTE0ZC90YWJsZXJhbmdlOjdmN2Q0NTlmMDFjMTRhNzY5NWMwMDdlNDhlZmVhMTRkXzUtMS0xLTEtMTI2NTk_002116e7-67a3-42d8-b32e-fbd0d3f3a57f"
      unitRef="usd">4069000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTk_54f30032-0c5b-4d2e-9a0e-cc215ea0662f">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2021&#160;and 2020 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzItMS0xLTEtMTI2NTk_71fb7452-3c1c-4e34-a45e-00938f5fb8d6"
      unitRef="usd">35441000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzItMy0xLTEtMTI2NTk_46c461ab-4560-4602-8f8f-abf847abb194"
      unitRef="usd">21929000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzMtMS0xLTEtMTI2NTk_900caed5-5fa0-4229-86c7-f8205b895b41"
      unitRef="usd">32243000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzMtMy0xLTEtMTI2NTk_5d03f6bb-83a5-4e21-9c58-17c1bbe45693"
      unitRef="usd">13512000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzQtMS0xLTEtMTI2NTk_990ae354-b127-4a0e-9b2b-54276a387121"
      unitRef="usd">67684000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZTpjNTE5NzcyMmVhMmQ0NzM4YTk2YjI0YWIwOWZkNmM5My90YWJsZXJhbmdlOmM1MTk3NzIyZWEyZDQ3MzhhOTZiMjRhYjA5ZmQ2YzkzXzQtMy0xLTEtMTI2NTk_d9d39e63-4ce3-41a5-8cd5-2e4a949b6084"
      unitRef="usd">35441000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <plrx:IncomeTaxExaminationNumberOfExaminationsPending
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzE5MDE_605f9340-8b55-443c-9c36-a24ef4899b08"
      unitRef="taxexamination">0</plrx:IncomeTaxExaminationNumberOfExaminationsPending>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzI0NDI_80dad6bb-bdfa-49c0-9888-0b9654d52996"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzI0NDI_caf8652a-c45e-47b5-bc0b-83ff4cc487dc"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzI0NDI_fcfc041c-1aa8-471f-874e-55bb61d4d6e1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90ZXh0cmVnaW9uOmNiYmY4OWMxYTEyOTQzMjQ4YzJhYTBiNTlkYWY4NTViXzMxNTQ_6f4dc6f5-f8fe-4e0e-b303-d575a11d88e7">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions (reductions) for tax positions of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzItMS0xLTEtMTI2NTk_bc78e259-d283-4bac-b41b-552f1fa3b1d7"
      unitRef="usd">2007000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzItMy0xLTEtMTI2NTk_6071c3a8-9928-4642-9ed2-0a0a5685eba0"
      unitRef="usd">1355000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="idcb6e46e8589417fbb6dce85ec4707e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzItNS0xLTEtMjg5MDY_80e891e7-58a6-4c22-a47d-4d4a1c821334"
      unitRef="usd">855000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzMtMS0xLTEtMTI2NTk_2634d419-bcbb-40b3-8190-1aa3bdd24332"
      unitRef="usd">1081000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzMtMy0xLTEtMTI2NTk_4a0a4e0c-a2cd-4b33-9207-9201c7dc0a7e"
      unitRef="usd">513000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzMtNS0xLTEtMjg5MDY_04ec61d1-e127-4a02-98d1-20f694c8cf0e"
      unitRef="usd">570000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzQtMS0xLTEtMTI2NTk_aa18ab38-c8e5-4d07-9526-6b1fbce35ea7"
      unitRef="usd">417000</plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzQtMy0xLTEtMTI2NTk_040966c5-9e2f-4eca-a46e-1f2b370da277"
      unitRef="usd">139000</plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzQtNS0xLTEtMjg5MDY_21cb9691-ed71-4dc0-8a47-3268e7ae68c0"
      unitRef="usd">-70000</plrx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzUtMS0xLTEtMTI2NTk_531d1441-6e7d-4c86-85de-0e3058830b6f"
      unitRef="usd">3505000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i19974a4386bd4627a7211a58dab7ab17_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzUtMy0xLTEtMTI2NTk_7f0651ef-16b6-4e22-b2c5-1f1f18ef4d42"
      unitRef="usd">2007000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic99a0121c2fc4728b94a6d33eca89dd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDUvZnJhZzpjYmJmODljMWExMjk0MzI0OGMyYWEwYjU5ZGFmODU1Yi90YWJsZToxMjllMDIxZDkyMTc0ZWJhYmM0ZjBmMzE3MzBkMzNlZS90YWJsZXJhbmdlOjEyOWUwMjFkOTIxNzRlYmFiYzRmMGYzMTczMGQzM2VlXzUtNS0xLTEtMjg5MDY_679e5cf6-eb94-4722-9351-eb1f8778712e"
      unitRef="usd">1355000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDgvZnJhZzpmNWI1ZmY0OTViODg0YzIyYjc1ZDZkMjdmN2U3NmQyYS90ZXh0cmVnaW9uOmY1YjVmZjQ5NWI4ODRjMjJiNzVkNmQyN2Y3ZTc2ZDJhXzMzMDc_23c97baf-f0e3-4310-8652-740bd41ab961">Commitments and Contingencies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contractual arrangements with research and development organizations and suppliers; however, these contracts are generally cancellable on 30 days&#x2019; notice and the obligations under these contracts are largely based on services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential payments related to the Company&#x2019;s license and research agreements, including milestone and royalty payments, are detailed in Notes 6 and 7.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become involved in legal proceedings arising from the ordinary course of business. The Company record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. Management is currently not aware of any legal matters that could have a material adverse effect on our financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <plrx:ContractualArrangementsCancellationPeriod
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNDgvZnJhZzpmNWI1ZmY0OTViODg0YzIyYjc1ZDZkMjdmN2U3NmQyYS90ZXh0cmVnaW9uOmY1YjVmZjQ5NWI4ODRjMjJiNzVkNmQyN2Y3ZTc2ZDJhXzIxMw_33d3be2a-bf0e-429b-933b-820a39731d22">P30D</plrx:ContractualArrangementsCancellationPeriod>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF80Mzk4MDQ2NTE1MjEz_edfcee80-5089-424f-b959-de97aa2325b0">Leases&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 1, 2021, the Company adopted ASC 842 and the following disclosures as of and for the year ended December 31, 2021 are presented under ASC 842.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a non-cancelable lease agreement (the &#x201c;Lease&#x201d;) for premises consisting of approximately 32,974 square feet located in South San Francisco, California (the &#x201c;Premises&#x201d;). The Company moved into the Premises in July 2018. The Premises is being used for the Company&#x2019;s corporate headquarters and principal operating facility. The term of the Lease is eighty-four months, which commenced on July 1, 2018. Base rent was abated for the first two months of the lease term and thereafter is $0.2 million per month during the first year of the lease term, with specified annual increases thereafter. The Company paid a refundable security deposit of approximately $0.4 million, which is included in other non-current assets in the Balance Sheets at December&#160;31, 2021 and 2020. The Company has the right to extend the lease term by seven years upon written notice not more than twelve months nor less than nine months prior to the expiration of the original lease term, with monthly payments equal to the &#x201c;fair rental value&#x201d; as defined in the Lease. The exercise of lease renewal options is at the sole discretion of the Company and is not included in the ROU asset and lease liability as it is not reasonably certain of exercise. This lease does not contain material variable rent payments, residual value guarantees, covenants, or other restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2021, the Company recognized expenses associated with the operating leases of  $2.3&#160;million. Additionally, the Company incurred variable lease costs of $0.9 million which is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance. Short-term lease expense and variable lease payments recorded in operating expenses were immaterial for the year ended December 31, 2021. Cash paid for amounts included in the measurement of operating lease liabilities was $2.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Maturities of the Company's operating lease liability as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Present value discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The weighted-average remaining lease terms and discount rates related to the Company's operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total rent expense under ASC 840 was $2.5 million during each of the years ending December&#160;31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Future minimum lease payments under the Lease as of December 31, 2021 were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <plrx:LeasedSpaceUnderNonCancellableOperatingLease
      contextRef="ia6b323227a6846f1b65d034e58f88164_D20180201-20180228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI3OTA5_4144565f-e7ea-4392-8f43-f6a361c4ace9"
      unitRef="sqft">32974</plrx:LeasedSpaceUnderNonCancellableOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i598f80db39ac4c599c0538ab9aae3c30_I20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4MTYz_b456def0-51eb-4221-b957-ac65657c359d">P84M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <plrx:PeriodOfBaseRentAbatement
      contextRef="ib125d2281fd7483b97614c1e8f176399_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMjY0NDM4MzcyNjY0NA_b36e1998-fb31-4016-a152-33355da9c0c9">P2M</plrx:PeriodOfBaseRentAbatement>
    <plrx:BaseRentAbatedAmount
      contextRef="ib125d2281fd7483b97614c1e8f176399_D20180201-20180228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4Mjgz_f841c18a-46bc-49a9-a3d1-4113466228d1"
      unitRef="usd">200000</plrx:BaseRentAbatedAmount>
    <us-gaap:SecurityDeposit
      contextRef="ic31ace94ac1847898d10e8026fbd8b04_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NDQ2_6702c845-49c1-4c3d-b9c3-034f9ce64fe7"
      unitRef="usd">400000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i4c910fd3e4444dd2b8564e3ace9a8326_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NDQ2_ba739d4b-46c7-4e59-972d-2ddd65d78b82"
      unitRef="usd">400000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i54765707cbc04888952c42feb9bd45de_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NTg5_77b953c4-7730-427a-beca-25bfbaff6010">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <plrx:LeaseTermExtensionNoticePeriod
      contextRef="i429668ed867b4b9eb0766f77046f00f3_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NjI3_f0260496-9972-45b7-ade9-395d24839586">P12M</plrx:LeaseTermExtensionNoticePeriod>
    <plrx:LeaseTermExtensionNoticePeriod
      contextRef="i339a84165f6b4c48adba2aba4271bc4a_D20180201-20180228"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjI4NjQ1_51b48131-3091-430e-9ba2-d325b36bb1ae">P9M</plrx:LeaseTermExtensionNoticePeriod>
    <us-gaap:OperatingLeaseCost
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjMxODYy_38dd1cad-7b77-421b-9974-4be0f5d402ad"
      unitRef="usd">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjMxODUz_9b084ffc-431d-4d76-8952-6a9918c8231d"
      unitRef="usd">900000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMDk5NTExNjM0MzE1_53499496-d3a0-4361-b943-a5423778f37b"
      unitRef="usd">2400000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF80Mzk4MDQ2NTE1MjEy_d9d60c37-8808-4f36-9e8c-20caea75b8fe">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Maturities of the Company's operating lease liability as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Present value discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV8xLTItMS0xLTE1NDEy_650c06bc-55b5-4304-9e9b-e8b061881f4b"
      unitRef="usd">2360000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV8yLTItMS0xLTE1NDEy_c3e2096c-f2d5-41f0-8435-16c5f577c527"
      unitRef="usd">2295000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV8zLTItMS0xLTE1NDEy_0d19d880-5e57-476a-863d-91c69b8a4b92"
      unitRef="usd">2365000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV80LTItMS0xLTE1NDEy_fd6f9450-6658-4cc2-891c-91e56ba0bca9"
      unitRef="usd">1202000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV81LTItMS0xLTE1NDEy_b1b2cbc1-1143-4e7c-9094-3f52eafff848"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV82LTItMS0xLTE1NDEy_6bb96d65-4140-472f-a0f6-3b1defc5f3e7"
      unitRef="usd">8222000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV83LTItMS0xLTE5OTYx_1b89fa83-0647-4b6d-923d-11bf48af7f09"
      unitRef="usd">1028000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6YTVlOGZjYjMwMGY3NGYwMjlhYjk2MWVlZmVhOWMzZmEvdGFibGVyYW5nZTphNWU4ZmNiMzAwZjc0ZjAyOWFiOTYxZWVmZWE5YzNmYV84LTItMS0xLTE5OTYx_180fd4b5-2a6a-45b6-9b88-c6d419dfb412"
      unitRef="usd">7194000</us-gaap:OperatingLeaseLiability>
    <plrx:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8xMjY0NDM4MzcyNjY0Mw_8f59776d-e636-4d98-8022-993d1306e966">&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The weighted-average remaining lease terms and discount rates related to the Company's operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</plrx:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6NjIyNTk3ODEyNTliNDFiNmJiZjdmZDZlZTA2MjEzYmEvdGFibGVyYW5nZTo2MjI1OTc4MTI1OWI0MWI2YmJmN2ZkNmVlMDYyMTNiYV8xLTItMS0xLTE1NTk1_19485ac6-3bc2-44c8-b043-61bcdc81dd31">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4c2aeb24bd264584a324aec3746051a6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6NjIyNTk3ODEyNTliNDFiNmJiZjdmZDZlZTA2MjEzYmEvdGFibGVyYW5nZTo2MjI1OTc4MTI1OWI0MWI2YmJmN2ZkNmVlMDYyMTNiYV8yLTItMS0xLTE1NTk1_8bc952b4-e81d-485d-aafd-176bd69b4a8c"
      unitRef="number">0.0790</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseAndRentalExpense
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8yMTk5MDIzMjU5NTE3_0f741759-6c34-4610-9fc9-b55bf2613a7d"
      unitRef="usd">2500000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF8yMTk5MDIzMjU5NTE3_b6f738f8-edef-4843-bac2-30a74527908d"
      unitRef="usd">2500000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGV4dHJlZ2lvbjpiZWVkNGM3NWUzODU0ZmQxODRkNmYzZDFkMzA2MDhmMF80Mzk4MDQ2NTE4MTc3_f7abaaa6-ecb3-4fa5-a17c-b30708785739">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Future minimum lease payments under the Lease as of December 31, 2021 were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i54765707cbc04888952c42feb9bd45de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl8xLTItMS0xLTI3Mzc0_2148b6b0-208a-4573-b486-5a3970925a27"
      unitRef="usd">2098000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i54765707cbc04888952c42feb9bd45de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl8yLTItMS0xLTI3Mzc0_c45ed3c1-e014-41a4-9ab9-8005fb1b4d35"
      unitRef="usd">2171000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i54765707cbc04888952c42feb9bd45de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl8zLTItMS0xLTI3Mzc0_d43c46ca-2990-4efb-af42-7a0ac743c0ac"
      unitRef="usd">2247000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="i54765707cbc04888952c42feb9bd45de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl80LTItMS0xLTI3Mzc0_c3aa6ca7-4569-4e6a-99e5-06fa8856bb00"
      unitRef="usd">1144000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i54765707cbc04888952c42feb9bd45de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjk4L2ZyYWc6YmVlZDRjNzVlMzg1NGZkMTg0ZDZmM2QxZDMwNjA4ZjAvdGFibGU6MTBlNGQ0ZDBmODM2NDg2YThjODg2OTQ2YjFhYmNkY2YvdGFibGVyYW5nZToxMGU0ZDRkMGY4MzY0ODZhOGM4ODY5NDZiMWFiY2RjZl81LTItMS0xLTI3Mzc0_89735b13-1d1b-420e-a2bc-f53ba848fc52"
      unitRef="usd">7660000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzIyNTY_dba0097d-ae0c-4d58-9ccb-8949d64b64f1">Related Party TransactionsIn 2019, certain employees of Third Rock Ventures, a stockholder of the Company, provided consulting services to the Company. Commencing January 2020, Third Rock Ventures ceased providing management consulting services to the Company.&#160;The Company recorded no consulting expenses for consulting services provided by Third Rock Ventures during&#160;the years ended December&#160;31, 2021 and 2020.&#160;The Company recorded Third Rock Ventures consulting expenses to general and administrative expense of $36,000 during the year ended December&#160;31, 2019.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2021, the Company granted 26,572 stock options with a grant date fair value of $0.5 million to partners of Third Rock Ventures who are also serving as non-employee directors on the Company's Board of Directors. The shares of common stock subject to these options ve&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;st 25% on&lt;/span&gt; the first day of each calendar quarter for three quarters with the final vest date being the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting of Stockholders. In March 2020, the Company granted 26,573 stock options with a grant date fair value of $0.1 million to a partner at Third Rock Ventures, who is also serving as a non-employee director on the Company&#x2019;s Board of Directors. The common shares subject to these options vest 1/12th on the last day of each calendar quarter over a three-year period and commenced vesting upon our IPO. In order to vest at each calendar quarter end date, the shareholder must be providing continuous service to the Company through such vesting date. The stock-based compensation expense related to these options was immaterial during the years ended December&#160;31, 2021.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i7166be69743e4e60a692a5adc04dcd3f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzI5Mg_0b873e56-4b32-41f8-a675-d81da435c1fa"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i48fa76d3d2dd4c4c86df500aed228234_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzQ5OQ_11ce0a5a-a991-48f6-92a4-efc3f9b2678e"
      unitRef="usd">36000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzEwOTk1MTE2MzIxNjQ_0c1d1ada-220a-4872-b7e3-f8904ca712ca"
      unitRef="shares">26572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzEwOTk1MTE2MzIxODQ_a9f9c0e8-a355-4064-aa05-6ab36892b969"
      unitRef="usd">500000</plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzQzOTgwNDY1MTU1NDA_05d672c0-4643-47c3-a701-cb12fabcd7c1"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic1f553a0f5fd4433b0cc4baba93fea24_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzU1Mg_9f8588db-c8ec-4983-880b-b1dbedfade56"
      unitRef="shares">26573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="ic1f553a0f5fd4433b0cc4baba93fea24_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzYwMQ_a3452e37-09b9-4ab3-aa98-69991f64a8c0"
      unitRef="usd">100000</plrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="i342e8370c50840b5ab283afd24abbf11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTEvZnJhZzo0ODgyYWRkZjE1ZmM0OGU3OGI0ZDkwMTAzNTVhODBkMy90ZXh0cmVnaW9uOjQ4ODJhZGRmMTVmYzQ4ZTc4YjRkOTAxMDM1NWE4MGQzXzcyNQ_39ff8f93-346c-4334-a6f1-0929b53bf82c">The common shares subject to these options vest 1/12th on the last day of each calendar quarter over a three-year period and commenced vesting upon our IPO.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTcvZnJhZzpjYWM2YjMzZmE4NDY0NzJiODFiYWU2Yzc3ZmQzMTYzOS90ZXh0cmVnaW9uOmNhYzZiMzNmYTg0NjQ3MmI4MWJhZTZjNzdmZDMxNjM5XzQyOQ_26e190ba-be27-4d52-8ff6-8671ebeadead">Defined Contribution PlanThe Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. The Company made contributions to the plan of $0.6 million, $0.4 million and $0.2 million during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTcvZnJhZzpjYWM2YjMzZmE4NDY0NzJiODFiYWU2Yzc3ZmQzMTYzOS90ZXh0cmVnaW9uOmNhYzZiMzNmYTg0NjQ3MmI4MWJhZTZjNzdmZDMxNjM5XzM3Ng_aac38d2d-b4d2-4097-9091-208e1eeaa394"
      unitRef="usd">600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTcvZnJhZzpjYWM2YjMzZmE4NDY0NzJiODFiYWU2Yzc3ZmQzMTYzOS90ZXh0cmVnaW9uOmNhYzZiMzNmYTg0NjQ3MmI4MWJhZTZjNzdmZDMxNjM5XzM4Mw_d5de81cf-f944-453b-86f0-98ad23890831"
      unitRef="usd">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNTcvZnJhZzpjYWM2YjMzZmE4NDY0NzJiODFiYWU2Yzc3ZmQzMTYzOS90ZXh0cmVnaW9uOmNhYzZiMzNmYTg0NjQ3MmI4MWJhZTZjNzdmZDMxNjM5XzEwOTk1MTE2MjgyOTI_73db2d88-e211-482d-b461-a967f5e04cd4"
      unitRef="usd">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90ZXh0cmVnaW9uOjdjZDM1MjZkMmQ3MzQ0ZGU4ODU5ZDE0NTk1NWRiZjQ0XzUzNg_c8d6c426-24fa-4103-8b7f-1c0da7748d45">Net Loss Per Share Attributable to Common Stockholders&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Redeemable convertible preferred stock (on an as-converted basis)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,442,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,620,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,993,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,337,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards granted and not purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;302,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,642,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,124,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,086,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net loss per share attributable to common stockholders is as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(97,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accretion to redemption value and dividends on redeemable convertible preferred shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(97,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,846,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,344,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,623,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,846,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,344,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,623,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share attributable to common stockholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90ZXh0cmVnaW9uOjdjZDM1MjZkMmQ3MzQ0ZGU4ODU5ZDE0NTk1NWRiZjQ0XzUzNw_1496fab3-c44e-4a79-aca8-7348483e537b">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Redeemable convertible preferred stock (on an as-converted basis)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,442,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,620,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,993,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,337,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards granted and not purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;302,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,642,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,124,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,086,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i47e995f177284199bb8b0695a7c9725d_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzItMS0xLTEtMTc4OTc_d3433095-447e-4fd7-b3c7-4e594d216968"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c0035b443cb469b9de089f502f3e9c5_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzItMy0xLTEtMTc5MDM_41ce48e3-120d-4c37-9034-4fe668ed48eb"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i18bd16bfffe94894922846cadcd48ed0_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzItNS0xLTEtMTc4NjA_58a30fc1-cd87-49e1-a9d0-6642a25c5a48"
      unitRef="shares">18442233</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie24ad985733c48bfb53bfbd864d91f27_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzMtMS0xLTEtMTI2NTk_06e861d1-4bd8-470e-9a01-4c031bfe76f9"
      unitRef="shares">3620180</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i68e2483823f6420cb6185c251c58ac55_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzMtMy0xLTEtMTI2NTk_68a83a9b-d9b2-4633-b7b3-4e3071dae3cf"
      unitRef="shares">2993855</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib34337582e984ae1ba7584d1346e1780_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzMtNS0xLTEtMTc4NjA_ed60ec29-7e8e-48c4-8d34-7c21b56baa1f"
      unitRef="shares">1337501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id4eb9436dd324df99ee7f4d8e63df7e7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzQtMS0xLTEtMTI2NTk_3b0ab701-85a8-45d9-ae87-92d8773003f1"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icf1265c8744c461286d3671e01ec1cc8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzQtMy0xLTEtMTI2NTk_e806190b-b992-4a79-8fa7-de5c0895e121"
      unitRef="shares">4195</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9964d5d87c0b4f47a4e7b2802949d585_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzQtNS0xLTEtMTc4NjA_99292222-927b-4e32-acdc-5f03790fbbe6"
      unitRef="shares">4195</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i123f913abe274f3b80052d070e8729c7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzUtMS0xLTEtMTI2NTk_9cf40cb1-2f77-4e71-8402-7ece916e7920"
      unitRef="shares">21841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib31f0ac37c034f85b050eb91b4830b28_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzUtMy0xLTEtMTI2NTk_bfe11d34-f009-47c4-99b7-ca46893e24e5"
      unitRef="shares">126522</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a427494f6ff428e8b8a4b08835c85f7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzUtNS0xLTEtMTc4NjA_df7ce5da-2598-42fb-8412-af179c99d40d"
      unitRef="shares">302211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzYtMS0xLTEtMTI2NTk_f46da389-0387-4866-91b2-5173e06c7d61"
      unitRef="shares">3642021</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzYtMy0xLTEtMTI2NTk_068d1579-e96e-4f80-b72d-0b6443f9948e"
      unitRef="shares">3124572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTozZDg4YTA3NjliOTE0N2U2YjBhM2QwMGUzNThkMDA1ZC90YWJsZXJhbmdlOjNkODhhMDc2OWI5MTQ3ZTZiMGEzZDAwZTM1OGQwMDVkXzYtNS0xLTEtMTc4NjA_68045170-beac-43bf-b95e-b81d715f6756"
      unitRef="shares">20086140</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90ZXh0cmVnaW9uOjdjZDM1MjZkMmQ3MzQ0ZGU4ODU5ZDE0NTk1NWRiZjQ0XzUzOA_9d5955af-cd6a-450e-ba05-34a8545875fe">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net loss per share attributable to common stockholders is as follows (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(97,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accretion to redemption value and dividends on redeemable convertible preferred shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(97,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,846,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,344,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,623,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,846,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,344,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,623,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share attributable to common stockholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzQtMS0xLTEtMTI2NTk_46aea6f7-f9c3-4758-a294-b83aa50f17eb"
      unitRef="usd">-97263000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzQtMy0xLTEtMTI2NTk_e43ecd6b-3927-4e65-a4a6-ca010a97a99b"
      unitRef="usd">-41533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzQtNS0xLTEtMTc5NDE_3f954780-2b62-4556-b0f9-b98f7367df67"
      unitRef="usd">-631000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzUtMS0xLTEtMTI2NTk_6d7b0a31-cf49-4ce2-86a2-8658aaef8a97"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzUtMy0xLTEtMTI2NTk_9f7d239b-63fc-487b-b634-73221647485e"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzUtNS0xLTEtMTc5NDE_f2382147-8ecd-4bd3-a67f-0d93e5ddb556"
      unitRef="usd">6225000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzYtMS0xLTEtMTI2NTk_9f9aac8a-3182-476a-a3b0-10c6db234e02"
      unitRef="usd">-97263000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzYtMy0xLTEtMTI2NTk_d90e0f17-daaa-406f-b5e8-8511e6c3919f"
      unitRef="usd">-41533000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzYtNS0xLTEtMTc5NDE_c32cd8e8-bf76-4f39-a4c3-f08547448baa"
      unitRef="usd">-6856000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzktMS0xLTEtMTI2NTk_fd59c366-8bd0-4b1b-9ccf-b6d48acb9a80"
      unitRef="shares">35846421</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzktMy0xLTEtMTI2NTk_e01452c5-e6b0-409d-8671-358b208db464"
      unitRef="shares">21344236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzktNS0xLTEtMTc5NDE_cd5b159a-6922-4c1c-98cf-359f7f58cbce"
      unitRef="shares">1623358</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEwLTEtMS0xLTEyNjU5_bae34ac6-9520-42ee-bd94-f82de65a6736"
      unitRef="shares">35846421</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEwLTMtMS0xLTEyNjU5_b9ecfa96-8b1c-4a7e-b382-9ba880846a38"
      unitRef="shares">21344236</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEwLTUtMS0xLTE3OTQx_9a17d35c-a486-46b1-9c54-e83d27f1cdf9"
      unitRef="shares">1623358</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEyLTEtMS0xLTEyNjU5_53973df0-8426-4e70-8b7b-42a88899f0d1"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEyLTMtMS0xLTEyNjU5_07cc6539-0413-446b-97f5-a09e492d3e1c"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEyLTUtMS0xLTE3OTQx_fd8b0e2e-fe60-4848-94cd-fe34ea19aa21"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEzLTEtMS0xLTEyNjU5_9fd87362-12b2-40c2-bcdc-f549a6f8d890"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id682893acc45496a970c56af4620e9fd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEzLTMtMS0xLTEyNjU5_db21e319-bff6-49cd-a786-a1a84f24b40f"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfc4d5ff106c4bf6872d71927529dff6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk4ODYyNWRmNzgzZTRjYzBhMjdiZDc2ZGYzODhkYTU3L3NlYzo5ODg2MjVkZjc4M2U0Y2MwYTI3YmQ3NmRmMzg4ZGE1N18xNjMvZnJhZzo3Y2QzNTI2ZDJkNzM0NGRlODg1OWQxNDU5NTVkYmY0NC90YWJsZTpmNzU1YTA4NTA3NjE0MTc4YWFhMGI1NWVmZmQ1YzNlZS90YWJsZXJhbmdlOmY3NTVhMDg1MDc2MTQxNzhhYWEwYjU1ZWZmZDVjM2VlXzEzLTUtMS0xLTE3OTQx_ec25fe1f-b923-46f6-9f24-5b2822e649aa"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>114
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )N37%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " ";DUQ4;7*;C^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*'%@!)/FLK%3"X,5-G8SMMJ:Q;&Q-9*^_1RO31G; ^QHZ?>G
M3Z!.>:%<P.?@/ 8R&.]F.XQ1*+]A)R(O *(ZH96Q3(DQ-0\N6$GI&8[@I?J0
M1P1>5?=@D:26)&$!%GXELK[32JB DERXX+5:\?XS#!FF%>" %D>*4)<UL'Z9
MZ,_ST,$-L, (@XW?!=0K,5?_Q.8.L$MRCF9-3=-43DW.I1UJ>-MM7_*ZA1DC
MR5%A^A6-H+/'#;M.?FT>'O=/K.<5YT7%"][N>2-X*YKV?7']X7<3MDZ;@_G'
MQE?!OH-?=]%_ 5!+ P04    " ";DUQ4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M )N37%2Z&K\0SP8  '0:   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI5E;;^)&%'[>_HH1756[4@CVF$NR32(Y!KIT<Z% =IM6?1CL :S8'CHS#LF_
M[QD;,(G,L:6^)/AR/G\^9^8[%U]LA'Q2*\XU>8FC1%TV5EJOO[1:RE_QF*E3
ML>8)7%D(&3,-AW+94FO)69 9Q5&+6E:W%;,P:5Q=9.?&\NI"I#H*$SZ61*5Q
MS.3K-8_$YK)A-W8G)N%RI<V)UM7%FBWYE.N']5C"46N/$H0Q3U0H$B+YXK+A
MVE_Z3L\89'=\#_E&'?PFYE7F0CR9@U%PV; ,(QYQ7QL(!O^>N<>CR" !CW^W
MH(W],XWAX>\=^C![>7B9.5/<$]&/,-"KR\99@P1\P=)(3\3F*]^^4,?@^2)2
MV5^RR>_MT ;Q4Z5%O#4&!G&8Y/_9R]81!P9GUA$#NC6@[PSL]A$#9VO@U#5H
M;PW:F6?R5\G\T&>:75U(L2'2W UHYD?FS,P:7C],3-RG6L+5$.STE2>>N21-
M\C#MDT\?/U^T-(":2RU_"W"= ] C #8EMR+1*T4&2<"#MP M8+.G1'>4KBF*
MV.?^*7'L$T(M:I<0\G#S(9^?$MK)S&F)>1\W_SU-X.E6V=/?O(VS=["3X3FH
M@_]VYTI+6.3_()#M/60[@VP?<Y#P4]AZFLQ>U[PL8KBY;36_(2PZ>Q:=>BS<
M)$E91"9\+:0NHX/C:)ERA$YW3Z=;C\Z8RU $9C42V!&E_JE VJZ_GSY\J%@#
MO3VW'HKHI5(::L-0^>"I1\XDR@]':S9MVG0P7F=[7F<U%Y)DH.29$!\/(XZU
M8)'"XGB^YW2.X@P2'>I7<%7$R5T:S[DLXX)C6);==,X=RT'XV%:AD%8=1A.^
M#,T>!G?=L;@T;A5 XYN1>S<CLZ^#B3L>/,Q&WO2$C.Z\4XSF@9#;=6B.$E](
M""$ST3PA4PUKC A)/)$F6K["_Z"<.X[>'V D:4&2UB$Y8R]D%,#*"Q>AGS%%
M8ET!V>XUV[1'VV?8CK +N;:=.@S=()!<J9/=#W(#]Y'[I-QW."3M6F"N=<07
M(8\"XC[S!-4\N\@$-J[E[]EZY@BB/1.;I)0I#C>%RG!%IBPA0UCH/LB5P&@6
MJ<+&-?X]S?VJ'$OQ'"9^N5=Q3,_%J!5IP\;5_CVUL5 :-/JO<'U\J^"(YVWK
MS,*X%6G#KL@;&3,HYX]3P0&Z'91(D2=L7-QOA,E;XY5(,%&N ($=VNSV>BBC
M(DO8N,3/0MA.1"R(33_-/Y,I]U,)WBJEA2-Y(HY!?Z9:^$\G9 VI^9E%*2<?
MK5,+$@E90_FF5DQB&Y86R83B.0 R;1 F2S)]C><B*J-; 3"^F?R),2GR!<45
M?><R,GCQ5RQ9\J-IK0+HSIWVW3\P3D5ZH+72PP]H YM/"6@8!)8I6'4!&2F5
MEB^["LP[3,)HD1=HK;SP74201Z%#SBH4J4H)X4@XH4+Z:2WIW]66>=V6+2T0
MU[2<&([XR!7&K%![6DOM1XGF,N_K3:7+=E1+F>&(%<P*L:>UQ#X+'?$@!RV%
M+-6,"IP;)F&_N+[/ 0A@@AP2XUB(/L4U>\MQ&K,H(M>I@LNJ/)HX3E5!3@OU
MI[AP;QD-8BZ79H']!@A0)H!PKEE2[K[_URO0(@U07+Q'WG!"W#0(-103KM8<
MDG=63@XCMBQEAN-5-*-.H?-.K:9AN@(IPSQ5 5/E*:>0>Z=6>S!.YU'H@WL$
M*]N(_2U*)T,Q0\/GJU['/K/;ED4O6L]E% IU=VJI^]N$.S6I59'[5$/HDBPW
M?@J3/..JLGF4MWU*]X"BT[5MIV-Z]5*&![,:7)IW#;$Z:*-@<\]-][?@(%[E
ME6H5ZKWW<#NXFTU-LW<_&=]/W-F@3ZX?R60P'$P&=]X RDYIUJTR)8U><2+W
MW>8O/Y]1N_>K,M/,, DS.86R^>4UKZ*S_GT!J]]8F9'7;AYSRWF6#@ P<_5*
M1 $D+*(%F7.R +T*R":$?6P,'TZGI[LB*H1P0"2*NL $+%39I'>=2I6:%AA0
MH"%.HWRWV6V7)$(3..2&"300-K5(P%X!:I&?XX0#Z/;U%ODDY-5,0GPS(<N]
MK%>A>CM/(F8O"QD3,[4BL"9(^"XR<A<9N$+&#$Q&HQ'TU> :9:SL=OY0%!G;
M8D5&=O#\Z4(L@BP>Q]2G J!RMQ<IV*DYG#L<.0WA9&DFJ0"KFH06Z=>I.:/;
MLMJ.ZH[SPN&&CQBK(N$ZM1*N!\0DD!HE 7\AWWBY7.-0IF'HM;OM7NGDJ74P
MIC>Y-/O<H6#]0T693^SW9_>?5-SL0T*KN#W_'G/+3"I6).(+,+5.>Q!!F7_B
MR ^T6&=#_[G06L39SQ5G( #F!KB^$$+O#LP#]A^:KOX#4$L#!!0    ( )N3
M7%3KEFW2)P(  'H%   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULC51-
MC]HP$/TK5@X]K0@D0*MMB,1'49'8"BW].%0]F&0@UL9V:D_*]M]W[(242FRZ
ME]ACSWOSQLYS<M;FR18 R)YEJ>PL*!"K^S"T60&2VX&N0-'.41O)D4)S"FUE
M@.<>),LP&@ZGH>1"!6GBUW8F372-I5"P,\S64G+S>P&E/L^"47!9>!2G MU"
MF"85/\$>\$NU,Q2%'4LN)"@KM&(&CK-@/KI?3%V^3_@JX&ROYLQU<M#ZR06;
M?!8,G2 H(4/'P&GX!4LH2T=$,GZVG$%7T@&OYQ?VM>^=>CEP"TM=?A,Y%K/@
M7<!R./*ZQ$=]_@AM/Q/'E^G2^B\[-[DQ5<QJBUJV8(JE4,W(G]MSN )$TQ<
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M;#TS&7H.9;G>\_)0('V[=JX";[ <^Y7YI,GQA+;Z24_HYQ::!B%S6Z!#=;Z
MMCIA>P';S DYU$B?^)[?+W)<=AC'9*08IZV:TI-J6F1%R@R\@7IA.3F',KF
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MJRPLTHI05SM[MV&\856RZUZ[;-?GT3::,SZZ@FHA=F#?66- S@V3W2>H,FU
MD53V-2"*/&SP4M QM//QR;P<0Y5IARY"5$ZF!H8<#.5"J8$1&)BR+E@;VFF[
M*HC#<I<X+Y_N-1_'POJ8EM=,ZYFOGC\?!;)C':BVP8*2H9V3/_-V;I/PBAY'
M_W";8SXWEMG)EVE6# N6K7B9W_*J5*UOM-:KG#R$,G-9,>TQ35 VLE-V:7FL
M'W/'M6C[L"B'H O5-DQP)8(OV*-.:NWM1!/708;#B1J3K9U%C^\IQTAEQ:'G
MHD!Z["8USM;A:%3)'8[N;DK2.BUJ1T?P-,*G'2"1H%1DI]33C)!()6+DER0
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M+]*TV'\HOYI^^!.7BW\!4$L#!!0    ( )N37%1JO%G \ <  /$C   8
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MC,!NHE.WXJ9%Q.)3(S[*>[%<LF#-I^QHB*UN+2L(P40L#A#$P6FQ. 8@DJ?
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MFE$F_EC0"1]"Q^>602(S&T?*Q:4=-U_:X'J&G2R/'V&=2/P@8F3PB[N3J'"
M"@3,X2[F0^>E<70VI!/L9PBJ!*;[LW6F>F^YYSLF9:2CR ;H;O&N 9"I*'H'
MG@Y3*>7^J/TL%I*H<$=(;RT.T#S $V.>8PB'.E""%\R+^1[E22G2\2'-GB%?
MC'1N=POSG:F3#I\4B[]]"S"?T0]3Y_,T7$D<$GW?I>*I#Z[9Z%.XUG[#'_S4
M(> O?14/3X??%-ZF3^G]\O2#Q$?I-YCI.&RN83HO3H\GPJ>/_'037<L?UBL7
MP1B^K' PU9X6X/W:X:"2;VB#X9>6B_\!4$L#!!0    ( )N37%2S ])E(B@
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ML7ID9;>'?X+)!5N**LSL6N(;C#1,XIO@\C58G3CD?#9QV YIP71"./)AAY%
M57BPRY1%>$ Q((TLX+X5<US7>JR87P<(GSQ'3U'%A8^B4<=8#6.!BO*_X?/'
M)BB#!5(HAHK92BKJ )FKLZF=?C)R(LL=>13U&6?V:,4Z$RA:K-U(ML"$_>,8
M_S@6)SO3FUP6KGGDW,6DC3(:WN$9@6*8L23;#A8)ID0.8U2_$2\-'I:M <KS
M#6LS$&I06K@\!X*-9X%$8I4J+'QKE=>TF5S@"_MLJ1T:2P+1Y8]9\:A:NN6"
M\RT3Y.!*)(^-SBD&)'I4X$],C8+;,;C'2';8"TVMDE^/.>%$XD+>Y)CKT=J-
M%\,L$3,1J"=)CR^A<Q1R$J,=)S*C8,5DS<? ;-BSO$'I!'XWKJ><^P8,DN^/
MEU:)!6/+P$H "PJD:ZEL$/(+(Q%=AIRES49/3]!%0OI4%9-B@J  L]M_)R_F
M)W8\68G9+&P) 04:7),)%^M@TC1A'8'11+OZ)'G#Q&9TS*LRV<?<;C@7 4!4
M.Q0H8Y)7KK]#G<&9;5861044(@<2WYF$"W4&G'44['$D;Q:RLXNF'.YT/4/D
M@VRD"+/FQ^5<4;97QUTD\J>2%)B&!2\\U1W[KGF)67DX-)B^E^55C0IR&[@0
M D!)[HM=JOQGV4C9G)A*P>.SW]=D]40[QY+,S%+Q;PQH'WPPQ)!&&<,D4BH:
ML^3>DI XM5AC"[4?\1/ SE&1*$T6"FM#8BF.BL>M&R1@B8:ZR#T[/_2/:/BQ
M=K,%-_44102>OW7BYBVH/%/ 3E>]4:B+6)2P'U*MK[+U,W2$25%KX5!K;N%]
M4(.DHJ4>U@UNM!$8L'YA5]7P$=40^P;PD:%]AZ$XO4D: KR&/A8?+WD='T%6
M:+Y?B#3\DTG]I$4IFOG]%#=YO_=MCUD2MM+#ZC=-BZNLLUD;3Z]LQ.GI-'A6
ML=^Z*:%V.-J 9:*P^ 5*XNW -3OHF<($#>YK1X?^0 ZCB#O5$3<8"32D/>@3
M4:S='GUU8+Q;H;]<!"[;.>MJA^4Z_'^[V+&'2]_/K3I;';)]G1>BIZ3XO,H;
MV23<C*H?)%ME2G5X"+=@GV%/9/([X-[V(&_I=YRZ-NQ<9G_5TEUJ+S%&H,JD
M%U<'LQER]-X[-(IU]I:?R*X:8";Y$I?"*G(+)+7]_NW5I2:S<0%#1U(.S,+Q
M_G#^W=GB[.PLY:4XFX&3$C#2LC'+C3P4\[L(.I'830R3Z@")XK&HH$Y<#QT7
M26$C-\24%3LO)'5PPHSDJH>F3@O%, N#59!BR_=G8'(./A*T!]K1Z0S),1T)
MU?8R>\M9)_P&L0D>0V<@Y"T0NEO!4PIFH?^>T:CG9T__O(@NK2Q.=/O3L[-_
MG]..(1#XBM,352KG\+68"T-CKC64[V[;&O,/CH)G475=T">#U2=HG8J^[42%
M%#88GE3F/+-,1SDCIH$/#:4ZTTHS;/4M@EM05W:LG,C]0'5<](%FBJ 6V6I@
MNX6N&HDB6?.%(?K >;^P\@*<&,IF]SBZ%#PP_DQB0#\Q1$A\DS:_S>NY/=+2
M"+B0954RL&$TFJ@Q!L=P*/;U8Q$JH9=B-;EFPXK5B=/G)Z 4@@XX4#Z=TP9L
MY9D6/CEUWFW0T!$5#(<@+4E^'^4 >ZS6H3\R7:#"O$WO-E4AB2W8K6VU]Y*L
MV./)H-4VV6>'ZKVL;JMRT(W 6AS\9^@PG!G(W>G\M$P?,T;]N; _/OKXA,1Y
MWTIZX6TW;+*+$OU(WQ]IN8N@Y-AH[-"'1W6#$4^U:1)1 .5!0"N&)E%(M0/-
MP%X1Q>'L+%6=+77^!BSU954(7 36A\F$O*%P@[+RHH?9,4-%>KQ<31&@C\X9
M?,V110XLM?2B"ODNQ]QP@VZD/K2( LW?UOF!)6/\XM!H4@:AH 1\":^24SI%
MZ +M&RL*B<3-T09_&788-#E, B^U2>BZS&[<YCB(864B-IWA+FRM5YA(1O.&
MJ=!&X5+!,8M*R/.PFM+CQ&U\'8ZB'!"5^[BI7#MH6LP%H:+,]Y4$J^MJ!:<#
M!!^\9H>@GVFYQ:SH&K09'"L2A7:]ALBK0UI:I82?B?26KJ@((8MXL0[K>[>(
M7$U<9<;N:EH9_F\#%@LM(KO@&C1@VD97I<8X 0":]! $\B!A==ML3FN* S5Z
MZ%P0@(>!?>#"JI=$_WAGO"2[K3&TPMA&_)RZ@J<31P?K.<4V5VP$B&FUJ3"K
M$9UFUJ5HKW<,3<5R&96#5!WH&!1:2O@W=N&$;NO4J;\+AQV49E5SGEM2M$PC
M\^,G\E5_8B7_GGW5E#\6[1CT37!GHVNZ8-5E_%E2.?:1^WU;]A0ZQS':*)*#
M$T;.^:_HG%\9)D])[HP?;X( (O77?\4BQ!M$J2,['?=ZY0XMN6EFOR6'4$IE
M0'<[=4TQE62 HL:A$C<,5<I<[ +_=YM7E*,^A6=/4=4GJ_&)\D2SB_D3_-"G
M#[)ZYQSVK6NB(9$ULN=/E0M+ >@VSC))#*+4$.4:IT8OCP :N?A!LR&9Q1N,
MF3_!\CN'?J/P/*00#$_%GT[#9M47;R1M>8-I2R80]NK(:19W^?QL83/27RF;
M=RXE:'K?..7><8:B,F=$O#0.UHD+0P/275-^I&ZQ=AZS1K LR1( ;9W;8E,#
ML <?TR7;-$GB@ZNCD;Z&]@_SWB#%S]C$2+!3.E"]:-QO9L0S+4V@<:4\%^6&
M<S0G"!1!JFQ2QQ,R(*3#:#&GF)N&"79X+KO#\DACDUL=XN%(A!CF+J0T5;<'
M0?W'D"/4CFMM^!!\4.O?8.#84<28-9JID+*0-6EQ\9ZC2ODH&+KK*0TI^:@K
M13FPXLH;XXK:56"\[$IV+^9R@@',O$!;$++Z:PZ40GRITA0R\9Z'"2$J@[9[
M06;$W'>Z1S7C-?)&ZFZ8%B#.TXNDQ23_"H-LV[H4X( N"<'9"$*8EX(C],V4
M)"R(9W$30,%"Y'!<HT"H#[%#TFD+S&(O?N>!X.7!"'>\>/9L=*RI_0\$P=\@
M=97?4H5[6M4<ITZT/L5I8<Q'Q16;XMX4@Y2_$4"?H,^GI34]7WG94N?$)"3Z
MTY[,F_H1%S>?@AMQ?O;T^].GSQ8F^7=EDG^GFD+\P!KL$:.CGYU___B%+1V8
M9*,\"4(Z/:2A0F>/010Q^V]Y,R!7 JM9OB%$("9+9&"Q'#$DH,,WD6MF(-2$
M0A][#[ #(\4=P?J+S! =^S1&B5 6 O*K$=5-AHLL+?-'; $#6?)&DA4Z%^&4
M=<5@N.N\D!G V Y40HS/Q:I$1&KLT>''BL(&G&'QS.W4I!="]L-"<""DCXH$
M/NMZ8D&B]QY0=CB7$D U[5 AL!2$Q$*![A^;0TQ+P&)BJXU'),>4^;8X#G-.
M%'-M: 2.=1I=34+0XEY9^N:J.!5$VO!6Z*W0A"^9&]8WIE-#MMDTU*AK U,V
M[0X'"-H]J.8D<\5FG))B$^\L(V02W\90:<^1ZL]@.9+OG'Z7@EAR[G9!+2M8
M7 :T.$J_P&-5-#8B#X*TOV?T\"9*90!K$41GL^U/R8PH#N]69#:".P;OU@,P
MK[IU(?.L]4]4=^/O]_.$Y%[:*OR+[ ,#;S +$Q_Z3C*PN-,#8B3,^Y1?6O=W
M.- S>>X#RA)925 W77LKQHC\*D98Q*"CQF<I:8P!Y<3ZUA $[ZF/M:]4A7:4
M!4J7O8B^A\4"?O5>R8[OVE";/8(!^)A,)Y<?Z<?Z-87"HC&LC?Y=WNE'+)1U
MFH<A#X0!CBC<;.[)Y58MMV1V>^8263=)S3_<]!,M3*Q!L-WZX?GY0@<V3^'G
M^F1Z^H/2('4T0E%B51WK_%C)IOW.)Y"7*7J.?!)FIF=LQ6F[/L74MI+S\9=/
MQAQB[9P*L#1^K)=/PCGR7IZC%!1\'IK* OY# \'@6XQ%-N"9PN&,HIQZ' 3]
MB-HQO!B"NW7U16)EY2*GUYA)C.1=)[0*6IGWAQN<T.A4Y,738=J 0N\5!O/T
M7 +*Q8@_"H(P]N=^+I#/Q9H6$[V[83=FAZ+?8]%HSBZ5;'?P-: :]$['G5T=
M(1,L!P6%X#/8<PUX$SI!3# 1C"H_;%"4 48'2@("P5V!V%U>ADXLC $8, W_
M%20.CVUDA'.OW$$F["Y!+172#AE]#VK7HFXQ.L#<I]3TI(ZC#T*43J<THS2E
M*816^Q);CFLXI\Q2(YA1?M5T;84F19!#[:TD8+.X\NX+YF&UG,$SB%Y1G4.\
MF]ER47L*<<#8,#5C'%(\>%# &RA(5?MIX;M?\-B&VI[0^P0L0KJ2=@VT6-CE
MW6N P9, ]>A0?V[:NX9IOF=DR3=WXGJA"H>5")8\)SES3@!!Y*+#5L(J*"ZD
MD00TBS#8'H-</9?*0W3I=^">\[YSMDM]4X<!?Q3I=)\:\VIPE%QS6W5MPVKE
M*D4#<1 \M]+4 FQ(ME-4&+;[I17_A=CZ=200/FIQ\!&UC%^&_\OK@_3;[YTM
MH['B P=CC07&R!.>,^R434W2G1:N'(>V,C-:GM \7%:2,P 'G@Y>HFTS>4_3
M!D'#LNN !!A==6R8CO 1P=1QS!#/W)A,VD9*S<QY%M]R ,57XKFQ0YHLSW@G
MK+<Q9FE>^S;RM:5SH@@]M?:"F HV%Q2U;O&"TH<AAYIT-!-NY($1/(ETLPE4
MAR]!F)-TU@<LN7R@DLL%;\N'R2(,UX$T71V'0(6!U7S**/=4_V"$*]]28%N^
M*>\EO;\*+#S&:07,'ZIW@47B5B!B@% ''_6/"/]G,CF#M'4UVYF!0D.O9I(,
M;RXUULH;[^H>&F!(4:\8Y%#Z>XTA08RZ>=+8XBG6G5Z/N;][IK"1<%31,FN<
M<28)EAH9G7PB()]!Q*4T'.>.S%JX<HRUV:8=Y42/ZW;E[\.IX.Z6#GQ*/&^7
M+<3B$(G@OZ\[)PCH&[PS@:J%^_ 9W:- I.5#WV)MLJ"2;\$CD,F3>CEBHNGI
M89]6@(.+<77]"XKNWP;0$$@<AJM2)Z'^4A[4$PXXB?1C[K^+BRC,(L8$MT./
M5H%R=/@!!H<PLE!"\20(^"-$TH+M?8S(9X2Q+"+M!+SOG( ZU(L1B#G?$M)W
M;:V'4]K3$24C4T\Q0%ZRL ZNC0KXF:/,+B)Q9PHE&H'*L@+"_^N88\KXM&KF
M*C>M<CX,S@9U$(6B5DLQ9[Y&#S](&H*?8!N?\V896A <\%O;B0XA;@)3,"1D
M\- W4$G:GDB-.-]Q4@^'^Y;UKPC?<%N5>HY"JC:[ Z+!QT7MB$AJG!,U!Z(-
M!DK[*9^.C:FFTZ**5I*$LY*:!^>^K!A-SO7%@\I:R=UA[DL./J&S(Z6:8[0>
MN1; -$1I+_.T8OI*+J$GPK[=U#+RA]O+X"QA0;<=-MNQS.!_CUH<'/FMHE#P
MBQN\4,5GET<JZEH+_Z:))!39_CQ=9+N2+IV5US/=.8$^@!9M*%'(=5V$_CI:
M*EL"*4#&Y)RT$.1EZ,4@J#$JA7Q?]8C%H93$(6 /&\$^FLP0*9Y1I0 ]3^J@
MP1 )V%66]&A7W>8<R,6&8DJB1WV9K1TU_OI0\_[*79:ZGK0RD19K&'6C+2(5
ML+*0[&+2ZO;6=*V]4YCU;#,<AZOS2:79%P.">Q*W,6J&#\GF8\3EW/!PUMJ#
MH]L/4->$MBX&)#:GXQFX_=!S*[FV3D@1-=<X LQ95W)+A';M=RZ %HGI^H?O
MP1"XK[L HH[94@'6^5%^U6;PY'H ;5B3/T/*:Y<W Y8WV9^0_6G*@"\2="\\
MPNY@[.OTXQI7O!3IH66*_R\K#7N;)%?B_2FQDW$_=!Y+S:.+8@1>S*,E<&Q!
MMC8$8XL8LV\D,+99<@RT<MN\7G.S^42O-+ +KS8D5[AV'/BQ F0GGT%IJ)'P
M9&&=7N5%KWU(V@JQ.38NEO9&%9[@F@>N'[+BBKO I7R+)EN)KI-$,TCG*4KG
M(=P4PQ912_V40V@82";2?V\)7N"_,#\UQ/&'28_B.FE9Y:!06C'=>HTH;XP&
MG8%W!4R8N5G,V@O*))E&?;E%3#I>,40[+&/O?<R\V9,9,F,^:>#DU 5V 45,
M[V@U;!5'S;AI$<=/=Z&,=>#H[8;@'H;R<<L"GV>RZT$:V+XP<);R!YS@#[=+
MM*I0%AFYN?'LNR-H9(0?\R$R/9Y\4P#=)=+6[8;.#5@>7VGB$S57:VK!-8E1
M[RR@EN#BLW: +/SI&]('E^;BMFDPF[GE37SZ_([*#IJ]Q$185U$\*0:/OE]H
MG+"/Q1$/UEZ[J!1P0)5%6\0=4T QUCNQ(6/WY+K.8\WCW<VUN0SQ9N9^.LY#
M\!I"OGX#@JDW$:BYRI*&@[2S2_0H#<,O,XI.JTF:[AGE435;(^X;/:DKLUVC
MF#YD;1'OF9JX8XNF-^C<V*'Q<,+H5KSNV'$?1F3+,UJ"8K=<15[?K"G%UF !
M\K#3'-'CMRX>T]\);$FLV'IHBK0G>U9E"#=+JK*L80WDR5&I-,$R)O$"\^%-
MG8,<W100?:%F)7$^Q390 E@R9(%"/)0=M5@C$(L113T="8)B\+$4$Z[#,_<<
MO>!KL[[_D=Q SMU@JH\.R?F/NEWQBP![]*F\25!Q3%#0%R8Q9$+**!)QCCE'
M,#WWF-@(58!2+M<)I7'*S5/:@>OB!OUAZ<\Q9[8)/+JC^X5=>:J?JS"'_&=2
M>9P0<7_?@E"/:,J_Q;L<XSE9'F_$;8O]&Z2<93M,RB7:4KX*9C^LP&2,ZJP)
MMJ>A%F *G!E1<0@!ATT!+8*:&1.!#(^YN.3 *+L,5".\*'CP),W$?VM;!]/.
M+<JH#+#VQ:]Q!4/8G)0K4@;+#E@!8>49;L@(DYF2 "%.L36G25:#K:"@5='.
MY)O0:TOH@N)0<)8'A#JG XBX%;PN@3!MB8M#J!M:69(XFW"$^ I8;D75:Q;Y
MGIU"[U Z-GDD2W+$L'(/OE9#[JK9 ^M&8B]"%](F9EL5O4DSR'TW<IE 0'9%
MZ<0VU],U0KU#K8JR]T9A=#./5",MFX+5#Q6FJ-$.<#/;J*+-IA!9\4_7M:>@
M6C';EP[!C:9CL+1I_:T/7R%$>HR/SB/!4S%K8M9JJQN<\2>G41_UL>ALI)]
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MA"_^P>ILLCW5+KR,P;.KFF7VAE'_B1ZLL:$;/=9W?[FDQ/% P?#,-2.!B=A
ML!NOQ(ZK9?)D(68=HZLUEN%'(\)54J,GF'6DR+3=5,"\H0Z\,C\V.I$S#44.
M/B0J@ N293V79^'$SEQKPG*OR-'8!Q\E-S)EO 3K()7:X-%W;;ABT4@W9;S
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MB*63M:(RS&LB:=K:6TVV<>I;HPE]<^4"&H=66T9DN4#O($H@;V\7C%(H"BM
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M >:7%J>#]$(,NJ]\M[\#4$L#!!0    ( )N37%3-%9RDX@(  '@&   9
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*U5;6O;,!#^*X?IAQ;<^#5I6I)
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MC=H9T'NIE#T=G(/^#V'Y&U!+ P04    " ";DUQ4%"WZ;/H"  ">!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RU55MOTS 4_BM'84(@E:5);UEI
M*VU<!-(0$QOP@'APDI/&PK&#[:[;O^?8N9!)7840O#3VN7S?=X[KX]5>Z1^F
M1+1P5PEIUD%I;;T,0Y.56#%SJFJ4Y"F4KIBEK=Z&IM;(<I]4B3 >C^=AQ;@,
M-BMON]*;E=I9P25>:3"[JF+Z_@*%VJ^#*.@,G_BVM,X0;E8UV^(UVL_UE:9=
MV*/DO$)IN)*@L5@'Y]'R8NKB?< 7CGLS6(.K)%7JA]N\S]?!V E"@9EU"(P^
MM_@*A7! ).-GBQGTE"YQN.[0W_K:J9:4&7REQ%>>VW(=) 'D6+"=L)_4_AVV
M]<P<7J:$\;^P;V)GDP"RG;&J:I-)0<5E\V5W;1\&"<GXD82X38B][H;(JWS-
M+-NLM-J#=M&$YA:^5)]-XKATAW)M-7DYY=G->9;I'>9PR5G*!;<<#3"9PT=;
MHH9+);<O;E!70_\JM$3LTL.L);EH2.)'2*(8/BAI2P-O9([Y0X"0%/>RXT[V
M17P4\35FIS")1A"/X^@(WJ1OP\3C3?ZN#0/KM_/46$U_IN]':*<][=333O]O
M]X^2N&N]-#7+<!W0O36H;S'X&V8XE-/9Q,"6*;JSQI)5%4!X4"A!EY_++3SC
MDBQJ9XC+/%\"G2-6*3%V9^E^QCVJD\MT5GII.=[2#*EI(EC .YI*AKA.8#9*
MY@E])Z-X,>TS,U6Y"-9<?<I.46+!K:'X.)K#=#2;QFVU[$ -9^,%1*/Y8D82
M"]3:BR'BIT^2.(I?0C*#&V69.)A\ E$T.CN+:'$VFBWF?Z"J[1G4FM-PY.+>
M]:[#3I7<F?: .MLMRSS,Z=$C:WS"^:SS_=MC>MB:D[XY="A)!)=(T[)4(@<N
M,PJ@Z0LJ%7S;E-\%Q\FDDSD0UWESK)5Q#>K#V[ZK(Y4-E23S.1RZJ>%@9E:H
MM_YE<$W92=N,S][:/S[GS<S]'=Z\7!^8WG)I0&!!J>/3Q2P W;P&S<:JVD_@
M5%F:YWY9T@.*V@60OU#*=AM'T#_)FU]02P,$%     @ FY-<5.BOBUUH"
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M[.'6"B=C_151!.O\ .Z$KPY$=/RW8&R !1[8*%F-4-'S?VMM2:<&H36-(NK
M33:L:DZ]$1T3/_:UIU 62/JCO>+DE=9)84JDCA4J1BD' 5U-@G^W1Y0'[ NU
MSW, 7C&=HBW%@X:K,X#?%!UA*6*I;I;D@*!;NA8"A\5HBK#!V-RIC@?;)H:
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MVVQ9;-M,AIF:ZJC3X_NXY'&5/XH>&OA2@7BY(SU4W9K^>R'N9%61SDVBDU=
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MMDVKD-+MR+89\]33[QU+R-82[(BF9M6=Q^R?,(T.G8B>]@Z82Z'OW#$ZG4$
MSOZLN7O;G=1?^@/JW7!_S(] (C/@!['$U' T30=,^Z-S_V#5VAU7+Y2UJG2W
M*\%1/FD OB^5LNT#+=#]_^+B_U!+ P04    " ";DUQ40(Z6\FD%  #A#
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M\3\(>S' ]\JA./H7<3#\5W/U-U!+ P04    " ";DUQ45A42^YX&  #Q#P
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M3X?S[&TZQNW$TV'XH_+8Q+QF5E#-)F>GH_31T-]$U\BA;NDBCHARR1^5VK,
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MHP!T_3#4&ZL*/XR7RM)H]\N,WE+4SH"^KY2R[<8%Z%[GZ4]02P,$%     @
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M\1;FK6<HZTX[0N6M>N+HTYEW3O]/2=)2G7K16S@*$75K"=E&7L;8N#T:!3O
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MQ73M33=QN@DMQ5H[:E#"L*2.$(TWH.\;33=%/_$!AA[S]&]02P,$%     @
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MM_5.F.2M.T%H9INV=+5(0+UY7*#J,U *MEV[($*DZ[M#]((;! VQ5E8/CWD
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MW/B];!))Z/6(8:W>, GE(MI4/TGU7%;+GOK=8+:AXI)MV<O99*0E8I8U"3C
MZ+Z6V!S7/I%<2Y-F.?41ZV0\-FHY^&H6;NXN+T,AK"AC"YM$O]^OSL#D3!;4
MW-V%F&Z]"];K"&(P=R="[U9CL"'U\LE8SU@G>:Z&@J@I->&-Z2S-^&U?#$(!
M@+3\*2'#X&"PZ*O=MN=@Z92K4!$-D M=[^Y9(T^VNJ&FDB+XB>_<)>;,A(EB
MZ30TB.:N2(TT^@_N>L0T%5BF@"U]+8^7[*:V<6.Q%<OX+$\\*O-C"XVSXYTP
M+A/O%):<34K^+YWD<M_I%:"$(HH%4RSID2+>&/"W22M_WD]7X5Z@5-,@<8G8
M.U$B;R$54S+;>M,6%'OF$(.QRR27^F<_Y;@S.L9^43)JL],%AL=>1A<[59P?
M[RZ!I3\(VNP:SG&#/NBIF_KB23)\W5L1+V6+E5GT0\4@&"0OCBP]:E(2[J_O
MNVHQ"#I;A5Y3822C;<_3U0R4"T$EF>1,W_/9F'09DXRF[JNW54W+WK/KJ,_\
MFW> &$8Y#B5N!-!C=M\JL8AZ>KTD$TPS%KQ(.C0-QGD+$H4D6R* (>K7$2!Z
M2]K>9^J>QN[- #>PXDXH^6SDV;3N%;3 -($DAJA1*\)D#R95HY4=W>PA;^S4
MILFS$7.N0HM4:<63-@"T \>Y?6[TBB+MNQ1=)-P?0MKT\?.41(.J4,-5Q^$U
M>[$''>6)1D_+M*/EHYA 503Q!(0J'XHP2S962$L>I8R.%O1T+RZTV9"D'LK\
M>6@&E&;2V-RGF-TS09H(;- P,%@BO"$B!V*C;>2_YZ@B#<ESUM,7;9,=;%S&
MOU87@AG'V" ]09A/\&7$S7&-5>QV$7Y1G!321U\ .ZGB&>=4F#FZLX<0'C5>
M2Q#7;)H9Q1[4&$AT"&G)Y$]B-BH;B?$T7WX4O,%#Q*1!9 V;YB$^@9[.M!%U
M@+/*Q[1;F5J?9KKXWA_A18*N4VS>O@. - 9I6AP'FY#?A,28XC[3LH,,2&7T
MN)W'^9-)YDA]X1>B(ML[44=&ZK_3*XVW4W6^CQF=Q_">42.5M=')(/Q&>I+;
M%#S!0>[WEU#1WC3M70.?U]4V*+'"2K]<ENY=+P$Y7&]Y^&ZX_D5<#,AM,3?;
M]+8-UR+KF5<6\%ZL%6Q%^GZ,8P2/.=Y4/,+>Q.+@D(/%QN<//II!NZ5$@N2<
MU-6]K_1LE+JYA^B6E-A5Y"WR/X#YS/9W]V5:0Q*K)U,RWY#]M#BD4CYD5H]%
M?7L7:X".#(.BRLP.X_OG) GC7G#^M@<Z5WXA[/Z("HGSV(CL_'C_L \.'1$
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M+/&1!&4-\#Z7TAPV%J![=M=_ %!+ P04    " ";DUQ41"J.0KT"    !@
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M!X01R/;"V7:T6-E+WDQHO#+:YA+OZ%R:"?A]+H3N.R; <.N_^@=02P,$%
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MU#<N%[,,7.QJFB^:%4'V"!V<@0!T,<7/F<;#20?/6O8Q>4'5W-VP_$&X5&!
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MEE$HOFX!_+Y6RCY-W-N3ZGW<XB]02P,$%     @ FY-<5$O7\6*R!   01
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M!V4WX/<K*<WKPBIH?S68_@M02P,$%     @ FY-<5(D)<%]G @  D08  !D
M  !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULM57=3]LP$/]73GG:)$;:E'X(
MM94H, T)I(J*[6':@YM<$@O'#O9E@?]^MI.:(JUYXZ7QV7>_CW-Z6;9*/YL2
MD>"U$M*LHI*HOHQCDY98,7.N:I3V)%>Z8F1#7<2FUL@R7U2).!F-9G'%N(S6
M2[^WU>NE:DAPB5L-IJDJIM\V*%2[BL;18>.1%R6YC7B]K%F!.Z2G>JMM% >4
MC%<H#5<2-.:KZ&I\N5FX?)_PDV-KCM;@G.R5>G;!7;:*1DX0"DS)(3#[^(O7
M*(0#LC)>>LPH4+K"X_4!_;OW;KWLF<%K)7[QC,I5M(@@PYPU@AY5^P-[/U.'
MERIA_"^T?>XH@K0QI*J^V"JHN.R>[+7OPU'!>':B(.D+$J^[(_(J;QBQ]5*K
M%K3+MFANX:WZ:BN.2W<I.]+VE-LZ6N^ZRP"5PXX7DN<\99+@*DU5(XG+ K9*
M\)2C@6]PE/QD,&\$W-N6&A=OM7U/-+T!DQG<OC2\MC='\.4&B7%AOBYCLFH=
M9YSVRC:=LN2$LG$"#TI2:>!69IA]!(BMS> U.7C=)(.(-YB>PV1\!LDH&0_@
M34+O)A[OX@3>/=LKS4C9CN#!\0#L18"]\+"3$["'5I[!5KB[^-C1W_<V'>X(
M*_-G@&P:R*:#'M[)ZD 6S)Q!TUVSX#G^[P:'L:?PADR; 96SH'(VB'2MJKHA
MU._2O%"C<FJ9Q@&&>6"8?W[3%X%L\8E-'\:>G&YZ?#0F*M2%'X8&_#^]FQAA
M-\S;JV[,O*=WP_J!Z8)+ P)S6SHZG]LW07<#L M(U7[H[!79$>:7I?UFH'8)
M]CQ7B@Z!(PA?H?4_4$L#!!0    ( )N37%0WE+38OP0  *L4   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;+U8VV[;.!#]%<+H0PLTD4A9DATX!A*G
MV0V0 D'=M _%/M 2;6LCB2Y)V4VQ'[^C2T1;%]J++/(22]3,\,SM#,/)CHLG
MN69,H5])G,K+P5JIS85ER6#-$BK/^8:E\&7)14(5O(J5)3>"T;!02F*+V+9G
M)31*!]-)L?8@IA.>J3A*V8- ,DL2*IZO6<QWEP,\>%GX$JW6*E^PII,-7;$Y
M4X^;!P%O5FTEC!*6RHBG2+#EY> *7\R<0J&0^!:QG=Q[1KDK"\Z?\I>[\')@
MYXA8S *5FZ#PLV4S%L>Y)<#QLS(ZJ/?,%?>?7ZS?%LZ#,PLJV8S'WZ-0K2\'
MHP$*V9)FL?K"=W^RRB$WMQ?P6!9_T:Z2M0<HR*3B2:4,")(H+7_IKRH0>PK8
MZU$@E0)I*@Q[%)Q*P2D<+9$5;MU01:<3P7=(Y-)@+7\H8E-H@S=1FJ=QK@1\
MC4!/36^CE*9!1&-TETHE,LB0DN@,S<NT(KY$,RK7B*9A^?#I9Q9M:9R+?42?
M><J>T6<JGJ#@;K,TE(7@?,V%.E-,)&!URZ0JK2Z>T3Q:I=$R"FBJ]CZ!9<56
M'+9[?\,4C6+Y 2 \SF_0^W<?T#L4I>CKFF<2;,N)I<#M'+P55"Y>ERZ2'A<Q
MR7&JM42?TI"%AP8LB%<=-/(2M&MBM'C#@G/DX(^(V 1W )J=KFX;X#AU#IW"
MGM-K;Z'0G 69B%3$("U76X@A7<3L#/K\3$*VT(][4$)WBB7R+\.6PWK+8;'E
ML&?+J_!OJ$T&-<&EZDI)J>X6ZCF5;*=XY(S=T<3:[@>J+48\QR?C6NP G5NC
M<XWH'E-@M#CZ#?C^ ";KK)G2@K</L(&M0\+MQN75N+Q3<=US*5DG,*^U[1G4
M20-;A]#0[P;GU^!\([BJB[_1.&-=N/QV.$:.[_H-9&TQR*@W[@$WJL&-C.#N
MV9;%"*-_.BC'4,[CVOSXK3H(VYIY[=?U4*5_6('.7G.4$>\0([XW\KHCCO<F
M WYU%U4F]O>VF_!,(H?0B(9&7M](E0TC-I/((39-QMAY51]5ZD>SVA8S9543
M-S8S=]E)!#IIQL6&"YB\<.R!\I=U^<.\#>(,1F4^>(.7Z5\\,#W]BT6I)WVD
M)[VI/32'8_?->E(3-#8S]/&>;#,O!GXC7C-]'7)XY+L]DPUKEL9FFCZI*SNX
MNHG/)'((37,T-I/T:5TY.F6^=4D-^VI?LSP>OZXUQUW)'1*WB:Y##I*+A]T
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MAA>?L23=.4<WL:KQ;VFA++Y,/ZS0;$&[ -Q?*F4W$Y=@L._L+U!+ P04
M" ";DUQ4T&2N.L,"  #7!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6R-E<ENVS 0AE^%$')( #>R9&T.; .)C:(Y%#6RM(>B!UH:6T0H427II7WZ
M#BE%<"+%]<46I?EGOOFY3?9"OJ@<0)-#P4LU=7*MJQO756D.!577HH(2OZR%
M+*C&H=RXJI) ,RLJN.L/AY%;4%8ZLXE]MY2SB=AJSDI82J*V14'EGSO@8C]U
M/.?UQ0/;Y-J\<&>3BF[@$?1SM90X<MLL&2N@5$R41,)ZZMQZ-_/$Q-N [PSV
MZNB9F$Y60KR8P7TV=88&"#BDVF2@^+>#.7!N$B'&[R:GTY8TPN/GU^R?;>_8
MRXHJF O^@V4ZGSJ)0S)8TRW7#V+_!9I^0I,O%5S97[*O8^/8(>E6:5$T8B0H
M6%G_TT/CPY' "SX0^(W /U<P:@0CVVA-9MM:4$UG$RGV1)IHS&8>K#=6C=VP
MTLSBHY;XE:%.SY82*LHR @=<%PH4H65&A,Y!8G4IH=2$*@5:D<L%:,JXNB*?
MR//C@EQ>7)$+PDKRE(NM0IF:N!J)3%XW;:K?U=7]#ZHO(+TF(V] _*'O]<CG
MY\N';^4N^M":X;=F^#;?Z,-\:\">,S(72JL!F=.*:<K97\@&I'%J8!WZ9AVZ
MK9U9,)5RH;82R,_;E=(2U^:O$SBC%F=D<8+_S(T$!52FN:V<P0ZW7H4;2??Y
M76<,;4:S@W<S/_'&$W=W[&HWR$O&21OT!C9H88.S8%F)1M RA3ZZ.D5T3!<F
MX3NZ;I 7A.-^NK"E"\^BXRRUR[P/+NS4[3K7C8FBL!\M:M&BDVCWI0:<88W3
MG +;T17OM2[J5!YUG.N+B?KIXI8N/DEG%WH?3]R=I3!ZQ].-&0_[<9(6)SF)
M\R1P/Y+JW$.K#SSI+/XHCH)WY-V@(.CL$/?HV#57WE<J-[C\"8<URH;7,>IE
M?8W4 RTJ>Q*OA,9SW3[F>/."- 'X?2V$?AV8P[V]RV?_ %!+ P04    " ";
MDUQ4\F._!)\"  !@!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R=
ME5MOFS 4Q[^*A?K02FNY0U(E2&VB:9,ZK6K:[6':@P.'8-5@9CM)]^UG&\IH
MH%FT%_#E_,_YG>/;;,_XLR@ )'HI:27F5B%E?6W;(BV@Q.**U5"IF9SQ$DO5
MY1M;U!QP9D0EM3W'B>P2D\I*9F;LGB<SMI645'#/D=B6)>:_;X&R_=QRK=>!
M![(II!ZPDUF--[ "^53?<]6S.R\9*:$2A%6(0SZW;MSK1:SMC<$W GO1:R.=
MR9JQ9]WYG,TM1P,!A51J#UC]=K  2K4CA?&K]6EU(;6PWW[U_M'DKG)98P$+
M1K^33!9S:V*A#'*\I?*![3]!FT^H_:6,"O-%^];6L5"Z%9*5K5@1E*1J_OBE
MK4-/X ;O"+Q6X)TJ\%N!;Q)MR$Q:2RQQ,N-LC[BV5MYTP]3&J%4VI-*KN))<
MS1*ED\E-FO(M9.B.X#6A1!(0"%<9^BH+X.B.59O+1^#EF_E+M&K6'+$<C3DX
M7X+$A(H+9?JT6J+SLPMTADB%'@NV%<J]F-E2P6L$.VU!;QM0[QW0):17R'<_
M(,_QW!'YXG2Y\U9NJY)U=?.ZNGG&G_]_=>N-_KA9"\G5=OUY)*S?A?5-V. ?
M83D(P#PM3,P,=NHTUNIL200OZGP+&"UPXSHTKO7IWB7A))K,[%V_C$,CWXN#
MSN@-==!1!R=1IZS4=+@YP(I\#17D1([2-BZC/JWG1@>T0Z,@#+QQVK"C#8_2
M-DN(6V;Z=RG'*,,!P-2)#R"'-FX4A^.040<9'85<0@Z<FYU0R3&P:!#4.< :
M6DS>@8H[J/@HU".3F)Y:N7BPT5QW.G4/((=6TS".#C#MWOVGWYXOF&]()1"%
M7,F<JUCI>7.?-QW):G,EKIE4%ZQI%NH)!*X-U'S.F'SMZ%NV>U23/U!+ P04
M    " ";DUQ4H*L=&7P"  "S!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6R=E6U/VS 0Q[^*E:$)I$&>VJQB;21H-0V):8C"]F+:"S>Y-!:.G=EN
MR[[]SDZ(PAH*VIO$#_<__^Z<NTQW4CWH$L"0QXH+/?-*8^ISW]=9"1759[(&
M@3N%5!4U.%5K7]<*:.Y$%?>C($C\BC+AI5.W=J/2J=P8S@3<**(W5475GTO@
M<C?S0N]IX9:M2V,7_'1:TS4LP=S7-PIG?N<E9Q4(S:0@"HJ9=Q&>SQ-K[PR^
M,]CIWIC82%92/MC)53[S @L$'#)C/5!\;6$.G%M'B/&[]>EU1UIA?_SD_;.+
M'6-940USR7^PW)0S;^*1' JZX>96[KY &\_8^LLDU^Y)=JUMX)%LHXVL6C$2
M5$PT;_K8YJ$G"$<O"*)6$+U5$+>"V 7:D+FP%M30=*KDCBAKC=[LP.7&J3$:
M)NPM+HW"788ZDUYDF=I 3JX973'.# --J,C)-U."(M=2K$_O0%7/]D_)LKES
M(HN#AL<+,)1Q?8*2^^6"'!^=D"/"!+DKY4;C,7KJ&PS"HOA9"WS9 $<O "\@
M.R-Q^(%$010.R.=OEP?/Y3ZFKLM?U.4O<O[B_\M?;_7GQ4H;A9_MKP/'QMVQ
ML3MV]&(8!2B%YRH09BB)C7SLY+:2MRE&N^WG:=]B/ D[FV=4HXYJ=)#J&K"@
M2LESO.,,P;! B5QQMJ:V9(<P&W_) <Q]BV@2#V...\SQ0<SF;GCO;MZ_FT1A
M] GKOY::F<'/<OPJZKY%- R:=*#)0= [:2@GLL&U%69LA?7 ASB35V]^WV*2
M)/^0^KV68MOY5ZK63&C"H4!5</81Y:IID<W$R-IUF94TV+/<L,2_"BAK@/N%
ME.9I8AM7]Y]*_P)02P,$%     @ FY-<5*4IFDR[!   ZQ0  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#@N>&ULS5A-;^,V$/TKA-!#%MA$)OT=. 82.T$#
M)%LCV6T/10^T-+:)E4B7I.WLHC^^I$1+CB4S3HH"SB$6I9G'QYGA&XF#C9#?
MU0) HY<TX>HJ6&B]O Q#%2T@I>I"+(&;)S,A4ZK-4,Y#M91 X\PI34+2:'3"
ME#(># ?9O8D<#L1*)XS#1"*U2E,J?]Q (C97 0ZV-Y[8?*'MC7 X6-(Y/(/^
MMIQ(,PH+E)BEP!43'$F87077^/*6]*Q#9O$[@XW:N49V*5,AOMO!?7P5-"PC
M2"#2%H*:GS6,($DLDN'QMP,-BCFMX^[U%OTN6[Q9S)0J&(GD#Q;KQ570"U ,
M,[I*])/8_ IN06V+%XE$9?_1QMDV A2ME!:I<S8,4L;S7_KB K'C0/ !!^(<
MR+$.3>?0/-:AY1Q:^P[] PYMYY M/<S7G@5N3#4=#J38(&FM#9J]R**?>9MX
M,6X+Y5E+\Y09/SW\(M94:J:0B71"IT+2/'\\1@\L,@4!Z'HN 4QM:'2F%X""
MPJ5X$'Q"Y^@ZCIGUI0FZYWD%6Z2S,6C*$F5-MIZ#4!OJED 8.9HW.4UR@&83
M/0JN%PK=\ACB&O^1WQ\3#T!H8E8$CFP#=T.\B(]47J F_HQ(@S2^/8_1V2^?
MZGCY4<80%2CX,,KX>!0/E]NC47#?H4A00&6T\ 2L651:,X-OO55I1=EX0%L%
M:"L#;1X W:G:M:E4*2F?Y[5J*WAW_)NI78GT@G+TVNG/!X.)[C6DZB\/HW;!
MJ.U=YD2*""!6:"9%BE9+\V-FYX*?&P5<\9A.$T")VUHS@+H\Y3.TLQFLTJ^'
M[4;^-PC7-=PZ!;>.E]L3K(&OP A\).:<_80X9RDAH=H,EB9!/^J*N%,A1/;X
MY&5:M6OAGH=XMR#>?8-X!&R=A:Y*&&F3946SQE,G+:,<N_,F^ZI=O^DAWRO(
M][SD1Z8 I*&'J%*@:QGV*C/O<_-9O&+5+UCUCV.5,#IEB9%NJ*76?Y.:S^(5
M-=PHFU+CG5J!_D'7T8*9 LY&8H;NF%0:3<PFMC?&0C$^1X\L =,S.7AV,M[I
MC?A$U 63DA/Y?_:PP]W-4[./:S>",WVUW]L^ <)E$\#O[0(FLT^NRV1A'9L%
M)F+Y1H/ 98? I](B<-DCL+])?#2)-[C:&G"G5Y/#D;/<37>W4V-X6V>(?;DN
MNPWVMYO:7&_?*N_V6]_K2<K.@+NGDMY2\+%?\3^:WEN'>WSGQZ7<8[_>UR;C
MD;ZP=)7Z7H=+S2:-$TD$*06<8/^B5^G43&6ZQ3W7,)?,?MPZK=%4SDT[-E&H
M?\EUK\RXJIKUJ2"EA!._A%<_M;;O@W2;F\^('21,4[':UT9'MJK;+=SQU0\I
MA9N\6[B?QLA\K*/)PY=SW.JV?!DKU9J<BEJ34JV)7ZV_EN^7:"E-JFQ!%?&@
M]9\S[NNO*JYD?T.[W%4M<;_C2UVIP^3=.NQ25^R*H@-_+7;%!YHR*56;G(IJ
MDU*UB5^U_TN:J[J-FZW:-!]AF?,/=PYU4C!9L:=I"D5V\^?'%,7=XL3N.CNG
MVKL_PI>W^;E;"9,? SZ:9#.N4 (S ]FXZ!I:,C]9RP=:++.CHZG06J39Y0)H
M#-(:F.<S(?1V8"<HSC>'_P)02P,$%     @ FY-<5$1W&FEB @  * 4  !D
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M]5UR!M<\HTX@S J-2$VQ,'#V;]^<QW%TN5Z\7'C5Z/(4WL,LS[FK/1.PDNT
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M>2[-%59-K&-!O)"*%PV8%!196=_9:U.'#8#;W0/P&H"W#0CV /P&X!\+"!I
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M%:GY+->_\\JA@=67R%27_]&Z&AOU4%)H([-*&"S(1.Y^V6,5B(8 Z&D7()4
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MX&N.&*R[&F&VBP^@<@%[&?!PL7=]4KK8EI..V7'4E11/'B1,'E>/*Z%< 3M
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MV,9( YLPT6Y\4@+>AB"G^D^*3UZ;MV"(  UY#-$AJ;%O$SVEGD5\BGXLS-Q
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M\S$.O'(^/<.4T_*.JB7#+'%8(&30ZB$?54Z@<F/DVO7DN338X=URA4,;E!7
M^X649K>Q!NK/@.%_4$L#!!0    ( )N37%1*I65S@@,  (P,   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;)V776_;-A2&_PJA84,&M/KR5]S:!A*K
MW7I1+(C7]:+8!2T=V40DTB6I.OWW.Z1D.6XE*LN-+5)\7_(\_#I:'(5\4'L
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MXQX_%T":!O@^%T*?"J:#]@-D]1]02P,$%     @ FY-<5 <A)J'2 P  JPT
M !D   !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULC9=M;]LJ%,>_"K+V8I/6
MVN"GN$HB=8VF3=KNK9IN>TT=DJ!BDP%ITF]_ ;M.:K!OWB1^./_#CV/\/WAZ
MX.)9;@E1X%BQ6LZ"K5*[FS"4Y9946%[S':GUG347%5;Z5&Q"N1,$KZRH8B&*
MHBRL,*V#^=1>NQ?S*=\K1FMR+X#<5Q46KU\(XX=9 (.W"P]TLU7F0CB?[O"&
M+(GZM;L7^BSLLJQH16I)>0T$6<^"6WBS@+D1V(C?E!SDV3$P4WGB_-F<?%_-
M@L@0$49*95)@_?="[@AC)I/F^-LF#;HQC?#\^"W[5SMY/9DG+,D=9W_H2FUG
MP20 *[+&>Z8>^.$;:2>4FGPE9]+^@D,;&P6@W$O%JU:L"2I:-__XV!;B3 "3
M 0%J!>A20=P*XDL%22M(;&6:J=@Z++#"\ZG@!R!,M,YF#FPQK5I/G];FN2^5
MT'>IUJGY][KD%0&/^$@DN ++YO$#O@8+LB9"D)6Y!VZE)$H"7*_ #XJ?**.*
M:L''!5&8,OE)2W\M%^#CAT_@ Z U>-SRO=31<AHJ36G&"LN6Z$M#A :(%J2\
M!C'\#%"$H$=^=[D\\L@7%\MA\5X>ZM)V]45=?9'-%P_F:ZNH=!6QK>+-2-JX
M2QO;M,E VG^T(^AW7V!%ZPU@7"?VEKK)DMHLQ@)>YBE,TV0:OIQ7U(U">93D
M7=0[Q*1#3$81'X@D6)1;NVA6Y$5;S$X;A@*E+@=57MPF8W8& N-B4O1PW:@\
M@P.T:4>;CM+>EJ78Z\=$CMI1!XJ9.N.B O78?#'0CY9U:-DHVK]J2X2/)W/K
MD*<]'C<FR1,_3][QY*,\W9(6^FGZN')GS*A'Y4:@+/-333JJR2C5#Z+='[#6
MG%Y]7!-WU"CJH[E!D1^LZ,"*4;"EXN6S[4TKH+W6+"]L6IZ/L'#7_P1F/4(W
M*$$3/R.,3FT@&J5\Y HSTS#[;N4U\,A=>5&"^J">L#B#*!Y@/6M9\')/9:=V
M-&:L\&38$(U6XBL]ZM1V\N:I47\%D#.UJPSVY^\)@FC@[8,GZX?CWG\OR [3
M<:MJ4[P;ND .H"<J38?6TLGXX?\XO]EKF2W$7K^1MI!>1-?&KV">]=]'3]C
M"PE/7@_'S=ZSV,^6D1?6]?4KE"=]]_>%91,TP'MJ '"\ _S&;(^;;3+3&W5<
ME\0+Z9I]EF>3?K?WA,5IDO06QZ(->[<K@ 4J!B9SZAYPO'V8K<MYZ0<*GCNC
M.RMC+*2!"\\VQN8SYB<6&UI+P,A::Z+K7(M%\V70G"B^LWOE)Z[TSML>;O77
M%!$F0-]?<Z[>3LSVN_L^F_\'4$L#!!0    ( )N37%0/2XQ#G0,  !<0   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;+5848_:.!#^*U;4AU;J;>(A
M!*@ J>QNU:VV=ZO2WJFJ^N!-!HB:Q)QMEJUT/_YL)\2L"EZ0FA<2.S/?S'QV
MOG@8;[GX(5>(BCR6124GP4JI]9LPE.D*2R8O^!HK_63!1<F4'HIE*-<"66:=
MRB*$*$K"DN55,!W;N3LQ'?.-*O(*[P21F[)DXN<,"[Z=!#3837S*ERME)L+I
M>,V6.$?U97TG]"AL4;*\Q$KFO"("%Y/@+7TS@Y%QL!9_Y[B5>_?$E'+/^0\S
MN,DF060RP@)392"8OCS@)1:%0=)Y_-N !FU,X[A_OT-_9XO7Q=PSB9>\^"?/
MU&H2# .2X8)M"O6);]]C4U#?X*6\D/:7;!O;*"#I1BI>-LXZ@S*OZBM[;(C8
M<P!ZQ $:![!YUX%LEE=,L>E8\"T1QEJCF1M;JO76R>65696Y$OIIKOW4]*9*
M>8GD,WM$2?X@\WIQ"%^0/_66^&N-@JF\6I);+J6V8%5F;,FEP"Q7Y)();:SI
MV3*12?+R"A7+"_F*O"!Y13ZO^$9J#SD.E4[5! S3)JU9G18<28L"^<@KM9+D
MNLHP>PH0ZAK;0F%7Z R\B%>87I >?4T@ OIE?D5>OGCE@>VU_/4L;'P$]AUF
MFJ+"@Q2W2+%%ZAU!>LIU3>UBQ^RW6VU-;A26\KLG5K^-U?=F;98PM4MX<&UJ
MY[YU-J_UPY3&T2@>AP\'8B9MS.04ILA_9*Z8L(4N!"_)!U9MS):S2T.'GNH&
M;:1!YTP.VUA#;U7F+>%MO,*^)8<HK5&2?4K[?>C1PYR.VNBC$SF=H:X0SR"3
M1DXAHL[II'MZ1'\+H0W,_B:%43Q,#A-*P<6'$RF]9J+(42HK>%^1"5]]3B]H
MKWLVG:;0^&PV7Y/KQW5NIO17\><O=37T^G$AZO5]"3HAHGXE<G3?,G4JV4YR
M:-(]V4YVZ* CLOVXFNR!+T&G5=0O5EIX%?J0G.[04>?$@E,@B'Z+)C0P3SY<
M0Q@E1[Y<X$0)_*+TS/<2?M6B.$I&1Z(Z*0*_%-GE.E.(P D1="]$X(0(.A*B
M9W"?$2)P0@0G'XE.2LN/IM-*?&DY!0/_J6FW!TY71W!Z!=V?D\")#YQ_4CIM
M!_AQ(8JI+T&G:> _3)V[ _QHQ](*]WJU$L72=J22I'Q3J;IM:V?;KO=MW>LY
M\[IE_LC$,J\D*7"A7:.+@=Z3HNY"ZX'B:]OYW7.E^TA[N]*=.PICH)\O.%>[
M@0G0_A<P_1]02P,$%     @ FY-<5-U$3J2R @  UP8  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C4N>&ULG57);MLP$/V5@9!# K21M5A98!OPTJ(Y! CB
M)#T4/=#2V"(BD2Y)V<G?=TC)JN.M12\6.9IY\V;Q4V\MU:O.$0V\E870?2\W
M9GGK^SK-L63Z4BY1T)NY5"4S=%4+7R\5LLP%E84?=CJ)7S(NO$'/V1[4H"<K
M4W"!#PIT599,O8^PD.N^%W@;PR-?Y,8:_$%OR18X1?.\?%!T\UN4C)<H-)<"
M%,[[WC"X'2?6WSF\<%SKK3/82F92OMK+7=;W.I80%I@:B\#HL<(Q%H4%(AJ_
M&DRO36D#M\\;]*^N=JIEQC2.9?&=9R;O>]<>9#AG56$>Y?H;-O5T+5XJ"^U^
M8=WX=CQ(*VUDV003@Y*+^LG>FCYL!03)D8"P"0AW ^(C 5$3$+E":V:NK DS
M;-!3<@W*>A.:/;C>N&BJA@L[Q:E1])93G!G<B526"$_L#35\AFD]3)!S&.=,
M+,C(!;RPHF*NZ\."QLY$BD +!!.<HU*8V7 8:HU&P_D$#>.%OB"TY^D$SL\N
MX,R"/.6RTDQDNN<;(F[3^VE#<E23#(^0#$*XE\+D&KZ(#+./ #Y5W)8=;LH>
MA2<1)YA>0A1\@K 3!@<(C?\]O'."3M1.(7)XT1&\0PW^,9QIHVC-?YY($+<)
M8I<@_FL"UB9@!DR.,,,%%X*+A1VZ-;PC4X=F5&?HN@Q6'%:#J!O'U+W5=N/V
MO<+@)KQIO3[0[[;TNR?ITY:21&G:1H6I5+0#8"0ME=M=0\NW5'+%K;(<(EYC
M)]O$PS".=HCO>P51-P@/$T]:XLG_]AU%]K>.)WN]3*Z2ZWB'^+[7Q[G4Q/TM
MC2A1+9QT:DAE)4S]OVFMK3H/G2CMV$>DVK7(_H&I)?^>*5HE#07.";)S>46<
M5"VC]<7(I5.BF32D:^Z8TY<'E76@]W,IS>9B$[3?LL%O4$L#!!0    ( )N3
M7%0(J1\P"P,  ( (   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;(U6
MVV[B,!#]%2OJ0RNUS8U+6P$2EZZV*U5"I=U]6.V#209B-;&SMBETOW['3DB!
M$,0+V.,YXW,\]DQZ:R'?50*@R29+N>H[B=;Y@^NJ*(&,JEN1 \>5A9 9U3B5
M2U?E$FAL05GJ!I[7<3/*N#/H6=M4#GIBI5/&82J)6F49E9\C2,6Z[_C.UO#"
MEHDV!G?0R^D29J#?\JG$F5M%B5D&7#'!B81%WQGZ#Y.N\;<./QFLU<Z8&"5S
M(=[-Y"GN.YXA!"E$VD2@^/<!8TA3$PAI_"UC.M66!K@[WD;_9K6CECE5,!;I
M+Q;KI._<.22&!5VE^D6LOT.IIVWB12)5]I>L2U_/(=%*:9&58&20,5[\TTUY
M#CL O], "$I < AH-0#"$A">"VB5@)8]F4**/8<)U730DV)-I/'&:&9@#].B
M43[C)NTS+7&5(4X/GG@D,B"O= .*W)!9D7TB%N0%(L$CEC)J$X26-R[1MN3L
M'\0&04; 8<&T(I<3T)2EZ@I#O,TFY/+BBEP0QLEK(E:*\ECU7(ULS9YN5#(;
M%<R"!F9^0)X%UXDBCSR&>#^ BS(KK<%6ZR@X&7$"T2T)_6L2>(%_A-#X?+AW
M!#XY&^[?GU 35ID+;;RP(5YC-J[)5U+)%#A--</D8A9P08,$I<GC!NN& O)[
M.%=:XN/[<X)1JV+4LHQ:#8Q^4+XRE^?8V8X*:-M"32WZ&&!EZO;<C]T$U)W\
ML-W>=YK4G>YV?/:8MROF[9/,AW',S"U7MH;$!.^[QL/+A2K-$E*J<4$+?)12
M M?D$Z@\)K38J;.KP;OS#X36G=I^>*#SB$_7.ZZS4^GLG*GS4D*\LJ47'RUV
MCP.]^-ISR=#<I+)3(]?R#[-9]_'#^P.1=9^;)I'=2F3WI$A\:)#-0>)C.\:\
M6[L^8=L[N&/CNE/]MD[J3GNWM2#O[M3F#.32]CA%(K'BNBA=E;5JHT/;/0[L
M(VRO13?\"E/TYF<JEPR3EL("0WJW7:0DBWY73+3(;0>8"XW]Q X3_$0 :1QP
M?2&$WD[,!M5'Q^ _4$L#!!0    ( )N37%2;%5D>&@(  *@$   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;)U438_3,!#]*U9.($'ST6Y!JS12/T#L
M8:5J5\ !<7#C:6*M/X+MD-U_S]A.0Y&V/7!)//;,>V\FSRD';9YL"^#(LQ3*
MKI+6N>XV36W=@J1VICM0>'+41E*'H6E2VQF@+!1)D199MDPEY2JIRK"W-U6I
M>R>X@KTAMI>2FI<-"#VLDCPY;3SPIG5^(ZW*CC;P".YKMS<8I1,*XQ*4Y5H1
M \=5LLYO-PN?'Q*^<1CLV9KX3@Y:/_G@CJV2S L" ;7S"!1?OV$+0G@@E/%K
MQ$PF2E]XOCZA?PZ]8R\':F&KQ7?.7+M*/B:$P9'VPCWHX0N,_=QXO%H+&YYD
MB+G+FX34O75:CL6H0'(5W_1YG,-90;Z\4%",!470'8F"RAUUM"J-'HCQV8CF
M%Z'54(WBN/(?Y=$9/.58YZJMEI([G+*SA"I&MEHYKAI0-0=+WI,U8]R/CPIR
MIZ('_##?[,!1+NS;,G6HPF.E]<BXB8S%!<:\(/=(TEKR23%@_P*D*'_JH3CU
ML"FN(NZ@GI%Y_HX469%?P9M/,YD'O/E_S63';2VT[0V0'^N#=0:-]?,*ZV)B
M7036Q456%;!Z'#4UAB)AE%!35:-KX^ [,%RSUZ9^'7V>$49?[&LZTS/W2#!-
MN"-(JWOEHI&FW>D:KJ/[_J;'.WQ/3<.5)0*.6)K-/J#K3;P7,7"Z"UX\:(?.
M#LL6?R5@? *>'[5VI\ 33#^GZ@]02P,$%     @ FY-<5&$:%J<*!   QP\
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MRP8_3J"L =XOI#3;C770?^Y&?P%02P,$%     @ FY-<5$65K%:K P  60T
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M;^*AE&UI)<R-W/_%FH!&EB^10KO_:-_8!AY**FUDWH#!@YP7]2^];Q)Q!(!
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M],ENF,'=AREK ,^W$CK39F(W:&]3B_\!4$L#!!0    ( )N37%0"T1XPT0,
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M619&  LK2!(,@;<11S %H %#DL3N@WO[4;S>I^+-?_M&OP%02P,$%     @
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M2P$"% ,4    " ";DUQ4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )N37%1M<IN/[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M )N37%297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ FY-<5+H:OQ#/!@  =!H  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M )N37%3KEFW2)P(  'H%   8              " @1(/  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " ";DUQ4AJ:"3G<%  !4%0  &
M            @(%O$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ FY-<5 OL=!QR @  PP8  !@              ("!'!<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( )N37%26:ZK93P4  "<5
M   8              " @<09  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " ";DUQ4OM#2A_X(  #N,@  &               @(%)'P
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ FY-<5&J\6<#P
M!P  \2,  !@              ("!?2@  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( )N37%0/H<694@<  '41   8              "
M@:,P  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " ";DUQ4
MLP/292(H  #L@0  &               @($K.   >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ FY-<5,["]V"N"0  \1L  !D
M     ("!@V   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )N37%3D7J]A3@,  )X'   9              "
M@3-\  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ FY-<
M5&#R.N/> P  ] @  !D              ("!N'\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " ";DUQ43 _AL3L#  "+!P  &0
M        @('-@P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( )N37%2]3P5%= 0  ) *   9              " @3^'  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ FY-<5%;BIC5@"P  6B(
M !D              ("!ZHL  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " ";DUQ4U>9&45\)  #+&   &0              @(&!EP
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( )N37%1 CI;R
M:04  .$,   9              " @1>A  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ FY-<5%85$ON>!@  \0\  !D
M ("!MZ8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " ";
MDUQ4A39-:C8#  "I!P  &0              @(&,K0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( )N37%03JQPZV (  #<&   9
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M970R."YX;6Q02P$"% ,4    " ";DUQ4+A=/MLH"  #^!0  &0
M    @(&4Z   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M )N37%2?E60NPP(   <&   9              " @97K  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ FY-<5&DX7](  P  @@<  !D
M             ("!C^X  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " ";DUQ41"J.0KT"    !@  &0              @('&\0  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( )N37%2IZ!N+L@4
M  $0   9              " @;KT  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ FY-<5%IA8DY%!@  'A$  !D              ("!
MH_H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " ";DUQ4
M.1IC_U@#  "\"   &0              @($? 0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( )N37%2:Q[$%E00  %X+   9
M      " @:X$ 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ FY-<5&WGU+OJ!   FQ,  !D              ("!>@D! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " ";DUQ42]?Q8K($  !!$
M&0              @(&;#@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( )N37%2)"7!?9P(  )$&   9              " @803 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ FY-<5#>4M-B_
M!   JQ0  !D              ("!(A8! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " ";DUQ4R OG2",#  #5"@  &0
M@($8&P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( )N3
M7%3LV^+2H (  .X'   9              " @7(> 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ FY-<5$"J66\R P  U0L  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( )N37%2E*9I,NP0  .L4   9
M  " @<LO 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MFY-<5$1W&FEB @  * 4  !D              ("!O30! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " ";DUQ4P?H;"<0"  #H!P  &0
M            @(%6-P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( )N37%29Z'LI$@(  ( $   9              " @5$Z 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ FY-<5%67LE:: @
MY08  !D              ("!FCP! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " ";DUQ4Z<5O7_$"  !_"0  &0              @(%K
M/P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( )N37%2^
MF:=A'@8  -$=   9              " @9-" 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ FY-<5"V1YN]I P  E@L  !D
M     ("!Z$@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )N37%3BHR"3"0,  ,@)   9              "
M@:E? 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ FY-<
M5"1@@)3] @  $@@  !D              ("!Z6(! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " ";DUQ42J5E<X(#  ",#   &0
M        @($=9@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( )N37%0'(2:AT@,  *L-   9              " @=9I 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ FY-<5 ]+C$.= P  %Q
M !D              ("!WVT! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " ";DUQ4W41.I+("  #7!@  &0              @(&S<0$
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( )N37%0(J1\P
M"P,  ( (   9              " @9QT 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ FY-<5)L561X: @  J 0  !D
M ("!WG<! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " ";
MDUQ481H6IPH$  #'#P  &0              @($O>@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( )N37%1*CD>3D0(  !P'   9
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M970W,RYX;6Q02P$"% ,4    " ";DUQ4196L5JL#  !9#0  &0
M    @('^C $ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M )N37%0"T1XPT0,  )$,   9              " @>"0 0!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ FY-<5%>I[Y@Z P  ^A,   T
M             ( !Z)0! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ";DUQ4
MEXJ[',     3 @  "P              @ %-F $ 7W)E;',O+G)E;'-02P$"
M% ,4    " ";DUQ4IJ('0LP%  "K,0  #P              @ $VF0$ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ FY-<5&?\4D), @  :"P  !H
M         ( !+Y\! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ FY-<5(:F8T@, @  82L  !,              ( !LZ$! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     %, 4P"\%@  \*,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>203</ContextCount>
  <ElementCount>445</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/Prepaidexpensesandothercurrentassets</Role>
      <ShortName>Prepaid expenses and other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilities</Role>
      <ShortName>Accrued Liabilities and Other Long-Term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Novartis Collaboration and License Agreement (the "Novartis Agreement")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreement</Role>
      <ShortName>Novartis Collaboration and License Agreement (the "Novartis Agreement")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Regents of the University of California License Agreement (the ???UC Agreement???)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement</Role>
      <ShortName>Regents of the University of California License Agreement (the ???UC Agreement???)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Adimab Development and Option Agreement (the "Adimab Agreement")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreement</Role>
      <ShortName>Adimab Development and Option Agreement (the "Adimab Agreement")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2132111 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2136112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2145113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2153114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2155115 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2161116 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2163117 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2165118 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/FinancialInstruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Prepaid expenses and other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsTables</Role>
      <ShortName>Prepaid expenses and other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/Prepaidexpensesandothercurrentassets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities and Other Long-Term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/CommonStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2346308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2356309 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2366310 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholders</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail</Role>
      <ShortName>Organization and Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Financial Instruments - Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails</Role>
      <ShortName>Financial Instruments - Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Financial Instruments - Summery of Remaining Contractual Maturities of Company's Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Summery of Remaining Contractual Maturities of Company's Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Property and Equipment, net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/PropertyandEquipmentnetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails</Role>
      <ShortName>Prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities and Other Long-Term Liabilities - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities and Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Novartis Collaboration and License Agreement (the "Novartis Agreement") - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails</Role>
      <ShortName>Novartis Collaboration and License Agreement (the "Novartis Agreement") - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreement</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Regents of the University of California License Agreement (the ???UC Agreement???) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails</Role>
      <ShortName>Regents of the University of California License Agreement (the ???UC Agreement???) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Adimab Development and Option Agreement (the "Adimab Agreement") - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails</Role>
      <ShortName>Adimab Development and Option Agreement (the "Adimab Agreement") - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreement</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Common Stock - Schedule of Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Stock-Based Compensation - Summary of Option Activity Under the 2015 Plan and 2020 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Option Activity Under the 2015 Plan and 2020 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Classification of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Income Taxes - Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company???s Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company???s Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Income Taxes - Summary of Net Operating Losses and Tax Credit Carry Forwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails</Role>
      <ShortName>Income Taxes - Summary of Net Operating Losses and Tax Credit Carry Forwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Leases - Schedule of Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails</Role>
      <ShortName>Leases - Schedule of Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Leases - Weighted-average Remaining Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails</Role>
      <ShortName>Leases - Weighted-average Remaining Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2460435 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2462436 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2464437 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/DefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="plrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2468439 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="plrx-20211231.htm">plrx-20211231.htm</File>
    <File>non-employeedirectorcompen.htm</File>
    <File>plrx-20211231.xsd</File>
    <File>plrx-20211231_cal.xml</File>
    <File>plrx-20211231_def.xml</File>
    <File>plrx-20211231_lab.xml</File>
    <File>plrx-20211231_pre.xml</File>
    <File>ye2021-ex312.htm</File>
    <File>ye2021-ex321.htm</File>
    <File>ye2021ex311.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plrx-20211231_g1.jpg</File>
    <File>plrx-20211231_g10.jpg</File>
    <File>plrx-20211231_g11.jpg</File>
    <File>plrx-20211231_g12.jpg</File>
    <File>plrx-20211231_g13.jpg</File>
    <File>plrx-20211231_g14.jpg</File>
    <File>plrx-20211231_g15.jpg</File>
    <File>plrx-20211231_g16.jpg</File>
    <File>plrx-20211231_g17.jpg</File>
    <File>plrx-20211231_g18.jpg</File>
    <File>plrx-20211231_g19.jpg</File>
    <File>plrx-20211231_g2.jpg</File>
    <File>plrx-20211231_g20.gif</File>
    <File>plrx-20211231_g21.jpg</File>
    <File>plrx-20211231_g22.jpg</File>
    <File>plrx-20211231_g23.jpg</File>
    <File>plrx-20211231_g24.gif</File>
    <File>plrx-20211231_g25.gif</File>
    <File>plrx-20211231_g26.jpg</File>
    <File>plrx-20211231_g27.jpg</File>
    <File>plrx-20211231_g3.jpg</File>
    <File>plrx-20211231_g4.jpg</File>
    <File>plrx-20211231_g5.jpg</File>
    <File>plrx-20211231_g6.jpg</File>
    <File>plrx-20211231_g7.jpg</File>
    <File>plrx-20211231_g8.jpg</File>
    <File>plrx-20211231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="749">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plrx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 30,
   "contextCount": 203,
   "dts": {
    "calculationLink": {
     "local": [
      "plrx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plrx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plrx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plrx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plrx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plrx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 564,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 7,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 11
   },
   "keyCustom": 52,
   "keyStandard": 393,
   "memberCustom": 29,
   "memberStandard": 33,
   "nsprefix": "plrx",
   "nsuri": "http://www.pliantrx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.pliantrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Financial Instruments",
     "role": "http://www.pliantrx.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Property and Equipment, net",
     "role": "http://www.pliantrx.com/role/PropertyandEquipmentnet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Prepaid expenses and other current assets",
     "role": "http://www.pliantrx.com/role/Prepaidexpensesandothercurrentassets",
     "shortName": "Prepaid expenses and other current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities",
     "role": "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilities",
     "shortName": "Accrued Liabilities and Other Long-Term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Novartis Collaboration and License Agreement (the \"Novartis Agreement\")",
     "role": "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreement",
     "shortName": "Novartis Collaboration and License Agreement (the \"Novartis Agreement\")",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Regents of the University of California License Agreement (the \u201cUC Agreement\u201d)",
     "role": "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement",
     "shortName": "Regents of the University of California License Agreement (the \u201cUC Agreement\u201d)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Adimab Development and Option Agreement (the \"Adimab Agreement\")",
     "role": "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreement",
     "shortName": "Adimab Development and Option Agreement (the \"Adimab Agreement\")",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:RedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:RedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132111 - Disclosure - Common Stock",
     "role": "http://www.pliantrx.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.pliantrx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.pliantrx.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145113 - Disclosure - Income Taxes",
     "role": "http://www.pliantrx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153114 - Disclosure - Commitments and Contingencies",
     "role": "http://www.pliantrx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155115 - Disclosure - Leases",
     "role": "http://www.pliantrx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161116 - Disclosure - Related Party Transactions",
     "role": "http://www.pliantrx.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163117 - Disclosure - Defined Contribution Plan",
     "role": "http://www.pliantrx.com/role/DefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165118 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.pliantrx.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.pliantrx.com/role/PropertyandEquipmentnetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Balance Sheets",
     "role": "http://www.pliantrx.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Prepaid expenses and other current assets (Tables)",
     "role": "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsTables",
     "shortName": "Prepaid expenses and other current assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities (Tables)",
     "role": "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesTables",
     "shortName": "Accrued Liabilities and Other Long-Term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Common Stock (Tables)",
     "role": "http://www.pliantrx.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.pliantrx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.pliantrx.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356309 - Disclosure - Leases (Tables)",
     "role": "http://www.pliantrx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2366310 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Description of Business - Additional Information (Detail)",
     "role": "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail",
     "shortName": "Organization and Description of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ibc7fc5b3ee324ff99cc7fc20d853fd6d_D20200601-20200630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "plrx:PercentageOfRevenueContributedByRelatedParty",
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "plrx:PercentageOfRevenueContributedByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "plrx:PercentageOfRevenueContributedByRelatedParty",
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "plrx:PercentageOfRevenueContributedByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i97ba5b3806e14f8cb378e134282cefff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)",
     "role": "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i97ba5b3806e14f8cb378e134282cefff_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.pliantrx.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Financial Instruments - Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category (Details)",
     "role": "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails",
     "shortName": "Financial Instruments - Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Financial Instruments - Summery of Remaining Contractual Maturities of Company's Short-term Investments (Details)",
     "role": "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails",
     "shortName": "Financial Instruments - Summery of Remaining Contractual Maturities of Company's Short-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i788f10f5c97047c98f3a91d33d462adc_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Financial Instruments - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)",
     "role": "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment, net - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Property and Equipment, net - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/PropertyandEquipmentnetAdditionalInformationDetails",
     "shortName": "Property and Equipment, net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "plrx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "plrx:PrepaidResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Prepaid expenses and other current assets (Details)",
     "role": "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails",
     "shortName": "Prepaid expenses and other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "plrx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "plrx:PrepaidResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "plrx:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities - Summary of Accrued Liabilities (Details)",
     "role": "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities and Other Long-Term Liabilities - Summary of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "plrx:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRentCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Accrued Liabilities and Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Details)",
     "role": "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails",
     "shortName": "Accrued Liabilities and Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRentCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4a11a4aeb6da425289c1166b59fd1bef_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "plrx:ProceedsFromUpfrontNonRefundableLicenseFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Novartis Collaboration and License Agreement (the \"Novartis Agreement\") - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
     "shortName": "Novartis Collaboration and License Agreement (the \"Novartis Agreement\") - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4a11a4aeb6da425289c1166b59fd1bef_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "plrx:ProceedsFromUpfrontNonRefundableLicenseFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ia97bea2e62e046a3b667360c66ca83de_D20200601-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "plrx:MilestoneAndAnnualRoyaltyPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Regents of the University of California License Agreement (the \u201cUC Agreement\u201d) - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails",
     "shortName": "Regents of the University of California License Agreement (the \u201cUC Agreement\u201d) - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ia97bea2e62e046a3b667360c66ca83de_D20200601-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "plrx:MilestoneAndAnnualRoyaltyPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Adimab Development and Option Agreement (the \"Adimab Agreement\") - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails",
     "shortName": "Adimab Development and Option Agreement (the \"Adimab Agreement\") - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i325f7f2d873247748a03caa8aa5d4255_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i854a3335aa6a4adc9776beabc85e03a9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i854a3335aa6a4adc9776beabc85e03a9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "plrx:NumberOfVotesPerShareOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Common Stock - Schedule of Shares Reserved for Future Issuance (Details)",
     "role": "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
     "shortName": "Common Stock - Schedule of Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i3ff87434abfc452d80645776f0f00c77_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i58ea8b06f17a484f9edfb9c294799d18_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "role": "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i58ea8b06f17a484f9edfb9c294799d18_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards (Details)",
     "role": "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails",
     "shortName": "Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ic49b523a91e6437ab4bdf316bcf56804_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "iaee36529cae34a1880d776adf134e69e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Stock-Based Compensation - Summary of Option Activity Under the 2015 Plan and 2020 Plan (Details)",
     "role": "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails",
     "shortName": "Stock-Based Compensation - Summary of Option Activity Under the 2015 Plan and 2020 Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ia3599cf33ab2482cac54b36a9c90a320_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "plrx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ie08b0d8bbc764ddfa7bbdedd05be39a6_I20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan (Details)",
     "role": "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
     "shortName": "Stock-Based Compensation - 2020 Employee Stock Purchase Plan - Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i48a3f13c0e0b47c5b1109071dc570c01_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ie5401e3f0f3d449e8847afa47baa6f9a_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ie5401e3f0f3d449e8847afa47baa6f9a_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock-based Compensation Expense (Details)",
     "role": "http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Classification of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i28a1619e7cc641e895b0a776ffb7951c_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Income Taxes - Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company\u2019s Effective Income Tax Rate (Details)",
     "role": "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company\u2019s Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "plrx:ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "iddb8c639eb9a45ed83884b3db05c0ffd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Income Taxes - Summary of Net Operating Losses and Tax Credit Carry Forwards (Details)",
     "role": "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails",
     "shortName": "Income Taxes - Summary of Net Operating Losses and Tax Credit Carry Forwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "plrx:ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "iddb8c639eb9a45ed83884b3db05c0ffd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i19974a4386bd4627a7211a58dab7ab17_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Details)",
     "role": "http://www.pliantrx.com/role/IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Changes in Valuation Allowance for Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i19974a4386bd4627a7211a58dab7ab17_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "idcb6e46e8589417fbb6dce85ec4707e9_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:ContractualArrangementsCancellationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:ContractualArrangementsCancellationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ib125d2281fd7483b97614c1e8f176399_D20180201-20180228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:PeriodOfBaseRentAbatement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Leases - Additional information (Details)",
     "role": "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "ib125d2281fd7483b97614c1e8f176399_D20180201-20180228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plrx:PeriodOfBaseRentAbatement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Leases - Schedule of Operating Lease Liability (Details)",
     "role": "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails",
     "shortName": "Leases - Schedule of Operating Lease Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Statements of Cash Flows",
     "role": "http://www.pliantrx.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "plrx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Leases - Weighted-average Remaining Lease Terms and Discount Rates (Details)",
     "role": "http://www.pliantrx.com/role/LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails",
     "shortName": "Leases - Weighted-average Remaining Lease Terms and Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "plrx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i4c2aeb24bd264584a324aec3746051a6_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i54765707cbc04888952c42feb9bd45de_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460435 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i54765707cbc04888952c42feb9bd45de_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462436 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "i2b63e0038cb9443181dc8069c7bec11a_D20210601-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464437 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "role": "http://www.pliantrx.com/role/DefinedContributionPlanAdditionalInformationDetails",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468439 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockDividendsAndOtherAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of Business",
     "role": "http://www.pliantrx.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.pliantrx.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plrx-20211231.htm",
      "contextRef": "id1a9faa1e91a4fc29f7395bcd1f67cac_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pliantrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plrx_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plrx_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plrx_AccretionOfShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of short-term investments.",
        "label": "Accretion Of Short Term Investments",
        "negatedLabel": "Accretion on short-term investments"
       }
      }
     },
     "localname": "AccretionOfShortTermInvestments",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion to redemption value and cumulative dividend on redeemable convertible preferred stock.",
        "label": "Accretion To Redemption Value And Cumulative Dividend On Redeemable Convertible Preferred Stock",
        "negatedLabel": "Accretion to redemption value and cumulative dividends on redeemable convertible stock"
       }
      }
     },
     "localname": "AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion to redemption value and dividends on redeemable convertible preferred stock.",
        "label": "Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock",
        "negatedLabel": "Accretion to redemption value and dividends on redeemable convertible preferred stock",
        "terseLabel": "Accretion to redemption value and dividends on redeemable convertible preferred stock"
       }
      }
     },
     "localname": "AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_AccruedExpensesAndOtherLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other liabilities.",
        "label": "Accrued Expenses And Other Liabilities [Member]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherLiabilitiesMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses, current",
        "label": "Accrued Research And Development Expenses, Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_AchievementOfFirstPatientDosingMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of first patient dosing milestone.",
        "label": "Achievement Of First Patient Dosing Milestone [Member]",
        "terseLabel": "Achievement of First Patient Dosing Milestone"
       }
      }
     },
     "localname": "AchievementOfFirstPatientDosingMilestoneMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_AdimabAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adimab agreement.",
        "label": "Adimab Agreement [Member]",
        "terseLabel": "Adimab Agreement"
       }
      }
     },
     "localname": "AdimabAgreementMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Weighted-average Remaining Lease Terms and Discount Rates"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.pliantrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "plrx_BaseRentAbatedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base rent abated amount.",
        "label": "Base Rent Abated Amount",
        "terseLabel": "Base rent abated amount"
       }
      }
     },
     "localname": "BaseRentAbatedAmount",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_BeforeJanuary12018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Before January 1,2018.",
        "label": "Before January12018 [Member]",
        "terseLabel": "Before January 1, 2018"
       }
      }
     },
     "localname": "BeforeJanuary12018Member",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement integrin research targets amount.",
        "label": "Collaboration And License Agreement Integrin Research Targets Amount",
        "terseLabel": "Collaboration and license agreement, integrin research targets amount"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementIntegrinResearchTargetsAmount",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_CommonStockFairMarketValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock fair market value percentage .",
        "label": "Common Stock Fair Market Value Percentage",
        "terseLabel": "Common stock fair market value percentage"
       }
      }
     },
     "localname": "CommonStockFairMarketValuePercentage",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plrx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_ContractualArrangementsCancellationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangements cancellation period.",
        "label": "Contractual Arrangements Cancellation Period",
        "terseLabel": "Contractual arrangements cancellation period"
       }
      }
     },
     "localname": "ContractualArrangementsCancellationPeriod",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plrx_DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument remaining maturity period at date of purchase.",
        "label": "Debt Instrument Remaining Maturity Period At Date Of Purchase",
        "terseLabel": "Debt instrument remaining maturity period at date of purchase"
       }
      }
     },
     "localname": "DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plrx_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs in accounts payable and accrued liabilities.",
        "label": "Deferred Offering Costs In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Deferred offering costs in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_DeferredRentAndLeaseholdIncentiveObligationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred rent and leasehold incentive obligation-current.",
        "label": "Deferred Rent And Leasehold Incentive Obligation Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentAndLeaseholdIncentiveObligationCurrent",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_DeferredTaxLiabilitiesFixedAssetBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Fixed Asset Basis",
        "label": "Deferred Tax Liabilities, Fixed Asset Basis",
        "negatedLabel": "Fixed asset basis"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssetBasis",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right Of Use Asset",
        "label": "Deferred Tax Liabilities, Right Of Use Asset",
        "negatedTerseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation general business tax credits federal.",
        "label": "Effective Income Tax Rate Reconciliation General Business Tax Credits Federal",
        "terseLabel": "General business credit\u2014federal"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plrx_EmployeeStockPurchasePlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan offering period.",
        "label": "Employee Stock Purchase Plan Offering Period",
        "terseLabel": "Employee stock purchase plan offering period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanOfferingPeriod",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plrx_FullTimeEmployeeCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Full-time employee cost.",
        "label": "Full Time Employee Cost [Member]",
        "terseLabel": "FTE costs"
       }
      }
     },
     "localname": "FullTimeEmployeeCostMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_IncentiveStockOptionsAndNonqualifiedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options and nonqualified stock options.",
        "label": "Incentive Stock Options And Nonqualified Stock Options [Member]",
        "terseLabel": "Incentive Stock Options and Nonqualified Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsAndNonqualifiedStockOptionsMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_IncomeTaxExaminationNumberOfExaminationsPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax examination, number pending.",
        "label": "Income Tax Examination Number Of Examinations Pending",
        "terseLabel": "Number of income tax examinations pending"
       }
      }
     },
     "localname": "IncomeTaxExaminationNumberOfExaminationsPending",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plrx_InterestAndOtherIncomeNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest And Other Income, Net",
        "label": "Interest And Other Income, Net",
        "terseLabel": "Interest and other income (expense), net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeNet",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_LeaseTermExtensionNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease term extension notice period.",
        "label": "Lease Term Extension Notice Period",
        "terseLabel": "Lease term extension notice period"
       }
      }
     },
     "localname": "LeaseTermExtensionNoticePeriod",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plrx_LeasedSpaceUnderNonCancellableOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased space under non cancellable operating lease.",
        "label": "Leased Space Under Non Cancellable Operating Lease",
        "terseLabel": "Leased premises under non cancelable operating lease"
       }
      }
     },
     "localname": "LeasedSpaceUnderNonCancellableOperatingLease",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "plrx_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Abstract]",
        "terseLabel": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://www.pliantrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "plrx_LicenseAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Line Items]",
        "terseLabel": "License Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAgreementsLineItems",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plrx_LicenseAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Table]",
        "terseLabel": "License Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAgreementsTable",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plrx_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of license agreements.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "Regents of the University of California License Agreement (the \u201cUC Agreement\u201d)"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_LicenseFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fee.",
        "label": "License Fee [Member]",
        "terseLabel": "License Fee"
       }
      }
     },
     "localname": "LicenseFeeMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_MatureInOneToTwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mature in one to two years.",
        "label": "Mature In One To Two Years [Member]",
        "terseLabel": "Mature in 1 to 2 years"
       }
      }
     },
     "localname": "MatureInOneToTwoYearsMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_MatureInOneYearOrLessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mature in one year or less.",
        "label": "Mature In One Year Or Less [Member]",
        "terseLabel": "Mature in 1 year or less"
       }
      }
     },
     "localname": "MatureInOneYearOrLessMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_MilestoneAndAnnualRoyaltyPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone and annual royalty paid.",
        "label": "Milestone And Annual Royalty Paid",
        "terseLabel": "Milestone and annual royalty paid"
       }
      }
     },
     "localname": "MilestoneAndAnnualRoyaltyPaid",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_NonemployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonemployee Director.",
        "label": "Nonemployee Director [Member]",
        "terseLabel": "Non-employee Director"
       }
      }
     },
     "localname": "NonemployeeDirectorMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_NovartisAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis agreement.",
        "label": "Novartis Agreement [Member]",
        "terseLabel": "Novartis Agreement"
       }
      }
     },
     "localname": "NovartisAgreementMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_NovartisAgreementRDForIntegrinResearchTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Agreement RD For Integrin Research Targets",
        "label": "Novartis Agreement RD For Integrin Research Targets [Member]",
        "terseLabel": "Novartis Agreement RD For Integrin Research Targets"
       }
      }
     },
     "localname": "NovartisAgreementRDForIntegrinResearchTargetsMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_NovartisAgreementRDForPLN1474Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Agreement RD For PLN-1474",
        "label": "Novartis Agreement RD For PLN-1474 [Member]",
        "terseLabel": "Novartis Agreement RD For PLN-1474"
       }
      }
     },
     "localname": "NovartisAgreementRDForPLN1474Member",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_NumberOfIntegrinResearchTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Integrin research targets.",
        "label": "Number Of Integrin Research Targets",
        "terseLabel": "Number of Integrin research targets"
       }
      }
     },
     "localname": "NumberOfIntegrinResearchTargets",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plrx_NumberOfVotesPerShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Votes Per Share Of Common Stock",
        "label": "Number Of Votes Per Share Of Common Stock",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "NumberOfVotesPerShareOfCommonStock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plrx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year that operating loss carryforwards expire.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating losses, Expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "plrx_OtherLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other losses.",
        "label": "Other Losses",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLosses",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_PercentageOfRevenueContributedByRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue contributed by related party.",
        "label": "Percentage Of Revenue Contributed By Related Party",
        "terseLabel": "Percentage of revenue contributed by related party"
       }
      }
     },
     "localname": "PercentageOfRevenueContributedByRelatedParty",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plrx_PeriodOfBaseRentAbatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Of Base Rent Abatement",
        "label": "Period Of Base Rent Abatement",
        "terseLabel": "Period of base rent abatement"
       }
      }
     },
     "localname": "PeriodOfBaseRentAbatement",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plrx_PliantTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pliant Therapeutics, Inc.",
        "label": "Pliant Therapeutics Inc [Member]",
        "terseLabel": "Pliant Therapeutics, Inc."
       }
      }
     },
     "localname": "PliantTherapeuticsIncMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses And Other Current Assets",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/Prepaidexpensesandothercurrentassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_PrepaidLicensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Licenses, Current",
        "label": "Prepaid Licenses, Current",
        "terseLabel": "Prepaid licenses"
       }
      }
     },
     "localname": "PrepaidLicensesCurrent",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_PrepaidResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development, Current",
        "label": "Prepaid Research And Development, Current",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCurrent",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_ProceedsFromUpfrontNonRefundableLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from upfront non-refundable license fee.",
        "label": "Proceeds From Upfront Non Refundable License Fee",
        "terseLabel": "Proceeds from upfront non-refundable license fee"
       }
      }
     },
     "localname": "ProceedsFromUpfrontNonRefundableLicenseFee",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of property plant and equipment useful lives.",
        "label": "Property Plant And Equipment Useful Lives Table [Table Text Block]",
        "terseLabel": "Summary of Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLivesTableTableTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of restricted stock awards from liabilities to common stock upon vesting.",
        "label": "Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting",
        "terseLabel": "Reclassification of restricted stock awards from liabilities to common stock upon vesting"
       }
      }
     },
     "localname": "ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock policy.",
        "label": "Redeemable Convertible Preferred Stock Policy Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockPolicyPolicyPolicyTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_RedeemableConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_RestrictedCommonStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted common stock awards.",
        "label": "Restricted Common Stock Awards [Member]",
        "terseLabel": "Restricted Common Stock Awards"
       }
      }
     },
     "localname": "RestrictedCommonStockAwardsMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_RestrictedStockAwardsGrantedAndNotPurchasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards granted and not purchased.",
        "label": "Restricted Stock Awards Granted And Not Purchased [Member]",
        "terseLabel": "Restricted stock awards granted and not purchased"
       }
      }
     },
     "localname": "RestrictedStockAwardsGrantedAndNotPurchasedMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_RestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards.",
        "label": "Restricted Stock Awards [Member]",
        "terseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockAwardsMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Table Text Block]",
        "terseLabel": "Schedule of Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net operating losses and tax credit carryforwards.",
        "label": "Schedule Of Net Operating Losses And Tax Credit Carryforwards Table [Table Text Block]",
        "terseLabel": "Summary of Net Operating Losses and Tax Credit Carryforwards"
       }
      }
     },
     "localname": "ScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsTableTableTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plrx_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C redeemable convertible preferred stock.",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series C"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were repurchased during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchases In Period",
        "negatedLabel": "Number of Shares, Repurchases (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesInPeriod",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options repurchases weighted average grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchases Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date fair value, Repurchases (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasesWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award exercise price with purchase price of common stock percentage of estimated grant date fair value for shareholders.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Exercise Price With Purchase Price Of Common Stock Percentage Of Estimated Grant Date Fair Value For Shareholders",
        "terseLabel": "Exercise price as a percentage of estimated grant date fair value of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceWithPurchasePriceOfCommonStockPercentageOfEstimatedGrantDateFairValueForShareholders",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options grants in period fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value",
        "terseLabel": "Grant date fair value of stock option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation options under plan may be granted for periods.",
        "label": "Share Based Compensation Options Under Plan May Be Granted For Periods",
        "terseLabel": "Options under plan may be granted for periods"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionsUnderPlanMayBeGrantedForPeriods",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plrx_StartingFromJanuary12018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Starting from January 1, 2018.",
        "label": "Starting From January12018 [Member]",
        "terseLabel": "Starting from January 1, 2018"
       }
      }
     },
     "localname": "StartingFromJanuary12018Member",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_TaxCreditCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforwards Expiration Year",
        "terseLabel": "Tax credits Expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationYear",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "plrx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of Series A, B, C convertible preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "plrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series C redeemable preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "plrx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period value conversion of convertible securities",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of Series A, B, C convertible preferred stock to common stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_ThirdRockVenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Rock Ventures.",
        "label": "Third Rock Ventures [Member]",
        "terseLabel": "Third Rock Ventures"
       }
      }
     },
     "localname": "ThirdRockVenturesMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_TwoThousandAndTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty employee stock purchase plan.",
        "label": "Two Thousand And Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "Shares of common stock available for future issuance under the 2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen and two thousand twenty equity incentive plan .",
        "label": "Two Thousand Fifteen And Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2015 Equity and 2020 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenAndTwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_UCRegentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UC Regents.",
        "label": "U C Regents [Member]",
        "terseLabel": "UC Regents"
       }
      }
     },
     "localname": "UCRegentsMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_UnderlyingCommonStockFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underlying common stock fair value.",
        "label": "Underlying Common Stock Fair Value",
        "terseLabel": "Underlying common stock fair value"
       }
      }
     },
     "localname": "UnderlyingCommonStockFairValue",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "plrx_UnderwritersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters.",
        "label": "Underwriters [Member]",
        "terseLabel": "Underwriters"
       }
      }
     },
     "localname": "UnderwritersMember",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "plrx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions (reductions) for tax positions of prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plrx_ValuationAllowanceAsPercentageOnDeferredTaxAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance as percentage on deferred tax assets.",
        "label": "Valuation Allowance As Percentage On Deferred Tax Assets",
        "terseLabel": "Valuation allowance as a percentage on total deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceAsPercentageOnDeferredTaxAssets",
     "nsuri": "http://www.pliantrx.com/20211231",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r57",
      "r59",
      "r107",
      "r108",
      "r240",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r239",
      "r252",
      "r308",
      "r309",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r547",
      "r550",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r239",
      "r252",
      "r308",
      "r309",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r547",
      "r550",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r179",
      "r291",
      "r293",
      "r498",
      "r546",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r179",
      "r291",
      "r293",
      "r498",
      "r546",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r239",
      "r252",
      "r296",
      "r308",
      "r309",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r547",
      "r550",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r239",
      "r252",
      "r296",
      "r308",
      "r309",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r547",
      "r550",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r58",
      "r59",
      "r107",
      "r108",
      "r240",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r291",
      "r294",
      "r549",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r291",
      "r294",
      "r549",
      "r580",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r183",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities and Other Long-Term Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r485"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r29",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r28",
      "r105",
      "r477",
      "r480",
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Receivable from related party transactions"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails",
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r214"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r62",
      "r63",
      "r64",
      "r535",
      "r558",
      "r562"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r61",
      "r64",
      "r72",
      "r73",
      "r74",
      "r110",
      "r111",
      "r112",
      "r407",
      "r553",
      "r554",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r348",
      "r349",
      "r350",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r114",
      "r115",
      "r116",
      "r117",
      "r127",
      "r187",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r225",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r384",
      "r385",
      "r386",
      "r387",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r473",
      "r499",
      "r500",
      "r501",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "auth_ref": [
      "r247",
      "r267",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "terseLabel": "Reclassification of convertible preferred stock into additional paid in capital upon initial public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r310",
      "r312",
      "r354",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r312",
      "r340",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "netLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r162",
      "r171",
      "r177",
      "r196",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r402",
      "r408",
      "r435",
      "r483",
      "r485",
      "r514",
      "r533"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r12",
      "r14",
      "r56",
      "r102",
      "r196",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r402",
      "r408",
      "r435",
      "r483",
      "r485"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain": {
     "auth_ref": [
      "r106",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.",
        "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]",
        "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis": {
     "auth_ref": [
      "r106",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.",
        "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]",
        "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r190",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Adjusted Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails",
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r189",
      "r191",
      "r203",
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails",
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r314",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r109",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r38",
      "r92"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r92",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r444"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r100",
      "r102",
      "r131",
      "r132",
      "r133",
      "r136",
      "r138",
      "r147",
      "r148",
      "r149",
      "r196",
      "r226",
      "r231",
      "r232",
      "r233",
      "r237",
      "r238",
      "r250",
      "r251",
      "r255",
      "r259",
      "r435",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r396",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Novartis Collaboration and License Agreement (the \"Novartis Agreement\")"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r223",
      "r522",
      "r540"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Dividends paid"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheetsParenthetical",
      "http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheetsParenthetical",
      "http://www.pliantrx.com/role/CommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheetsParenthetical",
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheetsParenthetical",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2021 and 2020; and 36,083,301 and 35,552,795 shares issued and outstanding at December 31, 2021 and 2020, respectively;"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r76",
      "r524",
      "r543"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r152",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties Policy"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r278",
      "r280",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r278",
      "r279",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r25",
      "r26",
      "r262",
      "r268",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock converted into common shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r297",
      "r305",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities included in cash and cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails",
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r22",
      "r23",
      "r372",
      "r515",
      "r531"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r451",
      "r471"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r20",
      "r452",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent and lease incentives"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "periodEndLabel": "Valuation allowance at the end of the year",
        "periodStartLabel": "Valuation allowance at the beginning of the year",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails",
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Payment made under defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/DefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanPlanNameExtensibleList": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates name of defined contribution plan designed to provide retirement benefits. Includes, but is not limited to, legal name of plan.",
        "label": "Defined Contribution Plan, Plan Name [Extensible Enumeration]",
        "terseLabel": "Defined Contribution Plan, Plan Name [Extensible List]"
       }
      }
     },
     "localname": "DefinedContributionPlanPlanNameExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/DefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/DefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r90",
      "r212"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share, attributable to common stockholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r77",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r128",
      "r131",
      "r136",
      "r137",
      "r138",
      "r143",
      "r144",
      "r423",
      "r424",
      "r525",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r77",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r131",
      "r136",
      "r137",
      "r138",
      "r143",
      "r144",
      "r423",
      "r424",
      "r525",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r104",
      "r363",
      "r390"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r363",
      "r390"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r363",
      "r390"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r363",
      "r390"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther": {
     "auth_ref": [
      "r363",
      "r390"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Other, Percent",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUSFederalStatutoryIncomeTaxRatetoCompanysEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock option awards",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r72",
      "r73",
      "r74",
      "r110",
      "r111",
      "r112",
      "r115",
      "r124",
      "r126",
      "r146",
      "r200",
      "r267",
      "r275",
      "r348",
      "r349",
      "r350",
      "r386",
      "r387",
      "r422",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r553",
      "r554",
      "r555",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Transfers of assets between Level 1 and Level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r425",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r426",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r425",
      "r426",
      "r428",
      "r429",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r241",
      "r297",
      "r298",
      "r303",
      "r305",
      "r426",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r297",
      "r298",
      "r303",
      "r305",
      "r426",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value Measurements, Non-recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities measured at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r90",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncentiveFromLessor": {
     "auth_ref": [
      "r451",
      "r453",
      "r454",
      "r455"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive received by lessee from lessor.",
        "label": "Incentive from Lessor",
        "terseLabel": "Leasehold incentive obligation"
       }
      }
     },
     "localname": "IncentiveFromLessor",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r103",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Pre-tax U.S. book loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r216",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r364",
      "r370",
      "r377",
      "r388",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r361",
      "r362",
      "r370",
      "r371",
      "r376",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r54",
      "r521",
      "r541"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Tax credit receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred rent and other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Tax credit receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r89",
      "r465"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r195",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails",
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails",
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summery of Remaining Contractual Maturities of Company\u2019s Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating leases, rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails",
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases and Rent Expense"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Operating Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term extension period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.",
        "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r102",
      "r172",
      "r196",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r403",
      "r408",
      "r409",
      "r435",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r102",
      "r196",
      "r435",
      "r485",
      "r517",
      "r537"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r102",
      "r196",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r403",
      "r408",
      "r409",
      "r435",
      "r483",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RegentsoftheUniversityofCaliforniaLicenseAgreementtheUCAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Percentage of noncontrolling ownership"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r65",
      "r68",
      "r74",
      "r75",
      "r91",
      "r102",
      "r114",
      "r119",
      "r120",
      "r121",
      "r122",
      "r125",
      "r126",
      "r134",
      "r162",
      "r170",
      "r173",
      "r176",
      "r178",
      "r196",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r424",
      "r435",
      "r523",
      "r542"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r129",
      "r135",
      "r138",
      "r162",
      "r170",
      "r173",
      "r176",
      "r178"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r127",
      "r143",
      "r187",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r225",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r384",
      "r385",
      "r386",
      "r387",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r473",
      "r499",
      "r500",
      "r501",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r162",
      "r170",
      "r173",
      "r176",
      "r178"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r463",
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases, After Adoption of 842:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesScheduleofOperatingLeaseLiabilityDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r459",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r467",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r466",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesWeightedaverageRemainingLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r66",
      "r69",
      "r400",
      "r401",
      "r406"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized loss on short-term investments",
        "verboseLabel": "Net unrealized loss on short-term investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails",
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Non-current Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Summary of Other Long-Term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r9",
      "r13",
      "r206"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21",
      "r516",
      "r534"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other liabilities \u2014 deposits"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesSummaryofOtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r314",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r129",
      "r139"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedTerseLabel": "Less: accretion to redemption value and dividends on redeemable convertible preferred shares"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r12",
      "r36",
      "r37"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Total prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets",
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r10",
      "r13",
      "r204",
      "r206"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInterest": {
     "auth_ref": [
      "r11",
      "r13",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Interest",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "PrepaidInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock upon initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of Series C preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of common stock upon completion of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r81",
      "r83"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments",
        "terseLabel": "Maturity of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r84",
      "r343"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r65",
      "r68",
      "r74",
      "r86",
      "r102",
      "r114",
      "r125",
      "r126",
      "r162",
      "r170",
      "r173",
      "r176",
      "r178",
      "r196",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r400",
      "r404",
      "r405",
      "r410",
      "r411",
      "r424",
      "r435",
      "r527"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r41",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r218",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r40",
      "r213"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r215",
      "r485",
      "r529",
      "r539"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets",
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r215",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "verboseLabel": "Redeemable convertible preferred stock (on an as-converted basis)"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r304",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r476",
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Transaction price of Novartis agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r304",
      "r476",
      "r477",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Consulting service expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r304",
      "r476",
      "r480",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r474",
      "r475",
      "r477",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the arrangement under which research and development costs acquired in other than a business combination were capitalized.",
        "label": "Research and Development Asset, Transaction [Domain]",
        "terseLabel": "Research and Development Asset, Transaction"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required disclosures pertaining to capitalized costs of research and development arrangements acquired in other than a business combination, by arrangement.",
        "label": "Research and Development Assets Acquired Other than Through Business Combination by Transaction [Axis]",
        "terseLabel": "Research and Development Assets Acquired Other than Through Business Combination by Transaction"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r357",
      "r497",
      "r596"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Adimab Development and Option Agreement (the \"Adimab Agreement\")"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted shares"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r275",
      "r351",
      "r485",
      "r536",
      "r557",
      "r562"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r110",
      "r111",
      "r112",
      "r115",
      "r124",
      "r126",
      "r200",
      "r348",
      "r349",
      "r350",
      "r386",
      "r387",
      "r422",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r169",
      "r174",
      "r175",
      "r179",
      "r180",
      "r182",
      "r290",
      "r291",
      "r498"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r79",
      "r229",
      "r231",
      "r232",
      "r236",
      "r237",
      "r238",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue recognized from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "terseLabel": "Description of customer payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from the initial public offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Initial public offering, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share price of shares issued in initial public offering (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AccruedLiabilitiesandOtherLongTermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails",
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash and Cash Equivalents, Money Market Funds and Short-term Investments by Significant Investment Category"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Classification of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company\u2019s Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r41",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesSummaryofUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/AdimabDevelopmentandOptionAgreementtheAdimabAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r314",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r320",
      "r329",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Activity Under the 2015 Plan and 2020 Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for 2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Black-Scholes Option Pricing Model to Estimate Stock-based Compensation Expense for Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r50",
      "r100",
      "r147",
      "r148",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r259",
      "r265",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r369",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Refundable security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares granted during period (in shares)",
        "verboseLabel": "Number of shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date fair value, Issued (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Outstanding and unvested, ending balance (in shares)",
        "periodStartLabel": "Number of Shares, Outstanding and unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date fair value, Outstanding and unvested, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-Average Grant Date fair value, Outstanding and unvested, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date fair value, Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofClassificationofStockbasedCompensationExpenseDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of payroll deductions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value of stock option (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r322",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding, Ending balance (in shares)",
        "periodStartLabel": "Number of Options, Outstanding, Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price per Share, Outstanding, Ending balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price per Share, Outstanding, Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Common stock shares outstanding percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of common stock issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award",
        "terseLabel": "Employee stock purchase plan, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r311",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price per Share, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r314",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting rights, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Total intrinsic value of outstanding unvested restricted stock awards"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate fair value of restricted stock awards vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period from date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r334",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Expected term of options (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensation2020EmployeeStockPurchasePlanSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpensefor2020EmployeeStockPurchasePlanDetails",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModeltoEstimateStockbasedCompensationExpenseforStockOptionAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term (in Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term (in Years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term (in Years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r19",
      "r518",
      "r519",
      "r532"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments [Abstract]",
        "terseLabel": "Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummeryofRemainingContractualMaturitiesofCompanysShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r98",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r100",
      "r102",
      "r131",
      "r132",
      "r133",
      "r136",
      "r138",
      "r147",
      "r148",
      "r149",
      "r196",
      "r226",
      "r231",
      "r232",
      "r233",
      "r237",
      "r238",
      "r250",
      "r251",
      "r255",
      "r259",
      "r267",
      "r435",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r53",
      "r72",
      "r73",
      "r74",
      "r110",
      "r111",
      "r112",
      "r115",
      "r124",
      "r126",
      "r146",
      "r200",
      "r267",
      "r275",
      "r348",
      "r349",
      "r350",
      "r386",
      "r387",
      "r422",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r553",
      "r554",
      "r555",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r146",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r242",
      "r267",
      "r268",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A, B, C convertible preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r267",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering/private placement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r26",
      "r27",
      "r267",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r267",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Vesting of founders\u2019 common stock and restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r267",
      "r275",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised (in shares)",
        "terseLabel": "Option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.pliantrx.com/role/StockBasedCompensationSummaryofOptionActivityUnderthe2015Planand2020PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r53",
      "r267",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A, B, C convertible preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r267",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering/private placement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r267",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r275",
      "r313",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Vesting of founders\u2019 common stock and restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r267",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r33",
      "r34",
      "r102",
      "r186",
      "r196",
      "r435",
      "r485"
     ],
     "calculation": {
      "http://www.pliantrx.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r266",
      "r275",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetail",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Changes in Valuation Allowance for Deferred Tax Assets"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofNetOperatingLossesandTaxCreditCarryForwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Accretion to redemption value and cumulative dividends on redeemable convertible stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r15",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r226",
      "r231",
      "r232",
      "r233",
      "r237",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]",
        "terseLabel": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Redeemable convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series C redeemable preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r114",
      "r115",
      "r116",
      "r117",
      "r127",
      "r187",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r225",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r384",
      "r385",
      "r386",
      "r387",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r473",
      "r499",
      "r500",
      "r501",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NovartisCollaborationandLicenseAgreementtheNovartisAgreementAdditionalInformationDetails",
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government agency securities included in short-term investments"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r106",
      "r297",
      "r305",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities included in short-term investments"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/FinancialInstrumentsSummaryofCashandCashEquivalentsMoneyMarketFundsandShorttermInvestmentsbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Net unrealized loss on short-term investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r360",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "December 31",
        "periodStartLabel": "January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]",
        "terseLabel": "Valuation Allowance [Abstract]"
       }
      }
     },
     "localname": "ValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increases recorded to income tax provision"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/IncomeTaxesSummaryofChangesinValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r464",
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease payments"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r130",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in computing net loss per share attributable to common stockholders:",
        "verboseLabel": "Weighted-average common shares outstanding used to calculate net loss per share attributable to common stockholders:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r128",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails",
      "http://www.pliantrx.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pliantrx.com/role/NetLossPerShareAttributabletoCommonStockholdersReconciliationofNumeratorandDenominatorUsedinCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 3.C)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386226&loc=d3e41620-112719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r599": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r601": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r602": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r603": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r604": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r605": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r606": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r607": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r608": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0001746473-22-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001746473-22-000010-xbrl.zip
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MV"")6G2?\(WH&GOA<N@82.L&8(W]?6<[ED069(]<;\CJ$4;9>0+!MF#HH]A
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MX+A&AU\*R6:>G/9X) O.@1(D7!J+& 8GA$;X%T<&.L]H%BM$LOE(3GM$TJ"
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MQ: 9BLYEHZHD$DA!(A;2$BPY"^51Q<Y8[:T"CHF_%M,T>\V37N*<!=/\@&D
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MPH; LQQ8U##CG9:I)+BQ3O& Z-@1F6NKX"+B4-J2MYYHO!4\,)\!XQ/X]CB
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M5@VO4,[=_)-X1AL#O:(JG68':IA9BI25+.W7EMI1[P)= /6#]T+\5-2]DBH
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MP0L/X(5W(?:*4$$NB%'&5%S/&);JYT:KB $[V5@:B0L,5PC:YX,=+C2*@;>
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M+6MT]V6TC"^NO2[[+B8-QE-/1^_K,WBK-$?_7*)+UUY\_"K0,O.]89J8DA>
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MO_]>';F^YXQL+&\M;R]GXXV613D%5^4P:_26?Z\@2\Q)O&3%^R+T^^._/L(
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M_D^1Z7$VG4^V(S\#A]P] 'CWIUYP_PJ4^W<BW/:8;ALEV2H)S3^]5G':6-V
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MYKRO*1E1+7BJ-,PRU0$OO07]-H\8,C-5U^C-C;JO/HYF"4H 13KY8 #@$]J
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M/O)-'I^>/U$XZ]EU IHCG?#]L=Q?)V"T]'8[G4D--F.C-RBC@J8H0QU@.)[
MQ]K'7N\P?;\PQ6]3&D]"X5LT4"FY3RZC=Z3:W$;@)WSB#0*#O?Y0VN([:+60
MX!<CP10D>-@!.^6L#&;F_4/P OO]GLM+]_%K\G\WAT4V23!=2&\UI#<=7?E]
MZ:VT<?"@E,IG (O;[+)9@<4#Q_( IA)@:JYL-;.-GT*!.6.):_>/"KN*9<D?
M/\+Y4D%&+[U-4<1QSLGR<^F&A>9_#&$&XBV4>N7DC?T]D[SZ(#D%."O+OR+:
M)!L]6S=NT"OZC_'^LPQGW4YB1AYRPL?+8>VJX1'A5\3QW<( F/U8'D:]G6X1
M^KWV,7CZVP,38[F2O0C254H"]0_\_ 5NSAW5U#1ND@5LSGXL#R/>IZ)WE*8Y
M+'"R.A*GZ0(GJT4UBJ=QDBYP<O9C>1CQ/H9]TTZYF"Z4!7,7<%D=P5O 9>6H
MQJ;ADBW@<O9C>1CQZG!+MFUB&)QEJWD_[:0;%@L;LT+B]R/07*RY+];<'X@+
M<K3F/@+UC<7*^P)K@"L8FE;U?*'J9S^6AQ%OO,L];4N[>P/Q6KD1_Q6T:)?)
M>%.[U+)Z*A54C/:AC4Y5S#X-"]<R_=&VY-&]4SO6%E9$921;__*+_)6C&IW&
M8[' X]F/Y6'$VPKP_./@%RA9&7G3?(&2%:.:F$9)N4#)V8_E8<2KWZQ%F>)4
MPU'I@V2*KG1-^ZR?C^K<7%2:?-_K^E$IT]0&L';8'I1--H_":$@+\[0Z(KP
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M :^3AG%4]*"[O O\F!9OTE"&;5"/9MB'Z\,B*\85R0:]S.<Q3O70/LMBT>M
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M%W. =/F)<K^SG6O=K^HL'+,KSU33JCB'RAMG_L*%('0SM_,5#!!7)^2:Q<2
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M'W:6T!_>NH1^?]<H8F^(O>9.J%P E,*+"R$$KU6^K67H!Q?R]90)#[?R^GT
M]OD\9V)7SG;,(.VPE&PD[CP\BWJI/4/JI9K6[,X$R[O&1BJ0[)L#L7UY95#<
MZGM6; 92^SB=)6/$Q<O#[;421749+.F!B%H=PBW\W>F2'4&.I(6]L0K6DDO<
M&V0/=&6,;,U5,DF)8BT9ZD E"3I*U;Q3Q495&A',N4P3D!*:U%?E-_$9^$(3
M./'#.7R$Z&V>23I//:+M07?>+,3"Z )""3>3"/(MO2DB>EY*5\'+G)<C8(=\
M:#F^&%OH+W*X&HP(Z4IR<7"*MB+S8C16HH#UOC_72'#]ZN+O?'I<NZ(@YMY.
M6;CTA@<=!)'^=HA?N7Z[)=)5,7V0#(W#'2E9'Y<W\T'CEE]T0/HU/8$^KKTJ
M#I[<+9L]9^C4;5U62GB0C=A*S)( &CQ-I7P/]8&YY*8%6(NF!WQPEP\NLWR:
M@>)M9CFQCCS8>FJ9BSDV9!%0E<^A=)>J"/,&P9W1BQ#*O: T-CCIW3AB:9@]
MF50<.N:B.'N9/P9!UE=11BK#2 *U,D 2NG(9H+7<$7*[I/4 AMR2!O)IGS#L
MZD].6.QBZCJ,]OS6Y../P+*&*)VUPZKHUCI^8PPXCH Y*$IE%H7+S!^PAR:F
M'>E;1B:N];@+UDOI!9QK2AN1Q8U_P0(,/ELDL#^7D18;P=U*'L3;NI@LK6\1
M4%(T9/R-.6?_[J\]MW\A)(AE.%!V"J8HD"S0(@3!XC$_(QS;+*MB9';77<K^
M#+MFH=0BLHUL83#PAR<//W?K*G^5C#W$%YHE*[!*D]9)<S=6NZ1!XRI=AH7S
MY:PSL*7P.DI96I5QPZ@KDS[6O9B?ZYO+KS_4[ENVZ*Y1(7/*.%XS0'U:"X>G
M\_K=8,IQ*]OU172+MPYTL$ XGSLIJKZ8PK3W"DM+I#TS4]#U=;WDT4/5>..=
M/NLTC]609BL97Y!65!XI$\,))(J@22_IT1$8(J<>=E#9Q8!^2C3Z'00S+ZO[
M13.KFOF^K1.!5?K^W5\CM!+??R)1=@'.083!(NJP-7H7IJ;X=W#1[QE!;B++
MK QD 2^ES]N<?CA]@!=]NYNJ9?Y8:7&'^PT0OC5#*5!+@;(*T* =.<.8&2K6
M/!'S<AD65$167*/H@.L5A(6QUA@/%NA&A4_FGQD@5&.%2\-Y;9I?D$[VJ5A,
MCPE!EQ </B8$=V L.U%9?>=Z#3]K.VWHL=@L?/A%::4<[I5Y(P&*8*NLE'J:
MMHW%7(S%U'7]IO,^"C!</N\A\)Z'EN4Z,?*[6>SD:B2T9\"]($ <8"NY*R\#
M?"RNUN$TA/YR;3>.AGVOB^-3S >;AK@-V.I&<P2!S;$].1%,-1<Z>.B@X4^N
MA67C.H^X)"I$A@4 4U:L9OO+<H17@6(,A?\O A:BG<@F7*'4-C%4\0)+T435
M%0$>3I#E;,\M2P:/AE"E!Q<D.ZGO#)[ED%=&M?1 853WCJ-[8"*E&6HAWVHY
M\T%A>;2QCNT*BUP6%R5OKBM'=Z$#7N UL"Q3>6 %6V^+U8EK9(EO@@S(DO11
M["((B':*C:/]#!0=-T>*W\U U_>D6#)N3XUL,P>_I*D0<+36-\7*\4-P+F#8
MN@@R8P]>Y(6Q]>@:#!W$3%".2F?@]#DF'U(L24^G<FWD#TS>.ICN-DI=9Q"]
M:,67\'5F]*VN*6G#S]3R;A*P97!?;KX<HSU=+Q/>M)%#5K<(R/(47_]TII$I
MZZB3LOXYR\9.1/=<?YV_#]Z#:K:4)HI,&' R(4\@%QG40JU79R>2W:"C#G R
M1H3L',22MAQ);[%:R$3()OS7X7-:0WCR 2N'=I'$+Y75HJ51;7%:B^ZW]5JF
M'\3IZS,SN)CN.]W94[>SN\<0<U.6ODE> GI'XOBNF9&&@FON:"9>D ]PP;WE
M=V^BVQ4*W0VY1!7X<++2[8&(O<_6 IJR094:6HJDLRDD[Z9,^EK!1+85C2B@
MREPHB;,TD4JEA2 <IZ#1_,*M9 #M4ZB@8ONL_[RV;T3;JR)HGQKJ^:A_%W^H
MW>KY2ZYE/?C&K39%&]T';;=Z_N[4&R>J$((S ,+D\M,*/.ETH8D69DB8TA1;
M0RZMTZ#G(S0]EWZ/]'J0]UT *7=NI9XI9W6T]@0V&<>VR0ZOM"_ ).>2W-S=
MY[!#:VDJ:PR<5F&T)$\\4]9J.HMLF@X$VO1)N] FQWOXT=,]&']CI2!R.+Y)
M+D3&K-UIE\2XY<[5.@IC?B#-?IE? LLI65+2\U=EQ1E8F,S,QH@H)KHC0)CH
MT&'F8UB!8:L!^?-!@@ -$W[B\X?&0OLN:FB 39*:(W:EPN.5U*OY8EG.XZ:F
M,,@+Y?['.C CQ23D]=(Z+'R;5,T2^<N@/ZJMY54Z^VCG92G_]R#YF2&2]EZ#
M%7D7J)=,*L[>"Z_]&,"/Y\DY#?>BR9Z#/N CQO9<XJ%SSL]8A1%20L_=62,7
M/EOFRTPZ#<J"\8>#Q.F:BA&OJE'$@5"W.8VD='@H4)=%5BZ$"8KOZX*9=M\O
M(7/*8"=5ZT5P)@[DIR3E^A!@H9E)UL0851^(-4"\'YJLG395I8TEI/<K4U([
M1]/UY(3E!4O(^$"9)=7: 2 $3QNI,9+@?(8.@W$"9F1],)4>5^"JWG6A$8F'
MC&54' (/PB:<V$?T@",QV*A\+JXBO$8AK^O&XAJM.K[S6Y/ZBL9S4!=>E2T@
M.(?4,7BVM:SWAG:$6/"C'$,SV7,_)"_K$7(0?_[/X9/#Y\FWB[S"[3(IB^R[
MGA0:*J?S+R6)>?*7<L9G]>1'0?W^_.KE/^RW!7R;";FZH]9/7Y39%'<,G;_7
M]+]GM(]S4L?,7*,DQLFDX5M(DL4Z.C]BVM@BO%MKVU*YJ^1[\,6AQ/T4>(A^
M6+XPF*U/J0SFB+@!O4Q0? &C(RE4U@,I%G!KSEUH //S&\DQNVSMTNW1#*1_
M!N=ZUPGT:SI@%OB\"#A(N G-KS';'JB@ZT6N;HI-_S.SIYU@$UZ.2Y7-4ZD9
M)W-FGI'(9IH/CF3?HK208X:E.K22A\:M>3$/39><Z6("Z.##-=HTEQMC0S;5
MZNM%:]S:1\'+.K\I"!*5KEL1-SJP#D7T]-K"K)U[CPM-/4@^3*_^<<J\X/$]
M<9Z?<\_K#F-FD/PBS0&L8*!N+BZR6LDUPKGXEDH%&VLZ/+-P$-A+I5\WQ&&<
MC<J0$-WZ'?,3@"X42*'8<)FTBWK+Y0GP/7OND)-KR@<R.HC6>$.B;A+%9M*=
M8+CLWX;$]'32T)L]/\\YN2+'SV&K'YA,_N0/+K.C!7%^V)-6"[Y<87J%-;0)
MF$P]*AP+%;4;\=@?<"5FY*+W::4!&Y_$7Q2PU]F/I&>#ID7K7WF%;TA11RV5
M5EDQ*:U3S/KW__'R1U)J/X6:67N DU!PY(,97)TF#;PD5:<X GX1Y(R-5JU3
M,4UGYSRLF4AM")F;D&^W<D7B['(PZAX<_G89N]9@81L4S]&>KK=2 4&G= 1
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M6"FU<K.P&):\#,&(^(T]EMA"$Z>N>^:8=A0$!ER_:17C-#@9I7>>3O.JFO*
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M?]/%=[JFZI6$TH$YYG[#T(9=4[D53UD)OD[M33/ON+5KU,B-/<)@G.*UU%D
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M@_)1,N]0,KMDSOJ9Z%8$,BC62U_N</:*I';#(=@?]^H.]^J])-BZPM+J$:9
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MB95?;*?!EA;.^9>.A0[I>K:W40AF?[1A\@(T<"&SBC:GS]W$%G7V@_T?SS6
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MD2F549;-2(?D%40)/QCN]SSY'LW$ W5SU$,9K&? C^,BXJ8609R[(Z['"]^
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MX5%N?K5);2\9-9PC7NF(95D$$BM3W=8L=S?/9D<12^J[%;5RWVH!01LSF*P
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M[ONV7%%$$T[WR_"_=1C?.OMA/7OA'<PX-E=\F(@YS(ZR^\=>5/Y%NSV?A=-
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M-;+M6:XW=;LOZ4%$6A NV@))$-^?M;BH*#>11[(8;FR*CFP<O4M/B8D7'^]
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MEJICT%S[HBTY$2/&-?@6NYXL(OU3+I\N+$:S0.EE$8$ODS-P\S+3OQ-S&69
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M*!R!/'$_X!<H6#!.N!;WD8M$++&6D22G<[M(7W"1PDVYB5WS8S"$ %S0=.C
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MNKO.VXO@ALPHZ#QL;/]\*)P'MRB<:S"6SXW"N2ZW\(O)BA!=(]O]1IS8>*'
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M<.%W1H3O%R><BU?AV^DVS/&R84^C59ES'-CLR=Z)S[*OT8$.3FG$S@RV-UE
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M&#JNK44=MV[OC+-4\\C4V;CC;NU]ZLT8H@R/S5$5S:\HKPH[RJQ,<FTQ44?
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M@Q@1_:QJKQ#RL9-G6\-U^G05,T_K\J7+ O>H0T4MCTZV@[\H%$LQ/RK6'BD
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MH/J,"Y64(I/=+<?D.#%B@A^>,CR/==US^Y:P]-293'_D([#4![L .R/Y25K
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M;*0 H-A7Q]\PMFJ@6MFJ<@\KAQ \@P6"&9C;[.-C&5\-^H/<Y!;V; &*1J]
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MKCS^KXB5(ZV\^.]@>;Q-E/@SS9OLHJV#>2O ?#W06/%P$GM6(C6GL"S^@OS
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MG!6^.+,5_E=ZW0@@M[(U_[KB]JJ^/:(D=FE5X4A=Z[J7T:B5@<(5AE,/DY^
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MT#V&E:O;?9GRF#_\AOV>L]7QTV.$S?3_BY+N,=XECQ^!1!0KW)P#:U)=H8:
M9B?VH+.?A1.>?'#[]HP]3^"7E>T3II JCV!MZ7S>2@BNR$K.PB)H<Y71?DG[
M4\GXAR@NO:!:)@"+1)=)I0U*0Y=&WHI!*0]8OZHV/ _I4#E/<-ZV'^;A7:>M
M\7MI9#+]VXJN^MS/#D];%:E.DI=6 D\TVRK,M->E5(R"3+RG"5H6<Z88(^Y>
ME=E0<@FD)D$IT)2UD 'L4C6.&"8XJQO9R>GCBJ#AJS5AW8_HFN!%0*#$AF"Z
MOO-N5VVC(ZG=>G $XAP04G=-R0]!DK,+QN]):#!F@I'YF.UZR@KR_N+\XSJR
MP<UV52U1#D ;5-9 ?L-]J@S!L\SFLIWO>G:+@EN'& X^ -0'>R@NR@<B![WC
MHY6SW0L\UIP,-/A3(2,XH=L]1CHKZZJ\D,<C4:_OG\VHS8BB["K$1EBSC>_<
M(46GYGR[DL,W(U]AUA5S2:/VI?\$[1!*A[0\5\1T;]T1"M'#>.S%XB+E<85R
M;VE XF:+A9U4<*L"Z;Y1%H#69E;,WYZ'O4- 4;>I^>"S^<I3U#%7/M2+BI;L
MMI)LE>2'MY7D:S"6SUE)ODZWVDF$!-(QMLP5X7JW6^)1='8]V(15^%LBD. ;
M$(8GV!W*?U\:RR\%=3OX3V0SM BU97OU'O=)7&@R(P9.OA!Z64*Y,D:72'W\
MOQ_=N_^6QBB-?I8_-5%.%?C9DH5:4GL.K6 /_YIN$N:4%/,+A/"JK4,0P7?R
M1:&\K=1-1Z95WS3U;IB<U-V0?2%58UCUMMFQ  NXYW<-Y]+1>XU+A"*@8'"#
MZY18T<'G'9N9NT$I>=OH+1QL].66/<DBZ]H92BL8I11;YV^M=!;>9-UN2]:1
M.YJ5/!U=V_=,!9[TXX0HK:9+Z]BKZV'I.2'8<:"C7.5V_4%U&(F4\V)W'I=>
M'&#V<WW(3!T\^%+<83?.5WS9Q+ !X')N%43!Q%P"/1AELZ)=S)F<2$1K[7H6
M'YB  SWG])>_OWQZ=/])AOK0NIH/LGZ7I549%GH CB"B9]N?NX\Z7._B^IMT
M2Z<1')?@L-L2CY9=#G(45NVZ5.]WJ_I-EV7Y%LYRN(_=8(GS%<J  A")CPQN
M1?@-B(#"D[GR0W][G/U"=BG"ZU="[\#[GNP4DC-BIB!R:YK<U D+Q=NR7)AW
M:38K&\CTV$Q>\UC[U%2X492RA.3+*,9STPY,,*F\Z1N3&%^X,B4DR26W_EI+
ME4^#5WC)+0#9WTCVZL&]^U_S=A'.NW!_E.\@,@]BZ"5EED,@ F[H$GB@!X_O
M93^%F*$.1[&L:3++L*WR['78$ZOL=9B(YW3%4.F.:'EK0O(V59$]>73OVWO2
M;;0CN:JZW*PH.)>++WS+G<=?W[N;/?KV_M'C;[ZYQ^.Z+&<X#\%T=K1GP\=6
MV^VF_^M77W&;:O?N.)S5&V?O*-@@C J:(,,$]2'TH21#I-F+,'B"!+P.B^*:
M+YZ]XTJC)V&%QK60Q[Q^=JJ,K^'S#3.2@U<?K!-4<KM_[^C'G#@<NN =@[]^
M]/O_+W=]F.EOOSWBGLZ"M%76D<NJ[4O[[!)=_O$-*4/N6J-?EXPIN?_P3G&7
M/G;_ZSL+(_>V-SRAUJC?2Y:0F;=</EA*D*=?Y5OCRI(KZT5W;@9+PG:BW6M=
MSB5NKS[K6^Y6IPN@;2"L(ZS8W"&+VLOE>-G"0-9QL<+$<U8@_(==9&BX9;;R
MDAIDMZ565^37IGD0;I-W>[D9O#QL.'U"QA:5Z]P'@B]1,+$W',:J1NQ,]^+E
MY7%?SH_/VXL;=T2<<7;L1$QIR'JI(C@35UB6L]?6X,0X4H5 0GA5?T#MN5!_
M7LC/3_B\_(HUR136MF5>//V9:B#9CO [@+^E:$04HFS$*TB&R'98F)(XRU<U
MPM-$*\!GUOZ<"H 32U@M_M__>'\$=O^;Q_?^P_W9E[F%7Y*V^?V3X^S7JG^;
M/0>!Y16>ZN?/-TP/^]>7KW_,GI^<OOGEU]?7MJ)T8.AAHHD9G(%989/1E?J\
MHKY-ZE,]4UH4<,67PMAU$FO!4IVX?F_]D6WJOTMN/MB#'31:/$$IV>2Z!<ZW
MKUAW5!%:DA!E.2^M=FFB&0\[]"2E/B..E;XL^6IB%H7K-YOO\U0^8N[XGO7S
MAS]>8L^5[/NY=+ZYG:#<94,NH3W_B6%SD*5WN60VN#^W%X0^L+K*%8MSN%QD
M5RK*A_0N73PQ&+#@Q.+ V3G5MX<VRE^>?'/\, L+4-/H_O+H_O'7]B_ZBK\\
M?G@?E,:Z-9C"CNW_1/V,F+GPA\%)?Y)G4; EW /9^ZIN+'NV6PLD<P'\,G)6
M?WD07/[[.C+,&U8HS$@[8-X1-+T$@3&^%9XOK0 ?FMA\>'Q$MLWH#+310F6R
M,"%@T^/N F$H"D\PDF40!.V$ $'+V>#=.,Z>$20U_#%R*PR1',/7C2T@)91!
ME;!C,M@4P>ZP7?GP92[+L4J%;#S'7_0Q&\]C790@6#LZP%=#-"?"+*RD)!Z\
M$]G!QL._@8;G0PWO>XVN[45:$T%!8PF1CM399T(T;9!(3P*H)LFKPS;XZX?.
MY886ISD_(LV5\%Z/CQ\.9_CH\<,O-L6($1]_IR_S^8>0SL_73XZ_IKD0&7(L
M3C 1B_%FSK.SGWX^^N;1M_>>Q)P"GZ4)3*;>+%$%:V"E<F$X%PJ8/".SV04O
M@Y*^ [;"[VZ7_A,N/3#?VGZFEH\ ;^-EO5V(SW4&-^$^G3@ZL9\%X+NIC]RN
MT:=<HZ&'$)MCI"6"[)DX;*YQYH![<[M6GW*M(O I+%<-5=2.E1"[W<9X3OU)
M$R#V!%TNN^.F>4TDG P"53R3)[V0WVJAJD,.]W(5/GG)^"PT8K5P6L%Z.%]1
MX7JQ.UPXN]TIGW*G!,_U[52[2']5VPF<V>C!U,JJN?T(_^7/AR1Z=(LDN@9C
M^<R<%+=6Z5^Q2FF^Q$5?5T9>6@>15L"IG(K+:-S>*Y]R!2VQ,63;>R^,'DD7
M QJYP.S6B?R\2[BB[CV7[IM.:(@N0Y21=C!M"044&F18^-MU^\3.OR6IM(9
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MDML,SA=;=M'C@(8G.%Z)G=OP;NKF"D3(97ENE^;S!3_B1LD:14F@&'P<(?@
M<SSJ*\-H)B;8;Y&*G].8FC<+]8 !7GP,#P]1+D.6E$/Y0Q7,KJBY,\_N.7,I
MKDIFZYFOVK:?P)\GNK 1.'[3ZL*_ ]5&-1[@/UA(3'442(^S@XP6C@I<&-2Q
M#+NC94E-&$Q PDS6HF@$'J<P%=9B&L,+C%/)># G\0"TZ-!R.LY^:[95K<H(
MAOASY5\#_Z50*U25TYI9LED80BB8P@C$\(^P2F^_$IYA)6@!\?BL:J)V$",Q
M6.$+JKM*_$T*BL1R2=[@;!O9POJ!YD3X=S@#)/],W4\U<<;.Z: P"!L'Q?$Y
M.X<QGB1* /F#Y/] D1J,S1BL3'RQ#WF/).@0#8O(^BK:S1#1KJM_D%X33U+L
MOG1<D[Q-($8!W3B3,V2'U^$;U^ 7;>=O5VU-[ #'V7-FE<B-$_H=_"]-=(S>
MU#!Y\JXH]Q><U?1? -&W^$+SM@GCVX+#$S3<S/>*[<I\(NYO\VPOUH+IWIDY
M 4(>LO,7%>7H%P.>=3J<Z?[ 1*I X$X%M<JHS1R5.J4BV(9S4-#>0$E7-H2I
M'TO8X<"@A!ZC>OV<&^[FN@L10O;"HX>-%^>0QDC&^RW#-T:H"CZ[BW).[/A4
MVZ^(RR'LL(/[;[@J5UP,R0&P_?1!IX@TX:</TK@%R.!(,)L@C@O&->SD8 ;4
MOOW_[+UKC^3&E2WZ5Q+W ',E@%U62[)LCRX&:+=:MNZ,K(9:]@#W&S.3644U
MB\PAF55*_?H;>^U'[""#657R5*O*2N!@CE6=R0S&8\=^K+T6H6]U!V3" QN<
M;&/AY\O!M'U;A4$KU::1-HR@E@S?Y*%,X7] I7O#4!>"_N-@X@PXU/*NO.EZ
MS4X<AHA $]25)9$)V4Q N3BI)#64UTR?9(1)%:#LFYJNCE%$"%JG5<H89HC+
M#S4/ABF.=6Z!XK+YROQ(-VE"T9,^_0V\ 1!DW!'0]?,+/M@;J!U\RS[]34?E
M-IP,+KZ#REXUQV?%O+C L3.2-^Z@8 N5UJ59CA:.8-D"=G0GD5F"[2B4<K%&
MX-PIG%T>VN,N2,-X]G&#^"N7=L1LSZ>@(\'BL7]-6D%RU\1^E*LJQ=GT&8 +
ME(SOP5_((YU]4*F-%V#J"JZX4=%Y(>AF!6? H711TI<C;.\$U$Y9'*AC^-97
M*@-'&EJ'T?"MJ*V7B6;%T\P=QKN3:B@/I%E])BCY'Y+.?>=+"0$BRU*++=6>
M M<K82@^G67:FKN&&D;A_27K)R*FNQ(7+,E0LC= "QC5V)14?9A<[V4X.,<!
M[0VDZY6H-O-*@G((J\;K23>Q#45NNP<OY*\?'GR73#FCJM&?\K#93Y2O%0%1
M$N2OKN W1O39=2*+7?8<JHNXLF*,2:.3DRU'=I?(CI%V-K-.;6O".\:D&]-H
MDOAH^*\S@NT#@&C4-3-EO]C&1([TO7%I<D?LM1=N[AHEE/:BLB#;S4LQ->$K
MX6;:VS92:<-)>\8 W2<VX,$27\X4%:&RUX_DNI_S>H^YDR;N3T(')HJ&<L=J
MR\*/E798S)IHM!]$V.I@LU$U-=-1,V$QZU9RYN*\OA]P?9<[29>M0Q'KF\[D
M;#H^Y;'4:5T\:0[PC+:+:+LOSFB[)S"6,]KN&1BNB;V1 @;;(C2TQ$A"8L[B
M7KQD;%_(75U.!+FP@UT=3C]0@PLEZ\+_?[ZT/E3%ZCXH2+]B:'#BIAM\@9U4
M<T".Z3,K4)^U(^?5]=&:6$C2Z[A)(^8'R4KWH+.C^D$=&='-+5;,;Q<]5##9
M[6K*SI^)ZCX42[66'%*-$\D&<4.U2P)[\9$SPN:#6U:[/;?5-1V<$WF!X0I)
MVO"M6-)7/W]F=)-DU'D9'WL9^WIX_SO1-V:"&J)@,HQ.7]77:RJN< M<UU )
M0JXM$88ZY0(EHD& 3"IV%CQQIADDR4;*"Y5[D'(,*E1)V9PJDE"<C_J'W2,,
MT-!B6"R9#%PZ#]<G""KHY!H"A4LSL?!,9QY*L5SQ.Q/[_RJ>,,4@>O*D.BH2
MO_27RZ9;T]*%!>ZH'EJU-W7?M8R)/(/K'EU/!?:OW&RHQ";I\[8[F-9\I_ER
M5FH[],EGQ2P_MX(5%15%*I!< L;L.A!26GCGVA6]?@.!9:U?69GVT$HY21U\
MF:G[U<0@;5C*?Q72CZ/!XKR"!C(X9@4)T_I"^$' !.=Q&M=5231_NX/2#U(9
M3<>7';1#&<0W[H1:3C(.U&VT4!/E0@EJ.([BF2NBS&VG55,#8F+H "0P[0XC
M5;K<6]]1DLW_4/@/_@J8*[IP&Y3T&<GOBCJ,8K[XGD&IJ-Z9IIY](_MI5!X?
M.*KBCGK^1@GZ:-NFBGP7JW>XV)(:LGZ2O]=M*%@!U2% '[>B=7E-@P7XM;JI
MN\- 4M\ Z!'1R@B&DTL"V!%@,9V?IWNV[RD _+W/JGTU88BAM?CSC)7M&]G-
M3^_5'\XQR(A=(V>)1RL8!0(V^S@(@O/!'4]*Y140:J.!F1G.PHG,^GW5U%==
M,$"=J0D^W0VS"&Y&QYW5 T4$<4[6I]R8B E.3"E <;<5U,X3-782MOU]P4O2
M&C!ML%"%RY*N!9I 4J4J"I-E5]BR:JTO:<,B7U%F"/SD[_S$=15,1*3M4>I?
M*Y*-9=@'KKP=?K,P;!-S[*$[C>!C#L99I#C]>[!Q<U16]:1.+V8_GPD_@1L4
M[(_A^HY>TSB$"^V@3[_LN]NP@GS+ATD82YC]'_[R]8M_^S]_^OR++PLD \I&
M)X)&?QGN9-H3]&1AIJ^!E+L*801C!/ CC4@=K(9-'Z8W[?_1:J25GNMV,)QB
M7@BRHVP'QZ?:Q8"\;E^5HT[)KEZ'<ZE4L-A-A$"2NTJ?>\S-9IZ_BIP# @$;
M'YC _]^WX:ISK:H&PA?X7V1.=FR&26<-L\U.,,OW5#VMX8-6H'S,,N5D)^>;
MMU_C+=Z^>RTE?J5F6_BUEY__X?.[?^QB]6<BSC(,[7VX7&?\9/I<V^_&0F;,
M;N$PU8P/I4,>F_L27*U7CC9TK"Y*"8T[I,GZ4YTM?(;65;#1:F?X+"X+4.O]
M0GOCB(:VX,@P;'HKD$E+>2M-5;X)9ZY8RZ@,!AC3E(Y"2>=YK)#96=X/#OT5
ML:Z"(<A,@&>ZKK@S(R&CT%$SGHBAW^S-.M@WWC4<E^!&2\//NB(.0.4W=C8Z
M=@*F/66K%GD+2FW0TQU%N$W;%!%+!\K5$I>99E.@JS'5T:6NX=!:^/%JHKP.
M<Q4VAM_/AWW8"=1OG,'L\[7A)>B#-R:]&>#V7M3JYO-#H0;;$=M'X?R$0X7^
M$7)*RHT08'O@\5#N""%H6<3+A066#0YZ[#B%X?5O:GK.M)."PC*[[>ZZ] WW
M7+6(C\.)/;0BR]T:AV218(DXV@NNG'8<"/(HMN20P6TE7N/_K;$IC 1\W1U9
MG0H0RBBY"=P2CL8=[HQ FNAZV=(3;KKF!I#UNFJHV>)U&)@^O[!XHNU<A*E3
M,$$P'_:0W:SY)DK<R(B/QL7/@2C'TVO5(9#4A ,'WE@ ZVG4 4$_\%89.->_
M41/(=.]@+06S8=7/%P[;R;]" B)S/#A3KD5TI1 ]K-YT_Y( [._<<CF#P25J
M7+%<HK9UVMU;Q)P"ZP9-"GKM&@3OA+ Y5^A4K-GH5OD"N%B]8@V !2\QO:6=
MH4J*>ND%D[U:XGTK%XS1^2^P0TO:8VL4T!EC'D+\,]K,T&9_.*/-GL!8/C3:
M[.ED!82>N#G. W;V:/KJ[L@]-@AGPB1V_O!7NT/4WT7 QKZM\J8OA3Q@\$UI
M[=6@1K;C^._!B)^RT+6GR#=G9E GBZIOZHB%;X>Q7\-QB4-B)Z;P1K >AD/E
M.BWC%Z?]X$QV"C_-/"^]S>?-5M3/IC&(\FEND>KN0J3T]HI$!5[FN/]MFJNV
M[UB_9KSMY!N?EOJ5,/,A?/3H_W+U]LT/J_JZ1$D+'[-G(7?NU!O*^+P0?/*'
MQ2$*:Q"W5QS#/IP^4[IQC[2^5#2^>[HGMYOL$MVA1_4&/86<&)@Q6?_MU;N_
MQLQ2G#H=\LMR]>[55[_[]M57X H^JOM& [#?";-S597->'6DNAYM$W134W7E
MF[]])=$XO6ET\LE#0RJFZJ5)U-Y$VW_J?ABU="+$Z2_93XP?'8 !"/YB+;QE
MD/ZQ@4W8LA/UHKL8LU>X1E:19'E"QBM%BU<F-21>>.G%-49K*N7@.[QG/%-2
M_EAFU*-JBKI7S5$>04%0PX^:AO\S5(0X1YH!B<8@B6]N97N%R=&7F'2L<EF&
M6Y_)S[,%F%"2\TSXE;Y8O:NJ%8J>GWQ)_]_+3[^<9>;)M?S>/?X'!-%ON7?Z
M E]^>>_Z_!.Y-_YL?F'",C'+UG(&X/[.<MHWO>0>1PTS7."7W4/]VL1J4ZVH
MNI6DF:,_\1VU/X9C-6CT-ME@]7V[=/U-&E\A!,Q2FX9,3><[D=U5FR)LB?)E
MHS5.2[?,U-EJIP.;49U1AA/Y"7;98=F&RKZWF/&+L&[+GVK RDW1,'-:)(T:
M#DP0S6W0]TIZ/\-2"S(DEJ4(T=)(3> &NN+:9U,>F3A$I2?FT53'"37'U@%A
M;_N@2($J7TB*ODUZ^(ME$)G>^N=NT,?$H+35)2<>60&OHUD?.$<MQ7^]BW(2
M!O-&/MT7&>TGV,UA0>@PF(GPQF4O5RPQY@2[+,B'D@KM]2#[R;$!);3N>6,[
M5H.2J&2&6J[#"!C5P;6$,R3M,7>;K/L++0ZB:UP10)/\J;6+3B.PN'IK"L_
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M<P?M!^MIO%=?+*V?V:$\?GM-^BK#X%P;((>9V3H<C8^JB\N+8@[@XOA&-P<
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M>HC;<4))+MK2%O<Y<4;!P#VWH!<(.!50,VZ3^=II.[9>V^B(F;@_&2B-N90
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M&!]&3Y 2IFU4:9J9;,XOQ?6.CR8G0QHZ<-QO^TY:;K+<<]ZG?8)+=)=8)2O
MRFK$G9DYB-*>1DENG$#SPXRF;>ZPY>=</"C]U:$:F;;-0&)Y\O?PK<O.JCJK
M_:&GP\^1 K7)'UH.?1Q3>0ZRQD&0$&&D'4>C:.':\F-V%,[I@N!X0>%-]!,P
M!/55Q_5(<>CG_<8#-8$3$"=B_Z8!&#*,M*<\0'BMWB]7G;5&/R=07DA4BU("
MZ0"'.%6*1=KM%FF=C:)8\OZXR4HADN*JA1))4>-V8N>2(QB,,'$+2(YS:Y4
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MZF\ZM*2FVUWC&-.;$[R,#,XDY3/C47$W6SX@3?>ZI602RPQ6^ G9FPN*W9'
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M#E,@H)O3,([9L2[1'\SRZ:!O@,ARC.?G>O._7I?D*PIT_[D<Z5/#?OSQXH_
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M:^]DCCWS[W.+8;_9)1@R0XYE<A:2'R!_N@98Y\[=R7F#85YQF%)E%9GH.:U
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M>$A&ZDM,8W3MQA*#XUJ_[I%)*2;)''KW0=V/Y'[01(!44D%'+7O>;>TO)P4
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M)9S1DNHI89%>PAZ^"H]O\)]Q4NO@I8=G$:X:^<(=F"3%J49]"5W+(1@)ES@
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M/DZ")'_8.<7(FK(%M1-2Q#5_XM9F.PB;F)I*OG-<$L5L%-P8^P$_BW-3S.I
M%RNM1(8%D/R+C01D1YR]=/L^W#[]927'A#Q%BIO 8/Q1=7%YP0OR77B!OFOU
MWW"F:1?2SON8/2ITYH')=\MIKV 7S8EEB3';D\GNF AHD+4@7AS*WH7_L>*R
MSPU BM;''X(** Q*<Y$<([1)DA!KU],5YW)0-M@D-)%/UM*HMN=MK9YE]KQR
M9/]5N$;YY/V)[2N]\?\;3 S][$O^VZ>3!LM3-K(P!S<B7D16!UX&V#LV5;T?
ME;0@=X<-?O^%^?B_<7W%"-9]+[.EQ&C5?6+OGV*.ZF3H]'T>Q*(::G.,!B(H
MRD*&,QW&4TX9;GKK_T)T;D5[Q!XR_TMGG@LO=$]2/Q\YE3' H> &L0WZFRS!
M>=ET:U.$! =:^,*05"$\Y:"TSIT$\(AFEAEI7F7^<._W0*&W?I%_IH_0%=+C
M $<IN7P^DY-X%XI,@_@4*,SBC[EVO#3G]3"@A*>V:J?Y"F1'& .M6*Q"BP#G
M*K95L5^>J]A/8"R_C2IVQD .<P"-N]1*,*IQCI!/LNJQ(5O&:FPQ[%5EXMII
M;AK,4OZ1)'V2RF]J-IY@,O&A=&1_YP)DRM$\49Z> #KGA&V3A7!:9$IF8-BH
M":N! 9_>'&CJPY2$*QFMY7"J$,\_Q6F^JT+-^0;6AJC>NX#$9F>AZD@EWT[\
M\3EI%9&RA0 1E0V->;U^HLG.395X1195%2&RWSW!.+%$<]4?E!;=;Q)3T9P.
M+8R>J"WUUYV<:V1K;X[R9=T8?R\\S YMPDA@IY6!A%#6,\"P[R*3[D?I/8G]
M84R*\OX'44(82F8X7\(A,XC$"X<6]H"VNNP  \"OUHEV.WDMSC^CA,Y(V22
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M^,K B-ZC_@+7SB9;;C?).:+&;AN92#9IK_":L*X5O?HU#:"0<I2HY.*:B&J
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M+8H!P']N0XW=6N 9+$]E0;>/KB,*9"G@0]J3V6RP&%8M!) 9H&MH8L&MQ@Y
M2( [)=B7+=TV?7KS1(?(&I"T<2IW[U.40X2;HJK-O9@BL9(/G<8K"@VK%@N@
M-#A4@#Y00!SSXM);TC3ENA-.3/R(5ELE^N#T.3_RI%._Q%E^D3 74D&XQ5:N
M1%UK4.:;2591&G/ &X:8AQK.A:7*(D!^N]/L!1P9SAU2@S5S%\>SBRJBY@#1
M+4IIS!SG2OHJ=G7/C*42,QPS^VS5QU3?PP])^)^ZM/C5,"+?'Z*U]JWXH.LT
M;S.-B1_Z^__BJQ9,J')I\?\4P/D-4$/KHZDE9X.\N#+E?&%<8558;-$PNC_X
M0\MVF19FTNGA?\?P6Q3@R4U(/PC(L&""2O<C%'-))"8\H%\0)]W+SPI.LP3;
M$!N^0K!<X0W%CR:SV;U7%G6?Q,*M&1SO\># 6>FPW\HL!:/V@Z4+OZ,\"4MS
M_/W=VQ^^*]@ *@/L[56WNA6VYNFZ2"^%[Y3ENJE?(F?<97(D6DV9[-YQ3H4J
M>?>>;^IA(<9JXE'!LS7Y\PNFGLJV-P8BDEDW\GHWLY/9X9Q99@J8^L.].*81
M/Z/60(8FT]GUAFF0SN5#_^S(T?\[VQF']Z$IX'QVCZ,B.X>F$F5* _R-5K*]
MZU.3/<0M:V9Y:_0ZHM?(KDQ3(KGEUCO5F8DJ2NH3,E^&]PJ3)>WZW%6"M]2!
M& SFY&@PDF*U/HSQ[U)X(_$WTBCAT0WW&AY&X+S5PLO,%*O@N-;7[!BNJZAI
M^H#WEU?\F^\(E%-R2;V+/*G![B[YKN9YA.@IG'BU99QT9O E)[+] +@G#(]6
M-YD'G\UY%T:"GW6#%YQ=&Q@_>3:J6I@[[)\TDVSGUN51.OL95)6QR=JR.?Y<
M^1V>N[?$//I$M=Z0MB$X567D%#"G:39?T;7VW1*L$%7E6H.XM5XEC);<:MZ;
MTR'1"TG:4!(Q;-U3>'E<],J-J..,D/A=NEG73;=YC]^I=F$E>8* 5U148.-C
MK^4(<S(;LFS,N[NYLE %>2BD7'EW@[%(YEKB':G)<4(^MJ9BN);M',IK([@L
MA[2M$=V3A)*PB@[X^>41<LQU7R6G)%;R<Y56K?O0KN4Q#L F<4 &1(#=M4G]
M!WW5*.GD@_5GYU%^SXHJA.%ADBD#6(!?RHMT"5.A@CX 4=:TI#LWM F"8<-4
M.KEHGZ2."S5S.;E:Y]#?*$;LD,>4;\IYD76Y"+Z.2"NM_JLJKXXOWEU3)/HJ
M!)?AP:MOX!S$%KWLWU7..9P+=F?FSM]UY_P.J,:'94D=.OSUY9?L-?F/A$5_
M01&4?H";/G3D]_EL@=OB6N=3P2Z.(F)GYE"OFQ(40X*#XJ&JIQ1#NMPM')NP
ME2!OXA#*%=ZFD06!;\I^VTCWO=5#6SV(\MLD3\+<-,FW2;VBIHH1&9;,*HEA
MI'WF9 J%&, I@SLI66"69+1->>MMJVOAXW:\>(/?EKDPUWA?N&2V)>17V)CD
MQ4;G!/?H0,6E>KBB<1)Y.7$37/8E#A68@77YZ44K\4V,R4J'#^ BT\"'A0@'
MC31^5?<%D08KU;,D4F.%SVHK6G-IOP&<\JV2.T][/,:%*><R=!*F,![OIO+S
MG)]B^L*IG1V7H.!7H28:NPM8=]*$9UY^EFG>@7<A;.+':O0J 6[40^576VV,
M,NXD!!?ZSM,9I/JX,7!HSC0XY8>!$!?DK9(<)@V#_<XJRL&H=)YT>5N#C.H4
M3=0!EE8!9%U4-0+'XA.VQX6&';^<UYJ1EG4;?..:N2]YT9_;W4KG>UL1819T
MVN1^G6>L,E@N\#F88B8WETFY\+HBLJV2?+PMGQNE>G"/5E;)$\GLZ (QS%)R
MMY?"=4):NXG7"J"!LL@E)$+_?M]UV=/Q;2]?--6.YNB+B\^FJ_7BB\\>LERO
M:#<M+=*G]UHD6*,OOM17^/#[))V5W__QXH\T ^)!*XK%A#_?5TH:"?C8H;5^
M<NIV$&"-,.3A$T.=A$49EY_"$WL$;9A)]BE-.SD'FUNVY.]6Z__R5]L-_ZN'
M]ZGMBS]=_)[F@C5BDPDOU"N !@KOF"(I^D-R"\0;S(]0BYK0>#77IJO5CQN4
M+"(B"<S(+Q;02 :1=\[TN?" T!/!?4OR\XK/U[ #1FEY"_WV0 F?GT$)3V L
M'QB4<+:-CVL; ; SS!U3S,[*G5G[UBGZ-Q;4SA?>8RZJ<X1<'C#&NQY-7#;2
M^4NI18_+IZ#EP,M8>0HS_Z'S,C[F,C)H-H7H<CO5<@4:V2<ZI3/0HK@AYR5[
M9'.:ZQWZB2D98UD:M46%-R<"&>?U^=!':N3*::])2>G C05Q0QER[D@A=AP=
M3"Y/J<NYS$[F+I7F1XL/.U7:.Y_17\NLQAN3FPT8@DAK<]LRI7\FI#NOTZ]W
M5@\MSNEPQ3JVKI:=S\MJ)X?0NU*;XN88"Y14%I:T;((OME:/M,;:YWJSI!WK
MO"L><U<@ 2(:*C.D=NR4<DG;!1.=-\V9O+)D7;CFSCV1\DT=QZSR>=X"C[T%
MT@1KUDBG?N^"70!<4UI1U54N;!N=:BPXK_&CAK#W7%5WX"&#<)#V$.83S%1A
MAD(+!-HV873?!<O\<->$^'FH'/@&"A:)E>@J;#_AJXG,ATJBKCT@YWWRV+9
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M3OZ3HCA<Z2WBN%.W.Z7K8@GM5$27K?H:9G*P5V,7?LG9+CPCHIRCPQ6]MD3
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MN>/EI]<G.E:UIO2JZIK83!/&76N1*<WD,V@TH;T?F&6IZHPLLIGX7@HO@DU
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M%BCL6K]O'+8K_0F,UH^)"DHNFWSJS;[7.S6;\YLXAF&X3@4/QD/.WH<S'3L
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M.I=V+=J@E&4W_L]./FH,.06+B(*Z;+@[B#I*D;9(> )V1IQ+(7)J=H)!F]E
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MTQ4DC:YO* KYMFYNGUTW0DHVIK2B]C&E03CQT%1(>3)%M&R2#[!)"'XXH^4
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M^1&]_N9_OOK\V8M/PT*$ [0+OA/>)$VN8D[':S!PCMU"9/.!G-^N4SZ@_^2
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MK[[HNU'6TCXG.%UQ%CSC1IN34^V1@#F3G9)MYRKNEB%-=]HR8WVT)Z[,^-5
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M9)(JS/D_M'= -_JN"1>TG$#7[J*V8 DXW_]")5?1>=.J/2?F38V1A3%B"+]
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MNW,O+:O#4R$!>KEI7NWIX/BJ>8)MBY*LSM>B(!7S+I''PL'ZZ?5I,5SC7J+
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ML#^2 N%HR[AP]H/3F:WZO412OJ@(;DA*K4 B\'#;/#N01B_'SB3;X!)":4K
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M4%??_XQU8:C:CA ZOC78,20RN6#:Y!%.[G4C)R3%:M&.HD43@P_3ITUW\A@
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M!TY$_J)IQY,/_Z[LWJZ^9.;GQ[=T]\R8?K5=$LJG<O %)$>7.3I=]-K1#;Z
MK,X44.NHE;U,U(GAL-[>,D6G  Q;R_4M\W02CH[.D&6.3NVEFV)!$)]$6#,=
M_G+43@Z'U8U#M+4 ]<YXE M*]O1P)"5.P?<R3Z<=[YRX^L#AO\S46=NT3-$9
M2.QRT=UM,R&UN<S1J=UD[=K+-)WR+-N\WURL7D49NL5Y.ID9<+GW9:).QKUH
M!&FZQ8,ZDQ[8DC39>IFF4\.1DO_B'MPMS2N5R&663@R'97*6*5H2*C\[H0)L
MSZVPU;>[1$5SF;DSELJQ]R]S=<I>$274,D.G2U(1?+O,U+DHYJE!<+_0TG5L
M,I#B6L<- >8=KNSB CE>71 0DOI'",/)!'"* 6^+JF1XY^#+';/HJJ(H ^[R
M3?&O'B+(9;<.L0VI ]D8R)BA^V43_DQJ*E U)EHSAE6K7H.&W*37G)<5_<8!
M<+R*F5F-FK<.\\:D?$S3K4_*6)E3V/$((QGB!Y(Z!L$_T^J6;?Q%A?1%ICF>
M WHZ_7]B&L?)B=/6!-^(H8!#="B!A(FP3[IN>LA5;/JU,$Z&_Z@%]8D94TK)
MCY]_G&E[ VE>AG<$)7+\)1H ;;)]@9TFXD!X)5$TS-=X2ZCAE.TN VJ.)I4P
M@A"<#?-01H#P/;:)$2E&%#S!\51SYK;(W])ESLU#IB&M\-6P/M U@H8N36-X
M6L[_J0R TOL5GXW6*@,K4@AX*+?:^I&31)5(4+7\%Y.4CSL".BAA=;9,>CI^
M7<>[R.MN8D<T'HK-5S'^U%GC22'::1MK2;C.76[P8.-Y$&V>FB1]Z6WOH,GS
M$*;G%Z(NC$9@N6S.(R 63_B<)QPOCV6J3@QG*5Z?+UXOI8\[A O<)[M>9NFD
M8:J69.NIX11MVRREH','+7C#RQR=R5UP7/C$@G(4CB4^B^&44,&;[(#K]E?Z
M__CA1-5(FL)\5_S%*G6VYR+N4<!-0513A^B>.OOP341N+IJ)L38'?/(0IC-@
MXB/-!E ?1LE];>%MJ-TT=BLF/?QE!TS4CIJ>B84 '=Z[75^7W"R&9@65L<S"
M[Z^;%BW;>),08VY(DF\7ECLLPT9:J"4DHY!:9',.8157D+O8="J@8M&_:[^F
M=[5I??/%ZXO5#T5XU:H,#D+L@+_#[$Y&F,.<!ZD;H0N1&M##G%7X[+I +SGJ
M4F'(- T9M:%;%@9"9K9<1<;\"D)ME/'JH?]<NW-7#394^%E[-Z7@9^P^-L.N
M.*@:05E?<X\@6H6E'5WE0UB+.*^XX13/B*UY848W87:IS_'9+G_+VM8U[99M
MWE>'8R;]BN%+("[:-+<UFNQ9QM8D.DC&#2F9%:X,B%F4'0D17*Q>61,F$7G$
M^)V?LR[;L)]NF"/ >#:@^MA#3H+/3=?PC@B3&%;BDG@6*F)B8'*'A8G*F*C^
MN#!1/8*Q?& FJE]HLQUN&Y.MV1?-GF\0T!6%"T14ELC.4VJRA2U,S%D7C,.:
M;HA@=\@V.&O"9F#2K$D=Q!M$(@'H!DG'NNNWG#8]N!N@6VUZI*3-3L$S0<:3
M31H+# IKR %RL+^.C![)6>4+%N>LJQI) Y:9.I7YS/?TV66.SI4BEQDZC7V+
M5;5EIDX!<:CB*&6K^FKA:S^=V",N,_;=EYDZ<P"I:@JW:9FHDYZ!UG<ILJ9R
M]4(S<!K25>5UES ,+M-UTKPOM8@SI/:4@%FF:"EGO;L)7_H&[M$!]M2J-3\0
M6_!>*C&LW>U)!CE<M2N<2?CZ@U5.0(+(78)(BY.Y$3IJ:,2/I'E1;(A/I(Q4
M67-RZ:HEFFPJOQ#QXFU.6O.4<XJ4F8[\4FERPX-!YLREEPEW8X4K%8^-+($Y
M"/GDY0[7()+4)\=H(7UA3P\8UND_\L.S\(_/6)[W/U@0>4CX3>-YS4DW(LC\
M@I_PC7ST01CH_WCQ\9_NDH8=)_9I9S[[Z.+C3\+7;XB$>9U7DIV_S+N"T\5O
MOCYU^!Y\N[[)J8KUZJHM&!F+^.YUF.W@,GU9'OY]12R F]7_R7?[S\+,HXV5
M.&M-15LEQKL#%9VNCD:P*1+<2,U"<SJZ^(QB->QL>Y1J9DE[<M\VA'5E&&BQ
MOJ[#3%R54FKC R4;RQ$C$_8W/T92?:)^=-&74&7*\QD8C,]H-I)IQ>?.*;T.
MYX1'HM@_47T0V$XJBH+R'9E>.;:<0RY;DE@/7[DN]T9I'8F<]W2DB=R:.%7[
M7[\F]4)'>/KVLVV]3--IR$O8W'VP.PM6\33L-:^.W8(-.AW6,<LZ4#;=]3)5
M)X83[JZ"2,F723IMG):]=)>TKW);+=-T>C?UM7&5+U-U!^NTRB^;_I"$*$MA
MX4Z%A6663I43E@[QN_ -+%P#9X=STU3];ME*)[$]:(!]F+3'!U&STNY<3FDB
M.S5*[' W-JM$(:\FZ'*[QPR<+K!IE_5R(?!*PSSU.^4"C )*>@U"/J>I"\-,
M"L[1?H D:-:$E>SHVX2UO@KO08^S9'!T;]$*KD[<*G545J<N8_=KW+P,X299
MZ^DA=FZ0ZR*G5G&,DW2>8LYL#WF_%JWWG!B4"=%9##,<WHLUTUH"?&Z*G<#X
MW:!L\Q%FOC!U*5IAU=$;O("S?"L^W;^JK-T/A6@FN43G8KY.!C>\=S;++)TT
M\DMNZHQ'%8E#EWDZ%<%LI?5I<3WOL*$6;KX[F"9NL5PFZ4R\1YY0;+A<INN4
M4]!90^PR3R>& \_YIED2PZ=+Q?UE1W"=A:[WS&XJEU3+N>-&5'A1AGR9K9.1
M71F.'%KCGUI:RI-)> J)46B_JHJKO,H\(Z"17@/V5'<%HP '[!.<O;HK\X0F
M5N1S!$3<-<2.B.<0%<-5EPDT4N@A %$3JH4PIKJG8?ZKS]M#02+J #+V;<L$
MA\(L(5+.BI),D&O(_1@1'U$M @4VUDM?O<G;RSQ\Y]DW/U7%D8>?=\S!$/X_
M,T)$ZD4:S*;9.TH!'C&COOZ1=YO\7ZLWR"!]C0PAZ!OY[UE*6.GDO95G8F(L
MHC?M5S&=_SI=>N#M(@B3/TO_JPBW"I)F>#@+WQ-NK09#1!B!:5QZ6HMT(CU5
MB:.R4+9&0 !)J)SRAE>4QN,?W[=$Z[BFO?4E$S.JDCCVF7NUR:]#NOVG8MTS
M-61XS;!1E8B$Z4+<7 H>]?-FLWGV99O7;T$O@MVFQ).Z; 3 I<7T*,%( <+9
MQ(/[T:X0BDG&(G:JG]Y1BS?E>H^JG2X$'S\19'*-!.T;IXX-DLNRV_$.U(V]
M;XA)8YV38/I-V3:U+93_U'4X^.$<WQ05K1G/$CX(#.*-L%VZ\3<M<800GPG2
ML561@TS%N1FX)OS;TK?='G"LII8S=;^4Z*WK7:/2ZX3O#-MRS?0CP=35!26X
MY6?"\1=FD_3XT@?R(]ACPK8@%(^\/FQ!F*1R'[[SU.RT W4G7#/)U._#!*Y5
MOGQXL@<+5T'R'@E)S!_,^\CV32P)R'3>%LQ]PKL1Q0<DYLFQ>@;8^$YO"/HF
M9=6IFD'LN3F,,J\/TJ%"!!3F-)@EFONKU57;W!ZN8_:^7GU>K(O=95C_CUYD
MJY?/7[Y 38#/56+3PDH6+<^2(W#=#F)2/F0@;JG#:=BVS4ZN&-M'(-%I:]PV
MQ3%A7Z5[@.HAGGTU+:E\#Z((R??*Y '*KP4$?+XNZ.BM:2)1NAG\4SA" L3W
MS+=,)!SBQ=Z6A=@G'(GM$(KM?QOX8BI/V,<\OCILSANQM0W=ZCE=./ 'XN;K
MYK:?;HSRP'O!Z)+Y%>A/[">0)8ZTT,TER*FT]8"]"OIF>!\BBBXKPG83<49K
M%ET@Y9>V]MA$XK,XX\33X[2J\?Y=SA/>E>&@YJT5C>"]B,W8A]\L:65;NOQ*
MHB7F/;4C[P=8]!);?( 3YY7FX?%XL%C=ON&C,]ZQLEG8T#63>]J1"L_,<)S.
ML.GIQI35P3L'7ZABJBJA*H(I((-O&[?)6YIUWP 2_T[UR3*<):XPA@T6+U19
MJ/?M]OXRY:R%Y?1L 2L]7\ML+86LG\>R048FW*$4E"U3=3H? V=L,5"GAH.P
MOKAIJINEY'=Z.%=5<[G8[],M(/DA)^?XL+  G1U.E=^.XH&E3'JN3)I'.9IE
MKDZW.X3 A1EMEXDZ,9QE,YT?#K-,+_[4G?TIY*NG#/PR=2>&L^023@]G$>V\
M-ZB*L8PD#_?$:A>4W^2 8S5PJH-=J3?=.M\7Q.'?YOMR4QTM@LL&N=[_G[UW
M86X;R=)$_PJBIKI7CH#8)/4NSW2$2K:[U5-5UEJNJ=VX<>,&1"0EM$& #1"2
MV;_^GF=F @0I2K8L4L;&[G99)(%\G#QYGM^7$[([1LN]]#)&)"D(SUG5K)J8
M(@<-/S8Q0I6$ 0$P*RX_#"MK56;UQ*W+?EU728QAYU#29<Q<9PCHG><0PGUB
M0B_G%6+5?U:.,5,IS1ESA]I?EA(UYEBLK$EHTX(^58*FN>5ETC;!B91D2K \
M^-P;$Z6SFU'$M'B([E^4;<2 V'A .<(9,NQAXT>=KA##>C&A E'6% <RTG2S
M)&$IZ9HFGPQL$P6V,; >5)E23(QSIF? I2Z-89I'0?=QV3_,1<">V)]1?+_1
M#A))9J4JM&%%DA-NCI@P'1R]#C1'@-(@&4&<O0SIG[ !)<;R.5M>\-U/"XK"
MD?L;AEM)DV?XE<86.1@FEY=@:D#,LK>G,A5I4#(#U&M2)Z+TK5O[QX:5POO7
M\0FH1CD^ZO@$-F LWP>?0/TFH9J<VDU">=-TO.O=&DZ3<NK.:0[+V\GI^03)
M3"AEK:0A7HX:D^FLBBE"[NX0$Q-Z6G0-^JVDGC[0%ZZ<@ZI 9K8ED/0/*)TM
MLQI^:]SDK)?I,F^_P%WATM_/+TY/Z0M_/__X]NSO>GDOW-QP:9<&%(#PK.IM
M'=I[0+E:,=M%ZA[N;?@R_&%7^&.9RIBOX-KES7J=[P_O[U1&QN.H"F:5@*_A
MQV07^'E[K'#AY+@^"(LV_-?Z[]NY.#]_Y:\"CVE7RYQJ8[A<YM1Q5119.4B?
MG-Q&(Y30NMGFH0/"'OGV'-Z::K[QACE+;9K/C):>8.::T?RH]&B*F6JA/OZX
MF/\6^\]^58B-J-Z%"9@B+0\BD^DV*E#VN:HC,S43@'+DF91+9/%?"(YN3AN=
M8L*?;EK^6$^WMSP]D2U;$ >O8>F!79;EXGFKX>=4@=I&WG+!YCM6H>;F+LJ4
MO[OR%!.WR=[.Q=_/7]$+U0JB&@<36\6P*"@-^Y%[BYEVJ_D0,I<BL:@,GJ8B
M)\L2ZWP\.YJA[LA,.WPM_^/*+,LR'R4@FF5/*]\N#"PCJ:VQ-.P*4[=O!46^
M;. *-D\[;O_<KPQ$>:.N:CIA CDI#V=!1AVMS%0CV(XTF(#<$!(AKF&!I1ZX
MP3H^%0,JR;",,J7Z&F!7%9F9E\&UR4AU(?,WEJJ6E24QXP?DR#9U$Z5C8I.B
M7\-=06( +SD#=3!C3BJ"ZX1S.('+H0R]<BS[,K6&QUBGH8<>7GR;Y'JV[6+!
M7I*_,8JX:/<&!\<?Q3F*-%;-L9$>L5CCP% Y4[V+G/4TS>_X"*L(2Y&9$2(W
M7DI4=%RAPF]P P(AG)7>":'JJBMCT$C&,TX2%%Q%9<(2$05QQ4J8A'641LF$
MYD(+QV_#)79%EK S)1<;P<4+=JL1F[PPHT\I2*%6#%*!85)2&W=!I&+P>W@/
MG".NSWECT.VR(L='CF2N LT37$KA%$*/HH^";SRC\7S 52N#G?=G'U[!!'%K
M1ER,Z.K#<,2^NR49\2#/?%>"I)^6T#^\5-"DRL97Y#N7^M</56K@9KA"?4MZ
M64ZNV@_66& /C78!SX=45=FB8_N:"0R;6(L\,B-7DP:Z]A.#85K-L%I;J4]&
MG/947:?X 5S FC-\+#Y7&OZ31EVX$RFKH+WEU/GZA:?V?-LS[14KTG]>504<
M0ZIR!-.WD/)FD7W!O*V3R/EEBH,^E2G"_P\;SS"E,9VE?$IDAUA"%X#XXE]A
M96>%R:YA*EGC/.FA+EB*\.ZBFF"'(MIZ3=1B&;"JM.LQ*+&$8%EQ(C(]'#2O
MF"IW>5[C.G!Q!IY[??VEB%LU240UI%P/33*/^F1N9GRV>3% AL=:#A]*T9M=
M'2T*7ZQ[K*:Q5OSRL+'R>:3;YW$G-FX-/"9<JNQ5WFV917R&97R@[!.0HZBD
MREF8E??7,[7(+IR)<<I5A</^X)A<%_K)V<5I:,NHN?X[UUI6T(;_B+(*SP8*
ML*XKRD%)2RC&(-LZ(IAD:LC;>2OPFS9D2>7_GD''7[<M!RXR5*N!;2T_ME:D
M"\*PAL9)!==$3^DMB;U-L?84?H]'KWF6J&0=E!67>";M=CLLWA3#4;2::A"U
M?9%B1S9ZB=J>VB*P%#.MF^$2ST/:SN7OQ< HWH:]X%V[/:0;*GK7\T+':&@I
M5Z8N4,%AP^6WNGA9%3U"# X!4J[3YWFK9SZ#>3,K(ML:,^;>%;\1P*W:;#[E
M\N/6^;*OC!J+['=VE:@.7)1AZ=0]C9N- K_(U]&:NCO+)ZTEB;9M)59XR)JS
MHBXSY4<W#MJI&%W!WYR!5QKS26R0:<V.I489.05U8TQW1?4F][7 AOL="["X
M(S.EV>+35MZD3+9;^EZ7LX[KX=^%X+=[YUV!U;[2XT0K0T>3*Y1U$YM%YJX3
M *Y@DF@8A]S%=@*)M7/8@_,].@L>KZ70RYY>OW3I/>X-UGQ%Y]!NG0J[)7)4
M84=#*];J<6?%\K9Y1UJE"/23&.=;=G<L]*[1OE)+PI5QNC%WRI_[+/90.YNL
M>0 N1/V+=6LO&31X])*Y^' :2L*FU*O@ULAY@P_I[>W]?:C&V[4XU>"[>#]Q
M< :RJ2J:)?88<)"M59&/N8\,GPI'05IJ]!E%7I;8P8+[1E2_,4'UEZ31K=MO
M?\M'63&ZO'Z3]E?S0C.;M&I!ND_9Y3!ELW,2M\GJO24Z.[2DSF.OU2-NJ"%:
M<D__2'\+*MK6E79<VX*G-3CDN\0M0D2W?(M8^/8'^ESSNB/AI9>L899&=W"T
M0:&1K>\Z_&B'#37Q3:8\<K(>ZLJ,UM"-F T<*^:N455;/BBT(W[_2G53CQS@
M59V0AO4TEXWHT=\2Z<RS$FX-6"]!Y+@'+/5!(MV..=S0DZ:I,\ECBF781AL[
M4F4P+[=,'WWT]X;6BG<#H?'8ZS<PZDP[; )TD%!-4QB$FE_P_(&30-E)EKH4
M?E**82 ^_>\9"<\E!@CXFE/&%/R#JBJ-,'L=D1-BC\ (AR??]B"2%\D7F-BK
M+JC'\OE[[[+GAW)J_50POE\)!V_(O6PL,?^3X$;Y9OP;E.JZ+6_-=I0L9#+W
M6M 6-3>VFR;7&9F=J"VC.SX+\-T*;L=C__5GN//@D-E#?-_;\ FK7M5;44/Q
M!?(U7$N^GI5$Y3T&A,"QY4A ;95!(*F=]A?8BC/LJRHI\:/HB7'M2Q=ZAZP0
M!)%D#I%?)YEM3/8,6W3!HQ0$-28[>$(MZ!'62N  \;(BQULM'U3'BTF7ME.&
M]B8Y\NR/ABZ4ZKRX%H<M1%T((C)'9Q$O7>)^^2QWNJ<.]13C89I(2_S]+J(T
M9Z+U[(H(;&_FEBG*IK5K@G>R-1\1A=,7HIUW'\]>2;]H-E\:C,9;U5Y?U-W_
M.2G9X5K8]+8<#]V=?)]C<-6F>Q8S'6U%,B[?5L^3@!@T$E;NUF[/HTETW/H-
MW(Y/\=#:2,914K?F735+5U%A*RJ.NXJ*#1C+]U%1@7=0E5Y''A(*J"Z]T<0Q
M<;H'W/D$*_!&-SG];ZVH3C$RSI9IJGK\6,%_2;U-Q*6,9F#FEZ,B 5<83?P[
MC%IG<=KN0 IL24X:Q(\:H"9B@ "*Z^&TX'1X3UL>Y2,T V8@:ZG_TT$GY+6A
M38F!^BJ;%94)O0))SW?T3%E*D]$]BUC,"=73@?!AP.26,:D]E!6W"7B16\ /
M'P=(;G&7,LD8W\;':)E061UB!16Q%!/8718?E(%@.&*L:8Y&5%F2P/H M#^C
M*=HJ!>:-80_-E#;UDS'3EH>U!F=1=HRF_.':FU54B4@+$PD,@KL@DLP5F/*(
M)Q,LUL,/:E'(2Q&Y XWKP5313-NZLIOWOA\,-QX5$=EUDPU'2DDLS:E7M#;/
M",4.;F$#;;$DQPS/O>]]5$:_>;!S_O$5XE[<Y<4G%JWSC^A"P4]&IEZ@.RH$
M[0:^<0N.8>X*%J:(,D2OF;E'4X1?:ECL@%T]=6!3I1J&"<FR!-' ZA"XX^S4
MY8\WT>@3)=5F,_@OF[FFXF3R3L&VNHU2SCYB2$F!V?74H #FF.94"(9R#N(\
M$9<T+RV"^>PF*>)=3#[/%RM@>QB)I@%44W)Z/=WA9J^/9L./K&=.,XI"&A=\
M?L&^)' @&YL'L]!0[7.93V_01ARYS:6H=LG&/*IA+%HU<J@QC\NJW?NA6G3%
M=911_N"ZR*NIP/QX6E2*/.XPGE40+!A6Q>6$KB;)ABE%Y$P/<ZNA(N4KGZ)-
MBOS=E;7@SRX8#T=2]Y<,-G*6DX)B=00&939*TM!+T7/>=C2_0H="9 1+PHFL
MD\U+KWI&YJ9A&H:-&E/I-FE)4%#E+E)]@J>$B/#,=>FT#3D_Y6S7HFFE<POT
M4AL"IWH(H+[V2E@I+'XA:QP+4NH1-1"JO__]$@8P^H3+;Z<1<@4 9J<$E$H6
MZ5S)!,YJ;[_0 ?\4_(K5BOBZCS=8+L(;I(XJ_/F"B^7*T();(:NE3EV@=>HU
MY0Q,@AYK1BY&,6/<LC%<>A0BRT'TK(OAK;Y2'SC(' [W\\7/(;<:6I>J%CH)
M]KB$'BZ0Y#XQ)(?':M38!@=DQH'IMDU"E+J(W%-'Q$LND]FZJ^$/XU@2L( B
M@1.$; EC#,UI,0DG/2W>C2I( =FKJ7=V[N[)LP1OX&&)I/Q;ORO5,HQ8 VLM
MQDFH>B^TZK]1G-;4LL$2+1NJ?75;I>A"*\"65^ZW>A*V'*D6ZD=+J*A*KT@7
M[YIDE.#-.LICM'A5/5&9"*VD%&,R-A0JUQOO'@I18Y;Y!"\LW)D,PRY86293
MLE^S;W3^=X&7J1LRG1TQS_%HHW%$N$".@Q<O8%T2M0A1(5)%E"F*O""S]HYK
MI@G(2PR C_:BEML[)$.OF=KV['<M=:H73]Z7Z1$#DM1*- ;9Q>@QI_M):%M-
M1->RH58&K3A&N-@\Q.&K:+4:WUX.OE:'Q.!JIO3%T*8F*7,LI4J63;N!<$7X
M67$#T-'78LP4,\7+)B25 X<2WPTB#'.YMN9J75.Y7?<&AIA<N$I8"2UG6SP)
MNMB6'D>,!%>9EX+7];Q#3G VFDWL@]5IG2VI4U@!3+MYN(';%K'S4JVJ]IRM
MN20QX2I@ZI)T4[=AO+IDOT[;IKB;Q<<VJ+9@FS<":ZP=19BIDL&KR&OTC>D4
MWKX]M3?M8E^>=]'B%VM%0SB!< $UTADD'+K6VHIF\/N#_5T8[+S]_176-AW^
MY?#HA,[[V]^#O[VY^$"99\1Y<\BDE'69!\.#4*JA6!%8F[,U8HD-8M'UDOX^
MIRI6MO9Y1=OZ@>R*]I5=1^PF^W:P6V5>#IF8A%VQA.>JR,$]MS:R)+.;"*\.
M +*16K8KU41\E=_Z$@;^#?X7@T1>$=62%*/HM&MS#G:2GNG)5>4_I]&]8&?[
M2MF2:%U)V].=67]J7LTP^*'K4BN#S5OS?;9V#;_#-5@E?Q<O?W^YW2;(->/M
M9R-NP[N&08?%B;.?'.J"-9W.Z+HPLKPB<VIW</UMKE]NSES:(ZE6/%0#2Q>U
MI5X4/3K!/C2?33%*2@T_26R%RJ08 'G9#!UB;]GTC]&<EK!_?:"R#P2TBS%)
MUQW1;/UU]57D/VH/KS>9$"\)M/;]E72W/R,/AJJFVKXDN7V\NLN2EUV*\L"N
MVI4=]("%[6#Y2@*_DW-XFBX>Z\%!G4>[QMTLYI8"4K9@3<^J0-BBK'''"]6/
MNZN-?T& VH7DON@_T>.VT3_AHE8$SEJ3*Q8]<*Z0CZ;73^VIC_/,0U\E(SB9
M28L !T4] ?6.(8$$@Q)&QX=-(%<$S!+BSQ5EB8P27!'J#2@;Z^ER1M[E8+%!
M]?<-!>;*=*12#;[_MBI@#2()\%+L!:,,($TCK[L(A D>-#,+J+=<,S9.3!J'
M%.*4<^2-RFM-WCHWK7992+*T;"P"Z3A;'@1SMYC*'/CUK! 1)',KO0]HQV=Y
MMNM2K[X>9OL68\U3?"SHH[W#_=>#?@ASQO]'E(#TT?!/UOG*L641_,(TIJ@/
M8[@'LZK(,(K=Z&."(\V59.B$)AE>P6,R4]FMJ;UWV/+>_77?*U:9P2& O%Q3
M/PS\=:PLA+@_Z*OI^^OW-.4DL:V,*J*7UMMBS2)='+S<+J9.R0QMDM*ZGS2/
MKUF[IBB<<HN ,X4.7HD.AZI5]H#1DOLG[(P@L$],G.B]**V%-4ATG)J6_#;J
M<!<K5V6B3,[H<!R;3IRNA[65/,L?/FMM0D1[%W4>V "HF,95RBXD]^1+KSS#
M1E>9_R5L5F.PW%4U %8Y_K[5AUOKE6^2JT1*(WW57;^8W=T$UGB;M22:&-P\
M!2S JXC4 UY$NB5X=UYS #<JU<R1L&$4@^J&9VFP;Q'MXZ[4A)_5X5X!0Y6E
MTMMB32(9J9T7*7M;20B#L->&=?#U2ILI6KHU*TU<7Y1>\#ZS?*=P0"?4..B>
MTY4'V/* DZX\8 /&\GV4!]C&4JK[JA$8<$)@E6K#6C=J,T.+P1;-.I]WEQZJ
M-8Z7-V@%PA.BB<' M.V2(_-15!7]HMX >B9Y8.IU0 MA%=KERRYV;"AS[/6%
M!?I'57+1AN1IWI[](W1MD"#<Q+A"S6981TJ=9FR#@F<)"B_F]N5UMDQ[; KK
M;:C"QR;8$1R921F<G[_RO+%XH0? K^.75@"M(JO%)4=I1"'[G<NSL_*5,WS#
M1E]ZK<.-3**HP&[R:D;%S'*;:4!LP4_5B&!;<P1_"YY*UZF#I=+.T+QQ/&Q<
M>)1,J557_4VU-+G#\^[&<$:@FBHJ5.&U^I(1H'T&.FZ_ZMGSGFR 1;X?>Z7Y
MN&Y<3YP9:\3Y%SI&+#+A#PIPHNJSX.I*3MURV#0MC)FXS;:QQ[/TWN6J5Z3B
MAV50J)SN0#AM:64SY$C%"%X$U=DL,*N==V\NSL]>P;MST!^VQ> V,7>U)29Y
MQA=3G,2**.6#5?1H&/>I*++$P!7(KCD8#)9OL!-+FHSJV2-E+7+BCRX,VF_,
M\(!VL3/#89'@Q;-_PRV# ][Q[#!>ERNA,6$ZEF19*/&5+?M8/@]M!R8=34$<
M=<OML7^U;1%_GYBJU;"U!06NSAN+K&'9\#CH80>?#M$),H:]\<-$N4+&L"*B
ML!L;R%@!@L4F)2D-US8S-G?<88U\;K<<;P5OGY7DK3.L\?V*N1+CJ<JG/N>(
M;9%"]\GKBG'1I;]XDA-*/Q9]V35IJ=:HL<UPGD)0$Y8]3@!:&B7?6N?MKY 7
M::,QR)^I+*8Q'*.8!1@'L9IXJ47ACZC5<=HZ:?7T(!HW_]VS?2TQ&3FH>_U0
MYL[/!1;GOZK%^]QOFH%9;U?\HH=:0^;O_\T8)'Y,JLH(MX=P&B?>C5'FNQC6
M<]4I\&,= 7B9''61OW$M.W8[@':TN0+XL*6#@K) :G3H!53:2!.\/K]N).W^
M6Z-J, WXQW?=Y/*[W2!9EM S>"A@;3&28F\!K\ "6I[G2(26SS/9<T6*(LJZ
M/*X1534;=^U[0D$5D3(527!@_N0V@7]JXVOC'M,-)N$>O!:[J<Y8*889G)&=
M:,:A9 1J>P724%Q3P"GE/BA)\*!*<L+L9P:$##"L<^M94BK;V5)#?W4D4_AX
MUURS$'@='.Z]'ASU#@)X7BIU#1S[%"Q6C7/"%5*2]8KQ/DH"4YS-0^LRG]EH
MQE6ZR_'JP?.XF-(IS#5*6!@H?(ZLE0-(DO('L1*\T1-8  R&&OI:P%NV+E!W
M[H?-*:X.'B/U*2W-IH<J@[ 8]6O0F6JM(;4%Y RI 4GDTL/U]JG4:F>LD;_3
MDG,^GDT(7K\895I1<H"M%L_ZGQB$;TE*Z6*MQ^7$M&]/'F!BRO,$KN;>V7;Q
M2*SUKX,BM2Y*R[KB</S;7+5 A%'YG*PN$DTD,93ZUEN[%+PT+2 E)3F\<8XS
M\#GWZHT'0G%;"T-[5?=<BZ F?,[4@ES6-E-4B(@AD'2+%JM%W.FRN1TTR6SA
M#X?98=]4DQ *=PM2,([2VK$^]H)/0\FCH#7T[WFJ=O2A?2-),+%[N2)30!5B
MGO7 6M..PZ\>\12X6G-2:R95SECLF=@.D\@]96D:VI:_T 3<4FJEC(5^0_!>
M:=70MXAZA3TN,'4";[SW?7A+^IR2#AFTSBEIF_-J_,2+5FT+[Q\Q>*>)YE&O
MDGR*&P[3J[BN3<NF;;D9912HOCHA705N 9C25!D.*@/L=CZQ)-SCJL1:$&^J
MF!?#E-&N#<2L]78I-;("5)5MK@+&R4DJ8OY6_?Z@@T'7% 4.W'VFT7VEP-TA
MA9K4$^*,4/UJI2FK@2-VQ28X<6LIKMCB) OJ")=4?2>#(<P#@N)<;Z'L%DEL
M8>Z[=-P:P]49]2Y:BHARCCNW=*SXWP[BC/]--01DB<O4PGKQ7DZ:)I&Z/KG%
MB1_84#@EYA01O#WV( KH;"OJM6P'_.0ZYVX![OI'Y 1Z]P(Q *%;4*$*5HDN
M\G)KQ3%L-G.:/A5._C/@_CM7C5VP4%G8+=]S1YMP#VV" 4'))\FH6Z@5P_&N
MZVZ=5@P';A>P$C-;)HAGLENP5=1=8QMDZM9I%7-7D4^Z!5HQ'(Z==$O444X]
MGOD-O2QNENG6:;7.QFX?\2V[I5HQ'/7NU.'M%FNE?D( IXX7=C5K/%49=TNT
MR@AWW8_=.JT2)8HRC3H-OM+PQJAFU3%6KQ%,T8KZ;I56K1(%[[LE6F5?MC=$
M=R&"^X.9C>:Y;KU6#(?@5[H56A53R>N)EFZQ5HD35G)4IENDE=:4IN>Z55IE
MF&OJLENE>^X[2>MVZ[0Z7+>]U/#O'6K]WD 9T]0<#$;,8\'%"U'P*X,Q4-6U
M:T*6^E_\OM85OOU=L>@C:A_Z;\'*)JZ!W*Y6<*IH'%3G\/',DF(MPX[A(0ZD
M:".BTH:XB.ZP@M$KF$;*IFR*1?\Q5;)Q>1<31U39*#51H:Q/K0U(M9ILU]93
MZRY M(;4""HZU4]2<6P8C*(IRD[H:F2I_"^ZHK)7;"*28=*D:X]Q7%'8#U\H
MVFF"3V-\":]1F]&M;I,B%X0I*LGRV#2TRH5@KZC"QC?[=US97QOM1@U%LHZ2
MHABD5.X$$EAANPL\O2CK,"FOZJQ'B]T+OLNQ)>?%K].B.C7FM+,;XIHC1C=8
MHTLL>E2JY]>:9=H>WZ@UJT&B)IFPL_B,8K8)R5M"9@[$C?Q7%3&\/]9\2MTI
M=5M@V1YVI#?JFJ3 *VS6Q(8BCW3LI7A8 )^<2,)+4I&&&&D-DZO*<N^TOP>/
M'X@U@0?0<86C^B819D=^T@>?%(MK;A9+E$3&J8Z)Y=I;(JZ!YJ(G!=B1LTL%
M6K>,R.<5N"&_:TR=3S7)#(.,5 3L':VRS[N ,L"]&G8BWL?,-D(Y'"K7RT35
M4+,+UTQAA5\>=PWN]F"=]+L&]PT8R_?1X(X]D.;S% OIP^!OA*[Y<Y%0+2EW
MQMKNSBMC>5FE&1U/20$'!@$X+*<A0P$3H N#.&'9^RZ!VBS1I)Z]HA;%KP9Q
M8K#LF3F[&$[OUU,!> 9[@I!W7$$\D4+6'HIU\$5U[6EV=\LOT7@"T28*VE=_
M6N)M>P[@T_IB.8@:A,+*&H.QUY+KJJC_/,_2.5>EQJ#9J#'"KJ% EL+?O!IK
M_C2DREM/Y:M>9XQRO_)8;A"_B!;F1??)M.#6D,J"@.G%EOQ[Q7+Y]ZYT1XK1
M*?Z2UZ[I!L[4+T0N3E$,84ZX2<PM_W=9E4QH6N3C9&9Y5<_'"MLZHP[1O)H)
MG1]"E_OHIT+J2."G.H9"UM4K]R= HI:E:YL7S(G$NG4AZCP%=;)W!J5<7E&\
M=;U$TN#H<3K4.$)GC/A-:Y^9ZWS&8'2@52-JXT<X5ZJ?5J?IMYSZE;/@'*]T
M0>S.838,.Y>0I41TKR"EH!1F7.\-AZ>!:R"[EJ%#PZ80>V/@2BD$'#'PL)7$
M,'DUY:,^0JN-Z9PFK"K_E"';-;4TDW@0+664S=UC2X>J[R.JJLVKKDGF-SJ'
MO@?Q1';GHYR,PZ77TS/$&,Z$CQOV&WOZNWC,JJAZ])F(]AHX9-V:=5G3+\V:
M=N'U+KS>A=>[\/J##,>B0G,%<<[1K*&X%.'R"-EC& A/) :)\Q&9XH3E#O>8
M= T7S ,Y8^N:NW+!D< >1'!*N7]<$:$=UH,-2'DMU/@2'U3MG(MGT^"#^"67
M2E0A<6CZUL>"0*CF'@9;+U"3A(C!/G-3\([X!/*1-?X*,\/.2.V23 44[M4R
MK-"*>2SR-!:"4J$:G2#/ 1C*GPA2F4%]@CD8OQ2QU+9@?;UP0AD,UTGR03^J
M,][XS:_,"25+J";U.[:?1W4KS,V[UD>LGL^2&*]KJQQ%Y4TP!B.]O:V2D9=;
MNBJQ6;@JKK7+.K<=O.3U*I1^4G@I QPI# <1:IM(Z]CP;YFMT8:V/;U+ITL]
MGPT.[84=VOK>S_>5A;7K[OO5]SV3LG6+M*IH6@AKND5:==<+]UZW2/<81*1L
M4\HI8]"FLR#OD2J*_G:+M-IIHX1^)TSW"I-86E'6]5)U#;%?5*V)U'A8 U0A
MQ%ZW5*O,)R% ZA9IQ7 LL66W2BN&X^<MV<'NEFO%<(CD2F,:W4JM&$Z<E$4U
M[0+?Z_DODISMEFJ51+D\N=)@;UT(W ^C!1HJ4OY>B3-[1-!^T3)&=*5TH>;M
MAI8AR?HL0<,NEP<G1;PKI-+(JI 0)0528]*[Z&]SC',FV2MF1J\13#,3ERT/
MXI$+9W085)G%U8VE2)P(#"LD, !=$"&)"?$U(Q-S4D["X"XJ>& F1;[6294I
M/0I5ZB+S*5'H$6DRLCX(X*?P1Z;);,9\OEDN/ )*@1X049O4M!/5I%^QK82%
M'!96#O#0$GXH1QTNBD\HK>CQL!Z3TH\LR_;!\&X2&-&=X>"WTB0R>B5O((7D
M;4R<?ZCS"W'=B)*4,:5K))>\ S-#,/I,X)U9.-_""]938)^8YDG.1 >7&I5V
MD7./GDQ*Q.AR<WI;A;#MW#'LIX\>ZS]8T54%')/YP2W/'34_P/0*(;"VG+53
M6"FB^6CEOU8H:C? DDN+S><(87JY4T/?5*_A]G#T]0@U<(^;"T&U8G;5VFK$
MM(XLRIH57RT$ 50-126 G,E@?<\5[<S]]3$7##?B*67:$"PG\K9C42ATZ_T-
ME!6@DD$YL[.<Z>B9O+7PLTY,4YAD-"W8 #P8CER85C+/QDR4&Y%_MF2C0D?7
M"/.'EUF(YU#3(5,S$WIT*<AV](Y8JF1BFVA3/AQ?]+C1PI4E1KZ,MM0FVF?3
M5IIXVZZ*/UK8+W&KL9&83SAE+R>@6^W>T3[ 7X@L.C71)R*+'H. .^XIX2?*
M!!07Q4'4#I$RIBBYH4.OA<_U3/G'<H+PC/#_7(:U1K_N76BJ8+W,Y93 8D6#
M@ Z+Z1IK(::N*0+A=82SGL^-U+R5LRJ>6[;*4(7$OH ?7I=A/F\>+WIHJ9SU
MBJ"NEAE,83IC4'*8!-T9=%'*Y#0^KR.3B>#?QT54Q55J1!W042<QI8EE)E4B
M*N\/]8>@NN=CB+J2&B5NZVN,JJD@(/\\N,9J6=>:9<^Z%">Z"XHK9#U,Y=D-
M%B$O_$I_XN_*!.TTHA@=Y9)!MM>_;SS@RD4CO%&G-TEYHSR^8J7,K_">H"]P
M=69641^=[ER*-<I>D:\.T$]+.P6+"A4!TKDXV-VLHA]%#7H"WI!^%6U[/["R
M\M=Y9D8W&9SYZ_G].X\W,&.D:RL<$83:ZY0TO+;Q\;7)3["*W3)<M:E&OHH4
M,9V7#$MBQ3QQ&H_4?DS[;?_H@^6C -2O+>3VJH138I)G9N[M&0R'<.KD&IM&
MB=YB!+;?=O!S9UAMF]ZM*88V"F):!&</*.$8'[51&B63DFLL:HP!K*^NB[R:
MDEFA#+P>(+['8JY,;$A15PHY=BPV8$3VO\<%5A&WF8#W>_LF2. >3GV#V=8_
MW3)PHA.F"^0^NX YMR.PA$V*-=W@ HQ%,F)#,G_K#:L7G*9P9JIKHG66>UUJ
MX_DFJ5T:8LACI9#TSI+MS08O*P;Z;VE7H(-7,/$=,T1(^8EE2P"E0?I_+ 7Y
MO.I6O?"9;9H;-#23$6RY54A6,]HQ2M/(B'GPL!B>4,UEM>G489D(0XP+!8QJ
MQ6H*ZRAL$U;34,LI,S1(TZ)V+*#"HWJH185Q9>@#T8W82 L**T<5C/7?,U0'
MO^:%82YI)7?P^ ]" ;$O+5&'G;(LM5UE-+.8-0W<-##+,Y).7%Z0U#DQN-Q1
M>P;K#>:G%DW7IBU@8M8*,-EU1-4\_"MV V'-1MPPJ,>-^6:B.:K=KF_0]@T.
MNK[!#1C+]]$W2&H/IFYLB E/OQQV\.W2O(IWA:RQY=2'TL[-5YO59^S?</>^
MFGFBTVL\G6+">$P_-3-%&;<IXN L.&KB61S+5MLHS,@#*AGU<98C(VM51&S<
M1S-1NA)R?*!ARS'#@(.&7H"1F3BJ6I11("+\V\K2)P7*Q>[VV;OE[1T6MA#I
M^)N)C$CHZI0S,O _Q?D=&C$"+>'%2D*V?6*#[H"<3^O))CX75HYN@\3AP,$9
M5]E(7,+"VALN>,38'^4L3PU3[.048'-.L/=0S],)FX&;D)S"DF-3>!6# .-E
MSWX16U[$TBKVB?UD,5V';[8%LY:1H\[\U.!8VFIIO],8J]J-N)8J\$A$,DJ,
MQX[%,3?EQM&8E'0+-HFF9-/L9H$"(JN1_0!K\^C3Z"4<^M !T.MP*RV9EPH^
M&M;^ZYG!F:.%&.6/0WZ>>]8"EQ4^[C9*4HW(5U1\[&)B*?8!1Z40XH#H3_B@
MHORDJ9!?2UR17F,*[?!& N)L[H;/+%E^R@'= W;8RXH"#<CSB^3/A8W.9.0S
MD/XG]D'U*>BEYO,(-;>;P.*B67IN-C2-F-U>Y?7B3M?"1H69)-7$#^$76M6M
M$4=X'H\M-A@P3*XXA3#*=]VS?8[%\)'E[&Y4R:QLJV@/V^O9&ZQHVU\X_CMX
MA;<Y9Y&$ZE%)<-QB:+ACH?>AOJ@/:@S8,B7WOEHR$1> :*X.!X"YFS[U%U,N
MH]IRJ^WC?^+64]#0>\%%7MCF!VKR:T^72)^]PT72"*I2K/B4Q.SH>G+0)@ U
M] 0"?8(+WF1"M6J[;V),?1:"6C"!;XC!LIC/ 1<\X>BH)/RP<X72"JBA)$B'
M=(G2.;.P)B,P11,;:@<I0940W.;H/EHB2R\;I0,7R"L7GINYY3T%2P !-"21
M0K@:CA4J0(,&B5!]_>$QS&G/.*_'V?O_.7^S.S@!\PRD%WXN1GA2\BJ"IC(X
M/2\;XN>)B-Z8O7RVN9L G#X5)OP2@]BQ#^-01$D-_]5.G'KAT4YG@CJ,2T]G
M_IV$;?-T)^&"X#Y+T"AEP! 5V-P:KO("3AW"DF/RV>H,1)\"4RJ27)W-;8/5
MA0&1&DDN]I3=)ZZA!$'H.O6$4F+<;L>;''+&)Y%;P'E0+T;L""2:'B53:G9+
M4WW*G20=><0^)H$[,VDRT1:YY@%>I5$]+#0+/;'UM\O'&S_BQ62-8]AW7A,X
M>Q$RPL[0Z2F5F+YDF#*2^3HVV;;=&9?^/!$GPX_]L:]2"5.R*[  R;D"\6?W
M3;7FTAP_A47AG-N*"%2@T91 );ASD-\C#Q!:9O19;"B68JCT]PH5Y[\%>DR"
MRK6]6D+^NICV52=S;"D)[X<S8[V3S7M!;=U<Y%ST]R+EI3AK\YHU;JC!M!E2
M;V(27E?P<C8J4P[T(NX,UF^@K.+Z&0WZ4[(4-0-%XP("9D2+&S86O\.X'LS(
M4=8I;5GK?\*I9WDV:O 1UT;GN)L7U'U-V7EDIBVY#G'"*XS[X!UFJV$:)-I>
M<L/+8>3C\2[X ";U $[\.I";Y(K4L4_U6ROTT*@3F2&XCC4A0G\A,ZGRCI),
M,Y1E4OBI3T9ITKC\58KG.6X6CC!O.QCD(&X$Z@2J J]L:__?4O_O'WCET;:Z
M)(G%)6JE3!;?/P,C(*4ABDG55-C6,;1\P$GJ4\G;O*G2%KL=KHU1YD!K[1')
MJD\H3Q</U]9\F;%9*/21S'4%3QE97%#LKY[QQ:26ASU0! TI%YRE"I4$"R=)
MX>N\8@H-199M;5?%#&H"E-YY@R\Q:V]UVZ("(/=5=@*-ALB>FE5YKO;L.R4X
MA2*9$V6XUX1'1@4_>:&R5\J8*FD5MO.2!"GUP9LK>(=9A+B2S$N]Q OAAHQ'
MA*LBL40,:@F_Y44ZM$LMAYUF1Z^E\TEV34-W++\WO<3(/T&%)N-Y'59H0VR)
M_KYX8,B@C4*\.6U?-+3-J<2EX6"- )W<;I56K=(4%2X871O4J+.)ZT2.#'A/
MHZC<(/2735RI[MRM,YSK(K^;$=A>MTPKAH/NTN9@"VSB"G'*Q9EVF]-)N(FK
M195*8*ZBE^T*(#N%OFHX-M)'9CD6R'<G<J6,,4APMT:KM)8$H]&<,G&W5/=:
M"F'-E^T6;,5P.IMJ]7 P?(9"A>DMZ5?KUFO%< J.R]L:E7L"21(U&N[W!L^1
M<QD<2)1(PI:>@^\"1UKFCRZ(]6HIT._U#_B-%\U(/N54J&@2PX5E64VF+K/@
M7N,0Q5'HR)C7&B$Q5WM!+:(5U/SL>CZ"DC+X^,]3KBN0"6@9(%;,:!:;WNF_
MSQG(O>#MH@$8M!@YP<08CM+2JU<O7ET_VRDWSEFP($LT?7E84OK+3^B88RUE
MK)-"2'4351MI^:)^9L=04C?8]=PV#2\^WN47W08G;2E&%N.__N=5\9>_/NS#
M((G_ZX?[:XR'!S^LSFBBY#_Y:6K/WYYCW>7@YU[P>X;ENX38>CF+QE@-S='S
M=5*R]#)?0^P]7U7T;WEFEJNQ[Z\C8;B\(^$!(GS\0]?&\,W'\BW;&)Y;!PU[
M2#LR-=3_NVTZYP_$MZ9&";S5M!DT4P*FO6%X<K0?E/^JT+88T]4[#BR"B+1Z
M8L$]&"G3"$G:[+6F!5-PIPX/^\$O!+HQ3DP:!Z=,01Q<YA7<L)<P[7=8/YN4
MHSP,SD#WP V>)5%PLM\_[G/I,(^2R:8H'?K.7!7$MSD\)C++ ^I9O3(I<0'9
M_@4M@I+9)48M*K]+P-H4/FH*DL'L8MD9%:1I30M6IY0WG >EA#=7JV$?<R+T
M,JZLC9;$%71K 7.+DE]/F>T--OP^WNL%OQ!8]@4V-1HTC;;N2)Q:>J'8\K."
M.)]F644 [VBY4S8<Y8@L:.IQD:)W6^;-H.$3Q (06!TJ:;>=]-)T:7]<_SXS
M?E(-?&3+,KG"'2''(ZHHJ@HN6G-\4'_8(D$A/.*?,-L5-9<HDLR2X7'IE?9X
MULMRE#0K%+B1I)P)$( I#"68Y@N\G(ZKJ*(^TTCJ[*@\1/JS2H.:@2I9"/(D
M#$!(X-=2= \;"M?UA M1M$_+M2J+,?[X,[6_X6=JOQ?\"I^ FB0NTC>N2FC;
M3M9O()>GMKJD,W6=J;OW-4S=O:/.U'WYIN[K;R^T[<KIXO3#QS__Q^"P__K\
M_+'*=[^_X<H7K,I?'3/Y!Z2"03"!F:U>/&.NCK?_JJ@4[H/4JEXB=P<3K\ #
MW)U^CK <17 !M]@-%T:/Y;?!)?<.MD9Z-D:QMR^5+-&YJW+<W!DL[Z'R:5<"
MI+8ESIL4S9Q8&>U_B\HX^E?P-^[XN22,"940)A3";Y7SR56>!B@DP_[KBU\^
M_!_ZS\%KI*D'B^D?%=SG>^2V]-%[3+A6F)P6ANKCPM^[""DCI6"6>E@83<D*
MY*/88C9)<O[NN(D^H':--W<"]WD+C+CEF>-U+_6 MGMHMQ;_OX,#WC:/H:F@
M56CG:D(_F)M_%?H*BXS]!X"?<DUE_E2;G;'GXKXK#Y=OA]+7AS%L4]8?='>3
M2XM&9M!11O/_+J,?754S_!AKYV^B0OSI&T.%P1C>1E\ZBR8$8G15Y)]4];&Y
MCIU(X#*7TI[@QK:X!E1I'>>&:5-EG O#=..0,G@=RJRHL-M_+B]&)V8KE>L;
MA($R6;QUYOX?BF:*?8O4I!<AB!CV+T9)S+1=L4Y.^Z#K$O^'\>B!73=08:B+
M'KO?7%<X\@1+JHH[3TU48!#+=N^$I#(;:$VAZY?5/!9,V4,-K#7AQ7G0Z,#C
M:4D?RC2:<SO.O#D[?3.FIDIC9,#,BG;J>N4)=H)0D;CQQ2<8XS>YD<++)@(9
M8=_CIFJ#3C-MQ$+45']>><1ZA@%P<SFE]+O8$$(*WWG9+KGZW)^H/8+-W%=K
MF[JL+'Q%VI-#BP12,>J*;<@(;0MHO87>KOZTR(7[><'U7S8=U >Q 2,.H2EO
M8<^V[N@[DS X=1C)*$MH1U*?%AL=8D*>88XT*UE&+E)X\^;.>!E@AVN4<0TY
MAJ<W\J<WQ>E)ZV)>3'/N_<&[%33#%3;@C@T#08#"X&3A$.7C(BK 4CT_;P_L
MT9T-(P@&_=W_WCIY^9T-$ F^"L(=.RT&5:^3I\V=V2KT\X3BD&(.YTCV(DW^
M-=,=K6:C, =\/B+KNI'L4+>V=O?1=E_N#H*==X@/\UO>"_;V]G:'>\>#_<-7
MFM# A]HKS )Q*@GHY=LS?-2OH'$& [7KN67,.A)9[H+# M$G(5V)B4YKVY:O
MF#&-!11Z<L7X0:J!4ZLF*T0.24WLVBMQB-.J0+5!.8\/%4QV?[B_<_7*4ZG8
MXIC'\"[N^:/.YUM$;H7[=_&!FRM%[>?C ^,U7!+Q/:PXE@Z\A,.1L4?)+D9?
M6O6RLII,. .'_]+4EJ*'$@(KG0&\3\2$;G$[VCJKR=W1%W@VQ1)Y[<&AND5\
MY#(XS\"2F!$& [[VYR3''LT1Z=\2##8$N#K/1CVNW)%B&7@4IDDRP?HEM""!
M=%;+I.85X)&;2H0E#GX<]'O] )8]%>SC%7,%:^G'P6&OW\>#P%_<NDM@K1#3
MYD[J,;4QSS[H!US'*',7?#[>>S>8Q!$I;KBY\UR*LD;ZAY4/3G"=V]:_:/&F
M7>.*]>\O6QA(2,>,<EWFB%L"EN/U-?I.G+T=],.]@WX(2^"=_-JIWR%?IJ2&
M['%P@E]=]75\T^"^9_I#I3L>[9 [.'R@H"S>H1*2< 0)$9#!4]X%MS9G/NA\
MRO3>6):X8 2 (N?F^*;&(LWJEB!#<!?T1JU]0;_9/^[MJ58, \H-*;(9@G_H
M< FA PLS*H$TFTQ@P6U5J1T-96Y1T:M?R@J><LT$N(F:B()>$T;B02\M%:0>
M^R]8K)WDE3:R$^L(%9=PBMJY=NQ-PX)%);7$4_WF3B(_52;W_(Z*6 ;]/UET
M.4F!@Y Y!'7Q+DKG;,&WX6'U@40PD)3>M,%ZJ/U\$O1>E'*V/5'/L?5H4!"3
M/'_?HN@%9PC'@0CD&OK^54IT^;(^R^\,1R7.F$(A#'[YY8S^<)&@8%["?Z;P
MOW^.)M/7\*5>0  5:,G^,T] U*_R_--N46491[@QY5^XL(FU)+J<L<T9[W>
MS1LPEN=)_VZ$3EG/N<4X#:+P/]C)I2]P2LSW=?&9%];+?739S_[>AF>>#WO!
M_X,^47%KXO_W2V^<+VL#V#_<\+4ZPBR]5HG9U#Q62E5DJ]!%=)I%Z1QA&?,Q
MERV\LS'K,XL)BE_\X+ TWS\,%/0;']"E+5/+S0"'>A;75R=RJ[,LH"\ 96U
MHU(12UPQ42PA@W\*(K9#8W,/+=4G4-@S+IO(<FKEF4X-YU1,6IH[1E[*6J*U
MDD1<-A4I9"8SXBXJXMT4C R.%MBW<[]4-46 -(F04 WQ&,$<*<3LNIMDL@*V
MS"!NU*P3UCMU>!2N_RH4VKW2?[%+[A#D%+X*?"?J! *+I0QK[PP=]5"HXU/R
MD']R9*;DKB676Z%M4B"^&7)MD*,IN% ,Y10GJ&VMZL8@'VO=G&HS-<NEBK<T
MJY8R(I@RQ@DE]*M;0I=MZ9;BYY=<Q( ]5JS62XDQS9(91AJE?.(#(FV]XX=H
M&05'=3F4'TIT_U3('^^1F$MC],F7L, HC+^!U*'+*OOQ3J;XBTS1^J_V]4L>
M#7XPX8:.(F*VFN<58>M;^IA58C@/./,GJ/HB+S)0MQ.A#D$^D7KWYI\5;7#Q
M[[#KS3]J#]W"WTD FW_E+&SSKY-HWOP3BO3"W[28.%W\.A<L-__,FJ7Y5\Q2
MZI_$17"8:I;_"R%C%UD@85H(&O="E'H-X=X3*%)2NEJV+T+7C)DG>3UJ.FF<
M6NQL3\OD4S#2!#9/J#<HH:JMBY3KP!/M*0/;BTJZU0? :R+11VL4W-?R<H(/
MJG#^VO-!A\9_$6.W1CZT/0PI\2(3;L#AXL^EG@1IBF9<MY P0J;!"BUE5?/F
M++>@("'234B4<S&#IRJWE(.^-I]O(L2V(X1 3'M3D4,>,C3Y;0)"@SQT6.?@
MG1QO >U&>.->LAE)AEJ1"BGL924%0'#=</Z?R$ (+93O8MH@&"SA&>,/I[G>
M ^[ICS?!3]8P*S>FW/7]+7*%F+O' /T^;Q$.;FODT$EAYZ[;H&J5_'*<CRJ)
M 5'@[]98RC&IF\%_9O#W5"!]$^,B-03@JW4IX^0*/+6D;N,I)C#;*^K]T5LQ
MG8\2AL\@%U!_3WQX!.ZJ .77,*A=PO>T>*\V%?7Q;^]V__P?)_N'KZF"B'M2
M"-H[%EIB,V43 M8BB\4P<B]+Z!*N =3BSRA315G6T8V9) 3K2_85LHNEBC0N
MWS*,%SO#\"[!H0IM'5D][ =;+MQ9WN2KTX675=\EM-$6IEK0&:-/PA=GM*,-
M>=1P:>]N<M066+<78_]<O/B$,+CXY;?=H_WC_DE(X*8(3XHL,.4$-,WN)(?K
MH$+<7.0AA*&G$I.7S<BI<@^7^N#U[9__8SC<>WU(8ZG]:6 WK+2(L5%A?&EJ
ME9XD!AF-X"X8!=,JG>34]:2[1#KR_.)=*&8P6##P:3E*#7Z, 6F8?90AM"Q_
M]^+RS$F#JG',C5Y@EBP81,'EZ9N__'KZ1O!UR8;7#Z]PZ?+Q+OS?B<'X1E).
M%.9W[-80#4,8DP5C<+5KA1D5%4LO\O(8>? P4M8!R>*G[#[%RK'\4S"[R_W'
M8O(3_DFS>8PJ.MQ[UAJ.$L'HEPKB8/]HG^6P(8!KB=Z@78Q2;";S5)%F#*24
M(<-3.\IOD!4&5@1^F-\8A(E6P?GM]/+OH4LWD?Q(.EJ?H>GMGIV%1W63SMO$
MK2%M"1:/%/"&87\X"*W;=DYWLT NHZ<"._&FJ*Y9^G][$_J$W)1 (V4$/IW0
MM=K$NP(J)Z#S FSGG7'9+;[/R\\G1*<!UWQ)_#:420+KPTZK5CD)$E&A=U?9
M"V(1;MTA<2NH.Y9EXDLHV^]?*[1APLB%PZ F8:5/$ !J:[A(,: :CCX(/1S[
MK3L;GAFO$,GVPE94?:[KL"J%!;$P]GOV6F2[VX+Q,P8+W7+9R)'93:H2CA8X
M /$<KC*D^WQ :NMY"WC^#G]*\<]KU3'@-D]Q=;/KW=2,\5F'O;WFYN\^X^Z3
M6W;X>@7"TA.O;'U]#DYZ![@6&@BEF! 51B/,O;OM[K\<8P/7-E?QQ$Q+$!@J
M5>;\8PX;Q !!;',QNCMKC+FJK+3*KNF@WY@HG=W,F6H=PR'H?*R"I7KR?7L;
M%<(4%$=S;HL^LQ3R68Y^%F,&!)Q?O#4>(R ,]_G7=.]PR;+JWM?>1E/QK1WE
M6W 6MV^*7Z''B.KL9/@G4CE'AW_"6H;#7?K7<'_W)B?6<[QR^'I/J4I?8]0E
MH8+&R&E!,QN9W1A<WWD0DXW7"TX)KPG_B0@1\//2LVCK8^\RQS9S?-!ECC=@
M+-^8ZK?]"GPF$8PKIG.;7D[ WT'[3D*R@1X\(F_%$M6KG%1&0*I"] ;_H^<=
M]3MEDT>"U<)9]Q/F4X<I-(A7I/LMRY56K?[I^@9D9UD\PK)XZ\AK<.><?Z0)
M_L9]"'[R^6\?W_[MP_GE+GK"UFE:&2/H/:=M4!\P^;2#(?S$? K 18OS"?;R
MA'1U[188J,BN\5\5'(M=8A0*5?YWA>P8<V+"_7,;I95@,%)M%R*#A"+[5XYB
M4")\F&TRQ+I5"U9@944N!<+[_3 X[J-7.3CL!Q-"FR%BF\^4&H(C=+Q/,0@E
M4.H%;S]/4X6!,ED\Q3*NTK9I_@N+'Y,9GV4T-YP'OO._?WGW*H#G\IR]?=.$
M\8PX@/1(8]Z4&ZW!HJ'F9SS['_,I+CH;5!2Z<MG*21+O8K/MVJQLW2%^Q"'^
MJ,R:[_*<ZV\Q-!&<QF 4N.K?G7=O3E\%D6M?8[)K%F"AU<WAT82TY0(WI+UK
M@35+W44?@2P^[_'&V</4J 3*F]VRF;'%6C^ ;!SO#>G L6';.L^ RQST+1+L
MP49-037#[!(1@@I@V32YS6>.T93#A_YU:>NV(MDL(_$B"CKO'_1A.:NX[A/X
M"7SU&9!<#NP1;?'6H8<:6@MBD(A=C?SC4N>8\*M=M:AT&G<P_B_G(S'N(R%Q
M0HGM#O03'NCSC!M_\?R]0;4JD%._,F$<;OS/U&:[\^;RUY]?49\^0JVB!UN[
M[>RE_;&0"B+F/D2IP)[.21X3AK'4K3SG.7YGG4T*CU9IC5E/PHOMDZ/3%=90
M'@9''LI#@*M46Z2%9\WN7Q^I<9)TL%RO,>>$55/PB-E\LOXPQK0+%R*E5^&U
M*0@C:/GR]F)SF"FRDB.*I!:D9"5A-CV=2W>=/N7I8]ABC!C5!3!J2-R"$1?Q
M?F,T9ZBV6\LE\IRG[*,7&;LRUQCZ<G,D3NFZ3?Q0*[C=J)7EJ-UQ?,UR;G5&
MJ**( _X923%G-^(4\KV\?QR@M4[W7L,6'AZW+3!.4A.1:A"C9;IH\+CARA&D
M?$_3>I>2N#R+VYX8E3#+4H5DP=1?9I^3V3"!:2/<!!CB:H?S_?T84YP7\U!6
MD-2-6G'?2NC:DP6=L?"4ZJK%1;=>^>IT?+!S<7GVJJ;EL.8C&GT26@ 7#EAP
MY)[7DX=Q?WM//GP*5QYGLJXK[Q?&Z)G7 M6+(M\]VZ,1OOWE72B]'^1RG/YR
M07_G_+NH&?1E&HZ[98Z WZ"?0 84#M]$!>K:_G"O,SR>\B2_7YD5GKM$,OT'
MQFFYBB6OKF^65B@$.^>_O<%#'N$1N"9_DNBXG]4.^3F?W;CY6+7#=_AO;VK5
M%&5U95M=M8E)C&$"1Z+:B>$S7W'/NIK!6C?L)G7DG[W_G_,WNP.XLS#O.DE&
MVU<F8LN$^NQD_I$7:1S\G0(RP?L";&N-$-E>>L$ IV0>>Q2CO(#3>IL4%=<X
MZ;J$W,0QE=61LJ=0XR^A=55+(O^9<HTSJP)T7/%-OV<)(Z!:6IX['.(=^)2N
M  ^]3,4?%,^; -!&TD<4^CTI5$YGR>TCA?:1PR@=.#5R>6P!'YFIVMO>US06
M17#M@9DF,E$W95VIT+4.R$,YZA6,$)#=:^II+J\N)LR62M2QR28985<,YK0$
MEQV>S2'R,<\BIV:95 '3I0;(M5C!8DVP&I4'-+MA8+M:G9!$^VA]J?@T87<R
MABG/Q;7!FG;WF<]5P-^J;P<V(6&WAYHG,Y!E%,I2D2.QLEX_U!D0$@!.8(Q>
MEX#%U,=(8L8-89^QB"%7HBNL.0>]BV6Y4NM>("2!T6K_EF=)*2D,WL08BL8&
MCPCMQ[#^[1(![:7T7KNNK.5Z\?;CBG).2E%Q8SQ,RS[1UK E]5.) )G8!C6I
MN_)<*IRX:HS$V.6&_2SB1EF>$%^ W)#=QEMA0U(*K,]X!E\@QPJ\J$A[X0-;
M_QJ @1;(T!;DE5H\23BA6+G5[$ 0RH(KHZ<#S6D7;,XH[N7Z,J@*A01Y8HIK
MH_$K:T-C+!E]:.Q!(_B)+U@<4CTCZ?N+/AFJSI.^0D)\I#+%F9R9@AN-2"W6
M#BS8/:>C$5$W7&.)RUTK3X/LL 4W^9)M<;$\B^J(:)"B.TD1%V:"L_#J_?'?
M2OV"A1(%3N J2@DOHKPQ9A:".?^O*HDU1N$&-4[-Y\2+7MB@)O*K< "Y)A4<
M4X _P6\MJ%2<E$7ED=;5VRJY;*J.R.D&@*@?4D54HZBSZKBK +(50(==!= &
MC.6[I0YPG?>NP3[0!JOUO8IG:,)<5I9,M>K;UQK&^,Q(B6DR*9LB!DJIO2>%
MJ[T:):$F>BC('+@AWP!\@5QM&>3-LMC&V/.A3Q,G F,^< (2)&P4C7X&-A)S
MBNFE]DLR(GZ@T^O"&%<0H'T*UMS_P78NV&^&/TB7$<* ?C:C2F)+PSZ:Y%NV
M1V@!+DXQ2,HV+.LE+1ABTE+_ADMO<!N2YP!H^X"S:[F.N$2*364VD)YJMD%;
MUAZO],*,#.TN+%<UA2V&D:6RGV-C?.#J'P]\;$:=DO47T?]09#9] @R]-ILH
M\R?QX_# >R#UJW++BP0[*4QJ,5.U%Z=F^M.35[3+],EX0F,6?*'K1/J89=+^
M6& 4V%B;&0>)!D_@U?]Q[V101Z6<8<4&X7?'!HP:4VN+P4\*<UVECG5O<9_M
M^]@G$L;[6+J)$DI_%?D<S-N$*?0B/=N[5_-=/>;<(>UHA+D+.T.LKU)Q4^6[
M:-7:Z:)9:P4B0H&(V=_-L3A=IPU'\-#.V@GCCX.]WKZ_&@CF[C<&+NT7\ON+
M&IU=-3%9*MWUZG.8$<WP#6PG,1/L,9SOH!%"_W'H[1XZ819N;^E(=4IL=I<^
M<CU,$N&1'(%(5& BP7 .;;T+<8.4EER'3D?-846P2@$+%Q96EB'FN+(75#2#
M!/YXY.0D#'[<'_2.:V+SX\%1;^"^4-_"==?K'G"D5;]Y?IOCO077?ROPBH^1
MDL'Q!F%9?/"/SAMW=+9,_-GF6:(%+!8FXB<G)=V"]F\)HS0K@-("YK+_(,%I
M6FP*[P4?[GVYI/9^>E1>[6C8S*D];+%/\;9=ML3#S<NDM7IUM179 _6$*V F
MTS2?&V,K'G7!+2VNDMA$2!J"?V>"'4%J(NA8:=^LD1THU]-2L6+(T\RDK[LM
M_;I;NG VA5% 3=Y2CV=2Q+O,YJHD)^"DN'0,WX;3PNQZ2!R4$PT70]H</\.X
M7F3!?"1VO98II#%=<Q.EXTXDOJY(2+JB86VB?G8-\8:CSP0ZPKDR[F%?NGMA
MK95;)$-H@&O"T>WFU]W-V.#")ZYDWY&;(S"T[UB7[,'5_ZR;W.W+-SEE9G23
MN6H5].I2K$>L&"<!$7?F&BHH">>LVY:ONBW2<:+*B5-GB%@_6FGPV&MT3-!F
M<G8LC1>GC=1JDJVW7] CMG89V(8X G7 U1GY^L29@JU"Y6J#KK9@#_:A=RA^
ME5<P^KA\M9:9OU"F(ZZA#%MS7@48/[LCC-=.2_.3_L?K."FG:33_*<EH&>A'
MK^7IDBC#Y- M(F+!729)"'H=?^SR1KT^YXYF!?R_6-\L'_?HH[_,XL7/#HYZ
M)R?+/^[W!DL_6_78P;#7/U[^TU6/7?W9?O]P>P9[<'#T-(,]6.NQ?R%A8($
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MV X3[ @0Y:L0X6*W4'\E_M18%R0R->-/394879'V1_)5N"LSALX=1>6-\%O
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MCC7'F\H1#):$K@ ?J)3XO<%_3L"9U<!62WPX7(Q5+5U1VV@J*?!Z1AU,C+S
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MC9GPGEO!\967>OMON"\X$*Q%VP3Y<2=B</2H W'OY;C\A2?#YAL??CL^SV&
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MZ;F6\],XEE:=?H?(*L,.664#QO)RD%56BAMV,RH-I*LMCRSU'S<H!"1CV),
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M2&U *)!42<"\"E@%Q:% #R#=G4ML'OMF7F)+N\0$]5@B)D"@E $J4;2LC8;
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MNHU-)>J,3!;TF]G=4AD*D^LZ5\5^R3CP(C@P;LIXSCPW,!V]PAI01U/FAM$
M4F0-"@(ZJ(JC5YQF',@X4+XIDW'@17!@W*H1BDD*-0%0>04H<:GD.T% *>\"
M8M0;F,(O]2C!)8"!E2\ELI.JN?ANKTCIZK?!:Q2*4OMM$)GY9[W6\NMV..0E
M C!GS<[%ZZ$\MEK]'EI]U-KSO8Q+,^#2_AWG/GA 6$ %I(R2H%8;((64J2D-
MCDR36(9"2MPJZR#DDOI35UQ7RPJ79%TM4U?';0E*K+5*8L"",X!J1('!V '$
M3"2(QDBF4E 495U=85TM+;J1=;5,71WG^QA*0@6*6VIQ8@,%"C3B'""*(\XZ
M&[Q(![#@9*[5R^GJ6IW9B&O\SE[6\W5'+'%!F)F?O]J06XVP3%R%V0$SAZ(O
M!Y,]EEQ '&LF0-PO(:"01$2V/(# 492=9L$R541D,'].7'G)/+$9[C+<+2[Z
ME.%N?G WUOI(6>UU, 0HE]H+:\:!#DX"2Z1"5F(31"@"3XQDN,MPM\9P-[\@
MVQC<942;"=&NCQD?',)XSR-/K3=2$."H48 ZC8&!! $BO8".1G*N=#2I<P!M
MW+P>Z9XSN!ZD+[]6PQLT6LZW>J^!*K#R)?1UR]J.+Q2UUZYUO/.G9\7??NKF
MN>]79&O\;,11NFXMOIV^X4^+QC]1E8N'3J_O;1I4U<?N^WK..C[X3GRF6M%,
M>JP5U_.RO^_H/[C:_M%RXX[7Z_*@_>EZ5?Z=%F4J@C-<DONM3]<+\NW->OPP
ME&O1]O,VW0V-"^_ E>^T\[XPT[[P;K)YLG-Q,S 4..LLH)8P$&7O <6$"8N%
M(HXD59,8X3?EUW-]1,.6*'"RUK!1:@@TPT8%86/,0':>4ZL@!G&3"(!"[($6
MW@(8/!1!L*"4S["QCK#Q(H?-YHL;V;OV// 8MT6C&%WPC %,8+1%I7- &\V!
M3W6PA%06(A=MT3K&S\GJ7AAJK/PAM6&TMZ9[O4[#G/>;QD9;T[9/3]NMON%U
MW&[&><X1X>PSK$I$>.NG;C334CUHORT6ZN>1=?J'[C9LAOGR8'YGPK2T)%"O
MK =1T#1R1 .!498")5S PE@M!<LQXPR(&1 7%#/.@+A@0!PSFJD4 7-N@!?6
M1-Y+#9"4(4"%A@1%<]HSEZ/*&1 S("XHJIP!<;& ..$(X Y!3#"PR$2&Z&D
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MG3%<%XJM&5!DGI1Y4@F0-\F31H^D]*E2)CPS0MG>&.&A,$2JXR0@4EA HUR
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M,EZ/*R_]6VYJ[*H<(5CS$P)K= #@::A7>N6ZE3P?L#@4O!I#08UX4(88P$U
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M.$B9($AS!E.-F;JDO XQ73.<R%0I4Z42$&]]N@8L$,G&6QL3$ZT[:C 01F%
M,;= !4=!7*J,2*B("R@B64:PC&#KC&"6Q_T](,>8HA13J@E"$%+%D' <N:F3
M 1ZK!KAJ?>H6B6QC',TSJ2S'&&BJ%:"!46 8(\ *SBT*U"/+YM2F+N-;I?1\
M7?%MID+[P1,,A4=>H%3NU'C'!(NT33"*"(7W ]R:%=I?(**-]S;F/C!D'0+,
M,0,H91X8!0U@% >#':'*AKNXVE/K0F<8JY0Z9QA[',:(I1'!**.!Z_BG4$)8
M$[CA&D?U<*04&,ON]](P[G+<_:X%UUSQ2-.8IH Z2(%F)JYL!:F, F56N8U-
MP>M8348@,]!EH%L3H+-*:8@PLCA8*K TBFKN"/%62^5<.7PM UV)0#=FGB(7
M$"): &N5!E2@%$(P!*"(>5&:""*JE@CH9CY8."@H_Z2#A?=4MDYEV_NWZ\<=
MU?!^C9;SK=YKH I0?0'-WNEVSXMSB>U0&]9LJ75N*N*=75?!ZR8UK-=:OJAB
MWQA>9]O=WLV!W7Z1[UFBLG?,]G*$5@?^F1G=,7<OKKGNX&,_^:38>992EE*6
M4I92EE+EI31;RD]@1%@KHC4K F40ZX I#$XSX@)S AUM8X@AC*0/I!</Y/Z<
M-3L7$WG2B3,DBN'=]GDGSN.'^$AMU\\)BH];?-3-&4%ET?F]MQ/)TT%1X9S6
M@)#@ =58 B4\!^GT,*8Z<GF(-C:QK#,LZ@21Y\:;LKI71-WOB*0\3]<?31"^
M1]O_ULUS/Z.R9]M]*F6?R!%61D(FL =1YUW4=D2 %LH *5TZ-^&#=%';&:X7
M56?66=.G+R6Z'#B0R5F64I92EE*64I92EE*6TI)):77*/TY,,!R/L]A^Z?<B
MH-)O@=&?]\D_S\_:J8-PHY<:!9^=FV;#QAL$GXRK^H-7/ARF><*QN759TW>O
MJV4YW)BEE*64I92EE*64I92EE*549FF$Y9/AC*%0$8SBWB-#*548&N&A0!8S
MCC5VBDP?"KV5N9C#GXN+B'P>+8AP&,>P<^0-5)I1!+37$E K+%".2,"\MM@S
MR9VR&YL(U@DKL[CXDB+ "NGX'?'/YRGX/6=F'P]XYICF3!I\4P@@:?#W(PL#
MA4@:@&!@@'H,@?$> AK_SHTB6@M57B& K+C54URE+<)("H]"H-HH8Z&(S\ML
M@(XHR^:EN#E3H42MOMF7\>[VQR.>CAD(@@ TF@"JA 1:*0.,%(1"8Q'3:5^F
MLHY%6>7,LFYGXRE+*4MIJ:0TPSY)(59&(FL88=0;KCWSDD6VRR#''(:\3U9^
MGQPYC1>?YF3G"*%HHFIF(^=E 5!N/##8<2!<-%VD(D0%.-PGR^H+LW3'[I8@
MH%N$<L\ZC9^ZYVMG36W]J7^@76/.,LBY(%E*64I92EE*64I92EE*:RFE]8[(
M"DX0Q(PIKE+$)EJTU ;.=?!0<\0?LV=S1/;E+=K&9$26"B((<W&I,V,!]8("
M&9  1###!3?$.I\:G;(RPK'+K?[+I^#K"-++)Z69ZDL3(DU0B,E !4P%"QW2
ME$5@)H0%DWV*U4?@\=B;1Q&!L3. :*$!#=H#F7)B)$':PB"(A+K(B<D O'2J
MG0$X2RE+:>';) [2&L9$ZL9 XY_2"0&99M08&@+6>9NL_#8Y$7I+7129M1@8
M*SB(!J@$)@05=TW+/84J%5*IX#:YZD<IW[9;<2C=I) W12NWZK4_ZK6W]T7?
M;'%-KW%'2<M[KNBU;X7UUNOHY/WU?N_TTS 2%01SPI05E%(4;00FI%%.10L!
M*3N-GV:L^._,U<1N5L5^>'LC[<_>QJ_V&MFI4R)6#G$RI?6=?$%[WX^8-M)H
M;@$2&@&* @-*8 ZBE8BH$IH2838V&4]0>2=<SEPW..<?O3@63+*@9P+!'47
M9\"!@AJ5! .9,DT% U<C,(!WOQ]QZ%)./@>*>PEH9,! .@B!U-[IR)@DYR:Y
M=NN43^8J90A8/@BXNXTPD\HCC!&AA'JHM+%&H-3-4:&("2[3@57# 32* _M;
M1]PR*AP+ #ON ?52 V6L!PIRA;C'V%BZL4E5G4%4CPLE8\$*8,$=W76?!P29
M#BP9#) 1&"![6T>>&<T8%X!S$JT"+ G0!#K@O9?&VV@OA @#@M4ESQ;!*D#
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MW1VU%]]X%"AZ4-&#UH!V9;S"QJ#?U]E8Z(\PKN$#IDA[IS1 A$% <7**4^T
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M"TFY\.[%9!CW\55\I(&K,W[BX^:W1B7?9UTZ^='SI9QHI)16/@B !96 BL"
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M;"D'%5<$&@PE%R@$IC\<7'.0^L(XDWJ ^O%D/!KK?MK!,C9]?6 V!;)I?\$
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M"/ :[>DBP/<BP(N&M-*,>PT)<-1Q0)''0 8; .3*:FX@%#8U>>@2=.N.J46
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MB/HFA@1+89,O1#"Z&;Z0XN>\CHQOEJ%Q+<DNC=A^7J@O+@LULI[ @"2 .EA
MF61 <R>!IY&, 0:LN2F=V)Z ;-^#J5%D^VYE^VCAP!9,ZZ"E 8%H BA4'BB!
M/? ,<TY<)#-GFRC;3RJ&T98 =>HJAVGU=6_0_PC&?GA6HAL;$MUH*76EJZ1
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M3N'"IR%ZP0().0*6&<$4I(2F!/"(_UW)^1:43!> V#9KIP#$!@'$X9)-%,%
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MS)B&;QT(O:D4;9$7\RDCP[KME8(,#X0,BR:,H\1&NH)HR5! /;) I_HLP6A
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MN]P1W2/$H+. 8T8 Y<0#[3 %S""HF6,^OKLVK7BK(DPW:=!5S.BUF-$%(#8
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MA_JB#N5CW.TDKW,W$VM*_[.F77X2Q0X"D=! ["(6A:Y^^KJ!V2@]?6,S=N:
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M&\U<RZCG5A.$E"4DPH+VS)O52+ TY/*PZ@^&484X2'G.?C0^_A*!;G1:G4<
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M6)5.IM-(O]1TLK[YE[A[IQ?-M]KWVHE1T^W<[?R?MM#JLI-F.IEKU/C74BY
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M@1AV"HF<.L2XH%JIG-O,/'L1-FLE]?VI83+4=FZX5-_[\_76FE*N=-_>XLC
MC=JY4;LY5 E/ @LZ=W%5"]?I9=.N8$S5:FOBANZC*@%0DM&4O,-X*9EZDX!O
M.HS#EU;A=HS=PC;ME4D-*?H5,MRB>_EG,@!+V*V8=_+3]M[+/[?_U?LS 4K
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MV>+"-,46ZUK%1U^ODM:+Q1:?[:0<>K0E:7P>S?>M:KVI W:[J_)R@EBI-VN
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MU2?-=R.D;+A:J91B*2&:[U2]RL+6@8FX.%P#)EX>;>R4'$\EM0->?G=L;HG
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M?\=!AH['-X/'NT#B/?+X<B#16JHS<,61I!9X7#J*E/0<:6$8]I0HE>N.QW\
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M4)%3#&N@,&TK2'%[3=R1US<CK_?'&O.<*J&0\9HC1H'&M)4%\MKF6G''O!=
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M!23ZT8WFL8"I1:T#-^T(\E8$>;I]S(AE< @.*:,S($A!D12>(FIDEEO+N<V
M(.F-XNHB&CS:]0)RYC1Z48-PCT@I&(O7$2<82X-H%%<F1WE/NT23JQ'!%:T*
MTW#@RXV"81P2=(/?=A?2%#;/G0K))90R)J7,I2R,9MK;H@!]>Q-I\HXT[Y<T
MK]X<9YD1.*<$9=CE*$28058"?5*<<>6- <H$59I=BTM>D>:) EM9.Q<CSU.0
M8M'XJ^WQ%;$V[>EY,.#.X(O-[4=PPUN1ZJ=H^@:W;CX;# =7@3T4;,=TAK2:
M1EX]AS6?@;\YCM[.F5,A626ZMN-)==73TB%1KXS!JQV:$(QWI7LV"6II/++Q
M!=%2"*P_2<Q0WB E??*\]RZ<RC!L*#R<G.0PB 9&KM\/#\,40!U-X52<4?/@
M)4=/N/S&M&?'T<\"-RGXX[V3\47P1Y/KZB:?47YA.B$;(;:N<Y/S8.@\[^V!
M_#D_'UZ&%:0UK=^DUK+*-<VB7H9WATFJ%!H(3T\#.L&\A,%*0+XQ"C"WX"A$
MQ.%I<HC]?.B!9C\SY>@03EWYR%I 8MC*B45Q,5'$!9XHOU_Y*>$^/+QLB&9
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MST(.(ZRN+AK:6E>F&'5MN(%)P\0D.]\S;A(?/U>SNJQ^YLS)"+;H_>7"4S5
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ME)PVR.-<*.O 3&EK C+629I9%H/#=]1 3]SA^:9"5CO\.#ML&",L188,F"]
M6 8!9Z06 >AR+2,#* 9OA&&<<Z\3\Z\3!DI=1P>375EPD\_!ESZSG=IWVYJB
MP?ROV"FV^ E$Z2_;V>G\781X7_*]77]U)36EU.QN']C >+9>*'G,LUWFR K#
M4>34<"9CD'G6\AP[^ACP7^WH%#L*.^<<E@Q%[&!'0P*0%UH@PWAT.$C'$LE)
M5T" \?[O<0@XBYU2]WM4<T/*#TY!=V02Q!#1^ED'POM6_!:[;Z9,.SV>-U1<
M\4TSTY[Z*0**+T728<6297EW>J'(=5YI%*^+G$,NRCAOE1F?6S7[.P0RBU;I
M&Y,B89%CMZ_!.VE(S5=C6.23J_HU_VM]-Q^UO3LP8-8A_'#@SPD,JAX4TL0&
M!$&L<)HSD1Q;VVR?3A@5F;>W*#<I4WAY#\9DY3"V0F'?P?\_B;%(Q&7)&@IZ
M2U;%\S[/8G&-_/8?G>;Y><R39\I(Z[36:L:+XM7^I:;ECE@:5-CJI2N[KP(8
M^H,,^TG:;N9=@QT%Q6[9G*-REU.FF3=J?]CNX?6%BM1U.?CC^FH@B6>V67SS
M_?=Z ??9*A*T%Z?%IZZOW2M['CD'&6(X+MX_8282?*K9Z2>(Y_!WYLHF3>OX
M#$2O_^5Y1<?+[)>Q2?39/:*] XIMM$QD!G<",$D5!YC,#.Y129^XHPG[/!)[
M'"6OY>I:@,9$]J8BY ,'7U8=YA_.>M5FJP5U_[T^4%DQL'N;^T ';1"]PYWK
M&H);CXIZW0L3L6<$3-9O?^>=B%H:V8X]+\B/>UT*H_!9DJH7-:9ED_%@:%5A
MK?.XIT[37?3K,+.8W;#'O<L6<S[[QOA[NP6(F6M?<WGIZ?6O0XNQGB]== <7
M9;UYI%9Y/'%QUE_%OH##BT7%:MN74Y[+,1>Y[CAF!KOA%2YNH^ITOK/3656=
MSDMP+T_9Z5RBX^33B/M/%QZQMN=O?QC#1>MF-)9KX3K?8WC?[KPOZ-&WN[DQ
MT<=B%<I_7O4QU^>#2*4/2GN4*,V\8M(BG5N&*:P^CE$(6/318ZLEL?1EOKVH
MY,Z;7!B9'@M^L[?/?<$^+Z1^ +D=4!WD\U3QLVY\T__A-S C9RU[^:9Y6GQ9
M\:'?>L+?P^D,3445!;BH/0PN%+-\^1JU<HHJ(]=Y!_X;^M_<>WFC>.G7\S#^
MFB(;2NE;7\8;Y-;7[KHLH1M8W_[1NRY[]VM"J,>Y63[597\MUK=<8]C&O-G_
MSQI;&Z%)>(-KI,"M_O4&;S5C;Z5G/_.;?QLSLJ/;7N[XHI5!3U4U,#QM:8#=
MBUB/Z[?VE*0HH3@[KX%+ N%"_\%6:K&RN;BQ2 ]XX->V<'@6Z7+6'W_K9&H
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M4AAT.D[,61GT%_FH+Q\[*H,^)W:,&'1GO(H>0@!N4D0\RHB<(P(QCATETO+
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M"MQ3PBAXE$96.OHLO4G)YYU)X,Y[[I+4B@9%#%6"FI"2O,>WKW1T975T-$G
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M$$I5(#O7V>%K -D''2Z^:)"=-9OAD^=!I$2P]-PE4$T:%#%4"6I"2K+*9JP
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MHERPA+C $ Q2S% PU 8>B# YOT3E))J!UP<V"SK/*S&#;E"QY*'AN]O(R!?
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MLTO1 O.W_Z(UQR=@0 JXS%4-WH'!%%[DKHZ7CSO,,9#Q:YXI8^STEXT5;-:
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MJ.1!:;P]5E_UVCZ;#]#"VCY[;8#V*>OE-9X](I[A*3Q+=)1P&F(412%#5*D
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M+2_IM5JH"W3P?JSOK0^WFM>]K;Z5,3J"PD6.SK-6K].U_IO;PH)/M+%56=V
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MKWU$89T1C;%!7,#Z4H6)+Q,31PE_\YZL10%>\]F"M$.M*Z<^$0" -1Q01EA
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M?O@'^QMTQVTU;&&[#7#PZU.S\7G;W_GULWW8_N8?7.VT#O<FMAG:!\1V;&W
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MWI<;P:*'<><9NG08NE1<26?+YXJ3LKV;@3-WM+2$_GI'*P0HA6&'.OT<>Q"
M/<P($4'9'E\',G2WI>QZ(/OX0780B?H[ D<:?E<[^PYS*<F,""IYJ]7SZQC,
M:I!6;QO5@'Y>0_??.Z26I%,"-KF5LX]B)\"^.V)S*=F,^ %])M<L*#U *F T
MJVT@H_(W:EOA1FR"5MB11(_6\",@L*-ZO"<ND4N"L4=&S'^&B$+^O),1!.&<
MN ^".=]E?ZE_9\QS"0^^_A52L;R0##E4U%'T>TF:+<'N]8Z,EK BCU+T4<(
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M(ROX=]$P.\I#6VUXEM:PG$4CJON%>!D[:&)NK(/:K/4CNW=23>O[23*E:;+
MU"6O"^('!-9>3,P(=T(.]5DX""I4ZI7"99X^CZUL!!RA13%>I5.%&46HD<:]
M5]M:5U>=64MC-$^S)X--$5!)%>[FI%O<\Y6=;'F49N=Z:O=.WZ'-'?2H0\?A
M(7&O*1Y33ZV_9??<0N]<,W_Z*-?=J5>ER\XK(37ZV'[/RBXG(_PHA45I59%
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MWTQ)<L6Z>@N7TD , %T+'WN!!%S5H/^]9,RZ/[4'F3 QT7U,M!M135T@KPU
M$=8?(XQ(JQSC;H;[NMOT 8=O$NT\G*M'=WA9YQ,#9=$9]7O4LP<Y,0K<#:\/
M8T38(YW&^'=2A_=$<D#<.\S%\I%C/\ .8*YP6#0'WAA)'EE6]@Q5A HI7"B-
M;*^/1I9IM7";1UO?'E30XWZ!EE;U!2 C:KG,Z3@$K%!(5%:;>>#F@3>PLB?:
M(DPHC4K5-.V5T<2PJX/:/.IL>U!>B?M!E];S#1&P%W1'N#JL.12ZLV!AK7;
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MHSI&CW"R7%R\LAXU8'PKL'__-I;-(-Z]=X]3FJVFR\7+\"G$"7[N(;=)E&C
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M$V/.4>=U+4%+D, I'T'D*+DUP7'5I_[<_AB/WDP.G]9;^&]FC]._5N,Y[KP
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M,>YI&6Q?KU\B629_^\O_ U!+ P04    " ";DUQ4"Z23FB=@   *6P0 %0
M '!L<G@M,C R,3$R,S%?9&5F+GAM;.R]:7-;.9(N_'U^1;TU7]_LPKYT3,\-
M+^6^CG"5';:K^\XG!I:$S%L2Z28I5ZE__4V06BE1.B0/2$KR3+2*HFB>!YD/
M@$P@E__Z7W^>'/_P#2?3X7CTMQ_Y7]B//^ HC?-P=/2W'W_[_ ;<C__KO__C
M/_[K_P/X/R\_OOOA]3B=GN!H]L.K"889YA_^&,Z^_/#/C-/??RB3\<D/_QQ/
M?A]^"P#_/?]'K\9?SR;#HR^S'P038OFOD[]FGDVT0@.W1H+*VH)SC$$R(CHF
MK Z)_?]'?\TL.L^] !=8!L6E@F!C 9VBB:SH8A/.O_1X./K]K_5'#%/\@08W
MFLY__=N/7V:SKW_]Z:<__OCC+W_&R?%?QI.CGP1C\J>+3_]X_O$_;WW^#SG_
M-/?>_S3_Z^5'I\.[/DA?RW_Z/[^\^Y2^X$F X6@Z"Z-T]0!Z?)Y=_L/K:/1/
MBS_21Z?#OT[G__[=.(797#T/#N&'E9^HO\'%QZ"^!5R Y'_Y<YI__.__^.&'
MA>3")$W&Q_@1RP_G+W_[^/8VTN%H]E,>GOQT_IF?PO$Q(9Y_P^SL*_[MQ^GP
MY.LQ7KSW98)E)?J+(5=0NL+YS_IM/VV-Z0L!F:33B$#OXJ@2O$>,=WW[]I@O
MOPLREG!Z/.L1\>WO[A7O^"0,^Q3PK:_N >W\B^ $3R).^H1ZXWNOX;P N8RP
M?N77XV$8S29__B6-3WZ:P_LTHP6UKJW3<?F(&6GJQV-\-1[1\CP;TLL/! LG
M$\R?9N/T>Q@M_OME?)QI_?[Y7Z?#V=EK+,,T[$";K\>3/VD$@G.Q6 3^L\_'
M7Y,!D6TX&M;UZQW]>HZACG=?TL _9SC*F'_\89C_]N.0,1492F6SYBI%ZW)T
M1DIMK-8E*#7H$T@5RX5@CL?I!J[CNLR/+WEY'"(>S]\=G$[A*(2O5TA(DOB6
M7DX'CBD1#4]@G F@;&#@ S? >8BI"!L"+[=9/;V8)25,XYS7YX_XJ3+B)SR>
M32_>F7,$&#_?*OYS-9:%TC<?W=M1(I-BBJ]Q\=^WH\]X\G4\"9.SA1 _CH^/
MWXPG?X1)'CC)N.!&$[*00 FGP;MD0?"@"MI09,E-QKT.RIL2N9H(+R87LCE?
MF39<NJJ]U2M#9N,=J63!"1K<CS^,)S1-_O8CVY8^2\@^?0D3G+X_G573JUJS
M S(E=:;)#BI839:F$1"EXV"RL,KYG -332CS$++=TZ2=7L<-E7*;-+QGTKP*
MD\D9P7IQ,CX=S5[,9I-A/)W5Y?[S^ -!'\T&Q67NC"8E%U9 :8X04H@0E,[2
M<\;0[X1%#T-]/K3J66VW>28VY5FULFY-@FH=O)U.3S&_/IT0[ \X&8[S8F[\
MBG_,_S0=),Y])C& 14;R,3* %TI#YE+HS-'2JOZ02;?YXY\@>7:DB]OLD7UO
M;7>#_D<X/L4KS &C2MEST*'0\JIX@:CJ$)3P!2-77+2Q##=!^P3IMC/EW2:<
MVMERM?""JI?^OESSB#YAHH_.AC22DHW2F"T$Y!Q4#)Q$5PR4F-%Z$6+0O/=E
M[$%83Y!O>];=;1;J';!P/FT>'H@V/G&G"TBO'2AI:"#9T2)NF- ^>1=4Z)&$
MW5 ];PXVT-QM"IKF3J5&6PQ#!DPKFB*('H+S!C1W(7.ON6+R )S*77A&T7.7
ME2K@(ME'2C!+>U8,D)+-S$3)LN&'Z!GU<5)U^\3O^E3"*%B4BES;HC.16!3P
M 4D\'DDF3M+?Q8X.J^X%^@3/J_I33(/3AU?CDY/Q N(=)R/6H ]9 L;D:66Q
MF3Q6<F"M*@)#8=&FV(0T]Z$ZA#VK1Y6.&^FC 5=NCWK '&&2M,PZR><[- .:
M,@JD<YSKR')6I@E#;F-YVKS84O8]GB?=0/3PN85S.<D0#2@3!0U:D@T7>80D
MT$KKHU.YS2W)XSED:LR:?G74X&RIVWD$4\6'J"-Y@HS,<&2EGIPFLLJ=\M)X
M:X3?)9$.[_1HYSS:0D,]GAAU(OO#;IYPUFB"3VX4[;#*V @^:04:M3<D,R\Q
M[7ZA>A0N_)X6L'YUVN/I49=ITP&\RB5K$IFWM!:KE#)$2>NS8PFC5R[[M%-"
M/IXCI?TLA/UJM,%)TKV3:?[S)8DODPOR%4?3>;SG0 G->+0<E%(:5.0<7"%S
MDZQ+<HZ]22*U.5'9 .RSI%YOVKM-.-MR_5N!.'E9+!)8;>J1K]06R'I08++*
M3OH0D@L[7_2^TZUWW=UFFVNZO'W$Z6PR3+/S",D753Z_XNQ](5D5',Y.Z3.#
MZ$(27!6(@OQHE3V)2D0%:%!X](4%[W:_V'6!_BRYV$BSMZGI6RZ$G?!SF9@0
MCF95"K8:LIPL!Y6!1RE#4$9QS7:^+'XGYD[U>L>)[M81J_<;%?6/[[]6=4U_
M_A,G:4@K_D!;4TPD*65!]BM-)23),1*?4"R[))F(K<*]U\7Z+,G7E^[NH%L_
M-PBKC(H[$2>-RDFA >L-]UQ P<H,+ H?8T(FQ>X7ON]DZUES=W!MZ_N)I2OY
M%XF$5"%^'M<,FI,YW#G\@?+<FLS)6F6>C(-ZAT*NN -ZH72BN2%,FY/ESA"?
M-K?::.H.3FU\4S$/*EJ-Z\4HOSH].3TF-^@;OAY^&V8<Y?>C#IE: V&3*C5:
M1R3E087J,WE18XV,9[IP1U+L%!;6 MW3I-UA*/,.>FY] _(B_]_3Z6R>)_AY
M_"+GN;+"\8<PS&]'K\+7X2P<S\V#N.R[?T02[70XPT\X^39,N%C=/V(:'RU4
MOIA_SC#,R0B@89+-6F@FAA =E(A9>8TZQS:G,ZU']C29?I"\N(/X6U^TO)]]
MP4G%/<$O-6/[&XDSC4_PMQ')]GCX;\S_F^1*5LO?237OQM/I^]'5L?R+"8UP
M='3=K)G[:9_#GX.<2T'M&4A53^R+"N T_0C*TNS.UAK?)GJAU8B>-M$/@@=W
M$'SKJQL"LAA)!3W@6BC)+0>=.8FH& Z1IB!Q*/C =/91MUF&;\!XVE3:7.)W
MZ'_KFY1[PP(#1\T2RQ"1:5"<5!=H-08D6]EG4DS2;8ZMNX=I]A)L&%!+R9@B
M.%Z"2IP\RFPTD.'O20&6]-,F'/6A8,--1G<>=/RY6I0TLI*8+0'(@#2@F'7@
M;=+ $]F-$GU,N4U&[TT</<[H:]5XFH=<;R',NZ)D?UC45OEK.AZ3-?2W'V>3
M4[QZ<SR:X9^SGX_G#_S;CU,\.NDAG/]R"*^. ^U*97%D_.=P.LB>66%(<X+K
M>JDF'9$^(*!+' UCB?M6I%\!J4>6W%,?Z1[6;*#F58S92MPMPO&OX7D]WQ0[
M(1HLE6KJ=Y6_A:G/G7]5M:E[]+^=TI8#[ON1^&ZXD"SQW!8-C%#1*DD>E\^!
M#%(B?"Y:H6\4;K\K#MRHX+5'"JPCZ!Y5/S^:(E>[>B,=#IQ^F=O+@X)1F508
M9.%I)93T(RBG(&>KG T2T2[=D:PX0USWR;OW +95U7A7<NZQNM UL"_7 !MY
M2*K>MRCO:'LLEL * 29K%X2)-31L#5)T?_)3($4C.;=9*5YU!\M=T%YQ#]8+
M\A3K474(!-N6B"2HG+1(:Y"B^Y.? BD:R;E):M;Y-GF>C3P^^3H>U=/?^59)
M2Q:YS80FAUI)1N0 D79-X%K97'P6!5N%6-X#ZREY%5N+O0$GEC"=3XDNH)HZ
M%W?"VK-_L;WZQJUDW\#-N!L<EF)HJ92@@RF@,'GPM9R"TT4QR3S+J4V]@!T2
MHJNSL2,^K"/RMI4 SG>QQ)20M29B\76(W,PS^PS0[F62RL)DT>;RZQ:4W9L/
M/:AH=6;_!O)M4*UTQ47P.3@=BV6"%>"VIHXXLF-B$@ID#,6'9 )O=-A^+ZRG
M0(3^Y-Y@%7B1TB+X!?.JR]1SH.C2O X<"&$X*%-J<:;(@-<F"TR7D&.;':(S
MQ"=!EB;Z:&!??L09C17SSV$R&HZ.IN>H@E0INGI3;ERL92L1(B\"HB^A6/H:
M3&V*4]V-YRE0H@=)MRCB<!JGPSP,D[-/X1BO'\U*)U/DM66*YX)6-*;!"2:!
M!(#::9]XJ\O-59">@J_9B[A;\. *SJ_AA%Y^GH31-*0JWW/R=T'8U.E\&..>
M/-!^E+I,E38::5%@ZF&D"A4R1T8RK\4<%,\&7 W)T2PJ5G+(GC<JBK GSCSD
MI.Z+,NLHH@%5WGYX?[[O">XBYDRV<@W(4S%:",YDLGN\UK(X+4.CRH87$/90
ML[!G_2S7,-Q(N U<U ^3X3?:,C\<AS3?-R^.UT426F. R B0"L3J6+#&OP7E
M RK#<QNC\FX\3T[_/8A]Y93_KY^6I/2.?MVT7=7[R5$8#?\]#U4/H_P:IVDR
MG*=RC,O+TRE9R=/IE;O]=E3&DY/YAU]7&[I#O[C;UU_;/K*'ME2]CGJI%97(
MZ)QB"3-'Q7SPTBN68](VFX1:#+9]^+9QT'^01UR+ZM88[0D]]'2TX.CT_>35
MES Z(J?X^B>&HS0DK;Z[##1,WM"*%A4X)6A%X[4:3Y*TK-DD.)9(NV,; V)K
MZ/U'U/XZGBV2-S\1R697]8L^5H7Q@; J(WH$ZU0M?)TB>!DLB.0]ER&(T.@.
M8%VDNU^ =\O#AXN!]JC)!MOX]>WJM J6?IG'BR\2BM^.KFU? ^>+U$IS,+S:
MK2$R<#QX$,[KZ*0+QC0Z+E@#Y;-C7"L-MO4B20KSG+4YU@%#FT,-*D>F\!*7
M 1&]9TSJX'6C8L4K$#UC%FVNF1;Q,E>X:.DD?QHGY]F/"8??,+^_26]C75*U
MJ*2D%54YI,%K@HV6+.Y<C&:EC?>Q%LQGS*V>==C@D/3G/VN&+3DZ\XN=S^/7
MP^FB140M'CE9Y-K6]A&C_!O9YI,_:H+BZ.@-XG20,69N,KE>:&DKK^%L02D&
M,01?5$Y:+8?P]168L3'FYT;%'6FW00GEE7&-US?[W[Z.1U<6YB!J*81!!CD9
M29(JF=;NB* UV9Q92HFE33VH#< ^-R:VUF>#FLE=:A5<Y '7-ZXWVGE_K3GV
M4FD.+%QZ:SG04F] 1=0T*GH5G=$Y*&,2MMFTVXSGN1'Y %C1H"#SK?SIQ80<
M>"TC2JL@"E/==1V S&":@LY:FH69O'5LM*3>">BYL:T/O;0HIURQS!TG<IBR
MU4Z03ZUMKD?QA*G0(DV+=[*HR(B-C7R02PS/C10;2K]!H6,:>D+,TS<DH<K,
M0%*H)><O23NP7J7,N 1M++DWS'MR;WP"YJTC"F.AS;S1!=D#T)X;:_K558/2
MQ+\,1V-R0,[>CF9(*]WL_1\C,@2_#+]^P$DB(84C?'GVZWA4"Q^0V.EKCA8?
M&<A<O DD$1=+K5VKR5=A5A K+',LBR@;5<O>&/)S(]]N=-NB+O&F<EL$UK%0
M"AI?T8L"*DL&3M1D<"\,RZHH%]LL?UO!WE7UE?UR<G>:/9C:+BM#M(IV4C(;
MP1I1$\IM(4>$9:C6I$;)F5Q.W'^JD;$[9$7G0-IUM+.?8,@N"+\'TFZNU/6C
M(C?1R'ZXPYW/S"4'&)#FC"NUHIV44-/.D@LHA6]SQO#H FD;4V8=130-I.4B
MI2(+UIIKOI9'<.!C"1 C.B]$4-BHW]QA!]*NI9^5@;3K"'>'@;0.<TX<P8M:
ML#J)6&,[(V JV1JC:S+S<P^DW4;_/8B]21_O^Q+;M4%CO/204ZVQ+QDC<+4E
M#4/A6=3%6-THZN\ RX/LT3#M34L[JR;2!=3W:B)KJZ]3]8A-9+^S:B)>9:NM
M%F +9Z **O R>=#&2"=]4LP\[VHB_?-A'9'OI)I(S-+:2&,*(M9\HGJDB*A!
M:I,9%L34J*#$P58364M%#U8364>^/5J8T\F,P)S6$^:O83([JV;4G-(B1)=J
MH6Y&5D[M"<$@Q.) A9Q%5B%%U:G,&#W@FJ[IMV4]KT+P?$R&7G308YACQ?,1
MOYY.TI<PQ1='$UP4;5V">#X-NH!<QVKH1)C.\'9K/?2CR?&NU-#CQK$>V&1R
M-#$$,-'7TDDU9D=4'RW6;):2M>]V>O48N++"L-@C5=:1?M\U3R]#9G%R4?E$
M\4 [G2V0G+&@&-?@/?U(7/.LI8]YN2/IBJJFM[][=Z9"0PV,^Q-?SX;#Y87T
MG+A<UL+*RH.,6H)R9!EYGB6D8'2.D7LA.T42=YK4-Q[]O$R%S:7>8\CY#2 7
M1VT=H/1N"2R!V/U^OX4Z[E+J%K+L>3M?AB3H:4[I&EDN:=&*HC:[=AX$.;]6
M:G2TCCTNM=ZS-;?1ZCHB['OG_3 O1/#Y"T["5SR=#=/T[2B=[R'28.U]F2#(
MG&D_2AR<Q$RXHF4"L\^2=]J"[WG(;O?BK20_;B"V'K?>C,/!.SP*QS_3MC([
M6S!4:(56F5K:A8$R(H OI4#FW%N!*MY?\'>*Z2]'XV\_T5?/Y^:_5'T)BY=S
M]=[QT.>S[6XK\1X3;2J4!8J+G:(#C@Z[;C<&7'_R;K?:K54P[E%^/:[-M_"@
M"T9$K V((P>E@B"F<E-)ZF2,Q@E_7V[ H>AQQ=[:3(WKB*WOK?77\3=R\(:7
M'IG/UH>402M&'IF+&2)M,O1*"L8C<UG;3KOIS>_=W0:ZG7#'_4AFY8;9:PFJ
M3Z<G)V%R-BZ?AD>C81DF^ONUK6-\/$RUR]#JBDC3FWB[5:'JX:D]%*+J>^Q+
MM:B<=1ZE<$&&J&PIT6;K@G.(J&PP9=##\[>8M+>?].XR0EIK$9@1%J)%5JNO
M.7#&:\B*^1R4,F7YPG/%#+[G(=M7;/Z&H]-:A&,NE9J8$H^'1^?BN2SK];Y\
M"&?SHK4XJ2/+09M2_1=?*P+JK""X6F%.1)&4%%PRW^0:;R.XNUOR>J7$[9+/
MK575=[^RJPR3FGX[1_^J9IG4,@B87YZ=%T?X4,\U!]8)7;) 2+(V9D)6(#KR
MA60D>YI<H8!*=YHMZSSUD5.CK90;1 1<U(UZ_W5>F65T]&F17C$=>&Z3++[0
MIEXT*&D\N=:I5/T6R2)!%KS)DK(2TB/G1K\B;Q ^=@'L(WX=3V;5J[Y$)FAG
MYX9%J)</H+S4$#,M7ZP(4Z2/4>DVF<VK,3TQ-FPI]![C!.;#?8UQ]G8TG4U.
M*Y:/6 5$8_\ES$YK[B(M<<-Q?C%[30L9[6_G]V,#I8K2PM".9BPY%+2RT2OM
M@:M8DC'%1M_MSF^CQS]R1NQ([@T*%+T]^1J&DPKX?7DW'AV]JZ6]7DRG6.N"
MO,37P^G7FMCWO@S(R(E!1 .ZL'KWK>PBK5HFFS73]#*W:5[5&>(C)U%;E32H
M+#0OX/"22)QK(!Z.IF$A[4D][ZWX7YY=?>3<D'[Q1YCD-S2^?X3C4Z11G9[,
M+>UIK?&5R+1Z/?PVS.2T?J1I,O#1RYABK;8?$%2R D)!A&B0EE.G>2O.-1_:
M$^'J85&@046A2TOO7:V$]'%X](5FY6]3G,_'@1-"<:D89)LR*,,2^"QH*J)"
M+6S4WK7)-[X7UA/A5G^B;U ZZ":X=\,0A\?#ZA,J%RT9?Q!8JJ>H9 (&AJ+6
M&\S22"9-:K-BK0#T)+FPF;@;% YZ?5[\[&,-+*/_#F>O3NGWT6R0C>19\6K[
MVP**R=K-M&[211JER>3CH4TV\$I(3X0)_8B\Q[H_*T:[N-K6+!7':A0"L[7=
M2T;:O9@&@](P6K2,7BX\U_G8>B<E3MIY2WU([% *DEPKIOAF/+DG&&)^N1HQ
MB\R4 RYI< I+ .=2@6RL#K2E9</;& UKP=QU*$E_I%A=Z;)GY30XT_U,GWM?
M7N3QW"*^2$3J@*EI%NA=J/:3!-I0F>-&FM@52X3RG@L][TI5:VEB@B DS3DN
MDS",:2QMJDWLCAT/9(3NF1SK**!-H^GSP7Z:A5$F'WOZV]=,+K1@W#!QT=28
M*2^<#S1,3VX3"C*2;&& VGHE5>V>VVCSZ0)O]XFDVVOR=G_IGM70H'K)^:BO
MCFGF,R)$@[H&S^8HR)EB->I+DP",P^B\S5JD-H7G[X3S9 R0[87=X,+P&ISI
MBU'^=3P*5^]<J]ERV0R[ ]RF-LB:@/=CGO2@ZN7E9 =Z:K$9K0F;H2_!<J0M
M6-?K<RXAUH1[(X,P69;$59L"HP=!JP?LFOVS:AWUM KEO<S@/,=D@HO.8 #-
MHZF77PY"JL%8WEG)$WK.ND4$KGC [FV1IEJY*P9X&Y$>4C#PY:=^FV(Y/:X7
MIM-Q(9N?MOW9&5EAM5S(USK0YA'"ZT/96=CPEE):BB4N4I?L98J"D2WK?4B(
M2B6II"7'JKB.L<3K@]JZU/_\FS\<5SC7OO[J2-/44\O"!207:&'5)4+P*"!P
M,M8E32Z=VQS=/XRMAT8'=S_A0OJ%3%T:O\5JZFJ>:%7)"KSA'K34/BKA&7-M
MJM!W +?[-;EGOMS1S:!7A;3H-9N^8#ZM51U7@EWX2"6*B(X,$I4C_3!.@4.N
MH7CTB?$26*/:EUT1[JH>?&/.-%'(H5REK!S2R[-J!L\M7Z:*P9KV;92K84^A
M%LHO&33+16<5D+,V)YT=P.TK [<-*;JN5ALJIX'CN7KT] 7GN7-=(#8]R^@
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M0)OK'XALHHK]D$86YZ6+$0RB!!4*K;E)!N#"**VD97DGB\DA'YXUYLHZ&FC
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M-O6JM-NDTCV<U\Z+X_]S./ORZG0Z&Y_@9)X^6P-RO)->FRP!:U:VTDJ!LUQ
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M]G594HU4 8E.@.)*0Z@EKIPWDF/65I9.Q?*ZJ?#ZHQ^A"C>6W,I9N(-8N,L
MHE?'83H=EF&:OSTN]P8*]1ZVMAV,9A%F/4IG*1A,!!VDIVG.=5',D7GNB&I:
M61\M\F!6!(-M!VCO<5NR1.Z952"BJ"'19&JZ@AH8^0BL!.W$O@X:FL=M=4R
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M6"\KXW<&$$]Z#&(9R:LU3&1%8<>=CG"N! HPQUT9N&$E@?W(<SW'5RALM?8
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ML)7/NP]X2@SZZ_W=$$94J)3O#,=4*ZM_T__",NYID,Q5QL7@5ZG@IHL$I*.
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M$+%7703NU:K[6L+B23U8OIYK32OW&T(&.B6IZYM39R#3H)H-9<[E,+_G+Y'
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MU,0U#LXG_%-J@<AO"9/K?URIODLG)]GM\BYK?/A9W9W3,'O-1MKD@S:@E':
M%[]$M9;J;6MCQ#_*FS(+<2@UU%LTJ8L5 5J$PKRN7U<4?HTJO^YKHSJCFK:/
M/T8:V%GM@A04_=*S3C323F-KRB>&9Z"M^&!0B8WMVP5J$WHVM3'=,3H<M6R5
MF,F><5^>UD(1]_I4?/#^ F-C%6QG[K"KGQSU\>44!R^0_4! *D]W3D\)*_')
M'=!X;8DW)3C0#J=+]#UK9>HK6QINS?7E\C[,V'H]2QB!CXD>BF4N4^?Y&$Z&
MS2U5'$9)WEWD*UDS>K;N4"F>P3;9L3-NZS45OXH6%,WT2SK=/36F?6G,JVPT
M0^FHI-0"ZE:]&4*;\69\Y$:4$Y9$G\0((QEA=*;5?->'$O#EV5E[Y8H#IN&N
M]HW815J^M*5+CH'H\?5%KFN<J]TG?,S/62^F*ZH728VV6G'/FE%@4O3?O.")
M<X5P96ACDT8_IN*S53N%KU>F<[W;]>>L+[L*^G'E/8!B$7S<U_3M1$^TEX6Z
M!)/G-E/%I9W,)9E-9.[Y3(<V27 N]'/(N>#AIKXN&]OX^"^8#+P\("8PT9U=
M$L%]#R!(KC 8M?Q0./U 7M5TC,>MY^F^0@PR"U,Y&2HBV8.7WB"KZ9!DQH-7
M>%F'8#33XZUNG>RW/OSC8J.5&T6\,V_8R.]3, O\YVC$MF?I/)&R2XQ'<B&+
MW<G*^]><O%P[ OP7A_#1M$%DG\QCO5@"O?T0"9.U,="3Q"D6=12 _&D06"][
M&MC-P\*RC+TP$7$HIN]9EM?UE253N*L0Q 'M2F]3:HH/\NI2@^03M&ELA)[M
M[@=I(>BEO_G)$@!N#:[?_.?;8\SZE312U6F^3J04AUR@18.>2OBIT>LDU@[-
M.#O+>E14KB6K$OBYJSB#R7,Q=0YTNE#I;%@W;9'?B\JY05I_ZQ#%.IQEU+LN
M";9+S[7+Y#G,@= U2'4&CF?R]/!M)Y.I:9Z!CIQKHO G9<?WL5(9K-3R0?!P
MIUS#2NB8S[F %-3'A&&\:?2WKVK+)_9+('JV88W9 LRTZ-J#K[4CHE[!^GNX
MVAE"ULQ%F%G0VF_N6FB.CAH;0@5+S-+U=;MHDZ#RJ5G<+X;'M6G$>"*=DN<+
M;(:'_A%E0%+A">;"\R"J#TF^Y5808^FKCB*1*[+%'41[!&3]8,)JB%JY\W[0
M_'4GIXJ]X&E8-8*JR]<]=7R2DSBDH6/V0!,KQY"W8CM4-1+XP)$(;)UTO:5[
MV*E4[#P!^%=O+ZTJ,DT6T$8:O*93%RT7640HF'*@;3)- ETA3XU<88*9QR9]
MG=@2\HI@,$__AQL,4F!37:".Y%MS7-_"8>*RO#((&,-:S=.E\P)JP;&1E'@9
M&_.1)AT25;H=NB91YK:OVIW.&SCX-NQ-64LLROQZ&=!($J2FF^6\T^0LS(]R
MQQ*%HZ:1#X7]\/0V&B#8<4LPHJN<Y.N: "'4QZE$J2F4\?,Z<VE>C@RFI^V8
M0SI:F)31!N-&?.B;<)UJK1V3SH?UZI'KRH[ 73H)Z^Q9$ZM'9P31"N3%E?#J
MVM<*,J+[[9O3U7! ?T:8C5HW4Z4#5@L]%R<Q#PU<W])JJELQQN#T T=%W7'W
M2# N<5!WD[AI:L"Z"" H"UEHCN"U>:]LGLY5HTKKL7CE]]X-NHOH\J;\)3AJ
M823T]._V@!LR[]#3K;RZB;-F9*/Z"3Z\*7:^ROPAQ-1(T918<PLZ*:@Z?7CT
MKPWFR:;1<\*9NW?%VUJE]WGF^7)B29;,[*O\,:QEFW4F*,C?W=Y!/_"7^OI/
M+^!-^,K8?E]8T#'N1$^)U=',Y*XH9$%RBDLDYT9TO7'K[I[_Y&*DJV#.8^76
M%%G2WX] IX!,DX[E?;IL[NX/V.+/L*@C9,+\UH* <_K"[B@!T3L<X++]T2C^
M=[H'HARA["/ =S*>S)#T_E22F&3DSI_AWH5R:-K/^B_DZK/?RZQ"_M@=K%92
M?'I7/D64OH^ E]K6OS.@FC<RK/+E*FZF28/V:"5_W5CEF+<&- GNZ59-/7L$
MN.L"[CYJ2\FHIV95"NV86FMY%#R[5[<2>\(CE,%/D)C\$1"S]B=*_B>L3O 9
MYB.@[P1\K#DZIKG/,/\-;+7T"-@< A_A/\C]!ZZ1J\IPIYR]DK@^I;Q#!,>,
M@#N0EUMOD,%K7K]SZQ&.%N\16D]$,^XT77G5GO1_OO#'>O#M?8)$QFLNBT<!
M5PX/ 8O7%+^3YB7O!)[PTN%=U.^$= P\'X5+T_N,CX^ #*XG5]2^)KN\H_(G
M?8J8/![D_D2*QY; > IX1!X!-/V/@&YM:1F*<;]?_W($!>_:%LAD^R8T,BYR
MHA\!_"6!H6+9MV4/(^V/@)'?(B66N] +;[_T#,I$<UO\ADN<[\0W-U.AC,4'
M"YL&YD0E.D6_?8&"\;>=AM_WO+YAW?Q0_8YIO&)\%_L(P '_$C>^1\H[6OQL
M5VQ7S$&5H0[T'\Y@O<D9&COY^*#;% 16$7DR4YMGO8R"DNP&5%)N*EY?IBNW
MZJ<\GVU0R(FIEC+* J*+ J"GFN4=Q\%V&K0CJ\5>9F7(-$2I?!G!06))"4I%
MMJ0)[OBJWMF"++@*M8:(E=36GCOI+/-=0WB-0_78"R!56@VOMB=@,(.!5](.
MKKH*<[V?V'#CGZT*4FGSD5>'3]\$%]U7+%"6.V"3-K]XZ^-WT=Z4%KE'9(=3
MSVT26R_([+7YB[% DS6P-\(&VK@#Q3C8JJH?Y\#Y!9IRS7_CN!A';7&BSUJ'
MJK)!CN191-*38[M\[>8Z5@WBT'MA$\:;3CBY]P@83W?_2HA]0A2KPYT0T08G
M+TA<:IA9!&5O-\D,9<$)^LTA_KHQW%6'W1]N 8$2Z\7&AV!I20+K?_$1G'](
M]:,\M[J_>'H<(A34.A^*'P$MBS<X!7^A%O]]R]^X+7JX>00(QV:E')3>[MYM
MP2LR9GY _2?M/^.LKUXBE,!E\8Y_"@0!638F2!%0!=/0".+^$'S[7!0!VC#
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M,R3\L>UP]#1\:08L0S$A6;XISG.T?]"X,J_&MO1-2Q4#K[8>)S;,.9'"PD1
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MF;UJ>FJP W)+*KT[+&OG75DXAM QX[MSWV]<?QGXV$MV@Z#']Q0 7R24!S@
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M:Q5?<:;W\M33X\T4_6AFQ'ENL!C[%$>M:,ERTO7G07@^U,9:C#GW)_@WA-D
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MK>FF:"90=RBD2\7?\IB3'D^>E2R4-^F79J!=Z9WJ**FY3[=S/8\;Q-2=\K_
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M*NVE3!9A 1/N,X9%0R@DZ-O?4B&_>RWAJ#[43^-D(UDW:4I5D<@A&M,T6T'
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M&"'T@2$D:S$S+R1MO_FE$;&P^5?0,G'QGS\"4'?9Y9Z>K>'T#M*0'I9(0/5
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MF:FAF SV**T,W:.BRVIH"SUZ>F.IQ'X[PG/*H/3M44.@:'CKQ-F1![W!<$Z
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M+.G,9\G-%4*%2!:9.<+/<W'-,K)U3-_8614:WQ@;Z".#9T^15]!\MU#1_.Z
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MAY A(:59J<K<@#9UMH$ @#[?M^Z;Q:7E<\'LK&G[M@_CY\0EI?7Z<1\(O>+
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MZG7OY!OZ%"QNU?EB2.H^4_\<#OL1$/UKR!'QX5<FKO=K0W;:C>\ACRFS 7
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MZU+B_0:61J/\' A>02!H$P<*B&3ZQ;RR[,CR=E,Z-F"$T-93;\>&7IQ#UMU
MXT8@KJNA[B$-I6LZK0>WZ_KMVO=8!PI8SH0"/I@N+US"00&KO5K7"D#Y5M!
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M*XF>IIXPHA;TR!7=DO*5]&MVN5[S3N&\X0MHJ#=62V-E:F7:?B8M#AJD>XD
M_'JJ1@"^70:?:_/[M)M.P2.N7> $60A 5,7]1&#K^EI?JI?T6Z;'[  <YEMP
M6.S5AX6&)8E/AT EDH0/QY?RPTS8VDN1C#200 P\Z1L7*$9FVFN,>.%TZQ,&
M!>:KTWHRUU>7J*+$>%LBCM^2XTJZ,-3('1" *[KY8*B4Z1-[M<)F=4!-</.U
M.:;FS5(= I"O>3__C]F!T79Z/\.@*3JTIKK<:8^,HCA_N^,BW[.]-/D0O:W8
M0NY)0UO%0FW*NW?PEI'JRK,P*=JN<[FA'R9KAY(FMKCTMN'WMO".7S$C5!'@
M)!)M4[ZW3K]P07MS0>P@G\G6BB#A>@3@7-N-GN0H[XIZ#@& "B&]*=[D$/86
MOHT;?D19"*+=;YN38M/_;)G5G\:H-L>BR]2A0EVP\>+KV]1[?/@\VQ/Q/K$/
MCPYT?IM_=<D!;:1<.ON\<WP<F<RT0KX?:UXDH!R8X@QM!KH $  G>Q\$H'8D
M&%8!)(ALR@X>MM%  'K^::<:%.AH!$.7T1-O=(H?I'UXC&>=JYJB.59=N<W#
M*9GG!3FB,YH'1',Y%4_U2!.2GHM2,I:2_E6"3OVY-#$R:HZPQANH'DB!5IF9
MI7%$Z&9+6.Q8,#*DF?.[CM3^*#QG:1B"?Q2DA^,D(P-:J0Z+USVK/*2'D;,B
M9Y8JJ.(V^>'/\'WST(TCS+5XQ4#%!E+FI /VY48CG&#O8Q3(M6:*$5HB-=W5
M_OPN]ZMVM? &?8A'V551Z(<6O@-@L-,WYNZ61 /3A-<);_)X7T:]S+\@D?_U
M&?M.69K0_JYWWA/W/K#B P(@UD#_0]#E'GL= =C0RMO2.A=<NPSV)V<_#N0+
M?I#TL3 XE[NIJ^S*KZ@>*"(+F=F]L:"Z,_]"VQ6\)L5-CWOW^EMCE"("8%T;
M<7-+#B*[5YVHGEAFBG5U*3<:8G*N,39@);866M';>?XP+D:C.XE5>]A]1=J%
M'-YRZ<%B8W^MK2>6]'48*2ML]GX^*#G8QZUF:$:8OJ'[&S=+=XJ=-Z^*/].+
M$>:N0G=JSCHQ,>4P2W1Z#]N!=/2H$*7=_+;'G  *SC5)L5$G_JUC-3N2Z57E
MPYAIB7<;@Y/J>UB<7Y4W@..^M;FZ)O,B"$!D\>T3NM*3P'G-808"D)!S^X0V
M\B00:-]]V=TAJFMQ',CZ 3CMT2XI-BUD 'Z7=L[M_ET.N_#B635HJALKB%>I
M<((NL=9(H!G?%6^[2C^?M>'%?.!#H%C@LRI:V=>X199$?T%OO.=3N$BT*9S,
M6I(@13'BOD5672$)Y&4U7BY$/@;@^]U1)UV5J(MY*J63M0.T1/::S?'680!-
MDK\FX[GN=ZMZX<AJ.RY;'%21]OC/R['K0L>NK>[7=$VU]>7PVE/1IX9W)^[5
M$M,STWI)]KGT8;M*/%5$D RN8IT<%"53:D9G'^OA/[D?Y722^]=>A-_[LRX(
M%'5\/4E;K=DBEG?#H'1/'*$-E&/^Z&);-]K)=B;097O 5A7)(Z#H>'JZMCO!
MQ;F4MNN5^NZ=[AFF(T3Q+#=%\#2\7HFRK9Z /KWSPUCJ)3[C\!1U/,X1N#3-
M./HFX<D*R6_?F$3U35^;$OA$3U)I7X<7F8FD'R<7M;^9%5<:DKW3UN_0A^#X
M:[IS-Q4I.+,([5IWQ/#\Q%"V\5Y#S?:LN''OYN%HI=<K*"B=K+I?I14D#:.K
M@RS5;M3%?YI=N_'Y?FY8_8>2CI^?5E>4D69O)FG($+I05"=84ERRRME [3,N
MS ;9 =3)A(Y]?A'70EFX--5 #RQ:34E?<U$WNI)Z!>T<S$>/,:C)X#H^I./P
M:)-EBI*7T9Y4?$F7FP+,O T7>-!W=FZ2%%I;HPZU8ZI?*:CX@/'!,KGO&US2
M]L:]LU6OJTY^TNAP;((6G332H<+'[\Y<"+1 _DP?C>]GJ?SZ*U6(/ %3Z43\
M1S]M0WH2'Q7-]+'&!8&L<HF!:$=AU[JU_C 3 @V9GK-0A8:\B]_W [22U[69
M8@8<N4A2$?$' 7 )&7K0_?#@-$2X_%@N,2)EWLV^Q[JK0^.-YE4BNQF,M=+G
M*R VF,JI8[0RG.Z:&IH=L"?-(^&^%F^C>6>ZPE.E_N1Y6VLZC RC2),+_A1S
MA4)PZ?"MS =LX/,/^:&DKZ<F<N)C/,&!>+HN+WS47;BJ\6N+<2H3J)X'S=/=
MR8B@R[NYR1P<_.-<78<<2<UNUY5'BHY.NFNA0]K@EFKN["<@O@4_>+2>S6S.
M2HF2U/V_$O&GV>@&P9B4= 'C:>NHZL<L)P1 0O>B\+_.*A;\.V4K65#U@]A"
M[:LZ"-12;9_-DZB_1==M0@ ,/1$ X^ ;N4I2$]"C$^@1V5PB^RIB&IF'4PS[
M5F%W&QE\\\;,0>2;+SL(0]&$)=%/B<*V5;9W^*I"C+5/U63=")2GE31SIKQ
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ME1$!" .X5VJR&NR30^)CI/=UY[NA1 C GV*U\"">*7@T%?#IF33L$P:Q;DO
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M7N;.9]BK35I))[K93W7?P6N4!<#F7/\OY=L""HZ_!**P/@=TI'[BQ><HG4$
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M<5-0MU1[(HP:(@H=;"VV]Y8V]SV^*C1?M]9%V;W$NH0.A5LRO0#M,HK4N'^
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MQ:YJ+!]-!F&*QZWDY^_JH_Q:F\FT]NYXN24)0,E0SP*[@^"(5D\L%/PU-![
M38LX3F?Q%:X:[X5< -^3.FTS =]6MSN+BE:."-8ZA?Q5X((@0ZC[#OK8FR$8
M^PX2GQ3L5[X@/I MC'I&L16R+ED8)KX+["" LH!ZJPO'6.JD2KU+UA0\N)F
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M50#Q+S/M^3,U!TK)[N19I,T\L<K0Y4OE^Q8.9D8L/4W9N98 4YSJ/^X]4T4
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MKJKAPQ-^/79]7<>:O84NE]3Y CTJ\M^$Y(@;"0=HGQD9V6,ZHKWS^V,A$(W
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M"R*P2[.53SC]E A$@?[* .^/DL2HLDT1@2^W*XG &RS=\;X]=K:(/6HSJ,'
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M5C;K,YV_&VFKP*.2GB55_HS#2.O!;;,>;N16K)H*N0,Q=>BI=ZC^EZVZNV"
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MH^L1PEI=- "=/0'-]%Y<!]2[*#<42.)O?X.8'P,;Z/Y:]ST@3N(8T,! ])&
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M/_>I2.X_+9K\9VT^BY [G0=;ELS"!P1QSKGQV$SL*M*$3T^G&8\RLO"L)JW
MMA/WH*0W9"[R=QLQ4IHTPA-[PS-*>VKF>*X]W'^QBZ-(V^H91SK5ZV^W;J@F
MK:;IL4=F&Y4E5&S+ODER$MFQ-U<.,>:]T2[RV@FVK3]-M\X[BP*1>\A@G'3(
M19==.)LSE%5:E07;;6<C)5]7]\%6X.:1S]/DO<^+X.<M?BZH-NE("HB!?)J
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MQW3Z']K;DP1T#Y, NB4DC, .HB,!BZ@%$A!?L'$ ?T7X+INT$8>$(L/"E$A
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MTHS9Q4**+_[N,R1 _!;4%ZK SH/I#);Z4-]&9>K=K='_6SKD/:*APY-,;DL
M;=8Y3YN^I#TFUWS1 PPML!E\?+@Z[\SV-?GE$6,GPV=F2FHUCL40N398C"4)
MH'RL)8K=Z<F:3V0X; DNY!.0,(D+?%60UN9(Q7>%]D[-JR1@W7ITX+SY]=KQ
M+:>'\\T3PW+;U8WN(+5/71\HJ>GXZ9>R E_GSD*^M?:A24!;DTED.>[*SR,S
M&VQZ!_B,?OE/1$5]?\O[UU]-KS &J+93"3X9BP"1@&<1 V6/LI1SO4NP<7+<
M&PC]PP]6S"YD^WS.DG8R#[_\0)XCY^$_$Y$)KOLXW/2ZHK9F)Q\J#;EUZ/,S
MS/^/\!>]C]-^3=U9W!]IM].>'!T(9H^0#W)N3TCF:1FSI!LH$)=T$"L&/RNP
M&H+6I<<@=^(%.= Q72:4Z\H1_*-+DQ[- N'\7G1!!=)JG*.MP&+1=8?I*+_Q
M'KVTH-MNJ,V9T/!#J-=KC[=:VKNIN/CCVW_(A)5&J$=\G1? *BT2 @Z-?+LC
MS4<>O$ UMPX]'?'7"W.268NMOAG2G]Q;Z>B66S/8"8VQ;+1/7"(!L2<9,7C/
MDI_]%<$!".O/HX^/2A^]3VO?XYGA_I80D1G[T%Q*UYBA:<OQQ&UF<'_V\EO]
M'UJF4&^HE.;O$K$X@';D3B7)\0;Q=?"VUI0$94F3 ,Z8E XC*CVN -ZP.UT^
M]M\,)$&143^9+F-B[N,N8LU.T81.4P=% EX(2H_OJPQI6JA$5VU=<N/>3OC^
M!'@PJT<C$6"]**GYL!AGPO =51B076L2.F.2!:IYM>?\1SRSPEYV"3QYFJ*Z
M&#(Y-@FMKLHHQ-M@Q%.A2^??HQFCD%/-M[VK9-ZK&+D):8BP$!8NIGF$W//K
MZP[PPHJT)Z(E%H?1]ODGB57%&$%5,\MQOUC+$^;N]KB@'RNI+CR(ZWK<J/P[
MA1S]?8&A?@%61AM;T^Z?0U7&L-FFRK<LS".'GIP/^XOM,;%P9RB=:U9R+X@3
MV]F-2$IS7EQ@J7Q=^6'=B\TOB4M#R*XLR1  SNF;2B4L5-=GEX29H7O2"H):
MG=%:=<@BC,.F57V>A_OC5+[Q LAK^/?/6WV#QBX/@T)#?R " J8U[!$_.Z=K
M5A;.@S_#TR32<^<@WUI(0 ^8/ ($[7@^3I0( O6H3S2X.5?H%,HDE=\7J'V5
MWK,D/KLF%&WZ>7$Q8;6"^%60!OVCU!M#U4.4'E["".8N)K+4&5P*3MZN\F#<
MRKFW77!_$9-"\T/ZCD-IF4)%:EC51%WV_BC$7%8_%*3>N]R7G6.[A/M\:2)E
MVOK9\!D-5NDM)G+LC!ZA&L^$D=#&<#UM5D0.A':>B"*VDRN"?$9_#9(E5YCZ
M!)+O)AE32SSQ<M-!07J+L%2+)L\F$) G>+Y*&]=6YKJQ4TROJRT,+@P[>T^4
MPD'D"U5JUBIQJ'3PEX5<!,XNH&7;2KAN)P]S:O5IQ M<9)8>5 R?WQ>E/2$_
M',+ZOS_%3ECQ7>R#;K]LOJXLI?H&P:Q<G_'E60&N89\OO=JI2=)CCM@&B;;<
M:?!B>FD!5J<C9&#["R&_H<8MR^;'+^%W6YUG&",>*/BV<93WJID6FKZ6W= 0
M"_7S'/SX1<EE7TO>>ND>M87(&)GA7^JKAB@:\:-1I9>))TP!(Q?M7H$G+PKJ
M[$S=/-GWZFU<,+$^P^.4))_<LGJ6]J*"XJ:]74G$8"LS)N.I.";P-.-Y(!N-
M#]^6VZS;=-F+?C*\+F.)TDV2+I3T>B 6K;T,A%/GYSCIN:CXS9\\WAY_:^.1
M9=<^^@@-^B/P@G_4VPET:>W76^1.I"#KI"P)J ^S::Q_/?3!=".+F?=AQ6 [
MYUZ7[4/P>JE 3-CD;2H\VS;*2%S@P@(VE<CFX@?=TE;_N?A36G:N8VC..3 S
M2<5O<,6,4!ZU;,&_'V'2CQZGJDG[%>;]I_8%L<1:':H,P2(XL6[=O-M-J-B%
MNZ,?QACSWO\LAQ:YO-7NLA*CR0C08QSO\5'M#JL4+C/8J!*S>)!_A9J>K$U5
M,^%$T*TJ6BK]7)]9X,KP#L%/K+O7!_PG@_PY)@P6_OR9'?A//X;?.6V7@XE6
MAV^^WF(Z%%C0)LY:[%;^<?64TJ1FD(#/ @O$&([@.PVX1$]TS0TH+]CJ9WX<
M_MK!F7]C #VGS]ECTTC O6!H8:A8<.Z6#%+ MA=.%N:-W**=W&KL*2CJ.UL)
M?U.ZJM9#N2K$U#5ISWA#-<LG]9,I)%,!>P?[5#=T#7\QIE?NA'7RM#6EP_$^
MR=C[3$F0?3$8D4$&BEV)&"04/",!N:<ZM64<YSC7Y#JT_82%D8!H9NP*";AJ
M<TJZ1DZ_FW2;!-"?P_03G]>=,J%"& G@+\#IGR4!X (2\%1NC\E9J_?IL/WQ
MWS]%Y-99RB#0G%*R2$,(44W_,(F."-4G 6<@JX(_PI/)\UOV_O:1OU5YBY\+
M3TPF4L"_7WZ'$Z3ZAT:!$*IRQP00G@;Z)E3M4 T: ^4S:P-11IS#REY6#ZX#
ML<U:S]JZGI>J"$CT%()FAE2+>L<=;@4>XB.[0!Q;FK;@*$_+'B:ZNS_%NST*
MYCTD_)US57L6TO34,?:^_]! >W_]UQ.I[S9T&Z"UC1]R[?MXY1[5&M0L+B!L
M.P(@#$3!(&CW/$4SAK-XD6^R<;BJ4DG>G>+IAX5Z/X3AO<5%P1LP8Q=-%]QM
M%^*%$2WU._K(S7X'C/#&-]0< LDT%9;XA?5>&.ZC=T.1*_R_]H+6X_*WN8B>
M(W@O844&AO^&(JPY5(Z0@,>>] C\-:S#TMODLZXQ75JL(^!J#WRV'KAF[HK,
M<N+-1U92,[/R$A][6UQLL37MRKG5T,C4GAR!SQCQS%#4EIYGC0OB25US_8-=
M]8^J0J4\>A0^?"+OK,C^SC,?3K.(";O4!$9'B4-_G3]U4*\TSX6:N648Q\/6
M!0\WF?V)F]#F7RZ;N76HH QK;)Y_,+)4YC'>#/D&+U]HC;@K.Z<\?WF&KH;I
M';[KG=E!+N)MI[TJFI@J%Q\F@S+,Y5QOO+$N[9\?E&6GU;%VK\OW.JL/?V O
MU6Z/U7_M&1<20",U4<[A,=I@&/@K\B@[";+(U%.B1;DI*(XYXY+!111K'GDX
MNA_?E79URDAN/CORC'6"K/Q.3MTD(F(2L?:"R(F%M\/9HG:ZJ \@-0/%=^]>
MYX<\R!*?VW.W$...^J'6\\N_!(Q\KJ4&'4J'8R^=NF3I-;23.LR'!.3)0-$N
M?_C")DVAL<9?PI31QNU[5>5I_SJFD8J_EI1\BP#3O%R$OXR!Q.#%D *A-SQ9
M7.#3*2Z-1:V3"+V<BB;'% 057R3+.\<CO+2$!>&#)ME2OSN;)88$=$KGL@<-
M7A_A,KBS-'Z3-WPC_Q5[31<E>C,EPFP2W2WW-W6"[@#QPW\:0O"\IW6.^?8-
M/'U[0LDT_/@ ,3._1%CS;/OR/F(TAP^.#49"&(,6.A#$/'#44OJ"\6?T0JS3
MJ$/.7)*E=!1_]CN@;8U\,T?#!COM5A[QXVB!P>I&<]+&6C<3BF/,N6EOW$'^
M-7.U9_84-.R@VP_^-V+_QE%I'UR=7@5:.+00+\NU3NYQE 6H2\-G1$Q:L"]\
MR^YBKX;NT+JVLD5V-/Y(5!JI&/T06GW!5++C776;5G$QQXV]PQSTPVPD*&:>
M&]WPU%^&SP"=''<?0XVS_)#!9B_E^#D (2_"J;GT"*#]]L^@7 4<*68S[E!\
MA*]<"-5@.LJ&D^5<(A0^UK1"RB6$7 IAF*O-N3RY./$^<^UJO1O/50<OJN_&
MHU^7LO;!D22@EKU5 9N-'C4:J6W1&O?SI#9$AN+DF%VEW2FK>6CM50MIKWG,
M1-R:,^AQ&R0!?Y,PB3BJ,._[D8L?1!;,_KA@M.)3M%C6#9WI_Y0<T0?M?':8
MT9)LA=TJ? 2AA3I6ZK</8=TUV<++@K+XRF4$UVQCS%J_)%+:!_,*6]QRGRH8
MD@U6VNMM,TFR.D7?L#NA)9U%MFX(K=*'B(#* GM^_6"/.2M5#>L 59$4)IO-
MR4-Z[&*Q2+LD$^'YUFFR:/P-SEGH%9UA=]*K#.K/K">L3,R[[V\S&!\9['^&
MN@U&2:./(&C[2#3.#!ON6?HH==U[,YV)87S6];K3DV6/1WT7OERX$8W7EU/9
M.H^.Z;;G0HOE)K:R;LR+C&M*%[07ZBIL:MUDK;CGR&ZJ4!CC9<PH_>Z?BE4!
M?YEZ67\H"6"SW6K9P2:?1HO\*78)$V^&7<=0KG6=I%6HNP;+(^ZL3W2]V9)9
MXC88.]JXKLHC\1YF>KK9VF)"M^(6!Y\VTRWM1"/@<8[HCY]W92N5/#\57!KA
M<J@S$'5XM':9P>FTSO[G4I;\>^VL;FXZU1331B#.Z[L93XS,%(=G*I>&3HTU
M$FKKQ+!?"K"I)NBZQ(S(_6QA$R;;H&LWP@J*OP)^+@!NS55@JFV*2G.-"H(]
M0 I((.=VGK8*!K&N74,?UI1TEK@5W!U+')OL8Z,TM' D=]3A_GH,-[.$_P.T
MD1*Y4*:\4BX@<XASA555JH2V>'"63BU@F+:\W^NC)[M;N= 94<W:A; 7%R:^
M&0HX0-P(BD8WP[9<Z!B^]=:;\(<\*,,V'!:A)[N,Q.E( "O6JFMPR=HO;91A
MXA7J147MNATE*S+/7N?I&".32=$_ .!KT$\%9>5\\T=KD\6VQ^>(>PV+C_'<
MA#)-:73,C:'B&C0T5D93M[!K4V%=2R1%0,[R9>0+CZU996-C PBZ=Y#WL%HE
MUG_+Q/)SDF25W'9A4XHJUV/7$;4'[ % CO3,/W*%=%&ZB$R!FGG4HWE;7!_1
M\WL&3YW;/T$K_*&/%N%K^U"T&-$1IW:HR1AW-/A? RJXU@NR=P+&LI* BX>^
MOX($.'9R_VOP>_U7&?=_K4VAU4]JB#2G%$M"C@1X:< )C%)+?XL3:?N@7XHX
MN3 CK#[FZR;Q AJU'F)R:-'=@#C[BY6(R5(H<%73W+K<9)69Z? Q[:+%?=IJ
M]^)Q7K/GKU,?$>CSXZ1WR8=I)?.?T$;O$"]_.#$?9UC AU[??T\O]?OBGT^P
M227''F1K&CEWXU0)IYP:T(N=V@$)PW&_4=G$1QPB\,R=17.7#[AN%L,'\D^L
MGX703B2"W6YK-]W-U++P7;<K3C9[Q[@FX"*-A"+4"9-+*EV;F54WH<Q^<Y .
M;RRG>';*TM<4"]R5NBL1_@&*-%[4;9U>9T,EM@0P(CU$06Q-/M:APUZD#KV5
MW1NE5!FR>L=O"B;PH5;2@08>1>5-5=*NZ4SA1[# U8>6$VF(\&#!4=^?-Z11
MME!$*BHI<C%^+F1WSQ C-E^([F'BF[XSL_Z ?;1*$'G..^K!2$<9\?ZL[Z[@
M$U2+\V$(MAB&[40U)&LJE@0M&6*(\?GKZD9SZ95%=W0\! V?GLOPCDUSV(49
M VV;668=YL5<XN,9>*:]L[=5''[R7C:YIV!2R+$,KC.)Q9,CP<]5;&!=:8U-
MZ*V692;!5&>O8:U2/^XW[@84P7$#1VE)LV=LG]X=6QH4XQ@;;I+.@2?0OSN[
MN"V1%.)KH&WV[*+;WM+U$9D+?I!H=6B7G8E^,I)8[HM*M%S2KQM/7[H^7&5S
M-J7?6+%\2X:6YPZ7III&".U!4(0X%M<.KI;KD/&0N6:-[37-U1E9;1YWC^H/
MMF*+;3!(?O;=03)8"#?Y&.VAO)*VO77*W%_%E;<,'T1QG/*(:*)*F,DH_CZ%
M.BS>;\OM9C7V?01HU@;JH.,I]HN!Y:7QR/EC,=,KM$_.D[]+O8DUPQE@)WL@
M+!'<M@O8)H-,38N*3<LL>"1RM,"PDD.&\S:]D;AAY.[Y!XN<$BO'OJ9H?U:/
M31/[@<-=4-V+0P'VVW<IVT_"70)R>WEZPT((TBC(#+37_MS;'B+?Z,-13<.B
M(,7.D.WX -D*OS['R+O-Z>L*.:Z8>NY=3BV8]!)(QKFS++QX:8PWQ40XS"05
MA;-^&USHU )AY)/I4(Y7X^RXH"+B0?1M;.%>G"TM_>+QE@BOI!>PU;#&%<4=
M*QZ^QJY@V-I:-;&IGD@HRY2+C=5S32YGU*-?VWZ?JVPV K\$(90#A"H>ERDF
MA=Q+\LU$)2-$4."G2,SAJW"4@.SN:L=.I[ <2^OK5[H%,ZZ9>RLI0C-VYWJ_
M_8#&>HCGJZJGQ*6X0;""]H\\RHQ[I\:L7A '0*QU@[$J<#9WI616:^RGF<Y6
M83LYXW$_G/5B4I#6 -_V.1I+L<Q/;4NC"5;U5C(W/-Z]X_G@]+WJV>OS'KDJ
MJHMKN3?6B.?LLU601W$>O3,UE*F!DL1^GB84%_@+:&\4UXJ%#<!I-KALF#I@
MO-J%$$1M8 XS>GR^5.5YU4KZA(95*TVPV";GA8PM-I4L\Z<?P3>MC$$,6Z.!
M]>4887\UIC&MMB3M968?!HX]_38!4Q#33W@M>9!>$-.S2W8/@L,4#C_15*"D
MBT53+U")W7QP_]WYF93.B6:8(1:'R=KKM)R$+<V)&@6BO[2>\R !ST.8YHS8
MMG *^"EY.$:^CR*LR;?[@FBA>*J-+50)*A]Z+;UXSL^J*Y<=[#K(OWX"3?"7
M!G$\:F7Z/*P)?K^A_C#&OUA?,VMT05AS3^_'3%R/=?YSBC,?ZL)K^#BCQ2_?
MX4@>>^)&6RNA*R$+1X,V[C[\\"OFMF[8RM(@XP8O=*L0[6O=@E$ZS',N97C
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MO[HDIN3G=EN7X^E]7?9;9+?F3EE+;>Z-K+PF$I#LHO6:+.KWY3^?UCE*DY=
M=%@SLXFPVS(5O)2Y7(BJU>;8Z[Q2+W7<V_OF$@":'_(#[I/1$0CY 1) *^[V
M$HJR<ZKZ>93U?NM0<B??)1[ZB9+FD+*N .1B*A]^1R' *-NX %.#3 BTEQSS
M/ AE:L!RZQ JE;I3^2HO&)/==%)Y,A,=X)RBO=K":20\?V*P_>%C-,KD?,'U
M#T_O//>@7*'7N]K (\ 4@J5:FOQURC1M,%P]@]Q80^WF7+.)NJE+>P_?LU0^
M^J3S^ Z2[Z,-#XJ1J>AD_]3":97N#!(@2)5  C[A>?UB)D3@+DZ32H4MNY'G
M1;L^'9^Y2;X;-9TS575\_V=)49D?@3-;HT9,#6(>4K' V<H2M*2/,4YT0'$_
M,%(Q^,P5R*O).G-7]SX;1^:6V#5*@R5_H3>&DB*%[G@^K ;2,WK(WDT+-"9W
M,'TPXV:*:"WP2;U47YUW4324A<6!K-^K.5TTQ6T5'@6E;C9!0D N(3E-Q9LV
M7)TD((8(PIPM3D5)5J:K+GY^T,>NV-4U5]4MZW@O[XINSZ_4?:I?\?=+7:"?
MCCIP[M;J"[)1Y!RI.Q?<TV-!'YS.2J$3)96, VTBX,NYW\])2.R(3$H5%>>O
MG^Q+>Y:Z3&2].]=P0>6TSU&NOZR@'KP<OC$GM2T3^V.:^IQ)@4/D\>3;ZB\K
M]:<\7(NE<C4#R5TX]-*-M_M'AE.Q[)MR-_\2VWL_XG'P"XVLE-O+]UCUI#^A
M!V/QES$ZUS\WC=@S^)K4P-._Z8A52PN,-T<)7&TD+'M=N:?AY8:$T^$9)K04
MPY2Q/(6=# ,M"S$>8<99.0U4H&G>$>,MBI&]EV$'9DD^- ?E]@*$=*(DW@!K
M\;X>CH0QKA/%8ZPGJ@[X(,P;(=GIDY\;6:F>WS'(*WC,2K>\WQVRUWG;=JP&
MOG&PWI+DKZ85,S$OBZU$3R))0'P%_C**0=]P5*FI%-7,W.]XYT&6_BXJ*YB#
MMF.[T[4YRE"0K,H9>=0.!_HP(K<QEIE5;B'$&N26Y39ES;C<S>KUC)$>BL^F
M<;]N>IQ1K'F2N/O.ZL<"._SA#D@_?S9(I;-1N<#-%^7)M&YC6>I?D-8R[)0^
ML9(9.'L7CG!_;M =+[!Z]\E%W7 R= #-V\,4+,;?4R[[@YZ?!M6KB,T%W8=A
M2T2T7BRHHR9-=;1HQ3@<; ZWFGSOJR+Z 5YIXG/*H/O5Z>7X@^*OG&ZAM@]R
MV8T\/?.M:WWZ9<;L70MVZ'C,V\6.TNAJG44??-& )4+H*V7#K"I-REW6PY%N
M)7[AKNAI%43%2MJX0]3;A[L5WZEX[JX-3<K@[DGWHG<Z,D:4YT FF*J8P'(/
M7/ZXQQBGYZ%.K2-!>A4>MU!CTN66S!)FC(%$^_&M-D\V^]4CHM]=D3 ;?EY?
MTQG(/)?0?<ED\,AN<Z03N3X6YR]VNO]I([8NY?B^MLNO"B<$(W'2L-K^P"(;
MHS6=E;O7O3T25Z^I4:_$2*JI:M)B(*=+8S4PSNW$BY_BNQ/=7)P?9C06Y>7W
MRE0.3@N_+)O5(T).=!L_I5W(6VH3PMA[Y'X"QT&6ZGKC/2[E4K:^4*Y6VNSC
M;*JDFXB:?M'U$")DH.,W\Y%ME*,'?QEKA4JFF7.U%\)8I-?E847:(4S^X63N
M^.MG:YT< BZ\U!>]$#%6]B)5GI;QUMD?KNO#A8VE90UXE5NO"Z=.9I F'0M,
M>)EASX(A#]D#IJWX5Z5V&X&C%:/V!L-E!>D6%K0BYA:T>5?(SS2Y[B5/UYB,
M7\J=7D)FI]<UNWX,"NB3Y31IKER1)3NBJXW@^'FP-@[7K-IV%WCY/DTH,M+>
M'S48!V5H92F",]:$%OV4G[[36^Z*:;\7\(&M?UFTAGKHF=WN>_X4,M4V\1;6
M5BGL]&*V<P_B:$L%&6HG:Q=H.\$45?7+[^<5!9.B<JG6V5=IEM=KDMY-3+EZ
METH;3;L<%YZDFAI+ZVSL,&)S.P(1X[V1?FH7$N=RLAGS3YS2/EI;_EC\F*1+
MFT?[Q7(Q0B2K&$/>;4^--?LP/1^4>:&V/[3"Q?)E;S'/ZF<*3MRE6ST)VY_/
MQDEM :RZ8:\*B=]( /-D%Y0]3/ D/*D0.>6W)6&,KB^MLINSM9FUUO&]T$?7
M_QCEJ<R1T;_X)(!^V:*8D(7W/LTT(G><.Z5R72W&Y+!RGP0P'$C/5-I/@*J;
MI0X'PL\YB<VXE?GKC"J-'X1H(LQ)0&0A":BD7DNKOQQY%PWJ@"+8ND[NKJ,J
M#6]%6@X_:(W1&_6\:1.15]QY$9)V,]B"]>P=5F6=H8NP]UI/R(;(AD*M>N%T
M82(H$ VVZ= .O5I>K%T0%*\_&J;C7SHUL[7 F?.-4U%Y1/_--H9+:+&OB>.0
MP_>!E?1MT\:)A5!(GOE!TT=+JA?-1L@=!E=>ZHFBAIA;8QZ(_AL+5)F*WQV<
M_9.!-$$;>8<VP,<MHEEBB=^W$W<#S]:875W8[PR;TFXJ/GR>7C:<?)1UZ353
M3W7A6;4[A]!GC[]HB'Q$Y_9 HW,D(8R;\Z#Q?5RIYOU \;?%"S,V"D;AFK3?
M,1J/Z6FIIXA[ JH;TO":8?=+UD6<(>'U;]D_71HAY%!$V0W.!R  T2-QN%8$
M$_$[F 5/4XKG,JBE>Q.F$>+I+\?L<N086;!1-+(Z\_UEN9-(CMJY'S]TQ/48
M0AK:H%,[5FC/N#I*3,X+)"5ZM:!PH&BN.W\S:_S[2$643Y2'DR1SE)K(ZKYF
MUG9E3 '=[A@AI&Z.1\\GM&"F,D(F3%:0*K>',ROG99ABX;Q1026A,L?"0[.=
M;Z:M[.V[II?*/=0^00->.:)H> <$(;[6>9XISC_4S=W6N/EC]4AMIGT/8G>>
MDRZ0[ 6*,!;?Y$:QNXPPN:6ZNSDX30*Z#DD !6JT(DRI=$KG%+;C)@6%C9CT
M_>N:WAJP-48Z1P,JZ<B79QBY$O@MHS,*L#^^[2U29J#(H9QU)(".RFS,K\G.
M\K9L@?M[L99V&I_%E+MZ/[E33+Z_3W'3O<'27#IH%W*L;)@:<BD\W,&!,M/!
MW<F%M=W%G56;_OJPB 5MV>4G@#E!,K_9]\,RWH@$4%M%[MMJN#L8CSS>'] Q
MC1Z9'\2IJR2A#A_.<%NG43L[Y+[E!ZX+D=^MBL<H+A(+D5&\=QO9LQB.8JEB
M>!$,%Z@=Q[7;HE"[&+ATY\4>0*W;(6+HF:%G'*B&F.?3[J<!Y;[.,>S9*)'^
MS;%.8O0HDWPN*JQW<6<Z%P5^[C]XQO50"]0:;S(>%BY>@,J6O:<R0\@Y#*@=
M ^9V"[3/Z_7>B^'8,"V@&35]]VL!#]K%WQX\7_OKU0EYI>W4G74?.]<A1'>Q
MR^9A<=:NTF[E<P>MA];W YX8(T<Y5NU!V -T<I>ZW41YL>N)=VUU<WU6L/BH
MX].\]/5ZV]FTH/%GWXPI%N^M[5@-M@H0DIO#D9=M(>.HH3!RWTL(^\*SM?*;
M(0-]67<JEPV&45]>=UC$GS(U0(*[RM@DIE4$#6F#)!RIS\? K-<G(ZA'+VFX
M)7-?\BQM+>61KVRIU@/_+-L1;"<LO<HJN5_2PK[3X %;97V7H;,)IHD8('*C
M/9.%,38+FXCZ4M<C$V=!6(2L2$UH DVFUI7OW5=NC2B^;*:W@JU#,>B(M!@D
M+K0)PK1^$5*/PU:\3UII<6(I\24!X>2V61!\&*@PN.9=$6'-UR]E:N*TC<I'
ML=^^<E;7K[!REBPUZ5DA['1CXUGEMS!=C)(9S_X^$7C;1:'6=^;K\->8)(O7
MSYA&Z@M,9BP2-68R"X]>-$EGGU+'%1*08T("PK*T!N7PNU#<\B2R&'\!RD4"
MAN903'B^N]#?$V*]&"B!85Z(!+37]9( +H@GL72,!.3V;Y. 9SX$AZ^$?IPF
M?*^/!.RDZO]U2?PE$A"5C"(!)WS-VJ?XYY;\>U#4FBA' O*:ND!8Y<^_A\U(
M@/D&='#E"-K.5!$,^@)USB &@PF[C_YC14AT+KH:#R$!.H&Q8+2[][\-N8&Z
M2<"^2E D":"<!.'M0!O9)L?XUAWLN8-DD2.Y7[LD8%""!+0:@?YM03?T*)$3
M'$\"?GI@J(@,56!L(QCI@(43HW>8H8N(I=^#<@2S4A( SCC=/E!H52]'K!!R
M(,?+)."HKT2N]LV!AMJOG0OINR-(>C/;V:NB2==$SMXQ:*<:FD0N_$.7Z9^4
MFA&A<DU$ZO#[ 6 ?AYH@!X,12H/AJV5ES.QD3X#];HV_JAS!^_??_SL)9?[@
MM5T<?#%F@LOAB!5W/=F\)N?'89^GC(0._\01\T[2-4T.)Q$*D(YI[R-,3\E+
M!>$G965O:($V(( ;UNGYG\3A[V)U8%J,)T("\<PG';_^Y(R"_VU--9-GI2_S
M"FAL48YT:.AX*]XU6;["-I!6W:C7=OQFT2E9@L/YO[MVVI^\\*>H6]4,YXVV
M#A\:4F]%#"O>-?H;.6?@3'\7_+_+CO$;N7O'X0MHG4VZ:ES&83!T+94$+(@G
MU_23 ,U<XK$2UN4_R<._R]4_U0K(>A?L=< @*&#3$RJ]2;U3L6:7,G.W0S1)
M=]_IGC;(YIWM-^",!."E90:)AO]325_X[TD?-?6G(K3XBPPW:=RIC-4_RQ#L
M^6];GG88'/07I0S_PP=PAG]B$?5_7T10?QOR5UB $1*9#I,/8Z9$B$.[$8.'
M<*'@5LNM>7N\L\=VP!K/ZO_#T,"K\XC#ZG]H=I&0NQ5Q9:^Y<J:Y!?MC;G;K
MA^+ G?\V)OTOP@.[],B?LMZMB7H["^'T^<D X$O_GEGT9G+:$XE5_E.D.OK'
M2&7^5Z3ZV/1_ 3:M4O6B[:[RK7U,W'F?F!^W_I[2>CA6M@S[E>'I2R95'ECG
MX/\S!"%P,EB>C<:9)!URO!*WWA9BE7Q%[>A%C7S]1'N#&E5QS)ISTX>-N [K
M-/D_4+%L\N0";X4TPV&NP"]IX9O5LU=$;PL+?%UDUEL18@YYIB#]OQ&DB&N]
MJ?S/24"CZ_Q;M@]=GQ02 BFLD"9_8Z[_ 1.>+;5'4&B"!#Q:<B]U.ZDO="?$
M^\WKKN!KQ!<Q][8>BFCFA&]F<'3Z=@QE.UMH683#%]-X\0/2H-)+MW7#[H^P
MW]8%.):@]2KXK*,N&(Z\GR ]+=WS>Y3E6&GG!>20*N/$RH..L)&!S5C]/0]]
MH:=21$HX(^"<A;EC2A# 9',J^CD8PDL"#EF&ZN2K3K6[,-UW"&MJ(EC.+03F
M9*O!;A!2PT#W4<F)O _SJA0ZD<GT.A*Q_J$OS&N]M3U4JA;5A/H^WO,)L9IH
MY:JKQBR<QO49"6#?A[!T+HD$<Q8@"0[6U34I@S^:HQ%6L6^6^5XEF#3D;I-#
MJE![3&4#[7J'\5 -Y;3#B<%!AQ\):FF#3\.T%\%L6.-YC<3 3IN>%Y[2Q]X#
MI=:&'DE3/X;LKD@ [\S5P<^52 #+G3F[=5[&TC*$S9ZWMX/3A>'.GH@ BW-!
M:UE'.XBLSN[;6-OKN59H:%<RP_IZQ#=G#.P%8ZFG:!2?:U?F,8@L*9R,8P/R
MJ9FHT(S568P7$.XT'ZM]=- ?K9[[S+_P4_-PH3-94J&GY&Z5<.^/ID_*:%?G
MY-<7O[6DS=1OS(7,P7KQD:GSU9C62/1IQ=E+U:AD@:(.*EV_JR7,NB#\)EFB
M!:Q\SO/P\(>.&SETG"S$.+"Z(I3S"O6<'I$OV/319G+M%%DSO0D4T W?6JR4
ML/R(E:N<PD9T=B\P:PUBZ"PMF['0"MFDW:IQPM[KXYN.[]SMR7U4J_B0Q<]7
ML<MPE@@6;*TK+\-A*HH/PFFK@S*$U\[/V&R;MR2Y-#8%TQ=?[AMPX!^>]TFY
M6QVR60ESFXEH>4G(W,V.Z93C<:WH=T R1!RDL5IRGMS=94Y22/!JIN2/G/4K
MC$0F)VS7\65K@:BPS]ROCDG?M=$O_#%ZE=N)[OW=DGN,"FJ]'(>]'0NQO,7=
M@W1ACS'B+_*PQ7<-8>S6^O>+L& +XD!+W#?)+-6KW]2%>\IN' TX8AVZ1L,T
MA[54-XB*HUI"01%3ADB,6,7\.8>J;K:F]]!Z\O2[V^="8?VF>U)]WV3I,GW*
M(;:M$ U"U<2H-TYI%MNQU-YZKK:EN2;WROB]YD\6H>7!CPOOR(S'FKNP5YG+
M"YT)20$J[[0R8T\0*BF>9[!9W$-..4:"2 O]4C%5CD/G'MNM&T8:J*B5YLI
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MP<=+:R@IV-(7#[)SL7MXB=!KUW5IP))5TPHTG:Z#^SF1<]Z$IWC+9.P>*;[
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MWRO/,(YA?G0T]V!G=!2#J+B!^MV1$6[].1UO6ZG&IB0?TSL&\<5?&3H%U04
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MH ]<N +]_@P:D&E21P-J<H=H@)&C#88;M@3O<D7^&*,[XM:]6AHP9B-(C#8
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ME 1;SV6]1T_ ZZ^CFKZIK=L6X&Q29V&;G5#!3$S'LS)>=*K ?8O+IB9#?N\
M0T76!;ZB2L:%J2O[HD0_=&IO<A@:E%H/$0VYN[UU_F?JPZ9;WY9/FZ**4S'&
MUV]FM];0*Z+#)T4=>I1\)*H<S*JOYJ'AB;& C:.7$I[>=EH_W.OF=$*%#PL.
MW55]NL=S$SG[*\*O']P8W#EZ9!T15A%^"U=I7/.[PR*V3'!KJWE004!FH6Z>
M,1>PG.<D/*&+#C<B(T9%O$NP>JK2ZT[3^/UM1I%?RJ[I-ZUC3IMR?AQAT[H(
M/1$N0Q<(4R$*]CM*L),A*C=PPY_$[&F <;I?=1WEI_'L2="=G^!U?!E9 $3X
MV4QYK^O@4NH1=' ,VK/ 8QS&Z9TBVYZ77/KS)E-D$+F\'<O<,G14_S[1&W=@
M3ZQ9QK)V4<4;O#^ZV[>EC,R=86=XN8--B2]6')ZUSOP6"7F+C(7RAVOB$SL/
MH4FZ)][!O8G!-VZ%.8S*FH9WOA]<4DRH.O.Y)WWBV(9")M$2MWJ5:(0;[:9R
M?GOFS<UY-;9;6^3.VYG(<TF0]N$L_2UO_!"!2*GL.$/6H[RGVQ+6 ^73-2KR
MR++1V/2YXQZ.[SOJ;6H;8S6N^ 5^#*"T%"'YL7 _2.J2>(<840<MW!U/-H)C
MB'N_Q:!XYD:W297CGY=4KX .=2\C1%0SJIN?/&?\^7MYF94>9AZ@V8/>6YH=
M^ME]5-%)Q*Y2XUN-=U(Y.?YM/KT/SRAJ#2ZDL8W2R6'LHR"Q .=.Y=C&2Z%'
MNYW\>CJD&J%BQ-QS-[\&+ICM?%V-$[;MN2IP^]W@W8>B\?VZJ_U($/*^9?*B
M:#8&$E]/+XN]<\^E4VI<0W,%>9]0:\5DW$X_=7N2(EG"UR/Y,Q(248Y8S23X
M4-IA"K 1JL+XK]MXC;<8%<ZJFNKMN$#OLN:FK*,/NI5^_%9ITG(=.!',PN@#
M-WC-B[^5OUS OM8A-?:3=#6SRNYBN=UPDE^L-4]RRNPM 0:$43@[7:0H4I -
MEK-CU?H29/TLD?9'Y0Z<;</7+]D99_OV/F5+XLB!,I%G.=X<%_]L\G,UJEV%
M9$&=5O4Z_S[&?QDJWN.GKZPB-^DJ-/;9&)NP,U@3R]'SX\9.['& 7G-<G+#9
MS5\V!\\I$*RFJF*18<M^P,+5?G//;*L<R?SGR5VNR5\>\L9\;]$5'.P2//2A
M$ULWI;7=C&3&_:@3IA^B$FY3-%M-*:WFNJN);."I^;0J*78I?AO\I?F[-.G-
MNWL Z5?"[U0"D1B&OT@7KVQN>%"WBO!FAP3>/2YZ0?]5B6,K]ZUYT0REA- 7
M_BUL3'FJ+C^98)?(9^FQ$!?^ "?7R\T*G2##$2'%5VI:S7SW?"[OET3M2&08
M=_XX8IVGH7\C>BX24GA:H:=#&C;]FAD'WJ+K8,X*L1\3[7JA=S/7KQ7[9! P
M!I=N=0;:+'(T]]]PR="_ 4W46&I,Q<K1*>:9>Q'Y$OY<[LC'\OOUWP)>E:5
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M\)O_M6L0-FA+LF#B<C99"3X7M=TS92/AFX@JA]2>Y)B]&'"55$HX0>B%;\;
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M=JM7 A_HQ^,*^I$NX6#T#!WB_(9-/CC/H#.V_3/]M^0G&<A9'73A'94'^W(
MJ8=L'2@MQK@>=)S!Y56_6__:W9*!.0FT/#%Y.,@8J7WO&;!I 'Y6P*@;4,"E
M?RZ$O^];FTS'L_=V&_Q;HK+R/XW37#JLSY"]#[T;6Q)V%A420Z][R!A*/S3N
MHM?E46P;;(B51V6LT= J.,Y2A7@J.W9OFVD=S 53]HHV:ONV[& AU]N49-&.
MX^$3BZ,!65>B.:3]GI>+):1G 12CHI9*RV>O0<AO-M8->.>X1Z6JVPZ#@2+V
M?!V%/2[@Y' 7D@^\ZZJN(*ZLVQX9TW',.XAZ&D_YP>TG3LTY.>SV=IM)-*E'
M0;J"YZ:PI.9BO\8'%I,$..K#ZZ,XUOYM8:*F$\Z'LAU7[W/529\[S*C5K"1[
M2$<\"?3!)21<=?#AV0'$!)(1?A_T%%[ONN2*TTQ2"A2WNZNFG_D@U2>DXFSS
M[^N +5=2[:_C^XB?AV82GL?,1/-GLNZY9)AMF"&FH40IT!8)$M<NA;%,;*U&
MOM!HHP%\^>#'Z.0JO]900^KFYXKB199] 0:""O8%GD05+2.$X"V3JWL?>I\U
M;GQ\Y7KDYX-,\70^T*+UI[2433$.:CA9&[TM0H81"WW>KJ\'8U*/A63L?[B7
M'3"MIF^WL)!ZG.7>/2V +T3PD-Z7S)WX^UDP!J(#.M+A\T2@SH)9)Z-8-29%
M?53//VAF>:I=F,K6A]8*1,S%.4[))6A#:MHU_16YED)E,SQ.<D&PKRY#4,Y[
M#"O(>C"9_Q&&!FPMX;#M/ACFK_L^'"S)?JYC*M(Y6\$?C%2KTLN8<VQ.-1\Q
M#OG9BB3*(+!ZY>&"1$IIR/E#_&BTKN>#W(B^.N0OU$>_K+E \9<=,Z]*;W9I
MSS13BHEC: 4_B7!)?%.<,MH.N^\DM#.<WCQ"=#(<O<O.)-%[#YECH6#=]G7?
M7,^X.ZBAHRY'66DU==ODY!FW.[_86'%O0!N/$PK?;+Q[O_8XZ.W1WN"LL>_R
MA$ N2#[T_YS]^K.]-*H0-FY?L+6+X] !<R\TI":0'1X<^KS][M-H[A!H,<U_
M8JM3P,#DM!L7C[7-3,.N)19.XB+Z$7K;<"NC\;H656L//<Y:"%8]?M@]5J">
MUG8F0+I@H1R5\IR!7BG"4=M)< _+^"P8'R[HE7(= BKT8O85;X^(=NC/-%R\
MJNK .TFN.@ 61?RS0:J9.(G31._3@*0&AC?$1+/Q(DWA=33IT[W<J:.J.ZUF
M7*$WC]=8S(C*19I2="A)\-O<<H3S>)N$P$H5P2%,CGJEZ7T,Z59>X\Y<A8Y.
M),:8Z_A+XMS9E92K(0=+R<YGQCK 9"E\:GSX145_CSG8"W_UT5=)YW^[,C&V
MW+WPY/L'QFH KH>L3<6>0,"^@$7J_80\-6]PGQD^?FSD=<GSC[6*NKT*:9P,
M61=@F\!C5_ ZCV@&1F3E6?3 R=A;XFQ2DM,[2V@5+BAQOL]>,RZ@O'>N%!'&
M4^ I=IPEUT[H'#CQ#&)#X4H==7C<1TGS]^M+9D)DEZ!)1LA;P Z1!$>50AM5
MR&K!W4BB<;MFR$EB#.:ELX)&$ODPHFPA:S,E>5)J?9>O1]^.=1V>#!%NA^#
MZ%CD,H+_RICG>:.6G.)4B?L[$E*Q9TR9%SZ7?V)4^L0HBV1$IP[0-<\UY%P=
M<TX#DF_1M8;%/.)D'T31A,MEI@Y>3XX,IT#'@SOAOT\@>>@^[#B.W,L]3_4.
M#T43V^664WD]'ES>-2SUTA2R^B2K>7Y 05+NN&L,8MT<!2&G+<7!"<J>2X<6
MXD"P]?\"=<D_#4$B(YU7Z$HH<XOXB@8\&*6HS]EL[\, &M!E10-^D/1E:<!W
M-1I@$?2<X8 &_.<).R@ _T\S>WO_Z/:6$?(%8@2:!B2\YIH,/X6I5A5W,9@\
ML:-<]7-$_"&;9,K-)PS11]@DCQH*$A$D>WB7$O4$F7]27=RO,TC361<GXJ+H
M<Z_#M]@-[%1WH5A9F/K8F*USB&D=VF)]C76GZ9&/>GYOFN,EG*688,B/ZU55
MYZ- %ZVF][:7(='Z #'Y01VQKG-1#*^[ =@%YI]<Q/:SL'#%FV):Q#4)>D31
M$D=V;,=1HOSE,Q?-"AW,ZJ/3C']HZ6,B(:]'8R!,Y& \TMD"W+DH--%N\MC)
M:CA/NH_E\;G:/&ESZGB: J&,P$PGOXAU9&U6OMRS=C.]CB:\+)6?JTGCM[?/
M>;Z'=R/3V.]U+IQ@U)H#1)7V?Z87K5/!->9*RMW3%G6IOQQFNVN,D4;7@,IZ
MP&:7WD7,I^@COT@LI@_C+>2AD1_T:P1<'XR[7O!;;SL!LK_O30-*;NTQ'"K0
MF<Z3&%9&A!,\)G6M/UP(]#NZ>8/=]P4\](=!Y7%__I0GY)^,U-QC?]8#GX_[
M(""N0YPYA3:OQWNG_)CRO]9K<L#/#*3DZS'[T1U+"OGC2X EB6,#?'B^%HZJ
M@>]X^-. F0$W&O#&P@"<M?3!KV=!!Y.-#<6-]K1^K(!ZUGHIA>K55XC*.'BX
MMLQTXJQ_:TGN,R5)O* (3:- _Z^U1BAR@H'\*3QLO+H>GE+ 6Z6(=@C3@?)N
MG+G(P77ZY()IQ9O' (!82IVY%:H,<:$!3U.EA.^@20%,A_)SK"@ ' -C@XTM
M[3Q8$H!L>4Y"]M[;4S8IT?1@&*'RT5^3!;QIP$L.I[R$N(\>@WN'C&+*8MHA
M_(/E?F3#<F?UZ*/QO)K?I>-#;MX4]4U@O>,L5D8WV1#IIC(+[=+H8,-Q8PDU
M;SUE#7D*T//:[UE6@X+^#_:^/*JI9TOW(& $5$1!9H(R*I. # (2$!$0-2(R
M#U$1$1 1%0D8$F64,0("BDJ405"&R#P3YD%%$) 9PR3(G""$0*9W^-WNM_K=
M>_OUZWMOM]VO_6.O!5EUSJG:M>O;WZ[:506[7G[5CNN:W#W*)CF2RL[D=J69
M>!)%8.[0?52OY6D$%U*?Z20%[^%/C(9SK2S)NO[XW)W[0.LJ-^1V8 Y%#K0(
MRUFHJ+[@#P*?_D$J]D)!S]H#MX(O1R^+W7XJ,&CU_=E7:F %][L=%W8OO)"'
MI*"_(4@6NBI#/^LW$2%WL1RP\-676E9G+QP_O;GH6IF8).PR6&!SP^-D!4S]
MZKM>$(M-HMXJL0!/TB/0M@,VM2;?+4404B*WSE8YA%L()V$I[HP4U#'?,96=
M)IGS-JF'RLIP%N65*=-SU]&M]SY59=PI\5.\&@I<W:WP@3 64TKNH#DZZ^9/
MAS=JQ89_J9[W[9QJ0A]EHP4BHC D*^\! E, &H.8* NY88<2GU# 49\-&P1?
M>XX>B0>@BI9B[Q>@M]IV1B&*$S= J^'T9[Q_7=*#&+,)DS/+5SYIHR];&?-P
MY;Q:^ZY7K:=DK$UF0W<<&ZD#T,[.U/4F^^2@U<X=HYY:"52W,Y4IE$[S^ N7
M@]Q/1(C;E-[;K;/--GK_#68NIEX&<X4\'KB?-^:;:J%ECL>MN/'G9@G3):67
MC$9?L #^5XOGM+%R<I^$Z-'7I6TON(CN<'JV_T26^R4V2>AYX3MK$B4T,W#$
M9#$*">.WD+O0^Y'YJ^V3*CN'L NT9P,W>^^NZ5YTJWX<DWV_<,'[:?A1MDWV
M7[AI_;^J0/Y(+/DCQ^0_][O?9^C[\9/) \5P"$KV/6[OMXK^$BO+M@@>DQOA
MO>H;GTQR33U7HL[VY)?$G.IK^ "IJ*Y,O!0DU&)O)A1JQ=X;#YE$]*A$U6Y#
MJ5$?YND73&##]?>197-_%)0P\:^'1L]]2.=^8R:E:""^'9G+4*&X4'5?S]U+
M27I.PM5MHM/=U!P=G(:HMS\?NA2WX^I=WVB!2P:2P8^-@;,T7;I,*5609%*?
MRE'"!88>3CK:-R5@53+U&S./,34*ID32X57[K05B=LH2]0 +X*%1$.3D<*5%
MYI?<(9"M>KH;["P;RJOWM5KW)0HRBC665__0<@&"= H62R0]0:F0!1L63TSZ
MKH>Y,;MZ++"R'^[I7\E>-2N$,_SL:<K>@Y9C+YOPB@1(-;MT?O,S8N/^DP5Z
M\?#$]KS.[:A=5&_2I+6730.&MUII/- B[;K(NO$7KSQ9U7BN$^2TTFXK,^%6
M]NX'1UB N_?@UIS<>D.@9;V$U.BV<R<I]B&F(@ZBF9W):NS]PI*Q6@I'VCY[
MDE0HT8PGZ(/HCTS9A#/DI*C#[IT*)B[Y]F_OBWX7WWG;):Q51G2W;B0S;BZI
M*,W]V\$>MYX23QXG2WBY4Y&]\XDBXX.;:D<DL=FO>+_'1S(?5</!<;G!>%GM
MI!B/0,E_D73GDG9'WTS=[M/E4,G64^+B#N+=&<)@^MEKU]&"PQ4WW!9%2NB-
MV+,_7Z#YV:ALF;-^E=/I7EFS?7XBH8Q/0?)*7E?<71/;ZZRL. KDW@ML#H+O
M[P<1^?8<"]CE2U.)@O+G&L=6;5/]HG=,)RS^RU.7176*G69"J7[.R]:= **F
M5HP.H=XAQ9C0#Z3NZ$)IR>[0$@D,\?E<QP("'+V]FU*6_\C"9E]9I]"WMKTY
M(W/L>VNEZ"*%9KX*[?8SUJ17OM'F4F+5?1ECV^5DTN3BS9QO9:VD.Y.8;\>=
MKBR;]17/UTA9%=\1:$Y<W;6SZ_U<?C2;Y8(QQE*CA7Z2JCX&BTK"N)*S@E<1
M^UH$/32S7,2Z3\$&;FL=6+^P"\"H'K59%?8'&]7-2,'C]T[#0_NB#FJ.O9^S
M^2)[)]7"C=ND0"B?!8P3%V)(+N/&O3;H_53/\45-YGZBP,_!O.9/;E^O)=_!
MC_6R;?#0!$%/J$'WI)WP#$#73"KIKS= =PN$%#HY9B7Z96?/?"R+"3M11E^3
MNBX\7!YMLZ02KJ?[!FEDT%-\?'^+N)9I3UYW7_?GT7NM.TU?6UT, #C=+0R@
M"0B2(V9#J'8/IC__+0MX/6P#^BH.$'[COT^R )H@^,W35_"VH.K&D=;FA&UT
M!;(\Y$//FL+BL<_(41_^"\JGCBLY$/#.W_C YRZ3'46T%H_CKZ_O-8%2.L-F
M8D>TOOFGI7)MP\-^?CK=&H1&N!A BU*E64"<WT46@+?#K+(C/AICSN%$Z$[>
M8RK!M=ID\=[:,R+6$?[(SGJ8M'(=$!!O /A)V_Q4RIC5"J#DN;ZQ->C76D_(
M+*GFBFZ7>F]ED3KU&"8",%/TN4!-D]Z@V"EX]47$@ CF^8P;F@44F53=\_]\
MYT6_Y\6CXH>.*O&>Z[ER+/;SD*ZO?MMKDY6<?Z;;%OT:';!&'24F/L>Y_LWL
MO3W'.[Y^[PW2?A7!7U15,"8/Q,,S ?4FYX/==*E7Q/F 449M8H8[J:3YZR)8
MZG7,*;MG6( -$0XCG4=0Y<59P*)Q'I2+:IQ_%Q\F@AJ.D_YTQW/?H0G_9*J+
M)3-?G4E##5OKP,IF%A=SF+VIA\M)RV%+^7>)H4.H@9*B:;G>43@=-:+B$_?$
M:/T4EVA$ZU>P<?!.JNQ."4$G]0F;%G%]W1K71.6[.&Y'Y1\+5;G]'DCW (&H
M--\;93O8P&B$XQTC9(V7=VX_000MZ1YO.Y+KQN1[*;NHV?:Z-\?9-#SQ0[P4
MA-9,7M^%SK!P/D3S]$QFBC,2T(?G1)RF^@1)/[2VZ3[W.R1]/]G]<./C6W"I
MN*$_)=]EPTKE&:]JY52"JE4#9ZCL#46%&7'0A/,$T7CSZ-6K!O9']4,']HJY
M+"]393$+]V#76$"H5%.M5.%*[0'J&_ZDM:O0XZ'Y?L8>ZNL.Z>W,/OZ9C]L)
MN_44)@*-ZM$RW6L,6=/+7X\.AU25Q-]'+O')G-J9ZQ)G)\K!'G9!&Y])&/]!
M+%YF\'?27[ECZ#$&$KO(SYGFD%C"PG$PGLKD17Q9_O/@ULTW[\IRDTXS,R?[
M+"6*-CM54?[\NM.*[OYK#0^VF\F!G?8*\5YPL9E<U HMMFF$AFT28]##8V5[
M;4N?,1)=)"Z'?;;<Z_]V1T*PR)TJ.;&$!-"&?X>__U^&O__G2LN_$N3YAT?!
MP&@KQ%F/O&NZ9@(65BO8KY'38EW1J[):[IIRA5]><:%"VXK]!R> A-#WZC+/
MM)YD >_S7[. ]!PY)@\(JK+A4$;T/<0FQU>*RD,ZVS@A+(4C !JRJL"[^P>Y
MRC1)QZNRGKM(K(CS_':S>0OJS_'.4*;\=9=39$SXZO+>V8-6N 7[S,).P:>O
M0KUR=[2USWQ[ .."_5EZ*8.)5R/Y+;23DL>7(Y3T#,>QX1+"7;X?C[, M]ZC
M##5YMZ@ -<U^*PY7X2<T58'98C9Z!_/_'KLY5.(7HDAPQZ\J&DHFX_ 0;U^>
M]M2)B>G @X+Q[N)1ND4"[5?,I%.G:^0:T2+=U>*O!J^G2+STRIC=K_K(Z\:-
M2;Y&[MV1[[39!\Y#QI+I_.ECSGDD-THVV6NM(S?=B.P[-<1\AKKX=/HG+K!A
M^VR%S#W..X_SA,>T\>:,QYBQ=_;X!2(I?[A.7Y+D0PY+?O-L=[+O[G2*^YC)
M%:;Y4DQC]K4;6IR&+3O8H870/;4B5)N)UK#O77HNXPQ84XI>M-C@W!'%;*&K
M$,>57+5;'X/4^VKOE8"^S0'=L3\@WEFEL?6Q%,3!WS=G/4I*Z,,SYN76$Z;'
M6T#V4$1)9Z37*J)'B$/Z2LF-E@.HXR3'$Y9N65)F[EG^W=+HJS\?Z[6_? :,
M7;Z8:+SMU'&PV]U:-+\), J+%1S>HA+[CPZ/*FMJ<U]5C4@TTW\CQGL;$L H
M*:#"QVI4ZFXC93L;*H_C0V1"\Z:ZQ@MCO*1C:DG7ZX8&E^,2>OME7C/;"=OU
MU/-LYS9-&I:YW5,RH]OO>/J[9S2*O3\=HE9YQ#%G&QM'P'G( 9H/^NLF9@%'
MNK9L'VLJ1T9GBW0V;J+2_9[YQ+KZ+HL9A'E;EMSFB:2+4P/'O 69W41AQ;OB
MQS+Z]!PF8HRG4N;&BRK-A-J/-^4QNK3:6KO$MB'Q/P@3@G78<,3^$AZ'91&D
MG!'Y[&CN*2'9K[DNY=<?OTB\4#=V=28RN Y61&R$A@;TIA""Z>SCQ)USA2?Z
M%N]GSA88JD8_/GW3"N)^. -[V0"J@W+?8GA4\R9$P5=L X[+P9CWD9Z&*.+'
M4$GK7D</CFMWU /@'^*^8/P>/NJUF< &HYPF< \Q^XH9?J?]5U7V(V_2W]L]
MSFD\>L-J(@ZI#5/327WU_KCGYGV\$AFV4$2ZWU+)6*K H]1(^06YSH3G=P+]
M,XVD>_2!D4\VTF.[SP+6C"06<#V/A_**JIM.'3ZE.CQRNO94UIO<YT,-9(.?
M!USJI1Y_,!6->S+F)C#OVT+7I6J-(4+< U*Y24G8\8NUAV\FFQ69^Z@Z+BKR
M[XPKG]1_4W7XEV]8_Z\F3*OYS6S\=V?"NU]?EW]-2(1A2\I]6''_ GD"MMU^
MPRS_LLIJQ#7)P]].FAF8T5[W5KM6<7'A9Y8;4P^0L770R/U#;U+7T8+DK+!E
MAVW72SN\U%R=Q(7NU+NZ7@[B@@0C>IJ1;JT@4N:,0Q<5CE23D\/X2DK.1^7-
M%HHZC*8_$.Z/ ,0Y'CY8C 3H=QFO"&.94"',]<[PY;$.W]6S^TZ4'Z(,K(J:
M';@_EG'$SM[LJJX?T"3;93H3JY -#AE[YB>=\!8\=L@MVCOW!5*]WH\KV]&Q
M$KUT_^M&WBO+T>#%Q,KQ\^PQ\[@JN@K(_WRHD'&&V4WO?#VG"5M#CL&YE%QW
M/HKL-R'<RLVO%/A#.F2<&(86+"3-A-YU4.']<>^T-0_/CI,6LN?,ZN::XLTE
MS*3CS5[MFE-X0NYOQG*@5&B\=%EG-1+H^6I'"0NXX<J,_8CK@V68Y.G*I>$:
M]>C)VS/9^39,D=:Q<,9^^-9IA!?!R($\!*S9*WP@C.>B=V"^7-TZMC#4&,L"
MQ-/_:DEZ!]C43G273:T("1^FO_?'.L;-R]_!NB_$.]S3EGB#CX_1FGC59?EF
M^NN#M9.%C+?Z.SUL'MO;HYQ(,E]'FZ+XCQA-.,CYB\<*6)VLD(X'V/,]4ZGM
M-'ZZ$.,5RC%5CKP>'$O(EWEGE_?EJ[<7F7N_J]/C3U'U]XZU^+_BG8'!>Y6+
M8TX,;;9,>RK,VUDCE;VF5-OY(XT4TMD3+QE(QAH*S!)(?;"M$Q@+408LH"&-
MQ@)B^Q?A=)U)RA46D.;& A(9()V)O\X"PAW1GQ"K9UC "N$=9N4L@%; --IN
M[?)+:R>#U(D[:IFIB_@B%W[T.504=>A+KIZQJS=^8$[G;'E-Z=>##D^7@D]F
MAKP;"V^?6OKL60\;[X<6"3+VP>CX.1P] 7%^MM*W%OMF:,#>9&K(ONFQD<3$
ML(6!E;"<'+"[F&T:0VHG<L!^Q-!A8"V=0:N, 3G9SI<D(^8C8B-(QF06,-2O
M 7G\;/1ZE'U160_Z,/)S=_>.12^EM9R!UT'\.^+2/H];7;P%  #DC,TJ'TV;
MSDEU?477HMZ9"%0?[P\!B4A^J,LMC>=G=_<IU"L,O?+[F72$]OS.U1DYGT[[
M[R5XJFSXPO"$.*@5JUY]L< TYJ:_\DU9YDAO,BJV^=G[,LF=\>> ;;78KKNZ
M*CM_!-S#OC&D>&G!2V.[A\07F(X6V2>=/IEI@PQ(KN^!RI?_ H3P5\M?I(8C
M"%__"@<_#R%NY3W!-S1P_" 8S?BR@ Q-C74&B@U$A:WS@NS(<$:L'V+3R 6!
MZ?K5$Y6_Y>^8;/U%D[Q_4UWKH"0K_*#W!&81#*FXJY@"K6&8<2EF,[.7AMD,
MS,,GS 1B/X!AUN&;G8ERHY\U?T9';QWZL+N<D87Y\8P%?,>8@Z%("H.9]@ &
M8$ P+%[^ PQG,?0$DRWX??G/\ MZOWC/]4W0R\I2P4"-HXN147V<+-40D/^:
M-+E V:]3DMG11!Q.\;P1(WOJ6L-(_"TV;2"%,?A?@)+\5Q0%$H3)#7ILN4&R
M%G,<M^E9C"?^MSV/X[?\W<*^88.?2R,D!C#?_?*Z_):_4_!U4.IA&!WGUD2D
MA6%F\[L)F)R_&.^O> DL8.M ,T_]K0/-/L^S -,;GLN;5';FCK<L0+9H D<3
M6R*LAK74LH!?O\7SM_S-POM'Q/Y'\/[+Z_);_DXA )BQ;##Z#,3MPRP);\T)
MGV8P_V+ /]!G_14//3_&^Y>N_$_W$_U/$?HD"XC: *-7*(B%\ZNW(S?HPX>8
MO5.,A=<? RN_$:=0M7YQ+. &#4;\@)-A2I25,I/H\,\P*@&W!L;:*VCL__Z+
M8"*/Q[& BX2YPVX?60#8*6NBEIL;N!<8,@8V!]*H*0;T?_^%CK4PV<QD 1:6
MO&M09KH'!J'^4]"9O-Z,X'&6>5,R 1.:%80+)5XBU%8]'.22/&)]R;1-2K^E
M5'%97\=#\Y;3$)S,/=>'[+/-"EU^*7U*V-I:;(\A!U^_QA!SE+AB<Q=+8VMD
M 9F" FO+]<0-:6<("W@OCF4F9**^0>12%8XT7?K^*.7B)O'.5.%"V!NMH\VN
M*\UG#SOHSK& ?>/_6NLR_JEU?7]#ZV:@ S3FOF5J#F9<FP6$)#"=]%M9 !=D
M"#9;]NS[!H&T<Y+Q@H)/STZK;51I"#39)0;3359:NU]5R@(LE]4^\5)N[A5R
M]M-WF%OW\V*6@IU7P][[R\WGWRFP+3ZE\ >U^N5U^2U_I_R5Z$AA??.OX#%
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M:4?F>29V:?)T[J,6L.V9MY^4CG&/"YXZ]2Y'6$KJ'@_]D]:EB=J,M$A@DJF
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M%<QV@9^(9CCU(#Z&#A-+)NZF^[RAXCY>F75YUS 46,?^>*^!DW!1K,-'Z&F
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M@4/'C3%'ONTC+79&ZUFE7]=TT4K)7- \,N8VDV1L/$E0E&=?AS*Y?4"K89N
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M+U?+C0_CA) YI[INM'AKF _<N%S7V:D8&=6*MCT/6>,<)VP(WB5LKH$^QD"
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M9O"!UD;QDK3;!*>F!.G7SB;7WUF,B9Y-&M2;.'5KC]4"PL'*0-*18$8Z3[Y
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M]K-YKK;W!X-;TY:0JJ-4Q(Z@P).=WK$1'99E<7T"\KXA44^-++99;$6^8%7
M1+0I'ZD82KP5J"]SJ$7YR,DID;A<WQ/I7ACS-NWOW3+._^6@_C='U\JR?H#H
M!3A07 ^6*N%TXMG)^?O#V>Y,-I\N'2+%2(2S'8HRV1/+_SHGXK0Q.QOJ!&VS
MH+H>[2HA[ND5W4-J?I(>HUC__4^6[<^I3(D%+>YXE4'F/SR>.X/(!4O7%ZZ-
M8@8X1X?%&<4>!PKS9OE+:Y*>U<G>6_QVBE/X*L_['J%ALK?O*19IN\F^0DA7
MO"&_4U^I21[!L@W8PRJXOXFD\//<JAPVXO4;%629^LH#W=H4U>DL76.BKL=J
M2GB\]4V_=D$AVROV76,#V2X; 9AN^( ,:0=A?3YAA'[51Y)^@PE$598F#9F/
M2;RO?A@3^_KPJXFLF"!;7S/E4Y9?;!"WX:-K(+3XIVTWBWS<F5MBG,0@Z G@
M2"XH5*,/W8J+P!NE"Q\9TH,YI+DORG1[%W2-_N+8*ONYX^JLONON,T1T/G #
M7XBA\?O4<-)^Z:(%$E41W<AC>=,K(3GFG:O7$^;'GU@N3B7:6XFU[%)Y:8B3
MU3K2B(K[!VNG_[MUTD..4P/!#_NZX/-:O(RD82LJQV9;K%Z(JFII,I*&.O_F
M?_LA2;=R!AQ"/]T :7V(==Y5_;B_)[:^'5I4# O>WW;P\R2[Z8F?'%7P,<L-
MT0G\."0-,E&(1NRR>@LX-\7X<O+OBN+_OW$46([U/1VE*XWZQ2S2['4<R1<5
M]BV4FIYZT.KUK3R]?-?BT&.7Q^-"?781J&&4< _-C2I%L^XJ"9I(/Y5D^,A]
M--3,5#;J]>MH=NFB+$7V<^/LV0!*&]4.+X1V<P71LE&%S,/!@-&TNV4D"DJW
M):XM9%VI%WTHO,WCUP.3$KUVTM\N"=+3H6W'!B?$S/CM+F_D]E4PNRP\YJ0A
M<E<S-U8[4:\\/A])A"YHI+_5E:(JGPM*K\_0MW^-U"JP%/JFW?N:5ZODB6#6
MH<+,0^];R[<*)A^\RN&-F4F>H@E*D (*N_"GDL9JHCX=])/C33_TF73O5(5^
MW;4% U@,?A?VDB-ZP'*\+'D4%JVI:4VV(.37>WV%':T<Z_PU-U']P4YI(YB:
M<<:1(Y=<EN!E,C0!35,R)T%!_V 0K*G?6>;3PN# TMX>A4Y.QV&5Y]8-,_U3
MB<HEF+TK";&2 HP=IM3S[K#2R(9\MB"COE%=I=$JC_P%#$9J>:(ZT=9:.E3[
MU46U';QM==)<(R$Z5!_DQ6*R'O28%/(-@BJB&$(F=U<:)(4[D>_MC5HY%C*^
M&O,KPX/4),^>XOWE*B &D)@ 65JI(88)[$9]B,F>5=5=)B/LWW8I?#5V<_$]
M+3?.EM'B=IU5]Z#LR'F[H5*",8TO'B?BH#E?GN^9(GM:SZ6A7'7HIII5'9LC
M=JGD 5CKM73S[T<=/]5:P>!G_PHB@_ Z--Q].;2TCFAP_EHEI-XEQ*F,&@"Z
M\B#XX34YA]&L@Z'O+<1@I__53NV_^_C1ONM,=.:E7MM\JB'&,+A:^?6M/Q-8
M3,;BE#Z@;>K!Y5,3^#5*"B-%H!X^D@*N6,,W 6KYC?60S9PG-@@%I*5^SUNK
MPE3-A6W6(0R!HQD/._*(QHP3-#\ZA(N[-ZNOO.M>SOR#\FAP"))'OZ4$/W_0
M_UT>_3Y2"#[NMR%RC.8% 8J$#3 *7#Z8PP00(HPD5<QFKP;B.GV+KB83N-T/
MVZPHY+L$ S])X4 RM_]FF?<Y/-FZ!GKG3V'0*;ER)C FRP3"=49@%+[O7NIT
MD+$O?AZYS@C# HRZ,4N**(-K@Y,A4=6,7^4@X!FLYT B!3Y:5;T9PA?/#9$%
M]68F ,-@P%$+,COC+KAYZ@4>4LU9#,&EV^"T,?2E'9OE_:/AA2MX"@^-E<I^
M#S[M0E;]IO3#X*9_&G[-NY\']]/X&<T=X+0.@7=>4AHZ'S_2\0#[T_BR?G@"
MROI/H_MI_%08M,4SEVKA;X*2&!'P,/U?_C.]_YG>_^/TSK7K'T8&]C,T0%?0
MUWZF##N0$9A$1PO>J_HX4!6P[LT$\LZY[#9'W0'KGQ!XZ1P,B<W\9>QFG(4"
M:EB?YY/N9M\+.Y)DY(MIO#O5[PD=[;%+\C*^>.'+&Z[Q:RYZ*B%>#>U%P_V\
MMW.M!:*G[I3V@\&.Q)Z-Q3TMJM6*CK9E2A(+<GG.>O1O*</S'0%_H"33ZE]R
MD]F!_\Z:3/!]\)'R/NUG-$.RRZT]UY[I)]_@KG*9$.%420UN=LKGG4 <972
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M'XFG\^ W3#>SF(0^K-%D:(QX!AOV(T5IS3(*G'9RA#:PY:8'8BR: ))]_>[
M5W7 B0/4W[KN<;<1C!F1?K3G>) 8K8_=S'?J9 *U*1N1E)P&^*IB/B3V<S;#
M@8B&07":IF8=C+(;NYP4\J>FC9.;03['RAFG_;#D1ABB'NR 2.*(&0U'MQZ#
M441L(70, 9%OED'/JF&_'ZH@B+N&W$RX&F("<IIXVL5XS"A\:A4D[&=<8.02
M>>F<>>!(+J299*JMG'E_&"A\M**&@PE\6F "#].7&,K&_03T"@5.YF<"AYG
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M#&EV&L:J[NT%Q;Y"!Q^HQLW<&TV-)UR_:*#1F*)@+'1^9.R#:2T3$-:2HVV
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M<0(5&Y!I-T[K!UA3_]ZGU;];6&M;X$!-+[Y.L2^V[M"5$UW\O5-"T+9V^:1
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MAP2$+,ST':Y(=6>2Y)3$'R<;[<9?D!,V(UF&%F;4E76H2"A#DX'<VLW/KVL
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M<Q>?7M,(+62F$5MB?P.?O>WGTW5@F*_<.EXNCO7GOR)FZ^F";G98 T88_8(
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M//!IDXG!(_:8U3LOEZ&9YBY41T ?O"2<BQ]C:FZ=5U)7<A/S>'(0&[MB]C!
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MZ^:1?3@ +YW^51\4.];PZP<HV#>^OL%+?[]_&)9"EI?^W@O\]LD792#&0OC
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M=3X^5++6VKY.A199'1W]2TW^_5$C1;&CNX^^\Q6E;V=ILC6P_?QU^ 6^.LO
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M!U8BT2I02\K28JI[D'JO7O<>0Z><9P4NE?S=C\SV9:];+.^\9FNWI>XO!RX
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MC0ML7"'(G$%PE!\.GL6_1N-3!3:GXH%=1W]K4&<P=*>I(#PE 7RMQ 66SH?
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MS7"3*=> *(4VE[T6&<O29HN@M3Y]4QQ1WKENDB&,\NM@U!]\GPX/2'W'5UR
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MOBE<()21]DTK[X!51WAARJEY_1CVYBDD?1"=P L!AYG[AP;XD6 >+P8<2?J
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M=HFG1$'H=E1TXZT<ZS+M7;$HD(' (?(0["34:W>62#Z6(QM6KOK2_9J>9&N
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MMQ0_956"#DC&1F8&)QBFS\VK+,LM.RD$=BB%2-(3#X-]D0_\/W'&(A%3U*&
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ML$HVL@7OA+UEO2G!,</*]\;;O+P@I3[,N,7$"_6C3U4=Y/H6O-7.0E$^8GD
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M[_^Q]]YQ36[9_O"#H"@M"B)2@Q1!JB(=)*#21,1&$92H@("4B(* A@110+J
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MA[Z.9F_4*0ZUJ,06&]UM^:Z4<4OO87O-*F ]HT'CQY-U,$/R%\(T/$N_OI5
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M%>4!N(CFH8S3H&D;[X<6+]'Y8#3,+)H6;TS3GB"G,($WSDP@@:[,!.)<6)=
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MD;4&F< L]QKH?L,!=.U-)@#*K;@E-X;Q9.PL>RMV:[S:B*WQO@#'F]FG1KT
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M$*;_QV=^_^Z&'*):H&K0'$S@IAN6$'"O=?X$Z:Q^VM"F_%MKWAQ KOWMV[A
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MQ7>UIWV( W7J]5(/)A27%X=W*F /L<4N8HF&V)C!(,I#D!GL5-,IE^F1*O9
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M?,Y0>#)\G,*E';1SRF9/KSF -EMK0YZBO!Z'/63P59"4(]?F83P_[@X?&YG
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M+C3YWHUO]G'U*K!OXR)^](X5\I5KK0_:*1ZD/1T(RQYD^* 1&%Z-<*Q[3(1
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M;,^4BKZQ!1_J<1F"%A5&N=/,6RN:52!7DIKOL5-"<TE"Q_'[+DVC\6^\)M9
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M\=Q^@2F)U#%JM;AYK3LY/Z[)E+F613*7T>CZ;%MB4M] HR"J*R412C [!J6
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ML4;WEJG<NK:HM'YJ0=:CN";7LZ!-24EDCF0M?'J29O8\DM33)<'$HZZGY.N
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M;)45]^A\>]"."3<X>4NY+5EN=[T+3#!\LS1>%,Z]N&[P0=5-8NS26?EA5$%
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MK8\K"1<R:?[]Q<5R('-GTW'JF_0IED;\XY,?Z=>U_B\W>*#.4DHA'DDR)&=
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MD,PHE6D^>M2;,'#W[I3)DZD!TL_9EN:UV8 T3HEWKK&7NT'P%?@$LM8F!OT
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MM@'06+W+0,(S;DGOK,K5(.U)P9A9OM2Q U:IK_"*;!!%[C]=&O$?R()0WU&
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MG*(:]K]\Z+Q=.ZX@V535&+.#,6@\5_]*2WF?Y?(E.I?X1VGR'C\V.'D>5(N
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MUB\4^WW)#J<\3HR5Z8M_&?)-CAB$^M7;]UT3\) [XFC;Q0K)P9X=TY7.#%7
M?8;(6HG0)MRGN,5BHK*N,BT%?^_.TV&,L%)RU%<8F):P,DJUV2S-3RR:)WLC
M'R+4YZW^\/;R'7!K68=(<,,? ^]U3Z"Q'T$ 3>"J2'><Y@5R3*>=4DU%S>Y6
M>:-9^6G]Q5@ER>NRHKN93ZL\696RO-#8:"1#=EPZDAWK1S;.A4F3!YQPM+&!
M]EF9)]3N4L,-S'&J_?7Z@A#OOO5PE[V^8*:D+CU(/<</L1T?E0L6L[[8^)0
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M@.H 3U\7/RK,#WX;^>3/M[NE'Y]4/)Q\C?[9\37VG=^YYDA&^VP0/5'4JX>
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M:'*KRJ/EU9+-?>(['FF!+@W9CPST\NEQI=C!V^HC0C0O60_BXP3;K9+OIGA
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M!'M?P[E_+2VT?7@.HUNY%6TQX?]X*CRS*]8;7%6#/\E-YO,]VD2T0)V:++4
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MQ^\[W+'2DNC0GJQ:GEIHS\ZF;W]SWI1[I.IRD%@MJ202!),@YM2 &\$]W[F
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M$^+^*W[%K_@5O^)7_(I?\2O^+Q1D0_\&4$L#!!0    ( )N37%38E'4 HU(
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MP;=]@QR=9HY'ID-(NVSF@<(K0;3]/1Q@+M1K*;?X9A-O2YJ]J%2E,[^"X2Y
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M>13ERY(AW'<)VAX1O,K7) ;>H2^7B:\ZPQKZGY5;3S%:44;?88\U[EZ\\-]
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MH@OP?_OT28R9;NO3(X:'X?J*U@GSYGKM^<:56((W[RQFB 2ITSR&F)%&F?_
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M=1I15L,8/[,?4>K4R%5T\7%4KSF/!M[! :')W,9BY\K>-E49W;"?B &\;G
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M8LY"I;+[/?I+N/9P$VQ:N_M":";L'A'YAI&P]$5&X#T3Z)4RZR/%D9"$0WX
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M$PO%=*U8G0P'VMU,[*C:L@AKK:;O@P&'<NVT8JU9Y[DIAP8M@PN^>MSL:'$
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M[N);H#G'WKZ6N%DE;9WD(CJ'W?E-=CK=_^_YEO\WQ?!K_A]02P,$%     @
MFY-<5%.J.R%2I $ I4$# !4   !P;')X+3(P,C$Q,C,Q7V<Q-2YJ<&?L?0LX
M5.W>]Q)RK$'D;"J*4G1"!TR2)$E**6**RBFIY)"8I3S.20A%&8<*B4DY%#(Y
MEY+S6<P,Y9P9QEAFUJSYEGWM=[][/SU[/\][^O9^OZ^Y_*_+X5[W??_O_^'W
M^]_K7@NOFT<!) [N-]L/\/'Q+3FYY"0 \/H 8X!_R9+%+_0C@'X)"@L*"@@(
MB@H)+146%Q47%Q,5$UNV7$IBV7+)Y6)B$BLE)%=(R\C(B&-DY59*RTE)RT@O
M=L+'CUXC("@B*"@BO4QLF?1_^,-[!T@*+_46S^'G6P,LD>3CE^3CU0!8 . 3
MY/O3!_CSAV\).L>E0L(BHF)H@R()8 D?/_\2 ?[%6:-_#43_#@A("DJMWF*T
M=(756:$U5Z2WWHQ-%U;=6U I<[2%KK;-\>HM$=&5LG+R"FO7J6NLW[!=1U=O
MQ\Y=QOM,]IL>,#MXS/KX"9N3IVR=SIV_X.SBZN9US=O'U^^Z?_ O(:%AX1&1
M<?'W$A*3[C](SLA\_.1I5G;.LY>O"HN*2UZ_*:VJKJFMJW__H:&UK;VCLZN[
MIY=*&QK^^FUD=&R<,3/+G&/-0POL1;WX 'Z^?_O\IEZ2J%Y+! 3X!806]>);
MXKO80%) </66I5)&5D)GKZQ8L_6FL/3>V/2"2A'5;4?I,HY76T17JFVGKF4L
MJO8GS?Z88K?^4YK]1;%_UZL7$.?G0XW'+PG@ .ZQC$@-X*?\E)_R4W[*3_DI
M/^6G_)2?\E-^RD_Y*3_EI_R4_Q6245H:VK RF>9""2$PXUX<QQYU7SY(4P_Q
MU.KM'*SIU9_7[)2;ICECZ1(]:<M#(TW.- CO%+IKL@F0MC+Y*3_E?X7(F)[N
M? [K98PK%&?J]3 Y8M>U\B_T-KY4._JY^XC9.P'*$K>Y*S@EW'"4'P] :KG&
M/,#L<?[S36OQDH?O%<>;3SO&O[S(F(:NRTZ.\0"3%3Q (SF&!ZBV\ #,&NXC
MW&@&^'6%%0\8]H=W9Y!?DFFB]'F8!^3Q@)MH5PG$W=PG=B]A\!.WA@>$Q1(^
M$YE6N)F(;!XP8X"ESVCWM"&1ZHB5#A8Q)567:O" <,WJP5FD!!'$(">PO<?+
MM.OAIG[+/S9\#'2KW( 'X"9 RA$>\/7L_]=#(W?+%8>6J=*$0JZ1I%QD0<\6
M;W/OTL+2F0&<KJ[\B5[*YO>3>W1>.>SD*/& #\\#-O& %X(D)$BS>P*:W5IM
M+'2'%/IT6NZPE<W A\+\0(&UC3+J[1H9D;-1HAH907\2*)Y%YP&W[K@27RG%
M4#'"=K90,$VZ(/3N:>7.4K?4T"./5U[=*1+;'=];\98Q']%5:2C(D T_)1!\
ML"U?NQA+FQERKA\JD8';W9(37S$^TB:3])*.VD\0U#LZ#LT&?#J7?"3MH?\E
M; +@KQ>.<]7N561%,L1?Q,CZ?:SQC9<:,FM6\8XPPE5[>H;P(_Q'W+IPA4F5
MNC$G.]2@1Y2TS1]O^'N+;3<,>G4&FT[ZP@-ZR"PO.CC91Y^VI,^';K^_22O@
MWJ[0]!>!&:R+ 4V:0^H/*=?XTV3&_(MCG4AC2;M\LIP]LUWGK>YG%95&GXNT
M-CA^[Y:P86@0;C7NG"6DZ1M9KI??[><YI#94XZ#RJ%.&(563<]TY/JAUJJHA
M^,V[LUV;6LGX:V^/MMFU>7B+B=V?WG@I\U3ZZY!@M?#JU3>_"Y,J\=!ZT\GZ
M)X1&4/D7!\7;=I!SS<J1HR]?6<WT!GQU6 66RBG=D,2GX>FFTU%=B"$WU;-<
M)Z??H&9@905G[:L#5PF?&Y1E1]]L, @! K_B=R,]^&+G4/(YO(#I]>M2$RH;
MVF5"$S(VIAQZ?/G<71X@?F9^W)+_C0KWF=N)7MT4WVR'@ZL+BT)&DO>/AC\[
M%4/A(XVHLXA08Q[2-EBH4D3:>2/^Q@V6\H9&2\DJQ7-6V4T$P\?-0E:,%:QF
M;CK.%;>BZ"%A/8-/[^*)P>J*%;-GHB[Y&4ECM]^?"ZPK\'Z$8R5!IN=*O^=B
M:K6%3^6W<3-]=!0/W&,M4SW#/VE!:$/0R'B)#\.=YP$ANSS*5TJ8T[A[OZSK
MU+FPYT+B?ODMN4YK=#XO0=35D]D*XYV*$ZX>^6?OT ;.KU?;FGW.6U7P@+Z$
MJ1L 7^7&@92\U"WT.V_/4WG ;;U--/*RPQ/"7?J%YGU*#ST#TT3N^C8UM@\S
M2=T>V),%C*7QKCEC)59XU_DK&YM/[ZV,VW?V[KL[:9'P2=23GQ+J2FW>><JZ
M(COIYX,*Z$GA:N=2ZV1J3M@8QTF HIMW\A>\5]8<\X148Z9$O(>TPY*[JI5M
M0=V1ZO.7MH_X+$0__P5^.-?[;DB93YJ/O=M$^@C?'Y.06[?,WBE; &>AOGH%
MV>H8,3=#5896EF?F:&G ?O>HLJ3>[,R%^&:^#_JB\#UN-H[R@J#).#[W+8+N
MW^V'WW?TB'O7W>=)LS'3:W2/K@JLUGM-TD/5229T)Q%5*C2^^.D9D<]2<,L/
M-]?=+99B??6[GL)YIQ329-2GTP96ZO, RD-W!KL7$XZ3J.D<$#03?M4Z=.&.
MO552[DHY30F#^DW=-S\ "TLFCD#I'&,H%NX).,Y0/ W>K\L8.DJD6[V^R93+
MZR/V8(:B4U.U+T#&0]=*ZLR0=Z4;,]OS&ZL9,MR5?EC4.J$5\A!AT)C^-,R)
MREW3[[C;PE P0NC-NV'.PWA[00#4P6,07,!I;NH<4;TZ=1-#*$3+PT[*->X@
M32EX_EQQO ;A=A';B;,*K+1C#H;;/HKY!=&V[85NG'I]/K2O1O?,DWO?_9:<
M4ULX9,G@+\%](14BNPF-. S.I6E9XQ._ONKBTE]"MQ:SX_9+S;0/A48>T1/W
M=Q9ZK0-9<IP([PW7<&.15?FQV8=U[/F/+---R-T?LJ\E>/XT*![53U"-!)"(
MH=AUT6K1B0?ZEYXX=M=HU"C+YAL>EK)AO2]C>$<%*#,"YWNUF="A4IG^J=D/
M2[BC(@8'YU3Z?4AM!P%XT1Y/4(BM5<!,!=,4#;;5)%<\<BG6/>\QI?TD<O,A
M8[4-+V1F+.%-,8H\H/DK#0,K6**MN]JP]!.8!?UI*; K) F)E&$+\0"!0!X0
M;V[)$?L"CEKS0>\--T*4J_KG:0 XN1[' V3M5O* 0IM:=S-)"O1H2,,!][IE
M8M[-9G3?0QMFPYXS1O)"V<_-IY= GM8W*6_IK 1?<2)AYV2&MV>V9B- $()1
M*+@51VC&B5W*=(%]?6E1.JJ!29$XVIF7&&-5XG;PW6F;<>RD,P\07$</FS+P
M]J1&7VH)4!WZMO=$+=$[[[O0.B']$6[H2'.1/?<QF?* *(SL</'U<MDEDQ14
M?E*BJ/A)QIY5-P=?) ORR9N-OULZ/X6/X $2,/\0IJ>)5O0M.'<C6SURNV8:
MHW]/[8'S.\V<+HW[K4(MD*)!>L #SF!ZKY-=FV[J[DK-\5*JV-AJ-[FK-)_/
M53K@Y5#Q7"7IZ;] ;?&?$GB46X:CY.#H3V'3G  #R$;P:18M=TVSF_]4\ZP'
M<^%FM;%2H%H"&%[0FW5+;EA#:/2M#$SU2V)U0_.TMR;3G@1MOPJ1AW$V%AU/
M7D01#U T@K/.VA.K4)Q1KQ\,V?5X!59IP*_DL,U2#[U:<<^X\TI.C>  2;FC
MWL!K#[;YN R%_!(S%4C%]TZ\TW[N,GHM#[347$E*MUBWL''XXM3YB\L8Q6U%
M]%T2>U9%SC\#4#+P4_X?%,T("$W6:G;U/("E/8YE6ZSUZ:B!+_. N$U#/( C
M.X?AKHLKF^$!\PTX6LRWB*2JIA&W2 W2G 1T]^\X-__\$&LGFK1.0G9H_(KA
MN8!-0=<=0CUNQATK!D[RN?. -%'6+AZP==O@@J(C#Y@8Y@',IX&/M*GU+8+2
M5@[RV58FT@ J?!_AH_0ROT%J5B1L&*YB?\S\S:OHDQ1/OP<VQ!P9N!LBC,]2
MT,0YI?L-&7#1UM_YO'8C?2MMS]G[*T^KC+C"$VP?4B,96N\[:4.OKUDR0;.%
MAHR@\[0(J]3Q9:=8?>/?<>$;+AAIY^P+_%)WU85_&H4MQ+ %T8!D]S%.!%]7
M1A*>V:W]M,VT.51^U9T:%>'\1'(*^28/*,JJQ??DNV?K"PZ)/"\<PV_M-I?J
M[VDPXE2MMPY1YS3(O'5O):SA 9669!=<.%NF+@87=:9Y\I+C3):"\FV?UO=9
MI.G+]EZ#[J( ,P;2G*][BZ69U@=J5^]2[AVHIKKK%I7'Z4MSCNV\<.3&E #_
M]V6!)B@2G(&N9/OY4H@1\+' B\W&)#>_EQ=X0&+LOIOF3FV$Z;P =8X8TD"0
MX&8%7,L=PD0HG(A0TN,C5N=I:N7DS,:I:A?YI$[>GNJZV4F^'J!*5<:^(\BW
ME>/23AH_&64':'IZN%XJ.[K=*@A(PRASR_1=U8/(Y\@1"H^WWL]7M- MD-FA
MUO!1'CO_48>@1J@:$ FC"4V=IP^:O8GY5(2TV>68ID78[@&GG]AR75!,>>6F
MG874VS;D3G+V/W'EO](N58^%I@A7P$J-B[5=4]%I<<\&+$+:,WTO;K@=0W#A
MGT^.U$C#Q*/T)-MA67 MN8!\>UTB;JN%,J4]0S7[_-UUX/IE!-2A*K4#O/1N
M\8"+EL+OXNZ%V9H5?MA_^?%667GXV!RINZGOQ"<\T@"N.'/^Q++,]Y>_[-@
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MCA;[N-5LS<*6D3L'SE2K%Q&2;1K(]&-YZS;9L'08!0G&@4D?WAQBG;_,Q[4
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M>@U?"FVZ;-@JNNXI9U_ZBTE&>IB4N9#R4KB8F]DD$HYZMQRM5(PV>2'H\O"
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M"_ISNCJ85GL$I?_W"588-8]3!;:)1NJY\-&A*.H&Y'ZZI.SUF6W% \?]%'G
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MW!<\8//?4M.=9'?2P@[L"K#,'27.!3:CC3]RM: A_(*L,8PV,(M=" O'SVQ
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MWIM'-;%MZ^)!5!#0* H("%%!01%1 >F)'2"B1E2D)RHB("(J(GT*04"01D!
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M!E0$BD;4E@%:=.E.$/(@D?GCY[_O/C >0IMD@+.SMBO7V%&Q0+,FF@8+0,0
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MYH<M@2&@:H]%78K;T\JB>)7#!QL.$-I9 M )XCM"=SY%-Y"E[B75HBGQSOP
M8.MO-3?$[=U0(5 G)3G\&MK&-;\$\R2F].C7ID!UEVRW0(,B.N-S&JOWB]7@
MD$^^]S/=;PD>Z_N\)[MDV($X1)^9<C8H14L(C;6W6QC6J\D..:1-&?E2'8P
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M?-^\^\40Q(U5!,K$M;<U4)W"Q9I"]_J'X0>GM=[I\RZ?G=^,X&G?'[6*6).
M[#G#"1;_@#A X# =8#^:12^<)!E:$*O0RWNU%6"UT1J%U08!W<%MK<[VND^[
M[?B-^&2JG;VQU7BA6XRWY<(#PT?8[_GEJ&4%2?CC9,7 !NE,)#&I""%'-X?X
MU6#)WO46Z!)$LP5(T^=P<D"9+7IX6$F!M09VUV_C$"LLB!>&&'LS5-@!!]%O
MO$E8/J!, ACN2/JW,Q_'N$>(3-E1\&5@)7%E+GP5H;<'=P8H.PP,SX%;%F%5
MT(EC.\"*$ ;4O?""S1Y!=A6Q<-]X.!G<*@)A%,I0IL0%TP1D"IJ2_Q3-R*^X
M4L=2B;B[AD$N)OP(YI"I77U5['#Z?O*/^4K&G.3+WGS4=^,TH.QJZ18+MTF&
MVR>Z42CQC?.@.5G;,3'":2?OE/<C_F52%9JFCPTS \KQ/6)#QSH/1C:=H]M\
M[)9NS=MF(27\Q&-C]S5\0@*R+YB3GM B4G*,-]>PT&[715"E4:;K-F%NC"X'
MTYM^HFK786A[4UMM?$">OA2 D[ W-NP'RM4_6]Y:?[0VC'H,$3(4XL^M_;B3
M!&[AAG1G@U&+0_:KB$1)'[3Y;\9D6(&Y/["BN\2=M8OIZVFWU/2VK^SCW2->
M.7M,D*PQG-'BM TSL>*A]B':0.K;"<,-.6S='@/3(:F/ZM'H<"4N<!%71MRZ
MFWF)=<4-:5)4(-SC1<)?+7JV,/=#_-XJPMN1,/;6Y$C I6?N:XWG35GZX.9.
MX.8J(E1LR6]QFUO<-TJ]]?W"-78;^K<%XUZ .K@JH$P=<'248P0QG:T'O>^O
M#)"HDD_7E&DE'NW\XH_@U[RZ."3N,^9=F(#\G/*.P\+2R#FQX3B>,8CG,VU3
MXD<WW)QGX)>BCG3J7OFG<^_/5IW9\3HR]'7(O6.H!.5J\ :]([\"[6\E1S_7
M/NDH&9O4</>SVM=-FZ=$EZXGT@G?B=VO(/X]'RL^FHT1Q1[4>V9HG]75U$_L
M?3$":[B''5=/17OUMO"9N&^<FDC<0#R*F9K0XW6$Z92FEVYW?_NLLN7UEJ9H
MM>J+:[6^-IJ3P]JYEKMWN,9KTM_5B,T0.UTV?E2'YNQ5V6;$)+2_]E8,%ZA$
M(P9&/53J5^=W+LXT6@]8D*AD4+"881\[I%!SVLO\8[=2O##MI0A&ZNW<"(SO
M8@Q'W]8,2.6MPXTV\U!(H-!3"*-2B?W;*9%I"SP0[Q*L''%$QO:_-19D07Q5
ML$J]HBK\K;&@T0I,N]9ZPI[B')8E8 F,7>9:VO-;"P D;.K"F$$B,%BSE5"I
MT#\B/T+\*%-7/#)'7?<J_&1$4ZYW Q4M:&^UN7G6Y8W3A?S6G#39$))([$7>
MH2">B_J$KZC>208,;0*2F!W:'Y*"=M,RGP74Z(<V'=GI%'==0T23)7!A_2H"
M%"1]S1C"]/*7+XEOKWJG<S2I(8S+J">![2K&IA,:FYA235/SSA1L@%E^Y9OK
MI%HB7<TDG3O\A>G;02+E7*16VL+Y_[[,+=,5XN>A09/5J,^W)AC!WP?$.J==
M]G58#YP]\-D\_[R/TECE0CD^A17\R<N=\D:&BO%U(?,YY*TB;K7DINV[?7"P
M[W+._5U7RG;X^3W3V^FC@P".DK-GJR:;?(ABFE)#D]O7M1=)S#7M*52=?WOU
MHEW9E)F*"T_63M("AF8]5/.(:(?<<)RJP.WF2S+]'*'WBD]51#CSV%ZU=VBE
M.XK-81XAOAL@;_0M5'=V)?GS;)6E7KG5SOR(#)6<GBLIVY:-&>_!R'W5*EP^
M]> !WG%?KZ8*2+H#E$G=F_CN5G[1T00?_Z*V&<D-ER43U#?KC1Y#M7^Q<4NL
MBE/P?2#WQ:%2/2,^Z+W9KDC/R>7.[=:&?=F;UP$J=*@#+[[K6 1XC3ZW<RR-
MZMG, ^ED*L(RMADTHO-1-X"7J([6E=E?>8//78?,\T)VW-@7$:;XJ*WY D\S
MS/(-"3VX"L8;)GO/4N '>R^IA)Y0A;,O/Z]K%(TW]WF_YFWW)T7P<.J0*LR)
M8#D]10-Z2^6]3M.OC'.U*9U6:D@(#9Q6##KBU@@T,T<+)WOG \^UW5E\HTO"
MM$W?+"4615_-S\T+J3O0>I@O)9CK0.4SQ(Y(AY5-;)]5Q,U]:!NBSU$QR:0M
M)9?2SKB<LXEZ%J6>8G*\Z72+D1LE;VC 1SOR?UB:6E.#BIG"T+#4I5!EI+!;
M?AF^9V!GNR8Q9P"X954QXGXOW7Y.[TA*^>XPQ'A4D_+W541%/F"+69$!ELW;
M@>7=I;'O2F/"M]H6>-Q+U),P.QRLO^>BO72._AXYZ9C:JI;W_7W&?5Z<@X'Z
MV6_08V\XI /&M,/!Z,%>8G8R>RL1S)A @Q%8@Q:S543&ZY.KB)-B9.91 'SV
MQ5]A&'M?VVX5$7@':L0OG(<14'X*_!\=%&V:W-T&!9&A*XLHZ#3APU@B^S85
MM;*]$_95,)0>]NNZ".DL28V$,Q_.3HVO(D[-<K*4L)^6-OSU35:L@M&=C;M@
MUQ_J!(JCH=-:?WNP-6S>?.]"C5GF9R9ILR.7I8'*6<,I]"25J-A;#@D(Z($[
M5XRQRR!,=8;CV%6E,#^1"U\9(=>2J%+LD172=*GXJ&C\C2S HJHCM;[NSJVH
MAT3EZ5EWJ<;J2X_5W*_'UK)D&!?93W&\7I9, ^03S9,T:(.R<$F<8.=*7J+8
M]$4$Q8*4!?Q^N=-Q7X$YISPR8TLA;'S]O5'8N'LB\.I[D85TP[1SK$7KI#\V
MUF%!/1LQI3>J^4+_B458)B]F/P'&K&&RL+Z)4WO.V$:,\*Y=3H0DBEGJ0(L&
MAQPFPO*T#?A%!,)__U/D-8-ED;[PN)\^LAZHX<IX 'L15TX>&09;D7+C'C T
M,E<-A *4B;3;,$'<^8^>*C2#VE@JQG0>1/HNK"(V, W.0W4T"#\B[H#6UB\A
M'M&-@-Q%7_SH#Y=>_$HM\I#S$X^_61BMK"<1G'IEWT#;Z_>$W*E>XVR/Y5BQ
MNWXEUY_!C(HJ]KO6.7_UJ?R9R?]?[5/ISMFOMG;2ZI"C%&MW_31@.^_5-/#.
ML;'/>T1TS..B6)_3+\$6@C93?M#Q4KF5>$EN1P:N_MZ>WC.I(W(_SNQLO!S1
M+K8@=G6)[Z_&2'\U1OHO9QQ^CL186IYTM5__UD$YH_UP7^_9T!V?OC^*/"6U
MSD22=^>SXRFOW=\-]8U7&%V6*T\S_F'/;AP=U!)BZ:PB^)"#X>RM^ T )8ST
MOP^-^OT=4AF0IDP<I;)>LAU7$5N(G(-48&)*,42+V!%Z%)@7  %@[#43YHYK
M'Q(YQZ_\?&/Q9CX(8IV1S-!E5S87;'37!#&+=7 M0+D?TQHV]J/E6*94[BIB
MZ,$?W/G;HU\ E4[UQ+%- ',;IJI'CO$4VH:J0*W(: O";E2"\+=#77^^PS;-
M6$6@1?HJ("D<9U,,_.F_OL,=;,'F8&D)T'9XT=1HL1#O-/#;V68_W9AH<%IF
MEHZ@Z.)SLRO<>&C=5OK#8/:[580_#ZT&"FIZ3*3I.7#.0_FC.U<<@*:JI4.K
MB"?D6*!Y!XST9/%/<XRG14!9= !ZX;S7'MA?:V A%;U?;JQDFT,XA<) 4!<L
MAGQ@J_+HU'?V"^+P (0"NL3(L*X2,!^+K&)MWMDS&&(NKX6%CXY)!71V[@F3
M??[ R B!T%IG1BA.1-J>/^0MJ#<7<"W(Y+O-[;-&SW_L,\_MO::S[4IR_.]"
MC;\&RP@#WY9CAVS!K<64I1IX#L8#2G3'&,+10K>(&KF>6_(";CI\!1=4*1?6
M*?P<4RL@^I%Y02V:XB#TBD+FU[LG')0<L%F^O=IT_5!4C):[<L\%+FP8FG9I
MM@M]F88)SD4_U5[?VM#T>)%G?M%30Z?>?CYJ7O\3<O&L>^V@?EF-*#LLJ4[L
MG'C-[@,1!?_[#()C*']45@VXK0:&V=D'HY'^+M-:)?:4)[V;S4H@HP[?I<V%
M:X56$=<*%G:7UG? @II+WG"UN<=1L2S^<$E''ACC:FA6MFE6]_GY8>3=P'&K
M1'HBM,&>IC"T_NV]C\??#S!EC N<I?,EQ=]<"]:5B;SJ8E<#<ETI>5@#\8;3
M1C0:2/C-)89:24#'\8TY3K!V/[^VB@AKYAD%IN59%SC[N9N9$3;.J;TJ,02&
M(ZK"XWI)T*8A'R&/DM!J<U$MGQW&DSS@5G.&TBO&+:;S42+UE7)@3>E.(\^4
M%P$.LCS[UNN)%]9;%U:[$2ZQ83][K>DQ*OMVA)7;I0H#9X)N,9"?&RAB7/K#
MQ"=KE!B3%K?T#2%';X/XLEC"$]I(>O1H%9EWW%'%?_$$RC2XPYDA%WG79K^Z
M+MOUP=JA,$66R 4K4_.)*U%F_65"'>FUUC&BS]35(WS3DWUYI^RXZ=P,.<YF
M]$EBME4@TJ_$_(.%&['L0OZ*0L0A\]YU,M'AKO6[/:2$:FYR!Z\0:E T<V1
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M/3]>YQOZL=],0RDV[WK28[4.^\K?9'\3-0;V29[?E;HCX6=2KT&'M+M+>&:
M*E,26-. >:$<EXPNF@C'[-^G!\8Z[OT4$6NF]'P74;WN#0\P,?E5S)7'DG@
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M@/^JXWA(".;U0'M@X$$GTF!C9ZMNOI2*L9R;ZA+PV\WS?3#LH=N)Q?:AA'F
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M][\5_>Q)Q2048#">/JVZ2C*%GQPRW!0B;BJ/KWM8[DU\5M18]NKME9>_X%M
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M>%:G=NSU,:1Y;TD<6=Q;AO0^Y^:NN:PPPS1[?1V%RH\5TH$N0X]5\078'I@
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MRMT&-5(PCWF\ELVN;%"O=<)'SZC(8H\7/'X97Q4G'*MWU$:H[>#.L-:8-PT
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M'SV*D1/\\'&A"&^$R #,<9S*?XG>&T# +J6W4242G(J:^?[7P\<7NCMI3^G
M\/E6]"2-L&#L-/%E!/W;7?<>Q0T@&"_P*YO<@+;&K\CU!?0MB4W$DS4D0*5%
MVI9?Y OF2UB7M]A#0ZMG&1?7%>U'C#&F>33XSPH.GE'X+AN@:R()'XN.7ZQ
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MQ ;=H3>)[J VR#@&/OK<[:12^?%TX(9;Z V%(J]<T64NSK%)8DQS)EFO7P_
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MU5L/WK!/?_G^8W940ESGH,SN</6D-,%7._68MA\;9C-]U/<^K'+D8CW1H6I
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MZET4B<B682>D&^##J4TA]@.UC=3"'SF\0I263HRG!I+5:'=/T8&$332_"LS
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MK-:,Q V!-!A!;F-<'6;A+!V8([P&Y\ZAB)-A'4%P0#RLOZ@%:R2P%N\26Z;
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M3(V JE=LZ)Z+*"6%_TPCJ2=_8IJ7J);T\R@K-C"3L8'[EGBKJ3ZH+?WZ;WP
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M-X-?JVH1TU(JT)UV_#(9K,+]V?^$)L-\_,*!'#T&]VGXJ_/.8-$QE,PO*>>
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M=6]>^656'6B4W#K0.1?AXN/3'7H>DQJ_M\3"[;RC\-(R4_#4\(;T;#^E>J2
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MV4"% TMAP9*6$'Z1E5:^UR#$62ZBP-QTG*NWF%"&&@Q;[L?@RO=TT9).YR9
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MC*U[QFW"@8:CBC]#5)VK;I2TE'"I@E]TH06#5CCV*!BN@ %41#ZO/*N4U,$
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M,1,9UJ#H+F6'1SRO8 !\RW8_#%:O9=ZU\!FR@_I^%I<(0"\J$YF^G!1-2F4
MSH*[](1 F@$#"#D!=NXG]-!BBQE 7JDY^U+EW_U)Y0_^]P<* C;9:L-EHS#W
M-GBM5;T3] ;6'B^-/_$+W3?!'^L347,G/M"M07XW I,-)YV,,<)6[;:VG I'
MZ/P 8+4*.9R@@CG[[_.T)FEO=(ZBOM,5"(OQ=8\TOL.57DIDYEO_;.Z?<!"1
MV9*Y)7(0L^+\_2S@ @0T[2I+@$T(;;-'&C]0G"2OO.4^CH,ALX[U*>MIK ]Z
MQ!TM^PUO+[+MW'M$@*]U4.1) \020F5'9)V$0HZ0CV(;_4VAZ7R+%Z_WF^=
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M0N> ,8 39M-0,G40MEUB2SD0#$N'C2'HU^1GX+18*RSYPNJ.&/U@&@.0%NZ
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M MR=@/@G+D9!I[.GT!/QKSEG41"J#![;N!%9:QB*/'D[150GX_!E"ZAZ24"
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M9Q<6COI,RJ;KU]O1ZT\P@-Y#*,7?<TAA<VN5($50&;;];ACCH6W& (Y/%3,
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M^ZP55>@[W60W!+9F;4:3KT%'Z; QC1)!8AJ.LU F \A7&1D'\7;*>\I3!QE
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M?SFQ(0-;+T)/7?G;=TWY@S_XGP'Y'Z"G\MX91$PV4<Z3 9#U%0-] Q+6]1G
MB2["(WK;(3@#,,K/@2RD8"Q^3^%B "LZI\'Z? 8@_YY:B!X"2<<PY(18Z(8'
M^&TE&';+G5GF)N+?\ZXQ Z@LH*9OM*$I@I7*M!.)F Q.@/;FW[-JO1>=,XY9
M^R4".VT50E,,J4NE'\QE7NAA!D**V"(#Z)<_MX,FG=*DID%:H;L?8=M5G "5
M#5W<H  VZ6D[H)$<>&@SG,W!@01OJ=6,7%>?=/PEO/G+]V2*H V___PQ-L&Q
M@TJJ=B$"R"3X.Q!OA!D5;H'S*NYD1]-5^W.&IP<08/FV%]?/UA<<R8)S-2YW
M(J4"W[L%7Q)W.0E ,VZZV[X^]]!3=7G$X\ZQYLDZ[N/.38W(VSM'*=%%W/UV
MIN*]7_M,Q-B-#[_XUCAWV/ 2?+"](-?:R]:T/;70>GQJN9KWB&MY393C22FI
M_2('FXZL>>TUT8KI(M;(H[0\'4E_PRN7A)(+5A*YM*(ZX]GW9J_N-I>*$',@
MQ2ANL,D!>1W/ (A/AZAG9TQ,$@2H>N7CB)Q5S<OJWOS[-!W$?SV)865/I 0[
MG;:FGI]%B/N/S&;'*6ML\'J*9L<@]7VW.M6?O7LA!_.U,. ]X&_!8GC[5'4S
MDPZQR%NDN&DT^W(L'\5^4+(TWD#$FMK!:9^@SU9&/(#)S0YF .6[OR?TF.T;
M]7=KJM46.MPF&I,Q&7T?X<*:YIHD\D0ZJXXG& "8EA)A-"4B>E;PY>!T<L1!
MG3"K>OI76.5&#.RN\G/+P(C,ISZ/IL\7]7K9BGCWV;>\5GN;)60A<JI%/)A'
M[SCF(@97#F6CPI[B4_5):5[O]-BC%2J-'J]^6$KRFK#M% _C.$AI<Q#VT YN
M=<5(R+&24_ CSS]J.TQ/JMGWEPAM7!TLSOU267,M\?**B'60GN WJ@^I9QH[
MR@"FXRMG0?Z) -O[&4*6@E(_/K\BB*O$_^KJJ);&[?/JPN"R:RO((VL^^$\!
M/\L[\F0^)8(1)]P'0>PI>1R,I AMSZAWGK&*T!&Q_6%ETO>QO2A M)K/P?1%
M1B2%%]!C .^*=:$GZ8/956 K;"RW-55M=>SUF%^$D,.PCFCY7\7YM0FUUMP!
MGP*_N,R]]A:'<)4-_*HTR:LJKTK_-4VROAW[I;J7Q_0QC*L!BD5:_N-E>,2_
MA'NEXG_J*X3*B_AQVE/DI+/S00,L"^B&W4_O1K&5XWM"*YX^/9BK3[' Z=Y7
MOMMX2 $]]"J[D1L  '/V+4-U5;MOA"MQXH57/FE)%AW5.QH7U$%A*MFF*W56
M>$WX %)^EG9MHQ7#4^#"?);/*8M&;#ACL>RTMT=GI7'<)2J5F*L,P#M[E*L%
M6K';/'E;)]E+./ZCMX2#F*TUL?M3X<2Q)^(5B+B:>^&3-=S1],"[L2U2[=@
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MG'BBPU7L!44%O<P_;=9JJC8ST@+R^'<8!I&?5#H+KNG2YGERDA$&[)+QK:+
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M&TO]BM.7]H+J@9H;[I;P'"0#U?6CSW[/]#KO52D&.$_J-T]G$NR< *V@RLS
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M>#/<S!%R]_,Q>Z<')GZBO5W<CU!Z&Q\A8<!A5>*M\T:!G*8"%=7&+]*_15=
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M-\]@9^23[J/PG-<C;&G6;O1HYNSO@NXHT/7 Z3P:D%  &9M]0 ,:<M;2#[5
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ME;7>-=><SS/77'.Q.K2+!#FR1 <KK3DS/XF<1^$>^8*!< 07PSF,3=-!45F
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MGE@/T'LF^_9")QONAK;Z+5LPE2]!,I&D1&3RXC"]^=E!TE/'41%Z *4!(D,
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MW.WHT-=E\6*!S4!# ^X(1,B1ZB5J=;?:5M>U"_$F?VXNO>5W<YY_T1R>JFW
MMZD8"PU[O-6N]$7]!M<8(+P3-0E=#H0*/D*R1IV3B?2U+/A:V'&>8CMF*U4_
MX$<'1<W2SGS(JOH2N3EU9B9>*O@.5X)^0]+KZ&"V%;8"F67P0G*J]ST]WIO'
M_PZ6^-^]_(G"^U#?A8=@U\RBZ*!KZX4D)%80.E,QO?E$G(N!"VXKT&2JWX.C
MZT%T4+LWF>%&[*72Z*"<6\/;H_ ?Z&^0/?EI+NC:@W[4]D<-(.W/S19!1'T%
MFN@@GEJ9?%]$B[!Q957F=-O"A*5M[OSC\27=>>[O$B>K\M^#?Z BT00],?"=
MP1(%+::Y@G)K0\,'_5[^".W[B^H\!2RQ(S(9&JDM! B5F]>@0$\ANEY2MO+T
M3%UEU(/+'=C)Z1-[R!IC9,&MBZ(*#=A@)!>9=28-<80L;1!UM2]3<QK1)=?\
M!M0NDV'[4P/]_MML]:2;WB>B>.*SG)7D1]/+P_'*:OQ5;+]KVAWYI*W+YQT)
MH@Z1?U>UA1/:7E9T%IOBNJ,>$(J42E%K@?K,CQ''>&[P7+Q\<)'IJGJ;52.9
MX4)9C$H_#\Y\)>[&C=_Z%+.YCWSY\+Z20F;23QC!%)X_</,0:Q"5]7V (B$C
M'8?F<'GDO"^%%HR<ZIM\]%$[T%#;4"NU;A8"=LF0[=DH=W=LY32Y5A]:O/YP
M_:;6D]:F@Q;B@UEZ(*1CP#V&$Y AHVR&UKW X4CEE*:AQ/,.?5[.G,V/$@Q/
MG+HM@E '%1SGRBV@GF7\I_2RE4>I^S,B<QNB</02!6W<6QQ]\EX&4])/,S_<
MTW69;2 2U$)P"E$V"<\0Z*^]@.M2G+[:J[ST@K_2N[-"XA:U^XF)9(*QX6SW
MX25 @S"5A:.#CKKTN([)9[%;3UK:E"PM7![@IOD%,_$5,[IG'_#["I4S2]7U
M%8\#"5NMF\[>IJH+?3M13S6:UCX73!B\EXE?<2;_YN*FO9XQKF.468%8R6%9
MG'MWSC+_+Y:T'N4B'Z:5 _/[D;0+'X(4:V5P[A(-XF+]Y6*L-ZKZ/-UU^*HJ
M/E<8E[8(QX(@PP62B5VNO7]\FOK?DMM#7FE@KF6UU-P"'\ZP=*=C)H^]'N$D
M(E6$'!VU0 >18LCI:<+-0#?2*^+!W1=:$EZJ2836GZ;"K>$/4VMD4"6O=[CG
M'22V%[[B FN (SL4&SOC8ND&$PZX,O^YDQ.^D18B;].#G/$O6=>?A]V;2,+\
MV&"?7AZ#1VR/=\&-@9$^_#J/=3KTYSE:[CE=Y]U8LW-S$AG.S*OP$3AP>&X6
M/!9U,ZHY0U) 1YR,0$B);\N/[O"S.&H&T$'@HC?'/84NM.%WFS;"Z\7(,)P8
MM$F<M\^]W)BK0577Q?6YF8\LJK9YTV+3L!W342S-@#'Y2\*VN6FYU%-]#STI
M5Y/9_9T5)F^?'KAWYZ(=Z$ Q'=2TL4,'[4L)(P".!W30K#/SSF=L.H-\G#8(
M=R!,XV.(.F<N@RM<8P)JL#5GPR'A*A0GBAC0,PRO8/U&@[95^6E9B0[#?/A;
M?PI=C_QPYDC(E^?#?'M?&2XYE:S@P]#/J'V!YB@W)W>%9GXW)Z]'AT_(OQ>Y
MA+[>5B;^1><UTRH#H%^1NZ1*]B$JMDETV9J/!3BEY_+4Z7S ZM?"?:M1+W8*
M\^Y''7R]F6P:?*"U#9J#Y$<U*--!KETB) =RNU^][->$_D:=$Y7\*3[78HY7
MQ%M[/DD2Q<\'7Y1FS<34H]PQY--Y31 PE6NXW.0 N62\&9 ;7LOXV>OYV5;N
MMEZ3L03W\U!I]H&,QB H;X5;-U[.G+0A.^W\=F%2>DKS34;@'F:)%3A<B-L+
MT*;P4S4,/VPZ5@?/XE,$U?U?'DG<L<TC8AH@!\AJIN3P.3F!)@V5\I34W&(?
ML?3:\]%EFI^8]Q8)F.44'#K8'1"F:A*Z0^6L?X3H]1>O\5^W1Z4(%SS1-F0!
ME)FH-.34O@C9A]1(SG.F?!ZKL>&<2OAP#6J Z4&03^H4BZ+9@!/+6>*>&A,P
MSFY-NX.WVJB@X1!4@X,.QR39>BXLCGAD:B &TCQTQEVE,>3Y,]#89?'FEH6Y
M87L_&&-"&Q11KOACC%=6]W&<7+TT0K[<7%F \/&3<*(H$\\[/[A;N];T/0^$
M?B,^P$1Y.8>_IBWPK5YB0"JQ/;+?^&OZ/*L(WWU':>U/!U$*8SG?J@?6?[%\
M2G!Z9!)0JD(QHGBB&J[H"+E #U OXS '?'.'6\3/$OD2+9JKO9=/5H;=JC24
M# #I7/IV^D*[D""F#1J./#@ 2)%7=0FY,>PF!:L"\:/?(FMB+3]9BP<]0-]U
M9MX=!@[WOT>#@58LY\T/K</FAPA!YX'2T><Z\_?K0X:5Y=2:Q_2FDHHLK%92
M'28<9:)DOIM;.%X>M!4\^FV?VW**B1!3%10 ?N_KT77'O3Q-\&'_W6^:1^51
M/$KD(1KH&8*JB&V(VY><.LQ@D7[]=%!,+QW$@2'8 R_5@E&$C-]W7'JMF-UD
M36:L$!FJ(!WTP7@&394NAOZNA-A!!QV"+B7Z2M-!AU=- #6[G-]GJ%$$4PC;
M$O(0K50+GD5^JO^IQ_.->Y&PC)CJJ-S,I:%X);XK3/J&DC-/##'5J']F]?Y3
M_AKT-6/)LKO4=&\&X+N?DP>\GH3A<Y"G&(O7"3N_6@ZG\,E!MW-7@G1@M#>H
M^?G?EQ..#.>@EFWNT,ZL: 268/(F1J8:Q ;3?QAS]%RK2;AR]_(9L0:62, -
MZ@C9NZ 0"B6I+,/W87PHH]?]CWVLGY,1%%?DCRHZZ/-T2V7@&4<ZZ(6)F??7
MWG4"4O==.0>J]FU;]2NW2 (F,I/(63_4[!.AXTL+;*M #@.]Z .>B#%IG&,A
M3LS6_((#7+5U5\C-.HGU0<BX%O?$,7A(AAK! TMX.GLH!X=WG%Q3J3NYD)D$
MOAS2Q#QI<3=D0AAX%0M+(;>]"C01.L71S5$LG/Z@^H)/U!B\4^$9PFGGG5CK
MERGF']HYFMWLMR@$FOV849Y7UCKV,F/-8,=YX.%/Q\A*K3[&"J'S=Y-]-GFZ
M\DJA7G7W&4J-3-K71CP6&^#NXHA25CSMF:#*493]X*C!33VDP+*W$YS@@'VY
M37#LIW:7V>8O%$NW>D/+N.[4;*_(K$)'5DG-B;B)H7IV8DZ_$>Z9X*F,3 8K
M\C^V:SUT$K6142>SQZ_4^@C0R#5ZI]N8H]:),4%;U/6/31ELB-HWC,B?;9 _
M@W/,^_DU1Y!6@I=/A+MJHUJPRYQ\HL?:O#B>7C[9Q1$I)AD3(G-&B(5[@/LV
M; #=F>;<&'GZO>X??H+K[US@T1""U<;>!3 K:J1  $B:A*W1D.=0#6[8^7DM
M,<:*R6:HMM=%B%  $QV4@"?, :W&:@SFE(59_HQ]@PBI'DP) ^1])6 #>?S5
MWN@2BTF;GQT6!CPV$IIW#]S@/?:MFX^"98"LL[14.F@I?_3W!26[=%#T3=9^
M,W/(<ZK[AX"KA(R4603G=$E!INNKJ"C-9GU=6:<LT+=SRQ-')OX.CG'];TK\
MFX\)AV99F8>2&7SK.KF=P0O&:5GUIZDPHD^4O+*QCO?@CF94Q3.5TTW/'BYV
MLBZE&>!L$%0-%"F<#LKT_[T']<Z+TLE@'IRHICPZR!FU+U#>315J,_@/_B=@
MDM'\/EEA%AT$+3-/G*&#!,>:G$JLIVV[)6_^.&7[^9KE#1S>KH#8-),7RFA+
M(5PX+YAJ[40JEM][\OE$<^5FW%=9]]&!;:KN=TF8/^-'^0(\&73G=H #V;[$
M!M5X)C<N0ASB9(_PR?V<TYBK1!EY$RT^?>;X7,4S1!C#NT''F%N$7Y@G8SDJ
M(M@_F:<2)+G?2V\H*7&Q5KKM2W\(TA&@/6?H0!IINLQXDSS>.JQ:/1UG)2%6
MKCH76/FFZ%R+8'3MBP<>WT"B8"O*AS\%M32H7(0J/)@P?9L CW+7Z<V=C.GM
M@O",7U?Z[#Q>=@8:(2G.B52D/F)TTXSJPNBF+9AC6:)M"K(E.&ZW[%&H'@TR
M2&,_:D;:,V*.'EZ?Y&6BXGW=2"#:>RW3_#87=T(WK'("9^7?\TI/W&3*T5$4
M_'!X!;(&9KS)A7+:6WDH3HF8-%A9-;>7>?ZRV)=)]]PSE$95"?GY1W#F6-"*
MV_K9?^=P_M ;1< +_?^K#*O"O4WB(C5.YR0=]"FF#8AQ!4)0=Q%[2J@7TZ2#
M?Z[PLKOR=Y"U^O^$4'^GP':CVH>=L:2S5JAEXT'D&&P63N7W!V[4Z/T.1C$@
M]#6/?.8%U.^(J!'.Y%\CHGT+*&54&9CZ+J4131'>QM!D(K$Y'2"961/R&>FU
M!!UYLEPM"I=V;DJAY[W4+\&47_7E=E?G"M^WBV=)]-6/9SMP9'._\CT^C(UW
MLBB!_#CCJ&ZPH8OO+2E%&J,R?MUQ:2T2E43I3)=-MUXF/&T31V8YT# X8V.=
MIA+GS<#Q-$>M^.63D+?6^2?KP\DX@DJ]N%XN.:UIV,".[%_2*J^<?O]\?$78
ME=OV6;$99.VMFZ@& ^R#,H)3FW2;N$C9Z,PD\GZ?'@^U4LWI5.*H2 (V8IO!
M *2K\-S9J)P ,#GR9!T!$6&1FSKLM%#Q%;'GE+A[.2.\S'X(ZT]4>D'0.3FO
M3"Z4@F-?!*ZOR_AB-W1IJVY+@>&@QS^5@I58]9$D<<14.# IWKTUNFM73!%#
MCB0$:*4.-R"5JUUJ%218R@8D3Z69W$>N^C6;T+:&<Y"Q#5H^-]N4%65[OF?V
M71U1_!S_2E=,EV]/@6*"_*%1]4V!6RB3QU6<M_8I2>ZRT)GICL3><(S?]O3(
M.*DQ$4=KP037NOCV^3KJC]JCSDB.G->2@>S-HXC3N6[D,KD?'^^N!!J)Y)0;
M;]-!ST>!\(UW;@V^.I(-=% 15<GEJ;Q+(]2MQBA[>"P.3D3L0_44A;*^A)YZ
M.621??/[TI,BMN_'=WGW*8E[3NZ"_SSX\[\6&6((P&[+,+TG9C8H? PCUU?S
MD8;^ZZAO/O/66.0*P$-&=K:@^;2$,E>N]BV/950X.#R)_ZKOG)W._>U>#]Z^
MVY7&H*SAAL!/U+:"*QU$UD#309'OP3=HP730_,]Z'@93X(+\&MSPZ@I0(_MG
M!4@3Y*-P8*ZF4_4OL\:+B[--K_55MRH%66SZ[98D__$&Y_^@_//8[3_E/RO_
M&P1='K9E0#E'![6W!YQA.$S,-<:2_U*X;_,G+,1E/PMOJA.8;7M>@3KB&S;J
M45Y\@YGCX\4.-,Y+^^T--IT/V(/UT(!CPU@G:.182J@7_/R#\L2?I?4WS6R^
MW;!/ N.Z,UE@VR?@*L@)!IFOP^*E"?4&_9E7B+F1,8]S3'HZSB=7V2^1YWJ#
M="HH"F&U#D#Q'% 0E4)1<7+QCJZ\O;VL(.<G[JT$QF=V05Z*FJR94'27L!73
M#?[=!WP73@P$&.6,R]51!00G_1&]\C!:YK?[%SA#INKM:'E81S'X##@BNN>E
M"OCPU%5D2[[]*<V]VW[G=C;@4M0SY+>SB-&-V5STK+%,UZ<A3_^$%/[$ _7W
M0RHM).&7%+.]]R-IW02UJ%HABGD ?_F@?56<*8'T%5$Y^_.A0+!N4^OTI*<'
M ^YI#*?/,BR<YR851@H[HIIY9TK._;#''"!0BW1QQRR+BQ-)"J&E6B5;60JQ
M##)8)]X'C^W.@@L!;=!*Y0R6U/X&'=4:%ZT+$FQK7D(WK)HS(MIJX?O@/JS^
MB53-B-L6Z0Z1>ARQX6>_10>#'\,34.6[:YT?J4Q$57)M)QUT9.JKJD;8= T=
M=#U[^_%^K-L@U!X]+FS"U.4R@Q&>+*\7C7_AK1&=)W??$">XR] .W7W85H;U
M6[.&@?UD-2-G-((L]I:"$B:8'XL@H%>A'%8VJZF/XL;6^Y952%G#5&L@IO=Z
MF//Z"</[7LEG>!4U1 N9_^Q-0_;<_NE-_WL\Z9Q"$'33MEX4-=+^VX*;>=%4
M85O2!%; J*HICB*D/$T[&XO-[?C#1_17(UQ0&"L$CIPGC)/N#D!T4WX2X5$#
M#MN!YU/X1X7$/<,7+O<O+'Q=ML7@OQ+W34:Q)$^B=-3#-_+E.$^:PI-Y]H(G
M?!%TT(-#"#(;9A%A-JA0JU=H,SUM8XS*G[K>UZ6579OPO4TR<2+!F7D[UX0L
MSQJI,_E5A]_E9#]T)>U."A(ZM4G<A_6BRN@@*E\5SJDEYM*X =&AKJUI\O[]
M_ 3XEX16 ^T73>N!-J=W,9V![*1CY)U9$\[<FGN$-IM$DWB6^+U7$0OQ)I=*
M2SET27QS=J<(]:4SDXZ+5X?+:^H@9I7W$RVG+_4:B7"U6!PXS;P?7_4E<IUM
M,=@L58A7T5#DD#EK)HL7WRFD&/ -2KAE#"<%#A5KB<W5K!;#<2W]18_;980<
M^@0)XEJ;]X%-[Y7Z<-+XE2$&A.5Q)OF5)#WCRLR=NE(V/FG]Q7<A)NQ.4OA-
M/5" ".4AJN%:K2%%ANJ*8%G.X.A7Z;R5U_",5%CX52*PSZ,#IRLH@K):0MV=
M)I^6PE+L?+>:-0X5X[2A383E9';?1,N)VJ+Y^LGL<Z*PQFF"A<F>)D.G/HFA
MM_S6L3,OL9M6 3X,!WV5X: ?O0>/K/P3M/P3M/R#@9;? OZA0#X+7DNDI7E)
MMS#<I.7](6\SXL$B=J"XF_T):R;.>IKUJ\HLE&""'6NG@YRP$4V7ASTL?$6:
M>8I\_.,ZG:!7OHB'E/D_I9[$.GG5\;<UIVJO)Q6,M?GGV362=OFW3C](4&51
M?.5_U(U00^JDO=G .B(BAS4>N$A.\0]$V3H/1Q_FY'_V,FZWYQWD5ODN9F4#
MO+6FP+^@HFZDX9,0]V5J7<8-Y2>"4=#WM?AXNVG@SC(=!"<LKH.C:B5^QW,K
MAJ**K2X7+ OTWGLU$\SVW4L[8H4-TX$=LR<Y#NF R*]>20YH*?@NKFDD3Z&W
M?YH80#"W['[GZ+72BK$X=<)FP!FB\3K>WS#<.^ZQ4L"P]\<+X=*%K1I^&$IN
M_1P1':*,BA 7J>OQ6CV]L=W9/"JI"&Y_3;HWP-V'35'O#UEU\%UYZRUGE:TC
MY/G:KKL7X%K-@MZ?T=%L)M2?N*&6(8X2A5J0$BBIO=MN6Q22!JTTFR ZE'&$
M6#QNA&L7-+#/[W@R)+FMKSWW>]\C':I_+U7SS6UGVW\%,YMLVBW(J\A^:)EJ
M*8&U^<5SQK2';HC2PF^/]V-3I+/BAO,QMK08.NBA.<$F&<E*+.X-9(J(;;K]
M>GXTL4\-NM7=0P>!^_,6WWHXF+*:KEA,RGU Y*7D.2*;6B?X7LS*2N]W-_&C
M%7^]LR?5M/]INR/0A\;WX2UO@9:+I,=G_1G%ZG=AK)FL?6CX(Y1LZ']CD>Q_
M*/GK?8S_C]-: 0Y_A5> !\!_D +VQX_I+PO#OILF6+-WOD$>)@N/G9MV3+..
MSVF8DSD\'C]=@ G'SKS1.=P;X$6YYWM[W"9,),U?T$-%\-X[!SO?Q//$GIEW
M6\OP/#3!K/N%&HH/ZR!V?\ZX2DT8';9N/\3-;:1Y):BHX2(=Y% 5R(,%UPM0
MKPW7@\F[>L3P, ^@K=A%C5V+ASM)?:5(LY C6)L3A#+9P:$K8&M1,YBQL@8E
M%S]:MK??]ND;:1A=08IQ%DD(.-V^$AXRSII* (]* T?>Y@*]=NH]6H<_DJ4V
M#(@Z[XN*O1P>G2J3S;=,<[L7[[MD%.BV<18$."(U ]B)L+4-HL@M@D_4P]2Q
M_<$RSL:0^<E&DT[9ZWX%-"[=>=@@E'!C@WS:>'AMZZ,U^5@;S-0NX$)MRE&;
M4OE]K>AG7F(X26J'1B!N C(0-[9(,B)@\0Z$7[9@V)W287>^G#Z5[.OM+N?%
MP+M9'LP*LQ= PS,*K7'!4[)DUKE5.HC-M_-ZH.:=BH>%7I&S6NF?FR>%1$0A
MWV:"3S,OH\DR^E_S?%-(V96#GFFK@2;&M82=UT.[W@F'3R9Q;0I9/-+S,Z!R
MJP%&)K$,@' 8 L3R[?5*;E[/EXQ_IU]S\[RT\\]'VJQ26+W?6./_>I C\QWE
MNA$W3?B!8E'!1,!'T(1XE&.GNP )-5;?_>M9F:3E=&EIS!ZE=K;.K_[R[X+)
MC'7VBMP/U)=OT.3"@G0<&8QTG@X:9*S:3L:/?77^B\]N6]+?D)Q8\LLY=^;&
M,>L&\9QB^.6\<97.UQ&&,B]NKS&=>-(D?:B^&?'[UK+6G?O0B@"!-IH>H]DY
M7J9U.(&*WL_"[C'6]:X<Y-]^\'6B:K#.H6@'M83HH!!#++D%0EB",,SX-B_!
M">"4^O/SJ/^WGR=ZU'U$N:^FQF8M[$$??DV8Z_SIO7%_I#O $:L+,/V^01B*
M,Z"*$-!!=! .QG"!J+NC<NAQ;)466I,E?5SGY[C?=GN)#"#&3,0"P1D<C">R
MIZGWX\B>X%8Z:/^(KQ(=="@118P$[4+)2!/:K6GJ%SJ(DASW;S_4*OWS^?_B
M\_4%M# ZR -%?MBN=1]+8/S=*,TP:^2*"T O!8Y>?(;=;E>=Z]C]N>%*-:5]
M0#DA>)$_D%HAC3IR:.,O@U*?HF[!^O)</FS..]TY^)9W_8=[J[;,-BO A@!J
MYE@IU?"MZO?@0;^_@]#S/Y3\M^\1_D\K30>Y@D<WKM*R =X5<?Z! [KYIRGZ
M;Y$P.;<G[_&(79/)>Q/'\'9?];QG2I,VJ<9:=OPV%<?[C3V=W^H9JW<ZHC2J
M5 %9,CM1[P,*JDM$A&WLQPJ?R?)@VS'=.Z<3AGV,<E 84S*BY=3S6OC&#K0=
M*@7QCU4$9[BO7Q3Z!LP%+NB$#PCO=0-''"B2J,8V0@WU!J$BF0XZYMPS9UH5
MBG0;UP.TN#"0E:_ $N8Y'?0 ,@:[17M;+VOE=JVO&S?>5UG=%0G9^>2T\9RV
M+?V(:N '5'8]^H+@);L*Q7*>BL[J[\9?[K-NV*6#JN(.O<LX5"59SX]<].UN
M2(4V@SFGEC1V7OOL.\P^3#C#.O_M-WF )T'*N]>ZBP*8B">.&Z)P_FW0>P.5
MVQL+[4MS.RLR.^%-]2?Z:RW?+^\/)?J(D=ZB#MA8VS2.6DK<2SI.XS0C5@5O
MHR+LA.I[5,:5Z_L11[/CO\S[*6;\ !\?)LJ[)1D("1PNL8H'BNB@8O 862*F
MU.94Y*J6UC063*O6SL;R92T-?V/,:#<^%N!,Z&X05ZMQ418X*<-YPS[1T>3*
M4SI(BP8FT&2V]<_<]NV[.OD@YIN#UP4.\"5P#E(/V8<NLZL@,#>WB#)Z7E,E
MU72;O0&RU443!7?G8Q[08J$/?0@/DS/8B'7CAN^_<H^X/A5-4_23R"!2&%2D
MK]Y?[L?'>V?_99]R$VG[=G]8A'#C6,2Y/X557=U2;\6-;9PN2?@S%>']:RKR
M)6]X M+YWYMN93JH$L7)-3"QHC8T%OA%?:LDQZ)?Y^W]@XY+@ ZA+:+D8'W2
MK+:T*1IX9CFM)X.\UCS4FV5^ZVFTM5%Q.=]0ZP[O+8OH/SK,^,<&8C>Q>:YJ
M5CJ9;BC[QW+I^*)"+8&C%PQ/QE]U\+KW_7B0KMAYNT(ZB#.0V E$[L9@"8$,
M+6OI8=U.T?/%K%G/RL%:L)\Q37+VU@,>%8%66P:1UFFKHU:6N4]N6$Z^E WL
M\K_SAY\[^+>BY^7&B2^OW.66[+D>=D$B7A=V^YPN:_Y)[$GH0P6R).9E.9;'
M5><T687%;RC4Y\3;6N6^%U_+[S\QY[>OO-*NSA+,*CJ\O-L*B04.D5D_6*X
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MP.:!"D"+FP)-[+'= @/2JM%!ML00VJ3"WN1-UI6Z/]J1_*/)7^>^8-UEB H
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MW ))TGZ#=UY"SL,WH'_0>R42M&3)P^Q_+NK[9V>U1888?B9U7I9E356PU%F
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M7^(DI&K/?!3OP34V2WE!>)PO@8 FYF57;&>/8KVOMSX;%9:0'J>]HL@2##O
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M(7D8G1-^6R3Z6@F0*$DMKU<A6_L+];!U?"/UZ\? *\IM)B8F^Z+4RQ_"+QH
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M'4JX =JF*R)=(;"7.E?9A& 2F3OP7$&M;DJ]9MP.[Q)W/B<K?_VK&K7P_A1
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M@1KN79:?7F!>5Z7*)>PC4.(<&[F@75DV#L:/UBO4^61EE>1/%Z.1="6"@Q2
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M)U82&M&M"3.E&OY)&!2)YQ<"Y_T_O7&&+&4(^3Y/DG;LA9S<Y!.EGLC!_E,
MNPUM)%4H92>H<*0)5Q+*,9552V[F7 4U?;>]XA,>+&%S@.N78T@YY#^->BJX
M9H]BO%$72,_9&LS,J\5K56XT1#])IN-8U.NZ=:E(U4)5H.0\RMQ((XEU)"R?
M(<+XC58Y0.$_PSG5"?IW/=<P"^H"4X5*RAP.20Y81YUH, 85_6FG2559O-2Y
M)7*@3P$Z>3G D>9_Y.+ZGULTGNS] ]Z18# G^!\6#"!7 _]ID0' _5\ARHB?
M_S\G$#&/^*/(_WEO1U70Y_]L'.'_Z1=<@#HU%N#G-N:+#7W$X2@\FY'N(IA-
M+L.J&"T*#8S3X<Z:J6I])2]0+(-!U31L+^*\\,_'9G2Q[36,E& KOY'#=_&]
MM6X!;[M%A4<> UTHH3"[A5D@AC92PAO(O&[6/!D?D&73F[IU3WN9;^&(]DU
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M$/G'W(T<O%J^>.MO/J:N&>5CLO/7]V7S,#\8+O\2R-ICHS31BW<J()U<M N
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M&6B:2HW9$W@O1.EFP:<ZAU=#:\)(/II/ -F>6!S;8BX;A+(;*6J\IIM2N?@
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M -2F)%#_ME3.P:.&9Q]1%/]RG0LRV!/ 2-]16H53W2+R5_]1)+"!L'W2ZD;
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M9V-NV<FYQA;E^0AQ/<OVV(>N$'G*D+.XBV6 -1WL"]_2)&;2N(TZZT/3OQV
MP#2?XF7A^R)YM6/Y#Q^Q+/Z>>5\J=C1X_Q;;56(RH+"ID87#H4X(J8,)WE86
MTUS[+VZ9+\)0L%J!-:'YY,F@'J-.A J6ZMB!3G-W?M1\KS8A5R)6QW]D1Z8B
MPO0]DQ +(]26-7.=\C\"/L;/DV?5I_IW"#;J%/0JFLE@J@ D2<"ZAJP46YF<
M1+/QKC<67N#*"*SF+$]UV3B][;:T=$D80C)%3:3= EA)BHZP3HT-#Z(/OXD8
MC5)=*3[Y4VG=^5[(B:O\$C\Y1RG>_TZ$3^:F&>() H\D6??+$!ZUE@0;$=RR
MX<1WC_J_:6I/SZ?=/_$\LNICBNMITLTK^[R7(*'!/01LE/X9J>I@%"X+]I)G
M/.WXLG7IQ83<PB#6!+SR >C$ "F;$=L0A259L1V >&$GF$^O?@#R-H^#UL;T
MP+@]Q+7QIUN&K4S@V6$B8;:$)*W#<2J?19(/)YF@!Y.%@G'&)+:H !CW"KYJ
M:5+_[:-=&QLK#?Z+(RY9H'DDX2V#%SFH06I@'+]W ")ZH$C]!Z!CX0-*##[\
M"]K .M*U'=7GC8 R1F&DVSZQ$*&Z/KIFVV0Z_EDX#WN<X*J]Z]K7Q8W>"WLI
MN9PC$N)%& NH@.Z3R:<8?34R.T9,$5GGOL5&XT \9-UG/DJT.\"T7->F.F:!
M<TR_%5MQ &*CR9!@.&KO>HLJP0QRJ?&=;J/;<'G^LW?^.3SO7=RPIPY K@<@
MX#RD"QS9U(TJ!IHM&\F+S_DZ'.P]P0M..$A@G/\6CS:AEZW(R(Y>#<#)(I>
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M8'*)7(>P+:7?PS?_]!P=;WEYE^W'J+PB)Q-JNM_^75(W. UU_%:,(HL)^QV
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M^#%G)1O%M,XR?7LL$W%Q(O5)\]%L"7^N2I<LFD]N=NV\%JG!3#Z>V5>D&/7
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MX2<+=,#XES":30U5I'=CV6JAZ:/#+Y*.77\WQ+_64!E11MJE>- _2M-?('2
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M '6T'-UE'-LB#Q$WB7=0N#"7U#?(SK9M2=3Z;2AI$9J$W9K%(8$+_YC&PWX
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M=K2P']3_^2I.@G/]80C3RFMPX#5EAQMBU;G#7]ZG'40KRT]T$4J=[P?*A/O
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MUE75ABJ@-0>[>\PR1;BH/=EBW&%T#ZHY7GY($))JA5%C^ZU4)__19\G7YO6
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MWLY%:2BJS": N-QA,I^MN:H]U <41W0^2DD1D5S-#"!VAWUO"/FU3M5K>-7
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M$JK!0,VB,;4*P6X<U^Y)R:5[54\K?&(<)UM?K^]CRBLOPT4HN 6&Q)0GX-!
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M'W[P [3%2":\YS[E"/ B%(\\.!.40@5D'@%>%=(%EN)1R[83(.(Q,/T\PQ<
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MX$[2LT,WZ "*MXBD3KH%YGLP&*LW03H2EZE:D'4G2BA;R+F[)O;ZK8A)A32
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MLB!MS*!$+C5$P^\Y_[V[9X=\ B8.(5O/Z],NMM1O:^R0W3$"R*L(;B)_,TI
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MAZA'B;:NICXW9!B1(.V!/!2_B=I?FNG#?*0#/*AOE44H;-[,/A/Z=^L6#<J
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MIQ1S2#;OMA^%2[3O%NT$Y4:M_:M\;(Z.5K[;<!;UF,6B\WHI<;2?%$W-T[#
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MB5HX)9H44I-OLM#J[K*LZOSK&@8_1&Y_/5[XXMA<#ED8LM4*)<]:0(CE<]=
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MCY@+UF*C52K13,A/:3CE]4.++^1KORP-3$CU^G\/&GTD.3UP]P528$]"A2J
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MYEX?FW<VK3Z]I\#EZSI5_?R[.Q"SJ+E@& HU=;0;M7"8":N"?]*/H!KDLQA
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ME#>\2W2KR74B[X7%*_</8.0\6[0Z3[>=M^;5IR[O?/PWU@%6FI8+<RQD)3\
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M\^#42DD,8)^=U0",%2GN1$&@]R_(EKF*E($8=),P[$MQ";A,EX^EGZSDGF(
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MK8^QEKA1I<!%P9,BX5 O!E R/0NS)F/GUPD.#>M'J&*DH/4(#7BV]4)Z<[:
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M^ 27!1/PQ'ID*OPPXNZ@9.1<Q$A#ATP4G7*C@X4!!$LOPD^CZO5P,]MUIQG
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M3K=E) ;D'2B_?<RP/S"]+Q2@Q"_B<K44_=6DF6\N29/C=\*&6R:5%T6*KCP
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MACOK2SCWZZQI-?WD[ITB&T%^$YJP0GB^+X Y+3Q79Z8A^9=D>?D@#O/!-T+
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M14YM.VL*6DCT7G"M.NFVW* &>/EW$N&M/2INHTB^3+L5G^ZYQ?YC$%B#0[L
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MQJZ:D?_">1 ?1"8?C/<.;AL]T:1?+HM;_IBY=04A0<;!/K^ <J$4T,UR3#5
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MR%X;3,@>F-M<"][IN:#P0ZBL-+FD2(7M:P^S8P>GO>OJN0"%.RQ@>>=7%E
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MFR'W@KD=JXVK.8&Z]X4P.%3?9WLFS$T]F4(WC'M77/8),/73W_4J IA9?JU
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M,,2L>711?L\>H,;_)!_,IR]Q[;TL(!"UO)>J$^0&32@S!+?&HA]4?K./&O\
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MFQ)6DJG)>L@7FT_2SXW?R+&A[ .DK8\\=+V5++5P=$G6B?-9^H5:S%D08Z4
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M,"7F$2VSM?;G?)I-74/IIK33NZ "+S0+OCGVDGI;T82^O4>XN-T.!P[-T\]
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M'D;H-IW%&?69_A*+)LYY\V4J\&EG+)F75#E8GE<_J]''!MC0?%'?#+"5T,Z
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MR*%=CK)'R7&8.X4!CK!Z0_PMB5 KSY3BUY=:,4O25$U&\2K:'QM=CT[:UQZ
MF3:8K,Z1@ G.O.-XRO4J[8 W]<2:F>SF_^GE =O;P!3O D]AJ4U =I$O;CC
M5*)VK,>.U]5"]T"#8(;T=>,(2DS: ZD=K[U^.FH$1)I"]$AW??!V9+5E6]6T
MW?<,T_Z8![N@ED=L*Y[SM O,UGF^79"_K6%Y=0!X55/L9H?IX1&ABTA2E,I/
MU2W"Y^Y3:K]L]WKV1 <@KP,\$TY?"M%M/H2ZQ*LEOJK#3\WGK%$[=[ZTJ$*;
MS""?<SF =CPBD0J]2<Y.OH<0<L,?Q$6LWGTZ< .T /'R")./LSJ,?4H+*"G3
M6+)%Z(YG"^7*ZJLLHPH?!8PV*M-<D3?(QBC'5(I!Q_A'3IQ\Q%D;KPNKY=:0
MR'SP3],DYOU -+X@K\KA57T[I)/?OF!+VX*]]H>7XE@$G,G#3[,("'D[1R)F
M?<S(I;:I2#-W3G/]S@<OW?WQB_<$SC:Q,%I/4E,A%O1@82(6>9E1W[R?#K%Q
M\@"BB@;"9<T_#K^<F[FU=51L#4L^QL-$TSTHH=U0P1,4@Y3@#4&^Q5O%[^UN
M0Y6]+M%U@..DO!1<W0A2E! (Z\@.C\9.YJL?NK_D":N/F4W(!P]BTED&S@YV
M,8ED!\ (%XH4O"VK,42;BI&C^V3RMSF?T<HB]AJ.UP.OB=@42&5:(1$NN1+J
MRJR]0S3J"&@HT!:QVB]J!E)->0D"+4Q\VYOV2A?Z"CLY[0%,O%,Y(S_2+G5N
M2GW-F+0+,D]G[F!&,!R .(NU\=,- _+#X%:5@U4!%Q)*5Z\)=347L[\W^;*P
MG<^/^W\K&!!$XS%P*0WC")J-9HQ<75 A8#JD3L\C& 2I9#IM_SEGNU8UQ%IU
M-2,=:4BS#.OM,%6B=";[HT3)2TDJ53^N5<S.VF2R/Y5;.^/^=-TC?-]>?XEJ
MJP0EBM7:48K%Q5?/7\"$Y@O6EX64[YD#JN\P8VC@\'K:,?0-N)!G9M%&HZT.
M9535?!\(+=A-R6?YQSP&?]4$ N'>9 L'((J\W7X;\(&3E\LZ^VI>2%C<#WA4
MSH>,['W4&G>"_R4EO1<>A1;5TXS.$S?6)-EI$-86AS%>+^P^&Q'Z%4\91<?&
MJ>T<8[R^1_F Y 32_:_IW,\]-+JOJ_!(SNJP(.AWO]J?9W+OY5*D0,RW6R:N
M_.@S'T?7SJ\$3(>M7S-]MRR!>NB HZ1/=G<\!AJH#H#'AUGH\SNF\;<4;RX^
M]<BCJ3]P2D,B"NCZY+@R8KK07*J1Q7 9;OG74M>O^Q<PCKC(BAV0'>C6$/S8
M+JA] 'HC;^?H<191+]C+YDFYL L"&S->H)?>=+/4C&4SF,?-()<N_//?S=K;
MDL7\,=F0V@5-E.?L@M[83^#0Y--Y?^3GH+N@BE3TU@M5^E_EE3%()W)MUP"N
ML%-6@WSCG5X>V--M2E$\6E)^SJLZ\5!@AD.<I/5""&80_(^V]<X$!_.GEDX8
MZ%@A$#R2BB\<>1+RKU<H1X(VS X.>>J1MZE=@ [E4M=PF&W;''3X-T+PJ+>;
M=6_Q2\N[AT/L/]UC[@O#>.^EH/0U:Z.&YOFQ/C2WHW0TL5=3('E<#<'7NO#"
M/5CMD/^WRZ$WKSP8Y'HSY+X=R90+"R+&QZ[2K0AV-T8\AS3%[QEDW458=MN'
MQ\F,XM.(]5(@E7?K&H>KHVT6,^3C]#1^6;<Z7.;+M%D"8:3)L+6G9#>B03HX
MQMB(PG5VE&[5V"U3('Y!1Z!$).6UHK&L4"HH_ PRGF7*W5C^D#REF!'A-[_C
MQA]Q_Q\EI)E!4O+^X3[DQ&8Q37\YJQ["HB83%YJS>RJK*;)YQL.!RM?4V\1.
M''K)AL.^?L75\0*>K+LP6A6^%,PK:3.MJYZ19[$4D0KR'3JCH.5PK$,U*A,&
M KN"7-52AE':86H>%.[!5>,S?G?>KZO(<T2N&JD)5:</3OBP^*<3E 1.D)4%
MT#ZB PEZUO<FBQ0M(<<VTAHN[X-]-Y/A%,TF8$7\/+6&"T>K H!@:>4CIP=?
M1EK96]E'I/JS#(KR>=B^NCXHR2 Z&";TBF>B(R3(/Z?F0)2\2WV@4]=P1%2^
MP/!?]*R5@DZK K,Y%_W OF]_VZH0:*%D:[@+\C939.XK#?/I?&"54E4U>L_N
ME(QE7YIQ#\QB:>\O0 %_[?VZ.V"ZTCG@80F^]F%I_7;GL%F'.=9N].O'=PT'
M34K]E;G43@E-W=)D^]D;@5FV_UGS;5KHS1<?TZ1"UNDC#51*T;QA[9:4FBP]
M&;!]_(4J9;^P=-4("=G+-"$W$39@EO7@4*P'5SR\"UIU_+0+&IH078>3+="_
MYR6@LZPW7XV%(?ZN!58!NE6*J0Y "?,)*#D_618'TV5]*FCS=OIGQMSQ,Y\S
M4"-/!"P'4=XMBC[&]ERKZGN,7[23[@CTX3%13&GF'&4@H91N5)3]:]BMP-9Z
MLG_T#.=+TJ<8%N)32EHAA^@G<!M12"L?HLEQ>&^F[46+TT#_A"7;(])++1&V
MZ;_NC*>ZP=HK\OEYHCGY4)[0O7N4$SFK7:,-]Z^YDWIU G^U^Z0V5.:>G*AB
M43;1;N1% (N?C\Z51 N&S7>(H62&'3JNA;\U#(&V);#Y(+PY!KF\SMR>/\ \
M$29.JHU?&&_D(MI"A7Y2;+Z?I78^):+7Z[7XWJ0]9]>;V3L?L;Z6]=^P4T"*
M,2^:(FQ=0S'(H894^R#4C_3KZ[8BJV]2HEL&N:HOV$QDV+*N_ O=#B@C0&)0
M8CD=*-V),F.30LLVG:"0R9G% M64RN.M!'-CR-E^P((RWP*7K3(,1K.%O1CH
M"+''9AM,]1Y[5'N%4B?P>>V1CIG,VE^WDC@GQZ@TY0&<B')D_1(*V*:28O!"
M+L#1Y^BAAWB%K^*]E@,WKIP)/_FIY_63.$=)/@%S$="R2CF<".W8X*'+DZN[
M$^A>Y5, ^DQD;'A)-XY7-JFPY#ASB8-B)FJJA_YRB#+/B$3L@K9>K5 N8EUO
M07W!\5A(,SOR]"B2G9@,%7+#+85^N?WQELU5I;ESB-2V^IB8:*L3+'=-'<[6
M,=]9M#2P,L !G;F#):4O#,QL".R">K!OT1.E\!U0&<\ >8.>O./#>-"Y"\KG
M^94GAIJ"<-+Y*=Q(<#GRU/"]79#P_6CQJHR7I=H0?*9]D0+BQE5X."06\D4/
MFZCI&*XGTE-D0[11",XT8'LZNJ!E' V^ _MPG$<M!XBA2+=#>9!J>RT8 AQ?
M""3ZZJA_)ZW9P\ZPEQQ?S3\8SK/8+, <G!=HAO[<#LT%41SR$@HKK]0*M=<;
M7ALX-53G"-J,23EDSU7P5QC&\S@I?5H!CVU'RQ3'(&U8"#AB?-K=DIHI?I7W
MT%7OC,MO?#+:/V*\HL/67Z?Y7G=YG6'Q)N.CM[>"7/3):)5]9U7*P[NQ@DA#
M,K9M.U>!XEGIE[^4=442@U"<3'X<R76W@PSZ8O*._75!XP1^?DV>/$V-K&W*
M;I$]]HDB5 G]*=@F:UC @3^>=L81!Z-XB?[<:X?)$F#8M#!^HBU/VH*@*1JV
M"[(=-C:7MQ_/%$<KUL+TQLZR;BN[0IHO^Y3*NT -/+8Z[@?.=UW]A[EBT.G6
MC-&4.([;YC++_B"54DWIL$6SO4;+ X) GE/UX):;WJS)VD*4 LQ\'7;%4*^;
M+L4H:I9$#=HBD6S$%4W!7N^^SL:KQ!=ZRFPI=U5K9B@-$MOY8+N_ C6-042G
MM1AR$ &<<IA<F]P8_M9W9RLGZ 9MX?@M2;AN08:L);C?BD/V]TJ(5&Q-B1<B
MW/N.Z&Q11\ QG3;"\.FKC[ZV1Q]85]G7*>((36Z\6A#&VUZ+VTZHMO60MOR4
MTGLG_+Y<VHF)F;S!8%VVBC/W$:U87#@A=(WMR*HI&R4V/4'CYN=<G%[86P?F
M=O;A$I:OZ\L7/O&>A=2B+*8G @W QNR"]AL[!!*PDF$;=D/!GZD9K+7YMBY=
MGRQ5X!JCF,FVGG$8T;,U"3A?,ZI+>X<HO57HDO^Y]I'QW4*^$C6! PIU):S[
M[V*J2O%,QZ,%YE?FY$;+JB*DNG3T^M86HD\47)AYO!&U;BW:@I1EO$>)TI'-
M39_(D)328-KT\?H Y_9.%7?2;1M16TV:F9"9;,E??LE]\4XT;IH@W@H6<O4U
MU:=TO2H($#\K>6S&YEC"&[QNM![BF&PGQ;.P<$5,5GYX3<]$XQ>_Q?F&U!NU
M]36/; Z]L[1@K<QTE.UNDII!!TIQF"[_>F[%=>XUHLA/_X)D.4)C0:CSH$#1
MLZU\?E6U+\V"S+$\;J9Q@/@+IRADP%6,?TB2IYLN6*3!O-7;1=3VG<F$0L:*
M9^6>?<RDNS-*30_2N<=7M]"'@&G88+7;1RDC@X.V*A=O2X[K74M"-TZR-*7L
M@@L30MG_G%@F-N TA%G[;:?QZ[A>T_?2:.LBBZ&G\1R.L2 1!YD@CY%&G<(Y
M__JFW\TY;UTZ1MP]9JT5DA39CSQ/!SD]1RHP2IL/(H,G-+80[, \;"+8S4&#
MZB][U,7\>\9U!XW"S^Y)H-_U?P6'OS UF6-H'M-]RUD/$&ETOZOYRP97=!W3
M%+,\B@NUNTH=T+B;/%MP/B#'AI(5XU6VY)K:7/8&?EJIIJGJD8W(NP>B5\<C
M=9<*WB_O-*5%%<TNN[Z:D4+E^0G;W0D.8@E9AJ4+:TUL,X.<7]5Z3$68$Y #
M*'T@<[&=R4/I?U6VHD](K+R@>/&$S+EK9^!:X,M]#Q@@D0N>3I1D:@'@0MZ_
MW#71W7R\8E!3TW))_;I3U@UWTAWKL>=.T XSV2VVY2>.L%BD4V$8J9WJNAC_
MV\C#R[HIQ181[J.2>51DFP.=X3H*NN 0;'=QX,Q(>3#_J65I-6EGG,OZK4.*
M=PZG9-TP!G$%>5X@8ZF-@ DEI_,QX-,Z9S027'97L'O5KUG_D>;<\6R'@R##
M/]QX83/9]O^I "-QGB[J0[TTQCQ$]V@$J@N=<P:XP^*"7_P>LN4UFN%O@YUY
ME-JR]>4P]CR+W.3AU%JALLW"2U)Y<;^3#37PG^*DUXY]*R!^]38K37O>(\G%
M]5I&[1>,R?.:!!-T8X[/:0\=GM"3V/)3/Q;SL_<><38JBGN_\9KQYD@9TL?K
MG8=?+:_)JV_CE9C93'&5]J4S(/0EYC7T??1)XP[F+V8PO4.S"R*K&BNK1SE@
MKP4:4V;IO&PA4UP\';T40@$S^?=Z,[UCWPD5*&NY AM_!4_ DL_F)>2J4I37
M(@JF_.>4QGX;Z8\@GDW/P6V/74\X+S!^35N-NOR7<Z?JCZO.BBF:]7=].J,O
M%5$:J+OM)'"0)2:V.K(@]B8DF&+%Y%4G8]I.%HWG$>RX7"C/'ZZY+;6YXGJL
MMFU?+82O[CC&T\5TB )%!-A4B=W@JE+FG*;@\A=$"*5"FI!J^VS@0]9T!K,/
MB:6)LTBS^CU-G#A!+&</MX#Q]:_S%^]S2(6DBG@77KZ&;<S8W#P(_BJ>?LE,
MMI<P#ZA/Q*QKBNH-Q$N-I;X_H3TYVWF[Y<%:8%Y_\\?A'X X+0*IXV&Q>M(G
M=>O*.77JLW-.6=K!JK"#IV<!.=G&I#_P3@CY] !;7V&_+CA!ZG=<@<BS[Z.O
MX\+,NZ6?.@A I?[T,KD=, %0?G1@P"Z(K1M9*Q6Q)17W"BE_]^K3LICZL\U8
M77>(I6D5VT](53Q=J/CR"']_!1GARARO_;X+(LB,7W=>%V<\*R9 EFBHM\U^
M ()V$36(_3B1"([3=+M045USXG&[K$K40BU.0$>,R'.TM36U)K=.CP&:D*98
ML$@;2M=7V9*"C:O:!0G]I#^Q[;$P/IUR*[7[6VK:LGD^^ G:!P:H@=LPR1G3
M?LW'@\@K'8B':N]LZKLL?]NF@ J9]9ST@+6E!1<O)TN!%.W28KF8.:PJU@\,
M*.C$?1XWY0^(?']D(%[OBZ',>?DZ=C(/B<D)?__ I 'G)Z9U5O^+B%"A0)V\
MF2X+857RP2U0X&C\PW4Z+\TOK/][C/SHFQC'J)Q'%@7X=. @Y"O6SEB(Q:@/
M 6<0-*V?<QI82DANKN*GX8.&]),C*J.*C=9M3YR#ZDI.]" :8EY2'-'X_/F/
MC>CJ[+B;P6CPC-O/9I,AK^M56?BG<;\.WKWR*+UA0'423QF<6( D[(*NH=.:
MQ2EL0^5,,2 KH(S&D:4/#F(/2DGTXGNVK11I7-EI>AA+V4ZI]K@+_*G/K8A0
MGYG\\BVSQSD*J$9;0BK![0'P*1HUD&P5B\F5,:DJ.ZZ(O9_G?Z3C>=9=EX;[
M:8P(-3QD4IS)C2:J"W?A?#J@R53NHM:BGMJ3B'B9<1OO5^<OVE 75-^W<F?:
M=-W>#YZ$DR\BP%^(L,D&HEZ5ZH:NEMNL7"JOP?KZM:!(DU,9P"!7QSS9,7U:
MN@TB7&4G34!$Z[FA!2U\4'KJ;A<_/8ZH[TGX<DB%% ]MO#N)%RPLOS/-$G\A
M)-@D[V&S(E!O/2N/;:@9N7:#0^V/:G_'@TU]-<+&U":5&VBBG0K0K_C)E&H@
M,Z-7WT:$NT:MK9'2%8Y%1?J=/\G)9=*S F_ LC7S^L(K%]M><;4TR_*-2[D;
MN1+-.+(/5LPJ8M*)-Q293]B6_ME*=-%_% =D5&$ZL,"Q;?JKD&36\RDJ9CZ9
MM>?ZN@OZNZ1\IN_?3PAY\G^O#6!;'OD2>$J9*>;S<)H(CUVM!0I/QS"5Q,B8
MOO ;C5G=H>F9)DX*+WEHY2^6/ZFIJ7A?C2[5/K"%>=VC\\U)X(=NY2&%[8+?
M'HKUG7_TMA'UVB7G]?()"F08U8KQIEIS*H?8F=LDE$DR:Y@.*'4^2@RXBR)#
MYF&-Q<LGA>$-*$F*4@X)#/Z)^Y$>*L/,?F>6K3]Q_%!IQL>>PUA9*+X _LD-
MR0U$(IT(*Z>:#U#XOBUE8'JOWD/Y/-Q1N]N[EH%K4F!RQ]#<T&UJI=WDQYU.
M#?=23UW$R7SKZVQJ/_2,VT1T0&UI"M()'SX4GD$(ZU4J[GRNW4B"L 3><9NY
M=7+;,X%"KCX2_V[I\O0.?6!,5:4 ^SC]WK\[Q_[?DZ__CX9,;"K_?93OO[,*
MLN9T+;%LL14[Y=:=>WC$)\#NW%2RFFU"#[](Y<=$=Y^ZV1?TZXSX7=!UVXUI
M=F)15_:==U^*PH)L$SS]=Z(U_IS-:NN6#9M;-,Z-%.[70GNB\46>!QHHBZN!
MI&G;(WY*%6DRYPKXLIR/N$BPS<?J_4G=!7'T,C!T*$T+>7I"=Q<DP2U'QB8>
M3C)$X!-ZQA]WG>_V/O1$?O(07TI,OPH[9A<4G8/J0?.S& GV /TD?-_/[=L>
M_L(SG??OA]\;L;TMI*#J5A"3B5I.JU[U%&9]VPE@)SFMOL+/"X?Y+V^W[X($
M@]7WSS%NW:C3GIIQU[V:]$52TL&KZS+]<S_X+!1?D_UHV90/L F]Q?1NW!:_
MVP4HW*VZ(W@[(C4\NPT]K4:P:@%/#A#&QK'$6?T5ITIRWX?RF*OW'L-MM1*N
M0=5M5&Q(ZI&&^>!OF$D8T;&69L2<1$E]^GS_)JEQ%$N0&5NM;$^$?.6Q.E?:
M<,"T>QR;_X%Y'WK#1-.140@-W."%/WOFL6QZA#G?X&O5R]-]]//=B/V7P1U.
M6P;_=>!5@?^KU;M.=1&V/^^#6'?3FIS:UU$)2:SOT38RW9\C+FG(9%CM@@3,
MR6B&R-I>B*X"30G>[N[<2)7E!X3QM'1A8-Z]=DCW6=J8GXV?$FJH*^9'B&ED
M^$N!@,T&H@%=C-@UQ[0VYB7_".@]0ZNM7\/'YC"G+*79F5QFTE#R H1K%S1T
M?AQ+=F-1'7$KNB%7ZRYHZU(UYC_Z&F<OL3Y*EVX-DW8$@EY[NFZG#:_[0I@[
M@:0M3!7Z!LO^BK=A<)8[$Q9NB8T*Q)_DBJ6=!A5Q<'H#7_OWH%R0D3/5%;0$
M]=J8;#_+>-1H1"Q3L*6H+R9X310G^60N3UW56K6T!SD:]A,#?C2%,P^4$4Q"
M74>#E8'LTC-'OG=D<XJ?3XC5Z*S8IMW 6K_+YP/',P\FMYBRD^?CY.K"Z^YY
MZ$_;V2:*J)W]V%$1)W=/40,M-?]/:@L 9O(J4$YML"ZXLC^9$&#X0HQB6?Q]
M1M2X45 EQ&+5I9 >BS)%:@ !Y<@K0-1KP*#]D7I79:E[675]S[2]\-@SJCV;
MX@X/0X,EJ01=)JRM6HZ1$TSAJJ&?R1L1Q4/(UD:V;IAI@;YU_>?R0XCK42Y!
MFX3]$0F<[]BWK*A[L^CO 0@J;%RX$T:49LEV6%N 0D"0/*_,R_"/SI:1M];&
MGC$XD;%_U29^5BJA<+7."P3^@'H/!PJ4A$*\=#\[#^"3YK?'4$V5G!=M6@YE
M!OSYRJA%*6EV8G Y1#$L7Y]>-C5Y"I=EV&%/U.*JN9S7%7D"'@WEV6#J(YW)
MV*BM\5_KP25+:^<F>Q*Y_RR8?OT,C451EZ ?-5L\P"TU3#$H?Y7)J;D3IR_"
MYUQ+YKZU7.D983"Z'[=*#$A@^C" @E7[!2("I^!"N4[.BFE_8/OLNH(<S% H
MZO?D=7H)M2 2FHN9GJ9>@DU9D=Q?:&1MSH3!'"+A/X7=]1>=O\@3;JQ?B-.9
M/?NX+X(EA1P.0*SI8TIMEZR 8HY=@)5XBW#;%X3<(?#%2@CM1P,"T#A6<X-%
M817]H<0K%?['%IG/'R-J?_/O3$2C6Q7L6A@55?,*ZRQL\_R#7;^*+L>!&!/_
M.VWUC9R67$J2JPI[IZD&J@N^'W7"N#(,T_+ NX\>K_YNZG55O?*<<U(%W0:3
M18>SEN($N)6XV^I'$></^AHUKS6FBGZSW9J)PNKK[4#.@%".,^A6@:$7T$JZ
MRW6/>>CS@O4C$?N5)/0&6<IR&GJ@NY(&)SI6!S$V*ES:Q>ZO-82<P(Q(J; O
MY,7M@LBVZ"D:82G.I5%-,PGCM7(',VM,:*[@8VEYVL2HJ32Y/!D_JR2C8SY\
MLRKPI.BT3%EL??M!L-D'D&C)/T>-T-IY$.Q" ])R%U21?H%EBIZK_=X%,0\0
M=D%*>:&[("_."6:4*.HB<[)9Y'$KO-J@4UW5 >?4(>[$4]=UT(^O![KQG!.5
MBVX5I9_6W&N0*.:GJ5I5CTYX-:X%4COTZ+0E&G]VBXW*@H?$@Y#87.U,*^>A
M>P%=-[PB05&_;# _Q/ _[A]8N 7MQQ;!<<GN,>W8RO2.7EK6Y5ACHPC)8[>U
MR9_ 8[%HW2TV!HN>MYJ.8E8#R"5RZ<"3F)Y=T-MT-W1-;CJ:")ZR(F;E%$W.
M++NFCL<;WW9U:1ON51/4^I#$[;7*&8#ZRA1"LS'[(?Q;D@*> Q;5CCO/VB$,
MGJ:+D=#G&, 'F@S9.F?LO0MZR)C?!4D7,B4'B-T,8; DF@ -W:MEV/$N^%>^
MF94G%.;C3$:5:61C_ QP2L4'+AW)*KQ)W92[(FECQ19GSG']+C^J:2_/W'P7
M% LA;>9""8<]H6NXDT#E?Y[0@?V'$SK,((7!"WG5V>T;@LC+C)?T< *,M_?[
M"B[WN:)^2:/<TSI33]+(;<Z@#<]:UB.&HBO!J[&4O,N,@D9-/TA,]0:?[1O_
M1S-S_K7C=]W:?3-Z>+4R(AV-!?<]?DGI1)L]V6ON8X9N=86R5"AQ3A%8\R-%
MB)N--3H12F9/\EJC/ZWE?B]]DRY?Z#LH9M^QSI]RL,,GB8$NB#258>&4'<NI
M'FC%1N%F<G4_U0^=__R>=UKF,%DT2^*A_ULKBZ_B"NNYM_-SJ[=%1>RYGJ-&
M3#DG3)60;)3%V$:].U2/\,O#;VLK'Z.^]5B&K*_5[?N\"_+'"J#V,;NA4M5Y
MZ9ZR0P5DQR;"=)/!I:2 LO,[P];J:V*&;#Z;";@9]M0WZVLOF ^7_J4Y).T#
ML2&_9NGGR&\$3V_:*;V_F7C(W^5YR@<0*%B/]IJF&";M00Y]J.=277*_U)%)
MN%Y;]3(PF.VV^_N?N<^,*?"D7=!>7*S[/\?%;+0-C5^^  5>"=L%G6FDB$?K
M]6G"LK\T-U1EJL!/_$GXF3OU$QAGL"PY 3\?8ZK?2.F+RZT793PASQ3:!.D>
MR^@0C5)O3#D4TOH#:_'T[(?HZ1Z0F GCY_2SE.ND%1LS3F0>[2K2B*)12XPP
M\A@IO55MHAXH-E/T09)/@%OQZ2'")\-N_YVVR,X'A^RY!E@+!$?I[8(.A/FX
M-(R7O?V8;)^E7U-5Q^G.R?_Y:ZZ3(7LNRG5G7[3MW?-V(FSI)'Z-%7=R;F6Q
MB]V"QZQ++Y^VC\2-4UPFGS&15>!HYHDZRM.:)R\$7ON%RK3%?0YSN9;,I\WT
MF94+QE,Q0ZX>?2G7B9$*<?I)!PI]-F6$'/)H'2!NNM_6!3/(,>9D'AAI0^2'
M6X]73:N]NG0^;J:%XB:?\3IBJG^H'XRI1J"ZF>P3=.6"%2=<9]5.<!/-4JZZ
M[F+I=%"VZGV9.WT1@A(8BR1N]2^&NB!'GR1=6BJ\_61U[$NL3T-]59:$=[^^
MD3P/>E_ ^200?7$$Q1/V@]29X?LE'SX-/]9JU][1*X)D[()TUO'!/28E6Q=Q
M^G'C!V9KZRT_]"V;@5YDW^G2OK-W=]MIUY F%/%$35T[K[.5=:.KZGC?(W%3
MO%7GW(QJTJQ-F\>V?K,E_1)08?^Q,;G18BI/;BK__'Z96BL5_&JY^Y!8K>J%
M5T\6OE3].D'*<]VQC+8--F2A@C06CYG_=6\'SD@:A^^<)#;? I3);EV[H$,(
MN#G9-/Y^R3)_Q$W9@'N'U>Q//\MT.6E9R+&0.W-]8ACZC^?4N%$>ADP7H=?&
M0*C7 -RN?HBN\V;2<R9GNM?-^O6+A=]/QT WZ-9*U7M9#KIH_,=Y$$J>?I:%
M79J=*)'AWV"AI1?GA%WG_'#W G4_6O=+V'W''#OPQP9$\NWG-& >V"2S$\7;
M'2FU272GPGD@R'*LC%!563%:X.N=>_ING^:3%E$0\K.<C^G3G:LL+SN':&=*
M<B2OO_?RNQVH41[H':<6NR+]2; ,.,COMS=1)G!^U8'2-4]\'&9(9\/8E>94
M"C;;ND@-,1&_VQ:E]=%BQ%E&&&;)J>6!^D8<'4Q84[[8<#+N]=7B:=S,[./'
MNN^E2K!$<VCJK2$60-UF@>>5YGUT<Z"H -#L\#PXO-%H]6:I(&SCWJRISK&/
ME4_5M%)1-WJDS[-U<:+26?^?S3*H5MBI#:)F>U]0E^EQBFGZNS"?4Z/J"I]J
M*T=?^QZISW"O0!^-O/)!FUVHGY3$,&,1O^)2G!VZ<-[-K7<!IGO0ZE A(/&>
M#;LO"-Z_"TK"7IM/$X.*:QH?T8S28]@Z9_YY&JRR)K-6KKV0R!Q*C7+;N/ZQ
MZ_YB$C-9)5\@@) 7OT$_0IYOJY=]'TR=A=D-E]U<+S<?R#EV^X.13[.SL(<Z
M"Q$7B^FB-#PTG:D>!FEUG8BIZIT7G/05GMD%^?H]>""I).N;?KU7XD^>M.1Y
M-H7;I,>>>ZX BI&+4@#$N^94*<4)6Q&P=EF9NI'.AXXOGO#?VJZ\'Q5S8')_
M&PAU32N4\H)QH2"2!_/.7'TL]IO6N< ?F4JGGS\H%#1#M&PZJN2#%Q%$S55O
M2DTWR?(](1')C?&O+YI[+9]L'SVT4%,GL)"().N#@C)M^7Q>.FVDM^;Q^N=R
M ;;X71!X)11]:VRK3Q4WO(Q<O)<H50(*C[34F1>=8CTN)!N+F88!PJ3Y9"P_
M4OX#8 !KG B\Q_MY850WAU/[;-MI^\?'O+*GJK/9E;=?G9R8W[+G(CG1A3'4
M8. QO@E*W$A#6KQ>SA4G#Y$]BXJ/G7P#9EV8;OB3A)G]\ON.SUA1(KF_8/0Q
M.&PJ_)>5,<L27V&Q9(;R _IE3"0101S>\OF]& U9/S%/Z?[ELWXCNJC1J!@T
MS5V5LE^FV;P/;3HOB?9"I[Z =<L$F>>TX*B?T>CWMD>:"WW\-Z<]2C./NQB3
M]?EB'M>EA':BS5'_97\9GSS4P!S_.$H6*42VBFNT"$%4-VF>C<:MAP1V]'S0
MUIF7T5GSC#DC:JG<!B<[#D0UGP0ZR8CV6D^^3PWC(Z=&99=IUI47?_6D2EY0
MS?_^-5<_[7;'Q, \V1HS-4"$/VS6"I UG+BG?JEM3BKY7%;KX\NUX3Y-3Z=X
M/G3ACSM,-X0<?\DV.K$2_+?F170J,H*1QM3SG9=M///&#C\@&):U83_ZX\6T
M0V5E9IBFF VWB_$@3_E=G;W+0A&9WYK9QYD2S 'F/C(F4<-TI/RGZSG]B5N0
ML(-L7]<W:HV"UCQ?G=D;XTH73<:GIZ%TD-Q#Z=&EMX*SA_2@M7 _QY>]QI;Z
M'DLQV:KG0])NVX RX B6XJ7/DVW04UAB:+RIL7L8R650#\X;=JVKC3B,7K,-
MK0F8.@2J^'""KQ7V[;R6/LD0,RFUE]"?MX'+H9X&>HN80\W':M%< 4SE0"_'
M%\N]CA65F42UNN^/GG@=COYPVTP^H<M$;8>M(-(XFPH#(C!(-18E8B? A7M_
M!-3?R!8QL*T[D5B1=TQKI4KF,Q7CNN?.L4A6&1G&@EY)%FEEF$(Y<#/+E;X[
MCYH;AP,-LY9E8N^6T+VY9ZN"EKC_(@U/T)7P#@:8FI#>A</&!R-XPP)L/]5%
M_[!SQ-E>"OFE-)HHU*(9;2&<PM\4!*_8^EO8!6^U%D4[@O0:0?NE2QJ%&7E2
M=%VIE2;K>1_\J'?=.^^(?!)+UXA\J'K@8EE*H$E< -6 J@T$$&$/H970*..C
MQ"G>E7$QY[J4.K1"4&6IX2&9I-83I.\8?Y;^_N%B\L20?;K04M@;/SZ2+XM+
M/?WQZIT5^LZ;Z0A:W5-GF4+@N<V,.%;O]V\1-J"!!1&UC.?,HW[8JJP\$K]5
M^XN)AW23PE;M.??EK$Q71N$#4<$//6S(QX^CHI(8!7N;5&0OZASC"4K+%37"
MU&J2/3B!O.!'Y#]OVV=T:>3F0GV:\\OO@I_8/^:W7:UH\RG6HPV< 859K1J2
ML1WS7&CO ?:P2YVKO9BIZ9[-Z<IX_38;S],/,T8+/GHV"IKA>;8?L)#F\5XK
M@SPNI#<%0_5J'#861FB\?N^RK.4O[/?Q(SB4AXNOA/&#,X9SHW9"],]>$A='
M#^,94Q7''''53-9$&I2%76K?$7R*6:^VM5'G(#QZ%^70<LQ&[B4??^/$6NQ_
M].^RI2%17['BZBP6J2GN/Q1VR8/B^(K(.Q):O/P@\$FV->6CO5 2^\=R?4)%
MRW[L919NP&--CP(Z-'7 MMWT^.;A<9*PN\F3-(FI-YEBSG>-(N]:7>L(P;S>
MHYA76!0SC7Z8@N["3 6Y#1H+'\I^T&@0LCU0W-;J297X,G]P,?H^'U?$,TSQ
M$HMF[H( I8W5)HH'U!_&!^2NM.$F8K<TP;:*.ZG4$K\C!?7/9HV?"K#=[=@"
M146?/X&9X=E3 P'H7@;<I\7.=, ?)@(D3;-^EJ0+%YQ1[W\5482S"4F*%45F
M30JTO?'B OV6Q,P\8)$2#*",;H.+(<49671#PH;DFRQ<KYW)XJ3W%<]^0^FC
MW-V@-!N9VFO-3_=JS%FZ($G.[LR3@GICA<-"6Z-M4WV^1:\ZGVYUI9Z8T>G@
M7C?KD?D:-8?58CVP7.RG@<YBQGMCY?(!@D=06STL?OW%BOUHL)&ANHBET)..
MAI8YN-%MG58E;-#2W\JR.C2!H]#5=LHU! [=X:E<0^ZJ)9;Q>F8<&<'<:[#1
M&-<[(-YS5>((3\8,WV+*Q-( 71C!,B?)3&YF+\XRGN1\_=-8N:8RUL[4<8;Z
MJ,?I>N#2C)C:=&AYP/)9%1 F#XV Q:*. @.T8\! VYS K%+3[4<#HA].6-8[
M%[G("L)"'>3VF2F#R %+JBKL9#15F/&$J>F!&O7D'\UK>[ 16\4R7<L7YOU/
M9A7Y'"GU$_'1E-#8_XNTT+88/W ^8#MZK_E[)QI0%5_MHURR9Q3]ADLXAP6X
M4.#QU>_P8DX// IG[QLI.&A]ZN*V>W,G(R:O##7* CTE=*MVLT!8-QZS.N!7
M! Q+;C%.47<"@'L-T0:XTT"+ F![I<)S"E.ZQ (N!2H>\"*B4Z"5X-1&=3S5
M"^,Q76AQ*TUPYL/)AE/<I$4'M8$RE"6J _L)W<6[@8MIS8YO.[D8IVYL4F(1
M\6[YQ=.76146(N=Y/U1&RCSC?^UD.#MP:&+#X7\H+&$_YVE>C(,%!^N&4 <5
M;(\-?[Q\^D+F-Q@(Q-V'NH$:AI-=U,#\*Z%2RFWJ A,=W.PBCSND:B@(^84;
M$D_B%$ZT'V]EKH$BJBE<5$L 2G'J-#!5H/A$;I4%N7V^;(.X57AD1G7-_OXJ
M2+0?W0YB#J"W;'4AM"UTUWMF2YYLHRW-&C6@C]*F^$RE56H4AM[<!5U/L)+M
M0#_BI')!8N_7TD74F#P@J'>.+9PG[.S<]$4*LX@M)Z)U5BR'FW#]'E/9Z]6'
M,)*RB0K[&)H0B?;![AQY 6;L0$E6="WPZO;>Z!F6&XZUH@>0,=V0:N5.; +N
MR43]+JA#4]"S5R'[5^=61M?+K=,71:T^BHXB91B?4;I(T7'U6UMHZ64GZG&#
M@3?+(]5C;THR'EWXTJJ0VANMTYH/GH7&0S\AVJ /4<K)'9Z"9(WL_)4+EI3_
MQ=Y[1S7U;_NB0124(DJ7%A40%!!%FE)BI8@4"R(U*@(B B(B+204Z24B4@0A
M%!60$NE("TTB*$9J*$)(Z#VAA 5I-^S]WGAOGWWN./MW[WGWW7O?^V,-QE@C
MK&^;Y3/+=T[YZ0^/+A3QG5G\8U7"5NUEJ&7_;"8>P3\U6%S2D4A2T;SD632W
M1&N(WM_U/1+(\WHODQTJ< .5_;=29YRSJ-$BJBN*F@L<*  <3=-U$(>L?]8E
MI/6^/CQST? M]LM](URI$D6(*0A)()0[H+US/N635B-O&YY?5Y'-<O.3]VHY
MRCG]7:_C$GJNJ)UYND=7Z%-I'HG?!G>M[V>1P CZT[V'![$\O&6@1SOIZ9/F
MO3 3%ZFD4>N%ZC?9CUQEC?-\=$,/?#_ZFWL]_S-\@"#3)&^@?KY)U@]SS_;C
M683+R/C/&Q.;MQ+76* ;$HS=LJ^WF>UL[O0FF:!C]2&]CWI.CPR4O##5I+S\
M4_ :ON;K4)@L?SF+C=.E7#:2S,D)X1\Z9^[-U06]??=K,?#>)"1-I.3_<H"+
MQ&8#?1<IEC-Y;KF+FA<J=UZ$2K:79SK1=%\]DEU6X$_ IH]D"[!):_D!N:@9
M(@PFLD&Z+M2)2!",.O[5R$>WC?=#</+QAYH"=7"*R(*$644^$&8>P0*9-%7W
M%SO;]]C;W"AOGQRP-MX;I+2.^7LF]@H%M;QOLE-?WD_L9E53?TJKDO$&;]ZT
M3E38@]RDE3?>\24)@?@9]WZ"!,8)?<C859FI#/@6%/E#E2MLE1*'[TF7<B%>
M)5X$]_IH]#RZ59KS=O/N$2X,2/<\&Q%?8.3I:KA)-SCHNTU?BM])CF_\@2JZ
M(&CJ0V%;-PZ(QQKQEE72!X;X1"_<N(\* #%Z+'FR%7FX+YY,%3MLW;QN?NH*
MGZ-WI^P^2YD/6:&8/56KP"FM94FT;2<O0-(1OF_P5'W43]RE)_G<#C[UQR0J
M 5Q97223-H*+TT7XV7$\K3!_?NA]R&M]2^F "0ONU1NH*FRK 9"4Z\>#[1CQ
MJ""5/$0<'\%>3UJ^J#GHV'2UZ_2>+%Z7D<90S$FVGD0")Z#MD$@62+CA+.4*
M=NONN(2$[J<%PN7+"G7),1<>WCHXU#SV?D\[S6KAV_]^8=I=</&=?@^ YL"<
M $2QWY7VNVP+K4]#\<;3BY(D>.%QF9\EH0)5<![84^ *"3P\2_J43S1UA&GM
MO&BUM?V^ENM7D98?MW.(@WHT(1>3D[[M3:4RWCY@Y,&/5.?DC190.L(D3?.-
MN/C[@QR&D4%#73M:_?AE_2.4U)UZY$Z"&G1I(#.3&E=]:V->54D_,C.NC?9X
MW9!T%?%%==E>;%F$W/.BVYG(G: N/B@)X+@6]*.?<3>=&8\3>*BT$,#T;^*E
MVU'$EM8IYJ84LX1'-?WJ\W&^=Y\[7:6X"+8<W3CJ.!0<:+5JW@J)L0%W("+K
M(+%TO6<*?3[B5\*9BJB\CK:*D]]E1U#1[R69I9--C6%(FH:+CWN>RI\@&<I:
MW9RXKF$U4KE)[B7[7.&G OY7KL[P]T?36%#X]%)!6-'99I%4?](RKRF!VNAF
M7C6D-N[3[UH9\#[KU*29CWIHK42_E70@):-9PH,%JO*;;$N9MO*RUKC'@2W5
MPFL5P@>@^]4C'OA0)-N^6VIEIGZF(YJ]YWL;>?P=]&O(!68.B4F,_=XQ8XEL
MG5J9'XYQ]MS3U$@ZPM\]-9K7MU$@?@ MSZE]9"XOOONWR]=F=#MAQ'MRIH)V
M&V: _-:D4%9>G3+2\U1Y6<5B*6*?[[.O<BDZF=$*^-XZ]*CC9 4,!FRCW43Q
MJ*=D1EBFCM')+7W<$=D %JAI%*6 2@NP"K.B(O< OJE.VCQ^Q1TQA='IINM*
M!5"'.UG1I>A 0LYZ;;'=@FG'P4Y!/_@U,BZJLL33/$+<AU]M16G459-/N:SV
MA9ROY%LO:#FJ#$D7YKW.R/6P:FTZ65U#WDH0T;I8=E9T))@3I>K552OU5F[V
MC1[WI!Z4S&Q$$(.>M]WK77'HNUF6>5IE-F[MS<E]YC-*<T!&\'./HZU=[Q]W
M)+L%5L08Y_=2:]164%T_.Q).?3SIL&6X\>[:,\P>YG%$ZS  (8+%WJY]&*B<
M*Y4STWX=ISW)R':K0T_P&<A\$JTD;UI^Y.K;-/NY4U EE\ZCF/NUXZ]T,[CB
M[\*5YZ)7TF^B5SG78R(<=FJA;>_AN4OH3C3;O#4:\S8!6CXM(O@:,J\TUXR\
M5_7]:*QHDJFF^=8_0^N07+R!N44SWWW\XNTSU_Y^U>$2-(-]PG21KKX6C)!0
M"X%OH\C>>;"+H>+#AAQ.N3!M096Z/><2#*C:>I&7+\JR%>E//TD'BE4X4VP4
M\&[;22E7\?#DQ'ZR[H2\K9?E?1WS3'M2/WF;0<91!8!%BLW.?G5,9'IUYEYD
M&=JGUC3NK,"J5D8$EO;9;6<O$$91:L/PTKD_^_UH#XA[*0/N<V\:T.CS3F8>
M8MN-T:"#4R'0=\S=4.68*3CJHSD?72O"G5_>R=I'9T:H*Y@\=.F5G'>"5]:G
M8/T\QBO,_499JF&/QZ;]]35I!';DPV6EQNO:WV,&E<.F+@IH_^(]V_*0&P12
M6KR^C:%>8GR%"='L77V]7&^:9 .?6_:FIO-/Q?3N59!Y>N/LS(EG!YJ/)B9^
M5YCG^:_&8D^6&Y49_%HZ+.ST+@'$V7BA@48-[V=#L6"$H.<2+^\BE'_AW$4+
MP=9KU:]+SQ*.6G 3!9:[:19/$)6S6'['VV(56J\JA[-PE\ODHB9#S'3',(37
M\5-9_IS9(@38[E4A:Q@4(&8/^X62[P$*EQINR@FY[>O^66!PI9CG'%LI5=ZA
M6<7 .^&2O;HN-%.85J_NQ6C-9/^2YIK#7<W*:>XMDGI7SG!*KR=L,N0-)=HD
M<A6OWJRR- !Q9K/-T4V2)W <BMQ@G)W^S3PZ=^$;F5:-OUL^4H1H7@/H1414
M+)B[P9.F!TS3(23&B<6VG;$RH<NT)FMA<,J]#P[BCYY=FAS";XQ",U%D&T_>
MQZD(3OI)])]K@HO5 ;7551E'C7HN"!T/2%P+2QA[S(E'3*1CJO;MIJ=+'\>7
M2LQ^:SJ2J+Y\^24-?[+FS,\@Z[>'@O!ZBXM/Z*'L=1]?L(JE7"'I!3O3..?(
MOWZ$U?RT;@W;;-. -_UKEV=W?1ZS-711!+$;&PW? SA^>TE\[^=M^>B=B#>M
M_A5O[0ZHIX %"K&:KEFJI_2N4[T  A$C;=.!/W3OIV-#]94PO8KX\NRMEN];
M>S!LHS=JG*.'>=)/TI:<A7E:$V" ?D*M.?P%QZ?]8*YY(FPH!!K,EK&^2UIL
MLP)*T1NJ[SNM@=FO_FK8+^*7(+E<ZG7Y),,V^#PW\DHW"!X+[T&1+5?#!UD@
M+@UU-D ;6]17'5@:'^_EJGH<GG1AHO.D!X>%&>B7$?K;O)S_!W^YAROM%>>D
MWIC?<JW:Q"_9LI$@P$:"LJ18:2O[OE*Z#GEMW&(K(+G?6:O>PC]BG^Z; -$Y
MCM6+X!PHV0@5=@MVGI$^1=%;XI(V[!"+V/ 0ASC'B1-Q_=N1<ZU-24 ;S0RF
M!AS^..;@A_TV\C)3I4Z4B3-.,?FZ_PC/E\*QI-&C @$;*MQ7RLB_8A]\<'W9
M,SQ??4B^JJKA"J_4XQQ+PR\@JPD!NG"1H;L8=1!XD^9YFD0:G]:2(E-[A "/
ML=V6!,L?:;<<F(/@(QX-%O<SS'^[/[15D35+#E,_I"J?(>7Q4A[9?W!@4XQ^
MV(I8\JN(@NC0U_83OS<O<:\O+PWYMELGXFA@>.S:@T6H .P((#T)06:I59)Q
MH1O6F[;S8Y;3EL<E?13>R<.C\DK-/R(N$LJA2Z,?X#\@7!L8KOE?J;[;M+N%
M!:<FEWV?<FUMCH!X\LH+L@6<_V(!J7^L33[*Y 73= A^OB3G#(J;::6KNMY+
M\26?DXZ7KXHEEO:[Z(5U"',N'I'^!END\3*'Q5!E;!/.U/!FAEF2+;FC8L_H
M0@#LUMXD1>.$1W*.SU<>A+7P!44Q $I^Z 8D*DNL'W:>9*I&L.KQV1^GI>E[
M\JO<;3KRF>'1-:5U\"1[GXS^+-YV@)VC%&L&/,I(<TW?>+HJEEM<H/]@I4V=
M8P93HTH7X<%30P$OK;;5/8]]TPVB"]0T"PN>*#>]F/N@UAK5<&H%],;,[#?7
M>?0[A*-J\(7(Y2-LH-_F(%$3DF$2ZM,TX*'I8>3N>+^[OJ8[.-M7!7H/,&3N
M1TW6=YN! 2.Z3ZYKW;/7_H0',<:?3A+N'ST-_X0QAC@CAFV;">68,-15<GA&
M8W>G%6:@E(S72N#>EW90V#M<BN\W=^FH+=;%4_A0=H+XZ^/'-RPY00*M'__O
MU<$.[T9+$9VK?GAFXPL"XWA$4Q_[C1P+U'F0/4-&G!L+]*''ZAOJ/[YN"6)(
M_KO]\_Z=T"L:K30#!11GVW""L-N,-S K(N[ 8[P-L]['^^'OH>'2>2GY?K-V
M :=;"!X071&0)"WK-$,D='E)[G9==0[(DF'"F+@0+%3QDV%046)2N/81--Z9
M/>LO=)"SPC)<88H%^BV.H(S0NUF@"%Y&#F0NR0^YFP@-[#;+$Z-=1O2<H("9
MG$A*MD"? !#(W2RP3:- F ?8-HUT'E.FA<S)A-/-V5]\P )AW=8A3''5W0OA
MN:8D")T;O.L\@"X?8(&N9K0C@(.0CF#(#0AQ"0R"S*ZV[_KZP/27R'_S5?1N
MZ_G[F!$A9K16% M$ED+$@\DMB$H%AJ G^P@FM%D@"1#C# L4^657%:$P0NR7
M:>PU_-L/8\ZQ0$2VT'YLOB,WSD8'S5Y,=43;/N9OU(9Q@R$+%#Q)?\RYT?9O
M%_'XG[],Q_W/LSO?,GX8%Y^>J:J-SZD-'SDOZ_&9+>=7]J.A9-22)Z4"ZR#9
M1[^4#=/$^]B+6429NP5Z@L[^C,P[B;L.VLU\^__FIOT/):E )@\OA=8*K8S$
M*JF*^)U=_=#[X/=RL?B"Z/C5K"?&Y[1^U%(B';P7H7:(%GZVE(#=9X%\39B^
MEA3S?[,TS%7V/!(A'/!C=,$,$H*N #_<WW!:0Z2OZ;O/_M8#5,E,FO_R5V\F
M.5N@Y_-?K+"DC?OG*."_&!GT_8<J@R[ /]0@M!K'$@W73#U))@/APC?O//S/
M;IGV/^J!L8]ZGR_0$TC&4[VJR#.I+P93F:I--.'2^ C-Q-+MMX[]:?VTL]*+
M:U"J,^,=W9IM85XUY_&S?!",%1M1]>$MCE(YMG?/<D*^0KA4$C0(T>)U T-Q
MY1B;0K3_\-SR1>3-4CH@U\.8^P.IYM4P2VPJE04ZC840UM9/0_AF@O6G=^O_
MN= 00VP:L/6S66TWM*TJ>Q-TG;1CM%=)AEAW@P_UUETA*9TNS,AE*CG0GP+#
MDP)''+H>74C)D6W6$A0\]+*]**ME#WXEGRXL2\J%R3.28-X%; R.Z7?'E#]=
MI]_"K26R0#!/2#A"3S.EG&!_Q7W/D1/O!M4O#:2]Y]A.!S'8C!%ZG]FB+P#D
M3.B@HS&"+WSP[J?S ^UEC>O^'!UZK_N+2VOJO>J#R@%/X"2*+K3:"ME/YX$K
MTK7*+VBB/+VE)*KC2KMYE.,.RT=));>)W&H\CRN!)S.["0<= 6,RN+E)T.BG
MZ2=7"^RIK-R[]FLNA$ -_TBZ<*1E>2];^T>M!IYJKQ@Q]!0E9O8V%!1P?Y6S
MX)[&T04#29;X$(1;B=AU8W%7YHG*VK[3>;B]K]3:O19D-,"7W;8",)F0H5-'
M\AE?FD24>98F;:(S'LP^[G3<Z'#;4?Y[R"4+X6D>*G.<D<T".3<B6O5%;/U]
M.D^$KNSW0#W\,=U$"JD_*WVNPXWBV0:5UH? L4VG4B_&VN'I\H$N)YQ_;][H
M]&CG>]2^;0"]K(V>^]S  DUR-YN#Z'Z_H<84;,33JN^:B5)]AM$3VD?5GPN\
M,^J<>\RY+DM$TD7;VG?L&^XR=<DJ"5_+]E3-(,]7I1BL?+NGALS^%L1-) #*
M^2UZUWO =_MT3?/^'$Z)LOY -/\T[87J:LB;U*(?-ALAS002(O3/:2:>=;97
M@EXF&FA;ON,R'PB'O9M4!4XH+ M,] Z1S:DDSN 1C3^^1V1JOT,^@N#OV0)J
MWR-&YI@(AGATP.K9K\'>J>]4C>Y%!/D>+L0&=OKI4<KIPE-3^^SU'MZE6[-
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MR_9OP<?%^SG>V';)&P8Q-SBV-VFG'198H K5Y3%BM\3"W,?!#)(6>29GJNS
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M0,RO'#^-2??OLKEW]LC^ZZ&/DC[=N<^WYOTM ->*'#EELCITSAPH*Z@P#GQ
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M/ *Q(UQAPQ)FO$C/(&:L-/92Y%#VNT<EOXGM+GBLAK7X J!>B.&+RDLOPP>
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M+%R-NMZNB40AME44PO'A:"2FL!)J:S?=0"'-'?#_"UEZK)U[TQVA<2H_S^K
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MP2AI-80YK28<;PQ*Z@A.D"3+!2%210^ET2GK?-Z&"Y>KY7@E[WOV3&9%0K4
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M"/0?*/OQ,YJSJ*>70O!WN+SV [19FOPWHK8>+^JOA[^VJB7]]2U) %/BGV!
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MFWZV/#6Y9X)\-^I%VJG;5F$ZJ*X$) [/K8EYF,%;0'HJ(N(91AEW[,#1E%A
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M3<7SJ+:E(<4\6R&K_W[0/IY,#38/5+V!)<P!4HRH1-9J6PY %V.Q?ZSKRMW
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M)&? 5TWT"[^X:0KPBT^D;HJ9V).\*CIT(0B$-U^=Z-N85WH!CO+<I/KB@[O
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MWO <5YQ# J?_8H@)>OZ@O 9YP@4W=HHLU9=LAQ0P, AD;TF;;OJR;-GS(_>
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ML^/7?*WZ4<*RH53>?E8Y"AP/IP!Y*UN.D<@\>9%768]L7=1WPG_WI+$\V9Y
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M83A:,KY\[/'!S66:]#TM>%9:UB4;FV??=U9J-$DM!")5T-S P1Q'"H%3P(*
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M?).K-0C;@A5>^'[5(R@ZRC]8ZD*[Y=I,N_6,+&.F&A?(B&">1RD#DI2'P]9
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M/$'@U:=P#A(BF6<6DD;+RFN_U2:X?OJ5IDC9BE1<QHYOS@S.-V%'30@Z?]_
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M[?!*_XH)1Y7H;^!@U"&DO.I0T\FABK*R\<6X,V;\?8^3[LCYUR=_*TNQ_CP
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MX$/'6,M!5("G0$O=#EY V"M4/*KTQ0N%\Z=#7ZD"*_F_A]T55A.&!-+C(8)
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MR_NNO)=R?,HE0')AX^8HI,\=^X-3_T?L(L%_3/S;6I=(.&K>\E\6P/+_I!
M/=YC$75@^$0B+VA[*I73;Z?OZ>H^Y9R:ZW;)%W+MNM]9FUG;70T]I=:(+R>,
M?V$"8H2?URDJ$,<8$UC:&]Q$4V4"[1WT?3 9U,*NWMM6M"GW#-&:#?H26KPW
MQ>IXF,#==0(]VI2N19S09.P8V\8$WM.(T''\5W<%-NHTM'N1F@%%>+/"%!JR
MR 1D3C,!W@"PDPD8:=[%4?1A@DE27!./ >@P;T3JT*\S@><9[PD@,H@)M#W"
M-65":KCN3A*:CH!3J\D3C BX/Z5P?V@HDC*-BR.NJ&'@E(=M$;<A0+A<L-7,
MK6;^K]1,)Q&:%;957YWQ\&&3)WG!RK#?I,[+N'I-N;EW?BFXA$9O<VX)GFI1
MZUY9I*VBG^ H]M[@.HB"(#R]N(!MF9?P2@<-KL4R&NE%&Q?QLPE#D!Z<Q][$
M'0!2_P+OR?SUH$@1;,FFG+8:5CE)3:AU\:1J0XH>01ODF$,NKL=>M+WGO3(/
M/$,0:[Y447X\="FR>C4RXV_M[IN?ICSO_[/<+.=>Y=.=S5?9PN[ NAXU/HFJ
M2&,(*QLQ : $!78B*4O(80LH)O4Y$PBUR:9?#T4]/Z'X^QE/Y .H%[URKA)!
M9ZU@ A/JN*8VG)O*Y@'[2(C%'D=-!Z!P!?PT'I(RHIGC>L[THRC<L":+ZX$S
MSSV,',+/0G<DN,V-";2XLJVO?W1"= ?[O;3,P3P\WE=GF//9,+GU7&7"#P[9
MYPJD0GI1)W8WU(;C;."G'WO8,L9#<<R/J#/:6YSJ?21;O9#G^'SQI\G%I5:%
MNO#M!,$_V!#B#6N;CPQ\@VJP#R/G8+#61+:$(^:>L>/VV07/?=5A&@+%#\)O
MY+AC=HS2NCEF%_[_/$'^=^(_8O'&EMQ*WU4.G8K]D+VV;P0WX[F [1OZ0QD0
MG/)GL1 _[;UV&9;+*: EG,_[/X3S^23;%?-_OO'8:[^_8T^8()*8 &V3L%2&
M[SM!_P1GD7VX5D(C$UA?Q4U=,T ^]F.<'H9E2P7Z%V(*W3&%.^=/H"Z(T.YM
M6+-7_)?O /GK09C^"S.QI@;.A4R@^2Z.T/=2;P\NNXL(F,JXG4GQ.WR(??=M
MZ:$54V, =Q1%^8B28@(_'X!-3&#;8280COQ#"<YT@))(%_9=*^W';J.K]-7Q
MCSM\4]*U)4\], _QHETK*SW&'I?_JBZ\2I$WU,R$<WLH2G#5\N#B\?Y?*W,_
MQ0?7>FW",'*TGK:<B+._.*49!X@1]+VO,1VT>?OM\04>:8^[OJV,7#@HUWIR
MP< R*']^+^V@RH(C=7"HR?[^LCW&Y525IY5=UG>RD5?<*QFC.(X OXMK$AF9
M;_'$[$C"3EU%2G;3D3$I"O:N\_BHU/?+RC<N<W)!RU*O6VL/R:WO"T5EIC >
M-&C59WQ/O->@O=13E:(O68O(TMZ3>&OW*IOP=,,!BE54'4]!R+WFFNV%XW._
M<#V5#EK*N1/X3S+WOMNN2EY<3-27!%W(D1&_ZE#D4>[69FV-CI3D+Q"_S.V6
M\:SSD=<O\@6R6W,LBXQG\XZ!M>@W/16+Y2$-F]?"$%6.'SWX_4G;4Z_;=;O4
MJ@IO)L+TT\.(P:I!74R@XGQKC&X0B3@OR;6BF*%1"_67O?N,EU,JJA++?,?Y
M?6*W'_X!BO0,678;789KP<_7RYB_UD66O/?;*64^XMN<$=/NU4DW.=*J-_ @
MRQ>-@2?3'B;@H6Q*-@U?1=[/VE^7O&Y+F2JHZUF4?U"1_-7KG*M=EGGTDR-,
MX WIIN #1,_?;P[_C\!_::JPH?AG3(;^0IR'O5M>D9(!M2S(,P$+&?S/Y'^^
M]7_@,G1>RM^^HI_'!!)Q]YC XBP3Z.@(1:G.;;ZLA,M<"=^1'824#JA@ 3<Q
MK++.L?2,R_4??,/V?U<H4CY!/&RO1MV15<(?ZQN]][4>*PW[+MC2U&"4".Y.
M1+^KW$#\7NP&=0+SZ084[^81!S<)B_X;N%*5ZZ<?)9#E V6^!XG$?T5LDEW9
M8,\(4Z4?[ZT[1#/$/&RRCZ...(*))M\N]?+I?GO^P.P*VE<LJ90)G.S$]MHN
MM;Z<$X$D!XIAEEL*09TI?^*E_'KAZJ%/.V(,;6U^;UKE1^>@V&$%7C&VE_(K
MWC,OV()RPTDQ2YB+49GS73FW.30@62!7+/'5H]TAPP CZ 5!&PWQN%'>*GI2
MY&,_.8=^Z&?%-GC"$[I%!7;IJ,I.J6DK\!8)HZOF>T#(T=FN1L3G8]+ GG/G
M=NCL<I$J,A!"D:I0_+=+@LC9H;K(:[J^LTY2?;^\\/>O(O>_3E<Y>$0OXP8+
M)<@L'RR:9@+@/OW*@)?8D>R=T*?ZU%F+3Q=>&H52ZY]N=!6<88/3B6W!(V0K
M ?<&U2'\:KVW]=L!OY!CU]_6U-<^:%?J/?1)[=!DLL<O^#:RB8T27:+!V'HP
M]M:-"6-*_*/2)A^,;<-;(X%GJ\TJ:LB3^7!2,!RS13);)/._*!1CP'8*K@DE
MI;][3HJ+ZIDV<MOSA![^S4*R",=^)4_ZP6(6CA%V/C.]$B$6^@HT0'P3T(S[
MYN)0D[YNE='LQ'.P9:AY^/:.[AM=K#?5)LT3GC><_3)X0WRCZF__J\/YJA]O
MG&I'DW2BD1/_1-=74Q)'<W26I\?X];!R'>_ VV^)E@$W)E,]KL<E!TV7 #AM
M(=O% +IVVIH[S3:3"7 :DQ*QB^5,P,MIOL6W6M]KWG\N^\X*@@6"70'0%_^N
MM"G_H9/S2\F[O0/\J_)&3Z?LIW(.8#,5V*C>:_:,\(:]4'_Z0+F;_=5AQ/T
M-E]RR(E=%N=/+NWAV![ !*X=Y9"(N9?.& 41%,T/Q')\DZ5:HSY?Q9%-S\<J
M2DN7.@-T6!H"[5C>C;!]!>"# [?;;8?';O>"&-97!>^!V\#9@O^,;W6S;=CA
MZHCVC-/P+!!E+,;C+$68@/?<TKL_?,'B&6+ _=\\J>S@VPWBVGLP9Z'F$6^&
M<CU^^,X?"Y\AD@G7D1M:Z/O$-4TWU.8%8=SQ%/H"]!FUY$/@(LQ[]>)6R@Y
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MXS:5NB)<=/0=0-69R!>N[-F\E;A^S7]WVF7:<V?R/O.1ZNO5@W=[+Z]N'5V
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M&[5=$K^!8P Y)[?$SP1V':.HL\AV7G<WE%$P[A-27_'Q<%9='BCWRC-39;]
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M3+%K(!8U'PMT^7@RN$**VO+DJ!N-79JD^F=B6^KF"4>1 [&4#VXYVYT7O)A
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MPC)ZTKB22>KUF BT4$5L5M4@#1'@\"!ZX#-9 P,G'RJ;._"OEOH1%"0[3#O
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M+ZS8,S@C?162#U'T[*YM'K>\_RC+4V'YP1Y:%$H3H)5C>CLH,JXT7MA9DD'
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M*.SD #1?@,X+HV'FT;08 YKF%/DN$T@%^U L_2H3B'9@)>X.H3- :G-KF]J
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M^EW<I= PR/BSU6=#][C2NK$*,$=3BA2ZMN-%ED<V@D./)%GC&+_B?&AEW5
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MGQK3O$GG/$_UR+[R1MRTX*RX*%![9U0\#*997?CT!L+[?,_E2,]N>' 'G-N
M$^+X,O&%=U$T=8@<2=/!3*'H'#A0IQ"M?$' >(VJF=\.7=V90V0"8,$-X&@)
M\,-,H$;#YQSX<B^P$G.PE&DHL0W'C9VU G^QX,HX>0LV/.1%WZG'!'9$;B;;
MDV>N,X'3H.HGGF "">OI?]);#,A%X)^G]S.!RC3&'?KW6%3G=1AM'VS&UY$)
M0+(H."9PIAAL9C0!.&K%%DK<PH:#R"?O ]L.?;2Q'?JH"?5W*=)4O&I=MP10
M*T]!'1EQF9X3C^K4AQ'!TGZ#<K&%K_&9,@'6R$VTY1]DV."7SXI=@?]=@DR
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MP!TH@Q(Q1IKH,!_3#Q2[AG?Y]^.C*D4CF@7]&X8>.252]*C&/BJ4C0PG,VN
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M"9OXWE#V@I=A>^N88FAAO^X(!L XP39/<(73 :+&+.CI'3B09P88OHWC6^@
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MPH;1A >%;W4"];%3O$\$NF>.=F@H&_9U(5.BTG3T,:0ZU_.\@IZD]521N0E
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M*Q'L@V*JIA>X@I_?VBOQH8QI2N[QP7Z-S9Z2%88#!#UQ['_BD\I?179BU;^
M?_H_?FIR@[(?B?M #"7KD_R:KEA0S@2=>G&HJ@,Z,ST\?,,*Q+N473IW@F6)
MD;7.U*H:(7SLY$;]:"(#Q8 P$T'A*NI >?2@RSO/?QV"NV*/EKQIF;^BW*8A
MRFUQD@& /$/B#98<S_;3 ==E[N&Q&J_Q<=+-25F)F72G=Y7)O<%$2?5>#L20
MS:J\V$ST=K9%'#?,15RB7XK %>7!-!2 C2K?Z[%T2/+%R^(T(T.KL)Q2?B?1
M&.H5$A](TI)(\,G"_4.CDSX1&V$^W\Y5"OCZ=M_+:0O8;Z'@G9=9?48-6C/
ML"5@$-0K3=F72G1+4+M+./,Q0DCKM@<+!8@Z7*,PY4?9;X5#193%YB,CJZX\
MG[KL]5-L8/ZH7VE_;[7R<F-A0O7)8P'N]@"!BR2__*"LNOO!.+NWK51\>:#8
ML97IN0O?TXZ\BK_&3(BT(F'CD76':<)?25/$NI[R1]F..?[V70L7JE,]VM1/
M]IQ^O_AI^B)CWMZOCR&*06=(#R<5XB'<Y18"_AAK]9'I0HV4Z96K)P_@+NP^
MYYLM QQ-V!6R&_$&T00I2U],)DL&R5[>A9W,F$=(#EQV+_]@ZQ]X 59F+L#
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M3@?XC2ARRX*@:QDN0DZT>=".?E"F";$U0==X>^C ,F6<<BN1=$-ANX'I*3J
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M3M.!E-!)#S++&')V*(L+@YEXL-681'$A1;R*5N3H"A5K-\HLY*^7T2#RJ<_
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M4+8KP[?$CQ TXIW>O^UK.SHB"UPPE7RZY\ W&:8IIBE)J"T6YTS9-TKT(,R
M1NRJP$?ZL.9 M6D0ET0M502\*E!0<3D3TO/><D4I$] QW)O%-00==B;6XA66
MX+C ,8MZ#Q\G9$Y5<Z[+5LR;+Z/[NX:T3"X:UC4P?@X/VXOV1+=WDR33%U>G
M8+OGQ>5($9/RQU;U>\ME-=:HNE^WU&),2T1+38M#M&R /<OOB_LPYV8!]#%J
M-M)E>0^M \;UG> <5_3*U%$Z&>[D$OK#X_"!9-%;QF(,4BF F(6D[@L8R!+J
MKM0"I.;)C?IN5CB-M_^'#YID\,/]1FW_[8%6Y5-*S>3O>DJC[)>FDB :'Z4
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M_T!Z,<H40' AOB#K=7OXIN.PZ=YTW@GYQ/YEVXZO'OX3=@/J61G&N3B67M%
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MAT=]=GI\@Q<GG?[K+[[X/T'\D!+@Y63R'OVC" ,XL#X5F(6E/F0 &9I+"Q0
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MR'[]4P4'J3^SOY=#:!U#M-U,U44*8+R2THY</",N$K7H(.IJ-]#^*;'&6MY
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M/]9-P?(77Q)7SDMQA-(TF'99+,\KFU0VY",U[, J59<MPT#"-7(PW^68VZT
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M(>_/>WJ6,1^"J4[N#O;@^Y.F1/13K=9[@MX9"Y^],^;FSK*J*1?[WK<VCO[
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M\5Z-WCDN4$\&=+\._0NYZ\V$N<%D#P9P?Q[%!+6_3*0S(8-VB0!$P+N0FR5
ME4D*X),[2G\_ R^[CV/6?D-HW,,<OV!4_C6Z&2P)M?/K'7(E2'O'G"KT^$88
M: J#/7;"177S8>%#Z:(ANY^D\Q EICYY,<ONY&8&X)SG08][#'F 9&I8 IP"
M=@6#3+U33GU!28IGO*GRK[X:>W$C?A#5%0%&A=+^7G?M^"O[ +9NM2@+6$WR
MA!E6E!B\F/L\^8V;KPO# MU=HQ_9(]GCL NU2L$7-[AHE7BG"\'%C>X2U(2Y
M=ZE7D4]J^XKF-4U 079]3)O=-I)?N$%+;'/5&A!;]U6NNG=NA9EE+C-U!^];
M>!7N!P&0G:[&9W_-"]%0VPR Y>V 3B,!NO)=YW7L][JGV1ZR'S1"7$+Q[3P
M0LGN'U<[+?WCQBFF]IQO(%=^*>VOH5=NTCEQ?T]T$H?H;<4,X.N(#<?(\_\&
M)R+^ORQ"_\_-!EDS=@8DB?/-)+ON!4'/;#/UD#*O(-M'8@[>(1D7^EI3>=GO
MV'!L;?\'/)04RW0J77BH,G+4D$DQHBV09&QX*].47VDI\'"*'*;'=2FD+L0\
MGOVE,A-^^A; 0T#>"QA_5?"DO'K!-LL>S[]MB4""P?_!2_X!S*PFG3.?%+0T
MN7%F24V*[/VSVV\EKW96NV4!TB_9/5B?*/_MC3SK#[/?P5@ WOKOF>:?/*&F
M&(+?\P#%[JEDN^^X=7/FF$ER(\6(/E(@3%I(5(7KR2>\>SOSI26<FO&9,GCW
MOM/[^S8(#[&?[Z [BA'@G(6$>=:Q#A'J)1+H:7UPGHJY&29OP&75SL]<J8G/
M##AKU,G>P21J44CZM!=%AFH^[JL=;KQTBQ@7?R)QX6;LD#3<2D(]T;.;7[1J
MG^6&V<6=/C&:-JV966-"139N!S  3DC<SA&X"NGHN6R1UCP-'VW!ZT\=(HH>
MN8D>,F6+$57\J+KP64T0V:D*]N+C@6@="Q8P\N7&^VZWWQA?0A9Z">&HG*8
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M_W,3$C+BWY!3T%!0T+ ST#&P_S\^"!T "S6E'>,H&8D00,I"0L9"0N@!! &
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MZ@Z72)XF0S 'L9W(,9(5SJ#ZJ+A#.+V_A45>=XMC>I*]O6CEZYK^U>ZB65W
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M<"?P6WD2G S^+_@O#S@M:,=T#'J8>.6PY<!X)@-OU+BLAXNU-L8G]]IE_/L
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MN\VG#*N#L8':.U6Y)FUL93$6]$E4B>,O?WA+RC$7-M1!.I?]_*OD\BLX(I,
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M,,\H>0S'TZ0BZ6 \D%XHT\<O;X:]2CY^S6QK@/HQ],0P'_<\4>BOAPA!OA,
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M%>D_?OOYUT+D_-W"*F\FCE\P+.<PWFBC4_!8O@2?\M \"<MR'V_DU LZOK$
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M9>OW0;](]J]5J?^P"(%V)T.(;O:[#EH63V9# - *JW !*"(^8#\<>[G4#<Z
M?;(HTUR;4*S"^,'A8G.FA4CT1XLK^XG1#WS"PU,H $BS2T!]>G/QG.L%C[7V
M#X]]N-/IRJW,+3_>O,YC:T#/5*KP#$X/0F2"ZJ?J44I(W60$ORO^51#52ESO
M^&I-3HPAW0RWU/T^IOGA-#T^4EZO-0K(QC>JO_*H0(B"/$H-U2#],36&9?7[
M9LUHRO*-X"S)A.OZ]AIFLG)KHV2K"?"T8*4_FT8:)OW6&(T$G[#]V31R 4(
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M0>_^E)D-=9_[VQ?V/J[0%?I^<N6R3AM$C+Q2O4T 3L99W8YN(O'4;@[3]^I
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ME!M,G],T?W;\67KH#E]=_+/SB?UMZ$_1WJ#>LXN0Q0M*.^%G_&ZS'@GO50A
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M9C6A4?AE+ 6XG-+:IJ3YS:(KP?KOSD^ 4^L![4DZ3%JNOBS-&I*6K.PC0XC
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MJ(+&G7'Q=.4$VTLQ3\0JREB*;G7V!57?G]B%_B,DE1Z*29G;]IMC0J^MKE$
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M)_?6)"V:-_Q8X[)7RAQP3S3]U3ADKN@8ZFCTUKF<O?PHK]%I&05>96AI,.F
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M=A1!9:AKL)D+$VT<4Z#((]SW80X:#]7VD2<6*F5;;6Y=W/?.G$E(/,L^>B%
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MN\)00+4I&".Y"5+!L'$^"ZS#(MM._BPJ61C9="T:;:/_\],S,@S[(N34O+N
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M&M%IIP)!8VM!?JD;7D2U*4H/%0!V08R>"4%0]J BV[9GY=";=*\__?Y\K*.
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MIZ?F,U>:J<!D:[L*TLEE%\)STYNL-4]?.>GX[DW?Y:_.._+9&5+G5:>E)JF
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M?5WIEC;XX_#_ <;HWS>H+&P4BC5!1E"!LIF&CE31)APTP0<LU5K[N/"MC:!
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MB X769F)NXA)7CWW,@/49<*TVO!_0(;V?SBC^W\0_;WWGX6*__/NQ O,IZ5
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MZ54&#A?Z0[B>%;?5/?DO74Y7&%X.%2Z"":*\G:S]L>@R<M6;0ENEON)Y8M5
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MVGC [NA*G/>*J_3VB54)UWH]?KDM XGR_W21PW]^L/QK]:W_C_?.7NW>2$C
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MUW+WTM!4[S/L@=WH(MYLGML*O[/IBMW@=+1H'MLI;)Y@GUVX,O*YJ?5E8CG
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M>_46[#\+;K- M9Q:#0R9WN4V!, E:)]0>//%6%2M9O(;@EV/.,@6OQBQ@%T
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M=?,0@?_\F___<UA.UU'5.V?U?J KU@6;;=,?BF3_(!+=XX4M QX&2LKM7V"
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M#G"6[C>BQS'ABS6+89B'%B=*8R@G\AW7!+L9GP0D[=LE@Y(]+ 97TQ+QZE&
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M2TJ0V2$ ;8_997 RWCI-L(3QD+B74:=4,HE)8F;9(3:9VW7]8I+6F^YNP"0
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M'KH@?GUI"$*H[7]C[[VCFOJV=N$ *E(4 0%!("@@*@)*E1H0 1$0&]*)2C=
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M/^)&7HK;11!/W6=5-KJ*-1Y'$XJ:/8WR1@LW^G[4&=7RZ_RFZ4:5@25MAMT
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M&.)4_(^9"XPX^7^2SL"(^UNR,UF$P2,[;Z-C2KUCXS$Z5!)-8(+X["8=C#^
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MVQB_N_$S9^'3$3UN>&ZM3Y9'[AQM4$KJW?#PJ,6[)F]OF42-9 O)2V9<9@K
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MEZ?Z$\390(M[\DA):\ZUSSP):&/=ST"%U9'QD7A8#8ZQ$W.6^<80[&B6EB)
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MY[.SOLO.$4)-8]E -"'X AMX*=W$!M:[AMB 4BX+ZD&U83V"\W'@BB&<$=2
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M^1=ZI(!\J.@-P8.SV03IK88ISNXU/<)M J@7B_+<W]T_7\MA?K<U5SU@"YG
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MY?M\^STNTY94,_E^AR;HGV(;H0)UO+0X'>ZY373KV;-Z4N[FY>^ZZ\JU5]D
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M?._;0BPY>IYW%@JI@WF]#'"S*/NF[W4^YLZ#>;]PB6X[23-9]92@U,\E;S6
M8I04"#M.78Y>UM<1]Y"ZLI00\%%[OQ^_E/M-Q?)B_D_&$?UBR4X26U^+9XAG
MT.X.5%G6P_DG/7XNUY?<^167%JWZ/50H)7?$BKM:<Y0ER.KDF J<6XBI%SR:
MM:/LFQSQQL.V28/^EB,MW2KZ\1^^[_7.->9R>?&_P,E_AZC^9\0ACN'!+#>%
M!'-=?D6-3EB;]SZW/R)W1/=CP_BPC.O89XP#P62>A(F9I#C:2(#KCJ;RX$[*
MEV7;?G4U[Z4J1Z65I7,CUD;W[H8(_*80ST%<>>/.QUV]M=HZ>T9'6_._I]L+
MQN2FG#(&3+RFX0DHR@5T&&P[@^[(L KV+L8GTR!";\<U$!:8W6+=5X]<9Q+
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MK@VL/SF07_<_V'O/L":[-6WX1I2."$@O4>E=D=ZB(DU$Q(9*B8HT$5"0'A)
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M0*]_NZCR[T \_QO G64\; !<Y=Z&&(>WH29LU49'A;JN5F5&.T:ZKX.7,^Z
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M7N1($;GI@]^@TW:B@"]X5-@S]\,+O'=!$9OUNGQ&Y8@OU65E8??#)0Y$ZZC
M\FC)?['@T/]D82)K*M"NQ&N$!0/$E/8AHY\=V8LI6M'H#+?;#YR9:([*B3Z+
M=J(X[WX-Q.U?F3B"41DM[XR.5^Y@HI?Z/H8S:H4092Q73]K/Q(*,$)V+I>C
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M40>;8K/[S>>'>.;CO7E!TZ6%JR5O*VJB6'T3F4Y=3>@0#+MQ4.X/ E;/@5)
M-$R"C:.($3I+J  S" V)K/&/RWNB__VN,[?N5/<;_$X*L+%T^+$6KG[L.VW7
M:$@'\YP* +<$=(2P@5I]UV(XB.DVA75-4K7<E^ZDZ+VX$6!9_H\+E*#?P>!;
M?PVP_S&? GX:S,O[0T_&M\L=/+OBHA[BYKFQNUZ_U0,W'R$ZTAZA[GX"^3P>
M/NN (M!?'OQ9A^>+4DRW('E5BG?8^<@Y.$F(A2J<=+SVA EZ]$8_(\T_E2/)
M/-S8Y$B\4C-%@%!=X8<S"S@_Z%J9'I9D^NE3N'E%>YG\BWXQ_)<L;-!Y<3N
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MI@&5$#<?;1YV7V ])?!'TR>>Y4R^_328$-'<SLK7=O27%\V )Y+=(O4^>=P
M9?$L;EKFA'_^M2)965"TXX]J_+[U,4/[);8J)R*6A/+;_U7+7I+!R[MXI))S
MLODYJ[ QC^4"XZ6T*+G)NTZ(;!.)A\<M#,[\'X[AR[=* [OB5ZG MTN87=V
MU3][P==OGAQ]!H1S['T*(D<2(%AXPB**$3Z7X NB-'N#]ZZ\^F8)POM03/AH
MIK/":$=SK8LV8?X:YCO^<!PD8?D>?,H9'@Y.I-EI76]_]A\VY=E#4'\AWR"!
MZ[&T'L[[I;*J/&@UF6J.-Q#D\R;SF '069(S95KT^'[\YFWYZ4D*%UAXB5-
M_IET'I/8E7.9N%H9T?, 7>WG$_<.?=WE)#A26$X2-F965TK]9E?UVY(5XNM\
MPD4J%RS,;TX)<&E0@<")ANA9<$>@RVQ$AQ*7[WP[UVY:9I7W&%NMQ'WS>F%3
MRI<3-T2_R*WUC9=2F%9+R!?QX6]FW"-MI=);3R\=0WNZOUW<;C4=B0P_GXID
MY9X%28Z*Z6!#*NGPL.!9!.>2K?+@?/W8EFGACZ;0+OFQ<FW-Z89$*TF4*Q7
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ME0,@0!ZE!AG19FM]OBSI&^<_UPPCJU^/]/%2?Y>"GQ)?D/?Y>->ZA)<+MAZ
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MF_/]ID,!=AC$$?K(>V8HY07[)(55_-[519 THAGZRO=#UJ!PW!Z9EK/'5W.
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MZ>FH!B,:5JFM/!ZXB?.P'%FK#.]-_#LG"4'U7@"EH2@DT$X19ML#M>6-]$?
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M/?\+?&J-.##SDS)(>G)[6Z<1XWY43G99K$J#>3FB2-W5QNHMP](/UVK=M-A
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MLY3<?8U(?R>$C\_+7ZKR*?Y;,J *LQJG5V8_V@Z'&REO_L\JYL\UP9X?4VK
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M=3%'W\%%.+:T2/)W(&9GON?%/' Z>Y7K_[<DY;^I&\4F:3DH-DF31PW.Y;"
MA>=]C(L#Z^9_8WT]B%W6U['+^A:^<FS1_G=M-^*1;.+G!-XE?G?8Q"_TY*;%
MGR8)VFD:,2Z)'5X;E\IV." BU'GU\L89DE-3%9QVEJY.#MUV?B9*(DYYS"Y
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M*23=*;QYLF\&!6\]PIP*388H5]ALX=;489LI/LGRRZ?U:IS=V>IE+VHZ0)"
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M]"/J7<[\KK^'H\3OMOUV @N!E^_THS9"'3<M_GV^R#50(+C0FYZL4HNCG=J
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MTA!!T907)O>1;_?0.^GV5!TL_2#U?0Y5N''OH-.P41CQ1OL]T6NM7'<^*1]
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M/T%4?:6.G4.+(*J !'5@XR:-=U3?DW:.+I'D(,+6?F4RHJ_-WTUE2>0B*E@
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M-@_E_'%^<&#QA NXX;&#M,1A_%14.@ZC%TE7.HX+&%EQT^?ZO/VU!DH-:.[
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MY?W:>?Y-/:,@:U0FMZC\BF1(C8/<Q.,W?]36$JK[.YA_M)+'9Q_&.M9P%S]
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MFIP0&ZOS9<G+:'PDIY[W2-,US<T^Z'V+6(/3,;&QQE:[,7YW_VO'P+172<I
MLB\/[I):5 :K5FIX<3A ]TKZL-ZRP=?LZDA%:!PUC9).=<);+4B$$WHSK=\L
MV ^HU42GV<WV3=><8U2=28(7^5C6005C*QK<'?GWB[* @0M;_"P@ !H2WN$^
M>BE>2HIB@:N;:R-0XR[6+D"/'*?)^K+U69EFX;>M <JP<]&H]8.;#BX8/_/1
M<WQ9ZM!F#.D]LAMTS*?G>05=PU;6AVC<<FV33VX"O64 L:&=H'8T"5[TG4()
MAR5F<:V-MVZ,G;W+UZ,TQP)<'LN=?.@:E_@Q=_]642L+,".;Y<HO\^AN_^I$
MCV]I-#>"BK?J85RKYE4&\*^&U6=[]E1(C+CO32,_LM8A@$=^_?[YD-01<@G[
MQ*9$M%?\R/K(EOT)#&T>"L>C!G'X_N""U4\U [.GX@+<3126"T*F!N.L*_ =
M'%3O6O+++D4-L-Z)6B?])U'HOL 6NCU%=45J*HM+BI;]GGDUH';Y2J(P7:]X
M7H>6G0*+QKBMA=$E<,7P1DW%9!$XWY N_>ZPS&?BYE%#?="WI*0!B@IY(.K2
MT:4FYA7CAA6I6?V "Y36>(!Q4( B<VR UR@W3SEG$:>J6#/#M'D@$9:W7<2U
M*573'6>T+>84,!?D Z-(4WU3GP7<4&,@'[70;&MOKR\7$/_EB;& CU/MMP-A
MGQ:&C9H.)93^C$;F'( 0G) 16Y>'7/@XZ5Q&Z.1_\9Z\G;P,7NFU$1P30^%0
M#6QHLP$Q^WL2CO_90^H'SAFS?2Z,66?*MB%+$T[_]G-]!WC:/)P%<&MZA.\6
MJ(O8+4J$-OASA;5R%O#OZ[!UU:$J>U@ %QUMR<%<TJ?+T=^P:5&_US\U*>U?
MCX>(:Z0 ; -X#S6NKNQWUY!3DFW[>[4++4?:^+4;_/%1\#Z-Q]0%/P/B).3R
MR(_U?1+"I5E7.O#70&TJ%)$LF@;=KSB?;/J1Y(CD'_CD/Z+]8&7M*53-(^K7
MKSWW.D,Y4[$+]^IKSO4@K#XY#(^C?8^G93@J+W@Z>7.XZ#[V/)3#E[H/NKY-
M>X0<L  1G;^:.171Y4M(B9&Y0?67BFR^*4XX!7*$S[QN2&4O(O?TX2NJ)S@4
M* &,2N1E9IN?61==@G!A15U=*/FYE?4>3R?AH[IR03=U8G7/GMBK*\I_#=2E
M(4#- M&/9TX%-7U#R$T*GGE8Y#!0H3DG^"X35;^XF\73F4O:;?Z[?V""_OX:
MJ$012BBC:V*G4 RN"?:^D*P"V%L:OU-+4Z;K]3+E$)PDE:B2=S(R)58>^A&4
M6>%C3UZ<#CO+H7 99"HQ'J@A_G?7[LO^&^(PWT4<CY^R]6^Z G0WP_W?YCD!
M]#U_#EW939F70+$QC/ NAM%FR]2\T\Z]?ZB$(-\!Z@3M"%V4NDZ)3(;7NRWX
M35=(6':Y.3UGHR3^R6-O:3]S84).$_DX(@=->K&(&CR)CKJDQ%"U;(MMZKX.
M=YWT2NB_\0C#$9T1?>4Z[&LO=&*:[O9QYA@SNSW[KM]53ZCZ2:+=-VO=C&GW
MWOI[7[=S[<9 '\'<J,EOPYDA)49X;!3SC\IN)2FO(Y"O#J7$0UT8\URQ,VAC
MDVK7Y.P5> A.N.H@.5OW9%A0E5'F$BF$1]1TC>"CPU ,R=\-WGAK1-:?1+]
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M9W]JAN)@SGFI52%/RQ)4\?!*T6="D,Z(=EE3+]/7;\][,MP;$B(NY/)>_K_
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M/77C9*A^ZYD( :/+K6>2 8Y:TXZ-?$2CA5591@;2TL7'XZ?W.^O[OXH:I-B
MMY4>KV;=%YZ2_Z_QZ/_V($RMZ;]8\;G#-0;;(1X2!A#Q:-&$($ _!3]W&Z(Q
M ^H0C1DC031&A95P#:(Q_TO'IQP71N&=#..,!\X^O4G.N7/E/&4H]=FC3O:B
M$1'[$&_Q$81+F#HI@K 7?>E$R"N\K 9'+L'<LOG G^095N7%X8^(8=<T>C!A
M))40(C$NW'<J>^G9\/5L0C;"8[MI5&XZ(N=ND(ES+BX..40J;5^4:\X03E:G
MR)3?/RN7/7#&KN*=K>\3+H,AL_YQ0C@(V3;G=="2*KU(TY)>(X@N& :Q@=!
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MU26J!#%4G,Z_$!'OD3F?WY@O^^.]C0[M;-*\GGB RNQ_&#!"%")(8^J0_A=
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M4=9&&[=5O\$4JMET.WYRY*I0FNTV,Q42>%MG8D+I$18O>^JJM&81*YDMK?>
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M:TIUH[GHLCI3C ->'T?-=.7S"B^9ZT3DQ1H1I9TMDTR7)&KRTWS22Q&^9(3
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M@O[=ELX^'@5)C]6N.>YNQ,4$2&X7>(>QE+PZK;X4L#:WN;I!K" #?4NRX)^
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MJ(9NHAOM2#R4SIG*  BY3Z=RVZS..<\T=U8E*?&U6B%L*:BL'V*5)%Q ?E+
M9+$#>5YGJ]X3PP XQJ8PM&,*[.#L7@694DA^+#PTJC)=@<K" #Y\3_^U^A2C
MY#SJ.+GYS*A6AB)B=N>PAE@Q,W1OYZXE<A!_*/^4/9R ]?ULDAT"+XW$KL5\
MB-XQ7CK;:15R!$8]")\Q* E\[1G&-P,EXO#,V/D<B@D#.!2)"GM032NI/63Z
M(T>R&<)5^"AR9MPC?>/NU?ST2-O^-^$\Z: U2]"ODTOVLWC-E=ZS EW8$2Q1
MC![\)I !H* ,("@/1\-B[2CC'ZFZWR3N<(U91,'.\RN5N#M?B6OTW=_Q+,P
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ML_FN/%S^MS;U& ?YW0#]"KT7"JG6?_1EW/Z%_= Y\VI^'IGBF"H/Q</3)U[
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MQY>>(UQ)QZQ%/\G_VEHS9 "-20@1!J#)\9 !U*DZ;I1&O[C>]WL#^?&)A\8
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MHP>%!S( )!Y4L;EO4(68NJ43G2^I\L2!LU>P7H^+T%U%+U>T<:HL<N<JXAB
M<]VEE_#.""8&$%BS;PZICJU0R@'0U;:Y6FW0V6G$9-7!47?#%A<-#[/\?#'
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ME6B5-+G&,6'Z]')-"YJEN??[QA.=7]FV8U(")]\<](89.>[\I%76'EZ$'F
M]AB!>9SRNG:F@TK1XNZ#90VS?,DWKO5KWV)#]UH<%YPI7EG-L%UN!&B<B'$4
M:9$$&XT@4X=0CC"VT051>8K7E*/>DH!:QQ%' WX.-\<HE:_%.M>TF%A,N>O4
MCAX&:)]IH52W+]2;M%CD"8=*M;XV9D^6I'=]J0S \*4S3^/%)V]&2=\$%L^]
MQ17C-ESV-)!##("7 =A>Z8@C2KXW[VY8H7;DGUF5J"A.*@QK4=[+]SXT*ST,
MV F;_+R,HA['$I:5O\8E'R%:#C;ZR;ZP;($,>LRA-X(!6E(:5I !3)'1QQC
MO"811=MP90"MV: &&=W/N)G*7\\ MKMPH/=+@8S<DOF-&F8E?P$O'9W]XGM"
MJ-I?%BK5MV)KE*,^V#\VD$O7>^MQ0V2Y]8W=(]R)@[6?_A/E#?_ULP?_AW8V
M6D:7XVM27OM5C<2[3$M=#. I?N<4'<1AS'&0!?J[&U 5,<T]NV?A._>J&0![
MP#99AY*38][AZ$9BE\FUUQHY%;^[T->:RO+"<?K\I7"-&K8^T[/R3X:6OA;N
MT!64.TFJ#A^/6RIU':^5VC)6Y_@KCCEM*4-6IR2DFB<XJ;3&CGK5$NCZ^;.#
MNA5;JD9,:I#V E2C-/4A2 IB&$",4 ^Q ($5^O3'MX_$'I8SA/RWZ0DRG1=N
M8UGTV&1KG>HED$_1\'NF&DQ]SE25R1I^O<$U6(F2T!6=J8K*B9[?E04<-M\O
M:50/;7DU7[IT[=:MKLUE9,B=.R]"O^2-CI7OFZRMSS\Z'O#_I79WXAHY5W>*
MU3Y20,7SR>/,-&^8!&JJ]?(<C:\&!HJQ5RC2+NQ/US2' D,"I-GY$%6R'W>/
M%!=\$<UI]KWIE4-<$.LGKZ/G.] VS+VLOUFIJOOY-=/*]T^YAQO08=I__@<\
M_U*/6*3>56@4ECB=Y$(/G@!5B>\E&(4&_=,U\IM#?$Q!2.;X(O] 1G[,%P6U
MC1\O"EN^FGU"7ST \W>!':&?=X=.'XJCI4YBCMN+2I;>Y4A27I%P+^[5\5Z]
ML5PG"%";00@17D)O&F\R "IW&P@J2YO%D]!& 20'58"(\LD<Y#6*NS:07N@X
M3#@OVWQ(A45\6N.S$OX_<9#V;^0Y-/I7/?'[YP;]#"4:1NQS8NA6"YX!Z.5N
M3F 589-94% W'X(MA6'I<28+-<C"9M3ZG2?PK54,/39<$-J2NX@]F18LL^Y2
M\5]_KO&_ME'>3@=2>< WI_PDP9N0*FC"D8D8^>(7\H+=ZG(2IM^"*SAM!/9J
M_?)?8(F_QX7HP6';=+9HD.F89%-M:!'(,]1KE"0"Y.A\K5I9_V;53M,WLYK9
M_A-QCT./YI:\@AB8$T#_YDL'I5+?[1(&4+?70S]36Q07C+#SS1*6%WTUXWLO
M_"/97&[**\YP\R&,A3AT.E3&N/MLPWW=BHH["Z5ORN<WU:"3L&5#F[W[5N[Q
M_4O-;J*BHOQ1)R)3B\SH?7,"UR3EJU[.0. U*U8@'^)RZL/.9^-1DY]AE"WX
M &HR"<^[:?L9?+3(@K+<^4.&3B]=!1!V0F4I/8:XP9]KE#^PH;!-0SD846-C
M?S,3))!ZC4 7Z;"?_20I-1"H%)-#R[FD3IA8]S(H)52'^%<DJ.;',X!GAH$E
M,P-1SW]]"U6II%LL>YW?.TOO(N.+\(UOL8='EXHH 5?"[ECJC.L_.REMI1IM
MV]LUT-[M,E$37QU-MJ$8$&!^:,CS$ACOTLNEW=#*T#A'5^$B'68G80=>1<!=
MJG4@?JNRD??3XV*'_E9KR\7!(0OG=5VO'U0#$?]4GZ:>(_Y?OQJ&%$7IGY5?
M4+\>+%5@_>X?6E>#N$?.IOG2U2G;Y ^4&((ZT]1/<GK:8OS6^'C2J.68=!?O
MCUO?CDB)G=P^B'WQ- 4RAZ&+5.WIHOKD!F%$Y8%_JUW/-4[[@IV/7812A.Q!
M ,K=/08";C*6\F9M18(!W"S?#\&.&=#5M?<WN$2!6&F1C9IT O%2%#-_/QB@
M>X(S9PQ;$D?C&;_! )B<P &%$E?PHWKTH.<@-?,I0U,]L:FWI)BF412)B'J8
M$/40#8VX-@7>8)[7W<WT.TFS>=.XN$/8/\51[Z9)Y[-&EO27.)B<5^1_9B?B
MOW0MYO]N_ZAF/%@JY 2]4XFMCG%:D7ML_SMF][24;*>7-^CE6[#$>Y"Q1=B(
MXTV_AMJCRC@\C^O3V]FV!W4V$UP^2$9>OE#8W:3VPJSB )PDUBJJ08(V87DL
M'>DR0VO5U_+&E1><7=E&S2#J!]2/V?F? %X ^3WAZ..N!N%H?C7#Z?Q'(P5;
MN;@*TV$2I]AL\*GER*\GR>:[DF0ND!>\7<269C3WO-\:VZ%>(:XVN#C)S7Z#
ME\)O'^,])N1CQ"[@IE/GDPBT7KD*>XQZ@GZ/)I9B;5$!M5+VG#C^>(EJ-T7>
M)!RW0C3(C+&1-9ZS+Z&'-(Y0[$!&D*]0KW&TK**TMX3V6VKUN:B;[*KE<+%H
M7F>7CS>;ZL$J3V!'C\[N0G*A\ZDL^Q/JF2?N9!'N)XN6UM=K(&_C=PZ<H>I@
M0)ERR'VZ"<95?<,1XPZWP!+IQ<]<^,A)+WK;:]-?17YXZU<O+$C_H*&&[!8%
M:!EJEQS3W!F II-5?[=6\L_TRM@)/8_#]:Y/AUTB'D8X4"-IWV&3GT:SEO&I
MORC3=:-AN& U-B9(6:-[+GGEO.X!RW:@J#7:=^I!@9:6XN"!K3DJ;RN=_2J^
MY,@,C(LNIE2*CC"67=A-E!8+,65G<Y52U6T(&X;'>#\^.,VZMDLW5U,AR.DU
MB)X<<.T27+>$&0\\MZXJJ7HW-15S0E%UFYD)WK]6APDB(IY2+DWBA2U:OH6Y
MW?9=US'Y<K\H0OD\?2D WN!]Y>O?F\/M7[9<Z?^+!OL;K.@)JOX.;&:AEA.%
M$T+1Y#$#GC3K8 8PD_@#NS0.I\D)7X2%F?Q$7ML/[LR]^.?;]K]N,Y$D&1#B
M FHY*!!C4D1(J7A_B8@B3-%C^/ACW0/WCKWJ[KSN+QSEF(=I5J#(M*Z<\B)Q
M3+^@V&6-ZR0+$-T-2J[GKS]<Y/))OLX*EQ.Q%IA']*S=/01?.<L 6&PHZ22+
M^]4#M= >R48T^_.SO&8?7"\-9"Y(SG5(%@Q_,\G\O01/9P!$?><0?A0_]HDS
M.WPQ;F/1<^*S7'=,MJ7EK?X.\<AV,X'Q(-D6R?=1=UXY$MVF\(UH'H0I*3QA
M"LYFKR(X496M.SLV:E&@NV6KSG>U358'.*A[$.NR7]J1 13%A6&?K 4DG^Q3
ML\E;B.M?XE_(;LY:L!F7Q7>PG5DX(?_[CT([#I_B7#MO2+ZC0K.H6"$1%>#J
M]=8P[L? ZZI+F((,6/TQ'<LQHI%2CI73GA95LI:R0#1H1AX<H%YC (>;=E>R
M2YUN6WBE=T1XQEDF#)P:/*9&%.YEG<H*0$VFHH6HO"0Q<Y)QR/25:<>O#BZ+
M]^<O)P:L&="6_3OU>-'CF"NH-W<G.;GA7U&%)M1C=@WP4CWMJ7SS41@;XJ9.
M!P.P*:G*7_NI9;:2N*XC<$9YQ[N-Q5L<:88<A!(-4,'HHI7$^.Y\>V<"['#N
M.SJ^+T3M[LP4@C+,^C[J:AO+JZN<NGP;F3Z810T^G*Q2DBC92<7H6Y*\D[-<
MXI</[>\4*R-[?5D E.%%DU!D*P. 6M,RL'9X#LIXTSV'XJ:AROQJV!N9'^%M
M+ZX<JHO4MHET')G_N]=P_A91,?D+JNRK-TE]4+VUJH/J32\S!8)?&[D"XM0D
M'L0I%?J'QK_@U%^M$3[]%UB7^N_V'\98GO95/K.0]HDN_] BQWZ:&)ZW$)X2
M<LF#>IG.MZC4@[A)3*-L@/PXJ%IQM?!,<<:X?8N6 /N9H'1P3M1F,^VX8^89
M %F.F!'G!WN"?S?J%?I2^UBR<%$M2OR1N<7[6 \AO(*,\'87ZI)G2[1;RB*N
MTF93SMG+YLJ8 8>K+G=P$3J5V6051>7!D3_T(\\AN^,5WIVI#E.SG.QP'7B>
M9UD7I7?SBM.<YJ*A[7#;\@^7L(X/D.+L?<%QI<F<)3"8"LN9C\^HM%R(CRF)
M=3->Y\R+U/$7T=F4ULD7)&%'.\C!?3!; ]_1M1!7F6R3!^NB>*U"6U&;V:6S
MW&F8^P<:SXOPF>X=A<R)60Q8: YA-LDOQ<P?ZAYPG6\V+=">A5?#B;>2;CG=
M((L1;[OP.Q?]6CPJ!G/=>])Y?EG%FHBI/YOY-LC*[$1U>//GA!S)*,?=_<4>
M!(5K::IGV9F(U:W1CS.TS\^IW#ZX:"__ /JB6 IV"]@5_7NCEM6Y?[%$LWU+
M?&P+6N*7"R;[9VC_XZ(>0#VP+Q@6:O<%PQPH&%XKT<[B0!7RUU&4_T5U.(GH
M40;0C.9'G"(R -TJB@KH-9S<@_7O/:[T6\Y]689K_Q@[VF0]QQVZA_L!.I0J
M!O!\;?<H;#V,GP'PP]T^O@@04VW(LU0S8K<OR[\<K#C0CG_987@TIR.F&7O3
M&.SKQ/U7.\$ "I09P*XE/'.+,D4*J8.5!K8:"+JCFC7.4EYZR>>G?LU/,!]N
MY0&*//Q>!<[]WD],XX_?<T/U^C" CT^QE$J:@=J4O>TE+3.?]/#&C:EI)9FA
M,,Q92XO:Y$"^R]0824E^3.2NI2;B_-X5JA$MOUJ3%-T8CVJ*8&4 MN[2=I\<
M5. CD<VS/LS^&B^:0G\<?;T&=\$1+DWHF8@U:4.,2R^'%3@.Q%T>SU7!ZU>9
M;N8,&O'U.P[N)[K:^._-!/\C</H-F\YZ+TFR:\%"'4TN7-S +^%P<F);5PJ$
MZ:;J5TPVI^"=/2N\4QZ@K]X@R/N[L/GJ08_"K_.>V+FY]BWB<878<#!  XFQ
M[SFJT,!K!3_D*4JTTC<O-ZM!Z)V J4';*ZH'J=F>8?UQXTNS6=N.FX^QL/WM
MS[!C)0R !]E=6>Y;O65IW6A>4J3TW?G3V,/'-S] #,[=KAW3SD=Z_R5 S"+B
MHOF-="8$]64Q-A*^$$=4S_^9M_3]3-!@;CK7Y/ZVAJZL%75BLH(/MH0UO/K(
ML_6:V(@<->,P%;SR,O.'5?6>V(4>9"E-]@+S_<[KV0+BFWQ4 ATT&MX\C?/(
MGS >-9.,V_*OJ_(-ELEQ[&.Q3YVF]5Y'&FR;/>)4?Y\"Z8-03D.#,JLI<))"
M8^=.^<!6B.,,7"N9)VR']ADE39/!="E03D,"?I=2[$@J5D\__U'[<^59E.&V
M68I_DO>N5RKJ/#RCY._GGO\=V?C_1SM  1&9Y3'M P8I1+U522F=JE$M]ZO6
MD_(R7%Y:'W:0VQ[QGH^&)JI0-^U8!1Y2E2:A[ZW$*1:$7 4>=SWSZEZE#N7Q
M(RL?_84]<Y;;/?G^N"9\5!-UQTJ*6!8Y[0QQ$.3"9HXY"BJG<OLNMJR?%S<\
MM2A@L .*Z8_84E8J=ZO%MY\*6WC?N%X'<\-H:0K\0<7ZZB/U?K:QV4@O9G\=
M$;,(<:9$ROZIE*^4B*FQ$T[5=I,U_"T*)^JK2I(V1V:W$;*1<[3!>RM6Z5 J
MOY#F^1S4.Y-%RH[O4O95C=8? I@N-!39@^)%'F]?(/0 E)!KFJH;:Q='C(\S
M@#>652?>^CKV9#-M9K5"B18808?8^YI3"@&C"H$% F^"MO2O6][,JC#2T?*<
MOB2BJD3$M$1$6%VAI:J9(C2G>XX^7"I?9+\:]>ADV0WJT:846<>Z[KZVF9D-
MT^0C%#L" W@?Y^@X!>=PM!*OL/81C<[J>(6/.HL!D<<.1A'7;NH)XH_U1#?9
M\TZM!6P'1 UIF8$23.U=J,WC'C%%X?"JPRD0(=H[V),:0W(VI>V1HWJB7]VH
M6M^XNR]EUK"-]?2X!=U3+RQ=V.<[-A ]?WUH2$CH:?X*04=NZIKP2ZU4HV.<
M+,!KX$W!E4D&4(\^C#A$5$>_J^9-;TQ_.L0 +CWHT%5[!_2WS\6Y^,1J>',"
MP$KVWP_@?U[3^;F?";\T@AK?TV*PQZN$IIV*]X8!J#_O,7*E#NVG!WF-WT\/
MXM*'W:P4I'^<_Z?[H_]N_VYH6] 46>WE*==)?,AQ^/&2'U;ZO,VW8BM#I!%E
MN-Z6[._J0*SX?=AH^(U?)LNE+G#N6A'WMX0>7U<4FWN6?HA1;ZD.)[]R?WC*
MNH#!_\'>F\=#_:[_XR])$D*R)491REHB0H8D)(T6^S*59,M2$FG,6$+V$(HL
M69)ULF<=NQ"2960;@Y1EF)'&B]E^XYS/Y_/X?4[G]_V=SWE_SN=\SN/;'_<_
M,_?K?MVOZ[[NZ[J>UWW=UV7J(*'T;HYW]X(VI)<!-*%BM11IKY"'+7U[FGUF
M!J]6[SJ>^4*PNO[),RN19WPUHJSO)0)T=NZ 6M%Y4,WV2%ZP[E(05-QR,7W'
M\+!YOT?Y65J"ZOW8W4KVFOALX9\J1 QANQ;7 !A&T5RLMLH+E4,C'DV?GI3R
MBPZIB5_L52?4A+-(LM*MCHUJ=XU='@/G Z!9LC#PF.HRX1&0!(W8.IQ/4$T5
M1>'D NB)_;[E]#W>%#7?JR+"5!W;6WBO*ISA8(FC8]-WT1Z.S7=T;RH#N*(-
M><T JH2H JEF8#L^3;<Y@^M!:C\'Z&,2U?RX"%X;?6%&\ME 5K9 B(5GVZF3
M.Z/09ZC@X(/Q!OLKE>_>526M;2V:!G'Z\M;'?VB3R7H[%V\ [,T9Z0^@BX$9
M,V%/;WRJ/Y+I(BXY/$])\G.KNP3VJ1[D2;SPR#Y (X46S;1W4,P]K3)-R_"0
M1TH@SKNZ7>NDFV\)I@I*50]L[+5&&4IWBH9UUVCX^"\"6ZID%9!IQ7)A*1J@
M>;,Y&\0BYFC]\.VH.96Y3D2 .%Y)DOU]U 'RV-]A__^KQ8;\;G]7*YAP?FB>
M?-(&YNBATF9QLE?J8M^+,\)2M[UZK?Z !_E?V?7]N_V-C80+SRA=;?:(XK>Q
M\47C&X-1_IY&QB@VS!>%.>E\9_SQ0U S]*VL "WE1J98,Z#W)=\-E6>U*!L?
MTBGJ\_'W2:+)PELSB$:0+YA6K*=-=9"[BN6A@]Q&9K5QPEME'#NJ/T4]-A]Y
M;L*N,@T+1?*!\-S3+YD&#Y>SN-"[6R*$]<ACA,11+O<; >X>7@FV\G_O#:A?
M7:),;OM%^FE#,+B_+ -47_A7LJ/]?Q7<^MW^5S>!/L0%$CF:B&[RVXBDZMR7
M5W83[#,:?_F8H-<W+/8E9C]+EQ3+2("ZNNPT3RB*:*'(2KW$A"TP]C%?SC9!
M'Z3$<+'R"_>CZ3OB-'](75QFZ6/QO'Q6=G4+.);5Z$++@4YG,H#=T#NV%VV%
M[(85*G'[S[,DZ'PZ;!WY5(E%W/64W#VBSEAOW4[>'+YG/+E.Z#Z"$)T33BSX
M<=7 &\KF6WZYW)&3_#9I['Y 1GW7?'[3:A#,AA7NAC@$#D^C8[5X(MOH.[&$
M>IT<C4V8E(BEQ#/@TOV.)F5W%G97P%/GNT[FWJD(V2"PES38A"M??0)O2]?$
M$M;E3_DD"KT0F7^?(,+7?B"H;ZI;340:X-<6(PAL?BE -=]M%+1>/"K+PPI6
MD;NL(4[/K<^U.;Z%J6"XXD#S3PR@'$98)::2L^OIW<21/.\<WU17*%5R:\Z(
M;2@B,WX@\8[A!1:U"W) UXX K:C_L#[_)X'%#P80#1>OYV#:1V;8M@S>2ARH
MOVY=.#2(KZ$<W-#(<YJ+NW;W9!U7T=6#<;'))08?V#.OP*%4>5H#<B?5B33U
M<AJW"_Q&<6Q+24XE&RDN1X*:_0K2B?1'-ZX+&TRLM:HUS07"M9G\@V  )"/R
M3Y"?"._TRPA&.,QF+'OL<VXT'UO&E"E^6Z-^B+^^.1/X[*N4;NM!1_9G>G[L
MS?!8NYVT+$U9[QE86.TJ5>J ?/'2P@\;6LQCM_*B>Q^ZJIP&8@0M^K0[>[$2
MTZR?_MFQ8[_;O[=Z=%M&I7ES/_M2]9A"#0G:4GL9;7\\=+'CAUGHF9OWABV-
M;O-]=V(=/E8PYI[K6K1051L2W>;ST/R*%-'F7'.\Q>@NLZOJ0;LE*,,IP+&W
M)>XWRZOC'X=?W2UY=54N2L!47RK>=T=]P1*Y!CQD_U8EB@$(U?,)=)?JFV$)
MGE%JAU*1+,(KOID\5EGY"^KMH9@\G;?./B-CB4^6:F4+#<TL<L0+N@TD%\RW
M-\"TYCV*-D()=/0G0P01.L3^,,4M6NS5X<Q0A-_FW>;2U9AU%MR 37( 7<$7
M,O-<J6<:)^QD)V. &F&:9"XG)H5K_8E1%]/UV<5<BW^#@]_MWQN/(CA+,4:H
MT%ZMHZI]-]K-_#31D)<>>;M^>+B'WGN1:5/'1:H3U;_/K@)B*!ZHYG/UQA1+
M&X7 -U8]>%38P_)'I<YV=QP;/9&&[B\\#18EX8F&?18!K>.8Z2(<%\*2Y$'N
M)B(#IW$\+N)2PU^)#J\%:Q&[SA62*?B&#WC>VPXO0L0^Y(Q@IE/(N'+,LB-)
ML1/'FSYN#H;17D)&EPGC'RL'6FW.<W S /FC,I[6*R4&MCA$  +^7XA*%A>@
MN"&0J"_5Y'LD6)3<I+GMR9*,'%E ?_RHQI5WOAJ[%G:?/7_;!_UMM8G.23+O
M] @?\PFKB-.JF\'QX00L%=[(2_TXHRA5]J$M8U7CS+)P"NT\TPZ>!@N,H !5
MCOA)<6Y1/6TE:Y125SP3<S+=;X90VHF>_9%'Y<.T5FUA"5[>CY1DN[+!.^2M
M':V)#Y.F=N@W?IGPY\CDPL3BB!<SPAG #J3 !/CU9QI_&SG% 3.F\OCLB>ZR
ML<R.;\;?-8=LXGO7GNUZ&/?JT0:5GP&0GV%HKU!.Q3M(J[?#6FJ720M6A)*U
MPTZWW?)/*1I_*O?@CB),98>=H3$UF6.86[TMWM;Q7$.T0_FPW)NR%%41,T/)
MVS?\G]K#>]P U/6Y[?JQ\#XTH8YBZ *MP';V\[KV^DO1A4O?Q[>VDNNZ(D25
MW;+TA(6=+VX6P<YXUAPRAU0BCX-YCU671=\B=$,F530RPO0M0_4A)]*--3Z>
M&X7B;KXZ0/=]4*QN;'^]_%U(XIW:EQ(7GCU[_3(HR%/]]B?V,?AVH:0$S'XM
M%<214M('K#*4N[/0JG@^(<_EJ%G2_%&1&$.1_4\3.T9LW-5N& BL(6NR?<NG
MX6U+#:>_3X(>'5HB0UQWB097K5V?IH;IVV5+*+U3DPCBV(7)$Y,VJOZT7GA6
MO>^D0.ZKXQY<]EE9QTPA 3LP>Z'3:+L#E9]0=UV7>AY<3[ 8D//X-CZE+<Z5
MX?].'D!6T3] Q*#X;)1C[&[?&?_(@DEK4?^K:EB7XKGSG2<YOU@F^\5T+]GU
MP%_!B>?1_$:/B>:=6YQURG[(!K&)F[6*&>X%VM0;?6=I2^L/ _;(=F/P1<C=
MJ(';V]G)0_1B&8!8-OU YW0831 6Q@# ZTP031H#?KT"JD]5B6WFV9++X&$
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M=0TO;T:H_'2\!4"N7:@IM@2]](94W"XX5 TNR\_5OG]9JW_@N*/].I!"?\@
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M$WM#=M.1::5@$OW^ZAE9$*K95"$=1Q8C+;M&E_>_Z=@4"Z'5W0/?HA^#/ Q
M2A6/HT6F^- 3].V@#(#M&)':*$5[2I<>/Y?9PUU<_%W#*R1HC>-5++A#]9LV
MY"GN5T^<$^;.V0ORDN3G( SE^;#9=6;RZ*.]]T*L/[R@!V%RQP J$\@'93/G
M1488,X#WCO04@NPJ##SL/XA9GIR5M8]5@ H:2\R^JDQ["]T"T/T, #R>E+^W
MF'(/89+.6K/OL:Q7<$:*!J?3. ,0UX5G8X@7,'N-LNA=/MC/Z .8<+3"C%NF
M6"1WO7#?(]'7J,MY,7.LI-79W/%%B&CC(5NC0*FI0T-2;MFL1^?/W=O$K@I1
M^;/IE_+P<%KP5Z;N>UE(Q)'??/I*Q!$42=;&*5#Y3-+E' %M8+_J525>C1VY
M!EM8 I;*KV\69L$DC(CA7OT$#Y^[BP8?G%:E=3=GM_/;$/M!^61J:G\0=-D9
M1I-ZCP[%3"?6/JE"54NW@O;C92MB%T54]SZ,UIJY?'8M<@L[#B%:1UOM1G)0
MM09% FIJ2)P36=_BX\8-BN[]? E5WQ2E<_#C!XN17ZQLIZ-MG ^<I2W<"HQP
MC])Y!M.E4&_[Q4U\8E^I1$J@FO4Q3K ()#NMO/'0]W11,'F6A^=[%>;+U(6T
MW"6LV0AQ9;#8MNI"/)M-^:F#>XWXA[ $VI]O..T!^4EYG7X94?4.TQZ$V'TN
M=N9CJZC*U>D?FN_CI38/IYG<E-1IB9J5CC<&D(+;T:T>V]&M)-;MX-95NL9V
MG'(' ]B2R^"%$M\V;L<I4ZXQ@+WO:2\PWU\R@*^HZTSQF0+%8R'E0C1^*!6]
MF$%-T(9$X(@CT&V46H;81JE9E.WPUQ27L4IR0\&4BU_:UX[L?+N/&ZKFR?<K
MRF&RI8YQD^%R']OBV^;B#=$X&.C=N<R47.>97"*[E<?DWX%?WPE0C3ZCG#%1
MZGL3'=\X9PA0[^4Y5YGD5A:GY3U=/1RZ.^Y<CE.DQ)Z"3"#S!@ 4HO[*A @P
MJOHL^1;SBYG(-I'&_+#X[0IS-LB/\/5+#& -4X!:8])%]A]+EX%?CN600TP!
M6P*]H[AU%+4)'X9N'HW]A2*?V&>J?YE$Q:\SA5="B4NQ7R+IX1ET\Y\PNF$V
M7>P>Y21J@*GMNK>E7)<R"UC\RQ0@O\GU7R'7(U,D T#]YTE@ "?6K;?H .AT
M)6K-54MP.P8;RP ,/ I7MT!6.J?Y]I$NWH-RD(!:#]T*@(K5\Y,XV^'<WI;>
MT-U@L@6Q)%?YZ)A1[SZZ]9GTP]T=2J2R^-RXO1.S,CPW;=&_4I0 )QHQE5;C
M3EH64FN)+@J&O$:UZ&2-@7=F34+'"5[C;FGNQ9+FDUQ/.SGE@G?.SB\\.[F%
M^FL;RXP)/DJWP8=> A-\" CAJ ]C05?(-G2QU&)"ERM,Z-+I2L[[A31_08$_
M.8:*D-O6W.UM:RY$;^/?;D@PS39!&--LNPY'D<9H^;]P$>0_+T(F3[O'+Q-P
M^G66&!?4?V8A_5\YEI5D_9<3@/XZR6TOU]\DA'[3ZC>M?M/J?XQ6V"8(T13]
MQ0,?MLR4I7OJZ *=H2C\0?H8?8B"VO(?QJ;-T6*[&0!<EM"9*CW9X>/UB@M
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M!/V#UNG*]]@'O8[-5I7U.:.NM8B/I0:M]4)7Q')FXU]7 X]8<P&4H<":#U6
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M:1KG/BU+?%[W5]]955%>95S:>B!*YNTZ8+(K[2_9%X%G &Q"#"#A.,C<^C=
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MBQNCT/?X3Z._H.%UQ-#@-ZHQFFXNIR>MVZ$)CC?F=@A:>K:_NKWOJ=IW2Y@
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MQG+RW7/TN:[(?IS]XEFG/[3W)XW+A#T2^2FC=+6E?\P5]H"4$8IWL[[SP9L
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M#]EV[&'_5X0XW'K,1<)AQF<\BZA'>6^.]7S&%R2?!K&%%N_\RX>V]EV8N@.
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MA)GXS\*+Z'FIJUJH^7JGB ZD"%@2JNGN-%C8S_H@U,LRU@L4F0[9_+C%-\D
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MDEVZK]RM/@[6?/ECBVP\Q;)30OI#%L9BIKKIG-4' (=:[-L#X,*7L4]BCTM
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MZJ%&T[(/ )] 203C505"#&@RG1Z.##H?@N)=+26>F7,NR(SCD:BL#!(7O3;
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M/LE(M;<B6/QWK[D!VH; ("QS8*4'=IO?_(GNMOHSP[79#/5W+IZJL*]Y["7
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M+ZY;",UX6.J4IM&C[XQ>GK:_J&=GRA.15L17:&.]?;[GX(LP;\J)28(#]6I
MFJ<B[E$J_6W-AA9<9-AP(=7HJ=" QIJLQ2X3>'Y&]QD*3"]K%6 ,Y0J,TG3G
M44F[>XG?]VJV.HOL5AL;Y_KYQHW2W>6J+A4(_;TH?5[J!F@501.TPI?74V_
MO^MDU"<K,*;&MK.G:KA+^NS.P.S$Y)P#+?R5E(YZE56HRZ?#TA!'4"&^U!.,
M4=ND%+^!6R\NMV?MF7N02_H._^J5BE?FP9]3DH?;\2<E)U@MU]/X9:8-*4JD
MP]CRH^E=7!)UQLIU7TUZAU]OH5192W6<!F9\)UF$MRI;]];Q7E=;ES8#V)9Z
M),S\=Y2'_WY^D0<+ NBWB6H)&BQGZ'AX2.]F0=_OE:SQ"(G$$IF/YYVL[*FX
M2+@JHMU:'^J>JTPO+J=IY[OO9F9913Q^,'K5]H>3<://TG4F<+)/[KO)C^#.
MWN*]7@87@GK=;0)9Z1^')_'^0."LXDMBV].?1;6GF;U)+O?GPM\<Y/\D$[Z5
M3WY 07QB3$+K9*(]RH[-,@$OCZ=KC=2_#WN&8B5^+\A\ 7^_]V[KV$X>> K]
M$X2[P,)9T"F7]@G;L?2!>5Y;P3)WE6?67ZOL[X]HS7X]*9HA#FJ4R5%:_EQ<
M_"M'V[3I2ZRH%E'W,SXYPY1]I1NNC^@DM"H@AE[BH-35)2:0= .T[A?"335"
MM*MOH-TVI].M2+LQ(3"12.Q:?+")Y:!Y3/\GB\6.3WC?9%558]Y8Z*SP(+P;
M3;R-D(2/PB#/DMD\X()#&CGZ?Z97_1LKW+Y_?A#[CJWEZT+R5;ID'K@+33DU
MV#;( 1_<J^] \5!$+]8/:XR/;,Q9)HAD_;;09$MS P_(O?-3?-G6!EA-H/?#
M 321^^$ 2WY,H$!+$XLAVH/_GL!PLT"$L#\3R$]K6?IG[LP$4)T8BK)Q)X6F
M2+7J+K?KD(OOFCY>NUU><+\HH:7)9ZU*++EULPR.LUHHHHF*3&B27#K,0J'!
MQS/S):68P.$^+^/5@;]#H&7(N@OIN@4+859M=B)%[*]-BD[:VMHY7L/S[&JM
M3VRQM#K(Y"U:@AQ'&65PR9WMHXJZ'MZP<1K7Y#2PF)4)/ >)522AJI;_IZI/
M_:?\2X0]C5*/M6Y5I"F3$!$*GJEKTX83V6AJE/5;=CCG2YH2<8G!530?G!R)
MKA>-J"'<Y W'F ;F.5X^?;A/J0LG=WYY+LCH"PJC\V\Y -[2Q,=8U <UW61&
M*<;%P <^4L+^:E+/CT/]O3]?/M;\S2?)IL-\4O&[]T860*]%_9;#:],RP=*(
MGT%4)G!5!EV CF " AKH! @/[2S>0;S>K7$QPFI8%7O->4PDL9)F,O-J3UC3
M'1:M+Y1EG&;!XSIBLE"MZT82Z-J1)ZP90.*01 IDFIL!U]-D/0Z2\:,9.>]-
M4")MDH?&59JUBU<EZN-%OV^5T31Q5-Z*A2/L8O?M^\("W+2%9]O%4<N@?ZBG
M:B?Q*+%HN2)0QR^Q-@*Z]6-".!%QG'UL"-0!)9I#?H)OTG.<FBB1I .'/I#F
M\KT\'V^/I9AH-#V2;25S%+\ELDU?'^=XN'%//Y5>I0^:@P_#JA$)S=P??]3M
MM6SS#]X;T1KSB'$VS3>ZD/']/A>AZ4+)M&L>>$D4B^E.CH54H%G$=GZX8$3/
MV%DH"U[X?BWS1[ROUZ*9$3X*J)(K*5Z-@SM_A1J%V-,_H%U1E!.O7]8F:E\D
M7G5%\SVSL_'SO+:RHIAZOBZAO\KL[;G4/VCY$VPJ-2G/-V!3L[#.((L8X8/%
MA5/NE_1O.-H5-,&S7W;;)8T<\HQL?M*3B7M^Z"Y@WOIF)0Z@*;)&\BJE9[0#
M66>4Z.%_.M0CR_GW:\'38F>$!$^ESRCP@&\9;,*:QE]Z$%GFF:RM;C\3X&U2
M_R4VO%?#4ETIGSWE(G>*<5G $H&7^I1VFOXFQ,X--RAM7C*]*AH4M&HYX%)4
M0S(33S,A1X,DVV,6I.Z=>;?5!L)KLP 7T9#%UYG =%%WH_D',8W$Z]X$@GRY
MJ&=+YUE/^V?\WXXG!!OQOM!EH0T;RG%Z XF[&RWD33"S7=;"FXXZ^W&:C^&?
M?2_Z]##F5.X[>W_"'PRAA'K=@?$3*3W39?O\K9]+OEV[2/K[E335-:2\[NDS
MIS(/VLBG)HF>XQ15J?>A%]&C& ?ZJ><9 _J"Q,)M[H-H9<]B=YS!X/22[I18
M$E?B<\-<QHT\</#_I4PX-$491LN20I#5IQ#+@E;?T,0KR+^JCE F4.F#V/YX
MBAXV_LP3ZE!+U2IT\OQDMP%>F+U4]1$WA'LIOC#N*=<1I!C].["F1=)B])'?
MSQ&;Z8)K_>^P&>QR&FPEL&PTT<Y;QO@C#4)!8'<R)I:L)@K&WMY(D5!RO7ID
M;J8\)30850\IN$MA$5#.(Z1'951;^"]+&)^>R,%/SYXG=VJI]TS%EO>+-F;$
M@%R-CDN1[9X&WP!-0HE&T*B1 ">R[V2SG<\1T^:;I>B4MA=4#^<_K]*9@(-Y
M&^W" #QT\CCQ-:XUFXC O8[2$\X/>T;GZU 2FXV2N!3';H(AZ'HY;?0T_N^A
M&;1JUI(<#5#L<E2=9 C61>:M!HVT>Q1S74>ZR,_KM=1I/[Z=@,7K1Z$UH;AK
MM(M,X+THRQ6?^,($YI7V_#^$0C,=/"Z--6M_NA!55C3KYC\<ZCA-/AAUE^.A
M0"F;.$C3I7,./$FS'RV/_.!N.VK EO&,:JJH'OY.Y"??V?#)H<EQ#-'2^^\%
M;T&6IX9:,(&1AR@XZXFD$%^[6<B]Y1F:SO<[%*J+^*?.R4J,0TNX'*<.9+5:
M;)EFBP+5N DA.GNUPEUDD+U*4DE63"G4Y%LJTFD%]GS8 #)0W[T9H:_71*G&
MNV&)%C$?PQR\=O!I%TX]M[JMFW*1ZZM<"WR<104T-!PN=V(JU3H3H7<K&D;5
M<(R1+17OHZZ%UU:MKFDK 4870;E=5A=0B/:[:)8V\:YE):6^*%T[&5STJ\]-
MISQ5B4W^\=U0N4]?]2:'$2!]U0!_?'WG"[E>?<'<8"1XM=5_JO!+1.?1/Q\#
M8"<"(7J>M&7VF@_-DN0(>IV^*/R[OMRH!E1Z52(RAY'O1I[QJZX,CE3??-BG
M-+1H(:S6AIDQPUD1N H"ZN\26QOD)6"1]Z/P5BT3LEHW9HQE7Y54?S68YA 0
M,&WKU6#;>&75SK*[4&PE\J">:+G%1U>)YVC\?6YAS\L68>=4Q,+#^ N?$$;+
M!XH2!!VLVF"44]'MR$2&0B7QU^;G "6'UM1[M<F.L9PM764C&KG:SARYH+?5
M\J%G3(38R)K"O]%2^R?,HC'5R5%6=J3-F'O#V%<9=;5 O]^S3HCR356;QH1W
M]USD7PZ$./NR=*B&XM@8U8]@HS3:L7Y8GKY>K #])9#*!))O@)9;A.=9YIP0
M3^PE?ZK\@N!8$V "[K9&5;/+6:\<#0F-[WB[S]P=$V![^.B&B?B"5=T0F^$C
M2GI7ED7XMA+!PV&L[-F+8SURFN,[Z_U"I_-6OZ\;'&B%_)OJIE!4<-*V=F#P
M2NLQTIL$+,9ZYGA+B6^8\$>_E.VU17QJ6##P8M$P1)AE;QG<)XEVW3H%6HZR
M(\VF6-S1WIER@E-#[76?+3&' IEF(V-8+\N.'J94&Y(&H]?],&#WNJRYQ!>0
M;,\73F?Z>4I&3WU[$L@!N71(@ZWLWU="82?A\2*I1# .$ML<6)8S87NA^.T]
M'N%R!7GE&\4[_LZPQTNU<&Z:-'$R!NUE,<-]-;IK4@ &"\BWU)X>[[H?UNLF
MMJ5PM_VOT)5<6Q[2']4@JY]0HFURLH"#1ZX Q;C(GM_;#4+>*/U\7<+R5^9P
M+B(R9%(V^:]K=*WC_F8:[:BIY#RHB_HIXRT/7+HBG5K$?6$0'^Z97!(T!%I-
MS'DGX?=.)+.BL*6&O_3F90G"'4.QN^P5 !NLOS<)NN!' M$C5*';3E8[DK#^
MU_^^Y09H<Y<FF,^X5H2#T<,76<K[MF1YCY).MJ?G,V3@ TR@ MJ1Z-([=RS<
M.,Y3_[Z':UZ_W_..W_8Q[^VKG>04):WDY*VX7["FJ9KBP%?@5$M4B_=2ONQ$
M$'B1I2UWX5)@43WU#MN>DF$ ;!U/=0M1HA<?"P@1+]<+6E /'%V6*'TPQY 7
MXZQ[6/))_L!P-5MJVAFEV1/L1%_&85^B$1X+)C@$HUSACW(* _*2^=U&IS,3
M9F9%F8#)W7M/Q1\=O)C@*9 GK;3C0>:G%\G1B_79W."R37XR)T;MJ&H.L4:8
M[8*[^JYB$.6XNSWG.-\B(B:3_BT8 %R4#'UD'>+@[?W;'<XS)M<H<&K#QT-7
M^>RGS<0>D/[PPVT\#D:1W^PUU1>"CT[D2C0UJ+OJ:T=33P7\# TC/"4G!:=_
M:39 C/H2#""--?^BDGG_$60_PXRKGK!^$U6+$MPE0MID=) XC+#XC<L:MXSL
MH#NCWR#$4XM0; S\5-@:+KD+S7N0"9A63*CLB-A#FO0.GO8=VG*'(V-0#2S0
M%F&)D=$'40;;K!0T="9RY+6VKC9E2F9TMI^4[KA:64\#U<)-$.V*M!?^1!=R
MZW@(^[S0BS,.\.DEPR\UV4#G)[OSJ<*##_0:\+W/GYQ@WX&2!YE NAD%S00>
MU+UG A]DT(?03JAX'4C;X/3M=OWS)-E&'85DO3_V\2<BTG"$P@3/6T9P%^F]
M1^CWJ#@$N+15.42;I!VNJ10?;PYU'/T]6I0[]BE3(^/P606L$18LSF'5"2$N
M8"(PV[J4009C&D&* U;W 6(OC3U*7%JEV>'LJ4S^WL(KXE^E#SYB5_SU<A/&
M <= B#?BDZ=7I<]VVO+%^N P["NO89[6F\Z6C:W(^X9I-QJL.Z)3.'@P 6FS
M !7*D,HF9C.B$>), #-CP5!W;-\_7!Y+A&!;RSQ++N;-!=1;UZ8/U+>0#+_-
M!E[CN\A_3%X^/$$@(N&AU!!H?[T?90+.#I=QB)<[L#A'Q0H/:8_NT\?K,KQU
M/#.ESYWV/<KA'+)TJ,W?>A@=]T6-HJH8K6E:!A?T6/&66\[<_&3=_P3<)]P5
M!C+4CYPX>8AE^5U&T+=##P/L!QJ0L3 >FCHIO#TH.8+FE#^SUG@P+UM5>>,,
M6_M79^>CJ2_;>0I.R\FR,$H):U3N,J9@A^$':#HDBW"]%Y^3>=RMLMK'56I-
MRQZF*;V9/I3_QZPGX<[[R#?>;?K>H//"BQCB;>\9BTYHK7:<GOJ' '$O12(J
MJKL+.?WZ]!MS>M<,VTE)8$U"^=Z!&5/5J1O"IE0=*N-0/=%RS<;C4X@QWDQ7
MY 7F?A)Y*BQYHZ2VX?&SM?1-QY)Y-$4!W>[IBWU+<2M8WJ(X67A0_!3':W9M
M-+E<$ATNZXV49$HZIWA2\P.G.8$ !(U?8>^D/F< ^:O+C^BNL$<KB2B/([ )
M+50I$WBL%F9*O03_ =<@/KA4M?I:Q-.W,!/ON0YM#G\G==#YD,6N0TD&/8T)
MW&?A#'CO='3,;V)][ [!<<8A3JBQ>CSK8(*>8<)3M=<2*0:IO>]YUY66'6[?
MK1K:GBDSOM44UM$QH9457/*6P^=*W)GOWZ\#[ UYX-_0#J1@B"D6RAO0WYGE
M@)]V:SU5'6\Q?J^=<T0IYK?]O02MY6_(NVF&<K]1HRC*,62[H%->P.A\+;WU
M.#K%5<>N\7Z$B:79:U!C]1NK)&+%'OPI8RAK(IHD28XC311AS4X6#&OFP'\[
MJ,[)/PJD]26-Q"8DKIN=<I(];>\#&TI>GR%&8;#0-C1G@ !G\O?A[65\8YIZ
M9.9*:W L"-:B9#)K80ML!WXPB\D]*:3G56AC_?!(@.QD$J)3+ 3$4L*+V$&:
M  O6=$U6WS20\<0BIZIQ5IV((Y?+*58X3!1-M[2C-!6STOCXQK6XMA+@6U[H
M1=G)@F&6J;G,6LM/H OY^YE2*NYB&$E7=Y'[98BS!N,0Z[[[98@E)<C)TX-D
M,-&?\*(\ '&'I-]2[KKE6C=B=RG+[)+P^$]UE=]&OQ:>=S^'5A6M-^$VIQ1Q
M&_DX,*][8R[J?O!GTQ*]O1(C9QL9L0>G]&INUA\YN?(N?0 (UH2?8_7MJ6<C
M\Y[4U.8H=>G[]*/0W7+_ WF_['4(O4[Q3RRJ5>"]5MADPG'5]U37_:23FI[L
MG=6:73J9]:+1Z\YW?U5,SYR(LVG;"#766/J)+ 3@1?M8M5E0^R7+/&&BG]A_
M[,\QXMIQP7_^92&?"J%N.Z&*UG0[X9!*(C+Z60OX6H3=2J-GJ:5E15)JMP2'
M(4W8H$SB__LL"6$4^ORL61OT %R.@C3*N#>^#>-=M<UX527K9XJK33/Y68P-
M_79.3V+3 ](C(S@:$HB3]N[4&>/US5^S/+LR65%2)2Z;I95DR%,@_*U2'"17
M"\ E$)U3:-?-/?%M-$U@!D$2^H?OPGLWF0!? 3V+"2Q?W3^:M+BYG^8E"X%]
MCZSP;D\.A59?+YIG88X ]Z5KDWEC*K)FL9JZ;]M,Y:<['R99I;)\LA83^._T
M\6>STT%BM O!WZQ4@.EQKD2/>WIZR5F>LM5^*QQE+">;:PA?1'060Q^A]P10
M"&)@\+_E"5F _JQG'%8A->&-"1>P,$Y*D>/HQC:O;2"^,4I:]5!.V(S9,=SX
M1<@9M:M[HHS#J53;$&/Z:P3.!M'1.J[R#$,8)$#K7WS\II3(L)C2:_8&>>FM
MZ/@-U@:#.S 4Q==M@^&.%T9"G'$6W YN#-F1G(6:AG3+QK<W:CPEG64N%2T^
METK:F:(AZ*_@$HQ1- M#5FS;U":O0VM>1/>U9LWT;S6CS^K;E:__5=_YH=Y[
MVP!RF#5\NFAOM01HC3%!%!P1XEGV$[.<6.C@\,9S^^<];W4M3]W4BQL!J+$X
M(C@,75'4CI[:ZNF?'V2G>"V938K,F=WT42WR?:)7WX.K,U;Z 3J'0N0=B#NE
M5/+IL>?"EX8LW0"Y6X/*I<)W^ K2VX385(2_+V,$:9+S%TQ6]BSBGUVX1;_.
M6Y9;R#,2/BIY-Y:N])'UZUX2)*$&#)HIW2,W?%Q.T>96*/27;D2^?WJ2(4-Z
M%#N_9MDX5)L(M:V[':Z%?):>QP1>'I6KI'UB_S_CCAZ.&GMR]VO$"YEHGVU@
MN\.WD)O1-T.[1Y3^G:<L2ZJ/5D#/5J]7KDX05#?-WV]E 6O+!99\[U]%W3IS
M:-GMWY>(RR_WL-27'/;CA=UN2!HT'R4L-#8VO,(=BQ6J;I)I.['_7W(B%%N
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M',:H,(#1LE0&\.'G: C3!*RP<]OU3-IRCP9C ,;)#10Z!Y.XR(BT,K^T/<@
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MDEQ?\23 A5UK[33"6DU*)_1=I2.ON=T\V.[XTSAI\QW%<FS8\BU]D &(G60
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M'>>+=\.)&Y'$Z;<EK,>K7O(90>:$6*A_F+$9%JP.?<Z\OE^H9D"NZJ)U9L>
MII07QJ"3?\V3;*XO%$G_,KJE6.AZ>L(0]109J#8Y/M$RU*-.+(CF4H?>8]&D
MSM/'4?LSR$&TCU1FR'Y_:E%UFIG+."YF'&< @0?09:V>)Y.H-ZJ#TZA(&CIG
M;\1[V]L4?9/](]O2']F)9(1MVIUR]MS(3SR@_]@061\I?R21][MG3-;9'UCG
MA 0I&=+)ZZ8^A6"QM5]%Y:. YP]?.=2SOG.XV17K0Y7)VJ8)(3A!&R>BV<QZ
M&)7+H3R[?VO,7399\UOZO2_I=Y_5A_^DE*-;54 Y9",2M(%51T05VNI5.M/Y
MPK<G4:I:BE=?R%6$]9]*&[RP5]QHY_]8HGN+Z2EU]"%/TKE9;ACW$[<&NAC1
M#543X/[F\_"X]U&=F3\G$.5M^J*1WO!2K!3FN U5$%2=A4G\#/?^L/C*ME7P
M':<CUTO[/HJY$!P4#F:E=^)XE)EN[CGQM7%7ZE-?85YI<::9=;H#;N&"J%M,
MYD+M6_Y4>?"CY#,^WE$S\!CO2B^*!>:4(>EVLVH# 9\53KB-=1$1N.!AZ%[Z
M!X@KKR'?[ BXZRM,%I8N,#CP_L3S$&#&O!\RWT<5@30^L.7%.\78LUA/_]JY
M\FYUOKXU_LX?\D;N+ WM.K%'/ZD74V^!+B3QQIOG*G[OYF+RV<D=7$_%94[$
M?],LN[R8ICZ<OLAD M4CS&A6*?_"XQJB@WK?\_!6LY4=4\.^/T!<!X]2R[!\
MF..&DB_<<\?+KQ(OIUR5>!:+ZNZ'+%?_"\3HO_BO0<J,8HG01,8RF5R+)T>C
M2&9 @?,0+5[]G6:WVZ]O9QA 7GENL-Q>R1JJ;Q8+K4I7TDR'P&5ZC> N9=L3
M\HL@$B]'=73&2EANB<)#D+5.C3V69#,:VG/[/+]LY9#*T_TDH\BR&NK+JQB7
M6#Y52F&8PMT%YUA4@QX4^P9D948W(V:*6@$S&(!7'TUSPG(ML@D6I>W9QANA
M>YA4EOAM<?<72GC%[=W;+@454:;_B#]&/=5\/@L=?X57:5$1L 7#6AC 01UU
MM%MJANY @:O8PYMFRBVW;'N_&S>=*"!?5V E=LW@J$*"L[!O\$BR%!<Q^*N]
MP_L[]147N'<?"JJER;I %QQDJ=UN/JTHXDT&, %KK;N;PCN+6WDK9V@,-1XJ
M+<V[9WCFC?WT"Y_0V'Q4'LP1AH_59=[ZP!$B,]O<8ZH3U]X,RE$J[Z#'X*]1
MO$AH3B:'PNK[R;/F'$?B.KPNL";U ,&\P7W8BIT6+)-67YQLWGTZ_Z.AM?'5
M+9+N^S)WI=I3:L8G>W;FSD6-<?J>/;-DM,5*5)D9":? J,>)#""$>J:4EO&Q
M<3YM#C#V4108O K2Y1]W!W+/>+'YU@6CW'*M6ET<W'DR/\H\\K)IX^=[QB;!
MLE4LQ *F,@<X#%0L\=<G)\#X,*V*H%]K3<H,O."81GVH</@'>ZK2?*OX<ZI>
MC7IUN1&9J:%#L^#T+A2/S;=GHV&IK<\DJP9_N@Q93W-9K7;'VLXB<B#F+9]T
M^)-U[\=AJS":1)7(8%G_Q\MZ)(NH^P1)@66IIQ&Y'I47YR0*)[[%AK) "H[P
M]R#P4*K .MDUX8Y8".AO+! 0^J,Z9I9]#>O5T]%'S#IG+W$=,N^W:D\Q09C3
M:DL\ZIV\\2X:R CZP:>Q%Q[8V;@=5Q;EO[KYZ<;);M^"IC*1[-ARW5$FHS<C
MF>9EDKK:M;F["WV*G!6]V6?CVD2''B?<C/(+$AI=/D 5)\HB>6V^1<W0A'4.
M=?!7"9?'6GWBEG \Z2[_.*)35-:I](&_%MD1-".NMUA,[(33)?W=FG>G"NX?
M_)"W6'Y!X_[K8F")1=3BR&ZH,^N0XI\MYO@D( YZ/L=6.T67EI92XWA;>&G8
MO%4*YNY*VRV)>_O?7OU@9,"U#/\:+ >VST#972VUD2]UO/$-7->KPSWDJX>K
MW0(#'D0]/[$6/U.46!IJ>'!H$1X-(]XRFXAI9@!5?FVKVD--(ORNNB+$TIRQ
MYB+#MR*U!RGY3^R[+IUNB_8.O3$F4,(#>*.(U_9V,\W6KCK@%;DZZ$.YSAM0
M/M= NON 345%\4.)R+0/^EF];KO\Z%X4* -M%"&BFGCYJ<;#2K%^62>^'DKA
M7NX;*^W:MQ0DY9@(W27D80T*_FVW+_I7!CF'=(FN0?N(47"[^7TP RW@RJY&
MLY#[_#0..:-0A U'FFC.B3" <@;PC;971VD3#WNA7+;VT"4ORU:*/4 RZF3W
ME0UCV5?K>I+M30R 2W_&,R)+@#A?[WA8(TAZR"Q>C>-$^<67+!#:Q.+O[!!%
M5^L78H:93X.>'HD>&9'/LA+/S@[M1@(\R-,82+\'UL5LPL=DJ%M %.%$"-GA
M%)F./Q>3O*DEF20ZAC+0I%@Q;5P)[.%MQ(TKMC8>N_6CWA1*E1E176M6S;R<
M%HE,83G>5S8PC9%A#I@:O>\Q&$,X]I7D>:L2-IX%C:KJ.6;,)YQ,ODW;+.SU
MD5"J(O5-L//NOPY9X?;^J%KBG?W1=5]1P3?@"7"SX/_#*C!_\?\8L$S/R?7&
MTAG/27$")JOCN[)FH:;!5);!1&FO8:"C/;P>6FD6#8G#.B$CGJVM]B'Q#;HN
M9WME3R\V^#Q_=QK?_P3= P65/!O3GF E_54(X9E?@V(LJMT%KR?I3:3RI20+
M3.WH>!Z1&J%]I9DRH]!K\'V6+BUIJT?,N+Y'O\EO1^Q64?NOC?%ZT 8Z-7FZ
MD0'<[<L%8/^AJ,\?,PHGX@D1M[) ,?J=I45Z ->-<G/SVX\=)T8Y\,B>C+Z8
M<C<V:1KK@7VD,CZ"G'@UD[D34KH]1CTGUS/5,#J96Z/%@LB?JKWGT!M<3=2B
MGIEEBLYLK /3RB$,8"X:V!G?*^[   !\A)&)I\C5[[DOO!=OL#^&7$@+Z=PY
M$CC:#JW5H@HQ)8"+ROZ^&5Y69ZUI2>*;N:3.@FG7>-2CAEOWE@]V=)UT^7([
M7C+&G?5YXO0;9JH]\P/[&SV.G&%*AC_2#8IX)RJ_)9X!1&PK>.H\G36U:2MO
MF\16KI1&I'G*4]3X-BX;4>(CIT-T;?96+].[1K&',%K65(/A51@AD6C[[;/Q
M0WC*@CF@P5]F=$S-XH'111GZ=O!>57;3TJ<F?6.1A"LNNO??/*A,?OHRL6W*
M\Y[+,U\.3D^RON6 % _1+HRXT^RK"R7VOG+Y\#OE^/SDV%B+3+3J"N1Q@"PS
M!&U:;*]RF9$,(PN<)ZK?:<>_*;#I=/%S\GJ>DR5B7A;+>_O$99EIIL4DC(6U
MTP5!..4VXCP)%L]MC,_@ZC1M&=+_]?$@>:.=N]7+/]XR;H/=TM%(&NN.40N>
M@K(''P0/+K3<]%_6)[$UAG3=SW5^]L(R5:O74J&@O-+=X@QM]KYA@"81V=8'
M2M=&R9#D?BPTH0\M6FIS]]J=5V]).*EUZ/WLG$"[>,E[G\U3^K&\;S<\J9S,
M45)<2EH>V8UL[3ODLIJK?\0G&W282UI[?6\EF7#)[*34!8X2[X'7&P!,]6G/
M@X46Z^D/1=-\HWZC K97N]Z)^)Z<,CYOO X?AH4[FB1PNPBT$"[/58:_>3W'
M=YW/(-@+\8!Y!=4Q<)9@\:4,U&\_I,M-G%^)DLM[4:=^M2;$\,/K,VF/N2+N
MM[.4]ZK#WT/9=82+$%J@&5Z%<UF[;GDW/C*O.=^XL,005O7RM?19\VY]X=N]
MQIV=3(KSC/G07#&03)-F.QX0?1]0=ZF0Y+WM<+4\XN+#VL>!)\Z\">A31S/S
M5JH6EK]Z51\_\F8F8-V*>C9OR5*[M*',K$N'U"J>U0"\N.>KO #&(2^B:LAO
MWKM!*XQ: Y$"%7EOZ]BZEU8^1/\TQ#B47[_<%;!\B-WP&KN1-=U?1Q#/8T*
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M<I'5,;LM3%#?5F%2P.'3VJ9 ?X"+(1T>3-^H=;EW7E\J_M%.C&B,9=[@#5=
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MP_#-:8K1HB^F>'A_@:EI.# 8EBGJ#!)L&7._(>"IB?^OTWMNIC?6KS5EY!D
M5$"/>?S2^-7M>)^>]VR;F&6>;)XB-YJ=7_]7 Q7<:L/MKH5/:W&H656^BL\
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M+8.ZU=?_0 _^M!8>M]#J?VF0_1YAEL\NQD\5*QRM<5"QIU)&SLHKS#>-9[&
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M;M09_TUYMB#YQZY+WN";9[4IJ52;PO8D>=WBA&5Y#M:S/IZ)_G!^0 USX@3
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MV1P0A,7/Q<B>_Y^((_\?V ? [5]@9WN2N%JS<<'<:E=1$K"*+H"M4QX)(.7
M.V1/= P@E!EM4Z2)AEM[Y;PS<Q1TB]CC%5F#_=F&#)+YBU=I9'J;?XWOGWHS
M3 7^%FJVE0;R(8?,W(_U=2^EI^78=1]H*WR)_[.W_N59,'IO.^I#+/47/-=,
ME%L3&KYUXN\"SWFZ Z.8*2V.9CKW$QZS^7(DU+FXPN*5))UO-4P7(WU> 6Z9
MV!J<%+B:H28>)&\W%%X![=J5-_R%3E"C=F6%*QLXJ[Z[ ;.DK<A??[0/@7S%
M#-Y '+9\;L*ADB)4%BOKIB9-\74P.CL* OSJ5RHA8[>*!Z5DYRJCJJ+R).?6
M89CM[WWH;!DT\&*0Z\J=B/WZS]?6NYY*QF9" T&,.P&01TM=+7@#JFA"2H^'
ME-X)* ]5A](:U-D<D]C3L7A-N.D4KC#^+)-VIQB$KNG;2@L.<&:EJ4*K9M*!
MA&MN)!C. Z:-/I/=B1]3=2;%3!KA_1D[&- I5="=%\>*@.M96K"E@Y(8C=M8
MO,?,K)S0&7O:I!,$MU$//+LW?+#;Z@"84DNCX)FQ!2+,6=_5,"LZ8F^1I(68
M) PC;I[XEBT1C)]>@@ZV3;%04U);NP0]HK97!?!_;/#-\#K]):CN,:L9>:^M
M>7'GNZ[=R[:T^J5I&L@IPU7N^F%D$JG$$+*Z9,/39ML"^<R;\STYR18() 'A
MN3>$\.$MM2//HR5OM-N:XL+&S*)4=RM.WZ\5Y *E0"!G-%0(SI$8_U3 K>T]
M)L_<2WO\CNVH=.+9$OP9=:8G72>C=+5&+9+-\!WWS^TU.W<C8#P9?:ZJ'LZ_
M$E]8>H6J"#C$. OICTL/:S_.LO?&C\^WB62W.23:6_.S4Z+]VG H?*'C_N'[
M"GBO3*"W[!ZIK R1/]#?H7RQNJH.<JOPD:+B.Z8=*#235W#'*%+^S&:+CJ&U
M]W#=O_*M+2"%$;@$;%K-:'R<_+4F\0SR5)@Y:<QPQON&2GBVKAM?)GP$0A>!
M*C9AZ7ZNDWPG*%-6H1%7HG:<2OPQN\ X[<Z2@(80:_AX@= %N7Q&WY;G .=H
M:LID* ,!C;?K'6&5WJ>$HJ(?Z7.V'#5G=K.LWH4O,2J,ADKD)!6^VG9^,[5\
M)B>^BQ,2U.*%,F3:?U2X!=TX-R-F":Y6UJLR:M<\<O*0\ I(33!'E83?3?##
M='$KXD9]0@1FRQ$!&$&F(1:,X/QH>FKZ_&C 9T[I&7DI@,;\3;NBD7+2F$K,
M9',R2;(S&88,57JHU,7+CZU''L@LL]8&K\MYB)R'\(A0LIZ&"@(Y=1)/W."N
MDV;P&;JY=1?VC)"H*_-@BFGM!$.X#6H#S\P399*3<+B]JMB[1M5&M9F_-Q5<
M%+W_I"PJQ(G#"T]&>?&F2D^N8/964! :M*W9U**+9C43DAP_&,2J*J4U'[#F
MMAI_DNS ZM>P0Y(PR/;<_&:?X@N@0<H["MI%&T],%_';2_F4N01RGS;<NEPK
M2[7Z^SHS<[&0G&KAYA7P5>O!,0J"2LBLWC?EZ[D+1XK*UJ*Q0?1BS)-IG.DJ
M1K: ]X.GZLWO2);S&S)YY>_(U&SKC3VG"[V9!!:B;N1=RZ65M]\K.YC-2KV2
M-6=A'&)QS#NN84V)7R=W+(7*CH1+$4RC0T9?YM0;Y:L$CE#;O45VIF7)2 [Z
M0O5A(%[8]I,>9<X+S42>\'*DZ2N@B@ EN-E,U"TQ%K82)%#.* #KUV,N+DSW
M7ZPS>7.<@+,B7ZA+(LQ6N#._ JXH.<3_9;U0<VIG/"FT^B.5>ZI8)U@,_Z"4
MV;&*]63Q;/"(),.*2#<O08#M%HVOFFIP0R#ZE^*<^45VJX705)7>BH%_NLX^
M(TD=6J%K,]]QSS^ZSLEY/XD"F_<R&%452SICK ^-K:VRRR_!7R>LX8G$_ZE_
M@6\ C=I4!4\RTY! ?-OTCT:'!XLN?7B5^7](3HOFG)$[1YM'Q>ARE%): [>%
MW\NWRQLHZ\Z=G%$_)JP94#O\$I.E#>(J+=1"R_L64FB.Y;/(#;F]O/0H<G0.
M+&K*>=/A2-;H$+#PGG2WB P^DY3"%K"27P^[% EE'FC$!OF )CSRJF# EC$%
MS,^A_"8W9;F+-Q592@8"J^H-Z0_D%A#PEI[.2RF&S#8]_"W>#\]M Y2^B4</
M2,FJ-P=RT75UHE SU0<E920D/J'M'.>:@[OD50GW"IT>YJ6WR]2M4C;!!RKO
MKZU6@KCH2\D?9AD/*G?:PEF*M;QR;0">FD>?;RG-S?]BCVH];](*ZIBK*Z*I
MG,FUMI^U#R>+"Q*9(D GOQXZ0(PP98\"2@?)>R  !UE@S&S"*&A/O\+UYKD%
MT6GGUXZ:FQ95$$*9QRN(]X_Z40 0*7&+0)LR/9K%+/<WZ^W/([D) KS38'3F
M?[6ID_NNM/) 2"I?_]#E2&ME(&P1ZZ_'M($/B>E?JC&0MFT')@LL+-#4-@R!
MJT.<E<Y"]>519%U'(<K4=PA5 -W\TO5C'\U0A>:5K*RZ9JDD$^[>DM1*62V[
M;+B>'F$G&[-%MQ&WXOGM>7L*94T6*$C@>PBX), YWF_ZS0JCL)]X@4@QU_Q"
MI=Z?B"U;%I51F>KQ_9NB+JA;'(>,HKQF?8,7[+W FCZUA4K3=/_[WE28,.<
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MV]EI<\'4:K7K+,A*]N)^8M,@QI6-W:_$.3EM539!.XKW8P;!K!8D?;;IEZ)
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MK&V OSJA]["O":02#%*.SG^P?,;_O?=S/T<VGJ<PY'=^W+$R$W3&E',H(]+
MG&?4L$.>5DGM4^6XI#RW0)6JLL)H(*&*S^.%8 '9N8GC(W3UZN-I&ORRW(*K
MF8(8+L2Q^KLZV45GHEYI2N%*"J/HE!#UX3?MGTI?$N%JR3.GP>128R6S-.E:
M](=%&W*1Q^1Y(X>W9.3]R0ML_%\)B(_6#]X2<3/[GT@H>8<E%$+\OFC%$CEE
M_BJ@P9,WZ):D:TZH=2E2_<WP>0,,)7ID:FX,C5GT3&@>7UF1HG ?_)38NC25
M<8BKW<H].HA8C8J8-%ZHL.6MS5='$=^ET_GRM?H)8&-[H2=G[$QA?+ 2M$Z@
MZ[PU"]I5[&\VRZ;[+7Q5?DV#$;0$:50==KW?4'T;&.OCK?BK06IQ.C9W^;B2
M;*:W9.QN0.B:\*#A#BADZ&<7_+"9D!@@?57Q! AM2=<[O$ES+%O57A*)7$*F
M\7^]I5AH.7MXJ&N+?2%NZY8P09/CJXW+OG'?J.1BUIXXKMW,]_K-,.8I?F%
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M@RPPCI!8Z,T8-(]JT%$B8&VUVF'QPTU"OT?QAT^=4*9<<U78E0YU=\$,R*X
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MA6SW-F1][IR3HJIZ!M M<!0B-8?#4X28J)H(4\51IO,G_-XX%YKH=U??V$V
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MU*'6%O!#$2N OIJ)P?G V)]0#2W#SZX>]$'A%)SIVE:WY)4^R9C-G1)=.R"
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M7%09]HK30^L0LAE%!\*/J^'U)),S5FT-WTB:FT:Q BSH05WGT99/=,W:9L^
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M[<=9N3GS!:7YUV31Z*,)>I$%QV[TH2DYI\4[6C#R&>7/BYK^]&-6+)B*--1
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M*ADWNSPM9E* F49P[ ^]L0,"J+_:MU=5V,*1+)GK_U$D_L!K[%,C J>D:'6
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MK3LU@45=X>$BVS/I.4ODL[Y#?3/V\)2\#B8^7Q%46S@MO\LD(J"1$U24J]T
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M8RU?EHNA79$XQV+K^<>F=7]]N4MA\CH^.\6?E4SME0,<JWN%&SQ(2H?II0<
MZ<X;ATD)9#O;+Y!DA(W<A@%G%=Q6T5_A$*1)(,^,WJ_'"C6:-:2!&T!_% 95
M2DZ>JCM!R[O9<.KAHPGL&?U>-9E#JWN\,;5@DH^2\FR/[LH]$E7>GH!C5?;5
M]!/H 5X_>MOCB0Z+0VAC35M4DJ@@:W.UU5Y;E:,$V_TZ^F22VI3DPZ<:5=7T
ME\<48\GC#O09Y->^_KDSN+E82JVC?>70RMRKICKT:65%_U=<_\X+_A\ [I^#
M!4M=-KC!2)WWA9>'!=]M_=6AV+>9D]%*^#W#0 N]0HAGVX_I1 L^M8%3%[23
M-<>IST.ZHHED&>>:A!?.0U*-GV6E0"O&&5@G;N95>2"8& ..O?L1I)=#9]V8
M0+,IB*;4&)$*EX4]L3\V-]M4)SJ95%.]M1K+/IE$>'_T+1U+D1=S/LXVC(W*
M2A:$B07NEP^"7,5R4V6Y+"?D,8?Y@AR\NIM?]X==U@C$RMY@YBZ_]*(MQ[BH
MS>JTL18X=K&^/K!0:IHC*'Y#)^GXN9M#@:A]5[*R >^:25'FK.&E<O#,#I4(
MIK5AO:=6$>SR>41ZG5S1,W?7'AR16H4G-QN74P:^.=8BR<=#@ NH[X1#%3RV
M*K"SZ+)JY8]3+2\31*X=A,#W50;XA8<@!&(U"2?#F##<"?"^R0?"[$F*M\=!
MCY/7;T,5]-6;^[TFP*-OF;YB*,WYR.(S6B7)^VQQ+BT.VJ,:0N/C<NQ%[88/
M%(2Y WP0:VVNV&!D65MBGNY\-^FA@I!0S9JR2*TM'7CO ?#>1YWXPS1_#_F5
MIQUO^0WY%JH(FM7W^DI;WH/BGY4OK(P_BF=F1&DT9]Z)K)F;M31^-*,+@Q=5
MJ3%H/:5/&2Z^DRZS*7:.GJI$YB>=B1X9N[>M]%18;H5=%_._F=BO%M',O4YA
M9]&+>M[%2QUJX>^:O%[VK-.K%)<0'!']VZX+W<(?L4>MR3/M6E?8$# W)FB#
M&W1HG;Z>.F3U4E7CDC-I1.,29 JE^#GZ)O-4/W!48M20<R"96W3<(&DGN:=L
M-_V10Y)J\B6U#VN1.LMP*8YX^SQKJSP=M'=7^6A<J'>P0DB>=]S0^&/;.+/&
MHR-9NN@;/UORFDXTXW9W4@R#Q"-8L>W0M!+(8>3?8OJQ%7+J)>]>4599/#9_
MQ*42-D+>JN 8=?[RQ^Y*;K8AD5@I"^&9ZUZ91P5!W,1Z2>9(2N[<[\1917P+
MIOU)H:6KQ'A.]-7IY(\SYS&SQI]-?2I+S^TYZ^O%Z"*NPFX-<-PECRKJX]_&
M]76YUR?4\[@0;9OY1OC2+OI'9ZYJ\0RVXP.)$2WU"V+'$81'9O3O,YU8S%<<
M7*<^5LXK2FQ__R;YU847EG;X@OM0YE2+=Q+9L/L]<YJZ,I&FG8.+-N\$/I"(
MI[%5Z=A7_R8U^5>RGE?JQ1MB\JGY Z,]W5\'+_'$9ZYW?(IIR>"7V;0:7Y4%
MZ.=\B@X4'8!54;MM4[>VYP.3:4,QAJZ/F 7WA,@RN*?3V]"[Z&<T^=8LY@QG
M;5+]MJWZ!F=W<\;HU+F>EAI6N?[_G:O^]L#A8OVKI[LS/&99*E2>U!>\C F/
M+I4JZ8Z^C2!)?IE,E[(P41]<Z[9*?<W#,6&E$NFD_XMI<<W!]7.7</R^GG%
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MY6ILHIST$MUJ)5U5E3\F^U4M_*>5=SI\=:(S>Z'!]T<_R8&_;N&+4YKXB>[
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MM#K'O"VUX6JV*0"1@F'@X\:4<-K9]K/\).A@S.Y'A 'OXV-M9!X!WYH2.=J
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M)3+A_'(/X_O&;K.4]\LY+_P5]"V>:?*<2^XO7Y--:H"?B!O]XC1)XS,;[G\
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M<;5_?&0GV9NM'Y&Y3&VOX["<'>[)2UJ<K%H_""GZPSVT$N B>02!<HV_)^)
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MF\0,,IA8&5@:][=:1V%5EMU\?)O]L,^+?'ZT('&RUIN?PGC:!;1]B$,L_"+
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MG _O]4K( "7Y$?\(1)S/T/8$7$+458*(?@^8,(Y=F7>)&6>/%L6IX*0,(/\
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M%C>:X\V9,]<[ 29]&ZCV]2S'@<,>#<6IX=)><-:8PYHI0P%N<^@QK.EJ@8[
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M7\HOY;>W30BFAM $_\!3H@)NB*#V:1;J5NR-9H#&">B&@H6UV.A(/;2SABW
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MR?)J_>OR0(D/OBF%\8RN!6-(;@EYV5U:#_BJKDA0.SPFW5YM%_;>$Y4=(&0
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M,EE7I9ZT2__/I//_E_/NH;:&;Q[^)77HQO[JTG,_BK5@?]"^]5O(SCTLX=.
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M;XK'EG3"N&W-HIU0WC_F$JRZ:[O7/M$?*BX)D%SGW8%8BC:RG^G&JXKZ>/S
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M G=U" &'])8!GKG$G:;]!<L*?03<V$^4^J[  YK40)PH@T,%Z'V^$(Q%5<'
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M1*KY8*(5HZ)G0*G?G$*ER_)E7.=ROK 7U@.MK6K(8)).JYIEL;N0< ,:^3?
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M7(D9:C&DN&^#QEYO)!O#;W3<B4CH%?0O@$Y8B.1W:G\=;5V=^OK0C)?J#9M
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MD+\(:"R7I,/A:0((F2XN65S*#KJ\HV"W-6]E=O!'']]<%F5>)\GN1=2EPDX
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M0+ W0?^FZ<DW*;$Y9MPZ9Y2E-,6TV%&T([2O4#!A:ZX7-M_0<)_V &E>^A=
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M M=X2>PS.V==B@13<&EFJBWTVQ3&]C2U0BW7]@D40N:+%D]QL*'<<-S7 >.
M/(5&<>;HAV<D5X:?CY/LO'Z7;15;.\2+?WTNO7K4T__!H >>K1!#.CZEOB;7
ML7YEQ N>6V&_Q:I1C.ED2E^QN#4K\"Z@ W-XH#M%DS&R!*\%]J@-PYVJOO ^
M&IE[#AMMKUF1GQU;G\;..==T9=B&JD^Y+%D;ZC<%B6EE/B$Y+?.=]_=;X67-
M-D[<%(@E&C2$#/OP4&:0[)HV"9?P9$KXZ<%@":SFT#?9'+_>%;*VH NO3L^X
MWC),CN'68HX]I(KPUMQY4Z;.9=71J.**.16!V5A\*7GIK93HN)$JGQAM$Y$(
MK%UB5/=C"3D=2\8KEZ(G++P_T.N#IT=ECV/O.)0)=Q!"EO$]6]]MQPW;%M!H
M[YZU8\H?N#9!AODGHN9N*23=WK?IMYJE8%#]]W)R?$?C6?GH6N:@$EWIY%O$
M)3#5^M?#_85-9P/?5)Y3Q'9H);TYRYI2K!]R)"W(2UN[45Q79+*+1:#Z?:BX
M/!$U)^\_-E*K%)ZAUT+30GX3S:(NG;Z*RTK_@ B86/0CO-_?Z0F:&6NGR<9Y
M.RU5OY(U>W&VF-]57(D)4HW ?1<[E*-5T @D>DG0?4'M*Y/[K08@:Y#\ ,2V
M\JHA1[N%_GXI5O+(.OZ;/>0U42D]F.;_G9X3,T28],+2QU24 7K]Y(4&.HFR
M3&OI?";C/)A<R)CPOFZ1@'Q) J_S_WG)R?\#A9A".1[BOW\"$@E,\(]UWJ'Y
M!>K9A%<*RW\!>@MN0-MQ--$(D=?:OM:N7G 5T(9DK\;%LXAF5-XU[Y,'HI9F
M4Z(KX.(\>,UN8*+6NU.%#ES9R=@R0FE7MU58J^\Y=V#G&-X4S -U@.JI!&"_
MISUMF4GB=$"*&3=G6S4X>(6 !GT.5>YF6[$<OML^K=1OQ3^.VFQ8 F_)2Q^O
MF_*TXNGF%;&ELXWI[1S'X6:PCWUSJ!Q_EQGZ;8WJE(UH+_3%6TIX*6X'8K+$
M-/0!B3YSA4V=+T&<Z((+5XWMN4O''X7]W@WMQ9I-5-BWI0U\*+&]6>\VZ"<*
M^6Y@MJ3ILFRG2FIL%DCKV_SVO8L+O>/D%F0YH1$\MO+*^=%<M[-3I$QU]N?I
MUODI/)7*ZDL.05U98TAJKUH8*YYU.14G7;8E(B>C, &E$N24S8(2<%_JH,:1
MWVE?<U%O\=I(0WL\0*&#!CEJTA1?3I1S6P@<D-R$)$)#T+3#9VFE(HTAA2NU
M&][.-6:YT6S!B8%)(VG7P!^?2 >WG#PHSV''B.TS'S_K"3_6[*"WG;__ MBJ
M?CJ:<7L:]&&YJ-=6IX@0;NDIU9V/X@WY5WV;_PC)^LI"1-IRSLKD2<1WJYNG
M%?>*6I]W(0-@=65!^*""Z#P6_/JR7)V3CR);[-T903;NZF3#S3+/#+[90PN)
M\%3VLOP^5?!P&..^F>7CAE0+&[EWJ&T,S=QYQKM/U6,7<J[QILH,KP\'KXRE
M*KZ0QK@EVOJ>3#?@G1@D\[-.R<?-5Z*LDP8C+D1HQ'6_64"@\AKO\6"\9K_W
M:P9AEV(.'UAQH7/#?):FE^RFW]D918NU&,/1>[I%^JF TH-GM./:A=C:FHEW
M%=Q!\AM5SM4P-0;-+LG2"VV=$4;N^WP2 PK;\[5'WJ)^7"<ETN$C *#I;Y'(
MJ._T,XN0Y#FQ;]@-6W^$1:S,E>$)HX<4KBC(543I,B/LX0RZ@#RJ<.Y3:P;+
ME/V?+Y*GP=]ZZ8H*73GIG_O0N/TV*W(^25\U6FX3@@N(]GC :V_0R--/!EJ3
MLHR._K)]B^0LX5@[V$^6O>4+>\A>[@5QD8%#=;&BZM#T=)W:DQ;-DLD N_!N
M7^F7U>(Y.2:,RE[-!R?S3KN4-?:GM\#NG4/CSGJ)7=]M^/*]C#R372ZE_DZ?
M1%2,A*0@B)&4N=,@X^*?:R//GM2RZ" M;7_H?#%/+X&_%C0:/# *-=XV.E*K
M=#_.<A"@I_E123]AA<B&T)"PM2UH1/97Q2!_LU]!T^UM1T:*,M5:H@5X9/4"
M(;$IR\$[8:E);=()//\0!\__J3=!9EPUD/??.A[N:^2]_8.KG&(\N6[6<NH[
MU++NUGJ,0CP#4M:]Y'7N@#!H5<M,F$S$")>1*_*NU1RIRT+?;=46;>B)O,L8
M-DYX8U506BYR3*59, _>RL^@US>,<MF7%2Z^R5E44[F#^_@$C0*:V!KJ1Q-!
M0L\<\"K\/C3Z6HK_,*"V?-T>0H^,RD8![=UT7LG29/5C1/5'3& :RN&T;II^
M#[\I?"93?800A\S690DXP.O_P*&YU_@75\>MTQ!IC]-:$7YOR8W7!%L@86[7
M=T<(Q9>=87#/SQ:5#O](XJIW!Z=R(8>&Y9O=B',JO:>O&#2CA^@F']*7'_+_
MX&!1 #/]3;ZDXUPNI;QP9Z4[RF1;3/I('R(B-?+2V3N"*[;49H]V2)4_D_X!
M\IH/#RO.CD8X$5T9.E2:+5/'LX.SJ1K2_.IB12UT/MG?)3J-1B-#,/J<7L*%
M*4VS\#L<<>[?'Y_A^IR1R=?YM>[>3PRSD.=8<V^16$[+7M&: 96-DE(E_K=[
M6;;SY7OBQ+/53#853O6[GK=M34K@KKP^#R='Q&LO2E0BW59$I6>,:,,J1)ZG
M0*;$TAKB^+2=#\Y%8WR"Z![!S.:)H<IKI?4E&ZY:"8=&WQ-M_3:/)+F!XSM_
M6-2I!47>I*"+2VO1&ELOX.3@?B4T]_1<_CP1<%KSF[V]I"ZAJ<WLA=/]N]$&
M?B^*8:*V8A^%WPHY7N#6%A1T.3R>\ZUYW]'&]T$EM]JXF%\(NPEU2F*3V:;F
MAE$IFM?%()S31P9:O7N@&,>@@':=W)FWY7#]*T_VAXF@D)8$_8WX'-$$$^T%
M6_C#UM=KYWZU(??%$G6XI!(^2W?%07T'^/S6T:F2@D=F3X3(:[9="/J:UNX<
MC\2[MG>A_&8;/)W)3$:#5$Q%,/.DV N=*X;I"]]H<A<]U%:S=!O%%_.K"NDS
M"[V)ITZ_[B&RQXOOPL/;0?8^3S[Q@FN<SO9[M'<,VFO4_HY(_"\E'($%;P,Y
M=^"%KX3*M<G+I&-RYD'IP0UZ_CC?[U_&=!92DH-LFD,[>OBX(,4RP^[TM1&%
M;D.:S.3S'6$TCYFI_.8I*HX/TK9>:6Q^X%YN9J4:C9C7"9Q.2"URHU7I^L59
M$7(%+^MM<WQK8SZ7Q"]![ZX RE_DZ:4?=G]]#\$T!,LI=I?XI06A^[*'4*%Z
M,V]\6^W69W QAZ;(H3>EW-Z[7W(%8=5=U=5_GO 0G_L]?+X8SW19^O=K&^XO
ML#1Q,!'D2+^$/9VJ7'V^6]_#R=R?ZZARUP_3=X#@6WA5V^ARQW"K;GP]WD%4
MX6XBE:37=%*Q =I#['_M8F&GQ!KU,& G100 HE)B!Q.WR+,5'F'ET[-YS__E
M< +QQ13FWB[2%:%]!;OZT5,=P+#^]'O2*R66VY7W?B99[997_+SR\$044!ZR
MPX*R5 (NRYNUD(-E"M&W!$4-HSI##PT6U 2.UAM??7LR4\KIG_W(6'7\EW:=
M^'PP@B$VN^R/D"0S(NXX#O5DLH(@;L5T'W8 C!"YA^@IU2[R'"#^,0*ZVYU0
M@>;/O"8QLQY]D]+U\R^ B::K<+[Q551^EL57GK-/MRUN/G4E4GXSBYN<7'E@
MJU\1!;@>-9'6POBDVQG\**3_O9]_<CF=2GYD,A,,S&C5D<RBCCT/OT[OYTKV
M&59W:\%1QZXUVU<[YOM3JZ$(_?@['70CHJ;SF(F?:5UO7IK.%GJ9!;;V:AZ'
MY0=7S#Y/KUB).,8.?\N(,)MNW/@ADK 3R!WY23="Q)$T#KZ3EG-G6/ 6"2%$
MF-!Z>2$U!SLZ%& 77 ^U?+7^B8[_&(QI^K4Z4[)D)C!DSV$>OF\I>L*N$:G=
M?)\X3$<Z:$:;M"F&-TOV55NJB+_-Q?G],.P0C*KE;0#BR_FU0^/D4[W6(R;C
M<6E*K@75A@_1#T#!!K/-T9,]SE_1O%];_Q01C_\W=:]I:, T #QB?GG->B3J
MN,>]@6\SW;?)^NG!2Q2C4P?O+Z(3$GZ#LTV6F.DTED?*'$.%YKT6?;"5=_?4
M;<MZ.5I]@;K0*@25ADDA*4@"J&XVF*)PT<?6.KG(\;H U:57([>V_7@>#MPN
M,.)U@?P%T$#XTCUAZ#P>15G[/Z+/)*5JG=$.\*R:KTC]*?,3=P'F"(X)%,V3
M,3FS2]SN9,CO4C_5M$V:;UYH-#"9D+UVZ,H,,F0HCD@SK3<=C!.MI#+P]U)O
M(DP1H$,!1UYZ\RJX_$3=TJ^ZY2NS.N.RE5]ZN;*++>&!^+6>6DE($%BF>_#Q
M9<;IR8@7BG L''=HN]G_"Q);<<&G\FGJ*+58*^=AHIK(#P-R]NFJ2EG>$K.!
M'OKLMCOP\U([PP;^+DJ*K7<_#,RUV03U \Q1"RDF)\[&SEFNM?O3U%6SYKQ_
MN, %SSZ /PB,9KB%R[^;_NUEN4C+\M*6N]G0[^$2:>?7]T&_\6F"Q;H-[W)*
MUJ#,FN9MQDEL0IX!N.\ZH>,V$5R+#S;.]'=_(3,8WVMM%]/TLZQT9A8%^-'2
M]1Q,-?'D&;Z9.NWJ__EAA%+2MJYZ%+S=%7O[T"SGR<P(UBOA3P6+9 7PQ<&+
MLZ1NI$;PP8]CL6P*^9,)?Y%N')XSS7V@&'@0CYN=>DWF*7^7(-]O5P/<K$)4
MD: /"^ZR;XLR+!,P\6W*/(6[.L 6V9-_5C<]^F?O,.5_\.$H_$TZ0H_*+$\;
MRWV@WX\(MBJ6PMK6W9HHQ#T^>J=PS-/BJB*(+1U<'/RTI'!7;X!/>QB2_LNH
MZ3ZL &0%%B,#)?4.3C>/4IH$>%P-2<G.@)@<@M+76;LMXXJ5-N;RUZO*53SM
M\^OV;FE(H\<?"/Q/&TPL!ZE3M(X&;,AZ/4^S>?R\T]*'5OK7C/WZ=;QOSWU;
M\V!VBL\:$;#9;+6[P_9[C\A=\RM'V?)9,;;9A/;O@5]==CL5ZWFSN@'ZT[A=
M7YMO4YE94[<^I&W5>Y>FTM,8LP?F3!KSWVN?4%()>2 #A19@ CC;0"55GZ,7
M[BG;(6:<'ISRCDP+%T/@4"E-<?&9\E'ZRI<-32@+V4=$?95"*3\TVW0#9\--
M[/ /M_$:*3%\D,O8;Q5:U:_L[TD=&HO=F#]]E8GQ2DO*L%_4@=,T)IBX=E-H
M3<P6500&!S:>?B$U3-QSLAYD.$N>LJ,C38 ,EZMOKE)#MX;:2Y*:,!7+JH*'
M19FY2Q6>5@G].&11HLNV6)5YIF,_5RUD<B%QK[=RWB(OV@I5C#5_.?; #+TN
M\%NE^DMTUI1,C(-FT]^90J5\)+_'\LW7U?)7$3]PG6K-A@N[ED&RP]O$<HC
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MIK34T_0'\'M_>J,KM]X]>PR#=-V,8!1^$Z*!D'P]^GIRM*I8S+)R>==[Y@_
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MBLQ/;/^]:-VC'G!P_3O(_]W5Y.4&\P]=NUUE.F+.G/]W>OOYNZ(V9H%.-QU
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MBWG>P1?65Z[,0%G^1A)F_'\3 %!+ P04    " ";DUQ4OS,SD7-D  "F9
M%0   '!L<G@M,C R,3$R,S%?9S(P+F=I9D1V=SC;[Q?VAQ K(79B[U%4""TM
M:L\@9NV:*:HM.HS2QB;V%JOVUJ*HU=:(G=IJJ]$J-8KB2ZO-V]_[_O&>_\YU
MSO6<^]SW><YU] QTE91=.D 6%/\!_\]0 ( %  ( D " #$@!@!0*D,("4@1
MB@1(D0$K +!" 598P(H 6)$ *S*  P <"L!A 1P!P)$ '!FH 8 :%%"#!6H(
M0 T)J"$#LP PBP)FL< L 9@E ;/D?V\#9!1 Q@)D D F >1_SK_:*!2 10$$
M%$#Z%T-) 2@I%$H*BY(BH*1(*"DRR@I 6:%05EB4%0%E14)9D5$X (5#H7!8
M%(Z PI%0.#*J!D#5H% U6%0- 55#0M604;, :A:%FL6B9@FH61)JEHPB R@R
M"D7&HL@$%)F$(O_#\:]M%!; 8@$"%B#]@X65 K!2**P4%BM%P$J1L%)DK!6
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MD#ILF',_!;JFSA0>85JMA!AM (WOY"LVT-$P0T\FM,\78J8(L*A(=QMA$SD
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M#GUR"7TRRXP+]S@>:BHZ-:M=D7/"-"/NV@,C-R-?+TI_SXL>.8QMS("(;W3
M&B$J^A^V[S$'YT(7#J$N/ .O!09<'1C<+J$>*@.>/@/W0@;<NEJP9L\6CWD;
MFS29(17F-8@?MA5&A)@'\)8Q8M>3H82-$A-[=A8_[O<98;6* D.^\7W?)AC?
M"0QGA0SO_]M@^<.Y(8QKA]#6B<9[<D9$9N$A2F6]_ >Y?A&#S\(ERVW >1/]
M/UC;X8%\#]>"IRF'68LAU#<^F-B\U9ED7!,8U"0I?]4P);4D&.0C^C%@Y<5L
M8@> _5T1Z1 S5PZ!$, K.BPR_4.*AIUZDXSS1KY_*"2^A&6+]-PA0<) C9!1
M#.0 ,HY!C_ZY*\HG-,I=S.0ATIDBU]2-9MMW9B"2.#0766Z)%:<T0NZI@T;R
MF&-&FW<I0$AYB%AQ_R.;=\\A$]L$9AIR5^0 ,ZOWE?=;^'%&YEH\G%?"'W@<
MT<_$_/:]0\NI/5O ,^839X8#&/NU35EPI6YV3_9@)_/D?%P+,Z]+D9WT/HQC
M_V.J7R^U>KON)*,I%Q%FQK01,FVJ80:;"921*Q4J*%7G[3</X9=@ >0$Z$2,
MF9N]:Y&.=/<P=#Y_/OV<8^V%,.ZO,>[[S@46S 6_FPL(9?R\QEBRS+9EJ20O
MUYRHTLAW-.&LA L0I\N%S>-##$\<X,U&#7.+$\I^A0NX@;6BEH9#Z"*&H;@>
M^OEPX:7J8@ETQ,5GVDQ.Q0HT5>.#V,(O;+ET/--WX4LC\3-#?Y-(-P^I&>'+
MO^T TSK6 [(S8U_^\LB[9=+*\C>!60,7[H'&'%F*%^S2[:S//C$6SU-6EG\X
M7N'F7OT<RKV^O_*N,8/KYNJVS.HWQ]7SN=55Z )<@^>HA4F29X%3YKW$:!-R
MMT;-KQO@6Z-46P.<V#WFN'^=O;UG@QA^]GF4XA.S'D^N.H35:9WM^3I'X3K\
M_3K7ZCK/WW765RM=D_=9U" ;FA A/N:NND\OY=Z'T7-+R*2>%K!$\R)&BT"!
MN?.STGZCZF#4X:8ZWQ=-M2_:3E]TGW]1?P56+W Q+@E8")KA%%\H.2J4A=&\
M9@X\"AM1X%M*[QF1'(/Y!OM[(4%TAYL>)EO8PBW/]UMW5[>\#[9\+OYN^1<"
M;L!74&I&*R5P18!/R?D;P_I4^@J<,V'^5:KE6$1H<#,I8YUT<L&\S.L[H@Y6
M%@#=,MG)9/R2I08BO-_)6=W)_KN3>[!3K/;=K8%YLD%$K!12W2DRL=]FSL=U
MU62I6BZCY6BE0[HUY-%*E!GDQ<579\9UT/6M6X6@/K6]#),]%&Y/";,W_&IG
MZ._>X-C>Z.K>QZN@<;4]M[7=<@Z0E_IDX?Q2@Q.8^(<+<%5J;9S5"Y^(;P3+
M=H<+'&U/MT+<G+<R"@%YS!8(LT7K_,-C]0=MT<Z?I*W_DK9^J8'()H<@\@_?
MI*WR,69SD$&-"8L![W:"7P^:?,G5P0'J?'.'KN]K*D58V16AUH]^IT7@]*M?
MW)!@+R38&PEV1_Y03CF63=Z3?'&LSO>3>' \I 923-Z_:;J350A>+"QV=71)
M6_M&G_I)=F5#PF:YME%SH')7_=U@*C.TC3Y*D.+'U,#H]5M[N6MC->]%9$SI
M7#Y ,F _<XOHU)QVE(OH,KJ/O4PAQ-6SN^1--W6(-_+PYOC/&$,C7=7>UP>5
M&P<G-7ZRF2PE^OS,;ITS"5=9Q.K9:J]^WAWP[+64E;CZ&1=]DC[.37L04/5\
M8Q[B65=+-^+[TC#Z1)3_RYD:* .Y;F0 R4@!9R";6%]]]U('2ZC]H'D-9E,#
MLYJ<!9&9+M4+]XE%OV[]!196F<>>B3!GG-.Z3!I]P!F;'E (L=+I'(4T0J@P
M8*T/,#LFMBNHE#[?DL9308AM%%&0CBE,C%2\A'LJW[(%(Z:Z#*2"(:Q&""R9
M?<,040P!BK'1"0AJJ)! :0*<@/#.D.1&"=.(&KL-1(9[^D:+>7@/>$YEI)@G
M>0C3B0T52]IIAX,8DA8X+;;0N8KW#RS$Q, X;E=YYDZ$914FV!.H4T=9[IA7
M&!>H17%9U7QTO>E=1\BUVK5^Y?ANT3)ZH++I)2$C](GA7G28@>?*^ZA.1;MR
MRKR- =)CX9V5NM&SB_LU#Z>@1?+3YQD7R(I%E[OC!]-DD2VYL3>3(NN!EPU\
MS7E,XM,D.N'$]SD3U^8LNF1_+#2B2B>?U9->O_<X.=,892NMS.&6$TN=#8T.
M@ S+99:'"0[<RPVGH]] *F$)33SR,S/3"GT7.3S* S#[K('V!)[^C%0"[;%*
M>0)8_,#M0$6OAX?N ]^<T1YJ.OCM[J085'SS03@6 D P2;+4G.X-U1XC$D7_
M<LL:>LO]00 .#IEOD&'(C'.)0DN+-&I7X*N+P=T;N<3KK%%V%3G&>%L_2>/>
M0YBXW,1\0HZ!_'#9+8\'YT>#'S..4G+0SRVC"Q5Z;7R&T3YO#-(^/\B-?+OA
M>^4>BVN1H&[EY^>Y<7Q10^1?T(\"V<-4(YZ>#%I-:/PSF42XKHAN&CQVUQMQ
M ,X=;T? ?*MR#B06]* 4 P+"4'EXIHS0_@"F(B=6K818ZBF!T$I4$+D?GQ9N
M(D1;\7K[HOI6E2=W-#Q)_F@4;<RU)%L1G*#Y7<<Q(*JFIC:0^MI\W?%(@PWP
MJ@XI#IRQM"Y07[=5UWSO[W9MWN-*=3% ^<FF0K=DJBT,-=3;_1,,==/'PWG.
M9AKJE_DZ7*@9^P^/HG>"-Y&)XR<[LE %^E(Z+KGGVL+#J@$=%H[L#X:\1G,4
M=KPJPSZ^8YVE<KN!3A>]Q:J5%J/ L>E:?\(\5)3E9!>=$SLS$9-&5?;,!FI\
M27[\L$,=NJ&/=<5/NJO)E^S8EH9/'5I+B4Q6959S,\521+.+Q.G61SR2GJ[R
M*.CGFO=X&DA16_<!W%FHS+3Z2)MAEK+;IV%N]7L/)?YIK4Z-,95T;O G"8$?
M77,8]@>Y\@LE#2G\7#S#<#Z\("2QKULZG?VD<5I:\EN9'H3G)(]JD%"1-RW^
MQ[,CM51:V2):7/29T.YQZ,2?/*4F)4O_P^58KTR[)NW5N[Z;3_=^FN[KSB9Y
MNC[.$83...42X(JQMI)AYA99S3/:XG3)0EM3\WJ65"*_0A,\#Z:]M,>RZ'PE
MF[*6O8BC(?*C%1Z^]5GW+RX6.W8O?LQ9V;IE&]OU()/)_7< 4TN0E[&1;&>'
MM>BGHFZ?'9F''AAG4>R7Z[RBHEQ?S*$/\<0LES4!UC+E!/EH/\!CS5->WW6>
MPC>#SG='2FYO!-:A]"F]T8M2/ !O()QR+6'CBS@K-8@%O.LG?AR%9*6YT1U&
M3($T"MX7<QU&#W69-Z5_O N>&M8W/-. Z%'HL'H!R67T+)(:Y=H(J!G?,WAX
MU5[.GFC-]_195UR$S#+.W-0LFOZ/$-C_5%8L;0AS2:4T5,<&TLP4<!=BS^!^
MO"_A#I1.B)\I7-=A]$<$OHD/_])::SPAH"-K U#PY+REGL&!J:LTQ"+2Z'AL
M]J031)9,:2VX)=XST*1+?";OQU* FB[$LC5.! @LK*]5_?19[!,H,%31T1Z'
M$PKO$7D/Q8IO>)[[(]+4[<3:@#)K53$CWV4]>+Y-SZMF/2%YV R[!;8_>5Z&
M:X26CD,TBN4062DPQZQO>,+:3(AK3%CM-(6?T>"0Y\S2KK@>MP<PG(%:A;.G
M>I\+++K3T-I2TEZJFY&C+5J^KJ?48YZ*6N:&>=YC1O%*YMN8!U]%-XLTHF5F
M"Y*>SMQJ@:NGB&2^% P0,'^-80@;S9D4NT8A2/-)/;R?ECHQFJ5"V:!7UH5K
M%'G2/Y,#T?61&AK^D! A0H(-2O<-$9'OKZ<'GS.D69T.B\=J0+*%QGP\#VW<
MQ\CA-SQ$M&[5\0Q (ZC:7WSTXC^%[]YYH80P;AM24BJJLOQ>'/V];%I4^3"6
M772JVD#%NVG;STE#2:C&?.$G/@FOS]C;IGH,$:%P+TJ[K6!6-GR4(49<2T\Z
M*4DO@_B)2P$ !/_$(O_LT_T@D(?O&ROPW-G3,EO%^+O=MND-;29ZQ"/H^ME,
M^K=K;-*"YGE^"]<XN=A29//8K%6O37932A>QA"F^-+**856 [<2D(<Q3>H4J
MX>J,CK::?6F]AVI"QIK2U^KB,L]0(I4#VOS7IVY#B';*H= (?5$>D-? HACW
MU";0< 6?+T&?*&U J7_U"5R.:#N61O>Q4?-1LJ[(30DI>6EA3RYEV_\<$C:*
MBP.DA!S,4Y]_R=C*-?8)^,JJ .;26O6>*[%"?)4(\":[BRV-E!/;*3@?3*@U
M0*+%7XLDS;!I:A5LTS@^$B)I4,R[-ZA6@?N=,4YX]-OB R"\/_2^J?EB0V&"
MF#@V;SK+# 6'#CS@S^RCV$RASI5]QR$7-YQFAV-)-"CS\N6M9;;GW&==])&6
M_YIN\, 7]K4P5E$N9F=:!'T&J%,\M-PA^6 =-PH- K4Q59^&] 8:WH5/_,*/
M*BZF![6+QTB*BLL!:)MPXE!.;/_\C6&,ZW"=?M'3F06>%8U5RV:?_3$#+3TY
M7*SO.WBCNZVBUQ(-EW;S,!H.Z , WNCC%B'F2[3,S-AB8,"$P.$-*=W^!C^+
M2$*.J.*6;)0N%#/DRL-/;C$5'%C'DE>)RWM"/.B-7_G>SNQ'1#8[1<M?#M[J
MPJ)BD]K\;)_Q<*@\W[>JX%FQIVYX1_\T*U;W_A.$Y=%Q 7O?:<5U8/L4$UV<
M1YRPCFB53Y0OP;)]ZGE6AJL?E$]Y7K_>N[#]<Q2:>KQ[)Q[%J001CH]]_T?K
M$_.FC0S7I-@"EWRC0%Z:Z8M)48L%@9<E*_MBWX="BOI4#SX.'CP9_+WRH]#U
MW2;OUK.7X_!6XY\NGKU6[4<V%@IA$6Y8._&JSKC9C#]/=9(X,TTJ0S[U-F/S
MJJ*<UG7_4Q-+O>;//UJ^@UUA3G:5YL'^U;$2O/H.NAN\**7/FJ$?P34SX;WZ
MPXD,;?O/\M"^ +P,NO5?.[_:8;SIY2:9[Z+W/\L*X)+]@WK$M9-N"E2>4.]X
M[+[X'POKR7MW#$9_.!]NTMCW/2_A3[ESG?25L9-B/O=7<\^=$R4?FX6'8T$G
M?=3VJXYEH.\?*$[HNW_5AC9PVVNH6[ET4U_64JETTUAV@RX+P77=='M,M&7O
M723@X0NL$=_IAX75-7NS1KDU+GI20,/7'MW\(!.N,KB>N@HP#BNIODXO'W=[
M97"CA[H:SZN.6KC9R<O6^W>:WTTC8B8\_G#S@R DZ[A/1:P,%K#T4F-7906F
M)-=VC8\N_IX%8]@Z+-^HF@!/JPWK?0N7!1Q$CJ3Z%)OIKI ;H?_ C9TG*UU*
M3<TGA I IP^95/:8I@/3;2X*!QN@Q\5:QQ>UR"_T'FV0 9=\XB9#,%R5RD6K
MH;'+*X_H[')]_+ E?!B2G4OEIR'H3L<JI*%-P##4=VJ_"H1Q843!U6\M'?IB
M<A@/J]AL9Y)W4A+MF_LSCB _J_KO$/MM(;KV&5#7$,V_N&Z.$_Q_RGC1R'YZ
M28V?SW194UG^P%CR,6E);^)N9L1-Y\05"4NI[B4P$@8T_=^XS= K2@W*L^D^
MW>R/ 9C^;/>C)'7O$'7&UW3.^G1^.G]PW=-SN*3_80$.72N^M$LIH2U[0I5E
MJ*T7-8,7GX9N-RG[Y\-@!-68:7>\IPVHM";E-E&?,D,G*J??M6MPYU G+6,P
M%4U(D]8-@0R[$'7L3N@9'Q4L*P'LL6$[\?&>W;WSOX98X@:B+PVJV@HBE%/8
MUUH4""EDOX&7=337[_4K6/05:W]P>#R<HS <%#(8TZ#G>*ES1R$Y@,HH&&*4
MN$3?H@08Q"8 VW1_U^/M#?1KFF'1&4;4&E"!H]>Z(!88NA?JU=911N>SGI?4
MI=_]^)US@MXKGV$']^$F'P,GGH&LLOZA?,:Z+T:AM<-,(F"J=G3N[O P"HT*
M"4LP)P],[-$_D&;VH-/L:\97H5$4*J\BENB1.^CHWZEOOB=XJ\0GHT9ECB'&
MZKUU=&W/'-!_E Q>-).(RWJI"F,;E@:A&3JOY]L5<-KL'8GLM&\Z&Q+:%(RI
MBT</?.2;+T8GEB,Y8U5['3YJ:*8=1=+7"(U([\3YT>-5Z!2X<I/ZAJ0&40QD
M5V[/ML&&KOYA2_0SR# ENT%V!JE.>F*$;7B-A.\5R@Y<,$6&$ M]# _S\45$
MC)A6WDG&J*$-,)<QPN#!K=,E^915RQB=(//;:+PHL<PK-8R.OSA'XZ0];  &
M,LB(,U!/::PU9M6 4CJBAXAZ03RC=NBQ' ?TEPP]NSWRQ[H)&IX4SCU+EA5Z
MEO>Q8.;EB;:&+EG8B P[?LH2%G\R4>P -OTU57>H3P!2")[31.=7G,J,AEPW
M7\)8D#_IEM2+>0436+GZY5)J+LOH5@/+M783Q!'_#D@F6+P0(BTROR]7R,.D
MMGG$Y60DP&&8LH $W!_LAXR^'F+8@Z09* %\9BDCDS 6ZND*7%:"X;25:.V[
MD"DP0LM*9M"XBD$NE.')\L"V@LY""MTBJ=R>J&#WU50N1&51LR)E!QHP"2U0
MU]E<:UGU5,W%28BN$Y$?H6^&NF7DKZD\JG[!''_;,>7!I,Z(-.:Y^\2=$\M
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M3,MY0A"=AW)MP")$O!+R%MIR(U,']((F_[N+Y1QTYA\0V"E],R2(.'F KRS
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MDRC!RR>E;*WZ7 1,3QN417W/;TVOG\^0;@$S$U6)*-/@XK$[89!RW;Z/?'E
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MM-3FRH1)@3G6B[G6GT,[_'4M''HVV,(KV(*BCX3.RX7)E_UUK81!Y@6]N>?
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MY*=)(L9BRQ#DB4(_=3.XNNNFIHN\8=H)[!M8KA527)"@@>:3.N9((@D,,/
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M8]_<"3IPR3Z+_ /4BQ_V";K>G5C^Y]J18WJ+&AKV<Y^DY?W^ 4(9O7W+,L4
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MJA(3\&\00L-%B5N)ME]_^<;KZ&1AD0244!!F*B%6)\4[F@H!A,&2TQES*E?
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M.)3B'JRXAB9("#[]W+EWYO>=.[/6[\Z:?<[SUWF3]3XY)^]^GKW?\[CT^!M
MHJ&BK@) 0T,#O/M[ !Y7 $H #'3T?\Z_@?GWQ,+%PL+$Q,+#P<'&)< C(,#'
MP\<G)"(C(20B)<+')Z$B(26GH*2D)""FIJ&BH"&CH*3XYTO0,/Y^!A/K"1;6
M$PI"?$**_W(\_@"0X@(FT;DQT)X"T$G1,$C1'@< S   &A;:OP7@WP,-_>\<
ML7%PG^#A_QW03 ) 1\/ 0,?$^&?6?Z\&_KT.P"3%(F,54L0FUWN/\]2-0C@T
MN1"7[65]+^6;:3B[R ?WL"=X5-0TM'0<G%S<SWA$Q<0E7DA**;U25E%54]?0
M?VM@:&1L8FIM8VMG[^#HY.'IY>WCZ^<?_CDB,BKZ2TQ*ZM>T](QOF5E%Q26E
M9>45E54-C4W-+9#6MO:^_H'!H>&1T9\SLW/S"XM+R]#-K>V=W;W]@\,CQ-GY
MQ27R"G5]\P\O-  &VG_$_Y87Z5]>Z)B8&)@X__!"0_?Y9P I)A:K$#:9HA[.
M>S?RI\*AN!0ODPOK>Y^PB;R!4WYPG\:C8A?=Y$#\0^W?F/W_(Q;V?\7L?Q#[
MG[R@  (,M+\W#X,4( ^XUR^*X0;\)W1>;:L.RQ.",.$[IE<Q1?,37W^-<4QD
ME.KXM_PF2/\Z -ZM<QD/S>,UZ@VFZ)3?3L1?/FYI'"];L5!GUP36_%B0T.L,
MB"U)^DDY'58)>H[C2E^('2(%Y:6;',ICFJMEA30M>HY5[B47)7 #V;Q]# A^
M%HBKXRFR>.*(L?DVOC+HL5OPO+204XZ!9Y<,-J:&-'B<D2\QZ&*#*4>=K2@Z
M)0N.\XAG:H$0K:WE4LB, $O<&%#F"X:VT;AY57H\8P;7'M3M+8@#T=&[+@YO
M/[XQK&-H(5/V<L,;(?"8).Q,9$A5)7\/E9WNIB%XWLM JL"X1CF&DMZRC^ST
MVK2@'S#5KG:]<:T#NG@XV;E11-C'J>,UB-.:)(?BJ016[4(20!)^HFYFJ'#-
M/!,.8U*VKB^9);:K%0!7XSH6+[8LP&I1Y?*Q:5"AGY^C8Z"+AY==K\"[2%N?
MT.@1HH)==89S2ZMM06CVYI]0D)M@A!<O3,/BY8*9K^"IZ/W3H]-9K93 ;@T+
M<V5Z57RYW1\?B&C(0Q0+B,V+ZLL1Y5'@-_=[BYXCJ3HLEJ(9R14M'#&AG&8[
M8^B2PRPQS?==9;2=A1506M!@[-CYHO=9WCMS^TJ=;\2GYS,A@M.6SGZW:B"Q
MI@6^BWE$9(:7FUNE>(KEPBY'S/JNB^E!S43Y1^N?*I(?L'TG?.M4(QU.6=4_
M>*4_HQ"6(C$(I<4DG=/%."B* 7#_5U'30^&;H0,'1GDQ>AAFPB[&Y7#:VM)?
M6-JIS=E&OS*T>W%2D'IHKM.G Q79_#.L+L8.5^F\Z9U5D'A]$SA?56:209O%
M3J"H@BF@D3S!C3%34?$+$;>G3(.9_\V34>=86YBGH?(=;;N WXMC!:*B@JP;
MZ (TX$OMTYAU3&%-WM:W\0JC=EPA@'W.SOW-?!@_?'*;"N)7C)(?3&\?*G7$
M@>:M*O-Q_%ZEGHC]I4PVV!JZI]KFKBH3 [B \@BYD0->12MBA:Y*$955'YD.
M1L:6KVX<4;<@Q<6G,^W;VM*L$]@Q.#*__ "@NP?H8OWDS87O#P@2H3J,%T2[
MF VC=+MGZ+"Z$ABVY*4HL_C$G_<6>WVL9,,N[4$,196B>C3@S0L%2<?04O @
M+#>;S<[XG5!-+3V]RJPHB.S)VI!? 2&4%\<0L1Y>Z!O[<JKNDAMV:>$!P]"&
MV%HC$UDQQB,Q'*#E\D),\QKG6QF1GH\ ZF64Y;&>LX4[TH\?[%+>DHEYI@I$
M1CUAU8JC8FO]_A$C;6(S!G!T4.M]OH43=0$S#10_US/C7=K3]$HXDHB=3-MR
M-&#E V2V\)+5I[,Y3A Z.=R,UW:4+CM1Q;-".B/LHR8C-I,* 6'6GVBU<4?>
MX9YB 2R+LAK8,Z$_EX[#L[P %'K*_T?X;< (X1-7VUR]5M2^O-I=X5I="S7Q
M-49&/.,,-M\EWW4F#SLAY.D>1AX$$(+QS6.Q+L%*L?T9ZZQS('6R<:#@"E5
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MAY'WIXSR+=^=&RKT[]I%X9C'AC"* O,)R(@P1]5<6 B<[1R>CZ2LI+4+-;%
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M4<5:!\M<W<PT+B76_R)3-K-I8V^SJ "U46Q&2XX,*?[ F62BOX_O5"SS7=1
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M&F!_^#X;R!\\=R7R9><L1[Z!]8U0PQXR0=#,V99RPVS#[*3&3W[ "JJOB0I
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M394P3:3SN(:D\7*V]/7[9 .%^\V4WMZX_'9527G!J2LYIID_;'-DVUI-N6(
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MH/=_@OE#96"-TI8FOK1CC>',KHW'WDJ'6H?XCLT+AM.+[?5V/  OM?EBK6A
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MQ.6/'Q]]XE*TXO@D7W3G/F_=Q-JJPEU'/]QR^A\#O@2%/DRVRR!=R'L#??Q
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MUBC#],HB<<99=AQ_F"4H'IZ[G7LH,&TJ^\UM-$GT?Q-D:PZF6KJ><9IU4!!
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M8]EO.<;!%V=6TL&V3O2ODD5Y8H0Z7GA,>4T"F/[\RWZB_P!EVA:0XI )?UK
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M/YM$;<UJ*?_I6Q"H&<TVSX:/FT">YB)!$^'7P!T#]/$&'@)H[  R\HMN]RF
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MX[AG<*LRDW?L![<^$5LRC/*I6F%2-?Z0%1J-^O<LFHB'R=[P*]1.4GE:$:_
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MB=L=%TFD(U8#T&@TF^<06?/\I8O'CO@VI.]M\6P;>GN7 /;+:%V2.\I;0&[
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M<S-<7$H']V):$S3V&T/P0:.=]S8Y,SF+[@T!]_=Z$L7L-& A937B$.^=5$/
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M5>C8WR&0J((RAPEXE9&^M:?SJ')_ PV.!=GAVUGV$#B]JZ2T)N/%QSYFQ).
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MO/.V3KRWK0^;3S,PR[G,..Z=Q:S!@.B0"<[3@@.%,*\RC&Q"><PP-0;58E)
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M:3<IK50RR?@EMU(K^)#S6JY^WZK USFE=V3M'N(\V-6F[,#A(1;NF05-E%-
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MR#.AR\]J'/&G#"'*X@8&)Z''.OG=_XB_7+E[66J'?.GD0H18U0A(W?DXOL!
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M7P(RFT6G_/_XU'GB?/(<='Q]"6K"1[4_A61\G=)VC3+$61B6UWEB%;@K3^I
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MWZAU$\5$>YE@D<^"5A-LF2Z8W5=P#%WC2S<JTS9-N%].FXQ8I(L>.NDURTA
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MZ4JN;.-X>UM<I1(AH7)8MQ\X[P5U'$LTX(Z3')?@I+"L,UEEAHQ9?6\[F"P
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MSYAA[T?=KNS*(#_P<-\KALU<YF;#?:]RYCR0@IC@F;'$8&\LOFM XDJ]!?=
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M>S!77D:"EC]_:T.<RC^82=@Z>IM_MRVYS. ;O2"X*?/5M2G539 #NOEWY!&
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MW%S0CZ(3W<!MT/=-?LV;-9 !7[.3"M<GF$!Z08]'LS7WOAYH=ANAW_?R/2'
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M$V<%&E*X)U.WN2=9KZ(@F,NJ.0$OT/B:K9";G[[\- ^B'9;G\ZP/!-?JJ(\
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MQ;B'\($5J)HJ97V3S<Z^Z"O0(J) Q]7U.;WH'<0>PEZ;\V"TN.=@\CH' X!
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MD9A QS@:"0^L&]!F3/IIUGG!%46XM\Y/.LM%U]R*?[U$%G#>Y2?BZ.^UX];
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M)*M:X5PM$=^:+7+7#[_9]H!_7FT.O^TG&>3(^'9?;A4,VH<F(*O=._EH>CC
MK(@E^G#]EU8]]@Y)@X'FD7N%L-A7@COQG2'J2WL<OC*#7N KJB;%_@H=@?$5
M>4X*ZB+C;@]EE<USSZ<NKG*:':&C*#T(CF8S D\717RXV=6+[12(4KU>TIJF
MMB_*^EA4A.$.3I4_B #5N[W3]Y)W&-2;?>ND616*W]6V->M&TOAL<Q@Z/V+Q
M\/&-SIPBEQP&9FR2I8[-8)H$]H:\:5L8B,">7KA@P.M>I/^Z0%'P^<^(WVL@
MN;!3X+S\ _BO1SE9"P2UJLU3@!KU5?;\W-*)C.HI\*7G%,BA PCNU&2_2563
M8V/2YE)63]@':_6W3QEG.3Q>[2T[7GP_BP-#GMIM\T9S<*%"',9@ >7P>2A;
M-1+8>!3(N+V2_K(N8V(6[FIU[[)4ANB13/*;(<"A\0.!N<=H&HE#AU2#V4@$
MRC5__5Z9FM3- ?OH(-WP6UU\E=JP)]FB--L)2FI.>Q9<0V"]O\G$=Z0FG(0&
MMN -WFLI99;;/=I'Q7=<3N(5]M9F 8:!_(/Y_"](6MGK5ND)BCBE_V@HO%D#
M*Q4I01!IQV21 ^'%[L$N%49.HZ^OQX7[@^IJ589!F%;/P)&5XETHF#)V"K"V
M"CN= M4B74878(KCB^](,4;(6W8"F<&S6 <<1( \Q>=A^Z!1NQ<9ND#K4^'V
M%=+3Q@^U$ZWTBWH:/V@)_+S[-,7T8M]HB'K:'L=D@ERP*S8A$LP,5R5+D?P0
MN#U"68U:D'Z-<MA\F$2LOM-&KE=W\VJ(]+!#4T(4DE\N"TH$9V(C(E:"K]@T
MCEUKU(ZD_?-"DJV=,3%V9_,.V"B*K9%;=5QM$R?%2%8YR:%(P51&59^> O2^
M4@P;'+XLCZV<B/)7V^_>N9MRE/JJ,)1*N #/T<<<">8\!1R0D8\2?V%$>I"T
MU;5U5ZR_(-4M6Y_\R+ND$'9#&_7 &#1%.:NH'[YV-%J\A5TA_>6(@=@'@2,Q
M-9V#7O;Y/XZ27S,C+USKH/DLY$@H0CQ#L/@/]4%HGQ'<XWRLY'BV?7=<FW0R
MY.ZZN655Y+1SK1D&]P#!-)JLQE3_G6*G=OP$\;V"K',*?%-=^-$2WG *\)!D
M'I#"EMS,NAI_,GKDNQC+M?S4^TU_;>.V$BO5G_ <!,Y2=XC\8P-"V#ATGPZV
MH' -+>$53X'WU\\>[COO]AUOUOF'+ IFXOX^]*X'-=7Z?55^5Q3!1%XE#'KS
M7\:'183"9 J=N.\++^B/;4]BYH6?]0B:A-P.D*7ZLTJ^TDR31[9=1/3C_,Y2
M*SJ&<G'7[WPSE*-,*$-Q!]VK\,!M.N0UTRT/$OA':PS)%>_5!;V FWR.'\R<
M%D8%'L5-!608[-4]6O[DO?[8&UH)Z1J QFA@U6HS/9RQ1M4\M<=J8Z67'VC1
M5P=TB$"R %CB(N(M/RO!8MOJK%ZV*J /AA@W%;@3QZL_%[HX#+H_>5]Q"KQY
M3T>IV;:&;-7AO=I/ 8YF 1%">4,PCMYJ<"6E8"-PI-[S^\"E=Z\5B;_42J;5
M;\$'X32D%8D7A%>QDJ@RQ;?&M2DY#;&!H,>\CI]X]QZJ7Z;\0#!1Z%Q&-^9Y
M1^9JHJX,**=^5IG]53QG_BDK=SUV&!0%8YRXV<I-F4%RJZJ4#_'%+42=;\TO
MT%4Y9_..ZSIK=N'*^I8+<KL)FP4V)LW@09HUXQ*%$VYD7;YN8H4.UY?8[YRF
M[=[?:6L1+G.NB_-EN!D)FC,:&W80+#]/[Y-I1$AIOAT E5;YLO=L@.')Z[N;
MPQ;1)&C[F55B,&^25R[YRHB4/7XU0@Z\G174X^>A?_PG3._^]0\O]MO!VZ\5
MA4/4FG!@<A[/XA"*:#"/V$TKGR%2-*'31KUY %,_8M_3HG 3 CHK.%)1W.#X
MW9<94):U$55V"P$':MF7RVR_+BX?E)TQ7B9OH^AYYA;\4&19QIY.\\SJO4K.
M@2?+GDH;HC2X7<PQY0%SARIQ%+)/!37W_\U!8;6K]TWXRW'&_4:]C$ECBY!W
MK5=A*M_PZC6%+4,1-V%(@6E''\$?@+ E[R<+^R)_^-!#_'9OE*I]J4B-JW:"
MQ[E>"V>N(V-0**+C#+R7QV!<IX [Y,CDNB^XQJ)'EJ2&5^BQNW;YK]^"HWRM
M.#)]1^CO)=&#<ZMX.0Q,AN3ZF2R$#TL+5U5X.1DHE[TKS/&^W\*+_961FF[I
M;C245E6*D,1W@YEU^GN1C7.::[ [D)ZH^GO-DF8OF!& I>!%B':DO45DN+)F
MZQN":5_G9%U%G):!O,%U^R0Q>ZJ/*ME63>!\A<5?:5C4-)+8'LS3I[ROO R]
M?!/C\;4+-(U-)=[6.:]-58$L)T#](HDA'"&*_!-=9!V2S!(BNJX5W$PX'S-K
MNZ: <!M;C7X4M906[YGWXBPH<Y@S*1P+,V2%DY96,>>,Y75[D>A2-Y3L]W)+
M@5^78/WO#M3\S_"O!8V%].TRD)4(?F'-TAZK&XV'D>5A9>7(@K#4^^"]R;O(
M%! *769+:CJ&D,1QX9FNSM@3/CE0M=MDG4F3I@?5F0[-9>_U;4O$1<2+4R "
M>?X@2@[![,PL7"5P!K#5!Q?G5Y8N$1\]\Z6P4IWQ&[Y7 A5G)ETP\!+HN.*,
M=A)*"?W\4H%+[2_;<PJ=F,#WLZ%Z&5M:V"OO?\.3>1[E1AHZ5B9)X7['A;7%
M[*,;DCH&,',V/T<,F#S><P5TM.,PR8]/LF <6*/S)&AG8TKLH;5V^$HXSBBN
M_+&R+F>GC+SG7- PZ/JQ"TREGO3F6'W3H$"0SUU#>M,ZJ%?=)Y4Y\_>A>+U%
M$N5GJRBXAF.;RH>@Y32U;L<^7%:=R99X!I$/4F@>JZO=O=EV3WQK70+6GR%L
M[C3MFZ)V8>UNN?82M&.!GLPUO%.=<'$]UZ"BH3&HP5C)<U3!+$FW%\#5 + A
M0J9E/:GLV,X*)DP 1Z&:Q1>=9#V*3E)[MS#R%4J0U]\_I?#B(8VN/TX!)Z,P
M,!V%A>Q 4BHD71M5\W6_=.?PV]GW:@.EU\;%W'[Z?J+X$/UZW:<+V]OX4W^2
MFG2/#28^BKL'N8MKJ+H$AFQX)3SO\3S#+"E\C$;E&+8&CXO)%.]NBS\I7U8P
MN'$R.KHJQ+RSOQL-[)T")-'[4>[@CO5\<5XQ[*;G'^G.H@/A)JF9(Z>"DR15
M)X).I9B->SHG"Z55'=OR'%O7L<! =L%GDOQZ,@(WN)T3[>]PYB4JKJUUO0_H
M\7H$KCR#S.I3X.TAA"$N:V+HW8[0GGTH=AMCX;9T"DPZ^LU3AZC[GI16SWQ$
M."2$PL5TA!K&R H^^0O02+3*M3_OV06'>>$^![%MK,WBX!"CF%.@=LLH(@R%
M:<6(V(;)KY8'$OOL)E#@M][]9 F.".Y?*G'L*N:5Q]?;]U@^TU<+.A;U^.N=
M AUJ%(;R8B)J2[S+=26@;3K".&TKLPIY$%21X (0D-,+^DWN4V.XB"B'4/T@
MR&7]$A=Y_:N"MSY.T=(,?Z*8[X.WE$M. 882_"IZB_$4R.5OL7B(%TXH\9??
M[$RRTF9ZX^$PR>CH?EQCJ;<]5=]+JR:&9":?52\9?'SF4A;M7)ELL#+DQCS[
M^P;S[VIG()'#G YY>@F40%$_!:8F3X$CUA0BV^LV9C@3R7$)GH_EV66>5LOO
M;?-W1TT7..X)*_T-$8DO?-/C]Y#J#X3,NDHQ^#5#Z:I%'*L%&YT-Y%^.ZJ&C
M@[/!N</VDVQ)TEAJB[/CL07U/#(*SB]=]Q2(?Q3[-RJK\,;='==OH=,2+[%U
ML6XZPP*QJR&W('K WRM+[)"EI05.Q!:C*_E+WDDUFW8?9'H&8"85@?_V0>\[
MM=&29<Y^)DH9G7"S-!MR>?/2]9;?(^D?=6)B&0O?'&KKJ?K\4WTOJ]Y=*G.T
MK0PJT^BJ$]XU3'1XP:+C\1U8W.=SHL%)86B6YL."CGVLF/DW,*@(526L =>U
ML1HW94(958-&@E@>?_UZWW77.L+JUEN\?F=M8)!_4Q]%*'YR8T>T[-EXS=X-
M ^DG@E07E)8/MC?$UY'18!!,G)#<M3#5*C6R-'E3(R QZC:*_A0(5. M/N+>
M0P"4;C!=*Q\I"6U;.2(R7L.C->=R5#,S)]&P96*YR#)UP$JUBN"2R*T[:6RE
M:D?*>JS[N33L7UBTL#GV(QL20%W@M[7)_G[&R9KU$W*6LIMQUBQ[TYU_YQ>)
MBGS!FVB?L[ANY2$H=$.820O&50$PS<_:0H\XQ&7.QSV^U%ZDJ&9D/4GH"]F'
M1/%SM. /HV2G?&P%"+Z#;HK]ZHM$P2+!? #VG#! ?$42682&')V-[ZY/29RC
MG9O$_,"C<9\&D=2=]>3EJ[1=]I$XSKR)3#_RY?*9!DI_PEG!&NL)$@D_!9Y
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MMW[(CX$QSV7O#1GH!;(>R1;+_,Y.I&&X6>.I1%Y%58#,K9.Y[B?XM;D+?:>
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M]]IUS5U:^E/L([FB7^\:;HC+N'!&^T=ZC?G=SUW7-X?/O:J*?$ H+;TM**D
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MP+W 0=RI#/>^+C4O(2MTT;$AA\FQ-XH0L;30?0J<)[D:D3YD_*Z+8^RIKMK
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MO0CT2]#X?62L-3@!)O?9J54ZE.^BM]5^EC7NNZL# \^OL'[![(C8Q4?:H12
M?#="E[1(N99P_^U#PD01N\>Z)ULHA_PV./4N%Q7<I*GU8@ZSW<D9K"\O4/A/
M@:G+Z%- ,QK?Q@4S)L@W$-)ZLWDF6J^? IWY!A*XA*[:,:O>:^-O[L#^"K]W
MLY_K'=827VM["V=MQ4MUMM'Y!YE*G[0]&/M<\ZESYGWC59#SCB)*E- 71A%G
M=.WAALUSX?^)'?J-\J'\,\+PH'9T_7,:+1>56>NM@'.7 G*8%4X*JL%<I)@E
MYJY@HVZ*J#*\TF=.?G)CX:YTRX?*ZCXWS&69>H9+,M$'R!@+=6&\8P19_$Q3
M9W\-OC>V"6U)T"H25([KY5C6$>P=75X58@+6'\<7'\N2N@Q/TE3%%@?H-PTL
M>N#\XVXU+W277]2EY'[L?\+D>2_$-S3XO"M9!\_<;73)OV3IL%N%F6$-DUV6
M.SUKO4 R,VWY*<WE2_G#Y8L+W.[567.B^4C2)J29$!Y5$)ZW[Y$J5 -RU[E%
MV\8.<*^N?2I-K'>R!P"]1#2-4KG&$G,$Y<;:*5 9_Q9G2].W;B^<G%_SNS!"
MO8O'RL"-RT&ZO]O]]BW0RB\JN74H$YR!K)& =>^&LI.^]-T;L^@^8@@,+HM/
MEA9_N<9[0TEP1?%E*MLO)S!#JRK)<=$-V1D4+-/ESCOI5M@6Q7X0,2V1U_^>
MTV.O_VLW]070VVA@"XW=*<9"HQ'4+[[5RV>(Q,@&#=[[,^2D,J7!DS-D4EVQ
M;F?QA53R$*_0CL3HVXY(MO:46/G7GBS68WB>!R3&+N+]A5O*6L\MK(-9*$Q0
M9ZF+PZH<^;;.5=4)43;>)E_8.%=W>$]<WS>>9)*M%#H6XOBY'E5P)\34#)1I
M&)X0I@02A\OW$CXL&0">2"Y5<)E_,BZMO:0#9PLU3'X4O?3%YD4,^\W:2-LO
M/PZ\T$J;/8$.R009,Y(/H:O/CH<0WG!]_NU)9+; R$H]78'B,],ZL?=*UT)>
M!LJ)] R%P6^G&9-,L.YTTY:;W*BW,7U>^7./_](KZUZ(B_[^ME]\UNNQQ7;N
MHJ*ZD!U,>G1;[OHH&5KD@IB^8C.CP_WH6_;M5^.XK*\EX\>!PR 4Y:=U7Q3,
M#(\T(HA$N^<UC<M]OS[^-%J3GNCJS/OQ&>![L8X@M^FCH3V:,[P_8ZL^*A<^
M.LD:RHG^\C4$((=!__.G1'-?'5S7FELO:R=7GU3(TCNW*KNBN7W3U>/^-^+>
M,ZK)+EH7#=*4*B+2006D2:]2$AM=!$%IH8@T 6G2 H0@(+U$0$! 0*5+B4CO
MO8ET")#00JBA)=0  0[?/N/NN\<N]]P[SAG[_ECC_?/^>-\UYUKS>>::SUP!
M369:MC;56X?P.41^8-.#PA:["T DDT37#KVCI="I>Z).KHY.C-1>FN=NE*K^
M$1^A;._P*X$A["?4$>GE=U!>.)-#(?5[ZU3TDOK307HWB!.\TRT=J,$$0L&3
M).VZ<A.S9\\FT>^'+P W"D$]\5]6FMO>ZUR;GB)JO1GK#N"R4#Z=V[@ A, 2
M!6=O)@JY?#L9+9@U]\J%%1\@XC5FLZA/Y8D9)@36N'-I-"X];X+$X1;-@_PC
M&D4KUGA7[LYU'_8!?U#G?(R20GL@ [V.*>N-LY_+[S8W2WY(S\P^GT9SO042
M%(&MY.G'DPMZ79<AA:1,3".TCW4V"XUYB::13.^7J_E)JGOMCKN2UPY<0F(>
M(- DR!K"<]K>?&<4,^P=Z'D*W.FV?#S[)!=S[7Y#^(2/HGY/<#K5D"8QB'"J
M2VB)0:@(^WW?X+E)4&M"H%M^'Q3>4DB?^>J7\+O<"/")@4'-0^_T+=''0L)X
MO/("<(U88#)6"2XJ]0;W<](33-F^%M\2"-^FVDE58?IJG$)21E:B=]#@CE\F
M)+5Z8N1M_,3^>ROS=U+MR\/'+^H!I3U_'PZ*UIYE>5P Z(8(%)>/.ZI!P M
M4THP9TU0=>I'OM'%R:U*/:9YB' F7U*7T8F?O-2MV[:)3UPH%GZQ41@;+HKY
M:ET PG86=![(B5EXBPY('SKK@!\\'%N-@S8-B1Q9)]3@G#LW)XS/K\7?!( 6
M4Y9LFG$;&;SX$:LK@2#,C>8+P(B[/E4Q;-J2.Y';KQ)!0RRPT&.<'7+\V5<P
M1:VC)QQ=47&++(+R5YWB1G0==B>*YQ;A>28^U;(:6558>19@5G/>GZ2>U ^.
M\'IS8X'WV.&#+^,+$U %< 0?M @'.'36;T,V3KL1=_%9(,P36#_OH5S;L6OZ
M!V D@7KK4<Y;F J!,?2^BL(B(Q,D28VI3RX^Z2W_+&<W[U\Z37V XM)2UH<)
M,<-%^PK"V$)).J+]&JK?N+&) SKF)+RLE[^H6T/Q?6B'R3-X(]JA+<^*Z B'
MTU=2[7D%-W!A-_,;-Q9 G;/,"SL=O+$P$0+% %6J#=;BV:^X]Z,//E&H\92X
M@S@ +8M!%#@00,4/CW*C)V([_2=6(ZMJ]P?T-) [ RC+UMX!L=8G1QPJ#J(?
M9*(;3FV<K6ZI""Y8L4#@'4#AL48I3)SXH'RL&9I=CC:-%C#?"+KO)--&+I>$
M=UMD#3Z LRIT(B*!ROC-9OEQOE/QM#P-_TN6_[:3)5B9'1RW-9ZE;.QWZO[Z
M_ ],A8^"\R4?]P7 _S/9^B0K\$XMT9IBCM=9"ZHAGLF,UBI*D4S39DQ_]E[#
MT%(!+VA.#&;<HL0.T1+GNQ*("26R&9R%HZ-38%3K;LK]\@++5ML]RR,,%R_5
M6O8!AOH\QHP  F#/.947LZ0N +>Y)2X #M\8OSGO65T2,[03Z%;5='C>O3JR
MUV:"%')I 'NIK&_>BRW:Q7L:A]6$@DBH*&',T,+X<575*%=15<H4_9'4 HSP
MA;=I,C3Z4+KN/=*M%[_G9!+].:D#>NF11@_@TSHZDY7P>/_KPP<-NDHHTW)O
M[KT@1 0QYU7/WR6O=:N?^F3+=/[&*Y.;.Q> JQ> J&81B*]^A&Z2\=OM5XVU
M;$7!I]HX9>&EU>BS>S';=*_LX\4ON:APYZM. QA*/G$D<42-93$+_Y_531K:
MGL;M%QCR<^98XX3(%_10.QU!*%X6\;Q4O8AG:1A#^G$-,9\&C;]8E07"V"_$
M7:(<Q@(XA'4+XY^HU(E[2DM,EZU\4YODCK[3NORH[?9A*0)MJ!?."^<H^_X-
M5[.+<RH_^SWW[F-PNSB%1GU"B$:94_;F)$%R_I(9;J7D%):%02<]?LR^4[;O
M W1JO)E5?8#X72#<<\V^LAQ?T?%&",MM+GO\8Z[X)\C@Y?YB;N%D^?^2>M(\
M,QAY>"WZG[P@GRQ9M)D0F?Q>NIG0-ZKD :5_4V;;$+@^?LG*[UV^=R6C9B[S
M_Q9/";R_946C(EA W#WM_K66TM'%&LF78?C:S.(;69C@=BS96)GHK__-.KJX
M\_4BX;CA8>H5P:T<3)T;4 :7-/3CR0]E2LG91Z,''IV(\TDVDBCCH1E!X S>
M[4;[]J0ZR;<,W.<3PEHC5C_=$FZ@\=*R0+48!7+FYGTT<G[[[Z[SB-6<DV*B
MA?RS"A2A;>@A8X$9-L@AFU&W@&0[+'X?^KA>Y=YK+DG!+1K_=F7H[ -$>4SL
MK\!,^ ?(!>!P,J+K29JG8] >2#-U&S&:(5(AT8_\FNT5*#Q!Z)G_NC79<0&@
MQ['>,+<@!FC7U7W:]LO_'3<-+^*W'<MH,^-\N[L.FJKW&,WE;X)/ZS]>.A"0
MBIU\I ;P/#$.J52E (MG_%A'7IF1C-A$]O&F,)J_]DAO<<LQ,T/UN=#G,H%[
M3;/8L#3Q)J3.V/=Z068C/S[(4(6^J7<[A/RN/J6:S;;;3?V#/INM[58MZE"O
M8@8/NEC+H M2Z1JHUL:Q=YXK4G,%F\GJ4WF7P9WMZ'ZA48_<;I8,W57_0&U_
MVOGA@6"=' W$5R^>4]-8K\K$!?PW1"[*IWU^[E&L\!$+0@V@'Z%34U.?M<()
MR:FK[<D4N4U_CXH*.\_],S>+9=2^*AVI*_Y'QW1ISR[LFT'\<9^]^>MLSP&7
M%P^Y6DBBH&O%HHBP?7U<6_ M)O*$^6WDP$JR2Y%94]5RI8+/H.3PW^"$YF\$
MX[5O5U.DN.XP/:21_$D%^#F\[H,\^CTG4"GL*_U32^G;#:7X#S4&5)#B<7T*
M<X)51E"5<?C]':"8\][ZJ+FELB;]1-/"*2(^X0)0894[<( (;G$>BF2MX;U>
M1:L)%3W4T66ZI9-IV.LF[74;T$6(2U/D.=A<?N]4G0G_.L1G9.*UUN(GT]-B
M#V(LRR:@.Q*[%OU4I$.6??.[[VUD$X]Z%US7!V E:N<E05D'QV>G"D0W_<E&
M78P;JQE1RUM7>N7-+1R&[+J+2\DQ-[NFX@#L0]>1<;J,EOHKPZ@R/<LF)PET
ML:R.VDWCV("V__3PY!.&<UTOOU>&D]$)0.0];*R&OR(BQ#))*'^]I6(S6GNK
M2HK6H2_4_*OY 6\:^Q<B/JY4$2<P:8P1U@1:#9]8E5:/Z]1GOA-*>^N&,#0'
M2VP+CYQST[W1H^<3/D\G988$^]S15!S !1OXL^B.LZ_G?%?/12#..@2QB8$8
M+3\N]SFPN$7N??D<^';Y0E5@LH(BA@69 KR1?RO7P[7Z!A2%J\\N%H'P5 D\
M;:HK<OZ?VTMPV'^'[.)_.0STR0;D3I$*,8UV.1!6M=J)@RUU>@G=C_8Z,1&H
MG"G_;&M+U6_G,Z"K4+72.&E&)M7&031?^O;LCS#T\(/S*H^"!\5=9%A0]3_K
M-Z*9?:Q18]'T("6BAR/W12!<Q[&BKD:D,IB:;XD:P>)[R%I!O 0B5]Z6S_0Y
M>F,S[YGFR>]J/OV3T:>.@AV2;8TVWR<.+&X]Z0EB:=0KP;U/*[-M29?MZ]5,
M_O-#XA? R+=CZ ;.DIZP$EKBR*SE5@BV5!^IM UI_47)6*AZ=2?]Q.&Q&V/O
MRO;[,Z.P[04X.NPT9_UYH9B]]'2'J#CR[43TB<=HW=!-Z'-\08A=O%A0IQ(L
M0394E&6B/2=A([YJ]]!EFEOCE9K=VCG?&/110=YA:@!5CCU6U,-1I#>"0%WJ
M&)KEZ)3YA?8_<T%-$PG#:'67XG1\-BKC\$OE6394^<WK"@O#3J4$:P>GK<B)
MA\>YGI-O%UY[%W\4,-!FFF'TFKFV,90'I3YUA$T@3Y(@$9CXX/P.%5ZQLKR?
MSV"OUS"Q'L%K#RFRCLN8+R<7K[\3A53"UT^\&:VR$,M8+=>QOD835(_]BD4V
M>Q(L<^7@S+CT+Z9&JH]QX%K2!:#QU4Q6$V$,.+%M[2Z>^=RI^#7PUUDLR%DG
MB.("8 -5)%#&ZK_=>SZ"<DI@KA/PZ35E/<V+5V!(0XPHMDS0I9.>$QTQ+CH]
MO-=EZ5DU0[1VRERQZ&6ZS_JM%=D/J;3D3@TY2_/2C\NN]/#^W727I!8$A7G:
MRV)HHGI\*)LZD+&AH\UBQ,Q+6L Q0I)9U"F5:*\GAX2C)OZ^=V(>6-;@(P_]
MY<VG>CI9?#X(JJJ)@ $#"Y[KF,KJ,:$EOIQX#7)I\<!(+C/^\3]J\\)+V?;^
M*)'M?#9\52,DB_N/HI;\OB/&T4S=H'K89S("ZU;8PBD62S$AYXP.B),G/#5B
MVJ&]S\95:)E[0R8K>:GE"DFFV+&%G:0@G^EF U4;W7&>,+_O=QPYI$[^G7L#
M!7H'#U[1)&D1[FYT63[U.=06DYUNG5T!L-K:9D7LO/;\BE38-,8/:1"3%@(E
M.D_"2Y6=_8U^K.A EBGJBZA4.W["88O-^5GW9/$!\_D]'2__$)S9"#<MD@+,
M3S_[]"#S"L>A.>L&QOV\[_]_UW#_7V-2T5 GW>'KE]/V#R 0:"&?AW]\B:#Q
MT>O*8+UB9>*1FUJB"]KO0 1P 6@N7FSZ5L9XMP4<Y#@??,Y!7,8$!'"#C2*>
M3&Q.]5D7*A=*E9.+_-'[6T .TB8=$2=.I7 7 /)]3ETK P)5TD_TG/E9^K37
MX7U;Q3ZWUX SYW5ITBM62BT0I-G8>0K7?/.\^V2H>R=,'B:&/R^FS_HQUD]1
M78.#UCW.XC;WVG^PCW EDI\"9B"@+B20CX#,<2C,N$:!1%ED/;-_<60Z=0#8
MBR:.M5\ V!M]%[ZXW!XF&1<Y5B._/G&CFXI2?Z\^%W&ON6NDQ:WHW?GEW[R;
M1X'GB-O*.05BS3X:HBXSXFR,&/)"[BZV+XO)XY:QH1N(R'.1I#80(U1MD2)6
M^\0U6VZTYVSE)3_C: LK26M15:?[9'FNJG2VKQ"G$&^7Z)CAL;3/OD;]6G1*
M N3"&'V28Y'_O10]OW[D46G,X54=M:3%>85=<>G*-9:_$./# $)+IQM]0:0*
M[X],7]U$AW!-%SLK^>FVP1X##;;;H3O&8=\/GLZ"R=;F?V5W#MBT@SADY^D?
M>=Y/YZEK9B^)^G/M2HKI31\^-FPY8CQY#9A,L-H,..7<"&* ZC+&09W*T4[Z
M3_MM\I]B_JJ%TR4R=6_:OO:?1!4?J4&(ZV-%1ON'9&]_1"_\!WU8HB<["YZ7
M=!/1YI^;7A-&,N:2ULGI>8>4T2Y.#C[:-IC+"#X3W3D91.Z#):X[5JR?)']5
M.%2@,7 .^,@0W_R18R[,S?K%,\8.ZS'5D\G)^8JCJ'-R"RC?"$F0(+XRN&IR
M^FR,;^8A=C,8_7'O(38^\(&<[R&>*+> ^#C'AM^?NXD?J$X YD'[/3P9GE_)
M?PS08Q?<1\2Q70%6[6^DLFMI69"=LN!K,!(=V>'UCN,D]MQUY*?9)XTX_5I/
M?I-!:#MLRQKZG-BW,.O9VBPZ7&G%MBZ]L>=8<QW]B 6U+?UEBI+Z^X,CQ, I
M*)Y'>.R<HG^!-@#]Q<O/^\:Y_P/#Y7<4Z-"SV1X/<F1CHWKT>P %5TCC=5A5
M!UW3'_,#@5\TY;^EXCX7"[=1AUQ5F:P_[T0J' 55IH9;M@+1WNG@%,L8UI36
MU:E$2E_>"KW-O05>."_]MIS$#2=C#JIR:QARP-?-JU#<T.GWLE5<![^MOS'J
M<H^$41 Y%P9312#:L_;I:V3 //X?COD]#ZU^'7*]>E.^_]E.3?GWC&TR2M44
MN%;PTJ.W04/VY'B4\M]77C1U_4'S]8F6O/B1XO#IPT]5K2US;W@WG-P)57-H
M@8BI#(C9]:&%;$]Z $._,EN)70#:-)N%<*A;&9AYJO7)&V9F3D4" YL)Y48)
M-S^4+_GT\9]10@'1=^T@/2FX]R4MPM3C3);5G.1;17M]J(4 WJU7!&,3XG="
MJ*7.1A2KSNCVTN_?Y3./GQ:B=5S.";<3 S<BB#8$45.B#M9"N=-,8/R3KIM(
MVG>C.^)\O;.<\0NQDQ88B>FC'EXV%69?K 0#^ +@-D"/!EN:'7\PEZ&DX_8\
M:J-P^+K2)+$ VI3 7K+\']VGW?Z&D(".ZHK[21WOL5NLM[DV7U$L\'Q,/YC5
MOEFDY+))O6Z9!*W/3W6 ?/AI_C@QS/6;="@<6:(KW=Z0.<&:OZ+(DHIP.LQB
MQ@^<YXAL58R56MJKG2^*NX/(K#[QWFI6A31@6:/*#E0-C1O#^W)MG O:E/F-
M"*O+^F3LBMU:..?57T33-[G'%I]X?T>C/W,MV<0:K+1<3J5="ZJX*XB^48TA
M--##8U&,@>BGC[(8]'23>&7GF4BVIM$4&.I\:F@.[LM\TCYZS+Z\6?8TGOJT
M@!TAP6L9#S8U0"C+^W\QKV&)S<?I1TAK#._3'939M %!PR2_O)@SGF,'^ ="
MS8VG0?4X/ZIZ[P?F\<FY(NJY+W]LIZT^OU$@>*U8%A@M5'KUOTVI)2PT !#[
M%PB9$5&8]Z_YT*NVGR4L0XL0Z>?")*]Q;S$SK!J^<J7[#_()RV#^-];DB%<Q
M4UYB6UW^$3UPEI:/S3RX&^#^I7G+K8H:.QPWL?>(7!"/^%SJ8C XIVC#IMGZ
MPHH]V]ZP0^!Q3$5 =F 'NZX*&)*.(X#OBL8!.?N6LG;^-M7Z].MZ\VEVGNPZ
M#P)EH:JI5OC1_MQ'&3$*>[#!$DUOOA547;>_<9%+;NMJ%?0YHV1I:&</,ZM/
MX]!HN6D@EQ$W9N9=M@UF;?^TKDRMQ"?UAGE2,,W3KKX+@"\[PIW@L%FT.'2-
M1#Y*<O0K,!?;LZA,]8<8V-94V5U1L./>O08,#@NX 'R42.HX!^)7?GYZ;.&6
M.&<D568JH,SP7/G&U2.6PZ%4+H)T;\Q=X",C=@J>3E\$ZO<YOU\R$-*1,F19
ML.C7_.K^SY_YLV,@VI374X 0<'#\^T IJX+Y7[P=F>#6(.J";+/JQ&ZL:8-"
M.5A;<N/6\$_-S><R^W>;8$,+H(X&^H!3U_FV=!6S_*T+@"/XU>!V'7G!NL6B
M>GFL2-B69;XH]T'D>S43? ^ 4NRF\>?_J@:-.I/D1I3((7GB58<BO$-&;*-*
M7;&\JI6MU[D#(?Q,,\Q6] HDYH!%QL.Z&HZY6)3/9F"-Q%>'LL&Z+MCG<7N!
M_;*?BNF?6;ZU'BMW6_UJCO# W^MO0XD1(RS'\IV)!\[)K;69GZ^1!X]<!=!Y
MM2(228RG0+8#VE3"S5^#*6.5=Y6U%'J$#>/:&A!YL"C8"(](ZF4@9\P/'ZF>
M=WI?&ONLZ:7"O%L;N?%??71>XXLN-IK(*V6JU"R$M// J(X.7*6=@Q@8] @#
MS<\2(?[$K;]-2"T@&FN.NB YP5??Q 9=Y0J$52&^SUH1G^]L^5-]]\B=.>AT
M?:87/Q@1(BP_NH48R(DL93]54P@RW#^V?OLRM$#H7G;"@41;2S3UXJU/ZP%<
M1ND3&91U(?)_:K?NGO(.+QGGT1!;,%F%*,;.>0:+'&EV5UC/O5'W_MNMU),K
M;8B*BCUC7!U0WF1&^O.Y0 [HQM!OXC*QAB:(=N+&BV=#_MX!!8/_EDM0?SA'
MSE= SKZIB-G+KO^H)-Q+,=U<SOB8 .9<M)GBNL+X1G0/L<BZN46@QEBFRN<M
M!E*?*CR/M_M@P3Z2J/&@]1G75ZRJLO%F@'IIB(;<'O76V8*88;<5I<&J=CBX
M2#9@N2EK3N!^MUA)R4-NCP;0L\FBT*[G7W.T3\@(U)<SC8KIF:?:-_$*HIN=
M!J\G_!UK:D3^/'>66JKP5GD-8SFB#KD N(+HG;(I$%"W4K.FE*("[6I?)7-!
M,=E-Z9#[%P#:UU^SOL@=1]J:!VZK^MN01(?SB#J+D4":"T"[IUAFIS]%>F);
MU></#Y]$E9_-9#8T;4QU6K\=KTB)"]Y16B7=!'?"[CIOT,Y?=73!]$_-S8%?
MI9V/+$O>)ITIO#X37788WK;7J"NOJ,W6DY;6$'H\RT@S=7Y;%!37@FR./$NO
M1!<',3CY&A:+575B>QF AR,A'6B2:/] ^:<^2033<Y$C,U_5D@*)\Y'.G_1H
M#83-)Z(HOL>@D<!2756(UG*PMO?M%F#SLZJF_K9AI7&V.5+Y(M;3ZJ/]=*GY
M7$MU<5ZUSO=3==.4T7ZA>GW?NN\8JYM#_[3^^$0,&:$+E_J-8\$.1=0"<[UY
M#@[SX85JQ8Y&J<-<'9XW_D1,ASMCHEZR32D\XYI$9E^Q3W?["+SE>$1URE$X
MVR:B:#5,<P)D[WP.W0?7FV4S=K.9>9UEW1496!MZ]",M23UPSPH"<P)&:YO]
M/W8F^#\U0G"V-36)IN8:',+V/HHTU/SIQT>'?F>YB&9)"+;+7SXOOZO 1/ D
M*,+59M!MG\#WU.[!3IVRC[592]41O*R1#V]_ 7@V:F!*TEET-'PR6NIR 4#V
MW>^AKYFYMT>DP6<S0^!&1' A]!Z!LJ!#[SI1XPG>,S^N<!Y'3_OT!-IFXW+*
M]C4"-;W^=9AZ&BA$6(UHI,TO/8JLRE"]-5P]D;)KS6:S5H>#)0] YK$%H21>
M_-QJMX9Y>=-H"FLB2E/\9MYX=-Y'[0X^CVXI2T.>#!ML-MH07$W@;E3*+(-C
M ASW=90[;SQM?A>W^NPG1*S5(%!D/K:9D\C<?DY''.,)%:A,-59Z5U.#HDF&
MW!<\50Z^JQ&K/O@ R][]EMQ^%?N;N+$PF(1EI""&/AQU=2V[/[JP\3XU?*;W
M95,#"^^&.UJC#F$U"M7+VV"=//'.^DZ)_)[_6R/ C=;NF[W%'S:?WB7C7BL6
M6308-.6 ::NI#I\?R.C8U5I6_\D=FP#M(4_:=BXC5BWRGV6=*^AB^TS4OD-R
M.I+,9GVH]:N>"+20K@W_AIOK4X\H!<4WJOXTPZ7*IP]\1=:;#[D%*OV] N[-
M#K2  ^(/P.T@9A5A[$'M95QRZU2"5;L,3AO]P=@*'P!6><Y$L6Z1<Y03).I3
M$(D?/RY?G5H#$R+<-T8M<7P=H*Q:_MM6L.N0X'?5/.P(1>E/'7;.0M($<3>R
M+@[HM)_3X]7R,^F[\E 0V$'-/+C>/8YGF-,&H)&O"PA\S>"7EWNSDFQO<@OL
M;IO4[F/5=ACE>O5 Y OO"3?DTXEQ%6PB98M[]6,9X;1%R?G][.^^A O MW2"
M^5$7[$4GZ\D^8@DVW8X\'XQK*!]O[TB8;P+6[D2F5W7EE59GVMV)QI%^5_8C
M%3\<?PG8!9Q,)H2V#W%;*OH']!Y6/.M.>16:)5TQ*I1^NLB04;"!O-Y&V?WS
MT/?3C+F:8W#5BPZ6.0@%%H]X7W%6XQ+7"D90.$FBF>'2HKVY[J!9K-SN06F)
MO/M]276^.'^A<]A*'AK5\DUZCKMC>3\PW=?-\YA<"?L5YAQY^%-$"BS!MR^!
M070STI*,QBQ7'[;LV7_8RAJT_KU(=1F &4%P[:V)#N,58,2BF$[K^>T*PKT(
MB82?)M6;7N#("T"\X(&!S+XB8F2>&A(]WS7',5K5\-S%F]9DVV:U0DB1)&.Z
M^&N(450,[B T<,M&=]9,Q],_6JB,>>V_/(-.G_?)U)RE!T )IR_-99R +%7G
M3(=1+==9@@YM+"4L!TX-T2Q(%6%/$J7XG:%3#1NRRX]()P1G'1S+!P8AM,^M
M$DZ#Z-Y? .S;YX*^V"=!5F5SC5D(G"8I<I4CI79O[1OI]G1X*>]PNP<P?P(I
M[4FR*7TA/77?/TK V4]GWL^A-F0'8Z+/4_^.U1"S\]9@XF,"X:A5D_/!1IVH
MT2&GLI=+XGO=GM&':!#:?Z),*F A4WN.[HPHCDW^<(FQHH_?SR%%-8W8]-4X
MW%G\#7NX\8'.1Z2:"/QT(*-])AH7Q+O*Y08?D+)$)ZN+/FV$C_"&7P!NJ<@1
M=#0N@1<CCM:KG+L"72LL2[^VYD>]7S;PW/ANBW2CS.*9#J8ER@5J^"/UU"+M
M[^&:)K@P*/H>-W&0\0TE[!/1U[*:(!Y1X%2MVXP\I*B-:GKU@>\8:5*BW/%G
MEC%(^"\VS;!A5,?36+;RA;E@X[]F2_KX;O 5"[WNH)#LE3T1(O^S<SEOH+"3
ME$;O8CBYXPV<0$V:RE=A-X,<^&C#/ZU9UU'Y4?)P[P*T7IX.:^*A'MMN=)"O
MVS.C"0'#SWG.31^.:1>'-O7P#>WGS),J3PH<C=UGT#TK:BZ'^9)W>L]YM3'W
M2ZW+J^)I(2EL?/I%7#9DZDID5HXD-?PI,:<5M9)\2P7=H'7W<5"C<>CQ9)>/
M=&-*H>T3KN)=+4[W5Y/AAFOO11<4?WKGB;@:0 MP*MQ"BB_AJ)8%$VIDN'5E
M4BM.[Z'47-A!F>$BL%+V D _\X3K2UV=78W%UV2Z-BW@5^:A4J@1*^/]5V]'
MX$:!2.O8<'):0V;5'QF2WG V*TB(W^O1@E.>Q(R$LG%[</C:8X=M1).#0,F?
M<K(B)[^PQ^KSKI]N EZ3A7:+:%KKF!BP?;[O4?CJQ=2;/&[1$T.Q/Y)UWBPT
M'I/%N"',S$:4)]T&L\C$3SG.M93>?5!$4*5&[#G'+#AOX*PGB@3\>&T3D1W8
M+EABX!_?H&=V&M%V+C0&=<0TT#MKUH%+@8=2]PV$-S4>*S,-PU]893Q=X!UL
MSCB+].Z#=2S.,R;"^AT\6)9HIU6&T:W[QY^RB4PE!*))NT@N(SAB3[O*Z<RL
MHL4&%[;^3R,@X8F%[&__'0EZ+N,H&.M;2TE"1#A4H_B1W.!WS#1_AIZ5;*1-
MPJ3C^TSV\N&LM%()3J*"#N$HS!O$L&&TLJH]_LTY(')\2T"/2\%F!U6O)$3>
MV^AP^H ([JZWBMA:K47*;ND\JKE5S3&7 1V>[[E.YE.9DTI-?OMHI0K*B >U
M-Y/CLPJ^.1YZ6H!QZ M Y38B3\9\7J8,*=WK]T:#9V+]$HQ&.X)^#WV4;8D0
M6_ 3ERO5Z(@)8LBA4*C9XD-7/BN]Z5$MS6>0LUS6LZCWCT#0?.2=;#;SM-Q!
M<N:2 KZ[Q)!9_7WN27RG+WL9+AJP1 K$[SPD9F+ V0R0&#WPF8C[-;B F;Q5
M_5I'\FL_"G]C%OS>X3O\?$<VDT99?@&"&/&R)A(]/52&T_,\U(2_BN6A\K?=
ML^Q0 ]P]&]%1D]:BL/EZXO&02[!KYPH\TI*I?HS/#JX?6W+H"7J:[,=^J,I8
MCHBW199N'M!F*IV\K!@OM94R!U?8YH2&4"G!_4\4L-0]U_95WUA0=X3<&K_;
M@]JY9['AJHFYZ0OU'-(^QG8<5D <N@V(^;/8<3E'BZ4O3E+7[GZNZ_<@@5Z,
MMB@/.;W>F(R5V!&;/D'0&_18X\>RQ18/M'8\#3M.@ @L;3!CQ'YQJ6X/E7[8
M'?,CA]=4P+0R7ZQO![<>9BBJ44&\&%)C.#_UE^9Q;;2@D?G/K%4Z:;V\P&Q\
M]B(E'-ZH<%CL[/VK+K@QHYB%[TB:+)%*J8@K=-U\=8L;'^X6PW.-_+D=W&J,
M7\&';I;_G?4/8'"X>@ 7QTELC'C[PL]+9CNP F6]90^9F:0UIA3:11>D[P$Y
MN!TG.&53:I*FYAX)Q.>X=@E6U%K\[I[[&&09GDMB4)K$$3[;EL%7HMKU4^\G
M?^ECN_^N)_\!J7B[9=H>M?A/$_O$)>E>E[0)<*%Z0AJ(/M>XVXH!QFL%?4-X
MO*;T,N,^UDXIZUNN2U5DEGI  ]T'$,_$B>B/]>J3>]G.!2B-93-4^Z\NWJ-7
MZ@#2!P2Y=#&[&:WAOCA;^\N"(4LSP>\%:O=PHAW _?^R\ZVSUW[!2\^@8EFR
MU7F.9MZ:3M#5#&=CDP.P%N5 1HV>E,8L\.\UWC@H+.OV;W!&S&7<F3N<10EO
MS9!Z<>X=\8U'B._-8J3WC:/>4?N,]'XZ'FZ[L_-_&Y#RJDRL#0Q+>-%6%=ZW
MYY2$I\VWRZ_/SP\T#,)?Q&HF;KOTG(WJ>5A]=?"6A,0^LPE0S0 98^I-2/(W
M#)<;+<OUU)TAOH^0C8Y2$0]'R^2HUAQLI1YF+4]YG1C?(61C9B\ '=F1'+8<
M>:BY62M'X-NW8^_>]M^AB]J(1<@=,5Z2+BX3XN4['DZW] /CG]X3C0%2)]WF
M*J-V?<_H[AQ]5@"\/D/2Q\<U(>%<+HMBW*@ -1OX \W.3ZO5"U2JK8BRWO<D
M<:I<*2;H4-WQ/*N]R0R:UI *V^^:]9:8<?--#CC6?,!%]CW8LK5+L#)-NY^9
M/(1=3TY0<5#TX)6 @-?02M^EN?E3<N[9Q;,Z*#[,35$-%]UIF9Z[5GI.0Y02
M[$TZ59()WPB1IEZ.)B(P#AW@[#B@B 7/,%8MY-7Y9+,Q0(W72EC/U[J;^J$6
M8H0;B*)70M(J0QJ_W%&+5VQM?44.8'Q'<[SYI\1^G/7)OB5;^^!7!S-G=8N;
MN$<ZEG>.K/]M D+7M1)G$X@#A/O=4+28G6 ROO_7G1K9S'WVK5$M'TU2/]4(
MI;@$<_>\']RAW"*=3<WV/(G/]498G^6I6+^?1&:Q5&9^JTF4J+)ZI^AX,_&&
MRB%%B-ZP<70/6[@4AY :-\NEYXDN>&[^8="CR0G@S<</&AI(F4QK3TX'I>&:
M&<^R' @"L0I'/.*5M6,K%G]03TWY_5U=DT=)!D3F7#24D< 3AYE5H7_ZM,91
M!KHWQ/^,G^SKKA8:WMTXM' !B+V'!\65+!KQ:8TOWYJ47%TR=KWQ4)E[AK<T
M\$/K[^NBT[WG14I.51R.<G5[C=KE(U]_U?Z,?^'\?-[CV-OA?6I*N1ZG'3]G
M1$WA>;*BW'Y+=\LT\&3'J(G &$Q?W^]U[H(,4X[$^H+\,+!H/0-&BLF( 7QV
MS^'N%SN\?-6* V]]F(7>2' ;8D((*_PR^GTR?)7.7C>Z8]PC5KS>9(4S+U#K
M] ;$U80$6@0QUTL_^CF3UU0AR0=U#Z%E?+,YGPR-"O0H6C]7<J&VP"_OKA\:
M"(U_KZZ+<WAM?%<NJ#X7S^@Q$%B*3SW\@>?)8\C$3/[.;DL4*6W**UVSXOMP
MY6=OBSBLJB>^6.3S\>LRN,/MCK'OD:L(_KS?&L..1VI*W^(QX+?<)_XO#_8B
MUJW_W^HA_P^.*QPAF.K.U5H#M>?^K_PFEWK,5^6D49?.3*OE=9(\L;R?FU96
M9I>VAS//7@[6,$,15L-=59BQNAHZ=?#^$,>LQ>XG[0.<W%,\."VV0ZIR]A!A
M^SLOZ1(AK2S$+.FOZY-?G=P\3P3)C9+-907UG'DR3Q5F5!&=.FA('Y.%"6M"
MP"T-3KW)%;G]$R%;<KF]G<T!C$[4O7'H*_<P,?M8LVG7<UEJB=N'@H! T37-
M2:;8/:M"V\^K>I24,H2LVT7/RZP?&*)MH@F3;=G44$U]U'F4FY]G7+%/CNW&
MOO?J'B*K60$V= %@ #)"0<V3=\<.N U.U,$ZHCH#ZNKPP4];!@\W&VLP5I8<
MQY.'J+"ACLQ;:XRS8!R!72]_V<[P A#(9*7WV&#U17-$V\I-1_6/&T*"_ V\
MK!#?=F066Z64J6JGP0/Z^^6#:X.S42B-9]EY 1KM>BB93BM:MQ\U2(0X]!%&
MXW6%0 >[^+O44T*-T8M9/<5U2^OYTCM8-++Y=SY/IN;N%"F',>V-Y,0KS?XE
M6(:C65YU53[::OI9JKRO5,FO ?8_];]Z^?#%S<F[J9O)!.VQAWCC2"^]ZTZ_
MIM=1-Z-4J[K&,XR4_=X_MCV1_D4^8]Q"5%Y,_4@*Y.OY!@GO>94BE1+.#H)0
MEXT-BBZ)&"0_4#P$O6Y?7%]T5/_AM/7.YZ;AJV 5KK%BYL;_+.'ABBLN-N>T
MD,?9+?4P X$?TFM>6*C_!O?&'9E<AX7G&SM.%:Y-#(54GA:Y;:DM=_BELCZ;
MO%&.,^VS(>&&WAG!HU7$)#Z07@1\?QZ;D%,QW< @\.%KD>%,[!;P2\FD-4=%
M X4:^_T9 /5[9P+=JP?ME3DOG#U/9*B-,LU5+KV%;R+(7E7=V8K'V8BF$SUK
M*M!1\!IWZDD,/Q-=3^.[P;72R'?X!@]%$IQ@PO5Q6(Z0DEO16(KVW$3BOKU*
M )GE40_6JMAV_!]W41WJK#CYO&'/(J!G$T)8;9.@)&G<L_!]$K)XY$JY:1KM
M<0$@MPQ2.D9C5S?/\'L8B8[^)FWDD/ZXG,[J+?D7\TX,:XFU(" 5$!<R'Q88
MV5$*G3QU,]45#(5*^=1)@C?(; \EF,- V;QQ@7+7M :EFB/:5UXZ]C J_;G6
M)[8)]<5<L@<4T>GO(QN!3OJOC>4S2C(U1_&C#Q"NQ">GVLXM] >T ;Q,\T-E
M1 .M*RI'8LTKK3SD5.>RW..[E'X:HPG)IMJ__F1=Y2L-5'LFIE3N\9943'OI
M-%4LFKUGBF-55^5$3<I*\[2V\M42A6T>&!M(7P5^?%,:?>QV:$ALLOY!>C!1
MF<WLY'/B71/A\+*FOOZ32%5CFJVE?_*=SV13-$?9U"1M? L<.H(Y\QEZ!5&W
MC;\FC9,9+UIEV943UOZ:7GY*Q<FJQ_1<1L_42PDE7'S;569 S-;W7Q.TNJJ.
MX\AOC$DPD&F_,^$-SO1!_,H?UMCLAR;7@1'9W;5*)T^P/:&R\S<=J\?Z?DZO
MG4P4V3@(S/1S_+UZG/,N*R(^X+KHLH5&9THZL.@L+?!N3^&R1C)=C(B\OXN[
M1TC Y++I'$.>RLN?8I?T#.(I66!,S:&G]71-MI9GSW*D%'.<GW5.H6:9NT.1
MW>JPBZ@S7-97+;=2A%+C5;_Z+YG-E18YCCH5AKVKK'4=-8X ^:NWG4YAR;_)
M[?OO19_\#:6]#^2NV^'#U&9ST]D+BP2HT8QL7P VC"1BJ@2'&R5*G)@2+9&#
MCN,!/YG/1'VY117 8X:FHVZ;_*>I^BJ":W\T#A _P<79[,J[#;Q?Z@-DJW_X
M<?5[N.MVCDKUJ\3[RC!OZUYB*NX9B9N% G'-NS5\%X!)G;,,S^^S<V^/1BJ-
M4;8[#M**;3-Q'V ?7\-M]!"U!7_6\X9)=VM41'4R-#QQO-.<6,K!TE4(LV63
M<_&I8N.9]*)-:OH4E[34=J_VV2.>Y -ZF"TDJ'L'/]25SAMM,*>3/U;F_OKC
MA]&<D#"RHUY2\>36!> =G*>C2&ZV.R%GJ"!1[Q#Z;N.VU:,["S7K5JI1;0,3
ML(&WL)@4A\\VX;$>TD?5P*F;=642&+?.,\[%FC!KI)<?V!7:$&,*24&^0"KP
MY!P;VXKV.G95#OV.Q2H6J<U*[;]0N]O^W]E_6BZMU$E_[<1EX*#C74U-U,JG
M$Y'8I)W1RO0BG)&'%:K/3?K:FV0.A2<CG_%JSQ N-'%EB/)=MYAF&2=>IOND
MAA:&]1N.?Z']WHT.,NI7,342LXH;T7MZC.OUX7%%<@.G*.=AFVN. 8WJ!0\H
MMC;6!_Q7.[-#Y'D99!M*]2&_ W0EY=$ZY&^3M$W.ICXEI9#\:7;I*>5,O<$0
M[[/G8J+/TT(X^YV]/[=W+K"3J4BH)(RVB/8\8>?2?I6^LEY^J@Y6H?B5"($T
M/ZV:/SF%YP*9H6Y-DU -1\P ^%G%;U:F7Q5)>ORWA626DU45U^':1X5[OQBJ
ML!< VF8*,XB@"<<RLOQ>@W^AT?1?T9L>H@R:Y$5\30%T02( T?W[]8J1PSK,
M!-Z4E=_M>C?FZ,WN9ILM 84AMR87C8.]@Q@L/MS:O5+>-_> 6JKV1)*J@<99
MG3/)L@0<4[?XG";7W,IP]QPW>*HV[KJ?:3:]>>!\C8Y5?EOR"4,L:-KUV]'-
MC_M;Z:<Q6./-HQPH^,J9H MKYW!^K[?)2RD[[AMJ:QLGT<=/%N=;Y[FA?/B4
M[XNTM?N9S]O'G+9K,I-G*ES8'LM\S4K>)T*]!&X6Y(!$_TISJ7$D9@I SC52
M=;D4YB0E_Z [Y8OOU,SNILSNEG,3T*HR8)\M8';1HZ)U7[$\W&&/=]-!33^_
MP\:,?VA;B="!;0W>'N[AC6F("6)"S_0+G.?1%=^=0??%"C\OKJ -W@QT?H]:
M5)XR<O9E5L>*] ]/VCYPNI=;HV+62/13&\O<<H&WG%\AZ5I%SS.6RD5=T2CJ
MU,TC"8\(/MECVNR@4XU$:"*^@*P#E#_BYV/=JI76C\Q^Q/BQ07]+=_[<;,[A
MXWUAI3?9BXR.TV#++E]PTJ[F8!%L>#RBQA(U\^^KB>0K5'1+VC#SC/,XWP>2
MINUCP+G:%TEFT DQJ^>A1J/;[\IR;J#-U=\DRI"TU:\6)A];B2]KI*9YOH,F
M8!ECT@LZ=4""^OC#>#%URUE[1SJ\0_/!&NRK<1;$ON?%L#>Y=Z&6P^+-%Z<-
MSF>+L@\&%ZD-T>D'O%%6E)OG;.O,3KSXE)G2XK[EJ?4M^\2_V[!-ZXJA\7V6
MY6:V4(-Z9*D+5*/X2:ZIN62<FYA+RJNHOO8H:8CAF#?,.#9<6O%SL=S?PZFS
M HFBU'YJP8B8I8VZ_9JV^;C).2'"74B0R5AIJ1V$%J7[IJ?_CE2RB+]'[)NF
M7GG<KEX8B%Q,A;P$B/ LUBW%Z3)%LYL)1"M^PMYYZ:O(-5DJU 6+2>UAXKCV
M!L:W6S)J8KH(;BM^<G"K-BCV L"80\S&KQKC"9\>>7CP;#C'.OQ)@]FZ?7L-
MHMF6>99 $<ISL)Z_.*818\!4Q'KMW5 _EGXB;F(B_#NY&<[G/9MXZ9?7/;<W
MB#S?CJA2$5@K%Y+;V5<O>/08_?/1A3688-P5\>\<5*:?O;0,B1$M+ZR$2*^)
MHMB6T'/FADE7S*@WIR:_9G*I*YM*["KY576MOG4KO8B>=@]M,YG=DHX[G=:X
M!P;&$;">]!*?R7/Q-/,HV( +^Z[6GYW[4V^:I*F?[("1K*SI/$54Y3GF\AFE
M8.YABW;W]P]04Z=_/'I5BV_I.G'R7B-Z+^''D4KC8I)(.8ID"]<74RSOJ45K
M #9C<@@W:8O'%8\W^'5[$_3^P)(G=442G#1W1>HP.+6QY*T)WF_SE.=WX=&6
M9*,'>S?0L[T<H@W>#Y@&(YP+@6GL/)W&0:CF]V>16ZXV1+?BF;Y:T]D-9BV7
MK-CO3*81U<MN?YKCS(XY1EX4+L*G\-X"QHS7^IR&<4(_?BL__F>'S<CZEY@>
M"U-T/"HF:)BF=LKOFH-[_WBMWXOL8TRHA!:UT?BZ#L&<0Z7?2BHDCDQWW5EG
M?LH2'TC&-8EJ8289NRS J7%*G8=]WORBU5=M 3O)\1.6@5HLA+SSC O -:KO
M]XJ+$[Q+_K3-K:N/QC*221T]WN?5)O4K=QAV3*YZNO2#>7^YKTB7B43<S4^,
MKCJ-*Q^[A36HUKW2%5ZQ@I@V&YU-F-CKL"7[H+P::SPO'Z(6?D>82C_'1]5C
M '(!V-S#]A#4DWSS<(\XP:-_<E/)KF1$FMAQ85O8@(M-F1!$<9_[KYPGJ,>N
MVAJ='E3R^8+7BU[F_\!\%Y!+R50+9-KMZ;>J8FU5WC([;O3 Q#@T-3-]G)"=
MTAARCVG_$]I0N!"/Y4G>_<LZ_&PPY-6-;I\^9A*"?9LFZQ'/P4G\>D+T[@4@
M.IOVG!?'\;QX$<0$L?QS#N;4<K5+,[0M8]*YKHWEQS;YUYI[%8EK.4'#'3^-
M=?4A\X^M#/=.-IZ/JVBF9D\=+AY[/;70,W@[N'./\K420^XJ",]L//'Q@]+U
M/_.2H!>7***$D8YH/ZEVB0FN2=P7&&<YRF6E:[#V3& ZQY.3IT_BK3Z2=(LL
MK!S3Y9,\%MG>O3']4'U[L+S\-GUV)QFW1B'"7^9SX$GZ/2C%6GM>(69["1$$
M>C(-LKT W/SG?K+8F-S0#&[8J%JBU-A@))7&R=8,2.3TNT>E<>]\!6/K!8#)
M\5Q6CQV2\2SC:?2?:W=^E=>U9FE J1(^!PZSWB;?L#*7T#[^:OM=J;3#9I\4
MG^RDJ-A>C?V7/FOX__T6?8/GJ,JSG1.[FNTO_-G-5@EP  \$9 88^?$C_#%.
M:W4L&G$O[\H<K5YENWAY[6-;*TGXD6<ZH$'-T'FMJ[5&IEN<9F>W)NXTT.>@
MRW,.2/#*8L/K11V 66MJ6T8KU[>1K.[N?>QV#-2WN?2IP6KN+==4 @7A0"Z(
M(;@E$3EO-+$_Y69;&44(66/;,O",WM#=#WI[W6\DZL\.4PKGGU7V'G-]2I1(
MQ.%7H&UY1N23=@7-YM=_&(W8%P(=BXO!6K(O\F;H^?N;94U?5B!^QNZJ=@'>
MCIC#OB^6OAGJ,>+0'RT=#)6+3550JIB[*WNC&%!^K)%XM6]V^)4;@&0^#.,?
M0CS*L?!+>HN*K;=K[WW)FBB9EP8 24,[5M;>DM?]R)F97WKQ\,:_UQM]C@OC
M&AVS76(0)MNMV>)&7 !<H-JA.D:S;CEH:M$IO3L;<(L/0?/JC7-OD9#<>#6Z
M>)I?JFW88Z.CSFY/0FAW6#=X2S(X>_M8.+I#CCCG;/1**IES;6A>VDPJ+W4T
M&HSX>^)VZ#(Y;T9T<'%3B9/K3I69DI'J=WFRZW!^Q:CI!>S=9/!YW[L+P#1,
MU.K85DY ]$ RWWD^0OM,1ZP0AQ'N.P2Q#Q2IQRN5\/VVUE%C6<_2',@92S]>
M/426-V9@PC-\:>K*RR?XLO;>#DX=UD>XO>YR7@M:?55%R^8M:BI6]B9^\=K+
MW 3M[\F?8Z\_VC S3*U(3+7)8-;8N&FG?5AW'#[*[YZ6-F'=O2.9G<IK=B*Z
MP+C9L3#$2A(<E7/QU?YD95XYQOM[5O:-9KJZ5 0 NXT="[4$G[Z "N/AX3!^
ML[?^]SZC7*)-SZIQ;*M!X@X)4R);@F&<X. -\Y;01I<B$L_X]TDOSN+(.U4B
MKEX7@ ?IM)&/CC]]YW?@OKKFO.:TMU@4H.W/FXZYQ2O:K1W.-]<<L;83ML\-
M:D>I5B?EHGIL"LR^Q7-"4FE"3TZ0$P[K"EJ%4^C9KO.?$.1+ZD(ZLE*:XQI8
M 4[JMW:;VDT#H7_/UX43+P#%LB>V:2B/A[P"4'\"!>JH2W@SQK5\Q 7)-AXT
MY$BUZG:Z^I:T$9Q^L[X&8JMOI"82Q#%'V).!:A+\@IK.OI_X.49W(;H]11*+
M8HL$9\XN ((Y-! :_>C1GO'LBOFH H)"AZ[<#N_?IM\2-C)9)3;*CX!+ .<Q
MT4Z0G<$\/GHCE$A5=&_^% ,J#0A"MKSJQRG5FGFFVL($T\;B[MN9:-A.51J,
M6$:MT-_V9=ECW&K+F]?%Z-'B7O !DVV**BS#UGG6I@W4#RFPH"WCL8G,(D>C
M^JJXKLRS1F.?I.]:K],41+]O_F/:[(K$;)LDED=OW@[&^-2#I O2A5QRTXU?
M?1!?26C>GO$^,1Z])/4@.P0Y,0EC%2&GZZ:5+%%V5T:'2^%^-.ZO-K6^_Q;:
M4O14\Y_K'H,)>J?D3T<MV]L'1\3%Q3JW;1*UKMVF%-PNY%8=RG. *A&ZB_#P
M3B.S?+B?!TMDNFSS&,HHD392!]#AS%SUX0&%O_$P\O#+3^U<69!"ZYG5_:Y&
MX!U/KWV06B4W57^'OTM^1KZ9ADT!^O:E=8V=U+^Y2YG5YG<O/C7:[) ].<XY
M8,M-";YDTOK_H@HTR]1UK23;F]^R*-2TQN>G,-RM;0J(X/FA."A#K(*4!DAL
M@=_U^2YL[!S;US"#R[=2X'Q[*.=N3ZO/!/+428M3OL.R6R_^*12H:""2%W*#
M%I<KK=H";60U9HJ,>$_E NVK=B5:&VXU$=OR:KG,3(=D8,HO@V2.C2<?KC2W
M1-0UYR)FLZ]UB8A*09L^G0C]:/YZ3):+]*G+;2MS]$T/'(>YE,Y(N(F<%%^Y
M2BI^GJX\LA(F5"0JLU>P&-26?8O$6M58USBZ/-'XP#F)I]B^-8''_8>:2O@2
M@U)ZS>D#J%,E4:_(Z:2Y!=-_=#ZRBS$MM; H+9T4_(S3XD^"/[+2A$US>"\?
MM=_*FN;1">!^3%M<&7L#^DU3#/Y0TV8?$4M:^TOU>NT-GV]:PW(/LAG."+5@
MY8@E#4E%]Q&B\SF4FO3&)!@V4GB$1ESD7.27)=Z)8V^TJ3C<^8Q$5$%X-QWN
MEY-N59NZ\J4_D! 7K ZSHQMY..BSQ)#VX+8_DR6189D:U0S+];-=A$5%_-PP
MB-/(^P<3?5O__UX'FE_ALM4%D/#7;2\G/5J,X:5;KU&H2>1.P6NYV\!7$D:H
MP&\.;.+;:ZU"+P"5C!% F=F-ZV__$OIL;M-R89W[F=9O6]8.:E0Y<AA^-A\=
M8?Z;5([S"C!PE=-Y-5%:">:,0?>ES(W.TOT>N-/^(SA1US[)M??'MKK_Z&0B
M5/@LAR1*< I8\^K)F@MX/'"[+O:'7\#A=SI(O[L'LLGR06@6I:/!UW6@:;&T
MC8 8G/^L&&I71&1< ,5XN_#85X\W1FY]KS7\2V5Z2T(RJ)XKN[W9]^P'R&&(
M!LI/5,"4&G84!3H75U?EJ04&'DY;5-&/?;<!FH0K_VH]E#N4B&]DSH>JX?.+
M,;-.EZNZ"%S52(AG8'0/N.[^Z( % [Q[!O>&LT-45106)6(X#HNL"RH-UCI1
MG7!'?ENV.0/0)$LWU:8_THY7[1EXT\[&@_D8PN OC&Z3.[X %$%8]?# #"A,
M["V/T%BCKOQW@?&@6_NB$8TAJF.N47U&9Z,BR09A[@"YHZKPB/O^E-69A7/R
M!=)HL::N_F]/W'TP7X*'L_1XJC#,Y[V^%P \?(8HCUZTKZ/NB$EQD^D8HGBO
M>==^9EBL'XJYQN_52WV3+-/-H^%P#E\'7AF_XT:FW;[&FQ(TG\_?BA5$8$W]
M.WB)IME50C/:C/2FKV^X@X;SUD3'8+=A@\*+W $=EG?P!5$(%:9%5:K>=9_)
MZE_\ZP+?T5]LXXA\RQ1<JW*L'UOLP4$,"/A*$\&^%.%D*5NNHZI^2+RW+,K9
MTP18<"=)/ I^R N\ +2'XKOAI]R.%X#KFSSG0SUF;A$_D&+>%X :K54U$75V
M?;JM72*ZAJW+7R&D\8GW(@(5BNDN]ZMS]6:,H/>6M@W;XWC;SQ6HMV'F?,IE
M41/F-4^A1U"PK"=ZNW!YZ&&.K>&![474_3)G&':^[7,6%%3[+#NCR_\H0N4)
M)HAY%L+7Z4]?;&(V9XK.':DJMI%L=&FS).,)_Z 28YJ0BF7=4B&71&.<'^=X
M7.)"M:2$=<L /[Q51SKOIL4WJ'8EZP:VF%Z\1[]ZDN/04-:M6?(Z=(II80L=
MG[SO^_$"8(<.8IR!;!_I$UR+$4[-TF/(GA=-C4\I6-0MUG(^2,Y(/(J>'0<Y
MG"E= !8H>&G +^MUI46OOJ,\^7F,MK&[4SXFZ )PM[Q?7D,0W+)>Z*?7ON-I
M%[C0L%1;8Z_,;Y0HV8J=2B BC3>#\2WM6>P$UBYZ/9WAK4W$)M0X( \]Q.XR
M@J:,C0S7>[9G.:;0KJ,#CS9CC4.=>P3DKALX2J'">, YOQ.7#H;Z3Y :P3 :
M"RB(&+<8Z*M'T!U;XSCH3/]XSI,R2^<Q6ZN_6](20"%T_)9\O.;%<_2.&D#I
MWV>N$E*]Q6Z2[3IL47_+9%RL3&WSZ2B9SHV>C2TGE8!V,@OV$*#[3#HWKA3V
M":*:RXD="]P*/5F<B<H;R;^RAL[NHD@7@/Z&#^^?!WV,OXI(@#&B$5U!7!(1
M!^#(ROZ;1HGJ%*%0E@^[PUEI&SV* S#'C.6D$YQ[53ZL(<%^'VE^EK>CZWS"
MJWO^5TEXK)F+_M%X,6Y2VI(N%AI!DYU>*+=QH*%3&=Z-5 Z ($4A"0:*X]8O
MR3X BJ<1P[_VF\*$1BV8CNU%&CHG,QT.OUQNC/7/7PAS9*H!((Q; O@K>XO>
M ^$-F-/(UP3*K_:SI=O/[S9\_+HE1KK/H E<E2,H1)8<%$O<L'R;RA&8[X5.
MCC^VK9WGRG,WN]V'+E<M/G@1!KL$I/BMG6#876*H]D2._*Y6@-QLY2BTR/-F
MO*FI"5ZSC[I9+< TT/C>VJ 9+WTGF\F8#LMSX-E0,9 <-BI_ ;@A?@' <(_O
MU^Y+7']"G49WO:^9-G(2<&R[>Q4KXCS']Z;?*F.>DJ3UPW&>DR3A$5AFYNAS
M$M#O(=>YZ_+<1JA\=2*&0942%CL]UW:Y,H:UDSINSR2JMR4';U]=F.01_^SX
MLE)>M3&;U9 UW*"4P'J)NC"J"_]!=*=U7C*VSID'@(82.M12'Q$K"AON@"W,
MV+8Q4'<+]1XK!$T0QV)N@G5<KN='?9.L*<1/F"*$48]0\''.N;AJ3'Q_>%)^
M<N!#^:<']%D_-2@"19>M@JL]2):$'XY*_?3R?RCVYN3X.6?D5:H$OVU[H%JD
M!Z2GS_R$ JMA+8FKU\\'7/^GF9^?#Z1SG4AT< J[YDB9.TEK07L[*$2K#4'X
MZU6X60_S_;E[([+<8+T15[?233?Q-S:.;J(4>Z\DV>[Y8_G@_G-[K-S.^TZR
M,(3V];6$8_5[_]C=U'5:[&9HGIBK9YC:G6-=':V'O,JPD>R*N1P"KT$%02+<
MO@9N$?(_*'O/J":^\&LTBH)*$^DU*"@J39'>(B $1$!!0$"(B$@3D-X"09#>
M! 2D!J372$=:I/=>0B^A]X02 B3AYO?^O]SRWKO6_9 /66?6S#QM/WO/F7.&
MP=[)SM4]=XXW#BGU^5H:4 7"80N<3?$(R^C5DNP72?!FV9=QH.Z2ZYQ^&FPV
MS28P%4[4JC/M\Z>\08;Y_!4MRHU_?I*35<+O)9K&#>/Z. <E(T+3^_C#=6AN
MR)]SH6K]"[;]MAU5EO"!U!PBTD5O3A'%BIUXZ@NP"<'X;Y+:N/C!+N3V;-L&
MIVL\]%E7&DM4/;93:=6P1MC/PV^0)#3L"H].41W,1AC;?#4R&6C6#)/,*>6=
M*0_>2DLC,9^S.LI[/"WYT5VA]D^LGBN 7IG>>ZEC-(HC^LG4.4TVN_QG=FU$
M^[O?X8*1I__SCJ'W6&'I<QXO;'&+F.?./P^<01'PC7]$\?,YOQ.ZYP0O8!0T
M.B5 7&@,6*G!+BBN!RUEI"MJFVS>P%)66R[/LYSJ(7^JV-@Q:O+56EYM9L:V
MQQ.4L4>>O7+6KD?KX/O-Z?<(<45<B/3]^9UES_ @JH=O?Y8*Y'<3@=^Q;-'&
M/[,X.^R.%"X!.&N,VT!Z31:Z86J&K_!QFR5G&=OSG/156%77X=6F,[L0O"&6
MHZ^+=$=+F:VYS\GA%:N[K?.'6/!CA?)NQ>!Z>EI\@QK6/:.V7C+7L6!64LF3
M2_*&-&]TE\2)D2^;;INRN%N,"[KR\8D=>D-V>[2Y<YYIH*5>+[&)8H E+C$<
M4.IDS]PNEE->$MM]JU[Z^CN>S,#)YJO$0A([7J<-R5@B3F14-169WQT@SGU5
M1\NL>CS._OP5,*-!,8E\_@N:?[51!Q=$A"^B)ZH3<W,6P/F>23IJT3<%KK7)
M?W'^&,\5G7S-50(57% XKFW"(VD7G"A(^W#,[%0%74H/:<);%:J@1>E?XEAK
M0(W6*\[E.FP7(_4;UQBZ7J&V\H(*RZI_VYQN9QB;FG1)ZXU3OG8Z1ZTA0UV;
MW!<AXU6"W_]$N>Y\NSY7L/YNW8WWI]Y6!OT*Q,)O"%25WA5U4@>]CS81U (9
M/&7YD]$>>[V7=TT27K_D$OV+>7.E\.)%T9@Q4.+'Q_2;?=2A\"9?AN-TI@A-
M,_;3_^UR_/^OWYN!]+2W/W]>P6[L!6;B^UK-'@PW\V[.)$QTIIL_6*R$)W]9
M5?"D^ G]L'&."H=X)HJ&*(I@+@$=]-?K2VM^]Z,XC.-K)IUB%.>[22R#:^<7
MAINH4'$YT!WK4V^SK*MS4_/MPP.,KI9\UPQ;#6"5L/#&9]AP&&57GE817O9<
M1]*D++:TO#=D?N;M->)7P>U#@NDC7==M(V>28&V1?/WQ:NX XYYC".RV^&*8
MWYVQ$^)C\_O5HY;90P.,,8V1<K?MUF)FZ5=^9O".QR_GA_#;1,;E>/_\PV.F
MK#9%5?-59TG!CG,)V#X+^\[71>(:J](<>+_E]-Y,R^W^YG.2WI=N[8@?:DX#
M7WDX,0[9:,05?'[G LW(?IG$W8(S4:ZXL[&9EEJ?1JOBOQ]EMJ\+25*FWSHL
M! 49HXYN3KH$A"\6I-3$NI[G16&R_R%PQ;E_-=P4=,?3:Z4""^=DP;>[ :>4
M2!4H,'M^4Y'G3_FXQ*/J"/S'FPHGG5*O\.SR%LQH2(7H/W>\S3)BC_CQGCRX
MF/>S!I7D"(\RK-&;3'[#$7)B[9TEQ#0)382[JWEAG8C5^/MPZ3*?+D612@PP
MZ$3+C_@@;DSG6WZ<G'5_7!W%?E&TA@" WAM[ 9O1-!EQ@]&2&9P5YN@U)BFD
M4<.#.S&]4-.#:X!KE*8SB0'Q-)'@M-!H\>><,ARKPTGP_F_+IC!&3]86,]IZ
M; ;2W)%[/:_/-7$2]T;175#.+;;\1[5>RV(U2U(9W@K-TH38DLI@+,=8CE0U
M1>.#T^JBC)*L#^KV &Y+IYGT'CF(#-!R?G4Z';?@>RRLK52S=>'61%XXI[VM
M25VN#^S)-\[W[?E/B^_([,6F3&#SN_;T5/#54FV7 'J\R$X'1\LHW\2'..J$
M<*%G"8H6M3>R*3+.,ND=XU3#)=TM5=_$]7^E:N)WOLG$_*%734GOA]V&X$%T
M"JS=,6"1F2J4(.B;9^O'4ITQ:X*YF-]S)TYBU_I#]BN.S0<@D&B6YIL84!LW
M8YL96\.DQ &CS4A-3%;I\-6'<;S]HX,;OP/$O%, Y]3A@BV[?C*>V>W&K)'B
M4XU47KF>IVU8OKZ<!=/'LWU<_K'B4@#[#Y3:LMCPP@L6_$7G)8!!D<Y&%AXI
M')D[7,71GJ3)7]OF<]4(P/G47Z$#X'M30_-_M]C[?4B'3BC+(C4)B _L\ @=
M,[%A<385?_SUTV-II7UMJI7GW+[,V,68YL<$#SP, R*Q:*T7+Q<J3OUXZ:K_
MQ])>429=.?:NX\(?FBM4W)Y;$!.;TSOOW\UV[R7%W?_HV[N*]E>$$@OD]276
M2_,]M6\F"]- [)M?@'8,I5\XXIQO@I3,A)WLUM6:]=@>A(8$6..MTWPG]6:9
MQPD&C;XJ*P(1.>[\*ORW>15^OL@_*R?LP(>8SRCMP])??<GU38^]* ,'YH-%
MOQOC$Q;[S[N61:-3.RX!=+MNJ>OJ^Q,<<JU(5PWVNT-CD:B[RXXS*_]X^+'Z
MZP$S*>\&N%N"9[8M2#'NSUK >\<2Z^2XG\0P&Q,XL1.([\(B(B=U;EPSQ(0D
M5Y-L-0$[W^66);<!*-8-37_+<^8</=LE*]Y,AV5Z"1W0TZQY'-<-VJBN_0AK
MK+XP4 F)-@^,LJV=S2/5@!@&LT^$[%\^F7YVO"#X[:&! 4V)&+NV$L'V%<;N
M"+X,[X@)@U"[17":LF ))IG;C"62V#JO#] _%#87([4*M'XA)H.M$SR;)7>^
MT&R_ ^1S19[?&F,-3&0QL!<?Y-!/T'=>V);BV)#0 7JZJ [-5A,EQW%W3'E!
M@W4FEX 9^'(P7*P5:F+GQ/?DN7 @B'^E@'F 0^(3@JWV4-PE?*02I8$0(.:6
M"B<M#86[L8[9NW$VR+'SS)?93^K=Y+N.XHND@]TZ>?C9*,O08*Y$+']JW#@H
MO3G7PLG&[=9[DU=17+'J8F4Y'P(4!*6;C<A,Y@_NA].^GZG-N65N7BIMXY-.
M\[> X-<>3N/GJ/%+0+EHJ,3-+_)OEJ<?Q-F+:B6RVU.DG5U][J&F4"%&93^Q
M#J\"_[.#!'I_84VA#]4>4-OI_C/JR'O$(;_ZAXY^3G\(8OX^J149;O84KV E
MSB%,3-^58DR-"!4M!1_,+3DOK7X%\"0<Z]M'9C;]= >)MQQ]PB_BDLE^#W%C
M7@==(TG9P-FJO.Z'T<%+C)8=CWLXA:EYO@/1*E.H?$&W+HFCBHB(2M"K7 /F
MS'PJUZXWJLP/LOXO;R+&UA2*;W^!NPY3]<.K:B.!QEB)_.]H=Q9))^&U[4(T
M^.,+ZX5,@+9"AQ?M^.?[T>OL6M43A7=:OJ:QI7M=LZAE'H.^^#5/T,:Z#O3Y
MEG^\=@EPLW@-0FR\,_5+.*.T#$]_Y9JW,'0(\NC!N&Y9#@=H+A@3!I]U-DMB
M-KKFS46K%0Q66A:$OAFP9:P;)&DG)P%N@P>H&1?S7^Y I2Z4R*(U8[_DV)'%
M1#3T^$V_BWBK;L\EX%4^.VV,6EG?<M?NSK)H) _MA!EI_IBHB])-N#LN3(=:
MT_<W'PDVR?5:R+J0((#Q%FAU\0LM,50'B:<I_>/=D8RI8.G^L!\6?"!/5\3F
MJUKV[UT?MA;M[$5'X/Z?WQG7R;]?GMY'=E\8+L,ZA 7074$?4*YOT^VY^RU%
M;A<+1F<O\OQN8''9@E!9(X&DAYN3PLN(ZYXLLSICQW]YIBTJ*^(^*9=X.$_U
M#&I(/,@O)8V01%7D(!K91OV_7]RS%F:TX:[E.BWSLG1VMG_YU.Q+QT==$\FA
M^A28L :4EUN32^_C7R-_ZVE34&-I+"2=AQ?C&/$Y40H+Z9A_T-8?R:(A896,
M';MB<6XX":SPL4E$TB2]&FM\G2%HPOE75[-[8EQ0:JAR?352"N+=QNC_SMML
M1/L2('"6I(VL2A*.L8OU0#=ZX/+&]DR6AL(<<\?L'?=+]P+:A-L?']RPNC68
M$QEP10"#^%3$T1EC4[95Z^U[?-/%RHU355R,ICB+[5YC75]"GHTQO"K_H0?H
MB7U5GZ8=?TWX G^M_BU6:YD59*FOVP4#/IQTT:IX=T3 *K%+O>EM96R/?>@F
M6^?-W?S838Y&35P@G@5Y?:_J*,LSK,Q0M^ZIT=;IL&/<PW]]C+SR19$6\H>"
MP&5(QP$'E'M,-3K&UZKP756I?$UMS3_V]!B!?KT?.CI?;IT_[MMQA;G6@"1;
M-%;QD^5Z(Y< 8WBV7,& UU#+)2#2V+$32)^Z<WO2.*CR!N)X.E3,Y"^P*&-@
MH8G-'9'^\SU$$+SU<UNMA&EI_S_9FS/\J'1'.T?\RC*D6K+I?GZP:Q2+9!>N
M%&,$+G$*6/4SM_O7>H%NBL$57W>+H41BO))N[M5E\AU3-GHC!='L+]]UL5:4
M7^A0ZT4ZG]QO^)(EVJ'NQP*S4W&Q4UA/1\R65O>[5_ZZKYS/\U'J\RW8RS7Y
M1\M$'=7Q^UB!5A!+CU_-RB#\9882[6',?N.+O9\^"(D="#449/G?1Y^TX053
M;07O-.Q<-I1D*0VT,F%BC\D<T7'J\Z1KDBX>YCGC.U.>="&Y-92H8\YYHK>5
M0@0'8JLLDHKTW#U\MF,&I)'T#]=UT^0$LK(P$-PXS]V)/:C4BO#]W>JP=1//
MLI*5^SS*3B':12YXPXFB+@>[HS%U1QXH=Y"\1IGGU=X#X_)&$VH%Y4-6*:'^
MJ*%N]1\6_E,'IF""J.@,9T?XA_+AU%='/ZJ$:GB,>!GBV(>^Q PVPQF2BL;6
ML_J8MZ&^\BH!5?O3IW1'Q(7'DDU1_#<^1<I(WWI_U2^@F:IYQ$]V>UT%@9\4
MYGG$$$'=9,;VG&UH7EO5B@ :_M((PE*WS>0U8$->-=15-X>1NNS$3Q_HU5EZ
M )/25B2&B(G9+/.:U=.2-B>I#0_AOZF/'HKWU+W9)]..S?'H[Y]#7K?%IF &
M%T(V!#I!-Q>A$OBP4J/M$7E)#U2\V3N(&/RQJ_N"VOZWG^77@"\'\'(KHC13
M!"O,_'XA8F;+VR^>;U['[9&<YI>'Y0%4>@T@)8@S:9CC-QZV3!]V<M?.T<7)
M\?/"\[JP3V]_$(JF>(\%),Y.\[?^V-0\G>W@^$#_:P_XS(V?:+>)&4M\')]W
M#%XWRKUE9"8F_6M[MBEF;)[S?3EJ]U[S&(*WN3+6 ZS0^&WDV_&]*MEUI R)
MD: [KDCM&2>L/*@+!3TKLO5VO$_S*;(W@B#2Y+E]!3%,E#WG?ME)W6!CX.,U
MK,$5ZLRNWLU+%.QL7UX+24C&33M8ZCS-'>+FF&?9_!V^IN#__W,V]DI)<P*C
MROC^2JF.5OR^U/ PU095\/(=SX.5NP$8-=97XZ\R/MVO%4@1H\HZ1;@1_;-C
M2,RH4'?U05C5V0H;<>9C(ZCUMB#Y<,C!"L6%P!MN>@*.>1^$T3FFQFRT\\O^
M)8VM@1WG2WWSS$E[H N/0_EP8#ODV;:;=HA,X:/B4U799J&3(0EB9C6"D>QO
MUO!J4<J6^UVA>WO4)D(:35U\/H]/+4W[J0H0(?)V!9ZL[6-0:20FNF$%SK[S
M^K_I:X/ZB>9A'"ZS6XK]=L';+SB*2 ZBX!2U U]*Q&ZY"N?9&W[+:.T."H'Q
M8:H^/<*+4:059$8.S7P095$_5@5D UMZY-D]G94?KOK1L=9#P41%._QM46*=
MPR^P@,P5K2Y4Z6FG3'UKCMJ';5G<66-_Y:5_5,^Y\?98I/B?XN_F7"RJ+89M
MQ^R>O44;CV)JVPZ_($V*)0[.O9?Y6/M^U+N F*'W:1.+@<@;>XJW-Z4FL_7J
M41*FNC@ML.X$ G#D4 8\>$H1Q 8 R%YY#I0GF./GL_R&D3=0RXA 80GJ14Z[
MSPNC]B)V[/=D/T\S]1Y5/M2_6764X=GA+17D6APEA6L>SW9-7@II8?GJFY4M
MQYWHWCT_G(%'9$Y.WECU8GDX";X8++KB6'B@?3@V_)JJXQP']UCS0RT9S5T"
M<I2 L:&_SI";SZ%IT+GSSZ6>:)V;,X1'>#GZ&()<B?'FFZW;/['1/T=5G7[/
M>VD&V0=Z4[&S=TJO-W<?HJ)E7?-Z:)SY^'[7/VD3I D\8;IRB-J=13<Y=AB'
MQ%25RIE-0&TPN,D)OI%JHL-4U]>C"JGD6W]O6:J>^7V4FT3L/EJA5=Q9:DY?
M(HZIH'5HDX6K3:A#>:1J?_3BK\4&II%I$-1]N#T\C./WP]:BR"O'3!&.-,[/
M2JPKGO:)%5R#ZSUG_-_MR6E(BRU>7B0(QP0U"V!^U9EH2)@(U(:[KX(?B)7X
M5ESW$"?K<TA['R3R$L#8?.4]5 9$P]'VKKPF2*1:YN1&5.G&C][G-8!]H0LJ
M6O]G$",\#^Y4#Y,8ZU*P%6>-.C3NM!I;_S!$L<>N#+X6N&72K*Z /]#D^BB_
MM.ZOJ( ?R6Z.PD:8+318C/,%'$J>G$$KS_-WWL,/$;^1UH[!IQE"Y56359Z$
M/8@F;:K3))KQ] ?P]7.^K0.()-YJ$!]2_"!D>7AL6]?ID>6,L*&T%?3<*M\%
MDO!YZE9Y9_5U-^&8F0JAP<C#U?7=I6HB_6^8I:EP*8&[>)N&;G9/32WRO.BZ
MSGI>/5E]PJ\1'F$A.HFT+J^B\AW_^MY@F%-S:J&3)=(ZXCG;6!:H,<WPW].K
ML]/MY<$.96 #Q=4C_!C4?B5=8/D2$+)?'>6P)?PE4]>+SZ5&C 'LKAB U.ZS
M&6\=S=>&M\=T/^/ ='Q\;) X +]O!ZR AY/N;"X\G&A\MB*3714\\;E:/[7[
MHTH R<'/[#870\^#QAK8K>T*4S*7;]7$>F@I?5UX']M6J/EUNX2^7QE[4EKJ
M@_/'LG;2L]K6&GK_QGO\Z[,3SIVH*K!4_=8"=/4]BW%4%AQ5I"=UPVF@L.4=
MT=LV)/X)MPB6+^*V!E=+9+,+K@4('BB48(;7.S4A]V'M9\WZ;V;B"#HTEX#O
M4LL\J6(:!?A+P-M)?@/.))W107KYY9E"Q29,H.K?!Z@V/WZ4$>>:W9ZR])M0
MT/QS+=^.WZ1N$+6X?8F\M&@:5W!C^BJHW] ^CP#$&,2M[4%%<SL7\B;>D3)1
M0I6VH 68G)]:'RV(+X-L "WP'^@Z&KN>3=.3VV%.LV-U8U[PF3]?&&Q&2!G%
MG$T:-I,8:7RS'*$3"J-G;)T1#2MC&=)"5H^SK&7660IS&=Y2W'G"7?%,B_BW
M='01YX%4G]"5&'?%%/D#J&;T_.4,GUTHVR@^P, CY;E7#N[8O<8'+I-B2XU_
M8E8E+P%6<:,:3EP>UUL4G=2^[$E?3!P.Y,V"<ZHTGL)KN=/Z7);L"(RV\7,F
MS]R-V"E$UYE0 XLKD$P(6S-7"];DGVSP]T,A5C&TCUSB^[-GB(<;L_+ UUK0
M*P7O%O$P@[\CU<4&8]6I>C5VA@>D42!:;YP!HIHX&2-0Z4O?CX^GTI68\"S.
M<X7<@IJZ8"X!:(^0DU2O6RKW6Z<6P3/O[M_]"IO_6*(8C%0S[[P)-";T#[L6
MQS#@$4HCP@PY3>.B66^CO(,,:?:.]:_!<_V23<J8(C<HF#N2G8L*R_)KVQ@+
MA<1_UN@H>S_\W1BX&_!_GHU)%CBOU,GK;O@9#L#WH4M3;6 LC6_L[^T]:S0,
M(XU67(G%%Y:Y1#<G'%/M,6-F#MY75V$?Q#CBTC5UHK+K_+^._5/GIW<#/2&H
M0H^6J;V:!6Q'-INY'!6]GFX,*E';,4A;?3D]YJD^T[9)FHB6Z!1<F2)6/AAX
MV">BFUI[K_(,EGSLL?O7=IB@D'$V_AV)3+$>5#P,_ ,DN)>#K!UG,MJ6A=N-
M%2.XO(?"C)(&:OE_[0WCOL 8N*]_\AN&L#HT _ "8 SB^_'T) G-8.<('8YG
MDF8[T\&JN_R0<T,DN9G2T8<D;I5X)J*UP&CN+:F;.94.%XK[!G;!W)]DNF,0
M8\P79IH)G>ELLC,Y5::7@"5@Z/JOC=#VMX6T(D/JD*!+ +O?(SN.:EQL24^.
M]6FML >.O?I)E.,ZH<5,?$V;'O9R\RXQL%&SQ$NX#+\@<%7"(%HBSC2'YH.#
M]%;XYB7 8B@@XSYF8&(H"JKDX_;A_#=WBHG4L^"6._WT,"54RGD;>]F<@;E!
MD(Z5VLN^"FF;UY$K X+P1ULPC Z26HGKXT4[1T++^^!#YGM4\,ZFAF6IEBB*
MI<$DMWP\U-1+2C<LSZZPL5.(\MFPQ3=3K+&^\6&QA2 J1EBC)KI@Y#LW.LCX
MD749G\6JXZS#@BI*GMF]G?BKR\V!WO')KCG^1_XA(FW ]Q2+6GX%8E$$SMN\
MW*'+IZ N55P..2]$Y?G^LM0I1WP3"#C0',\?K38Q''-+U:M8[_5CIR\@'6:T
M?[7;$ML><26F>F<?T?&WC$?SS>9FRXD&^$G 0F L5;2J[TKS<F5M/(KH*/BC
MO@L047Q /<AO!5H_*[Q<VZF9"/8TZ%B3Z4@D?SPSW7_[1_OV/NG?=4(W8NSZ
MWGOVN/#B_8Q+ $UOSI]2S4_'W*I,AC]]_?787'1^^\O;X7YA&G84KYJ^9+*J
M&RDS.+TE]LI34( DVTYB/OKN(E10]EVV]C'8*9K6=UJAQ.-V#U,HCPPE^[M/
M#%OA>!4T+CJ#!K],]5T\V0RE.LY?:\&VEGFGAMU"(20_%RIUVW*_)-N,VQ4$
M7H:.O/F.J=PZ$!T_04PGJ<2_QGZN1%.P7W"GW6ME!R'OWLWI*GORNSD(2Q7Z
MW^KXS5/OC'PW[H2@(M9$+VWFYZ1J>)8UAY4_]!ES=/H7[-1TNWJTQ"(?-L[7
M*(PP %7"RJ$%PI VHAQF-C<0RT/7-P\9O44556OT'2S3+@&PF 0%N[U#^>+$
M2!NS'MMIS-]!RY/&5\6SOM$Q7< J<&BSHD8)WJ5E4CAO>G: =B"Q9*R$)L.$
MN&5:]WJ.F=M984M\:!J\0A6>=]2HLL)48Q@5O"6ZFOX';-]H&+NU0 ]'>X3R
M8D!MW2(BQ_H_-25S76\EG[6DO!EY"[N587<,649^_X0!!525WK'77C&(&V3@
M-)U+:X!CN*G^,)],U?==8>NBM_2+,CT_ RJ\%&EPL.J7!1$8%R139*H1K#U?
MS_J$FYI=]OY&VU4,P\R!5[:D;L^9FMG.1+2V3+Q"2_!S1?HK%&_)ZY(H&XT^
MORLLEMET!]-K*U"V 9-N\6YFTO>FM8E7&::X<H5TB-X@]STO,BI",'C[F *C
MQH>7@'EGNK$S-%)&^ 4&,7UP[XG9[-_:OV'U7??2Q.#MAMMR:NQ_$:DD1;_^
M.,\N_3HL*'"@J:R)+ /SWND<JD#!:O,$,?<AE6B[\7]H_9O&)L_67.8J/+=M
M79L?PA]T1]P3D^[]T\)3?0K:S2_0*H#>P/Q+CN!TC9O0(*TZBR$VKT,9L;:B
MC%"^JF]0E>74^<?H(V<E_LA2!G,4#1W=E0&_8-+0P6]8:S(F%K-:ZI*3RM;O
MW'/:QY T3YK<W5BH=[GUIY#ML"'#D';9=GE'9Z;8IGR+Z8VJ)WCQ__>V GR^
M8\>Y.>9U#,^!='BK)='H$H(I5GO?GE)][\14$L<I8 59E(\+?BZS?]T;M6M%
MEA,06@)]J1$^7MM>;!M]"1B(%OB@\3S\65<=(I,02UQY6?YMF"2Q-=G_&)6W
MU2,HYT<E] 3[_6\\3_X:T[;#HK>;5\CKSA^BE/']%-S/R\#HCB,;.#U4U;G^
MV(_EZ70#S/Y5ZF2_!:56?B%%?A/4HL@S6P?OA("*3S8R%!">9^ N :958R?<
M.NU.VD(2U@_D/GWD/U/A6G/_%@ZXV%7GS(,]'L!*A;E> F[@8;J3U491->GY
MLTT3_0T:TQR1E1^\KT">2GWCQY=?&$*U1B0<[]@E9G#]&7.=AE54S:*^\<=.
M_/NHU$W!S<HND)'0)1#"V0ZLA'4!:>W.:PI+9_$">N-9HPYECES:?.I2:A5_
M^/HIG-B^!#X'&GB&H.^68S)B$-;&]R\!X:5N,O;M;VQ:5$KNQ%Z@V6(2E'H.
MC.IU.FZ>Z$3-7 +\M<)5Z9)R9FTUO;D2703K?PK.<GJC_#TKVS $&6*"'V?S
M-P_8Y_/@TJR!KY> +['3D5%L;M<R;L<L<_D8($,5V=NPSW#M6,L@4GF1S?DK
M'O;R.#1*\Z_DGONK.'OZ>X19PPS*9['/@88WK_K3N1SG'E'.+2,?X^M7R) !
MLH+1$MPQ\WF5;HBN96E[D6/J4@,=63NW^O<W5EWZOCNHV:F@!5I]59:0+3"\
M48IAE+R2VXHORXUJN9V('5P<2K>'\ET&X^%WWA^2*VQ,5W!7^TO'!# (<0RB
M(ZQ1%=O0F4'I*RM]%T.LSNTUNWG3IG&-O]!LJL,+'#JS@0O!K^7A7QX93(B#
M;FSY<=2BRH1<&_)JXL[1RZ&J7JSK-_QYJ/3>ZP3Y,9#U42N*F"7/G+\S4]I^
MN"G)IX.L__M@FW)J[\Y9]K6@#P %ITE_Q:FCI,7#0N9 FG#\D"8^J!3J3B[U
M?S#:^WL#P:4N;O=/PZ!A-,[WIJ!QV3]<COJ^19\A*K(Y#?R!__?90XT4M0_2
M>?L[+2LS_L"49Z\6]\Y?FZSSV0SP\M7I6UOR7W4'KD$829V"\"B>!\<70HOG
M,G9[88NG=S!^.RXQMOA4W%,^$JMA&')GTI'(58U>02Y8@R1]>4Q):^''D&1<
M?[CAOJ@$!M$U1.>)[((PN4EA)W-21 -<E?E-"BI7O_/=O:M'JOB\M0=Q/X/O
MIIT;WL2Z+/.0Y4R;?:X=0]U#S5GM2)=KWRT\N;M/$47_T 8<B&<0Q>+A,^-Q
M8LX7J,(RC'(;4A429C$BSY<K$"S/F5\1-LL^ ]K(B;H$"-\WG\T<\%W#C"T/
M1F J6R?/64(<5V=5^QI\SW*Z1+K^2DCY0RFR"9*8O9JPK!GATI]\:<ZC( ^7
M^9A2UX9..J6NT>I.BXS[AV!U8>1 O%IX7MDI#RW3T!.G0WAOROU!/P-"<9^L
M#@6Q[MAGZ+;?T$QI4%1UQ]SAPC0@,=3XN>)P\@? K@SA4>)BI60EPC:%SQ.%
MUJXDXP?=EA3#@K%U+<N(<L7+7T^KVQ!B]O+1:2ADI<,F/8JIZ!(@(@GO]6<+
ME&?H<,Z0QQLN0T*QG<UW1X1/*$,_ROQB3J#Z7;_T;2]EI_824.%$3G59&@ZG
M^.B",#4)5J&)D;/8"S4\\ VYIA0W>80Q.X.N4FY_*PQC?]TU>^ ?/Q5X)N$7
M@:?H-/9HI[^QE7%O-.=(2.(AB^>04VPO_*LSZ-;1XDS$TAR$0_'.=KUQ6X-A
ME9Y7OKKB87^VG%^D&#(*.GL)N+:''Q)N/$]JX_ZH%=<YY);/WRC[1SI1"*A=
M=XYZ@?3B^7P"CG\I>-.T15#-!.@3(!DX$SG^IK9O&#OX]$!;#%9A]PL'7H\<
MDV^9 _;&]_?P"G( XL4_)Z_[<$BY1 )[$S-!XI^SCP#7_OO4Y*<N#+PWPI\P
M//\HXP.P56=98]TIO?'U=5H7DA(K\N1 @!1@MP*:LB*]% @E*G9= JH%=^>=
MD&@=OZ=#/XC(:0DL?%?,"<O8#H7UP4GC"&IVTIG*NJ\(Y!)PCV#X6[$."P\L
MA1KE[7HNFRI?_US>D')78/KS8^7>(D^A9_#69E\\WP5_W_(!VZ)G?N<I:-8[
MTC!.(NZEQ\TGB\+MR22^R*"]E/-XF,[/(TTDO'XQP5=!7M_XM>O2L55O;YJE
MB-7PBS?5GLP"Y,RQR.H:)6?F;LJZ!+"#ZZW?AYVJ2T"0Z"]I-+G\I/.\DOD_
MA$L%7&DA%%R1MN2-5A",PFZT@FY"P8>ID.$]Q$:4>^[@K5?9P[)+*[,2T_N<
MY8$955[IGN+C:>[W7%=TY2L,P>L"G0CZ;60%<$\X!Q_SP@Z^^XC=P5X>945_
M\\RJEO^<?CB<R(=!A DU0C)MZB=3G]3]0=9JAG[22RL&@(\0_$2$(@VL=1VO
M66!BW$Y7F_?Y0N?CW_OCT)&84Q3?3C@6A!?0Z0QTR]L&TE:#+1O+Y]WRO4+B
M>6!>+/1N#D[[OH)DDBT_K_,X_)WQ8)Q!9(TBFC)RW(ZWTTFS$>9*?/I^XP\Y
MLJF-WKKBWYP.3S*I./".N.!+0'SQ\"5@L?P2,+RS_\!\TVYY<883A)E( 7*;
MD0.J9AB6"J-4+#A_%4)<ARU;S=W*+"(*;H!F^'!N$\V\+5:.RR8%XL5R$2V2
M69\*JZUB4X6=^& ,;X:]42.QM=W2"H\6/AR#WAL.ORZ5E_^Y_/>(^2Y[7G(K
M]"Y>\S>!%U/E+1G/X-[MD]H#.!+AW^_W5:"R/:"\.NIX"?BTL:6Q3J_R1C>G
M2*/782_ZZ1N->Z]&4ARP6QH-L\>%#_VL!Z0\.YW(Q^P/4^#SO.R(,_(MQ+&#
MKI?7X+LI@$/(3.#2'K(SYGM]7N1=@XD/>A[Y&O,.MS_19],@5B!/82URI"=S
M-O7!I9@VDX1,-ZN_8RNIP1I,:&L8[HNOW<$CMMHK7CN0-&"-5=N\RA*D2Y@/
M#0EYVV95,$_]K_O)O09EFE#?-)>SR>-%,2>KI/"(7&DTWQA,Y?C7$WFK%-.)
M3H(P/BB?H(M1C$+[/@VK&>>]PW3 >0FX _SJ+%@VO^OTKFID2^VE9O*=S^1B
M'$J2EA_U2HNM"MQ2_TVVTNK7TS0G</+8&B@!\+_J49:00V)J_K!3*PX@D)UP
M@+.A^68H+9U)12YEFE^[L,=2/L#>A']DISSIJ<5K'&?W;W!J^_U\_]^X5'0=
M:#3)HYQ04$<WP)[G%0C_27KK%5@?^^J_4?DAG,E6.-EU"PH^KRF.U&Q2SSII
M>:P@/X?_^]-0-SBC\XP8?_:_AC*L((F! CH_4@#D"X'7W<ZT1'^!&KI* :!P
M<@VEK=@0"A9D>+E\'_W/=<D8"7LL/X@450G_X 1A:^:<)9CA/<H\U0[7-:4E
MI"6I?ZD9"]"P<W+_^T GAPK'!^(<\5E8.A"UR@HP]-QMH#;X1,Y4>7)1:S12
MT]G\@\>KCC#A;]'2/0^:,XZH7M,IV'A81>7H4@S*"V/R=.@(G[!)T8-9&S&W
M9XQFJ9_RR,-YGPSNG\V?&[#$7(!*X2&*CS=1QMGO3?#;N.VM#&G,9+&\N62,
M[M,4G,ZSP@[.LTVO/*HA)&:H60A+U4*D:/%[@%4-ZC_GR;=PL?&R^#P24EMC
M^3 ZAWC(FLA3#>L$7H.:BW;,JZ"E AO-*:.*WF_]L<G71E8^F^D/[==)#N"4
MX;OFNC'9-/+>BND<@ '=\.MWJ@V">EFM-!DUZI5Y+FV\0X:#[C/K2W9Q"1(>
M!^;Y3#)W[6Y@Z3L4N<<:Z=&+H0;U"']A_D@MYN:TC^,2-_AX<YYII&=^%7O[
M"=V<3-:6FFBI%E/8:^QDS(ICR/E);; \V-*"F"0O-9EGISFK-9LHPW1;2:_[
M7B%4"F\(P_AT\DCC8U=@'&U%?27&SQW+.%"[P\8W/*P<!6Y<^3<D_[EINVAQ
M"V/K[C(S/]OF9B^V%\?^0U8V(^LG!ER>2?_K$F"I0[%E7-OA& YA$G?AKZ>L
M+N T99^Z'</6-J=Y&_3O,'[(]R^BD'4?\[@9GM^6-]ME;T\CB1MYJ+[\[>J]
MAYM7HP'G^D7_CXTKC@ZB)F?V4-]$P"'K<8+5L<8Z]W$-X+E')UMF EZ9!+T+
M>C),C>U':))RA#LY[KVS&% XCZX^K@V+[Q\UXY5)&'T:X\[</_0 [[I<'3.M
M/]]4TYM]SK&3JQ<G62'\Q7/5F[Y##SUORS2^=C3**BR:?I%,*<T0_>TO\&6/
M*1#]%:,.WZO]/67J<A-^2I3=D)G=PZ.0/4ZKVS-1R[IO5M+!S1,Z& F3W4/)
M'ZY[^0-25(>''C!9U*QBM\>AO-^*"KX0&%$5NCIQ_\CL^NR3U--;DG$JT=\Q
M?M7K?M=&W'(G)&+P8/"TFU1%[)JGNF'<TWNL^H[O_TB<--3.BI:4,7&7"]VM
MV^]> >(QB(QFBOH!+'4[PU4$SBUC>._4$T!4*I.=2M6F3K#UEK9U>%LDCE.+
M6H_ /M_RX^1[\_=N3'>QU #[ N!(QV_>+^%W/7T'"*]YDL"16GC([RC=<Q'"
MQL: ^+SJ*SAEI8?3]&R]!'0A?^D0*/5) 24]4DD%IMIJ^I.65)O%),IZ8N5N
MC.+&4#X8#R<KFL>]C@@:+8]V'H]SL'9#_=Z0[42J$CY/WC1;S0UL\XJA-N4^
MS\M(9RX/>6"I#Y\)R]CHD,U<I;<[@]79>'DO_\2>R!2TF.L1W!E!N@>O/53>
M].3.B,*^V&KF=QL72>"33C!;$;Y+X[+F[:KP5,/G-T'75+0M9W$>^:O]1=A7
MBDZ/KY]D5IUE<8BOM;J)4N4)=\MJQ,A4.\\1RY3T:M1XJD"E'C7@3A8WY%CK
MZ5?C7_.H4 9B]1O-B_[5IP4X4<!E\HAMM(U?N*^L^LI-&N+ [4=+R0]847 K
MDT8V*+GC'5_,5J;_W3,['_,R7IM8IVN-5Z,?>7T)4'FM:KLXC?CX]L &56O!
M LL5_7+!^W>551;8(8I_6<5LKZN\1^/SR0CF"A>]I[JI0Y5QHMOU I]3#PM#
MHLV_YBJ>-T[;^%G '^(VO0WK!;U0*:Y+T#\YG,C;;<""/+7\GH8S)]S/]WYB
M?TA53;5Q%*V(*E XWPO,#LSZ_1\K^]#X9;1<W9&.$Z&X6U$2#R7P8#_Y\8WO
ML@SI)ND;!NJ-\=TPMEK[Q3 5X*RPLV<2= E0#9),FTTV 6I<)ZLW3C^6=P03
MS&!NKIE(C_R*BY4B:$*+39E^)1BH;*>.0GVR,!;NW++U2DRUQP+?8JXT5DV(
MY)?''=G^UKDX;.--GW\^W\)<?T[?\0+[.80F)2?X<]"-'UH7!9TR=$U#5#LS
M=?33<'1-EA=ZATQ%%P.$]E_41\&3#ZO$<@YS8M..!6XYG2"*.!R?O:MHZ-H?
MX=4[\5WLNY>V[=Q@="M*WT!*GF.6["I[@F:4\N:-NF3CE0<J#;&L^8#C<SV1
M*DBXX.]->MS%[SAU@X>3*_3L<T\^*71--G52?JJ=<*9SE-&673> ;#]*NM79
M.LD,R4 -N?/T\6X<%N"&SM[\7;50PA= [0J5)6185G;W%YQ23VDD,<S>E.3D
M?Z  1/MX/D8K^7JM"D_1.F[ Y;'CDBZU^<S'C*\8S?XV\IW*?8H!J0__%WZ3
M6;'I5&69.,^AY34*XD/]QA_0&(YX)7SV)> F:TB@;9R#-=^L0.JO[),[HEC@
MAG[),?G&'=$!;IQ!CY&*9Q66=Y%K822>*UO'"->HQITH15_D=AQ@,7KYU30I
MQO,)>(:/EQS\H555G1K2-ONR88IH!Q-9189< M#FKBHO>V-+\''/8@/O[BLV
M";ZVAC'-=G%\MRL"_>)U_GP$J#6O]"^>6HW)LYL2O5U=0EVU/C?P" CN.BE,
M;TRWW=]Q["5]I(A1'R<;HC/KQ?OWJ'U&I[T-<_0F_6"_ Y$AI3Q&PD<Z*^W4
MQG9XUNZN6*'E#H#B9ES)>P<U48>.K8_W-V %B!K'3%=,:6=&7[*&KN<&41L-
M4X$\)G7LK1*4)W*W^<*N$#[-$NTVG$X<HS)W:ZW&U@Z(@8R'"@^ZE/&%EP#F
MYUIJRSSW']@?;?2?_3ULDJ;*'RU>V+P$,!FV>3/ED?9^VQCI2M2UQZ9%>H74
M[:!R?:JD>$QL1Y_(.61_@)]BDRX!GYGZ0J>KZNQKXG![7U<MRE#=)+=CLVD<
MN"_C)1GBU+#5NQ9O'4&[_="5AQ<RG++7=Z?YSB:%R"5*B;%<#3C'*.%R::^D
M$;,J9 NW6?F=#B!*[ $[H_,6JS/8C=KS:M#H[^I(8J3QSXNQ=F_8V!,-XD/<
M)6!>Y>_*'6LX$SA47IQ3[\=^\+-U(61]I%4L+XDO9K#8>!/)!$,7".BF*_-Y
M!:U? HS(;2D1,K_$ W]Y*GT)\+K_/0@V ;X!"N,=?Y7[89SID; +Y_5+ +($
M5) ]V]Q-?Z-YI/EA#-WFB\7Y)UY38(ZA, N%QK8YMYW1ZB1R[B[(-43:EJZ7
M-CR%#[1?^[)T_:0'&".Q@PHW[F0;_S1;=?CD7 HX6.*UH-WDY.YLX8REF U-
M0&9ES]I44,-!;3D$'<?KBZ]$#Z[7SQ581W5:.;HY9#F#F;.<?A/T2#.8T9K\
MIS;WM"(KZ45 ;P1.HY^>(#Y4U[J-='S3Y4]\9Y+_T9\LC_+R&-GS1JT EX!L
M%<I]4..L.O'1A;VK.CUCY3#I4;+\J^*".<'.[[UFT#!%QS/+K7\*@BN0"!YJ
MK,XN$<L(QOK6O[<)*U1'&8RV$D)HPRSX705DNK[:'2](/NTIZE6:=6/\?MH>
M20DZ*#J\!,RH+',03/"JL*S.;VZ:K'7-Y5"7=7!\[>:_%6SV+$23_ZO%(]FJ
M ^[)+H4ENP.@YZQ1^>3QO,N>)$=0")QVIB?5MQ1(77NQ7*?0PDPC*]H!Q+\X
MH;KP78K9>\S!"#KX=9YMM7\HC7AX"0B $HPN>+)\,4=OY[E&O% &BN8M9B ?
M%H70.:K)YM'*$")]]Z/@N'<F/+.4L&-&;7TOLVX4K9%!7NXX-DQ<)QPRF\$^
MF"_X-%R,VY(X9Z%P']CN=#8N62_0\> O5H56S?)P)"(I]1XDE60$\_#W]A6<
M^TA<K1%CE@Z79KJP#)6@#F8YA_<-C.M>/R4N4YR-^SCRN\YA? 98T>%X0[ %
MS-W")YBAO1+]2=[":U^,[<(P&OIIC*#IB%WO77Q;;Q+E%%40[LK'_?R]MPM)
M M=Q7OFN[5;6@^D-]W.:2T H(NX28"V8XSB3^O*'[[@/<)W64V9 V_;)"%3]
M7#Z&B(8L6WV8 770_Q&,:%+IO3#[%["SOABY4>:^@BE+O:!"%V+[7DB G_FF
M>L#)69V]-SWF^&KC9+WII9S[[="7-2=O7#V[*(5@LK-' 3M#3H%KEX"BH5%Y
M%'+OV$#];,L!BG7,)I ;YW=-O5\0,VISYZS?=I']&W]5TK[%*2*#('7DS"D]
M" ZTU4M,E'CZ!+X6DQ$736! ;9D-V#'8<\U<O[N>.(_=O$%%YI?BN.0<^P>O
M2R.L?R_N:@:1?A)K3U\CIGGNTX5@M:I%[]S;EJ+F=ZI\.0#JX1V$N6U^I7\9
ML +&9\@#<U^*[O>#;-P.$U<8[PY='W0V#.RR/84\Z9+,EM&K0<LD2.\#*<[&
MK&H==^.M_AQ$VRRR[3+!45]S]Q8_L<K_VH0P70*6Y=\-%BW8U)Q]/@*-8"OS
M%@^L"';W9E7^@_X;90@2W+VH]C&"6N=B0T;FX7P(W\YLKB^ B]M6KD)17Y!=
MX6^$A/&D6$TIXZ/^426!#=29+FYQ7LFEPZ%*)QST!5.1_O+CP)V$3ZEKD?MD
MX$ N+$4C7ZJ[0L*M=+&*$H]4P(Q)%J)] C)7[Q($V#=J7^(6C*HV-DX9P W;
MG\@%^1C<#YMQ#/ ;89KBN< 2;2ZLIF]@'E7!PJF7A26:Y[W6JONN?=>Y6)->
MJK22\Y3G:,&W80S)"IZ%Y:"MOKIKUNI"=D[EZ4^OF_?*U*A.P[I!QN<&AW=P
M3B:/TR</!S<VR?9C]:WV )ZA9DMG+T*_70)J+ M]_'H8'Q9V=)R I&"?'4,S
M1(8=JF-"&&Q961[8&*N7&.%D^T/NJ.67*WR5W4,4[U<YAFLZ+4>=IPVLWSNS
M% " $__'T)@UB 1I:I'.D<1&>#6JR+=9,(F%]#"W55R5+VXY^G3Q!)B%J"2Q
M$%Y4X@O)K;!U@:\<)#J=9;,R""U\$5X6LOF6Q%:JD/]8B]^K3J;>?GEMS%$E
M)$0%GT_\BQ;7TC;G=Y*3#W:<[WYV"1 *P:3YZ<,E8[$@TNW9F]>)LZJX_*O,
M\--ML/+ .((J_'2 9#J9K4@W_3O][7G"A^M@X6*1%)S/3<M$*R[O+-"%!)C<
MEA4TSW@TB$%8=<_]><ZW]NMS?I> _DL F,)*N6D6M/)NDMRT*3'-55K$X3>R
M5&%Y_67.SF\:Z,"3S0%S0(. #;RA+? "UUDTW6HP\ENP?\"!J* #Z@TR:7P]
MQ%C_'Y)"GP2^24Y?N7Y+ZQMPX!(@#&MJX;;!U0,[@'LQC$'CZP;J$)^J1?ZT
MZ'O 5J<S5X0][<6 S+_N8'X#D!& E,!N05.?@P<APYV1@=>O)M7X_HBYD@K&
M9V90_TE&./H-HEZQ,#A=8+L,9 ;GR'4P3>Z,^MBF$MHB$!QGJ?CUIV\:;6-
M$_4GP])YDTH;)Z/K]Y=3#.3=&>(O 96WZBK#Y,',&XJO!5EV86,/0)-D^J[D
M\L_>52=<:WG>0:=F0<A&+.RC3UKWAL!]>O/N+8/_N-MS3_/H+.=62XC ETO
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M@?;<G0^P4 @9;3I[KUAZ?00R_XT#^"4;N*ZJ6QL9I8B^FB/1I[P2<Z#N12C
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M?/%[J&!@-7S.:Q')Y2:,<O#QDSBF5NPK_HMQ_U-'@;D%RE7!Z>$8K&ICY7A
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M69_FAS0*_$'=4#['TSNTBCP?,JG4@KI2\X[G;:;C!=*1\8>LT:R[70ARTEX
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M5/:8A37DPT4:%,.\.H=#2-:U*N"MRL'>FW U&<M88BCN#N0)\0=&EWU:3C^
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MOLV<)$_\3A*] !8I'O2$<NWVP^)R%$@)&EA&XM.T-$_/QIR6!;VD$RS'4LP
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M>I[K\&2J_SD/L(:#G-;__,=:O#6-E[PNW18W?HBX9BE_F$ZW(@ /T:#W;F6
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MG39YE#;YOYK[SJ\FN#?;* @B37H'%03I@O06!>E21#H$5$ ((41Z)R!*"4U
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MQ:2$B3J5&6T7: FZ^Y@"\9=ATL)_LZO_HCOQW_%.6E@PR)9#<IB3:<1@_@=
M^+2IYR>=,RFJ-R'<:OZTO_6A0N*C'F;8JX(%3+5V'1)-6C?:D<2;1WOR^=9R
MQ94,\9%1^A:K],:SE(W=V5!#U9C$8F+;+>(W*,1THODYCJ+R6'YO9RVK,'3M
M<[R$&E>]D2^>T\R+BJ^L+HB&RL%:@_N6<:G\8M49Q\D$Z_V)(&M:3#WH!5XE
MHGC1 !I5>!!Z>1!BF$!<B0\TPZ0D.:7.*$S/KK5AX?#[%SVZ=B$ %_&#<MTO
M7'3Y"0SZB:,_H0QJ ;+DTQP-@]Z:XM.F_E)@LT_&ZY2VA<-%>ZWBOLE%"?AZ
MHZ2O47?,,63XT)KC86"A7VJL^-%LOT7-I>D3#\9JH;G'?YEM__CSS'/0CRL[
MXCCC4E58E-=BBJ\^R2?9]=OO8H#]LI9 CO3DA3!1$)<=I7(/PC\E7E[SW20=
M=US^Z<:K=AO_*F 1Y,N,41Y*E*;257VO?>M8%*(Y[EF?]UX#2F_>AYA4>6KH
M^YU'!XVGMM2C[/H#F/618:$N[MX?&-=F4[^EU7&CRB9CV6!&A.AB';I/WJVJ
MF%CD676[HXWKFJ(V2=+(=$#^U? "Q1A6WM6S;EKLXPH(8D9O(Z]2_S&9?..&
M6S\+Z>5XG,GZFY*NU('?$:K[^H7[_%?8Z0X%ZMWZU;"6N;*7M3&>OPMXN<[M
MT\_(_XIC4M=7DTNM^S=Z"@BJK(6%56^H?A5P=8>."["B7M95OYOB0[#:A?.Q
MFN,-R\ASKA=C\VN%XXJ$7HPZW2XU7;B(@W79TAR)4\SK>13-W'3E6R[T<7RI
M?.WU6^4O!72'F6O9NM9Q>EN8E=7Z^1IHX2!CU#5UMGR5(X";=GI^V3:S@B@*
M*[YWIRKLCE_U=[K@S&E%' QAPT:(\1XNW1KIKA-NY!%?%VM;8-W9T],PL#>*
M#N#] @EI\>5N*,&WQJEVV&L(GW[%QU<$5I^;^AY+S_-VC1#M0))K!C5ZU 6%
M:KGGA9_];P?;-!^AN)(,#^UYH.E; =H:FZ93^WA)V6<21A2]N2B=%#*3NT/S
M\6*%+D;=90_SYFQ?[/X!,/KB#0B%Z0:>:WHK[^/H*26X J;3?9OP4G553[C?
M'UA*@,9J(BGC8<\"IG^<%=:%\YGK5;RO>V"6G'[BDCO\Y/"XG*-"AH(/+-4_
MJ*L+]+%G2>2TFX^J+/-E1*>4G_+JE'NY71CD!6KCH9K=IIL>97,WZD*O!A))
MT!;M<[Y7I](=8!]_$F=L7&GMO!=%)JPQ-8T-T-ZA7+\AW)_1I2*8,O4#IZQK
MC.0HKRC:?O7@4UC\I]"^P8"]]VUV( .S$<_M>1^,[%G04<FW?O"- HO(8ZSY
MND 1G'W*!O/>]>?Z<_6 B0$XS1:X'+3U<&869*#0OZ; ]_<) ?0BUEQ5!,!(
MCJEC9?H3[*:TUAL1D8IE2:WS<#>TQV"0>/'5D,(++;[I9DV< 3UR?\&9FM'V
MM/L)^1*DE=#V=YZIB3(R>@Q/J\;=Y0-\C16#K$HO(+%X^AG.I&ZS))M!]_QU
M6,0B]044MR.*<OTG:@'CA=6!5%7?>+W6YI?F$2.3$^!O^6+PUVY/C!YM*VY[
M!-PORQJ'V1^:5[T1N;9BCZ3VN;+\ _#.KF/J4GJZ=LY<IM\G\P1BQY75_%8U
MFO-Y;!GB80[-SR\<@A-F\B3>5\:%8*?_=+7V?Q=H[+K;:(\,6)W3^7/+S>\?
M#T5[G/23^;S\.A@#:Y<3(,7?P=6@!\G&NQOU=I-+9^\O9 =0SLX]$9A/E&%U
MD/ZB_9C;$74UW$JQ+Q#NJ7Q]3V/&+K=$3TPW(,VN_AO [M2#;$'NM$+\^@4'
M =55(6OX;=2S,-:+*F-S]WY U&X?Z\ W>9$YM[X>'^.::ZOL++^FEPQHB)HF
M!'1MO# 19I0EQC_NV)*NE9!05X:A#$2PDGRXXP8*(=#$*#FP(/X JD>([Q3%
M?ZVT+,PPG]>Y8-QB#L>EQT<?<T[%+HDR//FGWEU765GTN.+5:]WS]E_/< ]5
MKU.TMPOD<$$*_T/!WK_P5V/GD#MB8R:@8J/#3,G :*GZ5XT?%]MQ,[H_Z#J$
MR&T$9UK"DP+8?SWFGF1,I6"O?@0U81/I!9AEJ.W/:J9KFP9813L8!M:Z\$@T
MB=M0H$B)#:7;V;=W%W2S;':5E5?-H349%L\>WI'OUZY94_7=>JLL7(;D]O#V
M9Q(R\48H\^-/Z@A'IV8CX$;0SE)M=M\C>6-M<F\;C]^AYC:2EQ7LTV9Q/#16
M%L/.)16"37;-B0U" "4[N3/$ 9!H<G)FI7D"J8T?2C"%YI/P_)JP/.WD(:]6
MXYNRT4P3PZ3(8@<,W V.4!:O2C2F)I8[7^T?E>GXIFD\WXBU90STWM=O*]<M
M[?HR!_Z8?>Q=>T K)C%.$@=G7WTUZM4TJ"EA =)4BE/JF[%0W5U)@;EE5WAZ
M_P&07TA[E)G_- <;Z7GQ/M3*:T@*GC3JJ7=M-GNQ# \5Q.V 19B532FU3J6[
MQ^?G2%G)G0_F,O'%+2Y;+XI:)A)VA*IUM<2;#\6)ZK!!@M5:A/X[F;G31S]R
M.&DDAOU3.\[$$G @UZV%;<M#YDDU3>X$Z/VCI"IRUIL/)::3YLS&D#<N/UW(
MYVTE+D(:O;/+<$ Q8>_8HB?(<LRSE7\Z)()8NA0<(UQ2QK6K:L>A9@6F54+B
MTP"O2J'/5Q\?(OFKB:#X"-I?L_N/>A+FAHO A(T3P]IMN[+ZN#7\!L)<X.(F
MXN@/(!Q>3=-2Y-MKT+HO49VMCX[Y3A"&6=@+Q]#%=1]O]@0]^_I!?EN?[GQ:
MI&K2OL(C"I.?K5@RQ-,))[L07,JRT3/0&N.M:TGB'7)T?$!KV"! L@GJ#&DA
M$_1&6"Y]*A2UWW69#?C 6)-1>E,07#[KIMVF,@'84NMYWCI5X8E^X>/!5&\7
MNB9G/2V*6T1@X1\J[]7=;CDJSYWM>X4V/EIO,;83=$$\A]G5@ %#>G[#/0:Q
MECR=<D?XLOL]$Z=CC A*0S:"1**[!N![I1E.H*?T>)"N_$+<_\QA\,=.XN]\
M*@+<]UXV[E3)8Z'5C8<:O\^TL[J0#_?S>? II[XIJRBK:JY*B?85XN@AT<;1
M/X-U*A^1:>UDH?+K]!R%K=:.UYMP@)"AFZ(\G%/I0ZKM0_NX)#+QVS9NE<$3
M2-[I&HMR.RN0"L[TQ_Q/>C9CK^>)?DH>UA6H+CT!D_"GDSB05D%,27Q6&3G;
MV20URS+/NTG7 N;81\*?%P?JA1BX,]SB,2VL([DL>0V^"K[IC!51JY^:DJ7%
MZ7PC,#(9L$J85Z3+\(U#@13S?6)FP(0[T=$6I&R/'(*6K=(O.-X:+5EYV[M*
MNH[8.MI[CX76ID+\H,7.AK.@:E;+H37W^QU"-$R-^Z#=[//[E54%%@;NYP(-
M>J>4<#<I%!W?$L"*-'3;3$1=(2AAH_&8M\;H-Y*V=$8M]^?C:?9:9)TD9TNU
M-56N0 A@:"_0#.1&R#":]#R7"V2 PG&03?(]UZ)O$-V'VGTP255)E9"UU@8"
MO,.6S%>,XU$1T4<O;G?AX3L"-C?MJT(*QAV"OAVG@8]_9I:EU&EV2B./$^ZO
M:*&-E!J>D<6!RJ<[M_"Z:;>^=$\=9#(#_326:+D+O%'^A/A?,\O? SD*P0OW
MQG,GT!R!S7426M]!GU?>/;D1,3W6DF5WJ[X8NBN<7B2&?IKD+5^**90-]OZA
MH!$+SMT\.3$U';7$6I5HY<:^+2$'7+-D-)KFVOLB39^"> #(^]\)$J!9*U11
MK[GIYL%O.BFD)55*NP#) 2H2"@?3<D&2;%H6RD^ ;8M4=.V\MYJ7_3BOO$Z5
M)R@]8")BDHF"JLJ1J*BKNX&4S83>*&3W(@9K/),N7YL@J&K0OYE@@Z08:S*1
ME=MG)8_3$?KRH<E+1ASNLMU5U%>T0'0TTF:GY;>JQY-6XV],(]\?CM7/ _'B
MX>N3%??:DHS&1-FZK*WUG"[XY7D>R \;Z$,$;(@^. ?"Q5E1=I%>&3@:./.A
M![7'H=)$+L?U"$3[+IB"&(]9N!?Q#/D#K_NU'9+1_]G<15\RAZZ?_:CAP8MH
M<)9SH9*T>L1)^FS=EKO_.J9"$LSR*_56%>9\VEUEK0.OY'94F=\1+)34K2+R
M+<A6=Y)#H]I.)&%FL_J[H\MM)AE4Z9 VX'5K'/HR]8(#@KOI92"VI1XUI5[E
M]R3L[0J]1.*CH4>(X^\X; LCSXF&<'B1)&=SS6CS%Q/TIS:2-6KRIU/'M+=%
M%Q*60&].)BD>UD4BA3F\!.XP&UK,DEPF6)*?F#7O5Q:X*H&_J,.*76FD0#<5
M, '+A8%5/(^%-PT?7 B'3F>K)3Y/-L!I5T<2LCMM*8GBABQ8_93:4U6@H(.C
MHX.U=Y_<)JC$Q*8S4R79Y%C8N%'7M#X&I)!J3AG[*[^4<B+4O$%'?R>5M60C
M6J?L$<)+U9611I\\\*22'Q9K0UN?].+KV/&Y*,2J.ER;)JEHKE=T]ML[G7N.
M*?A";<TGN#U6IRORD:+)XWD=:F&]J&2;K>63O)279;03'X7U%Y;OUUETA=&!
M.@X[6+>/4,E_ (Y_ )$V0&+;,HJ3:(=18,J>/;(0N_<(\H1[?=!CS9)"5/47
MEA&EV"!L#>RFC4QOZXZ?F?VGW .%MKH4.!>V C%@9!KM,3=2&,1G=DD>;([0
M;;#B0E2&1BY>Y1*1D,\UL6]ZC1,G3_1K?2CO1K5P@.4J&G^+8Q9I+L3/Y2\L
MB0[X87)P2BL7X23?XP_@YFXU=21=CY#^M;JT]J6/6V3XX4%;\W+$"CX=$*2Q
MLB-]7Q;6_YA'/GA\D4U)CW!J,N*Y<V,%;17BV-!X0!I2\O(ZU?XN_-;A(,M)
MP3[M>_L&Y EE&WV'[(]2]M(#GA+E.(G939O)\Z>!PMF]EDKL6<F=70%%^=EB
MCW6^1R0JQS,=BK9U*3])QRX,&3=-HASH*'V')E5"',<3M5$^U.P,A6!.VYG@
MJ<;N\S<5X[E5.#CV]3#&;-%E0BK(<@"#0!JB15@X5UYF>I7W#\>JL$5HU*0L
MG(&]!&W41&L(6GDWR%?89A>3>IFB>$*:0=!2YQ%K7[@APLJ/U,&4V5X@X> K
MJ\NYF^WC0.G+E!UI6HI^( +K) W!)=[#UD[7/*9AX.-,2D(J"X,;&>]E#6'E
M2O30^OXHWO5Y65S!Z?-YL2S2]#"I-&$8E*^2+=PC1 YE-'+GL)G'#N*8Z_O%
M>/^:8\H:1%FDEV9-?K81&A9'IAXDO$0;[@_L@MZMN>26$>1#NE0/=:PDGSG$
M*7_Y^CQN<MT$XP%T8S&JL !&$U1<;#]P/]K7"(44=^1MME)_<+<\.%FMW(OS
M$S%5XM<^MD-L7'"<"Q*!73+39!<VVXW),]1>?EX2>KV7R=9"J#KI7;E\0J6F
M36%YVM#FH>)@K>&89P:(&T.IJ$6_,$5*P>GTD$GSL1!!_:C8;5/]56OYJ##9
M@QY11BH=P?]9:_!? 6EY$+S3WPPA.D5M-*3X?6+W^9V-8/1?G:## )ZG5G1Y
M/GX4H"PT)*PK1S^%E7B/N(O67!+Z^?[Z364A'<$Y9!V#TU%>"D+M7^'8W^1X
MG]#C;.ZK24J!#\?R4BAF(JQ3L&3S$?D]ED_S#YT<;'&:AL9G]MR3Q\>!R3A8
MA.2%R655H E8I:[2*=TA^T,Y[O-&'=G/N=UTM=6:$'L:CP]W1LBF$:V2H$#+
MR^2+@!(G0[U\8IM>5?JX\9CL'T#!3_VPT_[M4S4FUPM39-(2/,P;?N-" .\P
M6BXJ14L[TU..W3+5_>:$R'GM4SPPH.]>D(FL 2]^R\KN@G,Y(>\2H4K^I"[4
MJ$@76$RJA/-)L8!X_?H@>3[#8OI(W65\X#58B:#Q).:]V-5<*[M"3-L,1&9G
MYN!1'=LZ;/XDAT:\QX8_8^D/H'<;&.6-E:DJ\WW4R\XG<_JE<$;IH,N/;8"6
MSUE2EG>G;Q.QX8D*D659)-1+4=8@:$E\%Z'''X?>H!M3E)YA5'Z^K93?3C^[
M^_JIB8FZR?,0P!*M#BCZ<O2W(3DE3V>%L 41EN^KUJ/3>A]=]6Y!GK_>"!GX
M<6?V+H#@GG-<N<#*?/OZ$0G)IA&4^U/-OQ;C<GXLCWXGMP&AU"-PA^5O)3K+
M^#LTLWRC8DN6!QR3C!,JPQ$^D%?S>3S58AY(</_M9X?9%=KJ=REJ_)_7&(T^
MIM#];_@2_I^$"2L=\_[G>Q&N;"%LP!=_#\3[[Z3?^%^@A_Y3C?1GYO\ 4$L#
M!!0    ( )N37%2T63U/!S4  " U   5    <&QR>"TR,#(Q,3(S,5]G,C0N
M9VEF17=U5-3?%^T'0;J&3J5K (&A!:2[86A0:J2E5!#%H6?HEJ&'9BCI1ND:
MD X)Z1(1% 04F/?]O??'._^===8Z9Y^]]UWW7BT=35DYQ^?WX'B7P/\+" #
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M! :&P< H&!@+ ^-@4  &A<"@,!@4!8-B85 <# [ X! 8' :#HV!P+ R.@V$
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M5\6F\A"G)#L@CE!!,]4Q,VYYLG =H/UZ7<.=^#B+AM8]MC.RT/&,]P!E'QF
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M),M'XRRU74 ZS82//^0&-Z]&*(NYZPC6BZ;)YR(;")<KD@WJE75X>'7_CHQ
M)M63JW98!!IA](JX(?^'D;:L0O_P=9(%3YYG\.QRY5CIH;HJGB_FV*HW,7 W
M<TAD-MKM/:RYW_I8=#*Q^KCTD?N"LO?77]Z!5>,6U>7C20C37!*_;&8I]W'*
M#!\XHYS]13KGT.N6@72Y+GM&$%3CA6::LG.'[1.J<'T=J5^"]M7<"^2D?)>\
M'MF@2K0J*-S 7H[.:N^&ZD+=0S]%FBBLQQRFA6*FO6;Z]9KGOK&J5$=R^I!?
MJ?!UEJ+]T6.)=P9HMF9WN9A#';'0WQG\>8)J]W>GRP!_'MNM2NW% Y!W% 2E
M)+*J$'.D.T2?+G&3*Z@PG@5UY*J550*7%.GN-YO8T%3D.@D962PA#C6@.(E&
MKI*+ZK^S[__65]=^7;8@\#2N@@M&._21"W^S-FM;#^052:"W<:;KMYDGKG)4
M)!;SOK1DI$@O5!_\"B&RID+],:OTC_UNF-M!_<BFIJ):TE S[:NE#6E&Z3Z/
MB\]CI&*)P\MFBI?5F0C!LGN_SM-2\<"P]SHK7OX6O ^=B\T[68IW8G_79.C6
M&#X@L96>C,U[L%SE_JAS&5Z49)1F]\U'BF9=T2,SM'9%U/4S@4+>#*)IFP+L
M7,^ZFJ[<FO78=6[[-,1@#S/7(KM;]GFA<D--Z'7Q?<JCL]"JSL\T&57!NZ5.
M@Y5/-SPR2E,VEQ=..]K<,S5:6'9/3:_C: Y8+#Y>QY34^>G]FYS%"';&.".%
MRDF+03'([@5V,>5-S_7=0)J"045A3;PI6[TRIF;P"2./1E4N=6/]D%4\O_5X
M2,76 6T2'IGQRW?!:Y1Z2S:<KG/DLYZ+%QZRU2X69V$/;1WM.M)+D,U[4&8!
MH_VRDM(H>U?_-UZ+;]IF>\>]/;W_8;?"-!?:/-EF,W#-1/O\(4M04$:))03K
M<E9TU)T?P>7#';QZP)<Y^R-*3*^P_MD?]P%AF2$2]5:IPJU:JE&G;'%8GI>S
M0,[ )Z\6W]4!_0WU\9('.RJO&CX%'$F-6K?5K9UEA2KL<?QK#CWXEZ3.&[O4
M^\:L3D_3#V,I\<C_B^?]+<'+KMBU8PTMZ[R:$WO7]S+'OB%_TVU]RI[/"Q4#
MFY \)S](V _%II>SI8N\)J[\.MTO>/=1=?BM?Y(GY.PN_C[NT/<+XEH;SS2.
MVMO@<?<>>:/P-+JU_NOM:C/J64*I0:W<>DK)@^XUH9,FNEP5REPQU;O5%TU"
M"BT;2DTE44W^X3LW''7W_AAJA>#F?%GS^&0^RID@$A5L=:T[3.E%;*FZ[<K-
MW(^B_7/^BMZMQ84<[/SWY3Z3N#M*>O*R[54+ELQ;RCLLK7&MA\$^>]?^^[.'
M^P-GC1,^;K4!_/0]AB^%WG9,SZD,?OE^&ET^NOA0@%Z2JN+;7[I*^**/&B+9
M95N54.KOP%U&?M79MY]3'33_Z'J(U.Q"#_(9*0>H"9=G[\X01C<_\B+QOZ;9
MB@ (A<E#M[\I*78?WELZO;5ZJKLH<_F5P^"[MI3331C>6G0Q9E;GM3V_:X@6
M[1HNM"$FY;@2*%B[NCN%8J1WBTQ_'9.X?&CPR/2O:\UK=H],>?,CZ_M-KQYS
M"0L_BIK*(!G'A$1'.A)_TE?^K,_QF2 ]ZV?$9YTK)=V12(>/62 \.$"LI&=+
MTD$CV,,M>4^7LH.V0,&=)E/G\:!V>=RS7C</E99MY3S4@U$NCG_9H!W6?*KE
MF*NK^),-LF9J_(=S<9QT?5QS9&?*^#I,^#K:^#J^">+/(B6I(P1<(GEX0#0J
M^$)T^'S5JI)N!)+:$9((54D\N*-8'X2GCS.PD%)'35*XSX@:7_24$EG/))_;
M+S^@)B^LK-#5KW_Z4,:K7]JEQ8\YI>$T[<]4''5PCC+!@&9NEK]:E[8Y@T[Z
M$ZVF 4D[M4_/!@P(Z#%M_8H$@PH\2<;D&DZG#UTWU W9!G3%X?JRN):1*UJB
MU$'KDD&;5075'=KG*5TV.X,.Y[G0]'2JPS2.^$$ C@>( <[JFJ[Z0\Y>FF&R
M +V5)CT3F2LY@&^,![,+\X@, S@00*&FK[XF<*#ICU5^OJJ)4=9\J3X4:#Y<
M[SO\S7DX.%TKN OYAHWX+1WB&P0>>#Q<?S7\BHWLU;'62Z_$<)=A;Z_$,+?$
M0(61J &M*/(1Y/EP+)OV,[9,:G>&@F>Q<'.R6 +M.+J1%(+1E/3A9+:X)+K1
M5!>=E)+AMY&C[P9((DM&HZIU@&3M5+O1V'2=7'7MYB#M<+AVKN1(T4UWL=UP
MTMOA4O,QVVJZ:Z:45Y64-"443^+Q.%7TTBIF*YP.T8D1E)A<BJJ!L4O:<LM<
M@G@7LH]OF3#4J<(K'5&^5#7Z>M^KJ.OG0*V!8F[*XRW&>I,?QUE5TO8>-T%S
M4'4E>J37>G0D.&RK'35;=>) -767BSZI'_8 KD^:@AV-I$1,@\P#=0\.$KOG
ML!,;6-8S?4Z2B6GSB7F7B87 B<7(B:5T@R85C=,1BE.F:#L=@\B*B2_Z))U3
M<4+,=.WZ) _)4T\.5+J7TK_232R;$^^<)Y)L4IY^SIG5)][Q,DQ5-HQ-1D('
M*#J,)U<0DT_.5"*S#+?B#:KF.$JL%-@V"FE((D;_I9'34)VS(7$K''5SJ>&=
MR4RG!O?]$0T"F<D"#%QA@W=T2;C R;<JM'\C-9P$4BF.D@\X.2-':$5//Y4R
M@<A3$S(025DJ;1;FL3H'P_T51#P>-)1K,;1K'/>C)EY/DY.+#X@)X,C<E--6
M/^/%7)%3(1''K*0T\_'RT^3Q\-3XH,Q6D#'7;1JBC8)_]#_$M-SN26%!&C>1
M)#2*TA6V4R-J$54WM/AN!"<5:2LC68,AE-!8CE[AR9"PL0C?W)6VV"?MA?UB
M,[RNIKS3O25!C#%91B8=M,07)&8[I!5@K @[DOCK-+TL.?]TY!]?DLC/!)1;
M]^@B!PN!.;6$L#UE_+^^)'\5]"0"*2C],XF+8ANKB4[,2$G'J!E,XU"CA0EV
M)FH)7>2JQ/S=<W6GE0J<J?PF".(C^?6!Y!2X,0:N0264:J#!I4&/ME,8='%D
M*-U(ID>0FU7SD44Q\N+U0-/FTY3-)31P$60@W;OD;HH$U.O*.?;>.H7-$4FY
M6#+4E"0)R I+("@U"&O'8YPHTHE/8O5%"H3%7[.-O%BS:#TPS3.;,^0AG@CZ
M@#PS(N0=S_9E\!\MA$( 43@AC7>D4K"%Z_0X.8TQJ8W)F38#OK$9014M4A!A
MQYN*X*#D8;=*#EEX(D[#P$O8[85HT)Z-\UZ*X)C.HH@-KD%%V5>,G%JQUI37
M'5J85\=&<"Q3#%I&FBD 6<POI3J=S>8^L-/9*!)+7L>*WY+B(_"ZSS])[DX8
MWI\68IYU,*!A^/NDY-W"<54,.6]TE4$F93#4[24%?TI2I1B5,3(^Z(PZ;/!K
M)**0\Y:%?QI';I8>^4X[POEFI.*4NL @I8EW->]EJMF[A=<FA&[:M$_MIX/S
MJ+GQ,DH-2$,'E7''BZN^#/S7M&=!ILMS2S;=BTZHN%#H0$!Q+ <J-F -5-,]
MR3I%^>3F2>J:"JPR9EPDTR!A\$MRTNS(;%$6004WI>1IO[;?3*5510C[:B3'
M]!?X=(=(W)N@"-[?R6<'E/Q2G8V@6%I[&R,3FP@QC8B-PNP?,V\$FAKG1B(J
MUO^X:2B_LTG="#\CYJB%)M1Z,TXTL_ZSF[KKH@@"F8WPICZ=H34_GFG@,''B
MB;VES^!P^3#!FTK;;8,NY4#"&?\:+RYX?^B$9I]Q4#IMK(!2/L10X]9_O;.?
MSUW4+F&2M ICW5!,:68] FR>\"PTVI%>"RA8J@_J1&IP^6E,W/(&<:X\2:$:
MB-M\([@V(K9H9M]003=SO6-)ONX [:7V!Y,11RG"T)O/0<O?U.8?2BF$02VO
MG3FS#BP"$L:VXP<:/B>GODPY0Q1B*AQ>:T#SO+?%[M(XA0R<?",>9#.E7'W:
M-9^\IQZ!X_V 3&%:;\HB(3$RO[&C5ADTD&LY6U6I-2;MGM);SF*ZS<@R\-O4
MDW9)\W5\D&YX8>5"2S$9 2=$X VR]"18O!I<-4[@S$@P\DG2X-MSR">0T5ZE
M=*4V+YN]@!,CI^/="%-4W^UZ#NUY+>QY[_'L^?S9>T&X[\NP/Q+'R\N^W[)A
MJ">Q'\ 02QS+N_7L>4N;/F\X;C_(Y_FCYI+WS<\;L_:_;\^^(R0E3B@-)3PH
MX#@@D#\(W[-X:\AS:')0I'UP-;T?DXA4"'[>4G+P:N@@>OT@/E34';J57#:0
MPG"8.JG8KW8X_/@PHTP]T\)I+>(PW5"!X_R@X <R*_$PX]5A'I][OO1A/N%1
MP9U[\\9\MB$)YY_!DE>Q1=(>*&6/TNBCW&='9:+(8-<$196$1UB/.5^*>5^*
M1RX4PC<>U82>M7\\EJ8\:O@\A>UH&D0]6QB^+V@GU*ZO=(AZ-I=Y+OHB*\L\
M,JB=E@"O3D//A:FCKGS/.0[/NDS/0</CNH6CUNB$-MAQ_9U'F\5Q?XMGAR:^
M:/*7'KY&DCB^TC=_O*A^'(C'NF$F"43;#N@]CF87'L0\^/%ESU/8_\?2>N_,
M$-=TBW>?JW?O\MJ:TA$['^^38^\-Z9-MS9,=BY-=V,G>JY/]Z).#S)/#LI.C
MEI/O/B?.2N:9!A1(9"KR\$3[#&N']T)WZ&2@;??'W:?3EJD'NA2P=16N/0--
MI1<$R*THV?6KH)S^Q^20?/4?\]_80Q.)A10<:E^T$-N5C+T8$5 H01CS!Z]3
M<ZX_WUQ4Q2GY!@^1]1[MGDSUUE5DK63M'"28_*JA_8.PI$6G6^X\5>KQ1:R3
M47R+.21/::PF/O'=H5Z<<<&3^>^E48ROFJ),0[.WQF!$^J0ZK37,-Z*-&E_6
M_V=AX7144F?%!G<I@@!J4[)43L[BKR[ERZ5%DD--Q6>929Y"O/4Y6>=D!JGR
MM?-J?464[,3,YNU)81S):N.%/UI,H\ -\6*"P\Y^KAE1R)IU:HQ<9Q=!&+)I
M@P;-9+%G?.^6'C.2JG.>XM2VB;A._UAU56BGJEY:^/*.>7I3@8+7BT.0HC'G
M*PY)E;+QHC]H?W]?V%X[B,[[M;) MO'R/")YH8[:VJ[LT(R1/ <7A*!>-E>7
MTM!JN5B1AI-,KUO+:&2=FK#+##!=$;Q.H)5$&3_ECX4-S^I4$(&&UXUCD!8R
MGY3J-]A:D9T"CH(.80@F[;"LJ19V?R^9N/-1U[,15XW;R&/!S/ANJUPZ8ZN=
M\]W;4MVUIT&KPU\^ZO[.O&1Z\<K-C2!5RL9<8;5.W#*(?DGP9QH]M6VLM;_;
MHAZZ6=?L:9#_,O-3Q1;=AW]0%(')WBX*-=-*1-_4#/^\24#0MN3 68-1B*<F
MG.L_+PH5HZ<H-VV/=JTQ8L;_7=F4,VGO. )(^;^^2U_-?1BKZOF!V?)K_\$R
M^58 [KQ?<93@-9J4_K8TP':!/W_/DMZ)"Y;RHO+GI.,#F.-DW,3NI!&EPA?R
M+_1KD[8PV$G%,A==<"65(=<@Q><V,B[%EL\53 ]=7'\:OU7',N+=3_KT_-]H
M^<U8Z\WX\ UV\69B_V;R\N8+T>T4X^TT_^V,S.VLUNV<Y>W\\]L%W.O;Q9C;
MI0^WR^6W7UMO5X9O5Q=OU_9OUR]OOQ'=;3#>;?+?;;TO/[][TM>M88RWWGA_
M3AGI<*NPHZ[W4R_MKCAM.U9<(4HKGL,ER9EV]3J7^N;8R<1Q;W:J_:GTW:C"
MTZ/=.%XT<77TBT'EX\#VB3,.$.V)3]W<4A@^L6O:%&*TQ.MA7R0IX\EX)&RC
M1)\,@@Q&1#.IAJ=)/W Y..,>2>92$^IT%-LFE;R@7H"T&VWTA]U'NV;/U:.9
M(L<&EM@.?_-/%:K&T(AXG O,E.A^D/ ^.C\<UW$B%0JP,D%]9G5".$ZHDU-D
MY\A:TL1Q9F[UZLM0FJ[QTW/65Q+RO*&3E<*9=6.D^B7H1ACJ&F+(R'KHNLR.
MM1!,Z,-WVN0L=A^#&&D>'UZ6]KZAE),VMZ!BL8RZX(H]1/ 1LG2,.3T+1(@[
M'];5X7^:C&00.EGM>/W[Y,<_F=,-VMX'<UC:38=XUW+#;AV0A.0"J2!79,O6
MHU_-%(^&LH[]&@=VS1X=5<LE6XTOF@ZN&S_B^YD0P__=,.&G===M'_:0K_I0
M+@V/:+ 4:^GD%A5MFZ9L9N1!JC*[KE&@<P'5XA.7'55=:\\@<8GA-#=61Y#(
M<"%YLX.X8@557=.\H^ZWT,31N(9_U9MQC-Y4NF Z98$1[[5M&S9G9%)+1K[;
M@<85#"3/>FR:!.(GXAYL!<["F:,TL*0RJ_!LQ&._($Z#F9I74YI))N7&SPB1
M:/1[D1,U+$5PI3E]TL7 O+$1 31JT\..I,Q8)7NY!)44<UW.5804ZA H3LBT
M8K"O?'G.H%JM$DU=^B]PG]=?K6%N03O9R8-:Q<[>AL:^]7#.H=PJ>,PZ^LC^
MW"YQ!N0RQ>/IZ"JD!1K\F)3R",J [U*JL5-HDP'BF]<M;8X$OW_(HIZC')BG
M!4I,].@4:5U[\[T" ZHQAZ)9,AE+2VV;LZDQ3S)<OKIXB 0GIQ/8_YVI<EJ-
MLS-R(T0(QGU:&+$@)ZRFCK!.8UI]H#&:[6I1#C!Q^*H<-<1]'  V8@E=AN[J
M,_>>T23 <G2)O4F4>Y5".R7&13IO&DQ\7]$):VRKKGY+'KO1RX+YW3O*TW:=
M8/NA!]9VX6DD;6[EL (+TG&IR="69\ZRW 7SJ/]3EG,)>#'T,57M+6\@_Z>P
M[@_%.M6POS.)-_F"K@8*?0HR:R]7*$Y2']63,CJ:&[5Z&?X[<&?,'KY6C\?3
MMSF>ACX%O8,^8\)D4 >3G^T(.;Q0.V8Q"(M[Q>*0YA;_ D.]Z.P3? -]3-T)
MCN\QVZBJO(%&4%2&'J^U?^_!/?[9(?)<;!K@4I#T)_;\,#T@U+@SD\Y1TU*&
M1RK_"48^TW\H>6%B2(,_%J2"7S5*;'3OS\2>3T'IZKSW^RE^@!C98)%R[Y:K
MD.!PI: ]#&W7/?OO[1,7187FVG701SBAPD;*UPAZD-\N7[XC2=@ 3:^H7(T$
MIXZ%FWJ#,E%#51@[SU3IJJ0TM:JOU['-AM9'TS[:-U/O$Y3)R9]R]3)G>W *
MS2$I-"(_L__Z&".:9NV+44W-N1@*YX\EBWE;,< K48]4PDOP]<GJ&P:T8E1R
MDV@;*P9%_.OC'&ZXF/H%AL13Z^-A"MPLLQ5#4@WU"3YON=FV!;1H@@FC+>8F
MV .:5'"2NZ6);8<T3G^DAE5H4I-YF>V_ \G#Y9]'@V4 @*?TMZ*VJ2E<_Y#V
MSGCO<P)=0UK^6V<]T[YBYN8)F1#=37,!1@$;%#95-YC'?LLIS?R(X'5!%Z_H
M*/'C^MX=^3:3#$.[T=KNE%HAI0BRWZE%S$#UH90/$\V6 %&3G6ECMFT\U8EN
M>)N.-_*#K4UJ/"E7SV,+I'W?3LXO\S;I9Q=QG-^XB66_G1M$3E1!7-%%YO(N
MQ<YA?(1$?1EA= 3\D2*$K_W"]-5;Z(0])9K02%-"1BQW8;.7H9)"YWC\O<QL
MNS50U@J>3M:]-VEV4=A8/$D2#?][+"OF0QS)UCJ!7/2=3&]Q16)CH C6'B?)
M)68>449F-B-YS?JCTL 42D4ATY>_A7'$+F^]'R?ZS3AESV")N0V.]-[1,%:8
M.?ARVQPBM1XZ#7)5CK]@<9G'!7+EM;U,=)A>(7DZYY^<=:_*1?F8I245L]C]
M:TAO7AZ;]8KF89 A*47"5*RX=V9/G[:KSDXEC?Y'65!**IWQ#SMM8 U>*=M-
MRU5Y^)"/V5ST^',&;T[X$6IIM%(,A96HW@9[.8_32=/O$.+3"@?0N>16%FI"
M[(+<)9CO85L-2O-4S4?F)C.I!<+2^9_%I2T+F:[F*)"9R>E]@$*:!04XS[/X
MPL#6 F6*NZ,M77LO%X6&(6*O+(8Q8;'GWZ!\K>O<P;J/.*;C$_QY%L9\,MV*
M>@]A[\)']R8.#)RX$8:O/$I6<D_$509_QEQMM?TV;>N[?#FJK+$@'1.T*S(V
MM?0Q_J7^G'@DTVT1K0[Y3@;F?(+'+FS6E=&TY$QJQY.[LC;4U*,S4?(8#&3M
MNFQ$\EBL'8&I;=,LSUTV>3$0.>T[VR]O6S^TZ:G4<4ESYJ11\;<D:S._RU+-
MPNO@IR$L'0O@%)P12+A$-])5HS2VC*R-I5G%>1[YTKLWFJ"J]Q4[4P94Q=D*
M\$7<9/9(O7Z*C+TFJCG0R/'C__?[A3$P<:!CEAW7.0;1$:HY- CHF,V_DZQ0
M$SDR2>N8*U.2PIC5'$$;.^9K0Z6JG46^6\]V++3T2-4&U'RW_]VQV',G]3%"
MY-B1MG-I2(E.NB&MYM@5TKD\&2K=5"SRP[U1F -X_'\ 4$L#!!0    ( )N3
M7%2S3X%+068  '1F   5    <&QR>"TR,#(Q,3(S,5]G,C4N9VEF1'IW--SO
M$^Z'92V[UA*]]V#UU858J[?H+7K8J-%%A&2UU47TU;)*!$&T:$'T*)M$6R1*
M$$241(1\0\K>_.[]X\Y?[YPYYYV9YYDY9^:<,30V4%/W?$#]C.H_X/\)"@"P
M $   !( 4  D "!1 !(+( D D@0@*8 = -BA #LL8$< [$B '07  0 .!>"P
M (X X$@ C@(T $ #"FC  @T$H($$-%  ,@"040 9"Y ) )D$D"G__@8H*(""
M!2@$@$("*/^4?[Y1* "+ @@H@/3/AD("*"0*A<2BD 04DH1"4E!V ,H.A;+#
MHNP(*#L2RHZ"P@$H' J%PZ)P!!2.A,)14 T J@&%:L"B&@BH!A*J@8(B R@R
M"D7&HL@$%)F$(E-0% !%0:$H6!2%@**04)1_<?Q+&X4%L%B @ 5(_\+"(@$L
M$H5%8K%( A9)PB(I6#L :X?"VF&Q=@2L'0EK1\'B "P.A<5AL3@"%D?"XBC8
M!@#;@,(V8+$-!&P#"=M P9(!+!F%)6.Q9 *63,*2*5@*@*6@L!0LED+ 4DA8
MRC\(_B&.(@!8 D @ *1_B!"0  &)(B"Q!"2!@"01D!2"'4"P0Q'LL 0[ L&.
M1+"C$'   8<BX+ $'(& (Q%P%$(#0&A $1JPA 8"H8%$:* 0R "!C"*0L00R
M@4 F$<@4 @4@4% $"I9 (1 H) +E'_K_R$:1 "P)()  TC\R2$B A$21D%@2
MDD!"DDA("LD.(-FA2'98DAV!9$<BV5%(.("$0Y%P6!*.0,*12#@*J0$@-:!(
M#5A2 X'40"(U4$AD@$1&D<A8$IE (I-(9 J) I H*!(%2Z(02!02B4+Y7R'\
M8^,?)/_B^F?\5PI(@()$49!8"I) 09(H2 K%#J#8H2AV6(H=@6)'HMA1*#B
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M&:V9YI9>C%?A$HSLB$_Y[*!>1?XOVM3UF9$YB;S/B4,&9*ML#X!;R..DHOF
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MZ'$7?:OQ+-&Y=!>2:DGO3+IKU7J?1NC9Z7O+?JE!,*5/_HU0HZC0I.]#W^]
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M177 XC+3UO+ ]V,9G2*F%_P88B;PSJFO/1,F=&I>#ZQRG?N.!C86O._.>GW
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MYT;NZ<0MMV^MLF8;T[A5#@5#)F0E<)BZ9!P-G31Y.BIU[HB$#S=*,[=C]9D
MWY7N,AIK*9/'G?@-II<FI7_L^(]5ZK>P_M+@,\N[:;-(^+E+VT<N&2>=I(C!
MS&C6)=$"4^W1!=T@=KT@@=LS0P;*U>^4[&77..CG""SZ()>S=%.9#+.UI+D6
MBR) @=;HS<'%M4B)E#W*A)SY+/^L*#E>?IKQ<?J:C6F[O-"7I.7[=UX'R]OV
MVTY$!\GUT%>I(HN%ACO6..>QWQAC_V24#7-_O)+M<8R_DXI'K,07AZ;L*?%9
MQ3 RD"W'1)7B!V?T:!\M]=EITUL]*)<W1[&;*;(;93'$N19WSR=E9-'WZ+R1
M$KOV"PFW%<-Q$VD&+2LX0\M$XQACU.@<B'/UU]-\=18J$!(_?G/$L]1EEF-Z
M=MXZ'CC6D%>*6[)&([+$U*>3A6K%PIT*=.;#C/ ^.LC"3"$G(G>(@NGRAM,0
MK>5F0$H4D')XQ3HVD&=6!!^.T+X72QONF^+6[5()>])OY^I39F)6X-RNEAI-
MH5:648?TX-AKT\ =54GF5J]6,9".Y<M+T=:!,V_:C$S]HO^UM;%?".W.&'A1
M])H''^+8Q<VOQ6UGS,WG9UGTB<9WE[6O^JEYC^WI_RR5.:.S?]+*">(,CY/=
M-U+O!J0$J/<J^C+<0=-\2-;Z8)DQW;U2I&Y>R?9<^O7J@9C'0=.,Z>$+ZK%Z
M&C</VK].W\,\ONM"O ;Q!TWK!Z_!27TP7U\1+W3Z]WBY8S;/>F_=I3^,#53V
M"1>Y\ER7^H4+O.5;O>NJN)?SV34Z(B2YY.C9Y'34]6W>%<I7>@JN/U>N+=/0
M%EFG"^_>H"X$A^>XB=Y[)5'HU6A.E&K.EZSMW?;9.J#$T3)69+"I 6P0W 4#
M8!+QGKE0O2* \;<43F" _O;/9*^-5#Y'965U&&T>JR<QB;HNOE4"'/P\KT@0
M+Q.6)"T(R FB?AZOU?O270>,0B; ?G6FX7OHK9$>SV'AF(UDF=TMM%;6M0$O
MJ;_,Q]O>!Z\]BAQU36QW+AM\+%D1?9WJ6K_&VD"[/"T!>C#-VZ\#]CMX@BP5
MI\E[FGN,^..*?RA1WKR1'%@,#IP !SJZ_7O8^J9HH@<25[:M"\$AW:M1:BF>
M&[O!X+40\*?0+]C0+\GA.I_"U3Y%8#]%&MR\;?\IJO!F5.VG:)44-_F4\ W:
MN'$WBR];140U)<1>1EX2CE)!TQVT(W-T78'HDV7LY,B>"O@@_^9V&M?%TT*F
M1X1+7:+;QJE729P>XF[K4<=>.;]?B!QIQ7ZA-1K'[OPQ_GO7[\_=SW^K/^L$
M[0:&))>.XQV6/U<,?"[#8A]AL<1;V(J_?F4&^V7B^T86;KR9WH':/K9NX!A?
M>.[4A(G73A)>+6G2/Z>F2_ TG<;K!2Z7U4T0Q"V1V/HS&26-'S=)BY)V+QP<
MV7'ULD6\SUS%;"!ONFV@KTM,!.,^EW>N0P<\>))&!G:'1NT#1\%T+RT"7]T*
M#"%ZX\H")SL#!RH"#0<"IVL/7S<?ONT,?+UXTV1\R-HB.7=Q?P'N+HQ.[/XB
M4!X<Q'CMU#F)$QSI:%/_+C_E9VV(+3WJ,0.2'Q+R#W45NF"#F[T9A[:!NSXJ
M_K8+>+Z([?"?>+%.#S^U%(T.S-'.B,;O:T=1+-JK7[Y&Y3+%PT^RLWN4OYX:
M?#W#9^]*!/_0#CZI@)[4;NSS!]I$!9$I!L[-85G7>)#^<32R^?27>!(Y9JBT
MS#N<HOOKBC,M!?$^CK7F1@VY;0SQUFDEH[NVD(7:\:N#_!/C;V[.G_5K9>Z%
MMWR%@C=*[Y@'5N!1BU^__Q;+__-UL8ZND:I_UXMFIZ[+RX/V:4:Z^6#^]U]=
MDQHO%5MD&X&9G%WO0"-]_KY/TY$I&H'9!WV[8I2K[4(^OW:]%NZ%-N&=GQU_
M15;99_BUW;%,<0ZAHE=/O5J;5I?J6M H?3^,BIJS;'**U-#$JGFH18C8M>XT
M#1)-_5B WVS^XF=TO=0IU,\HF6%\?3=K7S8E0C)I\5OYMX&#?_/::H\CG=(U
MZ'0T'=MP\H>HG%R*,_BZ43*=G*1 0'9T#5JF]M:O=<>&F10WX! 7D>RG,Q8O
M:M_.W%]0ZQU#PK]22?F=?<IL_N)O;38H-.MK^U778BK&UDP*%XWA,D-X#CX*
MX!B$^-"]TW+J^QJX04L2.[W7Z9&K;5L:*! S@QX8>>^U]-5,XL9/Z8Q#P,5+
M%3)BP]#AFQNV0;VJ,BEDU_PU@BY\XE.XD5N(6DK"U4)A'SJC+Y-V@:;A') K
MHO]19Y\U&NUB#,N7%L"W(V\;44Z<*U5)T5MT0_G4CH!B2#[?3'5!SP>&JRM^
M(<D,7R;UW<<P[OCIY\E8"]J=@D/FMT9)EEO4]Z)W^K]@GA_@L>Q13<D9%$IT
M4W:HR=4P#5%P8X]*B1=+?$[_E4A;L9M>(0XMGFHIW-M^!,IY6"1]J\--' E[
M2]Q5MHLA?(_\@]D^Y/CGD_NWR^7-7D.^UUK&)/FFM+/+?]9(8K?-O&6*1G_R
M#OH1,/C&SS$Y+ ;X$G6;Q4>-+K E.>M0MGUYVZWEMC[5V]I7O[S<??/%@.A6
MBT_=R7O.K9C"_H-)M9B6J+KUJT11UQZ8!D/_"91O+8)NZH5 G%SP6ER<:SN.
ME\KT:9,D0:?S]&^2-;7;UI4.P]7;+5'%COZ,[X,^E<[<OMC@\!S-O_W,B/[#
M%X8/=6U-0]1?YAC>R>W8T:2\?4;'</2W:<.BEREJ@_+?/27M*.XBGW8@51$*
M897PS?&@4AS[H1"X=RPTBC]]4YF+_;:E']C/:Y"Q]^VC=LQ1S3=JOQ-OC-O<
MFTB]SR=BI&*%S_T7*F;B;\HT;I\<?OY^>8:HF\(21Z ' *6S=,5,@UJ@M<+T
M/_WYKN!W-HG.T#G'91LNM4ROQSZ:JAW\S_R.BE5H_IOB7>G6_NP#^F0AN]X7
M\]_)T4%7<"TG,*ISXWHP8[SY-*=SP;LP]W[?L8F%Y5Z[5UL5IX%9;%"'.B-;
ML8\)(]@?<OLYL#5R7[V&\N%RV\WYYJ PELRAT$HM<E*[V\>-/.B;XLTM(IJ#
MX&D DFUU4,ED&QM0_/7SYOOY2314-7/W1_M1%9_J2RD!5^=SA^>!RO"O?[5^
M_SRY!N9O)+644 _P6/Q9_MLK[B-AB8-F'GK!?2!L>CIB,L__LS8\6@Y;CYBS
MC:A4FL?1+>@M9ZHLW-@U:F>V^_ZGANGFG$>BB4JS66*6_K/3F\)9RN^C;[CD
M\>;8NEA\5KUA-AUX8LNH;-8VK7JP]QTJ+->GX\&>#:C/JS\SLC'5'"F[82&W
MJT>7K7[]1/>MY71QWI3S5==/,TF//J/$LB7(F >*IPC,@_*(WL2;97$7E//+
M1 'RY?$X,S(F[5Y #(VW%F9Q8QCN#QN!J@_G]##)IO%^&A/LEL?G)2WW[<!#
MPG/ILY&?%ISV+2\R3X5L-KPQ7D2TI#.RN6=?:D44O#=>^,!*^73#^L*%(TLQ
MFZ4%(S;:T0Y7/^PHDF27\XZ'EB&:C&\6S.'FWSQF"MTMJ7Q'JUR@Z?QCSD)F
MO?G%K<H74YIR_6=X5=]N/;Y"1VR71LU;Q;%\-(9*H]$J4_$[C8V%YA%;8H:@
M'.*85O8O_)>?X45WHK_*[NK.0_4ZWR=-UR[*/C(T7H:CLI#O'/V$5.I32VK[
ME5=B46]T-POSQZXX[=AZ,6F,\F%TK6MUN.B^4C[N:^P8K2 4VD03ICDNW5QA
M]?[MMSJM6A?+$ZQ7-AL8@,%:C, 7M2)M'R1MX&Y U?JZ@^"KY[NQJNMW#E[/
MB":DA3Z_=K;]A'[#(:C*@%%NSW+\WD6+S1N-PQ"':PKMD*UI;[D<(1O-6Y&_
M%8R$ND _+$]A*&$]W4_;9=K!W*:U:W>GM36/GF-9=*P;5BY8%=)5.F$*(*3;
M>)APP272\B@D84+N3%K$0TQ6/_%R1%WL_)O,O^E-P6F7TDC,EEI+VMKG._-J
M>V$:G]_,#)1&LQYST\P3\;_@K=6FZM^5[!_(%?X:7AZ4:M5.[4Y$/0,,#[6%
MJSQ9X9<CWU]R=*'*UEBC2,;OOA $H[J?NOUA$!TZ9[W/?Z,Q!8&AHR7J8>^E
ML-$B-FC]';/M> VS(Y.@T0F()(=F73RMI; PU[_VDK:&SJ0]$%HQ+;T6_9 1
MYN2;ML=UW8*W9H@("TFW[Q/&[">"Y^*W%:S-UNQ.;N1PYPBA'(5TH$LYVO@9
M$<[U9?V!>T,,Z-_#0BFA0]S:"<U1?J,)@EQ% I'#S0[>U>S)$5S"KC9ZTE\>
MIV?&;O^,$L=7P?S0A:(8L7_;B')#-O_!\?@\9Q4L56B+SQ3)XQ/S\^%KQU'V
M+[XDX95<J;@A"V7O.4-!(7J>ITHAEP,R_RT)+&;%,)NB'%Y6#H&V3!^-8"[*
MZYI7BBOSG#[Y:'2A-([:3?ZEEV@(_TP;ZXW"AY).VS-"FK:)AF;_9;&7BQ15
M8OC<O?S,1B8>%X,BMNUL4ZX]. ROX#)+])CQR-WX3 33/C9#W]8!V6&SA/+K
MS*@:N6:Y$5^+[+G&-0:$8"E9[64^4 ^]U,W'MK$!E]?1M*SD[6OG:C85""NP
MV0V&3M7)? O^-#^]D ;2KYGZ8B8KL(+B0WHOQ&LM#=?ZH NL0,Z5!V#E$"ET
MV?X"AVX-"XL=@DE@KN*F_E.MTPE:X1!TYM]BAFO^(?'<Q]XV#V,3<W:-L&;L
M>Q85W:SU-_V,VA8LP8JV7E?M/,TV\X7P0RSLC,/IE''Y$ 1^:,NCA>!HH45$
M+[]2H>$>U0%YIEC5^7AXY1(0&/$-9R<OV ^P0G<\)W[3IB*$KJZJ_[.H3L#2
M>P_JV]1'P@HJ5O\[F*32J$NZQ19NTE<XI%C8B/ZC)IR;G!PFP(31DYVJ?^#9
M=Q3D)@@(K^ZJT/<TUFBK;P6&*P]O@E,]+JU1;7H-HT&C.O(*.3):Z[C\'^,
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MLOC-3V+3PR[AH$0[TT]/BN+Q\A?C-@0'^LP$3Y21!A7(+Z,Q&)=5 KZ/, !
MGF7U9S3HE%5\3W0%%LW$4(I"IX22<JT&P+33">\A-*TL&D2?1 ^AX"ZCH.K@
MSL0A\$ZJPN#K$F0Q, \ #L!$?L)"#LLOG$T%R@+TI@[N$,HQ]BG4^L86OB$;
M6,\5&J<%LV%;3.X<SL'DV&$&9U"G?B\'0:(>?FT09"'(>L(RBD(?QH[J<$ %
MM@+OLN\J*N0G   'HB[B?@,'#$ %[LH)ZR3>=BG/[@Q-T@  (C -ZLSNYJKP
MT((J[F,I(H_MHDL Z0S1),SRW"HN_H(1HF''5I(B&H8A#6A) ;?L!BPEKV[
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M29(E:9(GB9(IJ9(KR9$YX3?BN!W@!)-&=$SQ44MF(Q,O69,F@9/8."/DV'-
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M4\1;#P,YVJ0Y-&%E>O$ET'48%M$K"7]E*#Z#&6#HHO]C>A$P1DP+D:.JA"4
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MY=,E.?"5.RY4>&.=LCEC.GT(]RG>O0WV6\YJ9O8 +L^-RRJ4#E DF!;4-?\
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M5NWWIE5L*Z']OD4=3N@ZZCIOM[YJ9?_PYATRJE5POI*)^SCN-&3PTU-V[NP
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MIT.[1F_)W:%WS)&MM,)KP[<D:.)0895[ACFE2/[2Q$5 7A5 M:.R?PW2\0
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ME 0C<]O!V.-_)D81@,33@=)O@,WH.)^5L18%JW4^XGF@I^OQY/$J)<G AO.
MDJL?5Q?:VL5KC0^ETO8&U':LHA2?;=IIF=/EI0BDM?QW<J+6^Y%AZ,T(R/8P
M#JG>;WS2G44 TO7SW^A,AJ>K2Q=%7:@\ .IDYK:UDH=&6'I<F#@6&H^O?Q93
M5Z:N>=N7',[3W=]&>JG<1+0#B8/+UB/ ,BLD=5C3S-'#G,)SAAN P- ?Z)P_
MMW]&O/Q)D3NA+7ZVTBNA8/E"5.C$LA:;?=UP?J/*"N#H<_[J:G#P@84DZF"U
M/=;]F0<?F7W6B[:%D@53(8OYF[8(2UJ'+/<H%Q<R['>VFP1<9['\7/4HT2(X
M6 [AXP#7BD ;K-T&OEG8]^$>ML?J#5G_I$HP4$7 OX'3E"1]D/EQ#5AH-NI1
M^P"(^XF&)#D8$*YE82_:W?10"H+RS*?&,8EK5[1HW\WK"K[M(Z97E@;^@3KS
M-=1X'EM^^)8;R37UYC^[?,]G!QFQT]\SPA@CN)V$,E[!TDV6E$#YU4CWQ&Z[
M! $VE?.^(47)DB=6U /<JI@NY.=9/5#RD56+L#9F)!U%EG.Z:E7:!8^K<IK5
MVP57#*F-*N&SN Y&*C M<K;OR/PQ%\%C]I TRTLC!?:C;N 9[II.LA2#'_*<
MW"Z2S4,Q![#PV[X <5EXL/*8E"RR6X5TJ8YFZ2)[BF7J@L=\HO>+%HR$[IGQ
M/WTW1CG1)V3%@_LRP7<Y,DQ 66(P7Z[IGJB _9ZWS\R5<3["+X='SY$]"=<\
MJR7Y=>[@ R#SMZOBMQ4ZH<<\E$8<=3Z'UEN',LQ;M-U>F1%_F(J!_286 1\D
M8NM286Z1M9$!Y%8-)@1*D[2)/A*)CP# %^O$<1)3/J/=#P#N**#)0 */FU;M
M.^"X_ZD)^_Q&I")KLJSX\-%UT%DFA\RK_9O0G%M]\(OZIK'*\V9?;V$DUN99
MQYZ[3 ^VCLY\2C3C;SX+XQOF3U!B5)W K088\_%M?%R;"?)L8I?_+N Y..RR
MB2P.F\+0W-C-(BSV[9]NQ9K.$D^<EZ[>--.713MC[-V$!?B_W/,<OL1J;VDA
M_9L](-^QB2WM<^]Q@-/JJF_,EI-GY\]ZZ]';.M ,C,J_E7J?+LHQ(,XNC>6J
MF>9LIM\>D;%#R'3N>WE])17<HR^QTJT5^DA$CNJ@#: TK/8JKP90%!F>0DRY
MX$<&2ASF27JN<<<6 ]MB\*>)0VO2N7V+N0:6^27>V6T[E4Y&+@(N5]Q=X-M5
M2"_M&A-(UFZR/4W/S/<QZX?!H)$T_B6^!=TB!7?I(KRG78IP9,C+X$Z,A:=N
M(ZY]O]?0HD7->7>$S"9Y9V@(7_\8'#% Z+=^\9)<(G4U.O@^"LN%9CNX$&B!
M!6:GO\\"^M(Y%_Q4S='76^)6ZWDB6?;<3UX8)U28D0)%>_^B5=E<7<-",0A9
MA#WQX;)QW%(SYR<N<3+S,:YD&6$;#\JQ#0?EL+Z][B<BE*7Y/7W!*YPR$G05
MT.,H]JP?*F<_!!,E,MH]//<ORE.JT7M1Q%N-SNQKB)'!1UGIHZ;7"%6/OL!2
M#E.>]ENS_T@-Z+.297LFV_KUAR^QVH84(\*B!TX<*\-A:L? G2S]+B=TVEKC
M=OGC"^76+*^E ;,.V^CS]=8X[>FO,*T(?\+DH6/\XK11'4Z$2B4QVC<S>ZJ-
M\ &0$('$O&_[^@ X3^*4@:KI\:; ]^Y?3!?]MN(8T][9CF/23]#5_] *DS&9
MKHL+3X;4C%24CQOO&X/A/SQ.9_^F/<-$$&-\LV;8V3Z7\FQ[B<J VC.2M1'M
MI<T$NE@6%S3E[S-(EU_AO?J<H^"('Z260#Q9X6D&L49)@JL? 'MVE9-]:1X%
MH[W$86<CC@2US,M'\6,4IO+QP8?>E89KBU:4U+!\J9N[G0+NF1CCQ$L4J-6A
ME8_>U,_QBU>G0V6%K0L$N&5BH5ZD_@.\JT-?O1>F*WZC![4<X:[A5O\SK^=G
MN-X6="E#=R9-N491EH<:-9Y5CKF(H+C65G9:%U6),WA%K4;P0P"F)'Y1L1)I
M3MR.;.C*(D,Y_%M_4[R?IM$;_68)7/P%%!GJE[WZY2SPG'RL&VH_2^D&[_5S
MNN+?^!OQA39%6O"-$82DY9,,(UH621DQTK"0HCRYTRZR?PL>IZ%<:,:A[C?5
M.4IR=,IH)60?A8"1[>$6S^Y?@I5J)UH6')DU?7DX=]1#IPY>-!F;#E1[2_S^
M^J/2^GM>P'<BVC#3M,T*V2]9#"9H[89I%F23UIH8[)WR)-P[>*0@0O$L1ULD
M(NU6:H=!I\^[UZO*?R:3,;T_<3>!I[4P"6COZ.529KHHR%E>WR!*\(1L,W>!
M[E20-E:)L.+141&*H:U6#@V4Q(7Q[L)<>SSL,77;H<NT@=OOK)9@N1DF7G(X
MYO:IJ3*\*,KUT1>HN/YDG9'">12DE^8RJ3Q&Q\FL\DA_A,<U"B>EKED:2M@.
M$'&)CUR%C<Z+]C?UA]A4FYD/36S* \E*G$NUMO93XH5Z+V@#6;CQ![=?VH6+
MXT% S]Y*=_>O4 DS$J)^[TFPA3E77)LS-")I!UE/XK<5R<(S32',3T;:7_XF
MDJ6)'+W,03F[Y,5H0DB4B^ \B>;#PHN:U7VD6)F&?W_-6<>*ZG_1YQ;?" X@
M4E]S[HBC 6FMGZ&*S)$$/C&U<IUI,UM3*C2/!?ABSWBR0!]2DL,^5O3+:]:(
MJ]MPBGW*B#XK#\YNEB\DP>9^Q$=8J^*5[KZ0H\U81Y-/]4;923+H0JJKA$:-
MTR>1)ACA&\(K*Z;2%?]'9]\9UF33K1M$!:E*[U&J4@7I($%] 0$Q%.E-!:3$
M4*374 24%HJ TJN $)#>07H7Z=))Z#VAQ$!"<GCWM[_O[.OLL_=U]ODQ_^:9
M:SWKF;G7?<_,6D_&L08PD]^MNLR7SPT0+T6V>R)-UM&!!Q$>UH[7[,L"J4SZ
MBK9G(G5KZBV1MQN5W*5H%T"#= >- SO=F20 -4$)O1GFJ6.C/^81':A( IBD
M[W.\1V]Z3GZQ:3WR=?E\O!WR"Z \I(U;7RW=!W;)&0.I+C5FIL:+Q)_$J0WH
M7& #2* KZ##Y#DK9?<CM*%YH2D7&9V-&"_,)VTY=2]T\PG,AYC%OE]F.<J3F
M_NHPFOJ+^=VC/C*PZU.*6KT7)]&;DS6E2HVW(:9"X78.0*5\4;*Y=V3]/Q6I
M&E79VJ0G)3S@E)"9N;=67OF05\K8L3V)-L/8*-K\\J=<QL/6E$&B/O1]V2PV
MTYZ'@&AZ=FWHUQX;% NZ9\' PE+3)3I^7-H$/@1;C.0/*&+O"81&R?ZB^! T
M,V,VDMW)&LC8G1K$FKT_YCLS7>+!.C1W9OJF5B-E27E?T- @-A=, _''NJ8;
M-.-L(+ZE/LTZF,R1]>$_(H$%2[7K97=_/JW7_'P]7HA/E(S[OJ1)>VW1![%+
M7_X<*3=S6&F9@N[-&91KYYL*H@E+B]W4/=!>3A=]0_\I^"S8Z)<,. P;BVRG
MV0YBGA [%(<&C>1J"4T<\,<]KG!SD9UZH'&'\_U[N\81@#\/T@+>$VMC-A9
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M@ SE2LDF?]45LIFKE9=K)>:T@#C^?5BB3U?++I2GUS[DOM"L/\-MLQK[9N>
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M\CS3+_O\]OV=9RX-Y!S9+0]4>7[F&%-C6%$S$4' 17/'IH6DE.90[6@XK]B
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M@6R4P#\L^3L2*S=TH;Q:?6_B<HT?X[JF)PI>XUZS?K.0KTIQWP^N7I?.<96
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MJ?UB-](RP 3EY.6TEWZ#39BGR^&$6R-Q-1'>/W=<OPRDM)FMTV@&V[V]:7V
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M_?OJ=ZF3E\)?#G?#(7"]QPEZ*O0J0)Z0B7N7Y#DX$,+FJ?D?JPAI\XWO>GM
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M>4OJ C!7&N _\D9\;5@8("A8$P$WI- 2^LTY%YT)E*!P\IX$R$C, $$Q366
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M8!@Q?IU<*%[P>?MU?/O#GLRYMT^W3.KB+@,OM+S$<##]Y'/N?)<4J.\Z3%Y
MV7)N#Q(!V;TT;>??P&RMV"")1\X<VX-3DK0"4Q8>32)P@KP8! 75.:=1-X'F
MDL;RD:MU.@Q@!@ U_)6Y@'0.\AID07K[++LO*<TID:9!()>S^J,#53P7"QI,
M:!+0CEW53#FK%\H],H3_[-3^SXXDUZ1SX$%V5S[YUOS1)H=PFMH8S%(^C%1-
MZ86J#MNR%43_^3K$-#"$!-.HV !MLO,*A0>?:0PZD'_4\?_EO4Y=U7P"!Y]_
MLA6@CD\>_UUC(X$.SF.9,>Q6;<:C]VU[N+@"C&]AZI^<A^^,"5^;D<+[7Y@%
M60"5(GYR@_)[3^J3;/_'RYK*](NWKEVQST;=_@ONO<A.>_E2%UH) B,)I;:#
M?5<#]*I=<HR>0:$]OT1DGFSJN-!3EHK60) JQX/@SU**.7R&5S;!18(V0DN0
MO#6]=Q*'^O[S_JX"/$"__QZ\KH3W13BEH'W>;9HJ/67=,)2XUKA25U^J@[QW
M;M:-('A8<M+QJMS%?[/\W2*<L6-YZ[.O-M\3Z(:1YYC7AJ4HUB/HZM?K3NKI
M/B1*U"A@![VFR3VF35$M=ZC=R][HAGXAXAQH&L#D[5<1$UX_&.P:E5V_R9=L
MZ#(IDP4K8IB1BQ&Y\)[=W8C637;DRZXL$4#)BQ5>.[=D RUG/J\5=')ZW%0R
M5HBU&A%HVTM>GI=+D:CY.]BN_ZL.IARO*+LPUN:MML!S]91.AE!H](!<<8Y6
MBGFFRKWCWFKF)D7FLA*G<#MR9I8J3JIFBW[',J7F4!9 U#9]:C2(S'S\"?'#
M=4%X95R8<*4<.2))N EQ+7"TR-J!1\KD;2B=G&3*FP+G4)3_CZ.-_P:M\W(E
M0H0R0/['M1^<Y%EM 'K-'.>%_I?!O'R^1IG'@)VY\\N3BA&XG>BC%GQQBQ>8
M#?PBD9&_P_@QA[20W+V>[2^071<-:O7D>(Q:03SC^NT]@L>$GDH@&V4MOW=L
M=>@_K:X7%P_:2#%N&-D&:Y(Z;'UOC'E\*^,8%AE_V>#IL#^./%QV$]-5&!-[
M.^S&4N"2-!<L.N0BNN-S,R&$RI^EMG.^4TI!<VWW.Q$P$9QTJ>DZ:+'D2Y'-
MC6[@N JKRSO4KECE7W"H_59P9K1Q'&3D"F07?JR!J5(AFOY0Y=<]Q;X2_X_[
MJ8%1D=P*Z+7=XW1-;W<5N;\DW/'[+? '<D#GR]!KS5H/GM&.M2;\-CPVX%=G
MOH7OAE5UQ+<DFAR&X_';^.X+=N_#PN00'%ILPT*T;U0<:T+NQDGW//_&A9I=
MU-*?LE;V4-BZ3KORH&U/8W6[V^%#B6-_!2B/2\WQVD/*VO#D5J\QZB@''*;\
MS!>YA]J51$ +(6[ZSKXG@6-D]Q 42^ PJ :_33_39#^,7"[X)?^Q=/V[]MJI
MQPJ />BZKC4M9J'AH/:_FBO5#JL3@>3,%WD_>P,D HQ_C4!6[J%WTW%'$\&_
MO41+RNP=W\(E6/O KCW:+MXY;OTDJ^.'D\5,']$<F/P<G_-E12(EP7=:)%<_
MZ"3#\J[GV @*G]%3D]735?O;W1WEEXH!DKXZ[8<OLK&B[\VANW?YY1^@'^A]
MU?*8$,=XHZ-*3$T@7.;D?"'<F(FF+)V<MO(?1=<A-<[TS;Z'5N4-@U/1-ZY?
MBCIS#N[UH4=CL2R8?K7\2Y_99'9'!HA^L=Z*U#A;B4,TXF:MN@DTAF,;$CU+
M!$Z/=N>-.F3H,FHT/STS2+D]&7&QWO),M?'7!SYE ?HXVW=H5/!$NQ^/"^.R
M95J!B7*!V;EZS4=Z**!&F>^W%1H0WCO(X[8A4XB_W<>J_D=G\)HF4/_L")[Z
MK\5995$XD)19AOS C<RS-PJN YTMBO ,LEF%V-0;.=HE6#>6]#?-L5(<1N.+
MYZ61<SGHPS5\1Y!I'O+#9=@>X[XNV<J_>P1&4\T!R,G3_]UUR^*2-,&4+_YD
M<)(>[LF+:7\D/E8?.7(-OSKAC)@=OK!'L8DF'P"?=4PDO.-<M-P"F35'!;(6
MD>0U\ITN:BD;-2\"NBI)"Z@ P]^^K!QT9+)XA;]V6L1A:Y4B#YA+OB9(9F+:
M-GH(F+(A/#?MKRS/2P*D<F9J5WX_D@")?$4_JRC.<VBG+2NV9OE%V7<D)HKE
M2^8&RVA"*4^OO+ S=/G$#35M"D/Z>I'2IL6'5GO-):XG8;C$_" R+^YLER\O
M&C2(@/5;T$UHD9,D*3\O3VZU(@ZG#%%"+CKBPD<1/PB^JL<+JHIMSD1 'A2K
MD<PD.\Z.[0MZ5]AU?YKQ"",8W'%\B_O7K=SLG^<_$8$[OSH$63%)?/D/9,\)
M(K 1:B3P2OW1=ZN?1K^]06^7];?V0AVBC*?>U'P#@_XO^7)^R7 !E"%5X#V-
MG=$A=0T>$TW P8-0H##*Q\)4J#EX7GS_IW2H3R/.7%J2'R+$6@BTMQJ4;7&1
MA"LN"K'FMNOZB?(U;;X<O,U+;,9O.CY!+,6G&^75D!/T/['(8JL\!T,:FRX-
M ;@1^9V)OSGD3B+/@3#;[(FR5'S7A^B3F%IX0$H=^7*D4/CRKNNT@G '06 Y
M^L[KEM<?I%0N?8%I /-GL:ZQZXR![N.WMW[@'8<R'P?>%=W6%#&6\Z%*C+<J
M]9'ECZ\7&+VO\=GEJ5!(&SYU\"VVYE'!2U[K23]YZQ#9-9I;45X?4MVN/U^4
M+*1Q3$_Z8OQ@E9?I6Y#0VE\"P-F<_G#5O'_M+O\_]"3.3;W(7TYS"W0:6=C!
M HB-^N$$#9"8!C4]1Q=[H?<IKA !\Q'0F5KZDY]X_?MG\TA?^[\@ E&!31IU
M-ZOE@\*L\J2/5T\:$)R8)/5$(B *VT+[5X%.9E)'@("06.(.IIS78Y?/$KS7
MAUWRAT4XIS@_O7,:S[TZ5JTLY7'0OV%E-E\I45NE[VIEIK6ZJOR<IILY'ZR4
MNE#* !FWS]_@J')E/J[.D1A?S:AR@38PW'$?-/!!EY[?V<G^0M8-3QL93O0_
MZ+,#29@4^+,AR+[RC#P1F!'K>(-=-9VD4NT!A]7>*+[=7#*3(M\),1T@N-6R
MPF3L:)2K<:^(YID^#869V70  TBPM?XREA'U-IW(3>:4HUG+KTZ=\O>(P-D7
MR G):NKNPG5_J8?(.:K,*Q9 &;(5L4FNDU468F2HR".#OPI.3]0_VIDB!:'^
M(LU0P@SG/KGZMB1ZM (/,D*N[XH19:S9.77SC6 \37A"!.J%O\\0@9M-&MA,
M:B+PX<.Q>?<=F[?3+8]\=9!DWK;[NRWP$%_VXI9&4=;/1Y:GV!).S7FC_;J8
MT*=Q+0JMYBK#O7*RX6&%6L"U?#R;^+=K NF=.Q3A9@R3%!FC\[R:4<'Z,+/9
MJDD4@6_ F8ZLRN/U17$(HK^Z1/&B;_+*&L_3+P]Y20+#$'E 0%SBW:.T_"Z7
M]J<-JU?$XYS$KS4DZO?/U#Z_TZ,78Y1UO ?^^^+0V9P&\KB9$'F*O]_Q+E?\
MVWUQ>^C(89^J_Y_G7_Y1T>@90<S1(OJKA!'FH)M</S[!N6\&VQ=H^P42I2!(
ML%,<>5K-6PF"MGR."=DX^<5XZ)TQ/CP+9&-.^$*2J65--=E_?[64Q)!=E_/G
MLMIV\;BR"O8DCZU+Q..EYOW1V;7+HU\VN<\<MCJY^7:9QAH:G0>Z#"SS T6M
M^\6K;B?++%_!E&4@YY_@B]$_5(L8Y&L(9Q3N$?P(^8G'%_7((K0!!QS$E<7G
M^"+$].]7KY/L'["JIB!;[Y6 V0EBL _TD^1J,/P2 0/+K$#1@MDC$\Z07#!7
MLKE!6"$\"[!_P&_P!3%]:5@'7WFDQ8EYL7J-8!J<WR!'H$V_B*0D/..D=G@8
M-'0DL%O^4[CR"W):?%A'#>Q,"^QBU4";EPEAMKV!4Y'HB)DV+JCVNQ<MRE4]
M1'*]WG:[E$<_;4GXS9U9"XO&NS?BB_+ %@.F-O$7=B2_X6RN5KP;H)\S[&%W
MOQ7>QG(;X8W4>'$S/Z/E@5\*GL__ V(%? =(GD[F5V;N@*KJ@(WOW>!?1R\?
MYY%?T^(,$1J93CKE _=2P%3L7LEN_ Z8/MXM18(ZCQ3&GUK.G1+*_ 2FZR?R
M,X__@L2\S@^#GPHZHF W/2#)RT 6Y?YYB0;A^Z'!\3:4S68.@58+0?"+_Y0W
M''GG>X9,T>J[N"*&[]F(4F^00D_[QN0]BRDOZ\49-<?X7=ND]]3NYQK8\W,D
MU[K^NH"51.7)LC))<IVIM7[?G\D4W2^G9WGB7X&VDZ<RCO4=@9HB+3K?9E5?
MSJE;:@1A\(GL$9D72;D\-VQ7]EZO$:YDH6'A'N*QF:"XLN;U;V9F&H(FQUM:
M(L=QVH3D^ 3T.9+DIV N(["F_BKZ=Z__J!A1O<K3SKE)E;CDI.8BO>[G$X$%
M1Y"9"/@:5RH3BH*39CG8$%C]S+U' 1)6*RG+9L-C14_U^_6'R>_\[1+_2]_/
MG:.1D1NH:ZXB"1$$LA*!8!Z'FFG;H?OGI'>:"4DK/JD627OXP&9.Q>HOCHWD
MF+%/G^7=NMX?#D)4M8;K.8M.,TC/]NP]1S[R.NTPP9I(S?SPX+2RWU%/:X.P
MR*Y_#"U',Y1 _S10K'2YYL3;@[*E<-B[@N$0A>%1Z>S'O-+?9*T+UDPLV9^7
MO6#S'#O)Q^[DYK40\FM-_+?#;/[4[$O_PN,PI"5'GH0K9XZ$KU;N].R3'I_-
M3@)]_&D,8O*/5*_W.-4SW'SV#Y OY#S-LZKPO'__:,@Y>)4NB9XF>,'>#=<E
MMZOSV'WG]50UO=D=M>F =WC=Y;%4Q <AK 5(=M3[B#U+\*"VKGDDL>#12<\[
MG) 4=2^E)E;2(W@5Y$P239C4E6^=(R"A<AJ$/=P>0Q9JV&.2TS)W3MT2*CIC
M\X4B9N>VQK/$S%VG,WH-#4VU=%7W=?H;2NO/%8"0I5^5TVKFQKEB5&VX7!;Z
MR4\R$R4I)T"JEQ-*6-.6=R@._]1TM&69 WI.7-K+?6&-B3,#:L>MTOWOR^B<
M5Y08BIJV(NSG*4H.A=VSS=SK]G?#Q*4BYE']H!_RY\_%GQ,6O!G]3<23@QI+
MO5[@S^!]6\J'?FG*W=1(EC[O85JV,H5"\4UW\TT?03+V90=![K940?NLJW_[
MNXYGERW%9B7YS9X<B*'M)&<MQ<<DHR@Y?%B6VHHKS>324R)V#F]9B.H;,0,^
MI?$X#1%$/6+C]>8J@GK%)WE&3=-9,:P$1N'$.8'\E*16=ON980^HP\.,-L3_
MP]Y[QS6Y; O#3Z1$$8A*$*1% 2DBB@+222QTZ0+2152:@(A($0B"@H02$ 4%
M!90N37H'Z4UZB?0J$&I"#1#"EZAGGWWVW?>^][OGW/><]W?O'Y-Y\LR:66MF
MULRL-;-F/9[(L1O(&DV+/?+(\#*((=,,RT"Z[P-G- E7-] &Q#2!NK-HLL3[
M[&/M[M1: NE8$&0%W5Z.(1UEL.PC@\$G(/URYJN?IM%.#Q.ZJR8$/I,(Q+F?
M\+5KV>+D)_C-#60+^F=QJ=,!#[XK)2%KM"WV)L@8M<GC42%@*V!OP\R.W,+>
M.>1I[C4,%[# E;VMO3@Q+*6--<>]NHET^T'FKTP&T3_(]*CZKD0\M=.83KKQ
M1-*5\8:' ?'T<=@H;*L/1LE"KIG>3!7NA1VE*'+9_C_*Y@A;/JY$GNHH9>&W
MNWZB;R2CM_\-!%R]4\W:2KKQ[A0%O5+]<=@8[/T].Z.]5X/.GXIY_4:+X\B5
M"=Z;)7YB1]/-:UTST_G&^5"PX<+UU/K#$ZZ0[$BJD)J*:)XW&*S9^0FMV_U]
M<JP&>5>_VJTGW=2]UIOO&UGRU?</IT[4;LU2,%4\/&B++2DQ<%/MK>4PXP%,
MX7$JVQW,,T_-BB>.QXS%!^/R!&6G9+7 IU/FS&2JGM[S7\9].-'42-!SOX4/
MJ?B6'[TS=P'[$EY3,87 .P88*S^U#(>> <8$F&N("#QCG%?:4'W21-*Q4Z>5
M[@=W@H7LTMQ2:HK"U%(U9>J6:4TPG=[L?5%&W1:EX!5Z#,IM'S#/C]+([TG4
M.N?'Z!>+R-8@W*4/(^CTF4L=&O61,<O/']ZH/R$9#]96'R;KK6*N4&>%?T?2
MIIQ!4@[=MWX*VM'_^"FH\8\::U=WY'_"I/77#MAUG5L<.]J(R<@0A(- O72$
MF,E9/KDYHHUU2CSENFT"XEBP:[TP:SP5[F,D"@'5T>GYT^/C1/+(L&HHJRKD
M'2(+M&3ELB.X7?PM9%>Q\.-BF\VRQ_EG(%+CE5'?4JX+-[F.2'5%S0D]J;#2
MKKS--R9B?V)!+5_+.K6,;_%2MWW2Q_>-3I>ZESZBS@D%%H;D:]>S/:^U9[>Q
MKF>Q>#"DV*4HD,S"9,]!I::B,W3XJ=D&>I(&-I#+L2G^N2!B$O)#^'U0T1+4
MN[KR0[YUWILP:SU^Z9R<4$/YI2G2,5$2(?MN$)?6COYKU;>GA<GR;G#-'SG2
M_0NPD:7;(,_40U2WMBQ^I'+!1XTF*\]_!_/24QE==QY.5&,-K8!& ]/+WM"Q
M:B$E&V_?BV2F(4\L"QC-"9C_I?Z+0>D+B2^U>T1I204U9^5E&B_&[6XB&SX4
M5>'U*M/I#72A.K52.C)DX;1W _8<9TOB97L6<"&K&W"0S%;H6;S=DWEL]-1S
M[:<WUIED;$3>AAIS1/>!2^)IL(1>T9&AH7/8>R%. V_H#)-7(QX+5<M:N&<O
M</$;RYA?$&Z_+*.9"3QY79EY5VK;P4)VBKW>E%KBI*^<@N?8I#V5,<XE4:+9
M-4PU E,IMX"19R?XV[O6XENE6NFG.\'V[SII$ XGKUR][K-G(S] GAGD>M;B
M(72$<:5W/YAX[*>VB)'#ITU%WQ#D+FK]AKF,$T/6O?FUP/K]@;L%*<9T"6)
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M"?L VHUB\H: G66O.K$\$@BG+-4A\&!>:FDI<.HP.4L:J?8S62#_ ::TR1E
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MD"=/B(+D^B22937*3/O'5M7X5VO5?V:W6Q/^70)'R"74@W6>R1J U)Q?BV]
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M9C^S:CRXD4H5-Q_C^O7E2:ET#W2-%]\^<&,7N7)<?6#;F/E<"JY6HT^X^W#
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M2T3.ZI7W*T8Q'6F)"1P)?54UQ#)X=Z\O.,,P(<C5I!/\<6\EQA4ZKBCA,&[
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M?@-,=:+1%CAG81<B?U-#0OIVR<%RMEG5DL*H$X\&$]F6-J?"^\.9BSCK8*K
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M_LP(9/^P0D0E+D@GLV&5 :L7NP@#?U64(Y:U.33&\O]O @!02P,$%     @
MFY-<5"ZIA,/)8@$ B(,! !0   !P;')X+3(P,C$Q,C,Q7V<S+FIP9^2Z95!=
M7=<MN'&"A^">0'!WEQ#<W27!W8([!)<3$BPGN+N[N[L&#^Z$@T.0/N1YG_=^
MU=4_NOO^O)LJ?NRUUIQSC#G&/'M7[:>?3[\ +%E)&4D !@8&,(;^ 4]+@#B
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M=D@*SKV9D%3:G5^'49#56!/A/J:(@1E92KUBBPM *#?V-+4A1%8H7V7AYI^
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M5;58%"^MC;RII_RXF5E*=RX17GNZJW#NL-4<YZ==T3%+3G+@OT@TG<&GK1U
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MMH ."N!R(].&P25]A:4=MC3ZI>2D*):G<HN?#FB;M%(5WHC%.AIF,:<C&S:
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M61YYQR#-EL:AR85-!3%HIGCK3N9-!"Q-M<C;NV)6R@-^3GV\.$ED5!]*N'*
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MH#MO>>'\..KZI_B2S&E2V.UI&@%I-T"H-QL,G:4H"I*GLQ+P =GX9%$%/3W
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M1:[X_EG^A<][_\\//:-7''G?YG3R;$-[*/9.]"F[-%HIX4L9$SJT#3&T9"3
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MJY08K9$>18N)0,JK(DMM]]/+HD[UH'T4"K^B8"RM<ZZVY%P;+)/ *O;^ZW%
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M@!Y.9=@V</EG\AJT]X</L7*H<CCG:=8\=>OZ>T#'F)(.#1W/=:JGL25=DET
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M)+XL>FOVI[=3K79.?]CY'C_ .X&EMJ5,2\6F#EU ?Q@O8EMVP!'"BR12?RC
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MC9%W"[^,L)W%'AYSBWS9XHR:TU\]+TI%G@BHK&Q_K7VS8HR(S?ED< \RO:?
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M18D&7/W>T>9F_(6)JQ63AEX^LMHKI( YGWR:YZT6_2'),IGNR9XMK3(P[55
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M6%S+MNV"QC4$2' (!'=W:$AP=W<"- 1M7!L(DL;=W5V"NVN0H D0@A,L!(=
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MZ]5L*Q^0Y)B!=VI=((E) YHQE/LIIT6?*.].3<;@C-"DL6#+@+/1 "8^F5^
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MNNREO2(,P8U67LBS1"Y!RA=&TDD;G!8EXUC11IF[.[DX^BK)+XC7$S?B$I-
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M3JQ[:6-Q, I'-;*N/-_[QA46C%;VQ$MD8(-T^XXQ4_T &S?V-P@]^ Y)H%+
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M*W>4:W:<P7=2="EPZB%'Q<]?,F?QDK9X]X$ZT1+=RPV]HN_/:\9*V>_H)2)
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MX'BMA>IT-%N.U%Q7BA\)='H;UQ .A^  [MA2X#//V&42*,@'L":!;I% #1,
M!1@P>;>]W,ZBS62R-S$NHL'7B9Q*09PC@;[[3ZT30"C"T0+OHP4WJ8.QN&,0
M'/IF.BJ_G^BU&\ROI_0/;08_3;807]#3(R>/(Z<L U3!]PL(&P<-<0*IR 9%
MN!@)E([\7?45R-]-"7[/SEB6Q"8?3K4Q=6*G4NK(S[H@N%TB2)W(_,M:P>]V
M?\K^LN4KR+^O95F0,-A.G.@@XGZ$S$_@.J&GD0LW_M?4=HK6R#[PWB6(#S2
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MU:<@X200<QW/,%RJ'RZ=L<#QN)Y31\\"I7_6NQ\?"ZG2NQ/>CVGNI #:FGC
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M?%D24+5MGE*VI2VU,AN00M^NV5+NY];9HY325]QLI!UUT29K(D<AK'*C//-
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M.]8HA8N(*GKP\1TU\));<7] T&]:N^#1TJ9QKUE'K\N\;^58Q_V$CK6Z3_Z
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M7AQJICD.IG".Y-BFV,8'9HXO$]DSG"/#3_)M7$+W/I;MN.Y+(T4K4 F4'-R
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M3<3_\.>0-E%T;BL5MYD*1G['9"!<++H^S?4."&]MR[[';7C9[:*#D3C=]>.
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M\$D"M#M)#_\HP"GW%@5C.Z^_D.7R^1](FCV^I@F<%O2DQ;BFVQ2*94GNBJ?
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MW5%UR$P"/<\B@;[$XPZ(]1CP/B]6;GEKU!^;G9U5;1L3 JSX"1]< V@;+*4
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MP/GMPS5ZEL,JXZS7W3_#16_E76%6\Z:+XRW-BO4R-F+9/10N_DGO?EQ.9DI
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MIM"[/KO\WN_9F=O83IU.-^>--(C&/#JFOF'$OHI&0IAL<L>VQ#(QN_:)W,C
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MATIW[Z?Y,AU89["V#\O3O[D?T29Y @QD-LJ#L$=-55++D7BWBGFJ1AD<I9-
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M7O&8+&AY\+Z%=C&'N5(G^@,>0+$6"MT'"6-TFGKSWCBSC(MF)1U ,5:-++C
M00KH0IK#?A:.CE?QXNGH#F8,6S*6'>V\+67FU27@;$*8<4CO94-_U2Y&8>_U
M7^SI^&*#^8C'(PL/N'((#63J-0Y(9"KK9YB(Q0/^]ROF_2$OA7.2-/:+'YO.
M(Q7*$UZO*A03QLB+#3+^]RNL@$DT'B"S%@J\4%-]>VU2-'J+8:C?4^0\2R (
M$'4;DQ$YCR(HQ@%$9@E$0A=340J,T$60,',.TX O08&*?Q6P9@0B&5$*N!NK
M?WCS6V6*)>[N(,42[L<?97W_C[+RU@S0#O'%2"]H^U\/<"JNX3@&*5 3.-;_
MQS+YOX+E'=-/B A>8$;P*](0MS6Q$_\C^#_7,B,XE73N8YP[[I]"P7_]9:U/
M=*'#<@H9)K;_8B>&[9Q)H^[?:5:K#<DX.OZ+7]Q</P[EQP->>S:W1F&L2MAP
M@?,4>  A,+C'4>8\+3^C]%<C(3UX /+;4?HIM8_ZQ6\-_US:SW)QZ9\0YFRO
MZCZ3!">)PMCP@*"080_@?J1''C$A_.0$L9_]AI)D7?;W0LG.6RY<X]=K'#CP
M5VPSP4O_2B5<^<5OR$#%DHD!I=1E2M 71^'-X4;]5_!C4P2ODKU"L(0&=)=,
M& ^XIT( !V4VZ@_"1#?^KA0%EFK[)\Y]9R^L;SV3$%_TEZS\JV\JVU_()1$<
M/CGXO39Z2X(096&L@$YT/?-^)"8+B"9._K.A<.@PL>EMS+\HZ_R_09:WNGCU
M"":K%+A,)HQ1@UJ5L#KYB"Y^YH_Z$QMO6C3S?QT1-OP4A&5I8N\R_2=PO(HT
M@\'_&AME>>%=O0LW#.Y09W.T[*^%7L(#OO\%I47T(%:SB7T)AE6Z\)GDEWKB
M?QSQ1\':KF )-6\\H)N)$*<$'!V;,B&#W/_-((UMAJ[_H-T Q(QZY9$7'7WA
MHSH_+>@%H* 7@ )NDUT@?N5?Q#\__U89WWWA?A9<!L%T80)"%'>0\Q3,9P%_
M@W';S&OPG\2DS78A%&WW#MK_J/PGC_;^S:.<?Z4"+XSY[S<7/GOD10 I"V[A
M$(H2^"NUZS]27Z=C%'S4/XSB 7\A++=A^M^\YK7D.V09?VJ%@/1,H,.'#?."
M&]3^P0-! 9W8?Y91%<9H$IP ^F\H0H>AZT8HT-_<)-ZAS*YV1 Y2,+CB 2$7
MRE<DO#G\#S>5L,&P+&D<?_CA8J\Q@@=-,0H2ZE%G1/_QPH6^+YLK=3YW$1$R
MD2T/^^'?I/_VC@"ZE"417%=R'FPV:TKE7Z3]\4/E7^MZ@)-_6<H 1* BCO^P
MU/]H<0'7/YGXER)U !CW#D!:P!D3X01![ 69[BDN/%M('V[XPR#V:0PH:3R@
MYD)K-H(WHOYX@UAD22'Y8L>=R='U@$0ZK\Y4+T$E!/>S33.W;H]E[7,^;6!%
M%3D-%#R+G7W^Y1*VL!DK\.IS%EM;&L>/O?,HX8LNDY!HED1M:>QL?QC'JF#,
ME_>0<H0-US]*'S146DO#J@B,XYT49(@]C_"8 5_37H,S>+G^+MPZD[,F#?=P
M[B"6!"ZJ_R.)$,D_A$ZABJ,X3W58P<K.<C%*G2<0RS>P9/Q\OXUF&N5)SR^Z
MG,3]:P?WG;1F$-191,@<!9,F1M1S@G5R\TB5/W7!DI"T'H2DO7Z!>->+-[?4
MZ=D!U6T#LDSNC=K'*0Z(##)5EKS)=Q%[-&1D-[W*02\]"#(:([@V]1_F^D9@
MKC]\!5TW_A<;DJF@"Y4>X09'O_-G&==;LCV[Y3S/V/]DHR[XOC5ULC=G]_73
M=*\ '!VSXO]).8*8X&$@08S"OV),+\2P$<306^,ZZXC?#:QI=I4Z=@A8UT4.
MN$#*9]T2OT1UL22%_:\@#BCRFP#TE%KB'Y)(J"BL@B\RK6-<O.OUAMD%./.1
MTA_EHBDXV%B7& FL-W4:9@9].^?<==H!',Z\,&8(#U@W^5<-V3.Y]?,&\<7T
M/_6S1"^Y?6P?'>4CH01V?9S.G?U4'A4?_6$ Q'C5B_IK4]7R1<" %_2&!UR]
M!PT4ZT)_VD\]1ER!%5C'2G,$+M17>&1W Y8+:-<>QN9H&&1KQ(@.^N^V(;?O
M\Q'MZ!KC 1L5NFYFT#WA-2/F%N@)V_[% Z\3N$B;W?P2K-(5J;MS8*@'SL4S
MXGSI9,2J^";CJO!QU)K"U_DY8*I0*,#]SQ],?ZY!L%_Z<[&KJ5I33&?G*O)-
M3;U5EN4=@XCA)F(YQFE$;H[\]$.AYP^"2(@^[#IJTPM;V[)Y6WDZ?(1:V0$[
MDCJSK(5"2M9#\D2"<&=:(>"@<9E,?_$U?VEFWE+.!@=Z*\>-7Z9X@-UD&*TT
MGY'@<*!=LW?*@4*.1WS9_D2GFYOI7=;AHVF56D&'.]*^#J2M7?R2A9T?>HFO
M^LQ)&;?6[EW!#1IL]B,5&Z2_M3GG3F(((YYV356]U;)VJ!Z*UERML$OR.<"B
MT>&-3+:F1EF4P%*6U&=36JL =3H;B)N=W^0;6YX/[MW=79*^1;PFF!*D YF5
M6&ZM>ZFA2MY&@W&/'7N\8J1CN&4:9-GTVF3;(EF(;CPO!)?NF0\10LB-]Z:Y
MA@\'J4NL:XF5_KH<XZ?FL66L$WPF!($S$:$H W=#'&_7(0##2&%=J@.#&<72
MXAQR 0U1HY-P]UM)PWIB3^WJ_%=CI7(K4?+)[KE3FU2G<?7Z<Y\?I'0+]8*>
MWW9,"M- Y09_VSVSAUN:O85R8_LR;MFMRT//]6$2*%#;%AY YT,,_[4P]& ?
MW6CS>7;*&E7^1-J5Y)K&392_-';K)R_N%@:WU((F<<Q"F$+HENL"YYI7/M%Y
MV#^Z]%HKYL5KEIL90D/UH:M!3.$YGB_A'$R#B[P1.G5D(55V5)(\:YK>C$\8
MC90@3OZBVBMW=W0D!]RU89^8:2JAP?L&W*-]OOG&QM,&C&(D'P\3!MX5;HN%
MZWZ<\R%"I> HX_NW69)6&AC-LQE'.'A=&;O=9+P!627B[>F7)0Q=%^V4^9#)
MDG+]BQ!).PD0=ZOG_K3""C&<P7[)NLMF'4WCMC, $C@S.C5PH+-2FYLS8'3[
M.3O%TN?,X*X\_(1=E-6RFC-N?Z^+EPS3N=36@YR.VO$0_, B$*V<;W<Y?U5[
MX%T7RSZ,M0(CNR2INW0UK:)X?3QZ8\AX4XGK,Q>)/?I0KH<60<%_+_UK-TCR
MJJ4'".V+XBY-7O F%!A;">&"]6#-JOJQ-WPA;/IOIF]U),0(WVM9%Z4D(0U>
MP;3G 5>D$BI0N2%>#AHC^N4)9Q+V=7JE6B> =])K&8,&R2JHQXFE/1)>%D60
M?,%:DB>(F1NT2LOW CI\X+G8JRB[\:#X(J0A\#8H!V-PK)"D8OTK]>VJ>J ;
M9X^1_Y2]$R1GV.=!H<_U49B$:A[&AC,9BI$O%FC)FUP4:AB]TA"$X$\A=T]K
M_99+%QKP+BVG0/FT_?2>UGCQD;AIU:;!1SK?[Z_37$>_"<QX &+WC-@"_(0-
M/(9<>FR/^O+M'!P<;)N&N%OM K9GS1SV.-TZS'QL]U_!%XNBB&RJ#2CA(?<4
M&H6%YYC3M*=$K%)UF5XC.DC<MW[#A/>A/QS(-Y+< [EAE2H>.]NE@K7VMAEU
M/R+%<QZRRC/RISB.;"A',H7EG/78J'S9RSQRPDQ+QX)J1^\9ET&NL]Y5<6&[
M_+0K@TU2E7LMHE*<7EREJ-&M<PZQA9-<3MJ041EXEB<1?@Q+6,)0+U7O#R0X
M,*7M6QOP?$_029*EUV[R=KS]B[950.-9[,$>\7Q2>OO\%1_CB[=S1F>L(VZ5
M6P]/S7NB9OOLN'<:V_OC-+:3-5C\E=NOD>J.64WY[?L<XC0W;TBHYG853&\,
MV\3WY<\ ?AGZ9GC&!(Q8#<J^" X5Z#<X\!;GUD <[$Z?VS4\"[)"==VG.YGK
M0I*%'0W2>U@<OQK10&R=\2#:]$=+S2+U;G??#(IB\7'J[*+5$'8MP ,L"87"
M:_X#5CW7&.)&%ZY;IUW2WXP.G35,-FSF.WA7&+KM'"3UIGM'DTN2IE5C[;8G
M'L"QM[5H+%KEL#V_PVD^&GH2-)7#9*4^$3XAN&0:3L?[T8>Z"!.*\/@]*;#Q
M,'1QKG>%I$@BC$9JD@?XY*#1&\D6NB?%YI&[UH8&3HGYU4*<$A"!2QU/X^7#
M;!WLGQ^R@(<2=C\8^26?26(2FYBWA +D&^$H(NMJ+Z_SW(/Y[0DI[?97+ZTI
M(&F439XW)'X7Y@5GF7. X,L\ULR:4136$86&UOV%,H*B2[HJCQ/EEBF[EZ3B
MHA<=PIBH]MT2"FWH(ILMOF\DOQA55RY7#.^OO%R[<'A*M[^.N^+Q'JO7U#1:
MLK?'55J57Z5BK-R[>GWXJA;@!LF#V&,SWU';NQV:< SSHE+3;4Q"2X+?C>'.
MFC*E1_!/+Z,KZ[YT+BB6=+.2UY?KH=)EY?+5='R0@\ 5R3T93'(.)LJ@H;PL
MCD>@7EQD=Z X07%\F\:L8.V);I,O1&>BT^L1.OD\\UIC7C^XN5>XQ^G;TRZX
M":G/$LSG.HJIT6%1M#+]]I3'.QL#I@1FM"TI X3KEVJ=AU$&$<\U_GE7?BW,
MW440!4^%3QI5Q?Y*6E[Q!C];\.MXR1#*:KF*IZ:?[1GKA[@$:5EGN@@*2:4,
M_^Z3=/MI8ET7+HRV5:2^\Y+Q$J.3]&+!)&9"MMD07CZ^;7^5T'$K<CHUU^,!
MUK4;1M1MS,%)P1_>8D+L[/*FIO0WQ5(F#"0+ 0]N#CW)9Q=1KV&(4D9!H!^D
M)$<KYVE\*Y0B!_:T]NNM@T3Z&QQ[G"SF+G,I/TWVHIKQW1)!%O3T.*\S#&_[
MJCLLGI-OSNUNDKIU>HNS5.^NV'_IHH9^70,XZ\U=Q>2\6=H!MU?3V1MPWURD
MMZC3UU$L5<E\I^GP'783!=S>*7V""94DEJ^ E]66#3.?B3W66VI.FI,9:5^X
MQ=A&Y+@PD8F]NL]4@I146;R=E6^EDT99/;&[4%<^LKVLH_+N@3GG0>FU&XR<
M2FJ9--[E]==[=<5\P4O70K(P?<_W&]S5;82]XMK1!_2&-=V5?!E.P[=KNBA'
MIC!M"J,6!R6"]>*U;2>&#^MTQ*MWNXA+K_JT(8'O<3S#OT&W.H"!MES90_1:
MU ;+FEDJ!9Z;.$,FX==4:U )E*&7:8N=^X^YZQA#YV\>-@-K[72D(X.%DUT/
M90X%HKL#?WX]B?H)O.F<*1O/_6J@;36^^/3R8:?!HX@477>#E2]4L>(*#+'&
MEVJ[YA@].T".BZ12$ZJXH72-H/F74\T[&HI7@&D0Y#RC!TAGW[CT0R8F:1@Q
M[&Q>9&0B,Q!9PC#!-6?T<J'@<R2UU:RIM(_,OMU\E!09YHZ'@_39B])41W ^
MM!7H^TFUH\%&6 Y9<^L967]+!WFK9N[BS)ZC?':V&XX2T_(-\VV^/4%^D?%9
ME\(HH@5FSZ/95_OYULDG+SN6#,HQA45NH;>+W,IC8W9-O^HM-"2RL+Y>WD>P
M>!XI *97Y6H=?.C!R!*(8L8&#Y@4\VTWK?=71.='_92EIY38>0+8T2',5%/'
M[>-SE/OE'C+#$/'D,/$2:KU@C3J%>'KZD/:/NS<SRG&'-Z]=PW'TD<G@ 8PA
MJZGHVJ-63/T+L<"J;UM4%JLN^G8[_;W$L9(TMXZWQ2=$D:!P.N"G!F'/$N.?
M:4P5U<WIKX (ZDON/12!-TQ+^3$3H8317&)S''@/EF9(*G/<-E@P-3=IO'$L
MA'K4\"Y#6V&>^:L06%QM83718=^TH^[1:FSA+,9DL"-^'!%4PI7$</AX_BB$
MY(4(Z4%"E[9$^(C+TWYK38W:/$37T#'NV9! O4=NTX3MSLZJMM6<2A7]Z/FX
M9IIT3B,J/BRG.\2S5,]0N46?2J7*^*QI@U:2K]_'5[AUUKNMB75_/NCQ?G]4
MF* C4F7E[-8P+-IL>/ +N]'K$^]6%$97P?/LV=9$&OV$+:QRVMCD&'?GC)%-
MM2XQ;LKA;DN"]9NX$X]9C$8\/1EQ<5N:;U3>#M8XR\1@SDBZ1'_0VJR#)]<P
MSNQ39'VDQR:?J@/=>OI4F6FJ38_ "4VQ[K45':'I/H#S<7".S^QBU-1@>TS;
M8C*4;')Z PW_O+X;7WV@0#[;8]\^4'(0UX,[O'RCPV@$=VG.AANIS_:+YVHZ
MEO7 YC0GJ$* _*KFI>=]##;WK"6U;GN-GAN$)71E.(-.0/9-F%JDG;#1+X&"
MJFFWAO&QE1'T=_8%!J<?IT>%N(>8JER/_Z^]*PV'NFW[4Y)*3$DQMJF(DB6R
M9IF01HFYJ9 P98GA'M(H@V&R2Y8H4K<E6[(+8S<38^E.8^S*/H,F6V9D&8R9
M9^A]GO=Y[^<XWN7;^^'Y\/]R'O_K/,_?=?[.ZSK/:^:X_K#V.EB$.B+HTT/^
M_5Z#%K6U-A3+N$.9?*F)Q*/4"R(?,KC4O4G7R&*+E/4?[UXI-B%Y;)8Y5J;?
MZ5+],9O?P;M05T>(!PL^7#R"N=2]LJ79;)6NTCN_[-'!5]&0J'Y6K6BW%K"=
M1RXN\$R Q(54:\W+2@BI]L!)Q6-MWSZ-+=ZNB AH%?"2>"E_L/:[=;K!/&*.
M:G9^TV*Y=,'4.U#HE4,O2<KQL>H56O2Z=<LX@'V"1+$7)R*<$%C)Y.>NPIH#
M;'.G5S('YQ3B#H8!SN%O\41_7RD-U5?JT[U-Q77__O)*+VZ8/[RA 9^L'58-
M/)#5(,0KU&83HYIX4?),D2(_!W!(>YJ5U_4HZ%R/\ORB9_%*/6A^ ;AAUFP/
M5 *O=:*+8+R8W\H8'$ 4MT1 K"=+'G#+W'3O+"=J^UB+[UO5*DT_L96A:_IP
M0L]=:_EV!Q(QT=MC*CY7LT>D>[BCMMM*Q@(7"4+5Q.%F.0 >7?Y"--R!T9GW
MSDT#+U0]4.+XNL.LW,4E^-)M&PQ!:?XGLR?IP#E8TD]!U829^^CZ*[5]);\?
M'T"Z]"&;$ N64R!IB[XRLL%X3UHNL_#*0.FIJK(!A46Y.!69]\/F$@5280"/
M;Z7[6?L9]L6+D?-*&(A++C[4^QW,CVKS]KKLNPKI,-ABF4X$=<3;GJ^)'.Q?
M^AAC05^[CI0:AGE('ICML$D\9B%M=_[L<4P@HXF&,R5V552V@DQ6)$6HJ_&%
MZ.$6!Y'Z&C.-Q<MU$=UF"Y^4AQUN*.GFZK+>!.&PILQP%V]DD6E!QKRIGM)*
MD5GK_,=C]RR>$?EB5MIMZ<I1XSR8ZU1E"73_ N:\DR\P"B<.*F(9>*NN#_EX
M'W(^#DS9#?5$YR_B#S+S8(/@6Q>.$J+FBUFW4$4:3]2BK3;V2Q_.B1:?5L@Y
M$CF/&BB=_1)T$S&KA,">65CC (0KY^!B:)C!XT8Z0T)$1&,HYKSRL\)#EBT;
M<1Y>,$9$;'X@;GZE7B>I4L8NQ?-%$?K'%]U CV^-YU?]&3$:_HKE4,&4('+I
M6:B7YH_EMH8/$4?U[@-E\@#/[:IC\:+,R(MTV=PB.Z;M8',7(AUD+^A6-,VW
M:8DZK1\0)BD"&AE%D8_"!*XBC4WL>N+R^NHB6[;4CY@'GO09Q/?Z)WNM\B?)
M#M^'-'CZ\4CJ#.2Q9/UE+,<OJ<\=36SUM0]^\*;I!VM-?8E )/!!8A4O=OM,
M(TUA#)?TPH+99U%XDH+CWHN.SD,Y<J";$D(>F=UL4>8DD0#$88%#3&D3I/_9
M"#E[U,%R=Q4<.>6+H/8I00/48V.AYIZP6KN5,U<M^U9) =2!I)QQM+F.AMAG
M_1-]'$#%\=KW-;S2R/#RH)22^!L,V;1,TIX+R:5>"(46J!A9Z[JT:^INK.UZ
M_0?X'@P\>\RMU][F:4  '*11_G&IS5;'JHH_\?#%T9ITX5TSMN.2^@?G\*K,
M)%0A,6_,X\+>S.RWKU8#]:G[IL*3RC]C^I#U-=,FNE;>V=#TLT.^@HA5O1^P
MPP@Z48V<;U .PG?^<!&-,^J1)H^IDX<QEKW0,//: O#\S7%=!"+P?LBM@RZ/
M]Z'BO)GW&B(6)_0;""+%3E4F4TRLG[=7T>QNA)'NRV2&G]N^Q9HE$QYU$I0N
MTKJ!+'ERJCV\" ,3,BBPU4\+N+" 2Z0Z=I/)>YQJIF[V$N_V5*2LYPZU=P4)
M,XNSF'\TL:48O*3Y"VJV4U(/TW KG\XNP9A6TX-/U0)N3Y75#,S?;70]E%MH
M?_I!>T(;"G[FSTUMYGL?#D#0(!]178?+8$G_YC9HY8\DU36FYLO:A<J#7]!]
M+QLY6QM0@5]I5O@&!I+EKRMB&S-4E>#]=NS:;.\^Q8$3LN(5 GGZ.,OFKGA6
M@R#"QUK_&?P(HK"P(S?-L<_=(M.OJ/73^OO'YY-!$TZOU;"'$6/'JQ/--"UP
M?5E1"[ZX%]I&,TVEZ1 *C)E?A#_^G8\XP)_O<7Y\9 C=]3G+OD))2+K)>VO\
MFD2HO=?\"GU@L\EW",?.SG&WO;G5GXLKS!TEU5\:L\+V%\F+$,9T4S>MA+*O
MJM0E?;)\/FJS6JK" >#;XE4(#=@+7NO4Z)]K_6++__4LR-KQOSL;.O-&@MM%
M:M+@FIA+]SB \' JY ^VPTL.P!@*APZ2.(##D*E,=#P;OR.R_Z+W-=:,;+5]
MRX,,&[RQ4<<!=)/L^^\3>#F J0PB!P"WAF]H%]:5N(^W)N3H'\J*/KL[9/M2
MAW]Z]B5VCFD/^50%RWDUJK9DDOL?DZ[J.Z1:&.N4'3B=]6S[!V:^=_/^W=O7
M&0>/\'3Z!U5R)0X-.X)VAJLD8R#Z\N;;Q^)J[X>(,CV?$K*6EK1OQ@;NOZ=%
M0DG),I.RF0YSQ+)KW'H]WJ[>0R<@Q?Z@19+A_&=4/ 62]F"\4BX,YR6"]C6Z
M+:!D%M0!Z\]L[/.Q2;LQ;EMB8*?)E[B?K^1L6ZF^ #/13-FT[OF'<G*6<O3;
M?F@8JT4 X=;U8A_Q47?M^R7!O5#=P;S(3/,<OSQIT%53BGYJOZ[W&[>-Y-@\
M>_<JNKU[CU;Y[CN7ZB^;BVM]F$G?DB?1HA05%M3W.[W6R2^Z$Q!979ED:U%V
M;#AFZ\<^T,01$J8QBP4<]*D) KN_9/.RN\P@-OAT^V,:<5=\AD'FWP\_E3AJ
MM1X=\FA%>!@>CM=N8."^9;$/L_]\;:KG.$!9.!E]6@YAT?"X)*>RJ>941J8>
MKSN]T@]_[EO"BN!+JH>B*?0]P==,<\%;X8F'_TW92%^(*BTDL&"K=;JXL<]J
M:10J211HUI;9]6E#GB:+-\-O93P<=37NQU9BM-8T!_![<14]+3U*CGW9GH83
M=.)FO^/F!/FI,EZ&G^1KUE]"?6VF&A (@]E(#/F9A)A\'5F,\;22N_= X&IS
M-W*3L@!>RKC$K*#*)E$4;QOT>GXA^1;.\IB;%+^R:3H3FZ+V-#4X.+ZM )U-
MC4BC9(B[.0AI+#EXB)4APAXMG39%]Q;%IG]EBZUS !>9.M0 .-@--<:41>7;
MH,LG;^ 9UJ]C5SNL/SYU)3VOEC\'%2V]QGQ"K\(>9MWOQ1@?"Q>8UV!+]2''
MZ,AU9="^,%3G9/J^&:/<RTJ#^(QWZSDKT.*JTKPB5;)LIH>$2I5=T4R5*O1>
MYR[]R+$,C6Q7KP,-@X^Z+G_0\GUEI0E?/$.&1/JOH\R9XE@*EA=S+A&V1X,@
M$')M3*;+T<5/ML99/K&\=ECI\X0SHSXN23!\4\^CNHR[)[4X@#<=DI Y<WSS
M#SZ!%*:2#0?N(SNO..@%9U+R]6Z$=P[$@F^V!WH\E$EH\CZXI,1_\AJHS,_N
M,9I:DQ)T#K$FMEJ<8Y3G?IZ4.ULVHPD44^J6>6=G OD*N#/X"B/ A!2Q((SV
ML(=7*F_Y5$J)) [:O$JS:UQ,R35*9='$RP)V11>78.08QH,MBH[K/OG'FB?;
MZH+>5/RP$[>9/ EM\S^XG*6&0%T52DX>,?<<!D.WJH"C-77!8:'3ZT2_U$>@
M)BW0Y$ VCH#KD[Z'JXV853\%*J99R_LG),TLER:=8 (GOQ(H9[J=<!IBGJ$N
M@5X4[?1 /,J.U#!!D[\)N&BRZ!"^J<G2:Z3'#.&FOSTO<K.TOWW[P\!0F :]
M>2F+,J86-I%>Z_3GHH6"^NE639TDLG17PY')1CZJP^NU^T2^5P(CJ]2!S0Z$
MD>&TZ3MMK8\D[L+^>_4+):6[0P;.^@\6Y E^=2SB3 _>D1[_(0UEW*<K79@7
M^;K]%ES('37[,G@0^V7ZH#0P])-$_H<B[I[ 4F<L)P<=Z5%B23]T$HE8'G5O
M+<U).V!_Y8%$BY,=;<_"YI=BR7UFHR;IOOW@&QJXMP7U&MGWA%1YXBM+09NU
MM%!+TW>WH \E<]:2NT=,#'.$S-/OD@UW:<_!3PVS/_N:OAUJ5PYK2F6>RJS7
MZ0]UW\1;3D+.\WX?S<>XT*NI>VOE(A?(8==>7@@LB;G;K^CTA#8*@E7F/-?Q
MO+Q'\\ YA*ZDI!YC$]H-OJ64Z=:KL/O'WCJ%ICL(:[_VL0^=5TJ@;1S ,34"
M#_/IY:[<BKH^99SS:Y>(T1=J%B>G/F[&ZSVV^%-F\"F)#KG- 8258P_+1>8@
M[1L"I=Z\-#VY'@I;-RI/G42 /JVU/H*+Z NT3I*?BAW+UXQ$KB#U%<4MJ]/]
MI"^#W=S:G^V3TQY-E7K<)Z^%-B>-[N^T%^PP9C9F>4C)5/1X_C[5XT7K(> N
M#87DG-1J^)!^FY;V=>A+R=?2XNRTDXC,(]4CP3F_.4]*\Z<NTV;@DG",$$/W
MPN70K6SZAI>PKCXP$/QGW(U1%W2/BC5(=T%TRF?R:/\7-IE]JKZ!H=B6Z_IM
MKI"BHR.@;)TX<<C+2K%<]..4AI9B\):'>XH[T.;C5=1L(+ 033#L7KZ]946S
MQK%)Y9<]GD9]L[I)>^;W4>N[7D')R\E" 5>[Z&:2<VV$Z5&"6(R-1A.0U]0U
MHEUWM?1U4=#>.?SQGH<U)^CGT;8\%)5<4R<?Q\[<=R4'1N3SY;\0 5,AOI9F
M=,V6EV+VK'1QN@?Z,O5G\WXGE!=>Z[5'S;1E]WM+OX=\>S:H\05=515G7T/[
M8XMMC')'W!TW]BO<L?;S/-J?99:MP._*$TU;SGAB"XE25CNM]NB/Z]7];Q*I
MXG,87>^"W28IM"DYT:.=Z//-CWS'#ZR,2F+VX0]$+X'NLC_6J5"M50"G3CS8
M>YNG]!2J%5T=PMX[6Q=8'9J#W37J=MWF^T9Z6K&I9[>17L>+L\+!H<X_^"+4
MD^35"NRO.@2?Z3":)2RDJ0W_B=K*=E1,J%)K?G@XGSPZGNI*F+P>:_AUE^RL
M\!*C-J; <+?68IM_B/]J:4(.TY1*8%JI($@3PT14[FR\;#QRE=]")DKZ0#%V
M[Z(B42(FIAI4R%9F!C $G1D1?_"%#BTSLWJAWMY.]Y\@[R'-76)X0F,F!$<+
MT@7!G<IN',"+C?Q29/(,4HHJ7'>W%OFJ/87O[><I6K$9!S!7FCS/W6QC@U3M
MW,6JT@H[Q.>ZW34NM(9<[#8&.$C[P19W[VJZJ *WM-8X&8-XL-21TJ,[:L0!
M]$,)_J=+3C9O5Q4)W<Y64.,$\9"277RS0%O;,Z/!$L?H0^W337NLN$WA ]%F
MY:F]\E=/Y^S\-2W#_3^^QP:DM_[S)U9^/6:>N^":K$L<0"*W%MK8@&\=E0P\
M\5>)[\3:/77-"UX1$!"&ET+>SP'<F]T^W2AD>OZX5%5MG2^<\,U*2UM] $LT
M8"E[8BEWF+[TOI,<@-CI4L,2H3_2JT5T0]EB_!3LEC 8B)W P">A+#619@Y@
MX[2^% ?P@4EHBSX++#"J9T$^ZN7\CZ_*ZQ=*+=(Y@..KB4"FFW(X![#\&T:/
M PAF8&/!]"XXMX/^_H89P&UNJ=L^9,^^_\$! )> B.,<0$0($\XM[OB(XTRP
M"+.; Q#@I1/8T<!( EU?F9$5C;T9[\O$/@NXPO=7L_%_-25LL6*SAHU<YZM\
MQ@6.X5:)6:&411;P*<OM7^P8@_^M=T>O=?^)439X2JK'8&?J&S@ DB%]C<W7
M.L[(WHY[T#P'T-Q,7[T/96%;NU;G2,(WMAPTMH<HW=N)[2;&@$ZGZ<);!T57
M=D:@R2P[96!,#/:C(<1N8Z/;&/*+2'9+.^18)[,4P$!7;0X@GNO\<[88#\47
MQK31EVKC=A/@7^Z;^'+=/TH^ 5O@I3>F/&?P$Z<FP=Q4 L,Z=]!R76FBKTE"
M>JGS*G/&POC27_2C_<([(LX^!HPLW[MK\Q=;@<TLIVU)(W:2O4.I&Y';4XGZ
M"*&\P8MP>P@#.H,&X:H7@7>&;[W!BYYUQAC2Z9 5KJ0DT"TKH_\$<IS"-D0Y
M H?X*&C1[4:%PD[A )Z%^;%^7AVO%&E>G6/\8T:5"PR'"416./D7NQVXL$3X
MB2/<B@'VCPB$0"AWT0%\I1L8NY\9</?3!1LY.MPQT;\0G(/\_*U!;W#'I;^G
MA/:.56XP!EGP22[D0L%_ACS# ?#S$[\L;_X]/[=JN.^'4KI4XI2I"^1B8<M?
M!J)HS_)6PYAWB&!Z60,DWH,9N9*SX]'=G:#MY+>Q<*"ER': )99X-KFZ79J8
MH91YG_9AZ@*S:P?L'G"4OI2T*&2&@=K8QMN^'5[M*666FAQ1H(FP#>VX$QNR
MG>S&6V^"1)1A4?J2,W%>5%W_!SO3N:U=WV^'R>SSW)EKB<N8X8*-E0[J O/_
MH<VU-YFQ$07E %HMN,3?CE:"W9((6PQ(B:!BN>K10@^\L8?8E7^E=U9X>/3L
M_WII@?\?4NIFH*4DEP,&"S+_NJ#])XVV\X:M9G']_T%>_UOO+[UV]Y_5]7/I
MIHPXL1TG451\E)247._"-MW0M*@&TQQT?>L0.S=K]I%_;MC+NU;?AIR=98RE
M+FIG1<\3[^:WK5[ZJ>V)Y7S]&U!+ P04    " ";DUQ4(9692']X  !=F@
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M5SZ=PUTWR.U_,\A7XZ!RK5YB3R'FOL7EN0UM3B0"?3'@DOK"SWA\R$AAFZX
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M2:WC;*XV4Q9@G26^<)Y JLJ2=M'TS\SS!AO+V;VN>J-HHFL=VK' :KL:S)5
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MI-FBQ19@)PF97P!I[VI=J-)$BK_XG%WZ^9HC4G Q++0G*03)-)X0:0M^(?3
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M\'R:KQ"O.#?X TNI(#OOXSW@E[(\C=29<:5B.+? +FO9Y.:<.C)*QA?GF9H
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M%<#K</KM8J6/?"NJO_A*(:4U(MOE6O^[06W^>O[N**X)[1;7*SOMPC*29V]
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MK8VP[M3]9$P53U$9KXYQV2=(]B_[@+:8^!(Z<*AEPM+CI R#5]<KEYN,@D-
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M8S:AMN.05U/JV?YO]@M NNM)I=AD'MB>*6B3/(?25"/,3F(&G6U3[4(! <Y
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M*%"MRQRW%NS!?/^P9"'&ZJ]TM6:1U9^E&R/>'1-?;I6S=Z&@P[!3 =HBQ3^
MBS]R)Z:ZA]^*'(Q\:J8%;XTSA/JXML(,L<4^%T<5XH1\YG,6U.Y<O>=^'1:J
M.& ?E$N#NQX%0)Q8596O'1'NT&^^/2A98'C8D-_L?P3XQ ]"/>=OAY*9DU?/
M"-.#-:?2TBQ@,9 -;(;(46S)O>4[)DJ62\0E[%(A_C+N8-GQ5NQ/SLUA'PCY
M0#51R5WEXNQ1SFK7K U[CD O?TNLB:!P[0L2E0[;;7,E61#4[%I&';@P!5_E
M56CE!9$':8AN1,%6+BG;HUHTJD-HGDSN(@^R_]@!_K2C_YYIMEO5(-X=7U"P
MS-N]G%BHFINDLI9E/;? 82R>/'_"\29V?:)^7@UW0SR+*]>@FTX;"V!/E**)
MC?4O!\7@I(D^H0+_K\P_&Q["R C FA?B)H-%@I'XKR,$17M 7D*#5$K]?X4J
M^M?;F<Y&5%1S0_S#LZ(S4\Z4S0>AK#F$.X)/N)?O35,,+RP;'Z#V<T:I*.=<
M1#&8W8\5O1R$W-8 C[(BR0OU,!4!^]/(SV8D4ZDRC6=5RN3#M=F[!I^NTQ]&
M;XU2!B[S[?B4.>5S0$H#IV5ARXT;*\E1RG>F9< T;-TZ,'"9VTKIC]73OG6:
M4<,QB8]/ *ZOPSQ&?Q;\?'V5GQK\UX9:.>@] DXV*X9@M:/!CP"C;MC)R :R
MS[QF'AS'1C6@YWSU2BU^T8J)CIZE>FE_7^O.M*)EPA1WUB+>-_PYS:N.E&TF
MH)W#"81/AD9IKN6-F+DAK"ERTM >JVW:LYKQX!!(W,B,NTX^9FERL1W';9FT
M=_A+Z16<NU]GHV]#X&Z^<2,,81+@ISN?_=3Q]1?2IO:?<1S^\5 $::TSI^J1
MIKS=+-#:8U^&,ON7OIZ2F%0^D.,1(&%+^R'PHM3[.DF*4%@@L)X"W/2CQ3L0
M9]ZU1[:2N@_Y<81"[H7CX<##&8G(6 -:.>]UOG[BDBAX(7*;84G(QN:]VV;9
MRD; DLHA\;H,E8N$_,<P8(2&@J3\\^5"UI^SF987RHRTB3(B=[M+E,BB6<Y7
MC4W!%O9;?)%]GV3ZJ" C5Q$UI'4R%)1FB9Z6[AQC?MQ,/Z)KR8->C8J.K1IU
MRNP ;O"-_A-9]U^H]21^-F<P[+R^[/W75$A=KKL35]O<.0HM&\\(7'[KRT#;
M?U*ZR"RY(4'<H=U((D2C'8#1]VF;P,:C_S2'@I O9 GQ9ZTEN7N) S[Y6:'D
M6E\WUF;\ L\VF#/[RJW+^I-N2F+J^^8+TCWX89B=:[Z:H(B*E925\J%*H*9A
MO/2]PVE\)-QUWF/>V0QW^>!ED.RGO6)LB8>#@=^R?P*?R9 (HOFN$E,M7+OK
M),B3G$9:]P^F49QFTG9L4YP[7 02'<*SSF\SYAM)%:VB1(<=$]ZM(D2WSZL%
M9RJ@YI%+)/6SOYWUMK6F= S-$&A<@AV?:IUO_/QO]$T+N'/=5@,XS)-<A:IR
MGZM(2/@Z$2TI[_AL+PNB+<4_V8WX805JW4Q=_I.NM7I/(?9K_H$O7L-=54+4
M8I#PP%.4*9M_=\S5ZMTCX*NKTI%%[,,9WX-MZE>!6QP%B8#P^:E(Q&3RP[-6
MX+I-6>Y%3.VMEQ##\5)<X!;=TQOK0".-:\7SFN&/*L\NXKS-]Q6"'':BR>[\
M',B0#QG<W^,@L>D)S*W.?R.(F[+1_+Q%X]!'0#PW6_8O1KZ'Z-+E[AW"9L1&
MQR25I /Q!648="P'0A-17):]*_/RO=D,U]B-5Q*SULSO3<+ (W!G.1C"/%E5
M\(PJOFXX<#-U\'O&Q?ZUGM8TE"#P^A$P6<@NUEJ'%['9_26EU+]@;Z5CA+!R
MO)O]KANVZ!)X[V%"5$(=$V=?I258^MMWPK40BI']*O['LT= $(SI6,B!Y]F"
MX:KG$!/E^:UN@YET3\#F/6B!*#PJ"K5',.0)F;1.9Z8@BDUP,/JG5AW&9.VA
MA%J^D6."_:Q8:KU1:M=AU$P!VH(__I0DQ]>9!])=(T1/- ^YB:D)UTBIDO!N
M;))8P!0D?W<I2+S#78'QO# 'O4F:UB?=]<G<[G =5VKKXJ^0=4V?N]YZ.;P%
MI7?*&"S!Z?L<&#VOW65?%7 5JI3^,OGQ_.0Y_>T+#$+9/8'Y2H!.A.ZTH,\A
M](GJM0,<Z%4NJ"_<,%_(PN(E]U&&7!3@7?[,9TRE*>--%$MC7ROQ#TN6N7GK
MT"%^BP;>8OO1)V[I2N$%H8:S^<>QT,WLB"/!4B9AF.H '6J>WE=YH:1S&RJ?
M]^2=&D\$>%MN.E^,Z0]9D4'#;TNGB0WWP4/) %8,C>XE2>BD,\_ZB6*^NX!2
MN88+C ?-^MMK2XS:V!(IZ(SY-4)MJIIVR5W\^R">=3AVDLC0_?@P-IHH:2^!
MVM&U8LO[U8A)%\CM^]9&>X(WG]-4E+M_B%D0:7QA2R_*\"W>PY;$?J(J:8;5
M$%R'ES2FHZ"+.0 AB5,\Q.W8EQF=USXIBB]8D/"N'2Q]4>$^^K-. >.US"$V
M6<G^OL;TG64A2$"=IGM$P+CO5>.MX!/68-Q^.W:BB3C?:NGD-T_W*9&Q:SS$
MCI0%?JE3"\9#SFXL<\5*G?/T>OB-DI_$\)N(Y^\$W-=:A<]46]*Y5,S6)@\Q
MEU^.L8 475<Y8MQ1P31?:84GN3W5I;I>-H*@'+;P>M<ZJ8%$'0%G)ROZ9P@S
MD-.=8X'Y;M*RS%F9@A=2G3J!7]7N?2BY'+^&4-<<PMVZG4BH_S=W->>!X%SE
MUBWG%RLF-6I+(DG^8LB,MBF=T2WI:#YW= EO_8G0R#DXH=\*; \TS<BWH4]J
M_8@[MBY#<Y[]M$6:Z(?01>]T@I+KQX8IA"!1K0*3A]Y;:SNF2J$V>M 3QW+)
MGTWIZZJA8^GSOP^K^MW#-64&,SVI]?'6)*66-/!,37<@-#-K:5JM]7:W<D-<
M/5TLA(:IW]@!NQ!H:9D@"A8+S045+SNU'?^!AH.X3)GX[T;JDT16XON"L]K#
M+M;7>(A0#NJ.7#40H0])?>]+QBCV1/<5J]>RQ!5^Y,(%ACC=?">5G#%4)Y3N
M+_&))CHW9C30)8H[C:S)7L)>ULX; [G3GATX#^;02@H8Z+\6BPAK8W)(2[:_
M@H.S*KJ)4X52S!P5@!:EBC3!./3G^S)Q8%<RD-;<G(DL9UK(#8_4DKBRD2$P
M/J914R!.2>HB>*WZQ7USEY]7S6JL5A++=$ZX/&60 05Z+2\3NY(;,A<LJ:1T
M'0%:$V\5L[+T+XBF8&J09ZA-M%Y"T]T&X5#0]+K#BY+]BZY=3JV*E_IO8)%3
MFG%(7()ZS?)2SHZ 29E1R5X,<?(+QPR-;S>MK9=YRW/@F[?>'UX#@"S^V$[K
MXWJ0U'4N%H-IK-3\X>36=M0'PQ7[EE]UL3L&GX<..1*G>5Q?G3RTNA?;S^J;
MN7S]:7R?-_-50)5 N$L9(2>=JCE1<61STO>M9&$750\^W3DS-AEP>QIK^4F6
ME2PH"D ?:(3I]?RS\CCX<'2)+^#U?*&]LTWXH%*<E\D&4W!H#-U@U1ZMX,3Y
M4#+IPB0[< @31D @R-O_JZLER%*#J;K2-R+"4PU3@]C0,=X35+PS]:/RI:F4
M3$=F&1ZP;X'[,+^:-"^=LK?4 44<V2)=X?#A\L8X Y33F/P[.;]AA1H;OU #
MARG3-CBK\*K'G!ATYO!,W5U I:@V&AJ%4CH-19>G)FX.3O+#WW4^9&R&1FW-
M(95M94[@$ KE?J;C:M;G:MB5)\1>:25.[=!P#G6PRYM>KF$GDO7L[\%C9M E
M'W9]5PS[G6-U5Z"PFSS0O4\K,56&/O20]9GVU=KKB K:"^;&+%1GERFN<T$@
M!Y-X',[BU:[&M!3]M;_Z#\;T@\TD-8T&Q89CB2+EQC]I]J+[J*9H9QW#ZW:$
M5_$[>(O_-P8#,*Y:18P%AB73X;T&J5HWI>YRA(3;:C1!LW%36%PX4GOQ5;.@
MBH!(0/.-%;5=(<#[]9+HA,<C@'>,<X2$0;UG8KX9X=J(+M&'@=>) _E13IGV
MK7Z?CIF)LT[=\QF8I#YR^(#N[AP_YRZ?"9+:.S>_O -NXQFOKM\O[YMQJ7*I
ML(M[OONQCIZ* LZ&:;$-5<H%I1<'?U8K%KHO1!;:<4=C!4.0TH+S(Q3 4HR$
M8LF , SN:Q:$9D-H,7>3MZ^[6ZGY&%9EMW&-7D\,J6%05R91.-PQD&+W1:"#
M;]*0\WW**O?#%('2S^SFF/@,R9I9H6W>7P[();*)P\T)5\2E:Z0-/!WMI36?
M &RX3"S^NPZJ+ZW: 4;[JJ5FHBKQ8=XJT)FD@[7)((@S^\C?2Q#MEX/YL_IF
M+A;=IKBE4[5*_@6-5QGS$I^<1%&_+*]4:$#Z/>#T6$0X:NOT5AW>^N%D+E*5
M(/3GIOG'T8EIZI@5/9<F?_]U'K3]&@-[LH8D]6(X^](;)K A7S:7DMO1U&2I
MN?F(<.X*OV"ENA[2=*JFWG61F+6/P*IXY,9=AL;T$1!;;\H-2MKS_=SL^T:?
M# ^CA5<4,?A/RSXE,6E^?20WY8GWVZX1K%;"U=O=BTG,P ?YZHPC'>:&O!2+
M^[&:37JM?:8.;VIJ;X3[LTUR39A4W(6,3"@#MZ52TH'O?0(1L32+E7?C*!\_
MJA<>X*H!8,DGN031]4)T29:W,UR>L=S+6E-%AI4N3R4^$:W?Z.G5K3M3R35"
MJ/[8<CE3#GT:[YCD@K]63"@1E[VJ6 Y;\C GKG"N<N9V9@GJKU5P>Q8;S(W(
MW>-US#QI;:@L-?/)UU#GO]!6EY3J0?)9NN*^SQ:6'6#W(;C;P8"VG[1%%^])
M6Z2OJ7"WC5P61N'2*OJ<8NO;;YQ-0B2L\M5R4 ['"_7(V8KG<U:QZ2KFV0G,
M LVAB?.DO?:S29TG."JM39-0$>?5XSU4<VM^0M*AWGR?;X=0? ZBS$!VM=+J
MEDXK:5FUO=UX2-ZI2]=PX?N6KK0_QE0B/#BK.%AH/]:Q1XI=Q>70#@9M^48?
MM\7#M8HM47O0P91Y4;74&(\=4-EBN=;<=#[?;.P_MP)>4EE' ='IBT]&O,YQ
M_^^N*+N",ZZ<3)<:M](<'@$>7W3J-=&QM&)8R7<1JN@EY/B &^T)&;P:M]A\
MVN^%'>=_&\CE7  >2)QI0[,=_H;T *+_4G:7@TIWMFU$M&:*B4Q_P[KJ8T+\
MD>C!^9X]^F5^F1%([\'S=RZ:B"X&Y_:$S$9Z)]A9WP2H;/ZV5OIT@.IJDO@R
MXQKGY_92M+.(/%_[=/'KUU^M1UC0</*((MNWH6\\"2JU8HS8V3N(*$^U;FL>
M=AX$;CPO2Y_QB9D%V^,<KLKY #YM[\[$:TSFO7! I=WY]0A>BZM_;/HDJ2>U
M' \UJIDXJ-@4J'',:+B=%<@:_9*5XH_?+D/Q<>>E&CWX:+C]>^"06M%R?-XY
M7:J%V;4GXTSZTJ[.KE'<OO=V7>D?C6))XA+2V3&>9%?.9K4_]F-0OP9L-S.E
M1P#!.Q##Z<6^/0]#2Z0::6OUX09,@G^SUN>J0Y2&S_A]OEC:AJ(0AUQJTUSI
MBC0Q<<2#1,OX(;?9B@,X6C)L@.H-Q)B.G[]]F0)'LM<)U*UQ//M-*(#R2*M&
MG4<WQ<3(J+Y[. HD I9L3<GD'?,2ZKC.[_->XK]EG-M=ZQ,7;=EQ>5,\HHC2
M6;WNH$^0V=?QX,%?6MI[IN+ZPDQ,M4J.C2W!_:SF0&==->N^ OH;:EN_^Z&\
MD)WW*C#=;._.6W*M:^YW!6-#DA7?-Z\(RQ"9W>SNJ!H#OX<ZMR)S8TR?Y]BF
M9V2FOZ4^YF_V,_A*\Q+*(L@K_#4H%\0-"M=DJ?"L7_]&Z^J%HA@S+RS:K_?U
M,,15.6(C>M-@+Q/!2<C1-2&("M+>@ T_ZJ2$4);B28CO!K7N]<7\+'@;U)#\
M+"<.J$W)EAF4R#<V_/'3 J$FCI*"%<BHL!<)];>1:#A3(G0$?I)KQ.$<5'J?
M:96YLBWQH<$>4#;K%U!XX]S:$.<J-]1_0YM7,2%#@:/:7/>GOGR+7<QX<7-J
MA^J(Z*$5A%VW(1)M"'-DD<"C/HQMBQ,Y7[E%]@I-6,<F*>@KDMM8)BA-)E X
M%[(/NYS[H@97VSY,$"=I7"7G!RA).CQD52X(37L904NCO/OC?&HGU(*SRS*)
M(L;/#(_RAVS[U)];XK@[LC&_O/'6Z)X^T:NOU&6>3D*>,M>W=-Y/1QP1>NKM
M=#\"JF5HGI!HZ?#^*_'-C^+ Z1$[3[=!9A6#3H"HN&(.)9?:Y\_08^H:1#MH
M(DS&L8>]>=4Y$WL%78%O\$@-GG^]B9OA(=T4>]?$$@:MIC1WN+RL60BHG:0'
M_]83I1G'$I6(N9!T&S%.7K/9A+8UA"#'--/4:\DF3(SJ*IX7,Z2 ,2/(=R&R
M!S*T:;W4^D00_AE.H7ONY1XC3VA55H5B']+'AG-"K.@^"0/!)-*KGX&8O41A
M54?9_(1)T4!L%/%'+B/S[5"UV:M,(N)^07[I@'.TN)D?I=U$L")S$!@5D?1;
MX@<$O>+$^A.N:"?3+++IUYUYH/>:8ZRX1E0O&'E@D8Y4M'3??)8MJ227>1)\
MC12&K07(374_O&Z:K*BHGS\0WK3R353[$:S0G=QG3,@'^9Y#-"L[=7#'EV^P
M,^F@+@UNTZTSJ?U&([.JR)>)/[?6^ .J-F2JT24,KTR-W8!5[7%/4W=T\<]I
M?I+EZ!0M<;ES*WF"_PCH2;>);>V+*!YC5*T89@&+C,Z]TE@%6*P\ZZ=1 'C_
MR&L4_>Q88>[H?4E+-U6QI2RX4[T"6;/58A3IQT3KO+QW+#H>K7L$X!&'5PB9
M<_2_UOQ&Z#LZM6#7_@]ET'_7E]8T-U((M)3,ZK B[7&F"G,N*"67N"S=R2$R
MZNX,GP0V-,T*<>SC'C^?7)UUP5$  @P(/82F<KJF2OYI+HG\Y8]+)UIDRQSR
M=>#P /7N$9*R8#2M,([@Q.!>#Y'_:>(430=6.NF'N^=9KP;%'@&(F<&SC= [
MCH>Y>U; C-"/JBIS]0EJ/)*#QN8^/;I+_9E'@.Q2>=FOZR\==30Y#0;9/S;<
M;^IHI56!25,R4^M1Y*/NM:S)X,1XRX7DA7MUKO ?#(UD-U5SW">WC9V#QO&R
M>TN5%PA21H:XKFT#2^&J(BJG+7%Z7U=?XL"K+S^.C-ES2=@!9?EH,AT8D^ H
MBW_>#QTEF@J-(\ZMIJJ[=J\PVW,S7MS]B:ILLH7<?, ?[<F&DX&I0\=VS884
M[%C=!8]JYB)ZQX@I^MBD7/8> ;/#:VO7/H)7<4=*,Q".ZVF,RY*7_M[2%\.G
MV;H6#O?MWPHGB^*&>AOX=M69G,(OL1=M!&A#O;&%I1<_2GZK N<WPL(/D<:.
MC580O)2"1.7<U.D+3%HHZ%6>:+&V)YW@XB\53&VXX#B"2=&;P0,S]X)B5]FY
MLK\SA%&2T.KN2CK+W0O;',_Q)4JHIUHX^O.\X%SAAQ%';H%+6ZL!;316#0G2
M\ZJB'YC:J/DQQ@')%GYX@FY!#!^FAZA@IZ4MM]0X%_T+E\6MR(X/ >ZS0A^B
M +$,4<Q>4:P3!:)>NH"F"Y%][?],U;YF4H)'PCE(@*5,XN]P^\^+=,#+)\=_
MO27 7DN!Y#_TWDF'KF'=9/#6R^1R^S3->8?TM\,G ;DJ43J6T,23?DQOTFG-
M=U@ WP-$][WY^PRS#,WI _HT[:2EK<7*#Q^<B[\^*>;\8IFX.[;[]D2W/3+O
MVFZ-XK-NH"4PNK@_L3#&*3%):?D#XE5\3@?I<K?GDR'5GX-)@ERU,I59L3L!
MQ(QE^UXHT]$TELN+2NA(BORP1]-7Y5",JDEBZ749ZM'LU:%[[UNBHQY^0\FB
M+%<X[H$WG22$*V->VAO_'8E=,K)L_DYZ6BF<K$L_#5RWPS=*\ZJ;(/1IP!IC
MX_QL[-PN"KZ(O:Z6+5/?./Z29,I:_7(-MZ4>%4"&09>J1\L[D?VNM2WJ]X"S
MY>O$C[LO&A#K,6C)TQXYA)(:G:B&FHINKHUTOU[0%YAP6DTXF68/T6?(]\[=
MS'/))[J!Z/O>EV:\T&D73D;U@)Z?@H2_+6TT<WCIK3_G;.A_ >K-ATA9)H@G
MZM:/Z,WJPWQ_FT* J7D?)FJ?#GY4)">ZW\%(;3W>_E9U(4UH4@\W-&483B.
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MCCK=W!QFB&DWR,1.]+P7H*'P?@KJ^,0(0SC-^\F":B]!UVK*LWG&*LW_LB;
M_QN0JNE-YT_67S4EJC7((2@O$L<4Z-[+D$ /] PH! \$XV$+A.%,C)@[)H\
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M)4:D4#7:HB\J;%C X#I5<)V]IZ9EXL^WD/T8C#,/\EW3K#Y8*4A*0EUL[^Q
MS,./$^921/I<,++#!>C6/P; CWV@1-$(Z-:)%9Y0QN4(/3V"Q@B@%W]<A^AX
MEG=WGM&1=5:-52R\^U#OJ-B01#(/=/HT)_E)XUH31T@Z&KIOCK&[)';[00WD
M!G1U*_+E@%HD7L96QL[WR6ZLG'44.= RGNC4^" =N<RH/,>9%UW:K?66\GAO
MJ23A9[.0F0FCS]+0>JBZR/*"6I[\1V[&J2R=,E[G3N\+5JJLMAG=-MIW^VND
MM/2-.K._,A(O#1[,T.^*88-\-^,X[XE*LXF92\56OPQRT^AG?LZ().T86SOP
MF^JD=(T=V5-W=N-4E_JQR:H0KH1";_P#JY(%)A%+Z/L7@B9!J%<-66Z?9MO>
M?F 2Z".!QV'+K!?37H3:'-\@)T<E!0ZNGN]\7""(])@C5>V3=R%H+Y59",LA
M7!0>W6T3<IB,U=XHOK2I;S-4/AXT>\OPYQ/@[EY=>@T3)A;QK45@M0 .&1W2
M@>@W)RT.2GRCW!XB%*5@@14ZHGRTM^819%^8'E#I\IZ4W:_*98(Q'51T<4HZ
M62 7=CT/+QM.%*!E0VZ263.97?[&S9\P$Z3X$B&X""L9:J_4W$";SQ],^<=T
M6L0\JY+..AVYNE4V59C".%\_-R9?%^US"! PG 7/]E#2YE<JWUQ 3V5!/(GD
M]]/?^1I-+&)<1@/A?GH-B<<WDAR]?#Y1SA]N;M^?TA)\JQ)^N*<BQT0+(X@#
M5/YH$;#DB5XYH>((:*#2:R"_K<#K9UGXW.'/ET-$:0_U_:R[[A_ EMO<3NE<
MP#Z+8V]9 Z/%%AB@_RA:$6W<?JW&<IP6?NY#<9X1P+JD[NC+%C_J,S^DDU(B
MBA8,!,A6K06B2:1?/-2\;/+%6ERH@7^?D.LK*90C?6 (76X7>GU'#]9+V+53
M;,K0:)E<M\^%ZQ*9FJ?IO^]&][V49$4?"[V3$YHG^+[YDS( F?4)Z?UR4)Z1
M_Q'@$<1?\$F$= *I%Y8[OR-<JX0A4;OP=FI!@V4)K+B'F-H1TZO\[ZM/I:9=
M'[7*"-;!R@GHUSC>L'@$B#5KFB$X&P0*F[%2\QG(XS"LH@";6^8'E9JHBYIZ
M"Q=)X)<\Z9R]@)-QY*+>U.]DC9JX)8FL?$Y$><T>8B&]3IN^XE[>(/0=O &6
MQ%8(7G^%*>.!B3$= U$:Y/<[,2+-+K,_=MB+=N<<C.X&.J$W]DN$$!'3^5C$
M&UGH-ISH97EP?JX6][R8!M?D,^-+^"X80\CBV@^(C11.U L:)M2=G3U%$C=-
M(X/X(_L,?RJOA. B@,_>TA)/D0[US>)NRA#6GHI8)B(P#S>N4&TI^5UB'F^?
M1"\8<@NGA+S#9?MYO^*6"K#VPP=D'0E6>AF>&^;=6@L8X1429C?[S)/_C6K]
M,:F]^JM%CD'_T)=#4+8'NQ[9-M3#4S0LV:603N?JBS!NG"K]I5;VL6Z42W9I
M 'P0@[!-*S+,"R5+OXUYL:*?_MGFN/(\/37^FZ"X[U:65R\O3.XPIIBO#4=J
M.=59=:11\D>L<4$1G+;2SM*Q.->8PR/"F[O#)O.FCE;E)KU&UV/@T,4C6O0"
M]W-TDX42A.=05*OQBZ=#C3"^0%R*E@P%/^/.:SI'&)7@]N=%.9PA/)9[A[AN
M:1^/HU];:4'!KCC&"Q!8\H)IP)MD\;^#XMJ;=E3DHZ3=%&EKA1:.=K]K_>=I
MX/);]J5L$/:WO#D#5YVX2<R@ER*C,Q@WFE@H]M+IBK3*:?.KF=>W>HB'+^\O
MB@=O\7>:%/3#;Y#><X0[!S$KM X?=AH7]@2F6"@*;?FFM6:+!?\M>= V#D1T
M/0(@,S0JSH\ .H('?TWL,!*MMY;_71G)_UA@.T4W*-*&9[PWK6(>*QF15Y;]
MUTL9H(=(W@_.B4Z*)#O<T*8<G"E3I,C<PH$N!?"2-(VYT,VS-\I7ZQ$P!L)A
MV6$;G/1UJ!V<?"IJ>Z0[M*!/C6K\PGFPD7&??UKY9LKA1<!N$MHNY<:#;;8Z
MV& E;"NKQTVQ<'$^KX0"^$!JQ!6"$"WM\B0F!XF!T@W!8V*IR,M^JB\&:;2'
M:H$=' 6)+TU\R^APF#Z.<N!TN0UX.KI7+3*H7'S#[(]%BG\4[LJ^&AL.^(6\
M9XA]IBC&&'^-6XAJ7S0?!*<09N(#['5Q&&2DNC(XGZG'"Y&>3$F6A;5'"NZ'
M:]K:2W00!MK+TZ7CL>-O5S.1J*\]$::HS#=.^5%EFBA1A/FDW2<Y$\ O+0:H
MY\R7_VYF$']+Y*#@?QTXLU"1?UM;?4&J/6\RY9*C8M7Z%2>0DZ.1D"H[)=Z,
MF$2XJ0B/Z4UKN%*J8:*5Q7P0/9T+ ;XW:6*UH\\I&YE6Q5MB<J>_P2%^;;("
M$S^"49P'D\,ZJB?Y?6T<RO=AACIQOF&.T+FEW([JH_AVC [VMD:V54OXI*VM
M[O,MMM=$^=BI"31<_UI2^D(XD59A3'8ML!:8]^GDFP07KMU#7[HL#TK/X=?:
M3!VK$6X+;@O:;O;<#A,*)%'_V\LW_B=PF%4/5AY%E>H?ZGL\.1C1+*#_MSWR
MXA)S M;PB3:02*QDP&ZAMP6G!D/42QNT##KVY%C$9,W=-^Y79]7SPX&K,0'3
MQ?,(=C;0!@CH#A[HI^TJ+#=RXNJ*8J\J+)G?%7YN9E;'J;5"$V7XC04 $$M7
M ,[7<NEG^ASU^$5?#XYU-MPXP1KTCWN%?D'IVDZOLH:2O,(89(#K,3?(U*L8
M(?%]Q_[/HD42R9QOK3Y]VD<LS4])A0I%K(Y1&N_Z;2[H6VFVQ"FG#6?V67NP
M^P*S,UPE)?WP!X5(MG))_;.F.G0*Y73+ZIN<"R^F+YX".C1)B  809(<F?$]
M1JV;,WN[9K3&W[FX(=/#5[O/O-Y:']"ON)MBOE!RPW3O6%,NU-S9GPBFP/YY
M]^JAW.@1\'-F]HRTM(,.U<;\",@UHKNC1#P">F9%*Z_K$'I2'%-<'F,$2H+N
M;T:$8"C,H-6:YA$ [LE1YFRN%H05@VBH6U@+=&E_C&L;<Y020O$]U4('UG#6
M7T1,8,S+]FI_@#Y^",@>PZJK2TX;K"1Y9GPQV)9<_L93OKC/HKFQR9<>/BRK
MJV:7).6..(9(LP.:Z+Y6]D1-+:KQZMBG..EV\;K%B64O\8U-IER;O1;?;$DM
M< %:4I98GEI8>"# +5=;);*@2M,E$4,>>IAQ:](/[B;[;A:\!0N<@:/L?E/Q
MGB$B:WBZX>?CWC>#)4H2H9D'NPC8HB!:53HUJ*@U=%&<P^GI3P6]&(:%5IQA
MV6WF4ECH04&FAN1P4K\:V4(H:&#QM/IXY6RIG$:\AUE%.?48^"GF+*17>:<U
M+0YM?8=/S^FW4&%;E.\A\S/.T@:6QL7(.N:5Y24+PL^WFA@972^=/4FV])AY
MHZ$)I#:ZLE.S5P[NIMP9A([EP+(<<70\FNL2A]&L1P #;CO=I@S5N9:"<M?_
MD]#H_T)@6C8I2_;:/@N-FBX3D'MP=]:6%5T+8LC+WABX[[LK.;5^6/^B\U6>
M,YI0@VG;@<TJJ@>V["YN-BIEMR;TL/<(R#X;<5R\+Z5A#$>J8&;[(MZ0$O\Z
M#-P.?=!U?,,UAT4J_6]/.@%QVP\^TILR_1S@ZU@.I97R=L8M7&Z=BH1O)FP!
MQ9QDDN\63DPC_KTIX8T2*HA,#T_$#.(D>W(^(N2X_]-,S4!<H/^.Y41:9>*.
M'0Q+,%$K+7\NEU<V:AA']-!!2.3(TYM>>-!7Z1K@&U@XOV"NL-%"Z7:V1-Z-
M3L"[=^_GIZ^^3AQR11EVTGH\#'*9DK*M3W&.#3!4WCV_*W?O:"<T[DJ\+[I0
M6,J3U=RG&\"53)-(/G3T&7A_E3.[^ C [M%(:E:ML-D&V=]=J.^?B=[S\] )
M_V"\]E)LF+*,?)7N,*$((\H?1PN[7-1MD0P(L(4UH+*_'=8_T5,;L+N5*G2D
MB%+_]0=F@0&Y%MIOMVKZZ]IY_NBX@^+=:8<R^/@#O92[B?N1K[7-'JKA4Z?"
MVRFO_-A>S5797"\^0)0@"B="@M%%M2=RQL.K!$J^!?TL<9J2.M2Y-U.,)UE;
M373SV-#":T>UO2(5;?]2G-NFKGN^]'-6P3<-8W/U_;ECYMQ8)@]RWR4D75Z=
M*2:Z /<;C9D#)72*5H_W]^\-FL1TG;9?9IOI6S_<0D^]3B7VIC1/;*M+>.X8
MQ6(W>T.VA]N07.O*?^.YG[GRE,I"IBY]._,^0Z;3]?Y)R\V-<2B6N@2[&%XS
M:<H+NIJ%OTX=YZZ4LL];N]IEN+BL=H.N*QU4KC,[I3%TT<2?S5DM^ZE:VN\!
M=L^U(T>DXP[!D:K76?[G>!#_T;[_MV6B/!P2E?W;6_JL\Q' +H5P?P1(T)WF
MX++_QX^D?DLS=G<<.%A<TP 1_S6W9J.5F219@N$0Q5KZWU 9_O_Q_S&@/<[]
M'U!+ P04    " ";DUQ4*,MQUIL5 0 "%P$ %    '!L<G@M,C R,3$R,S%?
M9S8N:G!GG+=56!Q/]"TZN$-P=W</P4,(@P4)[H3@[FX!@@1W@D-P&=S=!X?@
M+C.X#NYP\OM_5U[.PSUW=>U^J=W][=6UJGJOMZ6W+< [!: \$  '!P=8^W<!
MWE8!T@ $>/C_QC\@_AM(J$A(B(A(Z"@HR*B8Z)B8&.@8&%C8>.^PL'&Q,3#>
M$;W#Q2<@)"3$Q"$F(2(@P2,@)/CO)7 (_YY!1$)#0D(CP,+ (O@_QEL/ !<5
M#@S_"0&.#@"/"X> "_<V * & ."0X/X'@/\+</#_:D1&045#Q_B7T/@.  ^'
M@ "/B/!?U?]F_?_- Q!QD?!H>:60\;^:H- Y$_ %)>2CTG^J[254^PMCX/_N
M$HR&3D1,0DK&R,3,PLHF(/A>Z(.PB/1G&:"LG+R"NH:FEK:.KIZIF;F%I96U
MC:N;NX>GE[=/R,_0L/"(7Y&)2<DIJ6F_TS/^%!06%9>4EI77U3<T-C6WM+;U
M]0\,#H&'1T9G9N?F%Q:7EE>V(="=W;W]@\.CB\NKZYO;N_N'Q_]XP0$0X/YO
M_&]YX?[C!8^(B("(\A\O.'C/_Q)P$9%H>9'QI+ZBF#CCT_$%H1)\2LBO[46C
MYU>#$7YW^8M.Q""PS7CQ'[7_8?;_C5CP_R]F_P^Q_Y?7"@ 3 >[?XB'@ B0!
M+^I_(ED _[LHEEO5EMPODDAG9G/]2.4.BX."PU[YWP .@=\XMU[!;4^,4ROY
MN,];^"D[.\Y&47OH]ZNO:-"8;@(T*-E>H+1^E]A]*$1)\O88IA(*NJEH$1/V
M+/*N/RR_#P.N.GGBQK;*G"^IHLP;6QEES3P<GS]HC]I>X ^ ;Y\E\%Y7V]\
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M:/PU[<4H.K[8WP+M4.9:205DORA8\Q;.P*G0;5K-?294_X5;-7%?)<51)HI
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MT1!LWIE89Y>J_JY-?ZJ/+9:2ZUL:N2O:$O)TN_UO (^T19NXH23+])@>NGW
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M'K7?[3CR>KA[/O+AJN<-@+6Q"/:1J'5VI=_X:, _L*J9#",,]T,PE@+?!:2
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M2-EVUH^Q^&CA_8$[>V'"<Z,QEY@](B:>>-NKFV9DM+?V\[L29E:#0TU90(
M**'W4*&ET-'!-D8BXH2OL9O0>@6KH\[0@.:RMI4@N'_VGQF+:&MJA5)CKG$X
M-61H7D\XHH/CUN,+?V%X:DF$-/HTM6X;XD$.;R@_22A 9"SZ)% 0X_3 L.S3
MM!@BUI-O[PYN^01X^T;5^5A[:4SSJLI=-!;YM/G])I;#TF O'*>GU9QJ[)Q
MN7>&R:IBMVC1M3<3FLT7*-$"(&^.J?"OUQ%SZ5RI'W5C/[!/75?+KA X#SKE
MOO/3K%@ZR@@(_Z//?D3V4TUD;9@OP1X!J:OP-2R+O(RIL/H1L6"X*MWUGPO
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M1*T$*G, BVE\"^4/RB.-PO55YE16JIBBAC$3O+4VL1Z_\=9!>:9\1\*^3U?
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M*&8+Q_C06%KVM5*;@Z[ +4XYNC4OG9'@JUXF$J&TSH)=AV2QH8U(:)^>KM[
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MND-O$D$"<+'&H51SGI]:?-N\I]OW]IVY/MQ7G:.6G4[MEN:&@L#JD8!!(/\
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M.LK-*Z(=/V<EV+.EV?B#4+.R;0KB/3M,9O-9;M"SLK$G ]#R*SOB1HMYX?\
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M%5N$8@X.*5XO4?- T$TNVCP$A0 =@!BD_LJV!R((P>I(4<GUJK_PDMDK8:8
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MA68==A'&TD^G>HAXD@W$,DB%?53_ (4"Y6;&WV%&WV%9*^([>120K-CFF_\
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MM>I6?_'K']*N!W8;J6****U.T**** "L;Q.JMIX#<#S%_F*V:Q_$;!;$,6"
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M,6TWE +$2 N<$ >F*T-%OHM3A?RXI$$9V?O5*GCC('I5E;Z+[3+$\<A,:@Y
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MP;J,2E"')*D$8P ?3WJ:;SMR&*1<*?FW8Z>U',0U?<=<:T8V"@$/M\PJ%.<
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M[J('15,>W!WYZYJ53MFVE4"8P7'+?G5Z$D&GD76^6-KB- -I1U&.O4?E4/\
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MM;_:=6L/W*PV\16 LHP"P/)X(Z&NK\*?M57)O+5?$6D0R6C+A)[& B6%CP&
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M8.6X/3L/2KK112KMEC60#H&4&LY;B".W(3S9(^@7R_FY[J<5MZ;9J+6*1MX
M&%5^O3O3LS-M+0C72U\L>7&H0<;2>.GI3HX)I+AV\I1%T$CDG..O&*=J&JQ6
MN-VY8V;:&"\?G4.JW5ZJ1FV6*2/!\P.Q7'!Q^9_G56,KR>A)/>17,80/O1CC
M*=/?]*Y/0Y-;TRTU%=3CBF873_8HX>"( !MRWKG/6MRSU1!:J;E$MW&U6"KA
M=Q." :GEN@UBT\<L<@4D'<NX#!YX]<4C1+E*EO;_ &K4H+P22);K"T:Q!L*2
M2#EAW.0:-6CNIF2WM4#C(8,S$-U&1TZ=:=:70:18[>*0V\D9E\]4PHYQMY[Y
MJ.PFGNG>.[E87,;$IM  9<\ \=>E1NKB9+)I@F6>*<K(LG(#*#@@=N/6O/\
M7/ NI6-]'-I!+ECE6:4@;LDD 8XKT#[#<"_DEC(>/(*HV058CG//2KS(\T*
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MX^OX&4"V;38XYH^-S\AMN?3COZ5V'B;QII'@RQM]'LSYE_Y8C@LH &FDP,
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MCW_A%[BYN=/TF.$.OE,%:5Q@X)_PKD_B-\,_$_AK2[J6RE\_3HYO.CMXV)=
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M7(;CS;BW1MR2Y)!)&."<"NI;386!$D8()#G;W8=\>N:L3:I]NDNW@1)'21D
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M!_'WQ<L-9M4U;PS;ZG)JZL%:,6KE6C!Y#<=/<5'X7_:>LIIHM)\20SZ1=JX
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M:4Y.,CF?AW/-K.C3V.H%KJ$HI7S3GY3G@UT&LZ[9>%=-*^6@VKMC@48!P"0
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MR1XF^$.I:!XDGUG364W!FDF2// )8G<?;!KR7XE?$"_C\;11N^W4+6-0TJ\
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MX>'"J49"9#RWLB+*3VX <8-'&=W].!#M%CW1QK!Y',VF -8/A ?ZUH:R#_+
MCP?>I=7XOC_&ZI'-H-^VJA!MJW:1&#*4XG 9,1\VAJX =\I"?L.(/B=[K(&[
M6ZRF=KZZ'\/G& VSJ73NNZ=<F1WQK%!?<R[[X;HOICCIO\U*(*F)4?IC+JPK
M^HU9%%F4FFP#BG#!>S^Z564Z'H8H'G]IYC]]-H/1I44\:I@Z\"ZK<'W1.'W
M,U8\)9JR<>2%;W^6047Q!\M];2R7RG@_C)P3KWSGOYKCOZ#XC][9%Q/C4  O
MY.]_"?U_A+G5CP/R)<1SHO7:"J79*$?%2&VA^?:1MJ0/6(N>RZY'YY9+)TJ
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MHZ!UGBQZ[68/KYBB-E&)\FMKO^WL?VUCD?]'._MK8W_O:P3@YV"##H]#"$
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MB2>;XVN=KMRTX<]U>-!HR(;4P70;:5-6EI1H>O0SY'S<1Z0DROERF*JMC\+
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M0=1G5+* 'UG_.A:?13!D?N:C%$Z[14T_IW!UQFOGPA^[\W4*4^Y$:*2ZW*M
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M>^LL^NE!A"?RZV0K@J^>N ^LOSH=KMQ$4*SJ=2LKZW6^6RG&]?9TH()"/,"
M_2$$.=HPA]$V Q@Q.]!5&\X_"E8Y#JW[YW^=VSB<.0RT[%54__Y6@^ALZ'R(
M7I@$<M/.S>-$";N],,(4>.0S<GJQ5T:80$F%V//$P3Y%K;Q%$Y7CI_*M=M\^
MI,]Y'C,J].,"7:V\@B+X:HJA=>9=?[(DW=WY2$>9ANDNTYD'<\J2_-NGA";>
M88<56G P^E&_UW.'[4 3M/.S)_>V/R=7)%3V=.7O?STG?_?FJ)VM1$JK4DR(
MA#;;"@N0*4$CO:?*E*."[HLW!GL>/D*MPBL_%HA^\#TD7?-83;3,MEU!;7@9
MT)QVV0A'5K>BX)KJ*R:.AQ0YSHWX%C_S2*VB5I3[3EC,?B7Q]^R/>[XE=W"P
MSIX:!PJXTTZB^%'F%RB"^!Q/OP#9YH\](SK>#QZKRCSIN6TQK.3?V9,Y"MJ3
MES>(]=%])VLH;OAI:N)YRJ3W,:']GA%B2CM:XH6,IWQ6!B.,@L&=E O'P'J:
M)VK2@4SN-VJ$1^WW>4([W6*OKU<\FOKS=&YII'[+X:&A@=6DF)WPJJK[W))R
MG'VK+.#V3>N>WSUVL+,O\1W^ (BG:#5/POS6?J#UR#4V%+KUN=I4!\_@2NK"
M]0\1HG>*>)05*7-.!1":C?K3S.CG$G63(>4$$^,TV6\VL!@J&';$!:5,;::T
M-B'XAE'W&G%E*_$51\0V;9=*4B^]/2<?L^\4_]0Z)T9T;0*"NUV0.V]MI+*
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M_LOCEV,@C&)O GZ$2 C)L5N^W_DM<IO-J&C_HDMY!JKZP5/%"!ETXU/KH7+
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MV474X,SXK_9U'\O[<K4<+,K=73R,5N4B@G6(!YG#Z7<W,#OH=IT'D\ 3WUC
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MV!QM_/6L&XJ]4G$KZ!S?>_^HWNSZU6?TKWV? =5_,(ZA7IW58+J(,_,,?KJ
M$06!5>\C#XXA#"\4Q[)D."-B/V(M2[6\1'T*3T^>9&,!P^S0]\QZ:T[_7K"7
M+B"96_CBXIB!;)391546H%1&?07=<P:RCCKRVE K\A>XU/\+,_E?KU=,_K->
M\4]X^?]0L#@_W^_@:WK?Y7Z<D@W[H9D;X1_HK\=%V' %<[I;SH<JRJO*;5T\
M76F&7K?'UMT^?$LJ]CAW)N6HU$Q4/!".IM PV+9"L)Y9;8N=<[BTQCV2X7'H
MT!'5V<G1N2KFYVSUJ]UUD!.VO7O)\<,>N_XKIIZ_)#J6_O8H!(JJ22H4':FU
MC"+$HOXO5\K OU4E^0W3F):KU#>07;Y#JO>92P[LK<>?[^_27A#T&36(F2)F
M.X)Z]BK3'.FL=QPIPQQOA(MA77$T%0VL4@ZLU+I^,,O"B078!?UB^/]19]"A
M>NL.=*!=:6I)8.>_^>S_2\(61%O0#&%;V4O_[K._&@4^@I\VC:OE(=9O]\P6
MK;UW>LC0=MH>#C-YW<'>N?^\NY%+H32ZZ./%)>Z$(2%R&;4(9PR:O_1"[!@Z
M-[A^1+KY<&QT/J%;V_. W%+Q>*5E=Q,LXSW0:>3XE;VN@*3<<$2!I!>=TQ/D
MB2]R&OPI>[+U?)_2SY*BDMP;/1;2.XQW;45N__0* Z.K]!#XP0,(F <^.$#:
MH2,L*.RE^?>Q\;$OW\W<TMYH?FG*!CAN&\,5?N J]&*N8[U6A,%E/QBJ'Q5*
M:QC,O*C) AH.!M>.F=Y8_GS!S7BD,9,* _W@L9-K[)1)IK!U/=TD7-;<&'Z(
M!32BZ$:0@XDG_OJ_JG402U-MJ;^.&+G7B)2L=ZN7!;4:C60IQ2UUA2.F L^U
MP&O+BFZV>0'I>V\W5"%/TSJA@-4CUB^]FDKBIQN22Y+"<E#?U ,9^P9[@Y"\
M3AK"IKR%P*V;FC"=GE^W0O_'K7XL-1X)R=-F6XW"3"!A&:G/4'.FK\A9LQ"0
M7EKK E64&]7</AO4"!BTA$8_OW/G706Y;BRY4E!08B\WIQ!HW5,=6?[ 7,I(
MEN0JL:X0OPK_ZDZL+"5'307'TI6GMU7Z7&Y>/E/O^K!-3O%=BLG'75B^I%9M
MMJ;_LFD51%5LXW<6\$@\,1:[*8+'@O%;!C?6\Y+L /H<(P/A$2Y.1#;A$T<&
MZXEXR<:KTY,B6*\Y*UA,R8SGKI'&  "W=^:&]P_</XP,Q3*)!0B0R#1FA),!
M="RG-UA '%X)BA6O>GZT R,+'42$"8+!+7T+H16QR=XR$^*U]R4W7GV\]DB&
M8Y#PXUF$D3&H1W-%:7U$\*"E<[PP<$I3:.+CYW9?QYYC1&M=;17N7HK8K2_)
MG>R81->+;5S98D.ML  >@TDHHR1"7X>81PP91*.D8(FK+.!:&G11Z.):/:BB
MUZCFU>:GS3!HL:8FVEZ>'FH4OZD@JJC!_]J4<T=X<[C&%U&S-;P"(XTIY8W;
MCN&;DQ.C<-CKYGL'A6LQTB\HAKG59KI 5N6/,@S*$31@2K<2-QA ;3 +N)/V
MZPC-_\O&\SP].%9Q5"]&;B R!BF),4 E.9*'$HB]=%N\$O,A!>6U?#)E5Y'F
MYYW?#!,%PB$!*4#\:PK+WZ=XF0-[BB768N#8;KY6+&@& 01%U-F,447G*9H?
MM LBW".Y9/^<-O!(F!"KO2^:%1GYY0+O>\/4;I>A[OZS[.=[_L!,@4Y==NM;
M$_X7+EZ8]6@)R.YG(XLO;E!46ZQ9@*B1.!@/R8W#@\7J2>OJ(G;>AY4&>E(Z
M1PSTN;_2X_SCSB #DX<,AY"T$V !"=Z2="=S);(( RS8!6:\/?YMH@-O<YA-
MM,$L);?LD]4@(8Z,_P"/G>"A?,\G6>QLJ*P.OEO!L3M[2W/VL81V]([*3^T/
M^$0X_!<RUU#](=ZMD#CZAO5 WGN=@VW40\5").&X((2AS;V0ZQY'0_O-\Z7
MF"*'L2Q ''D"8AP&_^6"DQ+9D:"#W@MV4*):-N!L%?>/3;9:4X?>V#:6V!2.
M[#_U^5(;^J!236!S^,*I<U9*IM^,X8;8OZ;A_F,:4[JV7O/*EN[*#HC*'(?@
MG1*T9K3V0=\A]'M&$K10)Q*U 8SR)A5:<9O1C!;FILUK)'54KF.KBC!A@3<2
M:54^Q#B)SI"2**:4]/0&0SHX#D'.[?OU^L'R>M(=_$M,]V'UIK3^M)U69$;+
M74;V[K: _>W*C^L-V:HDFD,O(N>'#G'7 >AUR!,$*&$%=*V_)Z @1GB8.F@O
M2FR#A>_0E&YI?NL45JBUI(M_:^E>1>\!Q*T[B,^MLE:B&[CV1/]X=OP5%8[9
M($8N03T HEWCTW"Z2B +8![(^+6TE5]+P_XQ\]8N%:<HD;/<G1VT8W1'UUW,
MCHG=K8R$W^VZF_P0[07ZT8S1UN!=Q(?P:UM#+?>O=]LT_S+KYNFC8\WDKU0\
M03=J)"(G$,"(L*W6_\.&@;\,[?@?!^EO,5&P2S/%P"W"R*Z&\8:PRP9%LB2'
MMRXR\,IQZ])[*Z3MU9<6A%VJ[B:[A(]6)FC':5A:>F/_:=@@9#1N9+)</)JY
M&^O5*M2S)KVD3%-[(/[(P9QO,[?L U)5HE5_P>E1WXFWBJ[=!K->*9K#"[<G
M(HQ"(:R( 2%$//FW=6H-J _A4@1#KTD!WT4FQX+4:="\Z>#"A?U;W^X]N>/@
MIM-(MCR<K;J2K3)RA M K_QV4,',^S5-"/#L'$2A'>'D[DGQ^A^CM<=90/1O
MCCS4\\NX$/K^XT(I6I^B6S&]PC,RC]E%KNB*"C*S;<HT&?]B+7R"8P</JNU"
M<I=<1=_YO]]#^:-QMV.KD/'H<&(]#TK 2'H>_P+,.TNY5/&<%U]I@$\>/JK\
M6O_L<[C=SRXNYJAUQE9]4Y>8O=VDM]![\O*]?-#R)W:/@<"U;R[Q*-DX(QO;
M2U65^KQ'O!<G)=%ZW;7A_CD=Q2-/WFL?.7W$[F/4VQ!KE>VF4ZOW6Z.:_;<R
M%LO([=:I+2M!Q#A%(ZT4Z?O7>61-FGH"9-ICY!QN$WS:HE(S 4K]#LRPDQ:Y
M?&A"G$"62]-KJH$)SV7+I30,70PHL-39GFD>0GJ4XRH#?&Y/'BR#.(H["L(\
MJ8(X-5\CN$=P*>ANWQ<H<&%QZTM\[]C$2=YP7"!JN"3$O57B ]Z_N]X5$6L$
M[ULL]EF[.YLR:A_5M&?K)]5SN8!PY]I>U\>/RI\<_7#^!K=7?1&F@\DV5%(Q
MMU)^*],QX%+YX,KHDC!,=WF8C3\+-7K[PU0W=_P8<VA"N8R<6%Z5+4,>CTTH
M3Q+M(H8L%0SLT;U9?N-N[2?V$^Z/TJY?O_CIHS+'<S@G"_"X[T=R;X5'5S^@
M6<;F+3CQ#2R7K(D^K85[5]7'P[0>\"C (D\:7Y>BJH51+X'!^/F=\SL],]*K
M'XZ,9>_2HQZ^0]W@"U$\MM?1Y237)9(T;^+V#D\T@O$4S45NO="C3C?(JTCK
MO.<:5&!S\'W*48&ZINF0U._.3S^QM;5)?,B!6?S+.\L<JS)H)*6RWIW<V7>.
M8I6TO%2!V F^'J$BMK777'P7/_9]?(=<H>1BZ('Y@<':"Y3,5E-0+Q<L69W>
M'WRXI0P?W;>F/U5)$?C^1&0?%>LQH_RH7DO7\M;0B)$DXPF:8XKA?;1_+6OW
MDI^V03MM@<>H1R'D@E/D 7O.U7=RL;='JL.#B971TY#V=F[:H+[P\6YTFYG+
M8!L.V8:BO[?LOO'54G]N)$*3R36W<3BX47:WNG33B[G&-D6,1I9R/ZD=GN)N
M]3!Y5+;4D6'"B;'#/;D5\GO5[?^QO3!G%C-C<&;&\&0Y:8K[O5IQ<GNCE&!A
M2,A+E%6KW)$8VHEZ6XFLPS\G+^T-\%AZNI0LZN+T=>R(]YP'"_"&R54E9-@<
MQL>R@+>P)CAX#$M$JA70+4X8^:51Z_4P$$O^.22M>WUE@E"=2L1'N_3ZE*>3
MEU,""^WQE:/#C'C$'NF(9GK_F:M(?[5W 2D6VFAU<A2JD2D\"9[4]I\N?H*H
M;+Z#O-YRD%DE7>T_&&&D!W%!#\1]N];;=)WI<]-8@2;"7@J1''[_50\?WZ%T
M:EB 0=436JN\QJT$0>Y7KVHY:.;HR[%-$\*I32/4Z%<>UG*Z X:B85R$AU=2
M+E5&FG%])\]ZNQJKY$EPOR<MQA%DP6L3G9\[U6%S_E^_.F8=&QR_3A+Z>-/F
M_6-Q"5L]+5UBIYGV/?)LXXX.CE8BXX!NS/JZ1/S7%OY@R^TA0XF*5TZI]7^/
M0!C6GJ-=0(U.ZT42=O\(3:SQ+$;Y.8%!Q=Z5XNDC-SU_FLP\*'UTK/-GR/7B
MP2O_(YH!9?ZL2,XK]!/A.6?X;>$G9]Y;1K,DDY)/D)S5&Q^!?P\TW[5]D\"^
M&[7[4DT4_DZ5"GFI+_K4;"_,KX&X'@]Z[.QL8=/AC@MXTA@B01QQ1J%5% P%
M '0 <?A0!9HHHH **** (I,^8OIFOS&^'OP/\8?%SQ=XKU/PIX=CT_5+'XFW
M<K?$.;Q%+'):6\-PC26RV:GY_ERO/!W^U?IVRG=UQFLO1O"VE>'8[J/2=/MM
M,CNKA[J=+2%8Q+,^-\K =7; RQY.* /S0\97.B>%_BWK?CZ?4;#QMI__  GR
MH=2T_6[G2_%>D3M.D8LQ:R?)-;H6 VJOS)D\=1V4=E\*O%3?&;Q5\;O$][HW
MCS1?&%Q:V]Q;:I-#J.EV<;Q_8EL8%))# \;4;=DDU]Q7/P=\#7OC!/%D_@_0
M9O%*$,FM2:;"UXK 8!\TKNR/7-/U?X2^"_$7B6T\1:KX4T34O$-F%^S:M=Z=
M%)=0[?N[967<,=N>* .CTEE;3;5D>21#&I5YL[V&T8+9 ^;UXZU<ID2[5P3D
MT^@ HHHH **** /_V5!+ P04    " ";DUQ4<FHQ;2YM  !U<   %    '!L
M<G@M,C R,3$R,S%?9S@N:G!GG+AU7-/_^RX^1$1%0,'1"@(*,D(Z918E M+-
MI+L[)R)= M(QZ68@W=V=H[N[&6RP,]^?>G^^Y_P>C]\YK^VO[7G=S_NZK^L9
M]PLSB5D$//PH+B4.P,'! 7S!?@"8&<![ .ZM6W^^V.<V]HMW%P_O]FV\^_CX
M=^X^N/_@ <%] @)"(I*'A$2/B @('I(]?$3Z& @$/B FIR![3$'R&/CX3Q <
M7"SF-MX]/+Q[CPD)"!__7S^8)L"CNX!YG%-<''K K4<XN(]P,&T 6@  !P_G
MKP?PSP?G%C;'._AW[]TGP XH?PBXA8.+>^LV[I^LL?]Z8O\'W'Z$1_*,\^T=
M4GE=?'K;QUS>$:EW&=Z5- ,5A@\9N?7LOMV[3T9.04GU_ 43\TL6'EX^?@%!
MH?<?Q,0E)*4^*BHIJZBJJ6OH&Q@:&9N8FMD[.#HYN[BZ^7SW]?,/" R*C/H9
M'1,;%Y^0EIZ1F96=DYOWN[2LO**RJKJFI;6MO:.SJ[MG9'1L? (Q.36]M+RR
MNK:^L;FU?71\<GIV?H&\O/K#"P> B_.OY__(ZQ&6UZW;MW%OX__AA7/+^<^
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MB'YQDJ=YJP90-=FXO4]W?JO80]_"X1I[/Y!57TLAD' (-/1LQQ$.NG[+2*M
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M8L0WBU_$F:1\C=]2,QC$NP<6&W&HK=W3_!RA7UX:Q+#^J<^&SV=F(=,KEC:
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M5/9#6"#D]!D*!*.8@BY*!"?H0V<U4(V+L$0)4"NVHW ]48+A>&A2[9L4E&
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MT2]MDVU<KJ#FAP%\K.$QG<AD8O\Z\RF_:+J]<(:']-OCL%=NJJ]@1*<80&F
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M+K&1U(G_'[BXU!0"W1[FS4Q@RG4T^'T-U>%]2 U_)\W6DO=U7^5ZGI+6"Y<
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M(5U$/*K.N\RLZV[U=@D*F'<Q?QTW':'5?C.$AG4.#AZ DK]K3WC$C5T!S*\
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MD#F)J/:RM"[1Q.\#5I$KP:I?']R,3B=)C)$XUH169B44B3< >?R94N#-M.O
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M]4C@]HXE:C<6NM7S[+_%_5\:Q=74_P-02P,$%     @ FY-<5,D0;+,'H@
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MS8/#H^.3T[/SB\M[OY  *$C_H/_4+QR$7\BHJ"BHZ/=^(2&[W0O@H*)1LS_
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MA];C5T O.1=R); O\9()!#^CG<JH6",TZ@0P\;JT=/T.4/CS5Y"5?I';]!T
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M9+,=^,']V M](&D,%SS=/F@ADP:=FF"6C9Y[B5S],P_UTE>Y7[K7-79.B//
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MFMR'T&+A9?1S#Y<8BL?:E:7(>OD1_6#N((,1&X*/Q/^=:#51N(B0"C,X6DS
MECC?.F/WC)()7B0-7K 0,U5[NB(MH(88$DRI%8:X3CJ'9H3 -K^V2=##4!&Y
ML#?N'3,.DJUXD1?*)!7N'<-\[2)0UI8?X43/JR+,<8I ZYGX='AJJ-%#]XM+
MRS\>XTJK1VRQ3B?YFY@#YV>B>H"4WX6)MR)4=P#W.P!3RK_Q?X$U\P3NTPK[
MCGKDVGVBH,]21&%.7;L^A1D%>G%AN2!,W$U7!X-@ R'?M_WCY)N_%K/WMAE\
M _.R==/ES%8,)=D&1S;P)?(TB0!OD:8^K]ET&HVA")4OTE<)#P3'C;P9S:P
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M&7^L.&T:8LT>]AYY7)O(1Z?3.+/3[[K68#3&S9UPTMBZ)EEN&$9G1O_Z:]@
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M\JF]]\OB6<'3O4-C_)'>72(<MI0&8SR4UH(@>,G8#GFF<^V D3@Y\@AX-6:
MD)ITD=?GE$K>E(%,*"0/"G?MY1IU8P(V&4[TH\J7<R?/Y'?SFYZ5+KRO8B4Z
M6/[4R'^QK>UNB'=&;KM7]GCZ"06D"6T1E&3S,?0Y?L9C.P+TU$DI]=D)=KH
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M\ME_Z*>M7S\[E!0^MXY!Z;@=%<]#_-Y_K'NLG8@DOH07]BDN5HJ8]KL:^^D
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M7O]9?EC=R$>3G :<O1T?=JB\ J?BA$NS[CW&BHD'6,\<=J3?:#8BQ(*FU<?
ME:4Y%'XIA"$,^9L."^!X!XD<XER)U)RU6T#9AQ]#C;HPCB](VD\R(^R;493A
M 4*#_)O\0U@0S:.$5OO,/K]IE<;P8C"+FYO0]$L6:$9%,'VPU"/O-%UX^C22
M,/*1PG'.B<MUA5#DSZ"]92V%G%VFSH:AFIH:5:5WWCCWC/!)52*.L;Q."-5>
M<7\3@3-XS$WBLS(%ARO.W0+:ZB:BQ6"5;<;+D?2*45@0E]@OXBP_/GBNW5A%
M?\@'10KJCD8O-=8ND9T!Y\[*)&37ZWQ/^H_YBE/'>N@[5Z!N4F=J 1(=LXGT
M7H?P><[2H2!]/\PCV_0(XQ@]D!XY56S/XA!06A5VUCO=6LW]\.V"785H\H>J
MZ((R/GY^H3C/7!*P5M["["$\;&^'H\FYR)HY(7EM@#W\Y?,<1V:C.WMBI4H/
MX-D=5_LERH1@#*ZG]/Y<:.941'K,N;EG5NX*0- WYQ>91T.-]EEE6;78A^<%
M>+*U%9NEEAZ2W4DKS?;JG_<U0T!YX- OJ&6P.#H_U.08T;R_OBGHW&TY%!:/
MV ?'/*7+S<DM[41+B%$=!Y3:HHO53Q]^Y$*CQ[J(<U.1S;1XI'MVU8$62R;:
M](F*N=QNI)I2G[2+KD8,0)6^=I5\XOBE2]RI!XH(C[ 3%!_-'.5>JZD1R\17
MY#?>L58- VZDIJ;]K/O/7X/3_:YM_/62,[K3ELKG%0W!S>%<O_U"[?K0B^C^
MAME,%W:VW5=:O%RW  N,&0Y>!/QT4-W3=8.H5>*&WG?\-#>'GE529IAZQ._I
M-H5Y@%WU[L7$6I/X<\]P2[: ER\OO_?LZM(\@E'GI>5N)7HESC*8C.7660<E
MA6!3PX'I2M2.R;O<!+@#>1X"^JR[O=[!.@!7<EJN58BSDP>^M3[I@JOE^%Y-
M@][4-"9 I\7,K3\*P5768F6WU3_V&A7N$9Z5[[.S\]#B#EJ:%@VNS\USOU^V
M9; C7X:-3$D%KZ9)2P1=KH^5V7//0&3IZYHM12?78-5$<5@0(\NKEJIRC^".
M!L<I-@C06C"S/^%;74R!%&5.;_O9]K#NH<F18B;R_D1U+#>-[\+J4.2G:A;^
MS:CJM:_W*>91M[84AJ9&V[&@J^X>_<#<Q>;5G=A4PB%' ^Y/<(W2_2='\<.A
M!*'Z*IF1Z_4=?.0,_+-:/ <&C&-F4T) ][RY2K8J*1*=*[P'X%S3722!K;QX
M)85WCW6)Y4ZDK1,FP %3_!9@ LWZO$IBIO[)E."!CUC#F*OI&/<UMKW]2JAI
MPXF=*HF8-UJGR<F(NFYY%S.[CV">X?9YN'!W-E B=N!Y=\AN9%MJC&#461IT
M.)@BKZ(D#V)MG:._J"<1ZGKW'!KR'5\E^(S$Z>2[;HX(5O682]=87@*?>?HL
M]"%=3(W V[AG4=5CN28TY[GG\  V&I)HE<8QQD?CBNQ?JT,[0G.8T*WQ<2Z&
MO#1M+R+.@,WTFF.N"T_U*55)S3QX^\GU7P0$J4V =4OS$%R3;(CG6XDUYPW)
M"Z7KU<J%O$=<R#OI#M(DMD*4T$C30TZ$FK?Q^52U-4C;5OQXA"BN,]W)0= M
M:V)\1'C5L,./T;Q&P+O]QY2 'A^FIDW2O4A%4=T-\,J+:5=1LNV\)46F-PWC
M9@FOB0*7J4AW4R/\(%^=EX>)= VE.0+ YA1ZVWVFGIN%C#B9^GV[XRW,M4<B
MC?G4^/+ %%D&2%7"T)Z<(KG>IA-L*K 7\JB)-)T[?4YJK$3H698"V-OU3M+;
M.)^0D8?/AWKFZ@OSX8G< CCS::3V^PS-()8]OON]:P^QA7NHK>J.M$)=K/6?
MGW2XN[U2@]3RCDL[9K"J]_'WDF.8C^75''&4V+ZKF["G2U%+496?JU&6 !1U
MH%*V)76_0\?K[N% (2WWTJ6E[8:6A%FSKT;B'N'!=[71L.EGPMI\[[?0>:1H
M(J=;F\(5QO.NA4@3:@GP-P[VU/V]_2 3VA;NI"W<DSSN+ESZ711/HIMPWN.#
M6;NG?'B@^J+Z]9--1-X601>TEM7-6 -L B_I7PJE3]XKOFX@ %F)#*^<+SR]
M>#T!D9]K9I5%G^.<U3?[B.?3\O9QR)#W-,_R+>".Q:KAY&;RH2J]?/,<5E+!
M#PUU\P+V /BT^8HPNL;X1L-$DW0!;K/<">44W6OE@JTB@I-"%T/\/E/7,LI#
M#FT>X*<GF<,+_,M(EYML+2U<FW<>MP##4)OJE-(GRXM?(,P!DN8<T%L UZ7'
M6;& >51YY.!^5//7P7=@>SL[HT"JETEWT/U?##_)GD+2B"6[5HO@A\W))0AV
MUINWT<73G1Z._2KI(8(JV E+'7;.1I:X'\^F@#2JU=:[<P,>RK;QSV)!+<O-
M5NWACM[31&+PHMGHD*CXPNW1.<'V<<DUO9S!0/*.NTQ8NZH>:E#;GE!7Y@E+
MG 2B@^/-J!7JD3NI#>CQV_/XUIP=2P1"LN90:@'D376*=DF6AX1.MFGELZ9/
M$]=J-BWDUG'PRL5;@*HMQY2@YYN@G2YRLWHR>KQF3.?TO,(BW;!CS@&8M>WI
M^*N\SBNAAU]RZOED&'I?,DBG=?J1Y);"%Q%6SMM(RE&32<U90L:) 3IQBF^]
MN.GY,UHLHNVX\#-/(TCMJ.GXQI>!\^*0F?FGJW&\ 0&78=L03AQXHM)47L.1
M[WZJPY)4Q7R/2_Z%MQ3Z4\%K5:OXR8#%'1.+%KK62CAO;<TA77-=O8>Q9Y]9
M9-*PWI5&\5(0,&];S2I!X+R()\5CUAXBO!91^3PB1CFM[N5VV-0H@N")CY (
M]509J6Q2V@^8FU%G$ UB6K 8K@8URZ6=N074EFC.,L^*\J,#YUG(.LJX7NQ^
M4I#E%]&RE1B:36,*%C+G*'0T-Q5N/608#QSO)U E_QP!_@[6S?6&T6QP$KP"
M6^:$,B1X&J'I)+P<-R:,VQ/;I'ZA/.\AW:D\OZV;&+Q6554?-;#G[J"4(%:_
M\OE#W]J5:TDADL(CB!HH?\W3G>'K;LY6RJ#UH2E_L?-P%5Z_+<OJ7G=(+[<$
M;33P,!I7K1S3W=BP7C69&I4AL^]V(J,B/-1IH8?= D),C[KV'"P.WQ7/++91
MP3P[ LWUWE4%Q(@AK"Z"D32[ K:02H-YG:J>HI0-+O_BZ@)*,00KBLV'J- J
MSGKLY[PX5>(@1L+<R7N8+1U?!5#I0DX7=[%BV".\<[8T+2J?XU/^ $U.N16'
M;$,O9:U#9BI^6K.U<1?MPS."^S9$6Q6%87<3U@9=8M_+]*GW4<+&(T9=EVWM
M+A0G9ZW#7[<T@]RC+1DQ8@^&/+;<-0UJCRZZ=!/R75WB+!^*9-L5.K*W5_$T
MVN"\]LNF%RXL-UNL09;07(@?>PQK3C19DM=4>'++1SXNPS[QCWDYX#KD[<<S
MXN'>=0X#Y99,#5M;DR;75@C%);)]67LHRQ!!,1#PW>OF<S)(=UZG-C&O.7#9
M25KO05\/1*G81[BU]6@QU/CNA/*P619N+0941@D_^^AI[C5?)L>[1# QQT,@
M&5MUP=H$Q]=K^5<\_:\K>E+QJAX\]P66')6'VB)4LL-['PW$4G5Q@P)L'"=,
M'*RC8>4=H$B09NTDM[4O[X;V,NFA;0'0TUM: N=4--AK&T&XDG_4_>%<-K!R
MD#Z) :3=WYUS3BYT8\6T=\E)W:\W/;&UE17V_=O_[&W!_W:@_2OS4?]7]>X?
M?0>:\J%8[2Q"(*BEZ\=)H<BMPG6;(:YG!J5O+(W5@EVQ1I*GXG7&$KEILBR%
MA]%N 8%W'6\!X@&W +];P-5$ZU'F@>@6%_AP^A:@VWPX%(#TDKX%^.((;8EN
MYH O1LK*RZ'@E*/7QZ^/E.#*B;2GCT0O4!ECZ:\F3*2K2/]-Y,VO6'*QZ4_Z
M['])$&D-1=JW83$H8:)TWO^ET_E?.K^B=+*!#Y=^Z5S]3SISSQ!*)W[8_$\\
MI!',X=%7N+37%[> J5R4'))?<HS_D#-YL.A">S(F>KVELHD*5811R5Y+(*UA
MYRV ;SD@CBD0W!Y>=PO(1#VB6\$W5NX(YKGH*YR,WZ+*G4]^E0;'HA9 B6@!
M@LMMVIM3YBLDTV4K!E6L$+</01WM"?$MH-=EY4@*!3+X#Y#S0O\99/.?(!_0
M8AQ@(;H(;JYO ;MJP6V@#[> 9R]0$]V=\_FON8AI[Z*X.J-OKG-I,>U$MQC
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M:$O:1E<;@8>OY":2!]G*JDMQ<C<-)%:10?N[.$7MKY1I"^W=6!B6W%]/A?L
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MNLPX:&#+Z,,[S1H.ME96O=E=D6\%682U7V7!]P:0E6\SD_W;_VFNZS];U%3
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M2]EKT-ASAXV%*)3#@S<&Y5T;#4.=/N638NA:=MK9IX]CQ>6.AK/R,$QC[<A
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MDS=3"@\TR<NDD?Q43=\^_#6$YV#>?]X*;B*X5*GN0;2V7*+21F7;AM]#&T[
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M:LM<04)3+S7(R.9A%R^(503 </@'58A.K0F,0+0NWLJK':&3PRWC8!/.=QN
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M6>_B<_YT.-!?\F\+&/OU_P%02P,$%     @ FY-<5#VXI1/A#0$ YD@+ !4
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M/HC\[H$L;I[T(XJ_BD+90!\7]39CYG,6!I)BR(1F*9D0B(,0P0#). QH$(K
MFW7M_+.?W%BB&WV[9[="3BEO]4C5Q[N4]?=;7(%:8O!SM@!%]:M?[$APM-?
MC$TG-;7CT'*E#]0.,0ZZ2H..UH"^@.YUC>:@4OT*U,J#CO:@4A^42G_0 +!^
M5]2K4H/@CN+'GC:G:\5HPH^ZZ(P]);NKU^CC]UL&/PDU_L-RSC\^/N7+YTJR
MXC>A:786QSCTL(RA%W !D< )3*FGEB^,*$DXYC)D-O;UB;&F9ENO10591U:[
MI>44M&:K@2/ !B;P#59=,<$?M: .#6D#.)P2XZGQ1N4R \5WZ<?DEGZ,\8%D
M^5_)?"5^4T.L\OK)ZU_^KTSDZI$/+^^6CR1;S+B/:"2IA(QX'D2)[\,4<03C
M&%$O("%.$V+#(5:C3XU5M)R@$A2L)05DP<'GZ[_:<8O=))BQS6#0#LP_IU %
M?]3B.F2A7C YY24["49EJE[@[')7OX?T8[//HJQ=EMJ3-A.^AU% -3VE'*)0
M2)@FBJV$I\,;L$PBC&?E^GCK[">U]70K-CIR4N?:?SA7<MDQSS9@G"M0<(IA
M'$A%[X(G$".>PB2D"D)$0F%G(O8';"2'ZZ6 F5%Q;Q@&IEJ-0',Z]+,6[1=P
M799Y1E<EH7,!RJ7:F>=.3XH.(N&43;='&)4M#RJWRX:'+[)CNZ=Y_GWV=CE7
M/R_S>B.ZX)\RIK:EXOH^%Q7%?ER4XC[/%K>B$)I@[TA^+\KB^G&Y6I0SGO@!
MBQ("0Q0K:HQ3!DDB$61>2&4B*&8R-?G2+Q=E:K2PI4QE>,QK=0!I];D"6:,1
MR!N50%GK!$BEE!FG.)C'TP0T[NP,S%;;$Z,4 8TF8*T*:'4!K3*@T09<CSLO
MO(G3K.Z>R/QLR?2J']#9[^=/ER\Y[K"MUR?]O&K1\8-FR7$PPBCKDSLDVL7,
MX1/[V?DW3T*/N[BO'".W.L#Y1OZN!B\*4<XBEDAE]L?*/, )1%Z"81K&" 81
MDCB) V7V6YFQ)T>;VOJU%A;,M;2@BOZ&2PE7^@O4$EM:O*>Q-K. G2$X\!JS
M :\2] K<MNC]KM<9+:T[8]@(%*?&\>D11S66C93?-9[-;NI'*>^$%'DN^!WY
M7CVNV RF+/6W),]?Y#+71SIJG^P+XL4XA91$RGI&*5?[9)I"R6F*?(%CST<V
M!&,Q]M3H1N\AEQO*4>(*2WZQ =Z,;0:"<V#N::6N(C5KN:] AY!T;-B6[.Z8
MJ =@3GG)9OQ16:H',+N<U><1/0,L'Y_FRQ<A;L6\"M[)",WF69F)XNTJUWZ<
MF91)B@D6$&'D0\0" 8GP*?28]).$8A)'=B&6YT:<&EM=,Y:OU"?&NI$I>HM"
MQ4+(S-8T.H^X&6$YQ7%@FFIEA7DM+.A(>P4:>1V&6YI"XS;@\NRHXX9<FH*P
M%W1I?&,_RJE=F3I<O-KRM5F5U]^S8I80(?V Q3"2 8(H#A)(4J'V8PP))E(O
M2J/0AFQ.C#4UFFF<ZFM902NL';V<0M>,6!QA-C"E'(4+_*$E=7C::X"'4QXY
M-=ZH#&*@^"YWF-QBQQI%7LYN=<!<$S8E0TQI@#F, ZJV48%4VZC4$Y#Z012%
M3)(H]$T88N>Y4V,##6%6E!DC<] Y S?C@EW,3G_W%R Q\#=^! 2'$1U'=#_U
M/:M;.M^R^J_=[WCWF:-\LT<4:;_/8W_NF3@A[O4\W(JG9:XW)75:QF[RD$QY
MC"234*;J'RC1:[DG),0!CREGJ?J,K=9RHU$G]QW70EON$<P -EO.G<,V]$=?
MRPO6 H^3HF4%D]O@>Z.1QXV<MP%C+^S=ZF8[!N(B4\]GJSPK7]Y_9P^:TCZK
MEVD6(1EZA"/H44$ADKXR"[!@D%*,XHA0+(51;,*Q :;'*[6,H!42:"G-6.8H
MB*<)Q04T@W.'%2K&)'%.]0-\4 CVI_OE\Z_JUHH*_H'TC[#^L?K^CSYTE$_]
MG$KM5WWV.OL/^/VBK-);V#)_:HZ"JQW#6WW(F[^\77)==8,21"-%E@EG$"%E
M-Q ?^U F/F5I*B-.I.GW;##>U#[O6F2P)?-5O=E5,(-&<J!%-__F37 _3P&.
MT1S:\^@ 2"N:L("G-VN8C#$:B5@HW.44F]OZ[5*N.<_T8\G\"\GXQ\5;\I25
M9/YV^?BHQZK*1[ P2+!/((H3Q3*AET+LJW_$,O42Z@O,2&*S13D_Y-2(9B,Q
M>%(BPVP!6"VTW8[% &RS[8I;" =FEPYZ6EJ=5]S(>P5JB4$ELKMMBCD\3O<H
M!L..ND$QAV%W=V)QIYN2-3OE<FA1YH25,RJPQVD<0$X\Q3\L1C -"(4)]AB.
M>22"U,C L1MV:O2S7Y!EISX5^*,5_?A>_Y)I,#QK=0[NT&:/"UPO+G-S&J9!
MJ]T<&?I5B]Z<AN-<[9LS=X]< J<I1/!AF4N1E2OU[J[+G B/2T[2$-(XE75-
M+AK[&!)/AHGO,Y_)9*1J-\>E-/I67ZFPS;I:22/WJQ2W.3'!AG[G5YJT'Z9D
MS>XT:TTG59GF_$1,HPC-"3E_C'HSYX%V5EK&8"@7V15_$SK.6O#K9_7;>[5V
MZ?/:]H]W(G_T9U%$ B2C $8X5GMOWT>0Q)Q PDB@UH_8]V+>/^'BO !3,X5;
MB2&I109Y*W.3E*&$>*P6@A=!<MMUP'IZS$A^2- '9O"]M(U6>M"(#];RUU<
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MUY'&[;<0-2WUOI"\?+E3'T9!F'[T^YKEJN3USJ^+OV7E0_>6F20L3$6*]8F
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MJJG15E<IW;RMHU85(MI53)=16:L&-KKU3L=P,\]F)#CZ[ U,E6--G'UU,)=
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M5!VLR-^LRL_+\C]$^85D?"8B$421E%"(@$'$&(*$T!@2) B/?<5&TJJVD^G
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MK>!"/!(Z%V]UL>*\U.6PON2-'[X:2Y<.JBH'S6(>A](/,8P(Y1!YJ:=LQHC
M. IES$//2Q/S8C V(T_-&-S(#CK"@[7TH!+?(DK#:AI.<\^@X Y,0F:X@C],
MJEE="+)%?,M08(\4M-(!G75 ?UJ#7BVJKJ).^H!U,I3$ZH'CQ8?TT7,KZ*/7
M _HW)5SFA\O"WBW?Z#1(H?LCSE))/1)' 8Q#RB"*.8)I@'R8BE2$8< IBK&5
MT6DX\$2-SPLJ/!M#;FAH#@#D",[097[ &=K*W;0?;$5WVW;0!BSGW0:-!A^]
MR: -)(=Z"UK=/WSWU ]JO!G%DD54^% &J2*LJG8,]U/%7V$B L1#+M!0S5.U
M %,S7-5+&0_7.[6"W)RPA@)R J<X>YU3M0ZOTSBUB]ZK]4VMA)ALV]0N1)=T
M3=UZSD -%8LSL;[OOXN<9858A_O^363W#Z7@U\J&)/>B_?N7/&-BY@D4!@F2
MT$_TCCYF.@4:48C3B%(1>SR)K2IJC2O^U-BUE16"1EK0B@LJ>74L?YWX<;7^
M"Z_ZXO'E?$[RHKJ@2@YPW2+/[6MCQO'3?1D&7B%,FN459[KEK?OAK4'0H<TU
M#%>@!>+(BS9BR[Q!YG#<OGEN59A6\[Q!IL>Z@]XP4ERRA_A4!YX7+,^>ZMI.
M=*Z60[4*JCT!ASY-=+M8G$*"@AA*B:1,98HC9-66YL184UN[6JNVL64[XH(_
M*H$M8\)/P6RS1;@8O)%V SUPZVGVGT1D  O_\'BO8,R?5/RPW7[ZEF&.YM>Q
MC!@Q*DB00$[]$*(0,4@3IGX*/*%^Y4N66J6^F0X\.6IYI4-ZRZ#2(>!]E4/[
M0<)&;=$9]1S_=<)%;2&Q/==W%":ZSO>]5HS85DZZ6U;_#NZ4C59(->3UXW*U
M4)SE<<ZBR(=)E""($.,P]6(?DE0*3V)*TK!?832#P:?&6VOQ=-P[J>0'5)3?
M=..*MBB8_NKJGX.>%=5,9L6,P(;">F 2Z]9<JR7?U%PKERVZ8*V NJI288 Z
M;!; #5.8S42 UZG49@'-T=)M-L_HV2X@7S(A>*%#,S\6Q8HH)3\N%,62^9<5
MG6?L1E?4SA;W,X%"C@EFD(DTU!U! DB%]& L>(IYXJ>IG7%F//+46*X5O*G;
MUHBN*8\M'Q_5-J:N,K1Z4C]FM4+@J=)(75.K= 46HM1WK.]FR\+V1-Q\ZLS8
M<) )&9@*M^>BE1HT8H-:;M *[K C@BU6;MLE&(\^;B\%6U#V&BU8/Z!' *>N
M=BWTUO9&?GU8YN6=R!_KFG!USW!/4IPFJ:?#-0.($AS"-(TYC!*2!E1Z01"2
MV4+<Z]R5TTQG,IS1MX3K;ZD[Z'"?U%I@G;%3:)'K@BO91FB+$,)S:)^F)F<(
MCL-&&^AN)*AD!5I8\'$0Z"P"+AU".%*,9><ME$?>0E<!EH;@G(RI//>,\<(H
M#;79BIPTO<=5V2LUGC9==89GY=[FW)<1"A$4NKPEPHC!E L!18#2*$H2G_+H
MLI)7.R-.S:1LQ=.QD5J^2RM:[0)L9@ ZA6U@JCU2R6H-Y)<S0#JH8G4$G($K
M6.V.^LK5JXZ <+YRU;$;^W%,6PBC<W)QO>!O2)$5-_*+>O':%6N3KT 3&F&6
M,A@AED(4$ QQG"CFB:5,F)]XL6>5Q6TOPM18Z":_)XOLOYH"G%6?],W9G%J&
M[2K:7# U9G0U+. #\U<K_!;&&O-*?HUV5P.S!!YK3NN/H%.2ZR'&J*S7'Z9=
M&KS@23W[#9)\H?;+Q1>15_$DFV_,CU@<^;[:UW*N<Z)Q!-,D#&%$(IVT(@B*
M?*N.@L=&FAK+Z7X GY;JR_O2QA:"Z[+,,[HJJY2N<JE#T+0?KWO 9-E.\"CL
M9M3F!,R!&:R5L8/C,"QU%@RWO?R.CC9NM[YS2N_UXSM[0P]?V:>,Z8YPU_>Y
MJ,/2.NF>G*+$CRBD7AQ!Y/L)3'$001E2/^1^*CVSR*\SXTR-/6[%?16+JA;H
M\D& WQ?9LQI5QQ"HW[PE\TPNU3P0T&@$UBJ!G_7U.GHC\/[E][>;/U2_\O_%
M,'[YW+08^-/<@#TPN^SA5_1-8C[U#IM[T-R -I+S[$Z]:6J43%$RWY1=52_H
MO$&5K-5PY40[C\])_]F)V\=SG9W78<MK9G#YA>48WS<-.==Q68A(GTO?@T&2
M**,M$AQBFDH8X93B-,:^0'&OVHN[(TV-=C>I8VV3TKXU%?<P-;/(G" U,&=N
M0&J%'+8>XC$HABE^N#?:ZU0Z/*;TT;*&1V_H6V+YXT)]<563./&.E*1MFTMC
MEJ110B'!U(,H92%,11+!,/5#PM6? F+$#><&FAHU-!6&.\("+>W9!KEVZ)YF
M"9>8#;UMZPE7C]+,I[&XL$;SD8>/7*SYM(K[59O/7-]CBZ8SA&YU=A#5L0%-
M^&.2"AQ[ 88DQ@PBQAG$$44PD0$-6, H]8VR^(^.,#42T#(VO6(J*0$Y'?%H
MB*/!;NI2=(;V,]<E/'6:9 W,F5!00V L=DZ7 C32GNG(&^1J?W0*A9,[HX,W
MCK<G.B7WUF[HY(4]>.TW4JI-Z\?%S4+<+>^^+76Y@*)M1DX\XM/8AYPCK+9!
M40139?U &4C!,<)I%)F7U3LQT-18KA95GW-7@=Y!52_9)J3H%*@&7.<(JH$I
MKT'IXP(H.<'=$BA)JYHBQ?F.Y':06;"@(^A&(L/-B[9<5"<BI8*P>ME<\:$!
M'B=I\=3]X[&C@19;)&ER?3^?T:U0N\N,*>K5/8^O%]6_=%;4,YEKW]3AWS;O
M,2$\\'#$8)@@#I&(E>&H&!9ZDGA"A+X7"ZNSP$N$F1KG5JW#]<%\]4-'7#O_
MTT7S8^:B&@OU@>G[*.#@CW?+1Y(M'+JR7$#FU-MUD4"C.L1<0+?K,W/RS)YE
MI/19O\XY$/S=2J<8U&4UJBRLZF\[A3>X)DWD2ZQFD<=$E[[P8!I&%*8\C!27
M"IP&=I6@;"68&E/6\@'1EB:Q+,AD/0%FK#@HK -385V\N18>U-*O"QHU^9_U
M)6T']+42#NL9]<7/;4DB:RG&K2K4%Z2]PD"]'V1'>T5>SG[+%MGCZK&Q,404
M>6&@ \ \$D'$,89I$ J8\!"E'N51G H3.MM[\M1HJA'.C)WV<3K-.A=I/_2^
MN);K_";8F"..:GOJVU<W=;Y[]5^[W_S^4T?YEH\JTWZCQR^XL-.R[I"CJ_U6
MJ1J"Q'&0"%TQG F($A1 C)" 08*PX$&*4FQE5AP<96K?I.XBQ7+!LQ+D:R%[
MME3>0M/,1K@8HX&_W$T;95& C817[@[MC) 8IH'RUDBOTSKYD+)'FR8?O'CX
MZMQWWY8S3*7Z/\(@\:0NSNTGD'#M!O>3Q!>18"&SX@;+\:?&&NK-"H>KS:T!
M-Z./ 6$<F%AZ5>96*KQ.8>X.=J]6EUO+,-FRW!V +JG*W7W,L/U1*G^X$J"J
M,KB)RPU3'G@42QA6U?]B'L+4#U,8QAY.A2\PQE9ACI>),S7:^\H>!%_-JX#>
M#ZOJH*8U[2O-UOU AFFP<F3.S*ERG)D8@3E/-6/9Z<5R!3YD!2/SFD%;[9J"
MIV"0M!DW4+]**Y<C(DVRP<MI^/JV?3GSU'ZL_*YIA:6,V+JPF/JA_5T3I7I3
M/HA\EN(H1![ET$-Z#XKB")*84QA('XDXY,(C5J6^3 >>&M-60MFQJ#'&9GPY
M!'(#,V,K7M4:NBU/J']>_Z$17)'G27RM&<\6+*?<9CSXJ"QF"\DN7UG?W[-\
M YGK6E]?'X0H/^EYSI:+^K!W%@G./.(E, W43A<Q90:F.O0K#3T9!ESRQ$^L
MRC0<'6IJ[--("BI102NK9?&%X\":$9 ;N :FG,-(#1 O<!X-MX41C@\W;@&$
MLVKO%3HX?T>/F-"6>=HR@&]UT<R]4C+7"ZX+6JT$[]2+GB%)?![0%,9<1A!%
M/H'$"P/H<P_Y/&$,6<2,7B#(U%AFO2JWM4GK4J0Z]H_L5*6JHG)(K5&WD;Q%
M-.4E,WB:L,:<E[$LJ%8-4.FA(UIWZUL!I0MHE &?1I\2BP#8D:9FI !9!U^-
MJTA:!\">C+2]Y/GC1>(Z0&$K4M?%\_H>"W,A==UH\4E[ CZJ=WEQKUM9UP;X
MFY??R'\N\[=S4A37W[-B)D,2,2003!(_A<@/,<2)\)0Y$0248<]/ FIW8&PU
M_M36LXWX<*[E!QL%FMVH[;FRW728GC@/!O+@9]'G\ 5_:)$=6MT]P7)\7&TG
MP\@'V;T VC_B[O>8GE4NM-] M[_+Q8-8%&K$^HA=U^;Z+,H;>4>^?UGF58VT
M3GVNN^47DE=Y9DW]!M_WDY!Q#)F'E&$?T!@2% 6*"4D:R33PN%U? D=R38T7
M*[5TAX*-7F"N5+*MH^%HULQH\A7F8F#ZK*=A2R70A/?\K+7ZY0I\KEM#*-6N
M0*/<7H6Z6K]ARGNXQ=QM,1!'LHU;.L0MH'N%1AP_OA^;_[[(!5O>+[+_JIS%
M;\1"+26ZFT(:B82IF924<(B2((24I2GD*(F\5*(84SQ[JH*<OY8D+\TX^LAH
M-M_Y[IC#??+_FRQ6)'\!OAW3'D,T]D2(8EVS,\!".\09)$3!&O$@%ARG/HVB
M!M'WBS,=*ISCV8XXY,Z;5<&W('2$I]E*Y "A@5>6KH35>5LKH[NEX0P(3JG^
MV%BC4O<9A7>I^-SE%\:)7Z_*AZ6."FA.<*3T(\]C#+(@D8H.> BQB!(8!!'6
MM>"BF%DU7SXVT-1,V4TX-%A+VC-8?!=2T]W[Y4 -ODW?QVB  [%S2 P3,KX[
MV.M$C1]1^6C@^+'K'07S_"57!M],!!P)G;P52^T-3%.J=L.,0R*25*0(,Y]%
MLW)9DKD9)QP>QHH1UH,-][;?Z3$ ;YWRI7KK20]?WQ%,S4CA<J3&.E;J!N94
M0@X8@K,%PK !-_50KQM>LZ7NV6":[:O[UH.LJ]57V:%5Y>_B9E46)5EPW?K1
M1ZENINY#*@F!B*0!Q#%E4.>812F+?)$8A<^8#3<U2Z$I=MBMYW]5UZHO0$=L
M\'.F6]WI7QN6X39$_S1SN,=T8 8QA--E#4D39"ZL)'ERB)'K29JHNU]5TNBN
MOO1RS;EZ8O&U)*6XR;_DR^=,*3.+0HS](!4P#DD 4<P\2#PO@+XD841"C")I
M5#/HW$ 3I91&6%V 08FK( 6MP+8$<@1?4^JX'+5Q2*,'8#WHXC0:%Q+%D8>/
M3!&G5=PGAS/7#YO@]5E\+^^^B?FS^&VY*!^*&?,52= @ADD0J?V)9 *FG"%(
M"..II&'@$ZM28WT%F1JMJ!<N&"9?:V\*S+8S8P [,/-8YVA5R5DW"X==(R]%
M\572K_:$F63BU3'(^J9<'7U>3X;<!(0U51K69]]$A"(0GJ(_Q)3IQ),$DL@C
M4! NDC".J-J967'@T:&FQG*->/;!PP:H&M*:$ZR&)JZ-D.L:'X.<]9]'PRT!
M'1]N7(HYJ_8>B9R_H^>Y^=>_+)]%OM!T]':9/RWS*G*YT)&E]V+!U(!?!=.Y
MH.JGI@15A#W?]QF&PHLP1+YB$ARD$90IC4C,U,XKE3;\T4.&J1'+[W_Z^B=P
MO]8"$"WW"RC68@-E],Y77'!0N7H.]9.W/$[N,7&&1\W#3L?0Q]!?P49\T)6_
M"H1O-0 ;%1P6)', H=M#[!YRC'O W1^HO</O"Q[EOF;K9_&M^HO:<:8^QSRF
M, DQ@2A5AE;JDQ F@O@!1A$1DKNJT[H>=6K\J*6J4B274L> :O=M454.73VI
M'W7,;T;FX&E%YQE;Y[3\^I1GS]I9\S173WT\56CL@ODQ(T7GJ ],@P:E6Y78
M]04.S]^L8!JM0NMFY,E49=T#PZ82Z_[-/9)9?U^H"[\I.A3K?A)Q$ <)"1CT
MF.!J8QB$$'/B01IR2D(J6,J,J.K(\Z=&2ET)+1(6#P!WFD,<P#&TT=01KD^3
MD@.06*1F7@;-2!F772%=I4X>5_QD1N2!V\9+=#PN\U;^XHG+>D<AYMIU]D[4
M__ZX.%),;B8#S$@<$^B)B$$4I,K@B@B#-(V#,$XD88F5P64\\M3X;>-WGE=U
MV7I[O<RQ-S.F!D%T8(IL908_MU+_HK?R.[[]3>%*IS&.=FBY#GHT''WL*$@[
M4 Z$15H^H!]O_44LU&/G>A?*']5&1WOM=/O-IGK13'AQXL=2PC"F2&T/(PRQ
MLKP4;R')6.!)+XYF"W&ON]J9\=69$8V^*5Q_4]UQA_NT&H'K0@5;(MO1U#FH
MS<C)!7SC4%(7MVU9VQ)G[DC($!6GU'-NS%$)QQ" 79HQO:VG!TI'6^G.EUPG
MX*D'5D;P=9ZKUZ1RF+QYV5S2'#I>?R,YWV[CH?/Q_B:R^P?=.?-9R7LOV@8?
M7_*,B1FC)$$1$I"$OMH8,JF+%]%8,95/TCCQ))-6)X8CR3TU@ZR5%8)&VG7#
M'%#)"]0*5,<S7H&.BE5X*%_.Y[J%I+ZD"A4UC!0=^U4Q=*=-[P48VB&GU8%4
MZP.Z.H..TH"^@.YU;9Q(I?E5VV5IZ]VX JW^1]XIA[Z]<>?,K7=P)-G']2^.
M.R%['LJ1A^^9IY05;+XL5KFXD5TY;\5<F[957:4],8M-77$<8<Z12"#!'M>U
MX"-(/1+#.! H4?\_C7RK@,$+Y9G:DE:YJ>&;/5JS3'RZ<)+,%IT1H1]Q,5DO
M$IUUY(]!*KH[PL]M%M:%,HV;KN4&P+V\+D>/O:2)4.4S*;XLYQE[V7R7B'L$
MTY"J?4/D*?+T(HA%G$ AD]A+)8L9L7+%GAAK:L18"UGMS6_U)WEN1VZ-K1GG
M.4)L8#YK^P UH/U12SI<7XHSB S0W>?P>*_0R>>DXH>[]IR^I1]K-(4L];FV
M?FXFBG4@;4(CP2E.(8U] 1&G'L0AYY![:9H$G,4!03:D<7RHJ7'&1E+0BFH2
M=FL+L!ESN(%M8.+HB9@U:9P'PREGG!AN5,HXK_8N8QC<<8&KDY[?;=(CN\U.
M2NK.;O-6Z'(858W=127IBLSO1/X8S"(68C5#!(8H0! %NK0M2@+HHT F/$FP
M%Q)KM^>X.DR-XO9=H&O104=VH(6O_)XZ)TI7)33)[Y[,BV/A!)WNZ_ #.40[
M2!QPB!Y_PQP[1U]G+MT[2D?68WRGZ>M,U$$'ZBN)TF\1;GT'-W(=GJJCNBL/
MPXQBDGA";?&%1,IN)TFD+7BDEDP2! 'E.$2^723#J>&F%\;0DM-2;BI!;;=G
ML%NX3H)MML)<#. X2T$KIH9N$[A>Y0N\/8F;-4V; .*43T\.."KQF:B^RU!&
M]SA-GJGKQVRR,VC J28/*&+FUR9XZI$$ADG,/,_S8TRMJJN;#3LUJ]E1^HQ]
MG2G+V3*T>YW/P="FZHEDFEKJ4;-IC@ U1CK-[M!3R*<Y H=A0LVQN_NQVN>5
M#G6_D;?B:9E7=<Z_BON*0F=A&E-!(@&E)$R;1[YV:U(8$8EPA/T0I58'R<>'
MFAI[U9)J[LK7LH*B$=:.AT[@:\8];E ;F&\V@&W$!%_/ 69-+^>Q<$HI)X8;
ME4;.J[U+'09W#%O&ZH-ZM2I'V(QSA#"G$90QBR%""56;K,2#7"+B^\SCB6=U
M.&(MP=3(1;ULT3"%JS:@FQ^U#@;E" >P]J6JM";CUZK:P^]5BE1MI)AD=:H]
MD/J6I=I_4(]<8V5J,9VB>2\TB3Z+Q4I4GBG=#$;P-R]-I,H7DI<OLY1RDJ1"
M*':3$B(12$@C'D(>X"CP:)3XR(CBK$>>&K5M9*]MITIZM?];BZ_=XWFM 'C2
M&EBD[%I-R6D"'!3HH5U/&XQOM+E58]R1'+QY 8WLX,N0&%LD3 ^%]4BIU/;O
MM:N$ZS[ G4S%MGK@>$G:??3<2M_N]8 >"\.=>-2%>O*7]_]89>7+J:(7:OQG
M1;KJS=11COKG,JLL\;:FSXQ[7J2,XQ!Z1/IJX="U775=:.K%-/*D'Y' Z+C>
MN6136U@V E<>=Z6)*,#U%7AS!=[J[[#5 #SE[4%&[6Y45F#7_6A!A4XGVF Y
M>JWI&WBY6JL%:KW <==D7>8'=.9:+7 =_3H5T%YK'BV6O->:SY&6Q,V\BGI>
MZ^\MJ^>5U_-:M[@#S]6\LJUON/O1%N?GU6[5' +[DZNJTP''6W6'P&EK51YD
M@)[=DX\4 $F"((UHJ+MLZG0IZF&(&8IA0*,H9A&F";?*%/Y!2JW4#:"6K@JN
M7%9>9?K%5/;<3 .431FS2,HD2J)8%D!Q6^Y$]WMXUZR5=SE9%%F=@:0=YC/J
MH2CARAPG,4<0R3B *8M3*#FAH9\P+".C@L&G!ID:([1R@HV@S6F.>8.6HX">
MY@%7, U, CT0LNK(<@Z"WMU8CCYXM$XLYU3K=F$Y>VW/4,!V:UA9(>^RYXR+
M!=?5=JN&X-?\/U=-7>M9["4$8\P@BIB$B'D4I@E+H,\"/PZC-/!#T08&WIF;
M!N82&+WTV[&"=R-0A';!_QD0QG)1O?QJ=ZVT439>]5^UF:_S!WFK&E"_UE>(
MQ^I$^,A.O0IHL PU-)],,Q/$\=R,Y M>8UCOJM=B5[-0"0XZDCN,2K1&RVV,
MHOGPXT8L6L.R%[]H_X1^;/C^\6F^?!%J?Y4_9TP<+HWQ>5D5^Q>\"N(NJCU#
M]^\ZK/+SLOP/4=ZNVWC76[H/R[SYE;[.GZ4I)\(G&/HIBM0N2R*8>FD"@YA+
MRK@O(]^J \.XXD_-5-OJ7,^ZJ2BB3MJ^ M_:G!+2Y)34OA@[EAWY)3%CZNE.
M_<!L?Z:&QA58*]VF&VDMU6]+\")*L%'TJG6XRF4..LJZ6Q]>9XZ<KC$CJS#J
M.O4ZT[.[UKV2%(,=^NUE L0)$EX80T9T>52:8$ABXD$4XB#BF,K$,R].WTN$
MJ:U;W:R YA#O;7=_L'-Z=P46HLI.RMK[JJ0D^Z2 "R;1V<G==),%;([HFM[5
M!KD#KB; ^9';!1,QP;.U^CM0'\JW^N_.2OU?!*:#P[)72=RX7/,>QU]N$SIZ
M%SFL9?RX*,I\5>?0Z1WGW0-9--F[ZZ5X)W?W+^K1Y3M2B@\DRZNSO)F/PDCB
M4,*4Z#):@4PA]F0 "<$\E,@3H<]G]1O\M21Y:;;IFX)J-G2QJ^!PC+$N4M%6
M$*@$!UIR()7HM6]NJ^Q Y2):-6I? 2KNLT55<H"2>;76OFH-7Y<O8Q1%2>@A
M'P:))!!)'T,:!PP&-)8LY#B):-J\C.\7AHG>4U#,_E5LU9ORBRCJ7_ZW>PO-
MG!M3$'5"IJF#DBN-3=M!IG&,EPJ;34&6-3P'RK%TWF$-4AVG-H$RU0/,^31J
M6+M4[,<H<#W 5#JK?CV$;#V<,-?L(1//E:0W\D.6%^47I8'ZKW?+0JT8OV5S
M)<-R(9IV;BSQ""5I##TOB2%*PA"FW$M@BEF$ T2B0#)C[XO=V%-SNW2DU]Z4
M2G[0* !J#<!:!8L-O>6,&+A2AL-YX(6J"_'-.8C[-"RTQ-K":S(<YB.Y2W9>
M;UEA_]1@SVOL'ULM7+E'^J%VTB]B^<CQ'"+]=-WRA/1\1*]E@N4KP6]%(=2-
M#]<+_DX-/%\^Z;&;FM;%VU6>J_^<)5'B>PGC4 12+1*4!)!23VT2(RQC25/B
M!['%(F$^\O26B$IVD#?"UV$\&_';@V4;?Z_53!@M#L/@._C24$/;R@V4X* C
M>5MH76U"&N&'PMAJ41@&Z]&6!,/7^0JP,YC;+@OVN)U9%"P>..:28*_GSH+0
MXP']/.)J0Y,5-W*GT//+7NL'Z0D6AQ@2'^E#6NE#$E(/JDU$&*0IIU%LM&&P
M&W9J"T$EM3:CONAOI_E0[=QMAGB;.<3<HS@PW:\!W(A\!9KV$(.VB;!#RJFC
MQW#H45TQ=G#L.DLL[^Y'3&^7CX]9'<VI^$^GJZN!Q$+7H-?%UPA/?0R3($HA
M(BR")/ P1#@(XY#$:>I9%5\[,=;4**@C:K5NLZZP=E1T"F$S_G&$V\"DLPO9
M6R/(K"G&  RGO')JO%')Q$#Q708QN>62_E7;V7"=UG)1B$(6$JP,ET!"E*(4
M4NE[4/KJ_U'BIR3"]BVLC@TW-?*HQ>O3M.HHH&9$X0ZF@;FB;5VUD]):#-2#
MSPR7 1I8'1WR%7I8G5/_<!NKLW?U[F2U>EQ5Y7"JDQQ]')2+![7CRI[%QP5;
M/HI/RZ+X+,H;>4>^SV1( X^P&$K"E &"J-H8!=S7R7%12'DHU']8MK>R&7]J
M#-,1'RRKDV3650#,E>S6G:^L)L2,D :$>7B/V1KA^JQ^2W90"P]^UN+_H@M9
M5WY_I8/3]EE]P'/=4\M*AK$;;?4!Z$#WK5Z/L<_U?Z\,L/+E_:/([Q6C_B5?
M?BL?]&AD\3)+*&6<A@C*,-2\)@G$**:081VC[^' ,SLK/C/.U)BL%A6TLH):
M6-!(:Y[U?PK:TUSE$+"!.:DG5E;Y_P9(]"X!<.K9HU4!,%"P6PC Y/*>)I R
MK\KBZW+.?U^HNZ[O<R&:0K*WXDF],P_*X/J-E+KTT$L=I?UNJ3L4S9*8Q2B)
M)8Q0$NE4GA 2EF"88"981'T4"*O=56])ID8F&VG!1HG*&?$U>\SF)*^K9A#6
M!-RU.C69);8F4^\)-#2>QIB6@2GKTAD!?]0JN>Q*>BFL;@VLWM*,:VI="MJ>
MT77Q _O'9;1'>VU%@T^;BF--Z%(@&?6E%T+J8P)1$DB(<:!C,M(@8:$7QDS8
MQF2<'75J;-H>8+>"=PIZ?+*MT68'_VE^' S4X;>4VWA>'\*S7V">(;#VT1=.
M 1XY\D)T7]S:3=(I+N@N"L\.*)-0B_,/&SW,PEB_0R$6YC?WLZ5O15'F&2N;
MFC7-VTX\#T<TP#"65+?!B_0IA*0P8CA,F8^E'R4V=O+!4:;&VK^W]3?RM;2]
MJEL=AM3,<KT8J,&MTC4T=9[Y6<ZUMC)/0N#4@CP\TJC6X4EE=RV_TQ?;.]4^
M,IE?KWBFYN.Z+-7#J]7EPYS<S]*$AY)@"GV. HBP;D7O(00C&@9^S"D7Q*CZ
MQ>EAIL8 ']]^N 6-J* C*]#"FGO43N!ZWJ'F!JV!:: ?4%;NM/,X]/:FG7CT
M:,ZT\^IU?6D&5_?8U+T1<IF+_TT6*Y*_^('GI\U:)2B/:2 1%$Q(B$B:0N)%
M 0PP9P23%,O0J ONR5&F]O'7<H)&4.!? 2VKQ5[B*)P&FS(7( W\S6_C4\G8
M9\=U%"6+'98+M$;:4>V]55I:5QNH<SB<W# =O7F\#=(Y^;<V1&<O[EEQA3T(
MOIJ+&WDX?[8RM9I469T%6^?=%L6JKIM;W.G:5YTX])0Q/U+F9N('%"+AQ9 @
M3/Y_[MZTN7$<2Q?^*XQ[(^961QAS21 D@9E/SJW?O)&5=F1E]<1$?5!@=6I:
MEMRB[$K/KW\!+A*U40 %T.R9I=+I)(%S'A /#H"S@((A N."Q2R+G0J(>Q5O
M:IS[V_/CHYD6*Q6]6U#^=Z#5U7V7361_=*_-W2KX<B7TT&U6T<=R,W\TH?R5
MWJ=R"S0;YBH[8KU%:=JJ4] YYI[P^W'8[0'?;L@#KR"M8E4"N?,Y'[JC5MY$
M6Q6CCH[1'Y6687SQPPR W^0,?D4<-\U"$'B/$B:$Z67@C?5R,Q?SQ?-F_M*I
MB?-5SY7F7C/+TDRA- 9Q;C(LPS@%1&0,9''.L4H*1I";E]Z%#J>V$'3E[50*
MNXF,R(Z7RY>PMKQ#]HA@Z.N1/O!"W -;0N/WNO=2I^/>ZEI"<'1Y:_N>&\^4
MZ\WL[L^EGJ@_YD^W/^?E+,,TY1D3 "N]CT>$FP,\C$"6\31'7+&L8#:$<M3R
MU)AC*YP=2QPCU4\'5^D?>-YOY8K^,))YF.%GM>V;ROJESC36?SN<PL>MCC)7
MSRK33LKS#[B?I7^1#W11N[Q57Q5B<8ID2D&:%@E *52 9D6A5W4N12KU_\?0
M]@#]H.VIS<!*O*B6S_Z0_!"PRR?C5\ 0>")V$? V%WM4'GSR?=C>:,?=9Q3I
MGG&?>\1]+C8GY695G<680<)3#(A*]#HH80Q8@B107"$"LX06/+.=AYUVIS8'
MV[L8>W/Y$*C+\V^@^J&-7QO-G2;="3T'3[AN6Z--MA,*="?:J7]VGV3O5R]R
M?<O*S9KRS0P62HHD%4#;G!"@!*4 YU*"3(D$H3RE*;-R&#EJ>6H3K1).<WPC
MGN7-QS%@EZ?;8!@"3SAK!)PFW4EM!T^[_=9&FW@GE>A.O=,/#+BZ_3+GYI2[
MX_QKCJMFF(@L0WJU4QG2JYW9\%'*F9Z&*LE1SK-,6,4W]/0QM0G92-EUDJ_/
MAETN)<_ V3])/8$4VC8-B(_#E>WU.(UT8=OB1;>2^KJM[8>@]Z[VS*OCW=3V
MR[YW3WOAT8&WM'K8J];>+VA9WJGJ]+[:-W)6<$:5 ()! 1 E'-"<,0"E3!&G
MN<B(U4'7Q9ZF1GR5?-55FI'0\5[S+)QVA^->0 IMI^SAXVU;;@V!W_N^L[V-
M>W5W2>FC6[B++PSC@P]-J;'O]&<=#Z5_:'_7> "8Y(3KE\ISOO*EIXNR\:GO
M^-#/DCA/"JPQYT5& ,I8 K!,4B#,_R 4DY@[7;SY$FQJ;',8&>+&-]Z&RXZ>
MWF(0 K-9*[Y)E!'52MU4/V__X6-;/+95K0K>:96[B=H1M(E <V9#WXA[)4]O
MPHW*M;XA/:1F[^T/3*-(2Y,_UOQA2E6\T(6Q&8_2NV:$)P@1@)6Q\ABB ,,8
M 1;35) XI82Z)52TZ75J'&RDK1,$FA\Z<CNF5;1"W(YIO>,8VB@\!^$X65Z=
MX/*;C-&JYW'3,KJ <92@T>GE8=1T4 #RW6O7B*U/0"!3*!$B T2@PNP^%2!,
M<!"KG.M=*$EPCEUXZ7*74R.EP_JS-Z:BU^'>R^7 R0%].X[RBVE@@O(!IS,M
MV2/DE9,LNAV5D.QA.&0CAS<'4I%^[4YURGU5AS5YGJ69E (H%6< %2@!!%$&
M.$28\CQ%@EDYF?3V,C7">6_J2;*5R:WY(O=*"5;[G<[?.Y4"]UYRY*&3T%M2
MS[6 !K_+NQ9+[^=JO9#YI9^3/8W+.'W*'I%,[\/^LE&W>[O7WY=B7E8I],V.
MD.M';Q_-WV8ID41EE ")& >((*9Y1^_&8I04!&(H<HBN35)]48JI\9)1XM_:
MPAMUI=RHE?SZC-:7!\6.D8)#'?HZ\W3^ZYOML9:VF+IJ1+4>4:U(V,38UC@&
MSY=]69(W3Z-M#99-=FW[QH8?4AUL-?7F\[<?J_7FNUP_?JXRQ]35 K8>48)I
M-D02:#*4  F$ "XR";)<,H*%PGGBQ)'N(DR-((WT-R<.7JJ<AD8/H*5XC#J:
M./M973%>]N==X49AA,,O_P,PZ!!L&(;>3\0<Q1C]>&P83*?.R@:V-, U[??W
MW^2#::S)ZY!!B HL"B!9C %BB@"].94@%80*D:6)PE9'9*<:GQK%_?X^:N1S
M<*XZ!*R?B:Z%(3#'_!YM(1B2'>00"P</LRLP&<FU;/=U^'(I.Z-SKR_9X3OC
M.9&=D7;/>^S<,P.(J'/!V;FN_&:*W-^IWTM9W7K.BB2',<MRD"24 I3R E!8
M,) 6N. *RURE?+:4#Z;(P7=+EK+JV>H#)?4'>M1_N(^TDM*<-3\;)T@CJ,/T
MM8/<@N#\(?@&[AD=B6^B&L\[%?UNG'"#X.E DMYQ'8DZO>#KQJU.4/4RKEU+
MX_&PDV9[[.SVIF,,^^9I/7M_.R-,_UH6 B"EC48DM/%.%)6 XUSD5&&12*N-
M<]/>U$S$]W0Q5ZOU<DXM ]8;6/I)<X"RH3>;MU\^?[K[]O7SK8>P]'WM>L*"
MS)/U%M#\5,W%.@2]:6&<P/-]<;?AY@>_'G8459=5,DY;SQN]@VO#IPM*,&<I
M!3DW><<(3P!+F (0,EF@+$F%FQ_KZ6ZF-IF:6F*53V0KI]M)T1DX[4Z#K@<I
M\"0\A8_W&[M^%+R>V9SI:M1SF7YU#\]>+CP],!J&5GFMC'/!^]6RG(OJ+'RU
M_":YG+](<;?LU(:985$D:4$8@!G/ <H@!KA ,<B43%%!\@Q+JUS.@WJ?&F/<
MKU=<2E%&9F"CS0\9S9?:B*&+Z.F9+>9<[WRTB3-?6J9['C8B=NP2#.? I&/D
MWCHKW41[LD>M\)'^N2.^Q[B<(:CYC=5QDF#<^)TAX!S%] QJ9, !SM?5"UUO
MYNU9(*8I$H6I9"LP JA((* PRX#(2<X2F#-.E/5!\G[;4V.I5CJ'HX(#L"S.
M6(9#$)A 6L&&'" ?P.!P-#(<CI'.0%H!?1T>GU:X]R3CX)7QCBQ.R[IW-G'F
MD8$).\5_/3=W8M]7MT+,S=#2Q3V=B\_+]_1IOJ$+;=JMC?.!^<5Z_:IMAMK7
MX$Y]DT+*1^/V>;]N3DPJNIRQ),,)5 DH9.44$!< IWD&9)R3-,YA >VR$845
M<VILJ!<6XTX[5W->&Q':N- ?S8O4PVV2 #^UTD=EY1\]7VY6$=VB$3UI./0O
M(UX#$CT_Z3:\F'V!/A,[^_#M!S_P.M!1T.3^WJD8W3<CVFAY$[5ZUK^L-6U\
MOLS7LE,VVFI[(6[>/2MJT.'PFTLUC*CC9F -"O=1WM:PO0U;I'1CAMJ:8,VV
M0EP=S/G^6?>RW,R*@F+,, 6YXAB@%&- 6($ 8T))$1,BF-/FWZ+/J2T?WU>&
M])]JP4^5-N2UW/5MIV,PI<T8Y"*'&2$%H,AL7#A+ 15< 48XRE16Y!+FLXV1
M\FW&8-OS_^ QL%M2/2,;>'ULI-V6O-A5F6T3!#0R^UOD' #RNF+9]#OJ\N,
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M"C) O;?Z?GL<[\(_"%)[O@!A>G!;TLOU9O8K_3E_?'YL[G,H253*]:8#884
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M! D7.<M$F@I(AKF(7^IZ:NS:2EYM;QPBUZX= <O-:!!<0^\X^R$=R1O;%K!
MCM87NW\C'VI;6,Z[1UNW,#!NL-HVZG>KJD\93+.<IQ@@3%* :$P HRH'$L."
M)+3(\\2J<N#)UJ?&195PD9'.,79O#S([9AD,1&#RV&'@O1#5297]QL;M]3!N
MY-LIY8[BVDX^%.A4O3QW)G17G0"7?]5/&K>'VJGA/^3\X<=&BML7N:8/\N-/
MN>;S4MZ;K%0SJ"E QHD$BIK*\XAG@$F) .:*%DHDC&,W<V4\V:?&,:VL(&JD
MC5IQHTI>XX34IM2KM-2+]R_S921,:.NZK/ZY-/_\%\]'^!X_%T\'_6_S$4S@
M.J"\<!_0Z-]\(*5Q8*LQN(E:%,Y\72/>'?@?O7%O&#S*/ZU["/\#XWQ;$4"$
M88OH5[FI,F"N5R8OIGCW^KL6Z//RTWQ)EWR^?&AB"[6-O74AD50@%6<8D 0S
M4TL[!EBOCX 5!<YS+GA6.)7P<!=A:DM:E?E5+59_-D=TJA4]HEO9_\UMM1HP
M+G:+3EBT Z\=6O@FS6XCOEDG?C$:Z"7@+]%6B6BG11 7G^$@>J7P 6*,RL3#
M83HDU"M:&MEEIR'PN^=-N:%+H67[O-RLY\MRSNMZ/ +FN6(X!XJ)1-.GR8])
MJ014Y)I/,11%X72@$$S2J;'L[</#N@K]C+9RUO5]M#VXTR%B=.$>K1UNN /[
M_/@<Q D8_K9V?T??F\//80+N0;:C,@V7H8O23LM\OQ9T;ZY%UAT.=#>292GE
MW9,TV;R6#U7*SO;,^[6]DS_,O,32G"*! 290V^8T+P N, 4)0RQ%249BD<WT
M+H*M;)>7 5*X<$Y7EG$NA+:JU"F$MQ=#CBF6AHR.I?M36,1#NTE5TM\<PGRS
MP_DFVCJ4A+R(NP)&ORY8 ^08UU5K.%!'+EU7-#703C=NWB:1L39 39J!S>N,
M29Z83$5 )+P J) ($,X* #,L18H1EBES<<T\[F*:'IIE1\Y_^=\8)L6_5\E*
MG)/''4.*$L*80A04&D& LHP 1E2B/WF:Z6V+H!E-9W7P\&\;NMZ, >QA=^'@
M?2<?YLOE\+W%,9Z")WE>I 5(N$81%;0 K! ,$"J$2 L4)X5L\/RXM$RVXP/-
MMK-P6'Z\9I-V#*3E[NHJ:$)OBSK"_9^H%B^ZW6A#DCUOJN5QLS(E7+SFPCF/
MB-\MR7$WX^XESJIYM DX_^2PA6FW"*[*LJIJJU9KLVLH9W'&>8Z+PM"G-M)C
M/?%U$QR@/%9<I#*&I' Y 3K?U=2.<,SY[6IK&"ZTN*X.;CVPVG&!'[ "<T+'
M>-921GMB^B.!RU!X)8.>[D8EA<MJ'Y*#Q1M75ZVLCAC*SV7Y+,4LI3E$3)I0
M3YH#E"(,&$HDB&,E8"JTJ2"M"BE=Z&=J]-!462SK*HN5DT<9S2M1*Q>0^C>.
M?A_G,+:C"P_(!>:*_=*4M9 W42UFD$J4IW (57QRKZ^WJC=Y2N&>$I,G'W?C
M!R'GL_?:!KE=2_I^)>2,QPBJ+&% Q(72)@/7A(!-7>Q<)'$A21YG5A%*APU/
MC@$JXU<+%QGI[";Z$5C],_L:"$)/93OMK2?O.55/S-92\G]]6+W\7_U*-5'_
M@<R/H/ZQFIU'C8TR'<^IT,Z_L_\^M(SKBUP^RWNYUBO\H]FB[NIB?=@E#[A3
MS3U %5T\XU02GO!8[]^5T&8\% #+0H"8R#C/,IC$T,DC9I 44YO*'4'-L3M_
MULOZHUQ'32129$*/'(W_8:-CM] 'QSPP=S3R5Q6I6PTZ!1%OHH/Q:&]6O_<.
MPX#"KU? Z+D$[!!)1BX&>P58QV5AKVGL"B\9=OGJE)VY.FT\&<TIU_[5:3*+
MTU@6C.5ZSV.V0"J!@#+* $ZA9 G+4T&<2@.&$W5JQ-OC)]-18H!_3)B!MCS"
MG<3PA3X*]N@ATU$XM(=,T&'Q[R(31MSQ?62"PG[2229LC^Y;Y(_+C3']A="3
ML#2[@+OU]]6?RUDA.2H*@8'@N7&Q) 4@&.M],Z)9DJ=*"FQU?-;3Q]1(OQ8S
M:N2\B:JMY&H=&5GMM]'G +V\H_8 4V!R'820TU;[ @:#=]WGVAUM WY!L>Y>
M_-*C0[?EI=0O_;A=B@_:S%VLJFH2'?9YOUI67M_?5XW]^VFUKLIBEN]>MW')
M,E&9I) #EB88()$C0-*< *S2@FK.($7BE$#1BU13(Y)6J2J?3$>M_7IWK6;5
MW72M6U41HM;N9D (N9\AMMWKCSQPP??^OL;,>\B[5Z@]GP_XD&SD\P*/8!Z?
M'_AL?$"!GX/ZAI7UV!9[5AEEHE QP%QD !60 LI9#F@:0R:5"4*T"IJYU-$$
MV?B@'FR_#X ;JOULZ1.K\ 1X"J;+E0;<\'(H2.,)MY'*RW3PJ_,FTTI>7\5?
M+,#H+>72]_YXA5DLM-@KLV+S_.!\EZ?KJ_U>2O6\^#)7<J90DN<9%8#23!N[
M,E6 L((!7'"22%40@9Q<2"SZG!IY[@H+FNS?F_WJC3?1<R5XM-"2.^>OO B_
MG2'J&=3 +'M0J'&_3N--5,L<?>G#<TBB25N$?">3O-COV DC;8$XD132^E5?
M41B[;!%,B PJ#B!)M.6&.3?1&!CD'"K]*QAKZ\WI'N=L5U.CGZZD^_$8IG:;
MFO/YQC6%T7F8+6]1O( 7^A;$WB$^2'*'RR %]I%_FV0-E]6^[#/O*_G"-M7C
MF5)UWU:+Q:?:!?<@Q%(QB*CB#.0BEYIN<@@831G0-D^1LC3)*1J85]95E,G1
MT?/C(UU72;R_2?--S!=SVGJ#G"T=.C3]K// 61+8*,,1FN ZT<CG:[8:3:)&
ME9$RU@[%-% &6V=QWBBC[5#8SF>X'=SBT# $K;$YW*LJ8LW+O[]?2S'?F)]F
M4&8QD30'4$B]CU19#BC!*8"2%KG*45&PV"T4X6Q?4V/,/5'-9*U%C8RLU>:G
M.OVL_EJGW_]=/[_>T/FR2CQUOUK,N6/L;=](V#&D)WP#4^ ^M$:XFRZZ-PUX
MT1_-GT&(SP(JSW$-Y_L;.;;AHN+'\0V77QE&/N_J4.#??DBY^6+&S/B5F+N\
M),4)9!(!4U()(")C@%F. ,L@*@B).4/0A7G.=30UVFGDC"I!HU92-QXY"ZH=
MB?B *C"#G$;)^_WE)22\$L39SD9EATLJ'U+#Q>='SL#WB<[7E6O9;5D^/];N
M9X:G/JVE\3V3^BO<?*,;^>M\:4HISQ F3.9*;QGC) 8H)@S0+,Y C$S2)%+$
M-!TG(9^CX%/C+2,J4%K6:-X(&^GE0MY$C[6\(V7D<QU^RXWG! <U]#;U>F]D
MHWSM<AQUU+^I+6B#0-1"$'VK/I5?+WPJXZ7P&SANT\CHYRK\/T>"OX%#XBW?
MW]#^KTT@LI=%ZZL&^7EM#K]G&4>*LY2"5 FNM^9I!@A'$ B4,ABK/&%H8!Z1
M,SU.;<6I$_AU*I/>1,O5$C32#DTL<@YNNX7"*XB!&;XO1]].X! )1RY@$RCO
MR+E>WRC]R 40SF<AN?3BP+I7XK^>FSJ GU;KK_+/6\Y7STO3X_UZM=0_\KIV
M0;615#%+.4D2  F1 !6( 28H!31!)"NR/%;4:7?NU/O4B&@G:_2;205;.9_]
M_B1,$-Z%':F'H; CIF  !R:I*[!U+] U!"._!;R<)!BWP-<0<(X*@ UJ9( W
M\><E7SW*[_3GQY]4;T K&^_KLW&^NU.=7Y7WLLI(.$-Y4L1"2)"8O3^"-#94
M1D%&&,LXRU666ET<#^E\:G16BVIN/.:5(M&&_HQD1^[HJ1;<P:_6=3SZ22TT
MRH$YK9:\NN_M"!HUN-^I[F_+Z#XXV Z.S0%!'\G9^?/);UIO'6KTFT_;E^_S
M0+QZ_:%=VQS/1WJ@MGM^TT/;&&;U;C?UOVJK^GE=+3YZ0_^/9[GDKQ]6CW2^
MG&5)CH1*C#^1\6&$10((C@L0:QM8;[,3D4(G6]>BSZDM"1U)HZVH;D:M#=)V
MIJQG_ *3_4GHHC]J.3T:KPZH>#59;?H=U5!U .+0/'5Y=> N>VOO;G<S]68&
MQDD>PR;22,(4T9QH&S2#)M[-U(>BM !"Z'UWKF*598G3[MJFUZEQ3M_.S\@-
M8NBXK;;"WG([[1O1-]Q&-V!>#I=SWU"[H.1W(VW5\[@;:!<PCC;.3B\/K#@T
MYW)9FG)Z#VM9;\.;.9%!F*!<4B!,<2'$& 28:F:*4Q'CE&BJ<KLC/]O3U#BH
M%E1&.SD=RP2=A=2.9KP %9A:MC)V4 K )1>A\%NVYVQOXQ;GN:3T40F>BR],
MP!WGX\\G:0)C_[9:Z&;,+49U;TI_5AX9B<R3F%$.LH(8AYQ4 :IB! 1&D"18
M82*=[C7'$WUJ[-4*&[ULI;V)'FM9W] =IW_X[8AQFH,:F&D#NN1L/Y4=!JU/
MSH7OY6U]<JR&;KI>.?WB__/ZY5@-2U#/'#L)ABV&'Z2:+XV4RSHJ5?=G@JMW
MT6P2J0(214&20 @0%01@K"UG)1!+,<T$L[M-LNUP:@M/(V_4%;C*&N"VZES$
MV6ZM\(E>8(8_"UST1Y 8&%MHO#+HQ4Y'Y3U;" [9ROJ]*PSN^[4VYV>*9@E#
M"0&2,0(0(K2NZHOR/)4HS44JG.X?=DU/C3<JR:(G(]H ^[1&R\%^=,9@#/LN
MNN]5?YBYM:>I?W.H;GY\<V5/K9/FQ/X30]./FJ!.*3[2M2D#6MYR_OSXK,T*
M*3[4B3QF,LU0H?04C7&1 \2I7O S% .BMZ\99%SQ7+CE%KW4Y=2F;D?"J$EO
MXIH!]"+*=E/;+W:!IWPK;-1*&_W21?+#I40Q S)RVJ+C.=WFQ6Y'SJ5I"\-Q
MHDSK-P?XK=U7A7COE-GC?#/[&Z8;-AN=&2:Q+(J8 :A2$P^+.*"0%*#(TY2G
M4F8YM:H!UM_-U&BE%M3XHIGCC*C*^D-;81U<HL[CVD\J_M *3"0-4'<J,E)&
MWZHS'Z] .7B)>0%L)'^P8<"Y>8%=Q*/7W^O\V^-Y=EW48,^'Z_+3 V\H95E*
MN1\)80H9W:DV._&L2#GBJD@ IFD,4)$KP(19DKB "A=(0.QT>W"YRZE19AT6
M9>JK.=Y57@;7\M+2*V2A;R\K84WEG(-@*"-QE?6ED=GC3:8U/GZO-"]W.^[=
MIC4,1Y><]F^.7-CLX\^G>9TDI:; F<Q)KADG!E3F7%MMA0!4T[O>(J:80&EJ
MFCD5G? FV=18:R=?]%2OR.:+B2H')3T+'[2"CAM*?X/H<*0T]M!,_\:Q,["U
M>A,H/W8.\6E4&SN2[I^CN-@Y4+W5$CO;P="LQ8U1>J=Z,NM"H4C&M14I,F9*
M;^,"8$E30#2-,XPUM2=NA2AM>IT:.6^%-E1\,D&O12;>*P;!DH!]0QN:7'V@
M.B"_L0-*GE,=V_0\<M9C!S".$R"[O#RTON&G^4*NW^N>'E;KUQF"C% &$<AX
MF@*D8@H8D7KIS6&:$:(0RW*WVH9[[4^->&H1HTK&J!72M:#A/H+]7.(!E\"L
MX0;)@ J&)Q6_LGKA?ILC5RX\J=!QU<+3CWFM6*BWK9OOVLXI-3%H,Z:)>DLS
ME":*Z^VAI'IG6,3:ND Y!3%-$XBHWC,63CEV73J?VH0_7\O.B'\3=13P4F#P
M](C87C2&P3GXE:,UQ '"%(> -D;AO],"3*&^7R\TEF7\^ML8[ 4IUVLIM@';
M7W:9N&:$%PE-50X$S#6G89D#BKD$:<Y2420<)BF:+:LZ]>+[:D,7=M36UZ?5
M%"/U%#OJ.=QTJ_HP+A&5X%7>@4[*,F>'R/.0VY'6U0B.Y@A9XV629'SIIGC[
MZWI5GH=MB ?D13Q\>S^>[W!LS\>+JI_P>KS\S@"_AT_/B\7W^:/\^/BT6+U*
M^7Y5;II(N21'!*42@:0H,FTC)1A@3H5QM:*"(Y&BV,K]\4(_4[.$/GW_&'$M
MG4NUSQX4^]G!(S:!B<$(&1DIHU;,R,@YI-9G#UH.O@Y^4!O)V<$("S8&/=FB
M9[XQ7]EN+F/1Z^C0\_IXG@Z7==AS=;!X? (1EZ?RU,YDRA6' @&89E03*X\!
MRU,$.!-$&G]6+/FD,I]/C:+/I#R?6*;SJ:0XG] B,GYN\XF&3_:-TW2C)D]*
M_<\;+-DW"*-G+[]RU?K]M^_K*G?2ZV^2/Z^K?4%C4\$8(QCG!:"9-N$1R5/
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MQ@O</2?O7L3NV8=\IOFKLQ_=+L5>WO.RBA%^G<6LH&D>$Z @A'JG*3A@C*2
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MA4GU_-3FUFD"*F'&%1>I2;C,$X X+ !). 20H!C*F"4D=3IFL.AS<LO!:OD
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MF8;"Z3"!+$7!!\@NPU%X,09N9?_Q/-^\&DE72RU(6^T@Q@D6*@,Y2BA "8*
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MJZ3E\[K:4GQ:RW\\RR5_K:)86985@D)-3$(J@+BI)JN26(]$HE":,5(D3EE
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MIETA-V8%#%#Q;H>JZS5:&*P&OT4[7^^N;EG"M%DK<+]8K/YDYL4!>F4HWFS
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M2%*5-\,D3K"0BLG(J=7AI0FF1NAM&8$5THU3+N+73<TA4!G<+W4$"/C#2AC
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MMV$_P.]_^_PWP%>K?Y6>X3Z92_V6QHT,1P)\8&*L\Y]^LGK\O+_$K%0!>UT
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MQ3'D61I#*1.<:95E*',JWG<R\M0HHA8.6.G AW?N-<\/\>I^^6]"8> WW14
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MS]9K.T.4"Y1APW@,<<-X&8$T35(HI"!(QYDDR+?;>2#1G%[64=MS?#36]7^
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MW[ORDR\6JS^9T;-5,3\5&BE$8)Y0#3$7TIB/BD!-LS3-2)Y*[G4\=)ET:OM
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MZ9IQY$P;!^5/<VM<OG3I.6^OW$?ST__Z'\UOS'_L>_B__L?_!U!+ P04
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M#0<-YRZ/%F<38<(_8#+YWU,,A#^#7^"9EMXN%I<EF19C-A[=6>ZI1K\F:>*
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MGWYR"2/EN=5>E3<O&?\AO"7!J(2?C.'@A?7YJ:S4X0C:B;P6$'44#&:U==(
MT#Y_G<V77P!=].DW6"R[2YZ1,@&LRX9 C)1(RM ]"\H0[WTPTAODYZD7:4><
MWX]0,TQ05 ]&1TN\ =2\B+%TAUI\@@BX$<($WL/RNNI9V425IY$(P55Y?Z6(
MU0F(BIZ9I'D2\%2X=,2Y]@15P\13]5#4FP8:0%.Y5#Z'+_X[W&%G9(V*6E.*
MAS[EY2F.QBWA+.&>QYP]%[*28_TH.</TCZV'G^-EW@!P/L[APH_3;]\O8+H
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MF(CA*(T$&,_E.8HE+I?+YR@$\)2%JY0(>(*H9CRF>FCJ2R4-V*(G)!1E$E:
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M&$F?X.)R'K_Z!;PXFT,GKDV6UILMZA1T\)[HX"*1S&@2>/$S@_">YZ3<;BF
MG>"U,UG#F*5^-#^KK8:ABZ!^GZ+X_YB/R]>MC:QD'HVJR21:749.,$6<PW]$
MIEA2PH6TV3%M2VW3P^\>#@J5M#?K3Y0#6YD/?TSQ>[Z.+[I-PD3B3F,H*8(J
M+W'Q '<L"1*]5BD$YKC8Z7723I;DWM)#MX<8XH0Z7/:M@&:]=SAD;Z6BI=$^
M[IV J@[".L(Q;#!"@<7MU#]LACYFCE#?8R X0)9#GR(?NVO]+U]A[B_@<CF.
MY1W'V@8*#2;*'(D7*:$]C8Q8 0GY"(9R2"YMSL3=<IP\L4@#NC]$:[,*(AP0
M"@G&HW=PYB>_H7%<7JUV U<22A=OQATMK>D\<3EGDAASAH,,*3Z56EE _//9
M[-NO^-6=0?B7+!_)ZF,'C4<6';KCRZF/D&/E/C!D5E2O]P]8KWD 5]X.E$E"
MGJ,DF"Y"L"($;?F3 YEVP\O=%8<Q'4>K;-:#_(8^-=[/OJ'O/;YQEETRSL=$
ME*3H+-N02$";B9\$IRQ0FY39Z:"X_[W#*?APQ<SZD5(#^=)#K>&[\13>+N%\
M,8I.!TA!$BMYF2.B$G%1&.)-Y QR,!GJ7$8?3?K0#9^&NC$ZK<X; 'F7HOXZ
MFZ!"%ZLT^/O9<M59\O/%9+Q<O9=;H.(_%?6S$3<R 3@@QLKR[#,&XH0WA$?G
M6$DS^">]HF-N./>C]'D6CAT(I <7GQ6UV@)J[U0J7):SI8PL\>4-_F)Q69JU
MW:E<&%F7A9**E4$EO)QA: ]*S0JW3@4K\'#3=0IR]Z'R>5[1]X366MIL"ZDH
MM0@?8=[Q-J)@DO?H10&5<,.')CPXAW0H[U2=$OMM%#W/^[7>$7BXEMI"6RFC
M'Z=N\"=:>8@P_@;IP_VMI(V-,BA"A>O&E*&P,(XC&,D!35DKFNM,$-Z+S.>9
M5>\=ESWKLP&P=KUS%O ))J7K[I?9ZW'I1A(NNX<>\\\P_S:.JZ?/-]=3^,<W
M  L,44-BNHQJ!H/NBLF*>"DI"=Z[+%-4DM<)K ZG^7EF]OJ!\8DTW0"FM[87
MN>O0E"XZMQ[X*"C!>>D+E6)I'<QRPC,F %$*??(DA(!<J9WB_L0^S[Q /RBN
MK=L&X/LB_=_+=;>'+[/;IZNED=G;Z;KEV753W_*#^?RJ[-OS(O#23NJZR\Y&
M:QW(3#AC&,$C21,9RI"^KCC!:I6\U#I"'4>C#C_#]F$<=A,T@) &]LF=\LZ[
MFW_DE @@C"2!ZY)&4660%<7M;LN[K)1\Y'4>LFTA:">DVI\3J7WHJ &H=;1W
M02D&H\DHRQWARB0,1BGRD/$PP4,F&I#HY(=*\=H-#3L!ROV<@#I0$PU@Z/')
M4G<VR,@X&1-E@BAM,'0LDS.\<F6(E+&X72"CPU(%6C\D;;<T/OTY(=>OX@Y&
M(GJS8=83%O\^GLXPOKMZ6PI88;&\J4+Z"/-85'L&+Z]*^[/9=(F+X]><K7YE
M)%)VVO-RKY<-D;J\H*"&(Z@,M33Q(%R=*=T'D[P;=G_2.ZC3*+K5GDB?+\_/
M_?QJEC^/SZ9=R]WI\HZH9Y-Q+'TP[W&Q6^NC';^YEPY'AW#14R.CA\O<]'E1
MR>:D%1 F3:E'T4!\3)K8;&R,5K!@ZO1%WT[3T5[>4_*][18FM:3,>4,T>JO(
M>7+E#2,0 '1F!;H@F55Z7KP3?<->N?>$F =N7_^J>=Y&J[[Q&L*(#67,O-
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M&PT![;-60@.E=8Z=BJ-3XE=(EV5.]M8'#ZNKQ1QX )LCD2G@/[25Q +NWNS
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M_M/K?F@R4Z=D)I S)5(#)=YE2W+4WN..M:[20/%CJ!X^LNT#.0^G4)Y&C0U
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M7.M[@R=0; M OF;IW=B'\:3+&3T2W8THX]X;,(27=X"2"4,\HPH_Z1!9H-%
MI3$RNQ'8R/E]$M1L0K:""EM YC4+J[O050?7+[-5F\TO<S]=(%DE]WXY78Y"
M4-(S;0G7Y>Z)18='5#!$1)J%HF!=K&Q.=Z"R%=,Y!$9K*;/5E/7U"$A_9_KC
M%):'9*:W?54O">B=Z.PIS[QU+.;MH 6'$4>,@?#2CUE:9HC5U!$!T45(2:I*
MO2Q^2%JU>:VW!OIV(I V5 D1+1&:HJ4&-->> R<FV)A!2PVJ3D7"/E0V.L'U
M("SM/,#U6&T],W-U^(C%I[^PINFJ.&CQQZ 3$B#A44BH*D.JP7KB:?(D.)]
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MD0V$6BN)02N776:AD?,[RO9[&7K1X]'?$ CGC?Y*\M:,%.FB$[4*1&T.H2S
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M47) [76(,;HHPB#$O+A45YFK!P-E7(Y.C8][L/]Q5M:(\TTZ[F!=$)'9I(H
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MM1LTJG0X;*:T44>([+'0#^#?Q&+_>3:O+\K;C0ON-->AMI*.!I34$5P1A/B
M3EHR@#BLP^L@P3]8>F+1'R*XQ1A<G%K\UPD%-V><+"DI%D&BJX&TTD!H]^"\
MD1RSMK(,:JHV3/SWEY[FR!A-_ =S\1QBMI<?)9PP4B<MP:3HR!%+%APW&HS
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M%YK0&)X*9\V/Q*/R1R>I7!DU:>5(J?1XM? +662,TEAG:>=*B_H6ER$(TLC
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M#6HMO#(@14J@E/(UEZ& 4X%Y-)YIUZ:N?\#FIK4]+6.>L273-=@N2O'6R)"
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M0NDLQ;N9XS\25@[)\-Y'* ?;Q3\WMR^;N_I1W/]OZ7A,ZDWCXZT7FDKA4JM
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M1\NH_.\41UMMDB89K>L8%L%((V2]:[<E0I:Z>!Y)F[!--Y[=>YK631E'Y@.
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M00:!U*AWT"S%[AB) ,V6D0PB9G+Z6/=?@H;""4T@D29&840::TF4H,%D$+@
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MSQ\_+V#KU;3UX^DJ5G/=A<_P&<WM=I?/O,U6?/H7Z]PK?A=_ %!+ P04
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M,_ON-XD%V[JPN"8!*S>:ZR;4!R;(S7:3;]QQ+#[==4M[\?/LWU!+ 0(4 Q0
M   ( )N37%0%R_C1BPP  !!(   >              "  0    !N;VXM96UP
M;&]Y965D:7)E8W1O<F-O;7!E;BYH=&U02P$"% ,4    " ";DUQ4O3;Z<MA6
M! #A["0 $0              @ ''#   <&QR>"TR,#(Q,3(S,2YH=&U02P$"
M% ,4    " ";DUQ4,]G.<L06  #)\@  $0              @ '.8P0 <&QR
M>"TR,#(Q,3(S,2YX<V102P$"% ,4    " ";DUQ4Z3:_JKP<   V%P$ %0
M            @ '!>@0 <&QR>"TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%
M  @ FY-<5 NDDYHG8   "EL$ !4              ( !L)<$ '!L<G@M,C R
M,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( )N37%1B6-Y$XP ! $-U 0 4
M          "  0KX! !P;')X+3(P,C$Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    (
M )N37%0/"M )<F(  !MJ   5              "  1_Y!0!P;')X+3(P,C$Q
M,C,Q7V<Q,"YJ<&=02P$"% ,4    " ";DUQ4T8P7(LQ#  "040  %0
M        @ '$6P8 <&QR>"TR,#(Q,3(S,5]G,3$N:G!G4$L! A0#%     @
MFY-<5)GDFXFR1   ]%0  !4              ( !PY\& '!L<G@M,C R,3$R
M,S%?9S$R+FIP9U!+ 0(4 Q0    ( )N37%2?^O&CV2H" ,:T P 5
M      "  :CD!@!P;')X+3(P,C$Q,C,Q7V<Q,RYJ<&=02P$"% ,4    " ";
MDUQ4V)1U *-2   \<@  %0              @ &T#PD <&QR>"TR,#(Q,3(S
M,5]G,30N:G!G4$L! A0#%     @ FY-<5%.J.R%2I $ I4$# !4
M     ( !BF() '!L<G@M,C R,3$R,S%?9S$U+FIP9U!+ 0(4 Q0    ( )N3
M7%3J1KU402@$  B<!0 5              "  0\'"P!P;')X+3(P,C$Q,C,Q
M7V<Q-BYJ<&=02P$"% ,4    " ";DUQ4Q4Y64SU% 0#Q7@( %0
M    @ &#+P\ <&QR>"TR,#(Q,3(S,5]G,3<N:G!G4$L! A0#%     @ FY-<
M5'E'%SOAV0, @WX% !4              ( !\W00 '!L<G@M,C R,3$R,S%?
M9S$X+FIP9U!+ 0(4 Q0    ( )N37%3$[4]Y! H! #<P 0 5
M  "  0=/% !P;')X+3(P,C$Q,C,Q7V<Q.2YJ<&=02P$"% ,4    " ";DUQ4
M/Z0$L 9+ 0#Y9@$ %               @ $^614 <&QR>"TR,#(Q,3(S,5]G
M,BYJ<&=02P$"% ,4    " ";DUQ4OS,SD7-D  "F9   %0
M@ %VI!8 <&QR>"TR,#(Q,3(S,5]G,C N9VEF4$L! A0#%     @ FY-<5&G2
MCJHT7@  +6(  !4              ( !' D7 '!L<G@M,C R,3$R,S%?9S(Q
M+FIP9U!+ 0(4 Q0    ( )N37%26'UZ%R(P  ("A   5              "
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M&@!P;')X+3(P,C$Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( )N37%0_V]1<Y)<
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M              "  2MX'@!P;')X+3(P,C$Q,C,Q7V<X+FIP9U!+ 0(4 Q0
M   ( )N37%3)$&RS!Z(  (_7   4              "  8OE'@!P;')X+3(P
M,C$Q,C,Q7V<Y+FIP9U!+ 0(4 Q0    ( )N37%0]N*43X0T! .9("P 5
M          "  <2''P!P;')X+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" ";DUQ4C^_D(K6A  "">0< %0              @ '8E2  <&QR>"TR,#(Q
M,3(S,5]P<F4N>&UL4$L! A0#%     @ FY-<5*[24T42"   /2@  !
M         ( !P#<A 'EE,C R,2UE>#,Q,BYH=&U02P$"% ,4    " ";DUQ4
MOJ'*5?4$  #G%@  $               @ $ 0"$ >64R,#(Q+65X,S(Q+FAT
M;5!+ 0(4 Q0    ( )N37%0-@J,S9@@  %,J   /              "  2-%
G(0!Y93(P,C%E>#,Q,2YH=&U02P4&     "4 )0"7"0  MDTA

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
